{"id": 1000000, "claim": "Fauci predicts us deaths from coronavirus", "label": "SUPPORTED", "evidence": ["Dr. Anthony Fauci said based on modeling of the current pace of the coronavirus' spread in the U.S., \"between 100,000 and 200,000\" people may die from COVID-19, the disease caused by the novel coronavirus.", "> Dr. Anthony Fauci says there could potentially be between 100,000 to 200,000 > deaths related to the coronavirus and millions of cases."]}
{"id": 1000001, "claim": "Fauci predicts us deaths globally coronavirus", "label": "REFUTED", "evidence": ["Dr. Anthony Fauci said based on modeling of the current pace of the coronavirus' spread in the U.S., \"between 100,000 and 200,000\" people may die from COVID-19, the disease caused by the novel coronavirus.", "> Dr. Anthony Fauci says there could potentially be between 100,000 to 200,000 > deaths related to the coronavirus and millions of cases."]}
{"id": 1000002, "claim": "Fauci predicts us deaths worldwide coronavirus", "label": "REFUTED", "evidence": ["Dr. Anthony Fauci said based on modeling of the current pace of the coronavirus' spread in the U.S., \"between 100,000 and 200,000\" people may die from COVID-19, the disease caused by the novel coronavirus.", "> Dr. Anthony Fauci says there could potentially be between 100,000 to 200,000 > deaths related to the coronavirus and millions of cases."]}
{"id": 1000003, "claim": "Leronlimab used in seven patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu , removed from icu and extubated with reduced pulmonary inflammation", "label": "SUPPORTED", "evidence": ["Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.", "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).", "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.", "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."]}
{"id": 1000004, "claim": "Leronlimab used in two patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu, removed from icu and extubated with reduced pulmonary inflammation", "label": "REFUTED", "evidence": ["Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.", "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).", "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.", "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."]}
{"id": 1000005, "claim": "Leronlimab used in three patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu, removed from icu and extubated with reduced pulmonary inflammation", "label": "REFUTED", "evidence": ["Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.", "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).", "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.", "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."]}
{"id": 1000006, "claim": "Leronlimab used in four patients in nyc with severe covid-19 demonstrated promise with two intubated patients in icu, removed from icu and extubated with reduced pulmonary inflammation", "label": "REFUTED", "evidence": ["Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved. Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, These preliminary results give hope that leronlimab may help hospitalized patients with COVID-19 recover from the pulmonary inflammation that drives mortality and the need for ventilators.", "The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).", "Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.", "Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs)."]}
{"id": 1000007, "claim": "Home testing for coronavirus to track levels of infection in the community", "label": "SUPPORTED", "evidence": ["The samples will be collected by courier and tested in the laboratory using the gold standard PCR (polymerase chain reaction) test, which detects the presence of genetic material from the virus.", "Home testing kits are widely used in health care, for example in the management of diabetes and the diagnosis of HIV."]}
{"id": 1000008, "claim": "Laboratory testing for coronavirus to track levels of infection in the community", "label": "REFUTED", "evidence": ["The samples will be collected by courier and tested in the laboratory using the gold standard PCR (polymerase chain reaction) test, which detects the presence of genetic material from the virus.", "Home testing kits are widely used in health care, for example in the management of diabetes and the diagnosis of HIV."]}
{"id": 1000009, "claim": "Studies testing for coronavirus to track levels of infection in the community", "label": "REFUTED", "evidence": ["The samples will be collected by courier and tested in the laboratory using the gold standard PCR (polymerase chain reaction) test, which detects the presence of genetic material from the virus.", "Home testing kits are widely used in health care, for example in the management of diabetes and the diagnosis of HIV."]}
{"id": 1000010, "claim": "The sars-cov-2-like virus found in captive pangolins from guangdong should be better sequenced .", "label": "SUPPORTED", "evidence": ["bioRxiv - Bioinformatics Pub Date : 2020-05-07 , DOI: 10.1101/2020.05.07.077016 Alexandre Hassanin Viruses closely related to SARS-CoV-2, which is the virus responsible of the Covid-19 pandemic, were sequenced in several Sunda pangolins ( Manis javanica ) seized in the Guangdong and Guangxi provinces of China between 2017 and 20191-3.", "The GD/P2S dataset2 contains reads that are identical to SARS-CoV-2, suggesting either the coexistence of two SARS-CoV-2-like viruses in the same pangolin or contamination by the human virus.", "To overcome this absence, I assembled these genomes from the Sequence Read Archive (SRA) data available for SARS- CoV-2-like viruses detected in five captive pangolins from Guangdong."]}
{"id": 1000011, "claim": "The sars-cov-2-like virus found in captive pangolins from guangdong cannot be better sequenced.", "label": "REFUTED", "evidence": ["bioRxiv - Bioinformatics Pub Date : 2020-05-07 , DOI: 10.1101/2020.05.07.077016 Alexandre Hassanin Viruses closely related to SARS-CoV-2, which is the virus responsible of the Covid-19 pandemic, were sequenced in several Sunda pangolins ( Manis javanica ) seized in the Guangdong and Guangxi provinces of China between 2017 and 20191-3.", "The GD/P2S dataset2 contains reads that are identical to SARS-CoV-2, suggesting either the coexistence of two SARS-CoV-2-like viruses in the same pangolin or contamination by the human virus.", "To overcome this absence, I assembled these genomes from the Sequence Read Archive (SRA) data available for SARS- CoV-2-like viruses detected in five captive pangolins from Guangdong."]}
{"id": 1000012, "claim": "High dose vitamin d improves total serum antioxidant capacity and icu outcome in critically ill patients.", "label": "SUPPORTED", "evidence": ["Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.", "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.", "Vitamin D status in critically ill patients: the evidence is now bioavailable!"]}
{"id": 1000013, "claim": "High dose vitamin d reduces total serum antioxidant capacity and icu outcome in critically ill patients.", "label": "REFUTED", "evidence": ["Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.", "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.", "Vitamin D status in critically ill patients: the evidence is now bioavailable!"]}
{"id": 1000014, "claim": "High dose vitamin d decreased total serum antioxidant capacity and icu outcome in critically ill patients.", "label": "REFUTED", "evidence": ["Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.", "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.", "Vitamin D status in critically ill patients: the evidence is now bioavailable!"]}
{"id": 1000015, "claim": "High dose vitamin d reduced total serum antioxidant capacity and icu outcome in critically ill patients.", "label": "REFUTED", "evidence": ["Perron RM, Lee P. Efficacy of high-dose vitamin D supplementation in the critically ill patients.", "Therefore, vitamin D has the ability to act synergistically on the immune response to acute systemic inflammation and infection (19, 34), lung epithelial function (35), muscle function and metabolism (36) and cardiac function (37), to name a few (Fig.", "Vitamin D status in critically ill patients: the evidence is now bioavailable!"]}
{"id": 1000016, "claim": "Epidemiologic features and clinical course of 1st 18 patients infected with sars-cov-2 in singapore", "label": "SUPPORTED", "evidence": ["Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."]}
{"id": 1000017, "claim": "Epidemiologic features and clinical course of 10 18 patients infected with sars-cov-2 in singapore", "label": "REFUTED", "evidence": ["Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."]}
{"id": 1000018, "claim": "Epidemiologic features and clinical course of all 18 patients infected with sars-cov-2 in singapore", "label": "REFUTED", "evidence": ["Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."]}
{"id": 1000019, "claim": "Epidemiologic features and clinical course of over 18 patients infected with sars-cov-2 in singapore", "label": "REFUTED", "evidence": ["Conclusions and relevance: Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection."]}
{"id": 1000020, "claim": "A bifidobacterial protein that can reduce inflammation in covid-19 found by a rudn geneticist", "label": "SUPPORTED", "evidence": ["The fact that bifidobacterial surface proteins were able to recognize specific classes of cytokines supported the team's theory: these bacteria are also capable of regulating our immune response.", "A fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus and other diseases."]}
{"id": 1000021, "claim": "A bifidobacterial protein that cannot reduce inflammation in covid-19 found by a rudn geneticist", "label": "REFUTED", "evidence": ["The fact that bifidobacterial surface proteins were able to recognize specific classes of cytokines supported the team's theory: these bacteria are also capable of regulating our immune response.", "A fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus and other diseases."]}
{"id": 1000022, "claim": "A bifidobacterial virus that can reduce inflammation in covid-19 found by a rudn geneticist", "label": "REFUTED", "evidence": ["The fact that bifidobacterial surface proteins were able to recognize specific classes of cytokines supported the team's theory: these bacteria are also capable of regulating our immune response.", "A fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus and other diseases."]}
{"id": 1000023, "claim": "Swissmedic begins rolling review of moderna 's mrna vaccine against covid-19", "label": "SUPPORTED", "evidence": ["This rolling review process allows Swissmedic to review data from ongoing clinical trials as soon as it is available."]}
{"id": 1000024, "claim": "Swissmedic begins rolling production of moderna's mrna vaccine against covid-19", "label": "REFUTED", "evidence": ["This rolling review process allows Swissmedic to review data from ongoing clinical trials as soon as it is available."]}
{"id": 1000025, "claim": "Sars-cov-2 spike protein promotes hyper-inflammatory response that can be ameliorated by spike-antagonistic peptide and fda-approved er stress and map kinase inhibitors in vitro", "label": "SUPPORTED", "evidence": ["We developed an antagonistic peptide that inhibits S1-ACE2 interaction and CoV2-S1-induced productions of pro-inflammatory cytokines.", "Here we demonstrate that 2019 SARS-CoV-2 spike protein subunit 1 (CoV2-S1) induces high levels of NF-κB activations, production of pro- inflammatory cytokines and mild epithelial damage, in human bronchial epithelial cells."]}
{"id": 1000026, "claim": "Sars-cov-2 spike protein promotes hyper-inflammatory response that cannot be ameliorated by spike-antagonistic peptide and fda-approved er stress and map kinase inhibitors in vitro", "label": "REFUTED", "evidence": ["We developed an antagonistic peptide that inhibits S1-ACE2 interaction and CoV2-S1-induced productions of pro-inflammatory cytokines.", "Here we demonstrate that 2019 SARS-CoV-2 spike protein subunit 1 (CoV2-S1) induces high levels of NF-κB activations, production of pro- inflammatory cytokines and mild epithelial damage, in human bronchial epithelial cells."]}
{"id": 1000027, "claim": "Finding suggests technology can be installed in air conditioning , vacuum , and water systems", "label": "SUPPORTED", "evidence": ["Eventually, as the science develops, the industry will be able to make the necessary adjustments and install the bulbs in robotic systems or air conditioning, vacuum, and water systems, and thereby be able to efficiently disinfect large surfaces and spaces.", "Disinfection systems based on LED bulbs, however, can be installed in the ventilation system and air conditioner, for example, and sterilize the air sucked in and then emitted into the room.", "In the future, the researchers will test their unique combination of integrated damage mechanisms and more ideas they recently developed on combined efficient direct and indirect damage to bacteria and viruses on different surfaces, air, and water."]}
{"id": 1000028, "claim": "Finding suggests technology cannot be installed in air conditioning, vacuum, and water systems", "label": "REFUTED", "evidence": ["Eventually, as the science develops, the industry will be able to make the necessary adjustments and install the bulbs in robotic systems or air conditioning, vacuum, and water systems, and thereby be able to efficiently disinfect large surfaces and spaces.", "Disinfection systems based on LED bulbs, however, can be installed in the ventilation system and air conditioner, for example, and sterilize the air sucked in and then emitted into the room.", "In the future, the researchers will test their unique combination of integrated damage mechanisms and more ideas they recently developed on combined efficient direct and indirect damage to bacteria and viruses on different surfaces, air, and water."]}
{"id": 1000029, "claim": "Oxford university vaccine shows 70 % protection - bbc news", "label": "SUPPORTED", "evidence": ["The researchers said it worked out at 70% protection, which is better than the seasonal flu jab."]}
{"id": 1000030, "claim": "Oxford university vaccine shows 70 % protection -19 news", "label": "REFUTED", "evidence": ["The researchers said it worked out at 70% protection, which is better than the seasonal flu jab."]}
{"id": 1000031, "claim": "Mast cells activated by sars-cov-2 release histamine which increases il-1 levels causing cytokine storm and inflammatory reaction in covid-19", "label": "SUPPORTED", "evidence": ["In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.", "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."]}
{"id": 1000032, "claim": "Mast cells activated by sars-cov-2 release histamine which reduces il-1 levels causing cytokine storm and inflammatory reaction in covid-19", "label": "REFUTED", "evidence": ["In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.", "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."]}
{"id": 1000033, "claim": "Mast cells activated by sars-cov-2 release histamine which decreases il-1 levels causing cytokine storm and inflammatory reaction in covid-19", "label": "REFUTED", "evidence": ["In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.", "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."]}
{"id": 1000034, "claim": "Mast cells activated by sars-cov-2 release histamine which inhibits il-1 levels causing cytokine storm and inflammatory reaction in covid-19", "label": "REFUTED", "evidence": ["In this pathologic environment, the activation of mast cells (MCs) causes the release of histamine, proteases, cytokines, chemokines and arachidonic acid compounds, such as prostaglandin D2 and leukotrienes, all of which are involved in the inflammatory network.", "IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)."]}
{"id": 1000035, "claim": "The furin cleavage site of sars-cov-2 spike protein is a key determinant for transmission due to enhanced replication in airway cells .", "label": "SUPPORTED", "evidence": ["Using lentiviral pseudotypes and a cell- culture adapted SARS-CoV-2 virus with a S1/S2 deletion, we show that the polybasic insertion is selected for in lung cells and primary human airway epithelial cultures but selected against in Vero E6, a cell line used for passaging SARS-CoV-2.", "The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission", "We find this selective advantage depends on expression of the cell surface protease, TMPRSS2, that allows virus entry independent of endosomes thus avoiding antiviral IFITM proteins.", "SARS-CoV-2 has a unique polybasic insertion at the S1/S2 CS, which we demonstrate can be cleaved by furin."]}
{"id": 1000036, "claim": "The furin cleavage site of sars-cov-2 spike protein is a key determinant for transmission due to enhanced infection in airway cells.", "label": "REFUTED", "evidence": ["Using lentiviral pseudotypes and a cell- culture adapted SARS-CoV-2 virus with a S1/S2 deletion, we show that the polybasic insertion is selected for in lung cells and primary human airway epithelial cultures but selected against in Vero E6, a cell line used for passaging SARS-CoV-2.", "The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission", "We find this selective advantage depends on expression of the cell surface protease, TMPRSS2, that allows virus entry independent of endosomes thus avoiding antiviral IFITM proteins.", "SARS-CoV-2 has a unique polybasic insertion at the S1/S2 CS, which we demonstrate can be cleaved by furin."]}
{"id": 1000037, "claim": "Is there an airborne component to the transmission of covid-19 ?", "label": "SUPPORTED", "evidence": ["Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.", "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.", "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."]}
{"id": 1000038, "claim": "Is there an airborne component to the entry of covid-19?", "label": "REFUTED", "evidence": ["Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.", "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.", "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."]}
{"id": 1000039, "claim": "Is there an airborne component to the development of covid-19?", "label": "REFUTED", "evidence": ["Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.", "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.", "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."]}
{"id": 1000040, "claim": "Is there an airborne component to the use of covid-19?", "label": "REFUTED", "evidence": ["Conclusions Given that live SARS-CoV-2 virions are known to be shed in high concentrations from the nasal cavity of both symptomatic and asymptomatic COVID-19 patients, the results suggest that those sharing enclosed spaces with infectors for long periods may be at risk of contracting COVID-19 by the aerosol route, even when practicing social distancing.", "In order to quantify the risk posed by COVID-19 infectors exhaling respiratory aerosols in enclosed spaces, we undertook a computer modelling study to simulate transmission in an office building.", "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."]}
{"id": 1000041, "claim": "Saliva-based antigen testing is better than the pcr swab", "label": "SUPPORTED", "evidence": ["And, just as importantly, antigen-based testing is highly specific: unlike its PCR counterpart, the antigen test isnt fooled by faint signals of lingering viral matter outside the period of infectiousness.", "Fortunately, other attributes of saliva-based antigen testing make this feasible: unlike PCR, it doesnt require trained personnel, specific chemical supplies, or centralized, expensive laboratory instrument; it is less vulnerable to the supply chain bottlenecks that plague PCR-based labs; it returns results in a matter of hours; it costs as little as $1 per test; and it could be as convenient as sucking on a piece of paper.", "Rapid, saliva-based antigen testing is an essential weapon in the fight to resume many of the activities and reopen many of the venues that comprise what we used to call normal life. It is practical, convenient, cost-effective, and easily scaled."]}
{"id": 1000042, "claim": "Saliva-based antigen testing is lower than the pcr swab", "label": "REFUTED", "evidence": ["And, just as importantly, antigen-based testing is highly specific: unlike its PCR counterpart, the antigen test isnt fooled by faint signals of lingering viral matter outside the period of infectiousness.", "Fortunately, other attributes of saliva-based antigen testing make this feasible: unlike PCR, it doesnt require trained personnel, specific chemical supplies, or centralized, expensive laboratory instrument; it is less vulnerable to the supply chain bottlenecks that plague PCR-based labs; it returns results in a matter of hours; it costs as little as $1 per test; and it could be as convenient as sucking on a piece of paper.", "Rapid, saliva-based antigen testing is an essential weapon in the fight to resume many of the activities and reopen many of the venues that comprise what we used to call normal life. It is practical, convenient, cost-effective, and easily scaled."]}
{"id": 1000043, "claim": "Saliva-based antigen testing is less than the pcr swab", "label": "REFUTED", "evidence": ["And, just as importantly, antigen-based testing is highly specific: unlike its PCR counterpart, the antigen test isnt fooled by faint signals of lingering viral matter outside the period of infectiousness.", "Fortunately, other attributes of saliva-based antigen testing make this feasible: unlike PCR, it doesnt require trained personnel, specific chemical supplies, or centralized, expensive laboratory instrument; it is less vulnerable to the supply chain bottlenecks that plague PCR-based labs; it returns results in a matter of hours; it costs as little as $1 per test; and it could be as convenient as sucking on a piece of paper.", "Rapid, saliva-based antigen testing is an essential weapon in the fight to resume many of the activities and reopen many of the venues that comprise what we used to call normal life. It is practical, convenient, cost-effective, and easily scaled."]}
{"id": 1000044, "claim": "10 % of stockholmers infected", "label": "SUPPORTED", "evidence": ["That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.", "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."]}
{"id": 1000045, "claim": "10 % of authorers infected", "label": "REFUTED", "evidence": ["That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.", "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."]}
{"id": 1000046, "claim": "10 % of readers infected", "label": "REFUTED", "evidence": ["That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.", "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."]}
{"id": 1000047, "claim": "10 % of allers infected", "label": "REFUTED", "evidence": ["That is a horrible number. With cases having crossed the 30,000 mark, Swedens death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.", "Published May 05, 2020 By the first weeks of April, 10 percent of Stockholms population had been infected with the coronavirus and developed antibodies, according to sampling collected via post from 1,000 of the citys residents."]}
{"id": 1000048, "claim": "Sars-cov-2 d614g variant exhibits enhanced replication ex vivo and earlier transmission in vivo", "label": "SUPPORTED", "evidence": ["Our study demonstrated the SARS-CoV2 D614G substitution enhances infectivity, replication fitness, and early transmission.", "This article has been published \"SARS-CoV-2 D614G Variant Exhibits Efficient Replication ex vivo and Transmission in vivo\" in Science."]}
{"id": 1000049, "claim": "Sars-cov-2 d614g variant inhibited enhanced replication ex vivo and earlier transmission in vivo", "label": "REFUTED", "evidence": ["Our study demonstrated the SARS-CoV2 D614G substitution enhances infectivity, replication fitness, and early transmission.", "This article has been published \"SARS-CoV-2 D614G Variant Exhibits Efficient Replication ex vivo and Transmission in vivo\" in Science."]}
{"id": 1000050, "claim": "Orf8 and orf3b antibodies are accurate serological markers of early and late sars-cov-2 infection", "label": "SUPPORTED", "evidence": ["We identified new targets of the immune response to SARS-CoV-2 and show that nucleocapsid, open reading frame (ORF)8 and ORF3b elicit the strongest specific antibody responses.", "We have identified ORF8 antibodies as a major marker of acute, convalescent and long-term antibody response to SARS-CoV-2 infection because of its immunodominance and specificity, in addition to N protein."]}
{"id": 1000051, "claim": "Orf8 and orf3b antibodies are accurate serological markers of early and acute sars-cov-2 infection", "label": "REFUTED", "evidence": ["We identified new targets of the immune response to SARS-CoV-2 and show that nucleocapsid, open reading frame (ORF)8 and ORF3b elicit the strongest specific antibody responses.", "We have identified ORF8 antibodies as a major marker of acute, convalescent and long-term antibody response to SARS-CoV-2 infection because of its immunodominance and specificity, in addition to N protein."]}
{"id": 1000052, "claim": "Plasma from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay", "label": "SUPPORTED", "evidence": ["Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.", "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.", "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."]}
{"id": 1000053, "claim": "Blood from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay", "label": "REFUTED", "evidence": ["Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.", "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.", "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."]}
{"id": 1000054, "claim": "Rna from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay", "label": "REFUTED", "evidence": ["Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.", "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.", "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."]}
{"id": 1000055, "claim": "Cdna from recovered covid19 subjects inhibits spike protein binding to ace2 in a microsphere-based inhibition assay", "label": "REFUTED", "evidence": ["Next, we find that plasma from all 22/24 subjects with anti-trimer IgGs inhibited ACE2-trimer binding to a greater degree than controls, and that the degree of inhibition correlated with anti-trimer IgG levels.", "This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID19 patients or vaccine recipients in a cell-free assay system.", "Here we present microsphere-based Flow Cytometry assays that quantify both anti-spike IgGs in plasma, and the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2)."]}
{"id": 1000056, "claim": "Dana-farber to test blood cancer drug in covid-19 patients", "label": "SUPPORTED", "evidence": ["Dana-Farber will collaborate with the study sponsor to carry out corollary studies to understand how the immune system functions in COVID-19 patients and how the addition of BTK-inhibitors can stop immune over-activity in response to the virus."]}
{"id": 1000057, "claim": "Dana-farber to test breast cancer drug in covid-19 patients", "label": "REFUTED", "evidence": ["Dana-Farber will collaborate with the study sponsor to carry out corollary studies to understand how the immune system functions in COVID-19 patients and how the addition of BTK-inhibitors can stop immune over-activity in response to the virus."]}
{"id": 1000058, "claim": "Dana-farber to test human cancer drug in covid-19 patients", "label": "REFUTED", "evidence": ["Dana-Farber will collaborate with the study sponsor to carry out corollary studies to understand how the immune system functions in COVID-19 patients and how the addition of BTK-inhibitors can stop immune over-activity in response to the virus."]}
{"id": 1000059, "claim": "Hydroxychloroquine improves airflow and lowers circulating ige levels in subjects with moderate symptomatic asthma", "label": "SUPPORTED", "evidence": ["Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."]}
{"id": 1000060, "claim": "Hydroxychloroquine improves airflow and increases circulating ige levels in subjects with moderate symptomatic asthma", "label": "REFUTED", "evidence": ["Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."]}
{"id": 1000061, "claim": "Hydroxychloroquine decreases airflow and lowers circulating ige levels in subjects with moderate symptomatic asthma", "label": "REFUTED", "evidence": ["Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."]}
{"id": 1000062, "claim": "Hydroxychloroquine improves airflow and increased circulating ige levels in subjects with moderate symptomatic asthma", "label": "REFUTED", "evidence": ["Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma."]}
{"id": 1000063, "claim": "Moderna has completed case accrual for first planned interim analysis of its mrna vaccine against covid-19", "label": "SUPPORTED", "evidence": ["About mRNA-1273 mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.", "The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection."]}
{"id": 1000064, "claim": "Moderna has no case accrual for first planned interim analysis of its mrna vaccine against covid-19", "label": "REFUTED", "evidence": ["About mRNA-1273 mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.", "The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection."]}
{"id": 1000065, "claim": "Moderna has completed case accrual for first planned interim analysis of its dna vaccine against covid-19", "label": "REFUTED", "evidence": ["About mRNA-1273 mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAIDs Vaccine Research Center.", "The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection."]}
{"id": 1000066, "claim": "Amplicon contamination in labs masquerades as covid19 in surveillance tests", "label": "SUPPORTED", "evidence": ["Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."]}
{"id": 1000067, "claim": "Amplicon contamination in human masquerades as covid19 in surveillance tests", "label": "REFUTED", "evidence": ["Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."]}
{"id": 1000068, "claim": "Amplicon contamination in labs masquerades as covid19 in preparation tests", "label": "REFUTED", "evidence": ["Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."]}
{"id": 1000069, "claim": "Amplicon contamination in labs masquerades as covid19 in children tests", "label": "REFUTED", "evidence": ["Minimizing instances of amplicon contamination and developing protocols for handling suspected cases are critical to propel research efforts and to avoid diverting university and healthcare resources from patients with COVID-19."]}
{"id": 1000070, "claim": "Male sex hormones appear to help the coronavirus infiltrate human cells", "label": "SUPPORTED", "evidence": ["Her studies at the UCSF stem cell laboratory found that androgens -- male hormones, including testosterone -- actually help SARS-CoV-2, the specific coronavirus that causes COVID-19, infiltrate human cells."]}
{"id": 1000071, "claim": "Male sex hormones fail to help the coronavirus infiltrate human cells", "label": "REFUTED", "evidence": ["Her studies at the UCSF stem cell laboratory found that androgens -- male hormones, including testosterone -- actually help SARS-CoV-2, the specific coronavirus that causes COVID-19, infiltrate human cells."]}
{"id": 1000072, "claim": "Il-6 : a novel signature associated with covid-19 disease progression and development of anti-sars-cov-2 antibodies", "label": "SUPPORTED", "evidence": ["Findings IL-6 and sMAdCAM expressed as a novel integrative marker (sMIL index) are associated both with disease-states (early infection and convalescence) as well as development of antiviral humoral responses.", "Share sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 Share This Article: Copy Citation Tools sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 "]}
{"id": 1000073, "claim": "Il-6 : a common signature associated with covid-19 disease progression and development of anti-sars-cov-2 antibodies", "label": "REFUTED", "evidence": ["Findings IL-6 and sMAdCAM expressed as a novel integrative marker (sMIL index) are associated both with disease-states (early infection and convalescence) as well as development of antiviral humoral responses.", "Share sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 Share This Article: Copy Citation Tools sMAdCAM:IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies Dhanashree Jagtap, Vikrant M Bhor, Shilpa Bhowmick, Nandini Kasarpalkar, Pooja Sagvekar, Bhalchandra Kulkarni, Manish Pathak, Nirjhar Chatterjee, Pranam Dolas, Harsha Palav, Snehal Kaginkar, Sharad Bhagat, Itti Munshi, Swapneil Parikh, Sachee Agrawal, Chandrakant Pawar, Mala Kaneria, Smita D Mahale, Jayanthi Shastri, Vainav Patel medRxiv 2020.10.13.20182949; doi: https://doi.org/10.1101/2020.10.13.20182949 "]}
{"id": 1000074, "claim": "Slovakia to test all adults for sars-cov-2", "label": "SUPPORTED", "evidence": ["Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."]}
{"id": 1000075, "claim": "He to test all adults for sars-cov-2", "label": "REFUTED", "evidence": ["Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."]}
{"id": 1000076, "claim": "Slovakia to represent all adults for sars-cov-2", "label": "REFUTED", "evidence": ["Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."]}
{"id": 1000077, "claim": "failed to test all adults for sars-cov-2", "label": "REFUTED", "evidence": ["Slovakia has begun a massive operation to test its entire adult population for SARS-CoV-2 in a bid to halt what its government has said is an alarming acceleration of the spread of the virus in the country."]}
{"id": 1000078, "claim": "Extra doses found in pfizer 's coronavirus vaccine.", "label": "SUPPORTED", "evidence": ["Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.", "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.", "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.", "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."]}
{"id": 1000079, "claim": "No doses found in pfizer's coronavirus vaccine.", "label": "REFUTED", "evidence": ["Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.", "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.", "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.", "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."]}
{"id": 1000080, "claim": "One doses found in pfizer's coronavirus vaccine.", "label": "REFUTED", "evidence": ["Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.", "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.", "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.", "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."]}
{"id": 1000081, "claim": "Low doses found in pfizer's coronavirus vaccine.", "label": "REFUTED", "evidence": ["Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply.", "Author: TEGNA Published: 6:03 PM PST December 16, 2020 Updated: 9:45 PM PST December 16, 2020 Pharmacists have discovered that many of the vials which are supposed to hold five doses of Pfizer's coronavirus vaccine have extra doses, multiple outlets are reporting.", "FDA says extra doses from vials of Pfizer's COVID-19 vaccine can be used.", "Reuters ; December 16, 2020. https://www.reuters.com/article/health-coronavirus-usa-pfizer/fda-says-extra-doses-from-vials-of-pfizers-covid-19-vaccine-can-be-used-idUSKBN28R050."]}
{"id": 1000082, "claim": "Bradykinin initiates cytokine-mediated inflammatory hyperalgesia", "label": "SUPPORTED", "evidence": ["These data show that bradykinin can initiate the cascade of cytokine release that mediates hyperalgesic responses to carrageenin and endotoxin (1 microgram).", "Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia."]}
{"id": 1000083, "claim": "Bradykinin initiates cytokine-independent inflammatory hyperalgesia", "label": "REFUTED", "evidence": ["These data show that bradykinin can initiate the cascade of cytokine release that mediates hyperalgesic responses to carrageenin and endotoxin (1 microgram).", "Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia."]}
{"id": 1000084, "claim": "Bradykinin cans cytokine-mediated inflammatory hyperalgesia", "label": "REFUTED", "evidence": ["These data show that bradykinin can initiate the cascade of cytokine release that mediates hyperalgesic responses to carrageenin and endotoxin (1 microgram).", "Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia."]}
{"id": 1000085, "claim": "Potently neutralizing human antibodies that block sars-cov-2 receptor binding and protect animals", "label": "SUPPORTED", "evidence": ["From a panel of monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein isolated from the B cells of infected subjects, we identified several mAbs that exhibited potent neutralizing activity with IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type ( wt ) SARS-CoV-2 neutralization tests, respectively."]}
{"id": 1000086, "claim": "Potently neutralizing mouse antibodies that block sars-cov-2 receptor binding and protect animals", "label": "REFUTED", "evidence": ["From a panel of monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein isolated from the B cells of infected subjects, we identified several mAbs that exhibited potent neutralizing activity with IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type ( wt ) SARS-CoV-2 neutralization tests, respectively."]}
{"id": 1000087, "claim": "Potently neutralizing human antibodies that block sars-cov-2 receptor binding and neutralization animals", "label": "REFUTED", "evidence": ["From a panel of monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein isolated from the B cells of infected subjects, we identified several mAbs that exhibited potent neutralizing activity with IC50 values as low as 0.9 or 15 ng/mL in pseudovirus or wild-type ( wt ) SARS-CoV-2 neutralization tests, respectively."]}
{"id": 1000088, "claim": "Persistence of viral rna , pneumocyte syncytia and thrombosis are hallmarks of advanced covid-19 pathology", "label": "SUPPORTED", "evidence": ["Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.", "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up."]}
{"id": 1000089, "claim": "Persistence of viral dna, pneumocyte syncytia and thrombosis are hallmarks of advanced covid-19 pathology", "label": "REFUTED", "evidence": ["Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.", "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up."]}
{"id": 1000090, "claim": "Persistence of viral replication, pneumocyte syncytia and thrombosis are hallmarks of advanced covid-19 pathology", "label": "REFUTED", "evidence": ["Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.", "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up."]}
{"id": 1000091, "claim": "The novel severe acute respiratory syndrome coronavirus 2 directly decimates human spleens and lymph nodes", "label": "SUPPORTED", "evidence": ["The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes", "SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions.", "The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes."]}
{"id": 1000092, "claim": "The primary severe acute respiratory syndrome coronavirus 2 directly decimates human spleens and lymph nodes", "label": "REFUTED", "evidence": ["The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes", "SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions.", "The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes."]}
{"id": 1000093, "claim": "The first severe acute respiratory syndrome coronavirus 2 directly decimates human spleens and lymph nodes", "label": "REFUTED", "evidence": ["The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes", "SARS-CoV-2 infection induces severe tissue damage including lymph follicle depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions.", "The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes."]}
{"id": 1000094, "claim": "Researchers discover new variant of covid-19 virus in columbus , ohio.", "label": "SUPPORTED", "evidence": ["The Ohio State Wexner Medical Center has been sequencing the genome of SARS- Cov-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus.", "Doctors at Ohio State talked about the COVID-19 vaccine and the new variant of the coronavirus in the briefing below.", "Scientists at The Ohio State University Wexner Medical Center and College of Medicine have discovered a new strain of COVID-19.", "> OSU COVID variant > > Researchers at Ohio State discuss COVID-19 vaccinations and a new variant of > the virus discovered in Columbus.", "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- CoV-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus."]}
{"id": 1000095, "claim": "Researchers no new variant of covid-19 virus in columbus, ohio.", "label": "REFUTED", "evidence": ["The Ohio State Wexner Medical Center has been sequencing the genome of SARS- Cov-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus.", "Doctors at Ohio State talked about the COVID-19 vaccine and the new variant of the coronavirus in the briefing below.", "Scientists at The Ohio State University Wexner Medical Center and College of Medicine have discovered a new strain of COVID-19.", "> OSU COVID variant > > Researchers at Ohio State discuss COVID-19 vaccinations and a new variant of > the virus discovered in Columbus.", "The Ohio State Wexner Medical Center has been sequencing the genome of SARS- CoV-2 viruses in patients with COVID-19 since March 2020 in order to monitor the evolution of the virus."]}
{"id": 1000096, "claim": "Coronavirus vaccine shows promising early results in china", "label": "SUPPORTED", "evidence": ["Lab research at CanSino Biologics in Tianjin, China, in 2018.Credit...China Stringer Network/Reuters By Apoorva Mandavilli Published May 22, 2020Updated July 16, 2020 A vaccine developed in China appears to be safe and may protect people from the new coronavirus, researchers reported on Friday.", "A vaccine for the new coronavirus is considered to be the best long-term solution for allowing countries to reopen their economies and return to normalcy.", "That vaccine has now entered mid-stage human trials, the manufacturer, Sinovac Biotech Ltd., said on Friday."]}
{"id": 1000097, "claim": "Coronavirus vaccine shows no early results in china", "label": "REFUTED", "evidence": ["Lab research at CanSino Biologics in Tianjin, China, in 2018.Credit...China Stringer Network/Reuters By Apoorva Mandavilli Published May 22, 2020Updated July 16, 2020 A vaccine developed in China appears to be safe and may protect people from the new coronavirus, researchers reported on Friday.", "A vaccine for the new coronavirus is considered to be the best long-term solution for allowing countries to reopen their economies and return to normalcy.", "That vaccine has now entered mid-stage human trials, the manufacturer, Sinovac Biotech Ltd., said on Friday."]}
{"id": 1000098, "claim": "Sars-cov-2 triggers inflammatory responses and cell death through caspase-8 activation", "label": "SUPPORTED", "evidence": ["4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.", "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1β processing.", "2 SARS-CoV-2 infection induces caspase-8 activation Fig.", "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.", "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."]}
{"id": 1000099, "claim": "Sars-cov-2 suppress inflammatory responses and cell death through caspase-8 activation", "label": "REFUTED", "evidence": ["4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.", "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1β processing.", "2 SARS-CoV-2 infection induces caspase-8 activation Fig.", "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.", "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."]}
{"id": 1000100, "claim": "Sars-cov-2 inhibits inflammatory responses and cell death through caspase-8 activation", "label": "REFUTED", "evidence": ["4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.", "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1β processing.", "2 SARS-CoV-2 infection induces caspase-8 activation Fig.", "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.", "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."]}
{"id": 1000101, "claim": "Sars-cov-2 inhibited inflammatory responses and cell death through caspase-8 activation", "label": "REFUTED", "evidence": ["4 SARS-CoV-2 infection triggers apoptosis through caspase-8 activation.", "2 SARS-CoV-2 infection induces caspase-8 activation to mediate pro-IL-1β processing.", "2 SARS-CoV-2 infection induces caspase-8 activation Fig.", "SARS-CoV-2 infection induces the cell death through the activation of caspase-8.", "Here we report that SARS-CoV-2 infection activates caspase-8 to trigger cell apoptosis and inflammatory cytokine processing in the lung epithelial cells."]}
{"id": 1000102, "claim": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks.", "label": "SUPPORTED", "evidence": ["Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.", "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."]}
{"id": 1000103, "claim": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 years.", "label": "REFUTED", "evidence": ["Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.", "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."]}
{"id": 1000104, "claim": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 days.", "label": "REFUTED", "evidence": ["Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.", "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."]}
{"id": 1000105, "claim": "Sars-cov-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 hours.", "label": "REFUTED", "evidence": ["Results Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test.", "Results: Among 43,044 anti-SARS-CoV-2 positive persons who were followed for a median of 16.3 weeks (range: 0-34.6), 314 individuals (0.7%) had at least one PCR positive swab 14 days after the first-positive antibody test."]}
{"id": 1000106, "claim": "Anakinra to prevent respiratory failure in covid-19", "label": "SUPPORTED", "evidence": ["Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.", "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.", "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."]}
{"id": 1000107, "claim": "Anakinra to prevent neurological failure in covid-19", "label": "REFUTED", "evidence": ["Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.", "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.", "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."]}
{"id": 1000108, "claim": "Anakinra to cause respiratory failure in covid-19", "label": "REFUTED", "evidence": ["Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.", "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.", "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."]}
{"id": 1000109, "claim": "Anakinra to causes respiratory failure in covid-19", "label": "REFUTED", "evidence": ["Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.", "We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.", "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score."]}
{"id": 1000110, "claim": "Hadassah doctors crack the cause of fatal corona blood clots", "label": "SUPPORTED", "evidence": ["Hadassah researchers discovered that the patients who form these fatal clots have an increased level of alpha defensin protein in their blood, explained Dr. Abd Alrauf Higavi, who directs a lab at Hadassah and has been studying blood clots for 30 years.", "The results show that alpha defensin speeds up blood clot formation, which can cause pulmonary embolism, heart attacks and stroke."]}
{"id": 1000111, "claim": "Hadassah virus crack the cause of fatal corona blood clots", "label": "REFUTED", "evidence": ["Hadassah researchers discovered that the patients who form these fatal clots have an increased level of alpha defensin protein in their blood, explained Dr. Abd Alrauf Higavi, who directs a lab at Hadassah and has been studying blood clots for 30 years.", "The results show that alpha defensin speeds up blood clot formation, which can cause pulmonary embolism, heart attacks and stroke."]}
{"id": 1000112, "claim": "Hadassah doctors remain the cause of fatal corona blood clots", "label": "REFUTED", "evidence": ["Hadassah researchers discovered that the patients who form these fatal clots have an increased level of alpha defensin protein in their blood, explained Dr. Abd Alrauf Higavi, who directs a lab at Hadassah and has been studying blood clots for 30 years.", "The results show that alpha defensin speeds up blood clot formation, which can cause pulmonary embolism, heart attacks and stroke."]}
{"id": 1000113, "claim": "Virus can infect heart cells in lab dish", "label": "SUPPORTED", "evidence": ["The study also demonstrated that human stem cell-derived heart cells infected by SARS-CoV-2 change their gene expression profile, further confirming that the cells can be actively infected by the virus and activate innate cellular \"defense mechanisms\" in an effort to help clear out the virus.", "A new study shows that SARS-CoV-2, the virus that causes COVID-19 (coronavirus), can infect heart cells in a lab dish, indicating it may be possible for heart cells in COVID-19 patients to be directly infected by the virus."]}
{"id": 1000114, "claim": "Virus cannot infect heart cells in lab dish", "label": "REFUTED", "evidence": ["The study also demonstrated that human stem cell-derived heart cells infected by SARS-CoV-2 change their gene expression profile, further confirming that the cells can be actively infected by the virus and activate innate cellular \"defense mechanisms\" in an effort to help clear out the virus.", "A new study shows that SARS-CoV-2, the virus that causes COVID-19 (coronavirus), can infect heart cells in a lab dish, indicating it may be possible for heart cells in COVID-19 patients to be directly infected by the virus."]}
{"id": 1000115, "claim": "Alpha-1 antitrypsin inhibits sars-cov-2 infection", "label": "SUPPORTED", "evidence": ["Our findings show that endogenous α1-AT restricts SARS-CoV-2 and repurposes α1-AT-based drugs for COVID-19 therapy.", "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified α1-antitrypsin (α1-AT) as specific inhibitor of SARS-CoV-2.", "α1-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."]}
{"id": 1000116, "claim": "Cox-1 antitrypsin inhibits sars-cov-2 infection", "label": "REFUTED", "evidence": ["Our findings show that endogenous α1-AT restricts SARS-CoV-2 and repurposes α1-AT-based drugs for COVID-19 therapy.", "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified α1-antitrypsin (α1-AT) as specific inhibitor of SARS-CoV-2.", "α1-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."]}
{"id": 1000117, "claim": "Mcp-1 antitrypsin inhibits sars-cov-2 infection", "label": "REFUTED", "evidence": ["Our findings show that endogenous α1-AT restricts SARS-CoV-2 and repurposes α1-AT-based drugs for COVID-19 therapy.", "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified α1-antitrypsin (α1-AT) as specific inhibitor of SARS-CoV-2.", "α1-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."]}
{"id": 1000118, "claim": "Il-1 antitrypsin inhibits sars-cov-2 infection", "label": "REFUTED", "evidence": ["Our findings show that endogenous α1-AT restricts SARS-CoV-2 and repurposes α1-AT-based drugs for COVID-19 therapy.", "To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified α1-antitrypsin (α1-AT) as specific inhibitor of SARS-CoV-2.", "α1-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations."]}
{"id": 1000119, "claim": "New study suggests children may carry covid-19 at high levels", "label": "SUPPORTED", "evidence": ["\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.", "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."]}
{"id": 1000120, "claim": "New study suggests cats may carry covid-19 at high levels", "label": "REFUTED", "evidence": ["\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.", "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."]}
{"id": 1000121, "claim": "New study suggests bats may carry covid-19 at high levels", "label": "REFUTED", "evidence": ["\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.", "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."]}
{"id": 1000122, "claim": "New study suggests coronaviruses may carry covid-19 at high levels", "label": "REFUTED", "evidence": ["\"Young children can potentially be important drivers of SARS-CoV-2 spread in the general population,\" the authors wrote.", "A much larger South Korean study recently found that children younger than 10 transmit to others much less often than adults do, while those between the ages of 10 and 19 can spread the virus at least as well as adults do."]}
{"id": 1000123, "claim": "In the coronavirus pandemic , we 're making decisions without reliable data", "label": "SUPPORTED", "evidence": ["In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.", "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."]}
{"id": 1000124, "claim": "In the coronavirus pandemic, we're making decisions with reliable data", "label": "REFUTED", "evidence": ["In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.", "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."]}
{"id": 1000125, "claim": "In the coronavirus pandemic, we're making decisions and reliable data", "label": "REFUTED", "evidence": ["In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.", "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."]}
{"id": 1000126, "claim": "In the coronavirus pandemic, we're making decisions in reliable data", "label": "REFUTED", "evidence": ["In the absence of data on the real course of the epidemic, we dont know whether this perspective was brilliant or catastrophic.", "As the coronavirus pandemic takes hold, we are making decisions without reliable data By John P.A."]}
{"id": 1000127, "claim": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly decreased mortality", "label": "SUPPORTED", "evidence": ["In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.", "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).", "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.", "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."]}
{"id": 1000128, "claim": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly increased mortality", "label": "REFUTED", "evidence": ["In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.", "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).", "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.", "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."]}
{"id": 1000129, "claim": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly increase mortality", "label": "REFUTED", "evidence": ["In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.", "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).", "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.", "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."]}
{"id": 1000130, "claim": "Early transfusion of a large cohort of covid-19 patients with high titer anti-sars-cov-2 spike protein igg convalescent plasma confirms a signal of significantly higher mortality", "label": "REFUTED", "evidence": ["In the aggregate, the analysis confirms and extends our previous preliminary finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein RBD IgG present in convalescent plasma significantly reduces mortality.", "Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 disease has emerged as a promising therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA).", "With respect to altering mortality, our analysis identified an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer convalescent plasma.", "We recently reported results from interim analysis of a propensity-score matched study suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality."]}
{"id": 1000131, "claim": "Egyptian doctors are speaking out against health authorities over increasing coronavirus infections and deaths among medical staff across the country .", "label": "SUPPORTED", "evidence": ["Another Egyptian doctor told Amnesty International that doctors who speak out are subjected to threats, interrogations by the National Security Agency (NSA), administrative questioning, and penalties.", "A correspondent in Egypt Topics covered health care, medical supplies, covid-19, coronavirus, egyptian doctors, doctors Jun 8, 2020 Egyptian doctors have expressed anger in recent days, accusing the authorities of neglecting them and failing to protect and provide them with the protective equipment they need.", "Egypts arrests of medical professionals who criticized its Covid-19 policies warrant unambiguous opposition from the World Bank, in line with its commitment not to tolerate reprisals, said Amr Magdi, Middle East and North Africa researcher at Human Rights Watch."]}
{"id": 1000132, "claim": "Egyptian doctors are ruled out against health authorities over increasing coronavirus infections and deaths among medical staff across the country.", "label": "REFUTED", "evidence": ["Another Egyptian doctor told Amnesty International that doctors who speak out are subjected to threats, interrogations by the National Security Agency (NSA), administrative questioning, and penalties.", "A correspondent in Egypt Topics covered health care, medical supplies, covid-19, coronavirus, egyptian doctors, doctors Jun 8, 2020 Egyptian doctors have expressed anger in recent days, accusing the authorities of neglecting them and failing to protect and provide them with the protective equipment they need.", "Egypts arrests of medical professionals who criticized its Covid-19 policies warrant unambiguous opposition from the World Bank, in line with its commitment not to tolerate reprisals, said Amr Magdi, Middle East and North Africa researcher at Human Rights Watch."]}
{"id": 1000133, "claim": "High sars-cov-2 viral load is associated with a worse clinical outcome of covid-19 disease", "label": "SUPPORTED", "evidence": ["Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).", "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.", "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."]}
{"id": 1000134, "claim": "High sars-cov-2 viral load is associated with a greater clinical outcome of covid-19 disease", "label": "REFUTED", "evidence": ["Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).", "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.", "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."]}
{"id": 1000135, "claim": "High sars-cov-2 viral load is associated with a better clinical outcome of covid-19 disease", "label": "REFUTED", "evidence": ["Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).", "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.", "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."]}
{"id": 1000136, "claim": "High sars-cov-2 viral load is associated with a higher clinical outcome of covid-19 disease", "label": "REFUTED", "evidence": ["Here we report a statistically significant correlation between viral load and disease severity, being high viral load associated with worse clinical prognosis, independently of several previously identified risk factors such as age, sex, hypertension, cardiovascular disease, diabetes, obesity, and lung disease (asthma and chronic obstructive pulmonary disease).", "The data presented here reinforce the viral load as a potential biomarker for predicting disease severity in SARS-CoV-2-infected patients.", "It is also an important parameter in viral evolution since it relates to the numbers and types of variant genomes present in a viral population, a potential determinant of disease progression."]}
{"id": 1000137, "claim": "In silico mutagenesis of human ace2 with s protein and translational efficiency explain sars-cov-2 infectivity in different species", "label": "SUPPORTED", "evidence": ["Genomic variability across species, including humans, results in ACE2 variants that destabilize its fold, modify ACE2/SARS- CoV-2 recognition, or both.", "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.", "Two significant factors conditioning infection are ACE2-mediated SARS-CoV-2 cellular entry and viral proteome translation efficiency.", "We observed that humans are the species in which SARS- CoV-2 is both most efficiently translated as well as optimally interacting with ACE2.", "SARS-CoV-2 translational efficiency and ACE2 expression across species."]}
{"id": 1000138, "claim": "In silico mutagenesis of bat ace2 with s protein and translational efficiency explain sars-cov-2 infectivity in different species", "label": "REFUTED", "evidence": ["Genomic variability across species, including humans, results in ACE2 variants that destabilize its fold, modify ACE2/SARS- CoV-2 recognition, or both.", "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.", "Two significant factors conditioning infection are ACE2-mediated SARS-CoV-2 cellular entry and viral proteome translation efficiency.", "We observed that humans are the species in which SARS- CoV-2 is both most efficiently translated as well as optimally interacting with ACE2.", "SARS-CoV-2 translational efficiency and ACE2 expression across species."]}
{"id": 1000139, "claim": "In silico mutagenesis of human ace2 with s protein and translational efficiency inhibited sars-cov-2 infectivity in different species", "label": "REFUTED", "evidence": ["Genomic variability across species, including humans, results in ACE2 variants that destabilize its fold, modify ACE2/SARS- CoV-2 recognition, or both.", "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.", "Two significant factors conditioning infection are ACE2-mediated SARS-CoV-2 cellular entry and viral proteome translation efficiency.", "We observed that humans are the species in which SARS- CoV-2 is both most efficiently translated as well as optimally interacting with ACE2.", "SARS-CoV-2 translational efficiency and ACE2 expression across species."]}
{"id": 1000140, "claim": "Plasmin cascade mediates thrombolytic events in sars-cov-2 infection via complement and platelet-activating systems", "label": "SUPPORTED", "evidence": ["Our results indicate that plasmin is a crucial mediator which primes interactions between complement and platelet-activating systems in lung epithelia upon SARS-CoV-2 infection, with a potential for therapeutic intervention."]}
{"id": 1000141, "claim": "Plasmin cascade mediates thrombolytic events in sars-cov-2 production via complement and platelet-activating systems", "label": "REFUTED", "evidence": ["Our results indicate that plasmin is a crucial mediator which primes interactions between complement and platelet-activating systems in lung epithelia upon SARS-CoV-2 infection, with a potential for therapeutic intervention."]}
{"id": 1000142, "claim": "Private firm running uk ppe stockpile was sold in middle of pandemic .", "label": "SUPPORTED", "evidence": ["Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.", "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."]}
{"id": 1000143, "claim": "Private firm running uk ppe stockpile was established in middle of pandemic.", "label": "REFUTED", "evidence": ["Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.", "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."]}
{"id": 1000144, "claim": "No firm running uk ppe stockpile was sold in middle of pandemic.", "label": "REFUTED", "evidence": ["Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.", "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."]}
{"id": 1000145, "claim": "Private firm running uk ppe stockpile was developed in middle of pandemic.", "label": "REFUTED", "evidence": ["Meanwhile, management of the stock has been passed from a Germanowned multinational to an American one.", "The distribution of that stockpiles PPE, it seems, may no longer solely be the responsibility of Movianto."]}
{"id": 1000146, "claim": "A systematic review uncovers a wide-gap between covid-19 in humans and animal models", "label": "SUPPORTED", "evidence": ["No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.", "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."]}
{"id": 1000147, "claim": "A systematic review focuseds a wide-gap between covid-19 in humans and animal models", "label": "REFUTED", "evidence": ["No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.", "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."]}
{"id": 1000148, "claim": "A systematic review focusess a wide-gap between covid-19 in humans and animal models", "label": "REFUTED", "evidence": ["No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.", "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."]}
{"id": 1000149, "claim": "A systematic review focuss a wide-gap between covid-19 in humans and animal models", "label": "REFUTED", "evidence": ["No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models.", "We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs."]}
{"id": 1000150, "claim": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the heart.", "label": "SUPPORTED", "evidence": ["In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.", "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.", "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.", "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."]}
{"id": 1000151, "claim": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the lung.", "label": "REFUTED", "evidence": ["In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.", "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.", "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.", "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."]}
{"id": 1000152, "claim": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the lungs.", "label": "REFUTED", "evidence": ["In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.", "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.", "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.", "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."]}
{"id": 1000153, "claim": "Cardiac sars-cov-2 infection is associated with distinct transcriptomic changes within the liver.", "label": "REFUTED", "evidence": ["In this autopsy series, cardiac replication of SARS-CoV-2 was associated with early death.", "Understanding both direct and indirect damage caused to the heart and the vascular system by SARS-CoV-2 infection is necessary to identify optimal clinical care strategies.", "Accordingly, there are several studies reporting a direct effect on heart function of coronaviruses with a pathogenicity similar to that of SARS-CoV-2.", "Indeed, upon SARS-CoV-2 infection, cardiac insufficiency is more likely to occur in these patients where cardiac function is already compromised by myocardial ischemia [4,5,6, 83, 84]."]}
{"id": 1000154, "claim": "'in a few weeks , we will have coronavirus vaccine '", "label": "SUPPORTED", "evidence": ["The vaccine could \"achieve safety approval in 90 days,\" he said.", "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.", "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"", "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."]}
{"id": 1000155, "claim": "'in a few years, we will have coronavirus vaccine '", "label": "REFUTED", "evidence": ["The vaccine could \"achieve safety approval in 90 days,\" he said.", "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.", "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"", "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."]}
{"id": 1000156, "claim": "'in a few hours, we will have coronavirus vaccine '", "label": "REFUTED", "evidence": ["The vaccine could \"achieve safety approval in 90 days,\" he said.", "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.", "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"", "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."]}
{"id": 1000157, "claim": "'in a few decades, we will have coronavirus vaccine '", "label": "REFUTED", "evidence": ["The vaccine could \"achieve safety approval in 90 days,\" he said.", "\"Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,\" MIGAL CEO David Zigdon said.", "Yes, in a few weeks, if it all works, we would have a vaccine to prevent coronavirus.\"", "\"We are in the middle of this process, and hopefully in a few weeks we will have the vaccine in our hands."]}
{"id": 1000158, "claim": "Indiana bans all non-essential gatherings over 250 people", "label": "SUPPORTED", "evidence": ["Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.", "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.", "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.", "Non-essential gatherings must be limited to no more than 250 people."]}
{"id": 1000159, "claim": "Indiana bans all non-essential gatherings over 15 people", "label": "REFUTED", "evidence": ["Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.", "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.", "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.", "Non-essential gatherings must be limited to no more than 250 people."]}
{"id": 1000160, "claim": "Indiana bans all non-essential gatherings over 10 people", "label": "REFUTED", "evidence": ["Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.", "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.", "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.", "Non-essential gatherings must be limited to no more than 250 people."]}
{"id": 1000161, "claim": "Indiana bans all non-essential gatherings over 20 people", "label": "REFUTED", "evidence": ["Eric Holcomb has announced additional steps the state will take to reduce the spread of novel coronavirus, or COVID-19 in Indiana, including limiting non-essential gatherings to no more than 250 people.", "Starting immediately - all non-essential gatherings are limited to fewer than 250 people.", "The state of Indiana has banned non-essential gatherings of more than 250 people, Gov.", "Non-essential gatherings must be limited to no more than 250 people."]}
{"id": 1000162, "claim": "Evaluation of four commercial , fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay", "label": "SUPPORTED", "evidence": ["Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.", "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.", "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.", "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."]}
{"id": 1000163, "claim": "Evaluation of two commercial, fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay", "label": "REFUTED", "evidence": ["Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.", "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.", "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.", "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."]}
{"id": 1000164, "claim": "Evaluation of each commercial, fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay", "label": "REFUTED", "evidence": ["Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.", "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.", "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.", "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."]}
{"id": 1000165, "claim": "Evaluation of both commercial, fully automated sars-cov-2 antibody tests suggests a revision of the siemens sars-cov-2 igg assay", "label": "REFUTED", "evidence": ["Conclusions Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories.", "The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the companys newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies.", "ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay.", "Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results."]}
{"id": 1000166, "claim": "Global covid-19 cases surpass 75 million.", "label": "SUPPORTED", "evidence": ["Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"]}
{"id": 1000167, "claim": "Global covid-19 cases surpass 75 days.", "label": "REFUTED", "evidence": ["Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"]}
{"id": 1000168, "claim": "Global covid-19 cases surpass 75 persons.", "label": "REFUTED", "evidence": ["Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"]}
{"id": 1000169, "claim": "Global covid-19 cases surpass 75 deaths.", "label": "REFUTED", "evidence": ["Global Covid-19 Cases Top 75 Million, Deaths Surpass 1.7 Million - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC : Digital Object Identifier : International Standard Serial Number : Medicines and Healthcare products Regulatory Agency : National Institute for Biological Standards and Control : Clinical Practice Research Datalink : Commission on Human Medicines [Today at 9:21 AM]: Saturday, January 23, 2021 at 9:21 AM [ Yesterday at 9:15 AM]: Friday, January 22, 2021 at 9:15 AM [January 21 at 10:54 AM]: Thursday, January 21, 2021 at 10:54 AM"]}
{"id": 1000170, "claim": "A false post on social media claims covid-19 vaccine causes infertility in women.", "label": "SUPPORTED", "evidence": ["KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.", "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.", "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.", "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."]}
{"id": 1000171, "claim": "A false post on social media claims covid-19 vaccine causes infertility in dogs.", "label": "REFUTED", "evidence": ["KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.", "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.", "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.", "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."]}
{"id": 1000172, "claim": "A false post on social media claims covid-19 vaccine causes infertility in children.", "label": "REFUTED", "evidence": ["KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.", "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.", "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.", "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."]}
{"id": 1000173, "claim": "A false post on social media claims covid-19 vaccine causes infertility in adults.", "label": "REFUTED", "evidence": ["KSAT is labeling the claim that the COVID-19 vaccines cause infertility and sterilization as NOT TRUE.", "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a very short amino acid sequence in the spike protein of SARS-CoV-2 virus that is shared with the placental protein, syncytin-1.", "\"It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein,\" she said in an email to the Associated Press.", "It has been incorrectly suggested that COVID-19 vaccines will cause infertility because of a shared amino acid sequence in the spike protein of SARS-CoV-2 and a placental protein, she said in an email."]}
{"id": 1000174, "claim": "Expert reaction to people being re-tested positive for coronavirus after initial recovery", "label": "SUPPORTED", "evidence": ["Clearly we need more information about these patients, such as were there underlying medical conditions or a change in circumstances that might have allowed the virus to escape immune control?", "However, the report reinforces the fact that we have to investigate all such findings really thoroughly and report such information if we are to make the best decisions based on sound scientific evidence.", "She has a prolonged excretion of virus from her initial infection and tests were either not done or were not done sufficiently well or enough to confirm clearance.", "Although coronaviruses generally cause short- term self-limiting infections which are cleared, there is some evidence in the scientific literature for persistent infections of animal coronaviruses (mainly in bats).", "This highlights the need for more research into the biology of the new coronavirus, it is very much early days in our efforts to understand it. On case in Japan: Prof Paul Hunter, Professor in Medicine, University of East Anglia (UEA), said: Regarding this reported case: There is so much we do not know about this case to give a properly informed opinion."]}
{"id": 1000175, "claim": "Expert reaction to people being re-tested positive for coronavirus before initial recovery", "label": "REFUTED", "evidence": ["Clearly we need more information about these patients, such as were there underlying medical conditions or a change in circumstances that might have allowed the virus to escape immune control?", "However, the report reinforces the fact that we have to investigate all such findings really thoroughly and report such information if we are to make the best decisions based on sound scientific evidence.", "She has a prolonged excretion of virus from her initial infection and tests were either not done or were not done sufficiently well or enough to confirm clearance.", "Although coronaviruses generally cause short- term self-limiting infections which are cleared, there is some evidence in the scientific literature for persistent infections of animal coronaviruses (mainly in bats).", "This highlights the need for more research into the biology of the new coronavirus, it is very much early days in our efforts to understand it. On case in Japan: Prof Paul Hunter, Professor in Medicine, University of East Anglia (UEA), said: Regarding this reported case: There is so much we do not know about this case to give a properly informed opinion."]}
{"id": 1000176, "claim": "Il-6 inhibition could be key to covid-19", "label": "SUPPORTED", "evidence": ["If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients.", "Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19."]}
{"id": 1000177, "claim": "Il-6 inhibition could be resistant to covid-19", "label": "REFUTED", "evidence": ["If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients.", "Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19."]}
{"id": 1000178, "claim": "Il-6 overexpression could be key to covid-19", "label": "REFUTED", "evidence": ["If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients.", "Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19."]}
{"id": 1000179, "claim": "Il-6 expression could be key to covid-19", "label": "REFUTED", "evidence": ["If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients.", "Tocilizumab is an IL-6 receptor (IL-6R) blocker that can effectively block the IL-6 signal transduction pathway and thus is likely to become an effective drug for patients with severe COVID-19."]}
{"id": 1000180, "claim": "Pompeo saying that chinese labs created covid-19 .", "label": "SUPPORTED", "evidence": ["ANDREW HARNIK/POOL/AFP via Getty Images Secretary of State Mike Pompeo on Sunday said there was \"enormous evidence\" that COVID-19 originated in a Chinese lab.", "Secretary of State Mike Pompeo on Sunday claimed there was \"enormous evidence\" that COVID-19, the disease caused by the novel coronavirus, originated in a laboratory in Wuhan, China, though there has been so far no public evidence to support such a theory."]}
{"id": 1000181, "claim": "Pompeo saying that our labs created covid-19.", "label": "REFUTED", "evidence": ["ANDREW HARNIK/POOL/AFP via Getty Images Secretary of State Mike Pompeo on Sunday said there was \"enormous evidence\" that COVID-19 originated in a Chinese lab.", "Secretary of State Mike Pompeo on Sunday claimed there was \"enormous evidence\" that COVID-19, the disease caused by the novel coronavirus, originated in a laboratory in Wuhan, China, though there has been so far no public evidence to support such a theory."]}
{"id": 1000182, "claim": "Interferons and viruses induce a novel truncated ace2 isoform and not the full-length sars-cov-2 receptor", "label": "SUPPORTED", "evidence": ["We then showed that dACE2 , but not ACE2 , is induced in various human cell types by IFNs and viruses; this information is important to consider for future therapeutic strategies and understanding COVID-19 susceptibility and outcomes.", "Our discovery of dACE2 , a truncated version of ACE2 , demonstrates that it is dACE2 and not ACE2 that is induced by IFNs and viruses, including SARS-CoV-2."]}
{"id": 1000183, "claim": "Interferons and viruses induce a novel truncated ace2 isoform and produce the full-length sars-cov-2 receptor", "label": "REFUTED", "evidence": ["We then showed that dACE2 , but not ACE2 , is induced in various human cell types by IFNs and viruses; this information is important to consider for future therapeutic strategies and understanding COVID-19 susceptibility and outcomes.", "Our discovery of dACE2 , a truncated version of ACE2 , demonstrates that it is dACE2 and not ACE2 that is induced by IFNs and viruses, including SARS-CoV-2."]}
{"id": 1000184, "claim": "Interferons and viruses induce a novel truncated ace2 isoform and induce the full-length sars-cov-2 receptor", "label": "REFUTED", "evidence": ["We then showed that dACE2 , but not ACE2 , is induced in various human cell types by IFNs and viruses; this information is important to consider for future therapeutic strategies and understanding COVID-19 susceptibility and outcomes.", "Our discovery of dACE2 , a truncated version of ACE2 , demonstrates that it is dACE2 and not ACE2 that is induced by IFNs and viruses, including SARS-CoV-2."]}
{"id": 1000185, "claim": "Interferons and viruses induce a novel truncated ace2 isoform and form the full-length sars-cov-2 receptor", "label": "REFUTED", "evidence": ["We then showed that dACE2 , but not ACE2 , is induced in various human cell types by IFNs and viruses; this information is important to consider for future therapeutic strategies and understanding COVID-19 susceptibility and outcomes.", "Our discovery of dACE2 , a truncated version of ACE2 , demonstrates that it is dACE2 and not ACE2 that is induced by IFNs and viruses, including SARS-CoV-2."]}
{"id": 1000186, "claim": "Neutralizing antibodies correlate with protection from sars-cov-2 in humans during a fishery vessel outbreak with high attack rate", "label": "SUPPORTED", "evidence": ["This article has been published \"Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate\" in J Clin Microbiol."]}
{"id": 1000187, "claim": "Neutralizing antibodies correlate with protection from sars-cov-2 in pigs during a fishery vessel outbreak with high attack rate", "label": "REFUTED", "evidence": ["This article has been published \"Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate\" in J Clin Microbiol."]}
{"id": 1000188, "claim": "Neutralizing antibodies correlate with protection from sars-cov-2 in mice during a fishery vessel outbreak with high attack rate", "label": "REFUTED", "evidence": ["This article has been published \"Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate\" in J Clin Microbiol."]}
{"id": 1000189, "claim": "Neutralizing antibodies correlate with protection from sars-cov-2 in animals during a fishery vessel outbreak with high attack rate", "label": "REFUTED", "evidence": ["This article has been published \"Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate\" in J Clin Microbiol."]}
{"id": 1000190, "claim": "Covid-19 infections leave an impact on the heart", "label": "SUPPORTED", "evidence": ["If this high rate of risk is confirmed,  then the crisis of COVID-19 will not abate but will instead shift to a new de novo incidence of heart failure and other chronic cardiovascular complications, they wrote.", "These are two studies that both suggest that being infected with Covid-19 carries a high likelihood of having some involvement of the heart.", "The connection between Covid-19 and blood clots emerged later, after doctors began connecting the pulmonary aneurysms, strokes, and heart attacks they were seeing to the virus."]}
{"id": 1000191, "claim": "Covid-19 infections leave an impact on the pandemic", "label": "REFUTED", "evidence": ["If this high rate of risk is confirmed,  then the crisis of COVID-19 will not abate but will instead shift to a new de novo incidence of heart failure and other chronic cardiovascular complications, they wrote.", "These are two studies that both suggest that being infected with Covid-19 carries a high likelihood of having some involvement of the heart.", "The connection between Covid-19 and blood clots emerged later, after doctors began connecting the pulmonary aneurysms, strokes, and heart attacks they were seeing to the virus."]}
{"id": 1000192, "claim": "Covid-19 infections leave an impact on the epidemic", "label": "REFUTED", "evidence": ["If this high rate of risk is confirmed,  then the crisis of COVID-19 will not abate but will instead shift to a new de novo incidence of heart failure and other chronic cardiovascular complications, they wrote.", "These are two studies that both suggest that being infected with Covid-19 carries a high likelihood of having some involvement of the heart.", "The connection between Covid-19 and blood clots emerged later, after doctors began connecting the pulmonary aneurysms, strokes, and heart attacks they were seeing to the virus."]}
{"id": 1000193, "claim": "Covid-19 infections leave an impact on the future", "label": "REFUTED", "evidence": ["If this high rate of risk is confirmed,  then the crisis of COVID-19 will not abate but will instead shift to a new de novo incidence of heart failure and other chronic cardiovascular complications, they wrote.", "These are two studies that both suggest that being infected with Covid-19 carries a high likelihood of having some involvement of the heart.", "The connection between Covid-19 and blood clots emerged later, after doctors began connecting the pulmonary aneurysms, strokes, and heart attacks they were seeing to the virus."]}
{"id": 1000194, "claim": "Sars-cov1 frequent mask use in public venues , frequent hand washing , and disinfecting the living quarters were significant protective factors", "label": "SUPPORTED", "evidence": ["In addition, frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were significant protective factors (OR 0.36 to 0.58).", "The three public health variables--frequently wearing a mask in public places (adjusted OR = 0.36, p < 0.001), washing hands >10 times a day (adjusted OR = 0.44, p = 0.008), and disinfecting the living quarters thoroughly (adjusted OR = 0.36, p < 0.001)--remained significant protective factors.", "A number of protective factors were related to relevant public health measures, including the frequency of using a face mask in public venues, the frequency of washing hands each day, and disinfection of living quarters thoroughly during the same period.", "On the other hand, using a mask frequently in public places (OR = 0.27, p < 0.001), washing one's hands >10 times a day (OR = 0.58, p = 0.008), and disinfecting the living quarters thoroughly (OR = 0.41, p < 0.001) during the reference period were significant protective factors (Table 2)."]}
{"id": 1000195, "claim": "Sars-cov1 frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were not protective factors", "label": "REFUTED", "evidence": ["In addition, frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were significant protective factors (OR 0.36 to 0.58).", "The three public health variables--frequently wearing a mask in public places (adjusted OR = 0.36, p < 0.001), washing hands >10 times a day (adjusted OR = 0.44, p = 0.008), and disinfecting the living quarters thoroughly (adjusted OR = 0.36, p < 0.001)--remained significant protective factors.", "A number of protective factors were related to relevant public health measures, including the frequency of using a face mask in public venues, the frequency of washing hands each day, and disinfection of living quarters thoroughly during the same period.", "On the other hand, using a mask frequently in public places (OR = 0.27, p < 0.001), washing one's hands >10 times a day (OR = 0.58, p = 0.008), and disinfecting the living quarters thoroughly (OR = 0.41, p < 0.001) during the reference period were significant protective factors (Table 2)."]}
{"id": 1000196, "claim": "Sars-cov1 frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were no protective factors", "label": "REFUTED", "evidence": ["In addition, frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were significant protective factors (OR 0.36 to 0.58).", "The three public health variables--frequently wearing a mask in public places (adjusted OR = 0.36, p < 0.001), washing hands >10 times a day (adjusted OR = 0.44, p = 0.008), and disinfecting the living quarters thoroughly (adjusted OR = 0.36, p < 0.001)--remained significant protective factors.", "A number of protective factors were related to relevant public health measures, including the frequency of using a face mask in public venues, the frequency of washing hands each day, and disinfection of living quarters thoroughly during the same period.", "On the other hand, using a mask frequently in public places (OR = 0.27, p < 0.001), washing one's hands >10 times a day (OR = 0.58, p = 0.008), and disinfecting the living quarters thoroughly (OR = 0.41, p < 0.001) during the reference period were significant protective factors (Table 2)."]}
{"id": 1000197, "claim": "Sars-cov1 frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were less protective factors", "label": "REFUTED", "evidence": ["In addition, frequent mask use in public venues, frequent hand washing, and disinfecting the living quarters were significant protective factors (OR 0.36 to 0.58).", "The three public health variables--frequently wearing a mask in public places (adjusted OR = 0.36, p < 0.001), washing hands >10 times a day (adjusted OR = 0.44, p = 0.008), and disinfecting the living quarters thoroughly (adjusted OR = 0.36, p < 0.001)--remained significant protective factors.", "A number of protective factors were related to relevant public health measures, including the frequency of using a face mask in public venues, the frequency of washing hands each day, and disinfection of living quarters thoroughly during the same period.", "On the other hand, using a mask frequently in public places (OR = 0.27, p < 0.001), washing one's hands >10 times a day (OR = 0.58, p = 0.008), and disinfecting the living quarters thoroughly (OR = 0.41, p < 0.001) during the reference period were significant protective factors (Table 2)."]}
{"id": 1000198, "claim": "Major new lineages of sars-cov-2 emerge and spread in south africa during lockdown .", "label": "SUPPORTED", "evidence": ["We also show that three lineages spread widely in South Africa and contributed to ~42% of all of the infections in the country.", "C.1 was the most geographically widespread lineage in South Africa, causing infections in multiple provinces and in all of the eleven districts in KwaZulu-Natal (KZN), the most sampled province."]}
{"id": 1000199, "claim": "Major new lineages of sars-cov-2 emerge and spread in south china during lockdown.", "label": "REFUTED", "evidence": ["We also show that three lineages spread widely in South Africa and contributed to ~42% of all of the infections in the country.", "C.1 was the most geographically widespread lineage in South Africa, causing infections in multiple provinces and in all of the eleven districts in KwaZulu-Natal (KZN), the most sampled province."]}
{"id": 1000200, "claim": "Major new lineages of sars-cov-2 emerge and spread in south asia during lockdown.", "label": "REFUTED", "evidence": ["We also show that three lineages spread widely in South Africa and contributed to ~42% of all of the infections in the country.", "C.1 was the most geographically widespread lineage in South Africa, causing infections in multiple provinces and in all of the eleven districts in KwaZulu-Natal (KZN), the most sampled province."]}
{"id": 1000201, "claim": "Researchers race to develop in-home testing for covid-19 , a potential game changer", "label": "SUPPORTED", "evidence": ["The company has already developed a lab-based test thats handheld and gives results in 15 minutes."]}
{"id": 1000202, "claim": "Researchers race to develop in-hospital testing for covid-19, a potential game changer", "label": "REFUTED", "evidence": ["The company has already developed a lab-based test thats handheld and gives results in 15 minutes."]}
{"id": 1000203, "claim": "Researchers race to develop in-line testing for covid-19, a potential game changer", "label": "REFUTED", "evidence": ["The company has already developed a lab-based test thats handheld and gives results in 15 minutes."]}
{"id": 1000204, "claim": "Researchers race to develop in-site testing for covid-19, a potential game changer", "label": "REFUTED", "evidence": ["The company has already developed a lab-based test thats handheld and gives results in 15 minutes."]}
{"id": 1000205, "claim": "Estimating the generation interval for covid-19 based on symptom onset data", "label": "SUPPORTED", "evidence": ["Conclusions Estimating generation and serial interval distributions from outbreak data requires careful investigation of the underlying transmission network."]}
{"id": 1000206, "claim": "Estimating the survival interval for covid-19 based on symptom onset data", "label": "REFUTED", "evidence": ["Conclusions Estimating generation and serial interval distributions from outbreak data requires careful investigation of the underlying transmission network."]}
{"id": 1000207, "claim": "Estimating the time interval for covid-19 based on symptom onset data", "label": "REFUTED", "evidence": ["Conclusions Estimating generation and serial interval distributions from outbreak data requires careful investigation of the underlying transmission network."]}
{"id": 1000208, "claim": "Inactivated rabies virus vectored sars-cov-2 vaccine prevents disease in a syrian hamster model .", "label": "SUPPORTED", "evidence": ["Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model.", "Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials."]}
{"id": 1000209, "claim": "Inactivated rabies virus vectored sars-cov-2 vaccine causes disease in a syrian hamster model.", "label": "REFUTED", "evidence": ["Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model.", "Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials."]}
{"id": 1000210, "claim": "Inactivated rabies virus vectored sars-cov-2 vaccine induces disease in a syrian hamster model.", "label": "REFUTED", "evidence": ["Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model.", "Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials."]}
{"id": 1000211, "claim": "Inactivated rabies virus vectored sars-cov-2 vaccine causing disease in a syrian hamster model.", "label": "REFUTED", "evidence": ["Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model.", "Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials."]}
{"id": 1000212, "claim": "100 percent of regular icu beds in texas medical center occupied , but hospitals have space for surge", "label": "SUPPORTED", "evidence": ["Abbott pauses reopening The average ICU occupancy rate at the world's largest medical center is 70 to 80 percent, but higher rates aren't unheard of.", "Hospitals in Houston's Medical Center will now move some ICU patients to beds not normally used for critical care."]}
{"id": 1000213, "claim": "Two percent of regular icu beds in texas medical center occupied, but hospitals have space for surge", "label": "REFUTED", "evidence": ["Abbott pauses reopening The average ICU occupancy rate at the world's largest medical center is 70 to 80 percent, but higher rates aren't unheard of.", "Hospitals in Houston's Medical Center will now move some ICU patients to beds not normally used for critical care."]}
{"id": 1000214, "claim": "One percent of regular icu beds in texas medical center occupied, but hospitals have space for surge", "label": "REFUTED", "evidence": ["Abbott pauses reopening The average ICU occupancy rate at the world's largest medical center is 70 to 80 percent, but higher rates aren't unheard of.", "Hospitals in Houston's Medical Center will now move some ICU patients to beds not normally used for critical care."]}
{"id": 1000215, "claim": "Five percent of regular icu beds in texas medical center occupied, but hospitals have space for surge", "label": "REFUTED", "evidence": ["Abbott pauses reopening The average ICU occupancy rate at the world's largest medical center is 70 to 80 percent, but higher rates aren't unheard of.", "Hospitals in Houston's Medical Center will now move some ICU patients to beds not normally used for critical care."]}
{"id": 1000216, "claim": "U.s. to suspend visa services in virus-hit countries including japan", "label": "SUPPORTED", "evidence": ["(File photo) [Getty/Kyodo] Beginning Thursday, the U.S. Embassy in Tokyo and all consulates in Japan will suspend routine nonimmigrant visa appointments, while most services for U.S. citizens will continue.", "The State Department decided to suspend visa services in \"response to worldwide challenges related to the outbreak of COVID-19,\" with countries subject to travel advisories higher than level 1 set to be affected, the U.S. Embassy in South Korea said in a statement.", "In South Korea, the U.S. embassy said it will cancel all routine immigrant and nonimmigrant visa appointments as of Thursday.", "The travel advisory for Japan is at level 2, which calls for U.S. citizens to \"exercise increased caution,\" while that for South Korea is at level 3, or \"reconsider travel.\""]}
{"id": 1000217, "claim": "U.s. to provide visa services in virus-hit countries including japan", "label": "REFUTED", "evidence": ["(File photo) [Getty/Kyodo] Beginning Thursday, the U.S. Embassy in Tokyo and all consulates in Japan will suspend routine nonimmigrant visa appointments, while most services for U.S. citizens will continue.", "The State Department decided to suspend visa services in \"response to worldwide challenges related to the outbreak of COVID-19,\" with countries subject to travel advisories higher than level 1 set to be affected, the U.S. Embassy in South Korea said in a statement.", "In South Korea, the U.S. embassy said it will cancel all routine immigrant and nonimmigrant visa appointments as of Thursday.", "The travel advisory for Japan is at level 2, which calls for U.S. citizens to \"exercise increased caution,\" while that for South Korea is at level 3, or \"reconsider travel.\""]}
{"id": 1000218, "claim": "U.s. to include visa services in virus-hit countries including japan", "label": "REFUTED", "evidence": ["(File photo) [Getty/Kyodo] Beginning Thursday, the U.S. Embassy in Tokyo and all consulates in Japan will suspend routine nonimmigrant visa appointments, while most services for U.S. citizens will continue.", "The State Department decided to suspend visa services in \"response to worldwide challenges related to the outbreak of COVID-19,\" with countries subject to travel advisories higher than level 1 set to be affected, the U.S. Embassy in South Korea said in a statement.", "In South Korea, the U.S. embassy said it will cancel all routine immigrant and nonimmigrant visa appointments as of Thursday.", "The travel advisory for Japan is at level 2, which calls for U.S. citizens to \"exercise increased caution,\" while that for South Korea is at level 3, or \"reconsider travel.\""]}
{"id": 1000219, "claim": "U.s. to create visa services in virus-hit countries including japan", "label": "REFUTED", "evidence": ["(File photo) [Getty/Kyodo] Beginning Thursday, the U.S. Embassy in Tokyo and all consulates in Japan will suspend routine nonimmigrant visa appointments, while most services for U.S. citizens will continue.", "The State Department decided to suspend visa services in \"response to worldwide challenges related to the outbreak of COVID-19,\" with countries subject to travel advisories higher than level 1 set to be affected, the U.S. Embassy in South Korea said in a statement.", "In South Korea, the U.S. embassy said it will cancel all routine immigrant and nonimmigrant visa appointments as of Thursday.", "The travel advisory for Japan is at level 2, which calls for U.S. citizens to \"exercise increased caution,\" while that for South Korea is at level 3, or \"reconsider travel.\""]}
{"id": 1000220, "claim": "Chloroquine inhibits hmgb1 inflammatory signaling and protects mice from lethal sepsis", "label": "SUPPORTED", "evidence": ["Chloroquine protects mice against lethal sepsis and inhibits HMGB1 release (A) The cecal Figure 3.", "Here, we show that chloroquine, an anti-malarial drug, prevents lethality in mice with established endotoxemia or sepsis.", "The protective effects of chloroquine were mediated through inhibition of HMGB1 release in macrophages, monocytes, and endothelial cells, thereby preventing its cytokine-like activities.", "Chloroquine protects mice against lethal sepsis and inhibits HMGB1 release (A) The cecal ligation and puncture technique was used to induce intraabdominal sepsis in mice (n = 20 per group)."]}
{"id": 1000221, "claim": "Chloroquine inhibits hmgb1 inflammatory signaling and protects humans from lethal sepsis", "label": "REFUTED", "evidence": ["Chloroquine protects mice against lethal sepsis and inhibits HMGB1 release (A) The cecal Figure 3.", "Here, we show that chloroquine, an anti-malarial drug, prevents lethality in mice with established endotoxemia or sepsis.", "The protective effects of chloroquine were mediated through inhibition of HMGB1 release in macrophages, monocytes, and endothelial cells, thereby preventing its cytokine-like activities.", "Chloroquine protects mice against lethal sepsis and inhibits HMGB1 release (A) The cecal ligation and puncture technique was used to induce intraabdominal sepsis in mice (n = 20 per group)."]}
{"id": 1000222, "claim": "Significant expression of furin and ace2 on oral epithelial cells may facilitate the efficiency of 2019-ncov entry", "label": "SUPPORTED", "evidence": ["Conclusions Based on these findings, we speculated that 2019-nCov could effectively invade oral mucosal cells though two possible routes: binding to the ACE2 receptor and fusion with cell membrane activated by FURIN protease.", "Our results indicated that oral mucosa tissues are susceptible to 2019-nCov, which provides valuable information for virus-prevention strategy in clinical care as well as daily life.", "Results The bioinformatics results indicated the differential expression of ACE2 and FURIN on epithelial cells of different oral mucosal tissues and the proportion of FURIN-positive cells was obviously higher than that of ACE2-positive cells.", "The S-glycoprotein, which recognized as the key factor for the entry of 2019-nCov into the cell, contains two functional domains: an ACE2 receptor binding domain and a second domain necessary for fusion of the coronavirus and cell membranes."]}
{"id": 1000223, "claim": "Significant expression of furin and ace2 on oral epithelial cells may reduce the efficiency of 2019-ncov entry", "label": "REFUTED", "evidence": ["Conclusions Based on these findings, we speculated that 2019-nCov could effectively invade oral mucosal cells though two possible routes: binding to the ACE2 receptor and fusion with cell membrane activated by FURIN protease.", "Our results indicated that oral mucosa tissues are susceptible to 2019-nCov, which provides valuable information for virus-prevention strategy in clinical care as well as daily life.", "Results The bioinformatics results indicated the differential expression of ACE2 and FURIN on epithelial cells of different oral mucosal tissues and the proportion of FURIN-positive cells was obviously higher than that of ACE2-positive cells.", "The S-glycoprotein, which recognized as the key factor for the entry of 2019-nCov into the cell, contains two functional domains: an ACE2 receptor binding domain and a second domain necessary for fusion of the coronavirus and cell membranes."]}
{"id": 1000224, "claim": "Significant expression of furin and ace2 on oral epithelial cells may decrease the efficiency of 2019-ncov entry", "label": "REFUTED", "evidence": ["Conclusions Based on these findings, we speculated that 2019-nCov could effectively invade oral mucosal cells though two possible routes: binding to the ACE2 receptor and fusion with cell membrane activated by FURIN protease.", "Our results indicated that oral mucosa tissues are susceptible to 2019-nCov, which provides valuable information for virus-prevention strategy in clinical care as well as daily life.", "Results The bioinformatics results indicated the differential expression of ACE2 and FURIN on epithelial cells of different oral mucosal tissues and the proportion of FURIN-positive cells was obviously higher than that of ACE2-positive cells.", "The S-glycoprotein, which recognized as the key factor for the entry of 2019-nCov into the cell, contains two functional domains: an ACE2 receptor binding domain and a second domain necessary for fusion of the coronavirus and cell membranes."]}
{"id": 1000225, "claim": "Significant expression of furin and ace2 on oral epithelial cells may limit the efficiency of 2019-ncov entry", "label": "REFUTED", "evidence": ["Conclusions Based on these findings, we speculated that 2019-nCov could effectively invade oral mucosal cells though two possible routes: binding to the ACE2 receptor and fusion with cell membrane activated by FURIN protease.", "Our results indicated that oral mucosa tissues are susceptible to 2019-nCov, which provides valuable information for virus-prevention strategy in clinical care as well as daily life.", "Results The bioinformatics results indicated the differential expression of ACE2 and FURIN on epithelial cells of different oral mucosal tissues and the proportion of FURIN-positive cells was obviously higher than that of ACE2-positive cells.", "The S-glycoprotein, which recognized as the key factor for the entry of 2019-nCov into the cell, contains two functional domains: an ACE2 receptor binding domain and a second domain necessary for fusion of the coronavirus and cell membranes."]}
{"id": 1000226, "claim": "High expression of angiotensin-converting enzyme-2 on tissue macrophages that may be targeted by virus sars-cov-2 in covid-19 patients", "label": "SUPPORTED", "evidence": ["Consequently, this broad expression of ACE2 associated with TMPRSS2 and FURIN may explain the high pathogenic potential of SARS-CoV-2 described in some COVID-19 patients with severe multi-organ dysfunction.", "Share High expression of angiotensin-converting enzyme-2 (ACE2) on tissue macrophages that may be targeted by virus SARS-CoV-2 in COVID-19 patients Xiang Song, Wei Hu, Haibo Yu, Laura Zhao, Yeqian Zhao, Yong Zhao bioRxiv 2020.07.18.210120; doi: https://doi.org/10.1101/2020.07.18.210120 Share This Article: Copy Citation Tools High expression of angiotensin-converting enzyme-2 (ACE2) on tissue macrophages that may be targeted by virus SARS-CoV-2 in COVID-19 patients Xiang Song, Wei Hu, Haibo Yu, Laura Zhao, Yeqian Zhao, Yong Zhao bioRxiv 2020.07.18.210120; doi: https://doi.org/10.1101/2020.07.18.210120 ", "These data indicate that alveolar macrophages, as the frontline immune cells, may be directly targeted by the SARS-CoV-2 infection and therefore need to be considered for the prevention and treatment of COVID-19.", "To better understand the pathogenesis of COVID-19 and build up the host anti-viral immunity, we examined the levels of ACE2 expression on different types of immune cells including tissue macrophages.", "Wong, S. K., Li, W., Moore, M. J., Choe, H. & Farzan, M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin- converting enzyme 2."]}
{"id": 1000227, "claim": "High expression of angiotensin-converting enzyme-2 on tissue macrophages that cannot be targeted by virus sars-cov-2 in covid-19 patients", "label": "REFUTED", "evidence": ["Consequently, this broad expression of ACE2 associated with TMPRSS2 and FURIN may explain the high pathogenic potential of SARS-CoV-2 described in some COVID-19 patients with severe multi-organ dysfunction.", "Share High expression of angiotensin-converting enzyme-2 (ACE2) on tissue macrophages that may be targeted by virus SARS-CoV-2 in COVID-19 patients Xiang Song, Wei Hu, Haibo Yu, Laura Zhao, Yeqian Zhao, Yong Zhao bioRxiv 2020.07.18.210120; doi: https://doi.org/10.1101/2020.07.18.210120 Share This Article: Copy Citation Tools High expression of angiotensin-converting enzyme-2 (ACE2) on tissue macrophages that may be targeted by virus SARS-CoV-2 in COVID-19 patients Xiang Song, Wei Hu, Haibo Yu, Laura Zhao, Yeqian Zhao, Yong Zhao bioRxiv 2020.07.18.210120; doi: https://doi.org/10.1101/2020.07.18.210120 ", "These data indicate that alveolar macrophages, as the frontline immune cells, may be directly targeted by the SARS-CoV-2 infection and therefore need to be considered for the prevention and treatment of COVID-19.", "To better understand the pathogenesis of COVID-19 and build up the host anti-viral immunity, we examined the levels of ACE2 expression on different types of immune cells including tissue macrophages.", "Wong, S. K., Li, W., Moore, M. J., Choe, H. & Farzan, M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin- converting enzyme 2."]}
{"id": 1000228, "claim": "Study adds to evidence that odor-sensing cells in the nose are the key entry point for sars cov-2", "label": "SUPPORTED", "evidence": ["A study adds to evidence that it could be through odor-sensing cells in the nose.", "Because the cells lining the nose may prove to be a key entry point for SARS- CoV-2, Lane says there may be ways to target those particular cells with topical antiviral drugs or other therapies directly to that area."]}
{"id": 1000229, "claim": "Study contrast to evidence that odor-sensing cells in the nose are the key entry point for sars cov-2", "label": "REFUTED", "evidence": ["A study adds to evidence that it could be through odor-sensing cells in the nose.", "Because the cells lining the nose may prove to be a key entry point for SARS- CoV-2, Lane says there may be ways to target those particular cells with topical antiviral drugs or other therapies directly to that area."]}
{"id": 1000230, "claim": "Mcconnell declares war on blue states , dismisses more covid-19 aid", "label": "SUPPORTED", "evidence": ["Rather than the big rescue fund for states and local governments that even Trump has acknowledged is necessary, McConnell says the states should just go bankrupt.", "Well, here's a hearty fuck you, McConnell, from all the blue states that have been paying Kentucky's goddamned bills."]}
{"id": 1000231, "claim": "Mcconnell declares war on blue states, enteres more covid-19 aid", "label": "REFUTED", "evidence": ["Rather than the big rescue fund for states and local governments that even Trump has acknowledged is necessary, McConnell says the states should just go bankrupt.", "Well, here's a hearty fuck you, McConnell, from all the blue states that have been paying Kentucky's goddamned bills."]}
{"id": 1000232, "claim": "Mcconnell declares war on blue states, passes more covid-19 aid", "label": "REFUTED", "evidence": ["Rather than the big rescue fund for states and local governments that even Trump has acknowledged is necessary, McConnell says the states should just go bankrupt.", "Well, here's a hearty fuck you, McConnell, from all the blue states that have been paying Kentucky's goddamned bills."]}
{"id": 1000233, "claim": "Mcconnell declares war on blue states, mentes more covid-19 aid", "label": "REFUTED", "evidence": ["Rather than the big rescue fund for states and local governments that even Trump has acknowledged is necessary, McConnell says the states should just go bankrupt.", "Well, here's a hearty fuck you, McConnell, from all the blue states that have been paying Kentucky's goddamned bills."]}
{"id": 1000234, "claim": "A neutrophil activation signature predicts critical illness and mortality in covid-19", "label": "SUPPORTED", "evidence": ["Neutrophil activation was present on the first day of hospitalization in patients who would only later require transfer to the intensive care unit, thus preceding the onset of critical illness and predicting increased mortality."]}
{"id": 1000235, "claim": "A neutrophil activation signature predicts mild illness and mortality in covid-19", "label": "REFUTED", "evidence": ["Neutrophil activation was present on the first day of hospitalization in patients who would only later require transfer to the intensive care unit, thus preceding the onset of critical illness and predicting increased mortality."]}
{"id": 1000236, "claim": "A neutrophil activation signature predicts respiratory illness and mortality in covid-19", "label": "REFUTED", "evidence": ["Neutrophil activation was present on the first day of hospitalization in patients who would only later require transfer to the intensive care unit, thus preceding the onset of critical illness and predicting increased mortality."]}
{"id": 1000237, "claim": "A neutrophil activation signature immunes critical illness and mortality in covid-19", "label": "REFUTED", "evidence": ["Neutrophil activation was present on the first day of hospitalization in patients who would only later require transfer to the intensive care unit, thus preceding the onset of critical illness and predicting increased mortality."]}
{"id": 1000238, "claim": "Candesartan could ameliorate the covid-19 cytokine storm", "label": "SUPPORTED", "evidence": ["Results: Hundreds of genes upregulated in SARS-CoV-2/COVID-19 transcriptomes were similarly upregulated by glutamate and normalized by Candesartan."]}
{"id": 1000239, "claim": "Undesartan could ameliorate the covid-19 cytokine storm", "label": "REFUTED", "evidence": ["Results: Hundreds of genes upregulated in SARS-CoV-2/COVID-19 transcriptomes were similarly upregulated by glutamate and normalized by Candesartan."]}
{"id": 1000240, "claim": "Exdesartan could ameliorate the covid-19 cytokine storm", "label": "REFUTED", "evidence": ["Results: Hundreds of genes upregulated in SARS-CoV-2/COVID-19 transcriptomes were similarly upregulated by glutamate and normalized by Candesartan."]}
{"id": 1000241, "claim": "Redesartan could ameliorate the covid-19 cytokine storm", "label": "REFUTED", "evidence": ["Results: Hundreds of genes upregulated in SARS-CoV-2/COVID-19 transcriptomes were similarly upregulated by glutamate and normalized by Candesartan."]}
{"id": 1000242, "claim": "Identifying silent covid-19 infections among children is critical for controlling the pandemic.", "label": "SUPPORTED", "evidence": ["Question What is the impact of a targeted strategy for identification of silent COVID-19 infections among children in the absence of their vaccination?", "The implications of silent transmission for the control of COVID-19 outbreaks.Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, Galvani AP.", "Conclusions and relevance: In the absence of vaccine availability for children, a targeted approach to rapid identification of silent COVID-19 infections in this age group can significantly mitigate disease burden.", "Key points: Question: What is the impact of a targeted strategy for identification of silent COVID-19 infections among children in the absence of their vaccination?", "Conclusions and Relevance In the absence of vaccine availability for children, a targeted approach to rapid identification of silent COVID-19 infections in this age group can significantly mitigate disease burden."]}
{"id": 1000243, "claim": "Identifying silent covid-19 infections among adults is critical for controlling the pandemic.", "label": "REFUTED", "evidence": ["Question What is the impact of a targeted strategy for identification of silent COVID-19 infections among children in the absence of their vaccination?", "The implications of silent transmission for the control of COVID-19 outbreaks.Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, Galvani AP.", "Conclusions and relevance: In the absence of vaccine availability for children, a targeted approach to rapid identification of silent COVID-19 infections in this age group can significantly mitigate disease burden.", "Key points: Question: What is the impact of a targeted strategy for identification of silent COVID-19 infections among children in the absence of their vaccination?", "Conclusions and Relevance In the absence of vaccine availability for children, a targeted approach to rapid identification of silent COVID-19 infections in this age group can significantly mitigate disease burden."]}
{"id": 1000244, "claim": "Politician raises alarm over trudeau govt 's plan to build covid quarantine/isolation camps", "label": "SUPPORTED", "evidence": ["Randy Hillier, Independent Ontario MPP for Lanark, Frontenac & Kingston, expressed concern over the \"Federal Quarantine/Isolation sites\" in the provincial question period late this week.", "\"The expansion of isolation/quarantine camps in Canada is something of concern and the Ontario government must know about it, so why won't they tell the people of Ontario?\"", "\"So your government must be in negotiations and aware of these plans to potentially detain and isolate citizens and residents of our country and our province, so speaker, to the Premier, where will these camps be built, how many people will be detained, and for what reason, for what reasons can people be kept in these isolation camps, and I'd like to have the Premier assure the people of Ontario,\" said Hillier, whose microphone was cut off before he could finish."]}
{"id": 1000245, "claim": "Politician raises support over trudeau govt's plan to build covid quarantine/isolation camps", "label": "REFUTED", "evidence": ["Randy Hillier, Independent Ontario MPP for Lanark, Frontenac & Kingston, expressed concern over the \"Federal Quarantine/Isolation sites\" in the provincial question period late this week.", "\"The expansion of isolation/quarantine camps in Canada is something of concern and the Ontario government must know about it, so why won't they tell the people of Ontario?\"", "\"So your government must be in negotiations and aware of these plans to potentially detain and isolate citizens and residents of our country and our province, so speaker, to the Premier, where will these camps be built, how many people will be detained, and for what reason, for what reasons can people be kept in these isolation camps, and I'd like to have the Premier assure the people of Ontario,\" said Hillier, whose microphone was cut off before he could finish."]}
{"id": 1000246, "claim": "Cdc announces modifications and extension of no sail order for all cruise ships", "label": "SUPPORTED", "evidence": ["This order ceases operations of cruise ships in waters in which the United States may exert jurisdiction and requires that they develop a comprehensive, detailed operational plan approved by CDC and the USCG to address the COVID-19 pandemic through maritime focused solutions, including a fully implementable response plan with limited reliance on state, local, and federal government support.", "Cruise Lines International Association (CLIA) voluntarily suspended cruise ship operations in March in conjunction with the earlier No Sail Order issued March 14.", "The CDC, the U.S. Coast Guard, and the Department of Homeland Security have been working with the industry to determine the most appropriate public health strategy to limit the impact of COVID-19 at cruise ship ports of entry in the United States.", "The No Sail Order reinforces the strong action by President Donald J. Trump and the White House Coronavirus Task Force to combat the spread of COVID-19 in the United States."]}
{"id": 1000247, "claim": "Cdc announces modifications and loss of no sail order for all cruise ships", "label": "REFUTED", "evidence": ["This order ceases operations of cruise ships in waters in which the United States may exert jurisdiction and requires that they develop a comprehensive, detailed operational plan approved by CDC and the USCG to address the COVID-19 pandemic through maritime focused solutions, including a fully implementable response plan with limited reliance on state, local, and federal government support.", "Cruise Lines International Association (CLIA) voluntarily suspended cruise ship operations in March in conjunction with the earlier No Sail Order issued March 14.", "The CDC, the U.S. Coast Guard, and the Department of Homeland Security have been working with the industry to determine the most appropriate public health strategy to limit the impact of COVID-19 at cruise ship ports of entry in the United States.", "The No Sail Order reinforces the strong action by President Donald J. Trump and the White House Coronavirus Task Force to combat the spread of COVID-19 in the United States."]}
{"id": 1000248, "claim": "Cdc announces modifications and lack of no sail order for all cruise ships", "label": "REFUTED", "evidence": ["This order ceases operations of cruise ships in waters in which the United States may exert jurisdiction and requires that they develop a comprehensive, detailed operational plan approved by CDC and the USCG to address the COVID-19 pandemic through maritime focused solutions, including a fully implementable response plan with limited reliance on state, local, and federal government support.", "Cruise Lines International Association (CLIA) voluntarily suspended cruise ship operations in March in conjunction with the earlier No Sail Order issued March 14.", "The CDC, the U.S. Coast Guard, and the Department of Homeland Security have been working with the industry to determine the most appropriate public health strategy to limit the impact of COVID-19 at cruise ship ports of entry in the United States.", "The No Sail Order reinforces the strong action by President Donald J. Trump and the White House Coronavirus Task Force to combat the spread of COVID-19 in the United States."]}
{"id": 1000249, "claim": "Virological assessment of hospitalized patients with covid-2019", "label": "SUPPORTED", "evidence": ["For sputum samples, interpolation based on a probit model was done to obtain laboratory-based infectivity criteria for the discharge of patients (Fig.", "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."]}
{"id": 1000250, "claim": "Virological assessment of hospitalized patients with covid-3", "label": "REFUTED", "evidence": ["For sputum samples, interpolation based on a probit model was done to obtain laboratory-based infectivity criteria for the discharge of patients (Fig.", "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."]}
{"id": 1000251, "claim": "Virological assessment of hospitalized patients with covid-1", "label": "REFUTED", "evidence": ["For sputum samples, interpolation based on a probit model was done to obtain laboratory-based infectivity criteria for the discharge of patients (Fig.", "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."]}
{"id": 1000252, "claim": "Virological assessment of hospitalized patients with covid-2", "label": "REFUTED", "evidence": ["For sputum samples, interpolation based on a probit model was done to obtain laboratory-based infectivity criteria for the discharge of patients (Fig.", "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."]}
{"id": 1000253, "claim": "Afucosylated immunoglobulin g responses are a hallmark of enveloped virus infections and show an exacerbated phenotype in covid-19", "label": "SUPPORTED", "evidence": ["Here, we report that afucosylated IgG which are of minor abundance in humans (6% of total IgG) are specifically formed against surface epitopes of enveloped viruses after natural infections or immunization with attenuated viruses, while protein subunit immunization does not elicit this low fucose response.", "In the case of COVID-19, the critically ill show aggravated afucosylated-IgG responses against the viral spike protein.", "Our findings indicate antibody glycosylation as a potential factor in inflammation and protection in enveloped virus infections including COVID-19."]}
{"id": 1000254, "claim": "Afucosylated immunoglobulin g responses are a hallmark of dengue virus infections and show an exacerbated phenotype in covid-19", "label": "REFUTED", "evidence": ["Here, we report that afucosylated IgG which are of minor abundance in humans (6% of total IgG) are specifically formed against surface epitopes of enveloped viruses after natural infections or immunization with attenuated viruses, while protein subunit immunization does not elicit this low fucose response.", "In the case of COVID-19, the critically ill show aggravated afucosylated-IgG responses against the viral spike protein.", "Our findings indicate antibody glycosylation as a potential factor in inflammation and protection in enveloped virus infections including COVID-19."]}
{"id": 1000255, "claim": "Afucosylated immunoglobulin g responses are a hallmark of respiratory virus infections and show an exacerbated phenotype in covid-19", "label": "REFUTED", "evidence": ["Here, we report that afucosylated IgG which are of minor abundance in humans (6% of total IgG) are specifically formed against surface epitopes of enveloped viruses after natural infections or immunization with attenuated viruses, while protein subunit immunization does not elicit this low fucose response.", "In the case of COVID-19, the critically ill show aggravated afucosylated-IgG responses against the viral spike protein.", "Our findings indicate antibody glycosylation as a potential factor in inflammation and protection in enveloped virus infections including COVID-19."]}
{"id": 1000256, "claim": "Covid-19 pandemic could end if 70 % of people wore masks consistently", "label": "SUPPORTED", "evidence": ["\"Even less efficient cloth masks could also slow the spread if worn consistently,\" Kumar added.", "The performance of face masks worn for many hours, such as by health care or other essential workers, impact how effective overall mask wearing can be, the researchers added.", "Singapore : The COVID-19 pandemic could end if at least 70% of the people wore face masks in public consistently, according to a review of studies which suggests that the type of material used and the duration of mask use play key roles in their effectiveness.", "According to the scientists, one key aspect of face mask function involves the size of fluid droplets expelled from the nose and mouth when a person talks, sings, sneezes, coughs, or even simply breathes."]}
{"id": 1000257, "claim": "Covid-19 pandemic could increase if 70 % of people wore masks consistently", "label": "REFUTED", "evidence": ["\"Even less efficient cloth masks could also slow the spread if worn consistently,\" Kumar added.", "The performance of face masks worn for many hours, such as by health care or other essential workers, impact how effective overall mask wearing can be, the researchers added.", "Singapore : The COVID-19 pandemic could end if at least 70% of the people wore face masks in public consistently, according to a review of studies which suggests that the type of material used and the duration of mask use play key roles in their effectiveness.", "According to the scientists, one key aspect of face mask function involves the size of fluid droplets expelled from the nose and mouth when a person talks, sings, sneezes, coughs, or even simply breathes."]}
{"id": 1000258, "claim": "Covid-19 pandemic could continue if 70 % of people wore masks consistently", "label": "REFUTED", "evidence": ["\"Even less efficient cloth masks could also slow the spread if worn consistently,\" Kumar added.", "The performance of face masks worn for many hours, such as by health care or other essential workers, impact how effective overall mask wearing can be, the researchers added.", "Singapore : The COVID-19 pandemic could end if at least 70% of the people wore face masks in public consistently, according to a review of studies which suggests that the type of material used and the duration of mask use play key roles in their effectiveness.", "According to the scientists, one key aspect of face mask function involves the size of fluid droplets expelled from the nose and mouth when a person talks, sings, sneezes, coughs, or even simply breathes."]}
{"id": 1000259, "claim": "A front-runner vaccine shows promise in older people", "label": "SUPPORTED", "evidence": ["The robust antibody and T-cell responses seen in older people in our study are encouraging, said Maheshi Ramasamy, a consultant and co-lead investigator at the Oxford Vaccine Group."]}
{"id": 1000260, "claim": "A front-runner vaccine shows promise in young people", "label": "REFUTED", "evidence": ["The robust antibody and T-cell responses seen in older people in our study are encouraging, said Maheshi Ramasamy, a consultant and co-lead investigator at the Oxford Vaccine Group."]}
{"id": 1000261, "claim": "Mexican doctor taken to icu after experiencing serious reaction to pfizer vaccine.", "label": "SUPPORTED", "evidence": ["A female doctor in Mexico was hospitalized after she received the Pfizer- BioNTech COVID-19 vaccine.", "REUTERS/Daniel Becerril MEXICO CITY (Reuters) - Mexican authorities said they are studying the case of a 32-year-old female doctor who was hospitalized after receiving the Pfizer- BioNTech COVID-19 vaccine.", "Mexican doctor hospitalized after receiving COVID-19 vaccine Wikimedia commons Acute Disseminated Encephalomyelitis ADEM is a rare kind of inflammation that affects the brain and the spinal cord.", "A 32-year-old female doctor in Mexico was hospitalized after receiving the Pfizer-BioNTech COVID-19 vaccine."]}
{"id": 1000262, "claim": "Mexican doctor taken to icu after no serious reaction to pfizer vaccine.", "label": "REFUTED", "evidence": ["A female doctor in Mexico was hospitalized after she received the Pfizer- BioNTech COVID-19 vaccine.", "REUTERS/Daniel Becerril MEXICO CITY (Reuters) - Mexican authorities said they are studying the case of a 32-year-old female doctor who was hospitalized after receiving the Pfizer- BioNTech COVID-19 vaccine.", "Mexican doctor hospitalized after receiving COVID-19 vaccine Wikimedia commons Acute Disseminated Encephalomyelitis ADEM is a rare kind of inflammation that affects the brain and the spinal cord.", "A 32-year-old female doctor in Mexico was hospitalized after receiving the Pfizer-BioNTech COVID-19 vaccine."]}
{"id": 1000263, "claim": "The coronavirus is most deadly if you are older and male", "label": "SUPPORTED", "evidence": ["The results also revealed that men are more likely to die of the infection than are women  the gap increasing with age.", "Gender is also a strong risk factor, with men almost twice more likely to die from the coronavirus than women.", "2 The immune system might also explain the much higher risk of older people dying from the virus.", "Trends in coronavirus deaths by age have been clear since early in the pandemic."]}
{"id": 1000264, "claim": "The coronavirus is not deadly if you are older and male", "label": "REFUTED", "evidence": ["The results also revealed that men are more likely to die of the infection than are women  the gap increasing with age.", "Gender is also a strong risk factor, with men almost twice more likely to die from the coronavirus than women.", "2 The immune system might also explain the much higher risk of older people dying from the virus.", "Trends in coronavirus deaths by age have been clear since early in the pandemic."]}
{"id": 1000265, "claim": "The coronavirus is less deadly if you are older and male", "label": "REFUTED", "evidence": ["The results also revealed that men are more likely to die of the infection than are women  the gap increasing with age.", "Gender is also a strong risk factor, with men almost twice more likely to die from the coronavirus than women.", "2 The immune system might also explain the much higher risk of older people dying from the virus.", "Trends in coronavirus deaths by age have been clear since early in the pandemic."]}
{"id": 1000266, "claim": "The coronavirus is most contagious if you are older and male", "label": "REFUTED", "evidence": ["The results also revealed that men are more likely to die of the infection than are women  the gap increasing with age.", "Gender is also a strong risk factor, with men almost twice more likely to die from the coronavirus than women.", "2 The immune system might also explain the much higher risk of older people dying from the virus.", "Trends in coronavirus deaths by age have been clear since early in the pandemic."]}
{"id": 1000267, "claim": "Risk of covid-19 hospitalisation rises exponentially with age , inversely proportional to t-cell production", "label": "SUPPORTED", "evidence": ["This mirrors the well studied exponential decline of both thymus volume and T-cell production, which halve every 16 years.", "The strikingly simple inverse relationship between COVID-19 risk and thymic T-cell output reported here begs a mechanistic understanding and suggests that T-cell based therapies may be a promising target.", "In addition, incidence of severe disease and mortality due to COVID-19 are both higher in men, consistent with the degree to which thymic involution (and the decrease in T-cell production with age) is more severe in men compared to women."]}
{"id": 1000268, "claim": "Risk of covid-19 hospitalisation decreased exponentially with age, inversely proportional to t-cell production", "label": "REFUTED", "evidence": ["This mirrors the well studied exponential decline of both thymus volume and T-cell production, which halve every 16 years.", "The strikingly simple inverse relationship between COVID-19 risk and thymic T-cell output reported here begs a mechanistic understanding and suggests that T-cell based therapies may be a promising target.", "In addition, incidence of severe disease and mortality due to COVID-19 are both higher in men, consistent with the degree to which thymic involution (and the decrease in T-cell production with age) is more severe in men compared to women."]}
{"id": 1000269, "claim": "Risk of covid-19 hospitalisation decreases exponentially with age, inversely proportional to t-cell production", "label": "REFUTED", "evidence": ["This mirrors the well studied exponential decline of both thymus volume and T-cell production, which halve every 16 years.", "The strikingly simple inverse relationship between COVID-19 risk and thymic T-cell output reported here begs a mechanistic understanding and suggests that T-cell based therapies may be a promising target.", "In addition, incidence of severe disease and mortality due to COVID-19 are both higher in men, consistent with the degree to which thymic involution (and the decrease in T-cell production with age) is more severe in men compared to women."]}
{"id": 1000270, "claim": "Risk of covid-19 hospitalisation rises exponentially with death, inversely proportional to t-cell production", "label": "REFUTED", "evidence": ["This mirrors the well studied exponential decline of both thymus volume and T-cell production, which halve every 16 years.", "The strikingly simple inverse relationship between COVID-19 risk and thymic T-cell output reported here begs a mechanistic understanding and suggests that T-cell based therapies may be a promising target.", "In addition, incidence of severe disease and mortality due to COVID-19 are both higher in men, consistent with the degree to which thymic involution (and the decrease in T-cell production with age) is more severe in men compared to women."]}
{"id": 1000271, "claim": "Experimental covid-19 vaccine protects upper and lower airways in nonhuman primates", "label": "SUPPORTED", "evidence": ["Moreover, none of the eight macaques vaccinated with 100 µg of mRNA-1273 had detectable virus in their noses two days after virus exposure.", "This is the first time an experimental COVID-19 vaccine tested in nonhuman primates has been shown to produce such rapid viral control in the upper airway, the investigators note."]}
{"id": 1000272, "claim": "Experimental covid-19 vaccine infects upper and lower airways in nonhuman primates", "label": "REFUTED", "evidence": ["Moreover, none of the eight macaques vaccinated with 100 µg of mRNA-1273 had detectable virus in their noses two days after virus exposure.", "This is the first time an experimental COVID-19 vaccine tested in nonhuman primates has been shown to produce such rapid viral control in the upper airway, the investigators note."]}
{"id": 1000273, "claim": "Covid-19 map was found to be malware", "label": "SUPPORTED", "evidence": ["Early COVID-19 related malicious email Now there are ongoing business email compromise (BEC) scams that use the disease as a hook.", "The emails had attachments that contain malware, which executes a PowerShell command that will download a file from a URL related to COVID-19.", "The URL is hxxps://recoverrryasitalycovid-19.xyz/over Upon further investigation, it was found that the malware used Evil Clippy, a tool for creating malicious MS Office Documents, to hide its macro.", "COVID-19 being used for extortion", "It contained recommendations on how to prevent infection and came with an attachment that supposedly contains the latest updates on COVID-19 but actually carried malware."]}
{"id": 1000274, "claim": "Covid-19 map was found to be stableware", "label": "REFUTED", "evidence": ["Early COVID-19 related malicious email Now there are ongoing business email compromise (BEC) scams that use the disease as a hook.", "The emails had attachments that contain malware, which executes a PowerShell command that will download a file from a URL related to COVID-19.", "The URL is hxxps://recoverrryasitalycovid-19.xyz/over Upon further investigation, it was found that the malware used Evil Clippy, a tool for creating malicious MS Office Documents, to hide its macro.", "COVID-19 being used for extortion", "It contained recommendations on how to prevent infection and came with an attachment that supposedly contains the latest updates on COVID-19 but actually carried malware."]}
{"id": 1000275, "claim": "Covid-19 map was found to be positiveware", "label": "REFUTED", "evidence": ["Early COVID-19 related malicious email Now there are ongoing business email compromise (BEC) scams that use the disease as a hook.", "The emails had attachments that contain malware, which executes a PowerShell command that will download a file from a URL related to COVID-19.", "The URL is hxxps://recoverrryasitalycovid-19.xyz/over Upon further investigation, it was found that the malware used Evil Clippy, a tool for creating malicious MS Office Documents, to hide its macro.", "COVID-19 being used for extortion", "It contained recommendations on how to prevent infection and came with an attachment that supposedly contains the latest updates on COVID-19 but actually carried malware."]}
{"id": 1000276, "claim": "Covid-19 map was found to be similarware", "label": "REFUTED", "evidence": ["Early COVID-19 related malicious email Now there are ongoing business email compromise (BEC) scams that use the disease as a hook.", "The emails had attachments that contain malware, which executes a PowerShell command that will download a file from a URL related to COVID-19.", "The URL is hxxps://recoverrryasitalycovid-19.xyz/over Upon further investigation, it was found that the malware used Evil Clippy, a tool for creating malicious MS Office Documents, to hide its macro.", "COVID-19 being used for extortion", "It contained recommendations on how to prevent infection and came with an attachment that supposedly contains the latest updates on COVID-19 but actually carried malware."]}
{"id": 1000277, "claim": "Researchers identify multiple molecules that shut down sars-cov-2 polymerase reaction", "label": "SUPPORTED", "evidence": ["They then demonstrated that sofosbuvir and four other nucleotide analogues (the active triphosphate forms of the HIV inhibitors Alovudine, Zidovudine, Tenofovir alafenamide, and Emtricitabine) also inhibited the SARS-CoV-2 polymerase with different levels of efficiency.", "While all 11 molecules tested displayed incorporation, six exhibited immediate termination of the polymerase reaction, two showed delayed termination, and three did not terminate the polymerase reaction.", "In an earlier set of experiments testing the properties of the polymerase of the coronavirus that causes SARS, the researchers found that the triphosphate of sofosbuvir was able to terminate the virus polymerase reaction.", "Researchers at Columbia Engineering and the University of Wisconsin-Madison have identified a library of molecules that shut down the SARS-CoV-2 polymerase reaction, a key step that establishes the potential of these molecules as lead compounds to be further modified for the development of COVID-19 therapeutics."]}
{"id": 1000278, "claim": "Researchers identify multiple genes that shut down sars-cov-2 polymerase reaction", "label": "REFUTED", "evidence": ["They then demonstrated that sofosbuvir and four other nucleotide analogues (the active triphosphate forms of the HIV inhibitors Alovudine, Zidovudine, Tenofovir alafenamide, and Emtricitabine) also inhibited the SARS-CoV-2 polymerase with different levels of efficiency.", "While all 11 molecules tested displayed incorporation, six exhibited immediate termination of the polymerase reaction, two showed delayed termination, and three did not terminate the polymerase reaction.", "In an earlier set of experiments testing the properties of the polymerase of the coronavirus that causes SARS, the researchers found that the triphosphate of sofosbuvir was able to terminate the virus polymerase reaction.", "Researchers at Columbia Engineering and the University of Wisconsin-Madison have identified a library of molecules that shut down the SARS-CoV-2 polymerase reaction, a key step that establishes the potential of these molecules as lead compounds to be further modified for the development of COVID-19 therapeutics."]}
{"id": 1000279, "claim": "Researchers identify multiple sites that shut down sars-cov-2 polymerase reaction", "label": "REFUTED", "evidence": ["They then demonstrated that sofosbuvir and four other nucleotide analogues (the active triphosphate forms of the HIV inhibitors Alovudine, Zidovudine, Tenofovir alafenamide, and Emtricitabine) also inhibited the SARS-CoV-2 polymerase with different levels of efficiency.", "While all 11 molecules tested displayed incorporation, six exhibited immediate termination of the polymerase reaction, two showed delayed termination, and three did not terminate the polymerase reaction.", "In an earlier set of experiments testing the properties of the polymerase of the coronavirus that causes SARS, the researchers found that the triphosphate of sofosbuvir was able to terminate the virus polymerase reaction.", "Researchers at Columbia Engineering and the University of Wisconsin-Madison have identified a library of molecules that shut down the SARS-CoV-2 polymerase reaction, a key step that establishes the potential of these molecules as lead compounds to be further modified for the development of COVID-19 therapeutics."]}
{"id": 1000280, "claim": "Remdesivir but not famotidine inhibits sars-cov-2 replication in human pluripotent stem cell-derived intestinal organoids", "label": "SUPPORTED", "evidence": ["Remdesivir, a promising drug to treat COVID-19, effectively suppressed SARS-CoV-2 infection of PSC-HIOs."]}
{"id": 1000281, "claim": "Remdesivir but also famotidine inhibits sars-cov-2 replication in human pluripotent stem cell-derived intestinal organoids", "label": "REFUTED", "evidence": ["Remdesivir, a promising drug to treat COVID-19, effectively suppressed SARS-CoV-2 infection of PSC-HIOs."]}
{"id": 1000282, "claim": "Remdesivir but only famotidine inhibits sars-cov-2 replication in human pluripotent stem cell-derived intestinal organoids", "label": "REFUTED", "evidence": ["Remdesivir, a promising drug to treat COVID-19, effectively suppressed SARS-CoV-2 infection of PSC-HIOs."]}
{"id": 1000283, "claim": "Remdesivir but its famotidine inhibits sars-cov-2 replication in human pluripotent stem cell-derived intestinal organoids", "label": "REFUTED", "evidence": ["Remdesivir, a promising drug to treat COVID-19, effectively suppressed SARS-CoV-2 infection of PSC-HIOs."]}
{"id": 1000284, "claim": "Two x-linked agammaglobulinemia patients develop pneumonia as covid-19 manifestation but recover", "label": "SUPPORTED", "evidence": ["Therefore, we evaluated the outcome of SARS-CoV-2 infection in patients with inborn errors of immunity (IEI) such as X-linked agammaglobulinemia (XLA).", "Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection.", "Results: We describe two patients with X-linked agammaglobulinemia (XLA) aged 34 and 26 years with complete absence of B cells from peripheral blood who developed COVID-19, as diagnosed by SARS-CoV-2 detection by nasopharyngeal swab, while receiving immunoglobulin infusions."]}
{"id": 1000285, "claim": "5 x-linked agammaglobulinemia patients develop pneumonia as covid-19 manifestation but recover", "label": "REFUTED", "evidence": ["Therefore, we evaluated the outcome of SARS-CoV-2 infection in patients with inborn errors of immunity (IEI) such as X-linked agammaglobulinemia (XLA).", "Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection.", "Results: We describe two patients with X-linked agammaglobulinemia (XLA) aged 34 and 26 years with complete absence of B cells from peripheral blood who developed COVID-19, as diagnosed by SARS-CoV-2 detection by nasopharyngeal swab, while receiving immunoglobulin infusions."]}
{"id": 1000286, "claim": "4 x-linked agammaglobulinemia patients develop pneumonia as covid-19 manifestation but recover", "label": "REFUTED", "evidence": ["Therefore, we evaluated the outcome of SARS-CoV-2 infection in patients with inborn errors of immunity (IEI) such as X-linked agammaglobulinemia (XLA).", "Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection.", "Results: We describe two patients with X-linked agammaglobulinemia (XLA) aged 34 and 26 years with complete absence of B cells from peripheral blood who developed COVID-19, as diagnosed by SARS-CoV-2 detection by nasopharyngeal swab, while receiving immunoglobulin infusions."]}
{"id": 1000287, "claim": "1 x-linked agammaglobulinemia patients develop pneumonia as covid-19 manifestation but recover", "label": "REFUTED", "evidence": ["Therefore, we evaluated the outcome of SARS-CoV-2 infection in patients with inborn errors of immunity (IEI) such as X-linked agammaglobulinemia (XLA).", "Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection.", "Results: We describe two patients with X-linked agammaglobulinemia (XLA) aged 34 and 26 years with complete absence of B cells from peripheral blood who developed COVID-19, as diagnosed by SARS-CoV-2 detection by nasopharyngeal swab, while receiving immunoglobulin infusions."]}
{"id": 1000288, "claim": "Full-dose clot prophylaxis halted for severe covid-19 in nhlbi trial.", "label": "SUPPORTED", "evidence": ["Cite this: COVID-19 Anticoagulation Trials 'Paused' for Futility, Safety - Medscape - Dec 22, 2020.", "Therapeutic dosing was safe in this moderately ill COVID-19 population, unlike in the critically ill population for which the trials halted the full-dose strategy after seeing signals of harm.", "All three trials have paused enrollment of critically ill COVID-19 patients requiring intensive care unit support for whom therapeutic doses of anticoagulation drugs did not reduce the need for organ support, the NHLBI statement notes.", "Informed by the deliberations of the data safety monitoring boards of these trials, all of the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19."]}
{"id": 1000289, "claim": "Full-dose clot prophylaxis continued for severe covid-19 in nhlbi trial.", "label": "REFUTED", "evidence": ["Cite this: COVID-19 Anticoagulation Trials 'Paused' for Futility, Safety - Medscape - Dec 22, 2020.", "Therapeutic dosing was safe in this moderately ill COVID-19 population, unlike in the critically ill population for which the trials halted the full-dose strategy after seeing signals of harm.", "All three trials have paused enrollment of critically ill COVID-19 patients requiring intensive care unit support for whom therapeutic doses of anticoagulation drugs did not reduce the need for organ support, the NHLBI statement notes.", "Informed by the deliberations of the data safety monitoring boards of these trials, all of the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19."]}
{"id": 1000290, "claim": "Full-dose clot prophylaxis allows for severe covid-19 in nhlbi trial.", "label": "REFUTED", "evidence": ["Cite this: COVID-19 Anticoagulation Trials 'Paused' for Futility, Safety - Medscape - Dec 22, 2020.", "Therapeutic dosing was safe in this moderately ill COVID-19 population, unlike in the critically ill population for which the trials halted the full-dose strategy after seeing signals of harm.", "All three trials have paused enrollment of critically ill COVID-19 patients requiring intensive care unit support for whom therapeutic doses of anticoagulation drugs did not reduce the need for organ support, the NHLBI statement notes.", "Informed by the deliberations of the data safety monitoring boards of these trials, all of the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19."]}
{"id": 1000291, "claim": "Full-dose clot prophylaxis allowed for severe covid-19 in nhlbi trial.", "label": "REFUTED", "evidence": ["Cite this: COVID-19 Anticoagulation Trials 'Paused' for Futility, Safety - Medscape - Dec 22, 2020.", "Therapeutic dosing was safe in this moderately ill COVID-19 population, unlike in the critically ill population for which the trials halted the full-dose strategy after seeing signals of harm.", "All three trials have paused enrollment of critically ill COVID-19 patients requiring intensive care unit support for whom therapeutic doses of anticoagulation drugs did not reduce the need for organ support, the NHLBI statement notes.", "Informed by the deliberations of the data safety monitoring boards of these trials, all of the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19."]}
{"id": 1000292, "claim": "Sars-cov-2 infects human neural progenitor cells and brain organoids", "label": "SUPPORTED", "evidence": ["h Representative images of SARS-CoV-2-infected human brain organoids immunostained for SARS-CoV-2-N and TUJ1.", "1: SARS-CoV-2 infects hNPCs, neurospheres and brain organoids.", "i Representative images of SARS- CoV-2-infected human brain organoids immunostained for SARS-CoV-2-N and NESTIN.", "f Representative images of SARS-CoV-2-infected brain organoids.", "1f), indicating that SARS-CoV-2 directly infected the brain organoids."]}
{"id": 1000293, "claim": "Sars-cov-2 infects human neural progenitor cells and lymphocytes organoids", "label": "REFUTED", "evidence": ["h Representative images of SARS-CoV-2-infected human brain organoids immunostained for SARS-CoV-2-N and TUJ1.", "1: SARS-CoV-2 infects hNPCs, neurospheres and brain organoids.", "i Representative images of SARS- CoV-2-infected human brain organoids immunostained for SARS-CoV-2-N and NESTIN.", "f Representative images of SARS-CoV-2-infected brain organoids.", "1f), indicating that SARS-CoV-2 directly infected the brain organoids."]}
{"id": 1000294, "claim": "Sars-cov-2 infects human neural progenitor cells and fibroblasts organoids", "label": "REFUTED", "evidence": ["h Representative images of SARS-CoV-2-infected human brain organoids immunostained for SARS-CoV-2-N and TUJ1.", "1: SARS-CoV-2 infects hNPCs, neurospheres and brain organoids.", "i Representative images of SARS- CoV-2-infected human brain organoids immunostained for SARS-CoV-2-N and NESTIN.", "f Representative images of SARS-CoV-2-infected brain organoids.", "1f), indicating that SARS-CoV-2 directly infected the brain organoids."]}
{"id": 1000295, "claim": "Serological responses to human virome define clinical outcomes of italian patients infected with sars-cov-2.", "label": "SUPPORTED", "evidence": ["Here, we studied 159 hospitalized Italian patients with pneumonia from the NIAID-NCI COVID-19 Consortium using a phage-display method to characterize circulating antibodies binding to 93,904 viral peptides encoded by 1,276 strains of human viruses."]}
{"id": 1000296, "claim": "Serological responses to bacterial virome define clinical outcomes of italian patients infected with sars-cov-2.", "label": "REFUTED", "evidence": ["Here, we studied 159 hospitalized Italian patients with pneumonia from the NIAID-NCI COVID-19 Consortium using a phage-display method to characterize circulating antibodies binding to 93,904 viral peptides encoded by 1,276 strains of human viruses."]}
{"id": 1000297, "claim": "Coronavirus fatality rate estimated by imperial scientists", "label": "SUPPORTED", "evidence": ["According to the latest estimates from the team, from the MRC Centre for Global Infectious Disease Analysis at Imperial, one percent of people with the disease will die from their infection."]}
{"id": 1000298, "claim": "Coronavirus fatality rate measured by imperial scientists", "label": "REFUTED", "evidence": ["According to the latest estimates from the team, from the MRC Centre for Global Infectious Disease Analysis at Imperial, one percent of people with the disease will die from their infection."]}
{"id": 1000299, "claim": "The human brain vasculature shows a distinct expression pattern of sars-cov-2 entry factors", "label": "SUPPORTED", "evidence": ["Our study serves as a publicly available single-cell atlas of SARS-CoV-2 related entry factors and interaction partners in human and mouse brain endothelial- and perivascular cells, which can be employed for future studies in clinical samples of COVID-19 patients.", "We observed a distinct expression pattern of the cathepsins B (CTSB) and -L (CTSL) - which are able to substitute for the ACE2 co-receptor TMPRSS2 - in the human vasculature with CTSB being mainly expressed in the brain vasculature and CTSL predominantly in the peripheral vasculature, and these observations were confirmed at the protein level in the Human Protein Atlas and using immunofluorescence stainings.", "This expression pattern of SARS-CoV-2 viral-entry associated proteases and SARS-CoV-2 interaction partners was also present in endothelial cells and microglia in the fetal brain, suggesting a developmentally established SARS-CoV-2 entry machinery in the human vasculature.", "At both the adult and fetal stages, we detected a distinct pattern of SARS-CoV-2 entry associated genes transcripts in brain vascular endothelial cells and microglia, providing a potential explanation for an inflammatory response in the brain endothelium upon SARS-CoV-2 infection."]}
{"id": 1000300, "claim": "The rat brain vasculature shows a distinct expression pattern of sars-cov-2 entry factors", "label": "REFUTED", "evidence": ["Our study serves as a publicly available single-cell atlas of SARS-CoV-2 related entry factors and interaction partners in human and mouse brain endothelial- and perivascular cells, which can be employed for future studies in clinical samples of COVID-19 patients.", "We observed a distinct expression pattern of the cathepsins B (CTSB) and -L (CTSL) - which are able to substitute for the ACE2 co-receptor TMPRSS2 - in the human vasculature with CTSB being mainly expressed in the brain vasculature and CTSL predominantly in the peripheral vasculature, and these observations were confirmed at the protein level in the Human Protein Atlas and using immunofluorescence stainings.", "This expression pattern of SARS-CoV-2 viral-entry associated proteases and SARS-CoV-2 interaction partners was also present in endothelial cells and microglia in the fetal brain, suggesting a developmentally established SARS-CoV-2 entry machinery in the human vasculature.", "At both the adult and fetal stages, we detected a distinct pattern of SARS-CoV-2 entry associated genes transcripts in brain vascular endothelial cells and microglia, providing a potential explanation for an inflammatory response in the brain endothelium upon SARS-CoV-2 infection."]}
{"id": 1000301, "claim": "The mouse brain vasculature shows a distinct expression pattern of sars-cov-2 entry factors", "label": "REFUTED", "evidence": ["Our study serves as a publicly available single-cell atlas of SARS-CoV-2 related entry factors and interaction partners in human and mouse brain endothelial- and perivascular cells, which can be employed for future studies in clinical samples of COVID-19 patients.", "We observed a distinct expression pattern of the cathepsins B (CTSB) and -L (CTSL) - which are able to substitute for the ACE2 co-receptor TMPRSS2 - in the human vasculature with CTSB being mainly expressed in the brain vasculature and CTSL predominantly in the peripheral vasculature, and these observations were confirmed at the protein level in the Human Protein Atlas and using immunofluorescence stainings.", "This expression pattern of SARS-CoV-2 viral-entry associated proteases and SARS-CoV-2 interaction partners was also present in endothelial cells and microglia in the fetal brain, suggesting a developmentally established SARS-CoV-2 entry machinery in the human vasculature.", "At both the adult and fetal stages, we detected a distinct pattern of SARS-CoV-2 entry associated genes transcripts in brain vascular endothelial cells and microglia, providing a potential explanation for an inflammatory response in the brain endothelium upon SARS-CoV-2 infection."]}
{"id": 1000302, "claim": "In the lab , st. jude researchers uncover origins of deadly inflammation caused by the novel coronavirus", "label": "SUPPORTED", "evidence": ["Researchers further concluded that existing drugs, Remicade and Gamifant, which are used to treat such inflammatory diseases as Crohns disease and colitis prevented COVID-19 complications in laboratory models.", "A team led by Thirumala-Devi Kanneganti, PhD, vice chair of the St. Jude Department of Immunology, identified a previously unknown interaction between two messenger proteins that can unleash a cascade of inflammatory cell death, leading to tissue damage and multiple organ failure."]}
{"id": 1000303, "claim": "In the lab, st. chinese researchers uncover origins of deadly inflammation caused by the novel coronavirus", "label": "REFUTED", "evidence": ["Researchers further concluded that existing drugs, Remicade and Gamifant, which are used to treat such inflammatory diseases as Crohns disease and colitis prevented COVID-19 complications in laboratory models.", "A team led by Thirumala-Devi Kanneganti, PhD, vice chair of the St. Jude Department of Immunology, identified a previously unknown interaction between two messenger proteins that can unleash a cascade of inflammatory cell death, leading to tissue damage and multiple organ failure."]}
{"id": 1000304, "claim": "In the lab, st.org researchers uncover origins of deadly inflammation caused by the novel coronavirus", "label": "REFUTED", "evidence": ["Researchers further concluded that existing drugs, Remicade and Gamifant, which are used to treat such inflammatory diseases as Crohns disease and colitis prevented COVID-19 complications in laboratory models.", "A team led by Thirumala-Devi Kanneganti, PhD, vice chair of the St. Jude Department of Immunology, identified a previously unknown interaction between two messenger proteins that can unleash a cascade of inflammatory cell death, leading to tissue damage and multiple organ failure."]}
{"id": 1000305, "claim": "In the lab, st.uk researchers uncover origins of deadly inflammation caused by the novel coronavirus", "label": "REFUTED", "evidence": ["Researchers further concluded that existing drugs, Remicade and Gamifant, which are used to treat such inflammatory diseases as Crohns disease and colitis prevented COVID-19 complications in laboratory models.", "A team led by Thirumala-Devi Kanneganti, PhD, vice chair of the St. Jude Department of Immunology, identified a previously unknown interaction between two messenger proteins that can unleash a cascade of inflammatory cell death, leading to tissue damage and multiple organ failure."]}
{"id": 1000306, "claim": "Researchers set to begin clinical trials on coronavirus treatment", "label": "SUPPORTED", "evidence": ["Please note: Only people whove been diagnosed as COVID-19 positive and been admitted to a hospital where the clinical trial will take place can participate.", "University of Queensland Centre for Clinical Research Director and Consultant Infectious Diseases Physician at the Royal Brisbane and Womens Hospital (RBWH) Professor David Paterson said the drugs proved highly effective when first used against the virus in test tubes.", "Were now ready to begin patient trials with the drugs, one of which is an HIV medication and the other an anti-malaria drug, Professor Paterson said."]}
{"id": 1000307, "claim": "Participants set to begin clinical trials on coronavirus treatment", "label": "REFUTED", "evidence": ["Please note: Only people whove been diagnosed as COVID-19 positive and been admitted to a hospital where the clinical trial will take place can participate.", "University of Queensland Centre for Clinical Research Director and Consultant Infectious Diseases Physician at the Royal Brisbane and Womens Hospital (RBWH) Professor David Paterson said the drugs proved highly effective when first used against the virus in test tubes.", "Were now ready to begin patient trials with the drugs, one of which is an HIV medication and the other an anti-malaria drug, Professor Paterson said."]}
{"id": 1000308, "claim": "Functional fear predicts public health compliance in the covid-19 pandemic", "label": "SUPPORTED", "evidence": ["The effectiveness of moral messages on public health behavioral intentions during the COVID-19 pandemic.", "In the current context, this appears to be the case with negative emotions being protective (i.e., encouraging of public health-promoting behaviors) during the COVID-19 pandemic.", "Changes in risk perception and protective behavior during the first week of the COVID-19 pandemic in the United States.", "That is, for most individuals, the anxious responses being assessed by the FCV-19 may represent a normal and adaptive response to a real and present danger that one cannot fight or flee from, within the environment (i.e., the COVID-19 pandemic)."]}
{"id": 1000309, "claim": "Functional fear predicts public financial compliance in the covid-19 pandemic", "label": "REFUTED", "evidence": ["The effectiveness of moral messages on public health behavioral intentions during the COVID-19 pandemic.", "In the current context, this appears to be the case with negative emotions being protective (i.e., encouraging of public health-promoting behaviors) during the COVID-19 pandemic.", "Changes in risk perception and protective behavior during the first week of the COVID-19 pandemic in the United States.", "That is, for most individuals, the anxious responses being assessed by the FCV-19 may represent a normal and adaptive response to a real and present danger that one cannot fight or flee from, within the environment (i.e., the COVID-19 pandemic)."]}
{"id": 1000310, "claim": "Functional fear predicts public economic compliance in the covid-19 pandemic", "label": "REFUTED", "evidence": ["The effectiveness of moral messages on public health behavioral intentions during the COVID-19 pandemic.", "In the current context, this appears to be the case with negative emotions being protective (i.e., encouraging of public health-promoting behaviors) during the COVID-19 pandemic.", "Changes in risk perception and protective behavior during the first week of the COVID-19 pandemic in the United States.", "That is, for most individuals, the anxious responses being assessed by the FCV-19 may represent a normal and adaptive response to a real and present danger that one cannot fight or flee from, within the environment (i.e., the COVID-19 pandemic)."]}
{"id": 1000311, "claim": "Functional fear predicts public media compliance in the covid-19 pandemic", "label": "REFUTED", "evidence": ["The effectiveness of moral messages on public health behavioral intentions during the COVID-19 pandemic.", "In the current context, this appears to be the case with negative emotions being protective (i.e., encouraging of public health-promoting behaviors) during the COVID-19 pandemic.", "Changes in risk perception and protective behavior during the first week of the COVID-19 pandemic in the United States.", "That is, for most individuals, the anxious responses being assessed by the FCV-19 may represent a normal and adaptive response to a real and present danger that one cannot fight or flee from, within the environment (i.e., the COVID-19 pandemic)."]}
{"id": 1000312, "claim": "Modified vaccinia ankara based sars-cov-2 vaccine expressing full-length spike induces strong neutralizing antibody response", "label": "SUPPORTED", "evidence": ["Following immunizations with MVA/S or MVA/S1, both spike protein recombinants induced strong IgG antibodies to purified full-length SARS-CoV-2 spike protein.", "These results demonstrate MVA/S is a potential vaccine candidate against SARS-CoV-2 infection.", "The MVA/S induced a robust antibody response to purified RBD, S1 and S2 whereas MVA/S1 induced an antibody response to the S1 region outside of the RBD region."]}
{"id": 1000313, "claim": "Modified vaccinia ankara based sars-cov-2 vaccine lacking full-length spike induces strong neutralizing antibody response", "label": "REFUTED", "evidence": ["Following immunizations with MVA/S or MVA/S1, both spike protein recombinants induced strong IgG antibodies to purified full-length SARS-CoV-2 spike protein.", "These results demonstrate MVA/S is a potential vaccine candidate against SARS-CoV-2 infection.", "The MVA/S induced a robust antibody response to purified RBD, S1 and S2 whereas MVA/S1 induced an antibody response to the S1 region outside of the RBD region."]}
{"id": 1000314, "claim": "Novel mutation identified in sars-cov-2 spike protein from sweden", "label": "SUPPORTED", "evidence": ["The mutation changes an arginine residue to a histidine residue at position 364 in the S1 subunit of the viral spike protein.", "The mutation is located at the surface of the S1 subunit of the SARS-CoV-2 spike protein, the main surface structure the virus uses to gain entry to host cells.", "SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein.", "Tatiany Soratto and colleagues from the Karolinska Institutet, Sweden, and the Federal University of Santa Catarina, in Brazil, say it is possible the unknown mutation could affect the ability of the virus to bind to host cells."]}
{"id": 1000315, "claim": "No mutation identified in sars-cov-2 spike protein from sweden", "label": "REFUTED", "evidence": ["The mutation changes an arginine residue to a histidine residue at position 364 in the S1 subunit of the viral spike protein.", "The mutation is located at the surface of the S1 subunit of the SARS-CoV-2 spike protein, the main surface structure the virus uses to gain entry to host cells.", "SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein.", "Tatiany Soratto and colleagues from the Karolinska Institutet, Sweden, and the Federal University of Santa Catarina, in Brazil, say it is possible the unknown mutation could affect the ability of the virus to bind to host cells."]}
{"id": 1000316, "claim": "One mutation identified in sars-cov-2 spike protein from sweden", "label": "REFUTED", "evidence": ["The mutation changes an arginine residue to a histidine residue at position 364 in the S1 subunit of the viral spike protein.", "The mutation is located at the surface of the S1 subunit of the SARS-CoV-2 spike protein, the main surface structure the virus uses to gain entry to host cells.", "SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein.", "Tatiany Soratto and colleagues from the Karolinska Institutet, Sweden, and the Federal University of Santa Catarina, in Brazil, say it is possible the unknown mutation could affect the ability of the virus to bind to host cells."]}
{"id": 1000317, "claim": "Our main findings are that cardiac involvement may occur with covid-19 even without respiratory tract signs and symptoms of infection .", "label": "SUPPORTED", "evidence": ["Heart palpitations have been reported to be the main presenting symptom of COVID-19 in patients without a fever or cough82.", "Patients with COVID-19 infection can present with symptoms mimicking CV events, including chest pain, dyspnoea, and shock, even in the absence of cardiac injury.", "An autopsy of a patient with COVID-19 and ARDS who died of a sudden cardiac arrest showed no evidence of myocardial structural involvement, suggesting that COVID-19 did not directly impair the heart57.", "These observations suggest that COVID-19 can cause ACS even in the absence of substantial systemic inflammation."]}
{"id": 1000318, "claim": "Our main findings are that cardiac involvement cannot occur with covid-19 even without respiratory tract signs and symptoms of infection.", "label": "REFUTED", "evidence": ["Heart palpitations have been reported to be the main presenting symptom of COVID-19 in patients without a fever or cough82.", "Patients with COVID-19 infection can present with symptoms mimicking CV events, including chest pain, dyspnoea, and shock, even in the absence of cardiac injury.", "An autopsy of a patient with COVID-19 and ARDS who died of a sudden cardiac arrest showed no evidence of myocardial structural involvement, suggesting that COVID-19 did not directly impair the heart57.", "These observations suggest that COVID-19 can cause ACS even in the absence of substantial systemic inflammation."]}
{"id": 1000319, "claim": "Sars-cov-2 viroporin triggers the nlrp3 inflammatory pathway", "label": "SUPPORTED", "evidence": ["We report that the SARS-CoV-2 viroporin encoded by ORF3a activates the NLRP3 inflammasome, the most promiscuous of known inflammasomes.", "In a pared-down system, we investigate the influence of ORF3a, an essential SARS-CoV-2 protein, on the inflammatory machinery and find that it activates NLRP3, the most prominent inflammasome by causing potassium loss across the cell membrane."]}
{"id": 1000320, "claim": "Sars-cov-2 viroporin regulates the nlrp3 inflammatory pathway", "label": "REFUTED", "evidence": ["We report that the SARS-CoV-2 viroporin encoded by ORF3a activates the NLRP3 inflammasome, the most promiscuous of known inflammasomes.", "In a pared-down system, we investigate the influence of ORF3a, an essential SARS-CoV-2 protein, on the inflammatory machinery and find that it activates NLRP3, the most prominent inflammasome by causing potassium loss across the cell membrane."]}
{"id": 1000321, "claim": "Gilead 's coronavirus wonder-drug remdesivir is masking a board contagion", "label": "SUPPORTED", "evidence": ["The report revealed that 36 of 53 patients hospitalized for severe COVID-19 who were treated with compassionate-use Remdesivir had clinical improvement."]}
{"id": 1000322, "claim": "Inead's coronavirus wonder-drug remdesivir is masking a board contagion", "label": "REFUTED", "evidence": ["The report revealed that 36 of 53 patients hospitalized for severe COVID-19 who were treated with compassionate-use Remdesivir had clinical improvement."]}
{"id": 1000323, "claim": "Anead's coronavirus wonder-drug remdesivir is masking a board contagion", "label": "REFUTED", "evidence": ["The report revealed that 36 of 53 patients hospitalized for severe COVID-19 who were treated with compassionate-use Remdesivir had clinical improvement."]}
{"id": 1000324, "claim": "Sead's coronavirus wonder-drug remdesivir is masking a board contagion", "label": "REFUTED", "evidence": ["The report revealed that 36 of 53 patients hospitalized for severe COVID-19 who were treated with compassionate-use Remdesivir had clinical improvement."]}
{"id": 1000325, "claim": "The sars-cov-2 spike protein disrupts the cooperative function of human cardiac pericytes.", "label": "SUPPORTED", "evidence": ["To date, it is still not known if the S protein alone, without the other viral elements, is able to trigger vascular cell signalling and provoke cell dysfunction."]}
{"id": 1000326, "claim": "The sars-cov-2 spike protein closelys the cooperative function of human cardiac pericytes.", "label": "REFUTED", "evidence": ["To date, it is still not known if the S protein alone, without the other viral elements, is able to trigger vascular cell signalling and provoke cell dysfunction."]}
{"id": 1000327, "claim": "Cepi and sk bioscience extend collaboration to develop next generation covid-19 vaccine", "label": "SUPPORTED", "evidence": ["CEPI has also partnered with bioscience facilities SK bioscience and GC Pharma to reserve manufacturing capacities exclusively for one or more CEPI-funded COVID-19 vaccines.", "Im pleased to expand our partnership with SK bioscience to develop their vaccine candidate, GBP510, which marks CEPIs first investment in Wave 2 vaccines.", "For the COVID-19 vaccine response, SK bioscience is undergoing development for its vaccine candidate against SARS- CoV-2 with support from the Bill and Melinda Gates Foundation and CEPI, and using its established development and manufacturing capabilities, it has recently agreed to develop and manufacture AstraZenecas and Novavaxs COVID-19 vaccine candidates.", "SK bioscience and CEPI are committed to global equitable access of COVID-19 vaccines and have agreed that this vaccine candidate will be made available for procurement and allocation, if proven to be safe and effective, through the COVID-19 Vaccine Global Access (COVAX) Facility."]}
{"id": 1000328, "claim": "Cepi and sk bioscience extend collaboration to develop first generation covid-19 vaccine", "label": "REFUTED", "evidence": ["CEPI has also partnered with bioscience facilities SK bioscience and GC Pharma to reserve manufacturing capacities exclusively for one or more CEPI-funded COVID-19 vaccines.", "Im pleased to expand our partnership with SK bioscience to develop their vaccine candidate, GBP510, which marks CEPIs first investment in Wave 2 vaccines.", "For the COVID-19 vaccine response, SK bioscience is undergoing development for its vaccine candidate against SARS- CoV-2 with support from the Bill and Melinda Gates Foundation and CEPI, and using its established development and manufacturing capabilities, it has recently agreed to develop and manufacture AstraZenecas and Novavaxs COVID-19 vaccine candidates.", "SK bioscience and CEPI are committed to global equitable access of COVID-19 vaccines and have agreed that this vaccine candidate will be made available for procurement and allocation, if proven to be safe and effective, through the COVID-19 Vaccine Global Access (COVAX) Facility."]}
{"id": 1000329, "claim": "Sars-cov-2 evolved into two major types", "label": "SUPPORTED", "evidence": ["term these two types L and S type: two major types (L and S types): the S type is ancestral, and the L type evolved from S type.", "We hypothesized that the two types of SARS-CoV-2 viruses might have experienced different selective pressures due to different epidemiological features."]}
{"id": 1000330, "claim": "Sars-cov-2 evolved into four major types", "label": "REFUTED", "evidence": ["term these two types L and S type: two major types (L and S types): the S type is ancestral, and the L type evolved from S type.", "We hypothesized that the two types of SARS-CoV-2 viruses might have experienced different selective pressures due to different epidemiological features."]}
{"id": 1000331, "claim": "Sars-cov-2 evolved into five major types", "label": "REFUTED", "evidence": ["term these two types L and S type: two major types (L and S types): the S type is ancestral, and the L type evolved from S type.", "We hypothesized that the two types of SARS-CoV-2 viruses might have experienced different selective pressures due to different epidemiological features."]}
{"id": 1000332, "claim": "Sars-cov-2 evolved into six major types", "label": "REFUTED", "evidence": ["term these two types L and S type: two major types (L and S types): the S type is ancestral, and the L type evolved from S type.", "We hypothesized that the two types of SARS-CoV-2 viruses might have experienced different selective pressures due to different epidemiological features."]}
{"id": 1000333, "claim": "A bra manufacturer has begun making masks , instead of bras", "label": "SUPPORTED", "evidence": ["Share The worlds leading manufacturer of respirator masks may have originally intended them to be bras.", "The shift came when an employee realized that the bra materials were similar to ones used in masks.", "Companies create lacy masks out of BRAS after people started turning their old lingerie into makeshift PPE People have been making their own face masks out of bras Molded bra cups actually inspired the N95 mask, though these homemade versions offer considerably less protection A Japanese lingerie company is also selling masks made from their bra materials In the US, the $39.99 Emergency Bra 'can be transformed into two facemasks to reduce the inhalation of harmful chemical, biohazard and dust particulate' By Carly Stern For Dailymail.com Published: 16:45 EST, 29 April 2020 ", "Fast Company points out that it's actually not so surprising that masks are being made from bras  since bras inspired the N95 mask."]}
{"id": 1000334, "claim": "A bra manufacturer has not making masks, instead of bras", "label": "REFUTED", "evidence": ["Share The worlds leading manufacturer of respirator masks may have originally intended them to be bras.", "The shift came when an employee realized that the bra materials were similar to ones used in masks.", "Companies create lacy masks out of BRAS after people started turning their old lingerie into makeshift PPE People have been making their own face masks out of bras Molded bra cups actually inspired the N95 mask, though these homemade versions offer considerably less protection A Japanese lingerie company is also selling masks made from their bra materials In the US, the $39.99 Emergency Bra 'can be transformed into two facemasks to reduce the inhalation of harmful chemical, biohazard and dust particulate' By Carly Stern For Dailymail.com Published: 16:45 EST, 29 April 2020 ", "Fast Company points out that it's actually not so surprising that masks are being made from bras  since bras inspired the N95 mask."]}
{"id": 1000335, "claim": "A bra manufacturer has no making masks, instead of bras", "label": "REFUTED", "evidence": ["Share The worlds leading manufacturer of respirator masks may have originally intended them to be bras.", "The shift came when an employee realized that the bra materials were similar to ones used in masks.", "Companies create lacy masks out of BRAS after people started turning their old lingerie into makeshift PPE People have been making their own face masks out of bras Molded bra cups actually inspired the N95 mask, though these homemade versions offer considerably less protection A Japanese lingerie company is also selling masks made from their bra materials In the US, the $39.99 Emergency Bra 'can be transformed into two facemasks to reduce the inhalation of harmful chemical, biohazard and dust particulate' By Carly Stern For Dailymail.com Published: 16:45 EST, 29 April 2020 ", "Fast Company points out that it's actually not so surprising that masks are being made from bras  since bras inspired the N95 mask."]}
{"id": 1000336, "claim": "A bra manufacturer has begun making attention, instead of bras", "label": "REFUTED", "evidence": ["Share The worlds leading manufacturer of respirator masks may have originally intended them to be bras.", "The shift came when an employee realized that the bra materials were similar to ones used in masks.", "Companies create lacy masks out of BRAS after people started turning their old lingerie into makeshift PPE People have been making their own face masks out of bras Molded bra cups actually inspired the N95 mask, though these homemade versions offer considerably less protection A Japanese lingerie company is also selling masks made from their bra materials In the US, the $39.99 Emergency Bra 'can be transformed into two facemasks to reduce the inhalation of harmful chemical, biohazard and dust particulate' By Carly Stern For Dailymail.com Published: 16:45 EST, 29 April 2020 ", "Fast Company points out that it's actually not so surprising that masks are being made from bras  since bras inspired the N95 mask."]}
{"id": 1000337, "claim": "Higher ace2 expression found in fat and cancer cells", "label": "SUPPORTED", "evidence": ["ACE2 expression correlated with increased macrophage abundance in some tumors, while TMPRSS2 was strongly associated with epithelial cells.", "Results Matched normal tissues generally display higher ACE2 and TMPRSS2 expression compared with cancer, with normal and tumor from digestive organs expressing the highest levels.", "The expression of ACE2 and TMPRSS2 was significantly higher in normal tissues relative to tumors (figure 1C).", "By the search for network database and re-analysis of pubic data, we found the level of ACE2 expression in adipose tissue was higher than that in lung tissue, which indicated the adipose tissue might be vulnerable to SARS-CoV-2 as well; the levels of ACE2 expressed by adipocytes and adipose progenitor cells were similar between non-obese individuals and obese individuals, but obese individuals have more adiposes so as to increase the number of ACE2-expressing cells; the expression of ACE2 in tumor tissues posed by five different types of cancers increased significantly compared with that in adjacent tissues."]}
{"id": 1000338, "claim": "No ace2 expression found in fat and cancer cells", "label": "REFUTED", "evidence": ["ACE2 expression correlated with increased macrophage abundance in some tumors, while TMPRSS2 was strongly associated with epithelial cells.", "Results Matched normal tissues generally display higher ACE2 and TMPRSS2 expression compared with cancer, with normal and tumor from digestive organs expressing the highest levels.", "The expression of ACE2 and TMPRSS2 was significantly higher in normal tissues relative to tumors (figure 1C).", "By the search for network database and re-analysis of pubic data, we found the level of ACE2 expression in adipose tissue was higher than that in lung tissue, which indicated the adipose tissue might be vulnerable to SARS-CoV-2 as well; the levels of ACE2 expressed by adipocytes and adipose progenitor cells were similar between non-obese individuals and obese individuals, but obese individuals have more adiposes so as to increase the number of ACE2-expressing cells; the expression of ACE2 in tumor tissues posed by five different types of cancers increased significantly compared with that in adjacent tissues."]}
{"id": 1000339, "claim": "Higher ace2 expression decreased in fat and cancer cells", "label": "REFUTED", "evidence": ["ACE2 expression correlated with increased macrophage abundance in some tumors, while TMPRSS2 was strongly associated with epithelial cells.", "Results Matched normal tissues generally display higher ACE2 and TMPRSS2 expression compared with cancer, with normal and tumor from digestive organs expressing the highest levels.", "The expression of ACE2 and TMPRSS2 was significantly higher in normal tissues relative to tumors (figure 1C).", "By the search for network database and re-analysis of pubic data, we found the level of ACE2 expression in adipose tissue was higher than that in lung tissue, which indicated the adipose tissue might be vulnerable to SARS-CoV-2 as well; the levels of ACE2 expressed by adipocytes and adipose progenitor cells were similar between non-obese individuals and obese individuals, but obese individuals have more adiposes so as to increase the number of ACE2-expressing cells; the expression of ACE2 in tumor tissues posed by five different types of cancers increased significantly compared with that in adjacent tissues."]}
{"id": 1000340, "claim": "Considering bcg vaccination to reduce the impact of covid-19", "label": "SUPPORTED", "evidence": ["New disease old vaccine: Is recombinant BCG vaccine an answer for COVID-19?", "The influence of vaccination against tuberculosis with the Bacillus-Calmette-Guérin(BCG) vaccine on COVID-19 incidence and mortality - review of the literature."]}
{"id": 1000341, "claim": "Considering bcg vaccination to enhance the impact of covid-19", "label": "REFUTED", "evidence": ["New disease old vaccine: Is recombinant BCG vaccine an answer for COVID-19?", "The influence of vaccination against tuberculosis with the Bacillus-Calmette-Guérin(BCG) vaccine on COVID-19 incidence and mortality - review of the literature."]}
{"id": 1000342, "claim": "Considering bcg vaccination to increase the impact of covid-19", "label": "REFUTED", "evidence": ["New disease old vaccine: Is recombinant BCG vaccine an answer for COVID-19?", "The influence of vaccination against tuberculosis with the Bacillus-Calmette-Guérin(BCG) vaccine on COVID-19 incidence and mortality - review of the literature."]}
{"id": 1000343, "claim": "Lack of immune homology with vaccine preventable pathogens suggests childhood immunizations do not protect against sars-cov-2 through adaptive cross-immunity", "label": "SUPPORTED", "evidence": ["In summary, lack of immune homology between SARS-CoV-2 and VPD pathogens suggests that childhood immunization history (i.e., BCG vaccination or others) does not provide protection from SARS-CoV-2 through adaptive cross-immunity.", "Little to no immune homology between SARS-CoV-2 and VPD pathogens: insignificant aligned protein sequences, unmapped immune epitopes, or matched N-glycosylation sites with different glycosylation potentials and positions.", "BCG vaccination is unlikely to confer SARS-CoV-2 protection through adaptive cross-immunity."]}
{"id": 1000344, "claim": "Lack of immune homology with vaccine preventable pathogens suggests childhood immunizations do also protect against sars-cov-2 through adaptive cross-immunity", "label": "REFUTED", "evidence": ["In summary, lack of immune homology between SARS-CoV-2 and VPD pathogens suggests that childhood immunization history (i.e., BCG vaccination or others) does not provide protection from SARS-CoV-2 through adaptive cross-immunity.", "Little to no immune homology between SARS-CoV-2 and VPD pathogens: insignificant aligned protein sequences, unmapped immune epitopes, or matched N-glycosylation sites with different glycosylation potentials and positions.", "BCG vaccination is unlikely to confer SARS-CoV-2 protection through adaptive cross-immunity."]}
{"id": 1000345, "claim": "Lack of immune homology with vaccine preventable pathogens suggests childhood immunizations do directly protect against sars-cov-2 through adaptive cross-immunity", "label": "REFUTED", "evidence": ["In summary, lack of immune homology between SARS-CoV-2 and VPD pathogens suggests that childhood immunization history (i.e., BCG vaccination or others) does not provide protection from SARS-CoV-2 through adaptive cross-immunity.", "Little to no immune homology between SARS-CoV-2 and VPD pathogens: insignificant aligned protein sequences, unmapped immune epitopes, or matched N-glycosylation sites with different glycosylation potentials and positions.", "BCG vaccination is unlikely to confer SARS-CoV-2 protection through adaptive cross-immunity."]}
{"id": 1000346, "claim": "Lack of immune homology with vaccine preventable pathogens suggests childhood immunizations do more protect against sars-cov-2 through adaptive cross-immunity", "label": "REFUTED", "evidence": ["In summary, lack of immune homology between SARS-CoV-2 and VPD pathogens suggests that childhood immunization history (i.e., BCG vaccination or others) does not provide protection from SARS-CoV-2 through adaptive cross-immunity.", "Little to no immune homology between SARS-CoV-2 and VPD pathogens: insignificant aligned protein sequences, unmapped immune epitopes, or matched N-glycosylation sites with different glycosylation potentials and positions.", "BCG vaccination is unlikely to confer SARS-CoV-2 protection through adaptive cross-immunity."]}
{"id": 1000347, "claim": "Poverty and economic dislocation reduce compliance with covid-19 shelter-in-place protocols", "label": "SUPPORTED", "evidence": ["Specifically, residents of low income areas complied with shelter-in- place ordinances less than their counterparts in areas with stronger economic endowments, even after accounting for potential confounding factors including partisanship, population density, exposure to recent trade disputes, unemployment, and other factors."]}
{"id": 1000348, "claim": "Poverty and economic dislocation increased compliance with covid-19 shelter-in-place protocols", "label": "REFUTED", "evidence": ["Specifically, residents of low income areas complied with shelter-in- place ordinances less than their counterparts in areas with stronger economic endowments, even after accounting for potential confounding factors including partisanship, population density, exposure to recent trade disputes, unemployment, and other factors."]}
{"id": 1000349, "claim": "Poverty and economic dislocation improved compliance with covid-19 shelter-in-place protocols", "label": "REFUTED", "evidence": ["Specifically, residents of low income areas complied with shelter-in- place ordinances less than their counterparts in areas with stronger economic endowments, even after accounting for potential confounding factors including partisanship, population density, exposure to recent trade disputes, unemployment, and other factors."]}
{"id": 1000350, "claim": "Poverty and economic dislocation are compliance with covid-19 shelter-in-place protocols", "label": "REFUTED", "evidence": ["Specifically, residents of low income areas complied with shelter-in- place ordinances less than their counterparts in areas with stronger economic endowments, even after accounting for potential confounding factors including partisanship, population density, exposure to recent trade disputes, unemployment, and other factors."]}
{"id": 1000351, "claim": "Reappearance of effector t cells predicts successful recovery from covid-19", "label": "SUPPORTED", "evidence": ["Understanding T cell-responses in the context of clinical severity might serve as foundation to overcome the lack of effective anti-viral immune response in severely affected COVID-19 patients and can offer prognostic value as biomarker for disease outcome and control.", "Follow up samples revealed a marked increase in effector T cells and memory subsets in convalescing but not in non-convalescing patients."]}
{"id": 1000352, "claim": "Reappearance of effector t cells cannots successful recovery from covid-19", "label": "REFUTED", "evidence": ["Understanding T cell-responses in the context of clinical severity might serve as foundation to overcome the lack of effective anti-viral immune response in severely affected COVID-19 patients and can offer prognostic value as biomarker for disease outcome and control.", "Follow up samples revealed a marked increase in effector T cells and memory subsets in convalescing but not in non-convalescing patients."]}
{"id": 1000353, "claim": "Cuomo questions testing rates in u.s. as cases top 1,000", "label": "SUPPORTED", "evidence": ["Meanwhile, the governor of New York has questioned the number of people who have been tested for the virus in the U.S. Full story "]}
{"id": 1000354, "claim": "Cuomo questions testing rates in u.s. as cases top 1,.", "label": "REFUTED", "evidence": ["Meanwhile, the governor of New York has questioned the number of people who have been tested for the virus in the U.S. Full story "]}
{"id": 1000355, "claim": "Sulfated polysaccharides effectively inhibit sars-cov-2 in vitro", "label": "SUPPORTED", "evidence": ["Our results reveal that specific sulfated polysaccharides bind tightly to the S-protein of SARS-CoV-2 in vitro, which suggests that they can act as decoys to interfere with S-protein binding to the heparan sulfate co-receptor in host tissues3,11, inhibiting viral infection.", "Vero cells were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 2.5 × 103 with varying dosages of polysaccharide to confirm antiviral activity."]}
{"id": 1000356, "claim": "Sulfated polysaccharides effectively activate sars-cov-2 in vitro", "label": "REFUTED", "evidence": ["Our results reveal that specific sulfated polysaccharides bind tightly to the S-protein of SARS-CoV-2 in vitro, which suggests that they can act as decoys to interfere with S-protein binding to the heparan sulfate co-receptor in host tissues3,11, inhibiting viral infection.", "Vero cells were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 2.5 × 103 with varying dosages of polysaccharide to confirm antiviral activity."]}
{"id": 1000357, "claim": "Sulfated polysaccharides effectively produce sars-cov-2 in vitro", "label": "REFUTED", "evidence": ["Our results reveal that specific sulfated polysaccharides bind tightly to the S-protein of SARS-CoV-2 in vitro, which suggests that they can act as decoys to interfere with S-protein binding to the heparan sulfate co-receptor in host tissues3,11, inhibiting viral infection.", "Vero cells were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 2.5 × 103 with varying dosages of polysaccharide to confirm antiviral activity."]}
{"id": 1000358, "claim": "Sulfated polysaccharides effectively induce sars-cov-2 in vitro", "label": "REFUTED", "evidence": ["Our results reveal that specific sulfated polysaccharides bind tightly to the S-protein of SARS-CoV-2 in vitro, which suggests that they can act as decoys to interfere with S-protein binding to the heparan sulfate co-receptor in host tissues3,11, inhibiting viral infection.", "Vero cells were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 2.5 × 103 with varying dosages of polysaccharide to confirm antiviral activity."]}
{"id": 1000359, "claim": "Mcdonald 's to shut seating and play areas due to covid-19", "label": "SUPPORTED", "evidence": ["Click here for complete coronavirus coverage from Microsoft News Follow Charisse Jones on Twitter @charissejones This article originally appeared on USA TODAY:McDonald's to shut seating, play areas due to COVID-19 Go to MSN Home AdChoices AdChoices ", "\"To align with increasing regulations throughout the country, effective at the close of business today, McDonalds USA company-owned restaurants will close seating areas, including the use of self-service beverage bars and kiosks, and shift our focus to serving customers through Drive-Thru, walk-in take-out and McDelivery,'' the company said in a statement.", "Veuer UP NEXT In the latest nod to how the coronavirus is disrupting Americans' daily rituals and patterns, McDonald's said Monday that it is closing all seating and play areas in its company-owned U.S. restaurants after close of business today.", "McDonald's To Shut Seating And Play Areas Amid COVID-19 Pandemic - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [."]}
{"id": 1000360, "claim": "Mcdonald's to become seating and play areas due to covid-19", "label": "REFUTED", "evidence": ["Click here for complete coronavirus coverage from Microsoft News Follow Charisse Jones on Twitter @charissejones This article originally appeared on USA TODAY:McDonald's to shut seating, play areas due to COVID-19 Go to MSN Home AdChoices AdChoices ", "\"To align with increasing regulations throughout the country, effective at the close of business today, McDonalds USA company-owned restaurants will close seating areas, including the use of self-service beverage bars and kiosks, and shift our focus to serving customers through Drive-Thru, walk-in take-out and McDelivery,'' the company said in a statement.", "Veuer UP NEXT In the latest nod to how the coronavirus is disrupting Americans' daily rituals and patterns, McDonald's said Monday that it is closing all seating and play areas in its company-owned U.S. restaurants after close of business today.", "McDonald's To Shut Seating And Play Areas Amid COVID-19 Pandemic - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [."]}
{"id": 1000361, "claim": "Mcdonald's to make seating and play areas due to covid-19", "label": "REFUTED", "evidence": ["Click here for complete coronavirus coverage from Microsoft News Follow Charisse Jones on Twitter @charissejones This article originally appeared on USA TODAY:McDonald's to shut seating, play areas due to COVID-19 Go to MSN Home AdChoices AdChoices ", "\"To align with increasing regulations throughout the country, effective at the close of business today, McDonalds USA company-owned restaurants will close seating areas, including the use of self-service beverage bars and kiosks, and shift our focus to serving customers through Drive-Thru, walk-in take-out and McDelivery,'' the company said in a statement.", "Veuer UP NEXT In the latest nod to how the coronavirus is disrupting Americans' daily rituals and patterns, McDonald's said Monday that it is closing all seating and play areas in its company-owned U.S. restaurants after close of business today.", "McDonald's To Shut Seating And Play Areas Amid COVID-19 Pandemic - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [."]}
{"id": 1000362, "claim": "Mcdonald's to have seating and play areas due to covid-19", "label": "REFUTED", "evidence": ["Click here for complete coronavirus coverage from Microsoft News Follow Charisse Jones on Twitter @charissejones This article originally appeared on USA TODAY:McDonald's to shut seating, play areas due to COVID-19 Go to MSN Home AdChoices AdChoices ", "\"To align with increasing regulations throughout the country, effective at the close of business today, McDonalds USA company-owned restaurants will close seating areas, including the use of self-service beverage bars and kiosks, and shift our focus to serving customers through Drive-Thru, walk-in take-out and McDelivery,'' the company said in a statement.", "Veuer UP NEXT In the latest nod to how the coronavirus is disrupting Americans' daily rituals and patterns, McDonald's said Monday that it is closing all seating and play areas in its company-owned U.S. restaurants after close of business today.", "McDonald's To Shut Seating And Play Areas Amid COVID-19 Pandemic - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [."]}
{"id": 1000363, "claim": "One art regimen tied to lower covid-19 risk in hiv", "label": "SUPPORTED", "evidence": ["Researchers estimated a risk for COVID-19 diagnosis of 30.0 per 10.000 and 3.7 per 10,000 for death among HIV-positive people receiving ART.", "Risk of COVID-19 diagnosis and hospitalization was lower for people living with HIV receiving Truvada, or tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), compared with those on other ART regimens, as well as the Spanish population ages 20-79, reported Julia del Amo, MD, PhD, of the National Plan Against AIDS in Madrid, and colleagues.", "Moreover, the risk of COVID-19 diagnosis was not higher among people living with HIV on ART than the general population of Spain, they wrote in the Annals of Internal Medicine.", "\"The lack of increased risk for serious COVID-19 among HIV-positive persons might be the result of their use of ART,\" they wrote, adding ART was proposed as a protective factor against SARS in 2003, but there were too few cases to draw meaningful conclusions about its role."]}
{"id": 1000364, "claim": "One art regimen tied to increasing covid-19 risk in hiv", "label": "REFUTED", "evidence": ["Researchers estimated a risk for COVID-19 diagnosis of 30.0 per 10.000 and 3.7 per 10,000 for death among HIV-positive people receiving ART.", "Risk of COVID-19 diagnosis and hospitalization was lower for people living with HIV receiving Truvada, or tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), compared with those on other ART regimens, as well as the Spanish population ages 20-79, reported Julia del Amo, MD, PhD, of the National Plan Against AIDS in Madrid, and colleagues.", "Moreover, the risk of COVID-19 diagnosis was not higher among people living with HIV on ART than the general population of Spain, they wrote in the Annals of Internal Medicine.", "\"The lack of increased risk for serious COVID-19 among HIV-positive persons might be the result of their use of ART,\" they wrote, adding ART was proposed as a protective factor against SARS in 2003, but there were too few cases to draw meaningful conclusions about its role."]}
{"id": 1000365, "claim": "One art regimen tied to increased covid-19 risk in hiv", "label": "REFUTED", "evidence": ["Researchers estimated a risk for COVID-19 diagnosis of 30.0 per 10.000 and 3.7 per 10,000 for death among HIV-positive people receiving ART.", "Risk of COVID-19 diagnosis and hospitalization was lower for people living with HIV receiving Truvada, or tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), compared with those on other ART regimens, as well as the Spanish population ages 20-79, reported Julia del Amo, MD, PhD, of the National Plan Against AIDS in Madrid, and colleagues.", "Moreover, the risk of COVID-19 diagnosis was not higher among people living with HIV on ART than the general population of Spain, they wrote in the Annals of Internal Medicine.", "\"The lack of increased risk for serious COVID-19 among HIV-positive persons might be the result of their use of ART,\" they wrote, adding ART was proposed as a protective factor against SARS in 2003, but there were too few cases to draw meaningful conclusions about its role."]}
{"id": 1000366, "claim": "One art regimen tied to higher covid-19 risk in hiv", "label": "REFUTED", "evidence": ["Researchers estimated a risk for COVID-19 diagnosis of 30.0 per 10.000 and 3.7 per 10,000 for death among HIV-positive people receiving ART.", "Risk of COVID-19 diagnosis and hospitalization was lower for people living with HIV receiving Truvada, or tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), compared with those on other ART regimens, as well as the Spanish population ages 20-79, reported Julia del Amo, MD, PhD, of the National Plan Against AIDS in Madrid, and colleagues.", "Moreover, the risk of COVID-19 diagnosis was not higher among people living with HIV on ART than the general population of Spain, they wrote in the Annals of Internal Medicine.", "\"The lack of increased risk for serious COVID-19 among HIV-positive persons might be the result of their use of ART,\" they wrote, adding ART was proposed as a protective factor against SARS in 2003, but there were too few cases to draw meaningful conclusions about its role."]}
{"id": 1000367, "claim": "Sars-cov-2 infection control implementation based on sources of infection showing directions for three age groups in japan.", "label": "SUPPORTED", "evidence": ["Methods and findings This retrospective observational case series study analyzed transmission patterns of real-time polymerase chain reaction (RT- PCR)-confirmed SARS-CoV-2 infections found by local health authorities and commercial laboratories during January 14 through July 31, 2020 in Japan."]}
{"id": 1000368, "claim": "Sars-cov-2 infection control implementation based on sources of infection showing directions for three age groups in canada.", "label": "REFUTED", "evidence": ["Methods and findings This retrospective observational case series study analyzed transmission patterns of real-time polymerase chain reaction (RT- PCR)-confirmed SARS-CoV-2 infections found by local health authorities and commercial laboratories during January 14 through July 31, 2020 in Japan."]}
{"id": 1000369, "claim": "Sars-cov-2 infection control implementation based on sources of infection showing directions for three age groups in australia.", "label": "REFUTED", "evidence": ["Methods and findings This retrospective observational case series study analyzed transmission patterns of real-time polymerase chain reaction (RT- PCR)-confirmed SARS-CoV-2 infections found by local health authorities and commercial laboratories during January 14 through July 31, 2020 in Japan."]}
{"id": 1000370, "claim": "Sars-cov-2 infection control implementation based on sources of infection showing directions for three age groups in taiwan.", "label": "REFUTED", "evidence": ["Methods and findings This retrospective observational case series study analyzed transmission patterns of real-time polymerase chain reaction (RT- PCR)-confirmed SARS-CoV-2 infections found by local health authorities and commercial laboratories during January 14 through July 31, 2020 in Japan."]}
{"id": 1000371, "claim": "Algernon retains novotech for trial of ifenprodil in covid-19 patients", "label": "SUPPORTED", "evidence": ["March 23, 2020 Algernon appoints U.S. Based Cascade Chemistry to support its quickly evolving clinical program for ALI, its urgent clinical focus on COVID-19 as well as its idiopathic pulmonary fibrosis (IPF) and chronic cough clinical program.", "March 20, 2020 Algernon appoints award winning Novotech as the contract research organization (CRO) for a planned physician-initiated study of Ifenprodil for COVID-19 patients in South Korea."]}
{"id": 1000372, "claim": "Algernon b novotech for trial of ifenprodil in covid-19 patients", "label": "REFUTED", "evidence": ["March 23, 2020 Algernon appoints U.S. Based Cascade Chemistry to support its quickly evolving clinical program for ALI, its urgent clinical focus on COVID-19 as well as its idiopathic pulmonary fibrosis (IPF) and chronic cough clinical program.", "March 20, 2020 Algernon appoints award winning Novotech as the contract research organization (CRO) for a planned physician-initiated study of Ifenprodil for COVID-19 patients in South Korea."]}
{"id": 1000373, "claim": "Algernon pre novotech for trial of ifenprodil in covid-19 patients", "label": "REFUTED", "evidence": ["March 23, 2020 Algernon appoints U.S. Based Cascade Chemistry to support its quickly evolving clinical program for ALI, its urgent clinical focus on COVID-19 as well as its idiopathic pulmonary fibrosis (IPF) and chronic cough clinical program.", "March 20, 2020 Algernon appoints award winning Novotech as the contract research organization (CRO) for a planned physician-initiated study of Ifenprodil for COVID-19 patients in South Korea."]}
{"id": 1000374, "claim": "Algernon retains novotech in trial of ifenprodil in covid-19 patients", "label": "REFUTED", "evidence": ["March 23, 2020 Algernon appoints U.S. Based Cascade Chemistry to support its quickly evolving clinical program for ALI, its urgent clinical focus on COVID-19 as well as its idiopathic pulmonary fibrosis (IPF) and chronic cough clinical program.", "March 20, 2020 Algernon appoints award winning Novotech as the contract research organization (CRO) for a planned physician-initiated study of Ifenprodil for COVID-19 patients in South Korea."]}
{"id": 1000375, "claim": "Expert partnership to explore and establish human challenge studies of covid-19 in the uk", "label": "SUPPORTED", "evidence": ["> > Our subsidiary hVIVO is the world leader in the testing of vaccines and > antivirals using human challenge studies and our contract with the UK > government to develop a COVID-19 human challenge study model will safely > accelerate the discovery of effective vaccines and antivirals against > COVID-19."]}
{"id": 1000376, "claim": "Expert partnership to prevent and establish human challenge studies of covid-19 in the uk", "label": "REFUTED", "evidence": ["> > Our subsidiary hVIVO is the world leader in the testing of vaccines and > antivirals using human challenge studies and our contract with the UK > government to develop a COVID-19 human challenge study model will safely > accelerate the discovery of effective vaccines and antivirals against > COVID-19."]}
{"id": 1000377, "claim": "California signs deal to provide cheaper covid-19 tests", "label": "SUPPORTED", "evidence": ["Gavin Newsom announced Wednesday that California has signed a contract worth up to $1.4 billion to provide cheaper coronavirus tests and to increase the number of people tested.", "He said the partnership will help drive down testing costs and improve turnaround time for results."]}
{"id": 1000378, "claim": "California signs deal to provide severe covid-19 tests", "label": "REFUTED", "evidence": ["Gavin Newsom announced Wednesday that California has signed a contract worth up to $1.4 billion to provide cheaper coronavirus tests and to increase the number of people tested.", "He said the partnership will help drive down testing costs and improve turnaround time for results."]}
{"id": 1000379, "claim": "Trim28 regulates sars-cov-2 cell entry by targeting ace2", "label": "SUPPORTED", "evidence": ["Our study identified TRIM28 as a novel regulator of ACE2 expression and SARS-CoV-2 cell entry.", "The expression level of ACE2 potentially determine the susceptibility and severity of COVID-19, it is thus of importance to understand the regulatory mechanism of ACE2 expression.", "This study showed that knockdown of TRIM28 induces ACE2 expression and increases pseudotyped SARS- CoV-2 cell entry of A549 cells and primary pulmonary alveolar epithelial cells (PAEpiCs)."]}
{"id": 1000380, "claim": "Trim28 regulates sars-cov-2 cell death by targeting ace2", "label": "REFUTED", "evidence": ["Our study identified TRIM28 as a novel regulator of ACE2 expression and SARS-CoV-2 cell entry.", "The expression level of ACE2 potentially determine the susceptibility and severity of COVID-19, it is thus of importance to understand the regulatory mechanism of ACE2 expression.", "This study showed that knockdown of TRIM28 induces ACE2 expression and increases pseudotyped SARS- CoV-2 cell entry of A549 cells and primary pulmonary alveolar epithelial cells (PAEpiCs)."]}
{"id": 1000381, "claim": "Trim28 regulates sars-cov-2 cell proliferation by targeting ace2", "label": "REFUTED", "evidence": ["Our study identified TRIM28 as a novel regulator of ACE2 expression and SARS-CoV-2 cell entry.", "The expression level of ACE2 potentially determine the susceptibility and severity of COVID-19, it is thus of importance to understand the regulatory mechanism of ACE2 expression.", "This study showed that knockdown of TRIM28 induces ACE2 expression and increases pseudotyped SARS- CoV-2 cell entry of A549 cells and primary pulmonary alveolar epithelial cells (PAEpiCs)."]}
{"id": 1000382, "claim": "Trim28 regulates sars-cov-2 cell apoptosis by targeting ace2", "label": "REFUTED", "evidence": ["Our study identified TRIM28 as a novel regulator of ACE2 expression and SARS-CoV-2 cell entry.", "The expression level of ACE2 potentially determine the susceptibility and severity of COVID-19, it is thus of importance to understand the regulatory mechanism of ACE2 expression.", "This study showed that knockdown of TRIM28 induces ACE2 expression and increases pseudotyped SARS- CoV-2 cell entry of A549 cells and primary pulmonary alveolar epithelial cells (PAEpiCs)."]}
{"id": 1000383, "claim": "Kids ' covid-linked ailment is not your typical kawasaki disease", "label": "SUPPORTED", "evidence": ["Notably, while half of patients presented with classic Kawasaki disease, the other half presented with an \"incomplete\" form of the disease.", "Still, they differed from the historical cohort of patients with Kawasaki disease, the authors said."]}
{"id": 1000384, "claim": "Kids'covid-linked ailment is also your typical kawasaki disease", "label": "REFUTED", "evidence": ["Notably, while half of patients presented with classic Kawasaki disease, the other half presented with an \"incomplete\" form of the disease.", "Still, they differed from the historical cohort of patients with Kawasaki disease, the authors said."]}
{"id": 1000385, "claim": "Kids'covid-linked ailment is called your typical kawasaki disease", "label": "REFUTED", "evidence": ["Notably, while half of patients presented with classic Kawasaki disease, the other half presented with an \"incomplete\" form of the disease.", "Still, they differed from the historical cohort of patients with Kawasaki disease, the authors said."]}
{"id": 1000386, "claim": "Kids'covid-linked ailment is considered your typical kawasaki disease", "label": "REFUTED", "evidence": ["Notably, while half of patients presented with classic Kawasaki disease, the other half presented with an \"incomplete\" form of the disease.", "Still, they differed from the historical cohort of patients with Kawasaki disease, the authors said."]}
{"id": 1000387, "claim": "Sars-cov-2-specific peripheral t follicular helper cells correlate with neutralizing antibodies and increase during convalescence .", "label": "SUPPORTED", "evidence": ["But, we also show that pTfh responses against other SARS-CoV-2 proteins correlate with antibody neutralization, indicating a possible role for intrastructural help.", "These responses suggest that SARS-CoV-2-specific pTfh continue to increase over time during convalescence."]}
{"id": 1000388, "claim": "Sars-cov-2-specific peripheral t follicular helper cells correlate with neutralizing antibodies and mortality during convalescence.", "label": "REFUTED", "evidence": ["But, we also show that pTfh responses against other SARS-CoV-2 proteins correlate with antibody neutralization, indicating a possible role for intrastructural help.", "These responses suggest that SARS-CoV-2-specific pTfh continue to increase over time during convalescence."]}
{"id": 1000389, "claim": "Sars-cov-2 replication triggers an mda-5-dependent interferon production which is unable to efficiently control replication", "label": "SUPPORTED", "evidence": ["Taken together, these results highlight the complex and ambiguous interplay between viral replication and the timing of IFN responses."]}
{"id": 1000390, "claim": "5-amino levulinic acid inhibits sars-cov-2 degradation in vitro", "label": "REFUTED", "evidence": ["Taken together, these results highlight the complex and ambiguous interplay between viral replication and the timing of IFN responses."]}
{"id": 1000391, "claim": "5-amino levulinic acid inhibits sars-cov-2 inhibition in vitro", "label": "REFUTED", "evidence": ["Taken together, these results highlight the complex and ambiguous interplay between viral replication and the timing of IFN responses."]}
{"id": 1000392, "claim": "Stat2 signaling restricts viral dissemination but drives severe pneumonia in sars-cov-2 infected hamsters", "label": "SUPPORTED", "evidence": ["We establish that in hamsters a dysregulated innate immune response is a driving force behind SARS-CoV-2 pathogenesis, in which in particular signal transducer and activator of transcription factor 2 (STAT2)-dependent type I and III IFN signaling plays a dual role: (i) restricting infection and dissemination on one hand but (ii) driving development of severe lung disease on the other.", "Together, these data suggest that STAT2 is critical for keeping virus replication and production of infectious progeny in the lungs down, as well as for restricting systemic SARS-CoV-2 spread and suppressing viral replication outside of the lung compartment.", "By using unique KO hamster lines, we demonstrated that STAT2 plays a critical role in mediating antiviral responses and restricting systemic dissemination of SARS-CoV-2 (see Fig."]}
{"id": 1000393, "claim": "Stat2 signaling restricts viral dissemination but not severe pneumonia in sars-cov-2 infected hamsters", "label": "REFUTED", "evidence": ["We establish that in hamsters a dysregulated innate immune response is a driving force behind SARS-CoV-2 pathogenesis, in which in particular signal transducer and activator of transcription factor 2 (STAT2)-dependent type I and III IFN signaling plays a dual role: (i) restricting infection and dissemination on one hand but (ii) driving development of severe lung disease on the other.", "Together, these data suggest that STAT2 is critical for keeping virus replication and production of infectious progeny in the lungs down, as well as for restricting systemic SARS-CoV-2 spread and suppressing viral replication outside of the lung compartment.", "By using unique KO hamster lines, we demonstrated that STAT2 plays a critical role in mediating antiviral responses and restricting systemic dissemination of SARS-CoV-2 (see Fig."]}
{"id": 1000394, "claim": "Stat2 signaling restricts viral dissemination but without severe pneumonia in sars-cov-2 infected hamsters", "label": "REFUTED", "evidence": ["We establish that in hamsters a dysregulated innate immune response is a driving force behind SARS-CoV-2 pathogenesis, in which in particular signal transducer and activator of transcription factor 2 (STAT2)-dependent type I and III IFN signaling plays a dual role: (i) restricting infection and dissemination on one hand but (ii) driving development of severe lung disease on the other.", "Together, these data suggest that STAT2 is critical for keeping virus replication and production of infectious progeny in the lungs down, as well as for restricting systemic SARS-CoV-2 spread and suppressing viral replication outside of the lung compartment.", "By using unique KO hamster lines, we demonstrated that STAT2 plays a critical role in mediating antiviral responses and restricting systemic dissemination of SARS-CoV-2 (see Fig."]}
{"id": 1000395, "claim": "Alberta bans all public gatherings of more than 250 people and asks all those returning from other countries self-isolate for 14 days .", "label": "SUPPORTED", "evidence": ["The risk of waiting is greater than the risk of implementing these measures now. All Albertans returning to the country are asked to self-isolate for 14 days after they return, no matter what country they visited.", "Albertas top doctor announced Thursday afternoon that a ban is now in place for all public gatherings of 250 or more people.", "All Albertans outside the country are asked to self-isolate for 14 days once they return, no matter which country they visited.", "The government has asked all those arriving in Canada from any international destination to self-isolate for 14 days.", "All Albertans returning to the country are asked to self-isolate for 14 days after they return, no matter what country they visited."]}
{"id": 1000396, "claim": "Alberta plans all public gatherings of more than 250 people and asks all those returning from other countries self-isolate for 14 days.", "label": "REFUTED", "evidence": ["The risk of waiting is greater than the risk of implementing these measures now. All Albertans returning to the country are asked to self-isolate for 14 days after they return, no matter what country they visited.", "Albertas top doctor announced Thursday afternoon that a ban is now in place for all public gatherings of 250 or more people.", "All Albertans outside the country are asked to self-isolate for 14 days once they return, no matter which country they visited.", "The government has asked all those arriving in Canada from any international destination to self-isolate for 14 days.", "All Albertans returning to the country are asked to self-isolate for 14 days after they return, no matter what country they visited."]}
{"id": 1000397, "claim": "Alberta bans all public gatherings of more than 250 people and asks all those returning from other countries self-isolate for 14 years.", "label": "REFUTED", "evidence": ["The risk of waiting is greater than the risk of implementing these measures now. All Albertans returning to the country are asked to self-isolate for 14 days after they return, no matter what country they visited.", "Albertas top doctor announced Thursday afternoon that a ban is now in place for all public gatherings of 250 or more people.", "All Albertans outside the country are asked to self-isolate for 14 days once they return, no matter which country they visited.", "The government has asked all those arriving in Canada from any international destination to self-isolate for 14 days.", "All Albertans returning to the country are asked to self-isolate for 14 days after they return, no matter what country they visited."]}
{"id": 1000398, "claim": "Alberta cares all public gatherings of more than 250 people and asks all those returning from other countries self-isolate for 14 days.", "label": "REFUTED", "evidence": ["The risk of waiting is greater than the risk of implementing these measures now. All Albertans returning to the country are asked to self-isolate for 14 days after they return, no matter what country they visited.", "Albertas top doctor announced Thursday afternoon that a ban is now in place for all public gatherings of 250 or more people.", "All Albertans outside the country are asked to self-isolate for 14 days once they return, no matter which country they visited.", "The government has asked all those arriving in Canada from any international destination to self-isolate for 14 days.", "All Albertans returning to the country are asked to self-isolate for 14 days after they return, no matter what country they visited."]}
{"id": 1000399, "claim": "Niclosamide inhibits sars-cov2 entry by blocking internalization through ph-dependent clic/geec endocytic pathway.", "label": "SUPPORTED", "evidence": ["Niclosamide inhibits SARS-CoV2 entry by blocking internalization through pH-dependent CLIC", "Here, we demonstrate that the receptor binding domain (RBD) of SARS-CoV2 is internalized via the clathrin and dynamin-independent, pH-dependent CLIC/GEEC (CG) endocytic pathway."]}
{"id": 1000400, "claim": "Niclosamide inhibits sars-cov2 entry by allowing internalization through ph-dependent clic/geec endocytic pathway.", "label": "REFUTED", "evidence": ["Niclosamide inhibits SARS-CoV2 entry by blocking internalization through pH-dependent CLIC", "Here, we demonstrate that the receptor binding domain (RBD) of SARS-CoV2 is internalized via the clathrin and dynamin-independent, pH-dependent CLIC/GEEC (CG) endocytic pathway."]}
{"id": 1000401, "claim": "Niclosamide inhibits sars-cov2 entry by promoting internalization through ph-dependent clic/geec endocytic pathway.", "label": "REFUTED", "evidence": ["Niclosamide inhibits SARS-CoV2 entry by blocking internalization through pH-dependent CLIC", "Here, we demonstrate that the receptor binding domain (RBD) of SARS-CoV2 is internalized via the clathrin and dynamin-independent, pH-dependent CLIC/GEEC (CG) endocytic pathway."]}
{"id": 1000402, "claim": "Red blood cell distribution width and mortality risk in hospitalized adults with sars-cov-2 infection.", "label": "SUPPORTED", "evidence": ["Increased Red Cell Distribution Width Is Associated With Disease Severity in Hospitalized Adults With SARS-CoV-2 Infection: An Observational Multicentric Study.", "Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection.", "Association of Red Blood Cell Distribution Width With Mortality Risk in Hospitalized Adults With SARS-CoV-2 Infection."]}
{"id": 1000403, "claim": "Red blood cell distribution width and survival risk in hospitalized adults with sars-cov-2 infection.", "label": "REFUTED", "evidence": ["Increased Red Cell Distribution Width Is Associated With Disease Severity in Hospitalized Adults With SARS-CoV-2 Infection: An Observational Multicentric Study.", "Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection.", "Association of Red Blood Cell Distribution Width With Mortality Risk in Hospitalized Adults With SARS-CoV-2 Infection."]}
{"id": 1000404, "claim": "Fda authorizes two-minute antibody testing kit to detect coronavirus", "label": "SUPPORTED", "evidence": ["What happened: A medical distribution company called Bodysphere said in a press release that the FDA had granted an emergency use authorization that could allow patients to get a diagnosis in only about two minutes.", "Due to a press release being issued about a two-minute COVID-19 test being granted Emergency Use Authorization (EUA) from the FDA, the story was shared with MPO readers.", "In its press release Tuesday, Bodysphere claimed its test had already been used successfully in several states. It was published a day after President Donald Trump touted the FDA's approval last week of a swab test that can detect the illness in five minutes."]}
{"id": 1000405, "claim": "Fda authorizes 15-minute antibody testing kit to detect coronavirus", "label": "REFUTED", "evidence": ["What happened: A medical distribution company called Bodysphere said in a press release that the FDA had granted an emergency use authorization that could allow patients to get a diagnosis in only about two minutes.", "Due to a press release being issued about a two-minute COVID-19 test being granted Emergency Use Authorization (EUA) from the FDA, the story was shared with MPO readers.", "In its press release Tuesday, Bodysphere claimed its test had already been used successfully in several states. It was published a day after President Donald Trump touted the FDA's approval last week of a swab test that can detect the illness in five minutes."]}
{"id": 1000406, "claim": "Fda authorizes 10-minute antibody testing kit to detect coronavirus", "label": "REFUTED", "evidence": ["What happened: A medical distribution company called Bodysphere said in a press release that the FDA had granted an emergency use authorization that could allow patients to get a diagnosis in only about two minutes.", "Due to a press release being issued about a two-minute COVID-19 test being granted Emergency Use Authorization (EUA) from the FDA, the story was shared with MPO readers.", "In its press release Tuesday, Bodysphere claimed its test had already been used successfully in several states. It was published a day after President Donald Trump touted the FDA's approval last week of a swab test that can detect the illness in five minutes."]}
{"id": 1000407, "claim": "Fda authorizes five-minute antibody testing kit to detect coronavirus", "label": "REFUTED", "evidence": ["What happened: A medical distribution company called Bodysphere said in a press release that the FDA had granted an emergency use authorization that could allow patients to get a diagnosis in only about two minutes.", "Due to a press release being issued about a two-minute COVID-19 test being granted Emergency Use Authorization (EUA) from the FDA, the story was shared with MPO readers.", "In its press release Tuesday, Bodysphere claimed its test had already been used successfully in several states. It was published a day after President Donald Trump touted the FDA's approval last week of a swab test that can detect the illness in five minutes."]}
{"id": 1000408, "claim": "Four minutes of your time can save thousands , if not millions , of lives !", "label": "SUPPORTED", "evidence": ["All we are asking for is four minutes of your time to share this post and fill out this simple, completely anonymous survey that can save thousands, if not millions of lives, as well as the livelihoods of most small business owners and day laborers."]}
{"id": 1000409, "claim": "Four minutes of your time can infect thousands, if not millions, of lives!", "label": "REFUTED", "evidence": ["All we are asking for is four minutes of your time to share this post and fill out this simple, completely anonymous survey that can save thousands, if not millions of lives, as well as the livelihoods of most small business owners and day laborers."]}
{"id": 1000410, "claim": "One minutes of your time can save thousands, if not millions, of lives!", "label": "REFUTED", "evidence": ["All we are asking for is four minutes of your time to share this post and fill out this simple, completely anonymous survey that can save thousands, if not millions of lives, as well as the livelihoods of most small business owners and day laborers."]}
{"id": 1000411, "claim": "Two minutes of your time can save thousands, if not millions, of lives!", "label": "REFUTED", "evidence": ["All we are asking for is four minutes of your time to share this post and fill out this simple, completely anonymous survey that can save thousands, if not millions of lives, as well as the livelihoods of most small business owners and day laborers."]}
{"id": 1000412, "claim": "Structural modeling of 2019-novel coronavirus spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to sars-cov and related sars-like coronaviruses", "label": "SUPPORTED", "evidence": ["Compared to SARS-CoV and all other coronaviruses in Betacoronavirus lineage B, we identify an extended structural loop containing basic amino acids at the interface of the receptor binding (S1) and fusion (S2) domains.", "This article is based on a previously available preprint: \" Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses \".", "Share Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses Javier A. Jaimes, Nicole M. André, Jean K. Millet, Gary R. Whittaker bioRxiv 2020.02.10.942185; doi: https://doi.org/10.1101/2020.02.10.942185 Share This Article: Copy Citation Tools Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses Javier A. Jaimes, Nicole M. André, Jean K. Millet, Gary R. Whittaker bioRxiv 2020.02.10.942185; doi: https://doi.org/10.1101/2020.02.10.942185 "]}
{"id": 1000413, "claim": "Structural modeling of sars-novel coronavirus spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to sars-cov and related sars-like coronaviruses", "label": "REFUTED", "evidence": ["Compared to SARS-CoV and all other coronaviruses in Betacoronavirus lineage B, we identify an extended structural loop containing basic amino acids at the interface of the receptor binding (S1) and fusion (S2) domains.", "This article is based on a previously available preprint: \" Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses \".", "Share Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses Javier A. Jaimes, Nicole M. André, Jean K. Millet, Gary R. Whittaker bioRxiv 2020.02.10.942185; doi: https://doi.org/10.1101/2020.02.10.942185 Share This Article: Copy Citation Tools Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses Javier A. Jaimes, Nicole M. André, Jean K. Millet, Gary R. Whittaker bioRxiv 2020.02.10.942185; doi: https://doi.org/10.1101/2020.02.10.942185 "]}
{"id": 1000414, "claim": "Structural modeling of mers-novel coronavirus spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to sars-cov and related sars-like coronaviruses", "label": "REFUTED", "evidence": ["Compared to SARS-CoV and all other coronaviruses in Betacoronavirus lineage B, we identify an extended structural loop containing basic amino acids at the interface of the receptor binding (S1) and fusion (S2) domains.", "This article is based on a previously available preprint: \" Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses \".", "Share Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses Javier A. Jaimes, Nicole M. André, Jean K. Millet, Gary R. Whittaker bioRxiv 2020.02.10.942185; doi: https://doi.org/10.1101/2020.02.10.942185 Share This Article: Copy Citation Tools Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses Javier A. Jaimes, Nicole M. André, Jean K. Millet, Gary R. Whittaker bioRxiv 2020.02.10.942185; doi: https://doi.org/10.1101/2020.02.10.942185 "]}
{"id": 1000415, "claim": "Structural modeling of hcov-novel coronavirus spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to sars-cov and related sars-like coronaviruses", "label": "REFUTED", "evidence": ["Compared to SARS-CoV and all other coronaviruses in Betacoronavirus lineage B, we identify an extended structural loop containing basic amino acids at the interface of the receptor binding (S1) and fusion (S2) domains.", "This article is based on a previously available preprint: \" Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses \".", "Share Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses Javier A. Jaimes, Nicole M. André, Jean K. Millet, Gary R. Whittaker bioRxiv 2020.02.10.942185; doi: https://doi.org/10.1101/2020.02.10.942185 Share This Article: Copy Citation Tools Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses Javier A. Jaimes, Nicole M. André, Jean K. Millet, Gary R. Whittaker bioRxiv 2020.02.10.942185; doi: https://doi.org/10.1101/2020.02.10.942185 "]}
{"id": 1000416, "claim": "Harm reduction principles can help us restore trust in public health messaging on covid-19", "label": "SUPPORTED", "evidence": ["Harm reductionwhen applied to disease prevention for infectious diseasesis the principle of advising individuals how to mitigate risk, while acknowledging the real world conditions that may lead individuals to take some risks.", "Such a framework can be applied to our covid-19 messaging.", "Returning to our disciplines basic principles and centering our approach around reducing harm may help restore trust in public health."]}
{"id": 1000417, "claim": "Harm reduction principles can help us avoid trust in public health messaging on covid-19", "label": "REFUTED", "evidence": ["Harm reductionwhen applied to disease prevention for infectious diseasesis the principle of advising individuals how to mitigate risk, while acknowledging the real world conditions that may lead individuals to take some risks.", "Such a framework can be applied to our covid-19 messaging.", "Returning to our disciplines basic principles and centering our approach around reducing harm may help restore trust in public health."]}
{"id": 1000418, "claim": "Harm reduction principles can help us reduce trust in public health messaging on covid-19", "label": "REFUTED", "evidence": ["Harm reductionwhen applied to disease prevention for infectious diseasesis the principle of advising individuals how to mitigate risk, while acknowledging the real world conditions that may lead individuals to take some risks.", "Such a framework can be applied to our covid-19 messaging.", "Returning to our disciplines basic principles and centering our approach around reducing harm may help restore trust in public health."]}
{"id": 1000419, "claim": "Harm reduction data can help us restore trust in public health messaging on covid-19", "label": "REFUTED", "evidence": ["Harm reductionwhen applied to disease prevention for infectious diseasesis the principle of advising individuals how to mitigate risk, while acknowledging the real world conditions that may lead individuals to take some risks.", "Such a framework can be applied to our covid-19 messaging.", "Returning to our disciplines basic principles and centering our approach around reducing harm may help restore trust in public health."]}
{"id": 1000420, "claim": "The first interim data analysis of the sputnik v vaccine against covid-19 phase iii clinical trials in the russian federation demonstrated 92 % efficacy", "label": "SUPPORTED", "evidence": ["Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Russian Direct Investment Fund (RDIF, Russias sovereign wealth fund), announce that the Sputnik V vaccine, the world's first registered vaccine against coronavirus (registered on the 11th of August under the emergency use authorization mechanism) created on the well-studied platform of human adenoviral vectors, demonstrated high efficacy."]}
{"id": 1000421, "claim": "The final interim data analysis of the sputnik v vaccine against covid-19 phase iii clinical trials in the russian federation demonstrated 92 % efficacy", "label": "REFUTED", "evidence": ["Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Russian Direct Investment Fund (RDIF, Russias sovereign wealth fund), announce that the Sputnik V vaccine, the world's first registered vaccine against coronavirus (registered on the 11th of August under the emergency use authorization mechanism) created on the well-studied platform of human adenoviral vectors, demonstrated high efficacy."]}
{"id": 1000422, "claim": "The subsequent interim data analysis of the sputnik v vaccine against covid-19 phase iii clinical trials in the russian federation demonstrated 92 % efficacy", "label": "REFUTED", "evidence": ["Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Russian Direct Investment Fund (RDIF, Russias sovereign wealth fund), announce that the Sputnik V vaccine, the world's first registered vaccine against coronavirus (registered on the 11th of August under the emergency use authorization mechanism) created on the well-studied platform of human adenoviral vectors, demonstrated high efficacy."]}
{"id": 1000423, "claim": "The third interim data analysis of the sputnik v vaccine against covid-19 phase iii clinical trials in the russian federation demonstrated 92 % efficacy", "label": "REFUTED", "evidence": ["Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Russian Direct Investment Fund (RDIF, Russias sovereign wealth fund), announce that the Sputnik V vaccine, the world's first registered vaccine against coronavirus (registered on the 11th of August under the emergency use authorization mechanism) created on the well-studied platform of human adenoviral vectors, demonstrated high efficacy."]}
{"id": 1000424, "claim": "In severe covid-19 , sars-cov-2 induces a chronic , tgf-β-dominated adaptive immune response", "label": "SUPPORTED", "evidence": ["In severe COVID-19, SARS- CoV-2 thus triggers a chronic immune reaction distracted from itself and instructed by TGF-β."]}
{"id": 1000425, "claim": "In severe covid-19, sars-cov-2 knocks a chronic, tgf-β-dominated adaptive immune response", "label": "REFUTED", "evidence": ["In severe COVID-19, SARS- CoV-2 thus triggers a chronic immune reaction distracted from itself and instructed by TGF-β."]}
{"id": 1000426, "claim": "Potent neutralizing antibodies from covid-19 patients define multiple targets of vulnerability", "label": "SUPPORTED", "evidence": ["Ward, Godelieve J. de Bree, Rogier W. Sanders, Marit J. van Gils Science 07 Aug 2020 : 643-650 Isolation of 403 monoclonal antibodies from COVID-19 patients revealed convergent gene usage and multiple target epitopes.", "Subsequent structural characterization of these potent NAbs will guide vaccine design, and simultaneous targeting of multiple non-RBD and RBD epitopes with mAb cocktails paves the way for safe and effective COVID-19 prevention and treatment.", "Indeed, therapeutic antibody cocktails with a variety of specificities have been used successfully against Ebola virus disease ( 7) and are being tested widely in clinical trials for HIV-1 ( 31).", "In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention."]}
{"id": 1000427, "claim": "Potent neutralizing antibodies from covid-19 patients define multiple targets of therapies", "label": "REFUTED", "evidence": ["Ward, Godelieve J. de Bree, Rogier W. Sanders, Marit J. van Gils Science 07 Aug 2020 : 643-650 Isolation of 403 monoclonal antibodies from COVID-19 patients revealed convergent gene usage and multiple target epitopes.", "Subsequent structural characterization of these potent NAbs will guide vaccine design, and simultaneous targeting of multiple non-RBD and RBD epitopes with mAb cocktails paves the way for safe and effective COVID-19 prevention and treatment.", "Indeed, therapeutic antibody cocktails with a variety of specificities have been used successfully against Ebola virus disease ( 7) and are being tested widely in clinical trials for HIV-1 ( 31).", "In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention."]}
{"id": 1000428, "claim": "Potent neutralizing antibodies from covid-19 patients define multiple targets of antigen", "label": "REFUTED", "evidence": ["Ward, Godelieve J. de Bree, Rogier W. Sanders, Marit J. van Gils Science 07 Aug 2020 : 643-650 Isolation of 403 monoclonal antibodies from COVID-19 patients revealed convergent gene usage and multiple target epitopes.", "Subsequent structural characterization of these potent NAbs will guide vaccine design, and simultaneous targeting of multiple non-RBD and RBD epitopes with mAb cocktails paves the way for safe and effective COVID-19 prevention and treatment.", "Indeed, therapeutic antibody cocktails with a variety of specificities have been used successfully against Ebola virus disease ( 7) and are being tested widely in clinical trials for HIV-1 ( 31).", "In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention."]}
{"id": 1000429, "claim": "O-glcnac transferase promotes influenza a virusinduced cytokine storm by targeting interferon regulatory factor5", "label": "SUPPORTED", "evidence": ["Furthermore, we characterized OGT-mediated IRF5 O -GlcNAcylation on S430, induced by IAV, as a key mechanism for IRF5 ubiquitination and activation of inflammatory cytokine expression."]}
{"id": 1000430, "claim": "Active compound in wp1122 reduces in vitro replication of sars-cov-2 by 100 %", "label": "SUPPORTED", "evidence": ["WP1122 is referred to as a prodrug of 2-DG whereby chemical elements are added to 2-DG to improve its delivery in vivo."]}
{"id": 1000431, "claim": "Active compound in wp1122 reduces in vitro replication of sars-cov-2 by 10 %", "label": "REFUTED", "evidence": ["WP1122 is referred to as a prodrug of 2-DG whereby chemical elements are added to 2-DG to improve its delivery in vivo."]}
{"id": 1000432, "claim": "Active compound in wp1122 increased in vitro replication of sars-cov-2 by 100 %", "label": "REFUTED", "evidence": ["WP1122 is referred to as a prodrug of 2-DG whereby chemical elements are added to 2-DG to improve its delivery in vivo."]}
{"id": 1000433, "claim": "Active compound in wp1122 enhanced in vitro replication of sars-cov-2 by 100 %", "label": "REFUTED", "evidence": ["WP1122 is referred to as a prodrug of 2-DG whereby chemical elements are added to 2-DG to improve its delivery in vivo."]}
{"id": 1000434, "claim": "Group of uk and us experts argues for focused protection instead of lockdowns", "label": "SUPPORTED", "evidence": ["They argue that focused protection would reduce the collateral harms of lockdown, including deaths from suicides, reduced childhood immunization, and increases in domestic violence."]}
{"id": 1000435, "claim": "Group of uk and us experts argues against focused protection instead of lockdowns", "label": "REFUTED", "evidence": ["They argue that focused protection would reduce the collateral harms of lockdown, including deaths from suicides, reduced childhood immunization, and increases in domestic violence."]}
{"id": 1000436, "claim": "Trump extends restrictions beyond easter", "label": "SUPPORTED", "evidence": ["The extension would leave the federal recommendations in place beyond Easter, April 12, by which time Trump had hoped the country and its economy could start to rev up again.", "Trumps decision to extend the guidelines reflected a recognition that the struggle will take place over the longer haul and the risk of deaths spiraling into the hundreds of thousands is real."]}
{"id": 1000437, "claim": "China extends restrictions beyond easter", "label": "REFUTED", "evidence": ["The extension would leave the federal recommendations in place beyond Easter, April 12, by which time Trump had hoped the country and its economy could start to rev up again.", "Trumps decision to extend the guidelines reflected a recognition that the struggle will take place over the longer haul and the risk of deaths spiraling into the hundreds of thousands is real."]}
{"id": 1000438, "claim": "Who extends restrictions beyond easter", "label": "REFUTED", "evidence": ["The extension would leave the federal recommendations in place beyond Easter, April 12, by which time Trump had hoped the country and its economy could start to rev up again.", "Trumps decision to extend the guidelines reflected a recognition that the struggle will take place over the longer haul and the risk of deaths spiraling into the hundreds of thousands is real."]}
{"id": 1000439, "claim": "Northern italy to 'quarantine 16 million people '", "label": "SUPPORTED", "evidence": ["ET Sunday The government of Italy has imposed mass restrictions across its northern region, limiting the movement of more than 16 million people, as it fights to control the coronavirus outbreak there.", "Coronavirus: Northern Italy quarantines 16 million people - BBC News - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [."]}
{"id": 1000440, "claim": "Northern italy to 'quarantine 16, people '", "label": "REFUTED", "evidence": ["ET Sunday The government of Italy has imposed mass restrictions across its northern region, limiting the movement of more than 16 million people, as it fights to control the coronavirus outbreak there.", "Coronavirus: Northern Italy quarantines 16 million people - BBC News - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [."]}
{"id": 1000441, "claim": "Northern italy to 'quarantine 16\" people '", "label": "REFUTED", "evidence": ["ET Sunday The government of Italy has imposed mass restrictions across its northern region, limiting the movement of more than 16 million people, as it fights to control the coronavirus outbreak there.", "Coronavirus: Northern Italy quarantines 16 million people - BBC News - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [."]}
{"id": 1000442, "claim": "Northern italy to 'quarantine 16 million years '", "label": "REFUTED", "evidence": ["ET Sunday The government of Italy has imposed mass restrictions across its northern region, limiting the movement of more than 16 million people, as it fights to control the coronavirus outbreak there.", "Coronavirus: Northern Italy quarantines 16 million people - BBC News - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [."]}
{"id": 1000443, "claim": "Sars-cov-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild covid-19 infection.", "label": "SUPPORTED", "evidence": ["Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.", "Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection.", "\"Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection\".", "Zheng X. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19."]}
{"id": 1000444, "claim": "Sars-cov-2 knocks a durable and antigen specific humoral immunity after asymptomatic to mild covid-19 infection.", "label": "REFUTED", "evidence": ["Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.", "Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection.", "\"Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection\".", "Zheng X. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19."]}
{"id": 1000445, "claim": "Serum 25d level on hospital admission associated with covid-19 stage and mortality", "label": "SUPPORTED", "evidence": ["To evaluate associations of plasma 25(OH)D status with the likelihood of coronavirus disease (COVID-19) infection and hospitalization.", "To investigate the association between serum 25-hydroxyvitamin D levels and its effect on adverse clinical outcomes, and parameters of immune function and mortality due to a SARS-CoV-2 infection.", "To examine ...the relationship between serum 25-hydroxy vitamin D (25(OH)D) level and COVID-19 infection, its severity, and its clinical case characteristics.", "To examine the relationship between serum 25-hydroxy vitamin D (25(OH)D) level and COVID-19 infection, its severity, and its clinical case characteristics."]}
{"id": 1000446, "claim": "Serum 25d level on hospital admission associated with covid-19 stage and patient", "label": "REFUTED", "evidence": ["To evaluate associations of plasma 25(OH)D status with the likelihood of coronavirus disease (COVID-19) infection and hospitalization.", "To investigate the association between serum 25-hydroxyvitamin D levels and its effect on adverse clinical outcomes, and parameters of immune function and mortality due to a SARS-CoV-2 infection.", "To examine ...the relationship between serum 25-hydroxy vitamin D (25(OH)D) level and COVID-19 infection, its severity, and its clinical case characteristics.", "To examine the relationship between serum 25-hydroxy vitamin D (25(OH)D) level and COVID-19 infection, its severity, and its clinical case characteristics."]}
{"id": 1000447, "claim": "Serum 25d level on asthma admission associated with covid-19 stage and mortality", "label": "REFUTED", "evidence": ["To evaluate associations of plasma 25(OH)D status with the likelihood of coronavirus disease (COVID-19) infection and hospitalization.", "To investigate the association between serum 25-hydroxyvitamin D levels and its effect on adverse clinical outcomes, and parameters of immune function and mortality due to a SARS-CoV-2 infection.", "To examine ...the relationship between serum 25-hydroxy vitamin D (25(OH)D) level and COVID-19 infection, its severity, and its clinical case characteristics.", "To examine the relationship between serum 25-hydroxy vitamin D (25(OH)D) level and COVID-19 infection, its severity, and its clinical case characteristics."]}
{"id": 1000448, "claim": "Debate over face masks ends , hong kong was right all along", "label": "SUPPORTED", "evidence": ["Dr Leung Chi-chiu, chairman of the advisory committee on communicable diseases at the Hong Kong Medical Association, said the universal use of masks was vital in reducing the spread of the virus.", "\"Universal masking, as a package of anti-epidemic measures, including greater social distancing and hand hygiene, has been instrumental in keeping Covid-19 in check,\" said infectious diseases expert Professor David Hui Shu-cheong of the Chinese University of Hong Kong.", "Wearing masks in public has been ingrained in Hongkongers' collective psyche since the deadly severe acute respiratory syndrome epidemic of 2003, and experts now believe the habit helped the city of 7.4 million keep its Covid-19 numbers down to 845, with four deaths as of Friday."]}
{"id": 1000449, "claim": "Debate over face masks ends, hong kong was not all along", "label": "REFUTED", "evidence": ["Dr Leung Chi-chiu, chairman of the advisory committee on communicable diseases at the Hong Kong Medical Association, said the universal use of masks was vital in reducing the spread of the virus.", "\"Universal masking, as a package of anti-epidemic measures, including greater social distancing and hand hygiene, has been instrumental in keeping Covid-19 in check,\" said infectious diseases expert Professor David Hui Shu-cheong of the Chinese University of Hong Kong.", "Wearing masks in public has been ingrained in Hongkongers' collective psyche since the deadly severe acute respiratory syndrome epidemic of 2003, and experts now believe the habit helped the city of 7.4 million keep its Covid-19 numbers down to 845, with four deaths as of Friday."]}
{"id": 1000450, "claim": "Debate over face masks ends, hong kong was removed all along", "label": "REFUTED", "evidence": ["Dr Leung Chi-chiu, chairman of the advisory committee on communicable diseases at the Hong Kong Medical Association, said the universal use of masks was vital in reducing the spread of the virus.", "\"Universal masking, as a package of anti-epidemic measures, including greater social distancing and hand hygiene, has been instrumental in keeping Covid-19 in check,\" said infectious diseases expert Professor David Hui Shu-cheong of the Chinese University of Hong Kong.", "Wearing masks in public has been ingrained in Hongkongers' collective psyche since the deadly severe acute respiratory syndrome epidemic of 2003, and experts now believe the habit helped the city of 7.4 million keep its Covid-19 numbers down to 845, with four deaths as of Friday."]}
{"id": 1000451, "claim": "The white house has erected a blockade stopping states and hospitals from getting coronavirus ppe", "label": "SUPPORTED", "evidence": ["In a time of pandemic, having evacuated federal responsibility, the White House is functionally waging a war against state leadership and the initiative of local hospitals to secure what they need to provide sufficient treatment.", "Over the last few weeks, it has started to appear as though, in addition to abandoning the states to their own devices in a time of national emergency, the federal government has effectively erected a blockade -- like that which the Union used to choke off the supply chains of the Confederacy during the Civil War -- to prevent delivery of critical medical equipment to states desperately in need.", "Over the last few weeks, it has started to appear as though, in addition to abandoning the states to their own devices in a time of national emergency, the federal government has effectively erected a blockade  like that which the Union used to choke off the supply chains of the Confederacy during the Civil War  to prevent delivery of critical medical equipment to states desperately in need."]}
{"id": 1000452, "claim": "The chinese house has erected a blockade stopping states and hospitals from getting coronavirus ppe", "label": "REFUTED", "evidence": ["In a time of pandemic, having evacuated federal responsibility, the White House is functionally waging a war against state leadership and the initiative of local hospitals to secure what they need to provide sufficient treatment.", "Over the last few weeks, it has started to appear as though, in addition to abandoning the states to their own devices in a time of national emergency, the federal government has effectively erected a blockade -- like that which the Union used to choke off the supply chains of the Confederacy during the Civil War -- to prevent delivery of critical medical equipment to states desperately in need.", "Over the last few weeks, it has started to appear as though, in addition to abandoning the states to their own devices in a time of national emergency, the federal government has effectively erected a blockade  like that which the Union used to choke off the supply chains of the Confederacy during the Civil War  to prevent delivery of critical medical equipment to states desperately in need."]}
{"id": 1000453, "claim": "The white house has received a blockade stopping states and hospitals from getting coronavirus ppe", "label": "REFUTED", "evidence": ["In a time of pandemic, having evacuated federal responsibility, the White House is functionally waging a war against state leadership and the initiative of local hospitals to secure what they need to provide sufficient treatment.", "Over the last few weeks, it has started to appear as though, in addition to abandoning the states to their own devices in a time of national emergency, the federal government has effectively erected a blockade -- like that which the Union used to choke off the supply chains of the Confederacy during the Civil War -- to prevent delivery of critical medical equipment to states desperately in need.", "Over the last few weeks, it has started to appear as though, in addition to abandoning the states to their own devices in a time of national emergency, the federal government has effectively erected a blockade  like that which the Union used to choke off the supply chains of the Confederacy during the Civil War  to prevent delivery of critical medical equipment to states desperately in need."]}
{"id": 1000454, "claim": "The local house has erected a blockade stopping states and hospitals from getting coronavirus ppe", "label": "REFUTED", "evidence": ["In a time of pandemic, having evacuated federal responsibility, the White House is functionally waging a war against state leadership and the initiative of local hospitals to secure what they need to provide sufficient treatment.", "Over the last few weeks, it has started to appear as though, in addition to abandoning the states to their own devices in a time of national emergency, the federal government has effectively erected a blockade -- like that which the Union used to choke off the supply chains of the Confederacy during the Civil War -- to prevent delivery of critical medical equipment to states desperately in need.", "Over the last few weeks, it has started to appear as though, in addition to abandoning the states to their own devices in a time of national emergency, the federal government has effectively erected a blockade  like that which the Union used to choke off the supply chains of the Confederacy during the Civil War  to prevent delivery of critical medical equipment to states desperately in need."]}
{"id": 1000455, "claim": "Identification of potential treatments for covid-19 through artificial intelligence-enabled phenomic analysis of human cells infected with sars-cov-2", "label": "SUPPORTED", "evidence": ["]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: Discuss this template [e]: Edit this template []: You need to accept this checkbox.", "However, Recursion has committed to free non-discriminatory licensing for any of its intellectual property around discoveries related to the treatment of COVID19.", "Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions."]}
{"id": 1000456, "claim": "Identification of potential treatments for covid-19 through artificial intelligence-enabled phenomic analysis of bat cells infected with sars-cov-2", "label": "REFUTED", "evidence": ["]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: Discuss this template [e]: Edit this template []: You need to accept this checkbox.", "However, Recursion has committed to free non-discriminatory licensing for any of its intellectual property around discoveries related to the treatment of COVID19.", "Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions."]}
{"id": 1000457, "claim": "Identification of potential genes for covid-19 through artificial intelligence-enabled phenomic analysis of human cells infected with sars-cov-2", "label": "REFUTED", "evidence": ["]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: Discuss this template [e]: Edit this template []: You need to accept this checkbox.", "However, Recursion has committed to free non-discriminatory licensing for any of its intellectual property around discoveries related to the treatment of COVID19.", "Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions."]}
{"id": 1000458, "claim": "Identification of potential proteins for covid-19 through artificial intelligence-enabled phenomic analysis of human cells infected with sars-cov-2", "label": "REFUTED", "evidence": ["]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: Discuss this template [e]: Edit this template []: You need to accept this checkbox.", "However, Recursion has committed to free non-discriminatory licensing for any of its intellectual property around discoveries related to the treatment of COVID19.", "Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions."]}
{"id": 1000459, "claim": "New look at covid-19 cases does not support link between bcg vaccination and lower mortality", "label": "SUPPORTED", "evidence": ["Ongoing clinical trials with the appropriate controls will provide a more conclusive answer. The Letter, \"Lack of evidence for BCG vaccine protection from severe COVID-19,\" includes co-authors Cecilia S. Lindestam Arlehamn and Alessandro Sette."]}
{"id": 1000460, "claim": "New look at covid-19 cases does indeed support link between bcg vaccination and lower mortality", "label": "REFUTED", "evidence": ["Ongoing clinical trials with the appropriate controls will provide a more conclusive answer. The Letter, \"Lack of evidence for BCG vaccine protection from severe COVID-19,\" includes co-authors Cecilia S. Lindestam Arlehamn and Alessandro Sette."]}
{"id": 1000461, "claim": "New look at covid-19 cases does also support link between bcg vaccination and lower mortality", "label": "REFUTED", "evidence": ["Ongoing clinical trials with the appropriate controls will provide a more conclusive answer. The Letter, \"Lack of evidence for BCG vaccine protection from severe COVID-19,\" includes co-authors Cecilia S. Lindestam Arlehamn and Alessandro Sette."]}
{"id": 1000462, "claim": "New look at covid-19 cases does a support link between bcg vaccination and lower mortality", "label": "REFUTED", "evidence": ["Ongoing clinical trials with the appropriate controls will provide a more conclusive answer. The Letter, \"Lack of evidence for BCG vaccine protection from severe COVID-19,\" includes co-authors Cecilia S. Lindestam Arlehamn and Alessandro Sette."]}
{"id": 1000463, "claim": "Amid covid-19 pandemic , u.s. has seen 300,000 excess deaths '", "label": "SUPPORTED", "evidence": ["> \"An estimated 299,028 more persons than expected have died since January 26, > 2020; approximately two thirds of these deaths were attributed to COVID-19,\" > CDC researchers wrote in the report."]}
{"id": 1000464, "claim": "Amid covid-19 pandemic, u.s. has seen 300,000 excess infections '", "label": "REFUTED", "evidence": ["> \"An estimated 299,028 more persons than expected have died since January 26, > 2020; approximately two thirds of these deaths were attributed to COVID-19,\" > CDC researchers wrote in the report."]}
{"id": 1000465, "claim": "Amid covid-19 pandemic, u.s. has seen 300,000 excess contacts '", "label": "REFUTED", "evidence": ["> \"An estimated 299,028 more persons than expected have died since January 26, > 2020; approximately two thirds of these deaths were attributed to COVID-19,\" > CDC researchers wrote in the report."]}
{"id": 1000466, "claim": "Amid covid-19 pandemic, u.s. has seen 300,000 excess costs '", "label": "REFUTED", "evidence": ["> \"An estimated 299,028 more persons than expected have died since January 26, > 2020; approximately two thirds of these deaths were attributed to COVID-19,\" > CDC researchers wrote in the report."]}
{"id": 1000467, "claim": "Nevan krogan 's lab at ucsf mapped interactions between human and sars-cov-2 proteins , identifying 66 human proteins that could be targeted with 69 fda-approved drugs or drugs in clinical trials .", "label": "SUPPORTED", "evidence": ["Among these, we identify 66 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials and/or preclinical compounds, that we are currently evaluating for efficacy in live SARS-CoV-2 infection assays.", "Shokat and other researchers at UCSF helped identify existing drugs that interact with the same human proteins that SARS-CoV-2 binds to.", "Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clinical trials and 28 are preclinical compounds)."]}
{"id": 1000468, "claim": "Nevan krogan's lab at ucsf mapped interactions between human and sars-cov-2 proteins, identifying 66 human proteins that cannot be targeted with 69 fda-approved drugs or drugs in clinical trials.", "label": "REFUTED", "evidence": ["Among these, we identify 66 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials and/or preclinical compounds, that we are currently evaluating for efficacy in live SARS-CoV-2 infection assays.", "Shokat and other researchers at UCSF helped identify existing drugs that interact with the same human proteins that SARS-CoV-2 binds to.", "Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clinical trials and 28 are preclinical compounds)."]}
{"id": 1000469, "claim": "Regn-cov2 antibody cocktail prevents and treats sars-cov-2 infection in rhesus macaques and hamsters", "label": "SUPPORTED", "evidence": ["We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987+REGN10933) targeting non-overlapping epitopes on the SARS-CoV-2 spike protein.", "In this report, we evaluate the in vivo efficacy of this antibody cocktail in both rhesus macaques and golden hamsters and demonstrate that REGN-COV-2 can greatly reduce virus load in lower and upper airway and decrease virus induced pathological sequalae when administered prophylactically or therapeutically.", "Our results provide evidence of the therapeutic potential of this antibody cocktail."]}
{"id": 1000470, "claim": "Pn-cov2 antibody cocktail prevents and treats sars-cov-2 infection in rhesus macaques and hamsters", "label": "REFUTED", "evidence": ["We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987+REGN10933) targeting non-overlapping epitopes on the SARS-CoV-2 spike protein.", "In this report, we evaluate the in vivo efficacy of this antibody cocktail in both rhesus macaques and golden hamsters and demonstrate that REGN-COV-2 can greatly reduce virus load in lower and upper airway and decrease virus induced pathological sequalae when administered prophylactically or therapeutically.", "Our results provide evidence of the therapeutic potential of this antibody cocktail."]}
{"id": 1000471, "claim": "Bn-cov2 antibody cocktail prevents and treats sars-cov-2 infection in rhesus macaques and hamsters", "label": "REFUTED", "evidence": ["We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987+REGN10933) targeting non-overlapping epitopes on the SARS-CoV-2 spike protein.", "In this report, we evaluate the in vivo efficacy of this antibody cocktail in both rhesus macaques and golden hamsters and demonstrate that REGN-COV-2 can greatly reduce virus load in lower and upper airway and decrease virus induced pathological sequalae when administered prophylactically or therapeutically.", "Our results provide evidence of the therapeutic potential of this antibody cocktail."]}
{"id": 1000472, "claim": "On-cov2 antibody cocktail prevents and treats sars-cov-2 infection in rhesus macaques and hamsters", "label": "REFUTED", "evidence": ["We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987+REGN10933) targeting non-overlapping epitopes on the SARS-CoV-2 spike protein.", "In this report, we evaluate the in vivo efficacy of this antibody cocktail in both rhesus macaques and golden hamsters and demonstrate that REGN-COV-2 can greatly reduce virus load in lower and upper airway and decrease virus induced pathological sequalae when administered prophylactically or therapeutically.", "Our results provide evidence of the therapeutic potential of this antibody cocktail."]}
{"id": 1000473, "claim": "In the lab , st. jude scientists identify possible covid-19 treatment", "label": "SUPPORTED", "evidence": ["Memphis, Tennessee, November 18, 2020 Thirumala-Devi Kanneganti, Ph.D., vice chair of St. Jude Immunology (center); and Bhesh Raj Sharma, PhD (left), and Rajendra Karki, PhD (right), both of Kanneganti's lab, contributed to research that helps increase understanding of the pathways and mechanism that drives COVID-19 inflammation so researchers can develop effective treatment strategies.", "St. Jude Childrens Research Hospital scientists have discovered a potential strategy to prevent life-threatening inflammation, lung damage and organ failure in patients with COVID-19.", "Kannegantis team focused on a select set of the most elevated cytokines in COVID-19 patients."]}
{"id": 1000474, "claim": "In the lab, st. chinese scientists identify possible covid-19 treatment", "label": "REFUTED", "evidence": ["Memphis, Tennessee, November 18, 2020 Thirumala-Devi Kanneganti, Ph.D., vice chair of St. Jude Immunology (center); and Bhesh Raj Sharma, PhD (left), and Rajendra Karki, PhD (right), both of Kanneganti's lab, contributed to research that helps increase understanding of the pathways and mechanism that drives COVID-19 inflammation so researchers can develop effective treatment strategies.", "St. Jude Childrens Research Hospital scientists have discovered a potential strategy to prevent life-threatening inflammation, lung damage and organ failure in patients with COVID-19.", "Kannegantis team focused on a select set of the most elevated cytokines in COVID-19 patients."]}
{"id": 1000475, "claim": "In the lab, st.org scientists identify possible covid-19 treatment", "label": "REFUTED", "evidence": ["Memphis, Tennessee, November 18, 2020 Thirumala-Devi Kanneganti, Ph.D., vice chair of St. Jude Immunology (center); and Bhesh Raj Sharma, PhD (left), and Rajendra Karki, PhD (right), both of Kanneganti's lab, contributed to research that helps increase understanding of the pathways and mechanism that drives COVID-19 inflammation so researchers can develop effective treatment strategies.", "St. Jude Childrens Research Hospital scientists have discovered a potential strategy to prevent life-threatening inflammation, lung damage and organ failure in patients with COVID-19.", "Kannegantis team focused on a select set of the most elevated cytokines in COVID-19 patients."]}
{"id": 1000476, "claim": "The approved dose of ivermectin alone is not the ideal dose for the treatment of covid-19", "label": "SUPPORTED", "evidence": ["In summary, the likelihood of a successful clinical trial using the approved dose of ivermectin is low.", "Repurposing drugs for use in coronavirus disease 2019 (COVID-19) treatment is an ideal strategy but is only feasible when product safety has been established and experiments of repurposed drugs are conducted at clinically relevant concentrations."]}
{"id": 1000477, "claim": "The approved dose of ivermectin alone is still the ideal dose for the treatment of covid-19", "label": "REFUTED", "evidence": ["In summary, the likelihood of a successful clinical trial using the approved dose of ivermectin is low.", "Repurposing drugs for use in coronavirus disease 2019 (COVID-19) treatment is an ideal strategy but is only feasible when product safety has been established and experiments of repurposed drugs are conducted at clinically relevant concentrations."]}
{"id": 1000478, "claim": "The approved dose of ivermectin alone is considered the ideal dose for the treatment of covid-19", "label": "REFUTED", "evidence": ["In summary, the likelihood of a successful clinical trial using the approved dose of ivermectin is low.", "Repurposing drugs for use in coronavirus disease 2019 (COVID-19) treatment is an ideal strategy but is only feasible when product safety has been established and experiments of repurposed drugs are conducted at clinically relevant concentrations."]}
{"id": 1000479, "claim": "The approved dose of ivermectin alone is at the ideal dose for the treatment of covid-19", "label": "REFUTED", "evidence": ["In summary, the likelihood of a successful clinical trial using the approved dose of ivermectin is low.", "Repurposing drugs for use in coronavirus disease 2019 (COVID-19) treatment is an ideal strategy but is only feasible when product safety has been established and experiments of repurposed drugs are conducted at clinically relevant concentrations."]}
{"id": 1000480, "claim": "Covid-19 twice as contagious as previously thought", "label": "SUPPORTED", "evidence": ["Ergo, a 5.7 is on a considerably different level of infectiousness, Dr Feigl-Ding said.", "This is double the previously estimated R0 of 2.2 to 2.7, meaning that the COVID-19 pandemic may be much more difficult to contain."]}
{"id": 1000481, "claim": "Covid-19 serves as contagious as previously thought", "label": "REFUTED", "evidence": ["Ergo, a 5.7 is on a considerably different level of infectiousness, Dr Feigl-Ding said.", "This is double the previously estimated R0 of 2.2 to 2.7, meaning that the COVID-19 pandemic may be much more difficult to contain."]}
{"id": 1000482, "claim": "Covid-19 are as contagious as previously thought", "label": "REFUTED", "evidence": ["Ergo, a 5.7 is on a considerably different level of infectiousness, Dr Feigl-Ding said.", "This is double the previously estimated R0 of 2.2 to 2.7, meaning that the COVID-19 pandemic may be much more difficult to contain."]}
{"id": 1000483, "claim": "Covid-19 has as contagious as previously thought", "label": "REFUTED", "evidence": ["Ergo, a 5.7 is on a considerably different level of infectiousness, Dr Feigl-Ding said.", "This is double the previously estimated R0 of 2.2 to 2.7, meaning that the COVID-19 pandemic may be much more difficult to contain."]}
{"id": 1000484, "claim": "Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 infection", "label": "SUPPORTED", "evidence": ["Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?.", "Based on our pooled analysis of available data, the use of proton pump inhibitors (PPIs) seems to be associated with an enhanced risk of severity and mortality from COVID-19 infection.", "View Large Image Figure Viewer Download Hi-res image Download (PPT) Based on our pooled analysis of available data, the use of proton pump inhibitors (PPIs) seems to be associated with an enhanced risk of severity and mortality from COVID-19 infection.", "Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection."]}
{"id": 1000485, "claim": "Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 3 infection", "label": "REFUTED", "evidence": ["Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?.", "Based on our pooled analysis of available data, the use of proton pump inhibitors (PPIs) seems to be associated with an enhanced risk of severity and mortality from COVID-19 infection.", "View Large Image Figure Viewer Download Hi-res image Download (PPT) Based on our pooled analysis of available data, the use of proton pump inhibitors (PPIs) seems to be associated with an enhanced risk of severity and mortality from COVID-19 infection.", "Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection."]}
{"id": 1000486, "claim": "Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 6 infection", "label": "REFUTED", "evidence": ["Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?.", "Based on our pooled analysis of available data, the use of proton pump inhibitors (PPIs) seems to be associated with an enhanced risk of severity and mortality from COVID-19 infection.", "View Large Image Figure Viewer Download Hi-res image Download (PPT) Based on our pooled analysis of available data, the use of proton pump inhibitors (PPIs) seems to be associated with an enhanced risk of severity and mortality from COVID-19 infection.", "Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection."]}
{"id": 1000487, "claim": "Blood test detects past infections with new coronavirus", "label": "SUPPORTED", "evidence": ["A new clinical blood test will start being conducted at the UW Medicine Virology Lab, beginning next week, to check people for past infection with SARS-CoV-2.", "It could spot a past infection with this new coronavirus and not confuse it with other viruses, including other respiratory coronaviruses.", "The test looks for the presence of an antibody, called IgG, which people produce in fending off the pandemic coronavirus."]}
{"id": 1000488, "claim": "Blood test detects novel infections with new coronavirus", "label": "REFUTED", "evidence": ["A new clinical blood test will start being conducted at the UW Medicine Virology Lab, beginning next week, to check people for past infection with SARS-CoV-2.", "It could spot a past infection with this new coronavirus and not confuse it with other viruses, including other respiratory coronaviruses.", "The test looks for the presence of an antibody, called IgG, which people produce in fending off the pandemic coronavirus."]}
{"id": 1000489, "claim": "Blood test cannots past infections with new coronavirus", "label": "REFUTED", "evidence": ["A new clinical blood test will start being conducted at the UW Medicine Virology Lab, beginning next week, to check people for past infection with SARS-CoV-2.", "It could spot a past infection with this new coronavirus and not confuse it with other viruses, including other respiratory coronaviruses.", "The test looks for the presence of an antibody, called IgG, which people produce in fending off the pandemic coronavirus."]}
{"id": 1000490, "claim": "Blood test detects new infections with new coronavirus", "label": "REFUTED", "evidence": ["A new clinical blood test will start being conducted at the UW Medicine Virology Lab, beginning next week, to check people for past infection with SARS-CoV-2.", "It could spot a past infection with this new coronavirus and not confuse it with other viruses, including other respiratory coronaviruses.", "The test looks for the presence of an antibody, called IgG, which people produce in fending off the pandemic coronavirus."]}
{"id": 1000491, "claim": "Taiwan scientists develop antibodies for 15-minute wuhan virus test in 19 days", "label": "SUPPORTED", "evidence": ["(gettyimages) TAIPEI (Taiwan News) -- Academia Sinica on Sunday (March 8) announced that a team of scientists has developed antibodies that can identify the protein that causes the Wuhan coronavirus (COVID-19) in just 19 days, paving the way for a new test for the virus that can provide results within 15 minutes.", "Yang said that if these antibodies can be successfully manufactured and validated, they could be used to create a rapid test for COVID-19 that could yield results in as little as 15 minutes, similar to rapid influenza tests."]}
{"id": 1000492, "claim": "Taiwan scientists received antibodies for 15-minute wuhan virus test in 19 days", "label": "REFUTED", "evidence": ["(gettyimages) TAIPEI (Taiwan News) -- Academia Sinica on Sunday (March 8) announced that a team of scientists has developed antibodies that can identify the protein that causes the Wuhan coronavirus (COVID-19) in just 19 days, paving the way for a new test for the virus that can provide results within 15 minutes.", "Yang said that if these antibodies can be successfully manufactured and validated, they could be used to create a rapid test for COVID-19 that could yield results in as little as 15 minutes, similar to rapid influenza tests."]}
{"id": 1000493, "claim": "Sars-cov-2 infection of african green monkeys results in mild respiratory disease discernible by pet/ct imaging and prolonged shedding of infectious virus from both respiratory and gastrointestinal tracts", "label": "SUPPORTED", "evidence": ["Infectious virus was shed from both respiratory and gastrointestinal (GI) tracts in all animals in a biphasic manner, first between 2-7 dpi followed by a recrudescence at 14-21 dpi.", "Infection of African green monkeys (AGM) with a low passage human isolate of SARS-CoV-2 by aerosol or mucosal exposure resulted in mild clinical infection with a transient decrease in lung tidal volume.", "One Sentence Summary Subclinical infection of African green monkeys infected with SARS-CoV-2 results in prolonged shedding of infectious virus from both respiratory and gastrointestinal tracts."]}
{"id": 1000494, "claim": "Sars-cov-2 infection of african green cat results in mild respiratory disease discernible by pet/ct imaging and prolonged shedding of infectious virus from both respiratory and gastrointestinal tracts", "label": "REFUTED", "evidence": ["Infectious virus was shed from both respiratory and gastrointestinal (GI) tracts in all animals in a biphasic manner, first between 2-7 dpi followed by a recrudescence at 14-21 dpi.", "Infection of African green monkeys (AGM) with a low passage human isolate of SARS-CoV-2 by aerosol or mucosal exposure resulted in mild clinical infection with a transient decrease in lung tidal volume.", "One Sentence Summary Subclinical infection of African green monkeys infected with SARS-CoV-2 results in prolonged shedding of infectious virus from both respiratory and gastrointestinal tracts."]}
{"id": 1000495, "claim": "Sars-cov-2 infection of african green sheep results in mild respiratory disease discernible by pet/ct imaging and prolonged shedding of infectious virus from both respiratory and gastrointestinal tracts", "label": "REFUTED", "evidence": ["Infectious virus was shed from both respiratory and gastrointestinal (GI) tracts in all animals in a biphasic manner, first between 2-7 dpi followed by a recrudescence at 14-21 dpi.", "Infection of African green monkeys (AGM) with a low passage human isolate of SARS-CoV-2 by aerosol or mucosal exposure resulted in mild clinical infection with a transient decrease in lung tidal volume.", "One Sentence Summary Subclinical infection of African green monkeys infected with SARS-CoV-2 results in prolonged shedding of infectious virus from both respiratory and gastrointestinal tracts."]}
{"id": 1000496, "claim": "Sars-cov-2 infection of african green rats results in mild respiratory disease discernible by pet/ct imaging and prolonged shedding of infectious virus from both respiratory and gastrointestinal tracts", "label": "REFUTED", "evidence": ["Infectious virus was shed from both respiratory and gastrointestinal (GI) tracts in all animals in a biphasic manner, first between 2-7 dpi followed by a recrudescence at 14-21 dpi.", "Infection of African green monkeys (AGM) with a low passage human isolate of SARS-CoV-2 by aerosol or mucosal exposure resulted in mild clinical infection with a transient decrease in lung tidal volume.", "One Sentence Summary Subclinical infection of African green monkeys infected with SARS-CoV-2 results in prolonged shedding of infectious virus from both respiratory and gastrointestinal tracts."]}
{"id": 1000497, "claim": "Uk government requests guidance on vitamin d use", "label": "SUPPORTED", "evidence": ["The health secretary told the National Institute for Health and Care Excellence (Nice) and Public Health England to create guidelines for the use of the sunshine nutrient two weeks ago, before it was reported that the government was planning to give four months worth of vitamin D supplements to more than 2 million vulnerable and elderly people, following the lead of Scotland.", "In a statement, a spokesperson for Nice, which sets NHS clinical guidelines, told the Guardian: Nice and PHE received a formal request to produce recommendations on vitamin D for prevention and treatment of Covid from the secretary of state for health and social care, Matt Hancock, on October 29. The move comes after the government began considering giving vitamin D supplements to elderly people and those who are shielding as the UK enters winter.", "Photograph: Jill Mead/The Guardian Vitamin D has moved a step closer to being used as a potential way to prevent and treat coronavirus after Matt Hancock asked government health advisers to produce new guidelines on its use."]}
{"id": 1000498, "claim": "Uk government requests guidance on time d use", "label": "REFUTED", "evidence": ["The health secretary told the National Institute for Health and Care Excellence (Nice) and Public Health England to create guidelines for the use of the sunshine nutrient two weeks ago, before it was reported that the government was planning to give four months worth of vitamin D supplements to more than 2 million vulnerable and elderly people, following the lead of Scotland.", "In a statement, a spokesperson for Nice, which sets NHS clinical guidelines, told the Guardian: Nice and PHE received a formal request to produce recommendations on vitamin D for prevention and treatment of Covid from the secretary of state for health and social care, Matt Hancock, on October 29. The move comes after the government began considering giving vitamin D supplements to elderly people and those who are shielding as the UK enters winter.", "Photograph: Jill Mead/The Guardian Vitamin D has moved a step closer to being used as a potential way to prevent and treat coronavirus after Matt Hancock asked government health advisers to produce new guidelines on its use."]}
{"id": 1000499, "claim": "Uk government requests guidance on r d use", "label": "REFUTED", "evidence": ["The health secretary told the National Institute for Health and Care Excellence (Nice) and Public Health England to create guidelines for the use of the sunshine nutrient two weeks ago, before it was reported that the government was planning to give four months worth of vitamin D supplements to more than 2 million vulnerable and elderly people, following the lead of Scotland.", "In a statement, a spokesperson for Nice, which sets NHS clinical guidelines, told the Guardian: Nice and PHE received a formal request to produce recommendations on vitamin D for prevention and treatment of Covid from the secretary of state for health and social care, Matt Hancock, on October 29. The move comes after the government began considering giving vitamin D supplements to elderly people and those who are shielding as the UK enters winter.", "Photograph: Jill Mead/The Guardian Vitamin D has moved a step closer to being used as a potential way to prevent and treat coronavirus after Matt Hancock asked government health advisers to produce new guidelines on its use."]}
{"id": 1000500, "claim": "Cyclosporine a plus low-dose steroid treatment in covid-19 improves clinical outcomes in patients with moderate to severe disease .", "label": "SUPPORTED", "evidence": ["Conclusion: CsA used as an adjuvant to steroid treatment for COVID-19 patients showed to improve outcomes and reduce mortality, mainly in those with moderate to severe disease."]}
{"id": 1000501, "claim": "Cyclosporine a plus low-dose steroid treatment in covid-19 reduces clinical outcomes in patients with moderate to severe disease.", "label": "REFUTED", "evidence": ["Conclusion: CsA used as an adjuvant to steroid treatment for COVID-19 patients showed to improve outcomes and reduce mortality, mainly in those with moderate to severe disease."]}
{"id": 1000502, "claim": "Cyclosporine a plus low-dose steroid treatment in covid-19 reduced clinical outcomes in patients with moderate to severe disease.", "label": "REFUTED", "evidence": ["Conclusion: CsA used as an adjuvant to steroid treatment for COVID-19 patients showed to improve outcomes and reduce mortality, mainly in those with moderate to severe disease."]}
{"id": 1000503, "claim": "Cyclosporine a single low-dose steroid treatment in covid-19 improves clinical outcomes in patients with moderate to severe disease.", "label": "REFUTED", "evidence": ["Conclusion: CsA used as an adjuvant to steroid treatment for COVID-19 patients showed to improve outcomes and reduce mortality, mainly in those with moderate to severe disease."]}
{"id": 1000504, "claim": "Five reasons covid-19 is less severe in younger age groups.", "label": "SUPPORTED", "evidence": ["Ludvigsson, J. F. Systematic review of COVID19 in children shows milder cases and a better prognosis than adults.", "Because children have lower susceptibility and exhibit more mildly symptomatic cases for COVID-19, school closures were slightly more effective at reducing transmission of COVID-19 when the infectiousness of subclinical infections was assumed to be high."]}
{"id": 1000505, "claim": "Two reasons covid-19 is less severe in younger age groups.", "label": "REFUTED", "evidence": ["Ludvigsson, J. F. Systematic review of COVID19 in children shows milder cases and a better prognosis than adults.", "Because children have lower susceptibility and exhibit more mildly symptomatic cases for COVID-19, school closures were slightly more effective at reducing transmission of COVID-19 when the infectiousness of subclinical infections was assumed to be high."]}
{"id": 1000506, "claim": "Three reasons covid-19 is less severe in younger age groups.", "label": "REFUTED", "evidence": ["Ludvigsson, J. F. Systematic review of COVID19 in children shows milder cases and a better prognosis than adults.", "Because children have lower susceptibility and exhibit more mildly symptomatic cases for COVID-19, school closures were slightly more effective at reducing transmission of COVID-19 when the infectiousness of subclinical infections was assumed to be high."]}
{"id": 1000507, "claim": "Five reasons covid-19 is more severe in younger age groups.", "label": "REFUTED", "evidence": ["Ludvigsson, J. F. Systematic review of COVID19 in children shows milder cases and a better prognosis than adults.", "Because children have lower susceptibility and exhibit more mildly symptomatic cases for COVID-19, school closures were slightly more effective at reducing transmission of COVID-19 when the infectiousness of subclinical infections was assumed to be high."]}
{"id": 1000508, "claim": "Selenium deficiency is associated with mortality risk from covid-19", "label": "SUPPORTED", "evidence": ["In comparison with reference data from a European cross-sectional analysis (EPIC, n = 1915), the patients showed a pronounced deficit in total serum Se (mean ± SD, 50.8 ± 15.7 vs. 84.4 ± 23.4 µg/L) and SELENOP (3.0 ± 1.4 vs. 4.3 ± 1.0 mg/L) concentrations."]}
{"id": 1000509, "claim": "Selenium growth is associated with mortality risk from covid-19", "label": "REFUTED", "evidence": ["In comparison with reference data from a European cross-sectional analysis (EPIC, n = 1915), the patients showed a pronounced deficit in total serum Se (mean ± SD, 50.8 ± 15.7 vs. 84.4 ± 23.4 µg/L) and SELENOP (3.0 ± 1.4 vs. 4.3 ± 1.0 mg/L) concentrations."]}
{"id": 1000510, "claim": "Selenium consumption is associated with mortality risk from covid-19", "label": "REFUTED", "evidence": ["In comparison with reference data from a European cross-sectional analysis (EPIC, n = 1915), the patients showed a pronounced deficit in total serum Se (mean ± SD, 50.8 ± 15.7 vs. 84.4 ± 23.4 µg/L) and SELENOP (3.0 ± 1.4 vs. 4.3 ± 1.0 mg/L) concentrations."]}
{"id": 1000511, "claim": "Pulmonary vascular dilation may cause hypoxemia in covid-19-related pneumonia", "label": "SUPPORTED", "evidence": ["Back to Healio Pulmonary vascular dilation appears to play a role in hypoxemia in patients with COVID-19-related pneumonia, researchers reported in a new study published in the American Journal of Respiratory and Critical Care Medicine.", "\"This study implicates abnormally dilated blood vessels of the lung as a major cause of low oxygen levels in COVID-19 respiratory failure,\" Hooman Poor, MD, assistant professor of medicine in the division of pulmonary, critical care and sleep medicine at the Icahn School of Medicine at Mount Sinai and director of pulmonary vascular disease at Mount Sinai-National Jewish Health Respiratory Institute, told Healio."]}
{"id": 1000512, "claim": "Pulmonary vascular dilation may prevent hypoxemia in covid-19-related pneumonia", "label": "REFUTED", "evidence": ["Back to Healio Pulmonary vascular dilation appears to play a role in hypoxemia in patients with COVID-19-related pneumonia, researchers reported in a new study published in the American Journal of Respiratory and Critical Care Medicine.", "\"This study implicates abnormally dilated blood vessels of the lung as a major cause of low oxygen levels in COVID-19 respiratory failure,\" Hooman Poor, MD, assistant professor of medicine in the division of pulmonary, critical care and sleep medicine at the Icahn School of Medicine at Mount Sinai and director of pulmonary vascular disease at Mount Sinai-National Jewish Health Respiratory Institute, told Healio."]}
{"id": 1000513, "claim": "Pulmonary vascular dilation may reduce hypoxemia in covid-19-related pneumonia", "label": "REFUTED", "evidence": ["Back to Healio Pulmonary vascular dilation appears to play a role in hypoxemia in patients with COVID-19-related pneumonia, researchers reported in a new study published in the American Journal of Respiratory and Critical Care Medicine.", "\"This study implicates abnormally dilated blood vessels of the lung as a major cause of low oxygen levels in COVID-19 respiratory failure,\" Hooman Poor, MD, assistant professor of medicine in the division of pulmonary, critical care and sleep medicine at the Icahn School of Medicine at Mount Sinai and director of pulmonary vascular disease at Mount Sinai-National Jewish Health Respiratory Institute, told Healio."]}
{"id": 1000514, "claim": "A generational war is brewing over coronavirus", "label": "SUPPORTED", "evidence": ["As authorities moved to restrict social gatherings last week, bars and restaurants from New York to Berlin filled up with revelers, illegal lockdown parties popped up in France and Belgium, and campuses in the U.S. lit up for end-of-the-world dorm parties."]}
{"id": 1000515, "claim": "A lesseral war is brewing over coronavirus", "label": "REFUTED", "evidence": ["As authorities moved to restrict social gatherings last week, bars and restaurants from New York to Berlin filled up with revelers, illegal lockdown parties popped up in France and Belgium, and campuses in the U.S. lit up for end-of-the-world dorm parties."]}
{"id": 1000516, "claim": "The d614g mutation of sars-cov-2 spike protein enhances viral infectivity and decreases neutralization sensitivity to individual convalescent sera", "label": "SUPPORTED", "evidence": ["The spike protein that mediates SARS- CoV-2 entry into host cells, is one of the major targets for vaccines and therapeutics."]}
{"id": 1000517, "claim": "The d614g mutation of sars-cov-2 spike protein enhances viral infectivity and enhanced neutralization sensitivity to individual convalescent sera", "label": "REFUTED", "evidence": ["The spike protein that mediates SARS- CoV-2 entry into host cells, is one of the major targets for vaccines and therapeutics."]}
{"id": 1000518, "claim": "The d614g mutation of sars-cov-2 spike protein enhances viral infectivity and improved neutralization sensitivity to individual convalescent sera", "label": "REFUTED", "evidence": ["The spike protein that mediates SARS- CoV-2 entry into host cells, is one of the major targets for vaccines and therapeutics."]}
{"id": 1000519, "claim": "The d614g mutation of sars-cov-2 spike protein enhances viral infectivity and increased neutralization sensitivity to individual convalescent sera", "label": "REFUTED", "evidence": ["The spike protein that mediates SARS- CoV-2 entry into host cells, is one of the major targets for vaccines and therapeutics."]}
{"id": 1000520, "claim": "Nyc map shows patients testing positive for coronavirus", "label": "SUPPORTED", "evidence": ["Data scientist Michael Donnelly, whos been crunching the citys coronavirus numbers since the start of the outbreak, noted the new map tracks with earlier MTA turnstile data.", "Wealthier parts of the city, including much of Manhattan, waterfront sections of Queens and brownstone Brooklyn, have the fewest number of coronavirus cases, according to the map released by the city Department of Health."]}
{"id": 1000521, "claim": "Nyc map shows patients not positive for coronavirus", "label": "REFUTED", "evidence": ["Data scientist Michael Donnelly, whos been crunching the citys coronavirus numbers since the start of the outbreak, noted the new map tracks with earlier MTA turnstile data.", "Wealthier parts of the city, including much of Manhattan, waterfront sections of Queens and brownstone Brooklyn, have the fewest number of coronavirus cases, according to the map released by the city Department of Health."]}
{"id": 1000522, "claim": "Nycin shows patients testing positive for coronavirus", "label": "REFUTED", "evidence": ["Data scientist Michael Donnelly, whos been crunching the citys coronavirus numbers since the start of the outbreak, noted the new map tracks with earlier MTA turnstile data.", "Wealthier parts of the city, including much of Manhattan, waterfront sections of Queens and brownstone Brooklyn, have the fewest number of coronavirus cases, according to the map released by the city Department of Health."]}
{"id": 1000523, "claim": "Nycus shows patients testing positive for coronavirus", "label": "REFUTED", "evidence": ["Data scientist Michael Donnelly, whos been crunching the citys coronavirus numbers since the start of the outbreak, noted the new map tracks with earlier MTA turnstile data.", "Wealthier parts of the city, including much of Manhattan, waterfront sections of Queens and brownstone Brooklyn, have the fewest number of coronavirus cases, according to the map released by the city Department of Health."]}
{"id": 1000524, "claim": "Plasma proteomics reveals tissue-specific cell death and mediators of cell-cell interactions in severe covid-19 patients", "label": "SUPPORTED", "evidence": ["By analyzing several thousand plasma proteins in 306 COVID-19 patients and 78 symptomatic controls over serial timepoints using two complementary approaches, we uncover COVID-19 host immune and non-immune proteins not previously linked to this disease.", "Integration of plasma proteomics with nine published scRNAseq datasets shows that SARS-CoV-2 infection upregulates monocyte/macrophage, plasmablast, and T cell effector proteins."]}
{"id": 1000525, "claim": "Plasma proteomics reveals tissue-wide cell death and mediators of cell-cell interactions in severe covid-19 patients", "label": "REFUTED", "evidence": ["By analyzing several thousand plasma proteins in 306 COVID-19 patients and 78 symptomatic controls over serial timepoints using two complementary approaches, we uncover COVID-19 host immune and non-immune proteins not previously linked to this disease.", "Integration of plasma proteomics with nine published scRNAseq datasets shows that SARS-CoV-2 infection upregulates monocyte/macrophage, plasmablast, and T cell effector proteins."]}
{"id": 1000526, "claim": "China set to clamp down permanently on wildlife trade in wake of coronavirus", "label": "SUPPORTED", "evidence": ["Last month, the national government temporarily suspended the buying and selling of wild-animal products, which are commonly used for food, fur and in traditional medicines in China."]}
{"id": 1000527, "claim": "Bats set to clamp down permanently on wildlife trade in wake of coronavirus", "label": "REFUTED", "evidence": ["Last month, the national government temporarily suspended the buying and selling of wild-animal products, which are commonly used for food, fur and in traditional medicines in China."]}
{"id": 1000528, "claim": "Data set to clamp down permanently on wildlife trade in wake of coronavirus", "label": "REFUTED", "evidence": ["Last month, the national government temporarily suspended the buying and selling of wild-animal products, which are commonly used for food, fur and in traditional medicines in China."]}
{"id": 1000529, "claim": "Sars-cov-2 activates lung epithelia cell proinflammatory signaling and leads to immune dysregulation in covid-19 patients by single-cell sequencing", "label": "SUPPORTED", "evidence": ["Results Compared to healthy controls, the overall ACE2 (receptor of SARS- CoV-2) expression was significantly higher in lung epithelial cells of COVID-19 patients, in particular in ciliated cell, club cell and basal cell.", "Moreover, SARS-CoV-2 infection altered the community interplay of lung epithelial cells and immune cells: the interaction between epithelial cells with macrophage, T and NK cell was stronger, but their interaction with neutrophils was lost in COVID-19 patients compared to healthy controls.", "Conclusions SARS-CoV-2 infection activates pro-inflammatory signaling in lung epithelial cells expressing ACE2 and causes dysregulation of immune response to release more pro-inflammatory cytokines."]}
{"id": 1000530, "claim": "Sars-cov-2 knocks lung epithelia cell proinflammatory signaling and leads to immune dysregulation in covid-19 patients by single-cell sequencing", "label": "REFUTED", "evidence": ["Results Compared to healthy controls, the overall ACE2 (receptor of SARS- CoV-2) expression was significantly higher in lung epithelial cells of COVID-19 patients, in particular in ciliated cell, club cell and basal cell.", "Moreover, SARS-CoV-2 infection altered the community interplay of lung epithelial cells and immune cells: the interaction between epithelial cells with macrophage, T and NK cell was stronger, but their interaction with neutrophils was lost in COVID-19 patients compared to healthy controls.", "Conclusions SARS-CoV-2 infection activates pro-inflammatory signaling in lung epithelial cells expressing ACE2 and causes dysregulation of immune response to release more pro-inflammatory cytokines."]}
{"id": 1000531, "claim": "Jeff bezos and amazon revealed fourth great unlock testing kits for covid19", "label": "SUPPORTED", "evidence": ["The fourth unlock, Galloway predicts, will be Jeff Bezos' reinvestment of $4 billion in Amazon profits back into his company to be used to develop 'protocols to adapt to a new world,' post-coronavirus.", "Specifically, Bezos outlined a vision for at-home COVID tests, plasma donors, PPE equipment, distancing, additional compensation, and protocols to adapt to a new world."]}
{"id": 1000532, "claim": "Jeff bezos and amazon revealed no great unlock testing kits for covid19", "label": "REFUTED", "evidence": ["The fourth unlock, Galloway predicts, will be Jeff Bezos' reinvestment of $4 billion in Amazon profits back into his company to be used to develop 'protocols to adapt to a new world,' post-coronavirus.", "Specifically, Bezos outlined a vision for at-home COVID tests, plasma donors, PPE equipment, distancing, additional compensation, and protocols to adapt to a new world."]}
{"id": 1000533, "claim": "Jeff bezos and amazon revealed two great unlock testing kits for covid19", "label": "REFUTED", "evidence": ["The fourth unlock, Galloway predicts, will be Jeff Bezos' reinvestment of $4 billion in Amazon profits back into his company to be used to develop 'protocols to adapt to a new world,' post-coronavirus.", "Specifically, Bezos outlined a vision for at-home COVID tests, plasma donors, PPE equipment, distancing, additional compensation, and protocols to adapt to a new world."]}
{"id": 1000534, "claim": "Jeff bezos and amazon revealed only great unlock testing kits for covid19", "label": "REFUTED", "evidence": ["The fourth unlock, Galloway predicts, will be Jeff Bezos' reinvestment of $4 billion in Amazon profits back into his company to be used to develop 'protocols to adapt to a new world,' post-coronavirus.", "Specifically, Bezos outlined a vision for at-home COVID tests, plasma donors, PPE equipment, distancing, additional compensation, and protocols to adapt to a new world."]}
{"id": 1000535, "claim": "Us will start testing people with flu symptoms for coronavirus , officials say", "label": "SUPPORTED", "evidence": ["She added that the system would act as an early warning if the virus spreads that would \"trigger a change in our response strategy.\"", "Samuel Corum U.S. health officials will monitor people with flu-like symptoms for the coronavirus in five cities, the Centers for Disease Control and Prevention said Friday.", "Nancy Messonnier, director of the US Centre for Immunisation and Respiratory Diseases (NCIRD), said that the US would begin to test individuals with flu- like symptoms for the coronavirus."]}
{"id": 1000536, "claim": "Us will not testing people with flu symptoms for coronavirus, officials say", "label": "REFUTED", "evidence": ["She added that the system would act as an early warning if the virus spreads that would \"trigger a change in our response strategy.\"", "Samuel Corum U.S. health officials will monitor people with flu-like symptoms for the coronavirus in five cities, the Centers for Disease Control and Prevention said Friday.", "Nancy Messonnier, director of the US Centre for Immunisation and Respiratory Diseases (NCIRD), said that the US would begin to test individuals with flu- like symptoms for the coronavirus."]}
{"id": 1000537, "claim": "Dreamlab app helps fight coronavirus by having phones run calculations while we sleep .", "label": "SUPPORTED", "evidence": ["Working with Vodafone Foundation, the 'Corona-AI' project will use the free DreamLab app, which crunches calculations using a smartphone's computing power while its user sleeps.", "DreamLab harnesses this processing power, of yours and thousands of other mobile phones, to examine such health data to look specifically at how existing drugs can be repurposed to help in the fight against cancer.", "When you plug your phone in and power DreamLab, it downloads tiny parts of a huge research project from the cloud to calculate and sends the results back to the team at Imperial College London.", "Vodafone and Imperial College launch DreamLab 08 Apr 2020Vodafone Foundation facebooklinkedintwitter Vodafone Foundation and Imperial College London scientists deploy DreamLab app to speed up coronavirus research DreamLab uses the processing power of smartphones to help analyse complex data while their owners sleep Data will help Imperial College London scientists identify existing drugs and food-based molecules with anti-viral properties, ultimately enabling tailored treatments for patients with coronavirus Smartphone users are being encouraged to harness the collective processing power of their mobile phones to help speed up research into treatments for the novel coronavirus (COVID-19) using the free DreamLab app, as part of a partnership between Vodafone Foundation and scientists at Imperial College London."]}
{"id": 1000538, "claim": "Dreamlab app cannot fight coronavirus by having phones run calculations while we sleep.", "label": "REFUTED", "evidence": ["Working with Vodafone Foundation, the 'Corona-AI' project will use the free DreamLab app, which crunches calculations using a smartphone's computing power while its user sleeps.", "DreamLab harnesses this processing power, of yours and thousands of other mobile phones, to examine such health data to look specifically at how existing drugs can be repurposed to help in the fight against cancer.", "When you plug your phone in and power DreamLab, it downloads tiny parts of a huge research project from the cloud to calculate and sends the results back to the team at Imperial College London.", "Vodafone and Imperial College launch DreamLab 08 Apr 2020Vodafone Foundation facebooklinkedintwitter Vodafone Foundation and Imperial College London scientists deploy DreamLab app to speed up coronavirus research DreamLab uses the processing power of smartphones to help analyse complex data while their owners sleep Data will help Imperial College London scientists identify existing drugs and food-based molecules with anti-viral properties, ultimately enabling tailored treatments for patients with coronavirus Smartphone users are being encouraged to harness the collective processing power of their mobile phones to help speed up research into treatments for the novel coronavirus (COVID-19) using the free DreamLab app, as part of a partnership between Vodafone Foundation and scientists at Imperial College London."]}
{"id": 1000539, "claim": "Effectiveness of facemasks to reduce exposure hazards for airborne infections among general populations", "label": "SUPPORTED", "evidence": ["Validation and application of models to predict facemask influenza contamination in healthcare settings.", "Aerosol-scavenging isolation barrier mitigates exposure risk during endonasal procedures in coronavirus-2019.", "In this work, two manikins labelled as 'source' and 'susceptible' were used to measure the protection provided by facemasks under various emission scenarios.", "The source was modified to generate polydisperse ultrafine particles, whereas the susceptible was modified to mimic a realistic breathing pattern.", "Facemasks for the prevention of infection in healthcare and community settings."]}
{"id": 1000540, "claim": "Effectiveness of facemasks to increase exposure hazards for airborne infections among general populations", "label": "REFUTED", "evidence": ["Validation and application of models to predict facemask influenza contamination in healthcare settings.", "Aerosol-scavenging isolation barrier mitigates exposure risk during endonasal procedures in coronavirus-2019.", "In this work, two manikins labelled as 'source' and 'susceptible' were used to measure the protection provided by facemasks under various emission scenarios.", "The source was modified to generate polydisperse ultrafine particles, whereas the susceptible was modified to mimic a realistic breathing pattern.", "Facemasks for the prevention of infection in healthcare and community settings."]}
{"id": 1000541, "claim": "Coronavirus may reactivate in cured patients , korean cdc says", "label": "SUPPORTED", "evidence": ["Rather than being infected again, the virus may have been reactivated in these people, given they tested positive again shortly after being released from quarantine, said Jeong Eun-kyeong, director-general of the Korean CDC.", "About 51 patients classed as having been cured in South Korea have tested positive again, the CDC said in a briefing on Monday.", "About 51 patients classed as having been cured in South Korea have tested positive again, the Korean CDC said.", "Coronavirus may 'reactivate' in cured patients: Korean CDC Can BCG vaccine help in coronavirus fight?"]}
{"id": 1000542, "claim": "Coronavirus cannot reactivate in cured patients, korean cdc says", "label": "REFUTED", "evidence": ["Rather than being infected again, the virus may have been reactivated in these people, given they tested positive again shortly after being released from quarantine, said Jeong Eun-kyeong, director-general of the Korean CDC.", "About 51 patients classed as having been cured in South Korea have tested positive again, the CDC said in a briefing on Monday.", "About 51 patients classed as having been cured in South Korea have tested positive again, the Korean CDC said.", "Coronavirus may 'reactivate' in cured patients: Korean CDC Can BCG vaccine help in coronavirus fight?"]}
{"id": 1000543, "claim": "Antibody responses to sars-cov2 are distinct in children with mis-c compared to adults with covid-19", "label": "SUPPORTED", "evidence": ["These results suggest a distinct infection course and immune response in children and adults who develop severe disease, with implications for optimizing treatments based on symptom and age.", "Moreover, MIS-C patients had reduced neutralizing activity compared to both COVID-19 cohorts, indicating a reduced protective serological response.", "Here, we show distinct antibody (Ab) responses in children with MIS-C compared to adults with severe COVID-19 causing acute respiratory distress syndrome (ARDS), and those who recovered from mild disease.", "There was a reduced breadth and specificity of anti-SARS-CoV-2-specific antibodies in MIS-C patients compared to the COVID patient groups; MIS-C predominantly generated IgG Abs specific for the Spike (S) protein but not for the nucleocapsid (N) protein, while the COVID-19 cohorts had anti-S IgG, IgM and IgA Abs, as well as anti-N IgG Abs."]}
{"id": 1000544, "claim": "Antibody responses to sars-cov2 are similar in children with mis-c compared to adults with covid-19", "label": "REFUTED", "evidence": ["These results suggest a distinct infection course and immune response in children and adults who develop severe disease, with implications for optimizing treatments based on symptom and age.", "Moreover, MIS-C patients had reduced neutralizing activity compared to both COVID-19 cohorts, indicating a reduced protective serological response.", "Here, we show distinct antibody (Ab) responses in children with MIS-C compared to adults with severe COVID-19 causing acute respiratory distress syndrome (ARDS), and those who recovered from mild disease.", "There was a reduced breadth and specificity of anti-SARS-CoV-2-specific antibodies in MIS-C patients compared to the COVID patient groups; MIS-C predominantly generated IgG Abs specific for the Spike (S) protein but not for the nucleocapsid (N) protein, while the COVID-19 cohorts had anti-S IgG, IgM and IgA Abs, as well as anti-N IgG Abs."]}
{"id": 1000545, "claim": "North korea 'shoots dead coronavirus patient ' after he 's 'seen at public baths '", "label": "SUPPORTED", "evidence": ["India TV News Desk Pyongyang Updated on: February 14, 2020 13:46 IST Image Source : AP Kim Jong-Un shoots dead official for using public bath during quarantine zone; exiles another North Korean leader Kim Jong-Un ordered the killing of a trade official after the man visited a public bath while he was told to remain in a quarantined zone as a precaution to coronavirus infection spread."]}
{"id": 1000546, "claim": "North korea 'no dead coronavirus patient'after he's'seen at public baths '", "label": "REFUTED", "evidence": ["India TV News Desk Pyongyang Updated on: February 14, 2020 13:46 IST Image Source : AP Kim Jong-Un shoots dead official for using public bath during quarantine zone; exiles another North Korean leader Kim Jong-Un ordered the killing of a trade official after the man visited a public bath while he was told to remain in a quarantined zone as a precaution to coronavirus infection spread."]}
{"id": 1000547, "claim": "North korea'shoots dead coronavirus patient'after he's'seen at public health '", "label": "REFUTED", "evidence": ["India TV News Desk Pyongyang Updated on: February 14, 2020 13:46 IST Image Source : AP Kim Jong-Un shoots dead official for using public bath during quarantine zone; exiles another North Korean leader Kim Jong-Un ordered the killing of a trade official after the man visited a public bath while he was told to remain in a quarantined zone as a precaution to coronavirus infection spread."]}
{"id": 1000548, "claim": "Chadox1 ncov-19 vaccine prevents sars-cov-2 pneumonia in rhesus macaques", "label": "SUPPORTED", "evidence": ["Here we show that the adenovirus- vector-based vaccine ChAdOx1 nCoV-19, which encodes the spike protein of SARS- CoV-2, is immunogenic in mice and elicites a robust humoral and cell-mediated response.", "Vaccination with ChAdOx1 nCoV-19 (using either a prime-only or a prime-boost regimen) induced a balanced humoral and cellular immune response of type-1 and type-2 T helper cells in rhesus macaques."]}
{"id": 1000549, "claim": "Chadox1 ncov-19 vaccine induces sars-cov-2 pneumonia in rhesus macaques", "label": "REFUTED", "evidence": ["Here we show that the adenovirus- vector-based vaccine ChAdOx1 nCoV-19, which encodes the spike protein of SARS- CoV-2, is immunogenic in mice and elicites a robust humoral and cell-mediated response.", "Vaccination with ChAdOx1 nCoV-19 (using either a prime-only or a prime-boost regimen) induced a balanced humoral and cellular immune response of type-1 and type-2 T helper cells in rhesus macaques."]}
{"id": 1000550, "claim": "Chadox1 ncov-19 vaccine causes sars-cov-2 pneumonia in rhesus macaques", "label": "REFUTED", "evidence": ["Here we show that the adenovirus- vector-based vaccine ChAdOx1 nCoV-19, which encodes the spike protein of SARS- CoV-2, is immunogenic in mice and elicites a robust humoral and cell-mediated response.", "Vaccination with ChAdOx1 nCoV-19 (using either a prime-only or a prime-boost regimen) induced a balanced humoral and cellular immune response of type-1 and type-2 T helper cells in rhesus macaques."]}
{"id": 1000551, "claim": "Chadox1 ncov-19 vaccine caused sars-cov-2 pneumonia in rhesus macaques", "label": "REFUTED", "evidence": ["Here we show that the adenovirus- vector-based vaccine ChAdOx1 nCoV-19, which encodes the spike protein of SARS- CoV-2, is immunogenic in mice and elicites a robust humoral and cell-mediated response.", "Vaccination with ChAdOx1 nCoV-19 (using either a prime-only or a prime-boost regimen) induced a balanced humoral and cellular immune response of type-1 and type-2 T helper cells in rhesus macaques."]}
{"id": 1000552, "claim": "Ivermectin exposure leads to up-regulation of detoxification genes in vitro and in vivo in mice", "label": "SUPPORTED", "evidence": ["Gene expression of ABC transporters and cytochromes was evaluated by RT-qPCR in murine hepatic and intestinal cell lines exposed to increasing ivermectin doses, and in liver and intestine of mice orally administered with single or repeated therapeutic doses of ivermectin (0.2 mg/kg)."]}
{"id": 1000553, "claim": "Ivermectin deficiency leads to up-regulation of detoxification genes in vitro and in vivo in mice", "label": "REFUTED", "evidence": ["Gene expression of ABC transporters and cytochromes was evaluated by RT-qPCR in murine hepatic and intestinal cell lines exposed to increasing ivermectin doses, and in liver and intestine of mice orally administered with single or repeated therapeutic doses of ivermectin (0.2 mg/kg)."]}
{"id": 1000554, "claim": "Ivermectin exposure leads to up-regulation of detoxification genes in vitro and in vivo in humans", "label": "REFUTED", "evidence": ["Gene expression of ABC transporters and cytochromes was evaluated by RT-qPCR in murine hepatic and intestinal cell lines exposed to increasing ivermectin doses, and in liver and intestine of mice orally administered with single or repeated therapeutic doses of ivermectin (0.2 mg/kg)."]}
{"id": 1000555, "claim": "Clinical predictors of mortality due to covid-19 based on an analysis of data of 150 patients from wuhan , china", "label": "SUPPORTED", "evidence": ["Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study."]}
{"id": 1000556, "claim": "Clinical predictors of infection due to covid-19 based on an analysis of data of 150 patients from wuhan, china", "label": "REFUTED", "evidence": ["Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study."]}
{"id": 1000557, "claim": "Clinical predictors of age due to covid-19 based on an analysis of data of 150 patients from wuhan, china", "label": "REFUTED", "evidence": ["Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study."]}
{"id": 1000558, "claim": "Clinical predictors of hospitalization due to covid-19 based on an analysis of data of 150 patients from wuhan, china", "label": "REFUTED", "evidence": ["Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study."]}
{"id": 1000559, "claim": "Millennials may be at a higher risk for catching coronavirus", "label": "SUPPORTED", "evidence": ["\"It may have been that the millennial generation, our largest generation, our future generation, that will carry us through for the next multiple decades  there may be a disproportional number of infections among that group."]}
{"id": 1000560, "claim": "Millennials may be at a lower risk for catching coronavirus", "label": "REFUTED", "evidence": ["\"It may have been that the millennial generation, our largest generation, our future generation, that will carry us through for the next multiple decades  there may be a disproportional number of infections among that group."]}
{"id": 1000561, "claim": "Millennials may be at a low risk for catching coronavirus", "label": "REFUTED", "evidence": ["\"It may have been that the millennial generation, our largest generation, our future generation, that will carry us through for the next multiple decades  there may be a disproportional number of infections among that group."]}
{"id": 1000562, "claim": "Millennials may be at a poor risk for catching coronavirus", "label": "REFUTED", "evidence": ["\"It may have been that the millennial generation, our largest generation, our future generation, that will carry us through for the next multiple decades  there may be a disproportional number of infections among that group."]}
{"id": 1000563, "claim": "California is monitoring at least 8,400 people for the coronavirus", "label": "SUPPORTED", "evidence": ["Gavin Newsom said Thursday that 33 people have tested positive for COVID-19 and the state is currently monitoring at least 8,400 others a day after U.S. health officials confirmed the first possible community transmission of the coronavirus in a Solano County resident."]}
{"id": 1000564, "claim": "California is monitoring at least 8,3 people for the coronavirus", "label": "REFUTED", "evidence": ["Gavin Newsom said Thursday that 33 people have tested positive for COVID-19 and the state is currently monitoring at least 8,400 others a day after U.S. health officials confirmed the first possible community transmission of the coronavirus in a Solano County resident."]}
{"id": 1000565, "claim": "California is monitoring at least 8,6 people for the coronavirus", "label": "REFUTED", "evidence": ["Gavin Newsom said Thursday that 33 people have tested positive for COVID-19 and the state is currently monitoring at least 8,400 others a day after U.S. health officials confirmed the first possible community transmission of the coronavirus in a Solano County resident."]}
{"id": 1000566, "claim": "California is monitoring at least 8,200 people for the coronavirus", "label": "REFUTED", "evidence": ["Gavin Newsom said Thursday that 33 people have tested positive for COVID-19 and the state is currently monitoring at least 8,400 others a day after U.S. health officials confirmed the first possible community transmission of the coronavirus in a Solano County resident."]}
{"id": 1000567, "claim": "Blood type could be linked to covid-19 risk and severity , new research suggests", "label": "SUPPORTED", "evidence": ["As for the novel coronavirus that causes Covid-19, \"We need to figure out the mechanism and understand it at the molecular level to be able to say for sure how this is occurring -- that this is really the O blood type and not something that kind of tracks with O blood type,\" Adalja said.", "Here's how to find out yours A separate study, published in The New England Journal of Medicine in June, found genetic data in some Covid-19 patients and healthy people suggesting that those with Type A blood had a higher risk of becoming infected, and those with type O blood were at a lower risk."]}
{"id": 1000568, "claim": "Blood type cannot be linked to covid-19 risk and severity, new research suggests", "label": "REFUTED", "evidence": ["As for the novel coronavirus that causes Covid-19, \"We need to figure out the mechanism and understand it at the molecular level to be able to say for sure how this is occurring -- that this is really the O blood type and not something that kind of tracks with O blood type,\" Adalja said.", "Here's how to find out yours A separate study, published in The New England Journal of Medicine in June, found genetic data in some Covid-19 patients and healthy people suggesting that those with Type A blood had a higher risk of becoming infected, and those with type O blood were at a lower risk."]}
{"id": 1000569, "claim": "Comment on analysis of hospital traffic and search engine data in wuhan china indicates early disease activity in the fall of 2019 by nsoesie et al .", "label": "SUPPORTED", "evidence": ["Analysis of hospital traffic and search engine data in Wuhan China indicates early disease activity in the Fall of 2019 (2020).", "It would have been interesting (and possibly much more convincing) to have seen control analyses of other Chinese cities outside of the Hubei region.  Analysis of hospital traffic and search engine data in Wuhan China indicates early disease activity in the Fall of 2019 by Nsoesie et al is posted on the Harvard website .", "analysed vehicle counts in hospital parking lots and internet search trends, and suggested that the COVID-19 outbreak might have started in Wuhan, China as early as August 2019."]}
{"id": 1000570, "claim": "Comment on analysis of hospital traffic and search engine data in wuhan china indicates early disease activity in the fall of 2011 by nsoesie et al.", "label": "REFUTED", "evidence": ["Analysis of hospital traffic and search engine data in Wuhan China indicates early disease activity in the Fall of 2019 (2020).", "It would have been interesting (and possibly much more convincing) to have seen control analyses of other Chinese cities outside of the Hubei region.  Analysis of hospital traffic and search engine data in Wuhan China indicates early disease activity in the Fall of 2019 by Nsoesie et al is posted on the Harvard website .", "analysed vehicle counts in hospital parking lots and internet search trends, and suggested that the COVID-19 outbreak might have started in Wuhan, China as early as August 2019."]}
{"id": 1000571, "claim": "Comment on analysis of hospital traffic and search engine data in wuhan china indicates early disease activity in the fall of 2003 by nsoesie et al.", "label": "REFUTED", "evidence": ["Analysis of hospital traffic and search engine data in Wuhan China indicates early disease activity in the Fall of 2019 (2020).", "It would have been interesting (and possibly much more convincing) to have seen control analyses of other Chinese cities outside of the Hubei region.  Analysis of hospital traffic and search engine data in Wuhan China indicates early disease activity in the Fall of 2019 by Nsoesie et al is posted on the Harvard website .", "analysed vehicle counts in hospital parking lots and internet search trends, and suggested that the COVID-19 outbreak might have started in Wuhan, China as early as August 2019."]}
{"id": 1000572, "claim": "Comment on analysis of hospital traffic and search engine data in wuhan china indicates early disease activity in the fall of 2013 by nsoesie et al.", "label": "REFUTED", "evidence": ["Analysis of hospital traffic and search engine data in Wuhan China indicates early disease activity in the Fall of 2019 (2020).", "It would have been interesting (and possibly much more convincing) to have seen control analyses of other Chinese cities outside of the Hubei region.  Analysis of hospital traffic and search engine data in Wuhan China indicates early disease activity in the Fall of 2019 by Nsoesie et al is posted on the Harvard website .", "analysed vehicle counts in hospital parking lots and internet search trends, and suggested that the COVID-19 outbreak might have started in Wuhan, China as early as August 2019."]}
{"id": 1000573, "claim": "Protonation states in sars-cov-2 main protease mapped by neutron crystallography", "label": "SUPPORTED", "evidence": ["This structure highlights the ability of neutron protein crystallography for experimentally determining protonation states at near- physiological temperature  the critical information for structure-assisted and computational drug design.", "A long-standing question in the field has been what the protonation states of the ionizable residues in the substrate-binding active site cavity are.", "The neutron structure also identified the protonation states of other amino acid residues, mapping electrical charges and intricate hydrogen bonding networks in the SARS-CoV-2 3CL Mpro active site cavity and dimer interface.", "Here, we present the room- temperature neutron structure of 3CL Mpro from SARS-CoV-2, which allows direct determination of hydrogen atom positions and, hence, protonation states."]}
{"id": 1000574, "claim": "Protonation states in sars-cov-2 main protease mapped by trypsin crystallography", "label": "REFUTED", "evidence": ["This structure highlights the ability of neutron protein crystallography for experimentally determining protonation states at near- physiological temperature  the critical information for structure-assisted and computational drug design.", "A long-standing question in the field has been what the protonation states of the ionizable residues in the substrate-binding active site cavity are.", "The neutron structure also identified the protonation states of other amino acid residues, mapping electrical charges and intricate hydrogen bonding networks in the SARS-CoV-2 3CL Mpro active site cavity and dimer interface.", "Here, we present the room- temperature neutron structure of 3CL Mpro from SARS-CoV-2, which allows direct determination of hydrogen atom positions and, hence, protonation states."]}
{"id": 1000575, "claim": "Protonation states in sars-cov-2 main protease mapped by pdb crystallography", "label": "REFUTED", "evidence": ["This structure highlights the ability of neutron protein crystallography for experimentally determining protonation states at near- physiological temperature  the critical information for structure-assisted and computational drug design.", "A long-standing question in the field has been what the protonation states of the ionizable residues in the substrate-binding active site cavity are.", "The neutron structure also identified the protonation states of other amino acid residues, mapping electrical charges and intricate hydrogen bonding networks in the SARS-CoV-2 3CL Mpro active site cavity and dimer interface.", "Here, we present the room- temperature neutron structure of 3CL Mpro from SARS-CoV-2, which allows direct determination of hydrogen atom positions and, hence, protonation states."]}
{"id": 1000576, "claim": "Protonation states in sars-cov-2 main protease mapped by blast crystallography", "label": "REFUTED", "evidence": ["This structure highlights the ability of neutron protein crystallography for experimentally determining protonation states at near- physiological temperature  the critical information for structure-assisted and computational drug design.", "A long-standing question in the field has been what the protonation states of the ionizable residues in the substrate-binding active site cavity are.", "The neutron structure also identified the protonation states of other amino acid residues, mapping electrical charges and intricate hydrogen bonding networks in the SARS-CoV-2 3CL Mpro active site cavity and dimer interface.", "Here, we present the room- temperature neutron structure of 3CL Mpro from SARS-CoV-2, which allows direct determination of hydrogen atom positions and, hence, protonation states."]}
{"id": 1000577, "claim": "Antibodies in covid-19 patients fade quickly", "label": "SUPPORTED", "evidence": ["In combination with certain previous findings on COVID-19 antibodies, the researchers concluded that their results \"might indicate the risks of using COVID-19 'immunity passports' and support the prolongation of public health interventions, including social distancing, hygiene, isolation of high-risk groups and widespread testing.\"", "Decreases in the neutralizing antibodies were seen in 81% (30/37) of the asymptomatic group and 62% (23/37) of the symptomatic group.", "Antibody levels dropped by 71.1% in asymptomatic patients and 76.2% in the symptomatic group.", "The median decreases in antibody level were 8.3% in the asymptomatic group and 11.7% in the symptomatic patients."]}
{"id": 1000578, "claim": "Antibodies in covid-19 cannot fade quickly", "label": "REFUTED", "evidence": ["In combination with certain previous findings on COVID-19 antibodies, the researchers concluded that their results \"might indicate the risks of using COVID-19 'immunity passports' and support the prolongation of public health interventions, including social distancing, hygiene, isolation of high-risk groups and widespread testing.\"", "Decreases in the neutralizing antibodies were seen in 81% (30/37) of the asymptomatic group and 62% (23/37) of the symptomatic group.", "Antibody levels dropped by 71.1% in asymptomatic patients and 76.2% in the symptomatic group.", "The median decreases in antibody level were 8.3% in the asymptomatic group and 11.7% in the symptomatic patients."]}
{"id": 1000579, "claim": "Antibodies in covid-19 patients remain quickly", "label": "REFUTED", "evidence": ["In combination with certain previous findings on COVID-19 antibodies, the researchers concluded that their results \"might indicate the risks of using COVID-19 'immunity passports' and support the prolongation of public health interventions, including social distancing, hygiene, isolation of high-risk groups and widespread testing.\"", "Decreases in the neutralizing antibodies were seen in 81% (30/37) of the asymptomatic group and 62% (23/37) of the symptomatic group.", "Antibody levels dropped by 71.1% in asymptomatic patients and 76.2% in the symptomatic group.", "The median decreases in antibody level were 8.3% in the asymptomatic group and 11.7% in the symptomatic patients."]}
{"id": 1000580, "claim": "Antibodies in covid-19 patients occur quickly", "label": "REFUTED", "evidence": ["In combination with certain previous findings on COVID-19 antibodies, the researchers concluded that their results \"might indicate the risks of using COVID-19 'immunity passports' and support the prolongation of public health interventions, including social distancing, hygiene, isolation of high-risk groups and widespread testing.\"", "Decreases in the neutralizing antibodies were seen in 81% (30/37) of the asymptomatic group and 62% (23/37) of the symptomatic group.", "Antibody levels dropped by 71.1% in asymptomatic patients and 76.2% in the symptomatic group.", "The median decreases in antibody level were 8.3% in the asymptomatic group and 11.7% in the symptomatic patients."]}
{"id": 1000581, "claim": "Broad phenotypic alterations and potential dysfunctions of lymphocytes in covid-19 recovered individuals", "label": "SUPPORTED", "evidence": ["This suggests SARS-CoV-2 infection imprints profoundly on lymphocytes and results in long-lasting potential dysfunctions.", "Interpretation The CR COVID-19 individuals still showed remarkable phenotypic alterations in lymphocytes after clinical recovery 4 to 11 weeks."]}
{"id": 1000582, "claim": "Broad phenotypic alterations and potential dysfunctions of lymphocytes in covid-19 infected individuals", "label": "REFUTED", "evidence": ["This suggests SARS-CoV-2 infection imprints profoundly on lymphocytes and results in long-lasting potential dysfunctions.", "Interpretation The CR COVID-19 individuals still showed remarkable phenotypic alterations in lymphocytes after clinical recovery 4 to 11 weeks."]}
{"id": 1000583, "claim": "Broad phenotypic alterations and potential dysfunctions of lymphocytes in covid-19 infection individuals", "label": "REFUTED", "evidence": ["This suggests SARS-CoV-2 infection imprints profoundly on lymphocytes and results in long-lasting potential dysfunctions.", "Interpretation The CR COVID-19 individuals still showed remarkable phenotypic alterations in lymphocytes after clinical recovery 4 to 11 weeks."]}
{"id": 1000584, "claim": "Broad phenotypic alterations and potential dysfunctions of lymphocytes in covid-19infected individuals", "label": "REFUTED", "evidence": ["This suggests SARS-CoV-2 infection imprints profoundly on lymphocytes and results in long-lasting potential dysfunctions.", "Interpretation The CR COVID-19 individuals still showed remarkable phenotypic alterations in lymphocytes after clinical recovery 4 to 11 weeks."]}
{"id": 1000585, "claim": "Sars-cov-2 infection damages airway motile cilia and impairs mucociliary clearance", "label": "SUPPORTED", "evidence": ["Rather, SARS-CoV-2 replication led to a rapid loss of the ciliary layer, characterized at the ultrastructural level by axoneme loss and misorientation of remaining basal bodies.", "This study identifies cilia damage as a pathogenic mechanism that could facilitate SARS- CoV-2 spread to the deeper lung parenchyma."]}
{"id": 1000586, "claim": "Sars-cov-2 infection promotes airway motile cilia and impairs mucociliary clearance", "label": "REFUTED", "evidence": ["Rather, SARS-CoV-2 replication led to a rapid loss of the ciliary layer, characterized at the ultrastructural level by axoneme loss and misorientation of remaining basal bodies.", "This study identifies cilia damage as a pathogenic mechanism that could facilitate SARS- CoV-2 spread to the deeper lung parenchyma."]}
{"id": 1000587, "claim": "Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe covid-19 illness", "label": "SUPPORTED", "evidence": ["Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis.", "Conclusions: In patients with severe COVID-19 receiving TCZ due to systemic host-immune inflammatory response syndrome, the use of CS in addition to TCZ therapy, showed a beneficial effect in preventing in-hospital mortality."]}
{"id": 1000588, "claim": "No effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe covid-19 illness", "label": "REFUTED", "evidence": ["Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis.", "Conclusions: In patients with severe COVID-19 receiving TCZ due to systemic host-immune inflammatory response syndrome, the use of CS in addition to TCZ therapy, showed a beneficial effect in preventing in-hospital mortality."]}
{"id": 1000589, "claim": "''walkthroughs are still permitted , but any group or team activity in city parks is banned . '", "label": "SUPPORTED", "evidence": ["\"We recognize that this decision will affect residents' enjoyment of the Greenbelt, but we must make every effort to protect employees, contractors and trail users from COVID-19 and ensure compliance with public health directives from all levels of government, particularly the call to avoid all non- essential trips,\" the NCC said in a news release."]}
{"id": 1000590, "claim": "''walkthroughs are still permitted, but any group or team activity in city parks is too. '", "label": "REFUTED", "evidence": ["\"We recognize that this decision will affect residents' enjoyment of the Greenbelt, but we must make every effort to protect employees, contractors and trail users from COVID-19 and ensure compliance with public health directives from all levels of government, particularly the call to avoid all non- essential trips,\" the NCC said in a news release."]}
{"id": 1000591, "claim": "''walkthroughs are still lacking, but any group or team activity in city parks is banned. '", "label": "REFUTED", "evidence": ["\"We recognize that this decision will affect residents' enjoyment of the Greenbelt, but we must make every effort to protect employees, contractors and trail users from COVID-19 and ensure compliance with public health directives from all levels of government, particularly the call to avoid all non- essential trips,\" the NCC said in a news release."]}
{"id": 1000592, "claim": "''walkthroughs are still permitted, but any group or team activity in city parks is considered. '", "label": "REFUTED", "evidence": ["\"We recognize that this decision will affect residents' enjoyment of the Greenbelt, but we must make every effort to protect employees, contractors and trail users from COVID-19 and ensure compliance with public health directives from all levels of government, particularly the call to avoid all non- essential trips,\" the NCC said in a news release."]}
{"id": 1000593, "claim": "Predictors of symptomatic laboratory-confirmed sars-cov-2 reinfection", "label": "SUPPORTED", "evidence": ["Healthcare workers and immunosuppressed or renal patients had at greater risk of SARS-COV-2 reinfection."]}
{"id": 1000594, "claim": "Predictors of symptomatic community-confirmed sars-cov-2 reinfection", "label": "REFUTED", "evidence": ["Healthcare workers and immunosuppressed or renal patients had at greater risk of SARS-COV-2 reinfection."]}
{"id": 1000595, "claim": "Predictors of symptomatic laboratory-free sars-cov-2 reinfection", "label": "REFUTED", "evidence": ["Healthcare workers and immunosuppressed or renal patients had at greater risk of SARS-COV-2 reinfection."]}
{"id": 1000596, "claim": "Predictors of symptomatic hospital-confirmed sars-cov-2 reinfection", "label": "REFUTED", "evidence": ["Healthcare workers and immunosuppressed or renal patients had at greater risk of SARS-COV-2 reinfection."]}
{"id": 1000597, "claim": "Spread of sars-cov-2 coronavirus likely to be constrained by climate", "label": "SUPPORTED", "evidence": ["You are going to email the following Spread of SARS-CoV-2 Coronavirus likely constrained by climate Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website.", "This is because the environment can mediate human-to-human transmission of SARS-CoV-2, and unsuitable climates can cause the virus to destabilize quickly, hence reducing its capacity to become epidemic."]}
{"id": 1000598, "claim": "Spread of sars-cov-2 coronavirus likely to be transmitted by climate", "label": "REFUTED", "evidence": ["You are going to email the following Spread of SARS-CoV-2 Coronavirus likely constrained by climate Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website.", "This is because the environment can mediate human-to-human transmission of SARS-CoV-2, and unsuitable climates can cause the virus to destabilize quickly, hence reducing its capacity to become epidemic."]}
{"id": 1000599, "claim": "Modified full-face snorkel masks as reusable personal protective equipment for hospital personnel", "label": "SUPPORTED", "evidence": ["The benefit of the Pneumask as PPE is that it is reusable for longer periods than typical disposable N95 respirators, as the snorkel mask can withstand rigorous decontamination protocols (that are standard to regular elastomeric respirators).", "Key points Full-face snorkel masks are adapted for use as Personal Protective Equipment during the COVID-19 crisis, using a custom adapter that facilitates the attachment of inline medical-grade respiratory filters or NIOSH industrial respirator filters.", "These tests found the Pneumask capable of forming a seal that exceeds the standards required for half-face respirators or N95 respirators."]}
{"id": 1000600, "claim": "Modified full-face snorkel masks as reusable personal protective equipment for sars personnel", "label": "REFUTED", "evidence": ["The benefit of the Pneumask as PPE is that it is reusable for longer periods than typical disposable N95 respirators, as the snorkel mask can withstand rigorous decontamination protocols (that are standard to regular elastomeric respirators).", "Key points Full-face snorkel masks are adapted for use as Personal Protective Equipment during the COVID-19 crisis, using a custom adapter that facilitates the attachment of inline medical-grade respiratory filters or NIOSH industrial respirator filters.", "These tests found the Pneumask capable of forming a seal that exceeds the standards required for half-face respirators or N95 respirators."]}
{"id": 1000601, "claim": "Modified full-face snorkel masks as reusable personal protective equipment for vaccination personnel", "label": "REFUTED", "evidence": ["The benefit of the Pneumask as PPE is that it is reusable for longer periods than typical disposable N95 respirators, as the snorkel mask can withstand rigorous decontamination protocols (that are standard to regular elastomeric respirators).", "Key points Full-face snorkel masks are adapted for use as Personal Protective Equipment during the COVID-19 crisis, using a custom adapter that facilitates the attachment of inline medical-grade respiratory filters or NIOSH industrial respirator filters.", "These tests found the Pneumask capable of forming a seal that exceeds the standards required for half-face respirators or N95 respirators."]}
{"id": 1000602, "claim": "Modified full-face snorkel masks as reusable personal protective equipment for quarantine personnel", "label": "REFUTED", "evidence": ["The benefit of the Pneumask as PPE is that it is reusable for longer periods than typical disposable N95 respirators, as the snorkel mask can withstand rigorous decontamination protocols (that are standard to regular elastomeric respirators).", "Key points Full-face snorkel masks are adapted for use as Personal Protective Equipment during the COVID-19 crisis, using a custom adapter that facilitates the attachment of inline medical-grade respiratory filters or NIOSH industrial respirator filters.", "These tests found the Pneumask capable of forming a seal that exceeds the standards required for half-face respirators or N95 respirators."]}
{"id": 1000603, "claim": "India to test 100-yr-old vaccine on humans as war against covid-19 heats up", "label": "SUPPORTED", "evidence": ["Pune-based Serum Institute's recombinant BCG vaccine- developed in 1919-has a proven safety record and the company can make at least 300 million doses of it."]}
{"id": 1000604, "claim": "unable to test 100-yr-old vaccine on humans as war against covid-19 heats up", "label": "REFUTED", "evidence": ["Pune-based Serum Institute's recombinant BCG vaccine- developed in 1919-has a proven safety record and the company can make at least 300 million doses of it."]}
{"id": 1000605, "claim": "Antigen-based testing but not real-time pcr correlates with sars-cov-2 virus culture", "label": "SUPPORTED", "evidence": ["Coupled with a rapid time-to-result, low cost, and scalability, antigen-based testing should facilitate effective implementation of testing and public health interventions that will better contain COVID-19.", "The correlation between SARS-CoV-2 antigen and SARS-CoV-2 culture represents a significant advancement in determining the risk for potential transmissibility beyond that which can be achieved by detection of SARS-CoV-2 genomic RNA."]}
{"id": 1000606, "claim": "Antigen-based testing but also real-time pcr correlates with sars-cov-2 virus culture", "label": "REFUTED", "evidence": ["Coupled with a rapid time-to-result, low cost, and scalability, antigen-based testing should facilitate effective implementation of testing and public health interventions that will better contain COVID-19.", "The correlation between SARS-CoV-2 antigen and SARS-CoV-2 culture represents a significant advancement in determining the risk for potential transmissibility beyond that which can be achieved by detection of SARS-CoV-2 genomic RNA."]}
{"id": 1000607, "claim": "Antigen-based testing but only real-time pcr correlates with sars-cov-2 virus culture", "label": "REFUTED", "evidence": ["Coupled with a rapid time-to-result, low cost, and scalability, antigen-based testing should facilitate effective implementation of testing and public health interventions that will better contain COVID-19.", "The correlation between SARS-CoV-2 antigen and SARS-CoV-2 culture represents a significant advancement in determining the risk for potential transmissibility beyond that which can be achieved by detection of SARS-CoV-2 genomic RNA."]}
{"id": 1000608, "claim": "Antigen-based testing but strong real-time pcr correlates with sars-cov-2 virus culture", "label": "REFUTED", "evidence": ["Coupled with a rapid time-to-result, low cost, and scalability, antigen-based testing should facilitate effective implementation of testing and public health interventions that will better contain COVID-19.", "The correlation between SARS-CoV-2 antigen and SARS-CoV-2 culture represents a significant advancement in determining the risk for potential transmissibility beyond that which can be achieved by detection of SARS-CoV-2 genomic RNA."]}
{"id": 1000609, "claim": "Lilly announces proof of concept data for neutralizing antibody ly-cov555 in the covid-19 outpatient setting", "label": "SUPPORTED", "evidence": ["Existing Lilly medicines are now being studied to understand their potential in treating complications of COVID-19, and the company is collaborating with two partner companies to discover novel antibody treatments for COVID-19.", "\"These interim data from the BLAZE-1 trial suggest that LY-CoV555, an antibody specifically directed against SARS-CoV-2, has a direct antiviral effect and may reduce COVID-related hospitalizations,\" said Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories.", "Lilly intends to test both single antibody therapy as well as combinations of antibodies (sometimes known as antibody cocktails) as potential therapeutics for COVID-19.", "LY-CoV555 emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.", "Lilly has successfully completed enrollment and primary safety assessments of LY-CoV555 in a Phase 1 study of hospitalized patients with COVID-19 (NCT04411628) and long-term follow-up is ongoing."]}
{"id": 1000610, "claim": "Lilly requires proof of concept data for neutralizing antibody ly-cov555 in the covid-19 outpatient setting", "label": "REFUTED", "evidence": ["Existing Lilly medicines are now being studied to understand their potential in treating complications of COVID-19, and the company is collaborating with two partner companies to discover novel antibody treatments for COVID-19.", "\"These interim data from the BLAZE-1 trial suggest that LY-CoV555, an antibody specifically directed against SARS-CoV-2, has a direct antiviral effect and may reduce COVID-related hospitalizations,\" said Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories.", "Lilly intends to test both single antibody therapy as well as combinations of antibodies (sometimes known as antibody cocktails) as potential therapeutics for COVID-19.", "LY-CoV555 emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.", "Lilly has successfully completed enrollment and primary safety assessments of LY-CoV555 in a Phase 1 study of hospitalized patients with COVID-19 (NCT04411628) and long-term follow-up is ongoing."]}
{"id": 1000611, "claim": "Biotech company moderna has first potential vaccine , developed in only 42 days .", "label": "SUPPORTED", "evidence": ["According to Moderna, the vaccine was developed within 42 days of the company obtaining genetic information on the coronavirus.", "The collaboration across Moderna, with NIAID, and with CEPI has allowed us to deliver a clinical batch in 42 days from sequence identification, said Juan Andres, Chief Technical Operations and Quality Officer at Moderna.", "The potential vaccine -- developed by Moderna, a small Massachusetts biotech company -- has had a speedy development: Moderna went from sequencing the virus' genetic information to shipping a vaccine candidate to US health officials in 42 days.", "Moderna developed the vaccine in what Juan Andres, Modernas chief technical operations and quality officer, called record speed  just 42 days.", "It took 42 days for Moderna to move from sequencing the virus to shipping a vaccine candidate to NIH officials."]}
{"id": 1000612, "claim": "Biotech company moderna has first potential vaccine, developed in only 42 years.", "label": "REFUTED", "evidence": ["According to Moderna, the vaccine was developed within 42 days of the company obtaining genetic information on the coronavirus.", "The collaboration across Moderna, with NIAID, and with CEPI has allowed us to deliver a clinical batch in 42 days from sequence identification, said Juan Andres, Chief Technical Operations and Quality Officer at Moderna.", "The potential vaccine -- developed by Moderna, a small Massachusetts biotech company -- has had a speedy development: Moderna went from sequencing the virus' genetic information to shipping a vaccine candidate to US health officials in 42 days.", "Moderna developed the vaccine in what Juan Andres, Modernas chief technical operations and quality officer, called record speed  just 42 days.", "It took 42 days for Moderna to move from sequencing the virus to shipping a vaccine candidate to NIH officials."]}
{"id": 1000613, "claim": "Biotech company moderna has first potential vaccine, developed in only 42 months.", "label": "REFUTED", "evidence": ["According to Moderna, the vaccine was developed within 42 days of the company obtaining genetic information on the coronavirus.", "The collaboration across Moderna, with NIAID, and with CEPI has allowed us to deliver a clinical batch in 42 days from sequence identification, said Juan Andres, Chief Technical Operations and Quality Officer at Moderna.", "The potential vaccine -- developed by Moderna, a small Massachusetts biotech company -- has had a speedy development: Moderna went from sequencing the virus' genetic information to shipping a vaccine candidate to US health officials in 42 days.", "Moderna developed the vaccine in what Juan Andres, Modernas chief technical operations and quality officer, called record speed  just 42 days.", "It took 42 days for Moderna to move from sequencing the virus to shipping a vaccine candidate to NIH officials."]}
{"id": 1000614, "claim": "Russia unveils coronavirus vaccine , claiming victory in global race before final testing is complete", "label": "SUPPORTED", "evidence": ["Russian President Vladimir Putin announced Tuesday that the country has become the first in the world to grant regulatory approval for a COVID-19 vaccine.", "Dmitriev said Russia has received preliminary applications for more than 1 billion doses of the vaccine from 20 countries and is prepared to manufacture more than 500 million doses of the vaccine per year in five countries.", "Putin said at a government meeting broadcast on state television that the vaccine is safe and has been administered to one of his adult daughters."]}
{"id": 1000615, "claim": "Russia unveils coronavirus vaccine, claiming victory in global race when final testing is complete", "label": "REFUTED", "evidence": ["Russian President Vladimir Putin announced Tuesday that the country has become the first in the world to grant regulatory approval for a COVID-19 vaccine.", "Dmitriev said Russia has received preliminary applications for more than 1 billion doses of the vaccine from 20 countries and is prepared to manufacture more than 500 million doses of the vaccine per year in five countries.", "Putin said at a government meeting broadcast on state television that the vaccine is safe and has been administered to one of his adult daughters."]}
{"id": 1000616, "claim": "Russia unveils coronavirus vaccine, claiming victory in global race as final testing is complete", "label": "REFUTED", "evidence": ["Russian President Vladimir Putin announced Tuesday that the country has become the first in the world to grant regulatory approval for a COVID-19 vaccine.", "Dmitriev said Russia has received preliminary applications for more than 1 billion doses of the vaccine from 20 countries and is prepared to manufacture more than 500 million doses of the vaccine per year in five countries.", "Putin said at a government meeting broadcast on state television that the vaccine is safe and has been administered to one of his adult daughters."]}
{"id": 1000617, "claim": "In unveils coronavirus vaccine, claiming victory in global race before final testing is complete", "label": "REFUTED", "evidence": ["Russian President Vladimir Putin announced Tuesday that the country has become the first in the world to grant regulatory approval for a COVID-19 vaccine.", "Dmitriev said Russia has received preliminary applications for more than 1 billion doses of the vaccine from 20 countries and is prepared to manufacture more than 500 million doses of the vaccine per year in five countries.", "Putin said at a government meeting broadcast on state television that the vaccine is safe and has been administered to one of his adult daughters."]}
{"id": 1000618, "claim": "High-profile coronavirus retractions raise concerns about data oversight", "label": "SUPPORTED", "evidence": ["Scientists say the affair raises serious questions about the way researchers and journals evaluate the data underlying papers that they publish, and may complicate the effort to trial drugs during the coronavirus pandemic."]}
{"id": 1000619, "claim": "High-profile coronavirus retractions of concerns about data oversight", "label": "REFUTED", "evidence": ["Scientists say the affair raises serious questions about the way researchers and journals evaluate the data underlying papers that they publish, and may complicate the effort to trial drugs during the coronavirus pandemic."]}
{"id": 1000620, "claim": "In the case of china , it is estimated that more than 700.000 cases of covid-19 actually occurred instead of the confirmed 80,932 cases as of 3/13/2020 .", "label": "SUPPORTED", "evidence": ["I don't believe > millions of people have died from it (at least I hope not), but I definitely > think the CCP has confiscated millions of people's cellphones to combat real > information being leaked by their citizens."]}
{"id": 1000621, "claim": "In the case of sars, it is estimated that more than 700.000 cases of covid-19 actually occurred instead of the confirmed 80,932 cases as of 3/13/2020.", "label": "REFUTED", "evidence": ["I don't believe > millions of people have died from it (at least I hope not), but I definitely > think the CCP has confiscated millions of people's cellphones to combat real > information being leaked by their citizens."]}
{"id": 1000622, "claim": "In the case of who, it is estimated that more than 700.000 cases of covid-19 actually occurred instead of the confirmed 80,932 cases as of 3/13/2020.", "label": "REFUTED", "evidence": ["I don't believe > millions of people have died from it (at least I hope not), but I definitely > think the CCP has confiscated millions of people's cellphones to combat real > information being leaked by their citizens."]}
{"id": 1000623, "claim": "In the case of mers, it is estimated that more than 700.000 cases of covid-19 actually occurred instead of the confirmed 80,932 cases as of 3/13/2020.", "label": "REFUTED", "evidence": ["I don't believe > millions of people have died from it (at least I hope not), but I definitely > think the CCP has confiscated millions of people's cellphones to combat real > information being leaked by their citizens."]}
{"id": 1000624, "claim": "Scientists prove sars-cov-2 potential to infect human brain organoids", "label": "SUPPORTED", "evidence": ["To explore the direct involvement of SARS-CoV-2 in the CNS in physiologically relevant models, the research team assessed SARS-CoV-2 infection in human neural progenitor cells (hNPCs), neurospheres and brain organoids derived from induced pluripotent stem cells (iPSCs).", "\"Overall, our study provides the first evidence of direct SARS-CoV-2 infection in human brain organoids, which contributes to our understanding of the pathogenesis of neurological complications in COVID-19,\" said Prof. HUANG Jiandong from HKU, who led the study.", "Extensive protein expression and infectious viral particles were detected in neurospheres and brain organoids infected with SARS-CoV-2, which suggested SARS-CoV-2 could productively infect the human brain.", "Importantly, SARS-CoV-2 infection in 3D human brain organoids was localised to TUJ1 (neuronal marker) - and NESTIN (NPC marker)-positive cells, suggesting SARS-CoV-2 could directly target cortical neurons and NPCs.", "The research team suggested that chronic and long-term consequences of SARS- CoV-2 infection of the CNS should be closely monitored."]}
{"id": 1000625, "claim": "Scientists prove sars-cov-2 potential to infect rat brain organoids", "label": "REFUTED", "evidence": ["To explore the direct involvement of SARS-CoV-2 in the CNS in physiologically relevant models, the research team assessed SARS-CoV-2 infection in human neural progenitor cells (hNPCs), neurospheres and brain organoids derived from induced pluripotent stem cells (iPSCs).", "\"Overall, our study provides the first evidence of direct SARS-CoV-2 infection in human brain organoids, which contributes to our understanding of the pathogenesis of neurological complications in COVID-19,\" said Prof. HUANG Jiandong from HKU, who led the study.", "Extensive protein expression and infectious viral particles were detected in neurospheres and brain organoids infected with SARS-CoV-2, which suggested SARS-CoV-2 could productively infect the human brain.", "Importantly, SARS-CoV-2 infection in 3D human brain organoids was localised to TUJ1 (neuronal marker) - and NESTIN (NPC marker)-positive cells, suggesting SARS-CoV-2 could directly target cortical neurons and NPCs.", "The research team suggested that chronic and long-term consequences of SARS- CoV-2 infection of the CNS should be closely monitored."]}
{"id": 1000626, "claim": "Scientists prove sars-cov-2 potential to infect canine brain organoids", "label": "REFUTED", "evidence": ["To explore the direct involvement of SARS-CoV-2 in the CNS in physiologically relevant models, the research team assessed SARS-CoV-2 infection in human neural progenitor cells (hNPCs), neurospheres and brain organoids derived from induced pluripotent stem cells (iPSCs).", "\"Overall, our study provides the first evidence of direct SARS-CoV-2 infection in human brain organoids, which contributes to our understanding of the pathogenesis of neurological complications in COVID-19,\" said Prof. HUANG Jiandong from HKU, who led the study.", "Extensive protein expression and infectious viral particles were detected in neurospheres and brain organoids infected with SARS-CoV-2, which suggested SARS-CoV-2 could productively infect the human brain.", "Importantly, SARS-CoV-2 infection in 3D human brain organoids was localised to TUJ1 (neuronal marker) - and NESTIN (NPC marker)-positive cells, suggesting SARS-CoV-2 could directly target cortical neurons and NPCs.", "The research team suggested that chronic and long-term consequences of SARS- CoV-2 infection of the CNS should be closely monitored."]}
{"id": 1000627, "claim": "Scientists prove sars-cov-2 potential to infect mouse brain organoids", "label": "REFUTED", "evidence": ["To explore the direct involvement of SARS-CoV-2 in the CNS in physiologically relevant models, the research team assessed SARS-CoV-2 infection in human neural progenitor cells (hNPCs), neurospheres and brain organoids derived from induced pluripotent stem cells (iPSCs).", "\"Overall, our study provides the first evidence of direct SARS-CoV-2 infection in human brain organoids, which contributes to our understanding of the pathogenesis of neurological complications in COVID-19,\" said Prof. HUANG Jiandong from HKU, who led the study.", "Extensive protein expression and infectious viral particles were detected in neurospheres and brain organoids infected with SARS-CoV-2, which suggested SARS-CoV-2 could productively infect the human brain.", "Importantly, SARS-CoV-2 infection in 3D human brain organoids was localised to TUJ1 (neuronal marker) - and NESTIN (NPC marker)-positive cells, suggesting SARS-CoV-2 could directly target cortical neurons and NPCs.", "The research team suggested that chronic and long-term consequences of SARS- CoV-2 infection of the CNS should be closely monitored."]}
{"id": 1000628, "claim": "The wuhan coronavirus has integrated in prevotella , which possibly causes the observed extreme virulence - as sequencing data from 2 different studies in china and hong-kong shows unequivocally", "label": "SUPPORTED", "evidence": ["Chakraborty S. The 2019 Wuhan outbreak could be caused by the bacteria Prevotella, which is aided by the coronavirusPrevotella is present (sometimes in huge amounts) in patients from two studies in China and one in Hong Kong."]}
{"id": 1000629, "claim": "The wuhan coronavirus has integrated in prevotella, which possibly reduces the observed extreme virulence - as sequencing data from 2 different studies in china and hong-kong shows unequivocally", "label": "REFUTED", "evidence": ["Chakraborty S. The 2019 Wuhan outbreak could be caused by the bacteria Prevotella, which is aided by the coronavirusPrevotella is present (sometimes in huge amounts) in patients from two studies in China and one in Hong Kong."]}
{"id": 1000630, "claim": "Genomic diversity of sars-cov-2 can be accelerated by a mutation in the nsp14 gene.", "label": "SUPPORTED", "evidence": ["Our results implicate nsp14 as a source of increased mutation rate in SARS-CoV-2 genomes."]}
{"id": 1000631, "claim": "Genomic diversity of sars-cov-2 cannot be accelerated by a mutation in the nsp14 gene.", "label": "REFUTED", "evidence": ["Our results implicate nsp14 as a source of increased mutation rate in SARS-CoV-2 genomes."]}
{"id": 1000632, "claim": "Covid-19 and the cardiovascular system < < given that ace2 is a functional receptor for sars-cov-2 , the safety and potential effects of antihypertension therapy with ace inhibitors or angiotensin-receptor blockers in patients with covid-19 should be carefully considered .", "label": "SUPPORTED", "evidence": ["Consequently, the authors suggest that the safety and potential effects of antihypertension therapy with ACE inhibitors or angiotensin-receptor blockers in patients with COVID-19 should be carefully considered.", "Given that ACE2 is a functional receptor for SARS-CoV-2, the safety and potential effects of antihypertension therapy with ACE inhibitors or angiotensin-receptor blockers in patients with COVID-19 should be carefully considered.", "Given that SARS-CoV-2 has a similar structure to SARS-CoV, this novel virus might also cause chronic damage to the cardiovascular system, and attention should be given to cardiovascular protection during treatment for COVID-19.", "Consequently, the authors suggest that \"the safety and potential effects of antihypertension therapy with ACE inhibitors or angiotensin-receptor blockers in patients with COVID-19 should be carefully considered\"."]}
{"id": 1000633, "claim": "Covid-19 and the cardiovascular system < < given that ace2 is a functional receptor for sars-cov-2, the safety and potential effects of antihypertension therapy with ace inhibitors or angiotensin-receptor blockers in patients with covid-19 cannot be carefully considered.", "label": "REFUTED", "evidence": ["Consequently, the authors suggest that the safety and potential effects of antihypertension therapy with ACE inhibitors or angiotensin-receptor blockers in patients with COVID-19 should be carefully considered.", "Given that ACE2 is a functional receptor for SARS-CoV-2, the safety and potential effects of antihypertension therapy with ACE inhibitors or angiotensin-receptor blockers in patients with COVID-19 should be carefully considered.", "Given that SARS-CoV-2 has a similar structure to SARS-CoV, this novel virus might also cause chronic damage to the cardiovascular system, and attention should be given to cardiovascular protection during treatment for COVID-19.", "Consequently, the authors suggest that \"the safety and potential effects of antihypertension therapy with ACE inhibitors or angiotensin-receptor blockers in patients with COVID-19 should be carefully considered\"."]}
{"id": 1000634, "claim": "Uk approve phizer vaccination", "label": "SUPPORTED", "evidence": ["Dogukan Keskinkilic/Anadolu Agency via Getty Images hide caption toggle caption Dogukan Keskinkilic/Anadolu Agency via Getty Images The U.K. has approved use of the COVID-19 vaccine developed by Pfizer and BioNTech."]}
{"id": 1000635, "claim": "Ukus phizer vaccination", "label": "REFUTED", "evidence": ["Dogukan Keskinkilic/Anadolu Agency via Getty Images hide caption toggle caption Dogukan Keskinkilic/Anadolu Agency via Getty Images The U.K. has approved use of the COVID-19 vaccine developed by Pfizer and BioNTech."]}
{"id": 1000636, "claim": "Systemic complement activation is associated with respiratory failure in covid-19 hospitalized patients", "label": "SUPPORTED", "evidence": ["Systemic complement activation is associated with respiratory failure in COVID-19 patients and provides a rationale for investigating complement inhibitors in future clinical trials."]}
{"id": 1000637, "claim": "Systemic complement activation is associated without respiratory failure in covid-19 hospitalized patients", "label": "REFUTED", "evidence": ["Systemic complement activation is associated with respiratory failure in COVID-19 patients and provides a rationale for investigating complement inhibitors in future clinical trials."]}
{"id": 1000638, "claim": "A more contagious coronavirus strain has been found in 8 states and 33 countries .", "label": "SUPPORTED", "evidence": ["The strain has been detected in at least 33 countries, including Australia, Belgium, Brazil, Canada, Chile, China, Denmark, Finland, France, Germany, Iceland, India, Ireland, Israel, Italy, Japan, Jordan, Lebanon, Malta, The Netherlands, Norway, Pakistan, Portugal, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, the United Arab Emirates, the United Kingdom and the United States.", "Less than a week later, the county reported 32 cases of the new strain have been detected.", "At least eight U.S. states and 33 countries have identified the new variant, known as B.1.1.7."]}
{"id": 1000639, "claim": "A single contagious coronavirus strain has been found in 8 states and 33 countries.", "label": "REFUTED", "evidence": ["The strain has been detected in at least 33 countries, including Australia, Belgium, Brazil, Canada, Chile, China, Denmark, Finland, France, Germany, Iceland, India, Ireland, Israel, Italy, Japan, Jordan, Lebanon, Malta, The Netherlands, Norway, Pakistan, Portugal, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, the United Arab Emirates, the United Kingdom and the United States.", "Less than a week later, the county reported 32 cases of the new strain have been detected.", "At least eight U.S. states and 33 countries have identified the new variant, known as B.1.1.7."]}
{"id": 1000640, "claim": "Intranasal fusion inhibitory lipopeptide prevents direct contact sars-cov-2 transmission in ferrets", "label": "SUPPORTED", "evidence": ["One-sentence summary A dimeric form of a SARS-CoV-2-derived lipopeptide is a potent inhibitor of fusion and infection in vitro and transmission in vivo.", "We have designed a dimeric lipopeptide fusion inhibitor that blocks this critical first step of infection for emerging coronaviruses and document that it completely prevents SARS-CoV-2 infection in ferrets.", "Daily intranasal administration to ferrets completely prevented SARS-CoV-2 direct-contact transmission during 24-hour co- housing with infected animals, under stringent conditions that resulted in infection of 100% of untreated animals."]}
{"id": 1000641, "claim": "Intranasal fusion inhibitory lipopeptide requires direct contact sars-cov-2 transmission in ferrets", "label": "REFUTED", "evidence": ["One-sentence summary A dimeric form of a SARS-CoV-2-derived lipopeptide is a potent inhibitor of fusion and infection in vitro and transmission in vivo.", "We have designed a dimeric lipopeptide fusion inhibitor that blocks this critical first step of infection for emerging coronaviruses and document that it completely prevents SARS-CoV-2 infection in ferrets.", "Daily intranasal administration to ferrets completely prevented SARS-CoV-2 direct-contact transmission during 24-hour co- housing with infected animals, under stringent conditions that resulted in infection of 100% of untreated animals."]}
{"id": 1000642, "claim": "Intranasal fusion inhibitory lipopeptide showed direct contact sars-cov-2 transmission in ferrets", "label": "REFUTED", "evidence": ["One-sentence summary A dimeric form of a SARS-CoV-2-derived lipopeptide is a potent inhibitor of fusion and infection in vitro and transmission in vivo.", "We have designed a dimeric lipopeptide fusion inhibitor that blocks this critical first step of infection for emerging coronaviruses and document that it completely prevents SARS-CoV-2 infection in ferrets.", "Daily intranasal administration to ferrets completely prevented SARS-CoV-2 direct-contact transmission during 24-hour co- housing with infected animals, under stringent conditions that resulted in infection of 100% of untreated animals."]}
{"id": 1000643, "claim": "Intranasal fusion inhibitory lipopeptide prevents direct contact denvs-cov-2 transmission in ferrets", "label": "REFUTED", "evidence": ["One-sentence summary A dimeric form of a SARS-CoV-2-derived lipopeptide is a potent inhibitor of fusion and infection in vitro and transmission in vivo.", "We have designed a dimeric lipopeptide fusion inhibitor that blocks this critical first step of infection for emerging coronaviruses and document that it completely prevents SARS-CoV-2 infection in ferrets.", "Daily intranasal administration to ferrets completely prevented SARS-CoV-2 direct-contact transmission during 24-hour co- housing with infected animals, under stringent conditions that resulted in infection of 100% of untreated animals."]}
{"id": 1000644, "claim": "Nih activ trial of blood thinners pauses enrollment of critically ill covid-19 patients.", "label": "SUPPORTED", "evidence": ["Informed by the deliberations of these oversight boards, all the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19.", "Coronavirus Patients Is Halted Giving anticoagulants to hospitalized Covid-19 patients is routine.", "Whether the use of full-dose compared to low-dose blood thinners leads to better outcomes in hospitalized patients with less COVID-19 severe disease remains a very important question.", "Informed by the deliberations of these oversight boards, all of the trial sites have paused enrollment of the most critically ill hospitalised patients with COVID-19.", "The trials are continuing to enroll moderately ill hospitalised COVID-19 patients."]}
{"id": 1000645, "claim": "Nih activ trial of blood thinners allowed enrollment of critically ill covid-19 patients.", "label": "REFUTED", "evidence": ["Informed by the deliberations of these oversight boards, all the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19.", "Coronavirus Patients Is Halted Giving anticoagulants to hospitalized Covid-19 patients is routine.", "Whether the use of full-dose compared to low-dose blood thinners leads to better outcomes in hospitalized patients with less COVID-19 severe disease remains a very important question.", "Informed by the deliberations of these oversight boards, all of the trial sites have paused enrollment of the most critically ill hospitalised patients with COVID-19.", "The trials are continuing to enroll moderately ill hospitalised COVID-19 patients."]}
{"id": 1000646, "claim": "Nih activ trial of blood thinners included enrollment of critically ill covid-19 patients.", "label": "REFUTED", "evidence": ["Informed by the deliberations of these oversight boards, all the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19.", "Coronavirus Patients Is Halted Giving anticoagulants to hospitalized Covid-19 patients is routine.", "Whether the use of full-dose compared to low-dose blood thinners leads to better outcomes in hospitalized patients with less COVID-19 severe disease remains a very important question.", "Informed by the deliberations of these oversight boards, all of the trial sites have paused enrollment of the most critically ill hospitalised patients with COVID-19.", "The trials are continuing to enroll moderately ill hospitalised COVID-19 patients."]}
{"id": 1000647, "claim": "Nih activ trial of blood thinners is enrollment of critically ill covid-19 patients.", "label": "REFUTED", "evidence": ["Informed by the deliberations of these oversight boards, all the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19.", "Coronavirus Patients Is Halted Giving anticoagulants to hospitalized Covid-19 patients is routine.", "Whether the use of full-dose compared to low-dose blood thinners leads to better outcomes in hospitalized patients with less COVID-19 severe disease remains a very important question.", "Informed by the deliberations of these oversight boards, all of the trial sites have paused enrollment of the most critically ill hospitalised patients with COVID-19.", "The trials are continuing to enroll moderately ill hospitalised COVID-19 patients."]}
{"id": 1000648, "claim": "Cytodyn to begin enrollment for leronlimab phase 2 trial to treat covid-19", "label": "SUPPORTED", "evidence": ["CytoDyn Files IND and protocol for phase 2 clinical trial for treatment of coronavirus patients with leronlimab (pro 140) [new release].", "CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality Rate at Two Weeks [news release].", "CytoDyn has also filed for the initiation of a phase II/III trial for the treatment of severely ill patients with COVID-19.", "We will aggressively pursue treatment for COVID-19 patients, and to explore leronlimabs role in helping to alleviate the impending burden of supply chain and institutional capacity issues, said Nader Pourhassan, PhD, president, and chief executive officer, CytoDyn, in a statement.3 < < View more resources regarding COVID-19 References 1.", "CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019."]}
{"id": 1000649, "claim": "Cytodyn to avoid enrollment for leronlimab phase 2 trial to treat covid-19", "label": "REFUTED", "evidence": ["CytoDyn Files IND and protocol for phase 2 clinical trial for treatment of coronavirus patients with leronlimab (pro 140) [new release].", "CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality Rate at Two Weeks [news release].", "CytoDyn has also filed for the initiation of a phase II/III trial for the treatment of severely ill patients with COVID-19.", "We will aggressively pursue treatment for COVID-19 patients, and to explore leronlimabs role in helping to alleviate the impending burden of supply chain and institutional capacity issues, said Nader Pourhassan, PhD, president, and chief executive officer, CytoDyn, in a statement.3 < < View more resources regarding COVID-19 References 1.", "CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019."]}
{"id": 1000650, "claim": "Cytodyn to assess enrollment for leronlimab phase 2 trial to treat covid-19", "label": "REFUTED", "evidence": ["CytoDyn Files IND and protocol for phase 2 clinical trial for treatment of coronavirus patients with leronlimab (pro 140) [new release].", "CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality Rate at Two Weeks [news release].", "CytoDyn has also filed for the initiation of a phase II/III trial for the treatment of severely ill patients with COVID-19.", "We will aggressively pursue treatment for COVID-19 patients, and to explore leronlimabs role in helping to alleviate the impending burden of supply chain and institutional capacity issues, said Nader Pourhassan, PhD, president, and chief executive officer, CytoDyn, in a statement.3 < < View more resources regarding COVID-19 References 1.", "CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019."]}
{"id": 1000651, "claim": "Ad26 vaccine protects against sars-cov-2 severe clinical disease in hamsters", "label": "SUPPORTED", "evidence": ["We assessed the clinical and virologic characteristics of high-dose SARS-CoV-2 infection in hamsters and evaluated the protective efficacy of an adenovirus serotype 26 (Ad26) vector- based vaccine19 encoding a stabilized SARS-CoV-2 spike (S) in this stringent model.", "In this study, we demonstrated that a single immunization of an Ad26 vector encoding a full-length prefusion stabilized S immunogen (S.PP) protected against severe clinical disease after high-dose SARS-CoV-2 challenge in hamsters.", "In summary, our data demonstrate that a single immunization of Ad26-S.PP provides robust protection against severe clinical disease after high-dose SARS-CoV-2 infection in hamsters."]}
{"id": 1000652, "claim": "Ad26 infection protects against sars-cov-2 severe clinical disease in hamsters", "label": "REFUTED", "evidence": ["We assessed the clinical and virologic characteristics of high-dose SARS-CoV-2 infection in hamsters and evaluated the protective efficacy of an adenovirus serotype 26 (Ad26) vector- based vaccine19 encoding a stabilized SARS-CoV-2 spike (S) in this stringent model.", "In this study, we demonstrated that a single immunization of an Ad26 vector encoding a full-length prefusion stabilized S immunogen (S.PP) protected against severe clinical disease after high-dose SARS-CoV-2 challenge in hamsters.", "In summary, our data demonstrate that a single immunization of Ad26-S.PP provides robust protection against severe clinical disease after high-dose SARS-CoV-2 infection in hamsters."]}
{"id": 1000653, "claim": "Severe immunosuppression and not a cytokine storm characterize covid-19 infections", "label": "SUPPORTED", "evidence": ["We conclude that the major immunologic abnormality in COVID-19 is a profound defect in host immunity and not hypercytokinemia-induced organ injury.", "Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.", "Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections.", "The results from the present study strongly suggest that the primary endotype of COVID-19 is one of immunosuppression rather than hyperinflammation."]}
{"id": 1000654, "claim": "Severe immunosuppression and also a cytokine storm characterize covid-19 infections", "label": "REFUTED", "evidence": ["We conclude that the major immunologic abnormality in COVID-19 is a profound defect in host immunity and not hypercytokinemia-induced organ injury.", "Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.", "Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections.", "The results from the present study strongly suggest that the primary endotype of COVID-19 is one of immunosuppression rather than hyperinflammation."]}
{"id": 1000655, "claim": "Severe immunosuppression and causes a cytokine storm characterize covid-19 infections", "label": "REFUTED", "evidence": ["We conclude that the major immunologic abnormality in COVID-19 is a profound defect in host immunity and not hypercytokinemia-induced organ injury.", "Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.", "Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections.", "The results from the present study strongly suggest that the primary endotype of COVID-19 is one of immunosuppression rather than hyperinflammation."]}
{"id": 1000656, "claim": "Severe immunosuppression and therefore a cytokine storm characterize covid-19 infections", "label": "REFUTED", "evidence": ["We conclude that the major immunologic abnormality in COVID-19 is a profound defect in host immunity and not hypercytokinemia-induced organ injury.", "Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.", "Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections.", "The results from the present study strongly suggest that the primary endotype of COVID-19 is one of immunosuppression rather than hyperinflammation."]}
{"id": 1000657, "claim": "White house does not have 'high confidence ' in china 's coronavirus information , official says", "label": "SUPPORTED", "evidence": ["Reuters reported that National Economic Council Director Larry Kudlow also said on Thursday that there does not appear to be good transparency by China regarding the outbreak.", "VIDEO0:5600:56 Official: US doesn't have high confidence in China's virus information Squawk Alley There has been skepticism among researchers that the official numbers reflect how contagious the virus truly is.", "There has been skepticism among researchers that the official numbers reflect how contagious the virus truly is.", "The official also noted that China \"continues to rebuff American offers of assistance.\""]}
{"id": 1000658, "claim": "White house does still have 'high confidence'in china's coronavirus information, official says", "label": "REFUTED", "evidence": ["Reuters reported that National Economic Council Director Larry Kudlow also said on Thursday that there does not appear to be good transparency by China regarding the outbreak.", "VIDEO0:5600:56 Official: US doesn't have high confidence in China's virus information Squawk Alley There has been skepticism among researchers that the official numbers reflect how contagious the virus truly is.", "There has been skepticism among researchers that the official numbers reflect how contagious the virus truly is.", "The official also noted that China \"continues to rebuff American offers of assistance.\""]}
{"id": 1000659, "claim": "White house does also have 'high confidence'in china's coronavirus information, official says", "label": "REFUTED", "evidence": ["Reuters reported that National Economic Council Director Larry Kudlow also said on Thursday that there does not appear to be good transparency by China regarding the outbreak.", "VIDEO0:5600:56 Official: US doesn't have high confidence in China's virus information Squawk Alley There has been skepticism among researchers that the official numbers reflect how contagious the virus truly is.", "There has been skepticism among researchers that the official numbers reflect how contagious the virus truly is.", "The official also noted that China \"continues to rebuff American offers of assistance.\""]}
{"id": 1000660, "claim": "White house does now have 'high confidence'in china's coronavirus information, official says", "label": "REFUTED", "evidence": ["Reuters reported that National Economic Council Director Larry Kudlow also said on Thursday that there does not appear to be good transparency by China regarding the outbreak.", "VIDEO0:5600:56 Official: US doesn't have high confidence in China's virus information Squawk Alley There has been skepticism among researchers that the official numbers reflect how contagious the virus truly is.", "There has been skepticism among researchers that the official numbers reflect how contagious the virus truly is.", "The official also noted that China \"continues to rebuff American offers of assistance.\""]}
{"id": 1000661, "claim": "Baricitinib in combination with remdesivir reduces time to recovery in hospitalized patients with covid-19 in niaid-sponsored actt-2 trial", "label": "SUPPORTED", "evidence": ["Baricitinib in combination with remdesivir met the primary endpoint of reduction of time to recovery in comparison with remdesivir.", "Study investigators noted an approximately one-day reduction in median recovery time for the overall patient population treated with baricitinib in combination with remdesivir versus those treated with remdesivir."]}
{"id": 1000662, "claim": "Baricitinib in combination with remdesivir increased time to recovery in hospitalized patients with covid-19 in niaid-sponsored actt-2 trial", "label": "REFUTED", "evidence": ["Baricitinib in combination with remdesivir met the primary endpoint of reduction of time to recovery in comparison with remdesivir.", "Study investigators noted an approximately one-day reduction in median recovery time for the overall patient population treated with baricitinib in combination with remdesivir versus those treated with remdesivir."]}
{"id": 1000663, "claim": "Sars-cov-2 rbd in vitro evolution follows contagious mutation spread , yet generates an able infection inhibitor.", "label": "SUPPORTED", "evidence": ["This said, the high-affinity RBD is also an efficient drug, inhibiting SARS-CoV-2 infection."]}
{"id": 1000664, "claim": "Sars-cov-2 rbd in vitro evolution follows contagious mutation spread, yet generates an able infection rate.", "label": "REFUTED", "evidence": ["This said, the high-affinity RBD is also an efficient drug, inhibiting SARS-CoV-2 infection."]}
{"id": 1000665, "claim": "Sars-cov-2 rbd in vitro evolution follows contagious mutation spread, yet generates an able infection phenotype.", "label": "REFUTED", "evidence": ["This said, the high-affinity RBD is also an efficient drug, inhibiting SARS-CoV-2 infection."]}
{"id": 1000666, "claim": "The papain-like protease of coronaviruses cleaves ulk1 to disrupt host autophagy", "label": "SUPPORTED", "evidence": ["Autophagy modulators have emerged as potential therapeutic candidates against SARS-CoV-2 but recent clinical setbacks underline the urgent need for better understanding the mechanism of viral subversion of autophagy.", "In conclusion, our study identified a new mechanism by which PLpro of betacoronaviruses induces viral pathogenesis by targeting cellular autophagic pathway (Word count=250) IMPORTANCE The recent COVID-19 global pandemic alongside the 2003 SARS and 2012 MERS outbreaks underscore an urgent need to better understand betacoronaviruses as pathogens that pose global challenge to human health.", "To investigate whether virus-encoded proteases target this protein, we conducted in vitro and cellular cleavage assays and identified ULK1 as a novel bona fide substrate of SARS-CoV-2 papain-like protease (PLpro).", "Using murine hepatitis virus-A59 (MHV-A59) as a model betacoronavirus , time-course infections revealed a significant loss in the protein level of ULK1, a canonical autophagy regulating serine-threonine kinase, and the concomitant appearance of a possible cleavage fragment.", "Consistent with this, over-expression of SARS-CoV-2 PLpro is sufficient to impair starvation-induced canonical autophagy and disrupt formation of ULK1-ATG13 complex."]}
{"id": 1000667, "claim": "The papain-like protease of coronaviruses cleaves ulk1 to facilitate host autophagy", "label": "REFUTED", "evidence": ["Autophagy modulators have emerged as potential therapeutic candidates against SARS-CoV-2 but recent clinical setbacks underline the urgent need for better understanding the mechanism of viral subversion of autophagy.", "In conclusion, our study identified a new mechanism by which PLpro of betacoronaviruses induces viral pathogenesis by targeting cellular autophagic pathway (Word count=250) IMPORTANCE The recent COVID-19 global pandemic alongside the 2003 SARS and 2012 MERS outbreaks underscore an urgent need to better understand betacoronaviruses as pathogens that pose global challenge to human health.", "To investigate whether virus-encoded proteases target this protein, we conducted in vitro and cellular cleavage assays and identified ULK1 as a novel bona fide substrate of SARS-CoV-2 papain-like protease (PLpro).", "Using murine hepatitis virus-A59 (MHV-A59) as a model betacoronavirus , time-course infections revealed a significant loss in the protein level of ULK1, a canonical autophagy regulating serine-threonine kinase, and the concomitant appearance of a possible cleavage fragment.", "Consistent with this, over-expression of SARS-CoV-2 PLpro is sufficient to impair starvation-induced canonical autophagy and disrupt formation of ULK1-ATG13 complex."]}
{"id": 1000668, "claim": "The papain-like protease of coronaviruses cleaves ulk1 to host host autophagy", "label": "REFUTED", "evidence": ["Autophagy modulators have emerged as potential therapeutic candidates against SARS-CoV-2 but recent clinical setbacks underline the urgent need for better understanding the mechanism of viral subversion of autophagy.", "In conclusion, our study identified a new mechanism by which PLpro of betacoronaviruses induces viral pathogenesis by targeting cellular autophagic pathway (Word count=250) IMPORTANCE The recent COVID-19 global pandemic alongside the 2003 SARS and 2012 MERS outbreaks underscore an urgent need to better understand betacoronaviruses as pathogens that pose global challenge to human health.", "To investigate whether virus-encoded proteases target this protein, we conducted in vitro and cellular cleavage assays and identified ULK1 as a novel bona fide substrate of SARS-CoV-2 papain-like protease (PLpro).", "Using murine hepatitis virus-A59 (MHV-A59) as a model betacoronavirus , time-course infections revealed a significant loss in the protein level of ULK1, a canonical autophagy regulating serine-threonine kinase, and the concomitant appearance of a possible cleavage fragment.", "Consistent with this, over-expression of SARS-CoV-2 PLpro is sufficient to impair starvation-induced canonical autophagy and disrupt formation of ULK1-ATG13 complex."]}
{"id": 1000669, "claim": "The papain-like protease of coronaviruses cleaves ulk1 to its host autophagy", "label": "REFUTED", "evidence": ["Autophagy modulators have emerged as potential therapeutic candidates against SARS-CoV-2 but recent clinical setbacks underline the urgent need for better understanding the mechanism of viral subversion of autophagy.", "In conclusion, our study identified a new mechanism by which PLpro of betacoronaviruses induces viral pathogenesis by targeting cellular autophagic pathway (Word count=250) IMPORTANCE The recent COVID-19 global pandemic alongside the 2003 SARS and 2012 MERS outbreaks underscore an urgent need to better understand betacoronaviruses as pathogens that pose global challenge to human health.", "To investigate whether virus-encoded proteases target this protein, we conducted in vitro and cellular cleavage assays and identified ULK1 as a novel bona fide substrate of SARS-CoV-2 papain-like protease (PLpro).", "Using murine hepatitis virus-A59 (MHV-A59) as a model betacoronavirus , time-course infections revealed a significant loss in the protein level of ULK1, a canonical autophagy regulating serine-threonine kinase, and the concomitant appearance of a possible cleavage fragment.", "Consistent with this, over-expression of SARS-CoV-2 PLpro is sufficient to impair starvation-induced canonical autophagy and disrupt formation of ULK1-ATG13 complex."]}
{"id": 1000670, "claim": "Sunlight ultraviolet radiation dose is negatively correlated with the percent positive of sars-cov-2 and four other common human coronaviruses in the u.s .", "label": "SUPPORTED", "evidence": ["The weekly percent positive of SARS-CoV-2 during April 17, 2020 to July 10, 2020 showed a significant negative correlation with the sunlight UV radiation dose in census regions 1 and 2 of the U.S. while no statistical significance in the other regions.", "UVC can inactivate coronaviruses, including severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).", "Additionally, sunlight UV radiation also showed some negative effects with respect to the early SARS-CoV-2 transmission.", "In this study, Spearman and Kendall rank correlation analysis tests were used to analyze the correlation between the average percent positive of five human coronaviruses (SARS-CoV-2, CoVHKU1, CoVNL63, CoVOC43, and CoV229E) in the U.S. and the corresponding sunlight UV radiation dose The results indicated that the monthly average percent positive of four common coronaviruses was significantly negatively correlated with the sunlight UV radiation dose."]}
{"id": 1000671, "claim": "Sunlight ultraviolet radiation dose is positively correlated with the percent positive of sars-cov-2 and four other common human coronaviruses in the u.s.", "label": "REFUTED", "evidence": ["The weekly percent positive of SARS-CoV-2 during April 17, 2020 to July 10, 2020 showed a significant negative correlation with the sunlight UV radiation dose in census regions 1 and 2 of the U.S. while no statistical significance in the other regions.", "UVC can inactivate coronaviruses, including severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).", "Additionally, sunlight UV radiation also showed some negative effects with respect to the early SARS-CoV-2 transmission.", "In this study, Spearman and Kendall rank correlation analysis tests were used to analyze the correlation between the average percent positive of five human coronaviruses (SARS-CoV-2, CoVHKU1, CoVNL63, CoVOC43, and CoV229E) in the U.S. and the corresponding sunlight UV radiation dose The results indicated that the monthly average percent positive of four common coronaviruses was significantly negatively correlated with the sunlight UV radiation dose."]}
{"id": 1000672, "claim": "Sunlight ultraviolet radiation dose is well correlated with the percent positive of sars-cov-2 and four other common human coronaviruses in the u.s.", "label": "REFUTED", "evidence": ["The weekly percent positive of SARS-CoV-2 during April 17, 2020 to July 10, 2020 showed a significant negative correlation with the sunlight UV radiation dose in census regions 1 and 2 of the U.S. while no statistical significance in the other regions.", "UVC can inactivate coronaviruses, including severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).", "Additionally, sunlight UV radiation also showed some negative effects with respect to the early SARS-CoV-2 transmission.", "In this study, Spearman and Kendall rank correlation analysis tests were used to analyze the correlation between the average percent positive of five human coronaviruses (SARS-CoV-2, CoVHKU1, CoVNL63, CoVOC43, and CoV229E) in the U.S. and the corresponding sunlight UV radiation dose The results indicated that the monthly average percent positive of four common coronaviruses was significantly negatively correlated with the sunlight UV radiation dose."]}
{"id": 1000673, "claim": "Sunlight ultraviolet radiation dose is strongly correlated with the percent positive of sars-cov-2 and four other common human coronaviruses in the u.s.", "label": "REFUTED", "evidence": ["The weekly percent positive of SARS-CoV-2 during April 17, 2020 to July 10, 2020 showed a significant negative correlation with the sunlight UV radiation dose in census regions 1 and 2 of the U.S. while no statistical significance in the other regions.", "UVC can inactivate coronaviruses, including severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).", "Additionally, sunlight UV radiation also showed some negative effects with respect to the early SARS-CoV-2 transmission.", "In this study, Spearman and Kendall rank correlation analysis tests were used to analyze the correlation between the average percent positive of five human coronaviruses (SARS-CoV-2, CoVHKU1, CoVNL63, CoVOC43, and CoV229E) in the U.S. and the corresponding sunlight UV radiation dose The results indicated that the monthly average percent positive of four common coronaviruses was significantly negatively correlated with the sunlight UV radiation dose."]}
{"id": 1000674, "claim": "North american deer mice are susceptible to sars-cov-2.", "label": "SUPPORTED", "evidence": ["SARS-CoV-2 infection and transmission possible in North American deer mice.", "\"SARS-CoV-2 infection and transmission possible in North American deer mice\"."]}
{"id": 1000675, "claim": "North american deer mice are resistant to sars-cov-2.", "label": "REFUTED", "evidence": ["SARS-CoV-2 infection and transmission possible in North American deer mice.", "\"SARS-CoV-2 infection and transmission possible in North American deer mice\"."]}
{"id": 1000676, "claim": "North american deer bats are susceptible to sars-cov-2.", "label": "REFUTED", "evidence": ["SARS-CoV-2 infection and transmission possible in North American deer mice.", "\"SARS-CoV-2 infection and transmission possible in North American deer mice\"."]}
{"id": 1000677, "claim": "North american deer calves are susceptible to sars-cov-2.", "label": "REFUTED", "evidence": ["SARS-CoV-2 infection and transmission possible in North American deer mice.", "\"SARS-CoV-2 infection and transmission possible in North American deer mice\"."]}
{"id": 1000678, "claim": "Fda authorizes monoclonal antibodies for treatment of covid-19", "label": "SUPPORTED", "evidence": ["The emergency authorization of these monoclonal antibodies administered together offers health care providers another tool in combating the pandemic, said Patrizia Cavazzoni, M.D., acting director of the FDAs Center for Drug Evaluation and Research."]}
{"id": 1000679, "claim": "Fda authorizes monoclonal antibodies for production of covid-19", "label": "REFUTED", "evidence": ["The emergency authorization of these monoclonal antibodies administered together offers health care providers another tool in combating the pandemic, said Patrizia Cavazzoni, M.D., acting director of the FDAs Center for Drug Evaluation and Research."]}
{"id": 1000680, "claim": "Fda authorizes monoclonal antibodies for generation of covid-19", "label": "REFUTED", "evidence": ["The emergency authorization of these monoclonal antibodies administered together offers health care providers another tool in combating the pandemic, said Patrizia Cavazzoni, M.D., acting director of the FDAs Center for Drug Evaluation and Research."]}
{"id": 1000681, "claim": "Fda authorizes monoclonal antibodies for development of covid-19", "label": "REFUTED", "evidence": ["The emergency authorization of these monoclonal antibodies administered together offers health care providers another tool in combating the pandemic, said Patrizia Cavazzoni, M.D., acting director of the FDAs Center for Drug Evaluation and Research."]}
{"id": 1000682, "claim": "Neutralising antibodies drive spike mediated sars-cov-2 evasion", "label": "SUPPORTED", "evidence": ["In vitro , the Spike escape variant conferred decreased sensitivity to multiple units of convalescent plasma/sera from different recovered patients, whilst maintaining infectivity similar to wild type.", "These data reveal strong positive selection on SARS-CoV-2 during convalescent plasma therapy and identify the combination of Spike mutations D796H and Δ H69/ Δ V70 as a broad antibody resistance mechanism against commonly occurring antibody responses to SARS-CoV-2."]}
{"id": 1000683, "claim": "Neutralising antibodies drive fc mediated sars-cov-2 evasion", "label": "REFUTED", "evidence": ["In vitro , the Spike escape variant conferred decreased sensitivity to multiple units of convalescent plasma/sera from different recovered patients, whilst maintaining infectivity similar to wild type.", "These data reveal strong positive selection on SARS-CoV-2 during convalescent plasma therapy and identify the combination of Spike mutations D796H and Δ H69/ Δ V70 as a broad antibody resistance mechanism against commonly occurring antibody responses to SARS-CoV-2."]}
{"id": 1000684, "claim": "Neutralising antibodies drive ifn mediated sars-cov-2 evasion", "label": "REFUTED", "evidence": ["In vitro , the Spike escape variant conferred decreased sensitivity to multiple units of convalescent plasma/sera from different recovered patients, whilst maintaining infectivity similar to wild type.", "These data reveal strong positive selection on SARS-CoV-2 during convalescent plasma therapy and identify the combination of Spike mutations D796H and Δ H69/ Δ V70 as a broad antibody resistance mechanism against commonly occurring antibody responses to SARS-CoV-2."]}
{"id": 1000685, "claim": "Neutralising antibodies drive tlr mediated sars-cov-2 evasion", "label": "REFUTED", "evidence": ["In vitro , the Spike escape variant conferred decreased sensitivity to multiple units of convalescent plasma/sera from different recovered patients, whilst maintaining infectivity similar to wild type.", "These data reveal strong positive selection on SARS-CoV-2 during convalescent plasma therapy and identify the combination of Spike mutations D796H and Δ H69/ Δ V70 as a broad antibody resistance mechanism against commonly occurring antibody responses to SARS-CoV-2."]}
{"id": 1000686, "claim": "Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with covid-19", "label": "SUPPORTED", "evidence": ["CONCLUSIONS AND RELEVANCE Hydroxychloroquine treatment is significantly associated with a decreased mortality in critically ill patients with COVID-19 through attenuation of inflammatory cytokine storm.", "Hydroxychloroquine treatment is significantly associated with a decreased mortality in critically ill COVID-19 patients and attenuated inflammatory cytokine IL-6 level."]}
{"id": 1000687, "claim": "Hydroxychloroquine deficiency is associated with a decreased mortality in critically ill patients with covid-19", "label": "REFUTED", "evidence": ["CONCLUSIONS AND RELEVANCE Hydroxychloroquine treatment is significantly associated with a decreased mortality in critically ill patients with COVID-19 through attenuation of inflammatory cytokine storm.", "Hydroxychloroquine treatment is significantly associated with a decreased mortality in critically ill COVID-19 patients and attenuated inflammatory cytokine IL-6 level."]}
{"id": 1000688, "claim": "Projected timeline for treatment and prevention by synbiobeta", "label": "SUPPORTED", "evidence": ["At the heart of the project is an infographic showing the timeline to the various treatments and preventions (click here to download it).", "A projected timeline for treatment and prevention of the novel coronavirus."]}
{"id": 1000689, "claim": "Projected timeline for treatment and death by synbiobeta", "label": "REFUTED", "evidence": ["At the heart of the project is an infographic showing the timeline to the various treatments and preventions (click here to download it).", "A projected timeline for treatment and prevention of the novel coronavirus."]}
{"id": 1000690, "claim": "Projected technology for treatment and prevention by synbiobeta", "label": "REFUTED", "evidence": ["At the heart of the project is an infographic showing the timeline to the various treatments and preventions (click here to download it).", "A projected timeline for treatment and prevention of the novel coronavirus."]}
{"id": 1000691, "claim": "Projected method for treatment and prevention by synbiobeta", "label": "REFUTED", "evidence": ["At the heart of the project is an infographic showing the timeline to the various treatments and preventions (click here to download it).", "A projected timeline for treatment and prevention of the novel coronavirus."]}
{"id": 1000692, "claim": "Nearly a third of 200 blood samples taken in chelsea show exposure to coronavirus", "label": "SUPPORTED", "evidence": ["Advertisement Related: Chelseas spike in coronavirus cases challenges hospitals and state Public health experts already knew Chelsea had the states highest rate of confirmed COVID-19 cases and that the actual rate was probably higher.", "General researcher says the results point to a raging epidemic, but may also indicate the city is further along the disease curve than some other municipalities By Jonathan Saltzman Globe Staff,Updated April 17, 2020, 6:26 p.m. Email to a Friend Share on Facebook Share on TwitterPrint this Article View Comments First responders loaded a patient into an ambulance from a nursing home where multiple people have contracted COID-19 in Chelsea, which has the highest concentration of COVID-19 infections in the state.Scott Eisen/Getty Nearly one third of 200 Chelsea residents who gave a drop of blood to researchers on the street this week tested positive for antibodies linked to COVID-19, a startling indication of how widespread infections have been in the densely populated city."]}
{"id": 1000693, "claim": "Nearly a third of five blood samples taken in chelsea show exposure to coronavirus", "label": "REFUTED", "evidence": ["Advertisement Related: Chelseas spike in coronavirus cases challenges hospitals and state Public health experts already knew Chelsea had the states highest rate of confirmed COVID-19 cases and that the actual rate was probably higher.", "General researcher says the results point to a raging epidemic, but may also indicate the city is further along the disease curve than some other municipalities By Jonathan Saltzman Globe Staff,Updated April 17, 2020, 6:26 p.m. Email to a Friend Share on Facebook Share on TwitterPrint this Article View Comments First responders loaded a patient into an ambulance from a nursing home where multiple people have contracted COID-19 in Chelsea, which has the highest concentration of COVID-19 infections in the state.Scott Eisen/Getty Nearly one third of 200 Chelsea residents who gave a drop of blood to researchers on the street this week tested positive for antibodies linked to COVID-19, a startling indication of how widespread infections have been in the densely populated city."]}
{"id": 1000694, "claim": "Nearly a third of 10 blood samples taken in chelsea show exposure to coronavirus", "label": "REFUTED", "evidence": ["Advertisement Related: Chelseas spike in coronavirus cases challenges hospitals and state Public health experts already knew Chelsea had the states highest rate of confirmed COVID-19 cases and that the actual rate was probably higher.", "General researcher says the results point to a raging epidemic, but may also indicate the city is further along the disease curve than some other municipalities By Jonathan Saltzman Globe Staff,Updated April 17, 2020, 6:26 p.m. Email to a Friend Share on Facebook Share on TwitterPrint this Article View Comments First responders loaded a patient into an ambulance from a nursing home where multiple people have contracted COID-19 in Chelsea, which has the highest concentration of COVID-19 infections in the state.Scott Eisen/Getty Nearly one third of 200 Chelsea residents who gave a drop of blood to researchers on the street this week tested positive for antibodies linked to COVID-19, a startling indication of how widespread infections have been in the densely populated city."]}
{"id": 1000695, "claim": "Nearly a third of eight blood samples taken in chelsea show exposure to coronavirus", "label": "REFUTED", "evidence": ["Advertisement Related: Chelseas spike in coronavirus cases challenges hospitals and state Public health experts already knew Chelsea had the states highest rate of confirmed COVID-19 cases and that the actual rate was probably higher.", "General researcher says the results point to a raging epidemic, but may also indicate the city is further along the disease curve than some other municipalities By Jonathan Saltzman Globe Staff,Updated April 17, 2020, 6:26 p.m. Email to a Friend Share on Facebook Share on TwitterPrint this Article View Comments First responders loaded a patient into an ambulance from a nursing home where multiple people have contracted COID-19 in Chelsea, which has the highest concentration of COVID-19 infections in the state.Scott Eisen/Getty Nearly one third of 200 Chelsea residents who gave a drop of blood to researchers on the street this week tested positive for antibodies linked to COVID-19, a startling indication of how widespread infections have been in the densely populated city."]}
{"id": 1000696, "claim": "Low dose of hydroxychloroquine reduces fatality of critically ill patients with covid-19", "label": "SUPPORTED", "evidence": ["Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants."]}
{"id": 1000697, "claim": "Low dose of hydroxychloroquine increased fatality of critically ill patients with covid-19", "label": "REFUTED", "evidence": ["Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants."]}
{"id": 1000698, "claim": "Low dose of hydroxychloroquine increase fatality of critically ill patients with covid-19", "label": "REFUTED", "evidence": ["Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants."]}
{"id": 1000699, "claim": "Low dose of hydroxychloroquine increases fatality of critically ill patients with covid-19", "label": "REFUTED", "evidence": ["Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants."]}
{"id": 1000700, "claim": "Furin cleavage site is key to sars-cov-2 pathogenesis", "label": "SUPPORTED", "evidence": ["By removing the furin cleavage site, we demonstrate the importance of this insertion to SARS-CoV-2 replication and pathogenesis.", "Together, these results demonstrate a critical role for the furin cleavage site insertion in SARS-CoV-2 replication and pathogenesis."]}
{"id": 1000701, "claim": "Furin binding site is key to sars-cov-2 pathogenesis", "label": "REFUTED", "evidence": ["By removing the furin cleavage site, we demonstrate the importance of this insertion to SARS-CoV-2 replication and pathogenesis.", "Together, these results demonstrate a critical role for the furin cleavage site insertion in SARS-CoV-2 replication and pathogenesis."]}
{"id": 1000702, "claim": "Furin catalytic site is key to sars-cov-2 pathogenesis", "label": "REFUTED", "evidence": ["By removing the furin cleavage site, we demonstrate the importance of this insertion to SARS-CoV-2 replication and pathogenesis.", "Together, these results demonstrate a critical role for the furin cleavage site insertion in SARS-CoV-2 replication and pathogenesis."]}
{"id": 1000703, "claim": "Furin recognition site is key to sars-cov-2 pathogenesis", "label": "REFUTED", "evidence": ["By removing the furin cleavage site, we demonstrate the importance of this insertion to SARS-CoV-2 replication and pathogenesis.", "Together, these results demonstrate a critical role for the furin cleavage site insertion in SARS-CoV-2 replication and pathogenesis."]}
{"id": 1000704, "claim": "Covid-19 vaccine shipped , and drug trials start", "label": "SUPPORTED", "evidence": ["That means that this vaccine method can be scaled up quickly, saving critical time when a new disease like COVID-19 emerges and starts infecting tens of thousands of people.", "The trial is the first to test a drug for treating COVID-19, and will be led by a team at the University of Nebraska Medical Center."]}
{"id": 1000705, "claim": "Covid-19 vaccine development, and drug trials start", "label": "REFUTED", "evidence": ["That means that this vaccine method can be scaled up quickly, saving critical time when a new disease like COVID-19 emerges and starts infecting tens of thousands of people.", "The trial is the first to test a drug for treating COVID-19, and will be led by a team at the University of Nebraska Medical Center."]}
{"id": 1000706, "claim": "The university of liverpool have developed an online database for checking drug-drug interactions with the experimental covid-19 specific medicinal products", "label": "SUPPORTED", "evidence": ["According to the Liverpool data, some of the riskiest drug-drug interactions are between experimental Covid-19 treatments and heart-related medications, including antiarrhythmics, beta blockers, anti-coagulants, calcium channel blockers, some hypertensives, and lipid-lowering statins.", "On the other hand, the Liverpool interactions group has provided prescribing resources where they categorized the interactions of experimental COVID-19 antiviral therapies as contraindicated medications, potential interactions requiring dose adjustment/close monitoring, potential interactions of weak intensity or no clinically significant interactions (University of Liverpool, 2020)."]}
{"id": 1000707, "claim": "The university of liverpool have received an online database for checking drug-drug interactions with the experimental covid-19 specific medicinal products", "label": "REFUTED", "evidence": ["According to the Liverpool data, some of the riskiest drug-drug interactions are between experimental Covid-19 treatments and heart-related medications, including antiarrhythmics, beta blockers, anti-coagulants, calcium channel blockers, some hypertensives, and lipid-lowering statins.", "On the other hand, the Liverpool interactions group has provided prescribing resources where they categorized the interactions of experimental COVID-19 antiviral therapies as contraindicated medications, potential interactions requiring dose adjustment/close monitoring, potential interactions of weak intensity or no clinically significant interactions (University of Liverpool, 2020)."]}
{"id": 1000708, "claim": "The race is on for antibodies that stop the new coronavirus", "label": "SUPPORTED", "evidence": ["One modification slows the antibody degradation to give it a longer effective life; another improves the so-called vaccinal effect, which summons T cellsanother arm of the immune systemto help destroy infected cells.", "Many researchers are optimistic that antibodies will, relatively quickly, prove their worth as a preventive or remedy that buys the world time until a vaccine arrivesif it does."]}
{"id": 1000709, "claim": "The race is on for pathogens that stop the new coronavirus", "label": "REFUTED", "evidence": ["One modification slows the antibody degradation to give it a longer effective life; another improves the so-called vaccinal effect, which summons T cellsanother arm of the immune systemto help destroy infected cells.", "Many researchers are optimistic that antibodies will, relatively quickly, prove their worth as a preventive or remedy that buys the world time until a vaccine arrivesif it does."]}
{"id": 1000710, "claim": "Test sensitivity is secondary to frequency and turnaround time for covid-19 surveillance", "label": "SUPPORTED", "evidence": ["This article has been published \"Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening\" in Sci Adv.", "The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application.", "We therefore conclude that surveillance should prioritize accessibility, frequency, and sample-to-answer time; analytical limits of detection should be secondary."]}
{"id": 1000711, "claim": "Test sensitivity is secondary to duration and turnaround time for covid-19 surveillance", "label": "REFUTED", "evidence": ["This article has been published \"Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening\" in Sci Adv.", "The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application.", "We therefore conclude that surveillance should prioritize accessibility, frequency, and sample-to-answer time; analytical limits of detection should be secondary."]}
{"id": 1000712, "claim": "Test sensitivity is equivalent to frequency and turnaround time for covid-19 surveillance", "label": "REFUTED", "evidence": ["This article has been published \"Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening\" in Sci Adv.", "The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application.", "We therefore conclude that surveillance should prioritize accessibility, frequency, and sample-to-answer time; analytical limits of detection should be secondary."]}
{"id": 1000713, "claim": "Test sensitivity is secondary to isolation and turnaround time for covid-19 surveillance", "label": "REFUTED", "evidence": ["This article has been published \"Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening\" in Sci Adv.", "The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application.", "We therefore conclude that surveillance should prioritize accessibility, frequency, and sample-to-answer time; analytical limits of detection should be secondary."]}
{"id": 1000714, "claim": "Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics", "label": "SUPPORTED", "evidence": ["These data highlight the value of Organ Chip technology as a more stringent and physiologically relevant platform for drug repurposing, and suggest that amodiaquine should be considered for future clinical testing.", "With the emergence of the COVID-19 pandemic, the Airway Chips were used to assess the inhibitory activities of approved drugs that showed inhibition in traditional cell culture assays only to find that most failed when tested in the Organ Chip platform.", "We provide a first demonstration of drug repurposing by using oseltamivir in influenza A virus-infected organ chip cultures and show that co-administration of the approved anticoagulant drug, nafamostat, can double oseltamivirs therapeutic time window.", "Here we show that human organ-on-a-chip (Organ Chip) microfluidic culture devices lined by highly differentiated human primary lung airway epithelium and endothelium can be used to model virus entry, replication, strain- dependent virulence, host cytokine production, and recruitment of circulating immune cells in response to infection by respiratory viruses with great pandemic potential."]}
{"id": 1000715, "claim": "Human organ chip-enabled pipeline to rapidly repurpose therapeutics during cancer pandemics", "label": "REFUTED", "evidence": ["These data highlight the value of Organ Chip technology as a more stringent and physiologically relevant platform for drug repurposing, and suggest that amodiaquine should be considered for future clinical testing.", "With the emergence of the COVID-19 pandemic, the Airway Chips were used to assess the inhibitory activities of approved drugs that showed inhibition in traditional cell culture assays only to find that most failed when tested in the Organ Chip platform.", "We provide a first demonstration of drug repurposing by using oseltamivir in influenza A virus-infected organ chip cultures and show that co-administration of the approved anticoagulant drug, nafamostat, can double oseltamivirs therapeutic time window.", "Here we show that human organ-on-a-chip (Organ Chip) microfluidic culture devices lined by highly differentiated human primary lung airway epithelium and endothelium can be used to model virus entry, replication, strain- dependent virulence, host cytokine production, and recruitment of circulating immune cells in response to infection by respiratory viruses with great pandemic potential."]}
{"id": 1000716, "claim": "Trial of oxford covid-19 vaccine in south africa begins", "label": "SUPPORTED", "evidence": ["The first clinical trial in South Africa and on the continent for a COVID-19 vaccine was announced today, 23 June, at a virtual press conference hosted by the University of the Witwatersrand, Johannesburg (Wits).", "We began screening participants for the South African Oxford 1 Covid-19 vaccine trial last week and the first participants will be vaccinated this week, says Madhi, who is also the National Research Foundation/Department of Science and Innovation SARChI (South African Research Chairs Initiative) Chair in Vaccine Preventable Diseases, based at the University of the Witwatersrand."]}
{"id": 1000717, "claim": "Trial of oxford covid-19 vaccine in south taiwan begins", "label": "REFUTED", "evidence": ["The first clinical trial in South Africa and on the continent for a COVID-19 vaccine was announced today, 23 June, at a virtual press conference hosted by the University of the Witwatersrand, Johannesburg (Wits).", "We began screening participants for the South African Oxford 1 Covid-19 vaccine trial last week and the first participants will be vaccinated this week, says Madhi, who is also the National Research Foundation/Department of Science and Innovation SARChI (South African Research Chairs Initiative) Chair in Vaccine Preventable Diseases, based at the University of the Witwatersrand."]}
{"id": 1000718, "claim": "Trial of oxford covid-19 vaccine in south thailand begins", "label": "REFUTED", "evidence": ["The first clinical trial in South Africa and on the continent for a COVID-19 vaccine was announced today, 23 June, at a virtual press conference hosted by the University of the Witwatersrand, Johannesburg (Wits).", "We began screening participants for the South African Oxford 1 Covid-19 vaccine trial last week and the first participants will be vaccinated this week, says Madhi, who is also the National Research Foundation/Department of Science and Innovation SARChI (South African Research Chairs Initiative) Chair in Vaccine Preventable Diseases, based at the University of the Witwatersrand."]}
{"id": 1000719, "claim": "Trial of oxford covid-19 vaccine in south brazil begins", "label": "REFUTED", "evidence": ["The first clinical trial in South Africa and on the continent for a COVID-19 vaccine was announced today, 23 June, at a virtual press conference hosted by the University of the Witwatersrand, Johannesburg (Wits).", "We began screening participants for the South African Oxford 1 Covid-19 vaccine trial last week and the first participants will be vaccinated this week, says Madhi, who is also the National Research Foundation/Department of Science and Innovation SARChI (South African Research Chairs Initiative) Chair in Vaccine Preventable Diseases, based at the University of the Witwatersrand."]}
{"id": 1000720, "claim": "Nanoparticle vaccine for covid-19 spurs robust immune response in preclinical tests", "label": "SUPPORTED", "evidence": ["The nanoparticle vaccine technology leverages a unique design that's unlike the majority of other COVID-19 vaccine candidates now in clinical testing.", "September 21, 2020 LA JOLLA, CA --In a new study that demonstrates the promise of a novel vaccine approach for COVID-19, Scripps Research scientist Jiang Zhu, PhD, showed that his protein nanoparticle technology successfully triggered a strong immune response in mice.", "\"Our vaccine design enables immune cells to encounter these proteins in a more natural conformation--embedded on a spherical particle--so they'll know what to do when they face the virus in real life.\"", "The study, \" Self-assembling nanoparticles presenting receptor binding domain and stabilized spike as next-generation COVID-19 vaccines , \" was authored by Linling He, Xiaohe Lin, Ying Wang, Ciril Abraham, Cindy Sou, Timothy Ngo, Yi Zhang, Ian Wilson and Jiang Zhu."]}
{"id": 1000721, "claim": "Nanoparticle vaccine for covid-19 spurs reduces immune response in preclinical tests", "label": "REFUTED", "evidence": ["The nanoparticle vaccine technology leverages a unique design that's unlike the majority of other COVID-19 vaccine candidates now in clinical testing.", "September 21, 2020 LA JOLLA, CA --In a new study that demonstrates the promise of a novel vaccine approach for COVID-19, Scripps Research scientist Jiang Zhu, PhD, showed that his protein nanoparticle technology successfully triggered a strong immune response in mice.", "\"Our vaccine design enables immune cells to encounter these proteins in a more natural conformation--embedded on a spherical particle--so they'll know what to do when they face the virus in real life.\"", "The study, \" Self-assembling nanoparticles presenting receptor binding domain and stabilized spike as next-generation COVID-19 vaccines , \" was authored by Linling He, Xiaohe Lin, Ying Wang, Ciril Abraham, Cindy Sou, Timothy Ngo, Yi Zhang, Ian Wilson and Jiang Zhu."]}
{"id": 1000722, "claim": "Nanoparticle vaccine for covid-19 spurs against immune response in preclinical tests", "label": "REFUTED", "evidence": ["The nanoparticle vaccine technology leverages a unique design that's unlike the majority of other COVID-19 vaccine candidates now in clinical testing.", "September 21, 2020 LA JOLLA, CA --In a new study that demonstrates the promise of a novel vaccine approach for COVID-19, Scripps Research scientist Jiang Zhu, PhD, showed that his protein nanoparticle technology successfully triggered a strong immune response in mice.", "\"Our vaccine design enables immune cells to encounter these proteins in a more natural conformation--embedded on a spherical particle--so they'll know what to do when they face the virus in real life.\"", "The study, \" Self-assembling nanoparticles presenting receptor binding domain and stabilized spike as next-generation COVID-19 vaccines , \" was authored by Linling He, Xiaohe Lin, Ying Wang, Ciril Abraham, Cindy Sou, Timothy Ngo, Yi Zhang, Ian Wilson and Jiang Zhu."]}
{"id": 1000723, "claim": "An inflammatory cytokine signature predicts covid-19 severity and survival", "label": "SUPPORTED", "evidence": ["Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.", "COVID-19: consider cytokine storm syndromes and immunosuppression.", "In this study, we asked whether inflammatory cytokine levels can help predict disease course and outcome in patients with COVID-19."]}
{"id": 1000724, "claim": "An inflammatory cytokine signature predicts covid-19 production and survival", "label": "REFUTED", "evidence": ["Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.", "COVID-19: consider cytokine storm syndromes and immunosuppression.", "In this study, we asked whether inflammatory cytokine levels can help predict disease course and outcome in patients with COVID-19."]}
{"id": 1000725, "claim": "An inflammatory cytokine signature immunes covid-19 severity and survival", "label": "REFUTED", "evidence": ["Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.", "COVID-19: consider cytokine storm syndromes and immunosuppression.", "In this study, we asked whether inflammatory cytokine levels can help predict disease course and outcome in patients with COVID-19."]}
{"id": 1000726, "claim": "An inflammatory cytokine signature predicts covid-19 transcription and survival", "label": "REFUTED", "evidence": ["Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.", "COVID-19: consider cytokine storm syndromes and immunosuppression.", "In this study, we asked whether inflammatory cytokine levels can help predict disease course and outcome in patients with COVID-19."]}
{"id": 1000727, "claim": "Trump adds confusion on covid-19 treatments as us deaths top 50,000", "label": "SUPPORTED", "evidence": ["\"I was asking a question sarcastically to reporters like you just to see what would happen,\" Trump said in the Oval Office."]}
{"id": 1000728, "claim": "Trump adds knowledge on covid-19 treatments as us deaths top 50,000", "label": "REFUTED", "evidence": ["\"I was asking a question sarcastically to reporters like you just to see what would happen,\" Trump said in the Oval Office."]}
{"id": 1000729, "claim": "Trump adds consensus on covid-19 treatments as us deaths top 50,000", "label": "REFUTED", "evidence": ["\"I was asking a question sarcastically to reporters like you just to see what would happen,\" Trump said in the Oval Office."]}
{"id": 1000730, "claim": "Trump lied about science", "label": "SUPPORTED", "evidence": ["As he was playing down the virus to the public, Trump was not confused or inadequately briefed: He flat-out lied, repeatedly, about science to the American people.", "But now, a U.S. president has deliberately lied about science in a way that was imminently dangerous to human health and directly led to widespread deaths of Americans.", "Find this author on Google Scholar Find this author on PubMed Search for this author on this site Article Info & Metrics eLetters PDF \"PHOTO: CAMERON DAVIDSON\" When President Donald Trump began talking to the public about coronavirus disease 2019 (COVID-19) in February and March, scientists were stunned at his seeming lack of understanding of the threat."]}
{"id": 1000731, "claim": "Trump is about science", "label": "REFUTED", "evidence": ["As he was playing down the virus to the public, Trump was not confused or inadequately briefed: He flat-out lied, repeatedly, about science to the American people.", "But now, a U.S. president has deliberately lied about science in a way that was imminently dangerous to human health and directly led to widespread deaths of Americans.", "Find this author on Google Scholar Find this author on PubMed Search for this author on this site Article Info & Metrics eLetters PDF \"PHOTO: CAMERON DAVIDSON\" When President Donald Trump began talking to the public about coronavirus disease 2019 (COVID-19) in February and March, scientists were stunned at his seeming lack of understanding of the threat."]}
{"id": 1000732, "claim": "Trump was about science", "label": "REFUTED", "evidence": ["As he was playing down the virus to the public, Trump was not confused or inadequately briefed: He flat-out lied, repeatedly, about science to the American people.", "But now, a U.S. president has deliberately lied about science in a way that was imminently dangerous to human health and directly led to widespread deaths of Americans.", "Find this author on Google Scholar Find this author on PubMed Search for this author on this site Article Info & Metrics eLetters PDF \"PHOTO: CAMERON DAVIDSON\" When President Donald Trump began talking to the public about coronavirus disease 2019 (COVID-19) in February and March, scientists were stunned at his seeming lack of understanding of the threat."]}
{"id": 1000733, "claim": "Clears pfizer vaccine , and millions of doses will be shipped right away", "label": "SUPPORTED", "evidence": ["Pfizer has said it will be able to supply up to 25 million doses before the end of the year, and 100 million total vaccines by March.Credit...Justin Tallis/Agence France-Presse  Getty Images By Katie Thomas, Sharon LaFraniere, Noah Weiland, Abby Goodnough and Maggie Haberman Published Dec. 11, 2020Updated Jan. 8, 2021 The Food and Drug Administration authorized Pfizers Covid-19 vaccine for emergency use on Friday, clearing the way for millions of highly vulnerable people to begin receiving the vaccine within days.", "Pfizer has a deal with the U.S. government to supply 100 million doses of the vaccine by next March.", "The authorization set off a complicated coordination effort from Pfizer, private shipping companies, state and local health officials, the military, hospitals and pharmacy chains to get the first weeks batch of about three million doses to health care workers and nursing home residents as quickly as possible, all while keeping the vaccine at ultracold temperatures.", "McKesson Corporation, a giant medical supplier, is sending kits of syringes, alcohol pads, face shields and other supplies to the same sites, where they will meet up with the vaccines that Pfizer is shipping in special boxes, packed with dry ice, designed to keep them at minus 94 degrees Fahrenheit."]}
{"id": 1000734, "claim": "Clears pfizer vaccine, and millions of doses will be shipped twice away", "label": "REFUTED", "evidence": ["Pfizer has said it will be able to supply up to 25 million doses before the end of the year, and 100 million total vaccines by March.Credit...Justin Tallis/Agence France-Presse  Getty Images By Katie Thomas, Sharon LaFraniere, Noah Weiland, Abby Goodnough and Maggie Haberman Published Dec. 11, 2020Updated Jan. 8, 2021 The Food and Drug Administration authorized Pfizers Covid-19 vaccine for emergency use on Friday, clearing the way for millions of highly vulnerable people to begin receiving the vaccine within days.", "Pfizer has a deal with the U.S. government to supply 100 million doses of the vaccine by next March.", "The authorization set off a complicated coordination effort from Pfizer, private shipping companies, state and local health officials, the military, hospitals and pharmacy chains to get the first weeks batch of about three million doses to health care workers and nursing home residents as quickly as possible, all while keeping the vaccine at ultracold temperatures.", "McKesson Corporation, a giant medical supplier, is sending kits of syringes, alcohol pads, face shields and other supplies to the same sites, where they will meet up with the vaccines that Pfizer is shipping in special boxes, packed with dry ice, designed to keep them at minus 94 degrees Fahrenheit."]}
{"id": 1000735, "claim": "Composition of the immunoglobulin g glycome associates with the severity of covid-19", "label": "SUPPORTED", "evidence": ["Fran Mihaljević, Zagreb, Croatia Find this author on Google Scholar Find this author on PubMed Search for this author on this site Alemka Markotić 8University Hospital for Infectious Diseases Dr."]}
{"id": 1000736, "claim": "Composition of the immunoglobulin g glycome associates with the surface of covid-19", "label": "REFUTED", "evidence": ["Fran Mihaljević, Zagreb, Croatia Find this author on Google Scholar Find this author on PubMed Search for this author on this site Alemka Markotić 8University Hospital for Infectious Diseases Dr."]}
{"id": 1000737, "claim": "Composition of the immunoglobulin g glycome associates against the severity of covid-19", "label": "REFUTED", "evidence": ["Fran Mihaljević, Zagreb, Croatia Find this author on Google Scholar Find this author on PubMed Search for this author on this site Alemka Markotić 8University Hospital for Infectious Diseases Dr."]}
{"id": 1000738, "claim": "Composition of the immunoglobulin g glycome associates with the absence of covid-19", "label": "REFUTED", "evidence": ["Fran Mihaljević, Zagreb, Croatia Find this author on Google Scholar Find this author on PubMed Search for this author on this site Alemka Markotić 8University Hospital for Infectious Diseases Dr."]}
{"id": 1000739, "claim": "A granulocytic signature identifies covid-19 and its severity", "label": "SUPPORTED", "evidence": ["Elevated Exhaustion Levels of NK and CD8+ T Cells as Indicators for Progression and Prognosis of COVID-19 Disease.", "Increased counts of CD15+CD16+ neutrophils, decreased granulocytic expression of integrin CD11b, and Th2-related CRTH2 downregulation in eosinophils and basophils established a COVID-19 signature."]}
{"id": 1000740, "claim": "A granulocytic signature identifies covid-19 and its species", "label": "REFUTED", "evidence": ["Elevated Exhaustion Levels of NK and CD8+ T Cells as Indicators for Progression and Prognosis of COVID-19 Disease.", "Increased counts of CD15+CD16+ neutrophils, decreased granulocytic expression of integrin CD11b, and Th2-related CRTH2 downregulation in eosinophils and basophils established a COVID-19 signature."]}
{"id": 1000741, "claim": "A granulocytic signature identifies covid-19 and its sequence", "label": "REFUTED", "evidence": ["Elevated Exhaustion Levels of NK and CD8+ T Cells as Indicators for Progression and Prognosis of COVID-19 Disease.", "Increased counts of CD15+CD16+ neutrophils, decreased granulocytic expression of integrin CD11b, and Th2-related CRTH2 downregulation in eosinophils and basophils established a COVID-19 signature."]}
{"id": 1000742, "claim": "A granulocytic signature identifies covid-19 and its genes", "label": "REFUTED", "evidence": ["Elevated Exhaustion Levels of NK and CD8+ T Cells as Indicators for Progression and Prognosis of COVID-19 Disease.", "Increased counts of CD15+CD16+ neutrophils, decreased granulocytic expression of integrin CD11b, and Th2-related CRTH2 downregulation in eosinophils and basophils established a COVID-19 signature."]}
{"id": 1000743, "claim": "Reven announces coronavirus treatment acceleration program submission to the fda", "label": "SUPPORTED", "evidence": ["Reven conducted the study in response a recent FDA request to provide additional pre-clinical support specific to the COVID-19 related Acute Respiratory Distress Syndrome (ARDS) clinical trial advice request from last month."]}
{"id": 1000744, "claim": "Reven announces coronavirus treatment acceleration program submission to the hospital", "label": "REFUTED", "evidence": ["Reven conducted the study in response a recent FDA request to provide additional pre-clinical support specific to the COVID-19 related Acute Respiratory Distress Syndrome (ARDS) clinical trial advice request from last month."]}
{"id": 1000745, "claim": "Reven announces coronavirus treatment acceleration program submission to the database", "label": "REFUTED", "evidence": ["Reven conducted the study in response a recent FDA request to provide additional pre-clinical support specific to the COVID-19 related Acute Respiratory Distress Syndrome (ARDS) clinical trial advice request from last month."]}
{"id": 1000746, "claim": "Reven announces coronavirus treatment acceleration program submission to the patient", "label": "REFUTED", "evidence": ["Reven conducted the study in response a recent FDA request to provide additional pre-clinical support specific to the COVID-19 related Acute Respiratory Distress Syndrome (ARDS) clinical trial advice request from last month."]}
{"id": 1000747, "claim": "High cortisol levels associated with greater risk of death from covid-19", "label": "SUPPORTED", "evidence": ["Excessive levels of cortisol during illness can be equally dangerous, leading to increased risk of infection and poor outcomes.", "Amongst the COVID-19 patients, those with a baseline cortisol level of 744 or less survived on average for 36 days."]}
{"id": 1000748, "claim": "High cortisol levels associated with reduced risk of death from covid-19", "label": "REFUTED", "evidence": ["Excessive levels of cortisol during illness can be equally dangerous, leading to increased risk of infection and poor outcomes.", "Amongst the COVID-19 patients, those with a baseline cortisol level of 744 or less survived on average for 36 days."]}
{"id": 1000749, "claim": "High cortisol levels associated with decreased risk of death from covid-19", "label": "REFUTED", "evidence": ["Excessive levels of cortisol during illness can be equally dangerous, leading to increased risk of infection and poor outcomes.", "Amongst the COVID-19 patients, those with a baseline cortisol level of 744 or less survived on average for 36 days."]}
{"id": 1000750, "claim": "High cortisol levels associated with lower risk of death from covid-19", "label": "REFUTED", "evidence": ["Excessive levels of cortisol during illness can be equally dangerous, leading to increased risk of infection and poor outcomes.", "Amongst the COVID-19 patients, those with a baseline cortisol level of 744 or less survived on average for 36 days."]}
{"id": 1000751, "claim": "Causal empirical estimates suggest covid-19 transmission rates are highly seasonal", "label": "SUPPORTED", "evidence": ["Moreover, Northern Hemisphere countries face a crucial window of opportunity: if contagion-containing policy interventions can dramatically reduce COVID-19 cases with the aid of the approaching warmer months, it may be possible to avoid a second wave of COVID-19 next winter.", "Using constructions of expected seasonal temperatures, we project that changing temperatures between March 2020 and July 2020 will cause COVID-19 transmission to fall by 43% on average for Northern Hemisphere countries and to rise by 71% on average for Southern Hemisphere countries."]}
{"id": 1000752, "claim": "Causal empirical estimates suggest covid-19 transmission rates are low seasonal", "label": "REFUTED", "evidence": ["Moreover, Northern Hemisphere countries face a crucial window of opportunity: if contagion-containing policy interventions can dramatically reduce COVID-19 cases with the aid of the approaching warmer months, it may be possible to avoid a second wave of COVID-19 next winter.", "Using constructions of expected seasonal temperatures, we project that changing temperatures between March 2020 and July 2020 will cause COVID-19 transmission to fall by 43% on average for Northern Hemisphere countries and to rise by 71% on average for Southern Hemisphere countries."]}
{"id": 1000753, "claim": "Causal empirical estimates suggest covid-19 transmission rates are limited seasonal", "label": "REFUTED", "evidence": ["Moreover, Northern Hemisphere countries face a crucial window of opportunity: if contagion-containing policy interventions can dramatically reduce COVID-19 cases with the aid of the approaching warmer months, it may be possible to avoid a second wave of COVID-19 next winter.", "Using constructions of expected seasonal temperatures, we project that changing temperatures between March 2020 and July 2020 will cause COVID-19 transmission to fall by 43% on average for Northern Hemisphere countries and to rise by 71% on average for Southern Hemisphere countries."]}
{"id": 1000754, "claim": "Causal empirical estimates suggest covid-19 transmission rates are constant seasonal", "label": "REFUTED", "evidence": ["Moreover, Northern Hemisphere countries face a crucial window of opportunity: if contagion-containing policy interventions can dramatically reduce COVID-19 cases with the aid of the approaching warmer months, it may be possible to avoid a second wave of COVID-19 next winter.", "Using constructions of expected seasonal temperatures, we project that changing temperatures between March 2020 and July 2020 will cause COVID-19 transmission to fall by 43% on average for Northern Hemisphere countries and to rise by 71% on average for Southern Hemisphere countries."]}
{"id": 1000755, "claim": "Eight sailors from uss theodore roosevelt who previously had coronavirus test positive again", "label": "SUPPORTED", "evidence": ["Politico was the first to report on the eight additional sailors.", "They had all tested negative twice before being allowed back on board before this latest incident of testing positive again for the virus.", "This latest development is in addition to five other sailors aboard the ship that CNN reported earlier this week who had also again tested positive after being thought to be clear of the virus.", "(CNN)Eight additional sailors aboard the coronavirus-stricken carrier USS Theodore Roosevelt have now tested positive for the virus according to a defense official."]}
{"id": 1000756, "claim": "Two sailors from uss theodore roosevelt who previously had coronavirus test positive again", "label": "REFUTED", "evidence": ["Politico was the first to report on the eight additional sailors.", "They had all tested negative twice before being allowed back on board before this latest incident of testing positive again for the virus.", "This latest development is in addition to five other sailors aboard the ship that CNN reported earlier this week who had also again tested positive after being thought to be clear of the virus.", "(CNN)Eight additional sailors aboard the coronavirus-stricken carrier USS Theodore Roosevelt have now tested positive for the virus according to a defense official."]}
{"id": 1000757, "claim": "No evidence of viral polymorphisms associated with paediatric inflammatory multisystem syndrome temporally associated with sars-cov-2 .", "label": "SUPPORTED", "evidence": ["No unique viral sequences found in pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2.", "\"No unique viral sequences found in pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2\".", "No unique viral sequences found in pediatric inflammatory multisystem syndrome temporally associated with SARS- CoV-2."]}
{"id": 1000758, "claim": "Covid-19-associated is disseminated encephalomyelitis", "label": "REFUTED", "evidence": ["No unique viral sequences found in pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2.", "\"No unique viral sequences found in pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2\".", "No unique viral sequences found in pediatric inflammatory multisystem syndrome temporally associated with SARS- CoV-2."]}
{"id": 1000759, "claim": "Extracellular vesicle-based vaccine platform displaying native viral envelope proteins elicits a robust anti-sars-cov-2 response in mice .", "label": "SUPPORTED", "evidence": ["DNA vaccines encoding antigens presented on EVs efficiently induce T-cell responses and EV-based vaccines containing the Spike (S) proteins of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) are highly immunogenic in mice.", "Immunizations with a two component CoVEVax vaccine, comprising DNA vector (DNAS-EV) primes, allowing in situ production of Spike harbouring EVs, and a boost using S-EVs produced in mammalian cells, trigger potent neutralizing and cellular responses in mice, in the absence of any adjuvants."]}
{"id": 1000760, "claim": "Extracellular vesicle-based vaccine platform displaying native viral envelope proteins elicits a robust anti-sars-cov-2 response in human.", "label": "REFUTED", "evidence": ["DNA vaccines encoding antigens presented on EVs efficiently induce T-cell responses and EV-based vaccines containing the Spike (S) proteins of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) are highly immunogenic in mice.", "Immunizations with a two component CoVEVax vaccine, comprising DNA vector (DNAS-EV) primes, allowing in situ production of Spike harbouring EVs, and a boost using S-EVs produced in mammalian cells, trigger potent neutralizing and cellular responses in mice, in the absence of any adjuvants."]}
{"id": 1000761, "claim": "Extracellular vesicle-based vaccine platform displaying native viral envelope proteins elicits a robust anti-sars-cov-2 response in humans.", "label": "REFUTED", "evidence": ["DNA vaccines encoding antigens presented on EVs efficiently induce T-cell responses and EV-based vaccines containing the Spike (S) proteins of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) are highly immunogenic in mice.", "Immunizations with a two component CoVEVax vaccine, comprising DNA vector (DNAS-EV) primes, allowing in situ production of Spike harbouring EVs, and a boost using S-EVs produced in mammalian cells, trigger potent neutralizing and cellular responses in mice, in the absence of any adjuvants."]}
{"id": 1000762, "claim": "Extracellular vesicle-based vaccine platform displaying native viral envelope proteins elicits a robust anti-sars-cov-2 response in yeast.", "label": "REFUTED", "evidence": ["DNA vaccines encoding antigens presented on EVs efficiently induce T-cell responses and EV-based vaccines containing the Spike (S) proteins of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) are highly immunogenic in mice.", "Immunizations with a two component CoVEVax vaccine, comprising DNA vector (DNAS-EV) primes, allowing in situ production of Spike harbouring EVs, and a boost using S-EVs produced in mammalian cells, trigger potent neutralizing and cellular responses in mice, in the absence of any adjuvants."]}
{"id": 1000763, "claim": "Ambroxol hydrochloride inhibits the interaction between severe acute respiratory syndrome coronavirus 2 spike protein 's receptor binding domain and recombinant human ace2 .", "label": "SUPPORTED", "evidence": ["Herein, we discovered that Ambroxol hydrochloride (AMB), and its progenitor, Bromhexine hydrochloride (BHH), both clinically approved drugs are potent effective modulators of the key interaction between the receptor binding domain (RBD) of SARS-CoV-2 spike protein and human ACE2."]}
{"id": 1000764, "claim": "Ambroxol hydrochloride inhibits the interaction between mild acute respiratory syndrome coronavirus 2 spike protein's receptor binding domain and recombinant human ace2.", "label": "REFUTED", "evidence": ["Herein, we discovered that Ambroxol hydrochloride (AMB), and its progenitor, Bromhexine hydrochloride (BHH), both clinically approved drugs are potent effective modulators of the key interaction between the receptor binding domain (RBD) of SARS-CoV-2 spike protein and human ACE2."]}
{"id": 1000765, "claim": "Fewer than 1 in 10 americans have antibodies to coronavirus , study finds", "label": "SUPPORTED", "evidence": ["Sep 28 2020 A new study has found that few Americans have antibodies to SARS-CoV-2, rendered here in an illustration."]}
{"id": 1000766, "claim": "more than 1 in 10 americans have antibodies to coronavirus, study finds", "label": "REFUTED", "evidence": ["Sep 28 2020 A new study has found that few Americans have antibodies to SARS-CoV-2, rendered here in an illustration."]}
{"id": 1000767, "claim": "greater than 1 in 10 americans have antibodies to coronavirus, study finds", "label": "REFUTED", "evidence": ["Sep 28 2020 A new study has found that few Americans have antibodies to SARS-CoV-2, rendered here in an illustration."]}
{"id": 1000768, "claim": "more than 1 in 10 americans have antibodies to coronavirus, study finds", "label": "REFUTED", "evidence": ["Sep 28 2020 A new study has found that few Americans have antibodies to SARS-CoV-2, rendered here in an illustration."]}
{"id": 1000769, "claim": "Canadian scientists have isolated covid-19", "label": "SUPPORTED", "evidence": ["handout/Sunnybrook Hospital Two teams of Canadian scientists have isolated the coronavirus that causes COVID-19 and successfully reproduced it in the laboratory.", "In both cases, the virus was isolated from clinical samples obtained from patients at Sunnybrook, the first hospital in Canada to treat someone with COVID-19."]}
{"id": 1000770, "claim": "Canadian patients have isolated covid-19", "label": "REFUTED", "evidence": ["handout/Sunnybrook Hospital Two teams of Canadian scientists have isolated the coronavirus that causes COVID-19 and successfully reproduced it in the laboratory.", "In both cases, the virus was isolated from clinical samples obtained from patients at Sunnybrook, the first hospital in Canada to treat someone with COVID-19."]}
{"id": 1000771, "claim": "Ace2 exhibits protective action against thrombosis", "label": "SUPPORTED", "evidence": ["Summary In clinical practice the protective effects of ARBs and ACEIs are thought to be associated with an increase in ACE2 expression and their inhibition of the overactive renin-angiotensin system through reduction of Ang II effects.", "Therefore, induction of the downstream pathway of ACE2, by activating the ACE2/Ang1-7/MAS axis may prove a useful strategy in preventing lung and cardiovascular damage associated with SARS-CoV-2 infections."]}
{"id": 1000772, "claim": "Ace2 exhibits no action against thrombosis", "label": "REFUTED", "evidence": ["Summary In clinical practice the protective effects of ARBs and ACEIs are thought to be associated with an increase in ACE2 expression and their inhibition of the overactive renin-angiotensin system through reduction of Ang II effects.", "Therefore, induction of the downstream pathway of ACE2, by activating the ACE2/Ang1-7/MAS axis may prove a useful strategy in preventing lung and cardiovascular damage associated with SARS-CoV-2 infections."]}
{"id": 1000773, "claim": "Coronavirus blood-clot mystery intensifies", "label": "SUPPORTED", "evidence": ["And the virus seems to activate the complement system, a defence mechanism that sparks clotting.", "One possibility is that SARS- CoV-2 is directly attacking the endothelial cells that line the blood vessels.", "They might have a genetic predisposition to clotting, or be taking medications that increase the risk."]}
{"id": 1000774, "claim": "Coronavirus non-clot mystery intensifies", "label": "REFUTED", "evidence": ["And the virus seems to activate the complement system, a defence mechanism that sparks clotting.", "One possibility is that SARS- CoV-2 is directly attacking the endothelial cells that line the blood vessels.", "They might have a genetic predisposition to clotting, or be taking medications that increase the risk."]}
{"id": 1000775, "claim": "Coronavirus blood-clot mystery censifies", "label": "REFUTED", "evidence": ["And the virus seems to activate the complement system, a defence mechanism that sparks clotting.", "One possibility is that SARS- CoV-2 is directly attacking the endothelial cells that line the blood vessels.", "They might have a genetic predisposition to clotting, or be taking medications that increase the risk."]}
{"id": 1000776, "claim": "Coronavirus blood-clot mystery pensifies", "label": "REFUTED", "evidence": ["And the virus seems to activate the complement system, a defence mechanism that sparks clotting.", "One possibility is that SARS- CoV-2 is directly attacking the endothelial cells that line the blood vessels.", "They might have a genetic predisposition to clotting, or be taking medications that increase the risk."]}
{"id": 1000777, "claim": "The analysis of the long-term impact of sars-cov-2 on the cellular immune system in individuals recovering from covid-19 reveals a profound nkt cell impairment", "label": "SUPPORTED", "evidence": ["Significant increases in regulatory T cell frequencies, TIM-3 expression on CD4 and CD8 T cells, as well as PD-L1 expression on B cells were also observed in CI, while the cytotoxic potential of T cells and NKT-like cells, defined by GzmB expression, was significantly diminished.", "Concomitant with the decrease in NKT-like cells, an increase in the percentage of Annexin V and 7-AAD double positive NKT-like cells was detected, suggesting that the reduction in NKT-like cells results from cell death months after recovery."]}
{"id": 1000778, "claim": "The analysis of the long-term impact of sars-cov-2 on the cellular immune system in individuals recovering from covid-19 reveals a few nkt cell impairment", "label": "REFUTED", "evidence": ["Significant increases in regulatory T cell frequencies, TIM-3 expression on CD4 and CD8 T cells, as well as PD-L1 expression on B cells were also observed in CI, while the cytotoxic potential of T cells and NKT-like cells, defined by GzmB expression, was significantly diminished.", "Concomitant with the decrease in NKT-like cells, an increase in the percentage of Annexin V and 7-AAD double positive NKT-like cells was detected, suggesting that the reduction in NKT-like cells results from cell death months after recovery."]}
{"id": 1000779, "claim": "The analysis of the long-term impact of sars-cov-2 on the cellular immune system in individuals recovering from covid-19 reveals a single nkt cell impairment", "label": "REFUTED", "evidence": ["Significant increases in regulatory T cell frequencies, TIM-3 expression on CD4 and CD8 T cells, as well as PD-L1 expression on B cells were also observed in CI, while the cytotoxic potential of T cells and NKT-like cells, defined by GzmB expression, was significantly diminished.", "Concomitant with the decrease in NKT-like cells, an increase in the percentage of Annexin V and 7-AAD double positive NKT-like cells was detected, suggesting that the reduction in NKT-like cells results from cell death months after recovery."]}
{"id": 1000780, "claim": "A human coronavirus evolves antigenically to escape antibody immunity.", "label": "SUPPORTED", "evidence": ["Upon infection, an individuals immune state, possibly impacted by pre-existing antibodies to other coronaviruses (among other mechanisms), may cause harm through immunopathogenesis, and the literature on this topic primarily consists of in vitro experiments.", "Antibody against nucleocapsid protein predicts susceptibility to human coronavirus infection."]}
{"id": 1000781, "claim": "A bat coronavirus evolves antigenically to escape antibody immunity.", "label": "REFUTED", "evidence": ["Upon infection, an individuals immune state, possibly impacted by pre-existing antibodies to other coronaviruses (among other mechanisms), may cause harm through immunopathogenesis, and the literature on this topic primarily consists of in vitro experiments.", "Antibody against nucleocapsid protein predicts susceptibility to human coronavirus infection."]}
{"id": 1000782, "claim": "A zoonotic coronavirus evolves antigenically to escape antibody immunity.", "label": "REFUTED", "evidence": ["Upon infection, an individuals immune state, possibly impacted by pre-existing antibodies to other coronaviruses (among other mechanisms), may cause harm through immunopathogenesis, and the literature on this topic primarily consists of in vitro experiments.", "Antibody against nucleocapsid protein predicts susceptibility to human coronavirus infection."]}
{"id": 1000783, "claim": "Sars-cov-2 proteins and anti-covid-19 drugs induce lytic reactivation of an oncogenic virus", "label": "SUPPORTED", "evidence": ["Due to the mechanisms of SARS-CoV-2 infection to host cells and its pathogenesis remain largely unclear, there are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention.", "In the current study, we have reported that SARS-CoV-2 encoded proteins and some anti-COVID-19 drugs currently used are able to induce lytic reactivation of Kaposis sarcoma- associated herpesvirus (KSHV), one of major human oncogenic viruses through manipulation of intracellular signaling pathways."]}
{"id": 1000784, "claim": "Sars-cov-2 proteins and anti-covid-19 drugs prevent lytic reactivation of an oncogenic virus", "label": "REFUTED", "evidence": ["Due to the mechanisms of SARS-CoV-2 infection to host cells and its pathogenesis remain largely unclear, there are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention.", "In the current study, we have reported that SARS-CoV-2 encoded proteins and some anti-COVID-19 drugs currently used are able to induce lytic reactivation of Kaposis sarcoma- associated herpesvirus (KSHV), one of major human oncogenic viruses through manipulation of intracellular signaling pathways."]}
{"id": 1000785, "claim": "Sars-cov-2 proteins and anti-covid-19 drugs inhibit lytic reactivation of an oncogenic virus", "label": "REFUTED", "evidence": ["Due to the mechanisms of SARS-CoV-2 infection to host cells and its pathogenesis remain largely unclear, there are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention.", "In the current study, we have reported that SARS-CoV-2 encoded proteins and some anti-COVID-19 drugs currently used are able to induce lytic reactivation of Kaposis sarcoma- associated herpesvirus (KSHV), one of major human oncogenic viruses through manipulation of intracellular signaling pathways."]}
{"id": 1000786, "claim": "Sars-cov-2 proteins and anti-covid-19 drugs block lytic reactivation of an oncogenic virus", "label": "REFUTED", "evidence": ["Due to the mechanisms of SARS-CoV-2 infection to host cells and its pathogenesis remain largely unclear, there are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention.", "In the current study, we have reported that SARS-CoV-2 encoded proteins and some anti-COVID-19 drugs currently used are able to induce lytic reactivation of Kaposis sarcoma- associated herpesvirus (KSHV), one of major human oncogenic viruses through manipulation of intracellular signaling pathways."]}
{"id": 1000787, "claim": "Sars-cov-2 d614g variant exhibits efficient replication ex vivo and transmission in vivo", "label": "SUPPORTED", "evidence": ["Using authentic SARS-CoV-2 isogenic variants, we show the role of the D614G substitution in enhancing viral infectivity in immortalized cell lines, growth, and fitness in primary human airway epithelial cells and hamsters, yet it marginally alters viral pathogenesis in hamster and hACE2 mouse models.", "1 SARS-CoV-2 D614G variant shows enhanced infectivity in immortalized cell lines and replication fitness in upper human respiratory epithelia compared with the ancestral WT virus.", "SARS-CoV-2 S pseudotyped viruses encoding the D614G substitution were reported to exhibit increased infectivity in continuous cell lines and increased sensitivity to neutralization ( 4, 5)."]}
{"id": 1000788, "claim": "Sars-cov-2 d614g variant inhibits efficient replication ex vivo and transmission in vivo", "label": "REFUTED", "evidence": ["Using authentic SARS-CoV-2 isogenic variants, we show the role of the D614G substitution in enhancing viral infectivity in immortalized cell lines, growth, and fitness in primary human airway epithelial cells and hamsters, yet it marginally alters viral pathogenesis in hamster and hACE2 mouse models.", "1 SARS-CoV-2 D614G variant shows enhanced infectivity in immortalized cell lines and replication fitness in upper human respiratory epithelia compared with the ancestral WT virus.", "SARS-CoV-2 S pseudotyped viruses encoding the D614G substitution were reported to exhibit increased infectivity in continuous cell lines and increased sensitivity to neutralization ( 4, 5)."]}
{"id": 1000789, "claim": "Sars-cov-2 d614g variant inhibited efficient replication ex vivo and transmission in vivo", "label": "REFUTED", "evidence": ["Using authentic SARS-CoV-2 isogenic variants, we show the role of the D614G substitution in enhancing viral infectivity in immortalized cell lines, growth, and fitness in primary human airway epithelial cells and hamsters, yet it marginally alters viral pathogenesis in hamster and hACE2 mouse models.", "1 SARS-CoV-2 D614G variant shows enhanced infectivity in immortalized cell lines and replication fitness in upper human respiratory epithelia compared with the ancestral WT virus.", "SARS-CoV-2 S pseudotyped viruses encoding the D614G substitution were reported to exhibit increased infectivity in continuous cell lines and increased sensitivity to neutralization ( 4, 5)."]}
{"id": 1000790, "claim": "Researchers identify a protein that may help sars-cov-2 spread rapidly through cells", "label": "SUPPORTED", "evidence": ["The N protein may also be associated with reducing an infected cell's anti- viral stress response.", "view more Credit: Eric Ross and Sean Cascarina/Colorado State University Eric Ross and Sean Cascarina, biochemistry and molecular biology researchers at Colorado State University, have released a research paper identifying a protein encoded by SARS-CoV-2, the virus that causes COVID-19, that may be associated with the quick spread of the virus through cells in the human body."]}
{"id": 1000791, "claim": "Researchers identify a protein that cannot help sars-cov-2 spread rapidly through cells", "label": "REFUTED", "evidence": ["The N protein may also be associated with reducing an infected cell's anti- viral stress response.", "view more Credit: Eric Ross and Sean Cascarina/Colorado State University Eric Ross and Sean Cascarina, biochemistry and molecular biology researchers at Colorado State University, have released a research paper identifying a protein encoded by SARS-CoV-2, the virus that causes COVID-19, that may be associated with the quick spread of the virus through cells in the human body."]}
{"id": 1000792, "claim": "Gilead sciences to donate 1.5 million dose of remdesivir", "label": "SUPPORTED", "evidence": ["The donation to the United States is part of 1.5 million vials of remdesivir the company is donating worldwide.", "Assuming a 10-day treatment course, Gileads donation of 1.5 million individual doses of remdesivir equates to more than 140,000 treatment courses that will be provided at no cost to treat patients following potential emergency authorizations and regulatory approvals, including this EUA.", "Gilead pledged to donate its initial supply of the drug, or 1.5 million doses."]}
{"id": 1000793, "claim": "Gilead sciences to donate 1.5 ml dose of remdesivir", "label": "REFUTED", "evidence": ["The donation to the United States is part of 1.5 million vials of remdesivir the company is donating worldwide.", "Assuming a 10-day treatment course, Gileads donation of 1.5 million individual doses of remdesivir equates to more than 140,000 treatment courses that will be provided at no cost to treat patients following potential emergency authorizations and regulatory approvals, including this EUA.", "Gilead pledged to donate its initial supply of the drug, or 1.5 million doses."]}
{"id": 1000794, "claim": "Gilead sciences to donate 1.5 μg dose of remdesivir", "label": "REFUTED", "evidence": ["The donation to the United States is part of 1.5 million vials of remdesivir the company is donating worldwide.", "Assuming a 10-day treatment course, Gileads donation of 1.5 million individual doses of remdesivir equates to more than 140,000 treatment courses that will be provided at no cost to treat patients following potential emergency authorizations and regulatory approvals, including this EUA.", "Gilead pledged to donate its initial supply of the drug, or 1.5 million doses."]}
{"id": 1000795, "claim": "Gilead sciences to donate 1.5 hour dose of remdesivir", "label": "REFUTED", "evidence": ["The donation to the United States is part of 1.5 million vials of remdesivir the company is donating worldwide.", "Assuming a 10-day treatment course, Gileads donation of 1.5 million individual doses of remdesivir equates to more than 140,000 treatment courses that will be provided at no cost to treat patients following potential emergency authorizations and regulatory approvals, including this EUA.", "Gilead pledged to donate its initial supply of the drug, or 1.5 million doses."]}
{"id": 1000796, "claim": "Cms implements broad regulatory flexibilities to respond to covid-19 national emergency", "label": "SUPPORTED", "evidence": ["CMS is issuing a sweeping array of new rules and waivers of federal requirements to ensure that local hospitals and health systems have the capacity to absorb and effectively manage potential surges of COVID-19 patients.", "COVID-19 Testing expanded : The new CMS guidelines have expanded COVID-19 testing facilities: Healthcare systems, hospitals, and communities can set up exclusive testing and screening sites in order to identify COVID-19 positive patients in a safe environment."]}
{"id": 1000797, "claim": "Cms implements broad health flexibilities to respond to covid-19 national emergency", "label": "REFUTED", "evidence": ["CMS is issuing a sweeping array of new rules and waivers of federal requirements to ensure that local hospitals and health systems have the capacity to absorb and effectively manage potential surges of COVID-19 patients.", "COVID-19 Testing expanded : The new CMS guidelines have expanded COVID-19 testing facilities: Healthcare systems, hospitals, and communities can set up exclusive testing and screening sites in order to identify COVID-19 positive patients in a safe environment."]}
{"id": 1000798, "claim": "Instant coffee covid-19 tests could be the answer to reopening the u.s .", "label": "SUPPORTED", "evidence": ["The coffee analogy is one used by Michael Mina, assistant professor of epidemiology at the Harvard T. H. Chan School of Public Health, and it's meant to describe the functional difference between two approaches to rapid testing for the virus.", "\"Espresso coffee\" tests are reverse transcriptase polymerase chain reaction (RT-PCR) tests or deluxe antigen tests, and several manufacturers, like Mesa Biotech, Quidel and Becton, Dickinson, have already been granted Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA)."]}
{"id": 1000799, "claim": "Instant coffee covid-19 tests cannot be the answer to reopening the u.s.", "label": "REFUTED", "evidence": ["The coffee analogy is one used by Michael Mina, assistant professor of epidemiology at the Harvard T. H. Chan School of Public Health, and it's meant to describe the functional difference between two approaches to rapid testing for the virus.", "\"Espresso coffee\" tests are reverse transcriptase polymerase chain reaction (RT-PCR) tests or deluxe antigen tests, and several manufacturers, like Mesa Biotech, Quidel and Becton, Dickinson, have already been granted Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA)."]}
{"id": 1000800, "claim": "Nitric oxide may slow progression of covid-19", "label": "SUPPORTED", "evidence": ["The authors highlight the potential for inhaled nitric oxide contributing to better clinical outcomes and alleviating the rapidly rising strain on health care capacity due to COVID-19.", "The authors suggest that if nitric oxides efficacy is illustrated for COVID-19, its use as a treatment can be pivotal in the fight against the pandemic."]}
{"id": 1000801, "claim": "Nitric oxide may promote progression of covid-19", "label": "REFUTED", "evidence": ["The authors highlight the potential for inhaled nitric oxide contributing to better clinical outcomes and alleviating the rapidly rising strain on health care capacity due to COVID-19.", "The authors suggest that if nitric oxides efficacy is illustrated for COVID-19, its use as a treatment can be pivotal in the fight against the pandemic."]}
{"id": 1000802, "claim": "Nitric oxide may facilitate progression of covid-19", "label": "REFUTED", "evidence": ["The authors highlight the potential for inhaled nitric oxide contributing to better clinical outcomes and alleviating the rapidly rising strain on health care capacity due to COVID-19.", "The authors suggest that if nitric oxides efficacy is illustrated for COVID-19, its use as a treatment can be pivotal in the fight against the pandemic."]}
{"id": 1000803, "claim": "Nitric oxide may improve progression of covid-19", "label": "REFUTED", "evidence": ["The authors highlight the potential for inhaled nitric oxide contributing to better clinical outcomes and alleviating the rapidly rising strain on health care capacity due to COVID-19.", "The authors suggest that if nitric oxides efficacy is illustrated for COVID-19, its use as a treatment can be pivotal in the fight against the pandemic."]}
{"id": 1000804, "claim": "Humoral and circulating follicular helper t cell responses in recovered patients with covid-19", "label": "SUPPORTED", "evidence": ["Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors.", "Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications.", "In this study, we characterized humoral and circulating follicular helper T cell (cTFH) immunity against spike in recovered patients with coronavirus disease 2019 (COVID-19)."]}
{"id": 1000805, "claim": "Humoral and circulating follicular helper t cell responses in septic patients with covid-19", "label": "REFUTED", "evidence": ["Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors.", "Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications.", "In this study, we characterized humoral and circulating follicular helper T cell (cTFH) immunity against spike in recovered patients with coronavirus disease 2019 (COVID-19)."]}
{"id": 1000806, "claim": "Humoral and circulating follicular helper t cell responses in immunocompromised patients with covid-19", "label": "REFUTED", "evidence": ["Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors.", "Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications.", "In this study, we characterized humoral and circulating follicular helper T cell (cTFH) immunity against spike in recovered patients with coronavirus disease 2019 (COVID-19)."]}
{"id": 1000807, "claim": "A study from the 2003 sars outbreak , and a recent corona virus case , suggest buildings with older faulty plumbing can transmit the disease to people on separate floors .", "label": "SUPPORTED", "evidence": ["During the 2003 SARS crisis, at Amoy Gardens the U-shaped pipe traps connecting to the floor drains were empty of water, allowing droplets containing viruses to come down the pipes from other apartments to collect in the U-bend.", "The bathrooms in the apartments had floor drains for cleaning, and when the U-shaped traps beneath these drains dried out, aerosolized SARS virus from the sick resident reached apartments through an air shaft.", "In 2003, during the outbreak of severe acute respiratory syndrome, or SARS (which is also caused by a coronavirus) officials found that the virus was likely transmitted in a Hong Kong apartment tower called Amoy Gardens through faulty plumbing, according to the World Health Organization.", "The case echoes a 2003 outbreak of severe acute respiratory syndrome (SARS) that spread through the pipes of a Hong Kong apartment buildingand some worry that transmission via toilets might have contributed to the COVID-19 outbreak that shut down New York City early in the pandemic."]}
{"id": 1000808, "claim": "A study from the first sars outbreak, and a recent corona virus case, suggest buildings with older faulty plumbing can transmit the disease to people on separate floors.", "label": "REFUTED", "evidence": ["During the 2003 SARS crisis, at Amoy Gardens the U-shaped pipe traps connecting to the floor drains were empty of water, allowing droplets containing viruses to come down the pipes from other apartments to collect in the U-bend.", "The bathrooms in the apartments had floor drains for cleaning, and when the U-shaped traps beneath these drains dried out, aerosolized SARS virus from the sick resident reached apartments through an air shaft.", "In 2003, during the outbreak of severe acute respiratory syndrome, or SARS (which is also caused by a coronavirus) officials found that the virus was likely transmitted in a Hong Kong apartment tower called Amoy Gardens through faulty plumbing, according to the World Health Organization.", "The case echoes a 2003 outbreak of severe acute respiratory syndrome (SARS) that spread through the pipes of a Hong Kong apartment buildingand some worry that transmission via toilets might have contributed to the COVID-19 outbreak that shut down New York City early in the pandemic."]}
{"id": 1000809, "claim": "A study from the 2014 sars outbreak, and a recent corona virus case, suggest buildings with older faulty plumbing can transmit the disease to people on separate floors.", "label": "REFUTED", "evidence": ["During the 2003 SARS crisis, at Amoy Gardens the U-shaped pipe traps connecting to the floor drains were empty of water, allowing droplets containing viruses to come down the pipes from other apartments to collect in the U-bend.", "The bathrooms in the apartments had floor drains for cleaning, and when the U-shaped traps beneath these drains dried out, aerosolized SARS virus from the sick resident reached apartments through an air shaft.", "In 2003, during the outbreak of severe acute respiratory syndrome, or SARS (which is also caused by a coronavirus) officials found that the virus was likely transmitted in a Hong Kong apartment tower called Amoy Gardens through faulty plumbing, according to the World Health Organization.", "The case echoes a 2003 outbreak of severe acute respiratory syndrome (SARS) that spread through the pipes of a Hong Kong apartment buildingand some worry that transmission via toilets might have contributed to the COVID-19 outbreak that shut down New York City early in the pandemic."]}
{"id": 1000810, "claim": "A study from the ebola sars outbreak, and a recent corona virus case, suggest buildings with older faulty plumbing can transmit the disease to people on separate floors.", "label": "REFUTED", "evidence": ["During the 2003 SARS crisis, at Amoy Gardens the U-shaped pipe traps connecting to the floor drains were empty of water, allowing droplets containing viruses to come down the pipes from other apartments to collect in the U-bend.", "The bathrooms in the apartments had floor drains for cleaning, and when the U-shaped traps beneath these drains dried out, aerosolized SARS virus from the sick resident reached apartments through an air shaft.", "In 2003, during the outbreak of severe acute respiratory syndrome, or SARS (which is also caused by a coronavirus) officials found that the virus was likely transmitted in a Hong Kong apartment tower called Amoy Gardens through faulty plumbing, according to the World Health Organization.", "The case echoes a 2003 outbreak of severe acute respiratory syndrome (SARS) that spread through the pipes of a Hong Kong apartment buildingand some worry that transmission via toilets might have contributed to the COVID-19 outbreak that shut down New York City early in the pandemic."]}
{"id": 1000811, "claim": "Sars-cov-2 lethality decreased over time in two italian provinces", "label": "SUPPORTED", "evidence": ["Some experts recently reported that SARS-CoV-2 lethality decreased considerably, but no evidence is yet available.", "We carried out a retrospective cohort study on 2493 SARS-CoV-2 infected subjects from two Italian provinces, evaluating the potential variation of the case-fatality rate over time."]}
{"id": 1000812, "claim": "Sars-cov-2 lethality increased over time in two italian provinces", "label": "REFUTED", "evidence": ["Some experts recently reported that SARS-CoV-2 lethality decreased considerably, but no evidence is yet available.", "We carried out a retrospective cohort study on 2493 SARS-CoV-2 infected subjects from two Italian provinces, evaluating the potential variation of the case-fatality rate over time."]}
{"id": 1000813, "claim": "Sars-cov-2 lethality increases over time in two italian provinces", "label": "REFUTED", "evidence": ["Some experts recently reported that SARS-CoV-2 lethality decreased considerably, but no evidence is yet available.", "We carried out a retrospective cohort study on 2493 SARS-CoV-2 infected subjects from two Italian provinces, evaluating the potential variation of the case-fatality rate over time."]}
{"id": 1000814, "claim": "Sars-cov-2 lethality peaked over time in two italian provinces", "label": "REFUTED", "evidence": ["Some experts recently reported that SARS-CoV-2 lethality decreased considerably, but no evidence is yet available.", "We carried out a retrospective cohort study on 2493 SARS-CoV-2 infected subjects from two Italian provinces, evaluating the potential variation of the case-fatality rate over time."]}
{"id": 1000815, "claim": "Fruitful neutralizing antibody pipeline brings hope to defeat sars-cov-2", "label": "SUPPORTED", "evidence": ["We discuss these neutralizing antibodies in COVID-19 and highlight how the robust antibody pipeline can help to combat the escape strategies presented by SARS-CoV-2.", "Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies."]}
{"id": 1000816, "claim": "Fruitful neutralizing antibody pipeline brings hope to create sars-cov-2", "label": "REFUTED", "evidence": ["We discuss these neutralizing antibodies in COVID-19 and highlight how the robust antibody pipeline can help to combat the escape strategies presented by SARS-CoV-2.", "Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies."]}
{"id": 1000817, "claim": "Fruitful neutralizing antibody pipeline brings hope to build sars-cov-2", "label": "REFUTED", "evidence": ["We discuss these neutralizing antibodies in COVID-19 and highlight how the robust antibody pipeline can help to combat the escape strategies presented by SARS-CoV-2.", "Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies."]}
{"id": 1000818, "claim": "Fruitful neutralizing antibody pipeline brings hope to generate sars-cov-2", "label": "REFUTED", "evidence": ["We discuss these neutralizing antibodies in COVID-19 and highlight how the robust antibody pipeline can help to combat the escape strategies presented by SARS-CoV-2.", "Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies."]}
{"id": 1000819, "claim": "Reduced prevalence of sars-cov-2 infection in abo blood group o", "label": "SUPPORTED", "evidence": ["This study identifies ABO blood group as a risk factor for SARS-CoV-2 infection but not for hospitalization or death from COVID-19.", "PMID: 32562665 Association between ABO blood groups and risk of SARS-CoV-2 pneumonia."]}
{"id": 1000820, "claim": "Increased prevalence of sars-cov-2 infection in abo blood group o", "label": "REFUTED", "evidence": ["This study identifies ABO blood group as a risk factor for SARS-CoV-2 infection but not for hospitalization or death from COVID-19.", "PMID: 32562665 Association between ABO blood groups and risk of SARS-CoV-2 pneumonia."]}
{"id": 1000821, "claim": "High prevalence of sars-cov-2 infection in abo blood group o", "label": "REFUTED", "evidence": ["This study identifies ABO blood group as a risk factor for SARS-CoV-2 infection but not for hospitalization or death from COVID-19.", "PMID: 32562665 Association between ABO blood groups and risk of SARS-CoV-2 pneumonia."]}
{"id": 1000822, "claim": "Higher prevalence of sars-cov-2 infection in abo blood group o", "label": "REFUTED", "evidence": ["This study identifies ABO blood group as a risk factor for SARS-CoV-2 infection but not for hospitalization or death from COVID-19.", "PMID: 32562665 Association between ABO blood groups and risk of SARS-CoV-2 pneumonia."]}
{"id": 1000823, "claim": "Who and unicef to partner on pandemic response through covid-19 solidarity response fund", "label": "SUPPORTED", "evidence": ["CEPI , the Coalition for Epidemic Preparedness Innovations, a key partner leading the financing for research and development for novel vaccines to combat COVID-19, working closely with WHO.", "As a key partner in this joined-up effort, UNICEF will lead emergency efforts to ensure families and communities in the most vulnerable countries are fully engaged in the response and have access to water, sanitation and hygiene and other infection prevention and control measures.", "UNICEF , to ensure children and families around the world are equipped with all the evidence-based information and latest WHO guidance as well as locally relevant information to protect themselves from the spread of COVID-19; to support vulnerable countries by providing access to water, sanitation and hygiene, and basic infection prevention and control measures; and to provide access to care for vulnerable families and children."]}
{"id": 1000824, "claim": "China and unicef to partner on pandemic response through covid-19 solidarity response fund", "label": "REFUTED", "evidence": ["CEPI , the Coalition for Epidemic Preparedness Innovations, a key partner leading the financing for research and development for novel vaccines to combat COVID-19, working closely with WHO.", "As a key partner in this joined-up effort, UNICEF will lead emergency efforts to ensure families and communities in the most vulnerable countries are fully engaged in the response and have access to water, sanitation and hygiene and other infection prevention and control measures.", "UNICEF , to ensure children and families around the world are equipped with all the evidence-based information and latest WHO guidance as well as locally relevant information to protect themselves from the spread of COVID-19; to support vulnerable countries by providing access to water, sanitation and hygiene, and basic infection prevention and control measures; and to provide access to care for vulnerable families and children."]}
{"id": 1000825, "claim": "Young kids could spread covid-19 as much as older children and adults", "label": "SUPPORTED", "evidence": ["Findings, published in JAMA Pediatrics, point to the possibility that the youngest children transmit the virus as much as other age groups.", "\"Our study was not designed to prove that younger children spread COVID-19 as much as adults, but it is a possibility,\" says Dr. Heald-Sargent.", "The ability of younger children to spread COVID-19 may have been under-recognized given the rapid and sustained closure of schools and daycare during the pandemic.", "\"We found that children under 5 with COVID-19 have a higher viral load than older children and adults, which may suggest greater transmission, as we see with respiratory syncytial virus, also known as RSV,\" says lead author Taylor Heald-Sargent, MD, PhD, pediatric infectious diseases specialist at Lurie Children's and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine."]}
{"id": 1000826, "claim": "Young kids could reduce covid-19 as much as older children and adults", "label": "REFUTED", "evidence": ["Findings, published in JAMA Pediatrics, point to the possibility that the youngest children transmit the virus as much as other age groups.", "\"Our study was not designed to prove that younger children spread COVID-19 as much as adults, but it is a possibility,\" says Dr. Heald-Sargent.", "The ability of younger children to spread COVID-19 may have been under-recognized given the rapid and sustained closure of schools and daycare during the pandemic.", "\"We found that children under 5 with COVID-19 have a higher viral load than older children and adults, which may suggest greater transmission, as we see with respiratory syncytial virus, also known as RSV,\" says lead author Taylor Heald-Sargent, MD, PhD, pediatric infectious diseases specialist at Lurie Children's and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine."]}
{"id": 1000827, "claim": "Sars-cov-2 elicits robust adaptive immune responses regardless of disease severity", "label": "SUPPORTED", "evidence": ["Overall, the majority of patients had robust adaptive immune responses, regardless of disease severity.", "SARS-CoV-2 specific CD8+ T-cell responses were clear and quantifiable in 90% of HLA-A2+ individuals.", "We investigated the breadth and potency of antibody-, and T-cell immune responses, in 203 recovered SARS-CoV-2 infected patients who presented with asymptomatic to severe infections.", "These data support the possibility of achieving protective immunity through natural infection and bode well for the prospects of inducing immunological memory through vaccination.", "To understand the immunological signature of SARS-CoV-2 infections and aid the search for treatments and vaccines, comprehensive characterization of adaptive immune responses towards SARS-CoV-2 is needed."]}
{"id": 1000828, "claim": "Sars-cov-2 elicits robust adaptive immune responses indicative of disease severity", "label": "REFUTED", "evidence": ["Overall, the majority of patients had robust adaptive immune responses, regardless of disease severity.", "SARS-CoV-2 specific CD8+ T-cell responses were clear and quantifiable in 90% of HLA-A2+ individuals.", "We investigated the breadth and potency of antibody-, and T-cell immune responses, in 203 recovered SARS-CoV-2 infected patients who presented with asymptomatic to severe infections.", "These data support the possibility of achieving protective immunity through natural infection and bode well for the prospects of inducing immunological memory through vaccination.", "To understand the immunological signature of SARS-CoV-2 infections and aid the search for treatments and vaccines, comprehensive characterization of adaptive immune responses towards SARS-CoV-2 is needed."]}
{"id": 1000829, "claim": "Sars-cov-2 elicits robust adaptive immune responses because of disease severity", "label": "REFUTED", "evidence": ["Overall, the majority of patients had robust adaptive immune responses, regardless of disease severity.", "SARS-CoV-2 specific CD8+ T-cell responses were clear and quantifiable in 90% of HLA-A2+ individuals.", "We investigated the breadth and potency of antibody-, and T-cell immune responses, in 203 recovered SARS-CoV-2 infected patients who presented with asymptomatic to severe infections.", "These data support the possibility of achieving protective immunity through natural infection and bode well for the prospects of inducing immunological memory through vaccination.", "To understand the immunological signature of SARS-CoV-2 infections and aid the search for treatments and vaccines, comprehensive characterization of adaptive immune responses towards SARS-CoV-2 is needed."]}
{"id": 1000830, "claim": "Sars-cov-2 elicits robust adaptive immune responses characteristic of disease severity", "label": "REFUTED", "evidence": ["Overall, the majority of patients had robust adaptive immune responses, regardless of disease severity.", "SARS-CoV-2 specific CD8+ T-cell responses were clear and quantifiable in 90% of HLA-A2+ individuals.", "We investigated the breadth and potency of antibody-, and T-cell immune responses, in 203 recovered SARS-CoV-2 infected patients who presented with asymptomatic to severe infections.", "These data support the possibility of achieving protective immunity through natural infection and bode well for the prospects of inducing immunological memory through vaccination.", "To understand the immunological signature of SARS-CoV-2 infections and aid the search for treatments and vaccines, comprehensive characterization of adaptive immune responses towards SARS-CoV-2 is needed."]}
{"id": 1000831, "claim": "Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of hiv-1 and dengue virus", "label": "SUPPORTED", "evidence": ["Ivermectin inhibits Impα/β1- but not Impβ1-dependent nuclear import, whereas mifepristone specifically inhibits IN Figure 1.", "Importantly, we establish for the first time that ivermectin has potent antiviral activity towards both HIV-1 and dengue virus, both of which are strongly reliant on importin α/β nuclear import, with respect to the HIV-1 integrase and NS5 (non-structural protein 5) polymerase proteins respectively.", "Ivermectin can inhibit HIV-1 and Figure 3."]}
{"id": 1000832, "claim": "Ivermectin is a common inhibitor of importin α/β-mediated nuclear import able to inhibit replication of hiv-1 and dengue virus", "label": "REFUTED", "evidence": ["Ivermectin inhibits Impα/β1- but not Impβ1-dependent nuclear import, whereas mifepristone specifically inhibits IN Figure 1.", "Importantly, we establish for the first time that ivermectin has potent antiviral activity towards both HIV-1 and dengue virus, both of which are strongly reliant on importin α/β nuclear import, with respect to the HIV-1 integrase and NS5 (non-structural protein 5) polymerase proteins respectively.", "Ivermectin can inhibit HIV-1 and Figure 3."]}
{"id": 1000833, "claim": "Ivermectin is a potential inhibitor of importin α/β-mediated nuclear import able to inhibit replication of hiv-1 and dengue virus", "label": "REFUTED", "evidence": ["Ivermectin inhibits Impα/β1- but not Impβ1-dependent nuclear import, whereas mifepristone specifically inhibits IN Figure 1.", "Importantly, we establish for the first time that ivermectin has potent antiviral activity towards both HIV-1 and dengue virus, both of which are strongly reliant on importin α/β nuclear import, with respect to the HIV-1 integrase and NS5 (non-structural protein 5) polymerase proteins respectively.", "Ivermectin can inhibit HIV-1 and Figure 3."]}
{"id": 1000834, "claim": "Ivermectin is a novel inhibitor of importin α/β-mediated nuclear import able to inhibit replication of hiv-1 and dengue virus", "label": "REFUTED", "evidence": ["Ivermectin inhibits Impα/β1- but not Impβ1-dependent nuclear import, whereas mifepristone specifically inhibits IN Figure 1.", "Importantly, we establish for the first time that ivermectin has potent antiviral activity towards both HIV-1 and dengue virus, both of which are strongly reliant on importin α/β nuclear import, with respect to the HIV-1 integrase and NS5 (non-structural protein 5) polymerase proteins respectively.", "Ivermectin can inhibit HIV-1 and Figure 3."]}
{"id": 1000835, "claim": "Weekly covid-19 testing with household quarantine and contact tracing is feasible and would probably end the epidemic", "label": "SUPPORTED", "evidence": ["Self-quarantine as soon as COVID-19 symptoms are noticed will further reduce transmissions.", "This large contribution to epidemic growth would be almost eliminated by strict household quarantine."]}
{"id": 1000836, "claim": "Weekly covid-19 testing with household quarantine and contact tracing is feasible and would not end the epidemic", "label": "REFUTED", "evidence": ["Self-quarantine as soon as COVID-19 symptoms are noticed will further reduce transmissions.", "This large contribution to epidemic growth would be almost eliminated by strict household quarantine."]}
{"id": 1000837, "claim": "Weekly covid-19 testing with household quarantine and contact tracing is limited and would probably end the epidemic", "label": "REFUTED", "evidence": ["Self-quarantine as soon as COVID-19 symptoms are noticed will further reduce transmissions.", "This large contribution to epidemic growth would be almost eliminated by strict household quarantine."]}
{"id": 1000838, "claim": "Weekly covid-19 testing with household quarantine and contact tracing is difficult and would probably end the epidemic", "label": "REFUTED", "evidence": ["Self-quarantine as soon as COVID-19 symptoms are noticed will further reduce transmissions.", "This large contribution to epidemic growth would be almost eliminated by strict household quarantine."]}
{"id": 1000839, "claim": "An infectivity-enhancing site on the sars-cov-2 spike protein is targeted by covid-19 patient antibodies.", "label": "SUPPORTED", "evidence": ["Enhancement of SARS-CoV-2 infection of primary B cells by COVID-19 patient plasma.", "These findings suggest that the production of antibodies against SARS-CoV-2 infectivity-enhancing site could be considered as a possible exacerbating factors for COVID-19 and that a spike protein lacking such antibody epitopes may be required for safe vaccine development, especially for individuals with pre-existing enhancing antibodies.", "COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses.", "Here we reported the observation of in vitro ADE of SARS-CoV-2 entry into FcγRII receptor-bearing cells by plasma and antibodies from patients who recovered from COVID-19.", "Antibody responses to SARS-CoV-2 in patients with COVID-19."]}
{"id": 1000840, "claim": "An infectivity-independent site on the sars-cov-2 spike protein is targeted by covid-19 patient antibodies.", "label": "REFUTED", "evidence": ["Enhancement of SARS-CoV-2 infection of primary B cells by COVID-19 patient plasma.", "These findings suggest that the production of antibodies against SARS-CoV-2 infectivity-enhancing site could be considered as a possible exacerbating factors for COVID-19 and that a spike protein lacking such antibody epitopes may be required for safe vaccine development, especially for individuals with pre-existing enhancing antibodies.", "COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses.", "Here we reported the observation of in vitro ADE of SARS-CoV-2 entry into FcγRII receptor-bearing cells by plasma and antibodies from patients who recovered from COVID-19.", "Antibody responses to SARS-CoV-2 in patients with COVID-19."]}
{"id": 1000841, "claim": "Darpa races to create firebreak treatment for the coronavirus", "label": "SUPPORTED", "evidence": ["Now, DARPA is racing against time as experts warn of a likely second wave of the coronavirus this fall."]}
{"id": 1000842, "claim": "Darpa races to receive firebreak treatment for the coronavirus", "label": "REFUTED", "evidence": ["Now, DARPA is racing against time as experts warn of a likely second wave of the coronavirus this fall."]}
{"id": 1000843, "claim": "Darpa races to avoid firebreak treatment for the coronavirus", "label": "REFUTED", "evidence": ["Now, DARPA is racing against time as experts warn of a likely second wave of the coronavirus this fall."]}
{"id": 1000844, "claim": "Darpa races to prevent firebreak treatment for the coronavirus", "label": "REFUTED", "evidence": ["Now, DARPA is racing against time as experts warn of a likely second wave of the coronavirus this fall."]}
{"id": 1000845, "claim": "Quebec seeks to avoid impending shortage of masks for health-care workers", "label": "SUPPORTED", "evidence": ["Here's a list COVID-19 in Quebec: a look back at 2020, the year of the novel coronavirus See current wait times at Quebec COVID-19 testing sites See the map: Tracking COVID-19 cases across Montreal See the map: Tracking COVID-19 cases across Quebec Tracking every case of COVID-19 in Canada SHARE Report Error Editorial standards and policies Why you can trust CTV News ", "Mask reserves are running out quickly right when the province anticipates a significant increase in the number of hospitalizations required in the coming weeks.", "Nurses, doctors and other members of the health network must now comply with the instruction to wear a mask only when it is absolutely necessary, Premier Francois Legault ordered on Monday during his daily COVID-19 update on the health crisis.", "Now is the time for rationing, advocating a judicious use of masks - both procedural masks and the N95, said Minister of Health Danielle McCann."]}
{"id": 1000846, "claim": "Quebec began to avoid impending shortage of masks for health-care workers", "label": "REFUTED", "evidence": ["Here's a list COVID-19 in Quebec: a look back at 2020, the year of the novel coronavirus See current wait times at Quebec COVID-19 testing sites See the map: Tracking COVID-19 cases across Montreal See the map: Tracking COVID-19 cases across Quebec Tracking every case of COVID-19 in Canada SHARE Report Error Editorial standards and policies Why you can trust CTV News ", "Mask reserves are running out quickly right when the province anticipates a significant increase in the number of hospitalizations required in the coming weeks.", "Nurses, doctors and other members of the health network must now comply with the instruction to wear a mask only when it is absolutely necessary, Premier Francois Legault ordered on Monday during his daily COVID-19 update on the health crisis.", "Now is the time for rationing, advocating a judicious use of masks - both procedural masks and the N95, said Minister of Health Danielle McCann."]}
{"id": 1000847, "claim": "Quebec seeks to increase impending shortage of masks for health-care workers", "label": "REFUTED", "evidence": ["Here's a list COVID-19 in Quebec: a look back at 2020, the year of the novel coronavirus See current wait times at Quebec COVID-19 testing sites See the map: Tracking COVID-19 cases across Montreal See the map: Tracking COVID-19 cases across Quebec Tracking every case of COVID-19 in Canada SHARE Report Error Editorial standards and policies Why you can trust CTV News ", "Mask reserves are running out quickly right when the province anticipates a significant increase in the number of hospitalizations required in the coming weeks.", "Nurses, doctors and other members of the health network must now comply with the instruction to wear a mask only when it is absolutely necessary, Premier Francois Legault ordered on Monday during his daily COVID-19 update on the health crisis.", "Now is the time for rationing, advocating a judicious use of masks - both procedural masks and the N95, said Minister of Health Danielle McCann."]}
{"id": 1000848, "claim": "Quebec started to avoid impending shortage of masks for health-care workers", "label": "REFUTED", "evidence": ["Here's a list COVID-19 in Quebec: a look back at 2020, the year of the novel coronavirus See current wait times at Quebec COVID-19 testing sites See the map: Tracking COVID-19 cases across Montreal See the map: Tracking COVID-19 cases across Quebec Tracking every case of COVID-19 in Canada SHARE Report Error Editorial standards and policies Why you can trust CTV News ", "Mask reserves are running out quickly right when the province anticipates a significant increase in the number of hospitalizations required in the coming weeks.", "Nurses, doctors and other members of the health network must now comply with the instruction to wear a mask only when it is absolutely necessary, Premier Francois Legault ordered on Monday during his daily COVID-19 update on the health crisis.", "Now is the time for rationing, advocating a judicious use of masks - both procedural masks and the N95, said Minister of Health Danielle McCann."]}
{"id": 1000849, "claim": "Molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event", "label": "SUPPORTED", "evidence": ["This is the first animal-human zoonotic pair of coronaviruses that can be analyzed in order to gain insights into the processes of adaptation of a nonhuman coronavirus to a human host, which is important for understanding the interspecies transmission events that led to the origin of the severe acute respiratory syndrome outbreak."]}
{"id": 1000850, "claim": "Molecular sequencing analysis suggests a relatively recent zoonotic coronavirus transmission event", "label": "REFUTED", "evidence": ["This is the first animal-human zoonotic pair of coronaviruses that can be analyzed in order to gain insights into the processes of adaptation of a nonhuman coronavirus to a human host, which is important for understanding the interspecies transmission events that led to the origin of the severe acute respiratory syndrome outbreak."]}
{"id": 1000851, "claim": "Molecular genetic analysis suggests a relatively recent zoonotic coronavirus transmission event", "label": "REFUTED", "evidence": ["This is the first animal-human zoonotic pair of coronaviruses that can be analyzed in order to gain insights into the processes of adaptation of a nonhuman coronavirus to a human host, which is important for understanding the interspecies transmission events that led to the origin of the severe acute respiratory syndrome outbreak."]}
{"id": 1000852, "claim": "Molecular spectrometry analysis suggests a relatively recent zoonotic coronavirus transmission event", "label": "REFUTED", "evidence": ["This is the first animal-human zoonotic pair of coronaviruses that can be analyzed in order to gain insights into the processes of adaptation of a nonhuman coronavirus to a human host, which is important for understanding the interspecies transmission events that led to the origin of the severe acute respiratory syndrome outbreak."]}
{"id": 1000853, "claim": "Poor correlation between antibody titers and neutralizing activity in sera from sars-cov-2 infected subjects", "label": "SUPPORTED", "evidence": ["Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study."]}
{"id": 1000854, "claim": "Significant correlation between antibody titers and neutralizing activity in sera from sars-cov-2 infected subjects", "label": "REFUTED", "evidence": ["Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study."]}
{"id": 1000855, "claim": "This correlation between antibody titers and neutralizing activity in sera from sars-cov-2 infected subjects", "label": "REFUTED", "evidence": ["Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study."]}
{"id": 1000856, "claim": "In correlation between antibody titers and neutralizing activity in sera from sars-cov-2 infected subjects", "label": "REFUTED", "evidence": ["Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study."]}
{"id": 1000857, "claim": "Apple closes all retail stores outside of china - cre herald", "label": "SUPPORTED", "evidence": ["After the starting of Covid-19 outbreak in Wuhan, Apple has closed its factories and stores in this country on February 1 and then applied the same measure for Spain and Italy, which were heavily affected by coronavirus.", "READ ALSO : Apple expands in Austin \"Apples committed donations to the global COVID-19 response, both to help treat those who are sick and to help lessen the economic and community impacts of the pandemic, reached $15 million worldwide,\" said in the statement.", "\"We will be closing all of our retail stores outside of Greater China until March 27,\" said Tim Cook, Apple CEO in the official statement.", "Apple has nearly 460 stores across 21 countries outside of China, including about 270 stores in the U.S. \"In our workplaces and communities, we must do all we can to prevent the spread of COVID-19,\" Cook said on Twitter."]}
{"id": 1000858, "claim": "Apple in all retail stores outside of china - cre herald", "label": "REFUTED", "evidence": ["After the starting of Covid-19 outbreak in Wuhan, Apple has closed its factories and stores in this country on February 1 and then applied the same measure for Spain and Italy, which were heavily affected by coronavirus.", "READ ALSO : Apple expands in Austin \"Apples committed donations to the global COVID-19 response, both to help treat those who are sick and to help lessen the economic and community impacts of the pandemic, reached $15 million worldwide,\" said in the statement.", "\"We will be closing all of our retail stores outside of Greater China until March 27,\" said Tim Cook, Apple CEO in the official statement.", "Apple has nearly 460 stores across 21 countries outside of China, including about 270 stores in the U.S. \"In our workplaces and communities, we must do all we can to prevent the spread of COVID-19,\" Cook said on Twitter."]}
{"id": 1000859, "claim": "Apple is all retail stores outside of china - cre herald", "label": "REFUTED", "evidence": ["After the starting of Covid-19 outbreak in Wuhan, Apple has closed its factories and stores in this country on February 1 and then applied the same measure for Spain and Italy, which were heavily affected by coronavirus.", "READ ALSO : Apple expands in Austin \"Apples committed donations to the global COVID-19 response, both to help treat those who are sick and to help lessen the economic and community impacts of the pandemic, reached $15 million worldwide,\" said in the statement.", "\"We will be closing all of our retail stores outside of Greater China until March 27,\" said Tim Cook, Apple CEO in the official statement.", "Apple has nearly 460 stores across 21 countries outside of China, including about 270 stores in the U.S. \"In our workplaces and communities, we must do all we can to prevent the spread of COVID-19,\" Cook said on Twitter."]}
{"id": 1000860, "claim": "Apple on all retail stores outside of china - cre herald", "label": "REFUTED", "evidence": ["After the starting of Covid-19 outbreak in Wuhan, Apple has closed its factories and stores in this country on February 1 and then applied the same measure for Spain and Italy, which were heavily affected by coronavirus.", "READ ALSO : Apple expands in Austin \"Apples committed donations to the global COVID-19 response, both to help treat those who are sick and to help lessen the economic and community impacts of the pandemic, reached $15 million worldwide,\" said in the statement.", "\"We will be closing all of our retail stores outside of Greater China until March 27,\" said Tim Cook, Apple CEO in the official statement.", "Apple has nearly 460 stores across 21 countries outside of China, including about 270 stores in the U.S. \"In our workplaces and communities, we must do all we can to prevent the spread of COVID-19,\" Cook said on Twitter."]}
{"id": 1000861, "claim": "Epidemiologist looks to the past to predict second post-pandemic 'roaring 20s '.", "label": "SUPPORTED", "evidence": ["Its miraculous. Then, once pandemics end, often there is a period in which people seek out extensive social interaction, and which Christakis predicts will be a second roaring 20s just as after the 1918 flu pandemic.", "He projects that the coronavirus pandemic will be no different, with the world experiencing an economic and social revival rivaling that which followed the 1918 flu pandemic by the year 2024.", "Dr Nicholas Christakis, a social epidemiologist who specializes in behavior patterns, put forward his prediction for life after the pandemic in his new book Apollo's Arrow: The Profound and Enduring Impact of Coronavirus on the Way We Live."]}
{"id": 1000862, "claim": "Epidemiologist looks to the goal to predict second post-pandemic 'roaring 20s '.", "label": "REFUTED", "evidence": ["Its miraculous. Then, once pandemics end, often there is a period in which people seek out extensive social interaction, and which Christakis predicts will be a second roaring 20s just as after the 1918 flu pandemic.", "He projects that the coronavirus pandemic will be no different, with the world experiencing an economic and social revival rivaling that which followed the 1918 flu pandemic by the year 2024.", "Dr Nicholas Christakis, a social epidemiologist who specializes in behavior patterns, put forward his prediction for life after the pandemic in his new book Apollo's Arrow: The Profound and Enduring Impact of Coronavirus on the Way We Live."]}
{"id": 1000863, "claim": "Epidemiologist looks to the right to predict second post-pandemic 'roaring 20s '.", "label": "REFUTED", "evidence": ["Its miraculous. Then, once pandemics end, often there is a period in which people seek out extensive social interaction, and which Christakis predicts will be a second roaring 20s just as after the 1918 flu pandemic.", "He projects that the coronavirus pandemic will be no different, with the world experiencing an economic and social revival rivaling that which followed the 1918 flu pandemic by the year 2024.", "Dr Nicholas Christakis, a social epidemiologist who specializes in behavior patterns, put forward his prediction for life after the pandemic in his new book Apollo's Arrow: The Profound and Enduring Impact of Coronavirus on the Way We Live."]}
{"id": 1000864, "claim": "Epidemiologist looks to the way to predict second post-pandemic 'roaring 20s '.", "label": "REFUTED", "evidence": ["Its miraculous. Then, once pandemics end, often there is a period in which people seek out extensive social interaction, and which Christakis predicts will be a second roaring 20s just as after the 1918 flu pandemic.", "He projects that the coronavirus pandemic will be no different, with the world experiencing an economic and social revival rivaling that which followed the 1918 flu pandemic by the year 2024.", "Dr Nicholas Christakis, a social epidemiologist who specializes in behavior patterns, put forward his prediction for life after the pandemic in his new book Apollo's Arrow: The Profound and Enduring Impact of Coronavirus on the Way We Live."]}
{"id": 1000865, "claim": "Ohio state is moving all classes to digital format until the end of the month at least", "label": "SUPPORTED", "evidence": ["Ohio State University announced late Monday it would be suspending in-person classes through March 30, moving instead to virtual instruction.", "Ohio University announced late Tuesday afternoon that it would move to online learning only through at least March 30."]}
{"id": 1000866, "claim": "Ohio state is moving all classes to digital format until the end of the epidemic at least", "label": "REFUTED", "evidence": ["Ohio State University announced late Monday it would be suspending in-person classes through March 30, moving instead to virtual instruction.", "Ohio University announced late Tuesday afternoon that it would move to online learning only through at least March 30."]}
{"id": 1000867, "claim": "Japanese flu drug 'clearly effective ' in treating coronavirus , says china", "label": "SUPPORTED", "evidence": ["Zhang Xinmin, an official at Chinas science and technology ministry, said favipiravir, developed by a subsidiary of Fujifilm, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients."]}
{"id": 1000868, "claim": "Japanese flu drug 'no effective'in treating coronavirus, says china", "label": "REFUTED", "evidence": ["Zhang Xinmin, an official at Chinas science and technology ministry, said favipiravir, developed by a subsidiary of Fujifilm, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients."]}
{"id": 1000869, "claim": "Avoidance of vitamin d deficiency to slow the covid-19 pandemic", "label": "SUPPORTED", "evidence": ["It is conceivable that vitamin D adequacy denies the virus easy footholds and thereby slows spreading of the contagion.", "This has been thought to decrease the amount of the 7-dehydrocholesterol precursor available for conversion to vitamin D and 25(OH)D level declines accordingly in advanced age.", "In the case of the current COVID-19 pandemic, vitamin D deficiency may provide the virus with an unguarded opening to spread from deficient to deficient individual when there are just too many of them.", "Editorial: low population mortality from COVID-19 in countries South of latitude 35 degrees North supports vitamin D as a factor determining severity."]}
{"id": 1000870, "claim": "Avoidance of vitamin d deficiency to promote the covid-19 pandemic", "label": "REFUTED", "evidence": ["It is conceivable that vitamin D adequacy denies the virus easy footholds and thereby slows spreading of the contagion.", "This has been thought to decrease the amount of the 7-dehydrocholesterol precursor available for conversion to vitamin D and 25(OH)D level declines accordingly in advanced age.", "In the case of the current COVID-19 pandemic, vitamin D deficiency may provide the virus with an unguarded opening to spread from deficient to deficient individual when there are just too many of them.", "Editorial: low population mortality from COVID-19 in countries South of latitude 35 degrees North supports vitamin D as a factor determining severity."]}
{"id": 1000871, "claim": "Avoidance of vitamin d deficiency to increase the covid-19 pandemic", "label": "REFUTED", "evidence": ["It is conceivable that vitamin D adequacy denies the virus easy footholds and thereby slows spreading of the contagion.", "This has been thought to decrease the amount of the 7-dehydrocholesterol precursor available for conversion to vitamin D and 25(OH)D level declines accordingly in advanced age.", "In the case of the current COVID-19 pandemic, vitamin D deficiency may provide the virus with an unguarded opening to spread from deficient to deficient individual when there are just too many of them.", "Editorial: low population mortality from COVID-19 in countries South of latitude 35 degrees North supports vitamin D as a factor determining severity."]}
{"id": 1000872, "claim": "Activation of vitamin d deficiency to slow the covid-19 pandemic", "label": "REFUTED", "evidence": ["It is conceivable that vitamin D adequacy denies the virus easy footholds and thereby slows spreading of the contagion.", "This has been thought to decrease the amount of the 7-dehydrocholesterol precursor available for conversion to vitamin D and 25(OH)D level declines accordingly in advanced age.", "In the case of the current COVID-19 pandemic, vitamin D deficiency may provide the virus with an unguarded opening to spread from deficient to deficient individual when there are just too many of them.", "Editorial: low population mortality from COVID-19 in countries South of latitude 35 degrees North supports vitamin D as a factor determining severity."]}
{"id": 1000873, "claim": "Microwave or autoclave treatments destroy the infectivity of infectious bronchitis virus and avian pneumovirus but allow detection by reverse transcriptase-polymerase chain reaction", "label": "SUPPORTED", "evidence": ["Autoclaving and microwave treatment for as little as 20 sec destroyed the infectivity of all four viruses.", "Microwave treatment appears to be a satisfactory method of inactivating virus while preserving nucleic acid for PCR identification.", "However, both IBV and APV could be detected by reverse transcriptase (RT)-PCR after autoclaving and as long as 5 min microwave treatment (Newcastle disease virus and avian influenza viruses were not tested)."]}
{"id": 1000874, "claim": "Microwave or autoclave cannot destroy the infectivity of infectious bronchitis virus and avian pneumovirus but allow detection by reverse transcriptase-polymerase chain reaction", "label": "REFUTED", "evidence": ["Autoclaving and microwave treatment for as little as 20 sec destroyed the infectivity of all four viruses.", "Microwave treatment appears to be a satisfactory method of inactivating virus while preserving nucleic acid for PCR identification.", "However, both IBV and APV could be detected by reverse transcriptase (RT)-PCR after autoclaving and as long as 5 min microwave treatment (Newcastle disease virus and avian influenza viruses were not tested)."]}
{"id": 1000875, "claim": "Microwave or autoclave not destroy the infectivity of infectious bronchitis virus and avian pneumovirus but allow detection by reverse transcriptase-polymerase chain reaction", "label": "REFUTED", "evidence": ["Autoclaving and microwave treatment for as little as 20 sec destroyed the infectivity of all four viruses.", "Microwave treatment appears to be a satisfactory method of inactivating virus while preserving nucleic acid for PCR identification.", "However, both IBV and APV could be detected by reverse transcriptase (RT)-PCR after autoclaving and as long as 5 min microwave treatment (Newcastle disease virus and avian influenza viruses were not tested)."]}
{"id": 1000876, "claim": "Innate lymphoid cell composition associates with covid-19 disease severity", "label": "SUPPORTED", "evidence": ["The activated ILC profile of COVID-19 patients was associated with soluble inflammatory markers, while frequencies of ILC subsets were correlated with laboratory parameters that reflect the disease severity."]}
{"id": 1000877, "claim": "Acute lymphoid cell composition associates with covid-19 disease severity", "label": "REFUTED", "evidence": ["The activated ILC profile of COVID-19 patients was associated with soluble inflammatory markers, while frequencies of ILC subsets were correlated with laboratory parameters that reflect the disease severity."]}
{"id": 1000878, "claim": "Chronic lymphoid cell composition associates with covid-19 disease severity", "label": "REFUTED", "evidence": ["The activated ILC profile of COVID-19 patients was associated with soluble inflammatory markers, while frequencies of ILC subsets were correlated with laboratory parameters that reflect the disease severity."]}
{"id": 1000879, "claim": "Increased lymphoid cell composition associates with covid-19 disease severity", "label": "REFUTED", "evidence": ["The activated ILC profile of COVID-19 patients was associated with soluble inflammatory markers, while frequencies of ILC subsets were correlated with laboratory parameters that reflect the disease severity."]}
{"id": 1000880, "claim": "Respiratory virus shedding in exhaled breath and efficacy of face masks", "label": "SUPPORTED", "evidence": ["1: Efficacy of surgical face masks in reducing respiratory virus shedding in respiratory droplets and aerosols of symptomatic individuals with coronavirus, influenza virus or rhinovirus infection.", "A subset of participants provided exhaled breath samples for both mask interventions (influenza A virus, n = 7; influenza B virus, n = 2).", "Influenza virus aerosols in human exhaled breath: particle size, culturability, and effect of surgical masks."]}
{"id": 1000881, "claim": "Respiratory virus shedding in acute breath and efficacy of face masks", "label": "REFUTED", "evidence": ["1: Efficacy of surgical face masks in reducing respiratory virus shedding in respiratory droplets and aerosols of symptomatic individuals with coronavirus, influenza virus or rhinovirus infection.", "A subset of participants provided exhaled breath samples for both mask interventions (influenza A virus, n = 7; influenza B virus, n = 2).", "Influenza virus aerosols in human exhaled breath: particle size, culturability, and effect of surgical masks."]}
{"id": 1000882, "claim": "Respiratory virus shedding in lower breath and efficacy of face masks", "label": "REFUTED", "evidence": ["1: Efficacy of surgical face masks in reducing respiratory virus shedding in respiratory droplets and aerosols of symptomatic individuals with coronavirus, influenza virus or rhinovirus infection.", "A subset of participants provided exhaled breath samples for both mask interventions (influenza A virus, n = 7; influenza B virus, n = 2).", "Influenza virus aerosols in human exhaled breath: particle size, culturability, and effect of surgical masks."]}
{"id": 1000883, "claim": "Respiratory virus shedding in reducing breath and efficacy of face masks", "label": "REFUTED", "evidence": ["1: Efficacy of surgical face masks in reducing respiratory virus shedding in respiratory droplets and aerosols of symptomatic individuals with coronavirus, influenza virus or rhinovirus infection.", "A subset of participants provided exhaled breath samples for both mask interventions (influenza A virus, n = 7; influenza B virus, n = 2).", "Influenza virus aerosols in human exhaled breath: particle size, culturability, and effect of surgical masks."]}
{"id": 1000884, "claim": "Raoult 's hydroxychloroquine-covid-19 study did not meet publishing society 's expected standard", "label": "SUPPORTED", "evidence": ["Another preprint by Raoult's group of 80 COVID-19 patients who received hydroxychloroquine and the antibiotic azithromycin similarly received criticism for a lack of control group, the inclusion of asymptomatic carriers, and questionable results.", "The April 3, 2020, notice, from the International Journal of Antimicrobial Agents , states that the March 20 article, Hydroxychloroquine and azithromycin as a treatment of Covid-19: results of an open-label non- randomized clinical trial > does not meet the [International Society of Antimicrobial Chemotherapys] > expected standard, especially relating to the lack of better explanations of > the inclusion criteria and the triage of patients to ensure patient safety."]}
{"id": 1000885, "claim": "Raoult's hydroxychloroquine-covid-19 study did indeed meet publishing society's expected standard", "label": "REFUTED", "evidence": ["Another preprint by Raoult's group of 80 COVID-19 patients who received hydroxychloroquine and the antibiotic azithromycin similarly received criticism for a lack of control group, the inclusion of asymptomatic carriers, and questionable results.", "The April 3, 2020, notice, from the International Journal of Antimicrobial Agents , states that the March 20 article, Hydroxychloroquine and azithromycin as a treatment of Covid-19: results of an open-label non- randomized clinical trial > does not meet the [International Society of Antimicrobial Chemotherapys] > expected standard, especially relating to the lack of better explanations of > the inclusion criteria and the triage of patients to ensure patient safety."]}
{"id": 1000886, "claim": "Raoult's hydroxychloroquine-covid-19 study did also meet publishing society's expected standard", "label": "REFUTED", "evidence": ["Another preprint by Raoult's group of 80 COVID-19 patients who received hydroxychloroquine and the antibiotic azithromycin similarly received criticism for a lack of control group, the inclusion of asymptomatic carriers, and questionable results.", "The April 3, 2020, notice, from the International Journal of Antimicrobial Agents , states that the March 20 article, Hydroxychloroquine and azithromycin as a treatment of Covid-19: results of an open-label non- randomized clinical trial > does not meet the [International Society of Antimicrobial Chemotherapys] > expected standard, especially relating to the lack of better explanations of > the inclusion criteria and the triage of patients to ensure patient safety."]}
{"id": 1000887, "claim": "Raoult's hydroxychloroquine-covid-19 study did still meet publishing society's expected standard", "label": "REFUTED", "evidence": ["Another preprint by Raoult's group of 80 COVID-19 patients who received hydroxychloroquine and the antibiotic azithromycin similarly received criticism for a lack of control group, the inclusion of asymptomatic carriers, and questionable results.", "The April 3, 2020, notice, from the International Journal of Antimicrobial Agents , states that the March 20 article, Hydroxychloroquine and azithromycin as a treatment of Covid-19: results of an open-label non- randomized clinical trial > does not meet the [International Society of Antimicrobial Chemotherapys] > expected standard, especially relating to the lack of better explanations of > the inclusion criteria and the triage of patients to ensure patient safety."]}
{"id": 1000888, "claim": "Synergism of tnf-α and ifn-γ triggers inflammatory cell death , tissue damage , and mortality in sars-cov-2 infection and cytokine shock syndromes", "label": "SUPPORTED", "evidence": ["In vivo neutralization of both TNF-α and IFN-γ in multiple disease models associated with cytokine storm showed that this treatment provided substantial protection against not only SARS-CoV-2 infection, but also sepsis, hemophagocytic lymphohistiocytosis, and cytokine shock models, demonstrating the broad physiological relevance of this mechanism."]}
{"id": 1000889, "claim": "Synergism of tnf-α and ifn-γ reduces inflammatory cell death, tissue damage, and mortality in sars-cov-2 infection and cytokine shock syndromes", "label": "REFUTED", "evidence": ["In vivo neutralization of both TNF-α and IFN-γ in multiple disease models associated with cytokine storm showed that this treatment provided substantial protection against not only SARS-CoV-2 infection, but also sepsis, hemophagocytic lymphohistiocytosis, and cytokine shock models, demonstrating the broad physiological relevance of this mechanism."]}
{"id": 1000890, "claim": "Co-infection of influenza a virus enhances sars-cov-2 infectivity", "label": "SUPPORTED", "evidence": ["Through experimental co-infection of IAV with either pseudotyped or SARS-CoV-2 live virus, we found that IAV pre-infection significantly promoted the infectivity of SARS-CoV-2 in a broad range of cell types.", "IAV promotes SARS-CoV-2 virus infectivity.", "The unique feature for IAV to augment SARS-CoV-2 infectivity indicates that the influenza virus is the key pathogen of prevention and control during the current coronavirus pandemic."]}
{"id": 1000891, "claim": "Co-infection of influenza a virus cans sars-cov-2 infectivity", "label": "REFUTED", "evidence": ["Through experimental co-infection of IAV with either pseudotyped or SARS-CoV-2 live virus, we found that IAV pre-infection significantly promoted the infectivity of SARS-CoV-2 in a broad range of cell types.", "IAV promotes SARS-CoV-2 virus infectivity.", "The unique feature for IAV to augment SARS-CoV-2 infectivity indicates that the influenza virus is the key pathogen of prevention and control during the current coronavirus pandemic."]}
{"id": 1000892, "claim": "Belief in covid-19 conspiracy theories reduces social distancing over time", "label": "SUPPORTED", "evidence": ["PMID: 33225745 Cultural orientation, power, belief in conspiracy theories, and intentions to reduce the spread of COVID-19.", "Keywords: COVID-19; conspiracy theories; longitudinal; social distancing.", "Conclusions: Our findings show that COVID-19 conspiracy theories pose a significant threat to public health as they may reduce adherence to social distancing measures.", "Results: Multivariate growth curve analyses showed that, although conspiracy beliefs decreased and social distancing increased over time, people holding more conspiracy beliefs at the beginning of the pandemic showed the lowest increase in social distancing.", "Moreover, cross-lagged analyses demonstrated that people who reported more conspiracy beliefs at any wave tended to report less social distancing at the following wave."]}
{"id": 1000893, "claim": "Belief in covid-19 conspiracy theories include social distancing over time", "label": "REFUTED", "evidence": ["PMID: 33225745 Cultural orientation, power, belief in conspiracy theories, and intentions to reduce the spread of COVID-19.", "Keywords: COVID-19; conspiracy theories; longitudinal; social distancing.", "Conclusions: Our findings show that COVID-19 conspiracy theories pose a significant threat to public health as they may reduce adherence to social distancing measures.", "Results: Multivariate growth curve analyses showed that, although conspiracy beliefs decreased and social distancing increased over time, people holding more conspiracy beliefs at the beginning of the pandemic showed the lowest increase in social distancing.", "Moreover, cross-lagged analyses demonstrated that people who reported more conspiracy beliefs at any wave tended to report less social distancing at the following wave."]}
{"id": 1000894, "claim": "Belief in covid-19 conspiracy theories are social distancing over time", "label": "REFUTED", "evidence": ["PMID: 33225745 Cultural orientation, power, belief in conspiracy theories, and intentions to reduce the spread of COVID-19.", "Keywords: COVID-19; conspiracy theories; longitudinal; social distancing.", "Conclusions: Our findings show that COVID-19 conspiracy theories pose a significant threat to public health as they may reduce adherence to social distancing measures.", "Results: Multivariate growth curve analyses showed that, although conspiracy beliefs decreased and social distancing increased over time, people holding more conspiracy beliefs at the beginning of the pandemic showed the lowest increase in social distancing.", "Moreover, cross-lagged analyses demonstrated that people who reported more conspiracy beliefs at any wave tended to report less social distancing at the following wave."]}
{"id": 1000895, "claim": "Belief in covid-19 conspiracy theories and social distancing over time", "label": "REFUTED", "evidence": ["PMID: 33225745 Cultural orientation, power, belief in conspiracy theories, and intentions to reduce the spread of COVID-19.", "Keywords: COVID-19; conspiracy theories; longitudinal; social distancing.", "Conclusions: Our findings show that COVID-19 conspiracy theories pose a significant threat to public health as they may reduce adherence to social distancing measures.", "Results: Multivariate growth curve analyses showed that, although conspiracy beliefs decreased and social distancing increased over time, people holding more conspiracy beliefs at the beginning of the pandemic showed the lowest increase in social distancing.", "Moreover, cross-lagged analyses demonstrated that people who reported more conspiracy beliefs at any wave tended to report less social distancing at the following wave."]}
{"id": 1000896, "claim": "Effectiveness of cloth masks depends on type of covering", "label": "SUPPORTED", "evidence": ["Adequate distancing is something that must not be ignored, since masks are not foolproof, Simha said."]}
{"id": 1000897, "claim": "Effectiveness of cloth masks depends on lack of covering", "label": "REFUTED", "evidence": ["Adequate distancing is something that must not be ignored, since masks are not foolproof, Simha said."]}
{"id": 1000898, "claim": "Effectiveness of cloth masks depends on cost of covering", "label": "REFUTED", "evidence": ["Adequate distancing is something that must not be ignored, since masks are not foolproof, Simha said."]}
{"id": 1000899, "claim": "Shared sars-cov-2 diversity suggests localised transmission of minority variants", "label": "SUPPORTED", "evidence": ["We show that SARS-CoV-2 infections are characterised by extensive within-host diversity, which is frequently shared among infected individuals with patterns consistent with geographical structure.", "Rapid sequencing and publication of consensus genomes have enabled phylogenetic analysis of the virus, demonstrating SARS-CoV-2 evolves relatively slowly1, but with multiple sites in the genome that appear inconsistent with the overall consensus phylogeny2.", "We conclude that SARS-CoV-2 diversity is transmissible, and propose that geographic patterns are generated by co- circulation of distinct viral populations."]}
{"id": 1000900, "claim": "Shared sars-cov-2 diversity reduces localised transmission of minority variants", "label": "REFUTED", "evidence": ["We show that SARS-CoV-2 infections are characterised by extensive within-host diversity, which is frequently shared among infected individuals with patterns consistent with geographical structure.", "Rapid sequencing and publication of consensus genomes have enabled phylogenetic analysis of the virus, demonstrating SARS-CoV-2 evolves relatively slowly1, but with multiple sites in the genome that appear inconsistent with the overall consensus phylogeny2.", "We conclude that SARS-CoV-2 diversity is transmissible, and propose that geographic patterns are generated by co- circulation of distinct viral populations."]}
{"id": 1000901, "claim": "Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against sars-cov-2.", "label": "SUPPORTED", "evidence": ["Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro", "Here, we report on the in vitro synergistic interaction between two FDA approved drugs, remdesivir (RDV) and ivermectin (IVM) resulting in enhanced antiviral activity against SARS-CoV-2, the causative pathogen of COVID-19."]}
{"id": 1000902, "claim": "Remdesivir-ivermectin combination displays synergistic interaction without improved in vitro antiviral activity against sars-cov-2.", "label": "REFUTED", "evidence": ["Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro", "Here, we report on the in vitro synergistic interaction between two FDA approved drugs, remdesivir (RDV) and ivermectin (IVM) resulting in enhanced antiviral activity against SARS-CoV-2, the causative pathogen of COVID-19."]}
{"id": 1000903, "claim": "Changes to the sebum lipidome upon covid-19 infection observed via non-invasive and rapid sampling from the skin", "label": "SUPPORTED", "evidence": ["Changes to the sebum lipidome upon COVID-19 infection observed via non-invasive and rapid"]}
{"id": 1000904, "claim": "Changes to the sebum lipidome upon covid-19 infection observed via non-invasive and rapid sampling from the blood", "label": "REFUTED", "evidence": ["Changes to the sebum lipidome upon COVID-19 infection observed via non-invasive and rapid"]}
{"id": 1000905, "claim": "Il6 inhibition in critically ill covid-19 patients is associated with increased secondary infections", "label": "SUPPORTED", "evidence": ["Anti-inflammatory therapies such as anti-IL-6 therapy have the potential to impair viral clearance, predispose to secondary infection, and cause harm."]}
{"id": 1000906, "claim": "Il6 inhibition in critically ill covid-19 patients is associated without increased secondary infections", "label": "REFUTED", "evidence": ["Anti-inflammatory therapies such as anti-IL-6 therapy have the potential to impair viral clearance, predispose to secondary infection, and cause harm."]}
{"id": 1000907, "claim": "Wearing face masks strongly confuses counterparts in reading emotions", "label": "SUPPORTED", "evidence": ["Lower accuracy and lower confidence in one's own assessment of the displayed emotions indicate that emotional reading was strongly irritated by the presence of a mask.", "This means that in natural contexts, the impact of face masks on reading emotions could even be stronger.", "A drop in performance in reading the emotional states of faces with masks can somehow be expected as being much harder when most visual information of the lower half of the face is blocked out.", "Face masks may complicate social interaction as they disturb emotion reading from facial expression."]}
{"id": 1000908, "claim": "Wearing face masks strongly ins counterparts in reading emotions", "label": "REFUTED", "evidence": ["Lower accuracy and lower confidence in one's own assessment of the displayed emotions indicate that emotional reading was strongly irritated by the presence of a mask.", "This means that in natural contexts, the impact of face masks on reading emotions could even be stronger.", "A drop in performance in reading the emotional states of faces with masks can somehow be expected as being much harder when most visual information of the lower half of the face is blocked out.", "Face masks may complicate social interaction as they disturb emotion reading from facial expression."]}
{"id": 1000909, "claim": "Steroids cut deaths of hospitalized covid-19 patients by one-third", "label": "SUPPORTED", "evidence": ["Corticosteroids are the first, and so far only, therapy shown to improve the odds of survival for critically ill patients with Covid-19.", "The first evidence that common steroids could improve the survival of patients with severe Covid-19 came in June when British researchers conducting a large clinical trial called RECOVERY reported that the use of dexamethasone reduced the death rate by 35% in patients requiring ventilation and by 20% in patients who needed oxygen but were not ventilated.", "But it cautioned against use of the steroids in patients with non-severe illness, saying that indiscriminate use of any therapy for COVID-19 would potentially rapidly deplete global resources and deprive patients who may benefit from it most as potentially life-saving therapy. advertisement The consistent findings of benefit in these studies provide definitive data that corticosteroids should be first-line treatment for critically ill patients with COVID-19, said Hallie Prescott and Todd Rice, professors of medicine at the University of Michigan and Vanderbilt University, respectively, in an accompanying JAMA editorial."]}
{"id": 1000910, "claim": "Steroids cut deaths of hospitalized covid-19 patients by one-one", "label": "REFUTED", "evidence": ["Corticosteroids are the first, and so far only, therapy shown to improve the odds of survival for critically ill patients with Covid-19.", "The first evidence that common steroids could improve the survival of patients with severe Covid-19 came in June when British researchers conducting a large clinical trial called RECOVERY reported that the use of dexamethasone reduced the death rate by 35% in patients requiring ventilation and by 20% in patients who needed oxygen but were not ventilated.", "But it cautioned against use of the steroids in patients with non-severe illness, saying that indiscriminate use of any therapy for COVID-19 would potentially rapidly deplete global resources and deprive patients who may benefit from it most as potentially life-saving therapy. advertisement The consistent findings of benefit in these studies provide definitive data that corticosteroids should be first-line treatment for critically ill patients with COVID-19, said Hallie Prescott and Todd Rice, professors of medicine at the University of Michigan and Vanderbilt University, respectively, in an accompanying JAMA editorial."]}
{"id": 1000911, "claim": "Steroids cut deaths of hospitalized covid-19 patients by one-two", "label": "REFUTED", "evidence": ["Corticosteroids are the first, and so far only, therapy shown to improve the odds of survival for critically ill patients with Covid-19.", "The first evidence that common steroids could improve the survival of patients with severe Covid-19 came in June when British researchers conducting a large clinical trial called RECOVERY reported that the use of dexamethasone reduced the death rate by 35% in patients requiring ventilation and by 20% in patients who needed oxygen but were not ventilated.", "But it cautioned against use of the steroids in patients with non-severe illness, saying that indiscriminate use of any therapy for COVID-19 would potentially rapidly deplete global resources and deprive patients who may benefit from it most as potentially life-saving therapy. advertisement The consistent findings of benefit in these studies provide definitive data that corticosteroids should be first-line treatment for critically ill patients with COVID-19, said Hallie Prescott and Todd Rice, professors of medicine at the University of Michigan and Vanderbilt University, respectively, in an accompanying JAMA editorial."]}
{"id": 1000912, "claim": "Steroids cut deaths of hospitalized covid-19 patients by one-day", "label": "REFUTED", "evidence": ["Corticosteroids are the first, and so far only, therapy shown to improve the odds of survival for critically ill patients with Covid-19.", "The first evidence that common steroids could improve the survival of patients with severe Covid-19 came in June when British researchers conducting a large clinical trial called RECOVERY reported that the use of dexamethasone reduced the death rate by 35% in patients requiring ventilation and by 20% in patients who needed oxygen but were not ventilated.", "But it cautioned against use of the steroids in patients with non-severe illness, saying that indiscriminate use of any therapy for COVID-19 would potentially rapidly deplete global resources and deprive patients who may benefit from it most as potentially life-saving therapy. advertisement The consistent findings of benefit in these studies provide definitive data that corticosteroids should be first-line treatment for critically ill patients with COVID-19, said Hallie Prescott and Todd Rice, professors of medicine at the University of Michigan and Vanderbilt University, respectively, in an accompanying JAMA editorial."]}
{"id": 1000913, "claim": "Male sex identified by global covid-19 meta-analysis as a risk factor for death and itu admission", "label": "SUPPORTED", "evidence": ["4: Male sex is associated with a significantly increased risk of mortality within COVID-19 patients.", "Taken together these data highlight that, whilst there is no difference in the proportion of COVID-19 cases between sexes, men have a higher risk of ITU admission (OR 2.84) and death (OR 1.39)."]}
{"id": 1000914, "claim": "Male sex identified by global covid-19 meta-analysis as a risk factor for health and itu admission", "label": "REFUTED", "evidence": ["4: Male sex is associated with a significantly increased risk of mortality within COVID-19 patients.", "Taken together these data highlight that, whilst there is no difference in the proportion of COVID-19 cases between sexes, men have a higher risk of ITU admission (OR 2.84) and death (OR 1.39)."]}
{"id": 1000915, "claim": "Male sex identified by global covid-19 meta-analysis as a risk factor for diabetes and itu admission", "label": "REFUTED", "evidence": ["4: Male sex is associated with a significantly increased risk of mortality within COVID-19 patients.", "Taken together these data highlight that, whilst there is no difference in the proportion of COVID-19 cases between sexes, men have a higher risk of ITU admission (OR 2.84) and death (OR 1.39)."]}
{"id": 1000916, "claim": "Male sex identified by global covid-19 meta-analysis as a risk factor for malaria and itu admission", "label": "REFUTED", "evidence": ["4: Male sex is associated with a significantly increased risk of mortality within COVID-19 patients.", "Taken together these data highlight that, whilst there is no difference in the proportion of COVID-19 cases between sexes, men have a higher risk of ITU admission (OR 2.84) and death (OR 1.39)."]}
{"id": 1000917, "claim": "Findings from serological surveys to assess the exposure of adult population to sars cov-2 infection in three cities of odisha , india .", "label": "SUPPORTED", "evidence": ["Objective To estimate and compare the sero-prevalence, hidden prevalence and determine the demographic risk factors associated with SARS-CoV-2 infection among adults in three largest cities of Odisha, India.", "MethodologyThis was a population based cross sectional serological survey carried out in August 2020 in the three largest cities of the state of Odisha.", "ObjectiveTo estimate and compare the sero- prevalence, hidden prevalence and determine the demographic risk factors associated with SARS-CoV-2 infection among adults in three largest cities of Odisha, India.", "Findings from serological surveys (in August 2020) to assess the exposure of adult population to SARS Cov-2 infection in three cities of Odisha, India.", "Share Findings from serological surveys (in August 2020) to assess the exposure of adult population to SARS Cov-2 infection in three cities of Odisha, India Jaya Singh Kshatri, Debdutta Bhattacharya, Srikanta Kanungo, Sidhartha Giri, Subrata Kumar Palo, Debaprasad Parai, Jyotirmayee Turuk, Asit Mansingh, Hariram Choudhary, Girish Chandra Dash, Niranjan Mishra, D.M."]}
{"id": 1000918, "claim": "Findings from serological surveys to assess the exposure of adult population to sars cov-2 infection in two cities of odisha, india.", "label": "REFUTED", "evidence": ["Objective To estimate and compare the sero-prevalence, hidden prevalence and determine the demographic risk factors associated with SARS-CoV-2 infection among adults in three largest cities of Odisha, India.", "MethodologyThis was a population based cross sectional serological survey carried out in August 2020 in the three largest cities of the state of Odisha.", "ObjectiveTo estimate and compare the sero- prevalence, hidden prevalence and determine the demographic risk factors associated with SARS-CoV-2 infection among adults in three largest cities of Odisha, India.", "Findings from serological surveys (in August 2020) to assess the exposure of adult population to SARS Cov-2 infection in three cities of Odisha, India.", "Share Findings from serological surveys (in August 2020) to assess the exposure of adult population to SARS Cov-2 infection in three cities of Odisha, India Jaya Singh Kshatri, Debdutta Bhattacharya, Srikanta Kanungo, Sidhartha Giri, Subrata Kumar Palo, Debaprasad Parai, Jyotirmayee Turuk, Asit Mansingh, Hariram Choudhary, Girish Chandra Dash, Niranjan Mishra, D.M."]}
{"id": 1000919, "claim": "Iga mab blocks sars-cov-2 spike-ace2 interaction providing mucosal immunity", "label": "SUPPORTED", "evidence": ["SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS- CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine."]}
{"id": 1000920, "claim": "Iga mab blocks sars-cov-2 spike-ace2 interaction against mucosal immunity", "label": "REFUTED", "evidence": ["SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS- CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine."]}
{"id": 1000921, "claim": "Iga b blocks sars-cov-2 spike-ace2 interaction providing mucosal immunity", "label": "REFUTED", "evidence": ["SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS- CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine."]}
{"id": 1000922, "claim": "Iga 1 blocks sars-cov-2 spike-ace2 interaction providing mucosal immunity", "label": "REFUTED", "evidence": ["SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS- CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine."]}
{"id": 1000923, "claim": "Infectious coronavirus retrieved from hospital air", "label": "SUPPORTED", "evidence": ["The scientists were able to collect virus at both distances and then to show that the virus they had plucked from the air could infect cells in a lab dish."]}
{"id": 1000924, "claim": "Infectious coronavirus retrieved from genbank air", "label": "REFUTED", "evidence": ["The scientists were able to collect virus at both distances and then to show that the virus they had plucked from the air could infect cells in a lab dish."]}
{"id": 1000925, "claim": "Infectious coronavirus retrieved from wuhan air", "label": "REFUTED", "evidence": ["The scientists were able to collect virus at both distances and then to show that the virus they had plucked from the air could infect cells in a lab dish."]}
{"id": 1000926, "claim": "Infectious coronavirus retrieved from china air", "label": "REFUTED", "evidence": ["The scientists were able to collect virus at both distances and then to show that the virus they had plucked from the air could infect cells in a lab dish."]}
{"id": 1000927, "claim": "Real-world data suggest antibody positivity to sars-cov-2 is associated with a decreased risk of future infection.", "label": "SUPPORTED", "evidence": ["This finding suggests that people who have a positive antibody test result using widely available assays have substantial immunity to SARS-CoV-2 and are at lower risk for future infection.", "Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate."]}
{"id": 1000928, "claim": "Real-world data suggest antibody positivity to sars-cov-2 is associated with a increased risk of future infection.", "label": "REFUTED", "evidence": ["This finding suggests that people who have a positive antibody test result using widely available assays have substantial immunity to SARS-CoV-2 and are at lower risk for future infection.", "Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate."]}
{"id": 1000929, "claim": "Real-world data suggest antibody positivity to sars-cov-2 is associated with a greater risk of future infection.", "label": "REFUTED", "evidence": ["This finding suggests that people who have a positive antibody test result using widely available assays have substantial immunity to SARS-CoV-2 and are at lower risk for future infection.", "Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate."]}
{"id": 1000930, "claim": "Real-world data suggest antibody positivity to sars-cov-2 is associated with a higher risk of future infection.", "label": "REFUTED", "evidence": ["This finding suggests that people who have a positive antibody test result using widely available assays have substantial immunity to SARS-CoV-2 and are at lower risk for future infection.", "Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate."]}
{"id": 1000931, "claim": "Host-viral infection maps reveal signatures of severe covid-19 patients", "label": "SUPPORTED", "evidence": ["Single-cell sequencing data of cells from an infected tissue, containing infected and bystander cells are analyzed by Viral-Track.", "Applying Viral-Track to bronchoalveloar-lavage samples from severe and mild COVID-19 patients reveals a dramatic impact of the virus on the immune system of severe patients compared to mild cases."]}
{"id": 1000932, "claim": "Host-viral infection cannot reveal signatures of severe covid-19 patients", "label": "REFUTED", "evidence": ["Single-cell sequencing data of cells from an infected tissue, containing infected and bystander cells are analyzed by Viral-Track.", "Applying Viral-Track to bronchoalveloar-lavage samples from severe and mild COVID-19 patients reveals a dramatic impact of the virus on the immune system of severe patients compared to mild cases."]}
{"id": 1000933, "claim": "Anti-viral infection maps reveal signatures of severe covid-19 patients", "label": "REFUTED", "evidence": ["Single-cell sequencing data of cells from an infected tissue, containing infected and bystander cells are analyzed by Viral-Track.", "Applying Viral-Track to bronchoalveloar-lavage samples from severe and mild COVID-19 patients reveals a dramatic impact of the virus on the immune system of severe patients compared to mild cases."]}
{"id": 1000934, "claim": "Neutralizing antibodies correlate with protection from sars-cov-2 in humans during a fishery vessel outbreak with a high attack rate", "label": "SUPPORTED", "evidence": ["This difference is statistically significant (Table 2, Fishers exact test, P = 0.002), indicating that preexisting neutralizing antibodies are significantly associated with protection against SARS-CoV-2 infection."]}
{"id": 1000935, "claim": "Neutralizing antibodies correlate with protection from sars-cov-2 in pigs during a fishery vessel outbreak with a high attack rate", "label": "REFUTED", "evidence": ["This difference is statistically significant (Table 2, Fishers exact test, P = 0.002), indicating that preexisting neutralizing antibodies are significantly associated with protection against SARS-CoV-2 infection."]}
{"id": 1000936, "claim": "Neutralizing antibodies correlate with protection from sars-cov-2 in mice during a fishery vessel outbreak with a high attack rate", "label": "REFUTED", "evidence": ["This difference is statistically significant (Table 2, Fishers exact test, P = 0.002), indicating that preexisting neutralizing antibodies are significantly associated with protection against SARS-CoV-2 infection."]}
{"id": 1000937, "claim": "Neutralizing antibodies correlate with protection from sars-cov-2 in chickens during a fishery vessel outbreak with a high attack rate", "label": "REFUTED", "evidence": ["This difference is statistically significant (Table 2, Fishers exact test, P = 0.002), indicating that preexisting neutralizing antibodies are significantly associated with protection against SARS-CoV-2 infection."]}
{"id": 1000938, "claim": "Scientists failed to use common sense early in the pandemic", "label": "SUPPORTED", "evidence": ["At the time, no direct evidence existed regarding community spread of this particular virus, and most previous studies were done in clinical settings.", "According to one report, officials were also concerned that widespread masking would lead to a false sense of security, leading people to ignore other safety measures, such as handwashing and self-isolation."]}
{"id": 1000939, "claim": "Scientists continue to use common sense early in the pandemic", "label": "REFUTED", "evidence": ["At the time, no direct evidence existed regarding community spread of this particular virus, and most previous studies were done in clinical settings.", "According to one report, officials were also concerned that widespread masking would lead to a false sense of security, leading people to ignore other safety measures, such as handwashing and self-isolation."]}
{"id": 1000940, "claim": "Scientists seems to use common sense early in the pandemic", "label": "REFUTED", "evidence": ["At the time, no direct evidence existed regarding community spread of this particular virus, and most previous studies were done in clinical settings.", "According to one report, officials were also concerned that widespread masking would lead to a false sense of security, leading people to ignore other safety measures, such as handwashing and self-isolation."]}
{"id": 1000941, "claim": "Scientists appears to use common sense early in the pandemic", "label": "REFUTED", "evidence": ["At the time, no direct evidence existed regarding community spread of this particular virus, and most previous studies were done in clinical settings.", "According to one report, officials were also concerned that widespread masking would lead to a false sense of security, leading people to ignore other safety measures, such as handwashing and self-isolation."]}
{"id": 1000942, "claim": "Inhibition of pikfyve kinase prevents infection by zaire ebolavirus and sars-cov-2", "label": "SUPPORTED", "evidence": ["We describe here potent inhibitory effects on content release and infection by chimeric vesicular stomatitis virus (VSV) containing the envelope proteins of Zaire ebolavirus (VSV-ZEBOV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (VSV-SARS-CoV-2) elicited by Apilimod and Vacuolin-1, small- molecule inhibitors of the main endosomal phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase, PIKfyve.", "We have constructed chimeric forms of vesicular stomatitis virus (VSV) bearing the fusion proteins of Zaire ebolavirus (ZEBOV) or SARS coronavirus 2 (SARS-CoV-2) and shown that two small-molecule inhibitors of an endosomal lipid kinase (PIKfyve) inhibit viral infection by preventing release of the viral contents from endosomes."]}
{"id": 1000943, "claim": "Inhibition of pikfyve kinase induces infection by zaire ebolavirus and sars-cov-2", "label": "REFUTED", "evidence": ["We describe here potent inhibitory effects on content release and infection by chimeric vesicular stomatitis virus (VSV) containing the envelope proteins of Zaire ebolavirus (VSV-ZEBOV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (VSV-SARS-CoV-2) elicited by Apilimod and Vacuolin-1, small- molecule inhibitors of the main endosomal phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase, PIKfyve.", "We have constructed chimeric forms of vesicular stomatitis virus (VSV) bearing the fusion proteins of Zaire ebolavirus (ZEBOV) or SARS coronavirus 2 (SARS-CoV-2) and shown that two small-molecule inhibitors of an endosomal lipid kinase (PIKfyve) inhibit viral infection by preventing release of the viral contents from endosomes."]}
{"id": 1000944, "claim": "Triple combination nitazoxanide , ribavirin , and hydroxychloroquine results in the multiplicative reduction of in vitro sars-cov-2 viral replication.", "label": "SUPPORTED", "evidence": ["ConclusionsA triple combination of tizoxanide, ribavirin, and hydroxychloroquine produced a reduction in SARS-COV-2 viral replication in Vero E6 cells, warranting exploration in additional cell lines as well as human clinical trials.", "Conclusions A triple combination of tizoxanide, ribavirin, and hydroxychloroquine produced a reduction in SARS-COV-2 viral replication in Vero E6 cells, warranting exploration in additional cell lines as well as human clinical trials."]}
{"id": 1000945, "claim": "Triple combination nitazoxanide, ribavirin, and hydroxychloroquine decrease in the multiplicative reduction of in vitro sars-cov-2 viral replication.", "label": "REFUTED", "evidence": ["ConclusionsA triple combination of tizoxanide, ribavirin, and hydroxychloroquine produced a reduction in SARS-COV-2 viral replication in Vero E6 cells, warranting exploration in additional cell lines as well as human clinical trials.", "Conclusions A triple combination of tizoxanide, ribavirin, and hydroxychloroquine produced a reduction in SARS-COV-2 viral replication in Vero E6 cells, warranting exploration in additional cell lines as well as human clinical trials."]}
{"id": 1000946, "claim": "Misconceptions about weather and seasonality must not misguide covid-19 response", "label": "SUPPORTED", "evidence": ["The signals of environmental drivers may be identifiable and interesting, butno matter how small an effect is found, or how carefully statements are qualifiedscientists who choose to produce scholarship on the topic should be prepared to have their work misread and misrepresented as indicating that some places or seasons are safe from COVID-19.", "With current scientific data, COVID-19 interventions cannot currently be planned around seasonality."]}
{"id": 1000947, "claim": "Misconceptions about weather and seasonality must facilitate misguide covid-19 response", "label": "REFUTED", "evidence": ["The signals of environmental drivers may be identifiable and interesting, butno matter how small an effect is found, or how carefully statements are qualifiedscientists who choose to produce scholarship on the topic should be prepared to have their work misread and misrepresented as indicating that some places or seasons are safe from COVID-19.", "With current scientific data, COVID-19 interventions cannot currently be planned around seasonality."]}
{"id": 1000948, "claim": "Misconceptions about weather and seasonality must help misguide covid-19 response", "label": "REFUTED", "evidence": ["The signals of environmental drivers may be identifiable and interesting, butno matter how small an effect is found, or how carefully statements are qualifiedscientists who choose to produce scholarship on the topic should be prepared to have their work misread and misrepresented as indicating that some places or seasons are safe from COVID-19.", "With current scientific data, COVID-19 interventions cannot currently be planned around seasonality."]}
{"id": 1000949, "claim": "Misconceptions about weather and seasonality must include misguide covid-19 response", "label": "REFUTED", "evidence": ["The signals of environmental drivers may be identifiable and interesting, butno matter how small an effect is found, or how carefully statements are qualifiedscientists who choose to produce scholarship on the topic should be prepared to have their work misread and misrepresented as indicating that some places or seasons are safe from COVID-19.", "With current scientific data, COVID-19 interventions cannot currently be planned around seasonality."]}
{"id": 1000950, "claim": "Longitudinal omics in syrian hamsters integrated with human data unravel complexity of moderate immune responses to sars-cov-2.", "label": "SUPPORTED", "evidence": ["Using the Syrian hamster model of self-limited moderate COVID-19, we defined the specific roles of endothelial and epithelial cells, among other myeloid and non-myeloid lung cell subtypes, for determining the disease course.", "In depth vascular and pulmonary compartment analyses (i) supported the hypothesis that monocyte-derived macrophages dominate inflammation, (ii) revealed endothelial inflammation status and T-cell attraction, and (iii) showed that CD4+ and CD8+ cytotoxic T-cell responses precede viral elimination.", "Comparison of hamster single-cell sequencing and proteomics with data sets from COVID-19 patients demonstrated inter- species concordance of cellular and molecular host-pathogen interactions.", "We performed detailed spatiotemporal analyses of cellular and molecular processes in SARS- CoV-2 infected Syrian hamsters."]}
{"id": 1000951, "claim": "Longitudinal omics in chinese hamsters integrated with human data unravel complexity of moderate immune responses to sars-cov-2.", "label": "REFUTED", "evidence": ["Using the Syrian hamster model of self-limited moderate COVID-19, we defined the specific roles of endothelial and epithelial cells, among other myeloid and non-myeloid lung cell subtypes, for determining the disease course.", "In depth vascular and pulmonary compartment analyses (i) supported the hypothesis that monocyte-derived macrophages dominate inflammation, (ii) revealed endothelial inflammation status and T-cell attraction, and (iii) showed that CD4+ and CD8+ cytotoxic T-cell responses precede viral elimination.", "Comparison of hamster single-cell sequencing and proteomics with data sets from COVID-19 patients demonstrated inter- species concordance of cellular and molecular host-pathogen interactions.", "We performed detailed spatiotemporal analyses of cellular and molecular processes in SARS- CoV-2 infected Syrian hamsters."]}
{"id": 1000952, "claim": "Longitudinal omics in cynomolgus hamsters integrated with human data unravel complexity of moderate immune responses to sars-cov-2.", "label": "REFUTED", "evidence": ["Using the Syrian hamster model of self-limited moderate COVID-19, we defined the specific roles of endothelial and epithelial cells, among other myeloid and non-myeloid lung cell subtypes, for determining the disease course.", "In depth vascular and pulmonary compartment analyses (i) supported the hypothesis that monocyte-derived macrophages dominate inflammation, (ii) revealed endothelial inflammation status and T-cell attraction, and (iii) showed that CD4+ and CD8+ cytotoxic T-cell responses precede viral elimination.", "Comparison of hamster single-cell sequencing and proteomics with data sets from COVID-19 patients demonstrated inter- species concordance of cellular and molecular host-pathogen interactions.", "We performed detailed spatiotemporal analyses of cellular and molecular processes in SARS- CoV-2 infected Syrian hamsters."]}
{"id": 1000953, "claim": "Higher serum levels of chemokine ccl19 are associated with poor sars-cov-2 acute respiratory distress syndrome outcomes .", "label": "SUPPORTED", "evidence": ["Higher plasma levels of Chemokine CCL19 are associated with poor SARS-CoV-2 acute respiratory distress syndrome (ARDS) outcomes.", "Higher plasma levels of Chemokine CCL19 are associated with poor SARS-CoV-2 acute respiratory distress syndrome (ARDS) outcomes.", "Share Unique inflammatory profile is associated with higher SARS-CoV-2 acute respiratory distress syndrome (ARDS) mortality."]}
{"id": 1000954, "claim": "Higher serum levels of chemokine ccl19 are associated with elevated sars-cov-2 acute respiratory distress syndrome outcomes.", "label": "REFUTED", "evidence": ["Higher plasma levels of Chemokine CCL19 are associated with poor SARS-CoV-2 acute respiratory distress syndrome (ARDS) outcomes.", "Higher plasma levels of Chemokine CCL19 are associated with poor SARS-CoV-2 acute respiratory distress syndrome (ARDS) outcomes.", "Share Unique inflammatory profile is associated with higher SARS-CoV-2 acute respiratory distress syndrome (ARDS) mortality."]}
{"id": 1000955, "claim": "Higher serum levels of chemokine ccl19 are associated with high sars-cov-2 acute respiratory distress syndrome outcomes.", "label": "REFUTED", "evidence": ["Higher plasma levels of Chemokine CCL19 are associated with poor SARS-CoV-2 acute respiratory distress syndrome (ARDS) outcomes.", "Higher plasma levels of Chemokine CCL19 are associated with poor SARS-CoV-2 acute respiratory distress syndrome (ARDS) outcomes.", "Share Unique inflammatory profile is associated with higher SARS-CoV-2 acute respiratory distress syndrome (ARDS) mortality."]}
{"id": 1000956, "claim": "Higher serum levels of chemokine ccl19 are associated with increased sars-cov-2 acute respiratory distress syndrome outcomes.", "label": "REFUTED", "evidence": ["Higher plasma levels of Chemokine CCL19 are associated with poor SARS-CoV-2 acute respiratory distress syndrome (ARDS) outcomes.", "Higher plasma levels of Chemokine CCL19 are associated with poor SARS-CoV-2 acute respiratory distress syndrome (ARDS) outcomes.", "Share Unique inflammatory profile is associated with higher SARS-CoV-2 acute respiratory distress syndrome (ARDS) mortality."]}
{"id": 1000957, "claim": "Bats are evolved to damp down immune response to viruses", "label": "SUPPORTED", "evidence": ["The evolution of flight in bats seem to have selected for a unique set of antiviral immune responses that control virus propagation, while limiting self-damaging inflammatory responses.", "Bats have evolved novel mechanisms to limit virus-induced pro-inflammatory responses while maintaining type I IFN responses to limit virus propagation (Figure 1).", "Bats Suppress the Pathological Effects of Excessive Virus-Induced Inflammation While bats are well prepared to control viral infections, they also have mechanisms to avoid over-induction of inflammatory genes.", "This suggests that many bats have a mechanism to suppress the expression of TNFα, thereby maintaining a balanced response to viral infection."]}
{"id": 1000958, "claim": "Covs are evolved to damp down immune response to viruses", "label": "REFUTED", "evidence": ["The evolution of flight in bats seem to have selected for a unique set of antiviral immune responses that control virus propagation, while limiting self-damaging inflammatory responses.", "Bats have evolved novel mechanisms to limit virus-induced pro-inflammatory responses while maintaining type I IFN responses to limit virus propagation (Figure 1).", "Bats Suppress the Pathological Effects of Excessive Virus-Induced Inflammation While bats are well prepared to control viral infections, they also have mechanisms to avoid over-induction of inflammatory genes.", "This suggests that many bats have a mechanism to suppress the expression of TNFα, thereby maintaining a balanced response to viral infection."]}
{"id": 1000959, "claim": "Bats are unable to damp down immune response to viruses", "label": "REFUTED", "evidence": ["The evolution of flight in bats seem to have selected for a unique set of antiviral immune responses that control virus propagation, while limiting self-damaging inflammatory responses.", "Bats have evolved novel mechanisms to limit virus-induced pro-inflammatory responses while maintaining type I IFN responses to limit virus propagation (Figure 1).", "Bats Suppress the Pathological Effects of Excessive Virus-Induced Inflammation While bats are well prepared to control viral infections, they also have mechanisms to avoid over-induction of inflammatory genes.", "This suggests that many bats have a mechanism to suppress the expression of TNFα, thereby maintaining a balanced response to viral infection."]}
{"id": 1000960, "claim": "Dcs are evolved to damp down immune response to viruses", "label": "REFUTED", "evidence": ["The evolution of flight in bats seem to have selected for a unique set of antiviral immune responses that control virus propagation, while limiting self-damaging inflammatory responses.", "Bats have evolved novel mechanisms to limit virus-induced pro-inflammatory responses while maintaining type I IFN responses to limit virus propagation (Figure 1).", "Bats Suppress the Pathological Effects of Excessive Virus-Induced Inflammation While bats are well prepared to control viral infections, they also have mechanisms to avoid over-induction of inflammatory genes.", "This suggests that many bats have a mechanism to suppress the expression of TNFα, thereby maintaining a balanced response to viral infection."]}
{"id": 1000961, "claim": "An outbreak of covid-19 associated with a recreational hockey game", "label": "SUPPORTED", "evidence": ["The indoor space and close contact between players during a hockey game increase infection risk for players and create potential for a superspreader event, especially with ongoing community COVID-19 transmission.", "In addition, outbreaks of COVID-19 infections among amateur hockey players in the United States have recently been reported in the news. On June 19, 2020, the Florida Department of Health was notified of a team A player (the index patient) who experienced fever, cough, sore throat, and a headache beginning on June 17, the day after he had participated in an evening game; 2 days later, a nasal specimen was obtained, which tested positive for SARS-CoV-2 by Sofia SARS Antigen Fluorescent Immunoassay (https://www.quidel.com/immunoassays/coronavirusexternal icon).", "COVID-19 cases associated with a recreational ice hockey game, by date of onset (N = 15) -- Florida, June 2020 Abbreviation: COVID-19 = coronavirus disease 2019."]}
{"id": 1000962, "claim": "An study of covid-19 associated with a recreational hockey game", "label": "REFUTED", "evidence": ["The indoor space and close contact between players during a hockey game increase infection risk for players and create potential for a superspreader event, especially with ongoing community COVID-19 transmission.", "In addition, outbreaks of COVID-19 infections among amateur hockey players in the United States have recently been reported in the news. On June 19, 2020, the Florida Department of Health was notified of a team A player (the index patient) who experienced fever, cough, sore throat, and a headache beginning on June 17, the day after he had participated in an evening game; 2 days later, a nasal specimen was obtained, which tested positive for SARS-CoV-2 by Sofia SARS Antigen Fluorescent Immunoassay (https://www.quidel.com/immunoassays/coronavirusexternal icon).", "COVID-19 cases associated with a recreational ice hockey game, by date of onset (N = 15) -- Florida, June 2020 Abbreviation: COVID-19 = coronavirus disease 2019."]}
{"id": 1000963, "claim": "An majority of covid-19 associated with a recreational hockey game", "label": "REFUTED", "evidence": ["The indoor space and close contact between players during a hockey game increase infection risk for players and create potential for a superspreader event, especially with ongoing community COVID-19 transmission.", "In addition, outbreaks of COVID-19 infections among amateur hockey players in the United States have recently been reported in the news. On June 19, 2020, the Florida Department of Health was notified of a team A player (the index patient) who experienced fever, cough, sore throat, and a headache beginning on June 17, the day after he had participated in an evening game; 2 days later, a nasal specimen was obtained, which tested positive for SARS-CoV-2 by Sofia SARS Antigen Fluorescent Immunoassay (https://www.quidel.com/immunoassays/coronavirusexternal icon).", "COVID-19 cases associated with a recreational ice hockey game, by date of onset (N = 15) -- Florida, June 2020 Abbreviation: COVID-19 = coronavirus disease 2019."]}
{"id": 1000964, "claim": "An prevalence of covid-19 associated with a recreational hockey game", "label": "REFUTED", "evidence": ["The indoor space and close contact between players during a hockey game increase infection risk for players and create potential for a superspreader event, especially with ongoing community COVID-19 transmission.", "In addition, outbreaks of COVID-19 infections among amateur hockey players in the United States have recently been reported in the news. On June 19, 2020, the Florida Department of Health was notified of a team A player (the index patient) who experienced fever, cough, sore throat, and a headache beginning on June 17, the day after he had participated in an evening game; 2 days later, a nasal specimen was obtained, which tested positive for SARS-CoV-2 by Sofia SARS Antigen Fluorescent Immunoassay (https://www.quidel.com/immunoassays/coronavirusexternal icon).", "COVID-19 cases associated with a recreational ice hockey game, by date of onset (N = 15) -- Florida, June 2020 Abbreviation: COVID-19 = coronavirus disease 2019."]}
{"id": 1000965, "claim": "Thanksgiving travel drops as americans rethink rituals", "label": "SUPPORTED", "evidence": ["Blue for The New York Times Americans have agonized over Thanksgiving this year, weighing skyrocketing numbers  more than 2,200 U.S. deaths from Covid-19 were reported on Tuesday for the first time since May 6  and blunt warnings from the Centers for Disease Control and Prevention against the need, after a grim and worrying year, to gather with family for a traditional, carbohydrate-laden ritual.", "Thanksgiving travel is clearly down compared with 2019."]}
{"id": 1000966, "claim": "Thanksgiving travel occurs as americans rethink rituals", "label": "REFUTED", "evidence": ["Blue for The New York Times Americans have agonized over Thanksgiving this year, weighing skyrocketing numbers  more than 2,200 U.S. deaths from Covid-19 were reported on Tuesday for the first time since May 6  and blunt warnings from the Centers for Disease Control and Prevention against the need, after a grim and worrying year, to gather with family for a traditional, carbohydrate-laden ritual.", "Thanksgiving travel is clearly down compared with 2019."]}
{"id": 1000967, "claim": "Thanksgiving travel occurred as americans rethink rituals", "label": "REFUTED", "evidence": ["Blue for The New York Times Americans have agonized over Thanksgiving this year, weighing skyrocketing numbers  more than 2,200 U.S. deaths from Covid-19 were reported on Tuesday for the first time since May 6  and blunt warnings from the Centers for Disease Control and Prevention against the need, after a grim and worrying year, to gather with family for a traditional, carbohydrate-laden ritual.", "Thanksgiving travel is clearly down compared with 2019."]}
{"id": 1000968, "claim": "Thanksgiving travel acts as americans rethink rituals", "label": "REFUTED", "evidence": ["Blue for The New York Times Americans have agonized over Thanksgiving this year, weighing skyrocketing numbers  more than 2,200 U.S. deaths from Covid-19 were reported on Tuesday for the first time since May 6  and blunt warnings from the Centers for Disease Control and Prevention against the need, after a grim and worrying year, to gather with family for a traditional, carbohydrate-laden ritual.", "Thanksgiving travel is clearly down compared with 2019."]}
{"id": 1000969, "claim": "Iran says coronavirus has spread to several cities.", "label": "SUPPORTED", "evidence": ["Based on existing reports, the spread of coronavirus started in Qom and with attention to peoples travels has now reached several cities in the country including Tehran, Babol, Arak, Isfahan, Rasht and other cities, health ministry official Minou Mohrez said, according to the official IRNA news agency.", "\"Based on existing reports, the spread of the coronavirus started in Qom and with attention to people's travels has now reached several cities in the country, including Tehran, Babol, Arak, Isfahan, Rasht, and other cities.", "> The spread of the coronavirus started in Qom and has reached other cities > in the country like Tehran, Babol, Arak, Isfahan, Rasht and other cities due > to people traveling.", "Earlier in the day, Iran confirmed 13 new coronavirus cases.", "Related Coverage Coronavirus has spread to several Iranian cities: health ministry official The new cases comprised seven people diagnosed in Qom, four in the capital Tehran and two in Gilan province, Health Ministry spokesman Kianush Jahanpur said in a tweet."]}
{"id": 1000970, "claim": "Iran says coronavirus has spread to several species.", "label": "REFUTED", "evidence": ["Based on existing reports, the spread of coronavirus started in Qom and with attention to peoples travels has now reached several cities in the country including Tehran, Babol, Arak, Isfahan, Rasht and other cities, health ministry official Minou Mohrez said, according to the official IRNA news agency.", "\"Based on existing reports, the spread of the coronavirus started in Qom and with attention to people's travels has now reached several cities in the country, including Tehran, Babol, Arak, Isfahan, Rasht, and other cities.", "> The spread of the coronavirus started in Qom and has reached other cities > in the country like Tehran, Babol, Arak, Isfahan, Rasht and other cities due > to people traveling.", "Earlier in the day, Iran confirmed 13 new coronavirus cases.", "Related Coverage Coronavirus has spread to several Iranian cities: health ministry official The new cases comprised seven people diagnosed in Qom, four in the capital Tehran and two in Gilan province, Health Ministry spokesman Kianush Jahanpur said in a tweet."]}
{"id": 1000971, "claim": "Iran says coronavirus has spread to several regions.", "label": "REFUTED", "evidence": ["Based on existing reports, the spread of coronavirus started in Qom and with attention to peoples travels has now reached several cities in the country including Tehran, Babol, Arak, Isfahan, Rasht and other cities, health ministry official Minou Mohrez said, according to the official IRNA news agency.", "\"Based on existing reports, the spread of the coronavirus started in Qom and with attention to people's travels has now reached several cities in the country, including Tehran, Babol, Arak, Isfahan, Rasht, and other cities.", "> The spread of the coronavirus started in Qom and has reached other cities > in the country like Tehran, Babol, Arak, Isfahan, Rasht and other cities due > to people traveling.", "Earlier in the day, Iran confirmed 13 new coronavirus cases.", "Related Coverage Coronavirus has spread to several Iranian cities: health ministry official The new cases comprised seven people diagnosed in Qom, four in the capital Tehran and two in Gilan province, Health Ministry spokesman Kianush Jahanpur said in a tweet."]}
{"id": 1000972, "claim": "Redhill biopharma 's opaganib demonstrates complete inhibition of sars-cov-2", "label": "SUPPORTED", "evidence": ["In addition to opaganib, RedHills in-vitro study evaluated the antiviral activity of its Phase-2 stage investigational drug, RHB-107 (upamostat), a serine protease inhibitor active against a number of human serine proteases, with results demonstrating potent inhibition of SARS-CoV-2 viral replication."]}
{"id": 1000973, "claim": "Redhill biopharma's opaganib demonstrates complete inhibition of aas-cov-2", "label": "REFUTED", "evidence": ["In addition to opaganib, RedHills in-vitro study evaluated the antiviral activity of its Phase-2 stage investigational drug, RHB-107 (upamostat), a serine protease inhibitor active against a number of human serine proteases, with results demonstrating potent inhibition of SARS-CoV-2 viral replication."]}
{"id": 1000974, "claim": "Redhill biopharma's opaganib demonstrates complete inhibition of xs-cov-2", "label": "REFUTED", "evidence": ["In addition to opaganib, RedHills in-vitro study evaluated the antiviral activity of its Phase-2 stage investigational drug, RHB-107 (upamostat), a serine protease inhibitor active against a number of human serine proteases, with results demonstrating potent inhibition of SARS-CoV-2 viral replication."]}
{"id": 1000975, "claim": "Redhill biopharma's opaganib demonstrates complete inhibition of ads-cov-2", "label": "REFUTED", "evidence": ["In addition to opaganib, RedHills in-vitro study evaluated the antiviral activity of its Phase-2 stage investigational drug, RHB-107 (upamostat), a serine protease inhibitor active against a number of human serine proteases, with results demonstrating potent inhibition of SARS-CoV-2 viral replication."]}
{"id": 1000976, "claim": "Lymphopenia-induced t cell proliferation is a hallmark of severe covid-19", "label": "SUPPORTED", "evidence": ["Lymphopenia is shown again to be a hallmark of severe COVID-19 infection.", "Expansion and recovery of poly-specific antiviral T cells suggests lymphopenia-induced T cell proliferation", "Finally, using the different sampling time of the included patients with severe COVID-19 to as a pseudo-longitudinal time course, the authors also observe lymphopenia induced homeostatic proliferation, driving expansion of poly-specific T cells and indicating an improvement of T cell functionality over time."]}
{"id": 1000977, "claim": "Lymphopenia-induced t cell death is a hallmark of severe covid-19", "label": "REFUTED", "evidence": ["Lymphopenia is shown again to be a hallmark of severe COVID-19 infection.", "Expansion and recovery of poly-specific antiviral T cells suggests lymphopenia-induced T cell proliferation", "Finally, using the different sampling time of the included patients with severe COVID-19 to as a pseudo-longitudinal time course, the authors also observe lymphopenia induced homeostatic proliferation, driving expansion of poly-specific T cells and indicating an improvement of T cell functionality over time."]}
{"id": 1000978, "claim": "Lymphopenia-induced t cell dysfunction is a hallmark of severe covid-19", "label": "REFUTED", "evidence": ["Lymphopenia is shown again to be a hallmark of severe COVID-19 infection.", "Expansion and recovery of poly-specific antiviral T cells suggests lymphopenia-induced T cell proliferation", "Finally, using the different sampling time of the included patients with severe COVID-19 to as a pseudo-longitudinal time course, the authors also observe lymphopenia induced homeostatic proliferation, driving expansion of poly-specific T cells and indicating an improvement of T cell functionality over time."]}
{"id": 1000979, "claim": "Lymphopenia-induced t cell apoptosis is a hallmark of severe covid-19", "label": "REFUTED", "evidence": ["Lymphopenia is shown again to be a hallmark of severe COVID-19 infection.", "Expansion and recovery of poly-specific antiviral T cells suggests lymphopenia-induced T cell proliferation", "Finally, using the different sampling time of the included patients with severe COVID-19 to as a pseudo-longitudinal time course, the authors also observe lymphopenia induced homeostatic proliferation, driving expansion of poly-specific T cells and indicating an improvement of T cell functionality over time."]}
{"id": 1000980, "claim": "Uk labs 'can process tens of thousands more tests '", "label": "SUPPORTED", "evidence": ["Anthony Costello, a global health professor at University College London, called for the UK to make use of testing machines in every university and big hospital around the country, setting up mobile testing units like Ireland, which is testing far more people per head of population."]}
{"id": 1000981, "claim": "Uk labs 'can process one of thousands more tests '", "label": "REFUTED", "evidence": ["Anthony Costello, a global health professor at University College London, called for the UK to make use of testing machines in every university and big hospital around the country, setting up mobile testing units like Ireland, which is testing far more people per head of population."]}
{"id": 1000982, "claim": "Uk labs 'can process instead of thousands more tests '", "label": "REFUTED", "evidence": ["Anthony Costello, a global health professor at University College London, called for the UK to make use of testing machines in every university and big hospital around the country, setting up mobile testing units like Ireland, which is testing far more people per head of population."]}
{"id": 1000983, "claim": "The use of povidone iodine nasal spray and mouthwash during the current covid-19 pandemic may reduce cross infection and protect healthcare workers", "label": "SUPPORTED", "evidence": ["The use of povidone iodine nasal spray and mouthwash during the current covid-19 pandemic may protect healthcare workers and reduce cross infection.", "We propose that a protocolised nasal spray and oropharyngeal wash of PVP-I should be used in the current COVID-19 pandemic to limit the spread of SARS-CoV-2 from patients to healthcare workers and potentially vice versa.", "Kirk-Bailey J, Combes J, Sunkaraneni S, Challacombe S. The use of Povidone Iodine nasal spray and mouthwash during the current COVID-19 pandemic for the reduction of cross infection and protection of healthcare workers.", "The application of PVP-I mouthwash and nasal spray in this way should reduce the cross-infection risk and therefore help to protect dentists."]}
{"id": 1000984, "claim": "The use of povidone iodine nasal spray and mouthwash during the current covid-19 pandemic may reduce cross infection and reduce healthcare workers", "label": "REFUTED", "evidence": ["The use of povidone iodine nasal spray and mouthwash during the current covid-19 pandemic may protect healthcare workers and reduce cross infection.", "We propose that a protocolised nasal spray and oropharyngeal wash of PVP-I should be used in the current COVID-19 pandemic to limit the spread of SARS-CoV-2 from patients to healthcare workers and potentially vice versa.", "Kirk-Bailey J, Combes J, Sunkaraneni S, Challacombe S. The use of Povidone Iodine nasal spray and mouthwash during the current COVID-19 pandemic for the reduction of cross infection and protection of healthcare workers.", "The application of PVP-I mouthwash and nasal spray in this way should reduce the cross-infection risk and therefore help to protect dentists."]}
{"id": 1000985, "claim": "Confirmed cases a pointless metric , says steve goodman , a professor of epidemiology at stanford university", "label": "SUPPORTED", "evidence": ["> > \"The numbers are almost meaningless,\" says Steve Goodman, a professor of > epidemiology at Stanford University.", "The numbers are almost meaningless, says Steve Goodman, a professor of epidemiology at Stanford University.", "Though death rate figures of around 1% have been tossed around, Goodman says hes skeptical that anyone knows the death rate of this disease since we dont know the true rates of infection."]}
{"id": 1000986, "claim": "Confirmed cases a similar metric, says steve goodman, a professor of epidemiology at stanford university", "label": "REFUTED", "evidence": ["> > \"The numbers are almost meaningless,\" says Steve Goodman, a professor of > epidemiology at Stanford University.", "The numbers are almost meaningless, says Steve Goodman, a professor of epidemiology at Stanford University.", "Though death rate figures of around 1% have been tossed around, Goodman says hes skeptical that anyone knows the death rate of this disease since we dont know the true rates of infection."]}
{"id": 1000987, "claim": "Confirmed cases a risk metric, says steve goodman, a professor of epidemiology at stanford university", "label": "REFUTED", "evidence": ["> > \"The numbers are almost meaningless,\" says Steve Goodman, a professor of > epidemiology at Stanford University.", "The numbers are almost meaningless, says Steve Goodman, a professor of epidemiology at Stanford University.", "Though death rate figures of around 1% have been tossed around, Goodman says hes skeptical that anyone knows the death rate of this disease since we dont know the true rates of infection."]}
{"id": 1000988, "claim": "Confirmed cases a reference metric, says steve goodman, a professor of epidemiology at stanford university", "label": "REFUTED", "evidence": ["> > \"The numbers are almost meaningless,\" says Steve Goodman, a professor of > epidemiology at Stanford University.", "The numbers are almost meaningless, says Steve Goodman, a professor of epidemiology at Stanford University.", "Though death rate figures of around 1% have been tossed around, Goodman says hes skeptical that anyone knows the death rate of this disease since we dont know the true rates of infection."]}
{"id": 1000989, "claim": "Researchers push for mass blood tests as a covid-19 strategy", "label": "SUPPORTED", "evidence": ["But with the severity of the Covid-19 outbreak, researchers around the world are racing to get tests out there quickly."]}
{"id": 1000990, "claim": "Researchers push for mass blood transfusion as a covid-19 strategy", "label": "REFUTED", "evidence": ["But with the severity of the Covid-19 outbreak, researchers around the world are racing to get tests out there quickly."]}
{"id": 1000991, "claim": "Researchers push for mass blood production as a covid-19 strategy", "label": "REFUTED", "evidence": ["But with the severity of the Covid-19 outbreak, researchers around the world are racing to get tests out there quickly."]}
{"id": 1000992, "claim": "The ace2 expression in sertoli cells and germ cells may cause male reproductive disorder after sars-cov-2 infection", "label": "SUPPORTED", "evidence": ["Moreover, the positive rate of ACE2 in testes of infertile men was higher than normal, which indicates that SARS-CoV-2 may cause reproductive disorders through pathway activated by ACE2 and the men with reproductive disorder may easily to be infected by SARS-CoV-2.", "The novel angiotensinconverting enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis.", "The expression level of ACE2 was related to the age, and the mid-aged with higher positive rate than young men testicular cells.", "F, Sertoli cells are the highest cluster with ACE2 positive cells in the young group Figure 2 ACE2 expression in health and Figure 2 ACE2 expression in health and male infertility donors."]}
{"id": 1000993, "claim": "The ace2 expression in sertoli cells and germ cells may reduce male reproductive disorder after sars-cov-2 infection", "label": "REFUTED", "evidence": ["Moreover, the positive rate of ACE2 in testes of infertile men was higher than normal, which indicates that SARS-CoV-2 may cause reproductive disorders through pathway activated by ACE2 and the men with reproductive disorder may easily to be infected by SARS-CoV-2.", "The novel angiotensinconverting enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis.", "The expression level of ACE2 was related to the age, and the mid-aged with higher positive rate than young men testicular cells.", "F, Sertoli cells are the highest cluster with ACE2 positive cells in the young group Figure 2 ACE2 expression in health and Figure 2 ACE2 expression in health and male infertility donors."]}
{"id": 1000994, "claim": "The ace2 deficiency in sertoli cells and germ cells may cause male reproductive disorder after sars-cov-2 infection", "label": "REFUTED", "evidence": ["Moreover, the positive rate of ACE2 in testes of infertile men was higher than normal, which indicates that SARS-CoV-2 may cause reproductive disorders through pathway activated by ACE2 and the men with reproductive disorder may easily to be infected by SARS-CoV-2.", "The novel angiotensinconverting enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis.", "The expression level of ACE2 was related to the age, and the mid-aged with higher positive rate than young men testicular cells.", "F, Sertoli cells are the highest cluster with ACE2 positive cells in the young group Figure 2 ACE2 expression in health and Figure 2 ACE2 expression in health and male infertility donors."]}
{"id": 1000995, "claim": "The ace2 expression in sertoli cells and germ cells cannot cause male reproductive disorder after sars-cov-2 infection", "label": "REFUTED", "evidence": ["Moreover, the positive rate of ACE2 in testes of infertile men was higher than normal, which indicates that SARS-CoV-2 may cause reproductive disorders through pathway activated by ACE2 and the men with reproductive disorder may easily to be infected by SARS-CoV-2.", "The novel angiotensinconverting enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis.", "The expression level of ACE2 was related to the age, and the mid-aged with higher positive rate than young men testicular cells.", "F, Sertoli cells are the highest cluster with ACE2 positive cells in the young group Figure 2 ACE2 expression in health and Figure 2 ACE2 expression in health and male infertility donors."]}
{"id": 1000996, "claim": "Millions of women lose contraceptives , abortions in covid-19", "label": "SUPPORTED", "evidence": ["(AP Photo/Themba Hadebe) NEW DELHI (AP)  Millions of women and girls globally have lost access to contraceptives and abortion services because of the coronavirus pandemic.", "Millions of women and girls globally have lost access to contraceptives, abortion services and related care because of the coronavirus pandemic.", "The World Health Organization this month said two-thirds of 103 countries surveyed between mid-May and early July reported disruptions to family planning and contraception services.", "Now many women face second-trimester abortions, which are more expensive and complicated, especially because everyone who is involved needs to wear PPE. Abortion access has improved in India, but the pandemic resulted in abortion pill shortages in several states surveyed by Foundation for Reproductive Health Services India."]}
{"id": 1000997, "claim": "None of women lose contraceptives, abortions in covid-19", "label": "REFUTED", "evidence": ["(AP Photo/Themba Hadebe) NEW DELHI (AP)  Millions of women and girls globally have lost access to contraceptives and abortion services because of the coronavirus pandemic.", "Millions of women and girls globally have lost access to contraceptives, abortion services and related care because of the coronavirus pandemic.", "The World Health Organization this month said two-thirds of 103 countries surveyed between mid-May and early July reported disruptions to family planning and contraception services.", "Now many women face second-trimester abortions, which are more expensive and complicated, especially because everyone who is involved needs to wear PPE. Abortion access has improved in India, but the pandemic resulted in abortion pill shortages in several states surveyed by Foundation for Reproductive Health Services India."]}
{"id": 1000998, "claim": "Two of women lose contraceptives, abortions in covid-19", "label": "REFUTED", "evidence": ["(AP Photo/Themba Hadebe) NEW DELHI (AP)  Millions of women and girls globally have lost access to contraceptives and abortion services because of the coronavirus pandemic.", "Millions of women and girls globally have lost access to contraceptives, abortion services and related care because of the coronavirus pandemic.", "The World Health Organization this month said two-thirds of 103 countries surveyed between mid-May and early July reported disruptions to family planning and contraception services.", "Now many women face second-trimester abortions, which are more expensive and complicated, especially because everyone who is involved needs to wear PPE. Abortion access has improved in India, but the pandemic resulted in abortion pill shortages in several states surveyed by Foundation for Reproductive Health Services India."]}
{"id": 1000999, "claim": "Five of women lose contraceptives, abortions in covid-19", "label": "REFUTED", "evidence": ["(AP Photo/Themba Hadebe) NEW DELHI (AP)  Millions of women and girls globally have lost access to contraceptives and abortion services because of the coronavirus pandemic.", "Millions of women and girls globally have lost access to contraceptives, abortion services and related care because of the coronavirus pandemic.", "The World Health Organization this month said two-thirds of 103 countries surveyed between mid-May and early July reported disruptions to family planning and contraception services.", "Now many women face second-trimester abortions, which are more expensive and complicated, especially because everyone who is involved needs to wear PPE. Abortion access has improved in India, but the pandemic resulted in abortion pill shortages in several states surveyed by Foundation for Reproductive Health Services India."]}
{"id": 1001000, "claim": "Chinese netizens use ethereum to avoid china 's covid-19 censorship", "label": "SUPPORTED", "evidence": ["China has also used keyword-based censorship approaches to domestic apps such as WeChat, stopping COVID-19 discussions that might be critical of the central government from happening.", "How Chinas Social Media Users Created a New Language to Beat Censorship on COVID-19.", "Harmoniously Denied: The Wider Implications of Chinas Censorship on COVID-19. OpenDemocracy.", "South Central Morning Post journalist Sarah Zhang posted about how her interview with Dr. Ai Fen, a subject of attempted Chinese state censorship, was relayed and posted on the Ethereum blockchain to circumvent that censorship.", "Chinese writers such as Yu Hua have long written about the spirit of May 35th, where Chinese netizens evade the controls of the Chinese Internet through clever methods, akin to a mouse evading a cat."]}
{"id": 1001001, "claim": "Chinese netizens use ethereum to include china's covid-19 censorship", "label": "REFUTED", "evidence": ["China has also used keyword-based censorship approaches to domestic apps such as WeChat, stopping COVID-19 discussions that might be critical of the central government from happening.", "How Chinas Social Media Users Created a New Language to Beat Censorship on COVID-19.", "Harmoniously Denied: The Wider Implications of Chinas Censorship on COVID-19. OpenDemocracy.", "South Central Morning Post journalist Sarah Zhang posted about how her interview with Dr. Ai Fen, a subject of attempted Chinese state censorship, was relayed and posted on the Ethereum blockchain to circumvent that censorship.", "Chinese writers such as Yu Hua have long written about the spirit of May 35th, where Chinese netizens evade the controls of the Chinese Internet through clever methods, akin to a mouse evading a cat."]}
{"id": 1001002, "claim": "Enhanced sars-cov-2 neutralization by secretory iga in vitro", "label": "SUPPORTED", "evidence": ["Thus, secretory IgA responses may be particularly valuable for protection against SARS-CoV-2 and for vaccine efficacy."]}
{"id": 1001003, "claim": "inhibit sars-cov-2 neutralization by secretory iga in vitro", "label": "REFUTED", "evidence": ["Thus, secretory IgA responses may be particularly valuable for protection against SARS-CoV-2 and for vaccine efficacy."]}
{"id": 1001004, "claim": "inhibited sars-cov-2 neutralization by secretory iga in vitro", "label": "REFUTED", "evidence": ["Thus, secretory IgA responses may be particularly valuable for protection against SARS-CoV-2 and for vaccine efficacy."]}
{"id": 1001005, "claim": "Enhanced ifns-cov-2 neutralization by secretory iga in vitro", "label": "REFUTED", "evidence": ["Thus, secretory IgA responses may be particularly valuable for protection against SARS-CoV-2 and for vaccine efficacy."]}
{"id": 1001006, "claim": "Lipid droplets fuels sars-cov-2 replication and inflammatory response", "label": "SUPPORTED", "evidence": ["It was hypothesized that the virus induces these changes to promote viral replication and that lipid droplets play an important in viral replication.", "Lipid droplets (LD) are organelles with major functions in lipid metabolism and energy homeostasis, and have multiple roles in infections and inflammation.", "Associations of Covid ROs with Lipid Droplets could also be examined in combinations with other vital-stains (e.g."]}
{"id": 1001007, "claim": "Lipid droplets inhibit sars-cov-2 replication and inflammatory response", "label": "REFUTED", "evidence": ["It was hypothesized that the virus induces these changes to promote viral replication and that lipid droplets play an important in viral replication.", "Lipid droplets (LD) are organelles with major functions in lipid metabolism and energy homeostasis, and have multiple roles in infections and inflammation.", "Associations of Covid ROs with Lipid Droplets could also be examined in combinations with other vital-stains (e.g."]}
{"id": 1001008, "claim": "Century-old vaccine investigates as a weapon against coronavirus", "label": "SUPPORTED", "evidence": ["They will test whether a century- old vaccine against tuberculosis (TB), a bacterial disease, can rev up the human immune system in a broad way, allowing it to better fight the virus that causes coronavirus disease 2019 and, perhaps, prevent infection with it altogether.", "PHOTO: AFP [MELBOURNE] A vaccine that's been used to prevent tuberculosis is being given to healthcare workers in Melbourne to see if it will protect them against the coronavirus."]}
{"id": 1001009, "claim": "Twenty-old vaccine investigates as a weapon against coronavirus", "label": "REFUTED", "evidence": ["They will test whether a century- old vaccine against tuberculosis (TB), a bacterial disease, can rev up the human immune system in a broad way, allowing it to better fight the virus that causes coronavirus disease 2019 and, perhaps, prevent infection with it altogether.", "PHOTO: AFP [MELBOURNE] A vaccine that's been used to prevent tuberculosis is being given to healthcare workers in Melbourne to see if it will protect them against the coronavirus."]}
{"id": 1001010, "claim": "Week-old vaccine investigates as a weapon against coronavirus", "label": "REFUTED", "evidence": ["They will test whether a century- old vaccine against tuberculosis (TB), a bacterial disease, can rev up the human immune system in a broad way, allowing it to better fight the virus that causes coronavirus disease 2019 and, perhaps, prevent infection with it altogether.", "PHOTO: AFP [MELBOURNE] A vaccine that's been used to prevent tuberculosis is being given to healthcare workers in Melbourne to see if it will protect them against the coronavirus."]}
{"id": 1001011, "claim": "One-old vaccine investigates as a weapon against coronavirus", "label": "REFUTED", "evidence": ["They will test whether a century- old vaccine against tuberculosis (TB), a bacterial disease, can rev up the human immune system in a broad way, allowing it to better fight the virus that causes coronavirus disease 2019 and, perhaps, prevent infection with it altogether.", "PHOTO: AFP [MELBOURNE] A vaccine that's been used to prevent tuberculosis is being given to healthcare workers in Melbourne to see if it will protect them against the coronavirus."]}
{"id": 1001012, "claim": "Human neutralizing antibodies elicited by sars-cov-2 infection", "label": "SUPPORTED", "evidence": ["Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.", "In this study, we report on RBD-specific monoclonal antibodies obtained from individuals infected with SARS-CoV-2."]}
{"id": 1001013, "claim": "No neutralizing antibodies elicited by sars-cov-2 infection", "label": "REFUTED", "evidence": ["Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.", "In this study, we report on RBD-specific monoclonal antibodies obtained from individuals infected with SARS-CoV-2."]}
{"id": 1001014, "claim": "Human neutralizing response elicited by sars-cov-2 infection", "label": "REFUTED", "evidence": ["Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.", "In this study, we report on RBD-specific monoclonal antibodies obtained from individuals infected with SARS-CoV-2."]}
{"id": 1001015, "claim": "Salt-coated masks achieve strong viral deactivation rate", "label": "SUPPORTED", "evidence": ["Salt-coated filters proved highly effective in deactivating influenza viruses regardless of subtypes and following storage in harsh environmental conditions.", "Mask with salt-coated filter for prevention and deactivation of airborne pathogens.", "Here, we report the development of a universal, reusable virus deactivation system by functionalization of the main fibrous filtration unit of surgical mask with sodium chloride salt."]}
{"id": 1001016, "claim": "Salt-coated masks achieve low viral deactivation rate", "label": "REFUTED", "evidence": ["Salt-coated filters proved highly effective in deactivating influenza viruses regardless of subtypes and following storage in harsh environmental conditions.", "Mask with salt-coated filter for prevention and deactivation of airborne pathogens.", "Here, we report the development of a universal, reusable virus deactivation system by functionalization of the main fibrous filtration unit of surgical mask with sodium chloride salt."]}
{"id": 1001017, "claim": "Salt-coated masks achieve reduced viral deactivation rate", "label": "REFUTED", "evidence": ["Salt-coated filters proved highly effective in deactivating influenza viruses regardless of subtypes and following storage in harsh environmental conditions.", "Mask with salt-coated filter for prevention and deactivation of airborne pathogens.", "Here, we report the development of a universal, reusable virus deactivation system by functionalization of the main fibrous filtration unit of surgical mask with sodium chloride salt."]}
{"id": 1001018, "claim": "Salt-coated masks achieve lower viral deactivation rate", "label": "REFUTED", "evidence": ["Salt-coated filters proved highly effective in deactivating influenza viruses regardless of subtypes and following storage in harsh environmental conditions.", "Mask with salt-coated filter for prevention and deactivation of airborne pathogens.", "Here, we report the development of a universal, reusable virus deactivation system by functionalization of the main fibrous filtration unit of surgical mask with sodium chloride salt."]}
{"id": 1001019, "claim": "Sars-cov-2 infections and covid-19 mortalities strongly correlate with ace1 i/d genotype", "label": "SUPPORTED", "evidence": ["COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation.", "These data suggest that the ACE1 II genotype may influence the prevalence and clinical outcome of COVID-19 and serve as a predictive marker for COVID-19 risk and severity."]}
{"id": 1001020, "claim": "Sars-cov-2 infections and covid-19 mortalities not correlate with ace1 i/d genotype", "label": "REFUTED", "evidence": ["COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation.", "These data suggest that the ACE1 II genotype may influence the prevalence and clinical outcome of COVID-19 and serve as a predictive marker for COVID-19 risk and severity."]}
{"id": 1001021, "claim": "Sars-cov-2 infections and covid-19 mortalities strongly correlate against ace1 i/d genotype", "label": "REFUTED", "evidence": ["COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation.", "These data suggest that the ACE1 II genotype may influence the prevalence and clinical outcome of COVID-19 and serve as a predictive marker for COVID-19 risk and severity."]}
{"id": 1001022, "claim": "Hydroxychloroquine proves ineffective in hamsters and macaques infected with sars-cov-2", "label": "SUPPORTED", "evidence": ["Similarly, HCQ prophylaxis/treatment (6.5 mg/kg) did not significantly benefit clinical outcome nor reduce SARS-CoV-2 replication/shedding in the upper and lower respiratory tract in the rhesus macaque disease model.", "In conclusion, HCQ prophylaxis and treatment had no beneficial effect in the two animal disease models tested."]}
{"id": 1001023, "claim": "Hydroxychloroquine proves protection in hamsters and macaques infected with sars-cov-2", "label": "REFUTED", "evidence": ["Similarly, HCQ prophylaxis/treatment (6.5 mg/kg) did not significantly benefit clinical outcome nor reduce SARS-CoV-2 replication/shedding in the upper and lower respiratory tract in the rhesus macaque disease model.", "In conclusion, HCQ prophylaxis and treatment had no beneficial effect in the two animal disease models tested."]}
{"id": 1001024, "claim": "Hydroxychloroquine proves efficiently in hamsters and macaques infected with sars-cov-2", "label": "REFUTED", "evidence": ["Similarly, HCQ prophylaxis/treatment (6.5 mg/kg) did not significantly benefit clinical outcome nor reduce SARS-CoV-2 replication/shedding in the upper and lower respiratory tract in the rhesus macaque disease model.", "In conclusion, HCQ prophylaxis and treatment had no beneficial effect in the two animal disease models tested."]}
{"id": 1001025, "claim": "Hydroxychloroquine proves activity in hamsters and macaques infected with sars-cov-2", "label": "REFUTED", "evidence": ["Similarly, HCQ prophylaxis/treatment (6.5 mg/kg) did not significantly benefit clinical outcome nor reduce SARS-CoV-2 replication/shedding in the upper and lower respiratory tract in the rhesus macaque disease model.", "In conclusion, HCQ prophylaxis and treatment had no beneficial effect in the two animal disease models tested."]}
{"id": 1001026, "claim": "The first u.s. company has announced an upcoming home covid-19 test", "label": "SUPPORTED", "evidence": ["Everlywell says it is ready to ship 30,000 COVID-19 tests, and plans to expand the number of labs processing the samples.", "After initially limiting testing to one provided by the Centers for Disease Control and conducted at state and local public health labs, the Food and Drug Administration allowed certified labs, including commercial lab testing companies, to develop and distribute COVID-19 tests on Feb. 29.", "Though other private companies have been involved with creating tests for COVID-19, this is the first company to offer its test directly to consumers.", "People can order the Everlywell COVID-19 test on the company's website, after first answering questions about their basic health, symptoms and risk factors for the coronavirus disease."]}
{"id": 1001027, "claim": "The chinese u.s. company has announced an upcoming home covid-19 test", "label": "REFUTED", "evidence": ["Everlywell says it is ready to ship 30,000 COVID-19 tests, and plans to expand the number of labs processing the samples.", "After initially limiting testing to one provided by the Centers for Disease Control and conducted at state and local public health labs, the Food and Drug Administration allowed certified labs, including commercial lab testing companies, to develop and distribute COVID-19 tests on Feb. 29.", "Though other private companies have been involved with creating tests for COVID-19, this is the first company to offer its test directly to consumers.", "People can order the Everlywell COVID-19 test on the company's website, after first answering questions about their basic health, symptoms and risk factors for the coronavirus disease."]}
{"id": 1001028, "claim": "The third u.s. company has announced an upcoming home covid-19 test", "label": "REFUTED", "evidence": ["Everlywell says it is ready to ship 30,000 COVID-19 tests, and plans to expand the number of labs processing the samples.", "After initially limiting testing to one provided by the Centers for Disease Control and conducted at state and local public health labs, the Food and Drug Administration allowed certified labs, including commercial lab testing companies, to develop and distribute COVID-19 tests on Feb. 29.", "Though other private companies have been involved with creating tests for COVID-19, this is the first company to offer its test directly to consumers.", "People can order the Everlywell COVID-19 test on the company's website, after first answering questions about their basic health, symptoms and risk factors for the coronavirus disease."]}
{"id": 1001029, "claim": "The second u.s. company has announced an upcoming home covid-19 test", "label": "REFUTED", "evidence": ["Everlywell says it is ready to ship 30,000 COVID-19 tests, and plans to expand the number of labs processing the samples.", "After initially limiting testing to one provided by the Centers for Disease Control and conducted at state and local public health labs, the Food and Drug Administration allowed certified labs, including commercial lab testing companies, to develop and distribute COVID-19 tests on Feb. 29.", "Though other private companies have been involved with creating tests for COVID-19, this is the first company to offer its test directly to consumers.", "People can order the Everlywell COVID-19 test on the company's website, after first answering questions about their basic health, symptoms and risk factors for the coronavirus disease."]}
{"id": 1001030, "claim": "Single covid vaccine dose in israel 'less effective than we thought '.", "label": "SUPPORTED", "evidence": ["MIRIAM ALSTER/POOL/AFP via Getty Images Israel's coronavirus chief warned the first Pfizer vaccine dose seems \"less effective\" than expected.", "The Israeli official leading the country's coronavirus response warned that it is seeing a smaller effect than it hoped after giving a dose of the vaccine."]}
{"id": 1001031, "claim": "Single covid vaccine dose in israel 'rather effective than we thought '.", "label": "REFUTED", "evidence": ["MIRIAM ALSTER/POOL/AFP via Getty Images Israel's coronavirus chief warned the first Pfizer vaccine dose seems \"less effective\" than expected.", "The Israeli official leading the country's coronavirus response warned that it is seeing a smaller effect than it hoped after giving a dose of the vaccine."]}
{"id": 1001032, "claim": "Single covid vaccine dose in israel 'as effective than we thought '.", "label": "REFUTED", "evidence": ["MIRIAM ALSTER/POOL/AFP via Getty Images Israel's coronavirus chief warned the first Pfizer vaccine dose seems \"less effective\" than expected.", "The Israeli official leading the country's coronavirus response warned that it is seeing a smaller effect than it hoped after giving a dose of the vaccine."]}
{"id": 1001033, "claim": "Single covid vaccine dose in israel'rather effective than we thought '.", "label": "REFUTED", "evidence": ["MIRIAM ALSTER/POOL/AFP via Getty Images Israel's coronavirus chief warned the first Pfizer vaccine dose seems \"less effective\" than expected.", "The Israeli official leading the country's coronavirus response warned that it is seeing a smaller effect than it hoped after giving a dose of the vaccine."]}
{"id": 1001034, "claim": "Genomic surveillance of sars-cov-2 in thailand reveals mixed imported populations , a local lineage expansion and a virus with truncated orf7a", "label": "SUPPORTED", "evidence": ["Several virus lineages supposedly originated in many countries were found, and a Thai-specific lineage, designated A/Thai-1, has expanded to be predominant in Thailand.", "A virus sample in the SARS-CoV-2 A/Thai-1 lineage contains a frame-shift deletion at ORF7a, encoding a putative host antagonizing factor of the virus."]}
{"id": 1001035, "claim": "Genomic surveillance of sars-cov-2 in europe reveals mixed imported populations, a local lineage expansion and a virus with truncated orf7a", "label": "REFUTED", "evidence": ["Several virus lineages supposedly originated in many countries were found, and a Thai-specific lineage, designated A/Thai-1, has expanded to be predominant in Thailand.", "A virus sample in the SARS-CoV-2 A/Thai-1 lineage contains a frame-shift deletion at ORF7a, encoding a putative host antagonizing factor of the virus."]}
{"id": 1001036, "claim": "Genomic surveillance of sars-cov-2 in africa reveals mixed imported populations, a local lineage expansion and a virus with truncated orf7a", "label": "REFUTED", "evidence": ["Several virus lineages supposedly originated in many countries were found, and a Thai-specific lineage, designated A/Thai-1, has expanded to be predominant in Thailand.", "A virus sample in the SARS-CoV-2 A/Thai-1 lineage contains a frame-shift deletion at ORF7a, encoding a putative host antagonizing factor of the virus."]}
{"id": 1001037, "claim": "Genomic surveillance of sars-cov-2 in kenya reveals mixed imported populations, a local lineage expansion and a virus with truncated orf7a", "label": "REFUTED", "evidence": ["Several virus lineages supposedly originated in many countries were found, and a Thai-specific lineage, designated A/Thai-1, has expanded to be predominant in Thailand.", "A virus sample in the SARS-CoV-2 A/Thai-1 lineage contains a frame-shift deletion at ORF7a, encoding a putative host antagonizing factor of the virus."]}
{"id": 1001038, "claim": "Us hits grim new daily record with 3,656 coronavirus deaths.", "label": "SUPPORTED", "evidence": ["And the rate keeps accelerating as the death toll tops 300,000 (CNN) Young People Have Less Covid-19 Risk, but in College Towns, Deaths Rose Fast (The New York Times) US virus deaths hit record levels with the holidays ahead (AP News) The Pandemics Final Surge Will Be Brutal (The Atlantic) Vaccines are coming, but pandemic experts expect a horrible winter.", "Wednesday marked the fourth day since the pandemic began that the U.S. surpassed 3,000 COVID-19 deaths in a day.", "(Moser, 12/17) Courier-Journal: Kentucky Suffers Worst Day For COVID-19 Deaths Thursday With 54 Losses The coronavirus pandemic that already has killed more than 2,300 Kentuckians exacted its deadliest toll yet Thursday  with 54 people dying in a single day from the virus.", "The nation also recorded 3,656 deaths on Wednesday, surpassing the previous record of 3,306 set Friday."]}
{"id": 1001039, "claim": "Us hits no new daily record with 3,656 coronavirus deaths.", "label": "REFUTED", "evidence": ["And the rate keeps accelerating as the death toll tops 300,000 (CNN) Young People Have Less Covid-19 Risk, but in College Towns, Deaths Rose Fast (The New York Times) US virus deaths hit record levels with the holidays ahead (AP News) The Pandemics Final Surge Will Be Brutal (The Atlantic) Vaccines are coming, but pandemic experts expect a horrible winter.", "Wednesday marked the fourth day since the pandemic began that the U.S. surpassed 3,000 COVID-19 deaths in a day.", "(Moser, 12/17) Courier-Journal: Kentucky Suffers Worst Day For COVID-19 Deaths Thursday With 54 Losses The coronavirus pandemic that already has killed more than 2,300 Kentuckians exacted its deadliest toll yet Thursday  with 54 people dying in a single day from the virus.", "The nation also recorded 3,656 deaths on Wednesday, surpassing the previous record of 3,306 set Friday."]}
{"id": 1001040, "claim": "Crispr-based covid test is rapid , accurate and costs less than $ 1", "label": "SUPPORTED", "evidence": ["Recent studies have indicated CRISPR tools have the potential for in vitro diagnostics, something Chinese scientists have leveraged to develop a 100% accurate COVID-19 test that can be mass manufactured for 70 cents.", "With two targets in hand, the team took advantage of the sensitivity of CRISPR/Cas--specifically the programmability of CRISPR/Cas13a--to create an isothermal-based assay that eliminates the need for sophisticated analytical instruments."]}
{"id": 1001041, "claim": "Crispr-based covid test is rapid, accurate and costs greater than $ 1", "label": "REFUTED", "evidence": ["Recent studies have indicated CRISPR tools have the potential for in vitro diagnostics, something Chinese scientists have leveraged to develop a 100% accurate COVID-19 test that can be mass manufactured for 70 cents.", "With two targets in hand, the team took advantage of the sensitivity of CRISPR/Cas--specifically the programmability of CRISPR/Cas13a--to create an isothermal-based assay that eliminates the need for sophisticated analytical instruments."]}
{"id": 1001042, "claim": "Crispr-based covid test is rapid, accurate and costs more than $ 1", "label": "REFUTED", "evidence": ["Recent studies have indicated CRISPR tools have the potential for in vitro diagnostics, something Chinese scientists have leveraged to develop a 100% accurate COVID-19 test that can be mass manufactured for 70 cents.", "With two targets in hand, the team took advantage of the sensitivity of CRISPR/Cas--specifically the programmability of CRISPR/Cas13a--to create an isothermal-based assay that eliminates the need for sophisticated analytical instruments."]}
{"id": 1001043, "claim": "Crispr-based covid test is rapid, accurate and costs larger than $ 1", "label": "REFUTED", "evidence": ["Recent studies have indicated CRISPR tools have the potential for in vitro diagnostics, something Chinese scientists have leveraged to develop a 100% accurate COVID-19 test that can be mass manufactured for 70 cents.", "With two targets in hand, the team took advantage of the sensitivity of CRISPR/Cas--specifically the programmability of CRISPR/Cas13a--to create an isothermal-based assay that eliminates the need for sophisticated analytical instruments."]}
{"id": 1001044, "claim": "Shanghai airport covid scare sparks 'chaotic ' mass testing", "label": "SUPPORTED", "evidence": ["However, other videos believed to be of the mass testing show officials in hazmat suits corralling large, yelling crowds into a restricted space."]}
{"id": 1001045, "claim": "Shanghai airport covid scare sparks 'no'mass testing", "label": "REFUTED", "evidence": ["However, other videos believed to be of the mass testing show officials in hazmat suits corralling large, yelling crowds into a restricted space."]}
{"id": 1001046, "claim": "Cdc study found geographic origin of sars-covid-19 in new york is from europe rather than china .", "label": "SUPPORTED", "evidence": ["Rather, the sequence analysis suggests probable introductions of SARS-CoV-2 from Europe, from other U.S. locations, and local introductions from within New York.", "Using genetic sequencing, CDC determined that the sequences of most SARS- CoV-2-positive specimens resembled those circulating in Europe, suggesting probable introductions of SARS-CoV-2 from Europe, from other U.S. locations, and local introductions from within New York."]}
{"id": 1001047, "claim": "Cdc study found geographic origin of sars-covid-19 in new york is not europe rather than china.", "label": "REFUTED", "evidence": ["Rather, the sequence analysis suggests probable introductions of SARS-CoV-2 from Europe, from other U.S. locations, and local introductions from within New York.", "Using genetic sequencing, CDC determined that the sequences of most SARS- CoV-2-positive specimens resembled those circulating in Europe, suggesting probable introductions of SARS-CoV-2 from Europe, from other U.S. locations, and local introductions from within New York."]}
{"id": 1001048, "claim": "Inhibition of papain-like protease plpro blocks sars- cov-2 spread and promotes anti-viral immunity", "label": "SUPPORTED", "evidence": ["We propose that therapeutic targeting of PLproCoV2 can suppress SARS-CoV-2 infection and promote anti-viral immunity.", "Pharmacological inhibition of PLproCoV2 blocks the virus-induced cytopathogenic effect upon infection with SARS-CoV-2, fosters the anti- viral interferon pathway and reduces viral release from infected cells.", "In human cells, PLproCoV2 cleaves ISG15 from interferon responsive factor 3 (IRF3), blocks its nuclear translocation, and reduces type I interferon responses, whereas PLproSARS preferentially mediates deubiquitination of critical components of the NF-kB pathway."]}
{"id": 1001049, "claim": "Inhibition of papain-like protease plpro blocks sars- cov-2 spread and prevent anti-viral immunity", "label": "REFUTED", "evidence": ["We propose that therapeutic targeting of PLproCoV2 can suppress SARS-CoV-2 infection and promote anti-viral immunity.", "Pharmacological inhibition of PLproCoV2 blocks the virus-induced cytopathogenic effect upon infection with SARS-CoV-2, fosters the anti- viral interferon pathway and reduces viral release from infected cells.", "In human cells, PLproCoV2 cleaves ISG15 from interferon responsive factor 3 (IRF3), blocks its nuclear translocation, and reduces type I interferon responses, whereas PLproSARS preferentially mediates deubiquitination of critical components of the NF-kB pathway."]}
{"id": 1001050, "claim": "Inhibition of papain-like protease plpro blocks sars- cov-2 spread and inhibit anti-viral immunity", "label": "REFUTED", "evidence": ["We propose that therapeutic targeting of PLproCoV2 can suppress SARS-CoV-2 infection and promote anti-viral immunity.", "Pharmacological inhibition of PLproCoV2 blocks the virus-induced cytopathogenic effect upon infection with SARS-CoV-2, fosters the anti- viral interferon pathway and reduces viral release from infected cells.", "In human cells, PLproCoV2 cleaves ISG15 from interferon responsive factor 3 (IRF3), blocks its nuclear translocation, and reduces type I interferon responses, whereas PLproSARS preferentially mediates deubiquitination of critical components of the NF-kB pathway."]}
{"id": 1001051, "claim": "Inhibition of papain-like protease plpro blocks sars- cov-2 spread and inhibits anti-viral immunity", "label": "REFUTED", "evidence": ["We propose that therapeutic targeting of PLproCoV2 can suppress SARS-CoV-2 infection and promote anti-viral immunity.", "Pharmacological inhibition of PLproCoV2 blocks the virus-induced cytopathogenic effect upon infection with SARS-CoV-2, fosters the anti- viral interferon pathway and reduces viral release from infected cells.", "In human cells, PLproCoV2 cleaves ISG15 from interferon responsive factor 3 (IRF3), blocks its nuclear translocation, and reduces type I interferon responses, whereas PLproSARS preferentially mediates deubiquitination of critical components of the NF-kB pathway."]}
{"id": 1001052, "claim": "In china , github is a free speech zone for covid-19 information", "label": "SUPPORTED", "evidence": ["All this has made GitHub one of the few sanctuaries from censors and a platform for online resistance.", "(Score:1) by bustinbrains ( 6800166 ) writes: \"Chinese authorities cannot censor individual projects, because GitHub uses the HTTPS protocol, which encrypts all traffic.\"", "But GitHub, known to some Chinese internet users as the \"last land of free speech in China,\" remains accessible.", "But GitHub, known to some Chinese internet users as the last land of free speech in China, remains accessible."]}
{"id": 1001053, "claim": "In equation, github is a free speech zone for covid-19 information", "label": "REFUTED", "evidence": ["All this has made GitHub one of the few sanctuaries from censors and a platform for online resistance.", "(Score:1) by bustinbrains ( 6800166 ) writes: \"Chinese authorities cannot censor individual projects, because GitHub uses the HTTPS protocol, which encrypts all traffic.\"", "But GitHub, known to some Chinese internet users as the \"last land of free speech in China,\" remains accessible.", "But GitHub, known to some Chinese internet users as the last land of free speech in China, remains accessible."]}
{"id": 1001054, "claim": "In 1, github is a free speech zone for covid-19 information", "label": "REFUTED", "evidence": ["All this has made GitHub one of the few sanctuaries from censors and a platform for online resistance.", "(Score:1) by bustinbrains ( 6800166 ) writes: \"Chinese authorities cannot censor individual projects, because GitHub uses the HTTPS protocol, which encrypts all traffic.\"", "But GitHub, known to some Chinese internet users as the \"last land of free speech in China,\" remains accessible.", "But GitHub, known to some Chinese internet users as the last land of free speech in China, remains accessible."]}
{"id": 1001055, "claim": "It 's too soon to assume success for moderna 's covid-19 vaccine", "label": "SUPPORTED", "evidence": ["Its way too early to get excited about Modernas mRNA vaccine to prevent COVID-19, concluded Evercore ISI analyst Umer Raffat after analyzing the companys data."]}
{"id": 1001056, "claim": "It's too long to assume success for moderna's covid-19 vaccine", "label": "REFUTED", "evidence": ["Its way too early to get excited about Modernas mRNA vaccine to prevent COVID-19, concluded Evercore ISI analyst Umer Raffat after analyzing the companys data."]}
{"id": 1001057, "claim": "It's too large to assume success for moderna's covid-19 vaccine", "label": "REFUTED", "evidence": ["Its way too early to get excited about Modernas mRNA vaccine to prevent COVID-19, concluded Evercore ISI analyst Umer Raffat after analyzing the companys data."]}
{"id": 1001058, "claim": "It's as soon to assume success for moderna's covid-19 vaccine", "label": "REFUTED", "evidence": ["Its way too early to get excited about Modernas mRNA vaccine to prevent COVID-19, concluded Evercore ISI analyst Umer Raffat after analyzing the companys data."]}
{"id": 1001059, "claim": "Severe covid-19 is associated with elevated serum iga and antiphospholipid iga-antibodies", "label": "SUPPORTED", "evidence": ["Since thrombotic events are frequent in severe COVID-19 and resemble hypercoagulation of antiphospholipid syndrome (APS), our approach focused on antiphospholipid antibodies (aPL)."]}
{"id": 1001060, "claim": "Introduction covid-19 is associated with elevated serum iga and antiphospholipid iga-antibodies", "label": "REFUTED", "evidence": ["Since thrombotic events are frequent in severe COVID-19 and resemble hypercoagulation of antiphospholipid syndrome (APS), our approach focused on antiphospholipid antibodies (aPL)."]}
{"id": 1001061, "claim": "Azd1222 vaccine met primary efficacy endpoint in preventing covid-19", "label": "SUPPORTED", "evidence": ["An independent Data Safety Monitoring Board determined that the analysis met its primary endpoint showing protection from COVID-19 occurring 14 days or more after receiving two doses of the vaccine."]}
{"id": 1001062, "claim": "Azd1222 vaccine met primary efficacy endpoint in treating covid-19", "label": "REFUTED", "evidence": ["An independent Data Safety Monitoring Board determined that the analysis met its primary endpoint showing protection from COVID-19 occurring 14 days or more after receiving two doses of the vaccine."]}
{"id": 1001063, "claim": "Azd1222 vaccine met one efficacy endpoint in preventing covid-19", "label": "REFUTED", "evidence": ["An independent Data Safety Monitoring Board determined that the analysis met its primary endpoint showing protection from COVID-19 occurring 14 days or more after receiving two doses of the vaccine."]}
{"id": 1001064, "claim": "Sars-cov-2 can infect human brain organoids", "label": "SUPPORTED", "evidence": ["Smirnova and Iwasaki, however, note several reports suggesting some ACE2 protein in certain patches of the human brain, as well as evidence of coronavirus genetic material inside brain neurons of patients who died during the SARS epidemic in China in the early 2000s, indicating that the original SARS virus could infect brain cells.", "E. Song et al., \"Neuroinvasive potential of SARS-CoV-2 revealed in a human brain organoid model,\" bioRxiv , doi: 10.1101/2020.06.25.169946, 2020.", "A BrainSphere organoid infected with SARS-CoV-2, showing the spike protein in green and neuron nuclei in blue Lena Smirnova, Johns Hopkins University If infection of the brain can feasibly occur in some people, it's certainly not common, Nath stresses.", "In addition, neural organoids lack the blood-brain barrier that would normally confer some degree of protection against most viruses, although Iwasaki notes it's possible that SARS-CoV-2 could circumvent this barrier by entering the brain through the olfactory system, something that's been shown in mice infected with common cold-causing coronaviruses.", "When the tissue was exposed to SARS-CoV-2, the virus readily infected increasing numbers of cells over the course of four days, suggesting that the coronavirus can use the machinery of neurons to generate more copies of itself."]}
{"id": 1001065, "claim": "Sars-cov-2 cannot infect human brain organoids", "label": "REFUTED", "evidence": ["Smirnova and Iwasaki, however, note several reports suggesting some ACE2 protein in certain patches of the human brain, as well as evidence of coronavirus genetic material inside brain neurons of patients who died during the SARS epidemic in China in the early 2000s, indicating that the original SARS virus could infect brain cells.", "E. Song et al., \"Neuroinvasive potential of SARS-CoV-2 revealed in a human brain organoid model,\" bioRxiv , doi: 10.1101/2020.06.25.169946, 2020.", "A BrainSphere organoid infected with SARS-CoV-2, showing the spike protein in green and neuron nuclei in blue Lena Smirnova, Johns Hopkins University If infection of the brain can feasibly occur in some people, it's certainly not common, Nath stresses.", "In addition, neural organoids lack the blood-brain barrier that would normally confer some degree of protection against most viruses, although Iwasaki notes it's possible that SARS-CoV-2 could circumvent this barrier by entering the brain through the olfactory system, something that's been shown in mice infected with common cold-causing coronaviruses.", "When the tissue was exposed to SARS-CoV-2, the virus readily infected increasing numbers of cells over the course of four days, suggesting that the coronavirus can use the machinery of neurons to generate more copies of itself."]}
{"id": 1001066, "claim": "Sars-cov-2 can infect human fibroblasts organoids", "label": "REFUTED", "evidence": ["Smirnova and Iwasaki, however, note several reports suggesting some ACE2 protein in certain patches of the human brain, as well as evidence of coronavirus genetic material inside brain neurons of patients who died during the SARS epidemic in China in the early 2000s, indicating that the original SARS virus could infect brain cells.", "E. Song et al., \"Neuroinvasive potential of SARS-CoV-2 revealed in a human brain organoid model,\" bioRxiv , doi: 10.1101/2020.06.25.169946, 2020.", "A BrainSphere organoid infected with SARS-CoV-2, showing the spike protein in green and neuron nuclei in blue Lena Smirnova, Johns Hopkins University If infection of the brain can feasibly occur in some people, it's certainly not common, Nath stresses.", "In addition, neural organoids lack the blood-brain barrier that would normally confer some degree of protection against most viruses, although Iwasaki notes it's possible that SARS-CoV-2 could circumvent this barrier by entering the brain through the olfactory system, something that's been shown in mice infected with common cold-causing coronaviruses.", "When the tissue was exposed to SARS-CoV-2, the virus readily infected increasing numbers of cells over the course of four days, suggesting that the coronavirus can use the machinery of neurons to generate more copies of itself."]}
{"id": 1001067, "claim": "Sars-cov-2 can infect human macrophages organoids", "label": "REFUTED", "evidence": ["Smirnova and Iwasaki, however, note several reports suggesting some ACE2 protein in certain patches of the human brain, as well as evidence of coronavirus genetic material inside brain neurons of patients who died during the SARS epidemic in China in the early 2000s, indicating that the original SARS virus could infect brain cells.", "E. Song et al., \"Neuroinvasive potential of SARS-CoV-2 revealed in a human brain organoid model,\" bioRxiv , doi: 10.1101/2020.06.25.169946, 2020.", "A BrainSphere organoid infected with SARS-CoV-2, showing the spike protein in green and neuron nuclei in blue Lena Smirnova, Johns Hopkins University If infection of the brain can feasibly occur in some people, it's certainly not common, Nath stresses.", "In addition, neural organoids lack the blood-brain barrier that would normally confer some degree of protection against most viruses, although Iwasaki notes it's possible that SARS-CoV-2 could circumvent this barrier by entering the brain through the olfactory system, something that's been shown in mice infected with common cold-causing coronaviruses.", "When the tissue was exposed to SARS-CoV-2, the virus readily infected increasing numbers of cells over the course of four days, suggesting that the coronavirus can use the machinery of neurons to generate more copies of itself."]}
{"id": 1001068, "claim": "U.k. approves pfizer coronavirus vaccine , a first in the west", "label": "SUPPORTED", "evidence": ["Approves Pfizer Coronavirus Vaccine, a First in the West https://nyti.ms/3qj8Mue ", "For Britain, which has suffered one of Europes highest per capita death tolls from the virus, the decision by its drug regulator was the latest evidence of a vaccination strategy that has been the most aggressive in the West.", "The Pfizer and BioNTech vaccine is delivered as a shot in the arm, like other typical vaccines."]}
{"id": 1001069, "claim": "U.k. approves pfizer coronavirus vaccine, a third in the west", "label": "REFUTED", "evidence": ["Approves Pfizer Coronavirus Vaccine, a First in the West https://nyti.ms/3qj8Mue ", "For Britain, which has suffered one of Europes highest per capita death tolls from the virus, the decision by its drug regulator was the latest evidence of a vaccination strategy that has been the most aggressive in the West.", "The Pfizer and BioNTech vaccine is delivered as a shot in the arm, like other typical vaccines."]}
{"id": 1001070, "claim": "U.k. approves pfizer coronavirus vaccine, a second in the west", "label": "REFUTED", "evidence": ["Approves Pfizer Coronavirus Vaccine, a First in the West https://nyti.ms/3qj8Mue ", "For Britain, which has suffered one of Europes highest per capita death tolls from the virus, the decision by its drug regulator was the latest evidence of a vaccination strategy that has been the most aggressive in the West.", "The Pfizer and BioNTech vaccine is delivered as a shot in the arm, like other typical vaccines."]}
{"id": 1001071, "claim": "The white house should encourage stay-at-home orders until public health officials say otherwise .", "label": "SUPPORTED", "evidence": ["And I guess what I expected when the President put out guidelines that said, Don't go to bars."]}
{"id": 1001072, "claim": "The white house should not stay-at-home orders until public health officials say otherwise.", "label": "REFUTED", "evidence": ["And I guess what I expected when the President put out guidelines that said, Don't go to bars."]}
{"id": 1001073, "claim": "First documented coronavirus reinfection reported in hong kong", "label": "SUPPORTED", "evidence": ["archived recording Researchers in China say a 33-year-old man living in Hong Kong is the first person confirmed to have been reinfected with the coronavirus.", "I believe this is the first reported case that is confirmed by genome sequencing, said Dr. Kelvin Kai-Wang To, a clinical microbiologist at the University of Hong Kong.", "So the case is about a man who gets infected in Hong Kong early in the year, recovers.", "The reinfection case underscores the need for a vaccine that produces a powerful immune response, scientists said.Credit...Anthony Kwan/Getty Images By Apoorva Mandavilli Aug. 24, 2020  A 33-year-old man was infected a second time with the coronavirus more than four months after his first bout, the first documented case of so-called reinfection, researchers in Hong Kong reported Monday."]}
{"id": 1001074, "claim": "No documented coronavirus reinfection reported in hong kong", "label": "REFUTED", "evidence": ["archived recording Researchers in China say a 33-year-old man living in Hong Kong is the first person confirmed to have been reinfected with the coronavirus.", "I believe this is the first reported case that is confirmed by genome sequencing, said Dr. Kelvin Kai-Wang To, a clinical microbiologist at the University of Hong Kong.", "So the case is about a man who gets infected in Hong Kong early in the year, recovers.", "The reinfection case underscores the need for a vaccine that produces a powerful immune response, scientists said.Credit...Anthony Kwan/Getty Images By Apoorva Mandavilli Aug. 24, 2020  A 33-year-old man was infected a second time with the coronavirus more than four months after his first bout, the first documented case of so-called reinfection, researchers in Hong Kong reported Monday."]}
{"id": 1001075, "claim": "All documented coronavirus reinfection reported in hong kong", "label": "REFUTED", "evidence": ["archived recording Researchers in China say a 33-year-old man living in Hong Kong is the first person confirmed to have been reinfected with the coronavirus.", "I believe this is the first reported case that is confirmed by genome sequencing, said Dr. Kelvin Kai-Wang To, a clinical microbiologist at the University of Hong Kong.", "So the case is about a man who gets infected in Hong Kong early in the year, recovers.", "The reinfection case underscores the need for a vaccine that produces a powerful immune response, scientists said.Credit...Anthony Kwan/Getty Images By Apoorva Mandavilli Aug. 24, 2020  A 33-year-old man was infected a second time with the coronavirus more than four months after his first bout, the first documented case of so-called reinfection, researchers in Hong Kong reported Monday."]}
{"id": 1001076, "claim": "Most documented coronavirus reinfection reported in hong kong", "label": "REFUTED", "evidence": ["archived recording Researchers in China say a 33-year-old man living in Hong Kong is the first person confirmed to have been reinfected with the coronavirus.", "I believe this is the first reported case that is confirmed by genome sequencing, said Dr. Kelvin Kai-Wang To, a clinical microbiologist at the University of Hong Kong.", "So the case is about a man who gets infected in Hong Kong early in the year, recovers.", "The reinfection case underscores the need for a vaccine that produces a powerful immune response, scientists said.Credit...Anthony Kwan/Getty Images By Apoorva Mandavilli Aug. 24, 2020  A 33-year-old man was infected a second time with the coronavirus more than four months after his first bout, the first documented case of so-called reinfection, researchers in Hong Kong reported Monday."]}
{"id": 1001077, "claim": "Small rct suggests gargling with iodine clears the virus in 4 days", "label": "SUPPORTED", "evidence": ["In a small Japanese experimental study from 2002, 23 patients with chronic respiratory disease gargled four or more times a day with a povidone-iodine solution."]}
{"id": 1001078, "claim": "Such rct suggests gargling with iodine clears the virus in 4 days", "label": "REFUTED", "evidence": ["In a small Japanese experimental study from 2002, 23 patients with chronic respiratory disease gargled four or more times a day with a povidone-iodine solution."]}
{"id": 1001079, "claim": "Kids rarely transmit covid-19 , say uvm docs in top journal", "label": "SUPPORTED", "evidence": ["A commentary published in the journal Pediatrics , the official peer- reviewed journal of the American Academy of Pediatrics, concludes that children infrequently transmit Covid-19 to each other or to adults and that many schools, provided they follow appropriate social distancing guidelines and take into account rates of transmission in their community, can and should reopen in the fall."]}
{"id": 1001080, "claim": "Kids all transmit covid-19, say uvm docs in top journal", "label": "REFUTED", "evidence": ["A commentary published in the journal Pediatrics , the official peer- reviewed journal of the American Academy of Pediatrics, concludes that children infrequently transmit Covid-19 to each other or to adults and that many schools, provided they follow appropriate social distancing guidelines and take into account rates of transmission in their community, can and should reopen in the fall."]}
{"id": 1001081, "claim": "Forecasting for covid-19 has failed", "label": "SUPPORTED", "evidence": ["Worse, COVID-19 had already started devastating nursing homes in the USA by then, but the nursing home data were mostly unavailable."]}
{"id": 1001082, "claim": "Forecasting for covid-19 has in", "label": "REFUTED", "evidence": ["Worse, COVID-19 had already started devastating nursing homes in the USA by then, but the nursing home data were mostly unavailable."]}
{"id": 1001083, "claim": "Forecasting for covid-19 has!", "label": "REFUTED", "evidence": ["Worse, COVID-19 had already started devastating nursing homes in the USA by then, but the nursing home data were mostly unavailable."]}
{"id": 1001084, "claim": "Less severe course of covid-19 is associated with elevated levels of antibodies against seasonal human coronaviruses oc43 and hku1", "label": "SUPPORTED", "evidence": ["Our results indicate that previous infections with seasonal coronaviruses might protect against a severe course of disease.", "Patients with critical disease had significantly lower levels of HCoV OC43- (p=0.016) and HCoV HKU1-specific (p=0.023) antibodies at the first encounter compared to other COVID-19 patients."]}
{"id": 1001085, "claim": "This severe course of covid-19 is associated with elevated levels of antibodies against seasonal human coronaviruses oc43 and hku1", "label": "REFUTED", "evidence": ["Our results indicate that previous infections with seasonal coronaviruses might protect against a severe course of disease.", "Patients with critical disease had significantly lower levels of HCoV OC43- (p=0.016) and HCoV HKU1-specific (p=0.023) antibodies at the first encounter compared to other COVID-19 patients."]}
{"id": 1001086, "claim": "Surgical mask partition reduces the risk of non-contact transmission in a golden syrian hamster model for coronavirus disease 2019", "label": "SUPPORTED", "evidence": ["Surgical mask partition for challenged index hamsters significantly reduced transmission to only 16.7% (2/12, P= 0.019) of exposed naive hamsters.", "Surgical mask partition for challenged index or naive hamsters significantly reduced transmission to 25% (6/24, P =0.018)."]}
{"id": 1001087, "claim": "Surgical mask partition increases the risk of non-contact transmission in a golden syrian hamster model for coronavirus disease 2019", "label": "REFUTED", "evidence": ["Surgical mask partition for challenged index hamsters significantly reduced transmission to only 16.7% (2/12, P= 0.019) of exposed naive hamsters.", "Surgical mask partition for challenged index or naive hamsters significantly reduced transmission to 25% (6/24, P =0.018)."]}
{"id": 1001088, "claim": "Cold-adapted live attenuated sars-cov-2 vaccine completely protects human ace2 transgenic mice from sars-cov-2 infection", "label": "SUPPORTED", "evidence": ["View Full-Text Keywords: SARS-CoV-2; live attenuated vaccine; cold adaptation SARS-CoV-2; live attenuated vaccine; cold adaptation  Show Figures Figure 1 This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited ", "The one-dose vaccinated mice were completely protected from SARS-CoV-2 infection and did not show body weight loss, death, or the presence of virus in tissues, such as the nasal turbinates, brain, lungs, and kidneys.", "Its single dose strongly induced neutralising antibodies (titre > 640), cellular immunity, and mucosal IgA antibodies in intranasally immunised K18-hACE2 mice, which are very susceptible to SARS-CoV-2 and SARS-CoV infections.", "These results demonstrate that the cold-adapted live attenuated SARS-CoV-2 vaccine we have developed may be a candidate SARS-CoV-2 vaccine for humans."]}
{"id": 1001089, "claim": "Cold-adapted live attenuated sars-cov-2 vaccine completely killed human ace2 transgenic mice from sars-cov-2 infection", "label": "REFUTED", "evidence": ["View Full-Text Keywords: SARS-CoV-2; live attenuated vaccine; cold adaptation SARS-CoV-2; live attenuated vaccine; cold adaptation  Show Figures Figure 1 This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited ", "The one-dose vaccinated mice were completely protected from SARS-CoV-2 infection and did not show body weight loss, death, or the presence of virus in tissues, such as the nasal turbinates, brain, lungs, and kidneys.", "Its single dose strongly induced neutralising antibodies (titre > 640), cellular immunity, and mucosal IgA antibodies in intranasally immunised K18-hACE2 mice, which are very susceptible to SARS-CoV-2 and SARS-CoV infections.", "These results demonstrate that the cold-adapted live attenuated SARS-CoV-2 vaccine we have developed may be a candidate SARS-CoV-2 vaccine for humans."]}
{"id": 1001090, "claim": "Cold-adapted live attenuated sars-cov-2 vaccine completely challenged human ace2 transgenic mice from sars-cov-2 infection", "label": "REFUTED", "evidence": ["View Full-Text Keywords: SARS-CoV-2; live attenuated vaccine; cold adaptation SARS-CoV-2; live attenuated vaccine; cold adaptation  Show Figures Figure 1 This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited ", "The one-dose vaccinated mice were completely protected from SARS-CoV-2 infection and did not show body weight loss, death, or the presence of virus in tissues, such as the nasal turbinates, brain, lungs, and kidneys.", "Its single dose strongly induced neutralising antibodies (titre > 640), cellular immunity, and mucosal IgA antibodies in intranasally immunised K18-hACE2 mice, which are very susceptible to SARS-CoV-2 and SARS-CoV infections.", "These results demonstrate that the cold-adapted live attenuated SARS-CoV-2 vaccine we have developed may be a candidate SARS-CoV-2 vaccine for humans."]}
{"id": 1001091, "claim": "Cold-adapted live attenuated sars-cov-2 vaccine completely inhibited human ace2 transgenic mice from sars-cov-2 infection", "label": "REFUTED", "evidence": ["View Full-Text Keywords: SARS-CoV-2; live attenuated vaccine; cold adaptation SARS-CoV-2; live attenuated vaccine; cold adaptation  Show Figures Figure 1 This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited ", "The one-dose vaccinated mice were completely protected from SARS-CoV-2 infection and did not show body weight loss, death, or the presence of virus in tissues, such as the nasal turbinates, brain, lungs, and kidneys.", "Its single dose strongly induced neutralising antibodies (titre > 640), cellular immunity, and mucosal IgA antibodies in intranasally immunised K18-hACE2 mice, which are very susceptible to SARS-CoV-2 and SARS-CoV infections.", "These results demonstrate that the cold-adapted live attenuated SARS-CoV-2 vaccine we have developed may be a candidate SARS-CoV-2 vaccine for humans."]}
{"id": 1001092, "claim": "Fda authorizes first test that detects neutralizing antibodies from recent or prior sars-cov-2 infection", "label": "SUPPORTED", "evidence": ["The ability to detect neutralizing antibodies can help us gain additional insight into what the existence of antibodies may mean for patients as we continue the fight against COVID-19, said Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDAs Center for Devices and Radiological Health.", "The FDA issued an emergency use authorization (EUA) for the cPass SARS-CoV-2 Neutralization Antibody Detection Kit, which specifically detects this type of antibody.", "There are still many unknowns about what the presence of SARS-CoV-2 antibodies may tell us about potential immunity, but todays authorization gives us another tool to evaluate those antibodies as we continue to research and study this virus."]}
{"id": 1001093, "claim": "Fda authorizes another test that detects neutralizing antibodies from recent or prior sars-cov-2 infection", "label": "REFUTED", "evidence": ["The ability to detect neutralizing antibodies can help us gain additional insight into what the existence of antibodies may mean for patients as we continue the fight against COVID-19, said Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDAs Center for Devices and Radiological Health.", "The FDA issued an emergency use authorization (EUA) for the cPass SARS-CoV-2 Neutralization Antibody Detection Kit, which specifically detects this type of antibody.", "There are still many unknowns about what the presence of SARS-CoV-2 antibodies may tell us about potential immunity, but todays authorization gives us another tool to evaluate those antibodies as we continue to research and study this virus."]}
{"id": 1001094, "claim": "Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine", "label": "SUPPORTED", "evidence": ["A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.", "Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.", "Being protected against influenza, TIV recipients may lack temporary non-specific immunity that protected against other respiratory viruses."]}
{"id": 1001095, "claim": "Increased risk of noninfluenza respiratory virus infections decreases with receipt of inactivated influenza vaccine", "label": "REFUTED", "evidence": ["A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.", "Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.", "Being protected against influenza, TIV recipients may lack temporary non-specific immunity that protected against other respiratory viruses."]}
{"id": 1001096, "claim": "Functional myeloid-derived suppressor cells expand in blood but not airways of covid-19 patients and predict disease severity", "label": "SUPPORTED", "evidence": ["In conclusion, M-MDSCs expand in blood of COVID-19 patients, suppress T cells and strongly associate with disease severity, suggesting a role for M-MDSCs in the dysregulated COVID-19 immune response.", "M-MDSCs isolated from COVID-19 patients suppressed T cell proliferation and IFNγ production partly via an arginase-1 (Arg-1) dependent mechanism."]}
{"id": 1001097, "claim": "Functional myeloid-derived suppressor cells expand in blood but also airways of covid-19 patients and predict disease severity", "label": "REFUTED", "evidence": ["In conclusion, M-MDSCs expand in blood of COVID-19 patients, suppress T cells and strongly associate with disease severity, suggesting a role for M-MDSCs in the dysregulated COVID-19 immune response.", "M-MDSCs isolated from COVID-19 patients suppressed T cell proliferation and IFNγ production partly via an arginase-1 (Arg-1) dependent mechanism."]}
{"id": 1001098, "claim": "Functional myeloid-derived suppressor cells expand in blood but are airways of covid-19 patients and predict disease severity", "label": "REFUTED", "evidence": ["In conclusion, M-MDSCs expand in blood of COVID-19 patients, suppress T cells and strongly associate with disease severity, suggesting a role for M-MDSCs in the dysregulated COVID-19 immune response.", "M-MDSCs isolated from COVID-19 patients suppressed T cell proliferation and IFNγ production partly via an arginase-1 (Arg-1) dependent mechanism."]}
{"id": 1001099, "claim": "Functional myeloid-derived suppressor cells expand in blood but infect airways of covid-19 patients and predict disease severity", "label": "REFUTED", "evidence": ["In conclusion, M-MDSCs expand in blood of COVID-19 patients, suppress T cells and strongly associate with disease severity, suggesting a role for M-MDSCs in the dysregulated COVID-19 immune response.", "M-MDSCs isolated from COVID-19 patients suppressed T cell proliferation and IFNγ production partly via an arginase-1 (Arg-1) dependent mechanism."]}
{"id": 1001100, "claim": "Efficacy of face masks , neck gaiters and face shields for reducing the expulsion of simulated cough-generated aerosols", "label": "SUPPORTED", "evidence": ["One of the primary benefits of face masks and other coverings is as source control devices to reduce the expulsion of respiratory aerosols during coughing, breathing, and speaking.", "Our results show that face masks and neck gaiters can significantly reduce the expulsion of small respiratory aerosol particles during coughing.", "Efficacy of masks and face coverings in controlling outward aerosol particle emission from expiratory activities.", "Efficacy of face shields against cough aerosol droplets from a cough simulator."]}
{"id": 1001101, "claim": "Efficacy of face masks, neck gaiters and face shields without reducing the expulsion of simulated cough-generated aerosols", "label": "REFUTED", "evidence": ["One of the primary benefits of face masks and other coverings is as source control devices to reduce the expulsion of respiratory aerosols during coughing, breathing, and speaking.", "Our results show that face masks and neck gaiters can significantly reduce the expulsion of small respiratory aerosol particles during coughing.", "Efficacy of masks and face coverings in controlling outward aerosol particle emission from expiratory activities.", "Efficacy of face shields against cough aerosol droplets from a cough simulator."]}
{"id": 1001102, "claim": "World 's 1st inactivated covid-19 vaccine produces antibodies", "label": "SUPPORTED", "evidence": ["People who received two doses of the vaccine at an interval of 28 days, saw their neutralizing antibody positive conversion rate reach 100%.", "CNBG said the study was designed to evaluate the safety and immunogenicity of the COVID-19 inactivated vaccine in healthy subjects aged from 18 to 59 for low, medium and high dosages and injections at intervals of 14, 21 and 28 days.", "For those aged 18 - 59 who received two medium-dose injections through the 14-day and 21-day interval procedures, they had a neutralizing antibody positive conversion rate of 97.6%."]}
{"id": 1001103, "claim": "A's 1st inactivated covid-19 vaccine produces antibodies", "label": "REFUTED", "evidence": ["People who received two doses of the vaccine at an interval of 28 days, saw their neutralizing antibody positive conversion rate reach 100%.", "CNBG said the study was designed to evaluate the safety and immunogenicity of the COVID-19 inactivated vaccine in healthy subjects aged from 18 to 59 for low, medium and high dosages and injections at intervals of 14, 21 and 28 days.", "For those aged 18 - 59 who received two medium-dose injections through the 14-day and 21-day interval procedures, they had a neutralizing antibody positive conversion rate of 97.6%."]}
{"id": 1001104, "claim": "Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with covid-19 pneumonia and acute respiratory distress syndrome", "label": "SUPPORTED", "evidence": ["Conclusion: This proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19."]}
{"id": 1001105, "claim": "Differences between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with covid-19 pneumonia and acute respiratory distress syndrome", "label": "REFUTED", "evidence": ["Conclusion: This proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19."]}
{"id": 1001106, "claim": "Us buys up world stock of key covid-19 drug remdesivir", "label": "SUPPORTED", "evidence": ["[Photo/Xinhua] The World Health Organization on Wednesday voiced concerns over news reports that the United States government has bought almost all the stocks of key COVID-19 drug remdesivir."]}
{"id": 1001107, "claim": "Us buys up one stock of key covid-19 drug remdesivir", "label": "REFUTED", "evidence": ["[Photo/Xinhua] The World Health Organization on Wednesday voiced concerns over news reports that the United States government has bought almost all the stocks of key COVID-19 drug remdesivir."]}
{"id": 1001108, "claim": "Johnson & johnson announces initiation of rolling submission for its single-dose janssen covid-19 vaccine candidate with the european medicines agency", "label": "SUPPORTED", "evidence": ["The EMAs Committee for Medicinal Products for Human Use (CHMP) enabled a rolling review of the investigational single-dose Janssen COVID-19 vaccine candidate based principally on positive non-clinical data showing that the vaccine candidate elicits a robust immune response, as demonstrated by neutralizing antibodies.", "134 Janssen-Cilag International N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has initiated a rolling submission with the European Medicines Agency (EMA) for its investigational single-dose vaccine candidate for the prevention of COVID-19.", "JANSSENS INVESTIGATIONAL COVID-19 VACCINE CANDIDATE The investigational Janssen COVID-19 vaccine candidate leverages the Companys AdVac® vaccine platform, which was also used to develop and manufacture Janssens European Commission-approved Ebola vaccine regimen and construct its Zika, RSV, and HIV investigational vaccine candidates.", "In addition to the EMA, Janssen is in discussions with other regulatory authorities worldwide, as it prepares to initiate regulatory review processes for use of its investigational single-dose COVID-19 vaccine candidate during the pandemic response period."]}
{"id": 1001109, "claim": "Johnson & johnson announces lack of rolling submission for its single-dose janssen covid-19 vaccine candidate with the european medicines agency", "label": "REFUTED", "evidence": ["The EMAs Committee for Medicinal Products for Human Use (CHMP) enabled a rolling review of the investigational single-dose Janssen COVID-19 vaccine candidate based principally on positive non-clinical data showing that the vaccine candidate elicits a robust immune response, as demonstrated by neutralizing antibodies.", "134 Janssen-Cilag International N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has initiated a rolling submission with the European Medicines Agency (EMA) for its investigational single-dose vaccine candidate for the prevention of COVID-19.", "JANSSENS INVESTIGATIONAL COVID-19 VACCINE CANDIDATE The investigational Janssen COVID-19 vaccine candidate leverages the Companys AdVac® vaccine platform, which was also used to develop and manufacture Janssens European Commission-approved Ebola vaccine regimen and construct its Zika, RSV, and HIV investigational vaccine candidates.", "In addition to the EMA, Janssen is in discussions with other regulatory authorities worldwide, as it prepares to initiate regulatory review processes for use of its investigational single-dose COVID-19 vaccine candidate during the pandemic response period."]}
{"id": 1001110, "claim": "Johnson & johnson announces out of rolling submission for its single-dose janssen covid-19 vaccine candidate with the european medicines agency", "label": "REFUTED", "evidence": ["The EMAs Committee for Medicinal Products for Human Use (CHMP) enabled a rolling review of the investigational single-dose Janssen COVID-19 vaccine candidate based principally on positive non-clinical data showing that the vaccine candidate elicits a robust immune response, as demonstrated by neutralizing antibodies.", "134 Janssen-Cilag International N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has initiated a rolling submission with the European Medicines Agency (EMA) for its investigational single-dose vaccine candidate for the prevention of COVID-19.", "JANSSENS INVESTIGATIONAL COVID-19 VACCINE CANDIDATE The investigational Janssen COVID-19 vaccine candidate leverages the Companys AdVac® vaccine platform, which was also used to develop and manufacture Janssens European Commission-approved Ebola vaccine regimen and construct its Zika, RSV, and HIV investigational vaccine candidates.", "In addition to the EMA, Janssen is in discussions with other regulatory authorities worldwide, as it prepares to initiate regulatory review processes for use of its investigational single-dose COVID-19 vaccine candidate during the pandemic response period."]}
{"id": 1001111, "claim": "Johnson & johnson announces instead of rolling submission for its single-dose janssen covid-19 vaccine candidate with the european medicines agency", "label": "REFUTED", "evidence": ["The EMAs Committee for Medicinal Products for Human Use (CHMP) enabled a rolling review of the investigational single-dose Janssen COVID-19 vaccine candidate based principally on positive non-clinical data showing that the vaccine candidate elicits a robust immune response, as demonstrated by neutralizing antibodies.", "134 Janssen-Cilag International N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has initiated a rolling submission with the European Medicines Agency (EMA) for its investigational single-dose vaccine candidate for the prevention of COVID-19.", "JANSSENS INVESTIGATIONAL COVID-19 VACCINE CANDIDATE The investigational Janssen COVID-19 vaccine candidate leverages the Companys AdVac® vaccine platform, which was also used to develop and manufacture Janssens European Commission-approved Ebola vaccine regimen and construct its Zika, RSV, and HIV investigational vaccine candidates.", "In addition to the EMA, Janssen is in discussions with other regulatory authorities worldwide, as it prepares to initiate regulatory review processes for use of its investigational single-dose COVID-19 vaccine candidate during the pandemic response period."]}
{"id": 1001112, "claim": "Mutated coronavirus shows significant boost in infectivity", "label": "SUPPORTED", "evidence": ["The mutation had the effect of markedly increasing the number of functional spikes on the viral surface, she adds.", "\"Our data are very clear, the virus becomes much more stable with the mutation,\" Choe says.", "A new mutation has appeared in the viral variant most common in New York and Italy that makes this spike both more stable and better able to infect cells."]}
{"id": 1001113, "claim": "Mutated coronavirus shows significant reduction in infectivity", "label": "REFUTED", "evidence": ["The mutation had the effect of markedly increasing the number of functional spikes on the viral surface, she adds.", "\"Our data are very clear, the virus becomes much more stable with the mutation,\" Choe says.", "A new mutation has appeared in the viral variant most common in New York and Italy that makes this spike both more stable and better able to infect cells."]}
{"id": 1001114, "claim": "Mutated coronavirus shows significant reductions in infectivity", "label": "REFUTED", "evidence": ["The mutation had the effect of markedly increasing the number of functional spikes on the viral surface, she adds.", "\"Our data are very clear, the virus becomes much more stable with the mutation,\" Choe says.", "A new mutation has appeared in the viral variant most common in New York and Italy that makes this spike both more stable and better able to infect cells."]}
{"id": 1001115, "claim": "Mutated coronavirus shows no boost in infectivity", "label": "REFUTED", "evidence": ["The mutation had the effect of markedly increasing the number of functional spikes on the viral surface, she adds.", "\"Our data are very clear, the virus becomes much more stable with the mutation,\" Choe says.", "A new mutation has appeared in the viral variant most common in New York and Italy that makes this spike both more stable and better able to infect cells."]}
{"id": 1001116, "claim": "Decreased serum levels of inflammaging marker mir-146a are associated with clinical response to tocilizumab in covid-19 patients", "label": "SUPPORTED", "evidence": ["We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p = 0.007).", "We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p=0.007).", "Share Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients Jacopo Sabbatinelli, Angelica Giuliani, Giulia Matacchione, Silvia Latini, Noemi Laprovitera, Giovanni Pomponio, Alessia Ferrarini, Silvia Svegliati Baroni, Marianna Pavani, Marco Moretti, Armando Gabrielli, Antonio Domenico Procopio, Manuela Ferracin, Massimiliano Bonafè, Fabiola Olivieri medRxiv 2020.07.11.20151365; doi: https://doi.org/10.1101/2020.07.11.20151365 Share This Article: Copy Citation Tools Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients Jacopo Sabbatinelli, Angelica Giuliani, Giulia Matacchione, Silvia Latini, Noemi Laprovitera, Giovanni Pomponio, Alessia Ferrarini, Silvia Svegliati Baroni, Marianna Pavani, Marco Moretti, Armando Gabrielli, Antonio Domenico Procopio, Manuela Ferracin, Massimiliano Bonafè, Fabiola Olivieri medRxiv 2020.07.11.20151365; doi: https://doi.org/10.1101/2020.07.11.20151365 ", "  Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients medRxiv - Infectious Diseases Pub Date : 2020-11-21 , DOI: 10.1101/2020.07.11.20151365 Jacopo Sabbatinelli; Angelica Giuliani; Giulia Matacchione; Silvia Latini; Noemi Laprovitera; Giovanni Pomponio; Alessia Ferrarini; Silvia Svegliati Baroni; Marianna Pavani; Marco Moretti; Armando Gabrielli; Antonio Domenico Procopio; Manuela Ferracin; Massimiliano Bonafè; Fabiola Olivieri Current COVID-19 pandemic poses an unprecedented threat to global health and healthcare systems."]}
{"id": 1001117, "claim": "Increasing serum levels of inflammaging marker mir-146a are associated with clinical response to tocilizumab in covid-19 patients", "label": "REFUTED", "evidence": ["We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p = 0.007).", "We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p=0.007).", "Share Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients Jacopo Sabbatinelli, Angelica Giuliani, Giulia Matacchione, Silvia Latini, Noemi Laprovitera, Giovanni Pomponio, Alessia Ferrarini, Silvia Svegliati Baroni, Marianna Pavani, Marco Moretti, Armando Gabrielli, Antonio Domenico Procopio, Manuela Ferracin, Massimiliano Bonafè, Fabiola Olivieri medRxiv 2020.07.11.20151365; doi: https://doi.org/10.1101/2020.07.11.20151365 Share This Article: Copy Citation Tools Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients Jacopo Sabbatinelli, Angelica Giuliani, Giulia Matacchione, Silvia Latini, Noemi Laprovitera, Giovanni Pomponio, Alessia Ferrarini, Silvia Svegliati Baroni, Marianna Pavani, Marco Moretti, Armando Gabrielli, Antonio Domenico Procopio, Manuela Ferracin, Massimiliano Bonafè, Fabiola Olivieri medRxiv 2020.07.11.20151365; doi: https://doi.org/10.1101/2020.07.11.20151365 ", "  Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients medRxiv - Infectious Diseases Pub Date : 2020-11-21 , DOI: 10.1101/2020.07.11.20151365 Jacopo Sabbatinelli; Angelica Giuliani; Giulia Matacchione; Silvia Latini; Noemi Laprovitera; Giovanni Pomponio; Alessia Ferrarini; Silvia Svegliati Baroni; Marianna Pavani; Marco Moretti; Armando Gabrielli; Antonio Domenico Procopio; Manuela Ferracin; Massimiliano Bonafè; Fabiola Olivieri Current COVID-19 pandemic poses an unprecedented threat to global health and healthcare systems."]}
{"id": 1001118, "claim": "Increased serum levels of inflammaging marker mir-146a are associated with clinical response to tocilizumab in covid-19 patients", "label": "REFUTED", "evidence": ["We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p = 0.007).", "We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p=0.007).", "Share Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients Jacopo Sabbatinelli, Angelica Giuliani, Giulia Matacchione, Silvia Latini, Noemi Laprovitera, Giovanni Pomponio, Alessia Ferrarini, Silvia Svegliati Baroni, Marianna Pavani, Marco Moretti, Armando Gabrielli, Antonio Domenico Procopio, Manuela Ferracin, Massimiliano Bonafè, Fabiola Olivieri medRxiv 2020.07.11.20151365; doi: https://doi.org/10.1101/2020.07.11.20151365 Share This Article: Copy Citation Tools Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients Jacopo Sabbatinelli, Angelica Giuliani, Giulia Matacchione, Silvia Latini, Noemi Laprovitera, Giovanni Pomponio, Alessia Ferrarini, Silvia Svegliati Baroni, Marianna Pavani, Marco Moretti, Armando Gabrielli, Antonio Domenico Procopio, Manuela Ferracin, Massimiliano Bonafè, Fabiola Olivieri medRxiv 2020.07.11.20151365; doi: https://doi.org/10.1101/2020.07.11.20151365 ", "  Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients medRxiv - Infectious Diseases Pub Date : 2020-11-21 , DOI: 10.1101/2020.07.11.20151365 Jacopo Sabbatinelli; Angelica Giuliani; Giulia Matacchione; Silvia Latini; Noemi Laprovitera; Giovanni Pomponio; Alessia Ferrarini; Silvia Svegliati Baroni; Marianna Pavani; Marco Moretti; Armando Gabrielli; Antonio Domenico Procopio; Manuela Ferracin; Massimiliano Bonafè; Fabiola Olivieri Current COVID-19 pandemic poses an unprecedented threat to global health and healthcare systems."]}
{"id": 1001119, "claim": "elevated serum levels of inflammaging marker mir-146a are associated with clinical response to tocilizumab in covid-19 patients", "label": "REFUTED", "evidence": ["We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p = 0.007).", "We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p=0.007).", "Share Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients Jacopo Sabbatinelli, Angelica Giuliani, Giulia Matacchione, Silvia Latini, Noemi Laprovitera, Giovanni Pomponio, Alessia Ferrarini, Silvia Svegliati Baroni, Marianna Pavani, Marco Moretti, Armando Gabrielli, Antonio Domenico Procopio, Manuela Ferracin, Massimiliano Bonafè, Fabiola Olivieri medRxiv 2020.07.11.20151365; doi: https://doi.org/10.1101/2020.07.11.20151365 Share This Article: Copy Citation Tools Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients Jacopo Sabbatinelli, Angelica Giuliani, Giulia Matacchione, Silvia Latini, Noemi Laprovitera, Giovanni Pomponio, Alessia Ferrarini, Silvia Svegliati Baroni, Marianna Pavani, Marco Moretti, Armando Gabrielli, Antonio Domenico Procopio, Manuela Ferracin, Massimiliano Bonafè, Fabiola Olivieri medRxiv 2020.07.11.20151365; doi: https://doi.org/10.1101/2020.07.11.20151365 ", "  Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients medRxiv - Infectious Diseases Pub Date : 2020-11-21 , DOI: 10.1101/2020.07.11.20151365 Jacopo Sabbatinelli; Angelica Giuliani; Giulia Matacchione; Silvia Latini; Noemi Laprovitera; Giovanni Pomponio; Alessia Ferrarini; Silvia Svegliati Baroni; Marianna Pavani; Marco Moretti; Armando Gabrielli; Antonio Domenico Procopio; Manuela Ferracin; Massimiliano Bonafè; Fabiola Olivieri Current COVID-19 pandemic poses an unprecedented threat to global health and healthcare systems."]}
{"id": 1001120, "claim": "Moderna receives confirmation of eligibility for submission of marketing authorization application to the european medicines agency for mrna vaccine against covid-19", "label": "SUPPORTED", "evidence": ["Modernas investigational Zika vaccine (mRNA-1893), currently in a Phase 1 study, was granted FDA Fast Track designation in August 2019.", "Confirmation of eligibility was given in response to the submission of a letter of intent enabling Moderna to evaluate the opportunity for submitting a Marketing Authorization Application (MAA) for mRNA-1273 with the EMA."]}
{"id": 1001121, "claim": "Moderna receives loss of eligibility for submission of marketing authorization application to the european medicines agency for mrna vaccine against covid-19", "label": "REFUTED", "evidence": ["Modernas investigational Zika vaccine (mRNA-1893), currently in a Phase 1 study, was granted FDA Fast Track designation in August 2019.", "Confirmation of eligibility was given in response to the submission of a letter of intent enabling Moderna to evaluate the opportunity for submitting a Marketing Authorization Application (MAA) for mRNA-1273 with the EMA."]}
{"id": 1001122, "claim": "Moderna receives lack of eligibility for submission of marketing authorization application to the european medicines agency for mrna vaccine against covid-19", "label": "REFUTED", "evidence": ["Modernas investigational Zika vaccine (mRNA-1893), currently in a Phase 1 study, was granted FDA Fast Track designation in August 2019.", "Confirmation of eligibility was given in response to the submission of a letter of intent enabling Moderna to evaluate the opportunity for submitting a Marketing Authorization Application (MAA) for mRNA-1273 with the EMA."]}
{"id": 1001123, "claim": "Sleep quality has declined since covid-19 lockdown , particularly among those working from home", "label": "SUPPORTED", "evidence": ["Working from home may lead to increased screen time, including time spent in front of the computer or television screen late at night, which can impact sleep quality.", "Interestingly, those who reported smart working  using technology to work from home showed a greater loss in sleep quality than those who did not.", "The researchers address how stress related to the pandemic likely affected participants sleep, creating a destructive cycle.", "When it came to specific aspects of sleep, participants showed increased sleep disturbance and daytime dysfunction, less efficient sleep, and an increase in the time it took them to fall asleep."]}
{"id": 1001124, "claim": "Sleep quality has increased since covid-19 lockdown, particularly among those working from home", "label": "REFUTED", "evidence": ["Working from home may lead to increased screen time, including time spent in front of the computer or television screen late at night, which can impact sleep quality.", "Interestingly, those who reported smart working  using technology to work from home showed a greater loss in sleep quality than those who did not.", "The researchers address how stress related to the pandemic likely affected participants sleep, creating a destructive cycle.", "When it came to specific aspects of sleep, participants showed increased sleep disturbance and daytime dysfunction, less efficient sleep, and an increase in the time it took them to fall asleep."]}
{"id": 1001125, "claim": "Sleep quality has improved since covid-19 lockdown, particularly among those working from home", "label": "REFUTED", "evidence": ["Working from home may lead to increased screen time, including time spent in front of the computer or television screen late at night, which can impact sleep quality.", "Interestingly, those who reported smart working  using technology to work from home showed a greater loss in sleep quality than those who did not.", "The researchers address how stress related to the pandemic likely affected participants sleep, creating a destructive cycle.", "When it came to specific aspects of sleep, participants showed increased sleep disturbance and daytime dysfunction, less efficient sleep, and an increase in the time it took them to fall asleep."]}
{"id": 1001126, "claim": "Sleep quality has high since covid-19 lockdown, particularly among those working from home", "label": "REFUTED", "evidence": ["Working from home may lead to increased screen time, including time spent in front of the computer or television screen late at night, which can impact sleep quality.", "Interestingly, those who reported smart working  using technology to work from home showed a greater loss in sleep quality than those who did not.", "The researchers address how stress related to the pandemic likely affected participants sleep, creating a destructive cycle.", "When it came to specific aspects of sleep, participants showed increased sleep disturbance and daytime dysfunction, less efficient sleep, and an increase in the time it took them to fall asleep."]}
{"id": 1001127, "claim": "Targeted immunosuppression distinguishes covid-19 from influenza in moderate and severe disease", "label": "SUPPORTED", "evidence": ["Single cell transcriptional profiling of COVID-19 and influenza subjects with respiratory failure identified profound suppression in type I and type II interferon signaling in COVID-19 patients across multiple clusters."]}
{"id": 1001128, "claim": "Targeted immunosuppression distinguishes covid-19 from influenza in acute and severe disease", "label": "REFUTED", "evidence": ["Single cell transcriptional profiling of COVID-19 and influenza subjects with respiratory failure identified profound suppression in type I and type II interferon signaling in COVID-19 patients across multiple clusters."]}
{"id": 1001129, "claim": "Ohio researchers say they 've identified two new covid strains likely originating in the u.s .", "label": "SUPPORTED", "evidence": ["Researchers in Ohio said Wednesday that they've discovered two new variants of the coronavirus that likely originated in the U.S.  one of which quickly became the dominant strain in Columbus, Ohio, over a three-week period in late December and early January.", "The variants were found by researchers at The Ohio State University.", "Published Wed, Jan 13 202110:07 AM ESTUpdated Wed, Jan 13 20214:43 PM EST Will ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Key Points Ohio researchers said Wednesday that they've discovered two new variants of the coronavirus, one of which has become the dominant strain in Columbus, Ohio.", "Fox News: 2 New Coronavirus Variants That Likely Originated In US Identified In Ohio: Researchers Ohio researchers on Wednesday announced that theyve identified two coronavirus variants that likely originated in the United States."]}
{"id": 1001130, "claim": "Ohio researchers say they've identified all new covid strains likely originating in the u.s.", "label": "REFUTED", "evidence": ["Researchers in Ohio said Wednesday that they've discovered two new variants of the coronavirus that likely originated in the U.S.  one of which quickly became the dominant strain in Columbus, Ohio, over a three-week period in late December and early January.", "The variants were found by researchers at The Ohio State University.", "Published Wed, Jan 13 202110:07 AM ESTUpdated Wed, Jan 13 20214:43 PM EST Will ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Key Points Ohio researchers said Wednesday that they've discovered two new variants of the coronavirus, one of which has become the dominant strain in Columbus, Ohio.", "Fox News: 2 New Coronavirus Variants That Likely Originated In US Identified In Ohio: Researchers Ohio researchers on Wednesday announced that theyve identified two coronavirus variants that likely originated in the United States."]}
{"id": 1001131, "claim": "Uv-c irradiation is highly effective in inactivating and inhibiting sars-cov-2 replication", "label": "SUPPORTED", "evidence": ["At a virus density comparable to that observed in SARS-CoV-2 infection, an UV-C dose of just 3.7 mJ/cm2 was sufficient to achieve a 3-log inactivation, and complete inhibition of all viral concentrations was observed with 16.9 mJ/cm2."]}
{"id": 1001132, "claim": "Uv-c irradiation is less effective in inactivating and inhibiting sars-cov-2 replication", "label": "REFUTED", "evidence": ["At a virus density comparable to that observed in SARS-CoV-2 infection, an UV-C dose of just 3.7 mJ/cm2 was sufficient to achieve a 3-log inactivation, and complete inhibition of all viral concentrations was observed with 16.9 mJ/cm2."]}
{"id": 1001133, "claim": "Uv-c irradiation is not effective in inactivating and inhibiting sars-cov-2 replication", "label": "REFUTED", "evidence": ["At a virus density comparable to that observed in SARS-CoV-2 infection, an UV-C dose of just 3.7 mJ/cm2 was sufficient to achieve a 3-log inactivation, and complete inhibition of all viral concentrations was observed with 16.9 mJ/cm2."]}
{"id": 1001134, "claim": "Most of new york city 's covid-19 cases came from europe", "label": "SUPPORTED", "evidence": ["Instead, the majority of introductions of the virus seem to have come from Europe and from elsewhere in the United States.", "The majority is clearly European, said Harm van Bakel, a geneticist at Icahn School of Medicine at Mount Sinai, who co-wrote a study awaiting peer review.", "Officially, the first case of coronavirus disease 2019 (COVID-19) was reported in New York City on February 29, but a new report based on genomic analysis suggests the disease was introduced as early as January, and that most cases were linked to Europe, rather than Asia.", "Of the remaining isolates, the vast majority (87%) clustered with clade A2a, and the majority of isolates in that clade (72%) are cases of patients with COVID-19 in Europe, suggesting that Europe was the major origin of COVID-19 cases in New York in march, the authors write."]}
{"id": 1001135, "claim": "None of new york city's covid-19 cases came from europe", "label": "REFUTED", "evidence": ["Instead, the majority of introductions of the virus seem to have come from Europe and from elsewhere in the United States.", "The majority is clearly European, said Harm van Bakel, a geneticist at Icahn School of Medicine at Mount Sinai, who co-wrote a study awaiting peer review.", "Officially, the first case of coronavirus disease 2019 (COVID-19) was reported in New York City on February 29, but a new report based on genomic analysis suggests the disease was introduced as early as January, and that most cases were linked to Europe, rather than Asia.", "Of the remaining isolates, the vast majority (87%) clustered with clade A2a, and the majority of isolates in that clade (72%) are cases of patients with COVID-19 in Europe, suggesting that Europe was the major origin of COVID-19 cases in New York in march, the authors write."]}
{"id": 1001136, "claim": "Progesterone-based therapy protects against influenza by promoting lung repair and recovery in females", "label": "SUPPORTED", "evidence": ["Repair and production of AREG by damaged respiratory epithelial cell cultures in vitro was increased by progesterone.", "Administration of exogenous progesterone (at concentrations that mimic the luteal phase) to progesterone-depleted adult female mice conferred protection from both lethal and sublethal influenza A virus (IAV) infection.", "Progesterone treatment promoted faster recovery by increasing TGF-β, IL-6, IL-22, numbers of regulatory Th17 cells expressing CD39, and cellular proliferation, reducing protein leakage into the airway, improving pulmonary function, and upregulating the epidermal growth factor amphiregulin (AREG) in the lungs.", "Administration of rAREG to progesterone- depleted females promoted pulmonary repair and improved the outcome of IAV infection."]}
{"id": 1001137, "claim": "Progesterone-based therapy failed against influenza by promoting lung repair and recovery in females", "label": "REFUTED", "evidence": ["Repair and production of AREG by damaged respiratory epithelial cell cultures in vitro was increased by progesterone.", "Administration of exogenous progesterone (at concentrations that mimic the luteal phase) to progesterone-depleted adult female mice conferred protection from both lethal and sublethal influenza A virus (IAV) infection.", "Progesterone treatment promoted faster recovery by increasing TGF-β, IL-6, IL-22, numbers of regulatory Th17 cells expressing CD39, and cellular proliferation, reducing protein leakage into the airway, improving pulmonary function, and upregulating the epidermal growth factor amphiregulin (AREG) in the lungs.", "Administration of rAREG to progesterone- depleted females promoted pulmonary repair and improved the outcome of IAV infection."]}
{"id": 1001138, "claim": "Neurologic and radiographic findings associated with covid-19 infection in children", "label": "SUPPORTED", "evidence": ["Objective: To report the neurological manifestations of children with COVID-19.", "Conclusions and relevance: In this case-series study, children with COVID-19 presented with new neurological symptoms involving both the central and peripheral nervous systems and splenial changes on imaging, in the absence of respiratory symptoms."]}
{"id": 1001139, "claim": "Neurologic and radiographic findings associated with covid-19 mortality in children", "label": "REFUTED", "evidence": ["Objective: To report the neurological manifestations of children with COVID-19.", "Conclusions and relevance: In this case-series study, children with COVID-19 presented with new neurological symptoms involving both the central and peripheral nervous systems and splenial changes on imaging, in the absence of respiratory symptoms."]}
{"id": 1001140, "claim": "Neurologic and radiographic findings associated with covid-19 infection in humans", "label": "REFUTED", "evidence": ["Objective: To report the neurological manifestations of children with COVID-19.", "Conclusions and relevance: In this case-series study, children with COVID-19 presented with new neurological symptoms involving both the central and peripheral nervous systems and splenial changes on imaging, in the absence of respiratory symptoms."]}
{"id": 1001141, "claim": "Early mortality rates for coronavirus are likely misleading , experts say", "label": "SUPPORTED", "evidence": ["MORE: White House imposes guest restrictions amid new coronavirus concerns Right now, death rate estimates vary per country.", "Its so critical that we do not waste resources among the young and healthy and that we really focus on the areas where this might really get out of control. MORE: Timeline: How coronavirus got started Dr. William Schaffner, professor of preventive medicine and infectious diseases at the Vanderbilt University School of Medicine in Nashville, says our understanding of the disease is still developing and the statistics are preliminary.", "If you had an outbreak on a cruise ship, and theres any sign that care was delayed or that people who really shouldve been protected werent, then you actually have reason to say Oh, actually, whatever we found on the cruise ship, its actually thats the worst case scenario because they didnt get treatment on time. Athit Perawongmetha/Reuters A bus arrives near the Diamond Princess cruise ship, where dozens of passengers were tested positive for the novel coronavirus, at Daikoku Pier Cruise Terminal in Yokohama, south of Tokyo, Japan, Feb. 16, 2020."]}
{"id": 1001142, "claim": "Early mortality rates for coronavirus are not misleading, experts say", "label": "REFUTED", "evidence": ["MORE: White House imposes guest restrictions amid new coronavirus concerns Right now, death rate estimates vary per country.", "Its so critical that we do not waste resources among the young and healthy and that we really focus on the areas where this might really get out of control. MORE: Timeline: How coronavirus got started Dr. William Schaffner, professor of preventive medicine and infectious diseases at the Vanderbilt University School of Medicine in Nashville, says our understanding of the disease is still developing and the statistics are preliminary.", "If you had an outbreak on a cruise ship, and theres any sign that care was delayed or that people who really shouldve been protected werent, then you actually have reason to say Oh, actually, whatever we found on the cruise ship, its actually thats the worst case scenario because they didnt get treatment on time. Athit Perawongmetha/Reuters A bus arrives near the Diamond Princess cruise ship, where dozens of passengers were tested positive for the novel coronavirus, at Daikoku Pier Cruise Terminal in Yokohama, south of Tokyo, Japan, Feb. 16, 2020."]}
{"id": 1001143, "claim": "Trump halts travel from europe to us", "label": "SUPPORTED", "evidence": ["Trump said the halt on travel from Europe would not include the United Kingdom, and that there would be \"exemptions for Americans who have undergone appropriate screenings.\"", "In his speech he said all travel from Europe would be suspended, but a presidential proclamation later said it would only apply to anyone who had been in the EU's Schengen border-free area in the 14 days before their arrival in the US."]}
{"id": 1001144, "claim": "Bats halts travel from europe to us", "label": "REFUTED", "evidence": ["Trump said the halt on travel from Europe would not include the United Kingdom, and that there would be \"exemptions for Americans who have undergone appropriate screenings.\"", "In his speech he said all travel from Europe would be suspended, but a presidential proclamation later said it would only apply to anyone who had been in the EU's Schengen border-free area in the 14 days before their arrival in the US."]}
{"id": 1001145, "claim": "Trumperes travel from europe to us", "label": "REFUTED", "evidence": ["Trump said the halt on travel from Europe would not include the United Kingdom, and that there would be \"exemptions for Americans who have undergone appropriate screenings.\"", "In his speech he said all travel from Europe would be suspended, but a presidential proclamation later said it would only apply to anyone who had been in the EU's Schengen border-free area in the 14 days before their arrival in the US."]}
{"id": 1001146, "claim": "Trumpears travel from europe to us", "label": "REFUTED", "evidence": ["Trump said the halt on travel from Europe would not include the United Kingdom, and that there would be \"exemptions for Americans who have undergone appropriate screenings.\"", "In his speech he said all travel from Europe would be suspended, but a presidential proclamation later said it would only apply to anyone who had been in the EU's Schengen border-free area in the 14 days before their arrival in the US."]}
{"id": 1001147, "claim": "Sars-cov-2 epidemic after social and economic reopening in three us states reveals shifts in age structure and clinical characteristics", "label": "SUPPORTED", "evidence": ["Using a Bayesian inference framework on eleven daily data streams and flexible daily population contact parameters, we show that population-average mixing rates dropped by >50% during the lockdown period in March/April, and that the correlation between overall population mobility and transmission-capable mobility was broken in May as these states partially re-opened.", "Infection fatality rates (IFR) estimates are higher in our analysis (>2%) than previously reported values, likely resulting from the epidemics in these three states affecting the most vulnerable sub-populations, especially the most vulnerable of the 80 age group.", "A second key question to follow during this time was whether clinical characteristics of the epidemic would improve after the initial surge of cases."]}
{"id": 1001148, "claim": "Sars-cov-2 epidemic after social and economic reopening in two us states reveals shifts in age structure and clinical characteristics", "label": "REFUTED", "evidence": ["Using a Bayesian inference framework on eleven daily data streams and flexible daily population contact parameters, we show that population-average mixing rates dropped by >50% during the lockdown period in March/April, and that the correlation between overall population mobility and transmission-capable mobility was broken in May as these states partially re-opened.", "Infection fatality rates (IFR) estimates are higher in our analysis (>2%) than previously reported values, likely resulting from the epidemics in these three states affecting the most vulnerable sub-populations, especially the most vulnerable of the 80 age group.", "A second key question to follow during this time was whether clinical characteristics of the epidemic would improve after the initial surge of cases."]}
{"id": 1001149, "claim": "Hydroxychloroquine trial continues at duke", "label": "SUPPORTED", "evidence": ["The dosing regimen for hydroxychloroquine was 800 mg (4 tablets) once, then 600 mg (3 tablets) 6 to 8 hours later, then 600 mg (3 tablets) daily for 4 more days for a total course of 5 days (19 tablets total)."]}
{"id": 1001150, "claim": "Hydroxychloroquine trial died at duke", "label": "REFUTED", "evidence": ["The dosing regimen for hydroxychloroquine was 800 mg (4 tablets) once, then 600 mg (3 tablets) 6 to 8 hours later, then 600 mg (3 tablets) daily for 4 more days for a total course of 5 days (19 tablets total)."]}
{"id": 1001151, "claim": "Hydroxychloroquine trial continues at home", "label": "REFUTED", "evidence": ["The dosing regimen for hydroxychloroquine was 800 mg (4 tablets) once, then 600 mg (3 tablets) 6 to 8 hours later, then 600 mg (3 tablets) daily for 4 more days for a total course of 5 days (19 tablets total)."]}
{"id": 1001152, "claim": "Hydroxychloroquine trial occurred at duke", "label": "REFUTED", "evidence": ["The dosing regimen for hydroxychloroquine was 800 mg (4 tablets) once, then 600 mg (3 tablets) 6 to 8 hours later, then 600 mg (3 tablets) daily for 4 more days for a total course of 5 days (19 tablets total)."]}
{"id": 1001153, "claim": "A sars-cov-2 vaccine candidate would likely match all currently circulating variants", "label": "SUPPORTED", "evidence": ["Here we analyzed SARS-CoV-2 sequences sampled since the beginning of the pandemic and found that mutations were rare, indicating that potential vaccine candidates should cover all circulating variants."]}
{"id": 1001154, "claim": "A sars-cov-2 vaccine candidate would not match all currently circulating variants", "label": "REFUTED", "evidence": ["Here we analyzed SARS-CoV-2 sequences sampled since the beginning of the pandemic and found that mutations were rare, indicating that potential vaccine candidates should cover all circulating variants."]}
{"id": 1001155, "claim": "Sars-cov-2 can infect immune cells", "label": "SUPPORTED", "evidence": ["This preprint study reports that immune cells (monocytes, CD4+ T cells, CD8+ T cells and B cells) are susceptible to SARS-CoV-2 infection.", "This was observed by in vitro infection of immune cells and by ex vivo detection of SARS-CoV-2 in peripheral blood mononuclear cells from patients with severe COVID-19."]}
{"id": 1001156, "claim": "Sars-cov-2 cannot infect immune cells", "label": "REFUTED", "evidence": ["This preprint study reports that immune cells (monocytes, CD4+ T cells, CD8+ T cells and B cells) are susceptible to SARS-CoV-2 infection.", "This was observed by in vitro infection of immune cells and by ex vivo detection of SARS-CoV-2 in peripheral blood mononuclear cells from patients with severe COVID-19."]}
{"id": 1001157, "claim": "Sars-cov-2 can infect susceptible cells", "label": "REFUTED", "evidence": ["This preprint study reports that immune cells (monocytes, CD4+ T cells, CD8+ T cells and B cells) are susceptible to SARS-CoV-2 infection.", "This was observed by in vitro infection of immune cells and by ex vivo detection of SARS-CoV-2 in peripheral blood mononuclear cells from patients with severe COVID-19."]}
{"id": 1001158, "claim": "Novel coronavirus thought to have jumped to humans via pangolins", "label": "SUPPORTED", "evidence": ["The team found that coronavirus RNA isolated from those pangolins encodes spike proteins that are closely related to those of SARS-CoV-2 ( Nature 2020, DOI: 10.1038/s41586-020-2169-0)."]}
{"id": 1001159, "claim": "Novel coronavirus thought to have jumped to poultry via pangolins", "label": "REFUTED", "evidence": ["The team found that coronavirus RNA isolated from those pangolins encodes spike proteins that are closely related to those of SARS-CoV-2 ( Nature 2020, DOI: 10.1038/s41586-020-2169-0)."]}
{"id": 1001160, "claim": "Novel coronavirus thought to have jumped to birds via pangolins", "label": "REFUTED", "evidence": ["The team found that coronavirus RNA isolated from those pangolins encodes spike proteins that are closely related to those of SARS-CoV-2 ( Nature 2020, DOI: 10.1038/s41586-020-2169-0)."]}
{"id": 1001161, "claim": "Novel coronavirus thought to have jumped to bats via pangolins", "label": "REFUTED", "evidence": ["The team found that coronavirus RNA isolated from those pangolins encodes spike proteins that are closely related to those of SARS-CoV-2 ( Nature 2020, DOI: 10.1038/s41586-020-2169-0)."]}
{"id": 1001162, "claim": "Google releases regional aggregate location behavior data", "label": "SUPPORTED", "evidence": ["So from a pure anonymization perspective it's good work,\" de Montjoye told TechCrunch, discussing the technical side of Google's release of location data.", "Google says it's using \"aggregated, anonymized data to chart movement trends over time by geography, across different high-level categories of places such as retail and recreation, groceries and pharmacies, parks, transit stations, workplaces, and residential.\"", "Perhaps a bigger question related to Google's location data dump is around the issue of legal consent to be tracking people in the first place.", "Similar to the way Google Maps displays whether certain businesses or public places are busy at certain times of day, the resource aggregates anonymized location tracking data from mobile devices to identify large-scale behavior trends."]}
{"id": 1001163, "claim": "Cdc releases regional aggregate location behavior data", "label": "REFUTED", "evidence": ["So from a pure anonymization perspective it's good work,\" de Montjoye told TechCrunch, discussing the technical side of Google's release of location data.", "Google says it's using \"aggregated, anonymized data to chart movement trends over time by geography, across different high-level categories of places such as retail and recreation, groceries and pharmacies, parks, transit stations, workplaces, and residential.\"", "Perhaps a bigger question related to Google's location data dump is around the issue of legal consent to be tracking people in the first place.", "Similar to the way Google Maps displays whether certain businesses or public places are busy at certain times of day, the resource aggregates anonymized location tracking data from mobile devices to identify large-scale behavior trends."]}
{"id": 1001164, "claim": "Who releases regional aggregate location behavior data", "label": "REFUTED", "evidence": ["So from a pure anonymization perspective it's good work,\" de Montjoye told TechCrunch, discussing the technical side of Google's release of location data.", "Google says it's using \"aggregated, anonymized data to chart movement trends over time by geography, across different high-level categories of places such as retail and recreation, groceries and pharmacies, parks, transit stations, workplaces, and residential.\"", "Perhaps a bigger question related to Google's location data dump is around the issue of legal consent to be tracking people in the first place.", "Similar to the way Google Maps displays whether certain businesses or public places are busy at certain times of day, the resource aggregates anonymized location tracking data from mobile devices to identify large-scale behavior trends."]}
{"id": 1001165, "claim": "China releases regional aggregate location behavior data", "label": "REFUTED", "evidence": ["So from a pure anonymization perspective it's good work,\" de Montjoye told TechCrunch, discussing the technical side of Google's release of location data.", "Google says it's using \"aggregated, anonymized data to chart movement trends over time by geography, across different high-level categories of places such as retail and recreation, groceries and pharmacies, parks, transit stations, workplaces, and residential.\"", "Perhaps a bigger question related to Google's location data dump is around the issue of legal consent to be tracking people in the first place.", "Similar to the way Google Maps displays whether certain businesses or public places are busy at certain times of day, the resource aggregates anonymized location tracking data from mobile devices to identify large-scale behavior trends."]}
{"id": 1001166, "claim": "Researchers working on decoy molecule to fool covid-19", "label": "SUPPORTED", "evidence": ["Elizabeth says: April 11, 2020 at 9:50 am Acting as a decoy, \"human recombinant soluble angiotensin-converting enzyme 2 (hrsACE2) is soon to be tested in clinical trials by the European biotech company Apeiron Biologics, is useful as an antiviral therapy for COVID-19, says Dr. Art Slutsky, a scientist at the Keenan Research Centre for Biomedical Science of St. Michaels Hospital and professor at the University of Toronto who is a collaborator on the study.", "6 Summary: Researchers are working to create a decoy molecule that can trick coronavirus by attracting it before it can attach to lung cells, thus lowering the infection risk of COVID-19.", "Source: Victoria University of Wellington A decoy molecule that fools coronavirus by attracting it before it can attach to lung cells may provide a way forward in the fight against COVID-19."]}
{"id": 1001167, "claim": "Researchers working on decoy sites to fool covid-19", "label": "REFUTED", "evidence": ["Elizabeth says: April 11, 2020 at 9:50 am Acting as a decoy, \"human recombinant soluble angiotensin-converting enzyme 2 (hrsACE2) is soon to be tested in clinical trials by the European biotech company Apeiron Biologics, is useful as an antiviral therapy for COVID-19, says Dr. Art Slutsky, a scientist at the Keenan Research Centre for Biomedical Science of St. Michaels Hospital and professor at the University of Toronto who is a collaborator on the study.", "6 Summary: Researchers are working to create a decoy molecule that can trick coronavirus by attracting it before it can attach to lung cells, thus lowering the infection risk of COVID-19.", "Source: Victoria University of Wellington A decoy molecule that fools coronavirus by attracting it before it can attach to lung cells may provide a way forward in the fight against COVID-19."]}
{"id": 1001168, "claim": "Patients working on decoy molecule to fool covid-19", "label": "REFUTED", "evidence": ["Elizabeth says: April 11, 2020 at 9:50 am Acting as a decoy, \"human recombinant soluble angiotensin-converting enzyme 2 (hrsACE2) is soon to be tested in clinical trials by the European biotech company Apeiron Biologics, is useful as an antiviral therapy for COVID-19, says Dr. Art Slutsky, a scientist at the Keenan Research Centre for Biomedical Science of St. Michaels Hospital and professor at the University of Toronto who is a collaborator on the study.", "6 Summary: Researchers are working to create a decoy molecule that can trick coronavirus by attracting it before it can attach to lung cells, thus lowering the infection risk of COVID-19.", "Source: Victoria University of Wellington A decoy molecule that fools coronavirus by attracting it before it can attach to lung cells may provide a way forward in the fight against COVID-19."]}
{"id": 1001169, "claim": "Researchers working on decoy structures to fool covid-19", "label": "REFUTED", "evidence": ["Elizabeth says: April 11, 2020 at 9:50 am Acting as a decoy, \"human recombinant soluble angiotensin-converting enzyme 2 (hrsACE2) is soon to be tested in clinical trials by the European biotech company Apeiron Biologics, is useful as an antiviral therapy for COVID-19, says Dr. Art Slutsky, a scientist at the Keenan Research Centre for Biomedical Science of St. Michaels Hospital and professor at the University of Toronto who is a collaborator on the study.", "6 Summary: Researchers are working to create a decoy molecule that can trick coronavirus by attracting it before it can attach to lung cells, thus lowering the infection risk of COVID-19.", "Source: Victoria University of Wellington A decoy molecule that fools coronavirus by attracting it before it can attach to lung cells may provide a way forward in the fight against COVID-19."]}
{"id": 1001170, "claim": "Amilorides inhibit sars-cov-2 replication in vitro by targeting rna structures", "label": "SUPPORTED", "evidence": ["The RNA-biased amiloride scaffold was recently tuned to target a viral RNA structure critical for translation in enterovirus 71, ultimately uncovering a novel mechanism to modulate positive-sense RNA viral translation and replication."]}
{"id": 1001171, "claim": "Amilorides promote sars-cov-2 replication in vitro by targeting rna structures", "label": "REFUTED", "evidence": ["The RNA-biased amiloride scaffold was recently tuned to target a viral RNA structure critical for translation in enterovirus 71, ultimately uncovering a novel mechanism to modulate positive-sense RNA viral translation and replication."]}
{"id": 1001172, "claim": "Amilorides enhance sars-cov-2 replication in vitro by targeting rna structures", "label": "REFUTED", "evidence": ["The RNA-biased amiloride scaffold was recently tuned to target a viral RNA structure critical for translation in enterovirus 71, ultimately uncovering a novel mechanism to modulate positive-sense RNA viral translation and replication."]}
{"id": 1001173, "claim": "Amilorides induce sars-cov-2 replication in vitro by targeting rna structures", "label": "REFUTED", "evidence": ["The RNA-biased amiloride scaffold was recently tuned to target a viral RNA structure critical for translation in enterovirus 71, ultimately uncovering a novel mechanism to modulate positive-sense RNA viral translation and replication."]}
{"id": 1001174, "claim": "Clinical trials of monoclonal antibodies to prevent covid-19 now enrolling", "label": "SUPPORTED", "evidence": ["This network will allow us to test the safety and efficacy of monoclonal antibodies and other preventive measures to help identify how best to reduce the level of SARS-CoV-2 infection and ultimately end the COVID-19 pandemic. Monoclonal antibodies are laboratory-made versions of proteins naturally produced by the immune system in response to invading viruses or other pathogens."]}
{"id": 1001175, "claim": "Clinical trials of monoclonal antibodies to induce covid-19 now enrolling", "label": "REFUTED", "evidence": ["This network will allow us to test the safety and efficacy of monoclonal antibodies and other preventive measures to help identify how best to reduce the level of SARS-CoV-2 infection and ultimately end the COVID-19 pandemic. Monoclonal antibodies are laboratory-made versions of proteins naturally produced by the immune system in response to invading viruses or other pathogens."]}
{"id": 1001176, "claim": "Clinical trials of monoclonal antibodies to produce covid-19 now enrolling", "label": "REFUTED", "evidence": ["This network will allow us to test the safety and efficacy of monoclonal antibodies and other preventive measures to help identify how best to reduce the level of SARS-CoV-2 infection and ultimately end the COVID-19 pandemic. Monoclonal antibodies are laboratory-made versions of proteins naturally produced by the immune system in response to invading viruses or other pathogens."]}
{"id": 1001177, "claim": "Clinical trials of monoclonal antibodies to treat covid-19 now enrolling", "label": "REFUTED", "evidence": ["This network will allow us to test the safety and efficacy of monoclonal antibodies and other preventive measures to help identify how best to reduce the level of SARS-CoV-2 infection and ultimately end the COVID-19 pandemic. Monoclonal antibodies are laboratory-made versions of proteins naturally produced by the immune system in response to invading viruses or other pathogens."]}
{"id": 1001178, "claim": "Coronavirus prevalence remains high but some evidence of slowdown , react shows", "label": "SUPPORTED", "evidence": ["While the epidemic continued to rapidly grow during the first half of the study period, with a national R over 1, results from the most recent swabs suggest that there was a drop in infections followed by an uptick.", "We've shown that the prevalence of infection has remained high, reinforcing the need for people to act to help bring infections down and control the virus.", "But in the latest results these trends are reduced, suggesting that the epidemic has progressed from clustering in certain at-risk groups to generalised spread in the community."]}
{"id": 1001179, "claim": "Coronavirus prevalence remains low but some evidence of slowdown, react shows", "label": "REFUTED", "evidence": ["While the epidemic continued to rapidly grow during the first half of the study period, with a national R over 1, results from the most recent swabs suggest that there was a drop in infections followed by an uptick.", "We've shown that the prevalence of infection has remained high, reinforcing the need for people to act to help bring infections down and control the virus.", "But in the latest results these trends are reduced, suggesting that the epidemic has progressed from clustering in certain at-risk groups to generalised spread in the community."]}
{"id": 1001180, "claim": "Coronavirus prevalence remains rare but some evidence of slowdown, react shows", "label": "REFUTED", "evidence": ["While the epidemic continued to rapidly grow during the first half of the study period, with a national R over 1, results from the most recent swabs suggest that there was a drop in infections followed by an uptick.", "We've shown that the prevalence of infection has remained high, reinforcing the need for people to act to help bring infections down and control the virus.", "But in the latest results these trends are reduced, suggesting that the epidemic has progressed from clustering in certain at-risk groups to generalised spread in the community."]}
{"id": 1001181, "claim": "Coronavirus prevalence remains small but some evidence of slowdown, react shows", "label": "REFUTED", "evidence": ["While the epidemic continued to rapidly grow during the first half of the study period, with a national R over 1, results from the most recent swabs suggest that there was a drop in infections followed by an uptick.", "We've shown that the prevalence of infection has remained high, reinforcing the need for people to act to help bring infections down and control the virus.", "But in the latest results these trends are reduced, suggesting that the epidemic has progressed from clustering in certain at-risk groups to generalised spread in the community."]}
{"id": 1001182, "claim": "Covid-19 vaccine protects monkeys from new coronavirus , chinese biotech reports", "label": "SUPPORTED", "evidence": ["For the first time, one of the many COVID-19 vaccines in development has protected an animal, rhesus macaques, from infection by the new coronavirus, scientists report."]}
{"id": 1001183, "claim": "Covid-19 vaccine protects humans from new coronavirus, chinese biotech reports", "label": "REFUTED", "evidence": ["For the first time, one of the many COVID-19 vaccines in development has protected an animal, rhesus macaques, from infection by the new coronavirus, scientists report."]}
{"id": 1001184, "claim": "Covid-19 vaccine protects patients from new coronavirus, chinese biotech reports", "label": "REFUTED", "evidence": ["For the first time, one of the many COVID-19 vaccines in development has protected an animal, rhesus macaques, from infection by the new coronavirus, scientists report."]}
{"id": 1001185, "claim": "Covid-19 vaccine protects pigs from new coronavirus, chinese biotech reports", "label": "REFUTED", "evidence": ["For the first time, one of the many COVID-19 vaccines in development has protected an animal, rhesus macaques, from infection by the new coronavirus, scientists report."]}
{"id": 1001186, "claim": "Asymptomatic and symptomatic sars-cov-2 infections elicit polyfunctional antibodies .", "label": "SUPPORTED", "evidence": ["Asymptomatic individuals mount polyfunctional antibody response to SARS-CoV-2.", "\"Asymptomatic individuals mount polyfunctional antibody response to SARS-CoV-2\".", "In addition to the generation of anti-SARS-CoV-2 neutralizing antibodies, this polyfunctional response includes the induction of antibody-dependent cellular cytotoxicity (ADCC) and complement deposition.", "\\- Asymptomatic and symptomatic SARS-CoV-2-infected individuals harbor polyfunctional antibodies.", "Overall, asymptomatic SARS-CoV-2 infection elicits polyfunctional antibodies neutralizing the virus and targeting infected cells."]}
{"id": 1001187, "claim": "Asymptomatic and symptomatic cpvs-cov-2 infections elicit polyfunctional antibodies.", "label": "REFUTED", "evidence": ["Asymptomatic individuals mount polyfunctional antibody response to SARS-CoV-2.", "\"Asymptomatic individuals mount polyfunctional antibody response to SARS-CoV-2\".", "In addition to the generation of anti-SARS-CoV-2 neutralizing antibodies, this polyfunctional response includes the induction of antibody-dependent cellular cytotoxicity (ADCC) and complement deposition.", "\\- Asymptomatic and symptomatic SARS-CoV-2-infected individuals harbor polyfunctional antibodies.", "Overall, asymptomatic SARS-CoV-2 infection elicits polyfunctional antibodies neutralizing the virus and targeting infected cells."]}
{"id": 1001188, "claim": "Asymptomatic and symptomatic denvs-cov-2 infections elicit polyfunctional antibodies.", "label": "REFUTED", "evidence": ["Asymptomatic individuals mount polyfunctional antibody response to SARS-CoV-2.", "\"Asymptomatic individuals mount polyfunctional antibody response to SARS-CoV-2\".", "In addition to the generation of anti-SARS-CoV-2 neutralizing antibodies, this polyfunctional response includes the induction of antibody-dependent cellular cytotoxicity (ADCC) and complement deposition.", "\\- Asymptomatic and symptomatic SARS-CoV-2-infected individuals harbor polyfunctional antibodies.", "Overall, asymptomatic SARS-CoV-2 infection elicits polyfunctional antibodies neutralizing the virus and targeting infected cells."]}
{"id": 1001189, "claim": "Asymptomatic and symptomatic 3s-cov-2 infections elicit polyfunctional antibodies.", "label": "REFUTED", "evidence": ["Asymptomatic individuals mount polyfunctional antibody response to SARS-CoV-2.", "\"Asymptomatic individuals mount polyfunctional antibody response to SARS-CoV-2\".", "In addition to the generation of anti-SARS-CoV-2 neutralizing antibodies, this polyfunctional response includes the induction of antibody-dependent cellular cytotoxicity (ADCC) and complement deposition.", "\\- Asymptomatic and symptomatic SARS-CoV-2-infected individuals harbor polyfunctional antibodies.", "Overall, asymptomatic SARS-CoV-2 infection elicits polyfunctional antibodies neutralizing the virus and targeting infected cells."]}
{"id": 1001190, "claim": "Covid-19 attack rate increases with city size", "label": "SUPPORTED", "evidence": ["Here, we estimate the growth rates and reproductive numbers of COVID-19 in US cities from March 14th through March 19th to reveal a power-law scaling relationship to city population size.", "This means that COVID-19 is spreading faster on average in larger cities with the additional implication that, in an uncontrolled outbreak, larger fractions of the population are expected to become infected in more populous urban areas.", "We discuss the implications of these observations for controlling the COVID-19 outbreak, emphasizing the need to implement more aggressive distancing policies in larger cities while also preserving socioeconomic activity."]}
{"id": 1001191, "claim": "Covid-19 attack rate decreased with city size", "label": "REFUTED", "evidence": ["Here, we estimate the growth rates and reproductive numbers of COVID-19 in US cities from March 14th through March 19th to reveal a power-law scaling relationship to city population size.", "This means that COVID-19 is spreading faster on average in larger cities with the additional implication that, in an uncontrolled outbreak, larger fractions of the population are expected to become infected in more populous urban areas.", "We discuss the implications of these observations for controlling the COVID-19 outbreak, emphasizing the need to implement more aggressive distancing policies in larger cities while also preserving socioeconomic activity."]}
{"id": 1001192, "claim": "Covid-19 attack rate decreases with city size", "label": "REFUTED", "evidence": ["Here, we estimate the growth rates and reproductive numbers of COVID-19 in US cities from March 14th through March 19th to reveal a power-law scaling relationship to city population size.", "This means that COVID-19 is spreading faster on average in larger cities with the additional implication that, in an uncontrolled outbreak, larger fractions of the population are expected to become infected in more populous urban areas.", "We discuss the implications of these observations for controlling the COVID-19 outbreak, emphasizing the need to implement more aggressive distancing policies in larger cities while also preserving socioeconomic activity."]}
{"id": 1001193, "claim": "Coronavirus-infected americans flown home against cdc 's advice", "label": "SUPPORTED", "evidence": ["During one call, the CDCs principal deputy director, Anne Schuchat, argued against taking the infected Americans on the plane, according to two participants.", "But unhappy CDC officials demanded to be left out of the news release that explained that infected people were being flown back to the United States  a move that would nearly double the number ofknown coronavirus cases in this country.", "AD During one call, the CDCs principal deputy director, Anne Schuchat, argued against taking the infected Americans on the plane, according to two participants."]}
{"id": 1001194, "claim": "Coronavirus-infected americans flown home was cdc's advice", "label": "REFUTED", "evidence": ["During one call, the CDCs principal deputy director, Anne Schuchat, argued against taking the infected Americans on the plane, according to two participants.", "But unhappy CDC officials demanded to be left out of the news release that explained that infected people were being flown back to the United States  a move that would nearly double the number ofknown coronavirus cases in this country.", "AD During one call, the CDCs principal deputy director, Anne Schuchat, argued against taking the infected Americans on the plane, according to two participants."]}
{"id": 1001195, "claim": "Coronavirus-infected americans flown home at cdc's advice", "label": "REFUTED", "evidence": ["During one call, the CDCs principal deputy director, Anne Schuchat, argued against taking the infected Americans on the plane, according to two participants.", "But unhappy CDC officials demanded to be left out of the news release that explained that infected people were being flown back to the United States  a move that would nearly double the number ofknown coronavirus cases in this country.", "AD During one call, the CDCs principal deputy director, Anne Schuchat, argued against taking the infected Americans on the plane, according to two participants."]}
{"id": 1001196, "claim": "Coronavirus-infected americans flown home to cdc's advice", "label": "REFUTED", "evidence": ["During one call, the CDCs principal deputy director, Anne Schuchat, argued against taking the infected Americans on the plane, according to two participants.", "But unhappy CDC officials demanded to be left out of the news release that explained that infected people were being flown back to the United States  a move that would nearly double the number ofknown coronavirus cases in this country.", "AD During one call, the CDCs principal deputy director, Anne Schuchat, argued against taking the infected Americans on the plane, according to two participants."]}
{"id": 1001197, "claim": "Damage to multiple organs presents in young , low risk patients", "label": "SUPPORTED", "evidence": ["Measures of inflammation in the kidneys and pancreas, and ectopic fat in the pancreas and liver, were also higher in hospitalised individuals (P<0.05).", "Multi-organ impairment in low-risk individuals with long COVID.", "There was evidence of mild organ impairment in the heart (32% of patients), lungs (33%), kidneys (12%), liver (10%), pancreas (17%), and spleen (6%).", "The BMJ Young, low risk patients with ongoing symptoms of covid-19 had signs of damage to multiple organs four months after initially being infected, a preprint study has suggested.1 Initial data from 201 patients suggest that almost 70% had impairments in one or more organs four months after their initial symptoms of SARS-CoV-2 infection."]}
{"id": 1001198, "claim": "Damage to multiple populations presents in young, low risk patients", "label": "REFUTED", "evidence": ["Measures of inflammation in the kidneys and pancreas, and ectopic fat in the pancreas and liver, were also higher in hospitalised individuals (P<0.05).", "Multi-organ impairment in low-risk individuals with long COVID.", "There was evidence of mild organ impairment in the heart (32% of patients), lungs (33%), kidneys (12%), liver (10%), pancreas (17%), and spleen (6%).", "The BMJ Young, low risk patients with ongoing symptoms of covid-19 had signs of damage to multiple organs four months after initially being infected, a preprint study has suggested.1 Initial data from 201 patients suggest that almost 70% had impairments in one or more organs four months after their initial symptoms of SARS-CoV-2 infection."]}
{"id": 1001199, "claim": "Damage to multiple pathogens presents in young, low risk patients", "label": "REFUTED", "evidence": ["Measures of inflammation in the kidneys and pancreas, and ectopic fat in the pancreas and liver, were also higher in hospitalised individuals (P<0.05).", "Multi-organ impairment in low-risk individuals with long COVID.", "There was evidence of mild organ impairment in the heart (32% of patients), lungs (33%), kidneys (12%), liver (10%), pancreas (17%), and spleen (6%).", "The BMJ Young, low risk patients with ongoing symptoms of covid-19 had signs of damage to multiple organs four months after initially being infected, a preprint study has suggested.1 Initial data from 201 patients suggest that almost 70% had impairments in one or more organs four months after their initial symptoms of SARS-CoV-2 infection."]}
{"id": 1001200, "claim": "Damage to multiple countries presents in young, low risk patients", "label": "REFUTED", "evidence": ["Measures of inflammation in the kidneys and pancreas, and ectopic fat in the pancreas and liver, were also higher in hospitalised individuals (P<0.05).", "Multi-organ impairment in low-risk individuals with long COVID.", "There was evidence of mild organ impairment in the heart (32% of patients), lungs (33%), kidneys (12%), liver (10%), pancreas (17%), and spleen (6%).", "The BMJ Young, low risk patients with ongoing symptoms of covid-19 had signs of damage to multiple organs four months after initially being infected, a preprint study has suggested.1 Initial data from 201 patients suggest that almost 70% had impairments in one or more organs four months after their initial symptoms of SARS-CoV-2 infection."]}
{"id": 1001201, "claim": "Dozens of covid-19 vaccines are in development .", "label": "SUPPORTED", "evidence": ["Here are the COVID-19 vaccine prospects that have made it to phase three trials and beyond."]}
{"id": 1001202, "claim": "Dozens of covid-19 vaccines are in place.", "label": "REFUTED", "evidence": ["Here are the COVID-19 vaccine prospects that have made it to phase three trials and beyond."]}
{"id": 1001203, "claim": "Dozens of covid-19 cells are in development.", "label": "REFUTED", "evidence": ["Here are the COVID-19 vaccine prospects that have made it to phase three trials and beyond."]}
{"id": 1001204, "claim": "Dozens of covid-19 infection are in development.", "label": "REFUTED", "evidence": ["Here are the COVID-19 vaccine prospects that have made it to phase three trials and beyond."]}
{"id": 1001205, "claim": "Vaccine bcg may provide immune boost against coronavirus , herpes , and other viral infections", "label": "SUPPORTED", "evidence": ["Taken together, these findings suggest that the induction of trained immunity by BCG vaccination results in significant protection against multiple viral infections.", "Looking at absenteeism has the advantage that any beneficial effects of the BCG vaccine on influenza and other infections may be captured as well, he says.", "Apparently, a vaccination with BCG also activates the immune system against a viral infection.", "BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity."]}
{"id": 1001206, "claim": "Vaccine bcg may prevent immune boost against coronavirus, herpes, and other viral infections", "label": "REFUTED", "evidence": ["Taken together, these findings suggest that the induction of trained immunity by BCG vaccination results in significant protection against multiple viral infections.", "Looking at absenteeism has the advantage that any beneficial effects of the BCG vaccine on influenza and other infections may be captured as well, he says.", "Apparently, a vaccination with BCG also activates the immune system against a viral infection.", "BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity."]}
{"id": 1001207, "claim": "Toilets may pose risk for spreading covid-19", "label": "SUPPORTED", "evidence": ["The aerosolization effect that can occur in toilets, leading to microdroplets that can be inhaled or persist on surface areas, raises some real concerns regarding epidemiologic spread.", "However, I want to talk about one other potential means of its spread: the toilet.", "But what do we do to address concerns that the toilet microbiome may put us at risk for COVID-19?", "That is quite concerning when you consider that flushing a toilet can create an aerosolized plume of these viral particles, which can then spread elsewhere within proximity."]}
{"id": 1001208, "claim": "Toilets may pose risk for treating covid-19", "label": "REFUTED", "evidence": ["The aerosolization effect that can occur in toilets, leading to microdroplets that can be inhaled or persist on surface areas, raises some real concerns regarding epidemiologic spread.", "However, I want to talk about one other potential means of its spread: the toilet.", "But what do we do to address concerns that the toilet microbiome may put us at risk for COVID-19?", "That is quite concerning when you consider that flushing a toilet can create an aerosolized plume of these viral particles, which can then spread elsewhere within proximity."]}
{"id": 1001209, "claim": "Toilets may pose risk for developing covid-19", "label": "REFUTED", "evidence": ["The aerosolization effect that can occur in toilets, leading to microdroplets that can be inhaled or persist on surface areas, raises some real concerns regarding epidemiologic spread.", "However, I want to talk about one other potential means of its spread: the toilet.", "But what do we do to address concerns that the toilet microbiome may put us at risk for COVID-19?", "That is quite concerning when you consider that flushing a toilet can create an aerosolized plume of these viral particles, which can then spread elsewhere within proximity."]}
{"id": 1001210, "claim": "Cytokine profile in plasma of severe covid-19 does not differ from ards and sepsis", "label": "SUPPORTED", "evidence": ["Expression of inflammatory cytokines does not differ between COVID-19 and non-COVID sepsis and ARDS."]}
{"id": 1001211, "claim": "Cytokine profile in plasma of severe covid-19 does significantly differ from ards and sepsis", "label": "REFUTED", "evidence": ["Expression of inflammatory cytokines does not differ between COVID-19 and non-COVID sepsis and ARDS."]}
{"id": 1001212, "claim": "Cytokine profile in plasma of severe covid-19 does still differ from ards and sepsis", "label": "REFUTED", "evidence": ["Expression of inflammatory cytokines does not differ between COVID-19 and non-COVID sepsis and ARDS."]}
{"id": 1001213, "claim": "Cytokine profile in plasma of severe covid-19 does also differ from ards and sepsis", "label": "REFUTED", "evidence": ["Expression of inflammatory cytokines does not differ between COVID-19 and non-COVID sepsis and ARDS."]}
{"id": 1001214, "claim": "Duhs scientists make breakthrough in plasma treatment of covid-19", "label": "SUPPORTED", "evidence": ["Here's all you need to know about the approach DUHS Vice Chancellor Muhammad Saeed Quraishy called it an important breakthrough in the war against Covid-19, according to a press release issued by the university.", "Creative commons A team of scientists from the Dow University of Health Sciences (DUHS) on Monday claimed to have made a significant breakthrough in the treatment against Covid-19 after it prepared intravenous immunoglobulin (IVIG) with plasma obtained from recovered coronavirus patients.", "The university displayed confidence in the efficacy of its treatment by arguing that the Covid-19 strain currently infecting Pakistanis only has a \"few mutations\" and therefore local IVIG from infected patients holds the potential to provide an extremely potent form of immunisation against Covid-19 for Pakistanis."]}
{"id": 1001215, "claim": "Duhs scientists make difficulties in plasma treatment of covid-19", "label": "REFUTED", "evidence": ["Here's all you need to know about the approach DUHS Vice Chancellor Muhammad Saeed Quraishy called it an important breakthrough in the war against Covid-19, according to a press release issued by the university.", "Creative commons A team of scientists from the Dow University of Health Sciences (DUHS) on Monday claimed to have made a significant breakthrough in the treatment against Covid-19 after it prepared intravenous immunoglobulin (IVIG) with plasma obtained from recovered coronavirus patients.", "The university displayed confidence in the efficacy of its treatment by arguing that the Covid-19 strain currently infecting Pakistanis only has a \"few mutations\" and therefore local IVIG from infected patients holds the potential to provide an extremely potent form of immunisation against Covid-19 for Pakistanis."]}
{"id": 1001216, "claim": "Peaks of fine particulate matter may modulate the spreading and virulence of covid-19", "label": "SUPPORTED", "evidence": ["2019) and/or the role of high concentrations of fine particulate matter (PM2.5) in modulating or boosting COVID-19 prevalence, morbidity and mortality.", "We deem it both reasonable and plausible that high PM2.5 concentrationsfavored by air temperature inversions or Saharan dust intrusionsare not only modulating but even more so boosting severe outbreaks of COVID-19.", "Based on these lines of evidence and select examples presented in the following, we hypothesize that COVID-19 prevalence and virulence is linked closely to PM2.5 peaks forming predominantly during (1) the occurrence of air temperature inversions, characterized by rather cool and moist conditions, or (2) desert dust advection conditions characterized by dry and warm air masses."]}
{"id": 1001217, "claim": "Lack of fine particulate matter may modulate the spreading and virulence of covid-19", "label": "REFUTED", "evidence": ["2019) and/or the role of high concentrations of fine particulate matter (PM2.5) in modulating or boosting COVID-19 prevalence, morbidity and mortality.", "We deem it both reasonable and plausible that high PM2.5 concentrationsfavored by air temperature inversions or Saharan dust intrusionsare not only modulating but even more so boosting severe outbreaks of COVID-19.", "Based on these lines of evidence and select examples presented in the following, we hypothesize that COVID-19 prevalence and virulence is linked closely to PM2.5 peaks forming predominantly during (1) the occurrence of air temperature inversions, characterized by rather cool and moist conditions, or (2) desert dust advection conditions characterized by dry and warm air masses."]}
{"id": 1001218, "claim": "Peaks of fine particulate matter may modulate the stability and virulence of covid-19", "label": "REFUTED", "evidence": ["2019) and/or the role of high concentrations of fine particulate matter (PM2.5) in modulating or boosting COVID-19 prevalence, morbidity and mortality.", "We deem it both reasonable and plausible that high PM2.5 concentrationsfavored by air temperature inversions or Saharan dust intrusionsare not only modulating but even more so boosting severe outbreaks of COVID-19.", "Based on these lines of evidence and select examples presented in the following, we hypothesize that COVID-19 prevalence and virulence is linked closely to PM2.5 peaks forming predominantly during (1) the occurrence of air temperature inversions, characterized by rather cool and moist conditions, or (2) desert dust advection conditions characterized by dry and warm air masses."]}
{"id": 1001219, "claim": "Treatment with ace-inhibitors is not associated with early severe sars-covid-19 infection in a multi-site uk acute hospital trust", "label": "SUPPORTED", "evidence": ["Conclusions There was no evidence for increased severity of COVID19 disease in hospitalised patients on chronic treatment with ACEi or ARB.", "Share ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust Daniel M Bean, Zeljko Kraljevic, Thomas Searle, Rebecca Bendayan, Kevin OGallagher, Andrew Pickles, Amos Folarin, Lukasz Roguski, Kawsar Noor, Anthony Shek, Rosita Zakeri, Ajay M Shah, James TH Teo, Richard JB Dobson medRxiv 2020.04.07.20056788; doi: https://doi.org/10.1101/2020.04.07.20056788 Share This Article: Copy Citation Tools ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust Daniel M Bean, Zeljko Kraljevic, Thomas Searle, Rebecca Bendayan, Kevin OGallagher, Andrew Pickles, Amos Folarin, Lukasz Roguski, Kawsar Noor, Anthony Shek, Rosita Zakeri, Ajay M Shah, James TH Teo, Richard JB Dobson medRxiv 2020.04.07.20056788; doi: https://doi.org/10.1101/2020.04.07.20056788 "]}
{"id": 1001220, "claim": "Treatment with ace-inhibitors is also associated with early severe sars-covid-19 infection in a multi-site uk acute hospital trust", "label": "REFUTED", "evidence": ["Conclusions There was no evidence for increased severity of COVID19 disease in hospitalised patients on chronic treatment with ACEi or ARB.", "Share ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust Daniel M Bean, Zeljko Kraljevic, Thomas Searle, Rebecca Bendayan, Kevin OGallagher, Andrew Pickles, Amos Folarin, Lukasz Roguski, Kawsar Noor, Anthony Shek, Rosita Zakeri, Ajay M Shah, James TH Teo, Richard JB Dobson medRxiv 2020.04.07.20056788; doi: https://doi.org/10.1101/2020.04.07.20056788 Share This Article: Copy Citation Tools ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust Daniel M Bean, Zeljko Kraljevic, Thomas Searle, Rebecca Bendayan, Kevin OGallagher, Andrew Pickles, Amos Folarin, Lukasz Roguski, Kawsar Noor, Anthony Shek, Rosita Zakeri, Ajay M Shah, James TH Teo, Richard JB Dobson medRxiv 2020.04.07.20056788; doi: https://doi.org/10.1101/2020.04.07.20056788 "]}
{"id": 1001221, "claim": "Treatment with ace-inhibitors is significantly associated with early severe sars-covid-19 infection in a multi-site uk acute hospital trust", "label": "REFUTED", "evidence": ["Conclusions There was no evidence for increased severity of COVID19 disease in hospitalised patients on chronic treatment with ACEi or ARB.", "Share ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust Daniel M Bean, Zeljko Kraljevic, Thomas Searle, Rebecca Bendayan, Kevin OGallagher, Andrew Pickles, Amos Folarin, Lukasz Roguski, Kawsar Noor, Anthony Shek, Rosita Zakeri, Ajay M Shah, James TH Teo, Richard JB Dobson medRxiv 2020.04.07.20056788; doi: https://doi.org/10.1101/2020.04.07.20056788 Share This Article: Copy Citation Tools ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust Daniel M Bean, Zeljko Kraljevic, Thomas Searle, Rebecca Bendayan, Kevin OGallagher, Andrew Pickles, Amos Folarin, Lukasz Roguski, Kawsar Noor, Anthony Shek, Rosita Zakeri, Ajay M Shah, James TH Teo, Richard JB Dobson medRxiv 2020.04.07.20056788; doi: https://doi.org/10.1101/2020.04.07.20056788 "]}
{"id": 1001222, "claim": "Treatment with ace-inhibitors is strongly associated with early severe sars-covid-19 infection in a multi-site uk acute hospital trust", "label": "REFUTED", "evidence": ["Conclusions There was no evidence for increased severity of COVID19 disease in hospitalised patients on chronic treatment with ACEi or ARB.", "Share ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust Daniel M Bean, Zeljko Kraljevic, Thomas Searle, Rebecca Bendayan, Kevin OGallagher, Andrew Pickles, Amos Folarin, Lukasz Roguski, Kawsar Noor, Anthony Shek, Rosita Zakeri, Ajay M Shah, James TH Teo, Richard JB Dobson medRxiv 2020.04.07.20056788; doi: https://doi.org/10.1101/2020.04.07.20056788 Share This Article: Copy Citation Tools ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust Daniel M Bean, Zeljko Kraljevic, Thomas Searle, Rebecca Bendayan, Kevin OGallagher, Andrew Pickles, Amos Folarin, Lukasz Roguski, Kawsar Noor, Anthony Shek, Rosita Zakeri, Ajay M Shah, James TH Teo, Richard JB Dobson medRxiv 2020.04.07.20056788; doi: https://doi.org/10.1101/2020.04.07.20056788 "]}
{"id": 1001223, "claim": "Prolonged low-dose methylprednisolone in patients with severe covid-19 pneumonia", "label": "SUPPORTED", "evidence": ["We hypothesize that early prolonged methylprednisolone (MP) treatment could accelerate disease resolution, decreasing the need for ICU and mortality.", "Conclusion In patients with severe COVID-19 pneumonia, early administration of prolonged MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence."]}
{"id": 1001224, "claim": "Prolonged low-dose methylprednisolone in patients with mild covid-19 pneumonia", "label": "REFUTED", "evidence": ["We hypothesize that early prolonged methylprednisolone (MP) treatment could accelerate disease resolution, decreasing the need for ICU and mortality.", "Conclusion In patients with severe COVID-19 pneumonia, early administration of prolonged MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence."]}
{"id": 1001225, "claim": "Prolonged low-dose methylprednisolone in patients with no covid-19 pneumonia", "label": "REFUTED", "evidence": ["We hypothesize that early prolonged methylprednisolone (MP) treatment could accelerate disease resolution, decreasing the need for ICU and mortality.", "Conclusion In patients with severe COVID-19 pneumonia, early administration of prolonged MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence."]}
{"id": 1001226, "claim": "Cruise association hits back with measures to protect passengers from coronavirus", "label": "SUPPORTED", "evidence": ["CLIA has issued and updated industry precautionary measures for its members to follow to prevent the spread of the coronavirus."]}
{"id": 1001227, "claim": "Cruise association hits compliance with measures to protect passengers from coronavirus", "label": "REFUTED", "evidence": ["CLIA has issued and updated industry precautionary measures for its members to follow to prevent the spread of the coronavirus."]}
{"id": 1001228, "claim": "Cruise association hits along with measures to protect passengers from coronavirus", "label": "REFUTED", "evidence": ["CLIA has issued and updated industry precautionary measures for its members to follow to prevent the spread of the coronavirus."]}
{"id": 1001229, "claim": "Chop researchers find elevated biomarker related to blood vessel damage in all children with sars-cov-2 regardless of disease severity.", "label": "SUPPORTED", "evidence": ["To assess the role of complement activation in children with SARS-CoV-2, the Immune Dysregulation Frontier Program, including co-senior authors Edward Behrens, MD and Hamid Bassiri, MD, PhD and co-first authors Caroline Diorio, MD and Kevin McNerney, MD, analyzed 50 pediatric patients hospitalized at CHOP with acute SARS-CoV-2 infection between April and July 2020."]}
{"id": 1001230, "claim": "Chop researchers find no biomarker related to blood vessel damage in all children with sars-cov-2 regardless of disease severity.", "label": "REFUTED", "evidence": ["To assess the role of complement activation in children with SARS-CoV-2, the Immune Dysregulation Frontier Program, including co-senior authors Edward Behrens, MD and Hamid Bassiri, MD, PhD and co-first authors Caroline Diorio, MD and Kevin McNerney, MD, analyzed 50 pediatric patients hospitalized at CHOP with acute SARS-CoV-2 infection between April and July 2020."]}
{"id": 1001231, "claim": "Formulation of a composite nasal spray enabling enhanced surface coverage and prophylaxis of sars-cov-2.", "label": "SUPPORTED", "evidence": ["> \"This study has demonstrated the formulation of a potent antiviral nasal > spray, with not only prophylactic capacity, but the ability to prevent viral > transmission.", "\"Carrageenan-based composite nasal spray may help prevent SARS-CoV-2 infection\".", "Formulation of a composite nasal spray enabling enhanced surface coverage and prophylaxis", "Carrageenan-based composite nasal spray may help prevent SARS-CoV-2 infection.", "If approved for use, the nasal spray could potentially help mitigate SARS-CoV-2 infection and transmissibility."]}
{"id": 1001232, "claim": "Formulation of a composite water spray enabling enhanced surface coverage and prophylaxis of sars-cov-2.", "label": "REFUTED", "evidence": ["> \"This study has demonstrated the formulation of a potent antiviral nasal > spray, with not only prophylactic capacity, but the ability to prevent viral > transmission.", "\"Carrageenan-based composite nasal spray may help prevent SARS-CoV-2 infection\".", "Formulation of a composite nasal spray enabling enhanced surface coverage and prophylaxis", "Carrageenan-based composite nasal spray may help prevent SARS-CoV-2 infection.", "If approved for use, the nasal spray could potentially help mitigate SARS-CoV-2 infection and transmissibility."]}
{"id": 1001233, "claim": "Formulation of a composite hand spray enabling enhanced surface coverage and prophylaxis of sars-cov-2.", "label": "REFUTED", "evidence": ["> \"This study has demonstrated the formulation of a potent antiviral nasal > spray, with not only prophylactic capacity, but the ability to prevent viral > transmission.", "\"Carrageenan-based composite nasal spray may help prevent SARS-CoV-2 infection\".", "Formulation of a composite nasal spray enabling enhanced surface coverage and prophylaxis", "Carrageenan-based composite nasal spray may help prevent SARS-CoV-2 infection.", "If approved for use, the nasal spray could potentially help mitigate SARS-CoV-2 infection and transmissibility."]}
{"id": 1001234, "claim": "Formulation of a composite blood spray enabling enhanced surface coverage and prophylaxis of sars-cov-2.", "label": "REFUTED", "evidence": ["> \"This study has demonstrated the formulation of a potent antiviral nasal > spray, with not only prophylactic capacity, but the ability to prevent viral > transmission.", "\"Carrageenan-based composite nasal spray may help prevent SARS-CoV-2 infection\".", "Formulation of a composite nasal spray enabling enhanced surface coverage and prophylaxis", "Carrageenan-based composite nasal spray may help prevent SARS-CoV-2 infection.", "If approved for use, the nasal spray could potentially help mitigate SARS-CoV-2 infection and transmissibility."]}
{"id": 1001235, "claim": "Full-dose blood thinners decreased need for life support and improved outcomes in hospitalized covid-19 patients in international trial.", "label": "SUPPORTED", "evidence": ["Article by Don Ward Hackett Reference: Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients Fact checked by Robert Carlson, MD Relevant Links: CDC Vaccination Schedules Vaccine Price List Vaccines for Children Report Vaccine Side Effects Sponsored Links: Discounts Appointments Clinical Trials Lab Tests "]}
{"id": 1001236, "claim": "Full-dose blood thinners also need for life support and improved outcomes in hospitalized covid-19 patients in international trial.", "label": "REFUTED", "evidence": ["Article by Don Ward Hackett Reference: Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients Fact checked by Robert Carlson, MD Relevant Links: CDC Vaccination Schedules Vaccine Price List Vaccines for Children Report Vaccine Side Effects Sponsored Links: Discounts Appointments Clinical Trials Lab Tests "]}
{"id": 1001237, "claim": "China 's sinovac vaccine 78 % effective , says brazil.", "label": "SUPPORTED", "evidence": ["(AP Photo/Eraldo Peres) SAO PAULO (AP)  A vaccine candidate made by Chinas Sinovac is 78% effective in protecting against the coronavirus, according to results of a study announced Thursday by Brazilian state health officials seeking federal approval of the shot.", "The Sinovac vaccine is one of at least five Chinese shots undergoing late- stage trials The coronavirus vaccine developed by Chinese company Sinovac Biotech was found to be 78% effective in late-stage trials in Brazil , Brazilian media reported Thursday."]}
{"id": 1001238, "claim": "China's sinovac vaccine 78 % effective, says 2005.", "label": "REFUTED", "evidence": ["(AP Photo/Eraldo Peres) SAO PAULO (AP)  A vaccine candidate made by Chinas Sinovac is 78% effective in protecting against the coronavirus, according to results of a study announced Thursday by Brazilian state health officials seeking federal approval of the shot.", "The Sinovac vaccine is one of at least five Chinese shots undergoing late- stage trials The coronavirus vaccine developed by Chinese company Sinovac Biotech was found to be 78% effective in late-stage trials in Brazil , Brazilian media reported Thursday."]}
{"id": 1001239, "claim": "China's sinovac vaccine 78 % effective, saysed.", "label": "REFUTED", "evidence": ["(AP Photo/Eraldo Peres) SAO PAULO (AP)  A vaccine candidate made by Chinas Sinovac is 78% effective in protecting against the coronavirus, according to results of a study announced Thursday by Brazilian state health officials seeking federal approval of the shot.", "The Sinovac vaccine is one of at least five Chinese shots undergoing late- stage trials The coronavirus vaccine developed by Chinese company Sinovac Biotech was found to be 78% effective in late-stage trials in Brazil , Brazilian media reported Thursday."]}
{"id": 1001240, "claim": "China's sinovac vaccine 78 % effective, says vaccine.", "label": "REFUTED", "evidence": ["(AP Photo/Eraldo Peres) SAO PAULO (AP)  A vaccine candidate made by Chinas Sinovac is 78% effective in protecting against the coronavirus, according to results of a study announced Thursday by Brazilian state health officials seeking federal approval of the shot.", "The Sinovac vaccine is one of at least five Chinese shots undergoing late- stage trials The coronavirus vaccine developed by Chinese company Sinovac Biotech was found to be 78% effective in late-stage trials in Brazil , Brazilian media reported Thursday."]}
{"id": 1001241, "claim": "Convalescent plasma is ineffective for covid-19", "label": "SUPPORTED", "evidence": ["In prespecified, intention-to-treat analyses, the PLACID Trial investigators found no net benefit associated with convalescent plasma in patients admitted to hospital with moderate covid-19."]}
{"id": 1001242, "claim": "Convalescent plasma is suitable for covid-19", "label": "REFUTED", "evidence": ["In prespecified, intention-to-treat analyses, the PLACID Trial investigators found no net benefit associated with convalescent plasma in patients admitted to hospital with moderate covid-19."]}
{"id": 1001243, "claim": "Convalescent plasma is necessary for covid-19", "label": "REFUTED", "evidence": ["In prespecified, intention-to-treat analyses, the PLACID Trial investigators found no net benefit associated with convalescent plasma in patients admitted to hospital with moderate covid-19."]}
{"id": 1001244, "claim": "Convalescent plasma is required for covid-19", "label": "REFUTED", "evidence": ["In prespecified, intention-to-treat analyses, the PLACID Trial investigators found no net benefit associated with convalescent plasma in patients admitted to hospital with moderate covid-19."]}
{"id": 1001245, "claim": "Sars-cov-2 and malayan pangolin coronavirus infect human endoderm , ectoderm and induced lung progenitor cells", "label": "SUPPORTED", "evidence": ["In line with the SARS- CoV-2 results, GXP2V could also infected endoderm and ectoderm, and also was inhibited by Remdesivir treatment."]}
{"id": 1001246, "claim": "Sars-cov-2 and malayan pangolin coronavirus infect human endoderm, ectoderm and induced neural progenitor cells", "label": "REFUTED", "evidence": ["In line with the SARS- CoV-2 results, GXP2V could also infected endoderm and ectoderm, and also was inhibited by Remdesivir treatment."]}
{"id": 1001247, "claim": "Sars-cov-2 and malayan pangolin coronavirus infect human endoderm, ectoderm and induced intestinal progenitor cells", "label": "REFUTED", "evidence": ["In line with the SARS- CoV-2 results, GXP2V could also infected endoderm and ectoderm, and also was inhibited by Remdesivir treatment."]}
{"id": 1001248, "claim": "Sars-cov-2 and malayan pangolin coronavirus infect human endoderm, ectoderm and induced neuronal progenitor cells", "label": "REFUTED", "evidence": ["In line with the SARS- CoV-2 results, GXP2V could also infected endoderm and ectoderm, and also was inhibited by Remdesivir treatment."]}
{"id": 1001249, "claim": "Vaping linked to covid-19 risk in teens and young adults", "label": "SUPPORTED", "evidence": ["Among the participants who were tested for COVID-19, those who had ever used e-cigarettes were five times more likely to be diagnosed with COVID-19 than nonusers.", "Nery Zarate/Unsplash Vaping is linked to a substantially increased risk of COVID-19 among teenagers and young adults, according to a new study led by researchers at the Stanford University School of Medicine.", "Among young people who were tested for the virus that causes COVID-19, the research found that those who vaped were five to seven times more likely to be infected than those who did not use e-cigarettes.", "Aug 11 2020 Teenagers and young adults who vape face a much higher risk of COVID-19 than their peers who do not vape, a new study has found."]}
{"id": 1001250, "claim": "Vaping linked to covid-19 risk in elderly and young adults", "label": "REFUTED", "evidence": ["Among the participants who were tested for COVID-19, those who had ever used e-cigarettes were five times more likely to be diagnosed with COVID-19 than nonusers.", "Nery Zarate/Unsplash Vaping is linked to a substantially increased risk of COVID-19 among teenagers and young adults, according to a new study led by researchers at the Stanford University School of Medicine.", "Among young people who were tested for the virus that causes COVID-19, the research found that those who vaped were five to seven times more likely to be infected than those who did not use e-cigarettes.", "Aug 11 2020 Teenagers and young adults who vape face a much higher risk of COVID-19 than their peers who do not vape, a new study has found."]}
{"id": 1001251, "claim": "Vaping linked to covid-19 risk in women and young adults", "label": "REFUTED", "evidence": ["Among the participants who were tested for COVID-19, those who had ever used e-cigarettes were five times more likely to be diagnosed with COVID-19 than nonusers.", "Nery Zarate/Unsplash Vaping is linked to a substantially increased risk of COVID-19 among teenagers and young adults, according to a new study led by researchers at the Stanford University School of Medicine.", "Among young people who were tested for the virus that causes COVID-19, the research found that those who vaped were five to seven times more likely to be infected than those who did not use e-cigarettes.", "Aug 11 2020 Teenagers and young adults who vape face a much higher risk of COVID-19 than their peers who do not vape, a new study has found."]}
{"id": 1001252, "claim": "Vaping linked to covid-19 risk in infants and young adults", "label": "REFUTED", "evidence": ["Among the participants who were tested for COVID-19, those who had ever used e-cigarettes were five times more likely to be diagnosed with COVID-19 than nonusers.", "Nery Zarate/Unsplash Vaping is linked to a substantially increased risk of COVID-19 among teenagers and young adults, according to a new study led by researchers at the Stanford University School of Medicine.", "Among young people who were tested for the virus that causes COVID-19, the research found that those who vaped were five to seven times more likely to be infected than those who did not use e-cigarettes.", "Aug 11 2020 Teenagers and young adults who vape face a much higher risk of COVID-19 than their peers who do not vape, a new study has found."]}
{"id": 1001253, "claim": "Sterilizing immunity against sars-cov-2 infection in mice by a single-shot and modified imidazoquinoline tlr7/8 agonist-adjuvanted recombinant spike protein vaccine", "label": "SUPPORTED", "evidence": ["To correlate vaccine responses with control of virus replication in vivo , vaccinated mice were challenged with SARS-CoV-2 virus after being sensitized by intranasal adenovirus-mediated expression of the human angiotensin converting enzyme 2 (ACE2) gene.", "IMDQ-PEG-CHOL is used to induce a protective immune response against SARS-CoV-2 after single vaccination with trimeric recombinant SARS-CoV-2 spike protein in the BALB/c mouse model."]}
{"id": 1001254, "claim": "Sterilizing immunity against sars-cov-2 infection in humans by a single-shot and modified imidazoquinoline tlr7/8 agonist-adjuvanted recombinant spike protein vaccine", "label": "REFUTED", "evidence": ["To correlate vaccine responses with control of virus replication in vivo , vaccinated mice were challenged with SARS-CoV-2 virus after being sensitized by intranasal adenovirus-mediated expression of the human angiotensin converting enzyme 2 (ACE2) gene.", "IMDQ-PEG-CHOL is used to induce a protective immune response against SARS-CoV-2 after single vaccination with trimeric recombinant SARS-CoV-2 spike protein in the BALB/c mouse model."]}
{"id": 1001255, "claim": "Sterilizing immunity against sars-cov-2 infection in rats by a single-shot and modified imidazoquinoline tlr7/8 agonist-adjuvanted recombinant spike protein vaccine", "label": "REFUTED", "evidence": ["To correlate vaccine responses with control of virus replication in vivo , vaccinated mice were challenged with SARS-CoV-2 virus after being sensitized by intranasal adenovirus-mediated expression of the human angiotensin converting enzyme 2 (ACE2) gene.", "IMDQ-PEG-CHOL is used to induce a protective immune response against SARS-CoV-2 after single vaccination with trimeric recombinant SARS-CoV-2 spike protein in the BALB/c mouse model."]}
{"id": 1001256, "claim": "Sterilizing immunity against sars-cov-2 infection in rabbits by a single-shot and modified imidazoquinoline tlr7/8 agonist-adjuvanted recombinant spike protein vaccine", "label": "REFUTED", "evidence": ["To correlate vaccine responses with control of virus replication in vivo , vaccinated mice were challenged with SARS-CoV-2 virus after being sensitized by intranasal adenovirus-mediated expression of the human angiotensin converting enzyme 2 (ACE2) gene.", "IMDQ-PEG-CHOL is used to induce a protective immune response against SARS-CoV-2 after single vaccination with trimeric recombinant SARS-CoV-2 spike protein in the BALB/c mouse model."]}
{"id": 1001257, "claim": "Imhe estimates 81,114 deaths in united states over next four months", "label": "SUPPORTED", "evidence": ["With those inputs, the computer models project a total of 81,114 deaths in the U.S. over the next four months.", "We estimate 81,114 (95% UI 38,242 to 162,106) deaths in the United States from COVID-19 over the next 4 months.", "We estimate that there will be a total of 81,114 deaths (95% UI 38,242 to 162,106) from COVID-19 over the next 4 months in the US.", "We estimate that there will be a total of 81,114 (95% UI 38,242 to 162,106) deaths from COVID-19 over the next 4 months in the US."]}
{"id": 1001258, "claim": "Imhe estimates 81,114 days in united states over next four months", "label": "REFUTED", "evidence": ["With those inputs, the computer models project a total of 81,114 deaths in the U.S. over the next four months.", "We estimate 81,114 (95% UI 38,242 to 162,106) deaths in the United States from COVID-19 over the next 4 months.", "We estimate that there will be a total of 81,114 deaths (95% UI 38,242 to 162,106) from COVID-19 over the next 4 months in the US.", "We estimate that there will be a total of 81,114 (95% UI 38,242 to 162,106) deaths from COVID-19 over the next 4 months in the US."]}
{"id": 1001259, "claim": "Imhe estimates 81,114 people in united states over next four months", "label": "REFUTED", "evidence": ["With those inputs, the computer models project a total of 81,114 deaths in the U.S. over the next four months.", "We estimate 81,114 (95% UI 38,242 to 162,106) deaths in the United States from COVID-19 over the next 4 months.", "We estimate that there will be a total of 81,114 deaths (95% UI 38,242 to 162,106) from COVID-19 over the next 4 months in the US.", "We estimate that there will be a total of 81,114 (95% UI 38,242 to 162,106) deaths from COVID-19 over the next 4 months in the US."]}
{"id": 1001260, "claim": "Imhe estimates 81,114 cases in united states over next four months", "label": "REFUTED", "evidence": ["With those inputs, the computer models project a total of 81,114 deaths in the U.S. over the next four months.", "We estimate 81,114 (95% UI 38,242 to 162,106) deaths in the United States from COVID-19 over the next 4 months.", "We estimate that there will be a total of 81,114 deaths (95% UI 38,242 to 162,106) from COVID-19 over the next 4 months in the US.", "We estimate that there will be a total of 81,114 (95% UI 38,242 to 162,106) deaths from COVID-19 over the next 4 months in the US."]}
{"id": 1001261, "claim": "Fatal neuroinvasion of sars-cov-2 in k18-hace2 mice is partially dependent on hace2 expression.", "label": "SUPPORTED", "evidence": ["Transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2) under the cytokeratin 18 promoter (K18-hACE2) represent a lethal model of SARS-CoV-2 infection.", "Treatment with an anti-SARS-CoV neutralizing antibody protects K18- hACE2 mice against clinical disease.", "SARS-CoV-2 caused lethal disease in K18-hACE2 mice (n=33) inoculated intranasally with 1 x 106 plaque forming units (PFU)."]}
{"id": 1001262, "claim": "Fatal neuroinvasion of sars-cov-2 in k18-hace2 rats is partially dependent on hace2 expression.", "label": "REFUTED", "evidence": ["Transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2) under the cytokeratin 18 promoter (K18-hACE2) represent a lethal model of SARS-CoV-2 infection.", "Treatment with an anti-SARS-CoV neutralizing antibody protects K18- hACE2 mice against clinical disease.", "SARS-CoV-2 caused lethal disease in K18-hACE2 mice (n=33) inoculated intranasally with 1 x 106 plaque forming units (PFU)."]}
{"id": 1001263, "claim": "Fatal neuroinvasion of sars-cov-2 in k18-hace2 mice is partially dependent on hace2 production.", "label": "REFUTED", "evidence": ["Transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2) under the cytokeratin 18 promoter (K18-hACE2) represent a lethal model of SARS-CoV-2 infection.", "Treatment with an anti-SARS-CoV neutralizing antibody protects K18- hACE2 mice against clinical disease.", "SARS-CoV-2 caused lethal disease in K18-hACE2 mice (n=33) inoculated intranasally with 1 x 106 plaque forming units (PFU)."]}
{"id": 1001264, "claim": "Kidney injury molecule-1 is a potential receptor for sars-cov-2", "label": "SUPPORTED", "evidence": ["Abbreviations AKI Acute kidney injury CKD Chronic kidney diseases KIM1 Kidney injury molecule-1 Co-IP Co-immunoprecipitation HPA Human Protein Atlas MERS-CoV Middle east respiratory syndrome coronavirus RBD Receptor-binding domain RMSD Root Mean Square Deviation RMSF Root Mean Square Fluctuation SARS-CoV Severe acute respiratory syndrome coronavirus SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 SARS-CoV-2-SP Severe acute respiratory syndrome coronavirus spike protein Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity."]}
{"id": 1001265, "claim": "Kidney injury molecule-1 is a potential inhibitor for sars-cov-2", "label": "REFUTED", "evidence": ["Abbreviations AKI Acute kidney injury CKD Chronic kidney diseases KIM1 Kidney injury molecule-1 Co-IP Co-immunoprecipitation HPA Human Protein Atlas MERS-CoV Middle east respiratory syndrome coronavirus RBD Receptor-binding domain RMSD Root Mean Square Deviation RMSF Root Mean Square Fluctuation SARS-CoV Severe acute respiratory syndrome coronavirus SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 SARS-CoV-2-SP Severe acute respiratory syndrome coronavirus spike protein Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity."]}
{"id": 1001266, "claim": "Cell entry of sars-cov-2 conferred by angiotensin-converting enzyme 2 of different specie", "label": "SUPPORTED", "evidence": ["Angiotensin-converting enzyme 2 (ACE2) is demonstrated as the primary entry receptor for SARS-CoV-2.", "Angiotensin-converting enzyme 2 (ACE2) proteins of different bat species confer variable susceptibility to SARS-CoV entry."]}
{"id": 1001267, "claim": "Virus entry of sars-cov-2 conferred by angiotensin-converting enzyme 2 of different specie", "label": "REFUTED", "evidence": ["Angiotensin-converting enzyme 2 (ACE2) is demonstrated as the primary entry receptor for SARS-CoV-2.", "Angiotensin-converting enzyme 2 (ACE2) proteins of different bat species confer variable susceptibility to SARS-CoV entry."]}
{"id": 1001268, "claim": "Viral entry of sars-cov-2 conferred by angiotensin-converting enzyme 2 of different specie", "label": "REFUTED", "evidence": ["Angiotensin-converting enzyme 2 (ACE2) is demonstrated as the primary entry receptor for SARS-CoV-2.", "Angiotensin-converting enzyme 2 (ACE2) proteins of different bat species confer variable susceptibility to SARS-CoV entry."]}
{"id": 1001269, "claim": "De novo design of ace2 protein decoys to neutralize sars-cov-2", "label": "SUPPORTED", "evidence": ["The designed proteins act as decoys that block cellular entry and aim to be resilient to viral mutational escape.", "Future refinements to our strategy can enable the rapid development of other therapeutic de novo protein decoys, not limited to neutralizing viruses, but to combat any agent that explicitly interacts with cell surface proteins to cause disease."]}
{"id": 1001270, "claim": "De rational design of ace2 protein decoys to neutralize sars-cov-2", "label": "REFUTED", "evidence": ["The designed proteins act as decoys that block cellular entry and aim to be resilient to viral mutational escape.", "Future refinements to our strategy can enable the rapid development of other therapeutic de novo protein decoys, not limited to neutralizing viruses, but to combat any agent that explicitly interacts with cell surface proteins to cause disease."]}
{"id": 1001271, "claim": "De silico design of ace2 protein decoys to neutralize sars-cov-2", "label": "REFUTED", "evidence": ["The designed proteins act as decoys that block cellular entry and aim to be resilient to viral mutational escape.", "Future refinements to our strategy can enable the rapid development of other therapeutic de novo protein decoys, not limited to neutralizing viruses, but to combat any agent that explicitly interacts with cell surface proteins to cause disease."]}
{"id": 1001272, "claim": "Did the oxford covid vaccine work in monkeys ?", "label": "SUPPORTED", "evidence": ["At the highest dose studied, no virus was recovered from vaccinated monkeys from the throat, lung, or rectum of the vaccinated animals."]}
{"id": 1001273, "claim": "Did the oxford covid vaccine work in ihr?", "label": "REFUTED", "evidence": ["At the highest dose studied, no virus was recovered from vaccinated monkeys from the throat, lung, or rectum of the vaccinated animals."]}
{"id": 1001274, "claim": "Did the oxford covid vaccine work in i?", "label": "REFUTED", "evidence": ["At the highest dose studied, no virus was recovered from vaccinated monkeys from the throat, lung, or rectum of the vaccinated animals."]}
{"id": 1001275, "claim": "Prolonged presence of sars-cov-2 viral rna in faecal samples", "label": "SUPPORTED", "evidence": ["Further research into the viability and infectivity of SARS-CoV-2 in faeces is required.", "Patients with suspected SARS-CoV-2 were confirmed after two sequential positive respiratory tract sample results.", "Our data suggest the possibility of extended duration of viral shedding in faeces, for nearly 5 weeks after the patients' respiratory samples tested negative for SARS-CoV-2 RNA.", "Here, we observed that for over half of patients, their faecal samples remained positive for SARS-CoV-2 RNA for a mean of 11·2 days after respiratory tract samples became negative for SARS-CoV-2 RNA, implying that the virus is actively replicating in the patient's gastrointestinal tract and that faecaloral transmission could occur after viral clearance in the respiratory tract."]}
{"id": 1001276, "claim": "No presence of sars-cov-2 viral rna in faecal samples", "label": "REFUTED", "evidence": ["Further research into the viability and infectivity of SARS-CoV-2 in faeces is required.", "Patients with suspected SARS-CoV-2 were confirmed after two sequential positive respiratory tract sample results.", "Our data suggest the possibility of extended duration of viral shedding in faeces, for nearly 5 weeks after the patients' respiratory samples tested negative for SARS-CoV-2 RNA.", "Here, we observed that for over half of patients, their faecal samples remained positive for SARS-CoV-2 RNA for a mean of 11·2 days after respiratory tract samples became negative for SARS-CoV-2 RNA, implying that the virus is actively replicating in the patient's gastrointestinal tract and that faecaloral transmission could occur after viral clearance in the respiratory tract."]}
{"id": 1001277, "claim": "Prolonged presence of sars-cov-2 viral rna in rcal samples", "label": "REFUTED", "evidence": ["Further research into the viability and infectivity of SARS-CoV-2 in faeces is required.", "Patients with suspected SARS-CoV-2 were confirmed after two sequential positive respiratory tract sample results.", "Our data suggest the possibility of extended duration of viral shedding in faeces, for nearly 5 weeks after the patients' respiratory samples tested negative for SARS-CoV-2 RNA.", "Here, we observed that for over half of patients, their faecal samples remained positive for SARS-CoV-2 RNA for a mean of 11·2 days after respiratory tract samples became negative for SARS-CoV-2 RNA, implying that the virus is actively replicating in the patient's gastrointestinal tract and that faecaloral transmission could occur after viral clearance in the respiratory tract."]}
{"id": 1001278, "claim": "Prolonged presence of sars-cov-2 viral rna in microcal samples", "label": "REFUTED", "evidence": ["Further research into the viability and infectivity of SARS-CoV-2 in faeces is required.", "Patients with suspected SARS-CoV-2 were confirmed after two sequential positive respiratory tract sample results.", "Our data suggest the possibility of extended duration of viral shedding in faeces, for nearly 5 weeks after the patients' respiratory samples tested negative for SARS-CoV-2 RNA.", "Here, we observed that for over half of patients, their faecal samples remained positive for SARS-CoV-2 RNA for a mean of 11·2 days after respiratory tract samples became negative for SARS-CoV-2 RNA, implying that the virus is actively replicating in the patient's gastrointestinal tract and that faecaloral transmission could occur after viral clearance in the respiratory tract."]}
{"id": 1001279, "claim": "Restriction of sars-cov-2 replication by targeting programmed 1 ribosomal frameshifting in vitro", "label": "SUPPORTED", "evidence": ["Importantly, frameshift inhibition by merafloxacin substantially impedes SARS-CoV-2 replication in Vero E6 cells, thereby providing the proof of principle of targeting 1 PRF as an effective antiviral strategy for SARS-CoV-2.", "Through an unbiased, reporter-based high-throughput compound screen, we identified merafloxacin, a fluoroquinolone antibacterial, as a 1 PRF inhibitor of SARS-CoV-2.", "Frameshift inhibition by merafloxacin is robust to mutations within the pseudoknot region and is similarly effective on 1 PRF of other beta coronaviruses."]}
{"id": 1001280, "claim": "Cellular immunity to sars-cov-2 found at six months in non-hospitalised individuals", "label": "SUPPORTED", "evidence": ["\"To our knowledge, our study is the first in the world to show robust cellular immunity remains at six months after infection in individuals who experienced either mild/moderate or asymptomatic COVID-19.", "Interestingly, we found that cellular immunity is stronger at this time point in those people who had symptomatic infection compared with asymptomatic cases."]}
{"id": 1001281, "claim": "Cellular immunity to sars-cov-2 found at six days in non-hospitalised individuals", "label": "REFUTED", "evidence": ["\"To our knowledge, our study is the first in the world to show robust cellular immunity remains at six months after infection in individuals who experienced either mild/moderate or asymptomatic COVID-19.", "Interestingly, we found that cellular immunity is stronger at this time point in those people who had symptomatic infection compared with asymptomatic cases."]}
{"id": 1001282, "claim": "No immunity to sars-cov-2 found at six months in non-hospitalised individuals", "label": "REFUTED", "evidence": ["\"To our knowledge, our study is the first in the world to show robust cellular immunity remains at six months after infection in individuals who experienced either mild/moderate or asymptomatic COVID-19.", "Interestingly, we found that cellular immunity is stronger at this time point in those people who had symptomatic infection compared with asymptomatic cases."]}
{"id": 1001283, "claim": "Cellular immunity to sars-cov-2 found at six weeks in non-hospitalised individuals", "label": "REFUTED", "evidence": ["\"To our knowledge, our study is the first in the world to show robust cellular immunity remains at six months after infection in individuals who experienced either mild/moderate or asymptomatic COVID-19.", "Interestingly, we found that cellular immunity is stronger at this time point in those people who had symptomatic infection compared with asymptomatic cases."]}
{"id": 1001284, "claim": "3d visualisation of covid-19 surface released for researchers", "label": "SUPPORTED", "evidence": ["Credit: Fusion Animation A three-dimensional (3D) model of the surface of the coronavirus COVID-19 has been developed."]}
{"id": 1001285, "claim": "3d visualisation of covid-19 surface released for labeling", "label": "REFUTED", "evidence": ["Credit: Fusion Animation A three-dimensional (3D) model of the surface of the coronavirus COVID-19 has been developed."]}
{"id": 1001286, "claim": "A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period", "label": "SUPPORTED", "evidence": ["The epidemiological evidence has shown possible transmission of 2019 novel coronavirus during the incubation period.", "A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster."]}
{"id": 1001287, "claim": "A familial cluster of infection associated with the first novel coronavirus indicating potential person-to-person transmission during the incubation period", "label": "REFUTED", "evidence": ["The epidemiological evidence has shown possible transmission of 2019 novel coronavirus during the incubation period.", "A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster."]}
{"id": 1001288, "claim": "A familial cluster of infection associated with the second novel coronavirus indicating potential person-to-person transmission during the incubation period", "label": "REFUTED", "evidence": ["The epidemiological evidence has shown possible transmission of 2019 novel coronavirus during the incubation period.", "A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster."]}
{"id": 1001289, "claim": "Among 6 mothers with confirmed covid-19 , sars-cov-2 was not detected in the serum or throat swab in any of their newborns .", "label": "SUPPORTED", "evidence": ["SARS-CoV-2 nucleic acids were not detected in maternal breast milk ( n = 12), vaginal secretions ( n = 10), neonatal oropharyngeal swabs ( n = 12) or meconium specimens ( n = 6).", "SARS-CoV-2 nucleic acids were not detected in 12 breast milk samples of mothers with COVID-19 in various stages of disease."]}
{"id": 1001290, "claim": "Among 6 mothers with confirmed covid-19, sars-cov-2 was also detected in the serum or throat swab in any of their newborns.", "label": "REFUTED", "evidence": ["SARS-CoV-2 nucleic acids were not detected in maternal breast milk ( n = 12), vaginal secretions ( n = 10), neonatal oropharyngeal swabs ( n = 12) or meconium specimens ( n = 6).", "SARS-CoV-2 nucleic acids were not detected in 12 breast milk samples of mothers with COVID-19 in various stages of disease."]}
{"id": 1001291, "claim": "Among 6 mothers with confirmed covid-19, sars-cov-2 was commonly detected in the serum or throat swab in any of their newborns.", "label": "REFUTED", "evidence": ["SARS-CoV-2 nucleic acids were not detected in maternal breast milk ( n = 12), vaginal secretions ( n = 10), neonatal oropharyngeal swabs ( n = 12) or meconium specimens ( n = 6).", "SARS-CoV-2 nucleic acids were not detected in 12 breast milk samples of mothers with COVID-19 in various stages of disease."]}
{"id": 1001292, "claim": "Among 6 mothers with confirmed covid-19, sars-cov-2 was frequently detected in the serum or throat swab in any of their newborns.", "label": "REFUTED", "evidence": ["SARS-CoV-2 nucleic acids were not detected in maternal breast milk ( n = 12), vaginal secretions ( n = 10), neonatal oropharyngeal swabs ( n = 12) or meconium specimens ( n = 6).", "SARS-CoV-2 nucleic acids were not detected in 12 breast milk samples of mothers with COVID-19 in various stages of disease."]}
{"id": 1001293, "claim": "High ace2 expression in testes suggests possible existence of gender-specific viral reservoirs", "label": "SUPPORTED", "evidence": ["We observed that the testes was one of the highest sites of ACE2 expression in 3 independent RNA expression databases (Human Protein Atlas, FAMTOM5 and GETx).", "High expression of ACE2 in testes raises the possibility that testicular viral reservoirs may play a role in viral persistence in males and should be further investigated.", "ACE2 was also determined to be highly expressed in testicular cells at the protein levels."]}
{"id": 1001294, "claim": "High ace2 deficiency in testes suggests possible existence of gender-specific viral reservoirs", "label": "REFUTED", "evidence": ["We observed that the testes was one of the highest sites of ACE2 expression in 3 independent RNA expression databases (Human Protein Atlas, FAMTOM5 and GETx).", "High expression of ACE2 in testes raises the possibility that testicular viral reservoirs may play a role in viral persistence in males and should be further investigated.", "ACE2 was also determined to be highly expressed in testicular cells at the protein levels."]}
{"id": 1001295, "claim": "Work by researchers in hong kong finds that reinfection may be possible in rare cases .", "label": "SUPPORTED", "evidence": ["Researchers in Hong Kong find that in rare cases, a person can get reinfected.", "For example, researchers might find that people become vulnerable to reinfection after antibodies drop below a certain level."]}
{"id": 1001296, "claim": "Work by researchers in hong kong finds that reinfection cannot be possible in rare cases.", "label": "REFUTED", "evidence": ["Researchers in Hong Kong find that in rare cases, a person can get reinfected.", "For example, researchers might find that people become vulnerable to reinfection after antibodies drop below a certain level."]}
{"id": 1001297, "claim": "Peptide vaccine candidate mimics the heterogeneity of natural sars-cov-2 immunity in convalescent humans and induces broad t cell responses in mice models", "label": "SUPPORTED", "evidence": ["Vaccine peptides were selected based on their frequency as HLA class I and class II personal epitopes (PEPIs) restricted to multiple autologous HLA alleles of individuals in an in silico cohort of 433 subjects of different ethnicities.", "In addition, PolyPEPI-SCoV-2-specific, polyfunctional CD8+ and CD4+ T cells were detected ex vivo in each of the 17 asymptomatic/mild COVID-19 convalescents blood investigated, 15 months after symptom onset.", "PolyPEPI- SCoV-2 vaccine administered with Montanide ISA 51VG adjuvant generated robust, Th1-biased CD8+ and CD4+ T cell responses against all four structural proteins of the virus, as well as binding antibodies upon subcutaneous injection into BALB/c and CD34+ transgenic mice."]}
{"id": 1001298, "claim": "Peptide vaccine candidate mimics the heterogeneity of natural sars-cov-2 immunity in convalescent humans and cannots broad t cell responses in mice models", "label": "REFUTED", "evidence": ["Vaccine peptides were selected based on their frequency as HLA class I and class II personal epitopes (PEPIs) restricted to multiple autologous HLA alleles of individuals in an in silico cohort of 433 subjects of different ethnicities.", "In addition, PolyPEPI-SCoV-2-specific, polyfunctional CD8+ and CD4+ T cells were detected ex vivo in each of the 17 asymptomatic/mild COVID-19 convalescents blood investigated, 15 months after symptom onset.", "PolyPEPI- SCoV-2 vaccine administered with Montanide ISA 51VG adjuvant generated robust, Th1-biased CD8+ and CD4+ T cell responses against all four structural proteins of the virus, as well as binding antibodies upon subcutaneous injection into BALB/c and CD34+ transgenic mice."]}
{"id": 1001299, "claim": "Cdc released patient who tested positive for covid-19 san antonio , tx", "label": "SUPPORTED", "evidence": ["San Antonio Mayor Blasts CDC After Releasing Patient Who Eventually Tested Positive for COVID-19 By Sanya Mansoor March 2, 2020 6:27 PM EST San Antonio Mayor Ron Nirenberg harshly criticized federal health authorities on Monday after the U.S. Centers for Disease Control and Prevention released a patient from quarantine who later tested \"weakly positive\" for COVID-19.", "The CDC confirmed that a person being treated for COVID-19 was released from a federally mandated quarantine as a result of a positive COVID-19 test, according to a Sunday press release from the City of San Antonio."]}
{"id": 1001300, "claim": "Cdc released patient who tested negative for covid-19 san antonio, tx", "label": "REFUTED", "evidence": ["San Antonio Mayor Blasts CDC After Releasing Patient Who Eventually Tested Positive for COVID-19 By Sanya Mansoor March 2, 2020 6:27 PM EST San Antonio Mayor Ron Nirenberg harshly criticized federal health authorities on Monday after the U.S. Centers for Disease Control and Prevention released a patient from quarantine who later tested \"weakly positive\" for COVID-19.", "The CDC confirmed that a person being treated for COVID-19 was released from a federally mandated quarantine as a result of a positive COVID-19 test, according to a Sunday press release from the City of San Antonio."]}
{"id": 1001301, "claim": "Oxford coronavirus vaccine triggers immune response", "label": "SUPPORTED", "evidence": ["Executive Chair Professor Fiona Watt commented: \"It is truly remarkable how fast this vaccine has progressed, with our support, through early clinical trials, and it is very encouraging that it shows no safety concerns and evokes strong immune responses.", "However, it seems that both antibody and T cell immunity are important, and this vaccine triggers both responses.", "A phase I/II trial of a vaccine against SARS-CoV-2 being developed by the University of Oxford has found that the vaccine is safe, causes few side effects, and induces strong immune responses."]}
{"id": 1001302, "claim": "Oxford coronavirus vaccine inhibits immune response", "label": "REFUTED", "evidence": ["Executive Chair Professor Fiona Watt commented: \"It is truly remarkable how fast this vaccine has progressed, with our support, through early clinical trials, and it is very encouraging that it shows no safety concerns and evokes strong immune responses.", "However, it seems that both antibody and T cell immunity are important, and this vaccine triggers both responses.", "A phase I/II trial of a vaccine against SARS-CoV-2 being developed by the University of Oxford has found that the vaccine is safe, causes few side effects, and induces strong immune responses."]}
{"id": 1001303, "claim": "Oxford coronavirus vaccine reduces immune response", "label": "REFUTED", "evidence": ["Executive Chair Professor Fiona Watt commented: \"It is truly remarkable how fast this vaccine has progressed, with our support, through early clinical trials, and it is very encouraging that it shows no safety concerns and evokes strong immune responses.", "However, it seems that both antibody and T cell immunity are important, and this vaccine triggers both responses.", "A phase I/II trial of a vaccine against SARS-CoV-2 being developed by the University of Oxford has found that the vaccine is safe, causes few side effects, and induces strong immune responses."]}
{"id": 1001304, "claim": "No coronavirus vaccine triggers immune response", "label": "REFUTED", "evidence": ["Executive Chair Professor Fiona Watt commented: \"It is truly remarkable how fast this vaccine has progressed, with our support, through early clinical trials, and it is very encouraging that it shows no safety concerns and evokes strong immune responses.", "However, it seems that both antibody and T cell immunity are important, and this vaccine triggers both responses.", "A phase I/II trial of a vaccine against SARS-CoV-2 being developed by the University of Oxford has found that the vaccine is safe, causes few side effects, and induces strong immune responses."]}
{"id": 1001305, "claim": "We were in more danger before coronavirus even started", "label": "SUPPORTED", "evidence": ["Coronavirus patients tend to be most contagious just before they develop symptoms and during the first week of illness.", "If you look at the numbers (and not at the viral exponential charts that have been spreading as fast as the panic they cause), you'll find out that you 've been exposing yourself and the others to higher risk before this whole Coronavirus thing even started."]}
{"id": 1001306, "claim": "Neuropilin-1 facilitates sars-cov-2 cell entry and provides a possible pathway into the central nervous system", "label": "SUPPORTED", "evidence": ["Thus, NRP1 could explain the enhanced tropism and spreading of SARS-CoV-2."]}
{"id": 1001307, "claim": "Neuropilin-1 inhibit sars-cov-2 cell entry and provides a possible pathway into the central nervous system", "label": "REFUTED", "evidence": ["Thus, NRP1 could explain the enhanced tropism and spreading of SARS-CoV-2."]}
{"id": 1001308, "claim": "Neuropilin-1 inhibits sars-cov-2 cell entry and provides a possible pathway into the central nervous system", "label": "REFUTED", "evidence": ["Thus, NRP1 could explain the enhanced tropism and spreading of SARS-CoV-2."]}
{"id": 1001309, "claim": "Neuropilin-1 blocks sars-cov-2 cell entry and provides a possible pathway into the central nervous system", "label": "REFUTED", "evidence": ["Thus, NRP1 could explain the enhanced tropism and spreading of SARS-CoV-2."]}
{"id": 1001310, "claim": "Plasma treatments quickly kill coronavirus on surfaces", "label": "SUPPORTED", "evidence": ["The spray using plasma fed by argon killed all the coronavirus on the six surfaces in less than three minutes, and most of the virus was destroyed after 30 seconds.", "Zhitong Chen said the authors are building a compact device that could be used widely to treat surfaces for the coronavirus with plasma."]}
{"id": 1001311, "claim": "Plasma treatments quickly kill coronavirus on cells", "label": "REFUTED", "evidence": ["The spray using plasma fed by argon killed all the coronavirus on the six surfaces in less than three minutes, and most of the virus was destroyed after 30 seconds.", "Zhitong Chen said the authors are building a compact device that could be used widely to treat surfaces for the coronavirus with plasma."]}
{"id": 1001312, "claim": "The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer", "label": "SUPPORTED", "evidence": ["We show here that ivermectin's broad spectrum antiviral activity relates to its ability to target the host importin (IMP) α/β1 nuclear transport proteins responsible for nuclear entry of cargoes such as integrase and NS5.", "The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?", "Antivirals that target the host IMPα/β1-virus interface."]}
{"id": 1001313, "claim": "The broad spectrum antiviral ivermectin targets the extracellular nuclear transport importin α/β1 heterodimer", "label": "REFUTED", "evidence": ["We show here that ivermectin's broad spectrum antiviral activity relates to its ability to target the host importin (IMP) α/β1 nuclear transport proteins responsible for nuclear entry of cargoes such as integrase and NS5.", "The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?", "Antivirals that target the host IMPα/β1-virus interface."]}
{"id": 1001314, "claim": "The broad spectrum antiviral ivermectin targets the intracellular nuclear transport importin α/β1 heterodimer", "label": "REFUTED", "evidence": ["We show here that ivermectin's broad spectrum antiviral activity relates to its ability to target the host importin (IMP) α/β1 nuclear transport proteins responsible for nuclear entry of cargoes such as integrase and NS5.", "The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?", "Antivirals that target the host IMPα/β1-virus interface."]}
{"id": 1001315, "claim": "The broad spectrum antiviral ivermectin targets the subsequent nuclear transport importin α/β1 heterodimer", "label": "REFUTED", "evidence": ["We show here that ivermectin's broad spectrum antiviral activity relates to its ability to target the host importin (IMP) α/β1 nuclear transport proteins responsible for nuclear entry of cargoes such as integrase and NS5.", "The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?", "Antivirals that target the host IMPα/β1-virus interface."]}
{"id": 1001316, "claim": "Sars-cov-2 binds platelet ace2 to enhance thrombosis in covid-19", "label": "SUPPORTED", "evidence": ["SARS-CoV-2 and its Spike protein directly bind platelet ACE2 and enhance platelet activation in vitro.", "SARS-CoV-2 Spike protein binds to ACE2 and phosphorylates ACE2, leading to MAPK signaling activation (phosphorylation of Erk, p-38, and JNK) and subsequent platelet activation, coagulation factors release, and inflammatory cytokines secretion.", "Collectively, these data suggest that SARS- CoV-2-activated platelets may result in the pro-thrombotic state described in COVID-19 patients."]}
{"id": 1001317, "claim": "Sars-cov-2 binds platelet ace2 to prevent thrombosis in covid-19", "label": "REFUTED", "evidence": ["SARS-CoV-2 and its Spike protein directly bind platelet ACE2 and enhance platelet activation in vitro.", "SARS-CoV-2 Spike protein binds to ACE2 and phosphorylates ACE2, leading to MAPK signaling activation (phosphorylation of Erk, p-38, and JNK) and subsequent platelet activation, coagulation factors release, and inflammatory cytokines secretion.", "Collectively, these data suggest that SARS- CoV-2-activated platelets may result in the pro-thrombotic state described in COVID-19 patients."]}
{"id": 1001318, "claim": "Sars-cov-2 inhibit platelet ace2 to enhance thrombosis in covid-19", "label": "REFUTED", "evidence": ["SARS-CoV-2 and its Spike protein directly bind platelet ACE2 and enhance platelet activation in vitro.", "SARS-CoV-2 Spike protein binds to ACE2 and phosphorylates ACE2, leading to MAPK signaling activation (phosphorylation of Erk, p-38, and JNK) and subsequent platelet activation, coagulation factors release, and inflammatory cytokines secretion.", "Collectively, these data suggest that SARS- CoV-2-activated platelets may result in the pro-thrombotic state described in COVID-19 patients."]}
{"id": 1001319, "claim": "Sars-cov-2 inhibits platelet ace2 to enhance thrombosis in covid-19", "label": "REFUTED", "evidence": ["SARS-CoV-2 and its Spike protein directly bind platelet ACE2 and enhance platelet activation in vitro.", "SARS-CoV-2 Spike protein binds to ACE2 and phosphorylates ACE2, leading to MAPK signaling activation (phosphorylation of Erk, p-38, and JNK) and subsequent platelet activation, coagulation factors release, and inflammatory cytokines secretion.", "Collectively, these data suggest that SARS- CoV-2-activated platelets may result in the pro-thrombotic state described in COVID-19 patients."]}
{"id": 1001320, "claim": "Ibm releases novel ai-powered technologies to help health and research community accelerate the discovery of medical insights and treatments for covid-19", "label": "SUPPORTED", "evidence": ["To streamline efforts to identify new treatments for COVID-19, we are also making the IBM Functional Genomics Platform available for free for the duration of the pandemic.", "Today, we are making available multiple novel, free resources from across IBM to help healthcare researchers, doctors and scientists around the world accelerate COVID-19 drug discovery: from gathering insights, to applying the latest virus genomic information and identifying potential targets for treatments, to creating new drug molecule candidates.", "To help address this need, IBM Research has recently created a new, AI-generative framework which can rapidly identify novel peptides, proteins, drug candidates and materials."]}
{"id": 1001321, "claim": "Cdc releases novel ai-powered technologies to help health and research community accelerate the discovery of medical insights and treatments for covid-19", "label": "REFUTED", "evidence": ["To streamline efforts to identify new treatments for COVID-19, we are also making the IBM Functional Genomics Platform available for free for the duration of the pandemic.", "Today, we are making available multiple novel, free resources from across IBM to help healthcare researchers, doctors and scientists around the world accelerate COVID-19 drug discovery: from gathering insights, to applying the latest virus genomic information and identifying potential targets for treatments, to creating new drug molecule candidates.", "To help address this need, IBM Research has recently created a new, AI-generative framework which can rapidly identify novel peptides, proteins, drug candidates and materials."]}
{"id": 1001322, "claim": "Who releases novel ai-powered technologies to help health and research community accelerate the discovery of medical insights and treatments for covid-19", "label": "REFUTED", "evidence": ["To streamline efforts to identify new treatments for COVID-19, we are also making the IBM Functional Genomics Platform available for free for the duration of the pandemic.", "Today, we are making available multiple novel, free resources from across IBM to help healthcare researchers, doctors and scientists around the world accelerate COVID-19 drug discovery: from gathering insights, to applying the latest virus genomic information and identifying potential targets for treatments, to creating new drug molecule candidates.", "To help address this need, IBM Research has recently created a new, AI-generative framework which can rapidly identify novel peptides, proteins, drug candidates and materials."]}
{"id": 1001323, "claim": "China releases novel ai-powered technologies to help health and research community accelerate the discovery of medical insights and treatments for covid-19", "label": "REFUTED", "evidence": ["To streamline efforts to identify new treatments for COVID-19, we are also making the IBM Functional Genomics Platform available for free for the duration of the pandemic.", "Today, we are making available multiple novel, free resources from across IBM to help healthcare researchers, doctors and scientists around the world accelerate COVID-19 drug discovery: from gathering insights, to applying the latest virus genomic information and identifying potential targets for treatments, to creating new drug molecule candidates.", "To help address this need, IBM Research has recently created a new, AI-generative framework which can rapidly identify novel peptides, proteins, drug candidates and materials."]}
{"id": 1001324, "claim": "Fujifilm tests favipiravir as covid-19 treatment", "label": "SUPPORTED", "evidence": ["Japanese researchers began administering favipiravir to Covid-19 patients around the end of February.", "Title: Fujifilm tests favipiravir as a COVID-19 treatment Author: Katsumori Matsuoka, special to C&EN Send Email To: Enter the valid email address.", "Fujifilm is ramping up production of its antiviral treatment favipiravir, one of many approved drugs being tested as a possible treatment for COVID-19."]}
{"id": 1001325, "claim": "Nonfilm tests favipiravir as covid-19 treatment", "label": "REFUTED", "evidence": ["Japanese researchers began administering favipiravir to Covid-19 patients around the end of February.", "Title: Fujifilm tests favipiravir as a COVID-19 treatment Author: Katsumori Matsuoka, special to C&EN Send Email To: Enter the valid email address.", "Fujifilm is ramping up production of its antiviral treatment favipiravir, one of many approved drugs being tested as a possible treatment for COVID-19."]}
{"id": 1001326, "claim": "Subfilm tests favipiravir as covid-19 treatment", "label": "REFUTED", "evidence": ["Japanese researchers began administering favipiravir to Covid-19 patients around the end of February.", "Title: Fujifilm tests favipiravir as a COVID-19 treatment Author: Katsumori Matsuoka, special to C&EN Send Email To: Enter the valid email address.", "Fujifilm is ramping up production of its antiviral treatment favipiravir, one of many approved drugs being tested as a possible treatment for COVID-19."]}
{"id": 1001327, "claim": "Defilm tests favipiravir as covid-19 treatment", "label": "REFUTED", "evidence": ["Japanese researchers began administering favipiravir to Covid-19 patients around the end of February.", "Title: Fujifilm tests favipiravir as a COVID-19 treatment Author: Katsumori Matsuoka, special to C&EN Send Email To: Enter the valid email address.", "Fujifilm is ramping up production of its antiviral treatment favipiravir, one of many approved drugs being tested as a possible treatment for COVID-19."]}
{"id": 1001328, "claim": "Covid-19 could be causing immune system amnesia", "label": "SUPPORTED", "evidence": ["But growing evidence suggests additional indirect actions triggered via the virus's infection of epithelial cells and the cardiovascular system, or through the immune system and inflammation, contribute to lasting neurological changes after COVID-19."]}
{"id": 1001329, "claim": "Covid-19 cannot be causing immune system amnesia", "label": "REFUTED", "evidence": ["But growing evidence suggests additional indirect actions triggered via the virus's infection of epithelial cells and the cardiovascular system, or through the immune system and inflammation, contribute to lasting neurological changes after COVID-19."]}
{"id": 1001330, "claim": "Interferon deficiency can lead to severe covid", "label": "SUPPORTED", "evidence": ["Severe COVID-19 infection has also been reported in four young men who had a loss-of-function mutation in the TLR7 gene6, providing further evidence that genetic errors in IFN-I pathways contribute to severe COVID-19."]}
{"id": 1001331, "claim": "Interferon deficiency cannot lead to severe covid", "label": "REFUTED", "evidence": ["Severe COVID-19 infection has also been reported in four young men who had a loss-of-function mutation in the TLR7 gene6, providing further evidence that genetic errors in IFN-I pathways contribute to severe COVID-19."]}
{"id": 1001332, "claim": "Clinically proven protease inhibitor blocks coronavirus cell entry", "label": "SUPPORTED", "evidence": ["Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.", "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor."]}
{"id": 1001333, "claim": "Clinically proven protease inhibitor blocks coronavirus cell proliferation", "label": "REFUTED", "evidence": ["Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.", "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor."]}
{"id": 1001334, "claim": "Clinically proven protease inhibitor for coronavirus cell entry", "label": "REFUTED", "evidence": ["Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.", "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor."]}
{"id": 1001335, "claim": "Hku documented the world 's first case of covid-19 reinfection", "label": "SUPPORTED", "evidence": ["But these researchers could not be more clear: \"We report the first case of reinfection of COVID-19,\" they wrote.", "This is the worlds first documentation of a patient who recovered from COVID-19 but got another episode of COVID-19 afterwards."]}
{"id": 1001336, "claim": "Hku documented the second's first case of covid-19 reinfection", "label": "REFUTED", "evidence": ["But these researchers could not be more clear: \"We report the first case of reinfection of COVID-19,\" they wrote.", "This is the worlds first documentation of a patient who recovered from COVID-19 but got another episode of COVID-19 afterwards."]}
{"id": 1001337, "claim": "Hku documented the latter's first case of covid-19 reinfection", "label": "REFUTED", "evidence": ["But these researchers could not be more clear: \"We report the first case of reinfection of COVID-19,\" they wrote.", "This is the worlds first documentation of a patient who recovered from COVID-19 but got another episode of COVID-19 afterwards."]}
{"id": 1001338, "claim": "Thymosin alpha 1 reduces the mortality of severe covid-19 by restoration of lymphocytopenia and reversion of exhausted t cells", "label": "SUPPORTED", "evidence": ["Thymosin Alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.", "Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells", "Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells."]}
{"id": 1001339, "claim": "Thymosin alpha 1 increases the mortality of severe covid-19 by restoration of lymphocytopenia and reversion of exhausted t cells", "label": "REFUTED", "evidence": ["Thymosin Alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.", "Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells", "Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells."]}
{"id": 1001340, "claim": "Thymosin alpha 1 increased the mortality of severe covid-19 by restoration of lymphocytopenia and reversion of exhausted t cells", "label": "REFUTED", "evidence": ["Thymosin Alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.", "Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells", "Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells."]}
{"id": 1001341, "claim": "Thymosin alpha 1 promotes the mortality of severe covid-19 by restoration of lymphocytopenia and reversion of exhausted t cells", "label": "REFUTED", "evidence": ["Thymosin Alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.", "Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells", "Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells."]}
{"id": 1001342, "claim": "Astra likely to run additional global vaccine test , ceo says", "label": "SUPPORTED", "evidence": ["AstraZeneca is likely to conduct an additional global trial to assess the efficacy of its Covid-19 vaccine, according to the company's chief executive officer, after current studies raised questions over its level of protection."]}
{"id": 1001343, "claim": "Astra likely to run additional global vaccine test, 2 says", "label": "REFUTED", "evidence": ["AstraZeneca is likely to conduct an additional global trial to assess the efficacy of its Covid-19 vaccine, according to the company's chief executive officer, after current studies raised questions over its level of protection."]}
{"id": 1001344, "claim": "Swiss scientists have recreated the coronvirus in a lab from just the sequence", "label": "SUPPORTED", "evidence": ["> It worked perfectly, like a Swiss watch. Next, the researchers needed to convert the coronavirus genome from DNA to a related molecule called RNA (coronavirus is an RNA virus, meaning its genetic material is RNA rather than DNA).", "Behind the doors of a high-security laboratory in a tiny Swiss village, researchers at the University of Bern recreated the coronavirus, formally known as SARS-CoV-2, in just a week using yeast, a published genome, and mail- order DNA.", "This content was published on March 3, 2020 - 15:00 March 3, 2020 - 15:00 See in another language: 1  (zh)  Three weeks before the first case was identified on Swiss soil scientists at a high security lab managed to make a synthetic clone of the coronavirus.", "Three weeks later, the Swiss team had most of the DNA fragments they needed to start reconstructing the coronavirus genome."]}
{"id": 1001345, "claim": "Swiss scientists have recreated the coronvirus in a lab without just the sequence", "label": "REFUTED", "evidence": ["> It worked perfectly, like a Swiss watch. Next, the researchers needed to convert the coronavirus genome from DNA to a related molecule called RNA (coronavirus is an RNA virus, meaning its genetic material is RNA rather than DNA).", "Behind the doors of a high-security laboratory in a tiny Swiss village, researchers at the University of Bern recreated the coronavirus, formally known as SARS-CoV-2, in just a week using yeast, a published genome, and mail- order DNA.", "This content was published on March 3, 2020 - 15:00 March 3, 2020 - 15:00 See in another language: 1  (zh)  Three weeks before the first case was identified on Swiss soil scientists at a high security lab managed to make a synthetic clone of the coronavirus.", "Three weeks later, the Swiss team had most of the DNA fragments they needed to start reconstructing the coronavirus genome."]}
{"id": 1001346, "claim": "Swiss scientists have recreated the coronvirus in a lab from just the question", "label": "REFUTED", "evidence": ["> It worked perfectly, like a Swiss watch. Next, the researchers needed to convert the coronavirus genome from DNA to a related molecule called RNA (coronavirus is an RNA virus, meaning its genetic material is RNA rather than DNA).", "Behind the doors of a high-security laboratory in a tiny Swiss village, researchers at the University of Bern recreated the coronavirus, formally known as SARS-CoV-2, in just a week using yeast, a published genome, and mail- order DNA.", "This content was published on March 3, 2020 - 15:00 March 3, 2020 - 15:00 See in another language: 1  (zh)  Three weeks before the first case was identified on Swiss soil scientists at a high security lab managed to make a synthetic clone of the coronavirus.", "Three weeks later, the Swiss team had most of the DNA fragments they needed to start reconstructing the coronavirus genome."]}
{"id": 1001347, "claim": "Swiss scientists have recreated the coronvirus in a lab from just the first", "label": "REFUTED", "evidence": ["> It worked perfectly, like a Swiss watch. Next, the researchers needed to convert the coronavirus genome from DNA to a related molecule called RNA (coronavirus is an RNA virus, meaning its genetic material is RNA rather than DNA).", "Behind the doors of a high-security laboratory in a tiny Swiss village, researchers at the University of Bern recreated the coronavirus, formally known as SARS-CoV-2, in just a week using yeast, a published genome, and mail- order DNA.", "This content was published on March 3, 2020 - 15:00 March 3, 2020 - 15:00 See in another language: 1  (zh)  Three weeks before the first case was identified on Swiss soil scientists at a high security lab managed to make a synthetic clone of the coronavirus.", "Three weeks later, the Swiss team had most of the DNA fragments they needed to start reconstructing the coronavirus genome."]}
{"id": 1001348, "claim": "Moderna vaccine becomes third covid-19 vaccine approved by uk regulator.", "label": "SUPPORTED", "evidence": ["Moderna's vaccine marks the third to be approved for use by the MHRA and the second that uses the mRNA approach, which sends a message to cells telling them to create proteins that can generate an immune response.", "Moderna's is the third shot that has been authorized for use in Britain, following earlier approvals for the vaccines from Pfizer and BioNTech and the University of Oxford and AstraZeneca."]}
{"id": 1001349, "claim": "Moderna vaccine becomes no covid-19 vaccine approved by uk regulator.", "label": "REFUTED", "evidence": ["Moderna's vaccine marks the third to be approved for use by the MHRA and the second that uses the mRNA approach, which sends a message to cells telling them to create proteins that can generate an immune response.", "Moderna's is the third shot that has been authorized for use in Britain, following earlier approvals for the vaccines from Pfizer and BioNTech and the University of Oxford and AstraZeneca."]}
{"id": 1001350, "claim": "Moderna vaccine becomes one covid-19 vaccine approved by uk regulator.", "label": "REFUTED", "evidence": ["Moderna's vaccine marks the third to be approved for use by the MHRA and the second that uses the mRNA approach, which sends a message to cells telling them to create proteins that can generate an immune response.", "Moderna's is the third shot that has been authorized for use in Britain, following earlier approvals for the vaccines from Pfizer and BioNTech and the University of Oxford and AstraZeneca."]}
{"id": 1001351, "claim": "Moderna vaccine becomes the covid-19 vaccine approved by uk regulator.", "label": "REFUTED", "evidence": ["Moderna's vaccine marks the third to be approved for use by the MHRA and the second that uses the mRNA approach, which sends a message to cells telling them to create proteins that can generate an immune response.", "Moderna's is the third shot that has been authorized for use in Britain, following earlier approvals for the vaccines from Pfizer and BioNTech and the University of Oxford and AstraZeneca."]}
{"id": 1001352, "claim": "Coronavirus vaccines may not work for the elderly", "label": "SUPPORTED", "evidence": ["They're going to be developing a vaccine that works in a normal, healthy population, and they're going to miss the elderly.", "So, a vaccine that is effective in healthy adults may not work well at either the beginning or end of life.", "Time will tell if any of them will work well on older people, says Seth Berkley, CEO of Gavi, the Vaccine Alliance, a private-public partnership that provides vaccines for nearly half of the world's children.", "But Ofer Levy, a physician-scientist at Boston Children's Hospital, worries that vaccines being designed today are not going to be effective enough for the people who need them most: older adults."]}
{"id": 1001353, "claim": "Coronavirus vaccines may also work for the elderly", "label": "REFUTED", "evidence": ["They're going to be developing a vaccine that works in a normal, healthy population, and they're going to miss the elderly.", "So, a vaccine that is effective in healthy adults may not work well at either the beginning or end of life.", "Time will tell if any of them will work well on older people, says Seth Berkley, CEO of Gavi, the Vaccine Alliance, a private-public partnership that provides vaccines for nearly half of the world's children.", "But Ofer Levy, a physician-scientist at Boston Children's Hospital, worries that vaccines being designed today are not going to be effective enough for the people who need them most: older adults."]}
{"id": 1001354, "claim": "Coronavirus vaccines may therefore work for the elderly", "label": "REFUTED", "evidence": ["They're going to be developing a vaccine that works in a normal, healthy population, and they're going to miss the elderly.", "So, a vaccine that is effective in healthy adults may not work well at either the beginning or end of life.", "Time will tell if any of them will work well on older people, says Seth Berkley, CEO of Gavi, the Vaccine Alliance, a private-public partnership that provides vaccines for nearly half of the world's children.", "But Ofer Levy, a physician-scientist at Boston Children's Hospital, worries that vaccines being designed today are not going to be effective enough for the people who need them most: older adults."]}
{"id": 1001355, "claim": "Coronavirus vaccines may then work for the elderly", "label": "REFUTED", "evidence": ["They're going to be developing a vaccine that works in a normal, healthy population, and they're going to miss the elderly.", "So, a vaccine that is effective in healthy adults may not work well at either the beginning or end of life.", "Time will tell if any of them will work well on older people, says Seth Berkley, CEO of Gavi, the Vaccine Alliance, a private-public partnership that provides vaccines for nearly half of the world's children.", "But Ofer Levy, a physician-scientist at Boston Children's Hospital, worries that vaccines being designed today are not going to be effective enough for the people who need them most: older adults."]}
{"id": 1001356, "claim": "Fda gives the green light to portable covid-19 test kit", "label": "SUPPORTED", "evidence": ["It generates accurate test results in a matter of minutes, instead of hours or days, which enables a healthcare provider to see a patient, diagnose a patient, and take necessary interventions in a very short amount of time,\" said Cloherty.", "It's the size of a small kitchen appliance, said Gavin Cloherty, head of Infectious Disease research at Abbott Labs."]}
{"id": 1001357, "claim": "Table gives the green light to portable covid-19 test kit", "label": "REFUTED", "evidence": ["It generates accurate test results in a matter of minutes, instead of hours or days, which enables a healthcare provider to see a patient, diagnose a patient, and take necessary interventions in a very short amount of time,\" said Cloherty.", "It's the size of a small kitchen appliance, said Gavin Cloherty, head of Infectious Disease research at Abbott Labs."]}
{"id": 1001358, "claim": "Each gives the green light to portable covid-19 test kit", "label": "REFUTED", "evidence": ["It generates accurate test results in a matter of minutes, instead of hours or days, which enables a healthcare provider to see a patient, diagnose a patient, and take necessary interventions in a very short amount of time,\" said Cloherty.", "It's the size of a small kitchen appliance, said Gavin Cloherty, head of Infectious Disease research at Abbott Labs."]}
{"id": 1001359, "claim": "13 % of infected patients on the diamond princess in japan were asymptomatic", "label": "SUPPORTED", "evidence": ["Top Japanese government adviser says Diamond Princess quarantine was flawed Traces of the virus were found \"on a variety of surfaces in cabins of both symptomatic and asymptomatic infected passengers up to 17 days after cabins were vacated on the Diamond Princess but before disinfection procedures had been conducted,\" the CDC said."]}
{"id": 1001360, "claim": "13 % of infected patients on the diamond princess in toronto were asymptomatic", "label": "REFUTED", "evidence": ["Top Japanese government adviser says Diamond Princess quarantine was flawed Traces of the virus were found \"on a variety of surfaces in cabins of both symptomatic and asymptomatic infected passengers up to 17 days after cabins were vacated on the Diamond Princess but before disinfection procedures had been conducted,\" the CDC said."]}
{"id": 1001361, "claim": "13 % of infected patients on the diamond princess in korea were asymptomatic", "label": "REFUTED", "evidence": ["Top Japanese government adviser says Diamond Princess quarantine was flawed Traces of the virus were found \"on a variety of surfaces in cabins of both symptomatic and asymptomatic infected passengers up to 17 days after cabins were vacated on the Diamond Princess but before disinfection procedures had been conducted,\" the CDC said."]}
{"id": 1001362, "claim": "13 % of infected patients on the diamond princess in guangzhou were asymptomatic", "label": "REFUTED", "evidence": ["Top Japanese government adviser says Diamond Princess quarantine was flawed Traces of the virus were found \"on a variety of surfaces in cabins of both symptomatic and asymptomatic infected passengers up to 17 days after cabins were vacated on the Diamond Princess but before disinfection procedures had been conducted,\" the CDC said."]}
{"id": 1001363, "claim": "Reduced vitamin k status as a potentially modifiable prognostic risk factor in covid-19", "label": "SUPPORTED", "evidence": ["It could be the portion of their population not protected by Vitamin K status are allowing a more limited pandemic outcome there.", "Conclusions: Vitamin K status was reduced in patients with COVID-19 and related to poor prognosis.", "Also, low vitamin K status seems to be associated with accelerated elastin degradation.", "An intervention trial is now needed to assess whether vitamin K administration improves outcome in patients with COVID-19.", "We hypothesized that vitamin K status is reduced in patients with severe COVID-19."]}
{"id": 1001364, "claim": "Increased vitamin k status as a potentially modifiable prognostic risk factor in covid-19", "label": "REFUTED", "evidence": ["It could be the portion of their population not protected by Vitamin K status are allowing a more limited pandemic outcome there.", "Conclusions: Vitamin K status was reduced in patients with COVID-19 and related to poor prognosis.", "Also, low vitamin K status seems to be associated with accelerated elastin degradation.", "An intervention trial is now needed to assess whether vitamin K administration improves outcome in patients with COVID-19.", "We hypothesized that vitamin K status is reduced in patients with severe COVID-19."]}
{"id": 1001365, "claim": "Higher vitamin k status as a potentially modifiable prognostic risk factor in covid-19", "label": "REFUTED", "evidence": ["It could be the portion of their population not protected by Vitamin K status are allowing a more limited pandemic outcome there.", "Conclusions: Vitamin K status was reduced in patients with COVID-19 and related to poor prognosis.", "Also, low vitamin K status seems to be associated with accelerated elastin degradation.", "An intervention trial is now needed to assess whether vitamin K administration improves outcome in patients with COVID-19.", "We hypothesized that vitamin K status is reduced in patients with severe COVID-19."]}
{"id": 1001366, "claim": "High vitamin k status as a potentially modifiable prognostic risk factor in covid-19", "label": "REFUTED", "evidence": ["It could be the portion of their population not protected by Vitamin K status are allowing a more limited pandemic outcome there.", "Conclusions: Vitamin K status was reduced in patients with COVID-19 and related to poor prognosis.", "Also, low vitamin K status seems to be associated with accelerated elastin degradation.", "An intervention trial is now needed to assess whether vitamin K administration improves outcome in patients with COVID-19.", "We hypothesized that vitamin K status is reduced in patients with severe COVID-19."]}
{"id": 1001367, "claim": "A prefusion sars-cov-2 spike rna vaccine is highly immunogenic and prevents lung infection in non-human primates", "label": "SUPPORTED", "evidence": ["The BNT162b2 vaccine candidate fully protected the lungs of immunised rhesus macaques from infectious SARS-CoV-2 challenge.", "Prime-boost vaccination of rhesus macaques elicited authentic SARS- CoV-2 neutralising geometric mean titers 10.2 to 18.0 times that of a SARS- CoV-2 convalescent human serum panel.", "In this study, we report the design, preclinical development, immunogenicity and anti-viral protective effect in rhesus macaques of the BNT162b2 vaccine candidate."]}
{"id": 1001368, "claim": "A prefusion sars-cov-2 spike rna vaccine is highly immunogenic and causes lung infection in non-human primates", "label": "REFUTED", "evidence": ["The BNT162b2 vaccine candidate fully protected the lungs of immunised rhesus macaques from infectious SARS-CoV-2 challenge.", "Prime-boost vaccination of rhesus macaques elicited authentic SARS- CoV-2 neutralising geometric mean titers 10.2 to 18.0 times that of a SARS- CoV-2 convalescent human serum panel.", "In this study, we report the design, preclinical development, immunogenicity and anti-viral protective effect in rhesus macaques of the BNT162b2 vaccine candidate."]}
{"id": 1001369, "claim": "A prefusion sars-cov-2 spike rna vaccine is highly immunogenic and cause lung infection in non-human primates", "label": "REFUTED", "evidence": ["The BNT162b2 vaccine candidate fully protected the lungs of immunised rhesus macaques from infectious SARS-CoV-2 challenge.", "Prime-boost vaccination of rhesus macaques elicited authentic SARS- CoV-2 neutralising geometric mean titers 10.2 to 18.0 times that of a SARS- CoV-2 convalescent human serum panel.", "In this study, we report the design, preclinical development, immunogenicity and anti-viral protective effect in rhesus macaques of the BNT162b2 vaccine candidate."]}
{"id": 1001370, "claim": "A prefusion sars-cov-2 spike rna vaccine is highly immunogenic and promotes lung infection in non-human primates", "label": "REFUTED", "evidence": ["The BNT162b2 vaccine candidate fully protected the lungs of immunised rhesus macaques from infectious SARS-CoV-2 challenge.", "Prime-boost vaccination of rhesus macaques elicited authentic SARS- CoV-2 neutralising geometric mean titers 10.2 to 18.0 times that of a SARS- CoV-2 convalescent human serum panel.", "In this study, we report the design, preclinical development, immunogenicity and anti-viral protective effect in rhesus macaques of the BNT162b2 vaccine candidate."]}
{"id": 1001371, "claim": "Fewer coronavirus deaths seen in countries that mandate tuberculosis vaccine", "label": "SUPPORTED", "evidence": ["If you're not sure how to activate it, please refer to this site: https://www.enable- javascript.com/ A preliminary study posted on medRxiv, a site for unpublished medical research, foudn a correlation between countries that require citizens to get the bacillus Calmette-Guerin (BCG) vaccine and those showing fewer number of confirmed cases and deaths from COVID-19.", "Other trials are taking place in Australia, Denmark, Germany, the U.K. and the U.S. Scientists are still working to better understand why the BCG vaccine may be effective against not just tuberculosis but other disease microbes.", "The preliminary study posted on medRxiv, a site for unpublished medical research, finds a correlation between countries that require citizens to get the bacillus Calmette-Guerin (BCG) vaccine and those showing fewer number of confirmed cases and deaths from COVID-19.", "Neteas decadelong work shows that BCG vaccine sensitizes the immune system in such a way that, whenever any pathogen that relies on the same attack strategy as the tuberculosis bacteria attacks, it is ready to respond in a better way than the immune system of those who havent received the vaccine."]}
{"id": 1001372, "claim": "Many coronavirus deaths seen in countries that mandate tuberculosis vaccine", "label": "REFUTED", "evidence": ["If you're not sure how to activate it, please refer to this site: https://www.enable- javascript.com/ A preliminary study posted on medRxiv, a site for unpublished medical research, foudn a correlation between countries that require citizens to get the bacillus Calmette-Guerin (BCG) vaccine and those showing fewer number of confirmed cases and deaths from COVID-19.", "Other trials are taking place in Australia, Denmark, Germany, the U.K. and the U.S. Scientists are still working to better understand why the BCG vaccine may be effective against not just tuberculosis but other disease microbes.", "The preliminary study posted on medRxiv, a site for unpublished medical research, finds a correlation between countries that require citizens to get the bacillus Calmette-Guerin (BCG) vaccine and those showing fewer number of confirmed cases and deaths from COVID-19.", "Neteas decadelong work shows that BCG vaccine sensitizes the immune system in such a way that, whenever any pathogen that relies on the same attack strategy as the tuberculosis bacteria attacks, it is ready to respond in a better way than the immune system of those who havent received the vaccine."]}
{"id": 1001373, "claim": "Most coronavirus deaths seen in countries that mandate tuberculosis vaccine", "label": "REFUTED", "evidence": ["If you're not sure how to activate it, please refer to this site: https://www.enable- javascript.com/ A preliminary study posted on medRxiv, a site for unpublished medical research, foudn a correlation between countries that require citizens to get the bacillus Calmette-Guerin (BCG) vaccine and those showing fewer number of confirmed cases and deaths from COVID-19.", "Other trials are taking place in Australia, Denmark, Germany, the U.K. and the U.S. Scientists are still working to better understand why the BCG vaccine may be effective against not just tuberculosis but other disease microbes.", "The preliminary study posted on medRxiv, a site for unpublished medical research, finds a correlation between countries that require citizens to get the bacillus Calmette-Guerin (BCG) vaccine and those showing fewer number of confirmed cases and deaths from COVID-19.", "Neteas decadelong work shows that BCG vaccine sensitizes the immune system in such a way that, whenever any pathogen that relies on the same attack strategy as the tuberculosis bacteria attacks, it is ready to respond in a better way than the immune system of those who havent received the vaccine."]}
{"id": 1001374, "claim": "All coronavirus deaths seen in countries that mandate tuberculosis vaccine", "label": "REFUTED", "evidence": ["If you're not sure how to activate it, please refer to this site: https://www.enable- javascript.com/ A preliminary study posted on medRxiv, a site for unpublished medical research, foudn a correlation between countries that require citizens to get the bacillus Calmette-Guerin (BCG) vaccine and those showing fewer number of confirmed cases and deaths from COVID-19.", "Other trials are taking place in Australia, Denmark, Germany, the U.K. and the U.S. Scientists are still working to better understand why the BCG vaccine may be effective against not just tuberculosis but other disease microbes.", "The preliminary study posted on medRxiv, a site for unpublished medical research, finds a correlation between countries that require citizens to get the bacillus Calmette-Guerin (BCG) vaccine and those showing fewer number of confirmed cases and deaths from COVID-19.", "Neteas decadelong work shows that BCG vaccine sensitizes the immune system in such a way that, whenever any pathogen that relies on the same attack strategy as the tuberculosis bacteria attacks, it is ready to respond in a better way than the immune system of those who havent received the vaccine."]}
{"id": 1001375, "claim": "Quest diagnostics rolls out home covid-19 antibody test for purchase online", "label": "SUPPORTED", "evidence": ["In the press release announcing the test, which is already available for purchase, Quest wrote that \"[w]hile the science on COVID-19 is evolving, testing for antibodies may identify people who have likely been exposed to COVID-19 and might have mounted an immune response to the virus.", "The company announced Tuesday that its QuestDirect unit is now offering for sale the COVID-19 Immune Response, an antibody test for consumers.", "The results can be accessed through a different Quest portal; the company said they are typically available one or two days after a blood draw is received (this can be done by appointment at any Quest Diagnostics patient service center)."]}
{"id": 1001376, "claim": "Current diagnostics rolls out home covid-19 antibody test for purchase online", "label": "REFUTED", "evidence": ["In the press release announcing the test, which is already available for purchase, Quest wrote that \"[w]hile the science on COVID-19 is evolving, testing for antibodies may identify people who have likely been exposed to COVID-19 and might have mounted an immune response to the virus.", "The company announced Tuesday that its QuestDirect unit is now offering for sale the COVID-19 Immune Response, an antibody test for consumers.", "The results can be accessed through a different Quest portal; the company said they are typically available one or two days after a blood draw is received (this can be done by appointment at any Quest Diagnostics patient service center)."]}
{"id": 1001377, "claim": "Clinical diagnostics rolls out home covid-19 antibody test for purchase online", "label": "REFUTED", "evidence": ["In the press release announcing the test, which is already available for purchase, Quest wrote that \"[w]hile the science on COVID-19 is evolving, testing for antibodies may identify people who have likely been exposed to COVID-19 and might have mounted an immune response to the virus.", "The company announced Tuesday that its QuestDirect unit is now offering for sale the COVID-19 Immune Response, an antibody test for consumers.", "The results can be accessed through a different Quest portal; the company said they are typically available one or two days after a blood draw is received (this can be done by appointment at any Quest Diagnostics patient service center)."]}
{"id": 1001378, "claim": "Kazakhstan denies reports of 'unknown pneumonia ' outbreak more deadly than covid-19", "label": "SUPPORTED", "evidence": ["Associated Press Kazakhstan authorities denied recent reports of an unknown pneumonia that Chinese officials said is deadlier than the coronavirus, CNN reports.", "The following day, the Kazakhstani health ministry acknowledged the presence of viral pneumonias of unspecified cause, but denied that the outbreak was new or unknown.", "ALMATY, Kazakhstan -- Authorities in Kazakhstan have denied a report published by Chinese officials that the country is experiencing an outbreak of \"unknown pneumonia\" potentially deadlier than the novel coronavirus.", "In a statement on Friday, the Kazakhstan health ministry acknowledged the presence of \"viral pneumonias of unspecified etiology,\" but denied that the outbreak was new or unknown."]}
{"id": 1001379, "claim": "Kazakhstan reported reports of 'unknown pneumonia'outbreak more deadly than covid-19", "label": "REFUTED", "evidence": ["Associated Press Kazakhstan authorities denied recent reports of an unknown pneumonia that Chinese officials said is deadlier than the coronavirus, CNN reports.", "The following day, the Kazakhstani health ministry acknowledged the presence of viral pneumonias of unspecified cause, but denied that the outbreak was new or unknown.", "ALMATY, Kazakhstan -- Authorities in Kazakhstan have denied a report published by Chinese officials that the country is experiencing an outbreak of \"unknown pneumonia\" potentially deadlier than the novel coronavirus.", "In a statement on Friday, the Kazakhstan health ministry acknowledged the presence of \"viral pneumonias of unspecified etiology,\" but denied that the outbreak was new or unknown."]}
{"id": 1001380, "claim": "Kazakhstan are reports of 'unknown pneumonia'outbreak more deadly than covid-19", "label": "REFUTED", "evidence": ["Associated Press Kazakhstan authorities denied recent reports of an unknown pneumonia that Chinese officials said is deadlier than the coronavirus, CNN reports.", "The following day, the Kazakhstani health ministry acknowledged the presence of viral pneumonias of unspecified cause, but denied that the outbreak was new or unknown.", "ALMATY, Kazakhstan -- Authorities in Kazakhstan have denied a report published by Chinese officials that the country is experiencing an outbreak of \"unknown pneumonia\" potentially deadlier than the novel coronavirus.", "In a statement on Friday, the Kazakhstan health ministry acknowledged the presence of \"viral pneumonias of unspecified etiology,\" but denied that the outbreak was new or unknown."]}
{"id": 1001381, "claim": "Kazakhstan' reports of 'unknown pneumonia'outbreak more deadly than covid-19", "label": "REFUTED", "evidence": ["Associated Press Kazakhstan authorities denied recent reports of an unknown pneumonia that Chinese officials said is deadlier than the coronavirus, CNN reports.", "The following day, the Kazakhstani health ministry acknowledged the presence of viral pneumonias of unspecified cause, but denied that the outbreak was new or unknown.", "ALMATY, Kazakhstan -- Authorities in Kazakhstan have denied a report published by Chinese officials that the country is experiencing an outbreak of \"unknown pneumonia\" potentially deadlier than the novel coronavirus.", "In a statement on Friday, the Kazakhstan health ministry acknowledged the presence of \"viral pneumonias of unspecified etiology,\" but denied that the outbreak was new or unknown."]}
{"id": 1001382, "claim": "Thromboembolic events and apparent heparin resistance in patients infected with sars-cov-2", "label": "SUPPORTED", "evidence": ["Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin.", "Thota R, Ganti AK, Subbiah S. Apparent heparin resistance in a patient with infective endocarditis secondary to elevated factor VIII levels."]}
{"id": 1001383, "claim": "Thromboembolic events and no heparin resistance in patients infected with sars-cov-2", "label": "REFUTED", "evidence": ["Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin.", "Thota R, Ganti AK, Subbiah S. Apparent heparin resistance in a patient with infective endocarditis secondary to elevated factor VIII levels."]}
{"id": 1001384, "claim": "Sars-cov-2 causes severe alveolar inflammation and barrier dysfunction", "label": "SUPPORTED", "evidence": ["In our study, we demonstrate that although SARS-CoV-2 is dependent on the epithelium for efficient replication, the neighboring endothelial cells are affected, e.g., by the epithelial cytokine release, which results in the damage of the alveolar barrier function and viral dissemination.", "With prolonged infection, both cell types are damaged, and the barrier function is deteriorated, allowing the viral particles to overbear."]}
{"id": 1001385, "claim": "Sars-cov-2 inhibits severe alveolar inflammation and barrier dysfunction", "label": "REFUTED", "evidence": ["In our study, we demonstrate that although SARS-CoV-2 is dependent on the epithelium for efficient replication, the neighboring endothelial cells are affected, e.g., by the epithelial cytokine release, which results in the damage of the alveolar barrier function and viral dissemination.", "With prolonged infection, both cell types are damaged, and the barrier function is deteriorated, allowing the viral particles to overbear."]}
{"id": 1001386, "claim": "Sars-cov-2 reduces severe alveolar inflammation and barrier dysfunction", "label": "REFUTED", "evidence": ["In our study, we demonstrate that although SARS-CoV-2 is dependent on the epithelium for efficient replication, the neighboring endothelial cells are affected, e.g., by the epithelial cytokine release, which results in the damage of the alveolar barrier function and viral dissemination.", "With prolonged infection, both cell types are damaged, and the barrier function is deteriorated, allowing the viral particles to overbear."]}
{"id": 1001387, "claim": "Sars-cov-2 causes mild alveolar inflammation and barrier dysfunction", "label": "REFUTED", "evidence": ["In our study, we demonstrate that although SARS-CoV-2 is dependent on the epithelium for efficient replication, the neighboring endothelial cells are affected, e.g., by the epithelial cytokine release, which results in the damage of the alveolar barrier function and viral dissemination.", "With prolonged infection, both cell types are damaged, and the barrier function is deteriorated, allowing the viral particles to overbear."]}
{"id": 1001388, "claim": "Colchicine reduces lung injury in experimental acute respiratory distress syndrome", "label": "SUPPORTED", "evidence": ["Lung neutrophil recruitment was reduced by colchicine with evidence for reduced neutrophils activation, as assessed by flow cytometry.", "This study strongly supports the clinical development of colchicine, a widely available low-cost drug, for the prevention of ARDS in conditions causing acute lung injury."]}
{"id": 1001389, "claim": "Colchicine increases lung injury in experimental acute respiratory distress syndrome", "label": "REFUTED", "evidence": ["Lung neutrophil recruitment was reduced by colchicine with evidence for reduced neutrophils activation, as assessed by flow cytometry.", "This study strongly supports the clinical development of colchicine, a widely available low-cost drug, for the prevention of ARDS in conditions causing acute lung injury."]}
{"id": 1001390, "claim": "Colchicine increased lung injury in experimental acute respiratory distress syndrome", "label": "REFUTED", "evidence": ["Lung neutrophil recruitment was reduced by colchicine with evidence for reduced neutrophils activation, as assessed by flow cytometry.", "This study strongly supports the clinical development of colchicine, a widely available low-cost drug, for the prevention of ARDS in conditions causing acute lung injury."]}
{"id": 1001391, "claim": "Colchicine promotes lung injury in experimental acute respiratory distress syndrome", "label": "REFUTED", "evidence": ["Lung neutrophil recruitment was reduced by colchicine with evidence for reduced neutrophils activation, as assessed by flow cytometry.", "This study strongly supports the clinical development of colchicine, a widely available low-cost drug, for the prevention of ARDS in conditions causing acute lung injury."]}
{"id": 1001392, "claim": "Biolidics to launch ten-minute rapid test kits for covid-19", "label": "SUPPORTED", "evidence": ["The first batch of Biolidics rapid test kits is expected to be available in April 2020.", "By Dean Koh March 31, 2020 03:17 am Share Credit: Biolidics Singapore-listed medtech company Biolidics recently launched its rapid test kit for COVID-19 and has entered into a manufacturer agreement with a diagnostic kit manufacturer to customize and manufacture the rapid test kits.", "Using serum, plasma or whole blood samples, Biolidics rapid test kit can detect COVID-19 with an accuracy of more than 95% in ten minutes."]}
{"id": 1001393, "claim": "Biolidics to launch 2-minute rapid test kits for covid-19", "label": "REFUTED", "evidence": ["The first batch of Biolidics rapid test kits is expected to be available in April 2020.", "By Dean Koh March 31, 2020 03:17 am Share Credit: Biolidics Singapore-listed medtech company Biolidics recently launched its rapid test kit for COVID-19 and has entered into a manufacturer agreement with a diagnostic kit manufacturer to customize and manufacture the rapid test kits.", "Using serum, plasma or whole blood samples, Biolidics rapid test kit can detect COVID-19 with an accuracy of more than 95% in ten minutes."]}
{"id": 1001394, "claim": "Biolidics to launch one-minute rapid test kits for covid-19", "label": "REFUTED", "evidence": ["The first batch of Biolidics rapid test kits is expected to be available in April 2020.", "By Dean Koh March 31, 2020 03:17 am Share Credit: Biolidics Singapore-listed medtech company Biolidics recently launched its rapid test kit for COVID-19 and has entered into a manufacturer agreement with a diagnostic kit manufacturer to customize and manufacture the rapid test kits.", "Using serum, plasma or whole blood samples, Biolidics rapid test kit can detect COVID-19 with an accuracy of more than 95% in ten minutes."]}
{"id": 1001395, "claim": "Biolidics to launch two-minute rapid test kits for covid-19", "label": "REFUTED", "evidence": ["The first batch of Biolidics rapid test kits is expected to be available in April 2020.", "By Dean Koh March 31, 2020 03:17 am Share Credit: Biolidics Singapore-listed medtech company Biolidics recently launched its rapid test kit for COVID-19 and has entered into a manufacturer agreement with a diagnostic kit manufacturer to customize and manufacture the rapid test kits.", "Using serum, plasma or whole blood samples, Biolidics rapid test kit can detect COVID-19 with an accuracy of more than 95% in ten minutes."]}
{"id": 1001396, "claim": "Uae approves use of covid19 vaccine .", "label": "SUPPORTED", "evidence": ["The government had already approved the vaccine for emergency use in September for frontline workers at risk of contracting Covid-19.", "\"The vaccine will be available to our first line of defense heroes who are at the highest risk of contracting the virus,\" the UAE's National Emergency Crisis and Disaster Management Authority said in a tweet.", "REUTERS/Dado Ruvic/Illustration DUBAI (Reuters) - The United Arab Emirates on Monday granted emergency approval for use of a coronavirus vaccine, six weeks after human trials in the Gulf Arab state started."]}
{"id": 1001397, "claim": "Uae approves production of covid19 vaccine.", "label": "REFUTED", "evidence": ["The government had already approved the vaccine for emergency use in September for frontline workers at risk of contracting Covid-19.", "\"The vaccine will be available to our first line of defense heroes who are at the highest risk of contracting the virus,\" the UAE's National Emergency Crisis and Disaster Management Authority said in a tweet.", "REUTERS/Dado Ruvic/Illustration DUBAI (Reuters) - The United Arab Emirates on Monday granted emergency approval for use of a coronavirus vaccine, six weeks after human trials in the Gulf Arab state started."]}
{"id": 1001398, "claim": "Uae approves development of covid19 vaccine.", "label": "REFUTED", "evidence": ["The government had already approved the vaccine for emergency use in September for frontline workers at risk of contracting Covid-19.", "\"The vaccine will be available to our first line of defense heroes who are at the highest risk of contracting the virus,\" the UAE's National Emergency Crisis and Disaster Management Authority said in a tweet.", "REUTERS/Dado Ruvic/Illustration DUBAI (Reuters) - The United Arab Emirates on Monday granted emergency approval for use of a coronavirus vaccine, six weeks after human trials in the Gulf Arab state started."]}
{"id": 1001399, "claim": "Bacteriophage could decrease mortality", "label": "SUPPORTED", "evidence": ["Decreasing bacterial growth would also give the body more time to produce protective antibodies against the disease-causing coronavirus.", "\"The bacterial growth rate could potentially be reduced by the aerosol application of natural bacteriophages."]}
{"id": 1001400, "claim": "Bacteriophage could increase mortality", "label": "REFUTED", "evidence": ["Decreasing bacterial growth would also give the body more time to produce protective antibodies against the disease-causing coronavirus.", "\"The bacterial growth rate could potentially be reduced by the aerosol application of natural bacteriophages."]}
{"id": 1001401, "claim": "Bacteriophage could cause mortality", "label": "REFUTED", "evidence": ["Decreasing bacterial growth would also give the body more time to produce protective antibodies against the disease-causing coronavirus.", "\"The bacterial growth rate could potentially be reduced by the aerosol application of natural bacteriophages."]}
{"id": 1001402, "claim": "Bacteriophage could induce mortality", "label": "REFUTED", "evidence": ["Decreasing bacterial growth would also give the body more time to produce protective antibodies against the disease-causing coronavirus.", "\"The bacterial growth rate could potentially be reduced by the aerosol application of natural bacteriophages."]}
{"id": 1001403, "claim": "The return to the office will only succeed through radical transparency", "label": "SUPPORTED", "evidence": ["What I realized is that a return to the office will only succeed through radical transparency.", "We wont get it all right, but if we commit to having important conversations using radical transparency, well learn and well grow as we head back to a world very different from the one we left."]}
{"id": 1001404, "claim": "The return to the office will not succeed through radical transparency", "label": "REFUTED", "evidence": ["What I realized is that a return to the office will only succeed through radical transparency.", "We wont get it all right, but if we commit to having important conversations using radical transparency, well learn and well grow as we head back to a world very different from the one we left."]}
{"id": 1001405, "claim": "Ecuador sees massive surge in deaths in april", "label": "SUPPORTED", "evidence": ["Ecuador's coronavirus nightmare in pictures They said authorities had been unable to keep up with the huge rise in deaths, leaving corpses wrapped in sheets in family homes and even in the streets.", "Ecuador as a whole has had 8,225 confirmed cases of coronavirus to date, according to Johns Hopkins University, though a lack of widespread testing means this is likely a significant undercount."]}
{"id": 1001406, "claim": "Ecuador sees massive surge in investment in april", "label": "REFUTED", "evidence": ["Ecuador's coronavirus nightmare in pictures They said authorities had been unable to keep up with the huge rise in deaths, leaving corpses wrapped in sheets in family homes and even in the streets.", "Ecuador as a whole has had 8,225 confirmed cases of coronavirus to date, according to Johns Hopkins University, though a lack of widespread testing means this is likely a significant undercount."]}
{"id": 1001407, "claim": "Ecuador sees massive surge in practice in april", "label": "REFUTED", "evidence": ["Ecuador's coronavirus nightmare in pictures They said authorities had been unable to keep up with the huge rise in deaths, leaving corpses wrapped in sheets in family homes and even in the streets.", "Ecuador as a whole has had 8,225 confirmed cases of coronavirus to date, according to Johns Hopkins University, though a lack of widespread testing means this is likely a significant undercount."]}
{"id": 1001408, "claim": "Ecuador sees massive surge in compliance in april", "label": "REFUTED", "evidence": ["Ecuador's coronavirus nightmare in pictures They said authorities had been unable to keep up with the huge rise in deaths, leaving corpses wrapped in sheets in family homes and even in the streets.", "Ecuador as a whole has had 8,225 confirmed cases of coronavirus to date, according to Johns Hopkins University, though a lack of widespread testing means this is likely a significant undercount."]}
{"id": 1001409, "claim": "Prolonged sars-cov-2 replication in an immunocompromised patient", "label": "SUPPORTED", "evidence": ["This case highlights challenges in managing immunocompromised hosts, who may act as persistent shedders and sources of transmission."]}
{"id": 1001410, "claim": "Prolonged sars-cov-2 deficiency in an immunocompromised patient", "label": "REFUTED", "evidence": ["This case highlights challenges in managing immunocompromised hosts, who may act as persistent shedders and sources of transmission."]}
{"id": 1001411, "claim": "China reports smallest number of new covid-19 cases since january , but that doesnt mean virus is peaking.", "label": "SUPPORTED", "evidence": ["Only one in 19 infected people in Wuhan was being tested and confirmed, according to an estimate by Imperial College London as of Jan. 31.", "ET \"Yesterday, the number of new cases reported outside China exceeded the number of new cases in China for the first time,\" the head of the World Health Organization said Wednesday in an update on the coronavirus disease COVID-19.", "Photograph: Noel Celis/AFP/Getty Chinas Hubei province has reported its lowest number of new coronavirus cases since January, giving officials hope that the outbreak may be approaching its peak even as experts remained wary about its spread outside of China."]}
{"id": 1001412, "claim": "China reports smallest number of new covid-19 cases since january, but that ht mean virus is peaking.", "label": "REFUTED", "evidence": ["Only one in 19 infected people in Wuhan was being tested and confirmed, according to an estimate by Imperial College London as of Jan. 31.", "ET \"Yesterday, the number of new cases reported outside China exceeded the number of new cases in China for the first time,\" the head of the World Health Organization said Wednesday in an update on the coronavirus disease COVID-19.", "Photograph: Noel Celis/AFP/Getty Chinas Hubei province has reported its lowest number of new coronavirus cases since January, giving officials hope that the outbreak may be approaching its peak even as experts remained wary about its spread outside of China."]}
{"id": 1001413, "claim": "China reports smallest number of new covid-19 cases since january, but that gt mean virus is peaking.", "label": "REFUTED", "evidence": ["Only one in 19 infected people in Wuhan was being tested and confirmed, according to an estimate by Imperial College London as of Jan. 31.", "ET \"Yesterday, the number of new cases reported outside China exceeded the number of new cases in China for the first time,\" the head of the World Health Organization said Wednesday in an update on the coronavirus disease COVID-19.", "Photograph: Noel Celis/AFP/Getty Chinas Hubei province has reported its lowest number of new coronavirus cases since January, giving officials hope that the outbreak may be approaching its peak even as experts remained wary about its spread outside of China."]}
{"id": 1001414, "claim": "Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic covid-19a randomized clinical trial.", "label": "SUPPORTED", "evidence": ["Conclusions and relevance: In this preliminary study of adult outpatients with symptomatic COVID-19, patients treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration over 15 days.", "The use of fluvoxamine for the treatment of COVID-19 is considered investigational, which means the US Food and Drug Administration has not approved it for this use.", "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.", "Clinical deterioration occurred in 0 of 80 patients in the fluvoxamine group and in 6 of 72 patients in the placebo group (absolute difference, 8.7% [95% CI, 1.8%-16.4%] from survival analysis; log-rank P = .009)."]}
{"id": 1001415, "claim": "Fluvoxamine vs placebo and clinical improvement in outpatients with symptomatic covid-19a randomized clinical trial.", "label": "REFUTED", "evidence": ["Conclusions and relevance: In this preliminary study of adult outpatients with symptomatic COVID-19, patients treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration over 15 days.", "The use of fluvoxamine for the treatment of COVID-19 is considered investigational, which means the US Food and Drug Administration has not approved it for this use.", "Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.", "Clinical deterioration occurred in 0 of 80 patients in the fluvoxamine group and in 6 of 72 patients in the placebo group (absolute difference, 8.7% [95% CI, 1.8%-16.4%] from survival analysis; log-rank P = .009)."]}
{"id": 1001416, "claim": "'silent ' mutations gave the coronavirus an evolutionary edge", "label": "SUPPORTED", "evidence": ["Now, researchers at Duke University have identified a number of \"silent\" mutations in the roughly 30,000 letters of the virus's genetic code that helped it thrive once it made the leap -- and possibly helped set the stage for the global pandemic.", "SARS-CoV-2, the coronavirus that causes COVID-19, appears to have evolved silent changes to its RNA code that gave it a biological edge over previous strains.", "The researchers report that so-called silent mutations in two other regions of the SARS-CoV-2 genome, dubbed Nsp4 and Nsp16, appear to have given the virus a biological edge over previous strains without altering the proteins they encode."]}
{"id": 1001417, "claim": "' a'mutations gave the coronavirus an evolutionary edge", "label": "REFUTED", "evidence": ["Now, researchers at Duke University have identified a number of \"silent\" mutations in the roughly 30,000 letters of the virus's genetic code that helped it thrive once it made the leap -- and possibly helped set the stage for the global pandemic.", "SARS-CoV-2, the coronavirus that causes COVID-19, appears to have evolved silent changes to its RNA code that gave it a biological edge over previous strains.", "The researchers report that so-called silent mutations in two other regions of the SARS-CoV-2 genome, dubbed Nsp4 and Nsp16, appear to have given the virus a biological edge over previous strains without altering the proteins they encode."]}
{"id": 1001418, "claim": "' if'mutations gave the coronavirus an evolutionary edge", "label": "REFUTED", "evidence": ["Now, researchers at Duke University have identified a number of \"silent\" mutations in the roughly 30,000 letters of the virus's genetic code that helped it thrive once it made the leap -- and possibly helped set the stage for the global pandemic.", "SARS-CoV-2, the coronavirus that causes COVID-19, appears to have evolved silent changes to its RNA code that gave it a biological edge over previous strains.", "The researchers report that so-called silent mutations in two other regions of the SARS-CoV-2 genome, dubbed Nsp4 and Nsp16, appear to have given the virus a biological edge over previous strains without altering the proteins they encode."]}
{"id": 1001419, "claim": "' fact'mutations gave the coronavirus an evolutionary edge", "label": "REFUTED", "evidence": ["Now, researchers at Duke University have identified a number of \"silent\" mutations in the roughly 30,000 letters of the virus's genetic code that helped it thrive once it made the leap -- and possibly helped set the stage for the global pandemic.", "SARS-CoV-2, the coronavirus that causes COVID-19, appears to have evolved silent changes to its RNA code that gave it a biological edge over previous strains.", "The researchers report that so-called silent mutations in two other regions of the SARS-CoV-2 genome, dubbed Nsp4 and Nsp16, appear to have given the virus a biological edge over previous strains without altering the proteins they encode."]}
{"id": 1001420, "claim": "After 62 years of regulating immunity , dexamethasone meets covid-19", "label": "SUPPORTED", "evidence": ["Dexamethasone in hospitalized patients with Covid-19  preliminary report.", "An important observation from the RECOVERY trial was that dexamethasone provided benefit only to severely ill patients with COVID-19."]}
{"id": 1001421, "claim": "During 62 years of regulating immunity, dexamethasone meets covid-19", "label": "REFUTED", "evidence": ["Dexamethasone in hospitalized patients with Covid-19  preliminary report.", "An important observation from the RECOVERY trial was that dexamethasone provided benefit only to severely ill patients with COVID-19."]}
{"id": 1001422, "claim": "Within 62 years of regulating immunity, dexamethasone meets covid-19", "label": "REFUTED", "evidence": ["Dexamethasone in hospitalized patients with Covid-19  preliminary report.", "An important observation from the RECOVERY trial was that dexamethasone provided benefit only to severely ill patients with COVID-19."]}
{"id": 1001423, "claim": "Randomized trial finds hydroxychloroquine did not prevent covid-19", "label": "SUPPORTED", "evidence": ["\"This randomized trial did not demonstrate a significant benefit of hydroxychloroquine as postexposure prophylaxis for COVID-19,\" the authors of the study, a team of US and Canadian researchers, wrote in the paper.", "Analysis of the two treatment groups showed that the difference in the incidence of new illness compatible with COVID-19 was not statistically significant11.8% of those receiving hydroxychloroquine (49 of 414) got sick, compared with 14.3% of those receiving placebo (58 of 407).", "\"In the current trial, the long delay between perceived exposure to SARS-CoV-2 and the initiation of hydroxychloroquine ( 3 days in most participants) suggests what was being assessed was prevention of symptoms or progression of COVID-19, rather than prevention of SARS-CoV-2 infection,\" Myron Cohen, MD, of the Institute for Global and Infectious Diseases at the University of North Carolina, wrote."]}
{"id": 1001424, "claim": "Randomized trial finds hydroxychloroquine did only prevent covid-19", "label": "REFUTED", "evidence": ["\"This randomized trial did not demonstrate a significant benefit of hydroxychloroquine as postexposure prophylaxis for COVID-19,\" the authors of the study, a team of US and Canadian researchers, wrote in the paper.", "Analysis of the two treatment groups showed that the difference in the incidence of new illness compatible with COVID-19 was not statistically significant11.8% of those receiving hydroxychloroquine (49 of 414) got sick, compared with 14.3% of those receiving placebo (58 of 407).", "\"In the current trial, the long delay between perceived exposure to SARS-CoV-2 and the initiation of hydroxychloroquine ( 3 days in most participants) suggests what was being assessed was prevention of symptoms or progression of COVID-19, rather than prevention of SARS-CoV-2 infection,\" Myron Cohen, MD, of the Institute for Global and Infectious Diseases at the University of North Carolina, wrote."]}
{"id": 1001425, "claim": "Randomized trial finds hydroxychloroquine did also prevent covid-19", "label": "REFUTED", "evidence": ["\"This randomized trial did not demonstrate a significant benefit of hydroxychloroquine as postexposure prophylaxis for COVID-19,\" the authors of the study, a team of US and Canadian researchers, wrote in the paper.", "Analysis of the two treatment groups showed that the difference in the incidence of new illness compatible with COVID-19 was not statistically significant11.8% of those receiving hydroxychloroquine (49 of 414) got sick, compared with 14.3% of those receiving placebo (58 of 407).", "\"In the current trial, the long delay between perceived exposure to SARS-CoV-2 and the initiation of hydroxychloroquine ( 3 days in most participants) suggests what was being assessed was prevention of symptoms or progression of COVID-19, rather than prevention of SARS-CoV-2 infection,\" Myron Cohen, MD, of the Institute for Global and Infectious Diseases at the University of North Carolina, wrote."]}
{"id": 1001426, "claim": "Randomized trial finds hydroxychloroquine did indeed prevent covid-19", "label": "REFUTED", "evidence": ["\"This randomized trial did not demonstrate a significant benefit of hydroxychloroquine as postexposure prophylaxis for COVID-19,\" the authors of the study, a team of US and Canadian researchers, wrote in the paper.", "Analysis of the two treatment groups showed that the difference in the incidence of new illness compatible with COVID-19 was not statistically significant11.8% of those receiving hydroxychloroquine (49 of 414) got sick, compared with 14.3% of those receiving placebo (58 of 407).", "\"In the current trial, the long delay between perceived exposure to SARS-CoV-2 and the initiation of hydroxychloroquine ( 3 days in most participants) suggests what was being assessed was prevention of symptoms or progression of COVID-19, rather than prevention of SARS-CoV-2 infection,\" Myron Cohen, MD, of the Institute for Global and Infectious Diseases at the University of North Carolina, wrote."]}
{"id": 1001427, "claim": "A man in hong kong is the first confirmed case of coronavirus reinfection", "label": "SUPPORTED", "evidence": ["Hamilton, Ontario A 33 year old man from Hong Kong is reported to have the first confirmed case of covid reinfection.", "archived recording Researchers in China say a 33-year-old man living in Hong Kong is the first person confirmed to have been reinfected with the coronavirus.", "The reinfection case underscores the need for a vaccine that produces a powerful immune response, scientists said.Credit...Anthony Kwan/Getty Images By Apoorva Mandavilli Aug. 24, 2020  A 33-year-old man was infected a second time with the coronavirus more than four months after his first bout, the first documented case of so-called reinfection, researchers in Hong Kong reported Monday."]}
{"id": 1001428, "claim": "A gift in hong kong is the first confirmed case of coronavirus reinfection", "label": "REFUTED", "evidence": ["Hamilton, Ontario A 33 year old man from Hong Kong is reported to have the first confirmed case of covid reinfection.", "archived recording Researchers in China say a 33-year-old man living in Hong Kong is the first person confirmed to have been reinfected with the coronavirus.", "The reinfection case underscores the need for a vaccine that produces a powerful immune response, scientists said.Credit...Anthony Kwan/Getty Images By Apoorva Mandavilli Aug. 24, 2020  A 33-year-old man was infected a second time with the coronavirus more than four months after his first bout, the first documented case of so-called reinfection, researchers in Hong Kong reported Monday."]}
{"id": 1001429, "claim": "A man in hong kong is the second confirmed case of coronavirus reinfection", "label": "REFUTED", "evidence": ["Hamilton, Ontario A 33 year old man from Hong Kong is reported to have the first confirmed case of covid reinfection.", "archived recording Researchers in China say a 33-year-old man living in Hong Kong is the first person confirmed to have been reinfected with the coronavirus.", "The reinfection case underscores the need for a vaccine that produces a powerful immune response, scientists said.Credit...Anthony Kwan/Getty Images By Apoorva Mandavilli Aug. 24, 2020  A 33-year-old man was infected a second time with the coronavirus more than four months after his first bout, the first documented case of so-called reinfection, researchers in Hong Kong reported Monday."]}
{"id": 1001430, "claim": "A man in hong kong is the last confirmed case of coronavirus reinfection", "label": "REFUTED", "evidence": ["Hamilton, Ontario A 33 year old man from Hong Kong is reported to have the first confirmed case of covid reinfection.", "archived recording Researchers in China say a 33-year-old man living in Hong Kong is the first person confirmed to have been reinfected with the coronavirus.", "The reinfection case underscores the need for a vaccine that produces a powerful immune response, scientists said.Credit...Anthony Kwan/Getty Images By Apoorva Mandavilli Aug. 24, 2020  A 33-year-old man was infected a second time with the coronavirus more than four months after his first bout, the first documented case of so-called reinfection, researchers in Hong Kong reported Monday."]}
{"id": 1001431, "claim": "New coronavirus test 10 times faster is fda approved", "label": "SUPPORTED", "evidence": ["The 8800 version is capable of testing 4,128 patients a day, and the 6800 can test as many as 1,440."]}
{"id": 1001432, "claim": "New coronavirus test 10 times later is fda approved", "label": "REFUTED", "evidence": ["The 8800 version is capable of testing 4,128 patients a day, and the 6800 can test as many as 1,440."]}
{"id": 1001433, "claim": "New coronavirus test 10 times old is fda approved", "label": "REFUTED", "evidence": ["The 8800 version is capable of testing 4,128 patients a day, and the 6800 can test as many as 1,440."]}
{"id": 1001434, "claim": "Evidence that coronavirus superspreading is fat-tailed", "label": "SUPPORTED", "evidence": ["Here, we combine empirical observations of SARS-CoV and SARS-CoV-2 transmission and extreme value statistics to show that the distribution of secondary cases is consistent with being fat-tailed, implying that large superspreading events are extremal, yet probable, occurrences.", "SARS-CoV and SARS-CoV-2 SSEs correspond to fat tails."]}
{"id": 1001435, "claim": "Evidence that coronavirus superspreading is low-tailed", "label": "REFUTED", "evidence": ["Here, we combine empirical observations of SARS-CoV and SARS-CoV-2 transmission and extreme value statistics to show that the distribution of secondary cases is consistent with being fat-tailed, implying that large superspreading events are extremal, yet probable, occurrences.", "SARS-CoV and SARS-CoV-2 SSEs correspond to fat tails."]}
{"id": 1001436, "claim": "Evidence that coronavirus superspreading is one-tailed", "label": "REFUTED", "evidence": ["Here, we combine empirical observations of SARS-CoV and SARS-CoV-2 transmission and extreme value statistics to show that the distribution of secondary cases is consistent with being fat-tailed, implying that large superspreading events are extremal, yet probable, occurrences.", "SARS-CoV and SARS-CoV-2 SSEs correspond to fat tails."]}
{"id": 1001437, "claim": "Evidence that coronavirus superspreading is non-tailed", "label": "REFUTED", "evidence": ["Here, we combine empirical observations of SARS-CoV and SARS-CoV-2 transmission and extreme value statistics to show that the distribution of secondary cases is consistent with being fat-tailed, implying that large superspreading events are extremal, yet probable, occurrences.", "SARS-CoV and SARS-CoV-2 SSEs correspond to fat tails."]}
{"id": 1001438, "claim": "Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with covid-19", "label": "SUPPORTED", "evidence": ["In conclusion, we developed a scoring system (COVID-19MRS) that objectively and accurately predicts in-hospital mortality COVID-19 patients."]}
{"id": 1001439, "claim": "Development and lack of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with covid-19", "label": "REFUTED", "evidence": ["In conclusion, we developed a scoring system (COVID-19MRS) that objectively and accurately predicts in-hospital mortality COVID-19 patients."]}
{"id": 1001440, "claim": "Public disclosure of covid-19 cases is more effective than lockdowns", "label": "SUPPORTED", "evidence": ["The results reveal that public disclosure can help people \"target\" their social distancing and this proves especially helpful for vulnerable populations who can more easily avoid areas with a higher rate of infection.", "According to the authors, this publicly available data spurred signicant changes in the commuting patterns of people: individuals were more likely to commute to the districts with less conrmed cases, and less likely to commute to the districts with more cases."]}
{"id": 1001441, "claim": "Public disclosure of covid-19 cases is less effective than lockdowns", "label": "REFUTED", "evidence": ["The results reveal that public disclosure can help people \"target\" their social distancing and this proves especially helpful for vulnerable populations who can more easily avoid areas with a higher rate of infection.", "According to the authors, this publicly available data spurred signicant changes in the commuting patterns of people: individuals were more likely to commute to the districts with less conrmed cases, and less likely to commute to the districts with more cases."]}
{"id": 1001442, "claim": "Public disclosure of covid-19 cases is not effective than lockdowns", "label": "REFUTED", "evidence": ["The results reveal that public disclosure can help people \"target\" their social distancing and this proves especially helpful for vulnerable populations who can more easily avoid areas with a higher rate of infection.", "According to the authors, this publicly available data spurred signicant changes in the commuting patterns of people: individuals were more likely to commute to the districts with less conrmed cases, and less likely to commute to the districts with more cases."]}
{"id": 1001443, "claim": "Public disclosure of covid-19 cases is more effective during lockdowns", "label": "REFUTED", "evidence": ["The results reveal that public disclosure can help people \"target\" their social distancing and this proves especially helpful for vulnerable populations who can more easily avoid areas with a higher rate of infection.", "According to the authors, this publicly available data spurred signicant changes in the commuting patterns of people: individuals were more likely to commute to the districts with less conrmed cases, and less likely to commute to the districts with more cases."]}
{"id": 1001444, "claim": "Massachusetts general hospital covid-19 registry reveals two distinct populations of hospitalized patients by race and ethnicity", "label": "SUPPORTED", "evidence": ["Results: Overall, 43% of patients hospitalized with Covid-19 were women, median age was 60.4 [IQR = (48.2, 75)], 11.3% were Black/non-Hispanic and 35.2% were Hispanic."]}
{"id": 1001445, "claim": "Massachusetts general hospital covid-19 registry reveals four distinct populations of hospitalized patients by race and ethnicity", "label": "REFUTED", "evidence": ["Results: Overall, 43% of patients hospitalized with Covid-19 were women, median age was 60.4 [IQR = (48.2, 75)], 11.3% were Black/non-Hispanic and 35.2% were Hispanic."]}
{"id": 1001446, "claim": "Massachusetts general hospital covid-19 registry reveals five distinct populations of hospitalized patients by race and ethnicity", "label": "REFUTED", "evidence": ["Results: Overall, 43% of patients hospitalized with Covid-19 were women, median age was 60.4 [IQR = (48.2, 75)], 11.3% were Black/non-Hispanic and 35.2% were Hispanic."]}
{"id": 1001447, "claim": "Massachusetts general hospital covid-19 registry reveals three distinct populations of hospitalized patients by race and ethnicity", "label": "REFUTED", "evidence": ["Results: Overall, 43% of patients hospitalized with Covid-19 were women, median age was 60.4 [IQR = (48.2, 75)], 11.3% were Black/non-Hispanic and 35.2% were Hispanic."]}
{"id": 1001448, "claim": "Sars-cov-2 infection damages airway motile cilia and impairs mucociliary clearance.", "label": "SUPPORTED", "evidence": ["We examined the functional and structural consequences of SARS-CoV-2 infection in a reconstituted human bronchial epithelium model.", "SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract.", "This study identifies cilia damage as a pathogenic mechanism that could facilitate SARS- CoV-2 spread to the deeper lung parenchyma.", "Rather, SARS-CoV-2 replication led to a rapid loss of the ciliary layer, characterized at the ultrastructural level by axoneme loss and misorientation of remaining basal bodies."]}
{"id": 1001449, "claim": "Sars-cov-2 infection promotes airway motile cilia and impairs mucociliary clearance.", "label": "REFUTED", "evidence": ["We examined the functional and structural consequences of SARS-CoV-2 infection in a reconstituted human bronchial epithelium model.", "SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract.", "This study identifies cilia damage as a pathogenic mechanism that could facilitate SARS- CoV-2 spread to the deeper lung parenchyma.", "Rather, SARS-CoV-2 replication led to a rapid loss of the ciliary layer, characterized at the ultrastructural level by axoneme loss and misorientation of remaining basal bodies."]}
{"id": 1001450, "claim": "A previously uncharacterized gene in sars-cov-2 illuminates the functional dynamics and evolutionary origins of the covid-19 pandemic", "label": "SUPPORTED", "evidence": ["Our results liken ORF3c to other important viral accessory genes recombined, lost, split, or truncated before or during outbreaks, including ORF3b and ORF8 in sarbecoviruses.", "We investigate de novo OLG candidates in SARS-CoV-2 and identify a new gene here named ORF3c."]}
{"id": 1001451, "claim": "A newly uncharacterized gene in sars-cov-2 illuminates the functional dynamics and evolutionary origins of the covid-19 pandemic", "label": "REFUTED", "evidence": ["Our results liken ORF3c to other important viral accessory genes recombined, lost, split, or truncated before or during outbreaks, including ORF3b and ORF8 in sarbecoviruses.", "We investigate de novo OLG candidates in SARS-CoV-2 and identify a new gene here named ORF3c."]}
{"id": 1001452, "claim": "A novel uncharacterized gene in sars-cov-2 illuminates the functional dynamics and evolutionary origins of the covid-19 pandemic", "label": "REFUTED", "evidence": ["Our results liken ORF3c to other important viral accessory genes recombined, lost, split, or truncated before or during outbreaks, including ORF3b and ORF8 in sarbecoviruses.", "We investigate de novo OLG candidates in SARS-CoV-2 and identify a new gene here named ORF3c."]}
{"id": 1001453, "claim": "A new uncharacterized gene in sars-cov-2 illuminates the functional dynamics and evolutionary origins of the covid-19 pandemic", "label": "REFUTED", "evidence": ["Our results liken ORF3c to other important viral accessory genes recombined, lost, split, or truncated before or during outbreaks, including ORF3b and ORF8 in sarbecoviruses.", "We investigate de novo OLG candidates in SARS-CoV-2 and identify a new gene here named ORF3c."]}
{"id": 1001454, "claim": "Sauna use reduces pneumonia risk", "label": "SUPPORTED", "evidence": ["Having frequent sauna baths has been found to be associated with reduced risk of acute and chronic disease conditions.", "Frequent sauna baths may be associated with a reduced risk of acute and chronic respiratory conditions in a middle-aged male Caucasian population.", "Conclusions: Frequent sauna baths is associated with reduced pneumonia risk in a middle-aged male Caucasian population.", "Still, its possible that regular sauna bathing helps reduce blood pressure, inflammation, oxidative stress, circulation of bad cholesterol and stiffness in the arteries, the authors note."]}
{"id": 1001455, "claim": "Sauna use increased pneumonia risk", "label": "REFUTED", "evidence": ["Having frequent sauna baths has been found to be associated with reduced risk of acute and chronic disease conditions.", "Frequent sauna baths may be associated with a reduced risk of acute and chronic respiratory conditions in a middle-aged male Caucasian population.", "Conclusions: Frequent sauna baths is associated with reduced pneumonia risk in a middle-aged male Caucasian population.", "Still, its possible that regular sauna bathing helps reduce blood pressure, inflammation, oxidative stress, circulation of bad cholesterol and stiffness in the arteries, the authors note."]}
{"id": 1001456, "claim": "Sauna use is pneumonia risk", "label": "REFUTED", "evidence": ["Having frequent sauna baths has been found to be associated with reduced risk of acute and chronic disease conditions.", "Frequent sauna baths may be associated with a reduced risk of acute and chronic respiratory conditions in a middle-aged male Caucasian population.", "Conclusions: Frequent sauna baths is associated with reduced pneumonia risk in a middle-aged male Caucasian population.", "Still, its possible that regular sauna bathing helps reduce blood pressure, inflammation, oxidative stress, circulation of bad cholesterol and stiffness in the arteries, the authors note."]}
{"id": 1001457, "claim": "Sauna use with pneumonia risk", "label": "REFUTED", "evidence": ["Having frequent sauna baths has been found to be associated with reduced risk of acute and chronic disease conditions.", "Frequent sauna baths may be associated with a reduced risk of acute and chronic respiratory conditions in a middle-aged male Caucasian population.", "Conclusions: Frequent sauna baths is associated with reduced pneumonia risk in a middle-aged male Caucasian population.", "Still, its possible that regular sauna bathing helps reduce blood pressure, inflammation, oxidative stress, circulation of bad cholesterol and stiffness in the arteries, the authors note."]}
{"id": 1001458, "claim": "Coronavirus case counts are meaningless*", "label": "SUPPORTED", "evidence": ["CORRECTION (April 13, 2020, 1:47 p.m.): In describing what it would take for the new coronavirus to begin to die out, a previous version of this story incorrectly referred to the R value falling below zero, which is not possible.", "Given that includes people who probably do have the coronavirus (since asymptomatic cases are fairly common), we can assume the rate of false positives is even lower -- for the purpose of the scenarios, we'll guess that it's 0.2 percent."]}
{"id": 1001459, "claim": "Coronavirus case counts are defined*", "label": "REFUTED", "evidence": ["CORRECTION (April 13, 2020, 1:47 p.m.): In describing what it would take for the new coronavirus to begin to die out, a previous version of this story incorrectly referred to the R value falling below zero, which is not possible.", "Given that includes people who probably do have the coronavirus (since asymptomatic cases are fairly common), we can assume the rate of false positives is even lower -- for the purpose of the scenarios, we'll guess that it's 0.2 percent."]}
{"id": 1001460, "claim": "Coronavirus case counts are indicated*", "label": "REFUTED", "evidence": ["CORRECTION (April 13, 2020, 1:47 p.m.): In describing what it would take for the new coronavirus to begin to die out, a previous version of this story incorrectly referred to the R value falling below zero, which is not possible.", "Given that includes people who probably do have the coronavirus (since asymptomatic cases are fairly common), we can assume the rate of false positives is even lower -- for the purpose of the scenarios, we'll guess that it's 0.2 percent."]}
{"id": 1001461, "claim": "Coronavirus case counts are shown*", "label": "REFUTED", "evidence": ["CORRECTION (April 13, 2020, 1:47 p.m.): In describing what it would take for the new coronavirus to begin to die out, a previous version of this story incorrectly referred to the R value falling below zero, which is not possible.", "Given that includes people who probably do have the coronavirus (since asymptomatic cases are fairly common), we can assume the rate of false positives is even lower -- for the purpose of the scenarios, we'll guess that it's 0.2 percent."]}
{"id": 1001462, "claim": "Enisamium is an inhibitor of the sars-cov-2 rna polymerase and shows improvement of recovery in covid-19 patients in an interim analysis of a clinical trial.", "label": "SUPPORTED", "evidence": ["Here, we report that enisamium, which can be administered orally, can prevent SARS-CoV-2 replication and that its metabolite VR17-04 can inhibit the SARS-CoV-2 RNA polymerase in vitro .", "The researchers say the observations point to enisamium as a viable and accessible option for the treatment of SARS-CoV-2 infection and COVID-19.", "( D ) Quantification of SARS-CoV-2 RNA genome levels in NHBE cells infected with SARS-CoV-2 after treatment with enisamium iodide.", "Here, we report that enisamium, which can be administered orally, can prevent SARS-CoV-2 replication and that its metabolite VR17-04 can inhibit the SARS-CoV-2 RNA polymerase in vitro.", "The researchers say the findings suggest that enisamium is an inhibitor of SARS-CoV-2 RNA synthesis and shortens recovery time among COVID-19 patients who require oxygen supplementation."]}
{"id": 1001463, "claim": "Enisamium is an activator of the sars-cov-2 rna polymerase and shows improvement of recovery in covid-19 patients in an interim analysis of a clinical trial.", "label": "REFUTED", "evidence": ["Here, we report that enisamium, which can be administered orally, can prevent SARS-CoV-2 replication and that its metabolite VR17-04 can inhibit the SARS-CoV-2 RNA polymerase in vitro .", "The researchers say the observations point to enisamium as a viable and accessible option for the treatment of SARS-CoV-2 infection and COVID-19.", "( D ) Quantification of SARS-CoV-2 RNA genome levels in NHBE cells infected with SARS-CoV-2 after treatment with enisamium iodide.", "Here, we report that enisamium, which can be administered orally, can prevent SARS-CoV-2 replication and that its metabolite VR17-04 can inhibit the SARS-CoV-2 RNA polymerase in vitro.", "The researchers say the findings suggest that enisamium is an inhibitor of SARS-CoV-2 RNA synthesis and shortens recovery time among COVID-19 patients who require oxygen supplementation."]}
{"id": 1001464, "claim": "Enisamium is an indicator of the sars-cov-2 rna polymerase and shows improvement of recovery in covid-19 patients in an interim analysis of a clinical trial.", "label": "REFUTED", "evidence": ["Here, we report that enisamium, which can be administered orally, can prevent SARS-CoV-2 replication and that its metabolite VR17-04 can inhibit the SARS-CoV-2 RNA polymerase in vitro .", "The researchers say the observations point to enisamium as a viable and accessible option for the treatment of SARS-CoV-2 infection and COVID-19.", "( D ) Quantification of SARS-CoV-2 RNA genome levels in NHBE cells infected with SARS-CoV-2 after treatment with enisamium iodide.", "Here, we report that enisamium, which can be administered orally, can prevent SARS-CoV-2 replication and that its metabolite VR17-04 can inhibit the SARS-CoV-2 RNA polymerase in vitro.", "The researchers say the findings suggest that enisamium is an inhibitor of SARS-CoV-2 RNA synthesis and shortens recovery time among COVID-19 patients who require oxygen supplementation."]}
{"id": 1001465, "claim": "In 2004 , researchers began human trials for aerosolized hydroxychloroquine to be taken using an inhaler .", "label": "SUPPORTED", "evidence": ["There are reports about successful early clinical trials of chloroquine in China as early as beginning of February, and conclusion was that wide treatment is warranted."]}
{"id": 1001466, "claim": "In 20, researchers began human trials for aerosolized hydroxychloroquine to be taken using an inhaler.", "label": "REFUTED", "evidence": ["There are reports about successful early clinical trials of chloroquine in China as early as beginning of February, and conclusion was that wide treatment is warranted."]}
{"id": 1001467, "claim": "In 31, researchers began human trials for aerosolized hydroxychloroquine to be taken using an inhaler.", "label": "REFUTED", "evidence": ["There are reports about successful early clinical trials of chloroquine in China as early as beginning of February, and conclusion was that wide treatment is warranted."]}
{"id": 1001468, "claim": "In 1, researchers began human trials for aerosolized hydroxychloroquine to be taken using an inhaler.", "label": "REFUTED", "evidence": ["There are reports about successful early clinical trials of chloroquine in China as early as beginning of February, and conclusion was that wide treatment is warranted."]}
{"id": 1001469, "claim": "Pulmonary pathology of early covid-19 pneumonia identified retrospectively in two patients with lung cancer", "label": "SUPPORTED", "evidence": ["Photo credit: Getty The article describes two patients who recently underwent lung lobectomies for adenocarcinoma and were retrospectively found to have had COVID-19 at the time of surgery."]}
{"id": 1001470, "claim": "Pulmonary pathology of early covid-19 pneumonia identified retrospectively in two patients without lung cancer", "label": "REFUTED", "evidence": ["Photo credit: Getty The article describes two patients who recently underwent lung lobectomies for adenocarcinoma and were retrospectively found to have had COVID-19 at the time of surgery."]}
{"id": 1001471, "claim": "Pulmonary pathology of early covid-19 pneumonia identified retrospectively in 19 patients with lung cancer", "label": "REFUTED", "evidence": ["Photo credit: Getty The article describes two patients who recently underwent lung lobectomies for adenocarcinoma and were retrospectively found to have had COVID-19 at the time of surgery."]}
{"id": 1001472, "claim": "Pulmonary pathology of early covid-19 pneumonia identified retrospectively in all patients with lung cancer", "label": "REFUTED", "evidence": ["Photo credit: Getty The article describes two patients who recently underwent lung lobectomies for adenocarcinoma and were retrospectively found to have had COVID-19 at the time of surgery."]}
{"id": 1001473, "claim": "Covid-19 mortality increases with northerly latitude after adjustment for age suggesting a link with ultraviolet and vitamin d", "label": "SUPPORTED", "evidence": ["View this table: View inline View popup Table 1 Associations between COVID-19 mortality by country, latitude and % of population 65 years The proportion of older people in each country impacts greatly on COVID-19 mortality, but after adjustment for this, a strong association remains across the Northern hemisphere between latitude and higher COVID-19 mortality.", "This analysis supports the link between latitude and COVID-19 mortality reported within the USA by Dr Kohlmeier.1 Evidence linking vitamin D deficiency with COVID-19 severity is circumstantial but growing.", "There are exceptions, but COVID-19 mortality correlates with reported vitamin D levels across Europe,7 and in sunnier Brazil, where mortality is rising, 28% prevalence of vitamin D deficiency is reported.8 An association between vitamin D insufficiency and COVID-19 severity is supported by substantial evidence of its impact on cytokine response to pathogens.7 A direct effect of ultraviolet light on the environmental survival of severe acute respiratory syndrome coronavirus 2 is also possible but would not explain the association between mortality and ethnicity,9 whereas people with dark skin need more ultraviolet exposure for equivalent vitamin D synthesis."]}
{"id": 1001474, "claim": "Covid-19 mortality decreased with northerly latitude after adjustment for age suggesting a link with ultraviolet and vitamin d", "label": "REFUTED", "evidence": ["View this table: View inline View popup Table 1 Associations between COVID-19 mortality by country, latitude and % of population 65 years The proportion of older people in each country impacts greatly on COVID-19 mortality, but after adjustment for this, a strong association remains across the Northern hemisphere between latitude and higher COVID-19 mortality.", "This analysis supports the link between latitude and COVID-19 mortality reported within the USA by Dr Kohlmeier.1 Evidence linking vitamin D deficiency with COVID-19 severity is circumstantial but growing.", "There are exceptions, but COVID-19 mortality correlates with reported vitamin D levels across Europe,7 and in sunnier Brazil, where mortality is rising, 28% prevalence of vitamin D deficiency is reported.8 An association between vitamin D insufficiency and COVID-19 severity is supported by substantial evidence of its impact on cytokine response to pathogens.7 A direct effect of ultraviolet light on the environmental survival of severe acute respiratory syndrome coronavirus 2 is also possible but would not explain the association between mortality and ethnicity,9 whereas people with dark skin need more ultraviolet exposure for equivalent vitamin D synthesis."]}
{"id": 1001475, "claim": "Covid-19 mortality decreases with northerly latitude after adjustment for age suggesting a link with ultraviolet and vitamin d", "label": "REFUTED", "evidence": ["View this table: View inline View popup Table 1 Associations between COVID-19 mortality by country, latitude and % of population 65 years The proportion of older people in each country impacts greatly on COVID-19 mortality, but after adjustment for this, a strong association remains across the Northern hemisphere between latitude and higher COVID-19 mortality.", "This analysis supports the link between latitude and COVID-19 mortality reported within the USA by Dr Kohlmeier.1 Evidence linking vitamin D deficiency with COVID-19 severity is circumstantial but growing.", "There are exceptions, but COVID-19 mortality correlates with reported vitamin D levels across Europe,7 and in sunnier Brazil, where mortality is rising, 28% prevalence of vitamin D deficiency is reported.8 An association between vitamin D insufficiency and COVID-19 severity is supported by substantial evidence of its impact on cytokine response to pathogens.7 A direct effect of ultraviolet light on the environmental survival of severe acute respiratory syndrome coronavirus 2 is also possible but would not explain the association between mortality and ethnicity,9 whereas people with dark skin need more ultraviolet exposure for equivalent vitamin D synthesis."]}
{"id": 1001476, "claim": "Infectious diseases expert warns of second corona wave after fall", "label": "SUPPORTED", "evidence": ["He said it's unlikely that the outbreak will end this summer, and it's very likely that a second wave will take place after the fall.", "I said repeatedly two weeks ago that it's unlikely the pandemic will be over by the summer, that it will largely last till the next year.", "There is a high probability of a second international outbreak."]}
{"id": 1001477, "claim": "Infectious diseases expert warns of one corona wave after fall", "label": "REFUTED", "evidence": ["He said it's unlikely that the outbreak will end this summer, and it's very likely that a second wave will take place after the fall.", "I said repeatedly two weeks ago that it's unlikely the pandemic will be over by the summer, that it will largely last till the next year.", "There is a high probability of a second international outbreak."]}
{"id": 1001478, "claim": "Infectious diseases expert warns of each corona wave after fall", "label": "REFUTED", "evidence": ["He said it's unlikely that the outbreak will end this summer, and it's very likely that a second wave will take place after the fall.", "I said repeatedly two weeks ago that it's unlikely the pandemic will be over by the summer, that it will largely last till the next year.", "There is a high probability of a second international outbreak."]}
{"id": 1001479, "claim": "Doctors say cdc should warn people the side effects from covid vaccine shots wont be a walk in the park", "label": "SUPPORTED", "evidence": ["\"We really need to make patients aware that this is not going to be a walk in the park,\" Fryhofer said during a virtual meeting with the Advisory Committee on Immunization Practices, or ACIP, an outside group of medical experts that advise the CDC."]}
{"id": 1001480, "claim": "Doctors say cdc should warn people the side effects from covid vaccine shots tot be a walk in the park", "label": "REFUTED", "evidence": ["\"We really need to make patients aware that this is not going to be a walk in the park,\" Fryhofer said during a virtual meeting with the Advisory Committee on Immunization Practices, or ACIP, an outside group of medical experts that advise the CDC."]}
{"id": 1001481, "claim": "Vitamin d determines severity in covid-19 so government advice needs to change , experts urge", "label": "SUPPORTED", "evidence": ["This may be because vitamin D is important in regulation and suppression of the inflammatory cytokine response, which causes the severe consequences of COVID-19 and 'acute respiratory distress syndrome' associated with ventilation and death.", "The authors propose that, whereas optimising vitamin D levels will certainly benefit bone and muscle health, the data suggests that it is also likely to reduce serious COVID-19 complications."]}
{"id": 1001482, "claim": "Figure d determines severity in covid-19 so government advice needs to change, experts urge", "label": "REFUTED", "evidence": ["This may be because vitamin D is important in regulation and suppression of the inflammatory cytokine response, which causes the severe consequences of COVID-19 and 'acute respiratory distress syndrome' associated with ventilation and death.", "The authors propose that, whereas optimising vitamin D levels will certainly benefit bone and muscle health, the data suggests that it is also likely to reduce serious COVID-19 complications."]}
{"id": 1001483, "claim": "Uci develops low-cost , accurate covid-19 antibody detection platform", "label": "SUPPORTED", "evidence": ["This ensures accuracy equal to that of expensive imaging systems but makes the platform portable enough to deploy anywhere  at a cost of only $200.", "Timothy Abram Irvine, Calif., Aug. 19, 2020  A robust, low-cost imaging platform utilizing lab-on-a-chip technology created by University of California, Irvine scientists may be available for rapid coronavirus diagnostic and antibody testing throughout the nation by the end of the year.", "The TinyArray imager combines a 3D-printed prototype with an off-the-shelf LED and a small 5-megapixel camera to find markers for many antibodies simultaneously."]}
{"id": 1001484, "claim": "Rsv develops low-cost, accurate covid-19 antibody detection platform", "label": "REFUTED", "evidence": ["This ensures accuracy equal to that of expensive imaging systems but makes the platform portable enough to deploy anywhere  at a cost of only $200.", "Timothy Abram Irvine, Calif., Aug. 19, 2020  A robust, low-cost imaging platform utilizing lab-on-a-chip technology created by University of California, Irvine scientists may be available for rapid coronavirus diagnostic and antibody testing throughout the nation by the end of the year.", "The TinyArray imager combines a 3D-printed prototype with an off-the-shelf LED and a small 5-megapixel camera to find markers for many antibodies simultaneously."]}
{"id": 1001485, "claim": "Pcr develops low-cost, accurate covid-19 antibody detection platform", "label": "REFUTED", "evidence": ["This ensures accuracy equal to that of expensive imaging systems but makes the platform portable enough to deploy anywhere  at a cost of only $200.", "Timothy Abram Irvine, Calif., Aug. 19, 2020  A robust, low-cost imaging platform utilizing lab-on-a-chip technology created by University of California, Irvine scientists may be available for rapid coronavirus diagnostic and antibody testing throughout the nation by the end of the year.", "The TinyArray imager combines a 3D-printed prototype with an off-the-shelf LED and a small 5-megapixel camera to find markers for many antibodies simultaneously."]}
{"id": 1001486, "claim": "Cdc develops low-cost, accurate covid-19 antibody detection platform", "label": "REFUTED", "evidence": ["This ensures accuracy equal to that of expensive imaging systems but makes the platform portable enough to deploy anywhere  at a cost of only $200.", "Timothy Abram Irvine, Calif., Aug. 19, 2020  A robust, low-cost imaging platform utilizing lab-on-a-chip technology created by University of California, Irvine scientists may be available for rapid coronavirus diagnostic and antibody testing throughout the nation by the end of the year.", "The TinyArray imager combines a 3D-printed prototype with an off-the-shelf LED and a small 5-megapixel camera to find markers for many antibodies simultaneously."]}
{"id": 1001487, "claim": "Tga grants provisional determination for covid-19 vaccine", "label": "SUPPORTED", "evidence": ["In making its decision to grant Pfizer a provisional determination, the TGA considered all eligibility criteria, including factors such as the evidence of a plan to submit comprehensive clinical data and the seriousness of the current COVID-19 pandemic.", "The granting of a provisional determination means that the TGA has made a decision that Pfizer is now eligible to apply for provisional registration for the vaccine in the Australian Register of Therapeutic Goods (ARTG).", "The granting of a provisional determination means that the TGA has made a decision that Pfizer is now eligible to apply for provisional registration for the vaccine in the Australian Register of Therapeutic Goods."]}
{"id": 1001488, "claim": "Tga requires provisional determination for covid-19 vaccine", "label": "REFUTED", "evidence": ["In making its decision to grant Pfizer a provisional determination, the TGA considered all eligibility criteria, including factors such as the evidence of a plan to submit comprehensive clinical data and the seriousness of the current COVID-19 pandemic.", "The granting of a provisional determination means that the TGA has made a decision that Pfizer is now eligible to apply for provisional registration for the vaccine in the Australian Register of Therapeutic Goods (ARTG).", "The granting of a provisional determination means that the TGA has made a decision that Pfizer is now eligible to apply for provisional registration for the vaccine in the Australian Register of Therapeutic Goods."]}
{"id": 1001489, "claim": "The differential immune responses to covid-19 in peripheral and lung revealed by single-cell rna sequencing", "label": "SUPPORTED", "evidence": ["Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing.", "COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis."]}
{"id": 1001490, "claim": "The differential immune responses to covid-19 in peripheral and lung revealed by single-dimensional rna sequencing", "label": "REFUTED", "evidence": ["Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing.", "COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis."]}
{"id": 1001491, "claim": "The differential immune responses to covid-19 in brain and lung revealed by single-cell rna sequencing", "label": "REFUTED", "evidence": ["Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing.", "COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis."]}
{"id": 1001492, "claim": "The differential immune responses to covid-19 in peripheral and lung revealed by single-step rna sequencing", "label": "REFUTED", "evidence": ["Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing.", "COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis."]}
{"id": 1001493, "claim": "Older adults lack sars cov-2 cross-reactive t lymphocytes directed to human coronaviruses oc43 and nl63", "label": "SUPPORTED", "evidence": ["Second, we demonstrated that T cell memory lymphocytes to HCoVs OC43 and NL63 were virtually absent in the group of older adults and that accordingly SARS- CoV-2 cross-reactive T cells were absent.", "One subject in the older adults group, who did not respond to stimulation with the HCoVs NL63 and OC43, had a high frequency of T cells to the SARS CoV-2 M protein, (1000 SFC/106 PBMCs)."]}
{"id": 1001494, "claim": "Older adults have sars cov-2 cross-reactive t lymphocytes directed to human coronaviruses oc43 and nl63", "label": "REFUTED", "evidence": ["Second, we demonstrated that T cell memory lymphocytes to HCoVs OC43 and NL63 were virtually absent in the group of older adults and that accordingly SARS- CoV-2 cross-reactive T cells were absent.", "One subject in the older adults group, who did not respond to stimulation with the HCoVs NL63 and OC43, had a high frequency of T cells to the SARS CoV-2 M protein, (1000 SFC/106 PBMCs)."]}
{"id": 1001495, "claim": "Older adults had sars cov-2 cross-reactive t lymphocytes directed to human coronaviruses oc43 and nl63", "label": "REFUTED", "evidence": ["Second, we demonstrated that T cell memory lymphocytes to HCoVs OC43 and NL63 were virtually absent in the group of older adults and that accordingly SARS- CoV-2 cross-reactive T cells were absent.", "One subject in the older adults group, who did not respond to stimulation with the HCoVs NL63 and OC43, had a high frequency of T cells to the SARS CoV-2 M protein, (1000 SFC/106 PBMCs)."]}
{"id": 1001496, "claim": "Older adults also sars cov-2 cross-reactive t lymphocytes directed to human coronaviruses oc43 and nl63", "label": "REFUTED", "evidence": ["Second, we demonstrated that T cell memory lymphocytes to HCoVs OC43 and NL63 were virtually absent in the group of older adults and that accordingly SARS- CoV-2 cross-reactive T cells were absent.", "One subject in the older adults group, who did not respond to stimulation with the HCoVs NL63 and OC43, had a high frequency of T cells to the SARS CoV-2 M protein, (1000 SFC/106 PBMCs)."]}
{"id": 1001497, "claim": "Preliminary results from a multi-centre , randomized , controlled trial .", "label": "SUPPORTED", "evidence": ["A multicentre randomized clinical trial.", "Methods The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is a randomized, controlled, open-label, platform trial comparing a range of possible treatments with usual care in patients hospitalized with COVID-19."]}
{"id": 1001498, "claim": "Preliminary results from a multi-dose, randomized, controlled trial.", "label": "REFUTED", "evidence": ["A multicentre randomized clinical trial.", "Methods The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is a randomized, controlled, open-label, platform trial comparing a range of possible treatments with usual care in patients hospitalized with COVID-19."]}
{"id": 1001499, "claim": "Preliminary results from a multi-line, randomized, controlled trial.", "label": "REFUTED", "evidence": ["A multicentre randomized clinical trial.", "Methods The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is a randomized, controlled, open-label, platform trial comparing a range of possible treatments with usual care in patients hospitalized with COVID-19."]}
{"id": 1001500, "claim": "Florida sheriff bans his deputies and office visitors from wearing masks on a day his county broke records for covid-19 deaths", "label": "SUPPORTED", "evidence": ["(CNN)A mandate from a local sheriff in Florida is going against the recommendations from scientists and government officials: masks will not be worn."]}
{"id": 1001501, "claim": "Florida sheriff backs his deputies and office visitors from wearing masks on a day his county broke records for covid-19 deaths", "label": "REFUTED", "evidence": ["(CNN)A mandate from a local sheriff in Florida is going against the recommendations from scientists and government officials: masks will not be worn."]}
{"id": 1001502, "claim": "Inference of sars-cov-2 spike-binding neutralizing antibody titers in sera from hospitalized covid-19 patients by using commercial enzyme and chemiluminescent immunoassays", "label": "SUPPORTED", "evidence": ["Conclusions: the suitability of SARS-CoV-2-S-IgG commercial immunoassays for inferring neutralizing activity of sera from hospitalized COVID-19 patients varies widely across tests and is influenced by the time of sera collection after the onset of symptoms.", "Overall, the degree correlation between antibody titers resulting in 50% virus neutralization (NtAb50) in the pseudotyped virus assay and SARS-CoV-2 IgG levels was strong for the Euroimmun SARS-CoV-2 IgG ELISA (Rho=0.73) and moderate for the remaining assays (Rho=0.48 to 0.59).", "Patients and Methods: Ninety sera from 51 hospitalized COVID-19 patients were assayed by a pseudotyped virus neutralization assay, the LIAISON SARS-CoV-2 S1/S2 IgG, the Euroimmun SARS-CoV-2 IgG ELISA, the MAGLUMI 2019-nCoV IgG and the COVID-19 ELISA IgG assays."]}
{"id": 1001503, "claim": "Inference of sars-cov-2 spike-binding neutralizing antibody titers in sera from non covid-19 patients by using commercial enzyme and chemiluminescent immunoassays", "label": "REFUTED", "evidence": ["Conclusions: the suitability of SARS-CoV-2-S-IgG commercial immunoassays for inferring neutralizing activity of sera from hospitalized COVID-19 patients varies widely across tests and is influenced by the time of sera collection after the onset of symptoms.", "Overall, the degree correlation between antibody titers resulting in 50% virus neutralization (NtAb50) in the pseudotyped virus assay and SARS-CoV-2 IgG levels was strong for the Euroimmun SARS-CoV-2 IgG ELISA (Rho=0.73) and moderate for the remaining assays (Rho=0.48 to 0.59).", "Patients and Methods: Ninety sera from 51 hospitalized COVID-19 patients were assayed by a pseudotyped virus neutralization assay, the LIAISON SARS-CoV-2 S1/S2 IgG, the Euroimmun SARS-CoV-2 IgG ELISA, the MAGLUMI 2019-nCoV IgG and the COVID-19 ELISA IgG assays."]}
{"id": 1001504, "claim": "Vitamin k2 deficiency link to covid-19 mortality explained in new paper", "label": "SUPPORTED", "evidence": ["It supports an earlier study published in April that evaluated MK-7 in 123 patients with COVID-19 and 184 controls, revealing a link between vitamin K2 deficiency and disease severity.", "The researchers write: Therefore, MK-7 deficiency can be a risk factor for increasing the severity of the COVID-19 disease and SARS-CoV-2 infected patients with comorbid conditions tend to develop acute manifestations. This paper strengthens the concept that vitamin K2 as MK-7 is a nutrient with substantial ability to protect pulmonary function during an active virus.", "According to the authors, a profound increase in inactive matrix Gla protein (MGP) levels were observed in COVID-19 patients, indicating a poor K2 status and associated increased risk of mortality from comorbidities (such as obesity, diabetes, hypertension and cardiovascular diseases).", "This is the second study that associates K2 status with outcomes in COVID-19 patients."]}
{"id": 1001505, "claim": "Vitamin k2 deficiency link to covid-19 not explained in new paper", "label": "REFUTED", "evidence": ["It supports an earlier study published in April that evaluated MK-7 in 123 patients with COVID-19 and 184 controls, revealing a link between vitamin K2 deficiency and disease severity.", "The researchers write: Therefore, MK-7 deficiency can be a risk factor for increasing the severity of the COVID-19 disease and SARS-CoV-2 infected patients with comorbid conditions tend to develop acute manifestations. This paper strengthens the concept that vitamin K2 as MK-7 is a nutrient with substantial ability to protect pulmonary function during an active virus.", "According to the authors, a profound increase in inactive matrix Gla protein (MGP) levels were observed in COVID-19 patients, indicating a poor K2 status and associated increased risk of mortality from comorbidities (such as obesity, diabetes, hypertension and cardiovascular diseases).", "This is the second study that associates K2 status with outcomes in COVID-19 patients."]}
{"id": 1001506, "claim": "Chemists discover the structure of a key coronavirus protein", "label": "SUPPORTED", "evidence": ["To determine its structure, the researchers embedded it into a lipid bilayer, similar to a cell membrane, and then analyzed it with NMR, which uses the magnetic properties of atomic nuclei to reveal the structures of the molecules containing those nuclei."]}
{"id": 1001507, "claim": "Researchs discover the structure of a key coronavirus protein", "label": "REFUTED", "evidence": ["To determine its structure, the researchers embedded it into a lipid bilayer, similar to a cell membrane, and then analyzed it with NMR, which uses the magnetic properties of atomic nuclei to reveal the structures of the molecules containing those nuclei."]}
{"id": 1001508, "claim": "Post-covid syndrome severely damages children 's hearts ; immense inflammation causing cardiac blood vessel dilation", "label": "SUPPORTED", "evidence": ["For instance, troponin, the marker used in adults to diagnose heart attacks, was 50 times its normal level in children with MIS-C. \"Evidence suggests that children with MIS-C have immense inflammation and potential tissue injury to the heart, and we will need to follow these children closely to understand what implications they may have in the long term,\" Dr. Moreira said.", "Source: University of Texas Health Science Center at San Antonio Multisystem inflammatory syndrome in children (MIS-C), believed to be linked to COVID-19, damages the heart to such an extent that some children will need lifelong monitoring and interventions, said the senior author of a medical literature review published Sept. 4 in EClinicalMedicine.", "\"Almost 90 per cent of the children (581) underwent an echocardiogram because they had such a significant cardiac manifestation of the disease,\" Moreira said.", "Citing an example of this abnormality, they said, the molecular marker troponin used in adults to diagnose heart attacks, was 50 times its normal level in children with MIS-C. \"Evidence suggests that children with MIS-C have immense inflammation and potential tissue injury to the heart, and we will need to follow these children closely to understand what implications they may have in the long term,\" Moreira said."]}
{"id": 1001509, "claim": "Post-covid syndrome severely protected children's hearts ; immense inflammation causing cardiac blood vessel dilation", "label": "REFUTED", "evidence": ["For instance, troponin, the marker used in adults to diagnose heart attacks, was 50 times its normal level in children with MIS-C. \"Evidence suggests that children with MIS-C have immense inflammation and potential tissue injury to the heart, and we will need to follow these children closely to understand what implications they may have in the long term,\" Dr. Moreira said.", "Source: University of Texas Health Science Center at San Antonio Multisystem inflammatory syndrome in children (MIS-C), believed to be linked to COVID-19, damages the heart to such an extent that some children will need lifelong monitoring and interventions, said the senior author of a medical literature review published Sept. 4 in EClinicalMedicine.", "\"Almost 90 per cent of the children (581) underwent an echocardiogram because they had such a significant cardiac manifestation of the disease,\" Moreira said.", "Citing an example of this abnormality, they said, the molecular marker troponin used in adults to diagnose heart attacks, was 50 times its normal level in children with MIS-C. \"Evidence suggests that children with MIS-C have immense inflammation and potential tissue injury to the heart, and we will need to follow these children closely to understand what implications they may have in the long term,\" Moreira said."]}
{"id": 1001510, "claim": "Proteomics uncovers immunosuppression in covid-19 patients with long disease course", "label": "SUPPORTED", "evidence": ["Here, we studied the sera proteomic dynamics in 37 COVID-19 patients over nine weeks, quantifying 2700 proteins with high quality."]}
{"id": 1001511, "claim": "Proteomics studiess immunosuppression in covid-19 patients with long disease course", "label": "REFUTED", "evidence": ["Here, we studied the sera proteomic dynamics in 37 COVID-19 patients over nine weeks, quantifying 2700 proteins with high quality."]}
{"id": 1001512, "claim": "Proteomics haves immunosuppression in covid-19 patients with long disease course", "label": "REFUTED", "evidence": ["Here, we studied the sera proteomic dynamics in 37 COVID-19 patients over nine weeks, quantifying 2700 proteins with high quality."]}
{"id": 1001513, "claim": "Proteomics mays immunosuppression in covid-19 patients with long disease course", "label": "REFUTED", "evidence": ["Here, we studied the sera proteomic dynamics in 37 COVID-19 patients over nine weeks, quantifying 2700 proteins with high quality."]}
{"id": 1001514, "claim": "Coronavirus vaccine to be tested on humans by june 1", "label": "SUPPORTED", "evidence": ["BUT AFTER scientists sequenced the DNA of the novel coronavirus causing the current worldwide outbreak, the MIGAL researchers examined it and found that the poultry coronavirus has high genetic similarity to the human one, and that it uses the same infection mechanism, which increased the likelihood of achieving an effective human vaccine in a very short period of time, Katz said.", "(photo credit: COURTESY OF MIGAL) Advertisement A team of Israeli researchers says that they are days away from completing the production of the active component of a coronavirus vaccine that could be tested on humans as early as June 1."]}
{"id": 1001515, "claim": "Coronavirus vaccine to be tested on animals by june 1", "label": "REFUTED", "evidence": ["BUT AFTER scientists sequenced the DNA of the novel coronavirus causing the current worldwide outbreak, the MIGAL researchers examined it and found that the poultry coronavirus has high genetic similarity to the human one, and that it uses the same infection mechanism, which increased the likelihood of achieving an effective human vaccine in a very short period of time, Katz said.", "(photo credit: COURTESY OF MIGAL) Advertisement A team of Israeli researchers says that they are days away from completing the production of the active component of a coronavirus vaccine that could be tested on humans as early as June 1."]}
{"id": 1001516, "claim": "Coronavirus vaccine to be tested on mice by june 1", "label": "REFUTED", "evidence": ["BUT AFTER scientists sequenced the DNA of the novel coronavirus causing the current worldwide outbreak, the MIGAL researchers examined it and found that the poultry coronavirus has high genetic similarity to the human one, and that it uses the same infection mechanism, which increased the likelihood of achieving an effective human vaccine in a very short period of time, Katz said.", "(photo credit: COURTESY OF MIGAL) Advertisement A team of Israeli researchers says that they are days away from completing the production of the active component of a coronavirus vaccine that could be tested on humans as early as June 1."]}
{"id": 1001517, "claim": "Coronavirus vaccine to be tested on humans by vaccination 1", "label": "REFUTED", "evidence": ["BUT AFTER scientists sequenced the DNA of the novel coronavirus causing the current worldwide outbreak, the MIGAL researchers examined it and found that the poultry coronavirus has high genetic similarity to the human one, and that it uses the same infection mechanism, which increased the likelihood of achieving an effective human vaccine in a very short period of time, Katz said.", "(photo credit: COURTESY OF MIGAL) Advertisement A team of Israeli researchers says that they are days away from completing the production of the active component of a coronavirus vaccine that could be tested on humans as early as June 1."]}
{"id": 1001518, "claim": "Covid-19 lung injury is not high altitude pulmonary edema", "label": "SUPPORTED", "evidence": ["Among the variety of theories put forth, one argument that has been made and amplified via social media is that COVID-19 lung injury is not like typical acute respiratory distress syndrome (ARDS) and instead is similar to high altitude pulmonary edema (HAPE) (Solaimanzadeh, 2020).", "6 Letter to the Editor: COVID-19 Lung Injury Is Different From High Altitude Pulmonary Edema Hermann Brugger , Buddha Basnyat , John Ellerton , Urs Hefti , Giacomo Strapazzon , and Ken Zafren 17 June 2020 "]}
{"id": 1001519, "claim": "Covid-19 lung injury is also high altitude pulmonary edema", "label": "REFUTED", "evidence": ["Among the variety of theories put forth, one argument that has been made and amplified via social media is that COVID-19 lung injury is not like typical acute respiratory distress syndrome (ARDS) and instead is similar to high altitude pulmonary edema (HAPE) (Solaimanzadeh, 2020).", "6 Letter to the Editor: COVID-19 Lung Injury Is Different From High Altitude Pulmonary Edema Hermann Brugger , Buddha Basnyat , John Ellerton , Urs Hefti , Giacomo Strapazzon , and Ken Zafren 17 June 2020 "]}
{"id": 1001520, "claim": "Covid-19 lung injury is very high altitude pulmonary edema", "label": "REFUTED", "evidence": ["Among the variety of theories put forth, one argument that has been made and amplified via social media is that COVID-19 lung injury is not like typical acute respiratory distress syndrome (ARDS) and instead is similar to high altitude pulmonary edema (HAPE) (Solaimanzadeh, 2020).", "6 Letter to the Editor: COVID-19 Lung Injury Is Different From High Altitude Pulmonary Edema Hermann Brugger , Buddha Basnyat , John Ellerton , Urs Hefti , Giacomo Strapazzon , and Ken Zafren 17 June 2020 "]}
{"id": 1001521, "claim": "Covid-19 lung injury is with high altitude pulmonary edema", "label": "REFUTED", "evidence": ["Among the variety of theories put forth, one argument that has been made and amplified via social media is that COVID-19 lung injury is not like typical acute respiratory distress syndrome (ARDS) and instead is similar to high altitude pulmonary edema (HAPE) (Solaimanzadeh, 2020).", "6 Letter to the Editor: COVID-19 Lung Injury Is Different From High Altitude Pulmonary Edema Hermann Brugger , Buddha Basnyat , John Ellerton , Urs Hefti , Giacomo Strapazzon , and Ken Zafren 17 June 2020 "]}
{"id": 1001522, "claim": "Glycosaminoglycan binding motif at s1/s2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus host cell entry", "label": "SUPPORTED", "evidence": ["Our discovery of a novel insertion of glycosaminoglycan (GAG)-binding motif at S1/S2 proteolytic cleavage site (681-686 (PRRARS)) and two other GAG-binding-like motifs within SARS-CoV-2 spike glycoprotein (SGP) led us to hypothesize that host cell surface GAGs might be involved in host cell entry of SARS-CoV-2.", "You are going to email the following Glycosaminoglycan binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.", "Share Glycosaminoglycan binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry So Young Kim, Weihua Jin, Amika Sood, David W. Montgomery, Oliver C. Grant, Mark M. Fuster, Li Fu, Jonathan S. Dordick, Robert J.", "Our discovery of a novel insertion of glycosaminoglycan (GAG)-binding motif at S1/S2 proteolytic cleavage site (681-686 (PRRARS)) and two other GAG-binding-like motifs within SARS-CoV-2 spike glycoprotein (SGP) led us to hypothesize that host cell surface GAGs may interact SARS-CoV-2 SGPs to facilitate host cell entry."]}
{"id": 1001523, "claim": "Glycosaminoglycan binding motif at s1/s2 proteolytic cleavage site on spike glycoprotein may inhibit novel coronavirus host cell entry", "label": "REFUTED", "evidence": ["Our discovery of a novel insertion of glycosaminoglycan (GAG)-binding motif at S1/S2 proteolytic cleavage site (681-686 (PRRARS)) and two other GAG-binding-like motifs within SARS-CoV-2 spike glycoprotein (SGP) led us to hypothesize that host cell surface GAGs might be involved in host cell entry of SARS-CoV-2.", "You are going to email the following Glycosaminoglycan binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.", "Share Glycosaminoglycan binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry So Young Kim, Weihua Jin, Amika Sood, David W. Montgomery, Oliver C. Grant, Mark M. Fuster, Li Fu, Jonathan S. Dordick, Robert J.", "Our discovery of a novel insertion of glycosaminoglycan (GAG)-binding motif at S1/S2 proteolytic cleavage site (681-686 (PRRARS)) and two other GAG-binding-like motifs within SARS-CoV-2 spike glycoprotein (SGP) led us to hypothesize that host cell surface GAGs may interact SARS-CoV-2 SGPs to facilitate host cell entry."]}
{"id": 1001524, "claim": "Danish researchers ' inhalation treatment of covid-19 passes tests in animals", "label": "SUPPORTED", "evidence": ["Today, Danish researchers from the University of Copenhagen and Rigshospitalet can together with the Norwegian company SoftOx Solutions announce that their inhalation treatment for COVID-19 is safe to use in animals.", "Futurity: Proof-of-Concept COVID-19 Vaccine Prevents Pneumonia in Mice Texas Public Radio: The COVID-19 Vaccine: Inside Americas Race For An Answer Nature: What the immune response to the coronavirus says about the prospects for a vaccine", "Biopharma Dive: Preclinical done right: The importance of using relevant animal models in gene therapy studies Brink News: How and When Will We Know That a COVID-19 Vaccine Is Safe and Effective?"]}
{"id": 1001525, "claim": "Danish researchers'inhalation treatment of covid-19 passes poorly in animals", "label": "REFUTED", "evidence": ["Today, Danish researchers from the University of Copenhagen and Rigshospitalet can together with the Norwegian company SoftOx Solutions announce that their inhalation treatment for COVID-19 is safe to use in animals.", "Futurity: Proof-of-Concept COVID-19 Vaccine Prevents Pneumonia in Mice Texas Public Radio: The COVID-19 Vaccine: Inside Americas Race For An Answer Nature: What the immune response to the coronavirus says about the prospects for a vaccine", "Biopharma Dive: Preclinical done right: The importance of using relevant animal models in gene therapy studies Brink News: How and When Will We Know That a COVID-19 Vaccine Is Safe and Effective?"]}
{"id": 1001526, "claim": "Speech by asymptomatic individuals may produce enough aerosolized particles to transmit infection", "label": "SUPPORTED", "evidence": ["(SACRAMENTO)  Normal speech by individuals who are asymptomatic but infected with coronavirus may produce enough aerosolized particles to transmit the infection, according to aerosol scientists at the University of California, Davis.", "The results confirmed that masks and face coverings are effective in reducing the spread of airborne particles.", "(Getty Images) Normal speech by individuals who are asymptomatic but infected with coronavirus may produce enough aerosolized particles to transmit the infection, according to aerosol scientists at the University of California, Davis."]}
{"id": 1001527, "claim": "Speech by asymptomatic individuals may produce enough aerosolized particles to prevent infection", "label": "REFUTED", "evidence": ["(SACRAMENTO)  Normal speech by individuals who are asymptomatic but infected with coronavirus may produce enough aerosolized particles to transmit the infection, according to aerosol scientists at the University of California, Davis.", "The results confirmed that masks and face coverings are effective in reducing the spread of airborne particles.", "(Getty Images) Normal speech by individuals who are asymptomatic but infected with coronavirus may produce enough aerosolized particles to transmit the infection, according to aerosol scientists at the University of California, Davis."]}
{"id": 1001528, "claim": "Speech by asymptomatic individuals may produce enough aerosolized particles to avoid infection", "label": "REFUTED", "evidence": ["(SACRAMENTO)  Normal speech by individuals who are asymptomatic but infected with coronavirus may produce enough aerosolized particles to transmit the infection, according to aerosol scientists at the University of California, Davis.", "The results confirmed that masks and face coverings are effective in reducing the spread of airborne particles.", "(Getty Images) Normal speech by individuals who are asymptomatic but infected with coronavirus may produce enough aerosolized particles to transmit the infection, according to aerosol scientists at the University of California, Davis."]}
{"id": 1001529, "claim": "Speech by asymptomatic individuals may produce enough aerosolized particles to control infection", "label": "REFUTED", "evidence": ["(SACRAMENTO)  Normal speech by individuals who are asymptomatic but infected with coronavirus may produce enough aerosolized particles to transmit the infection, according to aerosol scientists at the University of California, Davis.", "The results confirmed that masks and face coverings are effective in reducing the spread of airborne particles.", "(Getty Images) Normal speech by individuals who are asymptomatic but infected with coronavirus may produce enough aerosolized particles to transmit the infection, according to aerosol scientists at the University of California, Davis."]}
{"id": 1001530, "claim": "Researchers show children are silent spreaders of virus that causes covid-19", "label": "SUPPORTED", "evidence": ["According to the authors, this finding suggests that children can carry a high viral load, meaning they are more contagious, regardless of their susceptibility to developing COVID-19 infection.", "The researchers note that although children with COVID-19 are not as likely to become as seriously ill as adults, as asymptomatic carriers or carriers with few symptoms attending school, they can spread infection and bring the virus into their homes."]}
{"id": 1001531, "claim": "Researchers show mutations are silent spreaders of virus that causes covid-19", "label": "REFUTED", "evidence": ["According to the authors, this finding suggests that children can carry a high viral load, meaning they are more contagious, regardless of their susceptibility to developing COVID-19 infection.", "The researchers note that although children with COVID-19 are not as likely to become as seriously ill as adults, as asymptomatic carriers or carriers with few symptoms attending school, they can spread infection and bring the virus into their homes."]}
{"id": 1001532, "claim": "Researchers show viruses are silent spreaders of virus that causes covid-19", "label": "REFUTED", "evidence": ["According to the authors, this finding suggests that children can carry a high viral load, meaning they are more contagious, regardless of their susceptibility to developing COVID-19 infection.", "The researchers note that although children with COVID-19 are not as likely to become as seriously ill as adults, as asymptomatic carriers or carriers with few symptoms attending school, they can spread infection and bring the virus into their homes."]}
{"id": 1001533, "claim": "Keep staying home , you are saving lives inder singh , kinsa", "label": "SUPPORTED", "evidence": ["People need to know their sacrifices are helping, said Inder Singh, founder of Kinsa."]}
{"id": 1001534, "claim": "Older adults with existing depression show resilience during the pandemic", "label": "SUPPORTED", "evidence": ["\"But what we learned is that older adults with depression can be resilient.", "They told us that coping with chronic depression taught them to be resilient\"."]}
{"id": 1001535, "claim": "Older adults without existing depression show resilience during the pandemic", "label": "REFUTED", "evidence": ["\"But what we learned is that older adults with depression can be resilient.", "They told us that coping with chronic depression taught them to be resilient\"."]}
{"id": 1001536, "claim": "Older adults with existing infections show resilience during the pandemic", "label": "REFUTED", "evidence": ["\"But what we learned is that older adults with depression can be resilient.", "They told us that coping with chronic depression taught them to be resilient\"."]}
{"id": 1001537, "claim": "Nobel laureate predicts a quicker coronavirus recovery", "label": "SUPPORTED", "evidence": ["A Nobel laureate and Stanford biophysicist estimates the United States may see a downturn in new coronavirus cases sooner than health experts have predicted, according to the Los Angeles Times.", "The Nobel laureate accurately predicted the number of coronavirus cases and deaths in China."]}
{"id": 1001538, "claim": "Nobel laureate predicts a few coronavirus recovery", "label": "REFUTED", "evidence": ["A Nobel laureate and Stanford biophysicist estimates the United States may see a downturn in new coronavirus cases sooner than health experts have predicted, according to the Los Angeles Times.", "The Nobel laureate accurately predicted the number of coronavirus cases and deaths in China."]}
{"id": 1001539, "claim": "Israel to begin clinical trials of brilife covid-19 vaccine !", "label": "SUPPORTED", "evidence": ["By Abigail Klein Leichman October 26, 2020, 11:01 am Vials of the experimental Covid-19 vaccine from the Israel Institute for Biological Research.", "By Abigail Klein Leichman Vials of the experimental COVID-19 vaccine from the Israel Institute for Biological Research.", "The Israel Institute for Biological Research (IIBR) began animal trials for its BriLife vaccine in March.", "Vials of BriLife, the experimental Covid-19 vaccine from the Israel Institute for Biological Research."]}
{"id": 1001540, "claim": "Israel to complete clinical trials of brilife covid-19 vaccine!", "label": "REFUTED", "evidence": ["By Abigail Klein Leichman October 26, 2020, 11:01 am Vials of the experimental Covid-19 vaccine from the Israel Institute for Biological Research.", "By Abigail Klein Leichman Vials of the experimental COVID-19 vaccine from the Israel Institute for Biological Research.", "The Israel Institute for Biological Research (IIBR) began animal trials for its BriLife vaccine in March.", "Vials of BriLife, the experimental Covid-19 vaccine from the Israel Institute for Biological Research."]}
{"id": 1001541, "claim": "Commonly used steroid reduces risk of death in sickest coronavirus patients , preliminary study results suggest", "label": "SUPPORTED", "evidence": ["If the finding is borne out, the drug, a steroid called dexamethasone, would be the first treatment shown to reduce mortality in severely ill patients.", "This story was first published on CNN.com,\"Steroid reduces risk of dying in sickest coronavirus patients, preliminary study results suggest\" ", "Your coronavirus questions, answered The two lead investigators of the Recovery Trial, a large UK-based trial investigating potential Covid-19 treatments, announced to reporters in a virtual press conference on Tuesday that a low-dose regimen of dexamethasone for 10 days was found to reduce the risk of death by a third among hospitalized patients requiring ventilation in the trial."]}
{"id": 1001542, "claim": "Commonly used steroid increased risk of death in sickest coronavirus patients, preliminary study results suggest", "label": "REFUTED", "evidence": ["If the finding is borne out, the drug, a steroid called dexamethasone, would be the first treatment shown to reduce mortality in severely ill patients.", "This story was first published on CNN.com,\"Steroid reduces risk of dying in sickest coronavirus patients, preliminary study results suggest\" ", "Your coronavirus questions, answered The two lead investigators of the Recovery Trial, a large UK-based trial investigating potential Covid-19 treatments, announced to reporters in a virtual press conference on Tuesday that a low-dose regimen of dexamethasone for 10 days was found to reduce the risk of death by a third among hospitalized patients requiring ventilation in the trial."]}
{"id": 1001543, "claim": "Commonly used steroid higher risk of death in sickest coronavirus patients, preliminary study results suggest", "label": "REFUTED", "evidence": ["If the finding is borne out, the drug, a steroid called dexamethasone, would be the first treatment shown to reduce mortality in severely ill patients.", "This story was first published on CNN.com,\"Steroid reduces risk of dying in sickest coronavirus patients, preliminary study results suggest\" ", "Your coronavirus questions, answered The two lead investigators of the Recovery Trial, a large UK-based trial investigating potential Covid-19 treatments, announced to reporters in a virtual press conference on Tuesday that a low-dose regimen of dexamethasone for 10 days was found to reduce the risk of death by a third among hospitalized patients requiring ventilation in the trial."]}
{"id": 1001544, "claim": "Survey suggests aerosol is significant form of covid-19 transmission", "label": "SUPPORTED", "evidence": ["The data in both countries, argue the researchers, could suggest that aerosol transmission is very likely, with taller individuals at higher risk - something that would not be expected if transmission was exclusively through droplets.", "Taking both samples together, being tall more than doubled the probability of having a COVID 19 medical diagnosis or positive test for people over 6ft.", "> The results of this survey in terms of associations between height and > diagnosis suggest downward droplet transmission is not the only transmission > mechanism and aerosol transmission is possible Professor Evan Kontopantelis  Follow me on Twitter (opens in new window) Professor Evan Kontopantelis, from The University of Manchester, said: \"The results of this survey in terms of associations between height and diagnosis suggest downward droplet transmission is not the only transmission mechanism and aerosol transmission is possible."]}
{"id": 1001545, "claim": "Survey suggests aerosol is no form of covid-19 transmission", "label": "REFUTED", "evidence": ["The data in both countries, argue the researchers, could suggest that aerosol transmission is very likely, with taller individuals at higher risk - something that would not be expected if transmission was exclusively through droplets.", "Taking both samples together, being tall more than doubled the probability of having a COVID 19 medical diagnosis or positive test for people over 6ft.", "> The results of this survey in terms of associations between height and > diagnosis suggest downward droplet transmission is not the only transmission > mechanism and aerosol transmission is possible Professor Evan Kontopantelis  Follow me on Twitter (opens in new window) Professor Evan Kontopantelis, from The University of Manchester, said: \"The results of this survey in terms of associations between height and diagnosis suggest downward droplet transmission is not the only transmission mechanism and aerosol transmission is possible."]}
{"id": 1001546, "claim": "Elevation of plasma angiotensin ii level is a potential pathogenesis for the critically ill covid-19 patients", "label": "SUPPORTED", "evidence": ["h The plasma Ang II positive rate in the critically ill COVID-19 cases was significantly higher than that of control.", "b The plasma Ang II concentration in the critically ill COVID-19 cases and severe COVID-19 cases was significantly higher than that of the mild COVID-19 cases.", "Therefore, elevation of Ang II triggered by interaction between ACE2 and S protein of SARS-CoV-2 may be important pathogenic factors for critically ill COVID-19 patients.", "Plasma Ang II level in critically ill COVID-19 patients was significantly higher than that of control and those with mild COVID-19 symptoms (Fig."]}
{"id": 1001547, "claim": "Loss of plasma angiotensin ii level is a potential pathogenesis for the critically ill covid-19 patients", "label": "REFUTED", "evidence": ["h The plasma Ang II positive rate in the critically ill COVID-19 cases was significantly higher than that of control.", "b The plasma Ang II concentration in the critically ill COVID-19 cases and severe COVID-19 cases was significantly higher than that of the mild COVID-19 cases.", "Therefore, elevation of Ang II triggered by interaction between ACE2 and S protein of SARS-CoV-2 may be important pathogenic factors for critically ill COVID-19 patients.", "Plasma Ang II level in critically ill COVID-19 patients was significantly higher than that of control and those with mild COVID-19 symptoms (Fig."]}
{"id": 1001548, "claim": "Inhibition of plasma angiotensin ii level is a potential pathogenesis for the critically ill covid-19 patients", "label": "REFUTED", "evidence": ["h The plasma Ang II positive rate in the critically ill COVID-19 cases was significantly higher than that of control.", "b The plasma Ang II concentration in the critically ill COVID-19 cases and severe COVID-19 cases was significantly higher than that of the mild COVID-19 cases.", "Therefore, elevation of Ang II triggered by interaction between ACE2 and S protein of SARS-CoV-2 may be important pathogenic factors for critically ill COVID-19 patients.", "Plasma Ang II level in critically ill COVID-19 patients was significantly higher than that of control and those with mild COVID-19 symptoms (Fig."]}
{"id": 1001549, "claim": "Lack of plasma angiotensin ii level is a potential pathogenesis for the critically ill covid-19 patients", "label": "REFUTED", "evidence": ["h The plasma Ang II positive rate in the critically ill COVID-19 cases was significantly higher than that of control.", "b The plasma Ang II concentration in the critically ill COVID-19 cases and severe COVID-19 cases was significantly higher than that of the mild COVID-19 cases.", "Therefore, elevation of Ang II triggered by interaction between ACE2 and S protein of SARS-CoV-2 may be important pathogenic factors for critically ill COVID-19 patients.", "Plasma Ang II level in critically ill COVID-19 patients was significantly higher than that of control and those with mild COVID-19 symptoms (Fig."]}
{"id": 1001550, "claim": "Israeli health ministry approves experimental treatments for coronavirus", "label": "SUPPORTED", "evidence": ["It was the first time the countrys attorney general has allowed the use of a generic version of a patent-protected drug in Israel, where there are 529 confirmed coronavirus cases.", "A Jerusalem Post article, Health Ministry approves experimental treatments for coronavirus, published on 16 March 2020, provides more context into the Israeli Health Ministry's response to the covid-19 pandemic."]}
{"id": 1001551, "claim": "Global health ministry approves experimental treatments for coronavirus", "label": "REFUTED", "evidence": ["It was the first time the countrys attorney general has allowed the use of a generic version of a patent-protected drug in Israel, where there are 529 confirmed coronavirus cases.", "A Jerusalem Post article, Health Ministry approves experimental treatments for coronavirus, published on 16 March 2020, provides more context into the Israeli Health Ministry's response to the covid-19 pandemic."]}
{"id": 1001552, "claim": "Human health ministry approves experimental treatments for coronavirus", "label": "REFUTED", "evidence": ["It was the first time the countrys attorney general has allowed the use of a generic version of a patent-protected drug in Israel, where there are 529 confirmed coronavirus cases.", "A Jerusalem Post article, Health Ministry approves experimental treatments for coronavirus, published on 16 March 2020, provides more context into the Israeli Health Ministry's response to the covid-19 pandemic."]}
{"id": 1001553, "claim": "Safety and immunogenicity study of 2019-ncov vaccine to prevent sars-cov-2 infection", "label": "SUPPORTED", "evidence": ["This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2.", "We aimed to assess the safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidate, BBIBP-CorV, in humans."]}
{"id": 1001554, "claim": "Safety and immunogenicity study of p-ncov vaccine to prevent sars-cov-2 infection", "label": "REFUTED", "evidence": ["This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2.", "We aimed to assess the safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidate, BBIBP-CorV, in humans."]}
{"id": 1001555, "claim": "Safety and immunogenicity study of pre-ncov vaccine to prevent sars-cov-2 infection", "label": "REFUTED", "evidence": ["This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2.", "We aimed to assess the safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidate, BBIBP-CorV, in humans."]}
{"id": 1001556, "claim": "Safety and immunogenicity study of c-ncov vaccine to prevent sars-cov-2 infection", "label": "REFUTED", "evidence": ["This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2.", "We aimed to assess the safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidate, BBIBP-CorV, in humans."]}
{"id": 1001557, "claim": "Fda approves expanded access to wilmington company 's experimental covid-19 therapy", "label": "SUPPORTED", "evidence": ["The protocol specifically makes the treatment available to pregnant women.", "Dr. Jonathan Javitt, chairman and CEO of NeuroRx, said the company's application covers the same type of coronavirus patients whom the FDA has already allowed to receive treatment under an expanded access protocol authorized by the federal agency in July."]}
{"id": 1001558, "claim": "Fda approves no access to wilmington company's experimental covid-19 therapy", "label": "REFUTED", "evidence": ["The protocol specifically makes the treatment available to pregnant women.", "Dr. Jonathan Javitt, chairman and CEO of NeuroRx, said the company's application covers the same type of coronavirus patients whom the FDA has already allowed to receive treatment under an expanded access protocol authorized by the federal agency in July."]}
{"id": 1001559, "claim": "Blood tests show 14 % of people are now immune to covid-19 in one town in germany", "label": "SUPPORTED", "evidence": ["In one German town a preliminary answer is in: about 14%."]}
{"id": 1001560, "claim": "Blood tests show 14 % of people are less immune to covid-19 in one town in germany", "label": "REFUTED", "evidence": ["In one German town a preliminary answer is in: about 14%."]}
{"id": 1001561, "claim": "Blood tests show 14 % of people are now immune to covid-19 in each town in germany", "label": "REFUTED", "evidence": ["In one German town a preliminary answer is in: about 14%."]}
{"id": 1001562, "claim": "Blood tests show 14 % of people are not immune to covid-19 in one town in germany", "label": "REFUTED", "evidence": ["In one German town a preliminary answer is in: about 14%."]}
{"id": 1001563, "claim": "Immune system shows abnormal response to covid-19", "label": "SUPPORTED", "evidence": ["Some people gravely ill with COVID-19 have tissue damage inflicted by their own immune response, and also show increased activity of immune-system molecules and cells regulated by a protein called IL-6.", "Complex immune dysregulation in COVID-19 patients with severe respiratory failure.", "Dysregulation of immune response in patients with COVID-19 in Wuhan, China."]}
{"id": 1001564, "claim": "Immune system shows host response to covid-19", "label": "REFUTED", "evidence": ["Some people gravely ill with COVID-19 have tissue damage inflicted by their own immune response, and also show increased activity of immune-system molecules and cells regulated by a protein called IL-6.", "Complex immune dysregulation in COVID-19 patients with severe respiratory failure.", "Dysregulation of immune response in patients with COVID-19 in Wuhan, China."]}
{"id": 1001565, "claim": "A discrete-time-evolution model to forecast progress of covid-19 outbreak", "label": "SUPPORTED", "evidence": ["We propose that the daily evolution of Covid-19 can be modelled by the following discrete-time equations: (1) (2) (3) (4) where t means the day, T means the duration of asymptomatic (incubation time) and symptomatic infected phases, both herein assumed to be 14 days.", "We hope the present model can contribute to global efforts made to understand and control the Covid-19 pandemic.", "Therefore, as current (in case of Covid-19) and future, yet unknown, infectious diseases will continue to impact us, the development of simple but efficient models to track pandemics evolution based on daily updated data may be valuable not only for Covid-19 but also for potential future outbreaks to come."]}
{"id": 1001566, "claim": "A discrete-non-evolution model to forecast progress of covid-19 outbreak", "label": "REFUTED", "evidence": ["We propose that the daily evolution of Covid-19 can be modelled by the following discrete-time equations: (1) (2) (3) (4) where t means the day, T means the duration of asymptomatic (incubation time) and symptomatic infected phases, both herein assumed to be 14 days.", "We hope the present model can contribute to global efforts made to understand and control the Covid-19 pandemic.", "Therefore, as current (in case of Covid-19) and future, yet unknown, infectious diseases will continue to impact us, the development of simple but efficient models to track pandemics evolution based on daily updated data may be valuable not only for Covid-19 but also for potential future outbreaks to come."]}
{"id": 1001567, "claim": "A discrete-host-evolution model to forecast progress of covid-19 outbreak", "label": "REFUTED", "evidence": ["We propose that the daily evolution of Covid-19 can be modelled by the following discrete-time equations: (1) (2) (3) (4) where t means the day, T means the duration of asymptomatic (incubation time) and symptomatic infected phases, both herein assumed to be 14 days.", "We hope the present model can contribute to global efforts made to understand and control the Covid-19 pandemic.", "Therefore, as current (in case of Covid-19) and future, yet unknown, infectious diseases will continue to impact us, the development of simple but efficient models to track pandemics evolution based on daily updated data may be valuable not only for Covid-19 but also for potential future outbreaks to come."]}
{"id": 1001568, "claim": "A discrete-and-evolution model to forecast progress of covid-19 outbreak", "label": "REFUTED", "evidence": ["We propose that the daily evolution of Covid-19 can be modelled by the following discrete-time equations: (1) (2) (3) (4) where t means the day, T means the duration of asymptomatic (incubation time) and symptomatic infected phases, both herein assumed to be 14 days.", "We hope the present model can contribute to global efforts made to understand and control the Covid-19 pandemic.", "Therefore, as current (in case of Covid-19) and future, yet unknown, infectious diseases will continue to impact us, the development of simple but efficient models to track pandemics evolution based on daily updated data may be valuable not only for Covid-19 but also for potential future outbreaks to come."]}
{"id": 1001569, "claim": "A cross-reactive human iga monoclonal antibody blocks sars-cov-2 spike-ace2 interaction", "label": "SUPPORTED", "evidence": ["A human monoclonal antibody blocking SARS-CoV-2 infection."]}
{"id": 1001570, "claim": "A cross-reactive mouse iga monoclonal antibody blocks sars-cov-2 spike-ace2 interaction", "label": "REFUTED", "evidence": ["A human monoclonal antibody blocking SARS-CoV-2 infection."]}
{"id": 1001571, "claim": "Humanized covid-19 decoy antibody effectively blocks viral entry and prevents sars-cov-2 infection", "label": "SUPPORTED", "evidence": ["Proposed model for the role of the decoy antibody ACE2Fc in SARSCoV2 entry and infection The decoy antibody (ACE2Fc) not only reduces SARSCoV2 infection but also decreases TNFα secretion and ADAM17 phosphorylation mediated by angiotensin II."]}
{"id": 1001572, "claim": "Humanized covid-19 decoy antibody effectively blocks viral entry and prevents prs-cov-2 infection", "label": "REFUTED", "evidence": ["Proposed model for the role of the decoy antibody ACE2Fc in SARSCoV2 entry and infection The decoy antibody (ACE2Fc) not only reduces SARSCoV2 infection but also decreases TNFα secretion and ADAM17 phosphorylation mediated by angiotensin II."]}
{"id": 1001573, "claim": "Humanized covid-19 decoy antibody effectively blocks viral entry and prevents aces-cov-2 infection", "label": "REFUTED", "evidence": ["Proposed model for the role of the decoy antibody ACE2Fc in SARSCoV2 entry and infection The decoy antibody (ACE2Fc) not only reduces SARSCoV2 infection but also decreases TNFα secretion and ADAM17 phosphorylation mediated by angiotensin II."]}
{"id": 1001574, "claim": "Humanized covid-19 decoy antibody effectively blocks viral entry and prevents aps-cov-2 infection", "label": "REFUTED", "evidence": ["Proposed model for the role of the decoy antibody ACE2Fc in SARSCoV2 entry and infection The decoy antibody (ACE2Fc) not only reduces SARSCoV2 infection but also decreases TNFα secretion and ADAM17 phosphorylation mediated by angiotensin II."]}
{"id": 1001575, "claim": "Human mast cells enhance interleukin-6 production by quiescent and lipopolysaccharide-stimulated human coronary artery endothelial cells", "label": "SUPPORTED", "evidence": ["Histamine-induced production of interleukin-6 and interleukin-8 by human coronary artery endothelial cells is enhanced by endotoxin and tumor necrosis factor-alpha.", "Endothelial cells (10,000 cells/well) Figure 2 Mast cells dose-dependently potentiate LPS-induced IL-6 production by HCAEC.", "Endothelial cells (10,000 cells/well) Figure 1 Mast cells potentiate LPS- induced IL-6 production by HCAEC."]}
{"id": 1001576, "claim": "Human mast cells inhibit interleukin-6 production by quiescent and lipopolysaccharide-stimulated human coronary artery endothelial cells", "label": "REFUTED", "evidence": ["Histamine-induced production of interleukin-6 and interleukin-8 by human coronary artery endothelial cells is enhanced by endotoxin and tumor necrosis factor-alpha.", "Endothelial cells (10,000 cells/well) Figure 2 Mast cells dose-dependently potentiate LPS-induced IL-6 production by HCAEC.", "Endothelial cells (10,000 cells/well) Figure 1 Mast cells potentiate LPS- induced IL-6 production by HCAEC."]}
{"id": 1001577, "claim": "Human mast cells suppress interleukin-6 production by quiescent and lipopolysaccharide-stimulated human coronary artery endothelial cells", "label": "REFUTED", "evidence": ["Histamine-induced production of interleukin-6 and interleukin-8 by human coronary artery endothelial cells is enhanced by endotoxin and tumor necrosis factor-alpha.", "Endothelial cells (10,000 cells/well) Figure 2 Mast cells dose-dependently potentiate LPS-induced IL-6 production by HCAEC.", "Endothelial cells (10,000 cells/well) Figure 1 Mast cells potentiate LPS- induced IL-6 production by HCAEC."]}
{"id": 1001578, "claim": "Early intervention is the key to success in covid-19 control", "label": "SUPPORTED", "evidence": ["The timing of interventions is crucial to their success."]}
{"id": 1001579, "claim": "Early intervention is the risk to success in covid-19 control", "label": "REFUTED", "evidence": ["The timing of interventions is crucial to their success."]}
{"id": 1001580, "claim": "Further intervention is the key to success in covid-19 control", "label": "REFUTED", "evidence": ["The timing of interventions is crucial to their success."]}
{"id": 1001581, "claim": "Early intervention is the challenge to success in covid-19 control", "label": "REFUTED", "evidence": ["The timing of interventions is crucial to their success."]}
{"id": 1001582, "claim": "Tests indicate coronavirus can survive in the air", "label": "SUPPORTED", "evidence": ["A study awaiting peer review from scientists at Princeton University, the University of California-Los Angeles and the National Institutes of Health (NIH) posted online Wednesday indicated that the COVID-19 virus could remain viable in the air \"up to 3 hours post aerosolization,\" while remaining alive on plastic and other surfaces for up to three days.", "ADVERTISEMENT The test results suggest that humans could be infected by the disease simply carried through the air or on a solid surface, even if direct contact with an infected person does not occur.", "\"Our results indicate that aerosol and fomite transmission of HCoV-19 is plausible, as the virus can remain viable in aerosols for multiple hours and on surfaces up to days,\" reads the study's abstract."]}
{"id": 1001583, "claim": "Tests indicate coronavirus cannot survive in the air", "label": "REFUTED", "evidence": ["A study awaiting peer review from scientists at Princeton University, the University of California-Los Angeles and the National Institutes of Health (NIH) posted online Wednesday indicated that the COVID-19 virus could remain viable in the air \"up to 3 hours post aerosolization,\" while remaining alive on plastic and other surfaces for up to three days.", "ADVERTISEMENT The test results suggest that humans could be infected by the disease simply carried through the air or on a solid surface, even if direct contact with an infected person does not occur.", "\"Our results indicate that aerosol and fomite transmission of HCoV-19 is plausible, as the virus can remain viable in aerosols for multiple hours and on surfaces up to days,\" reads the study's abstract."]}
{"id": 1001584, "claim": "Vaccination is the only acceptable path to herd immunity.", "label": "SUPPORTED", "evidence": ["Vaccinate those people and the the death counts and hospitalization rates will drop below that of the flu and we won't have a health emergency any more, regardless of where we are with respect to herd immunity.", "The vaccination campaign should be conducted in such a manner that harm is minimized, which is a bit different from the fastest path to total victory.", "22 Jan 2021 When a majority of the community is immune to an infectious disease, whether through vaccination or prior illness, it reduces the spread of the disease from one person to another, leading to herd immunity."]}
{"id": 1001585, "claim": "Vaccination is the least acceptable path to herd immunity.", "label": "REFUTED", "evidence": ["Vaccinate those people and the the death counts and hospitalization rates will drop below that of the flu and we won't have a health emergency any more, regardless of where we are with respect to herd immunity.", "The vaccination campaign should be conducted in such a manner that harm is minimized, which is a bit different from the fastest path to total victory.", "22 Jan 2021 When a majority of the community is immune to an infectious disease, whether through vaccination or prior illness, it reduces the spread of the disease from one person to another, leading to herd immunity."]}
{"id": 1001586, "claim": "Vaccination is the only acceptable path to herd control.", "label": "REFUTED", "evidence": ["Vaccinate those people and the the death counts and hospitalization rates will drop below that of the flu and we won't have a health emergency any more, regardless of where we are with respect to herd immunity.", "The vaccination campaign should be conducted in such a manner that harm is minimized, which is a bit different from the fastest path to total victory.", "22 Jan 2021 When a majority of the community is immune to an infectious disease, whether through vaccination or prior illness, it reduces the spread of the disease from one person to another, leading to herd immunity."]}
{"id": 1001587, "claim": "Vaccination is the only acceptable path to herd exposure.", "label": "REFUTED", "evidence": ["Vaccinate those people and the the death counts and hospitalization rates will drop below that of the flu and we won't have a health emergency any more, regardless of where we are with respect to herd immunity.", "The vaccination campaign should be conducted in such a manner that harm is minimized, which is a bit different from the fastest path to total victory.", "22 Jan 2021 When a majority of the community is immune to an infectious disease, whether through vaccination or prior illness, it reduces the spread of the disease from one person to another, leading to herd immunity."]}
{"id": 1001588, "claim": "Salivadirect receives fda eua on 8/15", "label": "SUPPORTED", "evidence": ["While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection.", "Additionally, the SalivaDirect methodology has been validated and authorized for use with different combinations of commonly used reagents and instruments, meaning the test could be used broadly in most high-complexity labs.", "most accurate of currently available saliva tests at about 90% accuracy."]}
{"id": 1001589, "claim": "Undirect receives fda eua on 8/15", "label": "REFUTED", "evidence": ["While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection.", "Additionally, the SalivaDirect methodology has been validated and authorized for use with different combinations of commonly used reagents and instruments, meaning the test could be used broadly in most high-complexity labs.", "most accurate of currently available saliva tests at about 90% accuracy."]}
{"id": 1001590, "claim": "Salivadirect receives state eua on 8/15", "label": "REFUTED", "evidence": ["While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection.", "Additionally, the SalivaDirect methodology has been validated and authorized for use with different combinations of commonly used reagents and instruments, meaning the test could be used broadly in most high-complexity labs.", "most accurate of currently available saliva tests at about 90% accuracy."]}
{"id": 1001591, "claim": "Redirect receives fda eua on 8/15", "label": "REFUTED", "evidence": ["While FDA has seen variable performance in tests using saliva, Yale School of Public Health submitted data with its EUA request from which the FDA determined that Yales test meets the criteria for emergency authorization when used to test saliva samples for SARS-CoV-2, the virus that causes COVID-19 infection.", "Additionally, the SalivaDirect methodology has been validated and authorized for use with different combinations of commonly used reagents and instruments, meaning the test could be used broadly in most high-complexity labs.", "most accurate of currently available saliva tests at about 90% accuracy."]}
{"id": 1001592, "claim": "The ground level ozone concentration is inversely correlated with the number of covid-19 cases in warsaw , poland", "label": "SUPPORTED", "evidence": ["The obtained results show an inverse correlation between ground level ozone concentration and the daily number of COVID-19 cases."]}
{"id": 1001593, "claim": "The ground level ozone concentration is equally correlated with the number of covid-19 cases in warsaw, poland", "label": "REFUTED", "evidence": ["The obtained results show an inverse correlation between ground level ozone concentration and the daily number of COVID-19 cases."]}
{"id": 1001594, "claim": "The ground level ozone concentration is equivalently correlated with the number of covid-19 cases in warsaw, poland", "label": "REFUTED", "evidence": ["The obtained results show an inverse correlation between ground level ozone concentration and the daily number of COVID-19 cases."]}
{"id": 1001595, "claim": "The ground level ozone concentration is greaterly correlated with the number of covid-19 cases in warsaw, poland", "label": "REFUTED", "evidence": ["The obtained results show an inverse correlation between ground level ozone concentration and the daily number of COVID-19 cases."]}
{"id": 1001596, "claim": "Identification of unique mutations in sars-cov-2 strains isolated from india suggests its attenuated pathotype", "label": "SUPPORTED", "evidence": ["In this study, we sequenced and analyzed the genomic information of the SARS-CoV-2 isolates from two infected Indian patients and explored the possible implications of point mutations in its biology.", "In addition to multiple point mutations, we found a remarkable similarity between relatively common mutations of 36-nucleotide deletion in ORF8 of SARS-CoV-2."]}
{"id": 1001597, "claim": "Identification of unique mutations in sars-cov-2 strains isolated from europe suggests its attenuated pathotype", "label": "REFUTED", "evidence": ["In this study, we sequenced and analyzed the genomic information of the SARS-CoV-2 isolates from two infected Indian patients and explored the possible implications of point mutations in its biology.", "In addition to multiple point mutations, we found a remarkable similarity between relatively common mutations of 36-nucleotide deletion in ORF8 of SARS-CoV-2."]}
{"id": 1001598, "claim": "Identification of unique mutations in sars-cov-2 strains isolated from brazil suggests its attenuated pathotype", "label": "REFUTED", "evidence": ["In this study, we sequenced and analyzed the genomic information of the SARS-CoV-2 isolates from two infected Indian patients and explored the possible implications of point mutations in its biology.", "In addition to multiple point mutations, we found a remarkable similarity between relatively common mutations of 36-nucleotide deletion in ORF8 of SARS-CoV-2."]}
{"id": 1001599, "claim": "Identification of unique mutations in sars-cov-2 strains isolated from china suggests its attenuated pathotype", "label": "REFUTED", "evidence": ["In this study, we sequenced and analyzed the genomic information of the SARS-CoV-2 isolates from two infected Indian patients and explored the possible implications of point mutations in its biology.", "In addition to multiple point mutations, we found a remarkable similarity between relatively common mutations of 36-nucleotide deletion in ORF8 of SARS-CoV-2."]}
{"id": 1001600, "claim": "Government bureau to examine covid antibody obtainment system as suggestions finished", "label": "SUPPORTED", "evidence": ["We need to make game plans to get the antibody at the soonest."]}
{"id": 1001601, "claim": "Government bureau to examine covid antibody obtainment system as control finished", "label": "REFUTED", "evidence": ["We need to make game plans to get the antibody at the soonest."]}
{"id": 1001602, "claim": "An inflammatory cytokine signature helps predict covid-19 severity and death", "label": "SUPPORTED", "evidence": ["Several studies have revealed that the hyper-inflammatory response induced by SARS-CoV-2 is a major cause of disease severity and death in infected patients.", "Importantly, when adjusting for disease severity score, common laboratory inflammation markers, hypoxia and other vitals, demographics, and a range of comorbidities, IL-6 and TNF-α serum levels remained independent and significant predictors of disease severity and death."]}
{"id": 1001603, "claim": "An inflammatory cytokine signature cannot predict covid-19 severity and death", "label": "REFUTED", "evidence": ["Several studies have revealed that the hyper-inflammatory response induced by SARS-CoV-2 is a major cause of disease severity and death in infected patients.", "Importantly, when adjusting for disease severity score, common laboratory inflammation markers, hypoxia and other vitals, demographics, and a range of comorbidities, IL-6 and TNF-α serum levels remained independent and significant predictors of disease severity and death."]}
{"id": 1001604, "claim": "An ultra-potent synthetic nanobody neutralizes sars-cov-2 by locking spike into an inactive conformation", "label": "SUPPORTED", "evidence": ["Cryogenic electron microscopy (cryo-EM) revealed that one exceptionally stable nanobody, Nb6, binds Spike in a fully inactive conformation with its receptor binding domains (RBDs) locked into their inaccessible down-state, incapable of binding ACE2."]}
{"id": 1001605, "claim": "An ultra-potent synthetic nanobody neutralizes sars-cov-2 by locking light into an inactive conformation", "label": "REFUTED", "evidence": ["Cryogenic electron microscopy (cryo-EM) revealed that one exceptionally stable nanobody, Nb6, binds Spike in a fully inactive conformation with its receptor binding domains (RBDs) locked into their inaccessible down-state, incapable of binding ACE2."]}
{"id": 1001606, "claim": "An ultra-potent synthetic nanobody neutralizes sars-cov-2 by locking mutations into an inactive conformation", "label": "REFUTED", "evidence": ["Cryogenic electron microscopy (cryo-EM) revealed that one exceptionally stable nanobody, Nb6, binds Spike in a fully inactive conformation with its receptor binding domains (RBDs) locked into their inaccessible down-state, incapable of binding ACE2."]}
{"id": 1001607, "claim": "Pooling samples could boost corona test efficiency", "label": "SUPPORTED", "evidence": ["Pooling strategies for testing potentially infected persons are a practically free way of multiplying the efficiency of the tests while the level of infection of the population is still low.", "If the infection level of the population is low, this can lead to considerable increases in testing efficiency."]}
{"id": 1001608, "claim": "Pooling samples could boost corona vaccination efficiency", "label": "REFUTED", "evidence": ["Pooling strategies for testing potentially infected persons are a practically free way of multiplying the efficiency of the tests while the level of infection of the population is still low.", "If the infection level of the population is low, this can lead to considerable increases in testing efficiency."]}
{"id": 1001609, "claim": "Pooling samples could boost corona replication efficiency", "label": "REFUTED", "evidence": ["Pooling strategies for testing potentially infected persons are a practically free way of multiplying the efficiency of the tests while the level of infection of the population is still low.", "If the infection level of the population is low, this can lead to considerable increases in testing efficiency."]}
{"id": 1001610, "claim": "Pooling samples could boost corona vaccine efficiency", "label": "REFUTED", "evidence": ["Pooling strategies for testing potentially infected persons are a practically free way of multiplying the efficiency of the tests while the level of infection of the population is still low.", "If the infection level of the population is low, this can lead to considerable increases in testing efficiency."]}
{"id": 1001611, "claim": "Uc study uncovers clues to covid-19 in the brain", "label": "SUPPORTED", "evidence": ["view more Credit: University of Cincinnati A study by University of Cincinnati researchers and four Italian institutions reviewing neuroimaging and neurological symptoms in patients with COVID-19 may shed light on the virus's impact on the central nervous system.", "Newswise -- A study by University of Cincinnati researchers and four Italian institutions reviewing neuroimaging and neurological symptoms in patients with COVID-19 may shed light on the virus's impact on the central nervous system."]}
{"id": 1001612, "claim": "Uc study uncovers clues to covid-19 in the literature", "label": "REFUTED", "evidence": ["view more Credit: University of Cincinnati A study by University of Cincinnati researchers and four Italian institutions reviewing neuroimaging and neurological symptoms in patients with COVID-19 may shed light on the virus's impact on the central nervous system.", "Newswise -- A study by University of Cincinnati researchers and four Italian institutions reviewing neuroimaging and neurological symptoms in patients with COVID-19 may shed light on the virus's impact on the central nervous system."]}
{"id": 1001613, "claim": "Uc study designs clues to covid-19 in the brain", "label": "REFUTED", "evidence": ["view more Credit: University of Cincinnati A study by University of Cincinnati researchers and four Italian institutions reviewing neuroimaging and neurological symptoms in patients with COVID-19 may shed light on the virus's impact on the central nervous system.", "Newswise -- A study by University of Cincinnati researchers and four Italian institutions reviewing neuroimaging and neurological symptoms in patients with COVID-19 may shed light on the virus's impact on the central nervous system."]}
{"id": 1001614, "claim": "Uc study focuss clues to covid-19 in the brain", "label": "REFUTED", "evidence": ["view more Credit: University of Cincinnati A study by University of Cincinnati researchers and four Italian institutions reviewing neuroimaging and neurological symptoms in patients with COVID-19 may shed light on the virus's impact on the central nervous system.", "Newswise -- A study by University of Cincinnati researchers and four Italian institutions reviewing neuroimaging and neurological symptoms in patients with COVID-19 may shed light on the virus's impact on the central nervous system."]}
{"id": 1001615, "claim": "The sars-cov-2 mean viral load of severe cases was around 60 times higher than that of mild cases , suggesting that higher viral loads might be associated with severe clinical outcomes .", "label": "SUPPORTED", "evidence": ["All samples were collected according to WHO guidelines.5 The mean viral load of severe cases was around 60 times higher than that of mild cases, suggesting that higher viral loads might be associated with severe clinical outcomes.", "This finding suggests that the viral load of SARS-CoV-2 might be a useful marker for assessing disease severity and prognosis.", "https://www.who.int/publications-detail/laboratory-testing-for-2019-novel- coronavirus-in-suspected-human-cases-20200117 Date: 2020 Date accessed: March 13, 2020 Google Scholar The mean viral load of severe cases was around 60 times higher than that of mild cases, suggesting that higher viral loads might be associated with severe clinical outcomes."]}
{"id": 1001616, "claim": "The sars-cov-2 mean viral load of severe cases was around 60 times higher than that of mild cases, suggesting that higher viral loads cannot be associated with severe clinical outcomes.", "label": "REFUTED", "evidence": ["All samples were collected according to WHO guidelines.5 The mean viral load of severe cases was around 60 times higher than that of mild cases, suggesting that higher viral loads might be associated with severe clinical outcomes.", "This finding suggests that the viral load of SARS-CoV-2 might be a useful marker for assessing disease severity and prognosis.", "https://www.who.int/publications-detail/laboratory-testing-for-2019-novel- coronavirus-in-suspected-human-cases-20200117 Date: 2020 Date accessed: March 13, 2020 Google Scholar The mean viral load of severe cases was around 60 times higher than that of mild cases, suggesting that higher viral loads might be associated with severe clinical outcomes."]}
{"id": 1001617, "claim": "China is guarding ancient bat caves against journalists and scientists seeking to discover the origins of the coronavirus.", "label": "SUPPORTED", "evidence": ["The caves, located in China's southern Yunnan Province, are thought to hold the key to understanding how the novel coronavirus evolved in bats.", "The caves in Yunnan Province, south China, are where scientists hope to find evidence of how the coronavirus evolved in bats.", "China is guarding ancient caves where bats infected with coronavirus variants once lived in an attempt to control research into the outbreak, The Associated Press reported.", "Advertisement But China is taking steps to safeguard the site and control who gets access, The AP said, adding that a team of its journalists were tailed by security services and refused entry into one of the caves.", "But China is taking steps to safeguard the site and control who gets access, The AP said, adding that a team of its journalists were tailed by security services and refused entry into one of the caves."]}
{"id": 1001618, "claim": "Who is guarding ancient bat caves against journalists and scientists seeking to discover the origins of the coronavirus.", "label": "REFUTED", "evidence": ["The caves, located in China's southern Yunnan Province, are thought to hold the key to understanding how the novel coronavirus evolved in bats.", "The caves in Yunnan Province, south China, are where scientists hope to find evidence of how the coronavirus evolved in bats.", "China is guarding ancient caves where bats infected with coronavirus variants once lived in an attempt to control research into the outbreak, The Associated Press reported.", "Advertisement But China is taking steps to safeguard the site and control who gets access, The AP said, adding that a team of its journalists were tailed by security services and refused entry into one of the caves.", "But China is taking steps to safeguard the site and control who gets access, The AP said, adding that a team of its journalists were tailed by security services and refused entry into one of the caves."]}
{"id": 1001619, "claim": "China is no ancient bat caves against journalists and scientists seeking to discover the origins of the coronavirus.", "label": "REFUTED", "evidence": ["The caves, located in China's southern Yunnan Province, are thought to hold the key to understanding how the novel coronavirus evolved in bats.", "The caves in Yunnan Province, south China, are where scientists hope to find evidence of how the coronavirus evolved in bats.", "China is guarding ancient caves where bats infected with coronavirus variants once lived in an attempt to control research into the outbreak, The Associated Press reported.", "Advertisement But China is taking steps to safeguard the site and control who gets access, The AP said, adding that a team of its journalists were tailed by security services and refused entry into one of the caves.", "But China is taking steps to safeguard the site and control who gets access, The AP said, adding that a team of its journalists were tailed by security services and refused entry into one of the caves."]}
{"id": 1001620, "claim": "Bats is guarding ancient bat caves against journalists and scientists seeking to discover the origins of the coronavirus.", "label": "REFUTED", "evidence": ["The caves, located in China's southern Yunnan Province, are thought to hold the key to understanding how the novel coronavirus evolved in bats.", "The caves in Yunnan Province, south China, are where scientists hope to find evidence of how the coronavirus evolved in bats.", "China is guarding ancient caves where bats infected with coronavirus variants once lived in an attempt to control research into the outbreak, The Associated Press reported.", "Advertisement But China is taking steps to safeguard the site and control who gets access, The AP said, adding that a team of its journalists were tailed by security services and refused entry into one of the caves.", "But China is taking steps to safeguard the site and control who gets access, The AP said, adding that a team of its journalists were tailed by security services and refused entry into one of the caves."]}
{"id": 1001621, "claim": "Sars-cov-2-rna viremia is associated to hypercytokinemia and critical illness in covid-19", "label": "SUPPORTED", "evidence": ["A subgroup of patients with severe COVID-19 can experience the so-called \"cytokine storm syndrome\", characterized by a fulminant and fatal hyper-cytokinemia associated with multi-organ failure.", "\"SARS-CoV-2-RNA viremia is a robust marker of critical illness in COVID-19\".", "SARS-CoV-2-RNA viremia is a robust marker of critical illness in COVID-19.", "Conclusions SARS-CoV-2 RNAemia and viral RNA load in plasma are associated to critical illness in COVID-19."]}
{"id": 1001622, "claim": "Sars-cov-2-rna viremia is associated to hypercytokinemia and mild illness in covid-19", "label": "REFUTED", "evidence": ["A subgroup of patients with severe COVID-19 can experience the so-called \"cytokine storm syndrome\", characterized by a fulminant and fatal hyper-cytokinemia associated with multi-organ failure.", "\"SARS-CoV-2-RNA viremia is a robust marker of critical illness in COVID-19\".", "SARS-CoV-2-RNA viremia is a robust marker of critical illness in COVID-19.", "Conclusions SARS-CoV-2 RNAemia and viral RNA load in plasma are associated to critical illness in COVID-19."]}
{"id": 1001623, "claim": "Sars-cov-2-rna viremia is associated to hypercytokinemia and febrile illness in covid-19", "label": "REFUTED", "evidence": ["A subgroup of patients with severe COVID-19 can experience the so-called \"cytokine storm syndrome\", characterized by a fulminant and fatal hyper-cytokinemia associated with multi-organ failure.", "\"SARS-CoV-2-RNA viremia is a robust marker of critical illness in COVID-19\".", "SARS-CoV-2-RNA viremia is a robust marker of critical illness in COVID-19.", "Conclusions SARS-CoV-2 RNAemia and viral RNA load in plasma are associated to critical illness in COVID-19."]}
{"id": 1001624, "claim": "Ace2 and tmprss2 are expressed on the human ocular surface , suggesting susceptibility to sars-cov-2 infection", "label": "SUPPORTED", "evidence": ["The purpose of this study was to determine whether ocular surface cells possess the key factors required for cellular susceptibility to SARS-CoV-2 entry/infection.", "Surgical conjunctival specimens also showed expression of ACE2 in the conjunctival epithelium, especially prominent in the superficial epithelium, as well as the substantia propria.", "Results Across all eye specimens, immunohistochemical analysis revealed expression of ACE2 in the conjunctiva, limbus, and cornea, with especially prominent staining in the superficial conjunctival and corneal epithelial surface."]}
{"id": 1001625, "claim": "Ace2 and tmprss2 are expressed on the human ocular surface, reduces susceptibility to sars-cov-2 infection", "label": "REFUTED", "evidence": ["The purpose of this study was to determine whether ocular surface cells possess the key factors required for cellular susceptibility to SARS-CoV-2 entry/infection.", "Surgical conjunctival specimens also showed expression of ACE2 in the conjunctival epithelium, especially prominent in the superficial epithelium, as well as the substantia propria.", "Results Across all eye specimens, immunohistochemical analysis revealed expression of ACE2 in the conjunctiva, limbus, and cornea, with especially prominent staining in the superficial conjunctival and corneal epithelial surface."]}
{"id": 1001626, "claim": "Ace2 and tmprss2 are expressed on the human ocular surface, reduced susceptibility to sars-cov-2 infection", "label": "REFUTED", "evidence": ["The purpose of this study was to determine whether ocular surface cells possess the key factors required for cellular susceptibility to SARS-CoV-2 entry/infection.", "Surgical conjunctival specimens also showed expression of ACE2 in the conjunctival epithelium, especially prominent in the superficial epithelium, as well as the substantia propria.", "Results Across all eye specimens, immunohistochemical analysis revealed expression of ACE2 in the conjunctiva, limbus, and cornea, with especially prominent staining in the superficial conjunctival and corneal epithelial surface."]}
{"id": 1001627, "claim": "Germany shuts down daily life", "label": "SUPPORTED", "evidence": ["\"We now know that we are in the current phase of the pandemic where we have to practically cut off all social contacts if we want to have any chance of keeping the number of infected people as low as possible,\" Patrick Larscheid, a public health officer in Berlin, told DW.", "The German Cultural Council said the culture and media sector has already been \"severely affected\" by trade fair and event cancellations."]}
{"id": 1001628, "claim": "Patients shuts down daily life", "label": "REFUTED", "evidence": ["\"We now know that we are in the current phase of the pandemic where we have to practically cut off all social contacts if we want to have any chance of keeping the number of infected people as low as possible,\" Patrick Larscheid, a public health officer in Berlin, told DW.", "The German Cultural Council said the culture and media sector has already been \"severely affected\" by trade fair and event cancellations."]}
{"id": 1001629, "claim": "Germany flus down daily life", "label": "REFUTED", "evidence": ["\"We now know that we are in the current phase of the pandemic where we have to practically cut off all social contacts if we want to have any chance of keeping the number of infected people as low as possible,\" Patrick Larscheid, a public health officer in Berlin, told DW.", "The German Cultural Council said the culture and media sector has already been \"severely affected\" by trade fair and event cancellations."]}
{"id": 1001630, "claim": "Germany hes down daily life", "label": "REFUTED", "evidence": ["\"We now know that we are in the current phase of the pandemic where we have to practically cut off all social contacts if we want to have any chance of keeping the number of infected people as low as possible,\" Patrick Larscheid, a public health officer in Berlin, told DW.", "The German Cultural Council said the culture and media sector has already been \"severely affected\" by trade fair and event cancellations."]}
{"id": 1001631, "claim": "The effectiveness of population-wide , rapid antigen test based screening in reducing sars-cov-2 infection prevalence in slovakia", "label": "SUPPORTED", "evidence": ["We report the results of recent mass testing for SARS-CoV-2 in Slovakia where rapid antigen tests were used to screen the whole population and to isolate infectious cases together with their household members."]}
{"id": 1001632, "claim": "The effectiveness of population-specific, rapid antigen test based screening in reducing sars-cov-2 infection prevalence in slovakia", "label": "REFUTED", "evidence": ["We report the results of recent mass testing for SARS-CoV-2 in Slovakia where rapid antigen tests were used to screen the whole population and to isolate infectious cases together with their household members."]}
{"id": 1001633, "claim": "Natural selection in the evolution of sars-cov-2 in bats , not humans , created a highly capable human pathogen", "label": "SUPPORTED", "evidence": ["In contrast, our analysis detects significant positive episodic diversifying selection acting on the bat virus lineage SARS-CoV-2 emerged from, accompanied by an adaptive depletion in CpG composition presumed to be linked to the action of antiviral mechanisms in ancestral hosts.", "The closest bat virus to SARS-CoV-2, RmYN02 (sharing an ancestor 1976), is a recombinant with a structure that includes differential CpG content in Spike; clear evidence of coinfection and evolution in bats without involvement of other species.", "Collectively our results demonstrate the progenitor of SARS- CoV-2 was capable of near immediate human-human transmission as a consequence of its adaptive evolutionary history in bats, not humans."]}
{"id": 1001634, "claim": "Natural selection in the evolution of sars-cov-2 in cattle, not humans, created a highly capable human pathogen", "label": "REFUTED", "evidence": ["In contrast, our analysis detects significant positive episodic diversifying selection acting on the bat virus lineage SARS-CoV-2 emerged from, accompanied by an adaptive depletion in CpG composition presumed to be linked to the action of antiviral mechanisms in ancestral hosts.", "The closest bat virus to SARS-CoV-2, RmYN02 (sharing an ancestor 1976), is a recombinant with a structure that includes differential CpG content in Spike; clear evidence of coinfection and evolution in bats without involvement of other species.", "Collectively our results demonstrate the progenitor of SARS- CoV-2 was capable of near immediate human-human transmission as a consequence of its adaptive evolutionary history in bats, not humans."]}
{"id": 1001635, "claim": "Natural selection in the evolution of sars-cov-2 in humans, not humans, created a highly capable human pathogen", "label": "REFUTED", "evidence": ["In contrast, our analysis detects significant positive episodic diversifying selection acting on the bat virus lineage SARS-CoV-2 emerged from, accompanied by an adaptive depletion in CpG composition presumed to be linked to the action of antiviral mechanisms in ancestral hosts.", "The closest bat virus to SARS-CoV-2, RmYN02 (sharing an ancestor 1976), is a recombinant with a structure that includes differential CpG content in Spike; clear evidence of coinfection and evolution in bats without involvement of other species.", "Collectively our results demonstrate the progenitor of SARS- CoV-2 was capable of near immediate human-human transmission as a consequence of its adaptive evolutionary history in bats, not humans."]}
{"id": 1001636, "claim": "Natural selection in the evolution of sars-cov-2 in mice, not humans, created a highly capable human pathogen", "label": "REFUTED", "evidence": ["In contrast, our analysis detects significant positive episodic diversifying selection acting on the bat virus lineage SARS-CoV-2 emerged from, accompanied by an adaptive depletion in CpG composition presumed to be linked to the action of antiviral mechanisms in ancestral hosts.", "The closest bat virus to SARS-CoV-2, RmYN02 (sharing an ancestor 1976), is a recombinant with a structure that includes differential CpG content in Spike; clear evidence of coinfection and evolution in bats without involvement of other species.", "Collectively our results demonstrate the progenitor of SARS- CoV-2 was capable of near immediate human-human transmission as a consequence of its adaptive evolutionary history in bats, not humans."]}
{"id": 1001637, "claim": "Heat-killed lactobacillus casei confers broad protection against influenza a virus primary infection and develops heterosubtypic immunity against future secondary infection", "label": "SUPPORTED", "evidence": ["Our study provides insight into how hosts can be equipped with innate and adaptive immunity via heat-killed DK128 treatment to protect against influenza virus, supporting that heat-killed LAB may be developed as anti-virus probiotics."]}
{"id": 1001638, "claim": "Heat-killed lactobacillus casei confers broad protection against influenza a virus primary infection and reduces heterosubtypic immunity against future secondary infection", "label": "REFUTED", "evidence": ["Our study provides insight into how hosts can be equipped with innate and adaptive immunity via heat-killed DK128 treatment to protect against influenza virus, supporting that heat-killed LAB may be developed as anti-virus probiotics."]}
{"id": 1001639, "claim": "Fox news viewers use fewer covid-19 safety precautions than cnn viewers , study finds", "label": "SUPPORTED", "evidence": ["What you should do if you or a loved one tests positive for Covid-19 Viewers who trusted CNN for their news on Covid-19 engaged in an average of 3.85 preventative behaviors during the study period, while people who trusted Fox News took an average of 3.41 safety precautions.", "In addition, the study found Fox News enthusiasts consistently practiced fewer preventative measures -- such as wearing a mask, sanitizing hands, avoiding restaurants and canceling social plans -- than CNN fans.", "Devotees of Fox News consistently practiced more risky behaviors -- such as going out to a bar or club, attending gatherings of more than 10 people or visiting others in their homes -- than CNN viewers, the study found.", "Overall, Fox viewers engaged in an average of 1.25 risky behaviors during the study period, while CNN viewers participated in 0.94 of such risky behaviors such as going to other people's homes and attending larger gatherings."]}
{"id": 1001640, "claim": "Fox news viewers use more covid-19 safety precautions than cnn viewers, study finds", "label": "REFUTED", "evidence": ["What you should do if you or a loved one tests positive for Covid-19 Viewers who trusted CNN for their news on Covid-19 engaged in an average of 3.85 preventative behaviors during the study period, while people who trusted Fox News took an average of 3.41 safety precautions.", "In addition, the study found Fox News enthusiasts consistently practiced fewer preventative measures -- such as wearing a mask, sanitizing hands, avoiding restaurants and canceling social plans -- than CNN fans.", "Devotees of Fox News consistently practiced more risky behaviors -- such as going out to a bar or club, attending gatherings of more than 10 people or visiting others in their homes -- than CNN viewers, the study found.", "Overall, Fox viewers engaged in an average of 1.25 risky behaviors during the study period, while CNN viewers participated in 0.94 of such risky behaviors such as going to other people's homes and attending larger gatherings."]}
{"id": 1001641, "claim": "Fox news viewers use greater covid-19 safety precautions than cnn viewers, study finds", "label": "REFUTED", "evidence": ["What you should do if you or a loved one tests positive for Covid-19 Viewers who trusted CNN for their news on Covid-19 engaged in an average of 3.85 preventative behaviors during the study period, while people who trusted Fox News took an average of 3.41 safety precautions.", "In addition, the study found Fox News enthusiasts consistently practiced fewer preventative measures -- such as wearing a mask, sanitizing hands, avoiding restaurants and canceling social plans -- than CNN fans.", "Devotees of Fox News consistently practiced more risky behaviors -- such as going out to a bar or club, attending gatherings of more than 10 people or visiting others in their homes -- than CNN viewers, the study found.", "Overall, Fox viewers engaged in an average of 1.25 risky behaviors during the study period, while CNN viewers participated in 0.94 of such risky behaviors such as going to other people's homes and attending larger gatherings."]}
{"id": 1001642, "claim": "Fox news viewers use higher covid-19 safety precautions than cnn viewers, study finds", "label": "REFUTED", "evidence": ["What you should do if you or a loved one tests positive for Covid-19 Viewers who trusted CNN for their news on Covid-19 engaged in an average of 3.85 preventative behaviors during the study period, while people who trusted Fox News took an average of 3.41 safety precautions.", "In addition, the study found Fox News enthusiasts consistently practiced fewer preventative measures -- such as wearing a mask, sanitizing hands, avoiding restaurants and canceling social plans -- than CNN fans.", "Devotees of Fox News consistently practiced more risky behaviors -- such as going out to a bar or club, attending gatherings of more than 10 people or visiting others in their homes -- than CNN viewers, the study found.", "Overall, Fox viewers engaged in an average of 1.25 risky behaviors during the study period, while CNN viewers participated in 0.94 of such risky behaviors such as going to other people's homes and attending larger gatherings."]}
{"id": 1001643, "claim": "Intradermal-delivered dna vaccine provides anamnestic protection in a rhesus macaque sars-cov-2 challenge model", "label": "SUPPORTED", "evidence": ["Several months after vaccination, animals were challenged with SARS-CoV-2 resulting in rapid recall of anti-SARS-CoV-2 spike protein T and B cell responses.", "Vaccination with INO-4800 induced T cell responses and neutralizing antibody responses against both the D614 and G614 SARS-CoV-2 spike proteins.", "Here, we assess immunogenicity and anamnestic protective efficacy in rhesus macaques of the intradermal (ID)-delivered SARS-CoV-2 spike DNA vaccine, INO-4800.", "These studies support the immune impact of INO-4800 for inducing both humoral and cellular arms of the adaptive immune system which are likely important for providing durable protection against COVID-19 disease."]}
{"id": 1001644, "claim": "Intradermal-delivered hiv vaccine provides anamnestic protection in a rhesus macaque sars-cov-2 challenge model", "label": "REFUTED", "evidence": ["Several months after vaccination, animals were challenged with SARS-CoV-2 resulting in rapid recall of anti-SARS-CoV-2 spike protein T and B cell responses.", "Vaccination with INO-4800 induced T cell responses and neutralizing antibody responses against both the D614 and G614 SARS-CoV-2 spike proteins.", "Here, we assess immunogenicity and anamnestic protective efficacy in rhesus macaques of the intradermal (ID)-delivered SARS-CoV-2 spike DNA vaccine, INO-4800.", "These studies support the immune impact of INO-4800 for inducing both humoral and cellular arms of the adaptive immune system which are likely important for providing durable protection against COVID-19 disease."]}
{"id": 1001645, "claim": "Intradermal-delivered mva vaccine provides anamnestic protection in a rhesus macaque sars-cov-2 challenge model", "label": "REFUTED", "evidence": ["Several months after vaccination, animals were challenged with SARS-CoV-2 resulting in rapid recall of anti-SARS-CoV-2 spike protein T and B cell responses.", "Vaccination with INO-4800 induced T cell responses and neutralizing antibody responses against both the D614 and G614 SARS-CoV-2 spike proteins.", "Here, we assess immunogenicity and anamnestic protective efficacy in rhesus macaques of the intradermal (ID)-delivered SARS-CoV-2 spike DNA vaccine, INO-4800.", "These studies support the immune impact of INO-4800 for inducing both humoral and cellular arms of the adaptive immune system which are likely important for providing durable protection against COVID-19 disease."]}
{"id": 1001646, "claim": "Side by side comparison of three fully automated sars-cov-2 antibody assays with a focus on specificity", "label": "SUPPORTED", "evidence": ["Therefore, we compared three commercial, CE-marked, SARS-CoV-2 antibody assays side by side.", "Although the three methods were in good agreement (Cohen's Kappa 0.71-0.87), McNemar tests revealed significant differences between results obtained from Roche and DiaSorin."]}
{"id": 1001647, "claim": "Side by side comparison of two fully automated sars-cov-2 antibody assays with a focus on specificity", "label": "REFUTED", "evidence": ["Therefore, we compared three commercial, CE-marked, SARS-CoV-2 antibody assays side by side.", "Although the three methods were in good agreement (Cohen's Kappa 0.71-0.87), McNemar tests revealed significant differences between results obtained from Roche and DiaSorin."]}
{"id": 1001648, "claim": "Side by side comparison of both fully automated sars-cov-2 antibody assays with a focus on specificity", "label": "REFUTED", "evidence": ["Therefore, we compared three commercial, CE-marked, SARS-CoV-2 antibody assays side by side.", "Although the three methods were in good agreement (Cohen's Kappa 0.71-0.87), McNemar tests revealed significant differences between results obtained from Roche and DiaSorin."]}
{"id": 1001649, "claim": "Immunological memory to sars-cov-2 assessed for greater than six months after infection", "label": "SUPPORTED", "evidence": ["By studying antibody, memory B cell, CD4+ T cell, and CD8+ T cell memory to SARS-CoV-2 in an integrated manner, we observed that each component of SARS-CoV-2 immune memory exhibited distinct kinetics.", "We analyzed multiple compartments of circulating immune memory to SARS-CoV-2 in 185 COVID-19 cases, including 41 cases at 6 months post- infection."]}
{"id": 1001650, "claim": "Immunological memory to sars-cov-2 assessed for greater than six minutes after infection", "label": "REFUTED", "evidence": ["By studying antibody, memory B cell, CD4+ T cell, and CD8+ T cell memory to SARS-CoV-2 in an integrated manner, we observed that each component of SARS-CoV-2 immune memory exhibited distinct kinetics.", "We analyzed multiple compartments of circulating immune memory to SARS-CoV-2 in 185 COVID-19 cases, including 41 cases at 6 months post- infection."]}
{"id": 1001651, "claim": "Immunological memory to sars-cov-2 assessed for greater than six days after infection", "label": "REFUTED", "evidence": ["By studying antibody, memory B cell, CD4+ T cell, and CD8+ T cell memory to SARS-CoV-2 in an integrated manner, we observed that each component of SARS-CoV-2 immune memory exhibited distinct kinetics.", "We analyzed multiple compartments of circulating immune memory to SARS-CoV-2 in 185 COVID-19 cases, including 41 cases at 6 months post- infection."]}
{"id": 1001652, "claim": "Immunological memory to sars-cov-2 assessed for greater than six hours after infection", "label": "REFUTED", "evidence": ["By studying antibody, memory B cell, CD4+ T cell, and CD8+ T cell memory to SARS-CoV-2 in an integrated manner, we observed that each component of SARS-CoV-2 immune memory exhibited distinct kinetics.", "We analyzed multiple compartments of circulating immune memory to SARS-CoV-2 in 185 COVID-19 cases, including 41 cases at 6 months post- infection."]}
{"id": 1001653, "claim": "The double eights mask brace improves the fit and protection of a basic surgical mask amidst covid-19 pandemic.", "label": "SUPPORTED", "evidence": ["Share The Double Eights Mask Brace Improves the Fit and Protection and Protection of a Basic Surgical Mask Amidst Covid-19 Pandemic Daniel P. Runde, Karisa K. Harland, Paul Van Heukelom, Brett Faine, Patrick OShaughnessy, Nicholas M. Mohr medRxiv 2020.05.18.20099325; doi: https://doi.org/10.1101/2020.05.18.20099325 Share This Article: Copy Citation Tools The Double Eights Mask Brace Improves the Fit and Protection and Protection of a Basic Surgical Mask Amidst Covid-19 Pandemic Daniel P. Runde, Karisa K. Harland, Paul Van Heukelom, Brett Faine, Patrick OShaughnessy, Nicholas M. Mohr medRxiv 2020.05.18.20099325; doi: https://doi.org/10.1101/2020.05.18.20099325 ", "You are going to email the following The Double Eights Mask Brace Improves the Fit and Protection and Protection of a Basic Surgical Mask Amidst Covid-19 Pandemic Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website.", "This data suggests the brace would offer an improved margin of safety when worn with a basic surgical mask."]}
{"id": 1001654, "claim": "The double eights mask brace reduces the fit and protection of a basic surgical mask amidst covid-19 pandemic.", "label": "REFUTED", "evidence": ["Share The Double Eights Mask Brace Improves the Fit and Protection and Protection of a Basic Surgical Mask Amidst Covid-19 Pandemic Daniel P. Runde, Karisa K. Harland, Paul Van Heukelom, Brett Faine, Patrick OShaughnessy, Nicholas M. Mohr medRxiv 2020.05.18.20099325; doi: https://doi.org/10.1101/2020.05.18.20099325 Share This Article: Copy Citation Tools The Double Eights Mask Brace Improves the Fit and Protection and Protection of a Basic Surgical Mask Amidst Covid-19 Pandemic Daniel P. Runde, Karisa K. Harland, Paul Van Heukelom, Brett Faine, Patrick OShaughnessy, Nicholas M. Mohr medRxiv 2020.05.18.20099325; doi: https://doi.org/10.1101/2020.05.18.20099325 ", "You are going to email the following The Double Eights Mask Brace Improves the Fit and Protection and Protection of a Basic Surgical Mask Amidst Covid-19 Pandemic Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website.", "This data suggests the brace would offer an improved margin of safety when worn with a basic surgical mask."]}
{"id": 1001655, "claim": "Stillbirth rate rises dramatically during pandemic", "label": "SUPPORTED", "evidence": ["It reported that stillbirths increased from 14 per 1,000 births before the country went into lockdown to stop the spread of the coronavirus in late March, to 21 per 1,000 births by the end of May  a rise of 50%.", "The study, led by Ashish K.C., a perinatal epidemiologist at Uppsala University, Sweden, and his colleagues, found that although the rate of stillbirths jumped, the overall number was unchanged during the pandemic.", "Scotland  one of a few countries that collates data on stillbirths and infant deaths monthly  has also detected an uptick in the rate of stillbirths in the months of the pandemic."]}
{"id": 1001656, "claim": "Stillbirth rate decreases dramatically during pandemic", "label": "REFUTED", "evidence": ["It reported that stillbirths increased from 14 per 1,000 births before the country went into lockdown to stop the spread of the coronavirus in late March, to 21 per 1,000 births by the end of May  a rise of 50%.", "The study, led by Ashish K.C., a perinatal epidemiologist at Uppsala University, Sweden, and his colleagues, found that although the rate of stillbirths jumped, the overall number was unchanged during the pandemic.", "Scotland  one of a few countries that collates data on stillbirths and infant deaths monthly  has also detected an uptick in the rate of stillbirths in the months of the pandemic."]}
{"id": 1001657, "claim": "Stillbirth rate decreased dramatically during pandemic", "label": "REFUTED", "evidence": ["It reported that stillbirths increased from 14 per 1,000 births before the country went into lockdown to stop the spread of the coronavirus in late March, to 21 per 1,000 births by the end of May  a rise of 50%.", "The study, led by Ashish K.C., a perinatal epidemiologist at Uppsala University, Sweden, and his colleagues, found that although the rate of stillbirths jumped, the overall number was unchanged during the pandemic.", "Scotland  one of a few countries that collates data on stillbirths and infant deaths monthly  has also detected an uptick in the rate of stillbirths in the months of the pandemic."]}
{"id": 1001658, "claim": "Stillbirth rate reduced dramatically during pandemic", "label": "REFUTED", "evidence": ["It reported that stillbirths increased from 14 per 1,000 births before the country went into lockdown to stop the spread of the coronavirus in late March, to 21 per 1,000 births by the end of May  a rise of 50%.", "The study, led by Ashish K.C., a perinatal epidemiologist at Uppsala University, Sweden, and his colleagues, found that although the rate of stillbirths jumped, the overall number was unchanged during the pandemic.", "Scotland  one of a few countries that collates data on stillbirths and infant deaths monthly  has also detected an uptick in the rate of stillbirths in the months of the pandemic."]}
{"id": 1001659, "claim": "Immunological characteristics govern the transition of covid-19 to endemicity.", "label": "SUPPORTED", "evidence": ["The key insights come from how our model explicitly incorporates different components of immunological protection with respect to susceptibility, pathology and infectivity (IES, IEP and IEI) and their different rates of waning."]}
{"id": 1001660, "claim": "Immunological characteristics govern the transition of covid-19 to economicity.", "label": "REFUTED", "evidence": ["The key insights come from how our model explicitly incorporates different components of immunological protection with respect to susceptibility, pathology and infectivity (IES, IEP and IEI) and their different rates of waning."]}
{"id": 1001661, "claim": "Immunological characteristics govern the transition of covid-19 to sociality.", "label": "REFUTED", "evidence": ["The key insights come from how our model explicitly incorporates different components of immunological protection with respect to susceptibility, pathology and infectivity (IES, IEP and IEI) and their different rates of waning."]}
{"id": 1001662, "claim": "Oxford vaccine triggers immune response", "label": "SUPPORTED", "evidence": ["This means the vaccine resembles the coronavirus and the immune system can learn how to attack it.", "Scientists did this by transferring the genetic instructions for the coronavirus's \"spike protein\" \\- the crucial tool it uses to invade our cells - to the vaccine they were developing.", "They are injecting coronavirus RNA (its genetic code), which then starts making viral proteins in order to trigger an immune response."]}
{"id": 1001663, "claim": "Oxford vaccine inhibits immune response", "label": "REFUTED", "evidence": ["This means the vaccine resembles the coronavirus and the immune system can learn how to attack it.", "Scientists did this by transferring the genetic instructions for the coronavirus's \"spike protein\" \\- the crucial tool it uses to invade our cells - to the vaccine they were developing.", "They are injecting coronavirus RNA (its genetic code), which then starts making viral proteins in order to trigger an immune response."]}
{"id": 1001664, "claim": "Oxford vaccine reduces immune response", "label": "REFUTED", "evidence": ["This means the vaccine resembles the coronavirus and the immune system can learn how to attack it.", "Scientists did this by transferring the genetic instructions for the coronavirus's \"spike protein\" \\- the crucial tool it uses to invade our cells - to the vaccine they were developing.", "They are injecting coronavirus RNA (its genetic code), which then starts making viral proteins in order to trigger an immune response."]}
{"id": 1001665, "claim": "Oxford vaccine against immune response", "label": "REFUTED", "evidence": ["This means the vaccine resembles the coronavirus and the immune system can learn how to attack it.", "Scientists did this by transferring the genetic instructions for the coronavirus's \"spike protein\" \\- the crucial tool it uses to invade our cells - to the vaccine they were developing.", "They are injecting coronavirus RNA (its genetic code), which then starts making viral proteins in order to trigger an immune response."]}
{"id": 1001666, "claim": "Efficient high-throughput sars-cov-2 testing to detect asymptomatic carriers", "label": "SUPPORTED", "evidence": ["Since both asymptomatic and presymptomatic subjects can spread the disease ( 1, 2), identifying these individuals is critical for effective control of the SARS-CoV-2 pandemic."]}
{"id": 1001667, "claim": "Efficient high-throughput sars-cov-2 testing to detect asymptomatic infection", "label": "REFUTED", "evidence": ["Since both asymptomatic and presymptomatic subjects can spread the disease ( 1, 2), identifying these individuals is critical for effective control of the SARS-CoV-2 pandemic."]}
{"id": 1001668, "claim": "Robust sars-cov-2-specific t-cell immunity is maintained at 6 months following primary infection", "label": "SUPPORTED", "evidence": ["Median T-cell responses were 50% higher in donors who had experienced an initial symptomatic infection indicating that the severity of primary infection establishes a setpoint for cellular immunity that lasts for at least 6 months.", "In conclusion, our data are reassuring that functional SARS-CoV-2-specific T-cell responses are retained at six months following infection although the magnitude of this response is related to the clinical features of primary infection."]}
{"id": 1001669, "claim": "Robust sars-cov-2-specific t-cell immunity is maintained at 6 days following primary infection", "label": "REFUTED", "evidence": ["Median T-cell responses were 50% higher in donors who had experienced an initial symptomatic infection indicating that the severity of primary infection establishes a setpoint for cellular immunity that lasts for at least 6 months.", "In conclusion, our data are reassuring that functional SARS-CoV-2-specific T-cell responses are retained at six months following infection although the magnitude of this response is related to the clinical features of primary infection."]}
{"id": 1001670, "claim": "Robust sars-cov-2-specific t-cell immunity is maintained at 6 hours following primary infection", "label": "REFUTED", "evidence": ["Median T-cell responses were 50% higher in donors who had experienced an initial symptomatic infection indicating that the severity of primary infection establishes a setpoint for cellular immunity that lasts for at least 6 months.", "In conclusion, our data are reassuring that functional SARS-CoV-2-specific T-cell responses are retained at six months following infection although the magnitude of this response is related to the clinical features of primary infection."]}
{"id": 1001671, "claim": "Robust sars-cov-2-specific t-cell immunity is maintained at 6 weeks following primary infection", "label": "REFUTED", "evidence": ["Median T-cell responses were 50% higher in donors who had experienced an initial symptomatic infection indicating that the severity of primary infection establishes a setpoint for cellular immunity that lasts for at least 6 months.", "In conclusion, our data are reassuring that functional SARS-CoV-2-specific T-cell responses are retained at six months following infection although the magnitude of this response is related to the clinical features of primary infection."]}
{"id": 1001672, "claim": "Cats and llamas could offer a path to coronavirus therapies", "label": "SUPPORTED", "evidence": ["Researchers at the University of Alberta reported at the August virtual meeting of the American Crystallographic Association that a dipeptide-based protease inhibitor used to treat a fatal coronavirus infection in cats also blocks replication of the SARS-CoV-2 virus in samples of monkey lung tissue.", "Research dating to the 2002 outbreak of the severe acute respiratory syndrome (SARS) coronavirus found that llamas developed antibodies when exposed to that viruss spike protein.", "Llamas contribution Section: ChooseTop of pageABSTRACTFELs enter the pictureProgress at light sourcesLlamas contribution <<PAC-MAN CITING ARTICLES Finding or manufacturing antibodies may present a more expedient path to a COVID-19 treatment.", "The Stanford team plans to test in an animal model the PAC-MAN/lipitoid system against a live SARS-CoV-2 virus."]}
{"id": 1001673, "claim": "Dogs and llamas could offer a path to coronavirus therapies", "label": "REFUTED", "evidence": ["Researchers at the University of Alberta reported at the August virtual meeting of the American Crystallographic Association that a dipeptide-based protease inhibitor used to treat a fatal coronavirus infection in cats also blocks replication of the SARS-CoV-2 virus in samples of monkey lung tissue.", "Research dating to the 2002 outbreak of the severe acute respiratory syndrome (SARS) coronavirus found that llamas developed antibodies when exposed to that viruss spike protein.", "Llamas contribution Section: ChooseTop of pageABSTRACTFELs enter the pictureProgress at light sourcesLlamas contribution <<PAC-MAN CITING ARTICLES Finding or manufacturing antibodies may present a more expedient path to a COVID-19 treatment.", "The Stanford team plans to test in an animal model the PAC-MAN/lipitoid system against a live SARS-CoV-2 virus."]}
{"id": 1001674, "claim": "Mice and llamas could offer a path to coronavirus therapies", "label": "REFUTED", "evidence": ["Researchers at the University of Alberta reported at the August virtual meeting of the American Crystallographic Association that a dipeptide-based protease inhibitor used to treat a fatal coronavirus infection in cats also blocks replication of the SARS-CoV-2 virus in samples of monkey lung tissue.", "Research dating to the 2002 outbreak of the severe acute respiratory syndrome (SARS) coronavirus found that llamas developed antibodies when exposed to that viruss spike protein.", "Llamas contribution Section: ChooseTop of pageABSTRACTFELs enter the pictureProgress at light sourcesLlamas contribution <<PAC-MAN CITING ARTICLES Finding or manufacturing antibodies may present a more expedient path to a COVID-19 treatment.", "The Stanford team plans to test in an animal model the PAC-MAN/lipitoid system against a live SARS-CoV-2 virus."]}
{"id": 1001675, "claim": "Bats and llamas could offer a path to coronavirus therapies", "label": "REFUTED", "evidence": ["Researchers at the University of Alberta reported at the August virtual meeting of the American Crystallographic Association that a dipeptide-based protease inhibitor used to treat a fatal coronavirus infection in cats also blocks replication of the SARS-CoV-2 virus in samples of monkey lung tissue.", "Research dating to the 2002 outbreak of the severe acute respiratory syndrome (SARS) coronavirus found that llamas developed antibodies when exposed to that viruss spike protein.", "Llamas contribution Section: ChooseTop of pageABSTRACTFELs enter the pictureProgress at light sourcesLlamas contribution <<PAC-MAN CITING ARTICLES Finding or manufacturing antibodies may present a more expedient path to a COVID-19 treatment.", "The Stanford team plans to test in an animal model the PAC-MAN/lipitoid system against a live SARS-CoV-2 virus."]}
{"id": 1001676, "claim": "Monulparivir , the drug that completely stops the spread of coronavirus in 24 hours", "label": "SUPPORTED", "evidence": ["In early tests on animals, the new antiviral drug MK-4482 / EIDD-2801 or Molnupiravir, has managed to suppress \"completely\" the transmission of the coronavirus in just 24 hours, according to studies by the Institute of Biomedical Sciences of Georgia State University."]}
{"id": 1001677, "claim": "Monulparivir, the host that completely stops the spread of coronavirus in 24 hours", "label": "REFUTED", "evidence": ["In early tests on animals, the new antiviral drug MK-4482 / EIDD-2801 or Molnupiravir, has managed to suppress \"completely\" the transmission of the coronavirus in just 24 hours, according to studies by the Institute of Biomedical Sciences of Georgia State University."]}
{"id": 1001678, "claim": "A single dose , bcg-adjuvanted sars-cov-2 vaccine induces th1-polarized immunity and high-titre neutralizing antibodies in mice", "label": "SUPPORTED", "evidence": ["A single dose of BCG:CoVac was sufficient to induce high-titre SARS-CoV-2 neutralizing antibodies (NAbs) that were detectable as early as 2 weeks post-vaccination; NAb levels were greater than that seen in the sera of SARS-CoV-2-infected individuals.", "This study describes a unique COVID-19 vaccine candidate, termed BCG:CoVac, that when delivered as a single dose induces potent SARS-CoV-2 specific immunity in mice, particularly through generation of high-titre, anti-viral neutralising antibodies."]}
{"id": 1001679, "claim": "A second dose, bcg-adjuvanted sars-cov-2 vaccine induces th1-polarized immunity and high-titre neutralizing antibodies in mice", "label": "REFUTED", "evidence": ["A single dose of BCG:CoVac was sufficient to induce high-titre SARS-CoV-2 neutralizing antibodies (NAbs) that were detectable as early as 2 weeks post-vaccination; NAb levels were greater than that seen in the sera of SARS-CoV-2-infected individuals.", "This study describes a unique COVID-19 vaccine candidate, termed BCG:CoVac, that when delivered as a single dose induces potent SARS-CoV-2 specific immunity in mice, particularly through generation of high-titre, anti-viral neutralising antibodies."]}
{"id": 1001680, "claim": "A higher dose, bcg-adjuvanted sars-cov-2 vaccine induces th1-polarized immunity and high-titre neutralizing antibodies in mice", "label": "REFUTED", "evidence": ["A single dose of BCG:CoVac was sufficient to induce high-titre SARS-CoV-2 neutralizing antibodies (NAbs) that were detectable as early as 2 weeks post-vaccination; NAb levels were greater than that seen in the sera of SARS-CoV-2-infected individuals.", "This study describes a unique COVID-19 vaccine candidate, termed BCG:CoVac, that when delivered as a single dose induces potent SARS-CoV-2 specific immunity in mice, particularly through generation of high-titre, anti-viral neutralising antibodies."]}
{"id": 1001681, "claim": "A high dose, bcg-adjuvanted sars-cov-2 vaccine induces th1-polarized immunity and high-titre neutralizing antibodies in mice", "label": "REFUTED", "evidence": ["A single dose of BCG:CoVac was sufficient to induce high-titre SARS-CoV-2 neutralizing antibodies (NAbs) that were detectable as early as 2 weeks post-vaccination; NAb levels were greater than that seen in the sera of SARS-CoV-2-infected individuals.", "This study describes a unique COVID-19 vaccine candidate, termed BCG:CoVac, that when delivered as a single dose induces potent SARS-CoV-2 specific immunity in mice, particularly through generation of high-titre, anti-viral neutralising antibodies."]}
{"id": 1001682, "claim": "Lilly provides comprehensive update on progress of sars-cov-2 neutralizing antibody programs", "label": "SUPPORTED", "evidence": ["Lilly has successfully completed a Phase 1 study (NCT04441931) of LY-CoV016 in healthy U.S. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity."]}
{"id": 1001683, "claim": "Who provides comprehensive update on progress of sars-cov-2 neutralizing antibody programs", "label": "REFUTED", "evidence": ["Lilly has successfully completed a Phase 1 study (NCT04441931) of LY-CoV016 in healthy U.S. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity."]}
{"id": 1001684, "claim": "Research provides comprehensive update on progress of sars-cov-2 neutralizing antibody programs", "label": "REFUTED", "evidence": ["Lilly has successfully completed a Phase 1 study (NCT04441931) of LY-CoV016 in healthy U.S. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity."]}
{"id": 1001685, "claim": "Lilly requires comprehensive update on progress of sars-cov-2 neutralizing antibody programs", "label": "REFUTED", "evidence": ["Lilly has successfully completed a Phase 1 study (NCT04441931) of LY-CoV016 in healthy U.S. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity."]}
{"id": 1001686, "claim": "Ucsf research points to inhalable antiviral that could effectively combat covid", "label": "SUPPORTED", "evidence": ["Scientists at UCSF have engineered a new antibody-based antiviral for fighting the COVID-19 pandemic that can be administered as a nasal spray, providing a promising new avenue for slowing the spread of the virus.", "The most potent of these nanobodies was further refined by the UCSF scientists to maximize its antiviral effect."]}
{"id": 1001687, "claim": "Ucsf research points to inhalable antiviral that could effectively benefit covid", "label": "REFUTED", "evidence": ["Scientists at UCSF have engineered a new antibody-based antiviral for fighting the COVID-19 pandemic that can be administered as a nasal spray, providing a promising new avenue for slowing the spread of the virus.", "The most potent of these nanobodies was further refined by the UCSF scientists to maximize its antiviral effect."]}
{"id": 1001688, "claim": "Ucsf research failed to inhalable antiviral that could effectively combat covid", "label": "REFUTED", "evidence": ["Scientists at UCSF have engineered a new antibody-based antiviral for fighting the COVID-19 pandemic that can be administered as a nasal spray, providing a promising new avenue for slowing the spread of the virus.", "The most potent of these nanobodies was further refined by the UCSF scientists to maximize its antiviral effect."]}
{"id": 1001689, "claim": "Structural biology helps drive coronavirus vaccine development", "label": "SUPPORTED", "evidence": ["The NIAID is now working with the biotechnology company Moderna, Cambridge, MA, to use the latest findings to develop a vaccine candidate using messenger RNA (mRNA), molecules that serve as templates for making proteins."]}
{"id": 1001690, "claim": "Structural biology helps inhibit coronavirus vaccine development", "label": "REFUTED", "evidence": ["The NIAID is now working with the biotechnology company Moderna, Cambridge, MA, to use the latest findings to develop a vaccine candidate using messenger RNA (mRNA), molecules that serve as templates for making proteins."]}
{"id": 1001691, "claim": "Structural biology helps prevent coronavirus vaccine development", "label": "REFUTED", "evidence": ["The NIAID is now working with the biotechnology company Moderna, Cambridge, MA, to use the latest findings to develop a vaccine candidate using messenger RNA (mRNA), molecules that serve as templates for making proteins."]}
{"id": 1001692, "claim": "Structural biology helps against coronavirus vaccine development", "label": "REFUTED", "evidence": ["The NIAID is now working with the biotechnology company Moderna, Cambridge, MA, to use the latest findings to develop a vaccine candidate using messenger RNA (mRNA), molecules that serve as templates for making proteins."]}
{"id": 1001693, "claim": "Options to reduce quarantine for contacts of persons with sars-cov-2 infection using symptom monitoring and diagnostic testing", "label": "SUPPORTED", "evidence": ["Reducing travel-related SARS-CoV-2 transmission with layered mitigation measures: symptom monitoring, quarantine, and testing medRxiv.", "Quarantine and testing strategies in contact tracing for SARS-CoV-2: a modelling study.", "Strategies to reduce the risk of SARS-CoV-2 reintroduction from international travellers."]}
{"id": 1001694, "claim": "Options to direct quarantine for contacts of persons with sars-cov-2 infection using symptom monitoring and diagnostic testing", "label": "REFUTED", "evidence": ["Reducing travel-related SARS-CoV-2 transmission with layered mitigation measures: symptom monitoring, quarantine, and testing medRxiv.", "Quarantine and testing strategies in contact tracing for SARS-CoV-2: a modelling study.", "Strategies to reduce the risk of SARS-CoV-2 reintroduction from international travellers."]}
{"id": 1001695, "claim": "Options to improve quarantine for contacts of persons with sars-cov-2 infection using symptom monitoring and diagnostic testing", "label": "REFUTED", "evidence": ["Reducing travel-related SARS-CoV-2 transmission with layered mitigation measures: symptom monitoring, quarantine, and testing medRxiv.", "Quarantine and testing strategies in contact tracing for SARS-CoV-2: a modelling study.", "Strategies to reduce the risk of SARS-CoV-2 reintroduction from international travellers."]}
{"id": 1001696, "claim": "Options to enable quarantine for contacts of persons with sars-cov-2 infection using symptom monitoring and diagnostic testing", "label": "REFUTED", "evidence": ["Reducing travel-related SARS-CoV-2 transmission with layered mitigation measures: symptom monitoring, quarantine, and testing medRxiv.", "Quarantine and testing strategies in contact tracing for SARS-CoV-2: a modelling study.", "Strategies to reduce the risk of SARS-CoV-2 reintroduction from international travellers."]}
{"id": 1001697, "claim": "Reinfection could not occur in sars-cov-2 infected rhesus macaques", "label": "SUPPORTED", "evidence": ["Combined with the follow-up virologic, radiological and pathological findings, the monkeys with re- exposure showed no recurrence of COVID-19, similarly to the infected monkey without rechallenge.", "Notably, neither viral loads in nasopharyngeal and anal swabs along timeline nor viral replication in all primary tissue compartments at 5 days post- reinfection (dpr) was found in re-exposed monkeys."]}
{"id": 1001698, "claim": "Reinfection could also occur in sars-cov-2 infected rhesus macaques", "label": "REFUTED", "evidence": ["Combined with the follow-up virologic, radiological and pathological findings, the monkeys with re- exposure showed no recurrence of COVID-19, similarly to the infected monkey without rechallenge.", "Notably, neither viral loads in nasopharyngeal and anal swabs along timeline nor viral replication in all primary tissue compartments at 5 days post- reinfection (dpr) was found in re-exposed monkeys."]}
{"id": 1001699, "claim": "Reinfection could still occur in sars-cov-2 infected rhesus macaques", "label": "REFUTED", "evidence": ["Combined with the follow-up virologic, radiological and pathological findings, the monkeys with re- exposure showed no recurrence of COVID-19, similarly to the infected monkey without rechallenge.", "Notably, neither viral loads in nasopharyngeal and anal swabs along timeline nor viral replication in all primary tissue compartments at 5 days post- reinfection (dpr) was found in re-exposed monkeys."]}
{"id": 1001700, "claim": "Reinfection could likely occur in sars-cov-2 infected rhesus macaques", "label": "REFUTED", "evidence": ["Combined with the follow-up virologic, radiological and pathological findings, the monkeys with re- exposure showed no recurrence of COVID-19, similarly to the infected monkey without rechallenge.", "Notably, neither viral loads in nasopharyngeal and anal swabs along timeline nor viral replication in all primary tissue compartments at 5 days post- reinfection (dpr) was found in re-exposed monkeys."]}
{"id": 1001701, "claim": "Sars-cov-2 spike d614g variant confers enhanced replication and transmissibility", "label": "SUPPORTED", "evidence": ["However, whether the increasing prevalence of the S-614G variant represents a fitness advantage that improves replication and/or transmission in humans or is merely due to founder effects remains elusive.", "Here, we generated isogenic SARS-CoV-2 variants and demonstrate that the S-614G variant has (i) enhanced binding to human ACE2, (ii) increased replication in primary human bronchial and nasal airway epithelial cultures as well as in a novel human ACE2 knock-in mouse model, and (iii) markedly increased replication and transmissibility in hamster and ferret models of SARS-CoV-2 infection.", "Collectively, our data show that while the S-614G substitution results in subtle increases in binding and replication in vitro , it provides a real competitive advantage in vivo , particularly during the transmission bottle neck, providing an explanation for the global predominance of S-614G variant among the SARS-CoV-2 viruses currently circulating."]}
{"id": 1001702, "claim": "Sars-cov-2 spike d614g variant confers reduced replication and transmissibility", "label": "REFUTED", "evidence": ["However, whether the increasing prevalence of the S-614G variant represents a fitness advantage that improves replication and/or transmission in humans or is merely due to founder effects remains elusive.", "Here, we generated isogenic SARS-CoV-2 variants and demonstrate that the S-614G variant has (i) enhanced binding to human ACE2, (ii) increased replication in primary human bronchial and nasal airway epithelial cultures as well as in a novel human ACE2 knock-in mouse model, and (iii) markedly increased replication and transmissibility in hamster and ferret models of SARS-CoV-2 infection.", "Collectively, our data show that while the S-614G substitution results in subtle increases in binding and replication in vitro , it provides a real competitive advantage in vivo , particularly during the transmission bottle neck, providing an explanation for the global predominance of S-614G variant among the SARS-CoV-2 viruses currently circulating."]}
{"id": 1001703, "claim": "Swissmedic starts rolling review of a covid-19 vaccine", "label": "SUPPORTED", "evidence": ["Using the procedure, Swissmedic can review data from ongoing clinical trials as soon as it is available.", "Rolling submission enables Swissmedic to build up a picture of the vaccines risk-benefit profile even before the pivotal clinical trials have been completed."]}
{"id": 1001704, "claim": "Swissmedic starts rolling transmission of a covid-19 vaccine", "label": "REFUTED", "evidence": ["Using the procedure, Swissmedic can review data from ongoing clinical trials as soon as it is available.", "Rolling submission enables Swissmedic to build up a picture of the vaccines risk-benefit profile even before the pivotal clinical trials have been completed."]}
{"id": 1001705, "claim": "Swissmedic starts rolling development of a covid-19 vaccine", "label": "REFUTED", "evidence": ["Using the procedure, Swissmedic can review data from ongoing clinical trials as soon as it is available.", "Rolling submission enables Swissmedic to build up a picture of the vaccines risk-benefit profile even before the pivotal clinical trials have been completed."]}
{"id": 1001706, "claim": "Swissmedic starts rolling generation of a covid-19 vaccine", "label": "REFUTED", "evidence": ["Using the procedure, Swissmedic can review data from ongoing clinical trials as soon as it is available.", "Rolling submission enables Swissmedic to build up a picture of the vaccines risk-benefit profile even before the pivotal clinical trials have been completed."]}
{"id": 1001707, "claim": "Zydus cadila begins human trials of its potential vaccine for coronavirus", "label": "SUPPORTED", "evidence": ["Zydus had earlier this month announced that its plasmid DNA vaccine candidate (ZyCoV-D) developed at its Vaccine Technology Centre in Ahmedabad, India had successfully completed the preclinical phase and had received permission from the Drug Controller General of India (DCGI) permission to initiate Adaptive Phase I/II human clinical trials in India.", "Trade Watchlist Portfolio Message Set Alert live bselive nselive Volume Todays L/H More × Zydus Cadila, on July 15 said that it has begun giving its potential coronavirus (COVID-19) vaccine to healthy volunteers in the first and second phases of human clinical trials across multiple sites."]}
{"id": 1001708, "claim": "Zydus cadila begins human eradication of its potential vaccine for coronavirus", "label": "REFUTED", "evidence": ["Zydus had earlier this month announced that its plasmid DNA vaccine candidate (ZyCoV-D) developed at its Vaccine Technology Centre in Ahmedabad, India had successfully completed the preclinical phase and had received permission from the Drug Controller General of India (DCGI) permission to initiate Adaptive Phase I/II human clinical trials in India.", "Trade Watchlist Portfolio Message Set Alert live bselive nselive Volume Todays L/H More × Zydus Cadila, on July 15 said that it has begun giving its potential coronavirus (COVID-19) vaccine to healthy volunteers in the first and second phases of human clinical trials across multiple sites."]}
{"id": 1001709, "claim": "Ag nanoparticles-based antimicrobial polycotton fabrics to prevent the transmission and spread of sars-cov-2", "label": "SUPPORTED", "evidence": ["Ag nanoparticles (AgNPs) acquire special attention due to its specificity and environment friendly approach with a wide application in industry and medicine due to its antibacterial, antifungal, larvicidal and anti-parasitic characters.", "As an antiviral agent, Ag NPs can interfere with viral replication by two separate mechanisms of adhesion to the surface of the viral envelope.", "The antiviral activity test was designed to determine the inactivation of viral particles upon short exposure to the products, which in this case were the Ag-based treated polycotton samples incubated in liquid media."]}
{"id": 1001710, "claim": "Ag nanoparticles-based antimicrobial polycotton fabrics to enhance the transmission and spread of sars-cov-2", "label": "REFUTED", "evidence": ["Ag nanoparticles (AgNPs) acquire special attention due to its specificity and environment friendly approach with a wide application in industry and medicine due to its antibacterial, antifungal, larvicidal and anti-parasitic characters.", "As an antiviral agent, Ag NPs can interfere with viral replication by two separate mechanisms of adhesion to the surface of the viral envelope.", "The antiviral activity test was designed to determine the inactivation of viral particles upon short exposure to the products, which in this case were the Ag-based treated polycotton samples incubated in liquid media."]}
{"id": 1001711, "claim": "Ag nanoparticles-based antimicrobial polycotton fabrics to promote the transmission and spread of sars-cov-2", "label": "REFUTED", "evidence": ["Ag nanoparticles (AgNPs) acquire special attention due to its specificity and environment friendly approach with a wide application in industry and medicine due to its antibacterial, antifungal, larvicidal and anti-parasitic characters.", "As an antiviral agent, Ag NPs can interfere with viral replication by two separate mechanisms of adhesion to the surface of the viral envelope.", "The antiviral activity test was designed to determine the inactivation of viral particles upon short exposure to the products, which in this case were the Ag-based treated polycotton samples incubated in liquid media."]}
{"id": 1001712, "claim": "Ag nanoparticles-based antimicrobial polycotton fabrics to facilitate the transmission and spread of sars-cov-2", "label": "REFUTED", "evidence": ["Ag nanoparticles (AgNPs) acquire special attention due to its specificity and environment friendly approach with a wide application in industry and medicine due to its antibacterial, antifungal, larvicidal and anti-parasitic characters.", "As an antiviral agent, Ag NPs can interfere with viral replication by two separate mechanisms of adhesion to the surface of the viral envelope.", "The antiviral activity test was designed to determine the inactivation of viral particles upon short exposure to the products, which in this case were the Ag-based treated polycotton samples incubated in liquid media."]}
{"id": 1001713, "claim": "Development and validation of the 4c deterioration model for adults hospitalised with covid-19", "label": "SUPPORTED", "evidence": ["Our 4C Deterioration model thus demonstrates unprecedented clinical utility and generalisability to predict clinical deterioration among adults hospitalised with COVID-19."]}
{"id": 1001714, "claim": "Development and validation of the 4cir model for adults hospitalised with covid-19", "label": "REFUTED", "evidence": ["Our 4C Deterioration model thus demonstrates unprecedented clinical utility and generalisability to predict clinical deterioration among adults hospitalised with COVID-19."]}
{"id": 1001715, "claim": "Development and validation of the 4c clinical model for adults hospitalised with covid-19", "label": "REFUTED", "evidence": ["Our 4C Deterioration model thus demonstrates unprecedented clinical utility and generalisability to predict clinical deterioration among adults hospitalised with COVID-19."]}
{"id": 1001716, "claim": "Development and validation of the 4c animal model for adults hospitalised with covid-19", "label": "REFUTED", "evidence": ["Our 4C Deterioration model thus demonstrates unprecedented clinical utility and generalisability to predict clinical deterioration among adults hospitalised with COVID-19."]}
{"id": 1001717, "claim": "Japanese flu drug could be effective in treating coronavirus , report says", "label": "SUPPORTED", "evidence": ["Patients treated with the drug, which was developed by a subsidiary of Fujifilm, in Shenzen were found to turn negative for COVID-19 after a median of four days, rather than 11 days for those who were not treated with favipiravir, NHK reported."]}
{"id": 1001718, "claim": "Japanese flu drug cannot be effective in treating coronavirus, report says", "label": "REFUTED", "evidence": ["Patients treated with the drug, which was developed by a subsidiary of Fujifilm, in Shenzen were found to turn negative for COVID-19 after a median of four days, rather than 11 days for those who were not treated with favipiravir, NHK reported."]}
{"id": 1001719, "claim": "Mutations not making coronavirus able to spread more rapidly -study", "label": "SUPPORTED", "evidence": ["ONLY] The COVID-19-causing coronavirus is mutating as it spreads around the world in the pandemic, but none of the mutations currently documented appears to be making it able to spread more rapidly, scientists said on Wednesday.Soraya Ali reports."]}
{"id": 1001720, "claim": "Mutations also making coronavirus able to spread more rapidly -study", "label": "REFUTED", "evidence": ["ONLY] The COVID-19-causing coronavirus is mutating as it spreads around the world in the pandemic, but none of the mutations currently documented appears to be making it able to spread more rapidly, scientists said on Wednesday.Soraya Ali reports."]}
{"id": 1001721, "claim": "Mutations are making coronavirus able to spread more rapidly -study", "label": "REFUTED", "evidence": ["ONLY] The COVID-19-causing coronavirus is mutating as it spreads around the world in the pandemic, but none of the mutations currently documented appears to be making it able to spread more rapidly, scientists said on Wednesday.Soraya Ali reports."]}
{"id": 1001722, "claim": "Mutations, making coronavirus able to spread more rapidly -study", "label": "REFUTED", "evidence": ["ONLY] The COVID-19-causing coronavirus is mutating as it spreads around the world in the pandemic, but none of the mutations currently documented appears to be making it able to spread more rapidly, scientists said on Wednesday.Soraya Ali reports."]}
{"id": 1001723, "claim": "Nsp7 and spike glycoprotein of sars-cov-2 are envisaged as potential targets of vitamin d and ivermectin", "label": "SUPPORTED", "evidence": ["Our study, therefore, opens up avenues for further investigations to consider vitamin D and ivermectin as potential drugs against SARS-CoV-2.", "We have analyzed available structures of SARS-CoV-2 proteins to identify probable binding partner(s) of vitamin D and ivermectin through knowledge-based docking studies and figured out possible implication of their binding in SARS-CoV-2 infection."]}
{"id": 1001724, "claim": "Nsp7 and spike glycoprotein of sars-cov-2 are envisaged as potential sources of vitamin d and ivermectin", "label": "REFUTED", "evidence": ["Our study, therefore, opens up avenues for further investigations to consider vitamin D and ivermectin as potential drugs against SARS-CoV-2.", "We have analyzed available structures of SARS-CoV-2 proteins to identify probable binding partner(s) of vitamin D and ivermectin through knowledge-based docking studies and figured out possible implication of their binding in SARS-CoV-2 infection."]}
{"id": 1001725, "claim": "Nsp7 and spike glycoprotein of sars-cov-2 are envisaged as potential causes of vitamin d and ivermectin", "label": "REFUTED", "evidence": ["Our study, therefore, opens up avenues for further investigations to consider vitamin D and ivermectin as potential drugs against SARS-CoV-2.", "We have analyzed available structures of SARS-CoV-2 proteins to identify probable binding partner(s) of vitamin D and ivermectin through knowledge-based docking studies and figured out possible implication of their binding in SARS-CoV-2 infection."]}
{"id": 1001726, "claim": "Nsp7 and spike glycoprotein of sars-cov-2 are envisaged as potential source of vitamin d and ivermectin", "label": "REFUTED", "evidence": ["Our study, therefore, opens up avenues for further investigations to consider vitamin D and ivermectin as potential drugs against SARS-CoV-2.", "We have analyzed available structures of SARS-CoV-2 proteins to identify probable binding partner(s) of vitamin D and ivermectin through knowledge-based docking studies and figured out possible implication of their binding in SARS-CoV-2 infection."]}
{"id": 1001727, "claim": "Covid-19 is far more lethal than influenza", "label": "SUPPORTED", "evidence": ["Yes, influenza is a serious disease, but the evidence shows quite strongly at this point that COVID-19 is far more of an issue.", "Right off the bat it seems like COVID-19 is worse than the flu  0.1% compared to 0.6% makes it about 6x as deadly.", "When we take the most appropriate figures on both diseases, COVID-19 comes out as deadlier in every aspect.", "COVID-19 is FAR deadlier than influenza.", "Sadly, the evidence shows that COVID-19 is far deadlier than influenza, and just overall a very nasty disease."]}
{"id": 1001728, "claim": "Covid-19 is slightly more lethal than influenza", "label": "REFUTED", "evidence": ["Yes, influenza is a serious disease, but the evidence shows quite strongly at this point that COVID-19 is far more of an issue.", "Right off the bat it seems like COVID-19 is worse than the flu  0.1% compared to 0.6% makes it about 6x as deadly.", "When we take the most appropriate figures on both diseases, COVID-19 comes out as deadlier in every aspect.", "COVID-19 is FAR deadlier than influenza.", "Sadly, the evidence shows that COVID-19 is far deadlier than influenza, and just overall a very nasty disease."]}
{"id": 1001729, "claim": "Covid-19 is far more lethal during influenza", "label": "REFUTED", "evidence": ["Yes, influenza is a serious disease, but the evidence shows quite strongly at this point that COVID-19 is far more of an issue.", "Right off the bat it seems like COVID-19 is worse than the flu  0.1% compared to 0.6% makes it about 6x as deadly.", "When we take the most appropriate figures on both diseases, COVID-19 comes out as deadlier in every aspect.", "COVID-19 is FAR deadlier than influenza.", "Sadly, the evidence shows that COVID-19 is far deadlier than influenza, and just overall a very nasty disease."]}
{"id": 1001730, "claim": "Protein structure and sequence reanalysis of 2019-ncov genome refutes snakes as its intermediate host and the unique similarity between its spike protein insertions and hiv-1 .", "label": "SUPPORTED", "evidence": ["Addnl., our findings suggest that 2019-nCoV has most similar genetic information with bat coronavirus and most similar codon usage bias with snake.", "In this Communication, we first analyzed two recent studies that concluded that snakes are the intermediate hosts of 2019-nCoV and that the 2019-nCoV spike protein insertions share a unique similarity to HIV-1."]}
{"id": 1001731, "claim": "Protein structure and sequence reanalysis of 2019-ncov genome refutes bats as its intermediate host and the unique similarity between its spike protein insertions and hiv-1.", "label": "REFUTED", "evidence": ["Addnl., our findings suggest that 2019-nCoV has most similar genetic information with bat coronavirus and most similar codon usage bias with snake.", "In this Communication, we first analyzed two recent studies that concluded that snakes are the intermediate hosts of 2019-nCoV and that the 2019-nCoV spike protein insertions share a unique similarity to HIV-1."]}
{"id": 1001732, "claim": "Iupui , isdh release findings from phase 2 of covid-19 testing in indiana", "label": "SUPPORTED", "evidence": ["In its second phase, the study -- a collaboration between the Indiana State Department of Health and the Fairbanks School of Public Health \\-- tested more than 3,600 Hoosiers between June 3 and June 8 for viral infections and antibodies of SARS-CoV-2, the novel coronavirus that causes COVID-19 disease."]}
{"id": 1001733, "claim": "Iupui, isdh release findings from phase 2 of covid-19 outbreaks in indiana", "label": "REFUTED", "evidence": ["In its second phase, the study -- a collaboration between the Indiana State Department of Health and the Fairbanks School of Public Health \\-- tested more than 3,600 Hoosiers between June 3 and June 8 for viral infections and antibodies of SARS-CoV-2, the novel coronavirus that causes COVID-19 disease."]}
{"id": 1001734, "claim": "Iupui, isdh release findings from phase 2 of covid-19 outbreak in indiana", "label": "REFUTED", "evidence": ["In its second phase, the study -- a collaboration between the Indiana State Department of Health and the Fairbanks School of Public Health \\-- tested more than 3,600 Hoosiers between June 3 and June 8 for viral infections and antibodies of SARS-CoV-2, the novel coronavirus that causes COVID-19 disease."]}
{"id": 1001735, "claim": "The explosion of new coronavirus tests that could help to end the pandemic", "label": "SUPPORTED", "evidence": ["But once they are available, they could work alongside the gold standard to push countries closer to the target of millions of tests per week  and prepare the world for the next pandemic.", "If those tests are ready soon, it would be good news for the current pandemic and for future outbreaks."]}
{"id": 1001736, "claim": "The explosion of new coronavirus tests that could help to confirm the pandemic", "label": "REFUTED", "evidence": ["But once they are available, they could work alongside the gold standard to push countries closer to the target of millions of tests per week  and prepare the world for the next pandemic.", "If those tests are ready soon, it would be good news for the current pandemic and for future outbreaks."]}
{"id": 1001737, "claim": "The explosion of new coronavirus tests that could help to study the pandemic", "label": "REFUTED", "evidence": ["But once they are available, they could work alongside the gold standard to push countries closer to the target of millions of tests per week  and prepare the world for the next pandemic.", "If those tests are ready soon, it would be good news for the current pandemic and for future outbreaks."]}
{"id": 1001738, "claim": "Second round of covid-19 community testing completed ; miami-dade county and the university of miami miller school of medicine announce initial findings", "label": "SUPPORTED", "evidence": ["In both weeks, 6% of participants tested positive for COVID-19 antibodies, which equates to 165,000 Miami-Dade County residents.", "This represents 85% of residents who were randomly selected to participate in the initiative; participants voluntarily shared information about their health, and gave two drops of blood to determine whether they had produced antibodies to the novel coronavirus infection."]}
{"id": 1001739, "claim": "One round of covid-19 community testing completed ; miami-dade county and the university of miami miller school of medicine announce initial findings", "label": "REFUTED", "evidence": ["In both weeks, 6% of participants tested positive for COVID-19 antibodies, which equates to 165,000 Miami-Dade County residents.", "This represents 85% of residents who were randomly selected to participate in the initiative; participants voluntarily shared information about their health, and gave two drops of blood to determine whether they had produced antibodies to the novel coronavirus infection."]}
{"id": 1001740, "claim": "Each round of covid-19 community testing completed ; miami-dade county and the university of miami miller school of medicine announce initial findings", "label": "REFUTED", "evidence": ["In both weeks, 6% of participants tested positive for COVID-19 antibodies, which equates to 165,000 Miami-Dade County residents.", "This represents 85% of residents who were randomly selected to participate in the initiative; participants voluntarily shared information about their health, and gave two drops of blood to determine whether they had produced antibodies to the novel coronavirus infection."]}
{"id": 1001741, "claim": "Three round of covid-19 community testing completed ; miami-dade county and the university of miami miller school of medicine announce initial findings", "label": "REFUTED", "evidence": ["In both weeks, 6% of participants tested positive for COVID-19 antibodies, which equates to 165,000 Miami-Dade County residents.", "This represents 85% of residents who were randomly selected to participate in the initiative; participants voluntarily shared information about their health, and gave two drops of blood to determine whether they had produced antibodies to the novel coronavirus infection."]}
{"id": 1001742, "claim": "Neurorx and relief therapeutics announce enrollment of 150 patients in phase 2b/3 trial of rlf-100 for critical covid-19 with respiratory failure", "label": "SUPPORTED", "evidence": ["Since July 2020, more than 210 patients with Critical COVID-19 and Respiratory Failure have been treated with RLF-100 under FDA-approved protocols."]}
{"id": 1001743, "claim": "Lancet retracts paper that halted hydroxychloroquine trials", "label": "SUPPORTED", "evidence": ["We do not agree with your premise or the nature of what you have put together, and I am sad to see that what should have been a scientific discussion has been denigrated into this sort of discussion. Shortly after the Lancet retracted its study, the New England Journal of Medicine retracted a paper based on the Surgisphere database, also co-authored by Mehra and Desai.", "Photograph: George Frey/Reuters Sarah Boseley and Melissa Davey Thu 4 Jun 2020 15.43 EDT Last modified on Wed 1 Jul 2020 12.19 EDT The Lancet paper that halted global trials of hydroxychloroquine for Covid-19 because of fears of increased deaths has been retracted after a Guardian investigation found inconsistencies in the data.", "As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process. The Lancet study had a dramatic impact on attempts to find out whether the antimalarial drug hydroxychloroquine, and its older version, chloroquine, could help treat patients with Covid-19."]}
{"id": 1001744, "claim": "Lancet retracts paper that received hydroxychloroquine trials", "label": "REFUTED", "evidence": ["We do not agree with your premise or the nature of what you have put together, and I am sad to see that what should have been a scientific discussion has been denigrated into this sort of discussion. Shortly after the Lancet retracted its study, the New England Journal of Medicine retracted a paper based on the Surgisphere database, also co-authored by Mehra and Desai.", "Photograph: George Frey/Reuters Sarah Boseley and Melissa Davey Thu 4 Jun 2020 15.43 EDT Last modified on Wed 1 Jul 2020 12.19 EDT The Lancet paper that halted global trials of hydroxychloroquine for Covid-19 because of fears of increased deaths has been retracted after a Guardian investigation found inconsistencies in the data.", "As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process. The Lancet study had a dramatic impact on attempts to find out whether the antimalarial drug hydroxychloroquine, and its older version, chloroquine, could help treat patients with Covid-19."]}
{"id": 1001745, "claim": "Lancet retracts paper that included hydroxychloroquine trials", "label": "REFUTED", "evidence": ["We do not agree with your premise or the nature of what you have put together, and I am sad to see that what should have been a scientific discussion has been denigrated into this sort of discussion. Shortly after the Lancet retracted its study, the New England Journal of Medicine retracted a paper based on the Surgisphere database, also co-authored by Mehra and Desai.", "Photograph: George Frey/Reuters Sarah Boseley and Melissa Davey Thu 4 Jun 2020 15.43 EDT Last modified on Wed 1 Jul 2020 12.19 EDT The Lancet paper that halted global trials of hydroxychloroquine for Covid-19 because of fears of increased deaths has been retracted after a Guardian investigation found inconsistencies in the data.", "As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process. The Lancet study had a dramatic impact on attempts to find out whether the antimalarial drug hydroxychloroquine, and its older version, chloroquine, could help treat patients with Covid-19."]}
{"id": 1001746, "claim": "Lancet retracts paper that includes hydroxychloroquine trials", "label": "REFUTED", "evidence": ["We do not agree with your premise or the nature of what you have put together, and I am sad to see that what should have been a scientific discussion has been denigrated into this sort of discussion. Shortly after the Lancet retracted its study, the New England Journal of Medicine retracted a paper based on the Surgisphere database, also co-authored by Mehra and Desai.", "Photograph: George Frey/Reuters Sarah Boseley and Melissa Davey Thu 4 Jun 2020 15.43 EDT Last modified on Wed 1 Jul 2020 12.19 EDT The Lancet paper that halted global trials of hydroxychloroquine for Covid-19 because of fears of increased deaths has been retracted after a Guardian investigation found inconsistencies in the data.", "As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process. The Lancet study had a dramatic impact on attempts to find out whether the antimalarial drug hydroxychloroquine, and its older version, chloroquine, could help treat patients with Covid-19."]}
{"id": 1001747, "claim": "The unexpected spectacular 2020 october covid-19 boost date in european countries correlated with the latitude , but not with the temperature", "label": "SUPPORTED", "evidence": ["Share The unexpected 2020 October COVID-19 boost date in European countries correlated with the latitude, but not with the temperature Stephan Walrand medRxiv 2020.10.28.20221176; doi: https://doi.org/10.1101/2020.10.28.20221176 Share This Article: Copy Citation Tools The unexpected 2020 October COVID-19 boost date in European countries correlated with the latitude, but not with the temperature Stephan Walrand medRxiv 2020.10.28.20221176; doi: https://doi.org/10.1101/2020.10.28.20221176 ", "The present study shows no correlation between the country COVID-19 boost date and its 2 weeks preceding temperature, but shows an impressive correlation with the country latitude.", "You are going to email the following The unexpected 2020 October COVID-19 boost date in European countries correlated with the latitude, but not with the temperature Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website.", "Share The autumn COVID-19 surge dates in Europe are linked to latitudes and not to temperature, nor to humidity, pointing vitamin D as a contributing factor Stephan Walrand medRxiv 2020.10.28.20221176; doi: https://doi.org/10.1101/2020.10.28.20221176 Share This Article: Copy Citation Tools The autumn COVID-19 surge dates in Europe are linked to latitudes and not to temperature, nor to humidity, pointing vitamin D as a contributing factor Stephan Walrand medRxiv 2020.10.28.20221176; doi: https://doi.org/10.1101/2020.10.28.20221176 "]}
{"id": 1001748, "claim": "The unexpected spectacular 2020 october covid-19 boost date in european countries correlated with the latitude, but also with the temperature", "label": "REFUTED", "evidence": ["Share The unexpected 2020 October COVID-19 boost date in European countries correlated with the latitude, but not with the temperature Stephan Walrand medRxiv 2020.10.28.20221176; doi: https://doi.org/10.1101/2020.10.28.20221176 Share This Article: Copy Citation Tools The unexpected 2020 October COVID-19 boost date in European countries correlated with the latitude, but not with the temperature Stephan Walrand medRxiv 2020.10.28.20221176; doi: https://doi.org/10.1101/2020.10.28.20221176 ", "The present study shows no correlation between the country COVID-19 boost date and its 2 weeks preceding temperature, but shows an impressive correlation with the country latitude.", "You are going to email the following The unexpected 2020 October COVID-19 boost date in European countries correlated with the latitude, but not with the temperature Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website.", "Share The autumn COVID-19 surge dates in Europe are linked to latitudes and not to temperature, nor to humidity, pointing vitamin D as a contributing factor Stephan Walrand medRxiv 2020.10.28.20221176; doi: https://doi.org/10.1101/2020.10.28.20221176 Share This Article: Copy Citation Tools The autumn COVID-19 surge dates in Europe are linked to latitudes and not to temperature, nor to humidity, pointing vitamin D as a contributing factor Stephan Walrand medRxiv 2020.10.28.20221176; doi: https://doi.org/10.1101/2020.10.28.20221176 "]}
{"id": 1001749, "claim": "Insight into vaccine development for alpha-coronaviruses based on structural and immunological analyses of spike proteins", "label": "SUPPORTED", "evidence": ["Our results indicate that Alpha-coronavirus is more conducive to escape host immune recognition, and also provide novel ideas for the development of vaccines targeting S protein.", "Coronavirus spike (S) protein is considered as a major target for vaccine development.", "Then, structural and immunological analyses were used to explore differences in the immune response with RBDs among these coronaviruses."]}
{"id": 1001750, "claim": "Insight into vaccine development for alpha-coronaviruses based on structural and immunological analyses of spike genes", "label": "REFUTED", "evidence": ["Our results indicate that Alpha-coronavirus is more conducive to escape host immune recognition, and also provide novel ideas for the development of vaccines targeting S protein.", "Coronavirus spike (S) protein is considered as a major target for vaccine development.", "Then, structural and immunological analyses were used to explore differences in the immune response with RBDs among these coronaviruses."]}
{"id": 1001751, "claim": "Susceptible supply limits the role of climate in the early sars-cov-2 pandemic", "label": "SUPPORTED", "evidence": ["In this scenario, as susceptibility declines, the climate plays a more substantial role in determining pandemic peak size (Fig.", "Furthermore, the relative importance of climate drivers when compared with high population susceptibility during the pandemic stage of an emerging infection such as SARS-CoV-2 has not been fully characterized.", "In terms of the SARS-CoV-2 pandemic, our results imply that both tropical and temperate locations should prepare for severe outbreaks of the disease and that summertime temperatures will not effectively limit the spread of the infection.", "A preliminary analysis of nonpharmaceutical control measures indicates that they may moderate the pandemic-climate interaction through susceptible depletion."]}
{"id": 1001752, "claim": "Susceptible supply supports the role of climate in the early sars-cov-2 pandemic", "label": "REFUTED", "evidence": ["In this scenario, as susceptibility declines, the climate plays a more substantial role in determining pandemic peak size (Fig.", "Furthermore, the relative importance of climate drivers when compared with high population susceptibility during the pandemic stage of an emerging infection such as SARS-CoV-2 has not been fully characterized.", "In terms of the SARS-CoV-2 pandemic, our results imply that both tropical and temperate locations should prepare for severe outbreaks of the disease and that summertime temperatures will not effectively limit the spread of the infection.", "A preliminary analysis of nonpharmaceutical control measures indicates that they may moderate the pandemic-climate interaction through susceptible depletion."]}
{"id": 1001753, "claim": "Susceptible supply increases the role of climate in the early sars-cov-2 pandemic", "label": "REFUTED", "evidence": ["In this scenario, as susceptibility declines, the climate plays a more substantial role in determining pandemic peak size (Fig.", "Furthermore, the relative importance of climate drivers when compared with high population susceptibility during the pandemic stage of an emerging infection such as SARS-CoV-2 has not been fully characterized.", "In terms of the SARS-CoV-2 pandemic, our results imply that both tropical and temperate locations should prepare for severe outbreaks of the disease and that summertime temperatures will not effectively limit the spread of the infection.", "A preliminary analysis of nonpharmaceutical control measures indicates that they may moderate the pandemic-climate interaction through susceptible depletion."]}
{"id": 1001754, "claim": "Susceptible supply highlights the role of climate in the early sars-cov-2 pandemic", "label": "REFUTED", "evidence": ["In this scenario, as susceptibility declines, the climate plays a more substantial role in determining pandemic peak size (Fig.", "Furthermore, the relative importance of climate drivers when compared with high population susceptibility during the pandemic stage of an emerging infection such as SARS-CoV-2 has not been fully characterized.", "In terms of the SARS-CoV-2 pandemic, our results imply that both tropical and temperate locations should prepare for severe outbreaks of the disease and that summertime temperatures will not effectively limit the spread of the infection.", "A preliminary analysis of nonpharmaceutical control measures indicates that they may moderate the pandemic-climate interaction through susceptible depletion."]}
{"id": 1001755, "claim": "Test sensitivity is secondary to frequency and turnaround time for covid-19 screening", "label": "SUPPORTED", "evidence": ["We therefore conclude that screening should prioritize accessibility, frequency, and sample-to-answer time; analytical limits of detection should be secondary."]}
{"id": 1001756, "claim": "Test sensitivity is equivalent to frequency and turnaround time for covid-19 screening", "label": "REFUTED", "evidence": ["We therefore conclude that screening should prioritize accessibility, frequency, and sample-to-answer time; analytical limits of detection should be secondary."]}
{"id": 1001757, "claim": "Test sensitivity is equal to frequency and turnaround time for covid-19 screening", "label": "REFUTED", "evidence": ["We therefore conclude that screening should prioritize accessibility, frequency, and sample-to-answer time; analytical limits of detection should be secondary."]}
{"id": 1001758, "claim": "Single-dose intranasal administration of adcovid elicits systemic and mucosal immunity against sars-cov-2 in mice", "label": "SUPPORTED", "evidence": ["Therefore, AdCOVID, which promotes concomitant systemic and local mucosal immunity, represents a promising COVID-19 vaccine candidate."]}
{"id": 1001759, "claim": "Single-dose intranasal administration of adcovid elicits systemic and mucosal immunity against sars-cov-2 in humans", "label": "REFUTED", "evidence": ["Therefore, AdCOVID, which promotes concomitant systemic and local mucosal immunity, represents a promising COVID-19 vaccine candidate."]}
{"id": 1001760, "claim": "Ontario significantly expanding covid-19 testing enhanced testing strategy will help stop the spread of the virus", "label": "SUPPORTED", "evidence": ["This testing strategy follows extensive efforts to expand Ontario's lab testing capacity, which helped to quickly eliminate a backlog of approximately 10,000 people within less than two weeks.", "Ontarios new long-term care guidelines have broadened the virus testing criteria, by allowing individuals with uncharacteristic symptoms related to COVID-19 to be tested.", "The province is also helping to significantly expand the capacity of public health units to conduct contact tracing and case management, both of which are critical to stopping the spread of the virus, by enabling the use of volunteers, including retired nurses and medical students.", "By implementing this strategy, Ontario expects to double the number of tests processed each day to 8,000 by April 15, 2020 and 14,000 by April 29, 2020, at which point overall lab capacity will have been further expanded."]}
{"id": 1001761, "claim": "Ontario significantly reduced covid-19 testing enhanced testing strategy will help stop the spread of the virus", "label": "REFUTED", "evidence": ["This testing strategy follows extensive efforts to expand Ontario's lab testing capacity, which helped to quickly eliminate a backlog of approximately 10,000 people within less than two weeks.", "Ontarios new long-term care guidelines have broadened the virus testing criteria, by allowing individuals with uncharacteristic symptoms related to COVID-19 to be tested.", "The province is also helping to significantly expand the capacity of public health units to conduct contact tracing and case management, both of which are critical to stopping the spread of the virus, by enabling the use of volunteers, including retired nurses and medical students.", "By implementing this strategy, Ontario expects to double the number of tests processed each day to 8,000 by April 15, 2020 and 14,000 by April 29, 2020, at which point overall lab capacity will have been further expanded."]}
{"id": 1001762, "claim": "Ontario significantly reduces covid-19 testing enhanced testing strategy will help stop the spread of the virus", "label": "REFUTED", "evidence": ["This testing strategy follows extensive efforts to expand Ontario's lab testing capacity, which helped to quickly eliminate a backlog of approximately 10,000 people within less than two weeks.", "Ontarios new long-term care guidelines have broadened the virus testing criteria, by allowing individuals with uncharacteristic symptoms related to COVID-19 to be tested.", "The province is also helping to significantly expand the capacity of public health units to conduct contact tracing and case management, both of which are critical to stopping the spread of the virus, by enabling the use of volunteers, including retired nurses and medical students.", "By implementing this strategy, Ontario expects to double the number of tests processed each day to 8,000 by April 15, 2020 and 14,000 by April 29, 2020, at which point overall lab capacity will have been further expanded."]}
{"id": 1001763, "claim": "Ontario significantly reduce covid-19 testing enhanced testing strategy will help stop the spread of the virus", "label": "REFUTED", "evidence": ["This testing strategy follows extensive efforts to expand Ontario's lab testing capacity, which helped to quickly eliminate a backlog of approximately 10,000 people within less than two weeks.", "Ontarios new long-term care guidelines have broadened the virus testing criteria, by allowing individuals with uncharacteristic symptoms related to COVID-19 to be tested.", "The province is also helping to significantly expand the capacity of public health units to conduct contact tracing and case management, both of which are critical to stopping the spread of the virus, by enabling the use of volunteers, including retired nurses and medical students.", "By implementing this strategy, Ontario expects to double the number of tests processed each day to 8,000 by April 15, 2020 and 14,000 by April 29, 2020, at which point overall lab capacity will have been further expanded."]}
{"id": 1001764, "claim": "Nhs patients to receive life-saving covid-19 treatments that could cut hospital time by 10 days.", "label": "SUPPORTED", "evidence": ["Tocilizumab will be used to further reduce mortality from COVID-19 and in addition to dexamethasone, which is already standard of care for hospitalised patients receiving supplemental oxygen.", "For patients needing oxygen, it cut the risk of death from 25% to 20%.", "Patients in intensive care units across the UK are to receive potentially life-saving treatments for COVID-19 Government ensures life-saving drugs will be available in NHS healthcare settings with immediate effect Patients across the UK who are admitted to intensive care units due to COVID-19 are set to receive new life-saving treatments which can reduce the time spent in hospital by up to 10 days, the government has announced yesterday (Thursday 7 January).", "Published 7 January 2021 From: Department of Health and Social Care Patients in intensive care units across the UK are to receive potentially life-saving treatments for COVID-19 Government ensures life-saving drugs will be available in NHS healthcare settings with immediate effect Patients across the UK who are admitted to intensive care units due to COVID-19 are set to receive new life-saving treatments which can reduce the time spent in hospital by up to 10 days, the government has announced today (Thursday 7 January)."]}
{"id": 1001765, "claim": "Nhs patients to receive life-saving covid-19 treatments that could cut hospital time by 10 years.", "label": "REFUTED", "evidence": ["Tocilizumab will be used to further reduce mortality from COVID-19 and in addition to dexamethasone, which is already standard of care for hospitalised patients receiving supplemental oxygen.", "For patients needing oxygen, it cut the risk of death from 25% to 20%.", "Patients in intensive care units across the UK are to receive potentially life-saving treatments for COVID-19 Government ensures life-saving drugs will be available in NHS healthcare settings with immediate effect Patients across the UK who are admitted to intensive care units due to COVID-19 are set to receive new life-saving treatments which can reduce the time spent in hospital by up to 10 days, the government has announced yesterday (Thursday 7 January).", "Published 7 January 2021 From: Department of Health and Social Care Patients in intensive care units across the UK are to receive potentially life-saving treatments for COVID-19 Government ensures life-saving drugs will be available in NHS healthcare settings with immediate effect Patients across the UK who are admitted to intensive care units due to COVID-19 are set to receive new life-saving treatments which can reduce the time spent in hospital by up to 10 days, the government has announced today (Thursday 7 January)."]}
{"id": 1001766, "claim": "Nhs patients to receive life-saving covid-19 treatments that could cut hospital time by 10 minutes.", "label": "REFUTED", "evidence": ["Tocilizumab will be used to further reduce mortality from COVID-19 and in addition to dexamethasone, which is already standard of care for hospitalised patients receiving supplemental oxygen.", "For patients needing oxygen, it cut the risk of death from 25% to 20%.", "Patients in intensive care units across the UK are to receive potentially life-saving treatments for COVID-19 Government ensures life-saving drugs will be available in NHS healthcare settings with immediate effect Patients across the UK who are admitted to intensive care units due to COVID-19 are set to receive new life-saving treatments which can reduce the time spent in hospital by up to 10 days, the government has announced yesterday (Thursday 7 January).", "Published 7 January 2021 From: Department of Health and Social Care Patients in intensive care units across the UK are to receive potentially life-saving treatments for COVID-19 Government ensures life-saving drugs will be available in NHS healthcare settings with immediate effect Patients across the UK who are admitted to intensive care units due to COVID-19 are set to receive new life-saving treatments which can reduce the time spent in hospital by up to 10 days, the government has announced today (Thursday 7 January)."]}
{"id": 1001767, "claim": "Nhs patients to receive life-saving covid-19 treatments that could cut hospital time by 10 seconds.", "label": "REFUTED", "evidence": ["Tocilizumab will be used to further reduce mortality from COVID-19 and in addition to dexamethasone, which is already standard of care for hospitalised patients receiving supplemental oxygen.", "For patients needing oxygen, it cut the risk of death from 25% to 20%.", "Patients in intensive care units across the UK are to receive potentially life-saving treatments for COVID-19 Government ensures life-saving drugs will be available in NHS healthcare settings with immediate effect Patients across the UK who are admitted to intensive care units due to COVID-19 are set to receive new life-saving treatments which can reduce the time spent in hospital by up to 10 days, the government has announced yesterday (Thursday 7 January).", "Published 7 January 2021 From: Department of Health and Social Care Patients in intensive care units across the UK are to receive potentially life-saving treatments for COVID-19 Government ensures life-saving drugs will be available in NHS healthcare settings with immediate effect Patients across the UK who are admitted to intensive care units due to COVID-19 are set to receive new life-saving treatments which can reduce the time spent in hospital by up to 10 days, the government has announced today (Thursday 7 January)."]}
{"id": 1001768, "claim": "Moderna announces initiation of rolling submission to health canada for mrna vaccine against covid-19", "label": "SUPPORTED", "evidence": ["We are pleased with the interactions with the Canadian regulatory authorities and we appreciate their guidance and confidence in Moderna to pursue a rolling submission in Canada for our COVID-19 vaccine candidate, mRNA-1273, said Stéphane Bancel, Modernas Chief Executive Officer."]}
{"id": 1001769, "claim": "Moderna announces out of rolling submission to health canada for mrna vaccine against covid-19", "label": "REFUTED", "evidence": ["We are pleased with the interactions with the Canadian regulatory authorities and we appreciate their guidance and confidence in Moderna to pursue a rolling submission in Canada for our COVID-19 vaccine candidate, mRNA-1273, said Stéphane Bancel, Modernas Chief Executive Officer."]}
{"id": 1001770, "claim": "Moderna announces instead of rolling submission to health canada for mrna vaccine against covid-19", "label": "REFUTED", "evidence": ["We are pleased with the interactions with the Canadian regulatory authorities and we appreciate their guidance and confidence in Moderna to pursue a rolling submission in Canada for our COVID-19 vaccine candidate, mRNA-1273, said Stéphane Bancel, Modernas Chief Executive Officer."]}
{"id": 1001771, "claim": "Una announces initiation of rolling submission to health canada for mrna vaccine against covid-19", "label": "REFUTED", "evidence": ["We are pleased with the interactions with the Canadian regulatory authorities and we appreciate their guidance and confidence in Moderna to pursue a rolling submission in Canada for our COVID-19 vaccine candidate, mRNA-1273, said Stéphane Bancel, Modernas Chief Executive Officer."]}
{"id": 1001772, "claim": "Covid-19 may attack immune system like hiv , doctors fear", "label": "SUPPORTED", "evidence": ["In many patients hospitalized with the coronavirus, the immune system is threatened by a depletion of certain essential cells, suggesting eerie parallels with H.I.V."]}
{"id": 1001773, "claim": "Covid-19 may support immune system like hiv, doctors fear", "label": "REFUTED", "evidence": ["In many patients hospitalized with the coronavirus, the immune system is threatened by a depletion of certain essential cells, suggesting eerie parallels with H.I.V."]}
{"id": 1001774, "claim": "Covid-19 may promote immune system like hiv, doctors fear", "label": "REFUTED", "evidence": ["In many patients hospitalized with the coronavirus, the immune system is threatened by a depletion of certain essential cells, suggesting eerie parallels with H.I.V."]}
{"id": 1001775, "claim": "Covid-19 may improve immune system like hiv, doctors fear", "label": "REFUTED", "evidence": ["In many patients hospitalized with the coronavirus, the immune system is threatened by a depletion of certain essential cells, suggesting eerie parallels with H.I.V."]}
{"id": 1001776, "claim": "Obesity  a risk factor for increased covid19 prevalence , severity and lethality", "label": "SUPPORTED", "evidence": ["Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity.", "Obesity and impaired metabolic health in patients with COVID-19.", "Finally, pregnancyassociated obesity needs to be studied further in connection to COVID19 as this infection could pose high risk both to pregnant women and the fetus."]}
{"id": 1001777, "claim": "Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude sars-cov-2 infection and severe covid-19", "label": "SUPPORTED", "evidence": ["Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study."]}
{"id": 1001778, "claim": "Baseline use of hydroxychloroquine in systemic lupus erythematosus does also preclude sars-cov-2 infection and severe covid-19", "label": "REFUTED", "evidence": ["Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study."]}
{"id": 1001779, "claim": "Baseline use of hydroxychloroquine in systemic lupus erythematosus does indeed preclude sars-cov-2 infection and severe covid-19", "label": "REFUTED", "evidence": ["Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study."]}
{"id": 1001780, "claim": "Baseline use of hydroxychloroquine in systemic lupus erythematosus does still preclude sars-cov-2 infection and severe covid-19", "label": "REFUTED", "evidence": ["Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study."]}
{"id": 1001781, "claim": "Ct scan is a viable alternative for coronavirus test", "label": "SUPPORTED", "evidence": ["Imaging Modality Chest radiograph (CXR) or computed tomography (CT) is an essential tool for COVID-19 diagnosis in clinical practice.", "According to a research article in Radiology, CT is far more sensitive, commonly detecting cases the swab misses.", "Now, computed tomography (CT) is widely used as the imaging modality for the detection of COVID-19 pneumonia."]}
{"id": 1001782, "claim": "Ct scan is a viable standard for coronavirus test", "label": "REFUTED", "evidence": ["Imaging Modality Chest radiograph (CXR) or computed tomography (CT) is an essential tool for COVID-19 diagnosis in clinical practice.", "According to a research article in Radiology, CT is far more sensitive, commonly detecting cases the swab misses.", "Now, computed tomography (CT) is widely used as the imaging modality for the detection of COVID-19 pneumonia."]}
{"id": 1001783, "claim": "The ace2 expression in human heart indicates new potential mechanism of heart injury among patients infected with sars-cov-2", "label": "SUPPORTED", "evidence": ["This study performed the first state-of-art single cell atlas of adult human heart, and revealed that pericytes with high expression of ACE2 might act as the target cardiac cell of SARS-CoV-2.", "And patients with basic heart failure disease showed increased ACE2 expression at both mRNA and protein levels, meaning that if infected by the virus these patients may have higher risk of heart attack and critically ill condition.", "Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts."]}
{"id": 1001784, "claim": "The ace2 expression in canine heart indicates new potential mechanism of heart injury among patients infected with sars-cov-2", "label": "REFUTED", "evidence": ["This study performed the first state-of-art single cell atlas of adult human heart, and revealed that pericytes with high expression of ACE2 might act as the target cardiac cell of SARS-CoV-2.", "And patients with basic heart failure disease showed increased ACE2 expression at both mRNA and protein levels, meaning that if infected by the virus these patients may have higher risk of heart attack and critically ill condition.", "Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts."]}
{"id": 1001785, "claim": "The ace2 expression in rat heart indicates new potential mechanism of heart injury among patients infected with sars-cov-2", "label": "REFUTED", "evidence": ["This study performed the first state-of-art single cell atlas of adult human heart, and revealed that pericytes with high expression of ACE2 might act as the target cardiac cell of SARS-CoV-2.", "And patients with basic heart failure disease showed increased ACE2 expression at both mRNA and protein levels, meaning that if infected by the virus these patients may have higher risk of heart attack and critically ill condition.", "Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts."]}
{"id": 1001786, "claim": "Single-cell analyses reveal sars-cov-2 interference with intrinsic immune response in the human gut", "label": "SUPPORTED", "evidence": ["Human intestinal epithelium cells produce interferon upon SARS-CoV-2 infection.", "Conclusion Our findings reveal that SARS-CoV-2 curtails the immune response in primary human intestinal epithelial cells to promote its replication and spread and this highlights the gut as a proinflammatory reservoir that should be considered to fully understand SARS-CoV-2 pathogenesis."]}
{"id": 1001787, "claim": "Single-world analyses reveal sars-cov-2 interference with intrinsic immune response in the human gut", "label": "REFUTED", "evidence": ["Human intestinal epithelium cells produce interferon upon SARS-CoV-2 infection.", "Conclusion Our findings reveal that SARS-CoV-2 curtails the immune response in primary human intestinal epithelial cells to promote its replication and spread and this highlights the gut as a proinflammatory reservoir that should be considered to fully understand SARS-CoV-2 pathogenesis."]}
{"id": 1001788, "claim": "Single-dimensional analyses reveal sars-cov-2 interference with intrinsic immune response in the human gut", "label": "REFUTED", "evidence": ["Human intestinal epithelium cells produce interferon upon SARS-CoV-2 infection.", "Conclusion Our findings reveal that SARS-CoV-2 curtails the immune response in primary human intestinal epithelial cells to promote its replication and spread and this highlights the gut as a proinflammatory reservoir that should be considered to fully understand SARS-CoV-2 pathogenesis."]}
{"id": 1001789, "claim": "Single-hybrid analyses reveal sars-cov-2 interference with intrinsic immune response in the human gut", "label": "REFUTED", "evidence": ["Human intestinal epithelium cells produce interferon upon SARS-CoV-2 infection.", "Conclusion Our findings reveal that SARS-CoV-2 curtails the immune response in primary human intestinal epithelial cells to promote its replication and spread and this highlights the gut as a proinflammatory reservoir that should be considered to fully understand SARS-CoV-2 pathogenesis."]}
{"id": 1001790, "claim": "Serology in children with multisystem inflammatory syndrome associated with covid-19", "label": "SUPPORTED", "evidence": ["COVID-19-associated multisystem inflammatory syndrome in children - United States, March-July 2020.", "COVID-19-Associated Multisystem Inflammatory Syndrome in Children -- United States, March-July 2020.", "Two of the children with MIS-C had concurrently positive SARS-CoV-2 nasopharyngeal RT-PCR results, and their clinical presentation of MIS-C appeared to coincide with symptomatic COVID-19.", "The patients' signs and symptoms were temporally associated with COVID-19 but presumed to have developed 2-4 weeks after acute COVID-19; all children had serologic evidence of infection with SARS-CoV-2, the virus that causes COVID-19 ( 1 )."]}
{"id": 1001791, "claim": "Serology in dogs with multisystem inflammatory syndrome associated with covid-19", "label": "REFUTED", "evidence": ["COVID-19-associated multisystem inflammatory syndrome in children - United States, March-July 2020.", "COVID-19-Associated Multisystem Inflammatory Syndrome in Children -- United States, March-July 2020.", "Two of the children with MIS-C had concurrently positive SARS-CoV-2 nasopharyngeal RT-PCR results, and their clinical presentation of MIS-C appeared to coincide with symptomatic COVID-19.", "The patients' signs and symptoms were temporally associated with COVID-19 but presumed to have developed 2-4 weeks after acute COVID-19; all children had serologic evidence of infection with SARS-CoV-2, the virus that causes COVID-19 ( 1 )."]}
{"id": 1001792, "claim": "Fda approves gilead 's remdesivir as coronavirus treatment", "label": "SUPPORTED", "evidence": ["FDA approves Gilead's Remdesivir as a coronavirus treatment - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [."]}
{"id": 1001793, "claim": "Fda hes gilead's remdesivir as coronavirus treatment", "label": "REFUTED", "evidence": ["FDA approves Gilead's Remdesivir as a coronavirus treatment - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [."]}
{"id": 1001794, "claim": "Mutations in host and pathogen may affect the course of pandemic.", "label": "SUPPORTED", "evidence": ["This point has to do with the evolution of the virus in the human host.", "Later on, the spread of the infection reduces the pool of susceptible hosts and may reverse the selection on virulence.", "Infectious sources are susceptible to evolution, and selective pressure by host characteristics and measure to control the pandemic may lead to emergence of more aggressive or indolent strains.", "More specifically, we expect drastic changes of virulence between early and later stages of global pandemics, but also between different stages of the pathogen life cycle."]}
{"id": 1001795, "claim": "Mutations in age and pathogen may affect the course of pandemic.", "label": "REFUTED", "evidence": ["This point has to do with the evolution of the virus in the human host.", "Later on, the spread of the infection reduces the pool of susceptible hosts and may reverse the selection on virulence.", "Infectious sources are susceptible to evolution, and selective pressure by host characteristics and measure to control the pandemic may lead to emergence of more aggressive or indolent strains.", "More specifically, we expect drastic changes of virulence between early and later stages of global pandemics, but also between different stages of the pathogen life cycle."]}
{"id": 1001796, "claim": "A serological assay to detect sars-cov-2 seroconversion in humans", "label": "SUPPORTED", "evidence": ["Our data show strong seroconversion with ELISA AUC values in the 1:1,000 range after natural infection with SARS-CoV-2.", "SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup.", "Analysis of serologic cross-reactivity between common human coronaviruses and SARS-CoV-2 using coronavirus antigen microarray.", "Full size image Here, we describe a serological method to detect seroconversion upon SARS- CoV-2 infection."]}
{"id": 1001797, "claim": "A serological assay to detect sars-cov-2 seroconversion in pigs", "label": "REFUTED", "evidence": ["Our data show strong seroconversion with ELISA AUC values in the 1:1,000 range after natural infection with SARS-CoV-2.", "SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup.", "Analysis of serologic cross-reactivity between common human coronaviruses and SARS-CoV-2 using coronavirus antigen microarray.", "Full size image Here, we describe a serological method to detect seroconversion upon SARS- CoV-2 infection."]}
{"id": 1001798, "claim": "The viral protein nsp1 acts as a ribosome gatekeeper for shutting down host translation and fostering sars-cov-2 translation", "label": "SUPPORTED", "evidence": ["One of the first proteins produced during viral infection, NSP1, binds to the host ribosome and blocks the mRNA entry channel.", "In spite of the presence of NSP1 on the ribosome, viral translation proceeds however.", "Thus, NSP1 acts as a ribosome gatekeeper, shutting down host translation or fostering SARS-CoV-2 translation depending on the presence of the SL1 5UTR hairpin.", "We show that NSP1 remains bound on the ribosome during viral translation."]}
{"id": 1001799, "claim": "Use of convalescent serum reduces severity of covid-19 in nonhuman hostss", "label": "REFUTED", "evidence": ["One of the first proteins produced during viral infection, NSP1, binds to the host ribosome and blocks the mRNA entry channel.", "In spite of the presence of NSP1 on the ribosome, viral translation proceeds however.", "Thus, NSP1 acts as a ribosome gatekeeper, shutting down host translation or fostering SARS-CoV-2 translation depending on the presence of the SL1 5UTR hairpin.", "We show that NSP1 remains bound on the ribosome during viral translation."]}
{"id": 1001800, "claim": "Use of convalescent serum reduces severity of covid-19 in nonhuman modelss", "label": "REFUTED", "evidence": ["One of the first proteins produced during viral infection, NSP1, binds to the host ribosome and blocks the mRNA entry channel.", "In spite of the presence of NSP1 on the ribosome, viral translation proceeds however.", "Thus, NSP1 acts as a ribosome gatekeeper, shutting down host translation or fostering SARS-CoV-2 translation depending on the presence of the SL1 5UTR hairpin.", "We show that NSP1 remains bound on the ribosome during viral translation."]}
{"id": 1001801, "claim": "Use of convalescent serum reduces severity of covid-19 in nonhuman batss", "label": "REFUTED", "evidence": ["One of the first proteins produced during viral infection, NSP1, binds to the host ribosome and blocks the mRNA entry channel.", "In spite of the presence of NSP1 on the ribosome, viral translation proceeds however.", "Thus, NSP1 acts as a ribosome gatekeeper, shutting down host translation or fostering SARS-CoV-2 translation depending on the presence of the SL1 5UTR hairpin.", "We show that NSP1 remains bound on the ribosome during viral translation."]}
{"id": 1001802, "claim": "Nsp1 of sars-cov-2 stimulates host translation termination", "label": "SUPPORTED", "evidence": ["Considering the presence of Nsp1 in the post- termination 80S ribosomal complex simultaneously with eRF1, we hypothesized that Nsp1 may be involved in translation termination.", "We show the direct influence of Nsp1 on translation termination.", "We identify that activity of Nsp1 in translation termination is localized in its N-terminal domain.", "Nsp1 inhibits host translation initiation by binding to the entry channel of the 40S ribosome subunit."]}
{"id": 1001803, "claim": "Nsp1 of sars-cov-2 stimulates host translation.", "label": "REFUTED", "evidence": ["Considering the presence of Nsp1 in the post- termination 80S ribosomal complex simultaneously with eRF1, we hypothesized that Nsp1 may be involved in translation termination.", "We show the direct influence of Nsp1 on translation termination.", "We identify that activity of Nsp1 in translation termination is localized in its N-terminal domain.", "Nsp1 inhibits host translation initiation by binding to the entry channel of the 40S ribosome subunit."]}
{"id": 1001804, "claim": "Nsp1 of sars-cov-2 stimulates host immunity termination", "label": "REFUTED", "evidence": ["Considering the presence of Nsp1 in the post- termination 80S ribosomal complex simultaneously with eRF1, we hypothesized that Nsp1 may be involved in translation termination.", "We show the direct influence of Nsp1 on translation termination.", "We identify that activity of Nsp1 in translation termination is localized in its N-terminal domain.", "Nsp1 inhibits host translation initiation by binding to the entry channel of the 40S ribosome subunit."]}
{"id": 1001805, "claim": "Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in covid-19", "label": "SUPPORTED", "evidence": ["Non-survivors had lower total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) levels during the entire course of the disease with complete resolution among survivors."]}
{"id": 1001806, "claim": "Low-density lipoprotein cholesterol levels are associated with improved clinical outcomes in covid-19", "label": "REFUTED", "evidence": ["Non-survivors had lower total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) levels during the entire course of the disease with complete resolution among survivors."]}
{"id": 1001807, "claim": "Low-density lipoprotein cholesterol levels are associated with increased clinical outcomes in covid-19", "label": "REFUTED", "evidence": ["Non-survivors had lower total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) levels during the entire course of the disease with complete resolution among survivors."]}
{"id": 1001808, "claim": "Low-density lipoprotein cholesterol levels are associated with greater clinical outcomes in covid-19", "label": "REFUTED", "evidence": ["Non-survivors had lower total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) levels during the entire course of the disease with complete resolution among survivors."]}
{"id": 1001809, "claim": "Development and validation of a machine learning model for predicting illness trajectory and hospital resource utilization of covid-19 hospitalized patients", "label": "SUPPORTED", "evidence": ["We further present the impact of several scenarios of patient influx on healthcare system utilization, and provide an R software package for predicting hospital-bed utilization.", "Interpretation: We developed a model that, given basic easily obtained data as input, accurately predicts total and critical care hospital utilization.", "The model predicts the patient's entire disease course in terms of clinical states, from which we derive the patient's hospital length-of-stay, length-of-stay in critical state, the risk of in-hospital mortality, and total and critical care hospital-bed utilization.", "The model enables evaluating the impact of various patient influx scenarios on hospital utilization and planning ahead of hospital resource allocation.", "There is a need for a model to help planners assess expected COVID-19 hospital resource utilization."]}
{"id": 1001810, "claim": "Development and validation of a social learning model for predicting illness trajectory and hospital resource utilization of covid-19 hospitalized patients", "label": "REFUTED", "evidence": ["We further present the impact of several scenarios of patient influx on healthcare system utilization, and provide an R software package for predicting hospital-bed utilization.", "Interpretation: We developed a model that, given basic easily obtained data as input, accurately predicts total and critical care hospital utilization.", "The model predicts the patient's entire disease course in terms of clinical states, from which we derive the patient's hospital length-of-stay, length-of-stay in critical state, the risk of in-hospital mortality, and total and critical care hospital-bed utilization.", "The model enables evaluating the impact of various patient influx scenarios on hospital utilization and planning ahead of hospital resource allocation.", "There is a need for a model to help planners assess expected COVID-19 hospital resource utilization."]}
{"id": 1001811, "claim": "Development and validation of a logistic learning model for predicting illness trajectory and hospital resource utilization of covid-19 hospitalized patients", "label": "REFUTED", "evidence": ["We further present the impact of several scenarios of patient influx on healthcare system utilization, and provide an R software package for predicting hospital-bed utilization.", "Interpretation: We developed a model that, given basic easily obtained data as input, accurately predicts total and critical care hospital utilization.", "The model predicts the patient's entire disease course in terms of clinical states, from which we derive the patient's hospital length-of-stay, length-of-stay in critical state, the risk of in-hospital mortality, and total and critical care hospital-bed utilization.", "The model enables evaluating the impact of various patient influx scenarios on hospital utilization and planning ahead of hospital resource allocation.", "There is a need for a model to help planners assess expected COVID-19 hospital resource utilization."]}
{"id": 1001812, "claim": "Development and validation of a decision learning model for predicting illness trajectory and hospital resource utilization of covid-19 hospitalized patients", "label": "REFUTED", "evidence": ["We further present the impact of several scenarios of patient influx on healthcare system utilization, and provide an R software package for predicting hospital-bed utilization.", "Interpretation: We developed a model that, given basic easily obtained data as input, accurately predicts total and critical care hospital utilization.", "The model predicts the patient's entire disease course in terms of clinical states, from which we derive the patient's hospital length-of-stay, length-of-stay in critical state, the risk of in-hospital mortality, and total and critical care hospital-bed utilization.", "The model enables evaluating the impact of various patient influx scenarios on hospital utilization and planning ahead of hospital resource allocation.", "There is a need for a model to help planners assess expected COVID-19 hospital resource utilization."]}
{"id": 1001813, "claim": "Us approves moderna as second vaccine.", "label": "SUPPORTED", "evidence": ["Like the Pfizer jab, the Moderna vaccine also requires a second booster shot."]}
{"id": 1001814, "claim": "Us approves moderna as second state.", "label": "REFUTED", "evidence": ["Like the Pfizer jab, the Moderna vaccine also requires a second booster shot."]}
{"id": 1001815, "claim": "Us hes moderna as second vaccine.", "label": "REFUTED", "evidence": ["Like the Pfizer jab, the Moderna vaccine also requires a second booster shot."]}
{"id": 1001816, "claim": "Us approves moderna as second work.", "label": "REFUTED", "evidence": ["Like the Pfizer jab, the Moderna vaccine also requires a second booster shot."]}
{"id": 1001817, "claim": "Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesis", "label": "SUPPORTED", "evidence": ["We demonstrate that a peptide derived from the nsp16-interacting domain of MHV nsp10 could inhibit 2'-O-MTase activity of different coronaviruses in vitro and viral replication of MHV and SARS-CoV replicon in cell culture, and it could strongly inhibit virus replication and pathogenesis in MHV-infected mice."]}
{"id": 1001818, "claim": "Coronavirus nsp10/nsp16 methyltransferase cannot be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesis", "label": "REFUTED", "evidence": ["We demonstrate that a peptide derived from the nsp16-interacting domain of MHV nsp10 could inhibit 2'-O-MTase activity of different coronaviruses in vitro and viral replication of MHV and SARS-CoV replicon in cell culture, and it could strongly inhibit virus replication and pathogenesis in MHV-infected mice."]}
{"id": 1001819, "claim": "Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to promote replication and pathogenesis", "label": "REFUTED", "evidence": ["We demonstrate that a peptide derived from the nsp16-interacting domain of MHV nsp10 could inhibit 2'-O-MTase activity of different coronaviruses in vitro and viral replication of MHV and SARS-CoV replicon in cell culture, and it could strongly inhibit virus replication and pathogenesis in MHV-infected mice."]}
{"id": 1001820, "claim": "Serum institute of india brings covid-19 vaccine into animal testing", "label": "SUPPORTED", "evidence": ["Vaccine researchers at Oxford recently made use of animal-testing results shared by the National Institutes of Healths Rocky Mountain Laboratory in Montana."]}
{"id": 1001821, "claim": "Serum institute of korea brings covid-19 vaccine into animal testing", "label": "REFUTED", "evidence": ["Vaccine researchers at Oxford recently made use of animal-testing results shared by the National Institutes of Healths Rocky Mountain Laboratory in Montana."]}
{"id": 1001822, "claim": "Serum institute of china brings covid-19 vaccine into animal testing", "label": "REFUTED", "evidence": ["Vaccine researchers at Oxford recently made use of animal-testing results shared by the National Institutes of Healths Rocky Mountain Laboratory in Montana."]}
{"id": 1001823, "claim": "Serum institute of concern brings covid-19 vaccine into animal testing", "label": "REFUTED", "evidence": ["Vaccine researchers at Oxford recently made use of animal-testing results shared by the National Institutes of Healths Rocky Mountain Laboratory in Montana."]}
{"id": 1001824, "claim": "Artemisinin raises hopes and fears amid covid-19", "label": "SUPPORTED", "evidence": ["Assuming artemisinin did successfully make the long journey through cell tests, animal tests, and clinical trials against COVID-19, using it to beat the coronavirus would still present a serious quandary.", "How we know disinfectants should kill the COVID-19 coronavirus Genetic study suggests that peoples blood type may affect their COVID-19 risk Credit: Henitsoa Rafalia/Anadolu Agency/Getty Images President Andry Rajoelina of Madagascar is an enthusiastic proponent of an herbal tonic containing Artemisia annua extracts, which he claims can treat COVID-19."]}
{"id": 1001825, "claim": "Artemisinin raises hopes and benefits amid covid-19", "label": "REFUTED", "evidence": ["Assuming artemisinin did successfully make the long journey through cell tests, animal tests, and clinical trials against COVID-19, using it to beat the coronavirus would still present a serious quandary.", "How we know disinfectants should kill the COVID-19 coronavirus Genetic study suggests that peoples blood type may affect their COVID-19 risk Credit: Henitsoa Rafalia/Anadolu Agency/Getty Images President Andry Rajoelina of Madagascar is an enthusiastic proponent of an herbal tonic containing Artemisia annua extracts, which he claims can treat COVID-19."]}
{"id": 1001826, "claim": "Artemisinin raises hopes and success amid covid-19", "label": "REFUTED", "evidence": ["Assuming artemisinin did successfully make the long journey through cell tests, animal tests, and clinical trials against COVID-19, using it to beat the coronavirus would still present a serious quandary.", "How we know disinfectants should kill the COVID-19 coronavirus Genetic study suggests that peoples blood type may affect their COVID-19 risk Credit: Henitsoa Rafalia/Anadolu Agency/Getty Images President Andry Rajoelina of Madagascar is an enthusiastic proponent of an herbal tonic containing Artemisia annua extracts, which he claims can treat COVID-19."]}
{"id": 1001827, "claim": "Antibody tests could be key to reopening the country .", "label": "SUPPORTED", "evidence": ["Why antibody testing is key to reopening America Dr. Neeraj Sood, professor and vice dean of research and faculty at the University of Southern California Sol Price School of Public Policy, leads a study in conjunction with the Los Angeles County Department of Public Health using antibody tests to determine how widely coronavirus has spread and how deadly it is."]}
{"id": 1001828, "claim": "Antibody tests could be key to reopening the study.", "label": "REFUTED", "evidence": ["Why antibody testing is key to reopening America Dr. Neeraj Sood, professor and vice dean of research and faculty at the University of Southern California Sol Price School of Public Policy, leads a study in conjunction with the Los Angeles County Department of Public Health using antibody tests to determine how widely coronavirus has spread and how deadly it is."]}
{"id": 1001829, "claim": "Ketogenesis restrains aging-induced exacerbation of covid in a mouse model", "label": "SUPPORTED", "evidence": ["\\- Ketones protect aged mice from infection by reducing inflammation.", "Ketogenic diet increases beta- hydroxybutyrate, expands tissue protective γδ T cells, deactivates the inflammasome and decreases pathogenic monocytes in lungs of infected aged mice."]}
{"id": 1001830, "claim": "Ketogenesis restrains cancer-induced exacerbation of covid in a mouse model", "label": "REFUTED", "evidence": ["\\- Ketones protect aged mice from infection by reducing inflammation.", "Ketogenic diet increases beta- hydroxybutyrate, expands tissue protective γδ T cells, deactivates the inflammasome and decreases pathogenic monocytes in lungs of infected aged mice."]}
{"id": 1001831, "claim": "Ketogenesis restrains tumor-induced exacerbation of covid in a mouse model", "label": "REFUTED", "evidence": ["\\- Ketones protect aged mice from infection by reducing inflammation.", "Ketogenic diet increases beta- hydroxybutyrate, expands tissue protective γδ T cells, deactivates the inflammasome and decreases pathogenic monocytes in lungs of infected aged mice."]}
{"id": 1001832, "claim": "Ketogenesis restrains ifn-induced exacerbation of covid in a mouse model", "label": "REFUTED", "evidence": ["\\- Ketones protect aged mice from infection by reducing inflammation.", "Ketogenic diet increases beta- hydroxybutyrate, expands tissue protective γδ T cells, deactivates the inflammasome and decreases pathogenic monocytes in lungs of infected aged mice."]}
{"id": 1001833, "claim": "Early high-titer plasma therapy to prevent severe covid-19 in older adults.", "label": "SUPPORTED", "evidence": ["Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.", "Conclusions: Early administration of high-titer convalescent plasma against SARS-CoV-2 to mildly ill infected older adults reduced the progression of Covid-19.", "Early safety indicators of COVID-19 convalescent plasma in 5000 patients.", "Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial."]}
{"id": 1001834, "claim": "Early high-titer plasma therapy to prevent severe covid-19 in older infants.", "label": "REFUTED", "evidence": ["Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.", "Conclusions: Early administration of high-titer convalescent plasma against SARS-CoV-2 to mildly ill infected older adults reduced the progression of Covid-19.", "Early safety indicators of COVID-19 convalescent plasma in 5000 patients.", "Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial."]}
{"id": 1001835, "claim": "Early high-titer plasma therapy to prevent severe covid-19 in older children.", "label": "REFUTED", "evidence": ["Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.", "Conclusions: Early administration of high-titer convalescent plasma against SARS-CoV-2 to mildly ill infected older adults reduced the progression of Covid-19.", "Early safety indicators of COVID-19 convalescent plasma in 5000 patients.", "Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial."]}
{"id": 1001836, "claim": "Early high-titer plasma therapy to prevent severe covid-19 in older calves.", "label": "REFUTED", "evidence": ["Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.", "Conclusions: Early administration of high-titer convalescent plasma against SARS-CoV-2 to mildly ill infected older adults reduced the progression of Covid-19.", "Early safety indicators of COVID-19 convalescent plasma in 5000 patients.", "Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial."]}
{"id": 1001837, "claim": "Evidence that vitamin d supplementation could reduce risk of influenza and covid-19 infections and deaths", "label": "SUPPORTED", "evidence": ["This article reviews the roles of vitamin D in reducing the risk of respiratory tract infections, knowledge about the epidemiology of influenza and COVID-19, and how vitamin D supplementation might be a useful measure to reduce risk.", "Through several mechanisms, vitamin D can reduce risk of infections.", "For treatment of people who become infected with COVID-19, higher vitamin D3 doses might be useful.", "Vitamin D and Inflammation: Potential Implications for Severity of Covid-19.", "Role of vitamin D in preventing of COVID-19 infection, progression and severity."]}
{"id": 1001838, "claim": "Evidence that vitamin d supplementation could increase risk of influenza and covid-19 infections and deaths", "label": "REFUTED", "evidence": ["This article reviews the roles of vitamin D in reducing the risk of respiratory tract infections, knowledge about the epidemiology of influenza and COVID-19, and how vitamin D supplementation might be a useful measure to reduce risk.", "Through several mechanisms, vitamin D can reduce risk of infections.", "For treatment of people who become infected with COVID-19, higher vitamin D3 doses might be useful.", "Vitamin D and Inflammation: Potential Implications for Severity of Covid-19.", "Role of vitamin D in preventing of COVID-19 infection, progression and severity."]}
{"id": 1001839, "claim": "Evidence that vitamin d supplementation could increases risk of influenza and covid-19 infections and deaths", "label": "REFUTED", "evidence": ["This article reviews the roles of vitamin D in reducing the risk of respiratory tract infections, knowledge about the epidemiology of influenza and COVID-19, and how vitamin D supplementation might be a useful measure to reduce risk.", "Through several mechanisms, vitamin D can reduce risk of infections.", "For treatment of people who become infected with COVID-19, higher vitamin D3 doses might be useful.", "Vitamin D and Inflammation: Potential Implications for Severity of Covid-19.", "Role of vitamin D in preventing of COVID-19 infection, progression and severity."]}
{"id": 1001840, "claim": "Evidence that vitamin d supplementation could increased risk of influenza and covid-19 infections and deaths", "label": "REFUTED", "evidence": ["This article reviews the roles of vitamin D in reducing the risk of respiratory tract infections, knowledge about the epidemiology of influenza and COVID-19, and how vitamin D supplementation might be a useful measure to reduce risk.", "Through several mechanisms, vitamin D can reduce risk of infections.", "For treatment of people who become infected with COVID-19, higher vitamin D3 doses might be useful.", "Vitamin D and Inflammation: Potential Implications for Severity of Covid-19.", "Role of vitamin D in preventing of COVID-19 infection, progression and severity."]}
{"id": 1001841, "claim": "Sars-cov-2 spike proteins disrupt the blood-brain barrier , potentially raising risk of neurological damage in covid-19 patients", "label": "SUPPORTED", "evidence": ["The study, published in the December print issue of the journal Neurobiology of Disease, is the first to show that SARS-CoV-2 spike proteins can cause this barrier to become leaky, potentially disrupting the delicate neural networks within the brain.", "Our findings support the implication that SARS-CoV-2, or its shed spike proteins circulating in the blood stream, could cause destabilization of the blood-brain barrier in key brain regions, Dr. Ramirez said.", "Moreover, as Dr. Buzhdygan explained, the brain vasculature is extremely branched, so even a small amount of neuroinflammation can be very damaging. Based on the team's observations of ACE2 expression in the brain, this neurological damage could be extensive in COVID-19 patients with pre-existing health conditions in which the vasculature has already suffered some amount of injury."]}
{"id": 1001842, "claim": "Sars-cov-2 spike proteins disrupt the blood-brain barrier, potentially reduce risk of neurological damage in covid-19 patients", "label": "REFUTED", "evidence": ["The study, published in the December print issue of the journal Neurobiology of Disease, is the first to show that SARS-CoV-2 spike proteins can cause this barrier to become leaky, potentially disrupting the delicate neural networks within the brain.", "Our findings support the implication that SARS-CoV-2, or its shed spike proteins circulating in the blood stream, could cause destabilization of the blood-brain barrier in key brain regions, Dr. Ramirez said.", "Moreover, as Dr. Buzhdygan explained, the brain vasculature is extremely branched, so even a small amount of neuroinflammation can be very damaging. Based on the team's observations of ACE2 expression in the brain, this neurological damage could be extensive in COVID-19 patients with pre-existing health conditions in which the vasculature has already suffered some amount of injury."]}
{"id": 1001843, "claim": "Sars-cov-2 spike proteins disrupt the blood-brain barrier, potentially reduces risk of neurological damage in covid-19 patients", "label": "REFUTED", "evidence": ["The study, published in the December print issue of the journal Neurobiology of Disease, is the first to show that SARS-CoV-2 spike proteins can cause this barrier to become leaky, potentially disrupting the delicate neural networks within the brain.", "Our findings support the implication that SARS-CoV-2, or its shed spike proteins circulating in the blood stream, could cause destabilization of the blood-brain barrier in key brain regions, Dr. Ramirez said.", "Moreover, as Dr. Buzhdygan explained, the brain vasculature is extremely branched, so even a small amount of neuroinflammation can be very damaging. Based on the team's observations of ACE2 expression in the brain, this neurological damage could be extensive in COVID-19 patients with pre-existing health conditions in which the vasculature has already suffered some amount of injury."]}
{"id": 1001844, "claim": "Sars-cov-2 spike proteins disrupt the blood-brain barrier, potentially reducing risk of neurological damage in covid-19 patients", "label": "REFUTED", "evidence": ["The study, published in the December print issue of the journal Neurobiology of Disease, is the first to show that SARS-CoV-2 spike proteins can cause this barrier to become leaky, potentially disrupting the delicate neural networks within the brain.", "Our findings support the implication that SARS-CoV-2, or its shed spike proteins circulating in the blood stream, could cause destabilization of the blood-brain barrier in key brain regions, Dr. Ramirez said.", "Moreover, as Dr. Buzhdygan explained, the brain vasculature is extremely branched, so even a small amount of neuroinflammation can be very damaging. Based on the team's observations of ACE2 expression in the brain, this neurological damage could be extensive in COVID-19 patients with pre-existing health conditions in which the vasculature has already suffered some amount of injury."]}
{"id": 1001845, "claim": "Clinical benefit of remdesivir in rhesus macaques infected with sars-cov-2", "label": "SUPPORTED", "evidence": ["Thus, treatment with remdesivir initiated early during infection had a clinical benefit in rhesus macaques infected with SARS-CoV-2.", "1: Reduced respiratory disease in rhesus macaques infected with SARS- CoV-2 and treated with remdesivir."]}
{"id": 1001846, "claim": "No benefit of remdesivir in rhesus macaques infected with sars-cov-2", "label": "REFUTED", "evidence": ["Thus, treatment with remdesivir initiated early during infection had a clinical benefit in rhesus macaques infected with SARS-CoV-2.", "1: Reduced respiratory disease in rhesus macaques infected with SARS- CoV-2 and treated with remdesivir."]}
{"id": 1001847, "claim": "Clinical infection of remdesivir in rhesus macaques infected with sars-cov-2", "label": "REFUTED", "evidence": ["Thus, treatment with remdesivir initiated early during infection had a clinical benefit in rhesus macaques infected with SARS-CoV-2.", "1: Reduced respiratory disease in rhesus macaques infected with SARS- CoV-2 and treated with remdesivir."]}
{"id": 1001848, "claim": "Belgium enters lockdown over coronavirus crisis until 5 april", "label": "SUPPORTED", "evidence": ["Speaking at the press conference after the meeting, Wilmes announced the lockdown is set to start on Wednesday (17 March) and run until 5 April.", "Belgium's health minister Maggie De Block (Open VLD) told local media after the meeting that tightening measures come at a \"crucial moment\" and are necessary to \"flatten the curve\" so that the number of patients does not rise too strongly and overburdens the healthcare system."]}
{"id": 1001849, "claim": "Belgium enters lockdown over coronavirus crisis after 5 april", "label": "REFUTED", "evidence": ["Speaking at the press conference after the meeting, Wilmes announced the lockdown is set to start on Wednesday (17 March) and run until 5 April.", "Belgium's health minister Maggie De Block (Open VLD) told local media after the meeting that tightening measures come at a \"crucial moment\" and are necessary to \"flatten the curve\" so that the number of patients does not rise too strongly and overburdens the healthcare system."]}
{"id": 1001850, "claim": "500,000 sharks may be killed to vaccinate against covid-19 , wildlife experts say", "label": "SUPPORTED", "evidence": ["Shark Allies, a nonprofit that advocates for the protection of sharks, projects that some 500,000 sharks could be killed if a coronavirus vaccine with shark squalene proves to be effective.", "Brendl says many pharmaceutical companies are using shark squalene to produce a coronavirus vaccine and that if everyone in the world received two doses, 500,000 sharks would have to be slaughtered to meet the demand.", "However some scientists believe two doses may be needed to immunise the population, meaning around 500,000 sharks would need to be slaughtered, according to the California-based group's calculations."]}
{"id": 1001851, "claim": "500,000 sharks cannot be killed to vaccinate against covid-19, wildlife experts say", "label": "REFUTED", "evidence": ["Shark Allies, a nonprofit that advocates for the protection of sharks, projects that some 500,000 sharks could be killed if a coronavirus vaccine with shark squalene proves to be effective.", "Brendl says many pharmaceutical companies are using shark squalene to produce a coronavirus vaccine and that if everyone in the world received two doses, 500,000 sharks would have to be slaughtered to meet the demand.", "However some scientists believe two doses may be needed to immunise the population, meaning around 500,000 sharks would need to be slaughtered, according to the California-based group's calculations."]}
{"id": 1001852, "claim": "Covid-2019 associated overexpressed prevotella proteins mediated host-pathogen interactions and their role in coronavirus outbreak", "label": "SUPPORTED", "evidence": ["As per the results, Prevotella proteins, but not viral proteins are involved in multiple interactions with NF-kB, which is involved in increasing clinical severity of COVID-2019.", "Prevotella may have role in COVID-2019 outbreak and should be given importance for understanding disease mechanisms and improving treatment outcomes."]}
{"id": 1001853, "claim": "Covid-1 associated overexpressed prevotella proteins mediated host-pathogen interactions and their role in coronavirus outbreak", "label": "REFUTED", "evidence": ["As per the results, Prevotella proteins, but not viral proteins are involved in multiple interactions with NF-kB, which is involved in increasing clinical severity of COVID-2019.", "Prevotella may have role in COVID-2019 outbreak and should be given importance for understanding disease mechanisms and improving treatment outcomes."]}
{"id": 1001854, "claim": "Covid-2 associated overexpressed prevotella proteins mediated host-pathogen interactions and their role in coronavirus outbreak", "label": "REFUTED", "evidence": ["As per the results, Prevotella proteins, but not viral proteins are involved in multiple interactions with NF-kB, which is involved in increasing clinical severity of COVID-2019.", "Prevotella may have role in COVID-2019 outbreak and should be given importance for understanding disease mechanisms and improving treatment outcomes."]}
{"id": 1001855, "claim": "Cdc releases new resources and tools to support opening schools", "label": "SUPPORTED", "evidence": ["\"The CDC resources released today will help parents, teachers and administrators make practical, safety-focused decisions as this school year begins.", "The resources, available at https://www.cdc.gov/coronavirus/2019-ncov/community/schools- childcare/index.html, also provide students, school administrators, parents, guardians, or caregivers the information they need to guide their decision- making on attending in-person curriculum and how to adapt to local conditions.", "CDC is prepared to work with K-12 schools to safely reopen while protecting the most vulnerable.\"", "CDC will host a media telebriefing tomorrow with Dr. Redfield to discuss the new resources: What CDC provide an update to media on the COVID-19 response, including school reopening guidance Who Robert Redfield, M.D., CDC Director Mitchell Zais, Ph.D., Deputy Secretary of Education Erin K. Sauber-Schatz, Ph.D., Lead, CDC Community Interventions and Critical Populations Task Force for the COVID-19 response When 12:30 p.m.", "The resources and tools made available today support how to open schools safely by promoting behaviors that prevent spread, altering how a school and school day is structured, and outlining how to keep the school environment healthy through cleaning, proper ventilation, and other practices."]}
{"id": 1001856, "claim": "Cdc releases new resources and tools to prevent opening schools", "label": "REFUTED", "evidence": ["\"The CDC resources released today will help parents, teachers and administrators make practical, safety-focused decisions as this school year begins.", "The resources, available at https://www.cdc.gov/coronavirus/2019-ncov/community/schools- childcare/index.html, also provide students, school administrators, parents, guardians, or caregivers the information they need to guide their decision- making on attending in-person curriculum and how to adapt to local conditions.", "CDC is prepared to work with K-12 schools to safely reopen while protecting the most vulnerable.\"", "CDC will host a media telebriefing tomorrow with Dr. Redfield to discuss the new resources: What CDC provide an update to media on the COVID-19 response, including school reopening guidance Who Robert Redfield, M.D., CDC Director Mitchell Zais, Ph.D., Deputy Secretary of Education Erin K. Sauber-Schatz, Ph.D., Lead, CDC Community Interventions and Critical Populations Task Force for the COVID-19 response When 12:30 p.m.", "The resources and tools made available today support how to open schools safely by promoting behaviors that prevent spread, altering how a school and school day is structured, and outlining how to keep the school environment healthy through cleaning, proper ventilation, and other practices."]}
{"id": 1001857, "claim": "Cdc releases existing resources and tools to support opening schools", "label": "REFUTED", "evidence": ["\"The CDC resources released today will help parents, teachers and administrators make practical, safety-focused decisions as this school year begins.", "The resources, available at https://www.cdc.gov/coronavirus/2019-ncov/community/schools- childcare/index.html, also provide students, school administrators, parents, guardians, or caregivers the information they need to guide their decision- making on attending in-person curriculum and how to adapt to local conditions.", "CDC is prepared to work with K-12 schools to safely reopen while protecting the most vulnerable.\"", "CDC will host a media telebriefing tomorrow with Dr. Redfield to discuss the new resources: What CDC provide an update to media on the COVID-19 response, including school reopening guidance Who Robert Redfield, M.D., CDC Director Mitchell Zais, Ph.D., Deputy Secretary of Education Erin K. Sauber-Schatz, Ph.D., Lead, CDC Community Interventions and Critical Populations Task Force for the COVID-19 response When 12:30 p.m.", "The resources and tools made available today support how to open schools safely by promoting behaviors that prevent spread, altering how a school and school day is structured, and outlining how to keep the school environment healthy through cleaning, proper ventilation, and other practices."]}
{"id": 1001858, "claim": "Cdc releases new resources and tools to avoid opening schools", "label": "REFUTED", "evidence": ["\"The CDC resources released today will help parents, teachers and administrators make practical, safety-focused decisions as this school year begins.", "The resources, available at https://www.cdc.gov/coronavirus/2019-ncov/community/schools- childcare/index.html, also provide students, school administrators, parents, guardians, or caregivers the information they need to guide their decision- making on attending in-person curriculum and how to adapt to local conditions.", "CDC is prepared to work with K-12 schools to safely reopen while protecting the most vulnerable.\"", "CDC will host a media telebriefing tomorrow with Dr. Redfield to discuss the new resources: What CDC provide an update to media on the COVID-19 response, including school reopening guidance Who Robert Redfield, M.D., CDC Director Mitchell Zais, Ph.D., Deputy Secretary of Education Erin K. Sauber-Schatz, Ph.D., Lead, CDC Community Interventions and Critical Populations Task Force for the COVID-19 response When 12:30 p.m.", "The resources and tools made available today support how to open schools safely by promoting behaviors that prevent spread, altering how a school and school day is structured, and outlining how to keep the school environment healthy through cleaning, proper ventilation, and other practices."]}
{"id": 1001859, "claim": "Coronavirus mutation may have made it more contagious .", "label": "SUPPORTED", "evidence": ["But the mutation appears to have made the pandemic spread further and faster than it would have without it.", "Patients with that strain of coronavirus carried more virus particles than other people, meaning they were probably more infectious, the study found.", "But one mutation near the beginning of the pandemic did make a difference, multiple new findings suggest, helping the virus spread more easily from person to person and making the pandemic harder to stop."]}
{"id": 1001860, "claim": "Coronavirus mutation may have made it less contagious.", "label": "REFUTED", "evidence": ["But the mutation appears to have made the pandemic spread further and faster than it would have without it.", "Patients with that strain of coronavirus carried more virus particles than other people, meaning they were probably more infectious, the study found.", "But one mutation near the beginning of the pandemic did make a difference, multiple new findings suggest, helping the virus spread more easily from person to person and making the pandemic harder to stop."]}
{"id": 1001861, "claim": "Trump announces 'halt ' in us funding to world health organization amid coronavirus pandemic", "label": "SUPPORTED", "evidence": ["VIDEO8:1608:16 Trump calls for halt to WHO funding: 'So much death has been caused by their mistakes' Coronavirus The U.S. will suspend funding to the World Health Organization while it reviews the agency's response to the Covid-19 pandemic, President Donald Trump announced Tuesday, saying the international health agency made mistakes that \"caused so much death\" as the coronavirus spread across the globe.", "Trump cuts funding to World Health Organization Coronavirus When asked by reporters why the administration is choosing now to withhold funds, Trump said the U.S. has had problems with WHO \"for years\" and the nation should have done this \"a long time ago.\"", "\"Today I'm instructing my administration to halt funding of the World Health Organization while a review is conducted to assess the World Health Organization's role in severely mismanaging and covering up the spread of the coronavirus,\" Trump said at a White House press conference.", "Follow live coronavirus updates \"I am directing my administration to halt funding while a review is conducted to assess the World Health Organization's role in severely mismanaging and covering up the spread of the coronavirus,\" Mr Trump told a news conference at the White House on Tuesday."]}
{"id": 1001862, "claim": "Trump announces 'in'in us funding to world health organization amid coronavirus pandemic", "label": "REFUTED", "evidence": ["VIDEO8:1608:16 Trump calls for halt to WHO funding: 'So much death has been caused by their mistakes' Coronavirus The U.S. will suspend funding to the World Health Organization while it reviews the agency's response to the Covid-19 pandemic, President Donald Trump announced Tuesday, saying the international health agency made mistakes that \"caused so much death\" as the coronavirus spread across the globe.", "Trump cuts funding to World Health Organization Coronavirus When asked by reporters why the administration is choosing now to withhold funds, Trump said the U.S. has had problems with WHO \"for years\" and the nation should have done this \"a long time ago.\"", "\"Today I'm instructing my administration to halt funding of the World Health Organization while a review is conducted to assess the World Health Organization's role in severely mismanaging and covering up the spread of the coronavirus,\" Trump said at a White House press conference.", "Follow live coronavirus updates \"I am directing my administration to halt funding while a review is conducted to assess the World Health Organization's role in severely mismanaging and covering up the spread of the coronavirus,\" Mr Trump told a news conference at the White House on Tuesday."]}
{"id": 1001863, "claim": "Trump announces 'with'in us funding to world health organization amid coronavirus pandemic", "label": "REFUTED", "evidence": ["VIDEO8:1608:16 Trump calls for halt to WHO funding: 'So much death has been caused by their mistakes' Coronavirus The U.S. will suspend funding to the World Health Organization while it reviews the agency's response to the Covid-19 pandemic, President Donald Trump announced Tuesday, saying the international health agency made mistakes that \"caused so much death\" as the coronavirus spread across the globe.", "Trump cuts funding to World Health Organization Coronavirus When asked by reporters why the administration is choosing now to withhold funds, Trump said the U.S. has had problems with WHO \"for years\" and the nation should have done this \"a long time ago.\"", "\"Today I'm instructing my administration to halt funding of the World Health Organization while a review is conducted to assess the World Health Organization's role in severely mismanaging and covering up the spread of the coronavirus,\" Trump said at a White House press conference.", "Follow live coronavirus updates \"I am directing my administration to halt funding while a review is conducted to assess the World Health Organization's role in severely mismanaging and covering up the spread of the coronavirus,\" Mr Trump told a news conference at the White House on Tuesday."]}
{"id": 1001864, "claim": "Chloroquine phosphate has shown apparent efficacy in treatment of covid-19 associated pneumonia in clinical studies", "label": "SUPPORTED", "evidence": ["Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China."]}
{"id": 1001865, "claim": "Chloroquine phosphate has no apparent efficacy in treatment of covid-19 associated pneumonia in clinical studies", "label": "REFUTED", "evidence": ["Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China."]}
{"id": 1001866, "claim": "Fda grants emergency authorization to moderna 's covid-19 vaccine.", "label": "SUPPORTED", "evidence": ["ModernaTX, Inc. has submitted a pharmacovigilance plan to the FDA to monitor the safety of Moderna COVID-19 Vaccine.", "FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine 1.", "The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older."]}
{"id": 1001867, "claim": "Who grants emergency authorization to moderna's covid-19 vaccine.", "label": "REFUTED", "evidence": ["ModernaTX, Inc. has submitted a pharmacovigilance plan to the FDA to monitor the safety of Moderna COVID-19 Vaccine.", "FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine 1.", "The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older."]}
{"id": 1001868, "claim": "Fda grants emergency authorization to moderna's covid-19 years.", "label": "REFUTED", "evidence": ["ModernaTX, Inc. has submitted a pharmacovigilance plan to the FDA to monitor the safety of Moderna COVID-19 Vaccine.", "FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine 1.", "The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older."]}
{"id": 1001869, "claim": "Antibodies in serum of convalescent patients following mild covid-19 do not always prevent virus receptor binding", "label": "SUPPORTED", "evidence": ["[Protective effect of specific antibody in serum of convalescent patient with SARS].", "The scientists from MedUni Vienna's Institute of Pathophysiology and Allergy Research discovered that only around 60% of patients who have had COVID-19 and recovered from it develop protective antibodies and, for the first time, they were able to show that some antibodies even \"assist\" the virus by augmenting its to the cells of the host."]}
{"id": 1001870, "claim": "Antibodies in serum of convalescent patients following mild covid-19 do also always prevent virus receptor binding", "label": "REFUTED", "evidence": ["[Protective effect of specific antibody in serum of convalescent patient with SARS].", "The scientists from MedUni Vienna's Institute of Pathophysiology and Allergy Research discovered that only around 60% of patients who have had COVID-19 and recovered from it develop protective antibodies and, for the first time, they were able to show that some antibodies even \"assist\" the virus by augmenting its to the cells of the host."]}
{"id": 1001871, "claim": "Antibodies in serum of convalescent patients following mild covid-19 do and always prevent virus receptor binding", "label": "REFUTED", "evidence": ["[Protective effect of specific antibody in serum of convalescent patient with SARS].", "The scientists from MedUni Vienna's Institute of Pathophysiology and Allergy Research discovered that only around 60% of patients who have had COVID-19 and recovered from it develop protective antibodies and, for the first time, they were able to show that some antibodies even \"assist\" the virus by augmenting its to the cells of the host."]}
{"id": 1001872, "claim": "Antibodies in serum of convalescent patients following mild covid-19 do only always prevent virus receptor binding", "label": "REFUTED", "evidence": ["[Protective effect of specific antibody in serum of convalescent patient with SARS].", "The scientists from MedUni Vienna's Institute of Pathophysiology and Allergy Research discovered that only around 60% of patients who have had COVID-19 and recovered from it develop protective antibodies and, for the first time, they were able to show that some antibodies even \"assist\" the virus by augmenting its to the cells of the host."]}
{"id": 1001873, "claim": "Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with covid-19.", "label": "SUPPORTED", "evidence": ["Conclusion Associations between gut microbiota composition, levels of cytokines and inflammatory markers in patients with COVID-19 suggest that the gut microbiome is involved in the magnitude of COVID-19 severity possibly via modulating host immune responses.", "Nevertheless, this survey of gut microbiota alterations in association with immune dysregulation revealed that gut microorganisms are likely involved in the modulation of host inflammatory responses in COVID-19.", "Conclusion: Associations between gut microbiota composition, levels of cytokines and inflammatory markers in patients with COVID-19 suggest that the gut microbiome is involved in the magnitude of COVID-19 severity possibly via modulating host immune responses.", "They hypothesized gut microbiota would be associated with host inflammatory immune responses in COVID-19.", "Composition of the gut microbiota in patients with COVID-19 is concordant with disease severity and magnitude of plasma concentrations of several inflammatory cytokines, chemokines and blood markers of tissue damage."]}
{"id": 1001874, "claim": "Gut microbiota composition decreases disease severity and dysfunctional immune responses in patients with covid-19.", "label": "REFUTED", "evidence": ["Conclusion Associations between gut microbiota composition, levels of cytokines and inflammatory markers in patients with COVID-19 suggest that the gut microbiome is involved in the magnitude of COVID-19 severity possibly via modulating host immune responses.", "Nevertheless, this survey of gut microbiota alterations in association with immune dysregulation revealed that gut microorganisms are likely involved in the modulation of host inflammatory responses in COVID-19.", "Conclusion: Associations between gut microbiota composition, levels of cytokines and inflammatory markers in patients with COVID-19 suggest that the gut microbiome is involved in the magnitude of COVID-19 severity possibly via modulating host immune responses.", "They hypothesized gut microbiota would be associated with host inflammatory immune responses in COVID-19.", "Composition of the gut microbiota in patients with COVID-19 is concordant with disease severity and magnitude of plasma concentrations of several inflammatory cytokines, chemokines and blood markers of tissue damage."]}
{"id": 1001875, "claim": "Gut microbiota composition reduces disease severity and dysfunctional immune responses in patients with covid-19.", "label": "REFUTED", "evidence": ["Conclusion Associations between gut microbiota composition, levels of cytokines and inflammatory markers in patients with COVID-19 suggest that the gut microbiome is involved in the magnitude of COVID-19 severity possibly via modulating host immune responses.", "Nevertheless, this survey of gut microbiota alterations in association with immune dysregulation revealed that gut microorganisms are likely involved in the modulation of host inflammatory responses in COVID-19.", "Conclusion: Associations between gut microbiota composition, levels of cytokines and inflammatory markers in patients with COVID-19 suggest that the gut microbiome is involved in the magnitude of COVID-19 severity possibly via modulating host immune responses.", "They hypothesized gut microbiota would be associated with host inflammatory immune responses in COVID-19.", "Composition of the gut microbiota in patients with COVID-19 is concordant with disease severity and magnitude of plasma concentrations of several inflammatory cytokines, chemokines and blood markers of tissue damage."]}
{"id": 1001876, "claim": "Russia claims it produces drug to treat covid-19.", "label": "SUPPORTED", "evidence": ["Thus, Avifavir has become the first Favipiravir-based drug in the world approved for the treatment of Covid-19,\" they said in the statement.", "Russia's Ministry of Health on Saturday temporarily approved the use of the drug as a coronavirus treatment.", "\"Avifavir is Russia's first Covid-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials.", "VIDEO3:1803:18 Russia to start using Avifavir as a Covid-19 treatment from June Squawk Box Europe Russia has approved an anti-influenza drug, Aviifavir, to treat Covid-19 and will start delivering it to hospitals this month, according to Russia's sovereign wealth fund."]}
{"id": 1001877, "claim": "Russia claims it produces strategies to treat covid-19.", "label": "REFUTED", "evidence": ["Thus, Avifavir has become the first Favipiravir-based drug in the world approved for the treatment of Covid-19,\" they said in the statement.", "Russia's Ministry of Health on Saturday temporarily approved the use of the drug as a coronavirus treatment.", "\"Avifavir is Russia's first Covid-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials.", "VIDEO3:1803:18 Russia to start using Avifavir as a Covid-19 treatment from June Squawk Box Europe Russia has approved an anti-influenza drug, Aviifavir, to treat Covid-19 and will start delivering it to hospitals this month, according to Russia's sovereign wealth fund."]}
{"id": 1001878, "claim": "Russia claims it produces evidence to treat covid-19.", "label": "REFUTED", "evidence": ["Thus, Avifavir has become the first Favipiravir-based drug in the world approved for the treatment of Covid-19,\" they said in the statement.", "Russia's Ministry of Health on Saturday temporarily approved the use of the drug as a coronavirus treatment.", "\"Avifavir is Russia's first Covid-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials.", "VIDEO3:1803:18 Russia to start using Avifavir as a Covid-19 treatment from June Squawk Box Europe Russia has approved an anti-influenza drug, Aviifavir, to treat Covid-19 and will start delivering it to hospitals this month, according to Russia's sovereign wealth fund."]}
{"id": 1001879, "claim": "Predictors of severe symptomatic laboratory-confirmed sars-cov-2 reinfection", "label": "SUPPORTED", "evidence": ["Conclusions To the best of our knowledge this is the first study evaluating disease outcomes in a large set of laboratory-positive cases of symptomatic SARS-COV-2 reinfection and factors associated with illness severity was characterized.", "Our results may contribute to the current knowledge of SARS-COV-2 pathogenicity and to identify populations at increased risk of a poorer outcome after reinfection.", "We used risk ratios (RR) and 95% confidence intervals (CI) to evaluate predictors of severe (dyspnea requiring hospital admission) secondary SARS-COV-2 infection.", "In multiple analysis, factors associated with an increased risk of severe symptomatic SARS-COV-2 reinfection were increasing age (RR per year = 1.007, 95% CI 1.003-1.010), comorbidities (namely obesity [RR = 1.12, 95% CI 1.01-1.24], asthma [RR = 1.26, 95% CI 1.06-1.50], type 2 diabetes mellitus [RR = 1.22, 95% CI 1.07 - 1.38] and previous severe laboratory- confirmed COVID-19 (RR = 1.20, 95% CI 1.03-1.39)."]}
{"id": 1001880, "claim": "Predictors of severe symptomatic laboratory-negative sars-cov-2 reinfection", "label": "REFUTED", "evidence": ["Conclusions To the best of our knowledge this is the first study evaluating disease outcomes in a large set of laboratory-positive cases of symptomatic SARS-COV-2 reinfection and factors associated with illness severity was characterized.", "Our results may contribute to the current knowledge of SARS-COV-2 pathogenicity and to identify populations at increased risk of a poorer outcome after reinfection.", "We used risk ratios (RR) and 95% confidence intervals (CI) to evaluate predictors of severe (dyspnea requiring hospital admission) secondary SARS-COV-2 infection.", "In multiple analysis, factors associated with an increased risk of severe symptomatic SARS-COV-2 reinfection were increasing age (RR per year = 1.007, 95% CI 1.003-1.010), comorbidities (namely obesity [RR = 1.12, 95% CI 1.01-1.24], asthma [RR = 1.26, 95% CI 1.06-1.50], type 2 diabetes mellitus [RR = 1.22, 95% CI 1.07 - 1.38] and previous severe laboratory- confirmed COVID-19 (RR = 1.20, 95% CI 1.03-1.39)."]}
{"id": 1001881, "claim": "Predictors of asymptomatic symptomatic laboratory-confirmed sars-cov-2 reinfection", "label": "REFUTED", "evidence": ["Conclusions To the best of our knowledge this is the first study evaluating disease outcomes in a large set of laboratory-positive cases of symptomatic SARS-COV-2 reinfection and factors associated with illness severity was characterized.", "Our results may contribute to the current knowledge of SARS-COV-2 pathogenicity and to identify populations at increased risk of a poorer outcome after reinfection.", "We used risk ratios (RR) and 95% confidence intervals (CI) to evaluate predictors of severe (dyspnea requiring hospital admission) secondary SARS-COV-2 infection.", "In multiple analysis, factors associated with an increased risk of severe symptomatic SARS-COV-2 reinfection were increasing age (RR per year = 1.007, 95% CI 1.003-1.010), comorbidities (namely obesity [RR = 1.12, 95% CI 1.01-1.24], asthma [RR = 1.26, 95% CI 1.06-1.50], type 2 diabetes mellitus [RR = 1.22, 95% CI 1.07 - 1.38] and previous severe laboratory- confirmed COVID-19 (RR = 1.20, 95% CI 1.03-1.39)."]}
{"id": 1001882, "claim": "Sars-cov-2 in human milk is inactivated by holder pasteurization but not cold storage", "label": "SUPPORTED", "evidence": ["Our findings demonstrate that SARS-CoV-2 can be effectively inactivated by Holder pasteurisation, and confirm that existing milk bank processes will effectively mitigate the risk of transmission of SARS-COV-2 to vulnerable infants through pasteurised donor human milk.", "Cold storage of SARS-CoV-2 in human milk (either at 4°C or - 30°C) did not significantly impact infectious viral load over a 48 hour period."]}
{"id": 1001883, "claim": "Sars-cov-2 in human milk is inactivated by holder pasteurization but also cold storage", "label": "REFUTED", "evidence": ["Our findings demonstrate that SARS-CoV-2 can be effectively inactivated by Holder pasteurisation, and confirm that existing milk bank processes will effectively mitigate the risk of transmission of SARS-COV-2 to vulnerable infants through pasteurised donor human milk.", "Cold storage of SARS-CoV-2 in human milk (either at 4°C or - 30°C) did not significantly impact infectious viral load over a 48 hour period."]}
{"id": 1001884, "claim": "Sars-cov-2 in human milk is inactivated by holder pasteurization but causes cold storage", "label": "REFUTED", "evidence": ["Our findings demonstrate that SARS-CoV-2 can be effectively inactivated by Holder pasteurisation, and confirm that existing milk bank processes will effectively mitigate the risk of transmission of SARS-COV-2 to vulnerable infants through pasteurised donor human milk.", "Cold storage of SARS-CoV-2 in human milk (either at 4°C or - 30°C) did not significantly impact infectious viral load over a 48 hour period."]}
{"id": 1001885, "claim": "Sars-cov-2 in human milk is inactivated by holder pasteurization but with cold storage", "label": "REFUTED", "evidence": ["Our findings demonstrate that SARS-CoV-2 can be effectively inactivated by Holder pasteurisation, and confirm that existing milk bank processes will effectively mitigate the risk of transmission of SARS-COV-2 to vulnerable infants through pasteurised donor human milk.", "Cold storage of SARS-CoV-2 in human milk (either at 4°C or - 30°C) did not significantly impact infectious viral load over a 48 hour period."]}
{"id": 1001886, "claim": "Comparing sweden 's response with the uk 's is misleading , experts argue", "label": "SUPPORTED", "evidence": ["It seems misleading to draw direct comparisons between Sweden and the UK.", "But the paper argues, firstly, that it is a misconception that Sweden has no restrictions or lockdown and, secondly, that assertions that the countrys strategy is successful are far from clear. The report noted the differing social conditions between the UK and Nordic countries, which have a high standard of living, less labour market insecurity, and higher levels of trust.", "Nor is it justifiable to imagine that policies adopted there can be applied seamlessly in the UK. In a media briefing on 25 September, Gabriel Scally, visiting professor of public health at the University of Bristol and a member of Independent SAGE, said Swedens model was being praised too readily in some sections of the UK media."]}
{"id": 1001887, "claim": "Comparing sweden's response with the uk's is in, experts argue", "label": "REFUTED", "evidence": ["It seems misleading to draw direct comparisons between Sweden and the UK.", "But the paper argues, firstly, that it is a misconception that Sweden has no restrictions or lockdown and, secondly, that assertions that the countrys strategy is successful are far from clear. The report noted the differing social conditions between the UK and Nordic countries, which have a high standard of living, less labour market insecurity, and higher levels of trust.", "Nor is it justifiable to imagine that policies adopted there can be applied seamlessly in the UK. In a media briefing on 25 September, Gabriel Scally, visiting professor of public health at the University of Bristol and a member of Independent SAGE, said Swedens model was being praised too readily in some sections of the UK media."]}
{"id": 1001888, "claim": "Two huge covid-19 studies are retracted after scientists sound alarms", "label": "SUPPORTED", "evidence": ["Critics were quick to point out anomalies in both pieces of research, including implausible findings that should have been detected during the peer review process  like the registrys apparent inclusion of a large number of Covid-19 cases very early on in the pandemic, even in Africa, where few hospitals have electronic health records.", "Though there had been other hints of side effects associated with the drugs, clinical trials were halted worldwide while alarmed investigators began safety reviews.", "Two prominent studies on the drugs chloroquine and hydroxychloroquine that used the same dataset from a company called Surgisphere were retracted on Thursday.Credit...John Locher/Associated Press By Roni Caryn Rabin and Ellen Gabler Published June 4, 2020Updated June 20, 2020 The studies, published in renowned scientific journals, produced astounding results and altered the course of research into the coronavirus pandemic."]}
{"id": 1001889, "claim": "No huge covid-19 studies are retracted after scientists sound alarms", "label": "REFUTED", "evidence": ["Critics were quick to point out anomalies in both pieces of research, including implausible findings that should have been detected during the peer review process  like the registrys apparent inclusion of a large number of Covid-19 cases very early on in the pandemic, even in Africa, where few hospitals have electronic health records.", "Though there had been other hints of side effects associated with the drugs, clinical trials were halted worldwide while alarmed investigators began safety reviews.", "Two prominent studies on the drugs chloroquine and hydroxychloroquine that used the same dataset from a company called Surgisphere were retracted on Thursday.Credit...John Locher/Associated Press By Roni Caryn Rabin and Ellen Gabler Published June 4, 2020Updated June 20, 2020 The studies, published in renowned scientific journals, produced astounding results and altered the course of research into the coronavirus pandemic."]}
{"id": 1001890, "claim": "All huge covid-19 studies are retracted after scientists sound alarms", "label": "REFUTED", "evidence": ["Critics were quick to point out anomalies in both pieces of research, including implausible findings that should have been detected during the peer review process  like the registrys apparent inclusion of a large number of Covid-19 cases very early on in the pandemic, even in Africa, where few hospitals have electronic health records.", "Though there had been other hints of side effects associated with the drugs, clinical trials were halted worldwide while alarmed investigators began safety reviews.", "Two prominent studies on the drugs chloroquine and hydroxychloroquine that used the same dataset from a company called Surgisphere were retracted on Thursday.Credit...John Locher/Associated Press By Roni Caryn Rabin and Ellen Gabler Published June 4, 2020Updated June 20, 2020 The studies, published in renowned scientific journals, produced astounding results and altered the course of research into the coronavirus pandemic."]}
{"id": 1001891, "claim": "Chloroquine is a potent inhibitor of sars coronavirus infection and spread", "label": "SUPPORTED", "evidence": ["We have provided evidence that chloroquine is effective in preventing SARS-CoV infection in cell culture if the drug is added to the cells 24 h prior to infection.", "In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine.", "These data clearly show that addition of chloroquine can effectively reduce the establishment of infection and spread of SARS-CoV if the drug is added immediately following virus adsorption.", "Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection."]}
{"id": 1001892, "claim": "Chloroquine is a potent cause of sars coronavirus infection and spread", "label": "REFUTED", "evidence": ["We have provided evidence that chloroquine is effective in preventing SARS-CoV infection in cell culture if the drug is added to the cells 24 h prior to infection.", "In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine.", "These data clearly show that addition of chloroquine can effectively reduce the establishment of infection and spread of SARS-CoV if the drug is added immediately following virus adsorption.", "Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection."]}
{"id": 1001893, "claim": "Chloroquine is a potent inducer of sars coronavirus infection and spread", "label": "REFUTED", "evidence": ["We have provided evidence that chloroquine is effective in preventing SARS-CoV infection in cell culture if the drug is added to the cells 24 h prior to infection.", "In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine.", "These data clearly show that addition of chloroquine can effectively reduce the establishment of infection and spread of SARS-CoV if the drug is added immediately following virus adsorption.", "Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection."]}
{"id": 1001894, "claim": "Disruption of the ccl5/rantes-ccr5 pathway restores immune homeostasis and reduces plasma viral load in critical covid-19", "label": "SUPPORTED", "evidence": ["Here, in 10 terminally-ill, critical COVID-19 patients we report profound elevation of plasma IL-6 and CCL5 (RANTES), decreased CD8+ T cell levels, and SARS-CoV-2 plasma viremia.", "Following compassionate care treatment with the CCR5 blocking antibody leronlimab, we observed complete CCR5 receptor occupancy on macrophage and T cells, rapid reduction of plasma IL-6, restoration of the CD4/CD8 ratio, and a significant decrease in SARS-CoV-2 plasma viremia.", "These results demonstrate a novel approach to resolving unchecked inflammation, restoring immunologic deficiencies, and reducing SARS-CoV-2 plasma viral load via disruption of the CCL5-CCR5 axis, and support randomized clinical trials to assess clinical efficacy of leronlimab-mediated inhibition of CCR5 for COVID-19."]}
{"id": 1001895, "claim": "Addition of the ccl5/rantes-ccr5 pathway restores immune homeostasis and reduces plasma viral load in critical covid-19", "label": "REFUTED", "evidence": ["Here, in 10 terminally-ill, critical COVID-19 patients we report profound elevation of plasma IL-6 and CCL5 (RANTES), decreased CD8+ T cell levels, and SARS-CoV-2 plasma viremia.", "Following compassionate care treatment with the CCR5 blocking antibody leronlimab, we observed complete CCR5 receptor occupancy on macrophage and T cells, rapid reduction of plasma IL-6, restoration of the CD4/CD8 ratio, and a significant decrease in SARS-CoV-2 plasma viremia.", "These results demonstrate a novel approach to resolving unchecked inflammation, restoring immunologic deficiencies, and reducing SARS-CoV-2 plasma viral load via disruption of the CCL5-CCR5 axis, and support randomized clinical trials to assess clinical efficacy of leronlimab-mediated inhibition of CCR5 for COVID-19."]}
{"id": 1001896, "claim": "Activation of the ccl5/rantes-ccr5 pathway restores immune homeostasis and reduces plasma viral load in critical covid-19", "label": "REFUTED", "evidence": ["Here, in 10 terminally-ill, critical COVID-19 patients we report profound elevation of plasma IL-6 and CCL5 (RANTES), decreased CD8+ T cell levels, and SARS-CoV-2 plasma viremia.", "Following compassionate care treatment with the CCR5 blocking antibody leronlimab, we observed complete CCR5 receptor occupancy on macrophage and T cells, rapid reduction of plasma IL-6, restoration of the CD4/CD8 ratio, and a significant decrease in SARS-CoV-2 plasma viremia.", "These results demonstrate a novel approach to resolving unchecked inflammation, restoring immunologic deficiencies, and reducing SARS-CoV-2 plasma viral load via disruption of the CCL5-CCR5 axis, and support randomized clinical trials to assess clinical efficacy of leronlimab-mediated inhibition of CCR5 for COVID-19."]}
{"id": 1001897, "claim": "Treatment of the ccl5/rantes-ccr5 pathway restores immune homeostasis and reduces plasma viral load in critical covid-19", "label": "REFUTED", "evidence": ["Here, in 10 terminally-ill, critical COVID-19 patients we report profound elevation of plasma IL-6 and CCL5 (RANTES), decreased CD8+ T cell levels, and SARS-CoV-2 plasma viremia.", "Following compassionate care treatment with the CCR5 blocking antibody leronlimab, we observed complete CCR5 receptor occupancy on macrophage and T cells, rapid reduction of plasma IL-6, restoration of the CD4/CD8 ratio, and a significant decrease in SARS-CoV-2 plasma viremia.", "These results demonstrate a novel approach to resolving unchecked inflammation, restoring immunologic deficiencies, and reducing SARS-CoV-2 plasma viral load via disruption of the CCL5-CCR5 axis, and support randomized clinical trials to assess clinical efficacy of leronlimab-mediated inhibition of CCR5 for COVID-19."]}
{"id": 1001898, "claim": "Sars-cov-2 viral load is associated with increased disease severity and mortality", "label": "SUPPORTED", "evidence": ["2: SARS-CoV-2 viral load is associated with markers of inflammation and disease severity.", "Here we show that SARS-CoV-2 viral loads, especially in the plasma, are predictive of mortality.", "SARS-CoV-2 viral loads, especially within plasma, are associated with systemic inflammation, disease progression, and increased risk of death.", "SARS-CoV-2 viral loads, especially plasma viremia, are associated with increased risk of mortality."]}
{"id": 1001899, "claim": "Repurposing of miglustat to inhibit the coronavirus severe acquired respiratory syndrome sars-cov-2", "label": "SUPPORTED", "evidence": ["The activity of Miglustat is here demonstrated for SARS-CoV-2 at concentrations achievable in the plasma by current clinical regimens without cytotoxicity.", "The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.", "The wealth of available data on the clinical use of Miglustat for the treatment of lysosomal storage disorders and the antiviral properties against SARS-CoV-2 make it an ideal candidate for drug repurposing."]}
{"id": 1001900, "claim": "Repurposing of miglustat to investigate the coronavirus severe acquired respiratory syndrome sars-cov-2", "label": "REFUTED", "evidence": ["The activity of Miglustat is here demonstrated for SARS-CoV-2 at concentrations achievable in the plasma by current clinical regimens without cytotoxicity.", "The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.", "The wealth of available data on the clinical use of Miglustat for the treatment of lysosomal storage disorders and the antiviral properties against SARS-CoV-2 make it an ideal candidate for drug repurposing."]}
{"id": 1001901, "claim": "Repurposing of miglustat to study the coronavirus severe acquired respiratory syndrome sars-cov-2", "label": "REFUTED", "evidence": ["The activity of Miglustat is here demonstrated for SARS-CoV-2 at concentrations achievable in the plasma by current clinical regimens without cytotoxicity.", "The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.", "The wealth of available data on the clinical use of Miglustat for the treatment of lysosomal storage disorders and the antiviral properties against SARS-CoV-2 make it an ideal candidate for drug repurposing."]}
{"id": 1001902, "claim": "Repurposing of miglustat to form the coronavirus severe acquired respiratory syndrome sars-cov-2", "label": "REFUTED", "evidence": ["The activity of Miglustat is here demonstrated for SARS-CoV-2 at concentrations achievable in the plasma by current clinical regimens without cytotoxicity.", "The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.", "The wealth of available data on the clinical use of Miglustat for the treatment of lysosomal storage disorders and the antiviral properties against SARS-CoV-2 make it an ideal candidate for drug repurposing."]}
{"id": 1001903, "claim": "Frequency and profile of objective cognitive deficits in hospitalized patients recovering from covid-19", "label": "SUPPORTED", "evidence": ["This study evaluated the frequency, severity, and profile of cognitive dysfunction in hospitalized patients recovering from COVID-19.", "A number of case reports and case series have suggested that cognitive deficits occur in patients with COVID-19.", "The goal of our study was to evaluate the frequency, severity, and profile of cognitive deficits in hospitalized and recovering patients with COVID-19."]}
{"id": 1001904, "claim": "Frequency and profile of objective cognitive benefits in hospitalized patients recovering from covid-19", "label": "REFUTED", "evidence": ["This study evaluated the frequency, severity, and profile of cognitive dysfunction in hospitalized patients recovering from COVID-19.", "A number of case reports and case series have suggested that cognitive deficits occur in patients with COVID-19.", "The goal of our study was to evaluate the frequency, severity, and profile of cognitive deficits in hospitalized and recovering patients with COVID-19."]}
{"id": 1001905, "claim": "Frequency and profile of systemic cognitive deficits in hospitalized patients recovering from covid-19", "label": "REFUTED", "evidence": ["This study evaluated the frequency, severity, and profile of cognitive dysfunction in hospitalized patients recovering from COVID-19.", "A number of case reports and case series have suggested that cognitive deficits occur in patients with COVID-19.", "The goal of our study was to evaluate the frequency, severity, and profile of cognitive deficits in hospitalized and recovering patients with COVID-19."]}
{"id": 1001906, "claim": "Frequency and profile of inflammatory cognitive deficits in hospitalized patients recovering from covid-19", "label": "REFUTED", "evidence": ["This study evaluated the frequency, severity, and profile of cognitive dysfunction in hospitalized patients recovering from COVID-19.", "A number of case reports and case series have suggested that cognitive deficits occur in patients with COVID-19.", "The goal of our study was to evaluate the frequency, severity, and profile of cognitive deficits in hospitalized and recovering patients with COVID-19."]}
{"id": 1001907, "claim": "High affinity nanobodies block sars-cov-2 spike receptor binding domain interaction with human angiotensin converting enzyme.", "label": "SUPPORTED", "evidence": ["( a ) Illustration of the structure of SARS-CoV-2 spike protein, with receptor binding domain in contact with the human ACE2 receptor on the surface of a lung epithelial cell.", "The SARS-CoV-2 virus gains entry to human cells via the angiotensin converting enzyme 2 (ACE2) receptor by the interaction of the receptor binding domain (RBD) of the spike protein on the viral surface4,5,6,7,8.", "We have isolated nanobodies that bind to the SARS-CoV-2 spike protein receptor binding domain and block spike protein interaction with the angiotensin converting enzyme 2 (ACE2) with 15 nM affinity.", "We have isolated nanobodies that bind to the SARS-CoV-2 spike protein receptor binding domain and block spike protein interaction with the angiotensin converting enzyme 2 (ACE2) with 1-5 nM affinity."]}
{"id": 1001908, "claim": "High affinity nanobodies include sars-cov-2 spike receptor binding domain interaction with human angiotensin converting enzyme.", "label": "REFUTED", "evidence": ["( a ) Illustration of the structure of SARS-CoV-2 spike protein, with receptor binding domain in contact with the human ACE2 receptor on the surface of a lung epithelial cell.", "The SARS-CoV-2 virus gains entry to human cells via the angiotensin converting enzyme 2 (ACE2) receptor by the interaction of the receptor binding domain (RBD) of the spike protein on the viral surface4,5,6,7,8.", "We have isolated nanobodies that bind to the SARS-CoV-2 spike protein receptor binding domain and block spike protein interaction with the angiotensin converting enzyme 2 (ACE2) with 15 nM affinity.", "We have isolated nanobodies that bind to the SARS-CoV-2 spike protein receptor binding domain and block spike protein interaction with the angiotensin converting enzyme 2 (ACE2) with 1-5 nM affinity."]}
{"id": 1001909, "claim": "Ifn-α2a therapy in two patients with inborn errors of tlr3 and irf3 infected with sars-cov-2.", "label": "SUPPORTED", "evidence": ["We report here the safety of a single subcutaneous injection of Peg-IFN-α2a in two patients with IEIs affecting the production of type I IFNs associated with a predisposition to severe COVID-19.", "The rationale for proposing IFN-α2a treatment to these two patients was based on (i) the impairment of type I IFN production by both AD TLR3 and IRF3 deficiencies [2,3,4,5]; (ii) the development of severe COVID-19, sometimes with a fatal outcome, in some patients with IEIs affecting type I IFN production; (iii) the anosmia/ageusia in both patients, whose IEI predispose to HSE, and the tropism of SARS-Cov2 for the central nervous system, which together stressed a risk of neurological manifestations of COVID-19; (iv) the high susceptibility of TLR3-deficient fibroblasts to SARS-Cov2 in vitro, a phenotype rescued by exogenous type I IFN; (v) the diagnosis of these two patients with COVID-19 at a very early stage of clinical manifestations, placing both patients in the so-called first phase of COVID-19; and (vi) the known safety profile of a single dose of Peg-IFN-α2a."]}
{"id": 1001910, "claim": "Ifn-α2a therapy in 5 patients with inborn errors of tlr3 and irf3 infected with sars-cov-2.", "label": "REFUTED", "evidence": ["We report here the safety of a single subcutaneous injection of Peg-IFN-α2a in two patients with IEIs affecting the production of type I IFNs associated with a predisposition to severe COVID-19.", "The rationale for proposing IFN-α2a treatment to these two patients was based on (i) the impairment of type I IFN production by both AD TLR3 and IRF3 deficiencies [2,3,4,5]; (ii) the development of severe COVID-19, sometimes with a fatal outcome, in some patients with IEIs affecting type I IFN production; (iii) the anosmia/ageusia in both patients, whose IEI predispose to HSE, and the tropism of SARS-Cov2 for the central nervous system, which together stressed a risk of neurological manifestations of COVID-19; (iv) the high susceptibility of TLR3-deficient fibroblasts to SARS-Cov2 in vitro, a phenotype rescued by exogenous type I IFN; (v) the diagnosis of these two patients with COVID-19 at a very early stage of clinical manifestations, placing both patients in the so-called first phase of COVID-19; and (vi) the known safety profile of a single dose of Peg-IFN-α2a."]}
{"id": 1001911, "claim": "Ifn-α2a died in two patients with inborn errors of tlr3 and irf3 infected with sars-cov-2.", "label": "REFUTED", "evidence": ["We report here the safety of a single subcutaneous injection of Peg-IFN-α2a in two patients with IEIs affecting the production of type I IFNs associated with a predisposition to severe COVID-19.", "The rationale for proposing IFN-α2a treatment to these two patients was based on (i) the impairment of type I IFN production by both AD TLR3 and IRF3 deficiencies [2,3,4,5]; (ii) the development of severe COVID-19, sometimes with a fatal outcome, in some patients with IEIs affecting type I IFN production; (iii) the anosmia/ageusia in both patients, whose IEI predispose to HSE, and the tropism of SARS-Cov2 for the central nervous system, which together stressed a risk of neurological manifestations of COVID-19; (iv) the high susceptibility of TLR3-deficient fibroblasts to SARS-Cov2 in vitro, a phenotype rescued by exogenous type I IFN; (v) the diagnosis of these two patients with COVID-19 at a very early stage of clinical manifestations, placing both patients in the so-called first phase of COVID-19; and (vi) the known safety profile of a single dose of Peg-IFN-α2a."]}
{"id": 1001912, "claim": "Early immune pathology and persistent dysregulation characterise severe covid-19.", "label": "SUPPORTED", "evidence": ["Dysregulation in the immune system can lead to an unappropriated local and systemic immune responses and subsequently the rapid spread of the virus, leading to severe COVID-19 disease.", "Complex immune dysregulation in COVID-19 patients with severe respiratory failure."]}
{"id": 1001913, "claim": "Severe immune pathology and persistent dysregulation characterise severe covid-19.", "label": "REFUTED", "evidence": ["Dysregulation in the immune system can lead to an unappropriated local and systemic immune responses and subsequently the rapid spread of the virus, leading to severe COVID-19 disease.", "Complex immune dysregulation in COVID-19 patients with severe respiratory failure."]}
{"id": 1001914, "claim": "Chronic immune pathology and persistent dysregulation characterise severe covid-19.", "label": "REFUTED", "evidence": ["Dysregulation in the immune system can lead to an unappropriated local and systemic immune responses and subsequently the rapid spread of the virus, leading to severe COVID-19 disease.", "Complex immune dysregulation in COVID-19 patients with severe respiratory failure."]}
{"id": 1001915, "claim": "Increased immune pathology and persistent dysregulation characterise severe covid-19.", "label": "REFUTED", "evidence": ["Dysregulation in the immune system can lead to an unappropriated local and systemic immune responses and subsequently the rapid spread of the virus, leading to severe COVID-19 disease.", "Complex immune dysregulation in COVID-19 patients with severe respiratory failure."]}
{"id": 1001916, "claim": "Couple wrap themselves in plastic for domestic flight", "label": "SUPPORTED", "evidence": ["The video shows the couple in their seats, with a woman wrapped in a pink plastic outfit wearing a face mask, while her companion is wearing a white plastic sheet with holes cut out for his arms and legs, as well as a face mask.", "ABC NEWS UP NEXT Video provided by NBC News Two air passengers took virus prevention to new extremes by wrapping themselves completely in plastic foil during a flight.", "One of the passengers had covered himself in translucent plastic sheets, while his companion was wearing a pink protective suit."]}
{"id": 1001917, "claim": "Bats wrap themselves in plastic for domestic flight", "label": "REFUTED", "evidence": ["The video shows the couple in their seats, with a woman wrapped in a pink plastic outfit wearing a face mask, while her companion is wearing a white plastic sheet with holes cut out for his arms and legs, as well as a face mask.", "ABC NEWS UP NEXT Video provided by NBC News Two air passengers took virus prevention to new extremes by wrapping themselves completely in plastic foil during a flight.", "One of the passengers had covered himself in translucent plastic sheets, while his companion was wearing a pink protective suit."]}
{"id": 1001918, "claim": "Animals wrap themselves in plastic for domestic flight", "label": "REFUTED", "evidence": ["The video shows the couple in their seats, with a woman wrapped in a pink plastic outfit wearing a face mask, while her companion is wearing a white plastic sheet with holes cut out for his arms and legs, as well as a face mask.", "ABC NEWS UP NEXT Video provided by NBC News Two air passengers took virus prevention to new extremes by wrapping themselves completely in plastic foil during a flight.", "One of the passengers had covered himself in translucent plastic sheets, while his companion was wearing a pink protective suit."]}
{"id": 1001919, "claim": "Couple wrap themselves in plastic for domestic animals", "label": "REFUTED", "evidence": ["The video shows the couple in their seats, with a woman wrapped in a pink plastic outfit wearing a face mask, while her companion is wearing a white plastic sheet with holes cut out for his arms and legs, as well as a face mask.", "ABC NEWS UP NEXT Video provided by NBC News Two air passengers took virus prevention to new extremes by wrapping themselves completely in plastic foil during a flight.", "One of the passengers had covered himself in translucent plastic sheets, while his companion was wearing a pink protective suit."]}
{"id": 1001920, "claim": "Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized covid-19 patients", "label": "SUPPORTED", "evidence": ["In addition to hydroxychloroquine, Novartis plans to sponsor or co-sponsor clinical trials to study ruxolitinib and canakinumab for hospitalized patients with COVID-19 infections.", "The clinical trial complements a commitment by Novartis, through Sandoz, to donate up to 130 million tablets of hydroxychloroquine to supply global clinical research efforts in the event the medicine is proven beneficial for treatment of COVID-19."]}
{"id": 1001921, "claim": "Novartis to no large clinical trial of hydroxychloroquine in hospitalized covid-19 patients", "label": "REFUTED", "evidence": ["In addition to hydroxychloroquine, Novartis plans to sponsor or co-sponsor clinical trials to study ruxolitinib and canakinumab for hospitalized patients with COVID-19 infections.", "The clinical trial complements a commitment by Novartis, through Sandoz, to donate up to 130 million tablets of hydroxychloroquine to supply global clinical research efforts in the event the medicine is proven beneficial for treatment of COVID-19."]}
{"id": 1001922, "claim": "Novartis to sponsor large clinical trial of hydroxychloroquine in developing covid-19 patients", "label": "REFUTED", "evidence": ["In addition to hydroxychloroquine, Novartis plans to sponsor or co-sponsor clinical trials to study ruxolitinib and canakinumab for hospitalized patients with COVID-19 infections.", "The clinical trial complements a commitment by Novartis, through Sandoz, to donate up to 130 million tablets of hydroxychloroquine to supply global clinical research efforts in the event the medicine is proven beneficial for treatment of COVID-19."]}
{"id": 1001923, "claim": "Plasma treatments quickly kill coronavirus on surfaces .", "label": "SUPPORTED", "evidence": ["Cold atmospheric plasma  plasma produced near room temperature  has been found to be potentially effective in deactivating the SARS-CoV-2 virus (Source: Wikimedia Commons) When it comes to COVID-19, one of the modes of transmission between people is via contact with surfaces containing coronavirus viroids.", "The spray, using plasma fed by argon, killed all the coronaviruses on the 6 surfaces in less than 3 minutes, and most of the virus was destroyed after 30 seconds.", "Share: 68873 Study: Plasma Treatment Quickly Kill Coronavirus on Surfaces In a study published in Physics of Fluids , modeling conducted in June 2020 showed strains of COVID-19 on surfaces--such as metal, leather, and plastic-- were killed in as little as 30 seconds of treatment with argon-fed, cold atmospheric plasma.", "al have revealed a novel solution that can quickly and safely deactivate coronavirus on surfaces: cold atmospheric plasma."]}
{"id": 1001924, "claim": "Plasma treatments quickly kill coronavirus on cells.", "label": "REFUTED", "evidence": ["Cold atmospheric plasma  plasma produced near room temperature  has been found to be potentially effective in deactivating the SARS-CoV-2 virus (Source: Wikimedia Commons) When it comes to COVID-19, one of the modes of transmission between people is via contact with surfaces containing coronavirus viroids.", "The spray, using plasma fed by argon, killed all the coronaviruses on the 6 surfaces in less than 3 minutes, and most of the virus was destroyed after 30 seconds.", "Share: 68873 Study: Plasma Treatment Quickly Kill Coronavirus on Surfaces In a study published in Physics of Fluids , modeling conducted in June 2020 showed strains of COVID-19 on surfaces--such as metal, leather, and plastic-- were killed in as little as 30 seconds of treatment with argon-fed, cold atmospheric plasma.", "al have revealed a novel solution that can quickly and safely deactivate coronavirus on surfaces: cold atmospheric plasma."]}
{"id": 1001925, "claim": "Plasma treatments quickly kill coronavirus on cell.", "label": "REFUTED", "evidence": ["Cold atmospheric plasma  plasma produced near room temperature  has been found to be potentially effective in deactivating the SARS-CoV-2 virus (Source: Wikimedia Commons) When it comes to COVID-19, one of the modes of transmission between people is via contact with surfaces containing coronavirus viroids.", "The spray, using plasma fed by argon, killed all the coronaviruses on the 6 surfaces in less than 3 minutes, and most of the virus was destroyed after 30 seconds.", "Share: 68873 Study: Plasma Treatment Quickly Kill Coronavirus on Surfaces In a study published in Physics of Fluids , modeling conducted in June 2020 showed strains of COVID-19 on surfaces--such as metal, leather, and plastic-- were killed in as little as 30 seconds of treatment with argon-fed, cold atmospheric plasma.", "al have revealed a novel solution that can quickly and safely deactivate coronavirus on surfaces: cold atmospheric plasma."]}
{"id": 1001926, "claim": "Rapid endothelialitis and vascular inflammation characterise sars-cov-2 infection in a human lung-on-chip model", "label": "SUPPORTED", "evidence": ["Methods We establish a vascularised lung-on-chip infection model consisting of a co-culture of primary human alveolar epithelial cells (epithelial) and human lung microvascular endothelial cells (endothelial), with the optional addition of CD14+ macrophages to the epithelial side.", "A combination of qRT-PCR, RNAscope, immunofluorescence, and ELISA measurements are used to study the dynamics of viral replication and host responses to a low dose infection of SARS-CoV-2 delivered to the apical surface of the epithelial face maintained at an air-liquid interface."]}
{"id": 1001927, "claim": "Rapid endothelialitis and vascular inflammation characterise sars-cov-2 infection in a canine lung-on-chip model", "label": "REFUTED", "evidence": ["Methods We establish a vascularised lung-on-chip infection model consisting of a co-culture of primary human alveolar epithelial cells (epithelial) and human lung microvascular endothelial cells (endothelial), with the optional addition of CD14+ macrophages to the epithelial side.", "A combination of qRT-PCR, RNAscope, immunofluorescence, and ELISA measurements are used to study the dynamics of viral replication and host responses to a low dose infection of SARS-CoV-2 delivered to the apical surface of the epithelial face maintained at an air-liquid interface."]}
{"id": 1001928, "claim": "Rapid endothelialitis and vascular inflammation characterise sars-cov-2 infection in a rat lung-on-chip model", "label": "REFUTED", "evidence": ["Methods We establish a vascularised lung-on-chip infection model consisting of a co-culture of primary human alveolar epithelial cells (epithelial) and human lung microvascular endothelial cells (endothelial), with the optional addition of CD14+ macrophages to the epithelial side.", "A combination of qRT-PCR, RNAscope, immunofluorescence, and ELISA measurements are used to study the dynamics of viral replication and host responses to a low dose infection of SARS-CoV-2 delivered to the apical surface of the epithelial face maintained at an air-liquid interface."]}
{"id": 1001929, "claim": "Rapid endothelialitis and vascular inflammation characterise sars-cov-2 infection in a mouse lung-on-chip model", "label": "REFUTED", "evidence": ["Methods We establish a vascularised lung-on-chip infection model consisting of a co-culture of primary human alveolar epithelial cells (epithelial) and human lung microvascular endothelial cells (endothelial), with the optional addition of CD14+ macrophages to the epithelial side.", "A combination of qRT-PCR, RNAscope, immunofluorescence, and ELISA measurements are used to study the dynamics of viral replication and host responses to a low dose infection of SARS-CoV-2 delivered to the apical surface of the epithelial face maintained at an air-liquid interface."]}
{"id": 1001930, "claim": "Vascular brain pathology is more important than neurodegeneration in the pathogenesis of pre-stroke cognitive impairment.", "label": "SUPPORTED", "evidence": ["Cerebrovascular pathology was the dominating imaging finding associated with cognitive impairment, thus indicating that the pathogenesis of pre-stroke cognitive impairment might be driven more by small vessel disease (SVD) than neurodegenerative changes.", "Share Vascular brain pathology is more important than neurodegeneration in pathogenesis of pre-stroke cognitive impairment T Schellhorn, M Zucknick, T Askim, R Munthe-Kaas, H Ihle-Hansen, YM Seljeseth, AB Knapskog, H Næss, H Ellekjær, P Thingstad, T Bruun Wyller, I Saltvedt, MK Beyer medRxiv 2020.06.12.20129106; doi: https://doi.org/10.1101/2020.06.12.20129106 Share This Article: Copy Citation Tools Vascular brain pathology is more important than neurodegeneration in pathogenesis of pre-stroke cognitive impairment T Schellhorn, M Zucknick, T Askim, R Munthe-Kaas, H Ihle-Hansen, YM Seljeseth, AB Knapskog, H Næss, H Ellekjær, P Thingstad, T Bruun Wyller, I Saltvedt, MK Beyer medRxiv 2020.06.12.20129106; doi: https://doi.org/10.1101/2020.06.12.20129106 "]}
{"id": 1001931, "claim": "Vascular brain pathology is less important than neurodegeneration in the pathogenesis of pre-stroke cognitive impairment.", "label": "REFUTED", "evidence": ["Cerebrovascular pathology was the dominating imaging finding associated with cognitive impairment, thus indicating that the pathogenesis of pre-stroke cognitive impairment might be driven more by small vessel disease (SVD) than neurodegenerative changes.", "Share Vascular brain pathology is more important than neurodegeneration in pathogenesis of pre-stroke cognitive impairment T Schellhorn, M Zucknick, T Askim, R Munthe-Kaas, H Ihle-Hansen, YM Seljeseth, AB Knapskog, H Næss, H Ellekjær, P Thingstad, T Bruun Wyller, I Saltvedt, MK Beyer medRxiv 2020.06.12.20129106; doi: https://doi.org/10.1101/2020.06.12.20129106 Share This Article: Copy Citation Tools Vascular brain pathology is more important than neurodegeneration in pathogenesis of pre-stroke cognitive impairment T Schellhorn, M Zucknick, T Askim, R Munthe-Kaas, H Ihle-Hansen, YM Seljeseth, AB Knapskog, H Næss, H Ellekjær, P Thingstad, T Bruun Wyller, I Saltvedt, MK Beyer medRxiv 2020.06.12.20129106; doi: https://doi.org/10.1101/2020.06.12.20129106 "]}
{"id": 1001932, "claim": "Antibody cocktail to sars-cov-2 spike protein prevents rapid mutational escape seen with individual antibodies", "label": "SUPPORTED", "evidence": ["The prospective goal of generating this very large collection was to select pairs of highly potent individual antibodies that could simultaneously bind the RBD spike, and thus might be ideal partners for a therapeutic antibody cocktail that not only could be an effective treatment, but might also protect against antibody resistance resulting from virus escape mutants that could arise in response to selective pressure from single-antibody treatments.", "Our data strongly support the notion that cocktail therapy may provide a powerful way to minimize mutational escape by SARS-CoV-2; in particular, our studies point to the potential value of antibody cocktails in which two antibodies were chosen so as to bind to distinct and non-overlapping regions of the viral target (in this case, the RBD of the spike protein), and thus require the unlikely occurrence of simultaneous mutations at two distinct genetic sites for viral escape.", "To functionally confirm that the spike protein mutations detected by sequencing are responsible for the loss of SARS-CoV-2 neutralization by the antibodies, we generated VSV-SARS-CoV-2 spike pseudoparticles expressing the individual identified spike mutations.", "For an antibody cocktail in which the components demonstrate complete competition (REGN10989+REGN10934), a single amino acid substitution was sufficient to ablate neutralization of the cocktail; hence, both of these antibodies require binding to the Glu484 residue in order to neutralize SARS-CoV-2."]}
{"id": 1001933, "claim": "Antibody cocktail to sars-cov-2 spike protein induces rapid mutational escape seen with individual antibodies", "label": "REFUTED", "evidence": ["The prospective goal of generating this very large collection was to select pairs of highly potent individual antibodies that could simultaneously bind the RBD spike, and thus might be ideal partners for a therapeutic antibody cocktail that not only could be an effective treatment, but might also protect against antibody resistance resulting from virus escape mutants that could arise in response to selective pressure from single-antibody treatments.", "Our data strongly support the notion that cocktail therapy may provide a powerful way to minimize mutational escape by SARS-CoV-2; in particular, our studies point to the potential value of antibody cocktails in which two antibodies were chosen so as to bind to distinct and non-overlapping regions of the viral target (in this case, the RBD of the spike protein), and thus require the unlikely occurrence of simultaneous mutations at two distinct genetic sites for viral escape.", "To functionally confirm that the spike protein mutations detected by sequencing are responsible for the loss of SARS-CoV-2 neutralization by the antibodies, we generated VSV-SARS-CoV-2 spike pseudoparticles expressing the individual identified spike mutations.", "For an antibody cocktail in which the components demonstrate complete competition (REGN10989+REGN10934), a single amino acid substitution was sufficient to ablate neutralization of the cocktail; hence, both of these antibodies require binding to the Glu484 residue in order to neutralize SARS-CoV-2."]}
{"id": 1001934, "claim": "Antibody cocktail to sars-cov-2 spike protein induced rapid mutational escape seen with individual antibodies", "label": "REFUTED", "evidence": ["The prospective goal of generating this very large collection was to select pairs of highly potent individual antibodies that could simultaneously bind the RBD spike, and thus might be ideal partners for a therapeutic antibody cocktail that not only could be an effective treatment, but might also protect against antibody resistance resulting from virus escape mutants that could arise in response to selective pressure from single-antibody treatments.", "Our data strongly support the notion that cocktail therapy may provide a powerful way to minimize mutational escape by SARS-CoV-2; in particular, our studies point to the potential value of antibody cocktails in which two antibodies were chosen so as to bind to distinct and non-overlapping regions of the viral target (in this case, the RBD of the spike protein), and thus require the unlikely occurrence of simultaneous mutations at two distinct genetic sites for viral escape.", "To functionally confirm that the spike protein mutations detected by sequencing are responsible for the loss of SARS-CoV-2 neutralization by the antibodies, we generated VSV-SARS-CoV-2 spike pseudoparticles expressing the individual identified spike mutations.", "For an antibody cocktail in which the components demonstrate complete competition (REGN10989+REGN10934), a single amino acid substitution was sufficient to ablate neutralization of the cocktail; hence, both of these antibodies require binding to the Glu484 residue in order to neutralize SARS-CoV-2."]}
{"id": 1001935, "claim": "Antibody cocktail to sars-cov-2 spike protein provides rapid mutational escape seen with individual antibodies", "label": "REFUTED", "evidence": ["The prospective goal of generating this very large collection was to select pairs of highly potent individual antibodies that could simultaneously bind the RBD spike, and thus might be ideal partners for a therapeutic antibody cocktail that not only could be an effective treatment, but might also protect against antibody resistance resulting from virus escape mutants that could arise in response to selective pressure from single-antibody treatments.", "Our data strongly support the notion that cocktail therapy may provide a powerful way to minimize mutational escape by SARS-CoV-2; in particular, our studies point to the potential value of antibody cocktails in which two antibodies were chosen so as to bind to distinct and non-overlapping regions of the viral target (in this case, the RBD of the spike protein), and thus require the unlikely occurrence of simultaneous mutations at two distinct genetic sites for viral escape.", "To functionally confirm that the spike protein mutations detected by sequencing are responsible for the loss of SARS-CoV-2 neutralization by the antibodies, we generated VSV-SARS-CoV-2 spike pseudoparticles expressing the individual identified spike mutations.", "For an antibody cocktail in which the components demonstrate complete competition (REGN10989+REGN10934), a single amino acid substitution was sufficient to ablate neutralization of the cocktail; hence, both of these antibodies require binding to the Glu484 residue in order to neutralize SARS-CoV-2."]}
{"id": 1001936, "claim": "Severity of covid-19 is inversely correlated with increased number counts of non-synonymous mutations in tokyo", "label": "SUPPORTED", "evidence": ["Conclusion Viral genome sequencing in 90 patients treated in the Tokyo Metropolitan area showed that the accumulation of point mutations, including Pro108Ser in 3CLpro and Pro151Leu in nucleocapsid protein, was inversely correlated with COVID-19 severity.", "Results The number of non-synonymous mutations was inversely correlated with COVID-19 severity, as defined by requiring oxygen supplementation."]}
{"id": 1001937, "claim": "Severity of covid-19 is equally correlated with increased number counts of non-synonymous mutations in tokyo", "label": "REFUTED", "evidence": ["Conclusion Viral genome sequencing in 90 patients treated in the Tokyo Metropolitan area showed that the accumulation of point mutations, including Pro108Ser in 3CLpro and Pro151Leu in nucleocapsid protein, was inversely correlated with COVID-19 severity.", "Results The number of non-synonymous mutations was inversely correlated with COVID-19 severity, as defined by requiring oxygen supplementation."]}
{"id": 1001938, "claim": "Severity of covid-19 is greaterly correlated with increased number counts of non-synonymous mutations in tokyo", "label": "REFUTED", "evidence": ["Conclusion Viral genome sequencing in 90 patients treated in the Tokyo Metropolitan area showed that the accumulation of point mutations, including Pro108Ser in 3CLpro and Pro151Leu in nucleocapsid protein, was inversely correlated with COVID-19 severity.", "Results The number of non-synonymous mutations was inversely correlated with COVID-19 severity, as defined by requiring oxygen supplementation."]}
{"id": 1001939, "claim": "Severity of covid-19 is narrowly correlated with increased number counts of non-synonymous mutations in tokyo", "label": "REFUTED", "evidence": ["Conclusion Viral genome sequencing in 90 patients treated in the Tokyo Metropolitan area showed that the accumulation of point mutations, including Pro108Ser in 3CLpro and Pro151Leu in nucleocapsid protein, was inversely correlated with COVID-19 severity.", "Results The number of non-synonymous mutations was inversely correlated with COVID-19 severity, as defined by requiring oxygen supplementation."]}
{"id": 1001940, "claim": "Clinical and chest radiography features determine patient outcomes in young and middle age adults with covid-19", "label": "SUPPORTED", "evidence": ["Clinical and Chest Radiography Features Determine Patient Outcomes in Young and Middle-aged Adults with COVID-19.", "Clinical and Chest Radiography Features Determine Patient Outcomes in Young and Middle-aged Adults With COVID-19.", "\"Clinical and Chest Radiography Features Determine Patient Outcomes in Young and Middle-aged Adults With COVID-19.\"", "Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19.", "Diagnostic and Prognostic Value of Chest Radiographs for COVID-19 at Presentation."]}
{"id": 1001941, "claim": "Clinical and ct radiography features determine patient outcomes in young and middle age adults with covid-19", "label": "REFUTED", "evidence": ["Clinical and Chest Radiography Features Determine Patient Outcomes in Young and Middle-aged Adults with COVID-19.", "Clinical and Chest Radiography Features Determine Patient Outcomes in Young and Middle-aged Adults With COVID-19.", "\"Clinical and Chest Radiography Features Determine Patient Outcomes in Young and Middle-aged Adults With COVID-19.\"", "Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19.", "Diagnostic and Prognostic Value of Chest Radiographs for COVID-19 at Presentation."]}
{"id": 1001942, "claim": "Clinical and thoracic radiography features determine patient outcomes in young and middle age adults with covid-19", "label": "REFUTED", "evidence": ["Clinical and Chest Radiography Features Determine Patient Outcomes in Young and Middle-aged Adults with COVID-19.", "Clinical and Chest Radiography Features Determine Patient Outcomes in Young and Middle-aged Adults With COVID-19.", "\"Clinical and Chest Radiography Features Determine Patient Outcomes in Young and Middle-aged Adults With COVID-19.\"", "Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19.", "Diagnostic and Prognostic Value of Chest Radiographs for COVID-19 at Presentation."]}
{"id": 1001943, "claim": "Clinical and radiological radiography features determine patient outcomes in young and middle age adults with covid-19", "label": "REFUTED", "evidence": ["Clinical and Chest Radiography Features Determine Patient Outcomes in Young and Middle-aged Adults with COVID-19.", "Clinical and Chest Radiography Features Determine Patient Outcomes in Young and Middle-aged Adults With COVID-19.", "\"Clinical and Chest Radiography Features Determine Patient Outcomes in Young and Middle-aged Adults With COVID-19.\"", "Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19.", "Diagnostic and Prognostic Value of Chest Radiographs for COVID-19 at Presentation."]}
{"id": 1001944, "claim": "Astrazeneca covid-19 vaccine trial volunteer has died , brazil health authority says", "label": "SUPPORTED", "evidence": ["An employee is seen at the Reference Center for Special Immunobiologicals of the Federal University of Sao Paulo where the trials of the Oxford/AstraZeneca coronavirus vaccine are conducted, in Sao Paulo on June 24, 2020.Amanda Perobelli / Reuters file Oct. 21, 2020, 5:40 PM UTC / Updated Oct. 22, 2020, 12:29 PM UTC By Sara G. Miller A volunteer in AstraZeneca's Covid-19 vaccine trial has died in Brazil, the country's National Health Surveillance Agency said Wednesday.", "(Photo by Vincenzo PINTO / AFP) (Photo by VINCENZO PINTO/AFP via Getty Images) BRAZIL (NewsNation Now)  Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University has died, stating it had received data from an investigation into the matter."]}
{"id": 1001945, "claim": "Astrazeneca covid-19 vaccine trial volunteer has received, brazil health authority says", "label": "REFUTED", "evidence": ["An employee is seen at the Reference Center for Special Immunobiologicals of the Federal University of Sao Paulo where the trials of the Oxford/AstraZeneca coronavirus vaccine are conducted, in Sao Paulo on June 24, 2020.Amanda Perobelli / Reuters file Oct. 21, 2020, 5:40 PM UTC / Updated Oct. 22, 2020, 12:29 PM UTC By Sara G. Miller A volunteer in AstraZeneca's Covid-19 vaccine trial has died in Brazil, the country's National Health Surveillance Agency said Wednesday.", "(Photo by Vincenzo PINTO / AFP) (Photo by VINCENZO PINTO/AFP via Getty Images) BRAZIL (NewsNation Now)  Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University has died, stating it had received data from an investigation into the matter."]}
{"id": 1001946, "claim": "Astrazeneca covid-19 vaccine trial volunteer has become, brazil health authority says", "label": "REFUTED", "evidence": ["An employee is seen at the Reference Center for Special Immunobiologicals of the Federal University of Sao Paulo where the trials of the Oxford/AstraZeneca coronavirus vaccine are conducted, in Sao Paulo on June 24, 2020.Amanda Perobelli / Reuters file Oct. 21, 2020, 5:40 PM UTC / Updated Oct. 22, 2020, 12:29 PM UTC By Sara G. Miller A volunteer in AstraZeneca's Covid-19 vaccine trial has died in Brazil, the country's National Health Surveillance Agency said Wednesday.", "(Photo by Vincenzo PINTO / AFP) (Photo by VINCENZO PINTO/AFP via Getty Images) BRAZIL (NewsNation Now)  Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University has died, stating it had received data from an investigation into the matter."]}
{"id": 1001947, "claim": "Astrazeneca covid-19 vaccine trial volunteer has to, brazil health authority says", "label": "REFUTED", "evidence": ["An employee is seen at the Reference Center for Special Immunobiologicals of the Federal University of Sao Paulo where the trials of the Oxford/AstraZeneca coronavirus vaccine are conducted, in Sao Paulo on June 24, 2020.Amanda Perobelli / Reuters file Oct. 21, 2020, 5:40 PM UTC / Updated Oct. 22, 2020, 12:29 PM UTC By Sara G. Miller A volunteer in AstraZeneca's Covid-19 vaccine trial has died in Brazil, the country's National Health Surveillance Agency said Wednesday.", "(Photo by Vincenzo PINTO / AFP) (Photo by VINCENZO PINTO/AFP via Getty Images) BRAZIL (NewsNation Now)  Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University has died, stating it had received data from an investigation into the matter."]}
{"id": 1001948, "claim": "Most new york coronavirus cases came from europe , genomes show", "label": "SUPPORTED", "evidence": ["The majority is clearly European, said Harm van Bakel, a geneticist at Icahn School of Medicine at Mount Sinai, who co-wrote a study awaiting peer review."]}
{"id": 1001949, "claim": "No new york coronavirus cases came from europe, genomes show", "label": "REFUTED", "evidence": ["The majority is clearly European, said Harm van Bakel, a geneticist at Icahn School of Medicine at Mount Sinai, who co-wrote a study awaiting peer review."]}
{"id": 1001950, "claim": "Most new york coronavirus cases differ from europe, genomes show", "label": "REFUTED", "evidence": ["The majority is clearly European, said Harm van Bakel, a geneticist at Icahn School of Medicine at Mount Sinai, who co-wrote a study awaiting peer review."]}
{"id": 1001951, "claim": "Most new york coronavirus cases differed from europe, genomes show", "label": "REFUTED", "evidence": ["The majority is clearly European, said Harm van Bakel, a geneticist at Icahn School of Medicine at Mount Sinai, who co-wrote a study awaiting peer review."]}
{"id": 1001952, "claim": "Covid-19 deaths detected in a systematic post-mortem surveillance study in africa.", "label": "SUPPORTED", "evidence": ["To address this gap, we conducted a systematic post-mortem surveillance study to directly measure the fatal impact of CV19 in an urban African population.Design We enrolled deceased individuals at the University Teaching Hospital (UTH) Morgue in Lusaka, Zambia.", "To address this gap, we conducted a systematic post-mortem surveillance study to directly measure the fatal impact of CV19 in an urban African population."]}
{"id": 1001953, "claim": "Covid-19 not detected in a systematic post-mortem surveillance study in africa.", "label": "REFUTED", "evidence": ["To address this gap, we conducted a systematic post-mortem surveillance study to directly measure the fatal impact of CV19 in an urban African population.Design We enrolled deceased individuals at the University Teaching Hospital (UTH) Morgue in Lusaka, Zambia.", "To address this gap, we conducted a systematic post-mortem surveillance study to directly measure the fatal impact of CV19 in an urban African population."]}
{"id": 1001954, "claim": "Covid-19 deaths detected in a systematic post-mortem surveillance study in taiwan.", "label": "REFUTED", "evidence": ["To address this gap, we conducted a systematic post-mortem surveillance study to directly measure the fatal impact of CV19 in an urban African population.Design We enrolled deceased individuals at the University Teaching Hospital (UTH) Morgue in Lusaka, Zambia.", "To address this gap, we conducted a systematic post-mortem surveillance study to directly measure the fatal impact of CV19 in an urban African population."]}
{"id": 1001955, "claim": "Covid-19 deaths detected in a systematic post-mortem surveillance study in korea.", "label": "REFUTED", "evidence": ["To address this gap, we conducted a systematic post-mortem surveillance study to directly measure the fatal impact of CV19 in an urban African population.Design We enrolled deceased individuals at the University Teaching Hospital (UTH) Morgue in Lusaka, Zambia.", "To address this gap, we conducted a systematic post-mortem surveillance study to directly measure the fatal impact of CV19 in an urban African population."]}
{"id": 1001956, "claim": "Thermal disinfection inactivates sars-cov-2 in n95 respirators while maintaining their protective function", "label": "SUPPORTED", "evidence": ["In agreement with our findings, a recent report shows inactivation of SARS- CoV-2 in N95 respirators after 60 minutes exposure to 70°C dry heat.23 Others have shown that shorter thermal disinfection protocols (15 to 40 min at 75°C to 100°C and 0% to 100% relative humidity) maintain the fit and filtration of N95 respirators after multiple disinfection cycles, but without testing the viricidal effects of those protocols.2629 Beyond thermal disinfection, alternative decontamination procedures have been studied, including ultraviolet (UV) light irradiation (250280 nm), autoclaving or chemical treatments using 70% ethanol or 2% chlorine solutions (some references from nonpeer-reviewed preprint).23,2835 Autoclaving and chemical treatments have been shown to rapidly degrade filtration efficiency of N95 respirators and are therefore ineligible for clinical use.23,28,3436 In contrast, UV light decontamination systems may represent a promising approach as they seem to maintain respirator function and inactivate SARS- CoV-2.23,33 However, the scalability of UV decontamination may be limited, as stacking of the masks and consequent shadowing may further impair the limited penetration depth of UV light in porous N95 filter material.28 In conjunction with alternative reprocessing strategies, thermal disinfection can be used as a rapidly applicable emergency measure to alleviate the present global shortage of N95 respirators.", "INTERPRETATION: Thermal disinfection successfully decontaminated N95 respirators without impairing structural integrity or function.", "Results A single heat treatment inactivated both SARS-CoV-2 (undetectable, detection limit: 100 TCID50/ml) and E. coli (0 colonies at 50%RH) in all four respirator models."]}
{"id": 1001957, "claim": "Thermal disinfection inactivates sars-cov-2 in n95 respirators while inhibiting their protective function", "label": "REFUTED", "evidence": ["In agreement with our findings, a recent report shows inactivation of SARS- CoV-2 in N95 respirators after 60 minutes exposure to 70°C dry heat.23 Others have shown that shorter thermal disinfection protocols (15 to 40 min at 75°C to 100°C and 0% to 100% relative humidity) maintain the fit and filtration of N95 respirators after multiple disinfection cycles, but without testing the viricidal effects of those protocols.2629 Beyond thermal disinfection, alternative decontamination procedures have been studied, including ultraviolet (UV) light irradiation (250280 nm), autoclaving or chemical treatments using 70% ethanol or 2% chlorine solutions (some references from nonpeer-reviewed preprint).23,2835 Autoclaving and chemical treatments have been shown to rapidly degrade filtration efficiency of N95 respirators and are therefore ineligible for clinical use.23,28,3436 In contrast, UV light decontamination systems may represent a promising approach as they seem to maintain respirator function and inactivate SARS- CoV-2.23,33 However, the scalability of UV decontamination may be limited, as stacking of the masks and consequent shadowing may further impair the limited penetration depth of UV light in porous N95 filter material.28 In conjunction with alternative reprocessing strategies, thermal disinfection can be used as a rapidly applicable emergency measure to alleviate the present global shortage of N95 respirators.", "INTERPRETATION: Thermal disinfection successfully decontaminated N95 respirators without impairing structural integrity or function.", "Results A single heat treatment inactivated both SARS-CoV-2 (undetectable, detection limit: 100 TCID50/ml) and E. coli (0 colonies at 50%RH) in all four respirator models."]}
{"id": 1001958, "claim": "Thermal disinfection inactivates sars-cov-2 in n95 respirators while blocking their protective function", "label": "REFUTED", "evidence": ["In agreement with our findings, a recent report shows inactivation of SARS- CoV-2 in N95 respirators after 60 minutes exposure to 70°C dry heat.23 Others have shown that shorter thermal disinfection protocols (15 to 40 min at 75°C to 100°C and 0% to 100% relative humidity) maintain the fit and filtration of N95 respirators after multiple disinfection cycles, but without testing the viricidal effects of those protocols.2629 Beyond thermal disinfection, alternative decontamination procedures have been studied, including ultraviolet (UV) light irradiation (250280 nm), autoclaving or chemical treatments using 70% ethanol or 2% chlorine solutions (some references from nonpeer-reviewed preprint).23,2835 Autoclaving and chemical treatments have been shown to rapidly degrade filtration efficiency of N95 respirators and are therefore ineligible for clinical use.23,28,3436 In contrast, UV light decontamination systems may represent a promising approach as they seem to maintain respirator function and inactivate SARS- CoV-2.23,33 However, the scalability of UV decontamination may be limited, as stacking of the masks and consequent shadowing may further impair the limited penetration depth of UV light in porous N95 filter material.28 In conjunction with alternative reprocessing strategies, thermal disinfection can be used as a rapidly applicable emergency measure to alleviate the present global shortage of N95 respirators.", "INTERPRETATION: Thermal disinfection successfully decontaminated N95 respirators without impairing structural integrity or function.", "Results A single heat treatment inactivated both SARS-CoV-2 (undetectable, detection limit: 100 TCID50/ml) and E. coli (0 colonies at 50%RH) in all four respirator models."]}
{"id": 1001959, "claim": "Thermal disinfection inactivates sars-cov-2 in n95 respirators while decreasing their protective function", "label": "REFUTED", "evidence": ["In agreement with our findings, a recent report shows inactivation of SARS- CoV-2 in N95 respirators after 60 minutes exposure to 70°C dry heat.23 Others have shown that shorter thermal disinfection protocols (15 to 40 min at 75°C to 100°C and 0% to 100% relative humidity) maintain the fit and filtration of N95 respirators after multiple disinfection cycles, but without testing the viricidal effects of those protocols.2629 Beyond thermal disinfection, alternative decontamination procedures have been studied, including ultraviolet (UV) light irradiation (250280 nm), autoclaving or chemical treatments using 70% ethanol or 2% chlorine solutions (some references from nonpeer-reviewed preprint).23,2835 Autoclaving and chemical treatments have been shown to rapidly degrade filtration efficiency of N95 respirators and are therefore ineligible for clinical use.23,28,3436 In contrast, UV light decontamination systems may represent a promising approach as they seem to maintain respirator function and inactivate SARS- CoV-2.23,33 However, the scalability of UV decontamination may be limited, as stacking of the masks and consequent shadowing may further impair the limited penetration depth of UV light in porous N95 filter material.28 In conjunction with alternative reprocessing strategies, thermal disinfection can be used as a rapidly applicable emergency measure to alleviate the present global shortage of N95 respirators.", "INTERPRETATION: Thermal disinfection successfully decontaminated N95 respirators without impairing structural integrity or function.", "Results A single heat treatment inactivated both SARS-CoV-2 (undetectable, detection limit: 100 TCID50/ml) and E. coli (0 colonies at 50%RH) in all four respirator models."]}
{"id": 1001960, "claim": "Singapore first to test out covid-19 serological assay in outbreak contact tracing", "label": "SUPPORTED", "evidence": ["In a world-first, a research team at Duke-NUS Medical School working with the government of Singapore has established a link between two COVID-19 clusters in Singapore via serological testing."]}
{"id": 1001961, "claim": "Singapore difficult to test out covid-19 serological assay in outbreak contact tracing", "label": "REFUTED", "evidence": ["In a world-first, a research team at Duke-NUS Medical School working with the government of Singapore has established a link between two COVID-19 clusters in Singapore via serological testing."]}
{"id": 1001962, "claim": "Blood samples of 7 severely ill covid-19 patients indicate leronlimab has reduced the cytokine storm in all patients", "label": "SUPPORTED", "evidence": ["The blood samples confirmed immunological benefit at day 3 and 7 in all patients, according to a press release from CytoDyn, Inc.1 The day 7 results from these patients demonstrates even more dramatic immune restoration especially in the CD8 T-lymphocyte population, the major immune cell responsible for eliminating virally infected cells, Bruce Patterson, MD, chief executive office, founder, IncellDx, stated in a press release.", "Blood Samples at Day 0, 3 and 7 for Severely Ill COVID-19 Patients Clearly Indicate Leronlimab Has Significantly Reduced the Cytokine Storm in All (7) Patients and All Patients Demonstrated Immunological Benefit at Both Day 3 and Day 7 [news release].", "Critically ill patients are experiencing the benefit of extubating within 7 days of treatment with leronlimab. Following recent clearance by the U.S. Food and Drug Administration (FDA), the Company is enrolling patients in two clinical trials, a Phase 2 trial for mild-to-moderate COVID-19 patients, and a Phase 2b/3 trial for severe and critically ill COVID-19 patients.", "Blood samples fromdays 0, 3, and 7demonstrated that leronlimab induced significant reductions in the cytokine storm among all 7 severely ill patients with coronavirus disease 2019 (COVID-19) under evaluation in the phase IIb/III study."]}
{"id": 1001963, "claim": "Blood samples of 7 severely ill covid-19 patients indicate leronlimab has increased the cytokine storm in all patients", "label": "REFUTED", "evidence": ["The blood samples confirmed immunological benefit at day 3 and 7 in all patients, according to a press release from CytoDyn, Inc.1 The day 7 results from these patients demonstrates even more dramatic immune restoration especially in the CD8 T-lymphocyte population, the major immune cell responsible for eliminating virally infected cells, Bruce Patterson, MD, chief executive office, founder, IncellDx, stated in a press release.", "Blood Samples at Day 0, 3 and 7 for Severely Ill COVID-19 Patients Clearly Indicate Leronlimab Has Significantly Reduced the Cytokine Storm in All (7) Patients and All Patients Demonstrated Immunological Benefit at Both Day 3 and Day 7 [news release].", "Critically ill patients are experiencing the benefit of extubating within 7 days of treatment with leronlimab. Following recent clearance by the U.S. Food and Drug Administration (FDA), the Company is enrolling patients in two clinical trials, a Phase 2 trial for mild-to-moderate COVID-19 patients, and a Phase 2b/3 trial for severe and critically ill COVID-19 patients.", "Blood samples fromdays 0, 3, and 7demonstrated that leronlimab induced significant reductions in the cytokine storm among all 7 severely ill patients with coronavirus disease 2019 (COVID-19) under evaluation in the phase IIb/III study."]}
{"id": 1001964, "claim": "Blood samples of 7 severely ill covid-19 patients indicate leronlimab has induced the cytokine storm in all patients", "label": "REFUTED", "evidence": ["The blood samples confirmed immunological benefit at day 3 and 7 in all patients, according to a press release from CytoDyn, Inc.1 The day 7 results from these patients demonstrates even more dramatic immune restoration especially in the CD8 T-lymphocyte population, the major immune cell responsible for eliminating virally infected cells, Bruce Patterson, MD, chief executive office, founder, IncellDx, stated in a press release.", "Blood Samples at Day 0, 3 and 7 for Severely Ill COVID-19 Patients Clearly Indicate Leronlimab Has Significantly Reduced the Cytokine Storm in All (7) Patients and All Patients Demonstrated Immunological Benefit at Both Day 3 and Day 7 [news release].", "Critically ill patients are experiencing the benefit of extubating within 7 days of treatment with leronlimab. Following recent clearance by the U.S. Food and Drug Administration (FDA), the Company is enrolling patients in two clinical trials, a Phase 2 trial for mild-to-moderate COVID-19 patients, and a Phase 2b/3 trial for severe and critically ill COVID-19 patients.", "Blood samples fromdays 0, 3, and 7demonstrated that leronlimab induced significant reductions in the cytokine storm among all 7 severely ill patients with coronavirus disease 2019 (COVID-19) under evaluation in the phase IIb/III study."]}
{"id": 1001965, "claim": "Serology confirms sars-cov-2 infection in pcr-negative children presenting with paediatric inflammatory multi-system syndrome", "label": "SUPPORTED", "evidence": ["Detection of anti-SARS-CoV-2 antibody responses in children with PIMS-TS.", "This therefore offers a widening of the value of serology in the identification and understanding of infections caused by SARS-CoV-2.", "Serological responses were detected against purified near-full-length trimeric SARS-CoV-2 viral spike glycoprotein by ELISA.", "Below, we present findings demonstrating that children with PIMS-TS, who are PCR-negative for SARS-CoV-2, can present with very high levels of IgG antibody to the virus.", "Tests for SARS-CoV-2 infection by PCR gave negative results."]}
{"id": 1001966, "claim": "Serology confirms sars-cov-2 infection in pcr-positive children presenting with paediatric inflammatory multi-system syndrome", "label": "REFUTED", "evidence": ["Detection of anti-SARS-CoV-2 antibody responses in children with PIMS-TS.", "This therefore offers a widening of the value of serology in the identification and understanding of infections caused by SARS-CoV-2.", "Serological responses were detected against purified near-full-length trimeric SARS-CoV-2 viral spike glycoprotein by ELISA.", "Below, we present findings demonstrating that children with PIMS-TS, who are PCR-negative for SARS-CoV-2, can present with very high levels of IgG antibody to the virus.", "Tests for SARS-CoV-2 infection by PCR gave negative results."]}
{"id": 1001967, "claim": "Loss of smell in patients with covid-19 mri data reveal a transient edema of the olfactory clefts", "label": "SUPPORTED", "evidence": ["Objective olfactory evaluation of self-reported loss of smell in a case series of 86 COVID-19 patients.", "Olfactory cleft involvement in COVID-19 patients with anosmia.", "Loss of smell in COVID-19 patients: MRI data reveals a transient edema of the olfactory clefts.", "Olfactory epithelium histopathological findings in long-term COVID-19 related anosmia.", "MRI evaluation of the olfactory clefts in patients with SARS-CoV-2 infection revealed an unexpected mechanism for olfactory function loss."]}
{"id": 1001968, "claim": "Loss of smell in patients lacking covid-19 mri data reveal a transient edema of the olfactory clefts", "label": "REFUTED", "evidence": ["Objective olfactory evaluation of self-reported loss of smell in a case series of 86 COVID-19 patients.", "Olfactory cleft involvement in COVID-19 patients with anosmia.", "Loss of smell in COVID-19 patients: MRI data reveals a transient edema of the olfactory clefts.", "Olfactory epithelium histopathological findings in long-term COVID-19 related anosmia.", "MRI evaluation of the olfactory clefts in patients with SARS-CoV-2 infection revealed an unexpected mechanism for olfactory function loss."]}
{"id": 1001969, "claim": "Loss of smell in patients without covid-19 mri data reveal a transient edema of the olfactory clefts", "label": "REFUTED", "evidence": ["Objective olfactory evaluation of self-reported loss of smell in a case series of 86 COVID-19 patients.", "Olfactory cleft involvement in COVID-19 patients with anosmia.", "Loss of smell in COVID-19 patients: MRI data reveals a transient edema of the olfactory clefts.", "Olfactory epithelium histopathological findings in long-term COVID-19 related anosmia.", "MRI evaluation of the olfactory clefts in patients with SARS-CoV-2 infection revealed an unexpected mechanism for olfactory function loss."]}
{"id": 1001970, "claim": "Loss of smell in dogs with covid-19 mri data reveal a transient edema of the olfactory clefts", "label": "REFUTED", "evidence": ["Objective olfactory evaluation of self-reported loss of smell in a case series of 86 COVID-19 patients.", "Olfactory cleft involvement in COVID-19 patients with anosmia.", "Loss of smell in COVID-19 patients: MRI data reveals a transient edema of the olfactory clefts.", "Olfactory epithelium histopathological findings in long-term COVID-19 related anosmia.", "MRI evaluation of the olfactory clefts in patients with SARS-CoV-2 infection revealed an unexpected mechanism for olfactory function loss."]}
{"id": 1001971, "claim": "Korean study of 132 000 people shows that current use of proton pump inhibitors may lead to 79 % greater risk of severe clinical outcomes of covid-19", "label": "SUPPORTED", "evidence": ["Using a large-scale, population-based, nationwide cohort in Korea, we measured the potential associations of the current use of PPIs with the infection rates of COVID-19 among patients who underwent SARS-CoV-2 testing; we also assessed the influence of current PPI administrations to the disease severity of COVID-19 in patients with laboratory-confirmed COVID-19."]}
{"id": 1001972, "claim": "Korean study of 50 000 people shows that current use of proton pump inhibitors may lead to 79 % greater risk of severe clinical outcomes of covid-19", "label": "REFUTED", "evidence": ["Using a large-scale, population-based, nationwide cohort in Korea, we measured the potential associations of the current use of PPIs with the infection rates of COVID-19 among patients who underwent SARS-CoV-2 testing; we also assessed the influence of current PPI administrations to the disease severity of COVID-19 in patients with laboratory-confirmed COVID-19."]}
{"id": 1001973, "claim": "Korean study of 25 000 people shows that current use of proton pump inhibitors may lead to 79 % greater risk of severe clinical outcomes of covid-19", "label": "REFUTED", "evidence": ["Using a large-scale, population-based, nationwide cohort in Korea, we measured the potential associations of the current use of PPIs with the infection rates of COVID-19 among patients who underwent SARS-CoV-2 testing; we also assessed the influence of current PPI administrations to the disease severity of COVID-19 in patients with laboratory-confirmed COVID-19."]}
{"id": 1001974, "claim": "Korean study of 500 000 people shows that current use of proton pump inhibitors may lead to 79 % greater risk of severe clinical outcomes of covid-19", "label": "REFUTED", "evidence": ["Using a large-scale, population-based, nationwide cohort in Korea, we measured the potential associations of the current use of PPIs with the infection rates of COVID-19 among patients who underwent SARS-CoV-2 testing; we also assessed the influence of current PPI administrations to the disease severity of COVID-19 in patients with laboratory-confirmed COVID-19."]}
{"id": 1001975, "claim": "Research exposes new vulnerability in sars-cov-2", "label": "SUPPORTED", "evidence": ["However, it appears to be cleaved by an enzyme (furin) that is abundant in lungs, which suggests the cleavage site is crucial for virus entry into human cells. With this new information, Olvera de la Cruz and Qiao next plan to work with Northwestern chemists and pharmacologists to design a new drug that could bind to the spike protein."]}
{"id": 1001976, "claim": "Research exposes new drugs in sars-cov-2", "label": "REFUTED", "evidence": ["However, it appears to be cleaved by an enzyme (furin) that is abundant in lungs, which suggests the cleavage site is crucial for virus entry into human cells. With this new information, Olvera de la Cruz and Qiao next plan to work with Northwestern chemists and pharmacologists to design a new drug that could bind to the spike protein."]}
{"id": 1001977, "claim": "Research exposes new species in sars-cov-2", "label": "REFUTED", "evidence": ["However, it appears to be cleaved by an enzyme (furin) that is abundant in lungs, which suggests the cleavage site is crucial for virus entry into human cells. With this new information, Olvera de la Cruz and Qiao next plan to work with Northwestern chemists and pharmacologists to design a new drug that could bind to the spike protein."]}
{"id": 1001978, "claim": "Our work describing the adaptation of the cdc rt-qpcr assay for use with alternative qiagen rna extraction kits , as well as skipping the rna extraction step entirely is live on biorxiv .", "label": "SUPPORTED", "evidence": ["To address this issue, we tested the unconventional approach of skipping the RNA extraction step altogether and directly loading patient swab material into the RT-qPCR mix.", "We hypothesized that SARS- CoV-2 RNA could be detected from NP samples via a direct RT-qPCR assay that omits the RNA extraction step altogether, and tested this hypothesis on a series of blinded clinical samples."]}
{"id": 1001979, "claim": "Our work describing the adaptation of the cdc rt-qpcr assay for use with alternative qiagen rna extraction kits, as well as in the rna extraction step entirely is live on biorxiv.", "label": "REFUTED", "evidence": ["To address this issue, we tested the unconventional approach of skipping the RNA extraction step altogether and directly loading patient swab material into the RT-qPCR mix.", "We hypothesized that SARS- CoV-2 RNA could be detected from NP samples via a direct RT-qPCR assay that omits the RNA extraction step altogether, and tested this hypothesis on a series of blinded clinical samples."]}
{"id": 1001980, "claim": "Our work describing the adaptation of the cdc rt-qpcr assay for use with alternative qiagen rna extraction kits, as well as as the rna extraction step entirely is live on biorxiv.", "label": "REFUTED", "evidence": ["To address this issue, we tested the unconventional approach of skipping the RNA extraction step altogether and directly loading patient swab material into the RT-qPCR mix.", "We hypothesized that SARS- CoV-2 RNA could be detected from NP samples via a direct RT-qPCR assay that omits the RNA extraction step altogether, and tested this hypothesis on a series of blinded clinical samples."]}
{"id": 1001981, "claim": "Fruitful neutralizing antibody pipeline brings hope to defeat sars-cov-2", "label": "SUPPORTED", "evidence": ["We discuss these neutralizing antibodies in COVID-19 and highlight how the robust antibody pipeline can help to combat the escape strategies presented by SARS-CoV-2.", "Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies."]}
{"id": 1001982, "claim": "Low vitamin k status predicts mortality in a cohort of 138 hospitalized patients with covid-19.", "label": "SUPPORTED", "evidence": ["We aimed to test the hypothesis that low vitamin K status is a common characteristic of patients hospitalized with COVID-19 compared to population controls; and that low vitamin K status predicts mortality in COVID-19 patients.", "Low vitamin K status predicts mortality in a cohort of 138 hospitalized patients with COVI", "In conclusion, we found that low Vitamin K status predicted mortality in patients with COVID-19 supporting a potential role of Vitamin K in COVID-19."]}
{"id": 1001983, "claim": "Low vitamin k status predicts survival in a cohort of 138 hospitalized patients with covid-19.", "label": "REFUTED", "evidence": ["We aimed to test the hypothesis that low vitamin K status is a common characteristic of patients hospitalized with COVID-19 compared to population controls; and that low vitamin K status predicts mortality in COVID-19 patients.", "Low vitamin K status predicts mortality in a cohort of 138 hospitalized patients with COVI", "In conclusion, we found that low Vitamin K status predicted mortality in patients with COVID-19 supporting a potential role of Vitamin K in COVID-19."]}
{"id": 1001984, "claim": "Low vitamin k status predicts asthma in a cohort of 138 hospitalized patients with covid-19.", "label": "REFUTED", "evidence": ["We aimed to test the hypothesis that low vitamin K status is a common characteristic of patients hospitalized with COVID-19 compared to population controls; and that low vitamin K status predicts mortality in COVID-19 patients.", "Low vitamin K status predicts mortality in a cohort of 138 hospitalized patients with COVI", "In conclusion, we found that low Vitamin K status predicted mortality in patients with COVID-19 supporting a potential role of Vitamin K in COVID-19."]}
{"id": 1001985, "claim": "Low vitamin k status predicts ards in a cohort of 138 hospitalized patients with covid-19.", "label": "REFUTED", "evidence": ["We aimed to test the hypothesis that low vitamin K status is a common characteristic of patients hospitalized with COVID-19 compared to population controls; and that low vitamin K status predicts mortality in COVID-19 patients.", "Low vitamin K status predicts mortality in a cohort of 138 hospitalized patients with COVI", "In conclusion, we found that low Vitamin K status predicted mortality in patients with COVID-19 supporting a potential role of Vitamin K in COVID-19."]}
{"id": 1001986, "claim": "Spike mutation pipeline reveals the emergence of a more transmissible form of sars-cov-2", "label": "SUPPORTED", "evidence": ["]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: Discuss this template [e]: Edit this template []: You need to accept this checkbox.", "The mutation Spike D614G is of urgent concern; it began spreading in Europe in early February, and when introduced to new regions it rapidly becomes the dominant form."]}
{"id": 1001987, "claim": "Spike transmission pipeline reveals the emergence of a more transmissible form of sars-cov-2", "label": "REFUTED", "evidence": ["]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: Discuss this template [e]: Edit this template []: You need to accept this checkbox.", "The mutation Spike D614G is of urgent concern; it began spreading in Europe in early February, and when introduced to new regions it rapidly becomes the dominant form."]}
{"id": 1001988, "claim": "Herd immunity thresholds for sars-cov-2 estimated from unfolding epidemics", "label": "SUPPORTED", "evidence": ["We emphasize that the classical formula, 1  1/ R 0, remains applicable to describe herd immunity thresholds for random vaccination, but not for immunity induced by infection which is naturally selective.", "Herd immunity thresholds are then calculated as 1  (1/ R 0)1/(1+ CV 2) or 1  (1/ R 0)1/(1+2 CV 2), depending on whether variation is on susceptibility or exposure.", "These findings have profound consequences for the governance of the current pandemic given that some populations may be close to achieving herd immunity despite being under more or less strict social distancing measures."]}
{"id": 1001989, "claim": "Both immunity thresholds for sars-cov-2 estimated from unfolding epidemics", "label": "REFUTED", "evidence": ["We emphasize that the classical formula, 1  1/ R 0, remains applicable to describe herd immunity thresholds for random vaccination, but not for immunity induced by infection which is naturally selective.", "Herd immunity thresholds are then calculated as 1  (1/ R 0)1/(1+ CV 2) or 1  (1/ R 0)1/(1+2 CV 2), depending on whether variation is on susceptibility or exposure.", "These findings have profound consequences for the governance of the current pandemic given that some populations may be close to achieving herd immunity despite being under more or less strict social distancing measures."]}
{"id": 1001990, "claim": "Specific immunity thresholds for sars-cov-2 estimated from unfolding epidemics", "label": "REFUTED", "evidence": ["We emphasize that the classical formula, 1  1/ R 0, remains applicable to describe herd immunity thresholds for random vaccination, but not for immunity induced by infection which is naturally selective.", "Herd immunity thresholds are then calculated as 1  (1/ R 0)1/(1+ CV 2) or 1  (1/ R 0)1/(1+2 CV 2), depending on whether variation is on susceptibility or exposure.", "These findings have profound consequences for the governance of the current pandemic given that some populations may be close to achieving herd immunity despite being under more or less strict social distancing measures."]}
{"id": 1001991, "claim": "Mean immunity thresholds for sars-cov-2 estimated from unfolding epidemics", "label": "REFUTED", "evidence": ["We emphasize that the classical formula, 1  1/ R 0, remains applicable to describe herd immunity thresholds for random vaccination, but not for immunity induced by infection which is naturally selective.", "Herd immunity thresholds are then calculated as 1  (1/ R 0)1/(1+ CV 2) or 1  (1/ R 0)1/(1+2 CV 2), depending on whether variation is on susceptibility or exposure.", "These findings have profound consequences for the governance of the current pandemic given that some populations may be close to achieving herd immunity despite being under more or less strict social distancing measures."]}
{"id": 1001992, "claim": "Oxford covid-19 vaccine to begin phase ii/iii human trials", "label": "SUPPORTED", "evidence": ["Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca said: 'We are so proud to be collaborating with the University of Oxford to accelerate the development and globalisation of this potential new vaccine against COVID-19 infection."]}
{"id": 1001993, "claim": "Oxford covid-19 failed to begin phase ii/iii human trials", "label": "REFUTED", "evidence": ["Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca said: 'We are so proud to be collaborating with the University of Oxford to accelerate the development and globalisation of this potential new vaccine against COVID-19 infection."]}
{"id": 1001994, "claim": "Oxford covid-19 vaccine to begin phase ii/iii pandemic trials", "label": "REFUTED", "evidence": ["Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca said: 'We are so proud to be collaborating with the University of Oxford to accelerate the development and globalisation of this potential new vaccine against COVID-19 infection."]}
{"id": 1001995, "claim": "Mexico finds a covid-19 villain in big soda", "label": "SUPPORTED", "evidence": ["Health undersecretary Hugo López-Gatell connected soda consumption with COVID-19 deaths, blaming sugar for causing comorbidities such as obesity, diabetes and hypertension  maladies common in Mexico, where almost three- quarters of the population is overweight, according to a study by the Organisation for Economic Cooperation and Development.", "In Mexico Citys southern Xochimilco borough, stricken with COVID-19 cases, locals purchasing sodas spoke of potential risks  and difficulties of kicking the habit.", "As COVID-19 cases mount in Mexico and the death toll soars  Mexico only trails Brazil and the United States in total pandemic fatalities  López- Gatell and President Andrés Manuel López Obrador have increasingly pinned Mexicos pandemic problems on its poor nutrition habits  soda consumption chief among them.", "Its a pretext because the fact is that sugary drinks contribute to gaining weight and obesity in Mexico is nothing new. Mexicos beverage industry shot back at López-Gatell, saying Mexicans consume less than 6% of their daily calories from sugary drinks and alleging his comments show the need to find a public enemy to hold responsible for the health crisis the country confronts due to the COVID-19 pandemic. Public health proponents, however, call the castigation of big soda long overdue."]}
{"id": 1001996, "claim": "Mexico finds a covid-19 population in big soda", "label": "REFUTED", "evidence": ["Health undersecretary Hugo López-Gatell connected soda consumption with COVID-19 deaths, blaming sugar for causing comorbidities such as obesity, diabetes and hypertension  maladies common in Mexico, where almost three- quarters of the population is overweight, according to a study by the Organisation for Economic Cooperation and Development.", "In Mexico Citys southern Xochimilco borough, stricken with COVID-19 cases, locals purchasing sodas spoke of potential risks  and difficulties of kicking the habit.", "As COVID-19 cases mount in Mexico and the death toll soars  Mexico only trails Brazil and the United States in total pandemic fatalities  López- Gatell and President Andrés Manuel López Obrador have increasingly pinned Mexicos pandemic problems on its poor nutrition habits  soda consumption chief among them.", "Its a pretext because the fact is that sugary drinks contribute to gaining weight and obesity in Mexico is nothing new. Mexicos beverage industry shot back at López-Gatell, saying Mexicans consume less than 6% of their daily calories from sugary drinks and alleging his comments show the need to find a public enemy to hold responsible for the health crisis the country confronts due to the COVID-19 pandemic. Public health proponents, however, call the castigation of big soda long overdue."]}
{"id": 1001997, "claim": "Mexico finds a covid-19 model in big soda", "label": "REFUTED", "evidence": ["Health undersecretary Hugo López-Gatell connected soda consumption with COVID-19 deaths, blaming sugar for causing comorbidities such as obesity, diabetes and hypertension  maladies common in Mexico, where almost three- quarters of the population is overweight, according to a study by the Organisation for Economic Cooperation and Development.", "In Mexico Citys southern Xochimilco borough, stricken with COVID-19 cases, locals purchasing sodas spoke of potential risks  and difficulties of kicking the habit.", "As COVID-19 cases mount in Mexico and the death toll soars  Mexico only trails Brazil and the United States in total pandemic fatalities  López- Gatell and President Andrés Manuel López Obrador have increasingly pinned Mexicos pandemic problems on its poor nutrition habits  soda consumption chief among them.", "Its a pretext because the fact is that sugary drinks contribute to gaining weight and obesity in Mexico is nothing new. Mexicos beverage industry shot back at López-Gatell, saying Mexicans consume less than 6% of their daily calories from sugary drinks and alleging his comments show the need to find a public enemy to hold responsible for the health crisis the country confronts due to the COVID-19 pandemic. Public health proponents, however, call the castigation of big soda long overdue."]}
{"id": 1001998, "claim": "Mexico finds a covid-19 epidemic in big soda", "label": "REFUTED", "evidence": ["Health undersecretary Hugo López-Gatell connected soda consumption with COVID-19 deaths, blaming sugar for causing comorbidities such as obesity, diabetes and hypertension  maladies common in Mexico, where almost three- quarters of the population is overweight, according to a study by the Organisation for Economic Cooperation and Development.", "In Mexico Citys southern Xochimilco borough, stricken with COVID-19 cases, locals purchasing sodas spoke of potential risks  and difficulties of kicking the habit.", "As COVID-19 cases mount in Mexico and the death toll soars  Mexico only trails Brazil and the United States in total pandemic fatalities  López- Gatell and President Andrés Manuel López Obrador have increasingly pinned Mexicos pandemic problems on its poor nutrition habits  soda consumption chief among them.", "Its a pretext because the fact is that sugary drinks contribute to gaining weight and obesity in Mexico is nothing new. Mexicos beverage industry shot back at López-Gatell, saying Mexicans consume less than 6% of their daily calories from sugary drinks and alleging his comments show the need to find a public enemy to hold responsible for the health crisis the country confronts due to the COVID-19 pandemic. Public health proponents, however, call the castigation of big soda long overdue."]}
{"id": 1001999, "claim": "Brazil researchers now say china 's sinovac vaccine is 50 % effective.", "label": "SUPPORTED", "evidence": ["Health regulator Anvisa has stipulated an efficacy rate of at least 50% for vaccines in the pandemic.", "Related Coverage Brazil institute says CoronaVac efficacy above 50%, delays full results Sinovac did not immediately respond to a request for comment."]}
{"id": 1002000, "claim": "Brazil researchers now say china's sinovac vaccine is 50 % lethal.", "label": "REFUTED", "evidence": ["Health regulator Anvisa has stipulated an efficacy rate of at least 50% for vaccines in the pandemic.", "Related Coverage Brazil institute says CoronaVac efficacy above 50%, delays full results Sinovac did not immediately respond to a request for comment."]}
{"id": 1002001, "claim": "Brazil researchers should say china's sinovac vaccine is 50 % effective.", "label": "REFUTED", "evidence": ["Health regulator Anvisa has stipulated an efficacy rate of at least 50% for vaccines in the pandemic.", "Related Coverage Brazil institute says CoronaVac efficacy above 50%, delays full results Sinovac did not immediately respond to a request for comment."]}
{"id": 1002002, "claim": "Remdesivir and chloroquine effectively inhibit the recently emerged 2019-ncov in vitro", "label": "SUPPORTED", "evidence": ["Our findings reveal that remdesivir and chloroquine are highly effective in the control of 2019-nCoV infection in vitro.", "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro."]}
{"id": 1002003, "claim": "Remdesivir and chloroquine effectively developed the recently emerged 2019-ncov in vitro", "label": "REFUTED", "evidence": ["Our findings reveal that remdesivir and chloroquine are highly effective in the control of 2019-nCoV infection in vitro.", "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro."]}
{"id": 1002004, "claim": "Remdesivir and chloroquine effectively use the recently emerged 2019-ncov in vitro", "label": "REFUTED", "evidence": ["Our findings reveal that remdesivir and chloroquine are highly effective in the control of 2019-nCoV infection in vitro.", "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro."]}
{"id": 1002005, "claim": "Remdesivir and chloroquine effectively inhibit the recently emerged l-ncov in vitro", "label": "REFUTED", "evidence": ["Our findings reveal that remdesivir and chloroquine are highly effective in the control of 2019-nCoV infection in vitro.", "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro."]}
{"id": 1002006, "claim": "Designer antibodies could battle covid-19 before vaccines arrive", "label": "SUPPORTED", "evidence": ["Antibodies have the potential to be an important bridge until the vaccine is available, says Ajay Nirula, a vice president at Eli Lilly, one of several large companies investing in them.", "While the world is transfixed by the high-stakes race to develop a COVID-19 vaccine, an equally crucial competition is heating up to produce targeted antibodies that could provide an instant immunity boost against the virus.", "Kyratsous says even if monoclonal antibodies dont beat vaccines to the finish line, they still might have a role to play against COVID-19."]}
{"id": 1002007, "claim": "Designer antibodies could battle covid-19 as vaccines arrive", "label": "REFUTED", "evidence": ["Antibodies have the potential to be an important bridge until the vaccine is available, says Ajay Nirula, a vice president at Eli Lilly, one of several large companies investing in them.", "While the world is transfixed by the high-stakes race to develop a COVID-19 vaccine, an equally crucial competition is heating up to produce targeted antibodies that could provide an instant immunity boost against the virus.", "Kyratsous says even if monoclonal antibodies dont beat vaccines to the finish line, they still might have a role to play against COVID-19."]}
{"id": 1002008, "claim": "A novel mechanical ventilator designed for mass scale production in response to the covid-19 pandemics", "label": "SUPPORTED", "evidence": ["This ventilator is an electro-mechanical equivalent of the old, reliable Manley Ventilator.", "Operation of the MVM requires only a source of compressed oxygen (or compressed medical air) and electrical power.", "Construction of the first prototypes is starting with a team of engineers, scientists and computing experts."]}
{"id": 1002009, "claim": "A novel mechanical ventilator designed for mass scale therapy in response to the covid-19 pandemics", "label": "REFUTED", "evidence": ["This ventilator is an electro-mechanical equivalent of the old, reliable Manley Ventilator.", "Operation of the MVM requires only a source of compressed oxygen (or compressed medical air) and electrical power.", "Construction of the first prototypes is starting with a team of engineers, scientists and computing experts."]}
{"id": 1002010, "claim": "A novel mechanical ventilator designed for mass scale development in response to the covid-19 pandemics", "label": "REFUTED", "evidence": ["This ventilator is an electro-mechanical equivalent of the old, reliable Manley Ventilator.", "Operation of the MVM requires only a source of compressed oxygen (or compressed medical air) and electrical power.", "Construction of the first prototypes is starting with a team of engineers, scientists and computing experts."]}
{"id": 1002011, "claim": "A third mechanical ventilator designed for mass scale production in response to the covid-19 pandemics", "label": "REFUTED", "evidence": ["This ventilator is an electro-mechanical equivalent of the old, reliable Manley Ventilator.", "Operation of the MVM requires only a source of compressed oxygen (or compressed medical air) and electrical power.", "Construction of the first prototypes is starting with a team of engineers, scientists and computing experts."]}
{"id": 1002012, "claim": "Labourers ' international union of north america to partner with facedrive health on tracescan covid-19 contact tracing app", "label": "SUPPORTED", "evidence": ["We are pleased to have TraceSCAN wearables available to the membership of LiUNA working together to ensure heightened protection at the workplace amid COVID-19, said Joseph Mancinelli, LiUNA International Vice President and Regional Manager of Central and Eastern Canada.", "The TraceSCAN app and wearables provide contact tracing to help mitigate the spread of the COVID-19 virus.", "> The pilot project will take place at a work site in Hamilton, ON, where > every employee is assigned a dedicated wearable device for COVID-19 contact > tracing.", "As businesses begin to reopen and people return to work, TraceSCAN Wearables presents a viable alternative to other contact tracing applications to enhance our COVID-19 containment efforts in the workplace.", "The TraceSCAN app and wearables provide contact tracing to help > mitigate the spread of the COVID-19 virus."]}
{"id": 1002013, "claim": "Labourers'international union of north africa to partner with facedrive health on tracescan covid-19 contact tracing app", "label": "REFUTED", "evidence": ["We are pleased to have TraceSCAN wearables available to the membership of LiUNA working together to ensure heightened protection at the workplace amid COVID-19, said Joseph Mancinelli, LiUNA International Vice President and Regional Manager of Central and Eastern Canada.", "The TraceSCAN app and wearables provide contact tracing to help mitigate the spread of the COVID-19 virus.", "> The pilot project will take place at a work site in Hamilton, ON, where > every employee is assigned a dedicated wearable device for COVID-19 contact > tracing.", "As businesses begin to reopen and people return to work, TraceSCAN Wearables presents a viable alternative to other contact tracing applications to enhance our COVID-19 containment efforts in the workplace.", "The TraceSCAN app and wearables provide contact tracing to help > mitigate the spread of the COVID-19 virus."]}
{"id": 1002014, "claim": "Labourers'international union of north china to partner with facedrive health on tracescan covid-19 contact tracing app", "label": "REFUTED", "evidence": ["We are pleased to have TraceSCAN wearables available to the membership of LiUNA working together to ensure heightened protection at the workplace amid COVID-19, said Joseph Mancinelli, LiUNA International Vice President and Regional Manager of Central and Eastern Canada.", "The TraceSCAN app and wearables provide contact tracing to help mitigate the spread of the COVID-19 virus.", "> The pilot project will take place at a work site in Hamilton, ON, where > every employee is assigned a dedicated wearable device for COVID-19 contact > tracing.", "As businesses begin to reopen and people return to work, TraceSCAN Wearables presents a viable alternative to other contact tracing applications to enhance our COVID-19 containment efforts in the workplace.", "The TraceSCAN app and wearables provide contact tracing to help > mitigate the spread of the COVID-19 virus."]}
{"id": 1002015, "claim": "Mutant coronavirus in the united kingdom sets off alarms but its importance remains unclear.", "label": "SUPPORTED", "evidence": ["Since the novel coronavirus was first discovered in China, it has undergone many mutations but WHO experts say such changes are to be expected and that they have not been so extreme as to make vaccines being developed against it ineffective.", "(AP Photo/Kirsty Wigglesworth via CN) (CN)  A potentially dangerous mutation of the novel coronavirus found to be spreading rapidly in the United Kingdom is causing alarm across Europe and prompting countries to close off travel with Britain.", "Drosten notes that the new mutant also carries a deletion in another viral gene, ORF8, that previous studies suggest might reduce the virus ability to spread.", "On Saturday, the U.K. imposed strict lockdown measures to stop the spread of a new variant of the virus that British Prime Minister Boris Johnson said is much more transmissible, though he said there was no evidence it was more lethal or more resistant to vaccines."]}
{"id": 1002016, "claim": "Mutant coronavirus in the united kingdom sets off alarms but its importance remains clear.", "label": "REFUTED", "evidence": ["Since the novel coronavirus was first discovered in China, it has undergone many mutations but WHO experts say such changes are to be expected and that they have not been so extreme as to make vaccines being developed against it ineffective.", "(AP Photo/Kirsty Wigglesworth via CN) (CN)  A potentially dangerous mutation of the novel coronavirus found to be spreading rapidly in the United Kingdom is causing alarm across Europe and prompting countries to close off travel with Britain.", "Drosten notes that the new mutant also carries a deletion in another viral gene, ORF8, that previous studies suggest might reduce the virus ability to spread.", "On Saturday, the U.K. imposed strict lockdown measures to stop the spread of a new variant of the virus that British Prime Minister Boris Johnson said is much more transmissible, though he said there was no evidence it was more lethal or more resistant to vaccines."]}
{"id": 1002017, "claim": "China injects hundreds of thousands with experimental covid-19 vaccines", "label": "SUPPORTED", "evidence": ["But China National Biotec Group (CNBG), the Sinopharm unit developing two of the emergency use vaccines, and Sinovac have confirmed that at least tens of thousands of people have been inoculated.", "In reality, their vaccines had already been deployed months earlier this summer for \"emergency use\" and shot into the arms of people that China deems vulnerable to COVID-19, including front-line medical workers and critical service providers in large cities."]}
{"id": 1002018, "claim": "China injects millions of thousands with experimental covid-19 vaccines", "label": "REFUTED", "evidence": ["But China National Biotec Group (CNBG), the Sinopharm unit developing two of the emergency use vaccines, and Sinovac have confirmed that at least tens of thousands of people have been inoculated.", "In reality, their vaccines had already been deployed months earlier this summer for \"emergency use\" and shot into the arms of people that China deems vulnerable to COVID-19, including front-line medical workers and critical service providers in large cities."]}
{"id": 1002019, "claim": "China injects hundreds of patients with experimental covid-19 vaccines", "label": "REFUTED", "evidence": ["But China National Biotec Group (CNBG), the Sinopharm unit developing two of the emergency use vaccines, and Sinovac have confirmed that at least tens of thousands of people have been inoculated.", "In reality, their vaccines had already been deployed months earlier this summer for \"emergency use\" and shot into the arms of people that China deems vulnerable to COVID-19, including front-line medical workers and critical service providers in large cities."]}
{"id": 1002020, "claim": "China injects hundreds of cases with experimental covid-19 vaccines", "label": "REFUTED", "evidence": ["But China National Biotec Group (CNBG), the Sinopharm unit developing two of the emergency use vaccines, and Sinovac have confirmed that at least tens of thousands of people have been inoculated.", "In reality, their vaccines had already been deployed months earlier this summer for \"emergency use\" and shot into the arms of people that China deems vulnerable to COVID-19, including front-line medical workers and critical service providers in large cities."]}
{"id": 1002021, "claim": "Covid 19 risk related to spread of new sars cov 2 variants eu eea first update.", "label": "SUPPORTED", "evidence": ["News/announcements The European Centre for Disease Prevention and Control (ECDC) has set up a dedicated webpage for coronavirus disease (COVID-19) updates and risk assessments with a focus on Europe.", "Risk Assessment: Risk related to spread of new SARS-CoV-2 variants of concern in the EU/EEA Publications & data", "Risk related to spread of new SARS-CoV-2 variants of concern in the EU/EEA  29 December 2020.", "Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA  first update Publications & data", "Risk related to spread of new SARS-CoV-2 variants of concern in the EU/EEA, first update  21 January 2021\\."]}
{"id": 1002022, "claim": "Covid 19 risk related to selection of new sars cov 2 variants eu eea first update.", "label": "REFUTED", "evidence": ["News/announcements The European Centre for Disease Prevention and Control (ECDC) has set up a dedicated webpage for coronavirus disease (COVID-19) updates and risk assessments with a focus on Europe.", "Risk Assessment: Risk related to spread of new SARS-CoV-2 variants of concern in the EU/EEA Publications & data", "Risk related to spread of new SARS-CoV-2 variants of concern in the EU/EEA  29 December 2020.", "Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA  first update Publications & data", "Risk related to spread of new SARS-CoV-2 variants of concern in the EU/EEA, first update  21 January 2021\\."]}
{"id": 1002023, "claim": "Alcoholism treatment is potentially effective against covid-19", "label": "SUPPORTED", "evidence": ["These are disulfiram, which is used to treat alcoholism, and neratinib, an experimental drug being used to treat breast cancer."]}
{"id": 1002024, "claim": "Alcoholism treatment is potentially ineffective against covid-19", "label": "REFUTED", "evidence": ["These are disulfiram, which is used to treat alcoholism, and neratinib, an experimental drug being used to treat breast cancer."]}
{"id": 1002025, "claim": "Obesity is a major risk factor for covid-19 complications", "label": "SUPPORTED", "evidence": ["Metabolic changes caused by obesity  such as insulin resistance and inflammation  make it difficult for individuals with obesity to fight some infections, a trend that can be seen in other infectious diseases, such as influenza and hepatitis.", "Obesity already is associated with numerous underlying risk factors for COVID-19, including hypertension, heart disease, Type 2 diabetes, and chronic kidney and liver disease.", "Given the significant threat COVID-19 represents to individuals with obesity, healthy food policies can play a supportive  and especially important  role in mitigating COVID-19 mortality and morbidity, he says.", "The new paper reviews immunological and biomedical data to provide a detailed layout of the mechanisms and pathways that link obesity with increased risk of COVID-19 as well as an increased likelihood of developing more severe complications from the virus."]}
{"id": 1002026, "claim": "Influenza is a major risk factor for covid-19 complications", "label": "REFUTED", "evidence": ["Metabolic changes caused by obesity  such as insulin resistance and inflammation  make it difficult for individuals with obesity to fight some infections, a trend that can be seen in other infectious diseases, such as influenza and hepatitis.", "Obesity already is associated with numerous underlying risk factors for COVID-19, including hypertension, heart disease, Type 2 diabetes, and chronic kidney and liver disease.", "Given the significant threat COVID-19 represents to individuals with obesity, healthy food policies can play a supportive  and especially important  role in mitigating COVID-19 mortality and morbidity, he says.", "The new paper reviews immunological and biomedical data to provide a detailed layout of the mechanisms and pathways that link obesity with increased risk of COVID-19 as well as an increased likelihood of developing more severe complications from the virus."]}
{"id": 1002027, "claim": "Rsv is a major risk factor for covid-19 complications", "label": "REFUTED", "evidence": ["Metabolic changes caused by obesity  such as insulin resistance and inflammation  make it difficult for individuals with obesity to fight some infections, a trend that can be seen in other infectious diseases, such as influenza and hepatitis.", "Obesity already is associated with numerous underlying risk factors for COVID-19, including hypertension, heart disease, Type 2 diabetes, and chronic kidney and liver disease.", "Given the significant threat COVID-19 represents to individuals with obesity, healthy food policies can play a supportive  and especially important  role in mitigating COVID-19 mortality and morbidity, he says.", "The new paper reviews immunological and biomedical data to provide a detailed layout of the mechanisms and pathways that link obesity with increased risk of COVID-19 as well as an increased likelihood of developing more severe complications from the virus."]}
{"id": 1002028, "claim": "Hcv is a major risk factor for covid-19 complications", "label": "REFUTED", "evidence": ["Metabolic changes caused by obesity  such as insulin resistance and inflammation  make it difficult for individuals with obesity to fight some infections, a trend that can be seen in other infectious diseases, such as influenza and hepatitis.", "Obesity already is associated with numerous underlying risk factors for COVID-19, including hypertension, heart disease, Type 2 diabetes, and chronic kidney and liver disease.", "Given the significant threat COVID-19 represents to individuals with obesity, healthy food policies can play a supportive  and especially important  role in mitigating COVID-19 mortality and morbidity, he says.", "The new paper reviews immunological and biomedical data to provide a detailed layout of the mechanisms and pathways that link obesity with increased risk of COVID-19 as well as an increased likelihood of developing more severe complications from the virus."]}
{"id": 1002029, "claim": "Scientists seek to understand new variant.", "label": "SUPPORTED", "evidence": ["The team is now examining the effects of other mutations in the variants."]}
{"id": 1002030, "claim": "Scientists seek to understand one variant.", "label": "REFUTED", "evidence": ["The team is now examining the effects of other mutations in the variants."]}
{"id": 1002031, "claim": "Increase in sars-cov-2 viral rna identified in wastewater 48 hours before covid-19 clinical tests and 96 hours before hospitalizations", "label": "SUPPORTED", "evidence": ["In late July, increases of >400% in normalized SARS-CoV-2 RNA signal in wastewater were identified 48 hours prior to reported >300% increases in positive cases that were retrospectively attributed to community-acquired infections.", "During this resurgence period, SARS-CoV-2 RNA signal in wastewater preceded the reported >160% increase in community hospitalizations by approximately 96 hours."]}
{"id": 1002032, "claim": "Mortality in sars-cov-2 viral rna identified in wastewater 48 hours before covid-19 clinical tests and 96 hours before hospitalizations", "label": "REFUTED", "evidence": ["In late July, increases of >400% in normalized SARS-CoV-2 RNA signal in wastewater were identified 48 hours prior to reported >300% increases in positive cases that were retrospectively attributed to community-acquired infections.", "During this resurgence period, SARS-CoV-2 RNA signal in wastewater preceded the reported >160% increase in community hospitalizations by approximately 96 hours."]}
{"id": 1002033, "claim": "Two californians died of coronavirus weeks before previously known 1st us death", "label": "SUPPORTED", "evidence": ["Updated: 8:22 AM EDT Apr 22, 2020 KCRA Staff New autopsy results show the coronavirus killed two Californians in early and mid-February  up to three weeks before the previously known first U.S. death from the virus.These deaths now stand as the country's first two attributed to the novel coronavirus, a development that may change the understanding of how early the virus was spreading in the country, health experts told CNN Wednesday.Two deaths in Northern California's Santa Clara County happened Feb. 6 and Feb. 17, the county said in a news release Tuesday.", "\"Therefore, that means there was community spread happening in California as early as mid-January, if not earlier than that,\" Jha said.", "New autopsy results show the coronavirus killed two Californians in early and mid-February  up to three weeks before the previously known first U.S. death from the virus."]}
{"id": 1002034, "claim": "All californians died of coronavirus weeks before previously known 1st us death", "label": "REFUTED", "evidence": ["Updated: 8:22 AM EDT Apr 22, 2020 KCRA Staff New autopsy results show the coronavirus killed two Californians in early and mid-February  up to three weeks before the previously known first U.S. death from the virus.These deaths now stand as the country's first two attributed to the novel coronavirus, a development that may change the understanding of how early the virus was spreading in the country, health experts told CNN Wednesday.Two deaths in Northern California's Santa Clara County happened Feb. 6 and Feb. 17, the county said in a news release Tuesday.", "\"Therefore, that means there was community spread happening in California as early as mid-January, if not earlier than that,\" Jha said.", "New autopsy results show the coronavirus killed two Californians in early and mid-February  up to three weeks before the previously known first U.S. death from the virus."]}
{"id": 1002035, "claim": "C californians died of coronavirus weeks before previously known 1st us death", "label": "REFUTED", "evidence": ["Updated: 8:22 AM EDT Apr 22, 2020 KCRA Staff New autopsy results show the coronavirus killed two Californians in early and mid-February  up to three weeks before the previously known first U.S. death from the virus.These deaths now stand as the country's first two attributed to the novel coronavirus, a development that may change the understanding of how early the virus was spreading in the country, health experts told CNN Wednesday.Two deaths in Northern California's Santa Clara County happened Feb. 6 and Feb. 17, the county said in a news release Tuesday.", "\"Therefore, that means there was community spread happening in California as early as mid-January, if not earlier than that,\" Jha said.", "New autopsy results show the coronavirus killed two Californians in early and mid-February  up to three weeks before the previously known first U.S. death from the virus."]}
{"id": 1002036, "claim": "An 81 base-pair deletion in sars-cov-2 orf7a identified from sentinel surveillance in arizona", "label": "SUPPORTED", "evidence": ["Genomic characterization identified an isolate encoding a 27 amino acid in-frame deletion in accessory protein ORF7a, the ortholog of SARS- CoV immune antagonist ORF7a/X4."]}
{"id": 1002037, "claim": "An 81 base-pair deletion in sars-cov-2 orf7a identified from sentinel surveillance in china", "label": "REFUTED", "evidence": ["Genomic characterization identified an isolate encoding a 27 amino acid in-frame deletion in accessory protein ORF7a, the ortholog of SARS- CoV immune antagonist ORF7a/X4."]}
{"id": 1002038, "claim": "Ace2 expression in kidney and testis may cause kidney and testis damage after 2019-ncov infection", "label": "SUPPORTED", "evidence": ["Therefore, virus might directly bind to such ACE2 positive cells and damage the kidney and testicular tissue of patients."]}
{"id": 1002039, "claim": "Ace2 expression in kidney and testis may prevent kidney and testis damage after 2019-ncov infection", "label": "REFUTED", "evidence": ["Therefore, virus might directly bind to such ACE2 positive cells and damage the kidney and testicular tissue of patients."]}
{"id": 1002040, "claim": "Ace2 deficiency in kidney and testis may cause kidney and testis damage after 2019-ncov infection", "label": "REFUTED", "evidence": ["Therefore, virus might directly bind to such ACE2 positive cells and damage the kidney and testicular tissue of patients."]}
{"id": 1002041, "claim": "Ace2 expression in kidney and testis may limit kidney and testis damage after 2019-ncov infection", "label": "REFUTED", "evidence": ["Therefore, virus might directly bind to such ACE2 positive cells and damage the kidney and testicular tissue of patients."]}
{"id": 1002042, "claim": "Ethos labs develops viral neutralization covid-19 antibody test to evaluate protective immunity", "label": "SUPPORTED", "evidence": ["Ethos Laboratories (PRNewsfoto/Ethos Laboratories) The Tru-Immune lab test will identify patients with the most effective antibody response capable of inhibiting virus replication.", "Ethos Laboratories has entered a strategic partnership with Genscript to offer the first quantitative surrogate Viral Neutralization Test (sVNT) to evaluate COVID-19 protective immunity in the United States."]}
{"id": 1002043, "claim": "Ethos labs develops viral neutralization covid-19 antibody test to avoid protective immunity", "label": "REFUTED", "evidence": ["Ethos Laboratories (PRNewsfoto/Ethos Laboratories) The Tru-Immune lab test will identify patients with the most effective antibody response capable of inhibiting virus replication.", "Ethos Laboratories has entered a strategic partnership with Genscript to offer the first quantitative surrogate Viral Neutralization Test (sVNT) to evaluate COVID-19 protective immunity in the United States."]}
{"id": 1002044, "claim": "Ethos labs develops viral neutralization covid-19 antibody test to prevent protective immunity", "label": "REFUTED", "evidence": ["Ethos Laboratories (PRNewsfoto/Ethos Laboratories) The Tru-Immune lab test will identify patients with the most effective antibody response capable of inhibiting virus replication.", "Ethos Laboratories has entered a strategic partnership with Genscript to offer the first quantitative surrogate Viral Neutralization Test (sVNT) to evaluate COVID-19 protective immunity in the United States."]}
{"id": 1002045, "claim": "Ethos labs received viral neutralization covid-19 antibody test to evaluate protective immunity", "label": "REFUTED", "evidence": ["Ethos Laboratories (PRNewsfoto/Ethos Laboratories) The Tru-Immune lab test will identify patients with the most effective antibody response capable of inhibiting virus replication.", "Ethos Laboratories has entered a strategic partnership with Genscript to offer the first quantitative surrogate Viral Neutralization Test (sVNT) to evaluate COVID-19 protective immunity in the United States."]}
{"id": 1002046, "claim": "Moderna 's covid-19 vaccine shines in clinical trial", "label": "SUPPORTED", "evidence": ["The biotech company Moderna Inc. said Monday that its experimental vaccine was 94.5% effective in preventing disease, according to an analysis of its clinical trial."]}
{"id": 1002047, "claim": "Moderna's covid-19 vaccine shines in development trial", "label": "REFUTED", "evidence": ["The biotech company Moderna Inc. said Monday that its experimental vaccine was 94.5% effective in preventing disease, according to an analysis of its clinical trial."]}
{"id": 1002048, "claim": "Study finds over 80 percent of covid-19 patients have vitamin d deficiency", "label": "SUPPORTED", "evidence": ["The researchers found 80 percent of 216 COVID-19 patients at the Hospital Universitario Marques de Valdecilla had vitamin D deficiency, and men had lower vitamin D levels than women."]}
{"id": 1002049, "claim": "Study finds over 80 percent of covid-19 patients have vitamin d +.", "label": "REFUTED", "evidence": ["The researchers found 80 percent of 216 COVID-19 patients at the Hospital Universitario Marques de Valdecilla had vitamin D deficiency, and men had lower vitamin D levels than women."]}
{"id": 1002050, "claim": "Study finds over 80 percent of covid-19 patients have vitamin d!", "label": "REFUTED", "evidence": ["The researchers found 80 percent of 216 COVID-19 patients at the Hospital Universitario Marques de Valdecilla had vitamin D deficiency, and men had lower vitamin D levels than women."]}
{"id": 1002051, "claim": "Study finds over 80 percent of covid-19 patients have vitamin d+.", "label": "REFUTED", "evidence": ["The researchers found 80 percent of 216 COVID-19 patients at the Hospital Universitario Marques de Valdecilla had vitamin D deficiency, and men had lower vitamin D levels than women."]}
{"id": 1002052, "claim": "Cell-based culture of sars-cov-2 informs infectivity and safe de-isolation assessments during covid-19", "label": "SUPPORTED", "evidence": ["Conclusion: SARS-CoV-2 culture may be used as a surrogate marker for infectivity and inform de-isolation protocols.", "By contrast, the isolation of SARS-CoV-2 using cell-based culture likely indicates infectivity, but there are limited data on the correlation between SARS-CoV-2 culture and PCR."]}
{"id": 1002053, "claim": "Blood-based culture of sars-cov-2 informs infectivity and safe de-isolation assessments during covid-19", "label": "REFUTED", "evidence": ["Conclusion: SARS-CoV-2 culture may be used as a surrogate marker for infectivity and inform de-isolation protocols.", "By contrast, the isolation of SARS-CoV-2 using cell-based culture likely indicates infectivity, but there are limited data on the correlation between SARS-CoV-2 culture and PCR."]}
{"id": 1002054, "claim": "Dna-based culture of sars-cov-2 informs infectivity and safe de-isolation assessments during covid-19", "label": "REFUTED", "evidence": ["Conclusion: SARS-CoV-2 culture may be used as a surrogate marker for infectivity and inform de-isolation protocols.", "By contrast, the isolation of SARS-CoV-2 using cell-based culture likely indicates infectivity, but there are limited data on the correlation between SARS-CoV-2 culture and PCR."]}
{"id": 1002055, "claim": "Game-changer insights and recommendations from patterns of multi-organ involvement and affected subgroups in covid-19", "label": "SUPPORTED", "evidence": ["We recount the suggested inflammatory pathway for COVID-19 and its effects on various organ systems, including respiratory, cardiac, hematologic, reproductive, and nervous organ systems, as well examine the role of hypercytokinemia in the at-risk geriatric and obesity subgroups with upregulated cytokines' profile."]}
{"id": 1002056, "claim": "Game-changer insights and recommendations from patterns of multi-organ dysfunction and affected subgroups in covid-19", "label": "REFUTED", "evidence": ["We recount the suggested inflammatory pathway for COVID-19 and its effects on various organ systems, including respiratory, cardiac, hematologic, reproductive, and nervous organ systems, as well examine the role of hypercytokinemia in the at-risk geriatric and obesity subgroups with upregulated cytokines' profile."]}
{"id": 1002057, "claim": "If one assumes that the number of asymptomatic or minimally symptomatic cases is several times as high as the number of reported cases , the case fatality rate may be considerably less than 1 % .", "label": "SUPPORTED", "evidence": ["Among the those with severe disease, the percentage with normal radiographic and CT results was substantially lower at 2.9%.", "There are going to be people who are young who are going to wind up getting seriously ill. The virus has also disproportionately affected people of color.", "With testing limited and many cases mild or asymptomatic, experts say many cases go unreported."]}
{"id": 1002058, "claim": "If one assumes that the number of asymptomatic or minimally symptomatic cases is several times as high as the number of reported cases, the case fatality rate cannot be considerably less than 1 %.", "label": "REFUTED", "evidence": ["Among the those with severe disease, the percentage with normal radiographic and CT results was substantially lower at 2.9%.", "There are going to be people who are young who are going to wind up getting seriously ill. The virus has also disproportionately affected people of color.", "With testing limited and many cases mild or asymptomatic, experts say many cases go unreported."]}
{"id": 1002059, "claim": "There is no specific medicine to treat covid-19 , so whether you test positive or negative , management of your illness will be the same .", "label": "SUPPORTED", "evidence": ["There is no specific medical treatment for COVID-19.", "However, there is no clear or convincing scientific evidence that it works for COVID-19 infections, and it is not a standard part of treatment for this infection."]}
{"id": 1002060, "claim": "There is no specific medicine to treat covid-19, so whether you test positive or negative, management of your illness will be the question.", "label": "REFUTED", "evidence": ["There is no specific medical treatment for COVID-19.", "However, there is no clear or convincing scientific evidence that it works for COVID-19 infections, and it is not a standard part of treatment for this infection."]}
{"id": 1002061, "claim": "Sickkids-led group of experts proposes latest guidance for school reopening", "label": "SUPPORTED", "evidence": ["The living document, Updated COVID-19: Guidance for School Reopening (pdf), published July 29, 2020, builds on the initial set of recommendations put forward by The Hospital for Sick Children (SickKids) and Unity Health Toronto, with input from experts from a wide range of disciplines across the province.", "TORONTO - A group of experts from across Ontario have come together to develop updated considerations for a safe school reopening amid the COVID-19 pandemic."]}
{"id": 1002062, "claim": "Sickkids-led group of experts proposes latest guidance for research reopening", "label": "REFUTED", "evidence": ["The living document, Updated COVID-19: Guidance for School Reopening (pdf), published July 29, 2020, builds on the initial set of recommendations put forward by The Hospital for Sick Children (SickKids) and Unity Health Toronto, with input from experts from a wide range of disciplines across the province.", "TORONTO - A group of experts from across Ontario have come together to develop updated considerations for a safe school reopening amid the COVID-19 pandemic."]}
{"id": 1002063, "claim": "Sickkids-led group of experts proposes latest guidance for health reopening", "label": "REFUTED", "evidence": ["The living document, Updated COVID-19: Guidance for School Reopening (pdf), published July 29, 2020, builds on the initial set of recommendations put forward by The Hospital for Sick Children (SickKids) and Unity Health Toronto, with input from experts from a wide range of disciplines across the province.", "TORONTO - A group of experts from across Ontario have come together to develop updated considerations for a safe school reopening amid the COVID-19 pandemic."]}
{"id": 1002064, "claim": "Sickkids-led group of experts proposes latest guidance for data reopening", "label": "REFUTED", "evidence": ["The living document, Updated COVID-19: Guidance for School Reopening (pdf), published July 29, 2020, builds on the initial set of recommendations put forward by The Hospital for Sick Children (SickKids) and Unity Health Toronto, with input from experts from a wide range of disciplines across the province.", "TORONTO - A group of experts from across Ontario have come together to develop updated considerations for a safe school reopening amid the COVID-19 pandemic."]}
{"id": 1002065, "claim": "Fibrinolysis influences sars-cov-2 infection in ciliated cells.", "label": "SUPPORTED", "evidence": ["Accordingly, SARS-CoV-2 may share and strengthen the ENaC fibrinolytic proteases network in ACE2 positive airway and alveolar epithelial cells, which may expedite virus infusion into the susceptible cells and bring about ENaC associated edematous respiratory condition.", "Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart."]}
{"id": 1002066, "claim": "Fibrinolysis influences sars-cov-2 production in ciliated cells.", "label": "REFUTED", "evidence": ["Accordingly, SARS-CoV-2 may share and strengthen the ENaC fibrinolytic proteases network in ACE2 positive airway and alveolar epithelial cells, which may expedite virus infusion into the susceptible cells and bring about ENaC associated edematous respiratory condition.", "Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart."]}
{"id": 1002067, "claim": "Fibrinolysis influences sars-cov-2 metabolism in ciliated cells.", "label": "REFUTED", "evidence": ["Accordingly, SARS-CoV-2 may share and strengthen the ENaC fibrinolytic proteases network in ACE2 positive airway and alveolar epithelial cells, which may expedite virus infusion into the susceptible cells and bring about ENaC associated edematous respiratory condition.", "Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart."]}
{"id": 1002068, "claim": "Global partnership to make available 120 million affordable , quality covid-19 rapid tests for low- and middle-income countries", "label": "SUPPORTED", "evidence": ["These agreements are critical to fulfil the key objective of the ACT- Accelerator: to ensure all countries, regardless of income, have fair access to new tests and tools to fight COVID-19.", "Both companies' tests are faster and cheaper than laboratory-based tests, enabling countries to increase the pace of testing, tracing and treating people for COVID-19 at the point of care particularly in areas with under-resourced health systems.", "These two arrangements will make available to LMICs 120 million antigen rapid diagnostic tests (Ag RDTs) - priced at a maximum of US$5 per unit - over a period of six months."]}
{"id": 1002069, "claim": "Global partnership to make available 1 million affordable, quality covid-19 rapid tests for low- and middle-income countries", "label": "REFUTED", "evidence": ["These agreements are critical to fulfil the key objective of the ACT- Accelerator: to ensure all countries, regardless of income, have fair access to new tests and tools to fight COVID-19.", "Both companies' tests are faster and cheaper than laboratory-based tests, enabling countries to increase the pace of testing, tracing and treating people for COVID-19 at the point of care particularly in areas with under-resourced health systems.", "These two arrangements will make available to LMICs 120 million antigen rapid diagnostic tests (Ag RDTs) - priced at a maximum of US$5 per unit - over a period of six months."]}
{"id": 1002070, "claim": "Global partnership to make available 5 million affordable, quality covid-19 rapid tests for low- and middle-income countries", "label": "REFUTED", "evidence": ["These agreements are critical to fulfil the key objective of the ACT- Accelerator: to ensure all countries, regardless of income, have fair access to new tests and tools to fight COVID-19.", "Both companies' tests are faster and cheaper than laboratory-based tests, enabling countries to increase the pace of testing, tracing and treating people for COVID-19 at the point of care particularly in areas with under-resourced health systems.", "These two arrangements will make available to LMICs 120 million antigen rapid diagnostic tests (Ag RDTs) - priced at a maximum of US$5 per unit - over a period of six months."]}
{"id": 1002071, "claim": "Global partnership to make available one million affordable, quality covid-19 rapid tests for low- and middle-income countries", "label": "REFUTED", "evidence": ["These agreements are critical to fulfil the key objective of the ACT- Accelerator: to ensure all countries, regardless of income, have fair access to new tests and tools to fight COVID-19.", "Both companies' tests are faster and cheaper than laboratory-based tests, enabling countries to increase the pace of testing, tracing and treating people for COVID-19 at the point of care particularly in areas with under-resourced health systems.", "These two arrangements will make available to LMICs 120 million antigen rapid diagnostic tests (Ag RDTs) - priced at a maximum of US$5 per unit - over a period of six months."]}
{"id": 1002072, "claim": "Taste bud cells might not be a target of sars-cov-2", "label": "SUPPORTED", "evidence": ["That means the virus probably does not cause taste loss through direct infection of these cells, the researchers say.", "Although the mouse version of ACE2 isn't susceptible to SARS-CoV-2, studying where it's expressed in mice could help clarify what happens when people become infected and lose the sense of taste."]}
{"id": 1002073, "claim": "Taste bud cells might also be a target of sars-cov-2", "label": "REFUTED", "evidence": ["That means the virus probably does not cause taste loss through direct infection of these cells, the researchers say.", "Although the mouse version of ACE2 isn't susceptible to SARS-CoV-2, studying where it's expressed in mice could help clarify what happens when people become infected and lose the sense of taste."]}
{"id": 1002074, "claim": "Taste bud cells might still be a target of sars-cov-2", "label": "REFUTED", "evidence": ["That means the virus probably does not cause taste loss through direct infection of these cells, the researchers say.", "Although the mouse version of ACE2 isn't susceptible to SARS-CoV-2, studying where it's expressed in mice could help clarify what happens when people become infected and lose the sense of taste."]}
{"id": 1002075, "claim": "Taste bud cells might thus be a target of sars-cov-2", "label": "REFUTED", "evidence": ["That means the virus probably does not cause taste loss through direct infection of these cells, the researchers say.", "Although the mouse version of ACE2 isn't susceptible to SARS-CoV-2, studying where it's expressed in mice could help clarify what happens when people become infected and lose the sense of taste."]}
{"id": 1002076, "claim": "Fda authorizes first next generation sequence test for diagnosing covid-19", "label": "SUPPORTED", "evidence": ["The FDA authorized the Illumina COVIDSeq Test for the qualitative detection of SARS-CoV-2 RNA from respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider."]}
{"id": 1002077, "claim": "Fda authorizes first one generation sequence test for diagnosing covid-19", "label": "REFUTED", "evidence": ["The FDA authorized the Illumina COVIDSeq Test for the qualitative detection of SARS-CoV-2 RNA from respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider."]}
{"id": 1002078, "claim": "Fda authorizes first first generation sequence test for diagnosing covid-19", "label": "REFUTED", "evidence": ["The FDA authorized the Illumina COVIDSeq Test for the qualitative detection of SARS-CoV-2 RNA from respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider."]}
{"id": 1002079, "claim": "Fda authorizes first time generation sequence test for diagnosing covid-19", "label": "REFUTED", "evidence": ["The FDA authorized the Illumina COVIDSeq Test for the qualitative detection of SARS-CoV-2 RNA from respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider."]}
{"id": 1002080, "claim": "Fda issued an emergency use authorization for cellex qsars-cov-2 igg/igm rapid test", "label": "SUPPORTED", "evidence": ["Notably, the FDA issued an emergency use authorization, on April 1, 2020, to Cellex Inc.s qSARS-CoV-2 IgG/IgM Rapid Test which is the first serology test to date to receive authorization to test for the presence of coronavirus antibodies.", "By Dave Muoio April 02, 2020 03:13 pm Share Editor's note: On the same day this story was published, the FDA publicized the first Emergency Use Authorization of a serology test,Cellex Inc.s qSARS- CoV-2 IgG/IgM Rapid Test."]}
{"id": 1002081, "claim": "Who issued an emergency use authorization for cellex qsars-cov-2 igg/igm rapid test", "label": "REFUTED", "evidence": ["Notably, the FDA issued an emergency use authorization, on April 1, 2020, to Cellex Inc.s qSARS-CoV-2 IgG/IgM Rapid Test which is the first serology test to date to receive authorization to test for the presence of coronavirus antibodies.", "By Dave Muoio April 02, 2020 03:13 pm Share Editor's note: On the same day this story was published, the FDA publicized the first Emergency Use Authorization of a serology test,Cellex Inc.s qSARS- CoV-2 IgG/IgM Rapid Test."]}
{"id": 1002082, "claim": "Cdc issued an emergency use authorization for cellex qsars-cov-2 igg/igm rapid test", "label": "REFUTED", "evidence": ["Notably, the FDA issued an emergency use authorization, on April 1, 2020, to Cellex Inc.s qSARS-CoV-2 IgG/IgM Rapid Test which is the first serology test to date to receive authorization to test for the presence of coronavirus antibodies.", "By Dave Muoio April 02, 2020 03:13 pm Share Editor's note: On the same day this story was published, the FDA publicized the first Emergency Use Authorization of a serology test,Cellex Inc.s qSARS- CoV-2 IgG/IgM Rapid Test."]}
{"id": 1002083, "claim": "China issued an emergency use authorization for cellex qsars-cov-2 igg/igm rapid test", "label": "REFUTED", "evidence": ["Notably, the FDA issued an emergency use authorization, on April 1, 2020, to Cellex Inc.s qSARS-CoV-2 IgG/IgM Rapid Test which is the first serology test to date to receive authorization to test for the presence of coronavirus antibodies.", "By Dave Muoio April 02, 2020 03:13 pm Share Editor's note: On the same day this story was published, the FDA publicized the first Emergency Use Authorization of a serology test,Cellex Inc.s qSARS- CoV-2 IgG/IgM Rapid Test."]}
{"id": 1002084, "claim": "Aging immunity may exacerbate covid-19", "label": "SUPPORTED", "evidence": ["Inflammaging has many implications for COVID-19 patients: The accumulation of senescent cells in the respiratory tract of older patients may be involved in the initiation of an inflammatory cascade that could inhibit T cell responses to virally infected cells that are present.", "This may be of particular relevance for older patients with COVID-19 who have severe inflammation in the respiratory tract during disease progression that may hinder antiviral immunity."]}
{"id": 1002085, "claim": "Aging infections may exacerbate covid-19", "label": "REFUTED", "evidence": ["Inflammaging has many implications for COVID-19 patients: The accumulation of senescent cells in the respiratory tract of older patients may be involved in the initiation of an inflammatory cascade that could inhibit T cell responses to virally infected cells that are present.", "This may be of particular relevance for older patients with COVID-19 who have severe inflammation in the respiratory tract during disease progression that may hinder antiviral immunity."]}
{"id": 1002086, "claim": "Aging infection may exacerbate covid-19", "label": "REFUTED", "evidence": ["Inflammaging has many implications for COVID-19 patients: The accumulation of senescent cells in the respiratory tract of older patients may be involved in the initiation of an inflammatory cascade that could inhibit T cell responses to virally infected cells that are present.", "This may be of particular relevance for older patients with COVID-19 who have severe inflammation in the respiratory tract during disease progression that may hinder antiviral immunity."]}
{"id": 1002087, "claim": "Aging immunity cannot exacerbate covid-19", "label": "REFUTED", "evidence": ["Inflammaging has many implications for COVID-19 patients: The accumulation of senescent cells in the respiratory tract of older patients may be involved in the initiation of an inflammatory cascade that could inhibit T cell responses to virally infected cells that are present.", "This may be of particular relevance for older patients with COVID-19 who have severe inflammation in the respiratory tract during disease progression that may hinder antiviral immunity."]}
{"id": 1002088, "claim": "Single-cell transcriptome of bronchoalveolar lavage fluid reveals dynamic change of macrophages during sars-cov-2 infection in ferrets", "label": "SUPPORTED", "evidence": ["Moreover, trajectory analysis revealed gene expression changes from monocyte-derived infiltrating macrophages toward M1 or M2 macrophages and identified the distinct macrophage subpopulation that had rapidly undergone SARS-CoV-2-mediated activation of inflammatory responses.", "Landscape analysis of the lung immune microenvironment showed dynamic changes in cell proportions and characteristics in uninfected control, at 2 days post-infection (dpi) (early stage of SARS-CoV-2 infection with peak viral titer), and 5 dpi (resolution phase)."]}
{"id": 1002089, "claim": "Single-cell transcriptome of bronchoalveolar lavage fluid reveals dynamic change of macrophages during sars-cov-2 production in ferrets", "label": "REFUTED", "evidence": ["Moreover, trajectory analysis revealed gene expression changes from monocyte-derived infiltrating macrophages toward M1 or M2 macrophages and identified the distinct macrophage subpopulation that had rapidly undergone SARS-CoV-2-mediated activation of inflammatory responses.", "Landscape analysis of the lung immune microenvironment showed dynamic changes in cell proportions and characteristics in uninfected control, at 2 days post-infection (dpi) (early stage of SARS-CoV-2 infection with peak viral titer), and 5 dpi (resolution phase)."]}
{"id": 1002090, "claim": "Long-term covid-19 containment will be shaped by strength and duration of natural , vaccine-induced immunity", "label": "SUPPORTED", "evidence": ["In the most recent paper, the researchers used a simple model to project the future incidence of COVID-19 cases  and the degree of immunity in the human population  under a range of assumptions related to how likely individuals are to transmit the virus in different contexts.", "The researchers used a simple model to project the future incidence of COVID-19 cases  and the degree of immunity in the human population  under a range of assumptions on host immune responses following natural infection or vaccination.", "A new study led by Princeton researchers suggests that the impact of natural and vaccine-induced immunity will be key factors in shaping the future trajectory of the global coronavirus pandemic, known as COVID-19."]}
{"id": 1002091, "claim": "Long-term covid-19 transmission will be shaped by strength and duration of natural, vaccine-induced immunity", "label": "REFUTED", "evidence": ["In the most recent paper, the researchers used a simple model to project the future incidence of COVID-19 cases  and the degree of immunity in the human population  under a range of assumptions related to how likely individuals are to transmit the virus in different contexts.", "The researchers used a simple model to project the future incidence of COVID-19 cases  and the degree of immunity in the human population  under a range of assumptions on host immune responses following natural infection or vaccination.", "A new study led by Princeton researchers suggests that the impact of natural and vaccine-induced immunity will be key factors in shaping the future trajectory of the global coronavirus pandemic, known as COVID-19."]}
{"id": 1002092, "claim": "Sars-cov-2 productively infects human gut enterocytes", "label": "SUPPORTED", "evidence": ["( B ) SARS-CoV-2 infects both postmitotic enterocytes identified by Apolipoprotein A1 (APOA1) and dividing cells that are KI67-positive.", "SARS-CoV also readily infected enterocyte lineage cells (fig.", "H. Shan , Evidence for gastrointestinal infection of SARS-CoV-2.", "used human intestinal organoids, a mini-gut cultured in a dish, to demonstrate that SARS-CoV-2 readily replicates in an abundant cell type in the gut liningthe enterocyteresulting in the production of large amounts of infective virus particles in the intestine.", "This study shows that SARS- CoV and SARS-CoV-2 infect enterocyte lineage cells in an hSIO model."]}
{"id": 1002093, "claim": "Sars-cov-2 productively infects human neurons enterocytes", "label": "REFUTED", "evidence": ["( B ) SARS-CoV-2 infects both postmitotic enterocytes identified by Apolipoprotein A1 (APOA1) and dividing cells that are KI67-positive.", "SARS-CoV also readily infected enterocyte lineage cells (fig.", "H. Shan , Evidence for gastrointestinal infection of SARS-CoV-2.", "used human intestinal organoids, a mini-gut cultured in a dish, to demonstrate that SARS-CoV-2 readily replicates in an abundant cell type in the gut liningthe enterocyteresulting in the production of large amounts of infective virus particles in the intestine.", "This study shows that SARS- CoV and SARS-CoV-2 infect enterocyte lineage cells in an hSIO model."]}
{"id": 1002094, "claim": "Sars-cov-2 productively infects human lymphocytes enterocytes", "label": "REFUTED", "evidence": ["( B ) SARS-CoV-2 infects both postmitotic enterocytes identified by Apolipoprotein A1 (APOA1) and dividing cells that are KI67-positive.", "SARS-CoV also readily infected enterocyte lineage cells (fig.", "H. Shan , Evidence for gastrointestinal infection of SARS-CoV-2.", "used human intestinal organoids, a mini-gut cultured in a dish, to demonstrate that SARS-CoV-2 readily replicates in an abundant cell type in the gut liningthe enterocyteresulting in the production of large amounts of infective virus particles in the intestine.", "This study shows that SARS- CoV and SARS-CoV-2 infect enterocyte lineage cells in an hSIO model."]}
{"id": 1002095, "claim": "Sars-cov-2 productively infects human hepatocytes enterocytes", "label": "REFUTED", "evidence": ["( B ) SARS-CoV-2 infects both postmitotic enterocytes identified by Apolipoprotein A1 (APOA1) and dividing cells that are KI67-positive.", "SARS-CoV also readily infected enterocyte lineage cells (fig.", "H. Shan , Evidence for gastrointestinal infection of SARS-CoV-2.", "used human intestinal organoids, a mini-gut cultured in a dish, to demonstrate that SARS-CoV-2 readily replicates in an abundant cell type in the gut liningthe enterocyteresulting in the production of large amounts of infective virus particles in the intestine.", "This study shows that SARS- CoV and SARS-CoV-2 infect enterocyte lineage cells in an hSIO model."]}
{"id": 1002096, "claim": "Hydroxychloroquine-mediated inhibition of sars-cov-2 entry is attenuated by tmprss2", "label": "SUPPORTED", "evidence": ["Thus TMPRSS2 expression on physiologically relevant SARS-CoV-2 target cells may bypass the antiviral activities of hydroxychloroquine, and explain its lack of in vivo efficacy."]}
{"id": 1002097, "claim": "Hydroxychloroquine-mediated inhibition of mbls-cov-2 entry is attenuated by tmprss2", "label": "REFUTED", "evidence": ["Thus TMPRSS2 expression on physiologically relevant SARS-CoV-2 target cells may bypass the antiviral activities of hydroxychloroquine, and explain its lack of in vivo efficacy."]}
{"id": 1002098, "claim": "Hydroxychloroquine-mediated inhibition of pas-cov-2 entry is attenuated by tmprss2", "label": "REFUTED", "evidence": ["Thus TMPRSS2 expression on physiologically relevant SARS-CoV-2 target cells may bypass the antiviral activities of hydroxychloroquine, and explain its lack of in vivo efficacy."]}
{"id": 1002099, "claim": "Hydroxychloroquine-mediated inhibition of gps-cov-2 entry is attenuated by tmprss2", "label": "REFUTED", "evidence": ["Thus TMPRSS2 expression on physiologically relevant SARS-CoV-2 target cells may bypass the antiviral activities of hydroxychloroquine, and explain its lack of in vivo efficacy."]}
{"id": 1002100, "claim": "Multivalency transforms sars-cov-2 antibodies into broad and ultrapotent neutralizers", "label": "SUPPORTED", "evidence": ["One Sentence Summary multimerization platform transforms antibodies emerging from discovery screens into potent neutralizers that can overcome SARS-CoV-2 sequence diversity.", "This MULTi-specific, multi-Affinity antiBODY (Multabody; or MB) platform contributes a new class of medical countermeasures against COVID-19 and an efficient approach to rapidly deploy potent and broadly-acting therapeutics against infectious diseases of global health importance.", "Here, we used the human apoferritin protomer as a modular subunit to drive oligomerization of antibody fragments and transform antibodies targeting SARS- CoV-2 into exceptionally potent neutralizers."]}
{"id": 1002101, "claim": "Multivalency transforms sars-cov-2 antibodies into specific and ultrapotent neutralizers", "label": "REFUTED", "evidence": ["One Sentence Summary multimerization platform transforms antibodies emerging from discovery screens into potent neutralizers that can overcome SARS-CoV-2 sequence diversity.", "This MULTi-specific, multi-Affinity antiBODY (Multabody; or MB) platform contributes a new class of medical countermeasures against COVID-19 and an efficient approach to rapidly deploy potent and broadly-acting therapeutics against infectious diseases of global health importance.", "Here, we used the human apoferritin protomer as a modular subunit to drive oligomerization of antibody fragments and transform antibodies targeting SARS- CoV-2 into exceptionally potent neutralizers."]}
{"id": 1002102, "claim": "Multivalency transforms sars-cov-2 antibodies into complex and ultrapotent neutralizers", "label": "REFUTED", "evidence": ["One Sentence Summary multimerization platform transforms antibodies emerging from discovery screens into potent neutralizers that can overcome SARS-CoV-2 sequence diversity.", "This MULTi-specific, multi-Affinity antiBODY (Multabody; or MB) platform contributes a new class of medical countermeasures against COVID-19 and an efficient approach to rapidly deploy potent and broadly-acting therapeutics against infectious diseases of global health importance.", "Here, we used the human apoferritin protomer as a modular subunit to drive oligomerization of antibody fragments and transform antibodies targeting SARS- CoV-2 into exceptionally potent neutralizers."]}
{"id": 1002103, "claim": "Multivalency transforms sars-cov-2 networks into broad and ultrapotent neutralizers", "label": "REFUTED", "evidence": ["One Sentence Summary multimerization platform transforms antibodies emerging from discovery screens into potent neutralizers that can overcome SARS-CoV-2 sequence diversity.", "This MULTi-specific, multi-Affinity antiBODY (Multabody; or MB) platform contributes a new class of medical countermeasures against COVID-19 and an efficient approach to rapidly deploy potent and broadly-acting therapeutics against infectious diseases of global health importance.", "Here, we used the human apoferritin protomer as a modular subunit to drive oligomerization of antibody fragments and transform antibodies targeting SARS- CoV-2 into exceptionally potent neutralizers."]}
{"id": 1002104, "claim": "Adaptive cyclic exit strategies from lockdown to suppress covid-19 and allow economic activity", "label": "SUPPORTED", "evidence": ["Here we propose exit strategies from lockdown that provide sustainable, albeit reduced, economic activity.", "The relative benefit of the cyclic strategy is further increased by considering non-COVID-19-related health consequences of extended lockdown during resurgences, alleviated by the cyclic strategy.", "The cyclic exit strategy from these lockdowns, proposed here, has at least two major types of effects: First, it provides for a partial release from the lockdown, enabling more production and consumption."]}
{"id": 1002105, "claim": "Adaptive cyclic exit strategies from lockdown to suppress covid-19 and decrease economic activity", "label": "REFUTED", "evidence": ["Here we propose exit strategies from lockdown that provide sustainable, albeit reduced, economic activity.", "The relative benefit of the cyclic strategy is further increased by considering non-COVID-19-related health consequences of extended lockdown during resurgences, alleviated by the cyclic strategy.", "The cyclic exit strategy from these lockdowns, proposed here, has at least two major types of effects: First, it provides for a partial release from the lockdown, enabling more production and consumption."]}
{"id": 1002106, "claim": "Adaptive cyclic exit strategies from lockdown to suppress covid-19 and reducing economic activity", "label": "REFUTED", "evidence": ["Here we propose exit strategies from lockdown that provide sustainable, albeit reduced, economic activity.", "The relative benefit of the cyclic strategy is further increased by considering non-COVID-19-related health consequences of extended lockdown during resurgences, alleviated by the cyclic strategy.", "The cyclic exit strategy from these lockdowns, proposed here, has at least two major types of effects: First, it provides for a partial release from the lockdown, enabling more production and consumption."]}
{"id": 1002107, "claim": "Adaptive cyclic exit strategies from lockdown to suppress covid-19 and reduce economic activity", "label": "REFUTED", "evidence": ["Here we propose exit strategies from lockdown that provide sustainable, albeit reduced, economic activity.", "The relative benefit of the cyclic strategy is further increased by considering non-COVID-19-related health consequences of extended lockdown during resurgences, alleviated by the cyclic strategy.", "The cyclic exit strategy from these lockdowns, proposed here, has at least two major types of effects: First, it provides for a partial release from the lockdown, enabling more production and consumption."]}
{"id": 1002108, "claim": "Hundreds of people volunteer to be infected with coronavirus", "label": "SUPPORTED", "evidence": ["Many note that they recognize the risk but believe the benefits of vaccine acceleration are so tremendous that it is worth it to them, he says.", "At the same time, we feel that the public policy decisions around challenge trials will be better informed if they highlight the voice of people interested in participating in such trials. Morrison says that the people who have signed up to be part of a challenge trial tend to be young and live in urban areas, and are highly motivated to do something constructive to address the coronavirus pandemic."]}
{"id": 1002109, "claim": "Two of people volunteer to be infected with coronavirus", "label": "REFUTED", "evidence": ["Many note that they recognize the risk but believe the benefits of vaccine acceleration are so tremendous that it is worth it to them, he says.", "At the same time, we feel that the public policy decisions around challenge trials will be better informed if they highlight the voice of people interested in participating in such trials. Morrison says that the people who have signed up to be part of a challenge trial tend to be young and live in urban areas, and are highly motivated to do something constructive to address the coronavirus pandemic."]}
{"id": 1002110, "claim": "None of people volunteer to be infected with coronavirus", "label": "REFUTED", "evidence": ["Many note that they recognize the risk but believe the benefits of vaccine acceleration are so tremendous that it is worth it to them, he says.", "At the same time, we feel that the public policy decisions around challenge trials will be better informed if they highlight the voice of people interested in participating in such trials. Morrison says that the people who have signed up to be part of a challenge trial tend to be young and live in urban areas, and are highly motivated to do something constructive to address the coronavirus pandemic."]}
{"id": 1002111, "claim": "One of people volunteer to be infected with coronavirus", "label": "REFUTED", "evidence": ["Many note that they recognize the risk but believe the benefits of vaccine acceleration are so tremendous that it is worth it to them, he says.", "At the same time, we feel that the public policy decisions around challenge trials will be better informed if they highlight the voice of people interested in participating in such trials. Morrison says that the people who have signed up to be part of a challenge trial tend to be young and live in urban areas, and are highly motivated to do something constructive to address the coronavirus pandemic."]}
{"id": 1002112, "claim": "Incorporating human movement data to improve epidemiological estimates for 2019-ncov", "label": "SUPPORTED", "evidence": ["One Sentence Summary A geo-stratified debiasing approach incorporating human movement data was developed to improve modeling of the 2019-nCoV epidemic.", "We developed an alternative geo-stratified debiasing estimation framework by incorporating human mobility with case reporting data in three stratified zones, i.e., Wuhan, Hubei Province excluding Wuhan, and mainland China excluding Hubei."]}
{"id": 1002113, "claim": "Incorporating network movement data to improve epidemiological estimates for 2019-ncov", "label": "REFUTED", "evidence": ["One Sentence Summary A geo-stratified debiasing approach incorporating human movement data was developed to improve modeling of the 2019-nCoV epidemic.", "We developed an alternative geo-stratified debiasing estimation framework by incorporating human mobility with case reporting data in three stratified zones, i.e., Wuhan, Hubei Province excluding Wuhan, and mainland China excluding Hubei."]}
{"id": 1002114, "claim": "Incorporating human movement data to improve epidemiological estimates for pre-ncov", "label": "REFUTED", "evidence": ["One Sentence Summary A geo-stratified debiasing approach incorporating human movement data was developed to improve modeling of the 2019-nCoV epidemic.", "We developed an alternative geo-stratified debiasing estimation framework by incorporating human mobility with case reporting data in three stratified zones, i.e., Wuhan, Hubei Province excluding Wuhan, and mainland China excluding Hubei."]}
{"id": 1002115, "claim": "Increase in delirium , rare brain inflammation and stroke linked to covid-19", "label": "SUPPORTED", "evidence": ["This paper also confirms the previously reported findings of a higher than expected number of patients with stroke which results from the excessive stickiness of the blood in COVID-19 patients.", "Joint first author Dr Rachel Brown (UCL Queen Square Institute of Neurology and UCL Infection & Immunity) said: \"Our study advances understanding of the different ways in which Covid-19 can affect the brain, which will be paramount in the collective effort to support and manage patients in their treatment and recovery.\"", "Some patients in the study did not experience severe respiratory symptoms, and the neurological disorder was the first and main presentation of Covid-19."]}
{"id": 1002116, "claim": "Differences in delirium, rare brain inflammation and stroke linked to covid-19", "label": "REFUTED", "evidence": ["This paper also confirms the previously reported findings of a higher than expected number of patients with stroke which results from the excessive stickiness of the blood in COVID-19 patients.", "Joint first author Dr Rachel Brown (UCL Queen Square Institute of Neurology and UCL Infection & Immunity) said: \"Our study advances understanding of the different ways in which Covid-19 can affect the brain, which will be paramount in the collective effort to support and manage patients in their treatment and recovery.\"", "Some patients in the study did not experience severe respiratory symptoms, and the neurological disorder was the first and main presentation of Covid-19."]}
{"id": 1002117, "claim": "The host 's angiotensin-converting enzyme polymorphism may explain epidemiological findings in covid-19 infections", "label": "SUPPORTED", "evidence": ["Could angiotensin-converting enzyme 1 I/D polymorphism be a modificator of COVID-19 response in different populations, diseases, and/or conditions?", "Ethnic and age-specific acute lung injury/acute respiratory distress syndrome risk associated with angiotensin-converting enzyme insertion/deletion polymorphisms, implications for COVID-19: A meta-analysis."]}
{"id": 1002118, "claim": "The variable's angiotensin-converting enzyme polymorphism may explain epidemiological findings in covid-19 infections", "label": "REFUTED", "evidence": ["Could angiotensin-converting enzyme 1 I/D polymorphism be a modificator of COVID-19 response in different populations, diseases, and/or conditions?", "Ethnic and age-specific acute lung injury/acute respiratory distress syndrome risk associated with angiotensin-converting enzyme insertion/deletion polymorphisms, implications for COVID-19: A meta-analysis."]}
{"id": 1002119, "claim": "Human challenge studies to accelerate coronavirus vaccine licensure", "label": "SUPPORTED", "evidence": ["The process to vaccine licensure through a controlled human challenge trial and large Figure 1."]}
{"id": 1002120, "claim": "Future challenge studies to accelerate coronavirus vaccine licensure", "label": "REFUTED", "evidence": ["The process to vaccine licensure through a controlled human challenge trial and large Figure 1."]}
{"id": 1002121, "claim": "Identification of a polymorphism in the n gene of sars-cov-2 that adversely impacts detection by a widely-used rt-pcr assay", "label": "SUPPORTED", "evidence": ["Article Summary Line A SARS-CoV-2 variant that occurs worldwide and has spread in California significantly affects diagnostic sensitivity of an N gene assay, highlighting the need to employ multiple viral targets for detection."]}
{"id": 1002122, "claim": "Lack of a polymorphism in the n gene of sars-cov-2 that adversely impacts detection by a widely-used rt-pcr assay", "label": "REFUTED", "evidence": ["Article Summary Line A SARS-CoV-2 variant that occurs worldwide and has spread in California significantly affects diagnostic sensitivity of an N gene assay, highlighting the need to employ multiple viral targets for detection."]}
{"id": 1002123, "claim": "Lymphocytopenia and neutrophilia deteriorate at the lowest oxygenation index timepoint in covid-19 patient", "label": "SUPPORTED", "evidence": ["And the oxygenation index was associated with ratio of lymphocyte and neutrophil in COVID-19 patients.", "Conclusions Lymphocytopenia and neutrophilia, which deteriorate in the progression of severe patients, are the main pathogenesis of COVID-19.", "Oxygenation index presented potentiality as predictor on the progression of COVID-19.", "Lymphocytopenia and neutrophilia deteriorated at the lowest oxygenation index timepoint in the severe patients."]}
{"id": 1002124, "claim": "Lymphocytopenia and neutrophilia deteriorate at the acute oxygenation index timepoint in covid-19 patient", "label": "REFUTED", "evidence": ["And the oxygenation index was associated with ratio of lymphocyte and neutrophil in COVID-19 patients.", "Conclusions Lymphocytopenia and neutrophilia, which deteriorate in the progression of severe patients, are the main pathogenesis of COVID-19.", "Oxygenation index presented potentiality as predictor on the progression of COVID-19.", "Lymphocytopenia and neutrophilia deteriorated at the lowest oxygenation index timepoint in the severe patients."]}
{"id": 1002125, "claim": "Lymphocytopenia and neutrophilia deteriorate at the primary oxygenation index timepoint in covid-19 patient", "label": "REFUTED", "evidence": ["And the oxygenation index was associated with ratio of lymphocyte and neutrophil in COVID-19 patients.", "Conclusions Lymphocytopenia and neutrophilia, which deteriorate in the progression of severe patients, are the main pathogenesis of COVID-19.", "Oxygenation index presented potentiality as predictor on the progression of COVID-19.", "Lymphocytopenia and neutrophilia deteriorated at the lowest oxygenation index timepoint in the severe patients."]}
{"id": 1002126, "claim": "Lymphocytopenia and neutrophilia deteriorate at the pulmonary oxygenation index timepoint in covid-19 patient", "label": "REFUTED", "evidence": ["And the oxygenation index was associated with ratio of lymphocyte and neutrophil in COVID-19 patients.", "Conclusions Lymphocytopenia and neutrophilia, which deteriorate in the progression of severe patients, are the main pathogenesis of COVID-19.", "Oxygenation index presented potentiality as predictor on the progression of COVID-19.", "Lymphocytopenia and neutrophilia deteriorated at the lowest oxygenation index timepoint in the severe patients."]}
{"id": 1002127, "claim": "Cdc released patient who tested positive for covid-19 san antonio , tx.", "label": "SUPPORTED", "evidence": ["The CDC confirmed that a person being treated for COVID-19 was released from a federally mandated quarantine as a result of a positive COVID-19 test, according to a Sunday press release from the City of San Antonio.", "He said the patient previously contracted COVID-19, was quarantined and fully isolated for treatment.", "San Antonio Mayor Blasts CDC After Releasing Patient Who Eventually Tested Positive for COVID-19", "San Antonio Mayor Blasts CDC After Releasing Patient Who Eventually Tested Positive for COVID-19 By Sanya Mansoor March 2, 2020 6:27 PM EST San Antonio Mayor Ron Nirenberg harshly criticized federal health authorities on Monday after the U.S. Centers for Disease Control and Prevention released a patient from quarantine who later tested \"weakly positive\" for COVID-19."]}
{"id": 1002128, "claim": "Cdc released patient who tested negative for covid-19 san antonio, tx.", "label": "REFUTED", "evidence": ["The CDC confirmed that a person being treated for COVID-19 was released from a federally mandated quarantine as a result of a positive COVID-19 test, according to a Sunday press release from the City of San Antonio.", "He said the patient previously contracted COVID-19, was quarantined and fully isolated for treatment.", "San Antonio Mayor Blasts CDC After Releasing Patient Who Eventually Tested Positive for COVID-19", "San Antonio Mayor Blasts CDC After Releasing Patient Who Eventually Tested Positive for COVID-19 By Sanya Mansoor March 2, 2020 6:27 PM EST San Antonio Mayor Ron Nirenberg harshly criticized federal health authorities on Monday after the U.S. Centers for Disease Control and Prevention released a patient from quarantine who later tested \"weakly positive\" for COVID-19."]}
{"id": 1002129, "claim": "Rapid evaluation confirms lateral flow devices effective in detecting new covid-19 variant.", "label": "SUPPORTED", "evidence": ["LFDs are one of the new tools being used to help detect COVID-19 and results can be delivered rapidly in under 30 minutes.", "This is good news as it means they can continue to be used to find > people who have COVID-19 without symptoms who might be unknowingly passing > it on.", "Each device successfully detected samples containing the new variant.", "Dr Susan Hopkins, Senior Medical Advisor to PHE and NHS Test and Trace, said: > This rapid evaluation confirms that lateral flow devices can detect the new > variant."]}
{"id": 1002130, "claim": "Rapid evaluation confirms lateral flow devices effective in generating new covid-19 variant.", "label": "REFUTED", "evidence": ["LFDs are one of the new tools being used to help detect COVID-19 and results can be delivered rapidly in under 30 minutes.", "This is good news as it means they can continue to be used to find > people who have COVID-19 without symptoms who might be unknowingly passing > it on.", "Each device successfully detected samples containing the new variant.", "Dr Susan Hopkins, Senior Medical Advisor to PHE and NHS Test and Trace, said: > This rapid evaluation confirms that lateral flow devices can detect the new > variant."]}
{"id": 1002131, "claim": "Rapid evaluation confirms lateral flow devices effective in developing new covid-19 variant.", "label": "REFUTED", "evidence": ["LFDs are one of the new tools being used to help detect COVID-19 and results can be delivered rapidly in under 30 minutes.", "This is good news as it means they can continue to be used to find > people who have COVID-19 without symptoms who might be unknowingly passing > it on.", "Each device successfully detected samples containing the new variant.", "Dr Susan Hopkins, Senior Medical Advisor to PHE and NHS Test and Trace, said: > This rapid evaluation confirms that lateral flow devices can detect the new > variant."]}
{"id": 1002132, "claim": "Rapid evaluation confirms lateral flow devices effective in designing new covid-19 variant.", "label": "REFUTED", "evidence": ["LFDs are one of the new tools being used to help detect COVID-19 and results can be delivered rapidly in under 30 minutes.", "This is good news as it means they can continue to be used to find > people who have COVID-19 without symptoms who might be unknowingly passing > it on.", "Each device successfully detected samples containing the new variant.", "Dr Susan Hopkins, Senior Medical Advisor to PHE and NHS Test and Trace, said: > This rapid evaluation confirms that lateral flow devices can detect the new > variant."]}
{"id": 1002133, "claim": "Far-uvc light efficiently and safely inactivates airborne human coronaviruses", "label": "SUPPORTED", "evidence": ["By contrast, far-UVC light (207-222 nm) efficiently kills pathogens without harm to exposed human cells or tissues.", "Based on these results for the beta HCoV-OC43 coronavirus, continuous far-UVC exposure in public locations at the currently recommended exposure limit (3 mJ/cm2/hour) would result in 99.9% viral inactivation in ~ 25 minutes."]}
{"id": 1002134, "claim": "Far-uvc binds efficiently and safely inactivates airborne human coronaviruses", "label": "REFUTED", "evidence": ["By contrast, far-UVC light (207-222 nm) efficiently kills pathogens without harm to exposed human cells or tissues.", "Based on these results for the beta HCoV-OC43 coronavirus, continuous far-UVC exposure in public locations at the currently recommended exposure limit (3 mJ/cm2/hour) would result in 99.9% viral inactivation in ~ 25 minutes."]}
{"id": 1002135, "claim": "Low testosterone levels predict clinical adverse outcomes in sars-cov-2 pneumonia patients", "label": "SUPPORTED", "evidence": ["Discussion and conclusion: Our study demonstrates for the first time that lower baseline levels of TT and cFT levels predict poor prognosis and mortality in SARS-CoV-2-infected men admitted to RICU.", "Epidemiological data showing a differential impact of SARS-CoV-2 infection on women and men have suggested a potential role for testosterone (T) in determining gender disparity in the SARS-CoV-2 clinical outcomes."]}
{"id": 1002136, "claim": "Low testosterone levels predict clinical adverse outcomes in sars-cov-2 diabetes patients", "label": "REFUTED", "evidence": ["Discussion and conclusion: Our study demonstrates for the first time that lower baseline levels of TT and cFT levels predict poor prognosis and mortality in SARS-CoV-2-infected men admitted to RICU.", "Epidemiological data showing a differential impact of SARS-CoV-2 infection on women and men have suggested a potential role for testosterone (T) in determining gender disparity in the SARS-CoV-2 clinical outcomes."]}
{"id": 1002137, "claim": "Low testosterone levels predict clinical adverse outcomes in sars-cov-2 mice patients", "label": "REFUTED", "evidence": ["Discussion and conclusion: Our study demonstrates for the first time that lower baseline levels of TT and cFT levels predict poor prognosis and mortality in SARS-CoV-2-infected men admitted to RICU.", "Epidemiological data showing a differential impact of SARS-CoV-2 infection on women and men have suggested a potential role for testosterone (T) in determining gender disparity in the SARS-CoV-2 clinical outcomes."]}
{"id": 1002138, "claim": "High sars-cov-2 viral load is associated with a worse clinical outcome of covid-19 disease.", "label": "SUPPORTED", "evidence": ["In prior analyses of the SARS-CoV-1 outbreak, viral load within the nasopharynx was associated with worsened disease severity and increased mortality1,2.", "Background The initial dose of virus and the amount of virus an individual has at any one time might worsen the severity of COVID 19 disease.", "Amongst the participants hospitalized with COVID-19, we report that a higher prevalence of detectable SARS-CoV-2 plasma viral load is associated with worse respiratory disease severity, lower absolute lymphocyte counts, and increased markers of inflammation, including C-reactive protein and IL-6.", "SARS-CoV-2 viral loads, especially plasma viremia, are associated with increased risk of mortality."]}
{"id": 1002139, "claim": "High sars-cov-2 viral load is associated with a better clinical outcome of covid-19 disease.", "label": "REFUTED", "evidence": ["In prior analyses of the SARS-CoV-1 outbreak, viral load within the nasopharynx was associated with worsened disease severity and increased mortality1,2.", "Background The initial dose of virus and the amount of virus an individual has at any one time might worsen the severity of COVID 19 disease.", "Amongst the participants hospitalized with COVID-19, we report that a higher prevalence of detectable SARS-CoV-2 plasma viral load is associated with worse respiratory disease severity, lower absolute lymphocyte counts, and increased markers of inflammation, including C-reactive protein and IL-6.", "SARS-CoV-2 viral loads, especially plasma viremia, are associated with increased risk of mortality."]}
{"id": 1002140, "claim": "High sars-cov-2 viral load is associated with a greater clinical outcome of covid-19 disease.", "label": "REFUTED", "evidence": ["In prior analyses of the SARS-CoV-1 outbreak, viral load within the nasopharynx was associated with worsened disease severity and increased mortality1,2.", "Background The initial dose of virus and the amount of virus an individual has at any one time might worsen the severity of COVID 19 disease.", "Amongst the participants hospitalized with COVID-19, we report that a higher prevalence of detectable SARS-CoV-2 plasma viral load is associated with worse respiratory disease severity, lower absolute lymphocyte counts, and increased markers of inflammation, including C-reactive protein and IL-6.", "SARS-CoV-2 viral loads, especially plasma viremia, are associated with increased risk of mortality."]}
{"id": 1002141, "claim": "High sars-cov-2 viral load is associated with a higher clinical outcome of covid-19 disease.", "label": "REFUTED", "evidence": ["In prior analyses of the SARS-CoV-1 outbreak, viral load within the nasopharynx was associated with worsened disease severity and increased mortality1,2.", "Background The initial dose of virus and the amount of virus an individual has at any one time might worsen the severity of COVID 19 disease.", "Amongst the participants hospitalized with COVID-19, we report that a higher prevalence of detectable SARS-CoV-2 plasma viral load is associated with worse respiratory disease severity, lower absolute lymphocyte counts, and increased markers of inflammation, including C-reactive protein and IL-6.", "SARS-CoV-2 viral loads, especially plasma viremia, are associated with increased risk of mortality."]}
{"id": 1002142, "claim": "Atazanavir inhibits sars-cov-2 replication and pro-inflammatory cytokine production", "label": "SUPPORTED", "evidence": ["However, limited evidence exists for other clinically approved antiretroviral protease inhibitors, such as atazanavir (ATV)."]}
{"id": 1002143, "claim": "Atazanavir inhibits sars-cov-2 release and pro-inflammatory cytokine production", "label": "REFUTED", "evidence": ["However, limited evidence exists for other clinically approved antiretroviral protease inhibitors, such as atazanavir (ATV)."]}
{"id": 1002144, "claim": "Blacks/african americans are 5 times more likely to develop covid-19", "label": "SUPPORTED", "evidence": ["In a multivariable model including estimates for age, COPD, heart disease, housing density and Black/African American race, the only variables that remained associated with positive COVID-19 testing with a probability greater than chance were the proportion of Black/African American residents and proportion of older persons.", "There was a nearly five-fold increase in the risk of a positive COVID-19 test.", "During the early months of the pandemic, the report asserts that blacks were more likely to have preexisting conditions that predispose them to COVID-19 infection, less likely to have health insurance, and more likely to work in jobs that do not accommodate remote work."]}
{"id": 1002145, "claim": "Blacks/african americans are 5 times less likely to develop covid-19", "label": "REFUTED", "evidence": ["In a multivariable model including estimates for age, COPD, heart disease, housing density and Black/African American race, the only variables that remained associated with positive COVID-19 testing with a probability greater than chance were the proportion of Black/African American residents and proportion of older persons.", "There was a nearly five-fold increase in the risk of a positive COVID-19 test.", "During the early months of the pandemic, the report asserts that blacks were more likely to have preexisting conditions that predispose them to COVID-19 infection, less likely to have health insurance, and more likely to work in jobs that do not accommodate remote work."]}
{"id": 1002146, "claim": "Danish vaccine against coronavirus passes tests in mice", "label": "SUPPORTED", "evidence": ["The amount and quality of these vaccine- induced antibodies have been tested directly on SARS-CoV-2 virus in two independently laboratories headed by Professor Søren Riis Paludan at Aarhus University and Professor Marjolein Kikkert, Leiden University Medical Center, which are part of the consortium Prevent-nCov.", "The vaccine has been tested in mice and shows promising results.", "We have tested the vaccine in mice and achieved positive immune responses.", "The researchers, supported by the Carlsberg Foundation, among others, have now tested the vaccine on mice with promising results."]}
{"id": 1002147, "claim": "Danish vaccine against coronavirus passes not in mice", "label": "REFUTED", "evidence": ["The amount and quality of these vaccine- induced antibodies have been tested directly on SARS-CoV-2 virus in two independently laboratories headed by Professor Søren Riis Paludan at Aarhus University and Professor Marjolein Kikkert, Leiden University Medical Center, which are part of the consortium Prevent-nCov.", "The vaccine has been tested in mice and shows promising results.", "We have tested the vaccine in mice and achieved positive immune responses.", "The researchers, supported by the Carlsberg Foundation, among others, have now tested the vaccine on mice with promising results."]}
{"id": 1002148, "claim": "Greater social distancing could curb covid-19 in 13 weeks", "label": "SUPPORTED", "evidence": ["The research found that if 90 percent of the Australian population adopted social distancing, the spread of COVID-19 could be controlled by July 2020, whereas social distancing of less than 70 percent would not suppress the pandemic.", "However, if ninety percent of the population complies, then the duration could be as short as thirteen to fourteen weeks  meaning if we began tomorrow we could expect a control of COVID-19 by July, he said.", "On the contrary, laxer protocols could mean a longer, more drawn out and ineffective struggle against COVID-19, he said.", "If social distancing measures were adopted by at least 80 percent of the Australian population, we could expect to see a control of the spread of the COVID-19 pandemic in just over three months, new research by the University of Sydney has found."]}
{"id": 1002149, "claim": "Greater social distancing could increase covid-19 in 13 weeks", "label": "REFUTED", "evidence": ["The research found that if 90 percent of the Australian population adopted social distancing, the spread of COVID-19 could be controlled by July 2020, whereas social distancing of less than 70 percent would not suppress the pandemic.", "However, if ninety percent of the population complies, then the duration could be as short as thirteen to fourteen weeks  meaning if we began tomorrow we could expect a control of COVID-19 by July, he said.", "On the contrary, laxer protocols could mean a longer, more drawn out and ineffective struggle against COVID-19, he said.", "If social distancing measures were adopted by at least 80 percent of the Australian population, we could expect to see a control of the spread of the COVID-19 pandemic in just over three months, new research by the University of Sydney has found."]}
{"id": 1002150, "claim": "Greater social distancing could induce covid-19 in 13 weeks", "label": "REFUTED", "evidence": ["The research found that if 90 percent of the Australian population adopted social distancing, the spread of COVID-19 could be controlled by July 2020, whereas social distancing of less than 70 percent would not suppress the pandemic.", "However, if ninety percent of the population complies, then the duration could be as short as thirteen to fourteen weeks  meaning if we began tomorrow we could expect a control of COVID-19 by July, he said.", "On the contrary, laxer protocols could mean a longer, more drawn out and ineffective struggle against COVID-19, he said.", "If social distancing measures were adopted by at least 80 percent of the Australian population, we could expect to see a control of the spread of the COVID-19 pandemic in just over three months, new research by the University of Sydney has found."]}
{"id": 1002151, "claim": "Greater social distancing could cause covid-19 in 13 weeks", "label": "REFUTED", "evidence": ["The research found that if 90 percent of the Australian population adopted social distancing, the spread of COVID-19 could be controlled by July 2020, whereas social distancing of less than 70 percent would not suppress the pandemic.", "However, if ninety percent of the population complies, then the duration could be as short as thirteen to fourteen weeks  meaning if we began tomorrow we could expect a control of COVID-19 by July, he said.", "On the contrary, laxer protocols could mean a longer, more drawn out and ineffective struggle against COVID-19, he said.", "If social distancing measures were adopted by at least 80 percent of the Australian population, we could expect to see a control of the spread of the COVID-19 pandemic in just over three months, new research by the University of Sydney has found."]}
{"id": 1002152, "claim": "Health canada begins first authorization review of a covid-19 vaccine submission", "label": "SUPPORTED", "evidence": ["Health Canada will be doing a rolling review of AstraZeneca's vaccine data to make sure it meets the Department's rigorous safety and efficacy requirements.", "Earlier this month, the Prime Minister announced that Canada has signed an agreement with AstraZeneca to buy 20 million doses of its COVID-19 vaccine, should that vaccine successfully complete clinical trials and be authorized by Health Canada.", "Following the authorization of any vaccine submission, Health Canada will publish the evidence it reviewed in making its decision for transparency."]}
{"id": 1002153, "claim": "Health canada begins under authorization review of a covid-19 vaccine submission", "label": "REFUTED", "evidence": ["Health Canada will be doing a rolling review of AstraZeneca's vaccine data to make sure it meets the Department's rigorous safety and efficacy requirements.", "Earlier this month, the Prime Minister announced that Canada has signed an agreement with AstraZeneca to buy 20 million doses of its COVID-19 vaccine, should that vaccine successfully complete clinical trials and be authorized by Health Canada.", "Following the authorization of any vaccine submission, Health Canada will publish the evidence it reviewed in making its decision for transparency."]}
{"id": 1002154, "claim": "I canada begins first authorization review of a covid-19 vaccine submission", "label": "REFUTED", "evidence": ["Health Canada will be doing a rolling review of AstraZeneca's vaccine data to make sure it meets the Department's rigorous safety and efficacy requirements.", "Earlier this month, the Prime Minister announced that Canada has signed an agreement with AstraZeneca to buy 20 million doses of its COVID-19 vaccine, should that vaccine successfully complete clinical trials and be authorized by Health Canada.", "Following the authorization of any vaccine submission, Health Canada will publish the evidence it reviewed in making its decision for transparency."]}
{"id": 1002155, "claim": "Remdesivir induced viral rna and subgenomic rna suppression , and evolution of viral variants in sars-cov-2 infected patients.", "label": "SUPPORTED", "evidence": ["Sequential viral loads and deep sequencing of SARS-CoV-2 recovered from the upper respiratory tract of hospitalised children revealed that remdesivir treatment suppressed viral RNA levels in one patient but not in a second infected with an identical strain.", "Reduced levels of subgenomic (sg) RNA during treatment of the second patient, suggest an additional effect of remdesivir on viral replication that is independent of viral RNA levels."]}
{"id": 1002156, "claim": "Remdesivir induced viral rna and subgenomic rna suppression, and evolution of viral variants in sars-cov-2 infected plants.", "label": "REFUTED", "evidence": ["Sequential viral loads and deep sequencing of SARS-CoV-2 recovered from the upper respiratory tract of hospitalised children revealed that remdesivir treatment suppressed viral RNA levels in one patient but not in a second infected with an identical strain.", "Reduced levels of subgenomic (sg) RNA during treatment of the second patient, suggest an additional effect of remdesivir on viral replication that is independent of viral RNA levels."]}
{"id": 1002157, "claim": "Remdesivir induced viral rna and subgenomic rna suppression, and evolution of viral variants in sars-cov-2 infected animals.", "label": "REFUTED", "evidence": ["Sequential viral loads and deep sequencing of SARS-CoV-2 recovered from the upper respiratory tract of hospitalised children revealed that remdesivir treatment suppressed viral RNA levels in one patient but not in a second infected with an identical strain.", "Reduced levels of subgenomic (sg) RNA during treatment of the second patient, suggest an additional effect of remdesivir on viral replication that is independent of viral RNA levels."]}
{"id": 1002158, "claim": "Estimating the infection and case fatality ratio for coronavirus disease using age-adjusted data from the outbreak on the diamond princess cruise ship , february 2020", "label": "SUPPORTED", "evidence": ["2009;14(26):19255. https://doi.org/10.2807/ese.14.26.19255-en PMID: 19573509 Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020 <p class=\"citation\"> <span>Citation style for this article:</span> <span class=\"meta-value authors\"> <a href=\"/search?value1=Timothy+W+Russell&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Russell Timothy W</a>, <a href=\"/search?value1=Joel+Hellewell&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Hellewell Joel</a>, <a href=\"/search?value1=Christopher+I+Jarvis&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Jarvis Christopher I</a>, <a href=\"/search?value1=Kevin+van+Zandvoort&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">van Zandvoort Kevin</a>, <a href=\"/search?value1=Sam+Abbott&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Abbott Sam</a>, <a href=\"/search?value1=Ruwan+Ratnayake&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Ratnayake Ruwan</a>, <a href=\"/search?value1=CMMID+COVID-19+working+group&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">CMMID COVID-19 working group</a>, <a href=\"/search?value1=Stefan+Flasche&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Flasche Stefan</a>, <a href=\"/search?value1=Rosalind+M+Eggo&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Eggo Rosalind M</a>, <a href=\"/search?value1=W+John+Edmunds&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Edmunds W John</a>, <a href=\"/search?value1=Adam+J+Kucharski&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Kucharski Adam J</a></span>.", "Share Estimating the infection and case fatality ratio for COVID-19 using age- adjusted data from the outbreak on the Diamond Princess cruise ship Timothy W Russell, Joel Hellewell, Christopher I Jarvis, Kevin Van Zandvoort, Sam Abbott, Ruwan Ratnayake, CMMID COVID-19 working group, Stefan Flasche, Rosalind M Eggo, W John Edmunds, Adam J Kucharski medRxiv 2020.03.05.20031773; doi: https://doi.org/10.1101/2020.03.05.20031773 Share This Article: Copy Citation Tools Estimating the infection and case fatality ratio for COVID-19 using age- adjusted data from the outbreak on the Diamond Princess cruise ship Timothy W Russell, Joel Hellewell, Christopher I Jarvis, Kevin Van Zandvoort, Sam Abbott, Ruwan Ratnayake, CMMID COVID-19 working group, Stefan Flasche, Rosalind M Eggo, W John Edmunds, Adam J Kucharski medRxiv 2020.03.05.20031773; doi: https://doi.org/10.1101/2020.03.05.20031773 ", "Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020."]}
{"id": 1002159, "claim": "Estimating the infection and case fatality ratio for coronavirus disease using age-adjusted data from the outbreak on the diamond princess cruise ship, january 2020", "label": "REFUTED", "evidence": ["2009;14(26):19255. https://doi.org/10.2807/ese.14.26.19255-en PMID: 19573509 Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020 <p class=\"citation\"> <span>Citation style for this article:</span> <span class=\"meta-value authors\"> <a href=\"/search?value1=Timothy+W+Russell&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Russell Timothy W</a>, <a href=\"/search?value1=Joel+Hellewell&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Hellewell Joel</a>, <a href=\"/search?value1=Christopher+I+Jarvis&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Jarvis Christopher I</a>, <a href=\"/search?value1=Kevin+van+Zandvoort&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">van Zandvoort Kevin</a>, <a href=\"/search?value1=Sam+Abbott&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Abbott Sam</a>, <a href=\"/search?value1=Ruwan+Ratnayake&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Ratnayake Ruwan</a>, <a href=\"/search?value1=CMMID+COVID-19+working+group&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">CMMID COVID-19 working group</a>, <a href=\"/search?value1=Stefan+Flasche&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Flasche Stefan</a>, <a href=\"/search?value1=Rosalind+M+Eggo&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Eggo Rosalind M</a>, <a href=\"/search?value1=W+John+Edmunds&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Edmunds W John</a>, <a href=\"/search?value1=Adam+J+Kucharski&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Kucharski Adam J</a></span>.", "Share Estimating the infection and case fatality ratio for COVID-19 using age- adjusted data from the outbreak on the Diamond Princess cruise ship Timothy W Russell, Joel Hellewell, Christopher I Jarvis, Kevin Van Zandvoort, Sam Abbott, Ruwan Ratnayake, CMMID COVID-19 working group, Stefan Flasche, Rosalind M Eggo, W John Edmunds, Adam J Kucharski medRxiv 2020.03.05.20031773; doi: https://doi.org/10.1101/2020.03.05.20031773 Share This Article: Copy Citation Tools Estimating the infection and case fatality ratio for COVID-19 using age- adjusted data from the outbreak on the Diamond Princess cruise ship Timothy W Russell, Joel Hellewell, Christopher I Jarvis, Kevin Van Zandvoort, Sam Abbott, Ruwan Ratnayake, CMMID COVID-19 working group, Stefan Flasche, Rosalind M Eggo, W John Edmunds, Adam J Kucharski medRxiv 2020.03.05.20031773; doi: https://doi.org/10.1101/2020.03.05.20031773 ", "Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020."]}
{"id": 1002160, "claim": "Estimating the infection and case fatality ratio for coronavirus disease using age-adjusted data from the outbreak on the diamond princess cruise ship, march 2020", "label": "REFUTED", "evidence": ["2009;14(26):19255. https://doi.org/10.2807/ese.14.26.19255-en PMID: 19573509 Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020 <p class=\"citation\"> <span>Citation style for this article:</span> <span class=\"meta-value authors\"> <a href=\"/search?value1=Timothy+W+Russell&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Russell Timothy W</a>, <a href=\"/search?value1=Joel+Hellewell&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Hellewell Joel</a>, <a href=\"/search?value1=Christopher+I+Jarvis&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Jarvis Christopher I</a>, <a href=\"/search?value1=Kevin+van+Zandvoort&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">van Zandvoort Kevin</a>, <a href=\"/search?value1=Sam+Abbott&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Abbott Sam</a>, <a href=\"/search?value1=Ruwan+Ratnayake&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Ratnayake Ruwan</a>, <a href=\"/search?value1=CMMID+COVID-19+working+group&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">CMMID COVID-19 working group</a>, <a href=\"/search?value1=Stefan+Flasche&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Flasche Stefan</a>, <a href=\"/search?value1=Rosalind+M+Eggo&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Eggo Rosalind M</a>, <a href=\"/search?value1=W+John+Edmunds&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Edmunds W John</a>, <a href=\"/search?value1=Adam+J+Kucharski&option1=author&noRedirect=true\" class=\"nonDisambigAuthorLink\">Kucharski Adam J</a></span>.", "Share Estimating the infection and case fatality ratio for COVID-19 using age- adjusted data from the outbreak on the Diamond Princess cruise ship Timothy W Russell, Joel Hellewell, Christopher I Jarvis, Kevin Van Zandvoort, Sam Abbott, Ruwan Ratnayake, CMMID COVID-19 working group, Stefan Flasche, Rosalind M Eggo, W John Edmunds, Adam J Kucharski medRxiv 2020.03.05.20031773; doi: https://doi.org/10.1101/2020.03.05.20031773 Share This Article: Copy Citation Tools Estimating the infection and case fatality ratio for COVID-19 using age- adjusted data from the outbreak on the Diamond Princess cruise ship Timothy W Russell, Joel Hellewell, Christopher I Jarvis, Kevin Van Zandvoort, Sam Abbott, Ruwan Ratnayake, CMMID COVID-19 working group, Stefan Flasche, Rosalind M Eggo, W John Edmunds, Adam J Kucharski medRxiv 2020.03.05.20031773; doi: https://doi.org/10.1101/2020.03.05.20031773 ", "Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020."]}
{"id": 1002161, "claim": "Reduced susceptibility to sars-cov-2 in metropolitan regions", "label": "SUPPORTED", "evidence": ["For instance, the REACT survey1 suggests that overall about 5-6% of adults in England have been infected with SARS-CoV-2, but rates of infection in London is about twice this (10-11%).", "During the post-growth phase, the lower susceptibility of these regions contributed to the decline in cases, independent of intervention effects."]}
{"id": 1002162, "claim": "Increased susceptibility to sars-cov-2 in metropolitan regions", "label": "REFUTED", "evidence": ["For instance, the REACT survey1 suggests that overall about 5-6% of adults in England have been infected with SARS-CoV-2, but rates of infection in London is about twice this (10-11%).", "During the post-growth phase, the lower susceptibility of these regions contributed to the decline in cases, independent of intervention effects."]}
{"id": 1002163, "claim": "Higher susceptibility to sars-cov-2 in metropolitan regions", "label": "REFUTED", "evidence": ["For instance, the REACT survey1 suggests that overall about 5-6% of adults in England have been infected with SARS-CoV-2, but rates of infection in London is about twice this (10-11%).", "During the post-growth phase, the lower susceptibility of these regions contributed to the decline in cases, independent of intervention effects."]}
{"id": 1002164, "claim": "High susceptibility to sars-cov-2 in metropolitan regions", "label": "REFUTED", "evidence": ["For instance, the REACT survey1 suggests that overall about 5-6% of adults in England have been infected with SARS-CoV-2, but rates of infection in London is about twice this (10-11%).", "During the post-growth phase, the lower susceptibility of these regions contributed to the decline in cases, independent of intervention effects."]}
{"id": 1002165, "claim": "Sars-cov-2 viral load is associated with increased disease severity and mortality", "label": "SUPPORTED", "evidence": ["2: SARS-CoV-2 viral load is associated with markers of inflammation and disease severity.", "Here we show that SARS-CoV-2 viral loads, especially in the plasma, are predictive of mortality.", "SARS-CoV-2 viral loads, especially within plasma, are associated with systemic inflammation, disease progression, and increased risk of death.", "SARS-CoV-2 viral loads, especially plasma viremia, are associated with increased risk of mortality."]}
{"id": 1002166, "claim": "Sars-cov-2 viral load is associated without increased disease severity and mortality", "label": "REFUTED", "evidence": ["2: SARS-CoV-2 viral load is associated with markers of inflammation and disease severity.", "Here we show that SARS-CoV-2 viral loads, especially in the plasma, are predictive of mortality.", "SARS-CoV-2 viral loads, especially within plasma, are associated with systemic inflammation, disease progression, and increased risk of death.", "SARS-CoV-2 viral loads, especially plasma viremia, are associated with increased risk of mortality."]}
{"id": 1002167, "claim": "Taiwan team develops antigen for wuhan coronavirus within 10 days", "label": "SUPPORTED", "evidence": ["(Academia Sinica photo) TAIPEI (Taiwan News) -- As scientists rush to develop treatment and vaccines for the Wuhan coronavirus, a team of Taiwanese scientists has developed the country's first self-produced antigen for the virus in 10 days.", "A research team at Academia Sinica completed gene synthesis and entered the stage of antigen production within 10 days, a process that usually takes six weeks, reported Liberty Times."]}
{"id": 1002168, "claim": "Taiwan team received antigen for wuhan coronavirus within 10 days", "label": "REFUTED", "evidence": ["(Academia Sinica photo) TAIPEI (Taiwan News) -- As scientists rush to develop treatment and vaccines for the Wuhan coronavirus, a team of Taiwanese scientists has developed the country's first self-produced antigen for the virus in 10 days.", "A research team at Academia Sinica completed gene synthesis and entered the stage of antigen production within 10 days, a process that usually takes six weeks, reported Liberty Times."]}
{"id": 1002169, "claim": "Taiwan team develops antigen for wuhan coronavirus within 10 min", "label": "REFUTED", "evidence": ["(Academia Sinica photo) TAIPEI (Taiwan News) -- As scientists rush to develop treatment and vaccines for the Wuhan coronavirus, a team of Taiwanese scientists has developed the country's first self-produced antigen for the virus in 10 days.", "A research team at Academia Sinica completed gene synthesis and entered the stage of antigen production within 10 days, a process that usually takes six weeks, reported Liberty Times."]}
{"id": 1002170, "claim": "Italian doctors find link between covid-19 and inflammatory disorder", "label": "SUPPORTED", "evidence": ["Photograph: Anadolu Agency/Getty Doctors in Italy have reported the first clear evidence of a link between Covid-19 and a rare but serious inflammatory disorder that has required some children to undergo life-saving treatment in intensive care units."]}
{"id": 1002171, "claim": "Italian doctors find differences between covid-19 and inflammatory disorder", "label": "REFUTED", "evidence": ["Photograph: Anadolu Agency/Getty Doctors in Italy have reported the first clear evidence of a link between Covid-19 and a rare but serious inflammatory disorder that has required some children to undergo life-saving treatment in intensive care units."]}
{"id": 1002172, "claim": "Immunoglobulin fragment f2 against rbd potently neutralizes sars-cov-2 in vitro", "label": "SUPPORTED", "evidence": ["Techniques Used: Neutralization, Binding Assay, Infection, Immunofluorescence Figure Legend Snippet: Neutralization of SARS-CoV-2 by RBD-specific immunoglobulins and F(ab) 2 fragments and their binding to the RBD.", "Immunoglobulin fragment F(ab)2 against RBD potently neutralizes SARS-CoV-2 in vitro.", "Article Title: Immunoglobulin fragment F(ab)2 against RBD potently neutralizes SARS-CoV-2 in vitro Article Snippet: .."]}
{"id": 1002173, "claim": "Immunoglobulin fragment f2 against rbd potently neutralizes ms-cov-2 in vitro", "label": "REFUTED", "evidence": ["Techniques Used: Neutralization, Binding Assay, Infection, Immunofluorescence Figure Legend Snippet: Neutralization of SARS-CoV-2 by RBD-specific immunoglobulins and F(ab) 2 fragments and their binding to the RBD.", "Immunoglobulin fragment F(ab)2 against RBD potently neutralizes SARS-CoV-2 in vitro.", "Article Title: Immunoglobulin fragment F(ab)2 against RBD potently neutralizes SARS-CoV-2 in vitro Article Snippet: .."]}
{"id": 1002174, "claim": "Immunoglobulin fragment f2 against rbd potently neutralizes ps-cov-2 in vitro", "label": "REFUTED", "evidence": ["Techniques Used: Neutralization, Binding Assay, Infection, Immunofluorescence Figure Legend Snippet: Neutralization of SARS-CoV-2 by RBD-specific immunoglobulins and F(ab) 2 fragments and their binding to the RBD.", "Immunoglobulin fragment F(ab)2 against RBD potently neutralizes SARS-CoV-2 in vitro.", "Article Title: Immunoglobulin fragment F(ab)2 against RBD potently neutralizes SARS-CoV-2 in vitro Article Snippet: .."]}
{"id": 1002175, "claim": "Immunoglobulin fragment f2 against rbd potently neutralizes fs-cov-2 in vitro", "label": "REFUTED", "evidence": ["Techniques Used: Neutralization, Binding Assay, Infection, Immunofluorescence Figure Legend Snippet: Neutralization of SARS-CoV-2 by RBD-specific immunoglobulins and F(ab) 2 fragments and their binding to the RBD.", "Immunoglobulin fragment F(ab)2 against RBD potently neutralizes SARS-CoV-2 in vitro.", "Article Title: Immunoglobulin fragment F(ab)2 against RBD potently neutralizes SARS-CoV-2 in vitro Article Snippet: .."]}
{"id": 1002176, "claim": "Rutgers researchers have developed and submitted an emergency use authorization request for a saliva collection method for broader population covid-19 screening .", "label": "SUPPORTED", "evidence": ["RUCDR submitted an emergency use authorization request for a new collection method using saliva, according to the release.", "Source/Rutgers University This devices detects the genetic material of the coronavirus in saliva, rapidly determining if a person has COVID-19.", "Rutgers University Cell and DNA Repository (RUCDR) Infinite Biologics launched a test for the coronavirus disease (COVID-19) and aims to test tens of thousands of samples daily using its infrastructure, according to a press release.", "Photo: Rutgers University Download High-Res The Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Rutgers RUCDR Infinite Biologics and its collaborators for a new collection approach that utilizes saliva as the primary test biomaterial for the SARS-CoV-2 coronavirus, the first such approval granted by the federal agency.", "A new, rapid saliva test for COVID-19 created by Rutgers University researchers could soon screen thousands of people a day for the coronavirus, reducing risks to health care workers and greatly scaling up the New Jersey's response to the coronavirus pandemic."]}
{"id": 1002177, "claim": "Rutgers could have developed and submitted an emergency use authorization request for a saliva collection method for broader population covid-19 screening.", "label": "REFUTED", "evidence": ["RUCDR submitted an emergency use authorization request for a new collection method using saliva, according to the release.", "Source/Rutgers University This devices detects the genetic material of the coronavirus in saliva, rapidly determining if a person has COVID-19.", "Rutgers University Cell and DNA Repository (RUCDR) Infinite Biologics launched a test for the coronavirus disease (COVID-19) and aims to test tens of thousands of samples daily using its infrastructure, according to a press release.", "Photo: Rutgers University Download High-Res The Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Rutgers RUCDR Infinite Biologics and its collaborators for a new collection approach that utilizes saliva as the primary test biomaterial for the SARS-CoV-2 coronavirus, the first such approval granted by the federal agency.", "A new, rapid saliva test for COVID-19 created by Rutgers University researchers could soon screen thousands of people a day for the coronavirus, reducing risks to health care workers and greatly scaling up the New Jersey's response to the coronavirus pandemic."]}
{"id": 1002178, "claim": "Rutgers should have developed and submitted an emergency use authorization request for a saliva collection method for broader population covid-19 screening.", "label": "REFUTED", "evidence": ["RUCDR submitted an emergency use authorization request for a new collection method using saliva, according to the release.", "Source/Rutgers University This devices detects the genetic material of the coronavirus in saliva, rapidly determining if a person has COVID-19.", "Rutgers University Cell and DNA Repository (RUCDR) Infinite Biologics launched a test for the coronavirus disease (COVID-19) and aims to test tens of thousands of samples daily using its infrastructure, according to a press release.", "Photo: Rutgers University Download High-Res The Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Rutgers RUCDR Infinite Biologics and its collaborators for a new collection approach that utilizes saliva as the primary test biomaterial for the SARS-CoV-2 coronavirus, the first such approval granted by the federal agency.", "A new, rapid saliva test for COVID-19 created by Rutgers University researchers could soon screen thousands of people a day for the coronavirus, reducing risks to health care workers and greatly scaling up the New Jersey's response to the coronavirus pandemic."]}
{"id": 1002179, "claim": "Genome sequencing of the first sars-cov-2 reported from patients with covid-19 in ecuador .", "label": "SUPPORTED", "evidence": ["IMPORTANCE COVID-19, an infectious disease caused by SARS-CoV-2, has spread globally including Latin American countries including Ecuador."]}
{"id": 1002180, "claim": "Genome sequencing of the two sars-cov-2 reported from patients with covid-19 in ecuador.", "label": "REFUTED", "evidence": ["IMPORTANCE COVID-19, an infectious disease caused by SARS-CoV-2, has spread globally including Latin American countries including Ecuador."]}
{"id": 1002181, "claim": "Genome sequencing of the four sars-cov-2 reported from patients with covid-19 in ecuador.", "label": "REFUTED", "evidence": ["IMPORTANCE COVID-19, an infectious disease caused by SARS-CoV-2, has spread globally including Latin American countries including Ecuador."]}
{"id": 1002182, "claim": "Genome sequencing of the novel sars-cov-2 reported from patients with covid-19 in ecuador.", "label": "REFUTED", "evidence": ["IMPORTANCE COVID-19, an infectious disease caused by SARS-CoV-2, has spread globally including Latin American countries including Ecuador."]}
{"id": 1002183, "claim": "Oxford covid-19 vaccine begins human trial stage", "label": "SUPPORTED", "evidence": ["The main focus of the study is to find out if this vaccine is going to work against COVID-19, if it wont cause unacceptable side effects and if it induces good immune responses.", "\">Video of Human trial of new COVID-19 vaccine begins The Oxford Vaccine Centre COVID-19 Phase I Clinical Trial Explained The study is to test a new vaccine against COVID-19 in healthy volunteers.", "To ensure you have the latest information or to find out more about the trial, please visit theOxford COVID-19 vaccine web hub or visit the COVID-19 trial website ."]}
{"id": 1002184, "claim": "Oxford covid-19 vaccine against human trial stage", "label": "REFUTED", "evidence": ["The main focus of the study is to find out if this vaccine is going to work against COVID-19, if it wont cause unacceptable side effects and if it induces good immune responses.", "\">Video of Human trial of new COVID-19 vaccine begins The Oxford Vaccine Centre COVID-19 Phase I Clinical Trial Explained The study is to test a new vaccine against COVID-19 in healthy volunteers.", "To ensure you have the latest information or to find out more about the trial, please visit theOxford COVID-19 vaccine web hub or visit the COVID-19 trial website ."]}
{"id": 1002185, "claim": "Metformin treatment was associated with decreased mortality in covid-19 patients with diabetes in a retrospective analysis", "label": "SUPPORTED", "evidence": ["Antidiabetic treatment with metformin was associated with decreased mortality compared with diabetics not receiving metformin.", "This retrospective analysis suggests that metformin may offer benefits in patients with COVID-19 and that further study is indicated."]}
{"id": 1002186, "claim": "Metformin treatment was associated with elevated mortality in covid-19 patients with diabetes in a retrospective analysis", "label": "REFUTED", "evidence": ["Antidiabetic treatment with metformin was associated with decreased mortality compared with diabetics not receiving metformin.", "This retrospective analysis suggests that metformin may offer benefits in patients with COVID-19 and that further study is indicated."]}
{"id": 1002187, "claim": "Metformin treatment was associated with increased mortality in covid-19 patients with diabetes in a retrospective analysis", "label": "REFUTED", "evidence": ["Antidiabetic treatment with metformin was associated with decreased mortality compared with diabetics not receiving metformin.", "This retrospective analysis suggests that metformin may offer benefits in patients with COVID-19 and that further study is indicated."]}
{"id": 1002188, "claim": "Chadox1 ncov-19 vaccination prevents sars-cov-2 pneumonia in rhesus macaques", "label": "SUPPORTED", "evidence": ["We observed a significantly reduced viral load in bronchoalveolar lavage fluid and respiratory tract tissue of vaccinated animals challenged with SARS-CoV-2 compared with control animals, and no pneumonia was observed in vaccinated rhesus macaques.", "A single vaccination with ChAdOx1 nCoV-19 induced a humoral and cellular immune response in rhesus macaques."]}
{"id": 1002189, "claim": "Chadox1 ncov-19 vaccination induces sars-cov-2 pneumonia in rhesus macaques", "label": "REFUTED", "evidence": ["We observed a significantly reduced viral load in bronchoalveolar lavage fluid and respiratory tract tissue of vaccinated animals challenged with SARS-CoV-2 compared with control animals, and no pneumonia was observed in vaccinated rhesus macaques.", "A single vaccination with ChAdOx1 nCoV-19 induced a humoral and cellular immune response in rhesus macaques."]}
{"id": 1002190, "claim": "Chadox1 ncov-19 vaccination induced sars-cov-2 pneumonia in rhesus macaques", "label": "REFUTED", "evidence": ["We observed a significantly reduced viral load in bronchoalveolar lavage fluid and respiratory tract tissue of vaccinated animals challenged with SARS-CoV-2 compared with control animals, and no pneumonia was observed in vaccinated rhesus macaques.", "A single vaccination with ChAdOx1 nCoV-19 induced a humoral and cellular immune response in rhesus macaques."]}
{"id": 1002191, "claim": "Chadox1 ncov-19 vaccination caused sars-cov-2 pneumonia in rhesus macaques", "label": "REFUTED", "evidence": ["We observed a significantly reduced viral load in bronchoalveolar lavage fluid and respiratory tract tissue of vaccinated animals challenged with SARS-CoV-2 compared with control animals, and no pneumonia was observed in vaccinated rhesus macaques.", "A single vaccination with ChAdOx1 nCoV-19 induced a humoral and cellular immune response in rhesus macaques."]}
{"id": 1002192, "claim": "Covid-19 induces a hyperactive phenotype in circulating platelets", "label": "SUPPORTED", "evidence": ["Circulating levels of PF4, sP-selectin levels and TPO are significantly elevated in COVID-19.", "Moreover, we have determined that COVID-19 patients possess hyperactive circulating platelets.", "Strikingly, agonist-induced ADP release was dramatically higher in COVID-19 patients compared with non-COVID-19 hospitalized patients and circulating levels of PF4, sP-selectin and TPO were also significantly elevated in COVID-19."]}
{"id": 1002193, "claim": "Covid-19 induces a hyperactive phenotype in circulating cellslets", "label": "REFUTED", "evidence": ["Circulating levels of PF4, sP-selectin levels and TPO are significantly elevated in COVID-19.", "Moreover, we have determined that COVID-19 patients possess hyperactive circulating platelets.", "Strikingly, agonist-induced ADP release was dramatically higher in COVID-19 patients compared with non-COVID-19 hospitalized patients and circulating levels of PF4, sP-selectin and TPO were also significantly elevated in COVID-19."]}
{"id": 1002194, "claim": "Early peek at data on remdesivir suggests patients are responding to treatment", "label": "SUPPORTED", "evidence": ["All the patients have been treated with daily infusions of remdesivir.", "Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment A vial of the remdesivir, an investigational drug from Gilead.", "Provided Gilead has not restricted access to their drug for these trials and they have managed to recruit and follow up sufficient patients, we have the hope of finding whether remdesivir does have genuine efficacy and safety based on good evidence."]}
{"id": 1002195, "claim": "Early peek at data on remdesivir suggests patients are resistant to treatment", "label": "REFUTED", "evidence": ["All the patients have been treated with daily infusions of remdesivir.", "Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment A vial of the remdesivir, an investigational drug from Gilead.", "Provided Gilead has not restricted access to their drug for these trials and they have managed to recruit and follow up sufficient patients, we have the hope of finding whether remdesivir does have genuine efficacy and safety based on good evidence."]}
{"id": 1002196, "claim": "Early peek at data on remdesivir suggests patients are unable to treatment", "label": "REFUTED", "evidence": ["All the patients have been treated with daily infusions of remdesivir.", "Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment A vial of the remdesivir, an investigational drug from Gilead.", "Provided Gilead has not restricted access to their drug for these trials and they have managed to recruit and follow up sufficient patients, we have the hope of finding whether remdesivir does have genuine efficacy and safety based on good evidence."]}
{"id": 1002197, "claim": "Early peek at data on remdesivir suggests patients are difficult to treatment", "label": "REFUTED", "evidence": ["All the patients have been treated with daily infusions of remdesivir.", "Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment A vial of the remdesivir, an investigational drug from Gilead.", "Provided Gilead has not restricted access to their drug for these trials and they have managed to recruit and follow up sufficient patients, we have the hope of finding whether remdesivir does have genuine efficacy and safety based on good evidence."]}
{"id": 1002198, "claim": "Sars-cov-2 evades immune detection in alveolar macrophages", "label": "SUPPORTED", "evidence": ["Alveolar macrophages do not produce an IFN response upon SARSCoV2 challenge 1.", "SARSCoV2 challenge does not affect the IFN response in alveolar macrophages 1."]}
{"id": 1002199, "claim": "Sars-cov-2 cans immune detection in alveolar macrophages", "label": "REFUTED", "evidence": ["Alveolar macrophages do not produce an IFN response upon SARSCoV2 challenge 1.", "SARSCoV2 challenge does not affect the IFN response in alveolar macrophages 1."]}
{"id": 1002200, "claim": "Sars-cov-2 +/s immune detection in alveolar macrophages", "label": "REFUTED", "evidence": ["Alveolar macrophages do not produce an IFN response upon SARSCoV2 challenge 1.", "SARSCoV2 challenge does not affect the IFN response in alveolar macrophages 1."]}
{"id": 1002201, "claim": "Sars-cov-2 (s immune detection in alveolar macrophages", "label": "REFUTED", "evidence": ["Alveolar macrophages do not produce an IFN response upon SARSCoV2 challenge 1.", "SARSCoV2 challenge does not affect the IFN response in alveolar macrophages 1."]}
{"id": 1002202, "claim": "Danish researchers ' inhalation treatment of covid-19 passes tests in animals.", "label": "SUPPORTED", "evidence": ["Today, Danish researchers from the University of Copenhagen and Rigshospitalet can together with the Norwegian company SoftOx Solutions announce that their inhalation treatment for COVID-19 is safe to use in animals.", "Belfast Telegraph: Animal studies could help test for Covid-19 airborne transmission Science: Can boosting interferons, the bodys frontline virus fighters, beat COVID-19?"]}
{"id": 1002203, "claim": "Danish researchers'inhalation treatment of covid-19 passes tests in patients.", "label": "REFUTED", "evidence": ["Today, Danish researchers from the University of Copenhagen and Rigshospitalet can together with the Norwegian company SoftOx Solutions announce that their inhalation treatment for COVID-19 is safe to use in animals.", "Belfast Telegraph: Animal studies could help test for Covid-19 airborne transmission Science: Can boosting interferons, the bodys frontline virus fighters, beat COVID-19?"]}
{"id": 1002204, "claim": "Danish researchers'inhalation treatment of covid-19 passes poorly in animals.", "label": "REFUTED", "evidence": ["Today, Danish researchers from the University of Copenhagen and Rigshospitalet can together with the Norwegian company SoftOx Solutions announce that their inhalation treatment for COVID-19 is safe to use in animals.", "Belfast Telegraph: Animal studies could help test for Covid-19 airborne transmission Science: Can boosting interferons, the bodys frontline virus fighters, beat COVID-19?"]}
{"id": 1002205, "claim": "Danish researchers'inhalation treatment of covid-19 passes tests in children.", "label": "REFUTED", "evidence": ["Today, Danish researchers from the University of Copenhagen and Rigshospitalet can together with the Norwegian company SoftOx Solutions announce that their inhalation treatment for COVID-19 is safe to use in animals.", "Belfast Telegraph: Animal studies could help test for Covid-19 airborne transmission Science: Can boosting interferons, the bodys frontline virus fighters, beat COVID-19?"]}
{"id": 1002206, "claim": "Endemic human coronaviruses induce distinct antibody repertoires in adults and children", "label": "SUPPORTED", "evidence": ["Our findings shed light on the humoral immune responses to natural infection with endemic HCoVs and may have important implications for understanding of the highly variable clinical outcomes of human coronavirus infections, for the development of prophylactic or therapeutic monoclonal antibodies and vaccine design.", "Here we report a comprehensive retrospective analysis of CoV-specific antibody specificities in a large number of samples from children and adults using Phage-Immunoprecipitation Sequencing (PhIP-Seq)."]}
{"id": 1002207, "claim": "Endemic bat coronaviruses induce distinct antibody repertoires in adults and children", "label": "REFUTED", "evidence": ["Our findings shed light on the humoral immune responses to natural infection with endemic HCoVs and may have important implications for understanding of the highly variable clinical outcomes of human coronavirus infections, for the development of prophylactic or therapeutic monoclonal antibodies and vaccine design.", "Here we report a comprehensive retrospective analysis of CoV-specific antibody specificities in a large number of samples from children and adults using Phage-Immunoprecipitation Sequencing (PhIP-Seq)."]}
{"id": 1002208, "claim": "Endemic avian coronaviruses induce distinct antibody repertoires in adults and children", "label": "REFUTED", "evidence": ["Our findings shed light on the humoral immune responses to natural infection with endemic HCoVs and may have important implications for understanding of the highly variable clinical outcomes of human coronavirus infections, for the development of prophylactic or therapeutic monoclonal antibodies and vaccine design.", "Here we report a comprehensive retrospective analysis of CoV-specific antibody specificities in a large number of samples from children and adults using Phage-Immunoprecipitation Sequencing (PhIP-Seq)."]}
{"id": 1002209, "claim": "Tissue-resident cd8+ t cells drive age-associated chronic lung sequelae after viral pneumonia", "label": "SUPPORTED", "evidence": ["These results provide insight into how age and prior infection may affect T cellmediated immunity to respiratory viruses such as influenza and SARS-CoV-2 and how these factors contribute to chronic lung pathology after viral pneumonia in older individuals.", "Here, we report that influenza viral pneumonia leads to chronic nonresolving lung pathology and exacerbated accumulation of CD8+ tissue-resident memory T cells (TRM) in the respiratory tract of aged hosts."]}
{"id": 1002210, "claim": "Tissue-resident cd8+ t cells drive age-associated acute lung sequelae after viral pneumonia", "label": "REFUTED", "evidence": ["These results provide insight into how age and prior infection may affect T cellmediated immunity to respiratory viruses such as influenza and SARS-CoV-2 and how these factors contribute to chronic lung pathology after viral pneumonia in older individuals.", "Here, we report that influenza viral pneumonia leads to chronic nonresolving lung pathology and exacerbated accumulation of CD8+ tissue-resident memory T cells (TRM) in the respiratory tract of aged hosts."]}
{"id": 1002211, "claim": "Prospective mapping of viral mutations that escape antibodies used to treat covid-19", "label": "SUPPORTED", "evidence": ["Here we map how all mutations to SARS-CoV-2s receptor-binding domain (RBD) affect binding by the antibodies in Regenerons REGN-COV2 cocktail and Eli Lillys LY-CoV016.", "Finally, the maps reveal that mutations escaping each individual antibody are already present in circulating SARS-CoV-2 strains."]}
{"id": 1002212, "claim": "Sequence mapping of viral mutations that escape antibodies used to treat covid-19", "label": "REFUTED", "evidence": ["Here we map how all mutations to SARS-CoV-2s receptor-binding domain (RBD) affect binding by the antibodies in Regenerons REGN-COV2 cocktail and Eli Lillys LY-CoV016.", "Finally, the maps reveal that mutations escaping each individual antibody are already present in circulating SARS-CoV-2 strains."]}
{"id": 1002213, "claim": "Frankencovid conquers the right", "label": "SUPPORTED", "evidence": ["Which points to another possible reason FrankenCovid is so popular: Conservatives can avoid being called racist.", "But thanks to FrankenCovid mania, rightists, rather than standing up to the lefts racial demagoguery, are allying with the left to absolve the wet markets.", "FrankenCovid is all the rage on the right, which is unfortunate."]}
{"id": 1002214, "claim": "Frankencovid conquers the manuscript", "label": "REFUTED", "evidence": ["Which points to another possible reason FrankenCovid is so popular: Conservatives can avoid being called racist.", "But thanks to FrankenCovid mania, rightists, rather than standing up to the lefts racial demagoguery, are allying with the left to absolve the wet markets.", "FrankenCovid is all the rage on the right, which is unfortunate."]}
{"id": 1002215, "claim": "Frankencovid conquers the first", "label": "REFUTED", "evidence": ["Which points to another possible reason FrankenCovid is so popular: Conservatives can avoid being called racist.", "But thanks to FrankenCovid mania, rightists, rather than standing up to the lefts racial demagoguery, are allying with the left to absolve the wet markets.", "FrankenCovid is all the rage on the right, which is unfortunate."]}
{"id": 1002216, "claim": "Frankencovid 1990s the right", "label": "REFUTED", "evidence": ["Which points to another possible reason FrankenCovid is so popular: Conservatives can avoid being called racist.", "But thanks to FrankenCovid mania, rightists, rather than standing up to the lefts racial demagoguery, are allying with the left to absolve the wet markets.", "FrankenCovid is all the rage on the right, which is unfortunate."]}
{"id": 1002217, "claim": "Structure-guided multivalent nanobodies block sars-cov-2 infection and suppress mutational escape.", "label": "SUPPORTED", "evidence": ["We further validated virus neutralization microscopically by quantifying the replication of an mNeonGreen expressing clone of SARS-CoV-2 on human Caco2 cells in the presence of nanobodies over time (fig.", "Affinity maturation and structure-guided design of multivalency yielded a trivalent nanobody, mNb6-tri, with femtomolar affinity for SARS-CoV-2 Spike and picomolar neutralization of SARS-CoV-2 infection.", "The structure-based multivalent nanobodies we present have strong potential clinical applications owing to increased neutralizing activity and in-built protection from rapid emergence of escape mutants."]}
{"id": 1002218, "claim": "Structure-guided multivalent nanobodies promote sars-cov-2 infection and suppress mutational escape.", "label": "REFUTED", "evidence": ["We further validated virus neutralization microscopically by quantifying the replication of an mNeonGreen expressing clone of SARS-CoV-2 on human Caco2 cells in the presence of nanobodies over time (fig.", "Affinity maturation and structure-guided design of multivalency yielded a trivalent nanobody, mNb6-tri, with femtomolar affinity for SARS-CoV-2 Spike and picomolar neutralization of SARS-CoV-2 infection.", "The structure-based multivalent nanobodies we present have strong potential clinical applications owing to increased neutralizing activity and in-built protection from rapid emergence of escape mutants."]}
{"id": 1002219, "claim": "Structure-guided multivalent nanobodies induce sars-cov-2 infection and suppress mutational escape.", "label": "REFUTED", "evidence": ["We further validated virus neutralization microscopically by quantifying the replication of an mNeonGreen expressing clone of SARS-CoV-2 on human Caco2 cells in the presence of nanobodies over time (fig.", "Affinity maturation and structure-guided design of multivalency yielded a trivalent nanobody, mNb6-tri, with femtomolar affinity for SARS-CoV-2 Spike and picomolar neutralization of SARS-CoV-2 infection.", "The structure-based multivalent nanobodies we present have strong potential clinical applications owing to increased neutralizing activity and in-built protection from rapid emergence of escape mutants."]}
{"id": 1002220, "claim": "Structure-guided multivalent nanobodies enhance sars-cov-2 infection and suppress mutational escape.", "label": "REFUTED", "evidence": ["We further validated virus neutralization microscopically by quantifying the replication of an mNeonGreen expressing clone of SARS-CoV-2 on human Caco2 cells in the presence of nanobodies over time (fig.", "Affinity maturation and structure-guided design of multivalency yielded a trivalent nanobody, mNb6-tri, with femtomolar affinity for SARS-CoV-2 Spike and picomolar neutralization of SARS-CoV-2 infection.", "The structure-based multivalent nanobodies we present have strong potential clinical applications owing to increased neutralizing activity and in-built protection from rapid emergence of escape mutants."]}
{"id": 1002221, "claim": "Nih-moderna investigational covid-19 vaccine shows promise in mouse studies", "label": "SUPPORTED", "evidence": ["The investigational vaccine also induced robust CD8 T-cell responses in mice.", "The investigators vaccinated mice with sub-protective doses of mRNA-1273 and then challenged the mice with SARS-CoV-2.", "Additional experiments found that mice given two injections of the 1-mcg dose and later challenged with SARS-CoV-2 virus either 5 or 13 weeks after the second injection were protected from viral replication in the lungs and nose.", "Importantly, mice challenged 7 weeks after only a single dose of 1 mcg or 10 mcg of mRNA-1273 were also protected against viral replication in the lung ."]}
{"id": 1002222, "claim": "Nih-moderna investigational covid-19 vaccine shows promise in cancer studies", "label": "REFUTED", "evidence": ["The investigational vaccine also induced robust CD8 T-cell responses in mice.", "The investigators vaccinated mice with sub-protective doses of mRNA-1273 and then challenged the mice with SARS-CoV-2.", "Additional experiments found that mice given two injections of the 1-mcg dose and later challenged with SARS-CoV-2 virus either 5 or 13 weeks after the second injection were protected from viral replication in the lungs and nose.", "Importantly, mice challenged 7 weeks after only a single dose of 1 mcg or 10 mcg of mRNA-1273 were also protected against viral replication in the lung ."]}
{"id": 1002223, "claim": "Nih-moderna investigational covid-19 vaccine shows promise in human studies", "label": "REFUTED", "evidence": ["The investigational vaccine also induced robust CD8 T-cell responses in mice.", "The investigators vaccinated mice with sub-protective doses of mRNA-1273 and then challenged the mice with SARS-CoV-2.", "Additional experiments found that mice given two injections of the 1-mcg dose and later challenged with SARS-CoV-2 virus either 5 or 13 weeks after the second injection were protected from viral replication in the lungs and nose.", "Importantly, mice challenged 7 weeks after only a single dose of 1 mcg or 10 mcg of mRNA-1273 were also protected against viral replication in the lung ."]}
{"id": 1002224, "claim": "Nih-moderna investigational covid-19 vaccine shows promise in clinical studies", "label": "REFUTED", "evidence": ["The investigational vaccine also induced robust CD8 T-cell responses in mice.", "The investigators vaccinated mice with sub-protective doses of mRNA-1273 and then challenged the mice with SARS-CoV-2.", "Additional experiments found that mice given two injections of the 1-mcg dose and later challenged with SARS-CoV-2 virus either 5 or 13 weeks after the second injection were protected from viral replication in the lungs and nose.", "Importantly, mice challenged 7 weeks after only a single dose of 1 mcg or 10 mcg of mRNA-1273 were also protected against viral replication in the lung ."]}
{"id": 1002225, "claim": "Dexamethasone reduces length of stay , icu admission in patients with pneumonia", "label": "SUPPORTED", "evidence": ["\"In conclusion, oral dexamethasone reduced the length of stay by half a day in patients with community-acquired pneumonia and also reduced the number of ICU admissions,\" Wittermans said.", "Median length of stay was shorter in those assigned oral dexamethasone compared with those assigned placebo (4.5 days vs. 5 days; P = .03).", "Back to Healio Oral dexamethasone reduced length of stay and ICU admissions in adults with community-acquired pneumonia, according to research presented at the virtual European Respiratory Society International Congress.", "Those treated with dexamethasone had a lower rate of ICU admissions compared with placebo (3% vs. 7%; RR = 0.35; 95% CI, 0.13-0.95; P = .03)."]}
{"id": 1002226, "claim": "Dexamethasone increased length of stay, icu admission in patients with pneumonia", "label": "REFUTED", "evidence": ["\"In conclusion, oral dexamethasone reduced the length of stay by half a day in patients with community-acquired pneumonia and also reduced the number of ICU admissions,\" Wittermans said.", "Median length of stay was shorter in those assigned oral dexamethasone compared with those assigned placebo (4.5 days vs. 5 days; P = .03).", "Back to Healio Oral dexamethasone reduced length of stay and ICU admissions in adults with community-acquired pneumonia, according to research presented at the virtual European Respiratory Society International Congress.", "Those treated with dexamethasone had a lower rate of ICU admissions compared with placebo (3% vs. 7%; RR = 0.35; 95% CI, 0.13-0.95; P = .03)."]}
{"id": 1002227, "claim": "Dexamethasone reduces length of stay, icu admission in patients with ards", "label": "REFUTED", "evidence": ["\"In conclusion, oral dexamethasone reduced the length of stay by half a day in patients with community-acquired pneumonia and also reduced the number of ICU admissions,\" Wittermans said.", "Median length of stay was shorter in those assigned oral dexamethasone compared with those assigned placebo (4.5 days vs. 5 days; P = .03).", "Back to Healio Oral dexamethasone reduced length of stay and ICU admissions in adults with community-acquired pneumonia, according to research presented at the virtual European Respiratory Society International Congress.", "Those treated with dexamethasone had a lower rate of ICU admissions compared with placebo (3% vs. 7%; RR = 0.35; 95% CI, 0.13-0.95; P = .03)."]}
{"id": 1002228, "claim": "Dexamethasone reduces length of stay, icu admission in patients without pneumonia", "label": "REFUTED", "evidence": ["\"In conclusion, oral dexamethasone reduced the length of stay by half a day in patients with community-acquired pneumonia and also reduced the number of ICU admissions,\" Wittermans said.", "Median length of stay was shorter in those assigned oral dexamethasone compared with those assigned placebo (4.5 days vs. 5 days; P = .03).", "Back to Healio Oral dexamethasone reduced length of stay and ICU admissions in adults with community-acquired pneumonia, according to research presented at the virtual European Respiratory Society International Congress.", "Those treated with dexamethasone had a lower rate of ICU admissions compared with placebo (3% vs. 7%; RR = 0.35; 95% CI, 0.13-0.95; P = .03)."]}
{"id": 1002229, "claim": "Eighty percent of coronavirus tests donated by china to czechs are faulty", "label": "SUPPORTED", "evidence": ["Up to 80 percent of the 150,000 portable, quick coronavirus test kits China delivered to the Czech Republic earlier this month were faulty, according to local Czech news site Expats.cz.", "(Internet image) TAIPEI (Taiwan News) -- A Czech news site on Monday (March 23) revealed that 80 percent of the much-touted traunch of Wuhan coronavirus (COVID-19) rapid test kits \"donated\" from China are faulty, forcing healthcare workers to rely on conventional laboratory tests.", "(Mussa Qawasma/Reuters) The majority of rapid test coronavirus test kits supplied by China to Spain and the Czech Republic are faulty, local news outlets reported.", "However, Czech news site iROZHLAS on Monday revealed that local healthcare workers have discovered that up to 80 percent of the Chinese kits give false results."]}
{"id": 1002230, "claim": "Five percent of coronavirus tests donated by china to czechs are faulty", "label": "REFUTED", "evidence": ["Up to 80 percent of the 150,000 portable, quick coronavirus test kits China delivered to the Czech Republic earlier this month were faulty, according to local Czech news site Expats.cz.", "(Internet image) TAIPEI (Taiwan News) -- A Czech news site on Monday (March 23) revealed that 80 percent of the much-touted traunch of Wuhan coronavirus (COVID-19) rapid test kits \"donated\" from China are faulty, forcing healthcare workers to rely on conventional laboratory tests.", "(Mussa Qawasma/Reuters) The majority of rapid test coronavirus test kits supplied by China to Spain and the Czech Republic are faulty, local news outlets reported.", "However, Czech news site iROZHLAS on Monday revealed that local healthcare workers have discovered that up to 80 percent of the Chinese kits give false results."]}
{"id": 1002231, "claim": "One percent of coronavirus tests donated by china to czechs are faulty", "label": "REFUTED", "evidence": ["Up to 80 percent of the 150,000 portable, quick coronavirus test kits China delivered to the Czech Republic earlier this month were faulty, according to local Czech news site Expats.cz.", "(Internet image) TAIPEI (Taiwan News) -- A Czech news site on Monday (March 23) revealed that 80 percent of the much-touted traunch of Wuhan coronavirus (COVID-19) rapid test kits \"donated\" from China are faulty, forcing healthcare workers to rely on conventional laboratory tests.", "(Mussa Qawasma/Reuters) The majority of rapid test coronavirus test kits supplied by China to Spain and the Czech Republic are faulty, local news outlets reported.", "However, Czech news site iROZHLAS on Monday revealed that local healthcare workers have discovered that up to 80 percent of the Chinese kits give false results."]}
{"id": 1002232, "claim": "Eight percent of coronavirus tests donated by china to czechs are faulty", "label": "REFUTED", "evidence": ["Up to 80 percent of the 150,000 portable, quick coronavirus test kits China delivered to the Czech Republic earlier this month were faulty, according to local Czech news site Expats.cz.", "(Internet image) TAIPEI (Taiwan News) -- A Czech news site on Monday (March 23) revealed that 80 percent of the much-touted traunch of Wuhan coronavirus (COVID-19) rapid test kits \"donated\" from China are faulty, forcing healthcare workers to rely on conventional laboratory tests.", "(Mussa Qawasma/Reuters) The majority of rapid test coronavirus test kits supplied by China to Spain and the Czech Republic are faulty, local news outlets reported.", "However, Czech news site iROZHLAS on Monday revealed that local healthcare workers have discovered that up to 80 percent of the Chinese kits give false results."]}
{"id": 1002233, "claim": "We need an immediate five-week national lockdown to defeat coronavirus in america", "label": "SUPPORTED", "evidence": ["Our relaxed approach to social distancing is insufficient to stop the exponential growth of COVID-19.", "During a five-week national lockdown, federal, state and local authorities would ensure that all Americans stay home except to obtain food and other essentials, access medical care or do work essential to the functioning of society.", "Until Americans consistently adopt strong social distancing recommendations  a lockdown  the disease will continue to spread exponentially.", "The fastest and even the only way to contain COVID-19 in the United States is a five-week national lockdown."]}
{"id": 1002234, "claim": "We need an immediate five-minute national lockdown to defeat coronavirus in america", "label": "REFUTED", "evidence": ["Our relaxed approach to social distancing is insufficient to stop the exponential growth of COVID-19.", "During a five-week national lockdown, federal, state and local authorities would ensure that all Americans stay home except to obtain food and other essentials, access medical care or do work essential to the functioning of society.", "Until Americans consistently adopt strong social distancing recommendations  a lockdown  the disease will continue to spread exponentially.", "The fastest and even the only way to contain COVID-19 in the United States is a five-week national lockdown."]}
{"id": 1002235, "claim": "We need an immediate five-hour national lockdown to defeat coronavirus in america", "label": "REFUTED", "evidence": ["Our relaxed approach to social distancing is insufficient to stop the exponential growth of COVID-19.", "During a five-week national lockdown, federal, state and local authorities would ensure that all Americans stay home except to obtain food and other essentials, access medical care or do work essential to the functioning of society.", "Until Americans consistently adopt strong social distancing recommendations  a lockdown  the disease will continue to spread exponentially.", "The fastest and even the only way to contain COVID-19 in the United States is a five-week national lockdown."]}
{"id": 1002236, "claim": "We need an immediate five-day national lockdown to defeat coronavirus in america", "label": "REFUTED", "evidence": ["Our relaxed approach to social distancing is insufficient to stop the exponential growth of COVID-19.", "During a five-week national lockdown, federal, state and local authorities would ensure that all Americans stay home except to obtain food and other essentials, access medical care or do work essential to the functioning of society.", "Until Americans consistently adopt strong social distancing recommendations  a lockdown  the disease will continue to spread exponentially.", "The fastest and even the only way to contain COVID-19 in the United States is a five-week national lockdown."]}
{"id": 1002237, "claim": "Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum", "label": "SUPPORTED", "evidence": ["Another previous report by Callow (4) suggested that HCoV-229E-specific antibodies in serum and nasal wash specimens were correlated with protection from experimental infection with HCoV-229E and disease, and IgA antibodies to HCoV-229E in nasal wash specimens were associated with a reduced duration of viral shedding in nasal secretions.", "Based on the much lower frequency of patients with HCoV-specific IgA antibody in nasal wash specimens than of those with IgG in serum in our older adult population, one might hypothesize that antibodies to HCoV in nasal secretions decline in titer more rapidly after infection than do serum antibodies or that infection does not induce IgA antibody to HCoV in nasal secretions to high titers or at all in a significant proportion of older, chronically ill patients with COPD.", "Hence, despite the near-universal presence of serum antibodies to the HCoV strains in our study, the lower rates of detectable IgA antibodies to HCoV suggest a possible reason for susceptibility to reinfections with HCoV, if IgA antibodies in nasal secretions are indeed protective."]}
{"id": 1002238, "claim": "Prevalence of antibodies to four human coronaviruses is greater in nasal secretions than in serum", "label": "REFUTED", "evidence": ["Another previous report by Callow (4) suggested that HCoV-229E-specific antibodies in serum and nasal wash specimens were correlated with protection from experimental infection with HCoV-229E and disease, and IgA antibodies to HCoV-229E in nasal wash specimens were associated with a reduced duration of viral shedding in nasal secretions.", "Based on the much lower frequency of patients with HCoV-specific IgA antibody in nasal wash specimens than of those with IgG in serum in our older adult population, one might hypothesize that antibodies to HCoV in nasal secretions decline in titer more rapidly after infection than do serum antibodies or that infection does not induce IgA antibody to HCoV in nasal secretions to high titers or at all in a significant proportion of older, chronically ill patients with COPD.", "Hence, despite the near-universal presence of serum antibodies to the HCoV strains in our study, the lower rates of detectable IgA antibodies to HCoV suggest a possible reason for susceptibility to reinfections with HCoV, if IgA antibodies in nasal secretions are indeed protective."]}
{"id": 1002239, "claim": "Prevalence of antibodies to four human coronaviruses is higher in nasal secretions than in serum", "label": "REFUTED", "evidence": ["Another previous report by Callow (4) suggested that HCoV-229E-specific antibodies in serum and nasal wash specimens were correlated with protection from experimental infection with HCoV-229E and disease, and IgA antibodies to HCoV-229E in nasal wash specimens were associated with a reduced duration of viral shedding in nasal secretions.", "Based on the much lower frequency of patients with HCoV-specific IgA antibody in nasal wash specimens than of those with IgG in serum in our older adult population, one might hypothesize that antibodies to HCoV in nasal secretions decline in titer more rapidly after infection than do serum antibodies or that infection does not induce IgA antibody to HCoV in nasal secretions to high titers or at all in a significant proportion of older, chronically ill patients with COPD.", "Hence, despite the near-universal presence of serum antibodies to the HCoV strains in our study, the lower rates of detectable IgA antibodies to HCoV suggest a possible reason for susceptibility to reinfections with HCoV, if IgA antibodies in nasal secretions are indeed protective."]}
{"id": 1002240, "claim": "Prevalence of antibodies to four human coronaviruses is larger in nasal secretions than in serum", "label": "REFUTED", "evidence": ["Another previous report by Callow (4) suggested that HCoV-229E-specific antibodies in serum and nasal wash specimens were correlated with protection from experimental infection with HCoV-229E and disease, and IgA antibodies to HCoV-229E in nasal wash specimens were associated with a reduced duration of viral shedding in nasal secretions.", "Based on the much lower frequency of patients with HCoV-specific IgA antibody in nasal wash specimens than of those with IgG in serum in our older adult population, one might hypothesize that antibodies to HCoV in nasal secretions decline in titer more rapidly after infection than do serum antibodies or that infection does not induce IgA antibody to HCoV in nasal secretions to high titers or at all in a significant proportion of older, chronically ill patients with COPD.", "Hence, despite the near-universal presence of serum antibodies to the HCoV strains in our study, the lower rates of detectable IgA antibodies to HCoV suggest a possible reason for susceptibility to reinfections with HCoV, if IgA antibodies in nasal secretions are indeed protective."]}
{"id": 1002241, "claim": "Circulating mitochondrial dna is an early indicator of severe illness and mortality from covid-19", "label": "SUPPORTED", "evidence": ["These results show that high circulating MT-DNA levels is a potential indicator for poor COVID-19 outcomes.", "Multivariate regression analysis revealed that high circulating MT-DNA levels is an independent risk factor for all of these outcomes after adjusting for age, sex and comorbidities."]}
{"id": 1002242, "claim": "Circulating mitochondrial inflammation is an early indicator of severe illness and mortality from covid-19", "label": "REFUTED", "evidence": ["These results show that high circulating MT-DNA levels is a potential indicator for poor COVID-19 outcomes.", "Multivariate regression analysis revealed that high circulating MT-DNA levels is an independent risk factor for all of these outcomes after adjusting for age, sex and comorbidities."]}
{"id": 1002243, "claim": "Residual sars-cov-2 viral antigens detected in gastrointestinal and hepatic tissues from two recovered covid-19 patients", "label": "SUPPORTED", "evidence": ["]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.", "This raises concern for persistence of SARS-CoV-2 virus particles and faecal- oral transmissibility in recovered COVID-19 patients.", "These findings might have important implications in terms of disease management and public health policy regarding transmission of COVID-19 via faecal-oral and iatrogenic routes during the convalescence phase.", "Using multiplex immunohistochemistry, we unexpectedly detected SARS-CoV-2 viral antigens in intestinal and liver tissues, in surgical samples obtained from two patients who recovered from COVID-19.", "We further validated the presence of virus by RT- PCR and flow cytometry to detect SARS-CoV-2-specific immunity in the tissues."]}
{"id": 1002244, "claim": "Residual sars-cov-2 viral antigens detected in gastrointestinal and hepatic tissues from all recovered covid-19 patients", "label": "REFUTED", "evidence": ["]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox.", "This raises concern for persistence of SARS-CoV-2 virus particles and faecal- oral transmissibility in recovered COVID-19 patients.", "These findings might have important implications in terms of disease management and public health policy regarding transmission of COVID-19 via faecal-oral and iatrogenic routes during the convalescence phase.", "Using multiplex immunohistochemistry, we unexpectedly detected SARS-CoV-2 viral antigens in intestinal and liver tissues, in surgical samples obtained from two patients who recovered from COVID-19.", "We further validated the presence of virus by RT- PCR and flow cytometry to detect SARS-CoV-2-specific immunity in the tissues."]}
{"id": 1002245, "claim": "Lung and gut microbiota are altered by hyperoxia and contribute to oxygen-induced lung injury in mice", "label": "SUPPORTED", "evidence": ["During exposure of mice to hyperoxia, both lung and gut bacterial communities were altered, and these communities contributed to oxygen-induced lung injury.", "Variation in lung inflammation correlates with variation in lung microbiota in hyperoxia-exposed mice.", "7.. Hyperoxia alters microbial growth conditions in the mouse lung microenvironment.", "1.. Hyperoxia alters lung microbiota in humans and in neonatal and adult mice."]}
{"id": 1002246, "claim": "Lung and gut microbiota are altered by hyperoxia and contribute to oxygen-induced lung injury in humans", "label": "REFUTED", "evidence": ["During exposure of mice to hyperoxia, both lung and gut bacterial communities were altered, and these communities contributed to oxygen-induced lung injury.", "Variation in lung inflammation correlates with variation in lung microbiota in hyperoxia-exposed mice.", "7.. Hyperoxia alters microbial growth conditions in the mouse lung microenvironment.", "1.. Hyperoxia alters lung microbiota in humans and in neonatal and adult mice."]}
{"id": 1002247, "claim": "Lung and gut microbiota are altered by hyperoxia and contribute to oxygen-induced lung injury in patients", "label": "REFUTED", "evidence": ["During exposure of mice to hyperoxia, both lung and gut bacterial communities were altered, and these communities contributed to oxygen-induced lung injury.", "Variation in lung inflammation correlates with variation in lung microbiota in hyperoxia-exposed mice.", "7.. Hyperoxia alters microbial growth conditions in the mouse lung microenvironment.", "1.. Hyperoxia alters lung microbiota in humans and in neonatal and adult mice."]}
{"id": 1002248, "claim": "Pre-existing cardiovascular disease rather than cardiovascular risk factors drives mortality in covid-19", "label": "SUPPORTED", "evidence": ["Interpretation In patients hospitalised with COVID-19, pre-existing established CVD appears to be a more important contributor to mortality than CV risk factors in the absence of CVD.", "Pre-existing CVD, CV risk factors and associations with mortality and CV complications were ascertained."]}
{"id": 1002249, "claim": "Pre-existing cardiovascular disease rather than cardiovascular risk factors drives improvement in covid-19", "label": "REFUTED", "evidence": ["Interpretation In patients hospitalised with COVID-19, pre-existing established CVD appears to be a more important contributor to mortality than CV risk factors in the absence of CVD.", "Pre-existing CVD, CV risk factors and associations with mortality and CV complications were ascertained."]}
{"id": 1002250, "claim": "Pre-existing cardiovascular disease rather than cardiovascular risk factors drives progression in covid-19", "label": "REFUTED", "evidence": ["Interpretation In patients hospitalised with COVID-19, pre-existing established CVD appears to be a more important contributor to mortality than CV risk factors in the absence of CVD.", "Pre-existing CVD, CV risk factors and associations with mortality and CV complications were ascertained."]}
{"id": 1002251, "claim": "Pre-existing cardiovascular disease rather than cardiovascular risk factors drives survival in covid-19", "label": "REFUTED", "evidence": ["Interpretation In patients hospitalised with COVID-19, pre-existing established CVD appears to be a more important contributor to mortality than CV risk factors in the absence of CVD.", "Pre-existing CVD, CV risk factors and associations with mortality and CV complications were ascertained."]}
{"id": 1002252, "claim": "Fda authorizes 15-minute coronavirus test", "label": "SUPPORTED", "evidence": ["The approval comes as cities across the nation scramble to get testing done and prevent the spread of the coronavirus."]}
{"id": 1002253, "claim": "Fda authorizes 15-year coronavirus test", "label": "REFUTED", "evidence": ["The approval comes as cities across the nation scramble to get testing done and prevent the spread of the coronavirus."]}
{"id": 1002254, "claim": "Fda authorizes 15-day coronavirus test", "label": "REFUTED", "evidence": ["The approval comes as cities across the nation scramble to get testing done and prevent the spread of the coronavirus."]}
{"id": 1002255, "claim": "Fda authorizes 15-kda coronavirus test", "label": "REFUTED", "evidence": ["The approval comes as cities across the nation scramble to get testing done and prevent the spread of the coronavirus."]}
{"id": 1002256, "claim": "Large-scale single-cell analysis reveals critical immune characteristics of covid-19 patients", "label": "SUPPORTED", "evidence": ["HIGHLIGHTS Large-scale scRNA-seq analysis depicts the immune landscape of COVID-19 Lymphopenia and active T and B cell responses coexist and are shaped by age and sex SARS-CoV-2 infects diverse epithelial and immune cells, inducing distinct responses Cytokine storms with systemic S100A8/A9 are associated with COVID-19 severity "]}
{"id": 1002257, "claim": "Large-scale single-dose analysis reveals critical immune characteristics of covid-19 patients", "label": "REFUTED", "evidence": ["HIGHLIGHTS Large-scale scRNA-seq analysis depicts the immune landscape of COVID-19 Lymphopenia and active T and B cell responses coexist and are shaped by age and sex SARS-CoV-2 infects diverse epithelial and immune cells, inducing distinct responses Cytokine storms with systemic S100A8/A9 are associated with COVID-19 severity "]}
{"id": 1002258, "claim": "Large-scale single-dimensional analysis reveals critical immune characteristics of covid-19 patients", "label": "REFUTED", "evidence": ["HIGHLIGHTS Large-scale scRNA-seq analysis depicts the immune landscape of COVID-19 Lymphopenia and active T and B cell responses coexist and are shaped by age and sex SARS-CoV-2 infects diverse epithelial and immune cells, inducing distinct responses Cytokine storms with systemic S100A8/A9 are associated with COVID-19 severity "]}
{"id": 1002259, "claim": "Vitamin d insufficiency is prevalent in severe covid-19", "label": "SUPPORTED", "evidence": ["Emerging health disparities data regarding African American and homeless populations suggest that vitamin D insufficiency (VDI) may be an underlying driver of COVID-19 severity."]}
{"id": 1002260, "claim": "C d insufficiency is prevalent in severe covid-19", "label": "REFUTED", "evidence": ["Emerging health disparities data regarding African American and homeless populations suggest that vitamin D insufficiency (VDI) may be an underlying driver of COVID-19 severity."]}
{"id": 1002261, "claim": "Nasal-swab testing misses patients with low sars-cov-2 viral loads", "label": "SUPPORTED", "evidence": ["These findings counsel caution in use of nasal testing in healthcare settings and contact-tracing efforts, as opposed to screening of asymptomatic, low-prevalence, low-risk populations.", "Those with viral loads below 1,000 copies/mL, the majority in our cohort, exhibited low concordance (Cohens kappa = 0.49); most of these would have been missed by nasal testing alone.", "To resolve this disagreement, we compared nasal and NP specimens collected by healthcare workers in a cohort consisting of individuals clinically suspected of COVID-19 and outpatients known to be SARS-CoV-2 RT-PCR positive undergoing follow-up."]}
{"id": 1002262, "claim": "Nasal-swab testing confirmed patients with low sars-cov-2 viral loads", "label": "REFUTED", "evidence": ["These findings counsel caution in use of nasal testing in healthcare settings and contact-tracing efforts, as opposed to screening of asymptomatic, low-prevalence, low-risk populations.", "Those with viral loads below 1,000 copies/mL, the majority in our cohort, exhibited low concordance (Cohens kappa = 0.49); most of these would have been missed by nasal testing alone.", "To resolve this disagreement, we compared nasal and NP specimens collected by healthcare workers in a cohort consisting of individuals clinically suspected of COVID-19 and outpatients known to be SARS-CoV-2 RT-PCR positive undergoing follow-up."]}
{"id": 1002263, "claim": "Nasal-swab testing performed patients with low sars-cov-2 viral loads", "label": "REFUTED", "evidence": ["These findings counsel caution in use of nasal testing in healthcare settings and contact-tracing efforts, as opposed to screening of asymptomatic, low-prevalence, low-risk populations.", "Those with viral loads below 1,000 copies/mL, the majority in our cohort, exhibited low concordance (Cohens kappa = 0.49); most of these would have been missed by nasal testing alone.", "To resolve this disagreement, we compared nasal and NP specimens collected by healthcare workers in a cohort consisting of individuals clinically suspected of COVID-19 and outpatients known to be SARS-CoV-2 RT-PCR positive undergoing follow-up."]}
{"id": 1002264, "claim": "Nasal-swab testing revealed patients with low sars-cov-2 viral loads", "label": "REFUTED", "evidence": ["These findings counsel caution in use of nasal testing in healthcare settings and contact-tracing efforts, as opposed to screening of asymptomatic, low-prevalence, low-risk populations.", "Those with viral loads below 1,000 copies/mL, the majority in our cohort, exhibited low concordance (Cohens kappa = 0.49); most of these would have been missed by nasal testing alone.", "To resolve this disagreement, we compared nasal and NP specimens collected by healthcare workers in a cohort consisting of individuals clinically suspected of COVID-19 and outpatients known to be SARS-CoV-2 RT-PCR positive undergoing follow-up."]}
{"id": 1002265, "claim": "Human trials expected to start next month for covid-19 treatment derived from cows ' blood", "label": "SUPPORTED", "evidence": ["That way, the animals produce disease-fighting human antibodies to Covid-19, which are then turned into a drug to attack the virus.", "The cows are now producing human antibodies to the coronavirus."]}
{"id": 1002266, "claim": "Human trials expected to start this month for covid-19 treatment derived from cows'blood", "label": "REFUTED", "evidence": ["That way, the animals produce disease-fighting human antibodies to Covid-19, which are then turned into a drug to attack the virus.", "The cows are now producing human antibodies to the coronavirus."]}
{"id": 1002267, "claim": "Human trials expected to start 1 month for covid-19 treatment derived from cows'blood", "label": "REFUTED", "evidence": ["That way, the animals produce disease-fighting human antibodies to Covid-19, which are then turned into a drug to attack the virus.", "The cows are now producing human antibodies to the coronavirus."]}
{"id": 1002268, "claim": "A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against sars-cov-2 in mice.", "label": "SUPPORTED", "evidence": ["Analysis of antisera from immunized mice revealed that the only groups with notable neutralizing activity after a single dose of antigen were those immunized with S-Fer or SΔC-Fer (Figure 4C), underscoring that multivalent presentation greatly enhances the neutralizing antibody response in a single- dose regimen of an adjuvanted SARS-CoV-2 subunit vaccine.", "After a single dose, mice immunized with SΔC-Fer exhibited a significantly higher neutralizing antibody response than all nonferritin groups as determined using a spike-pseudotyped lentiviral assay.", "Taken together, these results provide insights into development of SARS-CoV-2 subunit vaccines and demonstrate that spike- functionalized ferritin nanoparticles elicit an enhanced antibody response compared to the spike trimers or RBD alone."]}
{"id": 1002269, "claim": "A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against sars-cov-2 in humans.", "label": "REFUTED", "evidence": ["Analysis of antisera from immunized mice revealed that the only groups with notable neutralizing activity after a single dose of antigen were those immunized with S-Fer or SΔC-Fer (Figure 4C), underscoring that multivalent presentation greatly enhances the neutralizing antibody response in a single- dose regimen of an adjuvanted SARS-CoV-2 subunit vaccine.", "After a single dose, mice immunized with SΔC-Fer exhibited a significantly higher neutralizing antibody response than all nonferritin groups as determined using a spike-pseudotyped lentiviral assay.", "Taken together, these results provide insights into development of SARS-CoV-2 subunit vaccines and demonstrate that spike- functionalized ferritin nanoparticles elicit an enhanced antibody response compared to the spike trimers or RBD alone."]}
{"id": 1002270, "claim": "A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against sars-cov-2 in ferrets.", "label": "REFUTED", "evidence": ["Analysis of antisera from immunized mice revealed that the only groups with notable neutralizing activity after a single dose of antigen were those immunized with S-Fer or SΔC-Fer (Figure 4C), underscoring that multivalent presentation greatly enhances the neutralizing antibody response in a single- dose regimen of an adjuvanted SARS-CoV-2 subunit vaccine.", "After a single dose, mice immunized with SΔC-Fer exhibited a significantly higher neutralizing antibody response than all nonferritin groups as determined using a spike-pseudotyped lentiviral assay.", "Taken together, these results provide insights into development of SARS-CoV-2 subunit vaccines and demonstrate that spike- functionalized ferritin nanoparticles elicit an enhanced antibody response compared to the spike trimers or RBD alone."]}
{"id": 1002271, "claim": "A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against sars-cov-2 in rabbits.", "label": "REFUTED", "evidence": ["Analysis of antisera from immunized mice revealed that the only groups with notable neutralizing activity after a single dose of antigen were those immunized with S-Fer or SΔC-Fer (Figure 4C), underscoring that multivalent presentation greatly enhances the neutralizing antibody response in a single- dose regimen of an adjuvanted SARS-CoV-2 subunit vaccine.", "After a single dose, mice immunized with SΔC-Fer exhibited a significantly higher neutralizing antibody response than all nonferritin groups as determined using a spike-pseudotyped lentiviral assay.", "Taken together, these results provide insights into development of SARS-CoV-2 subunit vaccines and demonstrate that spike- functionalized ferritin nanoparticles elicit an enhanced antibody response compared to the spike trimers or RBD alone."]}
{"id": 1002272, "claim": "Covid-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes , the severity of which correlate with patient outcome", "label": "SUPPORTED", "evidence": ["Conclusions The detection and serial monitoring of this subset of inflammatory monocytes using flow cytometry could be of great help in guiding the prognostication and treatment of patients with COVID-19 and merits further evaluation.", "Findings While we did not detect significant differences in the number of monocytes between patients with COVID-19 and normal healthy individuals,we did identify significant morphological and functional differences, which are more pronounced in patients requiring prolonged hospitalization and ICU admission.", "Patients with COVID-19 have larger than normal monocytes, easily identified on forward scatter, side scatter analysis by routine flow cytometry,with the presence of a distinct population of monocytes with high forward scatter (FSC- high).", "Methods We performed detailed flow cytometric analysis of peripheral blood samples from 28 COVID-19 patients treated at Xian No.8 Hospital and the First Affiliated Hospital of Xian Jiaotong University in early 2020 in an attempt to identify factors that could help predict severity of disease and patient outcome."]}
{"id": 1002273, "claim": "Covid-19 infection cannots readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome", "label": "REFUTED", "evidence": ["Conclusions The detection and serial monitoring of this subset of inflammatory monocytes using flow cytometry could be of great help in guiding the prognostication and treatment of patients with COVID-19 and merits further evaluation.", "Findings While we did not detect significant differences in the number of monocytes between patients with COVID-19 and normal healthy individuals,we did identify significant morphological and functional differences, which are more pronounced in patients requiring prolonged hospitalization and ICU admission.", "Patients with COVID-19 have larger than normal monocytes, easily identified on forward scatter, side scatter analysis by routine flow cytometry,with the presence of a distinct population of monocytes with high forward scatter (FSC- high).", "Methods We performed detailed flow cytometric analysis of peripheral blood samples from 28 COVID-19 patients treated at Xian No.8 Hospital and the First Affiliated Hospital of Xian Jiaotong University in early 2020 in an attempt to identify factors that could help predict severity of disease and patient outcome."]}
{"id": 1002274, "claim": "'scientists in the vektor state virology and biotechnology centre in the city of novosibirsk have developed vaccine prototypes based on six different technological platforms '", "label": "SUPPORTED", "evidence": ["August 6, 2020 \\- Another 86 volunteers will be inoculated with the vaccine against the novel coronavirus developed by the Vektor State Research Center of Virology and Biotechnology during the second stage of clinical trials, the press service of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing told TASS.", "The State Scientific Center of Virology and Biotechnology \"Vector,\" located in Novosibirsk, has received patents for the vaccine from COVID-19.", "August 17, 2020 \\- The Vector State Research Center of Virology and Biotechnology in Novosibirsk has started the second phase of clinical studies of the vaccine against the novel coronavirus."]}
{"id": 1002275, "claim": "'scientists in the vektor state virology and biotechnology centre in the city of novosibirsk have developed vaccine prototypes based on two different technological platforms '", "label": "REFUTED", "evidence": ["August 6, 2020 \\- Another 86 volunteers will be inoculated with the vaccine against the novel coronavirus developed by the Vektor State Research Center of Virology and Biotechnology during the second stage of clinical trials, the press service of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing told TASS.", "The State Scientific Center of Virology and Biotechnology \"Vector,\" located in Novosibirsk, has received patents for the vaccine from COVID-19.", "August 17, 2020 \\- The Vector State Research Center of Virology and Biotechnology in Novosibirsk has started the second phase of clinical studies of the vaccine against the novel coronavirus."]}
{"id": 1002276, "claim": "'scientists in the vektor state virology and biotechnology centre in the city of novosibirsk have developed vaccine prototypes based on three different technological platforms '", "label": "REFUTED", "evidence": ["August 6, 2020 \\- Another 86 volunteers will be inoculated with the vaccine against the novel coronavirus developed by the Vektor State Research Center of Virology and Biotechnology during the second stage of clinical trials, the press service of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing told TASS.", "The State Scientific Center of Virology and Biotechnology \"Vector,\" located in Novosibirsk, has received patents for the vaccine from COVID-19.", "August 17, 2020 \\- The Vector State Research Center of Virology and Biotechnology in Novosibirsk has started the second phase of clinical studies of the vaccine against the novel coronavirus."]}
{"id": 1002277, "claim": "'scientists in the vektor state virology and biotechnology centre in the city of novosibirsk have developed vaccine prototypes based on four different technological platforms '", "label": "REFUTED", "evidence": ["August 6, 2020 \\- Another 86 volunteers will be inoculated with the vaccine against the novel coronavirus developed by the Vektor State Research Center of Virology and Biotechnology during the second stage of clinical trials, the press service of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing told TASS.", "The State Scientific Center of Virology and Biotechnology \"Vector,\" located in Novosibirsk, has received patents for the vaccine from COVID-19.", "August 17, 2020 \\- The Vector State Research Center of Virology and Biotechnology in Novosibirsk has started the second phase of clinical studies of the vaccine against the novel coronavirus."]}
{"id": 1002278, "claim": "Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate covid-19", "label": "SUPPORTED", "evidence": ["METHODS We conducted a placebo-controlled, phase-2 clinical trial involving ambulatory COVID-19 patients.", "Combined metabolic cofactors supplementation (CMCS) consisting of L-serine, N-acetyl-L-cysteine (NAC), nicotinamide riboside (NR), and L-carnitine tartrate is being studied for the treatment of patients with COVID-19.", "CONCLUSIONS In patients with mild-to-moderate COVID-19, CMCS resulted in a significant reduction in recovery time and liver enzymes associated with hepatic function compared to placebo."]}
{"id": 1002279, "claim": "Combined metabolic cofactor supplementation accelerates death in mild-to-moderate covid-19", "label": "REFUTED", "evidence": ["METHODS We conducted a placebo-controlled, phase-2 clinical trial involving ambulatory COVID-19 patients.", "Combined metabolic cofactors supplementation (CMCS) consisting of L-serine, N-acetyl-L-cysteine (NAC), nicotinamide riboside (NR), and L-carnitine tartrate is being studied for the treatment of patients with COVID-19.", "CONCLUSIONS In patients with mild-to-moderate COVID-19, CMCS resulted in a significant reduction in recovery time and liver enzymes associated with hepatic function compared to placebo."]}
{"id": 1002280, "claim": "Combined metabolic cofactor supplementation accelerates mortality in mild-to-moderate covid-19", "label": "REFUTED", "evidence": ["METHODS We conducted a placebo-controlled, phase-2 clinical trial involving ambulatory COVID-19 patients.", "Combined metabolic cofactors supplementation (CMCS) consisting of L-serine, N-acetyl-L-cysteine (NAC), nicotinamide riboside (NR), and L-carnitine tartrate is being studied for the treatment of patients with COVID-19.", "CONCLUSIONS In patients with mild-to-moderate COVID-19, CMCS resulted in a significant reduction in recovery time and liver enzymes associated with hepatic function compared to placebo."]}
{"id": 1002281, "claim": "Combined metabolic cofactor supplementation accelerates apoptosis in mild-to-moderate covid-19", "label": "REFUTED", "evidence": ["METHODS We conducted a placebo-controlled, phase-2 clinical trial involving ambulatory COVID-19 patients.", "Combined metabolic cofactors supplementation (CMCS) consisting of L-serine, N-acetyl-L-cysteine (NAC), nicotinamide riboside (NR), and L-carnitine tartrate is being studied for the treatment of patients with COVID-19.", "CONCLUSIONS In patients with mild-to-moderate COVID-19, CMCS resulted in a significant reduction in recovery time and liver enzymes associated with hepatic function compared to placebo."]}
{"id": 1002282, "claim": "Bacterial modification of the host glycosaminoglycan heparan sulfate modulates sars-cov-2 infectivity", "label": "SUPPORTED", "evidence": ["In vitro , bacterial glycosidases from unpurified culture media supernatants fully blocked SARS-CoV-2 spike binding to human H1299 protein lung adenocarcinoma cells.", "Understanding the impact of shifts in microbial community composition and bacterial lyases on SARS-CoV-2 infection may lead to new therapeutics and diagnosis of susceptibility."]}
{"id": 1002283, "claim": "Bacterial modification of the receptor glycosaminoglycan heparan sulfate modulates sars-cov-2 infectivity", "label": "REFUTED", "evidence": ["In vitro , bacterial glycosidases from unpurified culture media supernatants fully blocked SARS-CoV-2 spike binding to human H1299 protein lung adenocarcinoma cells.", "Understanding the impact of shifts in microbial community composition and bacterial lyases on SARS-CoV-2 infection may lead to new therapeutics and diagnosis of susceptibility."]}
{"id": 1002284, "claim": "Bacterial modification of the enzyme glycosaminoglycan heparan sulfate modulates sars-cov-2 infectivity", "label": "REFUTED", "evidence": ["In vitro , bacterial glycosidases from unpurified culture media supernatants fully blocked SARS-CoV-2 spike binding to human H1299 protein lung adenocarcinoma cells.", "Understanding the impact of shifts in microbial community composition and bacterial lyases on SARS-CoV-2 infection may lead to new therapeutics and diagnosis of susceptibility."]}
{"id": 1002285, "claim": "Bacterial modification of the host glycosaminoglycan heparan oxide modulates sars-cov-2 infectivity", "label": "REFUTED", "evidence": ["In vitro , bacterial glycosidases from unpurified culture media supernatants fully blocked SARS-CoV-2 spike binding to human H1299 protein lung adenocarcinoma cells.", "Understanding the impact of shifts in microbial community composition and bacterial lyases on SARS-CoV-2 infection may lead to new therapeutics and diagnosis of susceptibility."]}
{"id": 1002286, "claim": "The race is on in the drug battle against the coronavirus", "label": "SUPPORTED", "evidence": ["Various medications are being tested to treat Covid-19."]}
{"id": 1002287, "claim": "The race is on in the natural battle against the coronavirus", "label": "REFUTED", "evidence": ["Various medications are being tested to treat Covid-19."]}
{"id": 1002288, "claim": "The race is on in the human battle against the coronavirus", "label": "REFUTED", "evidence": ["Various medications are being tested to treat Covid-19."]}
{"id": 1002289, "claim": "The race is on in the public battle against the coronavirus", "label": "REFUTED", "evidence": ["Various medications are being tested to treat Covid-19."]}
{"id": 1002290, "claim": "The sars-cov-2 spike mutation d614g increases entry fitness across a range of ace2 levels , directly outcompetes the wild type , and is preferentially incorporated into trimers", "label": "SUPPORTED", "evidence": ["We developed a cell line with inducible ACE2 expression to confirm that D614G more efficiently enters cells with ACE2 levels spanning the different primary cells targeted by SARS-CoV-2.", "Mounting evidence suggests D614G enhances viral entry.", "Using a new assay for crosslinking and directly extracting Spike trimers from the pseudovirus surface, we found an increase in trimerization efficiency and viral incorporation of D614G protomers."]}
{"id": 1002291, "claim": "The sars-cov-2 spike mutation d614g reduces entry fitness across a range of ace2 levels, directly outcompetes the wild type, and is preferentially incorporated into trimers", "label": "REFUTED", "evidence": ["We developed a cell line with inducible ACE2 expression to confirm that D614G more efficiently enters cells with ACE2 levels spanning the different primary cells targeted by SARS-CoV-2.", "Mounting evidence suggests D614G enhances viral entry.", "Using a new assay for crosslinking and directly extracting Spike trimers from the pseudovirus surface, we found an increase in trimerization efficiency and viral incorporation of D614G protomers."]}
{"id": 1002292, "claim": "Neutralization of sars-cov-2 lineage b.1.1.7 pseudovirus by bnt162b2 vaccine-elicited human sera.", "label": "SUPPORTED", "evidence": ["Recently, a new SARS-CoV-2 lineage called B.1.1.7 has emerged in the United Kingdom that was reported to spread more efficiently than other strains.", "While the pseudovirus system used is a surrogate for authentic SARS-CoV-2, previous studies have shown excellent concordance between pseudotype neutralization and SARS-CoV-2 neutralization assays.i The preserved neutralization of the pseudovirus bearing the U.K. strain spike by BNT162b2- immune sera makes it likely that COVID-19 caused by the U.K. virus variant will also be prevented by immunization with BNT162b2.", "Here, we investigated SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 16 participants in a previously reported trial with the mRNA- based COVID-19 vaccine BNT162b2.", "Here, we investigated SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 16 participants in a previously reported trial with the mRNA-based COVID-19 vaccine BNT162b2."]}
{"id": 1002293, "claim": "Neutralization of sars-cov-2 lineage b.1.1.7 pseudovirus by bnt162b2 vaccine-elicited rabbit sera.", "label": "REFUTED", "evidence": ["Recently, a new SARS-CoV-2 lineage called B.1.1.7 has emerged in the United Kingdom that was reported to spread more efficiently than other strains.", "While the pseudovirus system used is a surrogate for authentic SARS-CoV-2, previous studies have shown excellent concordance between pseudotype neutralization and SARS-CoV-2 neutralization assays.i The preserved neutralization of the pseudovirus bearing the U.K. strain spike by BNT162b2- immune sera makes it likely that COVID-19 caused by the U.K. virus variant will also be prevented by immunization with BNT162b2.", "Here, we investigated SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 16 participants in a previously reported trial with the mRNA- based COVID-19 vaccine BNT162b2.", "Here, we investigated SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 16 participants in a previously reported trial with the mRNA-based COVID-19 vaccine BNT162b2."]}
{"id": 1002294, "claim": "Neutralization of sars-cov-2 lineage b.1.1.7 pseudovirus by bnt162b2 vaccine-elicited goat sera.", "label": "REFUTED", "evidence": ["Recently, a new SARS-CoV-2 lineage called B.1.1.7 has emerged in the United Kingdom that was reported to spread more efficiently than other strains.", "While the pseudovirus system used is a surrogate for authentic SARS-CoV-2, previous studies have shown excellent concordance between pseudotype neutralization and SARS-CoV-2 neutralization assays.i The preserved neutralization of the pseudovirus bearing the U.K. strain spike by BNT162b2- immune sera makes it likely that COVID-19 caused by the U.K. virus variant will also be prevented by immunization with BNT162b2.", "Here, we investigated SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 16 participants in a previously reported trial with the mRNA- based COVID-19 vaccine BNT162b2.", "Here, we investigated SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 16 participants in a previously reported trial with the mRNA-based COVID-19 vaccine BNT162b2."]}
{"id": 1002295, "claim": "Neutralization of sars-cov-2 lineage b.1.1.7 pseudovirus by bnt162b2 vaccine-elicited mouse sera.", "label": "REFUTED", "evidence": ["Recently, a new SARS-CoV-2 lineage called B.1.1.7 has emerged in the United Kingdom that was reported to spread more efficiently than other strains.", "While the pseudovirus system used is a surrogate for authentic SARS-CoV-2, previous studies have shown excellent concordance between pseudotype neutralization and SARS-CoV-2 neutralization assays.i The preserved neutralization of the pseudovirus bearing the U.K. strain spike by BNT162b2- immune sera makes it likely that COVID-19 caused by the U.K. virus variant will also be prevented by immunization with BNT162b2.", "Here, we investigated SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 16 participants in a previously reported trial with the mRNA- based COVID-19 vaccine BNT162b2.", "Here, we investigated SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 16 participants in a previously reported trial with the mRNA-based COVID-19 vaccine BNT162b2."]}
{"id": 1002296, "claim": "Two dogs tested positive of sars-cov-2 .", "label": "SUPPORTED", "evidence": ["Oral and nasal swabs tested positive for SARS- CoV-2 RNA on the first two occasions (Table 1).", "The evidence suggests that these are instances of human-to-animal transmission of SARS-CoV-2.", "However, only two dogs and one cat have tested positive for SARS-CoV-2 infection.", "Infection of dogs with SARS- CoV-2."]}
{"id": 1002297, "claim": "Two children tested positive of sars-cov-2.", "label": "REFUTED", "evidence": ["Oral and nasal swabs tested positive for SARS- CoV-2 RNA on the first two occasions (Table 1).", "The evidence suggests that these are instances of human-to-animal transmission of SARS-CoV-2.", "However, only two dogs and one cat have tested positive for SARS-CoV-2 infection.", "Infection of dogs with SARS- CoV-2."]}
{"id": 1002298, "claim": "Six dogs tested positive of sars-cov-2.", "label": "REFUTED", "evidence": ["Oral and nasal swabs tested positive for SARS- CoV-2 RNA on the first two occasions (Table 1).", "The evidence suggests that these are instances of human-to-animal transmission of SARS-CoV-2.", "However, only two dogs and one cat have tested positive for SARS-CoV-2 infection.", "Infection of dogs with SARS- CoV-2."]}
{"id": 1002299, "claim": "Four dogs tested positive of sars-cov-2.", "label": "REFUTED", "evidence": ["Oral and nasal swabs tested positive for SARS- CoV-2 RNA on the first two occasions (Table 1).", "The evidence suggests that these are instances of human-to-animal transmission of SARS-CoV-2.", "However, only two dogs and one cat have tested positive for SARS-CoV-2 infection.", "Infection of dogs with SARS- CoV-2."]}
{"id": 1002300, "claim": "Ace2 levels are altered in comorbidities linked to severe outcome in covid-19", "label": "SUPPORTED", "evidence": ["Conclusion ACE2 levels are upregulated in some patient groups with comorbidities linked to COVID-19 and as such may have an emerging role as outcome in COVID-19."]}
{"id": 1002301, "claim": "Tlr2 levels are altered in comorbidities linked to severe outcome in covid-19", "label": "REFUTED", "evidence": ["Conclusion ACE2 levels are upregulated in some patient groups with comorbidities linked to COVID-19 and as such may have an emerging role as outcome in COVID-19."]}
{"id": 1002302, "claim": "M2 levels are altered in comorbidities linked to severe outcome in covid-19", "label": "REFUTED", "evidence": ["Conclusion ACE2 levels are upregulated in some patient groups with comorbidities linked to COVID-19 and as such may have an emerging role as outcome in COVID-19."]}
{"id": 1002303, "claim": "Ifit2 levels are altered in comorbidities linked to severe outcome in covid-19", "label": "REFUTED", "evidence": ["Conclusion ACE2 levels are upregulated in some patient groups with comorbidities linked to COVID-19 and as such may have an emerging role as outcome in COVID-19."]}
{"id": 1002304, "claim": "Sars-cov-2 igg antibody responses in new york city", "label": "SUPPORTED", "evidence": ["Levels of SARS-CoV-2 IgG antibody are plotted against SSI in Fig.", "Laboratory testing for SARS-CoV-2 IgG Semi-quantitative SARS-CoV-2 IgG testing was performed at Sherman Abrams Laboratory in Brooklyn, NY on serum specimens using the DiaSorin LIAISON SARS- CoV-2 S1/S2 IgG Antibody Assay on the LIAISON XL platform.", "These tests detect either individual SARS-CoV-2 specific IgG antibodies or total antibodies against SARS-CoV-2."]}
{"id": 1002305, "claim": "Pds-cov-2 igg antibody responses in new york city", "label": "REFUTED", "evidence": ["Levels of SARS-CoV-2 IgG antibody are plotted against SSI in Fig.", "Laboratory testing for SARS-CoV-2 IgG Semi-quantitative SARS-CoV-2 IgG testing was performed at Sherman Abrams Laboratory in Brooklyn, NY on serum specimens using the DiaSorin LIAISON SARS- CoV-2 S1/S2 IgG Antibody Assay on the LIAISON XL platform.", "These tests detect either individual SARS-CoV-2 specific IgG antibodies or total antibodies against SARS-CoV-2."]}
{"id": 1002306, "claim": "Aces-cov-2 igg antibody responses in new york city", "label": "REFUTED", "evidence": ["Levels of SARS-CoV-2 IgG antibody are plotted against SSI in Fig.", "Laboratory testing for SARS-CoV-2 IgG Semi-quantitative SARS-CoV-2 IgG testing was performed at Sherman Abrams Laboratory in Brooklyn, NY on serum specimens using the DiaSorin LIAISON SARS- CoV-2 S1/S2 IgG Antibody Assay on the LIAISON XL platform.", "These tests detect either individual SARS-CoV-2 specific IgG antibodies or total antibodies against SARS-CoV-2."]}
{"id": 1002307, "claim": "Ms-cov-2 igg antibody responses in new york city", "label": "REFUTED", "evidence": ["Levels of SARS-CoV-2 IgG antibody are plotted against SSI in Fig.", "Laboratory testing for SARS-CoV-2 IgG Semi-quantitative SARS-CoV-2 IgG testing was performed at Sherman Abrams Laboratory in Brooklyn, NY on serum specimens using the DiaSorin LIAISON SARS- CoV-2 S1/S2 IgG Antibody Assay on the LIAISON XL platform.", "These tests detect either individual SARS-CoV-2 specific IgG antibodies or total antibodies against SARS-CoV-2."]}
{"id": 1002308, "claim": "Novel 2019 coronavirus structure , mechanism of action , antiviral drug promises and rule out against its treatment", "label": "SUPPORTED", "evidence": ["The structure-based virtual screening computational approach will be used to filter the best drugs from the literature, the investigate the structural variation of COVID-19 with the interaction of the best inhibitor is a fundamental step to design new drugs and vaccines which can combat the coronavirus.", "This mini-review will address novel coronavirus structure, mechanism of action, and trial test of antiviral drugs in the lab and patients with COVID-19."]}
{"id": 1002309, "claim": "Novel sars coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment", "label": "REFUTED", "evidence": ["The structure-based virtual screening computational approach will be used to filter the best drugs from the literature, the investigate the structural variation of COVID-19 with the interaction of the best inhibitor is a fundamental step to design new drugs and vaccines which can combat the coronavirus.", "This mini-review will address novel coronavirus structure, mechanism of action, and trial test of antiviral drugs in the lab and patients with COVID-19."]}
{"id": 1002310, "claim": "Collider bias undermines our understanding of covid-19 disease risk and severity", "label": "SUPPORTED", "evidence": ["We illustrate these issues using data from the UK Biobank in which individuals tested for COVID-19 are highly selected for a wide range of genetic, behavioural, cardiovascular, demographic, and anthropometric traits.", "Here, we highlight the challenge of interpreting observational evidence from such samples of the population, which may be affected by collider bias.", "We discuss the sampling mechanisms that leave aetiological studies of COVID-19 infection and progression particularly susceptible to collider bias."]}
{"id": 1002311, "claim": "Collider bias focuss our understanding of covid-19 disease risk and severity", "label": "REFUTED", "evidence": ["We illustrate these issues using data from the UK Biobank in which individuals tested for COVID-19 are highly selected for a wide range of genetic, behavioural, cardiovascular, demographic, and anthropometric traits.", "Here, we highlight the challenge of interpreting observational evidence from such samples of the population, which may be affected by collider bias.", "We discuss the sampling mechanisms that leave aetiological studies of COVID-19 infection and progression particularly susceptible to collider bias."]}
{"id": 1002312, "claim": "Collider bias wills our understanding of covid-19 disease risk and severity", "label": "REFUTED", "evidence": ["We illustrate these issues using data from the UK Biobank in which individuals tested for COVID-19 are highly selected for a wide range of genetic, behavioural, cardiovascular, demographic, and anthropometric traits.", "Here, we highlight the challenge of interpreting observational evidence from such samples of the population, which may be affected by collider bias.", "We discuss the sampling mechanisms that leave aetiological studies of COVID-19 infection and progression particularly susceptible to collider bias."]}
{"id": 1002313, "claim": "Collider bias focuseds our understanding of covid-19 disease risk and severity", "label": "REFUTED", "evidence": ["We illustrate these issues using data from the UK Biobank in which individuals tested for COVID-19 are highly selected for a wide range of genetic, behavioural, cardiovascular, demographic, and anthropometric traits.", "Here, we highlight the challenge of interpreting observational evidence from such samples of the population, which may be affected by collider bias.", "We discuss the sampling mechanisms that leave aetiological studies of COVID-19 infection and progression particularly susceptible to collider bias."]}
{"id": 1002314, "claim": "A potently neutralizing antibody protects mice against sars-cov-2 infection", "label": "SUPPORTED", "evidence": ["In a murine model of SARS-CoV-2 infection, 2B04 protected challenged animals from weight loss, reduced lung viral load, and blocked systemic dissemination.", "mAb 2B04 protects mice from morbidity in a murine model of SARS-CoV-2 infection."]}
{"id": 1002315, "claim": "A potently neutralizing antibody protects humans against sars-cov-2 infection", "label": "REFUTED", "evidence": ["In a murine model of SARS-CoV-2 infection, 2B04 protected challenged animals from weight loss, reduced lung viral load, and blocked systemic dissemination.", "mAb 2B04 protects mice from morbidity in a murine model of SARS-CoV-2 infection."]}
{"id": 1002316, "claim": "A potently neutralizing antibody protects dcs against sars-cov-2 infection", "label": "REFUTED", "evidence": ["In a murine model of SARS-CoV-2 infection, 2B04 protected challenged animals from weight loss, reduced lung viral load, and blocked systemic dissemination.", "mAb 2B04 protects mice from morbidity in a murine model of SARS-CoV-2 infection."]}
{"id": 1002317, "claim": "A potently neutralizing antibody protects cells against sars-cov-2 infection", "label": "REFUTED", "evidence": ["In a murine model of SARS-CoV-2 infection, 2B04 protected challenged animals from weight loss, reduced lung viral load, and blocked systemic dissemination.", "mAb 2B04 protects mice from morbidity in a murine model of SARS-CoV-2 infection."]}
{"id": 1002318, "claim": "Abu dhabi health chief volunteers to be first patient to test covid-19 vaccine", "label": "SUPPORTED", "evidence": ["The chairman of the Department of Health Abu Dhabi, Sheikh Abdullah bin Mohammed Al Hamed, volunteered as the first patient to test the inactive vaccine, which contains a killed version of the germ that causes Covid-19.", "The chairman of the Department of Health Abu Dhabi, Sheikh Abdullah bin Mohammed Al Hamed, volunteered as the first patient to test the inactive vaccine, which contains a killed version of the germ that causes Covid-19, last month."]}
{"id": 1002319, "claim": "Abu dhabi health chief volunteers to be another patient to test covid-19 vaccine", "label": "REFUTED", "evidence": ["The chairman of the Department of Health Abu Dhabi, Sheikh Abdullah bin Mohammed Al Hamed, volunteered as the first patient to test the inactive vaccine, which contains a killed version of the germ that causes Covid-19.", "The chairman of the Department of Health Abu Dhabi, Sheikh Abdullah bin Mohammed Al Hamed, volunteered as the first patient to test the inactive vaccine, which contains a killed version of the germ that causes Covid-19, last month."]}
{"id": 1002320, "claim": "Abu dhabi health chief volunteers to be any patient to test covid-19 vaccine", "label": "REFUTED", "evidence": ["The chairman of the Department of Health Abu Dhabi, Sheikh Abdullah bin Mohammed Al Hamed, volunteered as the first patient to test the inactive vaccine, which contains a killed version of the germ that causes Covid-19.", "The chairman of the Department of Health Abu Dhabi, Sheikh Abdullah bin Mohammed Al Hamed, volunteered as the first patient to test the inactive vaccine, which contains a killed version of the germ that causes Covid-19, last month."]}
{"id": 1002321, "claim": "Abu dhabi health chief volunteers to be each patient to test covid-19 vaccine", "label": "REFUTED", "evidence": ["The chairman of the Department of Health Abu Dhabi, Sheikh Abdullah bin Mohammed Al Hamed, volunteered as the first patient to test the inactive vaccine, which contains a killed version of the germ that causes Covid-19.", "The chairman of the Department of Health Abu Dhabi, Sheikh Abdullah bin Mohammed Al Hamed, volunteered as the first patient to test the inactive vaccine, which contains a killed version of the germ that causes Covid-19, last month."]}
{"id": 1002322, "claim": "Johnson & johnson initiates second global phase 3 clinical trial of its janssen covid-19 vaccine candidate", "label": "SUPPORTED", "evidence": ["JANSSENS INVESTIGATIONAL COVID-19 VACCINE CANDIDATE The Janssen COVID-19 vaccine candidate leverages the Companys AdVac® technology platform, which was also used to develop and manufacture Janssens European Commission-approved Ebola vaccine and construct its Zika, RSV, and HIV investigational vaccine candidates.", "The Phase 3 ENSEMBLE and ENSEMBLE 2 trials follow positive interim results from the Companys ongoing Phase 1/2a clinical study, which is studying the safety profile and immunogenicity of both a single-dose and two-dose vaccination.", "In order to evaluate the efficacy of Janssens COVID-19 vaccine candidate, clinical trial sites in countries and areas with high incidence of COVID-19 and the ability to achieve a rapid initiation were selected.", "ENSEMBLE 2 is a complementary, planned, pivotal, large-scale, multi-country Phase 3 trial that will study the safety and efficacy of a two-dose regimen of the investigational Janssen vaccine candidate for the prevention of COVID-19 in up to 30,000 participants worldwide.", "PHASE 3 ENSEMBLE 2 STUDY The Phase 3 ENSEMBLE 2 study (NCT04614948) is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and efficacy of a two-dose vaccine regimen versus placebo in adults 18 years old and older with and without comorbidities associated with an increased risk for severe COVID-19."]}
{"id": 1002323, "claim": "Johnson & johnson initiates one global phase 3 clinical trial of its janssen covid-19 vaccine candidate", "label": "REFUTED", "evidence": ["JANSSENS INVESTIGATIONAL COVID-19 VACCINE CANDIDATE The Janssen COVID-19 vaccine candidate leverages the Companys AdVac® technology platform, which was also used to develop and manufacture Janssens European Commission-approved Ebola vaccine and construct its Zika, RSV, and HIV investigational vaccine candidates.", "The Phase 3 ENSEMBLE and ENSEMBLE 2 trials follow positive interim results from the Companys ongoing Phase 1/2a clinical study, which is studying the safety profile and immunogenicity of both a single-dose and two-dose vaccination.", "In order to evaluate the efficacy of Janssens COVID-19 vaccine candidate, clinical trial sites in countries and areas with high incidence of COVID-19 and the ability to achieve a rapid initiation were selected.", "ENSEMBLE 2 is a complementary, planned, pivotal, large-scale, multi-country Phase 3 trial that will study the safety and efficacy of a two-dose regimen of the investigational Janssen vaccine candidate for the prevention of COVID-19 in up to 30,000 participants worldwide.", "PHASE 3 ENSEMBLE 2 STUDY The Phase 3 ENSEMBLE 2 study (NCT04614948) is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and efficacy of a two-dose vaccine regimen versus placebo in adults 18 years old and older with and without comorbidities associated with an increased risk for severe COVID-19."]}
{"id": 1002324, "claim": "Johnson & johnson initiates the global phase 3 clinical trial of its janssen covid-19 vaccine candidate", "label": "REFUTED", "evidence": ["JANSSENS INVESTIGATIONAL COVID-19 VACCINE CANDIDATE The Janssen COVID-19 vaccine candidate leverages the Companys AdVac® technology platform, which was also used to develop and manufacture Janssens European Commission-approved Ebola vaccine and construct its Zika, RSV, and HIV investigational vaccine candidates.", "The Phase 3 ENSEMBLE and ENSEMBLE 2 trials follow positive interim results from the Companys ongoing Phase 1/2a clinical study, which is studying the safety profile and immunogenicity of both a single-dose and two-dose vaccination.", "In order to evaluate the efficacy of Janssens COVID-19 vaccine candidate, clinical trial sites in countries and areas with high incidence of COVID-19 and the ability to achieve a rapid initiation were selected.", "ENSEMBLE 2 is a complementary, planned, pivotal, large-scale, multi-country Phase 3 trial that will study the safety and efficacy of a two-dose regimen of the investigational Janssen vaccine candidate for the prevention of COVID-19 in up to 30,000 participants worldwide.", "PHASE 3 ENSEMBLE 2 STUDY The Phase 3 ENSEMBLE 2 study (NCT04614948) is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and efficacy of a two-dose vaccine regimen versus placebo in adults 18 years old and older with and without comorbidities associated with an increased risk for severe COVID-19."]}
{"id": 1002325, "claim": "Virus evolution affected early covid-19 spread", "label": "SUPPORTED", "evidence": ["In particular, higher proportions of clade 19A and 19B were negatively correlated with COVID-19 growth rate, whereas higher proportions of 20A and 20C were positively correlated with growth rate."]}
{"id": 1002326, "claim": "Virus transmission affected early covid-19 spread", "label": "REFUTED", "evidence": ["In particular, higher proportions of clade 19A and 19B were negatively correlated with COVID-19 growth rate, whereas higher proportions of 20A and 20C were positively correlated with growth rate."]}
{"id": 1002327, "claim": "Virus shedding affected early covid-19 spread", "label": "REFUTED", "evidence": ["In particular, higher proportions of clade 19A and 19B were negatively correlated with COVID-19 growth rate, whereas higher proportions of 20A and 20C were positively correlated with growth rate."]}
{"id": 1002328, "claim": "Virus replication affected early covid-19 spread", "label": "REFUTED", "evidence": ["In particular, higher proportions of clade 19A and 19B were negatively correlated with COVID-19 growth rate, whereas higher proportions of 20A and 20C were positively correlated with growth rate."]}
{"id": 1002329, "claim": "Relationship between average daily temperature and average cumulative daily rate of confirmed cases of covid-19", "label": "SUPPORTED", "evidence": ["BACKGROUND The rapid outbreak of the new Coronavirus (COVID-19) pandemic and the spread of the virus worldwide, especially in the Northern Hemisphere, have prompted various investigations about the impact of environmental factors on the rate of development of this epidemic.", "Besides, the analysis of the average air temperatures shows that the epidemic rates of COVID-19 were higher in the case studies with a lower average temperature.", "Conversely, if there are no significant differences in the mean daily temperature of two regions in the same country, no significant difference is observed in the average cumulative daily rate of confirmed cases for these regions."]}
{"id": 1002330, "claim": "Relationship between average daily dose and average cumulative daily rate of confirmed cases of covid-19", "label": "REFUTED", "evidence": ["BACKGROUND The rapid outbreak of the new Coronavirus (COVID-19) pandemic and the spread of the virus worldwide, especially in the Northern Hemisphere, have prompted various investigations about the impact of environmental factors on the rate of development of this epidemic.", "Besides, the analysis of the average air temperatures shows that the epidemic rates of COVID-19 were higher in the case studies with a lower average temperature.", "Conversely, if there are no significant differences in the mean daily temperature of two regions in the same country, no significant difference is observed in the average cumulative daily rate of confirmed cases for these regions."]}
{"id": 1002331, "claim": "Relationship between average daily weight and average cumulative daily rate of confirmed cases of covid-19", "label": "REFUTED", "evidence": ["BACKGROUND The rapid outbreak of the new Coronavirus (COVID-19) pandemic and the spread of the virus worldwide, especially in the Northern Hemisphere, have prompted various investigations about the impact of environmental factors on the rate of development of this epidemic.", "Besides, the analysis of the average air temperatures shows that the epidemic rates of COVID-19 were higher in the case studies with a lower average temperature.", "Conversely, if there are no significant differences in the mean daily temperature of two regions in the same country, no significant difference is observed in the average cumulative daily rate of confirmed cases for these regions."]}
{"id": 1002332, "claim": "Relationship between average daily counts and average cumulative daily rate of confirmed cases of covid-19", "label": "REFUTED", "evidence": ["BACKGROUND The rapid outbreak of the new Coronavirus (COVID-19) pandemic and the spread of the virus worldwide, especially in the Northern Hemisphere, have prompted various investigations about the impact of environmental factors on the rate of development of this epidemic.", "Besides, the analysis of the average air temperatures shows that the epidemic rates of COVID-19 were higher in the case studies with a lower average temperature.", "Conversely, if there are no significant differences in the mean daily temperature of two regions in the same country, no significant difference is observed in the average cumulative daily rate of confirmed cases for these regions."]}
{"id": 1002333, "claim": "The infection fatality rate of covid-19 inferred from seroprevalence data", "label": "SUPPORTED", "evidence": ["Infection fatality rates ranged from 0.00% to 1.63% and corrected values ranged from 0.00% to 1.31%.", "Infection fatality rate was estimated from each study dividing the number of COVID-19 deaths at a relevant time point by the number of estimated people infected in each relevant region.", "Estimates of infection fatality rates inferred from seroprevalence studies tend to be much lower than original speculations made in the early days of the pandemic."]}
{"id": 1002334, "claim": "The case fatality rate of covid-19 inferred from seroprevalence data", "label": "REFUTED", "evidence": ["Infection fatality rates ranged from 0.00% to 1.63% and corrected values ranged from 0.00% to 1.31%.", "Infection fatality rate was estimated from each study dividing the number of COVID-19 deaths at a relevant time point by the number of estimated people infected in each relevant region.", "Estimates of infection fatality rates inferred from seroprevalence studies tend to be much lower than original speculations made in the early days of the pandemic."]}
{"id": 1002335, "claim": "In fatal covid-19 , the immune response can control the virus but kill the patient", "label": "SUPPORTED", "evidence": ["These findings indicate that the pathogenesis of late severe COVID-19 pneumonia involves a dysregulated immune response, rather than direct viral damage.", "E. J. Giamarellos-Bourboulis et al ., Complex immune dysregulation in COVID-19 patients with severe respiratory failure."]}
{"id": 1002336, "claim": "In fatal covid-19, the immune response cannot control the virus but kill the patient", "label": "REFUTED", "evidence": ["These findings indicate that the pathogenesis of late severe COVID-19 pneumonia involves a dysregulated immune response, rather than direct viral damage.", "E. J. Giamarellos-Bourboulis et al ., Complex immune dysregulation in COVID-19 patients with severe respiratory failure."]}
{"id": 1002337, "claim": "In fatal covid-19, the immune response not control the virus but kill the patient", "label": "REFUTED", "evidence": ["These findings indicate that the pathogenesis of late severe COVID-19 pneumonia involves a dysregulated immune response, rather than direct viral damage.", "E. J. Giamarellos-Bourboulis et al ., Complex immune dysregulation in COVID-19 patients with severe respiratory failure."]}
{"id": 1002338, "claim": "Impact of new variant on children investigated.", "label": "SUPPORTED", "evidence": ["Now, researchers are trying to find out if it reacts differently in children.", "In the UK, younger children are testing positive at a higher rate for the new strain, according to researchers.", "Dr. Fuller questions if that could make children more susceptible to the virus.", "Experts say that could be because the new variant spreads more easily in children.", "Will a child who was more resistant to the old strain now be more vulnerable to infection with this new strain?"]}
{"id": 1002339, "claim": "Impact of new variant on strains investigated.", "label": "REFUTED", "evidence": ["Now, researchers are trying to find out if it reacts differently in children.", "In the UK, younger children are testing positive at a higher rate for the new strain, according to researchers.", "Dr. Fuller questions if that could make children more susceptible to the virus.", "Experts say that could be because the new variant spreads more easily in children.", "Will a child who was more resistant to the old strain now be more vulnerable to infection with this new strain?"]}
{"id": 1002340, "claim": "Impact of new variant on strain investigated.", "label": "REFUTED", "evidence": ["Now, researchers are trying to find out if it reacts differently in children.", "In the UK, younger children are testing positive at a higher rate for the new strain, according to researchers.", "Dr. Fuller questions if that could make children more susceptible to the virus.", "Experts say that could be because the new variant spreads more easily in children.", "Will a child who was more resistant to the old strain now be more vulnerable to infection with this new strain?"]}
{"id": 1002341, "claim": "Uk rolls out first doses of covid-19 vaccination .", "label": "SUPPORTED", "evidence": ["UK rolls out 1st doses of Pfizers COVID-19 vaccine - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.", "REUTERS More than 50 hospitals across England were designated as Covid-19 vaccine hubs, the first stage of what will be a lengthy vaccination campaign.", "The first shot came early in the morning at one of a network of hospital hubs around the country where the initial phase of the U.K. program will be rolled out on what has been dubbed V-Day. Public health officials are asking the public to be patient because only those who are most at risk from COVID-19 will be vaccinated in the early stages."]}
{"id": 1002342, "claim": "Uk rule out first doses of covid-19 vaccination.", "label": "REFUTED", "evidence": ["UK rolls out 1st doses of Pfizers COVID-19 vaccine - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.", "REUTERS More than 50 hospitals across England were designated as Covid-19 vaccine hubs, the first stage of what will be a lengthy vaccination campaign.", "The first shot came early in the morning at one of a network of hospital hubs around the country where the initial phase of the U.K. program will be rolled out on what has been dubbed V-Day. Public health officials are asking the public to be patient because only those who are most at risk from COVID-19 will be vaccinated in the early stages."]}
{"id": 1002343, "claim": "Uk ruled out first doses of covid-19 vaccination.", "label": "REFUTED", "evidence": ["UK rolls out 1st doses of Pfizers COVID-19 vaccine - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.", "REUTERS More than 50 hospitals across England were designated as Covid-19 vaccine hubs, the first stage of what will be a lengthy vaccination campaign.", "The first shot came early in the morning at one of a network of hospital hubs around the country where the initial phase of the U.K. program will be rolled out on what has been dubbed V-Day. Public health officials are asking the public to be patient because only those who are most at risk from COVID-19 will be vaccinated in the early stages."]}
{"id": 1002344, "claim": "Uk rolls out all doses of covid-19 vaccination.", "label": "REFUTED", "evidence": ["UK rolls out 1st doses of Pfizers COVID-19 vaccine - YouTube AboutPressCopyrightContact usCreatorsAdvertiseDevelopersTermsPrivacyPolicy & SafetyHow YouTube worksTest new features (C) 2021 Google LLC [DOI]: Digital Object Identifier [ISSN]: International Standard Serial Number [.", "REUTERS More than 50 hospitals across England were designated as Covid-19 vaccine hubs, the first stage of what will be a lengthy vaccination campaign.", "The first shot came early in the morning at one of a network of hospital hubs around the country where the initial phase of the U.K. program will be rolled out on what has been dubbed V-Day. Public health officials are asking the public to be patient because only those who are most at risk from COVID-19 will be vaccinated in the early stages."]}
{"id": 1002345, "claim": "A novel ace2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and rna respiratory virus infection.", "label": "SUPPORTED", "evidence": ["A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection", "Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2.", "ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia.", "Share A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection Cornelia Blume, Claire L Jackson, Cosma Mirella Spalluto, Jelmer Legebeke, Liliya Nazlamova, Franco Conforti, Jeanne-Marie Perotin-Collard, Martin Frank, Max Crispin, Janice Coles, James Thompson, Robert A Ridley, Lareb S N Dean, Matthew Loxham, Adnan Azim, Kamran Tariq, David Johnston, Paul J Skipp, Ratko Djukanovic, Diana Baralle, Chris McCormick, Donna E Davies, Jane S Lucas, Gabrielle Wheway, Vito Mennella bioRxiv 2020.07.31.230870; doi: https://doi.org/10.1101/2020.07.31.230870 Share This Article: Copy Citation Tools A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection Cornelia Blume, Claire L Jackson, Cosma Mirella Spalluto, Jelmer Legebeke, Liliya Nazlamova, Franco Conforti, Jeanne-Marie Perotin-Collard, Martin Frank, Max Crispin, Janice Coles, James Thompson, Robert A Ridley, Lareb S N Dean, Matthew Loxham, Adnan Azim, Kamran Tariq, David Johnston, Paul J Skipp, Ratko Djukanovic, Diana Baralle, Chris McCormick, Donna E Davies, Jane S Lucas, Gabrielle Wheway, Vito Mennella bioRxiv 2020.07.31.230870; doi: https://doi.org/10.1101/2020.07.31.230870 ", "You are going to email the following A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website."]}
{"id": 1002346, "claim": "A novel ace2 isoform is expressed in mouse respiratory epithelia and is upregulated in response to interferons and rna respiratory virus infection.", "label": "REFUTED", "evidence": ["A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection", "Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2.", "ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia.", "Share A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection Cornelia Blume, Claire L Jackson, Cosma Mirella Spalluto, Jelmer Legebeke, Liliya Nazlamova, Franco Conforti, Jeanne-Marie Perotin-Collard, Martin Frank, Max Crispin, Janice Coles, James Thompson, Robert A Ridley, Lareb S N Dean, Matthew Loxham, Adnan Azim, Kamran Tariq, David Johnston, Paul J Skipp, Ratko Djukanovic, Diana Baralle, Chris McCormick, Donna E Davies, Jane S Lucas, Gabrielle Wheway, Vito Mennella bioRxiv 2020.07.31.230870; doi: https://doi.org/10.1101/2020.07.31.230870 Share This Article: Copy Citation Tools A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection Cornelia Blume, Claire L Jackson, Cosma Mirella Spalluto, Jelmer Legebeke, Liliya Nazlamova, Franco Conforti, Jeanne-Marie Perotin-Collard, Martin Frank, Max Crispin, Janice Coles, James Thompson, Robert A Ridley, Lareb S N Dean, Matthew Loxham, Adnan Azim, Kamran Tariq, David Johnston, Paul J Skipp, Ratko Djukanovic, Diana Baralle, Chris McCormick, Donna E Davies, Jane S Lucas, Gabrielle Wheway, Vito Mennella bioRxiv 2020.07.31.230870; doi: https://doi.org/10.1101/2020.07.31.230870 ", "You are going to email the following A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website."]}
{"id": 1002347, "claim": "A novel ace2 isoform is expressed in canine respiratory epithelia and is upregulated in response to interferons and rna respiratory virus infection.", "label": "REFUTED", "evidence": ["A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection", "Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2.", "ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia.", "Share A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection Cornelia Blume, Claire L Jackson, Cosma Mirella Spalluto, Jelmer Legebeke, Liliya Nazlamova, Franco Conforti, Jeanne-Marie Perotin-Collard, Martin Frank, Max Crispin, Janice Coles, James Thompson, Robert A Ridley, Lareb S N Dean, Matthew Loxham, Adnan Azim, Kamran Tariq, David Johnston, Paul J Skipp, Ratko Djukanovic, Diana Baralle, Chris McCormick, Donna E Davies, Jane S Lucas, Gabrielle Wheway, Vito Mennella bioRxiv 2020.07.31.230870; doi: https://doi.org/10.1101/2020.07.31.230870 Share This Article: Copy Citation Tools A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection Cornelia Blume, Claire L Jackson, Cosma Mirella Spalluto, Jelmer Legebeke, Liliya Nazlamova, Franco Conforti, Jeanne-Marie Perotin-Collard, Martin Frank, Max Crispin, Janice Coles, James Thompson, Robert A Ridley, Lareb S N Dean, Matthew Loxham, Adnan Azim, Kamran Tariq, David Johnston, Paul J Skipp, Ratko Djukanovic, Diana Baralle, Chris McCormick, Donna E Davies, Jane S Lucas, Gabrielle Wheway, Vito Mennella bioRxiv 2020.07.31.230870; doi: https://doi.org/10.1101/2020.07.31.230870 ", "You are going to email the following A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website."]}
{"id": 1002348, "claim": "A novel ace2 isoform is expressed in chicken respiratory epithelia and is upregulated in response to interferons and rna respiratory virus infection.", "label": "REFUTED", "evidence": ["A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection", "Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2.", "ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia.", "Share A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection Cornelia Blume, Claire L Jackson, Cosma Mirella Spalluto, Jelmer Legebeke, Liliya Nazlamova, Franco Conforti, Jeanne-Marie Perotin-Collard, Martin Frank, Max Crispin, Janice Coles, James Thompson, Robert A Ridley, Lareb S N Dean, Matthew Loxham, Adnan Azim, Kamran Tariq, David Johnston, Paul J Skipp, Ratko Djukanovic, Diana Baralle, Chris McCormick, Donna E Davies, Jane S Lucas, Gabrielle Wheway, Vito Mennella bioRxiv 2020.07.31.230870; doi: https://doi.org/10.1101/2020.07.31.230870 Share This Article: Copy Citation Tools A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection Cornelia Blume, Claire L Jackson, Cosma Mirella Spalluto, Jelmer Legebeke, Liliya Nazlamova, Franco Conforti, Jeanne-Marie Perotin-Collard, Martin Frank, Max Crispin, Janice Coles, James Thompson, Robert A Ridley, Lareb S N Dean, Matthew Loxham, Adnan Azim, Kamran Tariq, David Johnston, Paul J Skipp, Ratko Djukanovic, Diana Baralle, Chris McCormick, Donna E Davies, Jane S Lucas, Gabrielle Wheway, Vito Mennella bioRxiv 2020.07.31.230870; doi: https://doi.org/10.1101/2020.07.31.230870 ", "You are going to email the following A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website."]}
{"id": 1002349, "claim": "Unc researchers create new type of accurate covid-19 antibody test", "label": "SUPPORTED", "evidence": ["The test can be ramped up to document past and recent COVID-19 infections and possibly used to identify asymptomatic virus infection and the level of immunity in individuals.", "Therefore, antibodies against this domain are likely to be highly specific to SARS-CoV-2, and so these antibodies reveal if an individual has been exposed to the virus that can cause COVID-19.", "Our assay is extremely specific for antibodies to the virus that causes COVID-19, which is not the case for some currently available antibody tests, said co-senior author Aravinda de Silva, professor of microbiology and immunology and member of the UNC Institute for Global Health and Infectious Diseases.", "The researchers, who published their work in Science Immunology, created a blood test to pinpoint SARS-CoV-2 antibodies that target one unique piece of the SARS-CoV-2 spike protein."]}
{"id": 1002350, "claim": "Unc researchers create one type of accurate covid-19 antibody test", "label": "REFUTED", "evidence": ["The test can be ramped up to document past and recent COVID-19 infections and possibly used to identify asymptomatic virus infection and the level of immunity in individuals.", "Therefore, antibodies against this domain are likely to be highly specific to SARS-CoV-2, and so these antibodies reveal if an individual has been exposed to the virus that can cause COVID-19.", "Our assay is extremely specific for antibodies to the virus that causes COVID-19, which is not the case for some currently available antibody tests, said co-senior author Aravinda de Silva, professor of microbiology and immunology and member of the UNC Institute for Global Health and Infectious Diseases.", "The researchers, who published their work in Science Immunology, created a blood test to pinpoint SARS-CoV-2 antibodies that target one unique piece of the SARS-CoV-2 spike protein."]}
{"id": 1002351, "claim": "Gilead data suggests coronavirus patients are responding to treatment", "label": "SUPPORTED", "evidence": ["Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests."]}
{"id": 1002352, "claim": "Gilead data suggests coronavirus patients are resistant to treatment", "label": "REFUTED", "evidence": ["Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests."]}
{"id": 1002353, "claim": "Gilead data suggests coronavirus patients are unable to treatment", "label": "REFUTED", "evidence": ["Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests."]}
{"id": 1002354, "claim": "Gilead data suggests coronavirus patients are difficult to treatment", "label": "REFUTED", "evidence": ["Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests."]}
{"id": 1002355, "claim": "An ancient coronavirus-like epidemic drove adaptation in east asians from 25,000 to 5,000 years ago", "label": "SUPPORTED", "evidence": ["These adaptive events were limited to ancestral East Asian populations, the geographical origin of several modern coronavirus epidemics.", "An arms race with an ancient corona-like virus may thus have taken place in ancestral East Asian populations.", "Here, we apply evolutionary analyses to human genomic datasets to recover selection events involving tens of human genes that interact with coronaviruses, including SARS-CoV-2, that started 25,000 years ago.", "Notably, modern human genomes contain evolutionary information tracing back tens of thousands of years, which may help identify the viruses that have impacted our ancestors  pointing to which viruses have future pandemic potential."]}
{"id": 1002356, "claim": "An recent coronavirus-like epidemic drove adaptation in east asians from 25,000 to 5,000 years ago", "label": "REFUTED", "evidence": ["These adaptive events were limited to ancestral East Asian populations, the geographical origin of several modern coronavirus epidemics.", "An arms race with an ancient corona-like virus may thus have taken place in ancestral East Asian populations.", "Here, we apply evolutionary analyses to human genomic datasets to recover selection events involving tens of human genes that interact with coronaviruses, including SARS-CoV-2, that started 25,000 years ago.", "Notably, modern human genomes contain evolutionary information tracing back tens of thousands of years, which may help identify the viruses that have impacted our ancestors  pointing to which viruses have future pandemic potential."]}
{"id": 1002357, "claim": "An novel coronavirus-like epidemic drove adaptation in east asians from 25,000 to 5,000 years ago", "label": "REFUTED", "evidence": ["These adaptive events were limited to ancestral East Asian populations, the geographical origin of several modern coronavirus epidemics.", "An arms race with an ancient corona-like virus may thus have taken place in ancestral East Asian populations.", "Here, we apply evolutionary analyses to human genomic datasets to recover selection events involving tens of human genes that interact with coronaviruses, including SARS-CoV-2, that started 25,000 years ago.", "Notably, modern human genomes contain evolutionary information tracing back tens of thousands of years, which may help identify the viruses that have impacted our ancestors  pointing to which viruses have future pandemic potential."]}
{"id": 1002358, "claim": "An emerging coronavirus-like epidemic drove adaptation in east asians from 25,000 to 5,000 years ago", "label": "REFUTED", "evidence": ["These adaptive events were limited to ancestral East Asian populations, the geographical origin of several modern coronavirus epidemics.", "An arms race with an ancient corona-like virus may thus have taken place in ancestral East Asian populations.", "Here, we apply evolutionary analyses to human genomic datasets to recover selection events involving tens of human genes that interact with coronaviruses, including SARS-CoV-2, that started 25,000 years ago.", "Notably, modern human genomes contain evolutionary information tracing back tens of thousands of years, which may help identify the viruses that have impacted our ancestors  pointing to which viruses have future pandemic potential."]}
{"id": 1002359, "claim": "Furin cleavage of sars-cov-2 spike promotes but is not essential for infection and cell-cell fusion", "label": "SUPPORTED", "evidence": ["Here we show that CRISPR- Cas9 knockout of furin reduces, but does not prevent, the production of infectious SARS-CoV-2 virus.", "Comparing S processing in furin knockout cells to multibasic site mutants reveals that while loss of furin substantially reduces S1-S2 cleavage it does not prevent it.", "Our results show that while furin promotes both SARS-CoV-2 infectivity and cell-cell spread it is not essential, suggesting furin inhibitors will not prevent viral spread.", "We show that loss of furin in either donor or acceptor cells reduces, but does not prevent, TMPRSS2-dependent cell-cell fusion, unlike mutation of the multibasic site that completely prevents syncytia formation."]}
{"id": 1002360, "claim": "Furin cleavage of sars-cov-2 spike promotes but is also essential for infection and cell-cell fusion", "label": "REFUTED", "evidence": ["Here we show that CRISPR- Cas9 knockout of furin reduces, but does not prevent, the production of infectious SARS-CoV-2 virus.", "Comparing S processing in furin knockout cells to multibasic site mutants reveals that while loss of furin substantially reduces S1-S2 cleavage it does not prevent it.", "Our results show that while furin promotes both SARS-CoV-2 infectivity and cell-cell spread it is not essential, suggesting furin inhibitors will not prevent viral spread.", "We show that loss of furin in either donor or acceptor cells reduces, but does not prevent, TMPRSS2-dependent cell-cell fusion, unlike mutation of the multibasic site that completely prevents syncytia formation."]}
{"id": 1002361, "claim": "Furin cleavage of sars-cov-2 spike promotes but is therefore essential for infection and cell-cell fusion", "label": "REFUTED", "evidence": ["Here we show that CRISPR- Cas9 knockout of furin reduces, but does not prevent, the production of infectious SARS-CoV-2 virus.", "Comparing S processing in furin knockout cells to multibasic site mutants reveals that while loss of furin substantially reduces S1-S2 cleavage it does not prevent it.", "Our results show that while furin promotes both SARS-CoV-2 infectivity and cell-cell spread it is not essential, suggesting furin inhibitors will not prevent viral spread.", "We show that loss of furin in either donor or acceptor cells reduces, but does not prevent, TMPRSS2-dependent cell-cell fusion, unlike mutation of the multibasic site that completely prevents syncytia formation."]}
{"id": 1002362, "claim": "Furin cleavage of sars-cov-2 spike promotes but is still essential for infection and cell-cell fusion", "label": "REFUTED", "evidence": ["Here we show that CRISPR- Cas9 knockout of furin reduces, but does not prevent, the production of infectious SARS-CoV-2 virus.", "Comparing S processing in furin knockout cells to multibasic site mutants reveals that while loss of furin substantially reduces S1-S2 cleavage it does not prevent it.", "Our results show that while furin promotes both SARS-CoV-2 infectivity and cell-cell spread it is not essential, suggesting furin inhibitors will not prevent viral spread.", "We show that loss of furin in either donor or acceptor cells reduces, but does not prevent, TMPRSS2-dependent cell-cell fusion, unlike mutation of the multibasic site that completely prevents syncytia formation."]}
{"id": 1002363, "claim": "Serological responses to human virome define clinical outcomes of italian patients infected with sars-cov-2", "label": "SUPPORTED", "evidence": ["Here, we studied 159 hospitalized Italian patients with pneumonia from the NIAID-NCI COVID-19 Consortium using a phage-display method to characterize circulating antibodies binding to 93,904 viral peptides encoded by 1,276 strains of human viruses."]}
{"id": 1002364, "claim": "Serological responses to bacterial virome define clinical outcomes of italian patients infected with sars-cov-2", "label": "REFUTED", "evidence": ["Here, we studied 159 hospitalized Italian patients with pneumonia from the NIAID-NCI COVID-19 Consortium using a phage-display method to characterize circulating antibodies binding to 93,904 viral peptides encoded by 1,276 strains of human viruses."]}
{"id": 1002365, "claim": "Equine hyperimmune globulin raised against the sars-cov-2 spike glycoprotein has extremely high neutralizing titers", "label": "SUPPORTED", "evidence": ["When compared with the plasma of three convalescent COVID-19 patients, sera of immunized horses displayed approximately 140-fold higher neutralizing titers measured as PRNT90.", "Here we demonstrate that hyperimmune globulin preparations raised in horses against the recombinant trimeric spike (S) glycoprotein of SARS-CoV-2 in the prefusion conformation provide very high ELISA titers as well as highly potent neutralizing activity against SARS- CoV-2.", "The high neutralizing titers against SARS-CoV-2 obtained for the unprocessed sera were confirmed for the F(ab)2 fragments and were 150-fold higher than the PRNT90 neutralizing titers of plasma of three COVID-19 convalescent patients."]}
{"id": 1002366, "claim": "Equine hyperimmune globulin raised against the sars-cov-2 spike glycoprotein has extremely low neutralizing titers", "label": "REFUTED", "evidence": ["When compared with the plasma of three convalescent COVID-19 patients, sera of immunized horses displayed approximately 140-fold higher neutralizing titers measured as PRNT90.", "Here we demonstrate that hyperimmune globulin preparations raised in horses against the recombinant trimeric spike (S) glycoprotein of SARS-CoV-2 in the prefusion conformation provide very high ELISA titers as well as highly potent neutralizing activity against SARS- CoV-2.", "The high neutralizing titers against SARS-CoV-2 obtained for the unprocessed sera were confirmed for the F(ab)2 fragments and were 150-fold higher than the PRNT90 neutralizing titers of plasma of three COVID-19 convalescent patients."]}
{"id": 1002367, "claim": "Equine hyperimmune globulin raised against the sars-cov-2 spike glycoprotein has extremely limited neutralizing titers", "label": "REFUTED", "evidence": ["When compared with the plasma of three convalescent COVID-19 patients, sera of immunized horses displayed approximately 140-fold higher neutralizing titers measured as PRNT90.", "Here we demonstrate that hyperimmune globulin preparations raised in horses against the recombinant trimeric spike (S) glycoprotein of SARS-CoV-2 in the prefusion conformation provide very high ELISA titers as well as highly potent neutralizing activity against SARS- CoV-2.", "The high neutralizing titers against SARS-CoV-2 obtained for the unprocessed sera were confirmed for the F(ab)2 fragments and were 150-fold higher than the PRNT90 neutralizing titers of plasma of three COVID-19 convalescent patients."]}
{"id": 1002368, "claim": "Equine hyperimmune globulin raised against the sars-cov-2 spike glycoprotein has extremely moderate neutralizing titers", "label": "REFUTED", "evidence": ["When compared with the plasma of three convalescent COVID-19 patients, sera of immunized horses displayed approximately 140-fold higher neutralizing titers measured as PRNT90.", "Here we demonstrate that hyperimmune globulin preparations raised in horses against the recombinant trimeric spike (S) glycoprotein of SARS-CoV-2 in the prefusion conformation provide very high ELISA titers as well as highly potent neutralizing activity against SARS- CoV-2.", "The high neutralizing titers against SARS-CoV-2 obtained for the unprocessed sera were confirmed for the F(ab)2 fragments and were 150-fold higher than the PRNT90 neutralizing titers of plasma of three COVID-19 convalescent patients."]}
{"id": 1002369, "claim": "An ultra-high affinity synthetic nanobody blocks sars-cov-2 infection by locking spike into an inactive conformation", "label": "SUPPORTED", "evidence": ["Affinity maturation and structure-guided design of multivalency yielded a trivalent nanobody, mNb6-tri, with femtomolar affinity for SARS-CoV-2 Spike and picomolar neutralization of SARS-CoV-2 infection.", "Here, we develop single-domain antibodies (nanobodies) that potently disrupt the interaction between the SARS-CoV-2 Spike and ACE2."]}
{"id": 1002370, "claim": "An ultra-high affinity synthetic nanobody facilitates sars-cov-2 infection by locking spike into an inactive conformation", "label": "REFUTED", "evidence": ["Affinity maturation and structure-guided design of multivalency yielded a trivalent nanobody, mNb6-tri, with femtomolar affinity for SARS-CoV-2 Spike and picomolar neutralization of SARS-CoV-2 infection.", "Here, we develop single-domain antibodies (nanobodies) that potently disrupt the interaction between the SARS-CoV-2 Spike and ACE2."]}
{"id": 1002371, "claim": "An ultra-high affinity synthetic nanobody blocks sars-cov-2 infection by locking water into an inactive conformation", "label": "REFUTED", "evidence": ["Affinity maturation and structure-guided design of multivalency yielded a trivalent nanobody, mNb6-tri, with femtomolar affinity for SARS-CoV-2 Spike and picomolar neutralization of SARS-CoV-2 infection.", "Here, we develop single-domain antibodies (nanobodies) that potently disrupt the interaction between the SARS-CoV-2 Spike and ACE2."]}
{"id": 1002372, "claim": "An ultra-high affinity synthetic nanobody blocks sars-cov-2 infection by locking light into an inactive conformation", "label": "REFUTED", "evidence": ["Affinity maturation and structure-guided design of multivalency yielded a trivalent nanobody, mNb6-tri, with femtomolar affinity for SARS-CoV-2 Spike and picomolar neutralization of SARS-CoV-2 infection.", "Here, we develop single-domain antibodies (nanobodies) that potently disrupt the interaction between the SARS-CoV-2 Spike and ACE2."]}
{"id": 1002373, "claim": "Sars-cov-2-specific antibody profiles distinguish patients with moderate from severe covid-19.", "label": "SUPPORTED", "evidence": ["\"SARS-CoV-2 antibody levels and types differ by disease severity, study finds\".", "To explore the potential relationship between virus-specific humoral responses and COVID-19 immunopathology, we measured serum antibody classes and subclasses to the receptor-binding domain of the SARS-CoV-2 spike protein and the nucleoprotein in a cohort of hospitalized COVID-19 patients with moderate to severe disease.", "SARS-CoV-2 antibody levels and types differ by disease severity, study finds."]}
{"id": 1002374, "claim": "Sars-cov-2-specific antibody cannot distinguish patients with moderate from severe covid-19.", "label": "REFUTED", "evidence": ["\"SARS-CoV-2 antibody levels and types differ by disease severity, study finds\".", "To explore the potential relationship between virus-specific humoral responses and COVID-19 immunopathology, we measured serum antibody classes and subclasses to the receptor-binding domain of the SARS-CoV-2 spike protein and the nucleoprotein in a cohort of hospitalized COVID-19 patients with moderate to severe disease.", "SARS-CoV-2 antibody levels and types differ by disease severity, study finds."]}
{"id": 1002375, "claim": "Climate affects global patterns of covid-19 early outbreak dynamics", "label": "SUPPORTED", "evidence": ["We showed that during the earliest phase of the global outbreak (January-March), COVID-19 growth rates were non-linearly related to climate, with fastest spread in regions with a mean temperature of ca.", "There is a strong relationship between local climate and Covid-19 growth rates, suggesting the possibility of seasonal variation in the spatial pattern of outbreaks, with temperate regions of the Southern Hemisphere becoming at particular risk of severe outbreaks during the austral autumn-winter.", "We show that showed that during the earliest phase of the global outbreak (January-March), COVID-19 growth rates were non-linearly related to climate, and in the most polluted regions."]}
{"id": 1002376, "claim": "Infection affects global patterns of covid-19 early outbreak dynamics", "label": "REFUTED", "evidence": ["We showed that during the earliest phase of the global outbreak (January-March), COVID-19 growth rates were non-linearly related to climate, with fastest spread in regions with a mean temperature of ca.", "There is a strong relationship between local climate and Covid-19 growth rates, suggesting the possibility of seasonal variation in the spatial pattern of outbreaks, with temperate regions of the Southern Hemisphere becoming at particular risk of severe outbreaks during the austral autumn-winter.", "We show that showed that during the earliest phase of the global outbreak (January-March), COVID-19 growth rates were non-linearly related to climate, and in the most polluted regions."]}
{"id": 1002377, "claim": "Influenza affects global patterns of covid-19 early outbreak dynamics", "label": "REFUTED", "evidence": ["We showed that during the earliest phase of the global outbreak (January-March), COVID-19 growth rates were non-linearly related to climate, with fastest spread in regions with a mean temperature of ca.", "There is a strong relationship between local climate and Covid-19 growth rates, suggesting the possibility of seasonal variation in the spatial pattern of outbreaks, with temperate regions of the Southern Hemisphere becoming at particular risk of severe outbreaks during the austral autumn-winter.", "We show that showed that during the earliest phase of the global outbreak (January-March), COVID-19 growth rates were non-linearly related to climate, and in the most polluted regions."]}
{"id": 1002378, "claim": "Prrsv affects global patterns of covid-19 early outbreak dynamics", "label": "REFUTED", "evidence": ["We showed that during the earliest phase of the global outbreak (January-March), COVID-19 growth rates were non-linearly related to climate, with fastest spread in regions with a mean temperature of ca.", "There is a strong relationship between local climate and Covid-19 growth rates, suggesting the possibility of seasonal variation in the spatial pattern of outbreaks, with temperate regions of the Southern Hemisphere becoming at particular risk of severe outbreaks during the austral autumn-winter.", "We show that showed that during the earliest phase of the global outbreak (January-March), COVID-19 growth rates were non-linearly related to climate, and in the most polluted regions."]}
{"id": 1002379, "claim": "The aircraft brought 100,000 protective masks and 25,000 coveralls for the federal emergency management agency .", "label": "SUPPORTED", "evidence": ["Airmen assigned to the 89th Airlift Wing and Pakistani aircrew offloaded the donated protective masks and coveralls from the aircraft.", "Both leaders expressed their gratitude for one another during the unloading of the 100,000 protective masks and 25,000 coveralls Pakistan donated for the Federal Emergency Management Agency in response to COVID-19."]}
{"id": 1002380, "claim": "The aircraft brought 2,000 protective masks and 25,000 coveralls for the federal emergency management agency.", "label": "REFUTED", "evidence": ["Airmen assigned to the 89th Airlift Wing and Pakistani aircrew offloaded the donated protective masks and coveralls from the aircraft.", "Both leaders expressed their gratitude for one another during the unloading of the 100,000 protective masks and 25,000 coveralls Pakistan donated for the Federal Emergency Management Agency in response to COVID-19."]}
{"id": 1002381, "claim": "The aircraft brought 15,000 protective masks and 25,000 coveralls for the federal emergency management agency.", "label": "REFUTED", "evidence": ["Airmen assigned to the 89th Airlift Wing and Pakistani aircrew offloaded the donated protective masks and coveralls from the aircraft.", "Both leaders expressed their gratitude for one another during the unloading of the 100,000 protective masks and 25,000 coveralls Pakistan donated for the Federal Emergency Management Agency in response to COVID-19."]}
{"id": 1002382, "claim": "The aircraft brought 1,000 protective masks and 25,000 coveralls for the federal emergency management agency.", "label": "REFUTED", "evidence": ["Airmen assigned to the 89th Airlift Wing and Pakistani aircrew offloaded the donated protective masks and coveralls from the aircraft.", "Both leaders expressed their gratitude for one another during the unloading of the 100,000 protective masks and 25,000 coveralls Pakistan donated for the Federal Emergency Management Agency in response to COVID-19."]}
{"id": 1002383, "claim": "Digestive symptoms tied to worse covid-19 outcomes", "label": "SUPPORTED", "evidence": ["The authors conclude, \"Clinicians should recognize that digestive symptoms, such as diarrhea, may be a presenting feature of COVID-19, and that the index of suspicion may need to be raised earlier in at-risk patients presenting with digestive symptoms rather than waiting for respiratory symptoms to emerge.\"", "Digestive symptoms appeared to be tied to worse outcomes."]}
{"id": 1002384, "claim": "Digestive symptoms tied to mild covid-19 outcomes", "label": "REFUTED", "evidence": ["The authors conclude, \"Clinicians should recognize that digestive symptoms, such as diarrhea, may be a presenting feature of COVID-19, and that the index of suspicion may need to be raised earlier in at-risk patients presenting with digestive symptoms rather than waiting for respiratory symptoms to emerge.\"", "Digestive symptoms appeared to be tied to worse outcomes."]}
{"id": 1002385, "claim": "Digestive symptoms tied to high covid-19 outcomes", "label": "REFUTED", "evidence": ["The authors conclude, \"Clinicians should recognize that digestive symptoms, such as diarrhea, may be a presenting feature of COVID-19, and that the index of suspicion may need to be raised earlier in at-risk patients presenting with digestive symptoms rather than waiting for respiratory symptoms to emerge.\"", "Digestive symptoms appeared to be tied to worse outcomes."]}
{"id": 1002386, "claim": "Digestive symptoms tied to acute covid-19 outcomes", "label": "REFUTED", "evidence": ["The authors conclude, \"Clinicians should recognize that digestive symptoms, such as diarrhea, may be a presenting feature of COVID-19, and that the index of suspicion may need to be raised earlier in at-risk patients presenting with digestive symptoms rather than waiting for respiratory symptoms to emerge.\"", "Digestive symptoms appeared to be tied to worse outcomes."]}
{"id": 1002387, "claim": "Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild covid-19 in shanghai , china", "label": "SUPPORTED", "evidence": ["Discordance between Serum Neutralizing Antibody Titers and the Recovery from COVID-19.", "Objective: To examine the association between clinical characteristics and levels of NAbs in patients who recovered from COVID-19.", "A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity."]}
{"id": 1002388, "claim": "Evaluating the lack of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild covid-19 in shanghai, china", "label": "REFUTED", "evidence": ["Discordance between Serum Neutralizing Antibody Titers and the Recovery from COVID-19.", "Objective: To examine the association between clinical characteristics and levels of NAbs in patients who recovered from COVID-19.", "A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity."]}
{"id": 1002389, "claim": "Evaluating the absence of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild covid-19 in shanghai, china", "label": "REFUTED", "evidence": ["Discordance between Serum Neutralizing Antibody Titers and the Recovery from COVID-19.", "Objective: To examine the association between clinical characteristics and levels of NAbs in patients who recovered from COVID-19.", "A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity."]}
{"id": 1002390, "claim": "Social distancing = > 80 % of the population , covid-19 may be curbed 13 weeks , < = 70 % may not be curbed .", "label": "SUPPORTED", "evidence": ["We report an important transition across the levels of social distancing compliance, in the range between 70% and 80% levels.", "Strong compliance with social distancing (at 80% and above) effectively controls the disease during the suppression period, while lower levels of compliance (at 70% or less) do not succeed for any duration of the suppression.", "This suggests that a compliance of below 70% is unlikely to succeed for any duration of social distancing, while a compliance at the 90% level is likely to control the disease within 13-14 weeks, when coupled with effective case isolation and international travel restrictions.", "The research found that if 90 percent of the Australian population adopted social distancing, the spread of COVID-19 could be controlled by July 2020, whereas social distancing of less than 70 percent would not suppress the pandemic.", "by Mihai Andrei April 7, 2020 in Health & Medicine, News, Research, Science Strong social distancing measures can curb the pandemic in 13 weeks or so -- but only if 80% of the people do it, a new study claims."]}
{"id": 1002391, "claim": "Social distancing = > 80 % of the population, covid-19 may be curbed 13 weeks, < = 70 % may always be curbed.", "label": "REFUTED", "evidence": ["We report an important transition across the levels of social distancing compliance, in the range between 70% and 80% levels.", "Strong compliance with social distancing (at 80% and above) effectively controls the disease during the suppression period, while lower levels of compliance (at 70% or less) do not succeed for any duration of the suppression.", "This suggests that a compliance of below 70% is unlikely to succeed for any duration of social distancing, while a compliance at the 90% level is likely to control the disease within 13-14 weeks, when coupled with effective case isolation and international travel restrictions.", "The research found that if 90 percent of the Australian population adopted social distancing, the spread of COVID-19 could be controlled by July 2020, whereas social distancing of less than 70 percent would not suppress the pandemic.", "by Mihai Andrei April 7, 2020 in Health & Medicine, News, Research, Science Strong social distancing measures can curb the pandemic in 13 weeks or so -- but only if 80% of the people do it, a new study claims."]}
{"id": 1002392, "claim": "A mysterious company 's coronavirus papers in top medical journals may be unraveling", "label": "SUPPORTED", "evidence": ["But just as quickly, the results have begun to unraveland Surgisphere, which provided patient data for two other high-profile COVID-19 papers, has come under withering online scrutiny from researchers and amateur sleuths.", "However, the failure to resolve such basic concerns about the data during the course of normal peer review raises serious questions about the standard of editing at the Lancet and NEJM  ostensibly two of the worlds most prestigious medical journals.", "As soon as the study was published, it came under attack by clinicians, as well as experts in biostatistics and medical ethics who questioned how Surgisphere, a tiny company without much publishing experience in big data analysis, could have collected and analyzed tens of thousands of patient records from hundreds of hospitalsparticularly given the complexities of navigating patient confidentiality agreements.", "They have pointed out many red flags in the Lancet paper, including the astonishing number of patients and details about patient demographics and dosing that seemed implausible."]}
{"id": 1002393, "claim": "A major company's coronavirus papers in top medical journals may be unraveling", "label": "REFUTED", "evidence": ["But just as quickly, the results have begun to unraveland Surgisphere, which provided patient data for two other high-profile COVID-19 papers, has come under withering online scrutiny from researchers and amateur sleuths.", "However, the failure to resolve such basic concerns about the data during the course of normal peer review raises serious questions about the standard of editing at the Lancet and NEJM  ostensibly two of the worlds most prestigious medical journals.", "As soon as the study was published, it came under attack by clinicians, as well as experts in biostatistics and medical ethics who questioned how Surgisphere, a tiny company without much publishing experience in big data analysis, could have collected and analyzed tens of thousands of patient records from hundreds of hospitalsparticularly given the complexities of navigating patient confidentiality agreements.", "They have pointed out many red flags in the Lancet paper, including the astonishing number of patients and details about patient demographics and dosing that seemed implausible."]}
{"id": 1002394, "claim": "A specific company's coronavirus papers in top medical journals may be unraveling", "label": "REFUTED", "evidence": ["But just as quickly, the results have begun to unraveland Surgisphere, which provided patient data for two other high-profile COVID-19 papers, has come under withering online scrutiny from researchers and amateur sleuths.", "However, the failure to resolve such basic concerns about the data during the course of normal peer review raises serious questions about the standard of editing at the Lancet and NEJM  ostensibly two of the worlds most prestigious medical journals.", "As soon as the study was published, it came under attack by clinicians, as well as experts in biostatistics and medical ethics who questioned how Surgisphere, a tiny company without much publishing experience in big data analysis, could have collected and analyzed tens of thousands of patient records from hundreds of hospitalsparticularly given the complexities of navigating patient confidentiality agreements.", "They have pointed out many red flags in the Lancet paper, including the astonishing number of patients and details about patient demographics and dosing that seemed implausible."]}
{"id": 1002395, "claim": "Icmr study suggests icmr covid-19 testing strategy was flawed .", "label": "SUPPORTED", "evidence": ["Also read: ICMR Study Suggests Its Testing Strategy Was Flawed, Airport Screening a Miss As of March 12, testing was limited to 52 government centres."]}
{"id": 1002396, "claim": "Icmr study suggests icmr covid-19 testing strategy was done.", "label": "REFUTED", "evidence": ["Also read: ICMR Study Suggests Its Testing Strategy Was Flawed, Airport Screening a Miss As of March 12, testing was limited to 52 government centres."]}
{"id": 1002397, "claim": "Icmr study suggests icmr covid-19 testing strategy was needed.", "label": "REFUTED", "evidence": ["Also read: ICMR Study Suggests Its Testing Strategy Was Flawed, Airport Screening a Miss As of March 12, testing was limited to 52 government centres."]}
{"id": 1002398, "claim": "Icmr study suggests icmr covid-19 testing strategy was in.", "label": "REFUTED", "evidence": ["Also read: ICMR Study Suggests Its Testing Strategy Was Flawed, Airport Screening a Miss As of March 12, testing was limited to 52 government centres."]}
{"id": 1002399, "claim": "A booster dose enhances immunogenicity of the covid-19 vaccine candidate chadox1 ncov-19 in aged mice", "label": "SUPPORTED", "evidence": ["Furthermore, we report that a second dose enhances the immune response to this vaccine in aged mice, indicating that a primeboost strategy may be a rational approach to enhance immunogenicity in older persons.", "We find that a single dose of this vaccine induces cellular and humoral immunity in aged mice, but at a reduced magnitude than in younger adult mice."]}
{"id": 1002400, "claim": "A booster dose dids immunogenicity of the covid-19 vaccine candidate chadox1 ncov-19 in aged mice", "label": "REFUTED", "evidence": ["Furthermore, we report that a second dose enhances the immune response to this vaccine in aged mice, indicating that a primeboost strategy may be a rational approach to enhance immunogenicity in older persons.", "We find that a single dose of this vaccine induces cellular and humoral immunity in aged mice, but at a reduced magnitude than in younger adult mice."]}
{"id": 1002401, "claim": "A booster dose woulds immunogenicity of the covid-19 vaccine candidate chadox1 ncov-19 in aged mice", "label": "REFUTED", "evidence": ["Furthermore, we report that a second dose enhances the immune response to this vaccine in aged mice, indicating that a primeboost strategy may be a rational approach to enhance immunogenicity in older persons.", "We find that a single dose of this vaccine induces cellular and humoral immunity in aged mice, but at a reduced magnitude than in younger adult mice."]}
{"id": 1002402, "claim": "A booster dose mays immunogenicity of the covid-19 vaccine candidate chadox1 ncov-19 in aged mice", "label": "REFUTED", "evidence": ["Furthermore, we report that a second dose enhances the immune response to this vaccine in aged mice, indicating that a primeboost strategy may be a rational approach to enhance immunogenicity in older persons.", "We find that a single dose of this vaccine induces cellular and humoral immunity in aged mice, but at a reduced magnitude than in younger adult mice."]}
{"id": 1002403, "claim": "Coronavirus infections may not be uncommon , tests suggest", "label": "SUPPORTED", "evidence": ["If the numbers prove accurate, the coronavirus may be much less deadly than originally expected, with a fatality rate more closely resembling that of a seasonal flu strain than a pandemic of profound lethality."]}
{"id": 1002404, "claim": "Coronavirus infections may only be uncommon, tests suggest", "label": "REFUTED", "evidence": ["If the numbers prove accurate, the coronavirus may be much less deadly than originally expected, with a fatality rate more closely resembling that of a seasonal flu strain than a pandemic of profound lethality."]}
{"id": 1002405, "claim": "Coronavirus infections may now be uncommon, tests suggest", "label": "REFUTED", "evidence": ["If the numbers prove accurate, the coronavirus may be much less deadly than originally expected, with a fatality rate more closely resembling that of a seasonal flu strain than a pandemic of profound lethality."]}
{"id": 1002406, "claim": "Coronavirus infections may still be uncommon, tests suggest", "label": "REFUTED", "evidence": ["If the numbers prove accurate, the coronavirus may be much less deadly than originally expected, with a fatality rate more closely resembling that of a seasonal flu strain than a pandemic of profound lethality."]}
{"id": 1002407, "claim": "Covid-19 ards is characterized by a dysregulated host response that differs from cytokine storm and may be modified by dexamethasone.", "label": "SUPPORTED", "evidence": ["COVID-19 ARDS was characterized by a dysregulated host response with increased PTEN signaling and elevated expression of genes with non-canonical roles in inflammation and immunity that were predicted to be modulated by dexamethasone and granulocyte colony stimulating factor.", "In contrast to a cytokine storm, we observed reduced proinflammatory gene expression in COVID-19 ARDS when compared to ARDS due to other causes.", "COVID-19 ARDS is characterized by a dysregulated host response that differs from cytokine", "In summary, assessment of host gene expression in the lower airways of patients with COVID-19 ARDS did not demonstrate cytokine storm but instead revealed a unique and dysregulated host response predicted to be modified by dexamethasone."]}
{"id": 1002408, "claim": "Covid-19 ards is characterized by a dysregulated host response that differs from cytokine storm and cannot be modified by dexamethasone.", "label": "REFUTED", "evidence": ["COVID-19 ARDS was characterized by a dysregulated host response with increased PTEN signaling and elevated expression of genes with non-canonical roles in inflammation and immunity that were predicted to be modulated by dexamethasone and granulocyte colony stimulating factor.", "In contrast to a cytokine storm, we observed reduced proinflammatory gene expression in COVID-19 ARDS when compared to ARDS due to other causes.", "COVID-19 ARDS is characterized by a dysregulated host response that differs from cytokine", "In summary, assessment of host gene expression in the lower airways of patients with COVID-19 ARDS did not demonstrate cytokine storm but instead revealed a unique and dysregulated host response predicted to be modified by dexamethasone."]}
{"id": 1002409, "claim": "Facebook cancels global marketing summit over virus concerns", "label": "SUPPORTED", "evidence": ["Facebooks call to cancel its conference because of the virus is an amplified example of how coronavirus fears are impacting day-to-day business in the tech industry.", "Facebook canceling its global marketing conference comes on the heels of this weeks cancellation of Mobile World Congress, also due to coronavirus concerns.", "But the Facebook marketing summit is the first publicly reported example of an event in the San Francisco Bay Area being canceled due to the virus.", "\"Out of an abundance of caution, we canceled our Global Marketing Summit due to evolving public health risks related to coronavirus,\" Anthony Harrison, a Facebook spokesman, said by email.", "Facebook is canceling an annual conference held in San Francisco out of health concerns regarding the coronavirus."]}
{"id": 1002410, "claim": "Facebook's global marketing summit over virus concerns", "label": "REFUTED", "evidence": ["Facebooks call to cancel its conference because of the virus is an amplified example of how coronavirus fears are impacting day-to-day business in the tech industry.", "Facebook canceling its global marketing conference comes on the heels of this weeks cancellation of Mobile World Congress, also due to coronavirus concerns.", "But the Facebook marketing summit is the first publicly reported example of an event in the San Francisco Bay Area being canceled due to the virus.", "\"Out of an abundance of caution, we canceled our Global Marketing Summit due to evolving public health risks related to coronavirus,\" Anthony Harrison, a Facebook spokesman, said by email.", "Facebook is canceling an annual conference held in San Francisco out of health concerns regarding the coronavirus."]}
{"id": 1002411, "claim": "Fda announces covid-19 treatment acceleration program", "label": "SUPPORTED", "evidence": ["Accelerating the investigation of products that could potentially benefit people affected by the COVID-19 pandemic is one of the FDAs highest priorities.", "The US Food and Drug Administration (FDA) has launched the Coronavirus Treatment Acceleration Program to accelerate the development of treatments for coronavirus disease 2019 (COVID-19).", "The US Food and Drug Administration (FDA) is prioritizing the development and review of new therapies to treat COVID-19 through a recently created special emergency program titled Coronavirus Treatment Acceleration Program (CTAP).", "Coronavirus (COVID-19) Update: FDA Continues to Accelerate Development of Novel Therapies for COVID-19 1."]}
{"id": 1002412, "claim": "Methods announces covid-19 treatment acceleration program", "label": "REFUTED", "evidence": ["Accelerating the investigation of products that could potentially benefit people affected by the COVID-19 pandemic is one of the FDAs highest priorities.", "The US Food and Drug Administration (FDA) has launched the Coronavirus Treatment Acceleration Program to accelerate the development of treatments for coronavirus disease 2019 (COVID-19).", "The US Food and Drug Administration (FDA) is prioritizing the development and review of new therapies to treat COVID-19 through a recently created special emergency program titled Coronavirus Treatment Acceleration Program (CTAP).", "Coronavirus (COVID-19) Update: FDA Continues to Accelerate Development of Novel Therapies for COVID-19 1."]}
{"id": 1002413, "claim": "Trial of oxford covid-19 vaccine starts in brazil", "label": "SUPPORTED", "evidence": ["Volunteers in Brazil have begun receiving a trial vaccine against COVID-19, in Latin Americas first phase 3 COVID-19 clinical trial.", "Professor Andrew Pollard, Chief investigator of the Oxford Vaccine Trial at Oxford University said: 'It is a privilege to be working with the researchers at the Federal University of São Paulo  UNIFESP on the first COVID-19 vaccine trial in Latin America in the next stage of this important trial.", "The Federal University of São Paulo - UNIFESP is collaborating with the University of Oxford and the Oxford Vaccine Group on the Brazil trial.", "The Brazilian Ox1Cov-19 Vaccine Trial aims to find a vaccine that will prevent infection by SARS-CoV-2, the virus that causes COVID-19."]}
{"id": 1002414, "claim": "Lack of oxford covid-19 vaccine starts in brazil", "label": "REFUTED", "evidence": ["Volunteers in Brazil have begun receiving a trial vaccine against COVID-19, in Latin Americas first phase 3 COVID-19 clinical trial.", "Professor Andrew Pollard, Chief investigator of the Oxford Vaccine Trial at Oxford University said: 'It is a privilege to be working with the researchers at the Federal University of São Paulo  UNIFESP on the first COVID-19 vaccine trial in Latin America in the next stage of this important trial.", "The Federal University of São Paulo - UNIFESP is collaborating with the University of Oxford and the Oxford Vaccine Group on the Brazil trial.", "The Brazilian Ox1Cov-19 Vaccine Trial aims to find a vaccine that will prevent infection by SARS-CoV-2, the virus that causes COVID-19."]}
{"id": 1002415, "claim": "Loss of oxford covid-19 vaccine starts in brazil", "label": "REFUTED", "evidence": ["Volunteers in Brazil have begun receiving a trial vaccine against COVID-19, in Latin Americas first phase 3 COVID-19 clinical trial.", "Professor Andrew Pollard, Chief investigator of the Oxford Vaccine Trial at Oxford University said: 'It is a privilege to be working with the researchers at the Federal University of São Paulo  UNIFESP on the first COVID-19 vaccine trial in Latin America in the next stage of this important trial.", "The Federal University of São Paulo - UNIFESP is collaborating with the University of Oxford and the Oxford Vaccine Group on the Brazil trial.", "The Brazilian Ox1Cov-19 Vaccine Trial aims to find a vaccine that will prevent infection by SARS-CoV-2, the virus that causes COVID-19."]}
{"id": 1002416, "claim": "Coronavirus might cause cardiovascular damage , and if it follows sars example it may lead to permanent cardiovascular damage", "label": "SUPPORTED", "evidence": ["Like SARS-CoV-2, some other viruses, such as Epstein-Barr, can damage heart tissue, for example.", "For patients with cardiac insufficiency who have underlying heart disease, SARS-CoV-2 infection might act as a precipitating factor to worsen the condition and lead to death.", "And while SARS-CoV-2 may lead to overt cardiac symptoms such as chest pain or shortness of breath resulting in heart attacks and blood clots, there is also the possibility that the virus may cause significant heart damage and inflammationbut without producing any immediate or more noticeable cardiac symptoms."]}
{"id": 1002417, "claim": "Coronavirus cannot cause cardiovascular damage, and if it follows sars example it may lead to permanent cardiovascular damage", "label": "REFUTED", "evidence": ["Like SARS-CoV-2, some other viruses, such as Epstein-Barr, can damage heart tissue, for example.", "For patients with cardiac insufficiency who have underlying heart disease, SARS-CoV-2 infection might act as a precipitating factor to worsen the condition and lead to death.", "And while SARS-CoV-2 may lead to overt cardiac symptoms such as chest pain or shortness of breath resulting in heart attacks and blood clots, there is also the possibility that the virus may cause significant heart damage and inflammationbut without producing any immediate or more noticeable cardiac symptoms."]}
{"id": 1002418, "claim": "More than 100 million people in china face new lockdown as second wave of covid-19 cases emerge", "label": "SUPPORTED", "evidence": ["FOX NEWS \\- Nearly 108 million people in China's Jilin province could be forced back into lockdown after a growing group of new coronavirus infections triggered a backslide in the nation's push to return to normal."]}
{"id": 1002419, "claim": "More than 20 million people in china face new lockdown as second wave of covid-19 cases emerge", "label": "REFUTED", "evidence": ["FOX NEWS \\- Nearly 108 million people in China's Jilin province could be forced back into lockdown after a growing group of new coronavirus infections triggered a backslide in the nation's push to return to normal."]}
{"id": 1002420, "claim": "More than 30 million people in china face new lockdown as second wave of covid-19 cases emerge", "label": "REFUTED", "evidence": ["FOX NEWS \\- Nearly 108 million people in China's Jilin province could be forced back into lockdown after a growing group of new coronavirus infections triggered a backslide in the nation's push to return to normal."]}
{"id": 1002421, "claim": "More than 5 million people in china face new lockdown as second wave of covid-19 cases emerge", "label": "REFUTED", "evidence": ["FOX NEWS \\- Nearly 108 million people in China's Jilin province could be forced back into lockdown after a growing group of new coronavirus infections triggered a backslide in the nation's push to return to normal."]}
{"id": 1002422, "claim": "Sars-cov-2 viral load predicts covid-19 mortality", "label": "SUPPORTED", "evidence": ["Viral loads for symptomatic, hospitalised patients who tested positive for SARS-CoV-2 were measured on samples collected between March 13 and May 4, 2020, that tested positive on both platforms at diagnosis.", "2019; 32: e00097-e00118 Crossref PubMed Scopus (10) Google Scholar Viral load in COVID-19 might correlate with infectivity, disease phenotype, morbidity, and mortality.", "Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients."]}
{"id": 1002423, "claim": "Sars-cov-2 viral load cannots covid-19 mortality", "label": "REFUTED", "evidence": ["Viral loads for symptomatic, hospitalised patients who tested positive for SARS-CoV-2 were measured on samples collected between March 13 and May 4, 2020, that tested positive on both platforms at diagnosis.", "2019; 32: e00097-e00118 Crossref PubMed Scopus (10) Google Scholar Viral load in COVID-19 might correlate with infectivity, disease phenotype, morbidity, and mortality.", "Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients."]}
{"id": 1002424, "claim": "Mrc laboratory of molecular biology seeks dna volunteers", "label": "SUPPORTED", "evidence": ["Prof Julian Gough, a group leader at the MRC Laboratory of Molecular Biology, is asking those who have had a consumer DNA test carried out by the likes of 23andMe or AncestryDNA to aid the research by volunteering their data."]}
{"id": 1002425, "claim": "Mrc laboratory of molecular diagnostics seeks dna volunteers", "label": "REFUTED", "evidence": ["Prof Julian Gough, a group leader at the MRC Laboratory of Molecular Biology, is asking those who have had a consumer DNA test carried out by the likes of 23andMe or AncestryDNA to aid the research by volunteering their data."]}
{"id": 1002426, "claim": "Mrc laboratory of molecular information seeks dna volunteers", "label": "REFUTED", "evidence": ["Prof Julian Gough, a group leader at the MRC Laboratory of Molecular Biology, is asking those who have had a consumer DNA test carried out by the likes of 23andMe or AncestryDNA to aid the research by volunteering their data."]}
{"id": 1002427, "claim": "Mrc laboratory of molecular methods seeks dna volunteers", "label": "REFUTED", "evidence": ["Prof Julian Gough, a group leader at the MRC Laboratory of Molecular Biology, is asking those who have had a consumer DNA test carried out by the likes of 23andMe or AncestryDNA to aid the research by volunteering their data."]}
{"id": 1002428, "claim": "China trial of gilead 's potential coronavirus treatment suspended", "label": "SUPPORTED", "evidence": ["[nL3N2BY1AH] The study was conducted by researchers in China and the suspension was posted bit.ly/3bcnyv4 on Wednesday on clinicaltrials.gov, a database maintained by the U.S. National Institutes of Health (NIH).", "REUTERS/Stephen Lam Gilead shares, which have risen nearly 20% in year through Tuesdays close, were down 3% at $75.27 Earlier, another trial in China testing the drug in those with severe COVID-19 was terminated because no eligible patients could be enrolled."]}
{"id": 1002429, "claim": "Two trial of gilead's potential coronavirus treatment suspended", "label": "REFUTED", "evidence": ["[nL3N2BY1AH] The study was conducted by researchers in China and the suspension was posted bit.ly/3bcnyv4 on Wednesday on clinicaltrials.gov, a database maintained by the U.S. National Institutes of Health (NIH).", "REUTERS/Stephen Lam Gilead shares, which have risen nearly 20% in year through Tuesdays close, were down 3% at $75.27 Earlier, another trial in China testing the drug in those with severe COVID-19 was terminated because no eligible patients could be enrolled."]}
{"id": 1002430, "claim": "Sri lankan muslims call for end to covid-19 cremations", "label": "SUPPORTED", "evidence": ["\"We are in agreement with the Human Rights Commission of Sri Lanka, which states that if the government wished to move away from the WHO regulation and its own previous regulation, which permitted both cremation and burial, the government should have consulted leaders of the Muslim community including medical professionals and scientists of the faith,\" said the NPC.", "Ahmed Shaheed, UN special rapporteur on freedom of religion and belief, has urged the Sri Lankan government to respect Islamic burial rights and stop hate speech against Muslims.", "Lakmal said there is no scientific evidence to support the conclusion that cremation is safer than burial to avoid infection from COVID-19.", "All Ceylon Jamiyyathul Ulama said that a Muslim who dies from COVID-19 should have the option of being buried, in line with WHO guidelines and as implemented in more than 180 countries, since it is an integral part of Islam and a religious obligation of the community towards the deceased.", "Two Catholics, Oshala Lakmal and Ranmal Anthony Amerasinghe, filed separate fundamental rights violation petitions in the Supreme Court challenging the gazette notification that the bodies of those who are confirmed or suspected COVID-19 victims should be cremated within 24 hours, preferably within 12 hours."]}
{"id": 1002431, "claim": "Sri lankan muslims call for access to covid-19 cremations", "label": "REFUTED", "evidence": ["\"We are in agreement with the Human Rights Commission of Sri Lanka, which states that if the government wished to move away from the WHO regulation and its own previous regulation, which permitted both cremation and burial, the government should have consulted leaders of the Muslim community including medical professionals and scientists of the faith,\" said the NPC.", "Ahmed Shaheed, UN special rapporteur on freedom of religion and belief, has urged the Sri Lankan government to respect Islamic burial rights and stop hate speech against Muslims.", "Lakmal said there is no scientific evidence to support the conclusion that cremation is safer than burial to avoid infection from COVID-19.", "All Ceylon Jamiyyathul Ulama said that a Muslim who dies from COVID-19 should have the option of being buried, in line with WHO guidelines and as implemented in more than 180 countries, since it is an integral part of Islam and a religious obligation of the community towards the deceased.", "Two Catholics, Oshala Lakmal and Ranmal Anthony Amerasinghe, filed separate fundamental rights violation petitions in the Supreme Court challenging the gazette notification that the bodies of those who are confirmed or suspected COVID-19 victims should be cremated within 24 hours, preferably within 12 hours."]}
{"id": 1002432, "claim": "Sri lankan muslims call for exposure to covid-19 cremations", "label": "REFUTED", "evidence": ["\"We are in agreement with the Human Rights Commission of Sri Lanka, which states that if the government wished to move away from the WHO regulation and its own previous regulation, which permitted both cremation and burial, the government should have consulted leaders of the Muslim community including medical professionals and scientists of the faith,\" said the NPC.", "Ahmed Shaheed, UN special rapporteur on freedom of religion and belief, has urged the Sri Lankan government to respect Islamic burial rights and stop hate speech against Muslims.", "Lakmal said there is no scientific evidence to support the conclusion that cremation is safer than burial to avoid infection from COVID-19.", "All Ceylon Jamiyyathul Ulama said that a Muslim who dies from COVID-19 should have the option of being buried, in line with WHO guidelines and as implemented in more than 180 countries, since it is an integral part of Islam and a religious obligation of the community towards the deceased.", "Two Catholics, Oshala Lakmal and Ranmal Anthony Amerasinghe, filed separate fundamental rights violation petitions in the Supreme Court challenging the gazette notification that the bodies of those who are confirmed or suspected COVID-19 victims should be cremated within 24 hours, preferably within 12 hours."]}
{"id": 1002433, "claim": "Sri lankan muslims call for up to covid-19 cremations", "label": "REFUTED", "evidence": ["\"We are in agreement with the Human Rights Commission of Sri Lanka, which states that if the government wished to move away from the WHO regulation and its own previous regulation, which permitted both cremation and burial, the government should have consulted leaders of the Muslim community including medical professionals and scientists of the faith,\" said the NPC.", "Ahmed Shaheed, UN special rapporteur on freedom of religion and belief, has urged the Sri Lankan government to respect Islamic burial rights and stop hate speech against Muslims.", "Lakmal said there is no scientific evidence to support the conclusion that cremation is safer than burial to avoid infection from COVID-19.", "All Ceylon Jamiyyathul Ulama said that a Muslim who dies from COVID-19 should have the option of being buried, in line with WHO guidelines and as implemented in more than 180 countries, since it is an integral part of Islam and a religious obligation of the community towards the deceased.", "Two Catholics, Oshala Lakmal and Ranmal Anthony Amerasinghe, filed separate fundamental rights violation petitions in the Supreme Court challenging the gazette notification that the bodies of those who are confirmed or suspected COVID-19 victims should be cremated within 24 hours, preferably within 12 hours."]}
{"id": 1002434, "claim": "Altered blood cell traits underlie a major genetic locus of severe covid-19", "label": "SUPPORTED", "evidence": ["Conclusions: Multiple blood cell traits, especially monocyte, eosinophil, and neutrophil numbers, are associated with the COVID-19 risk variant and the expression of its candidate target genes, representing probable mechanistic links between the genetic locus 3p21.31 and severe COVID-19."]}
{"id": 1002435, "claim": "Altered blood pressure traits underlie a major genetic locus of severe covid-19", "label": "REFUTED", "evidence": ["Conclusions: Multiple blood cell traits, especially monocyte, eosinophil, and neutrophil numbers, are associated with the COVID-19 risk variant and the expression of its candidate target genes, representing probable mechanistic links between the genetic locus 3p21.31 and severe COVID-19."]}
{"id": 1002436, "claim": "Fast , cheap tests could enable safer reopening", "label": "SUPPORTED", "evidence": ["Such tests cost as little as $1 to $2 each, give a yes/no readout within minutes, much like a pregnancy test, and are already used to detect influenza, HIV, and other viruses.", "By making it possible to identify and isolate infected individuals more quickly, proponents say, the shift would slow the virus' spread, key to safely reopening schools, factories, and offices."]}
{"id": 1002437, "claim": "Fast, multiple tests could enable safer reopening", "label": "REFUTED", "evidence": ["Such tests cost as little as $1 to $2 each, give a yes/no readout within minutes, much like a pregnancy test, and are already used to detect influenza, HIV, and other viruses.", "By making it possible to identify and isolate infected individuals more quickly, proponents say, the shift would slow the virus' spread, key to safely reopening schools, factories, and offices."]}
{"id": 1002438, "claim": "Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine", "label": "SUPPORTED", "evidence": ["A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.", "Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.", "Being protected against influenza, TIV recipients may lack temporary non-specific immunity that protected against other respiratory viruses."]}
{"id": 1002439, "claim": "Low risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine", "label": "REFUTED", "evidence": ["A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.", "Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.", "Being protected against influenza, TIV recipients may lack temporary non-specific immunity that protected against other respiratory viruses."]}
{"id": 1002440, "claim": "Convalescent covid-19 patients are susceptible to endothelial dysfunction due to persistent immune activation", "label": "SUPPORTED", "evidence": ["Convalescent patients had elevated circulating endothelial cells (CECs), and those with underlying cardiovascular risk had more pronounced endothelial activation hallmarks (ICAM1, P-selectin or CX3CL1) expressed by CECs.", "Several proinflammatory and activated T lymphocyte-associated cytokines correlated positively with CEC measures, implicating cytokine-driven endothelial dysfunction."]}
{"id": 1002441, "claim": "Convalescent covid-19 patients are resistant to endothelial dysfunction due to persistent immune activation", "label": "REFUTED", "evidence": ["Convalescent patients had elevated circulating endothelial cells (CECs), and those with underlying cardiovascular risk had more pronounced endothelial activation hallmarks (ICAM1, P-selectin or CX3CL1) expressed by CECs.", "Several proinflammatory and activated T lymphocyte-associated cytokines correlated positively with CEC measures, implicating cytokine-driven endothelial dysfunction."]}
{"id": 1002442, "claim": "Convalescent covid-19 patients are refractory to endothelial dysfunction due to persistent immune activation", "label": "REFUTED", "evidence": ["Convalescent patients had elevated circulating endothelial cells (CECs), and those with underlying cardiovascular risk had more pronounced endothelial activation hallmarks (ICAM1, P-selectin or CX3CL1) expressed by CECs.", "Several proinflammatory and activated T lymphocyte-associated cytokines correlated positively with CEC measures, implicating cytokine-driven endothelial dysfunction."]}
{"id": 1002443, "claim": "Eli lilly can produce up to one million doses of covid-19 antibody drug this year if allowed by fda", "label": "SUPPORTED", "evidence": ["Enlarge this image The Food and Drug Administration has authorized Eli Lilly's antibody-based drug bamlanivimab for emergency use as a treatment for COVID-19.", "Lilly is testing both single antibody therapy as well as combinations of antibodies as potential therapeutics for COVID-19."]}
{"id": 1002444, "claim": "Eli lilly can produce up to 50 million doses of covid-19 antibody drug this year if allowed by fda", "label": "REFUTED", "evidence": ["Enlarge this image The Food and Drug Administration has authorized Eli Lilly's antibody-based drug bamlanivimab for emergency use as a treatment for COVID-19.", "Lilly is testing both single antibody therapy as well as combinations of antibodies as potential therapeutics for COVID-19."]}
{"id": 1002445, "claim": "Eli lilly can produce up to 10 million doses of covid-19 antibody drug this year if allowed by fda", "label": "REFUTED", "evidence": ["Enlarge this image The Food and Drug Administration has authorized Eli Lilly's antibody-based drug bamlanivimab for emergency use as a treatment for COVID-19.", "Lilly is testing both single antibody therapy as well as combinations of antibodies as potential therapeutics for COVID-19."]}
{"id": 1002446, "claim": "Eli lilly can produce up to 40 million doses of covid-19 antibody drug this year if allowed by fda", "label": "REFUTED", "evidence": ["Enlarge this image The Food and Drug Administration has authorized Eli Lilly's antibody-based drug bamlanivimab for emergency use as a treatment for COVID-19.", "Lilly is testing both single antibody therapy as well as combinations of antibodies as potential therapeutics for COVID-19."]}
{"id": 1002447, "claim": "With more data on its covid-19 vaccine , russian institute offers new evidence of success", "label": "SUPPORTED", "evidence": ["Joining the flood of press releases announcing positive results from COVID-19 vaccine trials, developers of Russias Sputnik V vaccine today reported 91.4% efficacy from a second interim analysis of more than 18,000 people, bolstering a claim the team made on 11 November with scant evidence."]}
{"id": 1002448, "claim": "With no data on its covid-19 vaccine, russian institute offers new evidence of success", "label": "REFUTED", "evidence": ["Joining the flood of press releases announcing positive results from COVID-19 vaccine trials, developers of Russias Sputnik V vaccine today reported 91.4% efficacy from a second interim analysis of more than 18,000 people, bolstering a claim the team made on 11 November with scant evidence."]}
{"id": 1002449, "claim": "With limited data on its covid-19 vaccine, russian institute offers new evidence of success", "label": "REFUTED", "evidence": ["Joining the flood of press releases announcing positive results from COVID-19 vaccine trials, developers of Russias Sputnik V vaccine today reported 91.4% efficacy from a second interim analysis of more than 18,000 people, bolstering a claim the team made on 11 November with scant evidence."]}
{"id": 1002450, "claim": "This is the stanford vaccine algorithm that left out frontline doctors.", "label": "SUPPORTED", "evidence": ["Stanford doctors on Friday protested the system's vaccine rollout plan, as multiple hospitals come under fire for giving too many doses to staff who aren't on the front line, according to reports from San Francisco Chronicle.", "Jose M. Osorio/Chicago Tribune via AP Doctors protested at Stanford Medical Center Friday, saying the hospital failed to prioritize vaccines for front-line workers and instead gave too many to office staff and others working from home.", "In a statement, a representative for Stanford Medical said it took \"complete responsibility\" for issues with the vaccine's rollout.", "In Stanford's case, the hospital's chief medical officer, Dr. Niraj Sehgal, apologized to staff this week for \"unintended missteps\" in vaccine rollout, according to a screenshot of the email shared on Twitter."]}
{"id": 1002451, "claim": "This is the stanford vaccine algorithm that carry out frontline doctors.", "label": "REFUTED", "evidence": ["Stanford doctors on Friday protested the system's vaccine rollout plan, as multiple hospitals come under fire for giving too many doses to staff who aren't on the front line, according to reports from San Francisco Chronicle.", "Jose M. Osorio/Chicago Tribune via AP Doctors protested at Stanford Medical Center Friday, saying the hospital failed to prioritize vaccines for front-line workers and instead gave too many to office staff and others working from home.", "In a statement, a representative for Stanford Medical said it took \"complete responsibility\" for issues with the vaccine's rollout.", "In Stanford's case, the hospital's chief medical officer, Dr. Niraj Sehgal, apologized to staff this week for \"unintended missteps\" in vaccine rollout, according to a screenshot of the email shared on Twitter."]}
{"id": 1002452, "claim": "This is the stanford vaccine algorithm that left out frontline countries.", "label": "REFUTED", "evidence": ["Stanford doctors on Friday protested the system's vaccine rollout plan, as multiple hospitals come under fire for giving too many doses to staff who aren't on the front line, according to reports from San Francisco Chronicle.", "Jose M. Osorio/Chicago Tribune via AP Doctors protested at Stanford Medical Center Friday, saying the hospital failed to prioritize vaccines for front-line workers and instead gave too many to office staff and others working from home.", "In a statement, a representative for Stanford Medical said it took \"complete responsibility\" for issues with the vaccine's rollout.", "In Stanford's case, the hospital's chief medical officer, Dr. Niraj Sehgal, apologized to staff this week for \"unintended missteps\" in vaccine rollout, according to a screenshot of the email shared on Twitter."]}
{"id": 1002453, "claim": "This is the stanford vaccine algorithm that carried out frontline doctors.", "label": "REFUTED", "evidence": ["Stanford doctors on Friday protested the system's vaccine rollout plan, as multiple hospitals come under fire for giving too many doses to staff who aren't on the front line, according to reports from San Francisco Chronicle.", "Jose M. Osorio/Chicago Tribune via AP Doctors protested at Stanford Medical Center Friday, saying the hospital failed to prioritize vaccines for front-line workers and instead gave too many to office staff and others working from home.", "In a statement, a representative for Stanford Medical said it took \"complete responsibility\" for issues with the vaccine's rollout.", "In Stanford's case, the hospital's chief medical officer, Dr. Niraj Sehgal, apologized to staff this week for \"unintended missteps\" in vaccine rollout, according to a screenshot of the email shared on Twitter."]}
{"id": 1002454, "claim": "Ema starts first rolling review of a covid-19 vaccine in the eu", "label": "SUPPORTED", "evidence": ["These results will provide information on how effective the vaccine is in protecting people against COVID-19 and will be assessed in later rolling review cycles.", "A rolling review is one of the regulatory tools that EMA uses to speed up the assessment of a promising medicine or vaccine during a public health emergency."]}
{"id": 1002455, "claim": "Ema starts after rolling review of a covid-19 vaccine in the eu", "label": "REFUTED", "evidence": ["These results will provide information on how effective the vaccine is in protecting people against COVID-19 and will be assessed in later rolling review cycles.", "A rolling review is one of the regulatory tools that EMA uses to speed up the assessment of a promising medicine or vaccine during a public health emergency."]}
{"id": 1002456, "claim": "Ema starts first rolling production of a covid-19 vaccine in the eu", "label": "REFUTED", "evidence": ["These results will provide information on how effective the vaccine is in protecting people against COVID-19 and will be assessed in later rolling review cycles.", "A rolling review is one of the regulatory tools that EMA uses to speed up the assessment of a promising medicine or vaccine during a public health emergency."]}
{"id": 1002457, "claim": "Kanteron platform for covid-19 reviewed by who experts", "label": "SUPPORTED", "evidence": ["Here's what those experts had to say about Kanteron's Platform as applied to the COVID-19 pandemic: > Spectacular!"]}
{"id": 1002458, "claim": "Kanteron platform for covid-19 reviewed by fda experts", "label": "REFUTED", "evidence": ["Here's what those experts had to say about Kanteron's Platform as applied to the COVID-19 pandemic: > Spectacular!"]}
{"id": 1002459, "claim": "Kanteron platform for covid-19 reviewed by ncbi experts", "label": "REFUTED", "evidence": ["Here's what those experts had to say about Kanteron's Platform as applied to the COVID-19 pandemic: > Spectacular!"]}
{"id": 1002460, "claim": "Kanteron platform for covid-19 reviewed by genbank experts", "label": "REFUTED", "evidence": ["Here's what those experts had to say about Kanteron's Platform as applied to the COVID-19 pandemic: > Spectacular!"]}
{"id": 1002461, "claim": "Sars-cov-2 uses cd4 to infect t helper lymphocytes", "label": "SUPPORTED", "evidence": ["Thus, CD4-mediated SARS-CoV-2 infection of T helper cells may explain the poor adaptive immune response of many COVID- 19 patients.", "Here we show that SARS-CoV-2 infects human CD4+ T helper cells, but not CD8+ T cells, and is present in blood and bronchoalveolar lavage T helper cells of severe COVID-19 patients.", "We demonstrated that SARS-CoV-2 spike glycoprotein (S) directly binds to the CD4 molecule, which in turn mediates the entry of SARS- CoV-2 in T helper cells in a mechanism that also requires ACE2 and TMPRSS2."]}
{"id": 1002462, "claim": "Pds-cov-2 uses cd4 to infect t helper lymphocytes", "label": "REFUTED", "evidence": ["Thus, CD4-mediated SARS-CoV-2 infection of T helper cells may explain the poor adaptive immune response of many COVID- 19 patients.", "Here we show that SARS-CoV-2 infects human CD4+ T helper cells, but not CD8+ T cells, and is present in blood and bronchoalveolar lavage T helper cells of severe COVID-19 patients.", "We demonstrated that SARS-CoV-2 spike glycoprotein (S) directly binds to the CD4 molecule, which in turn mediates the entry of SARS- CoV-2 in T helper cells in a mechanism that also requires ACE2 and TMPRSS2."]}
{"id": 1002463, "claim": "Fs-cov-2 uses cd4 to infect t helper lymphocytes", "label": "REFUTED", "evidence": ["Thus, CD4-mediated SARS-CoV-2 infection of T helper cells may explain the poor adaptive immune response of many COVID- 19 patients.", "Here we show that SARS-CoV-2 infects human CD4+ T helper cells, but not CD8+ T cells, and is present in blood and bronchoalveolar lavage T helper cells of severe COVID-19 patients.", "We demonstrated that SARS-CoV-2 spike glycoprotein (S) directly binds to the CD4 molecule, which in turn mediates the entry of SARS- CoV-2 in T helper cells in a mechanism that also requires ACE2 and TMPRSS2."]}
{"id": 1002464, "claim": "Ads-cov-2 uses cd4 to infect t helper lymphocytes", "label": "REFUTED", "evidence": ["Thus, CD4-mediated SARS-CoV-2 infection of T helper cells may explain the poor adaptive immune response of many COVID- 19 patients.", "Here we show that SARS-CoV-2 infects human CD4+ T helper cells, but not CD8+ T cells, and is present in blood and bronchoalveolar lavage T helper cells of severe COVID-19 patients.", "We demonstrated that SARS-CoV-2 spike glycoprotein (S) directly binds to the CD4 molecule, which in turn mediates the entry of SARS- CoV-2 in T helper cells in a mechanism that also requires ACE2 and TMPRSS2."]}
{"id": 1002465, "claim": "Clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness", "label": "SUPPORTED", "evidence": ["As lung pathology appears grossly different at various stages of illness, a tailored phenotypic approach to management, guided by pathophysiology, would be more appropriate than a syndromic approach."]}
{"id": 1002466, "claim": "Clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a pandemic illness", "label": "REFUTED", "evidence": ["As lung pathology appears grossly different at various stages of illness, a tailored phenotypic approach to management, guided by pathophysiology, would be more appropriate than a syndromic approach."]}
{"id": 1002467, "claim": "Clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a few illness", "label": "REFUTED", "evidence": ["As lung pathology appears grossly different at various stages of illness, a tailored phenotypic approach to management, guided by pathophysiology, would be more appropriate than a syndromic approach."]}
{"id": 1002468, "claim": "Clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a clinical illness", "label": "REFUTED", "evidence": ["As lung pathology appears grossly different at various stages of illness, a tailored phenotypic approach to management, guided by pathophysiology, would be more appropriate than a syndromic approach."]}
{"id": 1002469, "claim": "Detection of antibodies to the sars-cov-2 spike glycoprotein in both serum and saliva enhances detection of infection", "label": "SUPPORTED", "evidence": ["Conclusions Detecting antibody responses in both saliva and serum is optimal for determining virus exposure and understanding immune responses after SARS-CoV-2 infection.", "Anti-spike, but not nucleocapsid, IgG, IgA and IgM antibody responses were readily detectable in saliva from non-hospitalized symptomatic and asymptomatic individuals.", "Antibody responses in saliva and serum were largely independent of each other and symptom reporting."]}
{"id": 1002470, "claim": "Detection of antibodies to the sars-cov-2 spike glycoprotein in both serum and saliva dids detection of infection", "label": "REFUTED", "evidence": ["Conclusions Detecting antibody responses in both saliva and serum is optimal for determining virus exposure and understanding immune responses after SARS-CoV-2 infection.", "Anti-spike, but not nucleocapsid, IgG, IgA and IgM antibody responses were readily detectable in saliva from non-hospitalized symptomatic and asymptomatic individuals.", "Antibody responses in saliva and serum were largely independent of each other and symptom reporting."]}
{"id": 1002471, "claim": "Detection of antibodies to the sars-cov-2 spike glycoprotein in both serum and saliva coulds detection of infection", "label": "REFUTED", "evidence": ["Conclusions Detecting antibody responses in both saliva and serum is optimal for determining virus exposure and understanding immune responses after SARS-CoV-2 infection.", "Anti-spike, but not nucleocapsid, IgG, IgA and IgM antibody responses were readily detectable in saliva from non-hospitalized symptomatic and asymptomatic individuals.", "Antibody responses in saliva and serum were largely independent of each other and symptom reporting."]}
{"id": 1002472, "claim": "Ivermectin exposure leads to up-regulation of detoxification genes in vitro and in vivo in mice", "label": "SUPPORTED", "evidence": ["Gene expression of ABC transporters and cytochromes was evaluated by RT-qPCR in murine hepatic and intestinal cell lines exposed to increasing ivermectin doses, and in liver and intestine of mice orally administered with single or repeated therapeutic doses of ivermectin (0.2 mg/kg)."]}
{"id": 1002473, "claim": "A chicago hospital treating severe covid-19 patients with gilead sciences ' antiviral medication remdesivir is seeing recoveries in patients ' symptoms , stat news reports .", "label": "SUPPORTED", "evidence": ["Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests.", "A Chicago hospital treating severe Covid-19 patients with Gilead Sciences' antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.", "Gilead Sciences via AP A Chicago hospital treating severe Covid-19 patients with Gilead Sciences antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.", "A Chicago hospital treating severe Covid-19 patients with remdesivir, the Gilead Sciences (GILD) antiviral, in a clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned."]}
{"id": 1002474, "claim": "A chicago hospital treating severe covid-19 patients with gilead sciences'antiviral medication remdesivir is no recoveries in patients'symptoms, stat news reports.", "label": "REFUTED", "evidence": ["Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests.", "A Chicago hospital treating severe Covid-19 patients with Gilead Sciences' antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.", "Gilead Sciences via AP A Chicago hospital treating severe Covid-19 patients with Gilead Sciences antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.", "A Chicago hospital treating severe Covid-19 patients with remdesivir, the Gilead Sciences (GILD) antiviral, in a clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned."]}
{"id": 1002475, "claim": "A chicago hospital treating severe covid-19 patients with gilead sciences'antiviral medication remdesivir is not recoveries in patients'symptoms, stat news reports.", "label": "REFUTED", "evidence": ["Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests.", "A Chicago hospital treating severe Covid-19 patients with Gilead Sciences' antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.", "Gilead Sciences via AP A Chicago hospital treating severe Covid-19 patients with Gilead Sciences antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.", "A Chicago hospital treating severe Covid-19 patients with remdesivir, the Gilead Sciences (GILD) antiviral, in a clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned."]}
{"id": 1002476, "claim": "Horror fans and morbidly curious individuals are more psychologically resilient during the covid-19 pandemic", "label": "SUPPORTED", "evidence": ["We also found that morbid curiosity, a personality trait that has been previously associated with interest in horror (Scrivner, in press), was associated with greater positive resilience during the COVID-19 pandemic."]}
{"id": 1002477, "claim": "Horror fans and morbidly curious individuals are less psychologically resilient during the covid-19 pandemic", "label": "REFUTED", "evidence": ["We also found that morbid curiosity, a personality trait that has been previously associated with interest in horror (Scrivner, in press), was associated with greater positive resilience during the COVID-19 pandemic."]}
{"id": 1002478, "claim": "Horror fans and morbidly curious individuals are not psychologically resilient during the covid-19 pandemic", "label": "REFUTED", "evidence": ["We also found that morbid curiosity, a personality trait that has been previously associated with interest in horror (Scrivner, in press), was associated with greater positive resilience during the COVID-19 pandemic."]}
{"id": 1002479, "claim": "A third of coronavirus cases may be silent carriers , classified chinese data suggests", "label": "SUPPORTED", "evidence": ["The number of \"silent carriers\" -- people who are infected by the new coronavirus but show delayed or no symptoms -- could be as high as one-third of those who test positive, according to classified Chinese government data seen by the South China Morning Post."]}
{"id": 1002480, "claim": "A third of coronavirus cases cannot be silent carriers, classified chinese data suggests", "label": "REFUTED", "evidence": ["The number of \"silent carriers\" -- people who are infected by the new coronavirus but show delayed or no symptoms -- could be as high as one-third of those who test positive, according to classified Chinese government data seen by the South China Morning Post."]}
{"id": 1002481, "claim": "Prior infection by seasonal coronaviruses does not prevent sars-cov-2 infection and associated multisystem inflammatory syndrome in children", "label": "SUPPORTED", "evidence": ["COVID-19 and MIS attack rates, and anti-SARS-CoV-2 antibodies titres were not significantly impacted by prior seasonal coronavirus infection.", "Interpretation Prior infection with HCoVs does not prevent SARS-CoV-2 infection and related MIS in children.", "The level of anti-SARS-CoV-2 antibodies was not significantly different in children who had prior seasonal coronavirus infection.", "Evidence before this study Children seem to be less likely affected by SARS-CoV-2 infection and clinical course of COVID-19 is less severe than in adults."]}
{"id": 1002482, "claim": "Prior infection by seasonal coronaviruses does also prevent sars-cov-2 infection and associated multisystem inflammatory syndrome in children", "label": "REFUTED", "evidence": ["COVID-19 and MIS attack rates, and anti-SARS-CoV-2 antibodies titres were not significantly impacted by prior seasonal coronavirus infection.", "Interpretation Prior infection with HCoVs does not prevent SARS-CoV-2 infection and related MIS in children.", "The level of anti-SARS-CoV-2 antibodies was not significantly different in children who had prior seasonal coronavirus infection.", "Evidence before this study Children seem to be less likely affected by SARS-CoV-2 infection and clinical course of COVID-19 is less severe than in adults."]}
{"id": 1002483, "claim": "Prior infection by seasonal coronaviruses does indeed prevent sars-cov-2 infection and associated multisystem inflammatory syndrome in children", "label": "REFUTED", "evidence": ["COVID-19 and MIS attack rates, and anti-SARS-CoV-2 antibodies titres were not significantly impacted by prior seasonal coronavirus infection.", "Interpretation Prior infection with HCoVs does not prevent SARS-CoV-2 infection and related MIS in children.", "The level of anti-SARS-CoV-2 antibodies was not significantly different in children who had prior seasonal coronavirus infection.", "Evidence before this study Children seem to be less likely affected by SARS-CoV-2 infection and clinical course of COVID-19 is less severe than in adults."]}
{"id": 1002484, "claim": "Prior infection by seasonal coronaviruses does potentially prevent sars-cov-2 infection and associated multisystem inflammatory syndrome in children", "label": "REFUTED", "evidence": ["COVID-19 and MIS attack rates, and anti-SARS-CoV-2 antibodies titres were not significantly impacted by prior seasonal coronavirus infection.", "Interpretation Prior infection with HCoVs does not prevent SARS-CoV-2 infection and related MIS in children.", "The level of anti-SARS-CoV-2 antibodies was not significantly different in children who had prior seasonal coronavirus infection.", "Evidence before this study Children seem to be less likely affected by SARS-CoV-2 infection and clinical course of COVID-19 is less severe than in adults."]}
{"id": 1002485, "claim": "Sars-cov-2 orf3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant", "label": "SUPPORTED", "evidence": ["Interestingly, extension of SARS-CoV2 ORF3b by removal of a premature stop codon enhances its ability to antagonise IFN-β induction.", "Finally, SARS-CoV2 isolates from two severe COVID-19 cases were shown to express the extended ORF3b which shows increased IFN-β antagonism.", "A natural elongation variant of SARS-CoV-2 ORF3b isolated from two patients showed a stronger suppression of interferon induction than wildtype SARS-CoV-2 ORF3b.", "They find the truncated ORF3b encoded by SARS-CoV-2 (22 aa) suppresses IFN-β induction more efficiently than the full-length SARS-CoV ortholog (~153 aa)."]}
{"id": 1002486, "claim": "Sars-cov-2 orf3b is a potent interferon antagonist whose activity is further inhibited by a naturally occurring elongation variant", "label": "REFUTED", "evidence": ["Interestingly, extension of SARS-CoV2 ORF3b by removal of a premature stop codon enhances its ability to antagonise IFN-β induction.", "Finally, SARS-CoV2 isolates from two severe COVID-19 cases were shown to express the extended ORF3b which shows increased IFN-β antagonism.", "A natural elongation variant of SARS-CoV-2 ORF3b isolated from two patients showed a stronger suppression of interferon induction than wildtype SARS-CoV-2 ORF3b.", "They find the truncated ORF3b encoded by SARS-CoV-2 (22 aa) suppresses IFN-β induction more efficiently than the full-length SARS-CoV ortholog (~153 aa)."]}
{"id": 1002487, "claim": "Sars-cov-2 orf3b is a potent interferon antagonist whose activity is further blocked by a naturally occurring elongation variant", "label": "REFUTED", "evidence": ["Interestingly, extension of SARS-CoV2 ORF3b by removal of a premature stop codon enhances its ability to antagonise IFN-β induction.", "Finally, SARS-CoV2 isolates from two severe COVID-19 cases were shown to express the extended ORF3b which shows increased IFN-β antagonism.", "A natural elongation variant of SARS-CoV-2 ORF3b isolated from two patients showed a stronger suppression of interferon induction than wildtype SARS-CoV-2 ORF3b.", "They find the truncated ORF3b encoded by SARS-CoV-2 (22 aa) suppresses IFN-β induction more efficiently than the full-length SARS-CoV ortholog (~153 aa)."]}
{"id": 1002488, "claim": "Sars-cov-2 orf3b is a potent interferon antagonist whose activity is further controlled by a naturally occurring elongation variant", "label": "REFUTED", "evidence": ["Interestingly, extension of SARS-CoV2 ORF3b by removal of a premature stop codon enhances its ability to antagonise IFN-β induction.", "Finally, SARS-CoV2 isolates from two severe COVID-19 cases were shown to express the extended ORF3b which shows increased IFN-β antagonism.", "A natural elongation variant of SARS-CoV-2 ORF3b isolated from two patients showed a stronger suppression of interferon induction than wildtype SARS-CoV-2 ORF3b.", "They find the truncated ORF3b encoded by SARS-CoV-2 (22 aa) suppresses IFN-β induction more efficiently than the full-length SARS-CoV ortholog (~153 aa)."]}
{"id": 1002489, "claim": "A trial of lopinavirritonavir in adults hospitalized with severe covid-19", "label": "SUPPORTED", "evidence": ["The question of whether earlier lopinavirritonavir treatment in Covid-19 could have clinical benefit is an important one that requires further study.", "A recent report showed that the median duration of viral shedding in Covid-19 was 20 days in patients with severe illness and could be as long as 37 days.24 Neither that study nor the current one found evidence that lopinavirritonavir exerted a significant antiviral effect."]}
{"id": 1002490, "claim": "High temperature and high humidity reduce the transmission of covid-19", "label": "SUPPORTED", "evidence": ["If assuming a 30 degree and 25 percent > increase in temperature and relative humidity from winter to summer in the > northern hemisphere, we expect the R values to decline about 0.89 (0.69 by > temperature and 0.20 by humidity).", "We find a similar influence of the temperature > and relative humidity on effective reproductive number (R values) of > COVID-19 for both China and the U.S. before lockdown in both countries: one- > degree Celsius increase in temperature reduces R value by about 0.023 (0.026 > (95% CI [-0.0395,-0.0125]) in China and 0.020 (95% CI [-0.0311, -0.0096]) in > the U.S.), and one percent relative humidity rise reduces R value by 0.0078 > (0.0076 (95% CI [-0.0108,-0.0045]) in China and 0.0080 (95% CI > [-0.0150,-0.0010]) in the U.S.)."]}
{"id": 1002491, "claim": "High temperature and high humidity increase the transmission of covid-19", "label": "REFUTED", "evidence": ["If assuming a 30 degree and 25 percent > increase in temperature and relative humidity from winter to summer in the > northern hemisphere, we expect the R values to decline about 0.89 (0.69 by > temperature and 0.20 by humidity).", "We find a similar influence of the temperature > and relative humidity on effective reproductive number (R values) of > COVID-19 for both China and the U.S. before lockdown in both countries: one- > degree Celsius increase in temperature reduces R value by about 0.023 (0.026 > (95% CI [-0.0395,-0.0125]) in China and 0.020 (95% CI [-0.0311, -0.0096]) in > the U.S.), and one percent relative humidity rise reduces R value by 0.0078 > (0.0076 (95% CI [-0.0108,-0.0045]) in China and 0.0080 (95% CI > [-0.0150,-0.0010]) in the U.S.)."]}
{"id": 1002492, "claim": "High temperature and high humidity allow the transmission of covid-19", "label": "REFUTED", "evidence": ["If assuming a 30 degree and 25 percent > increase in temperature and relative humidity from winter to summer in the > northern hemisphere, we expect the R values to decline about 0.89 (0.69 by > temperature and 0.20 by humidity).", "We find a similar influence of the temperature > and relative humidity on effective reproductive number (R values) of > COVID-19 for both China and the U.S. before lockdown in both countries: one- > degree Celsius increase in temperature reduces R value by about 0.023 (0.026 > (95% CI [-0.0395,-0.0125]) in China and 0.020 (95% CI [-0.0311, -0.0096]) in > the U.S.), and one percent relative humidity rise reduces R value by 0.0078 > (0.0076 (95% CI [-0.0108,-0.0045]) in China and 0.0080 (95% CI > [-0.0150,-0.0010]) in the U.S.)."]}
{"id": 1002493, "claim": "Reductions in commuting mobility predict geographic differences in sars-cov-2 prevalence in new york city", "label": "SUPPORTED", "evidence": ["Main outcomes: Population prevalence of SARS-CoV-2 by borough and correlation with the reduction in daily commuting-style movements into and out of each borough.", "Objective: To estimate the prevalence of SARS-CoV-2 infection by New York City borough between March 22nd and May 3rd, 2020, and to associate variation in prevalence with antecedent reductions in mobility, defined as aggregated daily physical movements into and out of each borough.", "Conclusions and relevance: Reductions in between-borough mobility predict geographic differences in the prevalence of SARS-CoV-2 infection in New York City."]}
{"id": 1002494, "claim": "Advances in commuting mobility predict geographic differences in sars-cov-2 prevalence in new york city", "label": "REFUTED", "evidence": ["Main outcomes: Population prevalence of SARS-CoV-2 by borough and correlation with the reduction in daily commuting-style movements into and out of each borough.", "Objective: To estimate the prevalence of SARS-CoV-2 infection by New York City borough between March 22nd and May 3rd, 2020, and to associate variation in prevalence with antecedent reductions in mobility, defined as aggregated daily physical movements into and out of each borough.", "Conclusions and relevance: Reductions in between-borough mobility predict geographic differences in the prevalence of SARS-CoV-2 infection in New York City."]}
{"id": 1002495, "claim": "Death rates amongst hospitalized patients has dropped from 6 % to 1.5 % in the uk", "label": "SUPPORTED", "evidence": ["They found that death rates dropped for all groups, even older patients by 18 percentage points on average.", "The BBC previously reported this fall in the death rate among patients admitted to hospital with coronavirus, when University of Oxford researchers estimated it had fallen from 6% to 1.5% between the peak in April and June.", "University of Oxford researchers found the proportion of coronavirus patients dying each day in England fell from 6% to 1.5% between April and June.", "The proportion of patients admitted to critical care who die fell by almost a quarter from the peak and as much as half in hospitals overall.", "Based on a much smaller number of patients admitted between the 1 September and the start of October, the death rate now appears to be about a quarter of that level."]}
{"id": 1002496, "claim": "Death rates amongst hospitalized patients has increased from 6 % to 1.5 % in the uk", "label": "REFUTED", "evidence": ["They found that death rates dropped for all groups, even older patients by 18 percentage points on average.", "The BBC previously reported this fall in the death rate among patients admitted to hospital with coronavirus, when University of Oxford researchers estimated it had fallen from 6% to 1.5% between the peak in April and June.", "University of Oxford researchers found the proportion of coronavirus patients dying each day in England fell from 6% to 1.5% between April and June.", "The proportion of patients admitted to critical care who die fell by almost a quarter from the peak and as much as half in hospitals overall.", "Based on a much smaller number of patients admitted between the 1 September and the start of October, the death rate now appears to be about a quarter of that level."]}
{"id": 1002497, "claim": "High-dose corticosteroid pulse therapy increases the survival rate in covid-19 patients at risk of cytokine storm", "label": "SUPPORTED", "evidence": ["Corticosteroids have primarily been thought about in COVID-19 as a means to stave off the 'cytokine storm\" and its consequences like ARDS, disseminated intravascular coagulation, hypotension, shock and death.", "Cytokine storm induction by SARS-CoV-2 was confirmed in COVID-19 patients at the intensive care unit (ICU), and elevated plasma levels of inflammatory cytokines have been associated with disease severity and prognosis [7, 8]."]}
{"id": 1002498, "claim": "High-dose corticosteroid pulse therapy reduces the survival rate in covid-19 patients at risk of cytokine storm", "label": "REFUTED", "evidence": ["Corticosteroids have primarily been thought about in COVID-19 as a means to stave off the 'cytokine storm\" and its consequences like ARDS, disseminated intravascular coagulation, hypotension, shock and death.", "Cytokine storm induction by SARS-CoV-2 was confirmed in COVID-19 patients at the intensive care unit (ICU), and elevated plasma levels of inflammatory cytokines have been associated with disease severity and prognosis [7, 8]."]}
{"id": 1002499, "claim": "High-dose corticosteroid pulse therapy reduce the survival rate in covid-19 patients at risk of cytokine storm", "label": "REFUTED", "evidence": ["Corticosteroids have primarily been thought about in COVID-19 as a means to stave off the 'cytokine storm\" and its consequences like ARDS, disseminated intravascular coagulation, hypotension, shock and death.", "Cytokine storm induction by SARS-CoV-2 was confirmed in COVID-19 patients at the intensive care unit (ICU), and elevated plasma levels of inflammatory cytokines have been associated with disease severity and prognosis [7, 8]."]}
{"id": 1002500, "claim": "High-dose corticosteroid pulse therapy decreases the survival rate in covid-19 patients at risk of cytokine storm", "label": "REFUTED", "evidence": ["Corticosteroids have primarily been thought about in COVID-19 as a means to stave off the 'cytokine storm\" and its consequences like ARDS, disseminated intravascular coagulation, hypotension, shock and death.", "Cytokine storm induction by SARS-CoV-2 was confirmed in COVID-19 patients at the intensive care unit (ICU), and elevated plasma levels of inflammatory cytokines have been associated with disease severity and prognosis [7, 8]."]}
{"id": 1002501, "claim": "High-quality masks can reduce infections and deaths in the us", "label": "SUPPORTED", "evidence": ["If 100% of people wear masks (or 60% wear masks that are 80% effective), this decreases the CAR by 38%, the peak prevalence by 67%, and the population mortality by 40%.", "Results: If 60% of the population wears masks that are 50% effective, this decreases the cumulative infection attack rate (CAR) by 25%, the peak prevalence by 51%, and the population mortality by 25%.", "We evaluated scenarios where wearing a mask reduces transmission and susceptibility by 50% or 80%; an individual wears a mask with a probability of 0%, 20%, 40%, 60%, 80%, or 100%."]}
{"id": 1002502, "claim": "High-quality masks can increase infections and deaths in the us", "label": "REFUTED", "evidence": ["If 100% of people wear masks (or 60% wear masks that are 80% effective), this decreases the CAR by 38%, the peak prevalence by 67%, and the population mortality by 40%.", "Results: If 60% of the population wears masks that are 50% effective, this decreases the cumulative infection attack rate (CAR) by 25%, the peak prevalence by 51%, and the population mortality by 25%.", "We evaluated scenarios where wearing a mask reduces transmission and susceptibility by 50% or 80%; an individual wears a mask with a probability of 0%, 20%, 40%, 60%, 80%, or 100%."]}
{"id": 1002503, "claim": "High-quality masks can cause infections and deaths in the us", "label": "REFUTED", "evidence": ["If 100% of people wear masks (or 60% wear masks that are 80% effective), this decreases the CAR by 38%, the peak prevalence by 67%, and the population mortality by 40%.", "Results: If 60% of the population wears masks that are 50% effective, this decreases the cumulative infection attack rate (CAR) by 25%, the peak prevalence by 51%, and the population mortality by 25%.", "We evaluated scenarios where wearing a mask reduces transmission and susceptibility by 50% or 80%; an individual wears a mask with a probability of 0%, 20%, 40%, 60%, 80%, or 100%."]}
{"id": 1002504, "claim": "The viruses that shaped our dna", "label": "SUPPORTED", "evidence": ["A retrovirus invades a host cell and inserts its genes into that cells DNA.", "Are these viruses a part of us?", "Although most symbiosis research has focused on the role of the microbiome, the viruses tucked into our DNA can play a similar role in splitting apart two populations, turning one species into two."]}
{"id": 1002505, "claim": "The viruses that shaped our data", "label": "REFUTED", "evidence": ["A retrovirus invades a host cell and inserts its genes into that cells DNA.", "Are these viruses a part of us?", "Although most symbiosis research has focused on the role of the microbiome, the viruses tucked into our DNA can play a similar role in splitting apart two populations, turning one species into two."]}
{"id": 1002506, "claim": "The viruses that shaped our knowledge", "label": "REFUTED", "evidence": ["A retrovirus invades a host cell and inserts its genes into that cells DNA.", "Are these viruses a part of us?", "Although most symbiosis research has focused on the role of the microbiome, the viruses tucked into our DNA can play a similar role in splitting apart two populations, turning one species into two."]}
{"id": 1002507, "claim": "The viruses that shaped our question", "label": "REFUTED", "evidence": ["A retrovirus invades a host cell and inserts its genes into that cells DNA.", "Are these viruses a part of us?", "Although most symbiosis research has focused on the role of the microbiome, the viruses tucked into our DNA can play a similar role in splitting apart two populations, turning one species into two."]}
{"id": 1002508, "claim": "Azithromycin and hydroxychloroquine accelerate recovery of outpatients with mild/moderate covid-19", "label": "SUPPORTED", "evidence": ["Azithromycin (AZM) and hydroxychloroquine (HCQ) have proven their antiviral effect in vitro."]}
{"id": 1002509, "claim": "Azithromycin and hydroxychloroquine accelerate death of outpatients with mild/moderate covid-19", "label": "REFUTED", "evidence": ["Azithromycin (AZM) and hydroxychloroquine (HCQ) have proven their antiviral effect in vitro."]}
{"id": 1002510, "claim": "Azithromycin and hydroxychloroquine accelerate mortality of outpatients with mild/moderate covid-19", "label": "REFUTED", "evidence": ["Azithromycin (AZM) and hydroxychloroquine (HCQ) have proven their antiviral effect in vitro."]}
{"id": 1002511, "claim": "Azithromycin and hydroxychloroquine accelerate infection of outpatients with mild/moderate covid-19", "label": "REFUTED", "evidence": ["Azithromycin (AZM) and hydroxychloroquine (HCQ) have proven their antiviral effect in vitro."]}
{"id": 1002512, "claim": "The cdc recommends organizers cancel or postpone events with 50 people or more for 8 weeks", "label": "SUPPORTED", "evidence": ["(CNN)The US Centers for Disease Control and Prevention on Sunday recommended that no gatherings with 50 people or more take place for the next eight weeks to slow the spread of the novel coronavirus."]}
{"id": 1002513, "claim": "The cdc recommends no cancel or postpone events with 50 people or more for 8 weeks", "label": "REFUTED", "evidence": ["(CNN)The US Centers for Disease Control and Prevention on Sunday recommended that no gatherings with 50 people or more take place for the next eight weeks to slow the spread of the novel coronavirus."]}
{"id": 1002514, "claim": "A single dose of chadox1 mers provides protective immunity in rhesus macaques", "label": "SUPPORTED", "evidence": ["1 Vaccination of rhesus macaques with ChAdOx1 MERS elicits a humoral immune response.", "Animals that received a vaccination with ChAdOx1 MERS, either via a prime-boost or prime-only regimen, had either no lesions or limited small multifocal areas of consolidation and congestion.", "In conclusion, we show that a single vaccination with ChAdOx1 MERS results in protection against disease progression and virus replication associated with MERS-CoV challenge in the rhesus macaque, and a prime-boost regimen reduced viral replication further.", "In the current manuscript, we show that a single dose of ChAdOx1 MERS vaccine protects rhesus macaque model against a mucosal challenge with HCoV-EMC/2012."]}
{"id": 1002515, "claim": "A large dose of chadox1 mers provides protective immunity in rhesus macaques", "label": "REFUTED", "evidence": ["1 Vaccination of rhesus macaques with ChAdOx1 MERS elicits a humoral immune response.", "Animals that received a vaccination with ChAdOx1 MERS, either via a prime-boost or prime-only regimen, had either no lesions or limited small multifocal areas of consolidation and congestion.", "In conclusion, we show that a single vaccination with ChAdOx1 MERS results in protection against disease progression and virus replication associated with MERS-CoV challenge in the rhesus macaque, and a prime-boost regimen reduced viral replication further.", "In the current manuscript, we show that a single dose of ChAdOx1 MERS vaccine protects rhesus macaque model against a mucosal challenge with HCoV-EMC/2012."]}
{"id": 1002516, "claim": "A high dose of chadox1 mers provides protective immunity in rhesus macaques", "label": "REFUTED", "evidence": ["1 Vaccination of rhesus macaques with ChAdOx1 MERS elicits a humoral immune response.", "Animals that received a vaccination with ChAdOx1 MERS, either via a prime-boost or prime-only regimen, had either no lesions or limited small multifocal areas of consolidation and congestion.", "In conclusion, we show that a single vaccination with ChAdOx1 MERS results in protection against disease progression and virus replication associated with MERS-CoV challenge in the rhesus macaque, and a prime-boost regimen reduced viral replication further.", "In the current manuscript, we show that a single dose of ChAdOx1 MERS vaccine protects rhesus macaque model against a mucosal challenge with HCoV-EMC/2012."]}
{"id": 1002517, "claim": "The recent cdc report on comorbidity is not good news or evidence of a hoax", "label": "SUPPORTED", "evidence": ["\"[The report] surely includes some new data, but the general findingthat comorbidities increase your risk of dying from COVID-19is not a surprise at all,\" Lessler has said.", "Lessler is an infectious disease specialist at the Bloomberg School of Public Health and was interviewed by John Hopkins publication Hub and clarified the recent CDC report:  The importance of this CDC data is showing the comorbidities in people who have died with COVID-19, in hopes of better understanding the risk factors for death."]}
{"id": 1002518, "claim": "The recent cdc report on comorbidity is very good news or evidence of a hoax", "label": "REFUTED", "evidence": ["\"[The report] surely includes some new data, but the general findingthat comorbidities increase your risk of dying from COVID-19is not a surprise at all,\" Lessler has said.", "Lessler is an infectious disease specialist at the Bloomberg School of Public Health and was interviewed by John Hopkins publication Hub and clarified the recent CDC report:  The importance of this CDC data is showing the comorbidities in people who have died with COVID-19, in hopes of better understanding the risk factors for death."]}
{"id": 1002519, "claim": "The recent cdc report on comorbidity is only good news or evidence of a hoax", "label": "REFUTED", "evidence": ["\"[The report] surely includes some new data, but the general findingthat comorbidities increase your risk of dying from COVID-19is not a surprise at all,\" Lessler has said.", "Lessler is an infectious disease specialist at the Bloomberg School of Public Health and was interviewed by John Hopkins publication Hub and clarified the recent CDC report:  The importance of this CDC data is showing the comorbidities in people who have died with COVID-19, in hopes of better understanding the risk factors for death."]}
{"id": 1002520, "claim": "The recent cdc report on comorbidity is a good news or evidence of a hoax", "label": "REFUTED", "evidence": ["\"[The report] surely includes some new data, but the general findingthat comorbidities increase your risk of dying from COVID-19is not a surprise at all,\" Lessler has said.", "Lessler is an infectious disease specialist at the Bloomberg School of Public Health and was interviewed by John Hopkins publication Hub and clarified the recent CDC report:  The importance of this CDC data is showing the comorbidities in people who have died with COVID-19, in hopes of better understanding the risk factors for death."]}
{"id": 1002521, "claim": "Emergence of zoonoses such as covid-19 reveals the need for health sciences to embrace an explicit eco-social conceptual framework of health and disease", "label": "SUPPORTED", "evidence": ["Others argue that a range of anthropogenic environmental degradations have played a vital role in the emergence of SARS- CoV-2 and other zoonoses.", "In this opinion piece, I argue that these divergent viewpoints stem, in part, from different foundational conceptual frameworks  biomedical individualist and eco-social frameworks, respectively.", "Based on the fact that the eco-social framework provides a more complete account of the different types of causal factors underpinning the emergence of zoonoses, I propose that the COVID-19 pandemic provides an additional reason for the health sciences to ground its theory of health and disease in an eco-social conceptual framework."]}
{"id": 1002522, "claim": "Emergence of zoonoses such as covid-19 reveals the need for health sciences to embrace an explicit eco-social conceptual framework of health and security", "label": "REFUTED", "evidence": ["Others argue that a range of anthropogenic environmental degradations have played a vital role in the emergence of SARS- CoV-2 and other zoonoses.", "In this opinion piece, I argue that these divergent viewpoints stem, in part, from different foundational conceptual frameworks  biomedical individualist and eco-social frameworks, respectively.", "Based on the fact that the eco-social framework provides a more complete account of the different types of causal factors underpinning the emergence of zoonoses, I propose that the COVID-19 pandemic provides an additional reason for the health sciences to ground its theory of health and disease in an eco-social conceptual framework."]}
{"id": 1002523, "claim": "New blood tests for antibodies could show true scale of coronavirus pandemic", "label": "SUPPORTED", "evidence": ["But scientists also need to test a persons blood for antibodies to the new virus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", "Widespread antibody testing could also provide key data for efforts to model the course of the pandemic."]}
{"id": 1002524, "claim": "New blood tests for antibodies could reduce true scale of coronavirus pandemic", "label": "REFUTED", "evidence": ["But scientists also need to test a persons blood for antibodies to the new virus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", "Widespread antibody testing could also provide key data for efforts to model the course of the pandemic."]}
{"id": 1002525, "claim": "Public health lessons learned from biases in coronavirus mortality overestimation", "label": "SUPPORTED", "evidence": ["Results of this critical appraisal reveal information bias and selection bias in coronavirus mortality overestimation, most likely caused by misclassifying an influenza infection fatality rate as a case fatality rate.", "Reference James45 For example, the publics belief that mitigation measures were responsible for reducing coronavirus mortality may be a post hoc fallacy if lower mortality was actually due to the overestimation of coronavirus deaths."]}
{"id": 1002526, "claim": "Public health lessons learned from biases in coronavirus transmission overestimation", "label": "REFUTED", "evidence": ["Results of this critical appraisal reveal information bias and selection bias in coronavirus mortality overestimation, most likely caused by misclassifying an influenza infection fatality rate as a case fatality rate.", "Reference James45 For example, the publics belief that mitigation measures were responsible for reducing coronavirus mortality may be a post hoc fallacy if lower mortality was actually due to the overestimation of coronavirus deaths."]}
{"id": 1002527, "claim": "Public health lessons learned from biases in coronavirus emergence overestimation", "label": "REFUTED", "evidence": ["Results of this critical appraisal reveal information bias and selection bias in coronavirus mortality overestimation, most likely caused by misclassifying an influenza infection fatality rate as a case fatality rate.", "Reference James45 For example, the publics belief that mitigation measures were responsible for reducing coronavirus mortality may be a post hoc fallacy if lower mortality was actually due to the overestimation of coronavirus deaths."]}
{"id": 1002528, "claim": "Public health lessons learned from biases in coronavirus spread overestimation", "label": "REFUTED", "evidence": ["Results of this critical appraisal reveal information bias and selection bias in coronavirus mortality overestimation, most likely caused by misclassifying an influenza infection fatality rate as a case fatality rate.", "Reference James45 For example, the publics belief that mitigation measures were responsible for reducing coronavirus mortality may be a post hoc fallacy if lower mortality was actually due to the overestimation of coronavirus deaths."]}
{"id": 1002529, "claim": "Sars-cov2 enables anaerobic bacteria to colonize the lungs disrupting homeostasis", "label": "SUPPORTED", "evidence": ["Patients infected by SARS-CoV-2 may have alterations in the oral and gut microbiota, while oral species have been found in the lung of COVID-19 patients.", "Conversely, the oropharyngeal microbiota in patients after lung transplantation showed severe dysbiosis community-wise with reduction of diversity and richness increasing anaerobic facultative bacteria.", "SARS-Cov2 enables anaerobic bacteria (Prevotella, et al) to colonize the lungs disrupting homeostasis, causing long-drawn chronic symptoms, and acute severe symptoms (ARDS, septic shock, clots, arterial stroke) which finds resonance, with key differences, in the forgotten disease Lemierre Syndrome, enabled by Epstein Barr Virus.", "In disease, we found lung abnormalities related to oral microbiome dysbiosis, suggesting the oral cavity as the microbial gateway for the lower respiratory tract [52]."]}
{"id": 1002530, "claim": "Sars-cov2 enables anaerobic bacteria to colonize the blood disrupting homeostasis", "label": "REFUTED", "evidence": ["Patients infected by SARS-CoV-2 may have alterations in the oral and gut microbiota, while oral species have been found in the lung of COVID-19 patients.", "Conversely, the oropharyngeal microbiota in patients after lung transplantation showed severe dysbiosis community-wise with reduction of diversity and richness increasing anaerobic facultative bacteria.", "SARS-Cov2 enables anaerobic bacteria (Prevotella, et al) to colonize the lungs disrupting homeostasis, causing long-drawn chronic symptoms, and acute severe symptoms (ARDS, septic shock, clots, arterial stroke) which finds resonance, with key differences, in the forgotten disease Lemierre Syndrome, enabled by Epstein Barr Virus.", "In disease, we found lung abnormalities related to oral microbiome dysbiosis, suggesting the oral cavity as the microbial gateway for the lower respiratory tract [52]."]}
{"id": 1002531, "claim": "Sars-cov2 enables anaerobic bacteria to colonize the gut disrupting homeostasis", "label": "REFUTED", "evidence": ["Patients infected by SARS-CoV-2 may have alterations in the oral and gut microbiota, while oral species have been found in the lung of COVID-19 patients.", "Conversely, the oropharyngeal microbiota in patients after lung transplantation showed severe dysbiosis community-wise with reduction of diversity and richness increasing anaerobic facultative bacteria.", "SARS-Cov2 enables anaerobic bacteria (Prevotella, et al) to colonize the lungs disrupting homeostasis, causing long-drawn chronic symptoms, and acute severe symptoms (ARDS, septic shock, clots, arterial stroke) which finds resonance, with key differences, in the forgotten disease Lemierre Syndrome, enabled by Epstein Barr Virus.", "In disease, we found lung abnormalities related to oral microbiome dysbiosis, suggesting the oral cavity as the microbial gateway for the lower respiratory tract [52]."]}
{"id": 1002532, "claim": "Sars-cov2 enables anaerobic bacteria to colonize the intestinal disrupting homeostasis", "label": "REFUTED", "evidence": ["Patients infected by SARS-CoV-2 may have alterations in the oral and gut microbiota, while oral species have been found in the lung of COVID-19 patients.", "Conversely, the oropharyngeal microbiota in patients after lung transplantation showed severe dysbiosis community-wise with reduction of diversity and richness increasing anaerobic facultative bacteria.", "SARS-Cov2 enables anaerobic bacteria (Prevotella, et al) to colonize the lungs disrupting homeostasis, causing long-drawn chronic symptoms, and acute severe symptoms (ARDS, septic shock, clots, arterial stroke) which finds resonance, with key differences, in the forgotten disease Lemierre Syndrome, enabled by Epstein Barr Virus.", "In disease, we found lung abnormalities related to oral microbiome dysbiosis, suggesting the oral cavity as the microbial gateway for the lower respiratory tract [52]."]}
{"id": 1002533, "claim": "Closed environments facilitate secondary transmission of coronavirus disease 2019", "label": "SUPPORTED", "evidence": ["Conclusions It is plausible that closed environments contribute to secondary transmission of COVID-19 and promote superspreading events.", "Our findings are also consistent with the declining incidence of COVID-19 cases in China, as gathering in closed environments was prohibited in the wake of the rapid spread of the disease."]}
{"id": 1002534, "claim": "Closed environments prevent secondary transmission of coronavirus disease 2019", "label": "REFUTED", "evidence": ["Conclusions It is plausible that closed environments contribute to secondary transmission of COVID-19 and promote superspreading events.", "Our findings are also consistent with the declining incidence of COVID-19 cases in China, as gathering in closed environments was prohibited in the wake of the rapid spread of the disease."]}
{"id": 1002535, "claim": "Surveys of infectious disease experts aim to predict covid-19 's toll", "label": "SUPPORTED", "evidence": ["Epidemiological and clinical predictors of covid-19.", "Systematic review and meta-analysis of predictive symptoms and comorbidities for severe COVID-19 infection."]}
{"id": 1002536, "claim": "None of infectious disease experts aim to predict covid-19's toll", "label": "REFUTED", "evidence": ["Epidemiological and clinical predictors of covid-19.", "Systematic review and meta-analysis of predictive symptoms and comorbidities for severe COVID-19 infection."]}
{"id": 1002537, "claim": "T cell anergy in covid-19 reflects virus persistence and poor outcomes", "label": "SUPPORTED", "evidence": ["Based on our data we were able to develop a score to predict fatal outcomes and to identify patients that may benefit from strategies to overcome T cell anergy.", "We applied novel approaches to analyze T cell reactivity and showed that T anergy is already present in non-ventilated COVID-19 patients, very pronounced in ventilated patients, strongly associated with virus persistence and reversible with clinical recovery.", "Downstream markers of T cell anergy were also found in fresh blood samples of critically ill patients with severe T cell anergy."]}
{"id": 1002538, "claim": "T cell anergy in covid-19 reflects virus persistence and survival outcomes", "label": "REFUTED", "evidence": ["Based on our data we were able to develop a score to predict fatal outcomes and to identify patients that may benefit from strategies to overcome T cell anergy.", "We applied novel approaches to analyze T cell reactivity and showed that T anergy is already present in non-ventilated COVID-19 patients, very pronounced in ventilated patients, strongly associated with virus persistence and reversible with clinical recovery.", "Downstream markers of T cell anergy were also found in fresh blood samples of critically ill patients with severe T cell anergy."]}
{"id": 1002539, "claim": "T cell anergy in covid-19 reflects virus persistence and replication outcomes", "label": "REFUTED", "evidence": ["Based on our data we were able to develop a score to predict fatal outcomes and to identify patients that may benefit from strategies to overcome T cell anergy.", "We applied novel approaches to analyze T cell reactivity and showed that T anergy is already present in non-ventilated COVID-19 patients, very pronounced in ventilated patients, strongly associated with virus persistence and reversible with clinical recovery.", "Downstream markers of T cell anergy were also found in fresh blood samples of critically ill patients with severe T cell anergy."]}
{"id": 1002540, "claim": "T cell anergy in covid-19 reflects virus persistence and persistence outcomes", "label": "REFUTED", "evidence": ["Based on our data we were able to develop a score to predict fatal outcomes and to identify patients that may benefit from strategies to overcome T cell anergy.", "We applied novel approaches to analyze T cell reactivity and showed that T anergy is already present in non-ventilated COVID-19 patients, very pronounced in ventilated patients, strongly associated with virus persistence and reversible with clinical recovery.", "Downstream markers of T cell anergy were also found in fresh blood samples of critically ill patients with severe T cell anergy."]}
{"id": 1002541, "claim": "Niaid-led study of mrna vaccine supports advance to phase 3 human trials", "label": "SUPPORTED", "evidence": ["Results from early-stage clinical testing indicate the investigational mRNA-1273 vaccine is safe and immunogenic, supporting the initiation of a Phase 3 clinical trial."]}
{"id": 1002542, "claim": "Niaid-led study of mrna vaccine supports advance to phase 3 animal trials", "label": "REFUTED", "evidence": ["Results from early-stage clinical testing indicate the investigational mRNA-1273 vaccine is safe and immunogenic, supporting the initiation of a Phase 3 clinical trial."]}
{"id": 1002543, "claim": "Herd immunity is not a realistic exit strategy during a covid-19 outbreak", "label": "SUPPORTED", "evidence": ["This study provides vital information on the extent of virus spread in a country where social distancing is in place, concluding that herd immunity to SARS-CoV-2 is not a realistic short-term exit strategy option.", "The \"herd immunity\" in the case of an epidemic with a pathogen with potential fatal outcome is not achievable because it's essential mechanism, randomisation of immunised (R) within a society is not achievable."]}
{"id": 1002544, "claim": "Herd immunity is also a realistic exit strategy during a covid-19 outbreak", "label": "REFUTED", "evidence": ["This study provides vital information on the extent of virus spread in a country where social distancing is in place, concluding that herd immunity to SARS-CoV-2 is not a realistic short-term exit strategy option.", "The \"herd immunity\" in the case of an epidemic with a pathogen with potential fatal outcome is not achievable because it's essential mechanism, randomisation of immunised (R) within a society is not achievable."]}
{"id": 1002545, "claim": "Herd immunity is still a realistic exit strategy during a covid-19 outbreak", "label": "REFUTED", "evidence": ["This study provides vital information on the extent of virus spread in a country where social distancing is in place, concluding that herd immunity to SARS-CoV-2 is not a realistic short-term exit strategy option.", "The \"herd immunity\" in the case of an epidemic with a pathogen with potential fatal outcome is not achievable because it's essential mechanism, randomisation of immunised (R) within a society is not achievable."]}
{"id": 1002546, "claim": "Herd immunity is therefore a realistic exit strategy during a covid-19 outbreak", "label": "REFUTED", "evidence": ["This study provides vital information on the extent of virus spread in a country where social distancing is in place, concluding that herd immunity to SARS-CoV-2 is not a realistic short-term exit strategy option.", "The \"herd immunity\" in the case of an epidemic with a pathogen with potential fatal outcome is not achievable because it's essential mechanism, randomisation of immunised (R) within a society is not achievable."]}
{"id": 1002547, "claim": "Bulletinniaid stops enrollment of severely ill covid-19 participants in clinical trial of investigational treatments", "label": "SUPPORTED", "evidence": ["]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: telephone [e]: email []: You need to accept this checkbox."]}
{"id": 1002548, "claim": "Neuropilin-1 facilitates sars-cov-2 cell entry and infectivity", "label": "SUPPORTED", "evidence": ["1 NRP1 facilitates the cellular entry of SARS-CoV-2 pseudotyped particles.", "now show that neuropilin-1 (NRP1), which is known to bind furin-cleaved substrates, potentiates SARS-CoV-2 infectivity."]}
{"id": 1002549, "claim": "Neuropilin-1 inhibits sars-cov-2 cell entry and infectivity", "label": "REFUTED", "evidence": ["1 NRP1 facilitates the cellular entry of SARS-CoV-2 pseudotyped particles.", "now show that neuropilin-1 (NRP1), which is known to bind furin-cleaved substrates, potentiates SARS-CoV-2 infectivity."]}
{"id": 1002550, "claim": "Neuropilin-1 inhibited sars-cov-2 cell entry and infectivity", "label": "REFUTED", "evidence": ["1 NRP1 facilitates the cellular entry of SARS-CoV-2 pseudotyped particles.", "now show that neuropilin-1 (NRP1), which is known to bind furin-cleaved substrates, potentiates SARS-CoV-2 infectivity."]}
{"id": 1002551, "claim": "Neuropilin-1 blocks sars-cov-2 cell entry and infectivity", "label": "REFUTED", "evidence": ["1 NRP1 facilitates the cellular entry of SARS-CoV-2 pseudotyped particles.", "now show that neuropilin-1 (NRP1), which is known to bind furin-cleaved substrates, potentiates SARS-CoV-2 infectivity."]}
{"id": 1002552, "claim": "The major genetic risk factor for severe covid-19 is inherited from neanderthals .", "label": "SUPPORTED", "evidence": ["3: Geographical distribution of the Neanderthal core haplotype that confers risk for severe COVID-19.", "The close relationship of the risk haplotype to the Vindija 33.19 Neanderthal is compatible with this Neanderthal being closer to the majority of the Neanderthals who contributed DNA to present-day people than the other two Neanderthals10."]}
{"id": 1002553, "claim": "The major genetic risk factor for severe covid-19 is far from neanderthals.", "label": "REFUTED", "evidence": ["3: Geographical distribution of the Neanderthal core haplotype that confers risk for severe COVID-19.", "The close relationship of the risk haplotype to the Vindija 33.19 Neanderthal is compatible with this Neanderthal being closer to the majority of the Neanderthals who contributed DNA to present-day people than the other two Neanderthals10."]}
{"id": 1002554, "claim": "The major genetic risk factor for severe covid-19 is distinct from neanderthals.", "label": "REFUTED", "evidence": ["3: Geographical distribution of the Neanderthal core haplotype that confers risk for severe COVID-19.", "The close relationship of the risk haplotype to the Vindija 33.19 Neanderthal is compatible with this Neanderthal being closer to the majority of the Neanderthals who contributed DNA to present-day people than the other two Neanderthals10."]}
{"id": 1002555, "claim": "The major genetic risk factor for severe covid-19 is different from neanderthals.", "label": "REFUTED", "evidence": ["3: Geographical distribution of the Neanderthal core haplotype that confers risk for severe COVID-19.", "The close relationship of the risk haplotype to the Vindija 33.19 Neanderthal is compatible with this Neanderthal being closer to the majority of the Neanderthals who contributed DNA to present-day people than the other two Neanderthals10."]}
{"id": 1002556, "claim": "Favorable outcomes among neonates not separated from their symptomatic sars-cov-2-infected mothers", "label": "SUPPORTED", "evidence": ["Breastfeeding may protect against the horizontal transmission of SARS-CoV-2, as specific antibodies against this virus have been found in the breast milk of a COVID-19-infected mother.18 This hypothesis appears consistent with the protective effect of breastfeeding against respiratory tract infections in infancy.19 Our results support early postnatal proximity, despite many mothers worldwide being separated from their newborn infants during the COVID-19 pandemic.", "Their newborns are at a higher risk of prematurity and early separation from their mothers, who may subsequently require intensive care for their own health.1,2 Although neonates born of mothers infected with SARS-CoV-2 during pregnancy are seemingly vulnerable to infection, studies have found that they were not at a high risk for severe infection and were very rarely affected by COVID-19.1,2,3,4,5,6 The presence of virus by real-time reverse transcriptase polymerase chain reaction (RT-PCR) has been reported in newborns before H 12 of life.1 In addition, antiviral immunoglobulin M has been detected in newborns at birth,7 suggesting that mother-to-infant viral transmission may occur.8 To date, however, only one case of vertical transmission has been clearly demonstrated.9 In several cases of early neonatal infection, postnatal contamination cannot be excluded.10 Moreover, only one case report found that the virus could pass from mother to infant through the mothers breast milk.11 Despite these findings, international or national guidelines on the management of newborns of mothers suspected or positive for COVID-19, including Chinese consensus guidelines and guidelines of the American Academic of Pediatrics, have recommended at least temporary separation of mother and newborn as a precaution.12,13 In contrast, other guidelines,14 including those of the French Society of Neonatology,15,16 do not recommend systematic separation."]}
{"id": 1002557, "claim": "Favorable outcomes among neonates also separated from their symptomatic sars-cov-2-infected mothers", "label": "REFUTED", "evidence": ["Breastfeeding may protect against the horizontal transmission of SARS-CoV-2, as specific antibodies against this virus have been found in the breast milk of a COVID-19-infected mother.18 This hypothesis appears consistent with the protective effect of breastfeeding against respiratory tract infections in infancy.19 Our results support early postnatal proximity, despite many mothers worldwide being separated from their newborn infants during the COVID-19 pandemic.", "Their newborns are at a higher risk of prematurity and early separation from their mothers, who may subsequently require intensive care for their own health.1,2 Although neonates born of mothers infected with SARS-CoV-2 during pregnancy are seemingly vulnerable to infection, studies have found that they were not at a high risk for severe infection and were very rarely affected by COVID-19.1,2,3,4,5,6 The presence of virus by real-time reverse transcriptase polymerase chain reaction (RT-PCR) has been reported in newborns before H 12 of life.1 In addition, antiviral immunoglobulin M has been detected in newborns at birth,7 suggesting that mother-to-infant viral transmission may occur.8 To date, however, only one case of vertical transmission has been clearly demonstrated.9 In several cases of early neonatal infection, postnatal contamination cannot be excluded.10 Moreover, only one case report found that the virus could pass from mother to infant through the mothers breast milk.11 Despite these findings, international or national guidelines on the management of newborns of mothers suspected or positive for COVID-19, including Chinese consensus guidelines and guidelines of the American Academic of Pediatrics, have recommended at least temporary separation of mother and newborn as a precaution.12,13 In contrast, other guidelines,14 including those of the French Society of Neonatology,15,16 do not recommend systematic separation."]}
{"id": 1002558, "claim": "No outcomes among neonates not separated from their symptomatic sars-cov-2-infected mothers", "label": "REFUTED", "evidence": ["Breastfeeding may protect against the horizontal transmission of SARS-CoV-2, as specific antibodies against this virus have been found in the breast milk of a COVID-19-infected mother.18 This hypothesis appears consistent with the protective effect of breastfeeding against respiratory tract infections in infancy.19 Our results support early postnatal proximity, despite many mothers worldwide being separated from their newborn infants during the COVID-19 pandemic.", "Their newborns are at a higher risk of prematurity and early separation from their mothers, who may subsequently require intensive care for their own health.1,2 Although neonates born of mothers infected with SARS-CoV-2 during pregnancy are seemingly vulnerable to infection, studies have found that they were not at a high risk for severe infection and were very rarely affected by COVID-19.1,2,3,4,5,6 The presence of virus by real-time reverse transcriptase polymerase chain reaction (RT-PCR) has been reported in newborns before H 12 of life.1 In addition, antiviral immunoglobulin M has been detected in newborns at birth,7 suggesting that mother-to-infant viral transmission may occur.8 To date, however, only one case of vertical transmission has been clearly demonstrated.9 In several cases of early neonatal infection, postnatal contamination cannot be excluded.10 Moreover, only one case report found that the virus could pass from mother to infant through the mothers breast milk.11 Despite these findings, international or national guidelines on the management of newborns of mothers suspected or positive for COVID-19, including Chinese consensus guidelines and guidelines of the American Academic of Pediatrics, have recommended at least temporary separation of mother and newborn as a precaution.12,13 In contrast, other guidelines,14 including those of the French Society of Neonatology,15,16 do not recommend systematic separation."]}
{"id": 1002559, "claim": "Favorable outcomes among neonates is separated from their symptomatic sars-cov-2-infected mothers", "label": "REFUTED", "evidence": ["Breastfeeding may protect against the horizontal transmission of SARS-CoV-2, as specific antibodies against this virus have been found in the breast milk of a COVID-19-infected mother.18 This hypothesis appears consistent with the protective effect of breastfeeding against respiratory tract infections in infancy.19 Our results support early postnatal proximity, despite many mothers worldwide being separated from their newborn infants during the COVID-19 pandemic.", "Their newborns are at a higher risk of prematurity and early separation from their mothers, who may subsequently require intensive care for their own health.1,2 Although neonates born of mothers infected with SARS-CoV-2 during pregnancy are seemingly vulnerable to infection, studies have found that they were not at a high risk for severe infection and were very rarely affected by COVID-19.1,2,3,4,5,6 The presence of virus by real-time reverse transcriptase polymerase chain reaction (RT-PCR) has been reported in newborns before H 12 of life.1 In addition, antiviral immunoglobulin M has been detected in newborns at birth,7 suggesting that mother-to-infant viral transmission may occur.8 To date, however, only one case of vertical transmission has been clearly demonstrated.9 In several cases of early neonatal infection, postnatal contamination cannot be excluded.10 Moreover, only one case report found that the virus could pass from mother to infant through the mothers breast milk.11 Despite these findings, international or national guidelines on the management of newborns of mothers suspected or positive for COVID-19, including Chinese consensus guidelines and guidelines of the American Academic of Pediatrics, have recommended at least temporary separation of mother and newborn as a precaution.12,13 In contrast, other guidelines,14 including those of the French Society of Neonatology,15,16 do not recommend systematic separation."]}
{"id": 1002560, "claim": "Cardiorespiratory fitness and neuromuscular performance in patients recovered from covid-19.", "label": "SUPPORTED", "evidence": ["Conclusion Patients recovered from severe COVID-19 present low cardiorespiratory fitness, activate glycolytic fibers at low power outputs, and show low neuromuscular efficiency; while patients recovered from mild COVID-19 do not present these sequels.", "Chronic pain following COVID-19: implications for rehabilitation.", "It is envisaged that an additional requirement for these procedures will emerge from requests to evaluate individuals recovering from severe COVID-19 infection.7 In this context, measurements obtained from an assessment of cardiorespiratory responses to physiological stress could provide insight regarding the integrity of the pulmonary-vascular interface and characterisation of any impairment or abnormal cardiorespiratory function."]}
{"id": 1002561, "claim": "Cardiorespiratory fitness and neuromuscular performance in patients died from covid-19.", "label": "REFUTED", "evidence": ["Conclusion Patients recovered from severe COVID-19 present low cardiorespiratory fitness, activate glycolytic fibers at low power outputs, and show low neuromuscular efficiency; while patients recovered from mild COVID-19 do not present these sequels.", "Chronic pain following COVID-19: implications for rehabilitation.", "It is envisaged that an additional requirement for these procedures will emerge from requests to evaluate individuals recovering from severe COVID-19 infection.7 In this context, measurements obtained from an assessment of cardiorespiratory responses to physiological stress could provide insight regarding the integrity of the pulmonary-vascular interface and characterisation of any impairment or abnormal cardiorespiratory function."]}
{"id": 1002562, "claim": "Cardiorespiratory fitness and neuromuscular performance in animals recovered from covid-19.", "label": "REFUTED", "evidence": ["Conclusion Patients recovered from severe COVID-19 present low cardiorespiratory fitness, activate glycolytic fibers at low power outputs, and show low neuromuscular efficiency; while patients recovered from mild COVID-19 do not present these sequels.", "Chronic pain following COVID-19: implications for rehabilitation.", "It is envisaged that an additional requirement for these procedures will emerge from requests to evaluate individuals recovering from severe COVID-19 infection.7 In this context, measurements obtained from an assessment of cardiorespiratory responses to physiological stress could provide insight regarding the integrity of the pulmonary-vascular interface and characterisation of any impairment or abnormal cardiorespiratory function."]}
{"id": 1002563, "claim": "Cardiorespiratory fitness and neuromuscular performance in dogs recovered from covid-19.", "label": "REFUTED", "evidence": ["Conclusion Patients recovered from severe COVID-19 present low cardiorespiratory fitness, activate glycolytic fibers at low power outputs, and show low neuromuscular efficiency; while patients recovered from mild COVID-19 do not present these sequels.", "Chronic pain following COVID-19: implications for rehabilitation.", "It is envisaged that an additional requirement for these procedures will emerge from requests to evaluate individuals recovering from severe COVID-19 infection.7 In this context, measurements obtained from an assessment of cardiorespiratory responses to physiological stress could provide insight regarding the integrity of the pulmonary-vascular interface and characterisation of any impairment or abnormal cardiorespiratory function."]}
{"id": 1002564, "claim": "Quercetin and its metabolites inhibit recombinant human angiotensin-converting enzyme 2 activity", "label": "SUPPORTED", "evidence": ["Quercetin metabolites (isorhamnetin, tamarixetin, 3,4-dihydroxyphenylacetic acid, and quercetin-3-glucuronide), rutinosides and glycosides of quercetin, and other flavonoids (luteolin, (±)-eriodictyol, and ()-epicatechin) also inhibited rhACE2.", "Quercetin inhibits rhACE2 activity.", "Polyphenols Inhibit rhACE2 Enzyme Activitya", "These results suggest an inhibitory effect of quercetin on the angiotensin-converting enzyme activity, similar to that of captopril."]}
{"id": 1002565, "claim": "Quercetin and its metabolites produce recombinant human angiotensin-converting enzyme 2 activity", "label": "REFUTED", "evidence": ["Quercetin metabolites (isorhamnetin, tamarixetin, 3,4-dihydroxyphenylacetic acid, and quercetin-3-glucuronide), rutinosides and glycosides of quercetin, and other flavonoids (luteolin, (±)-eriodictyol, and ()-epicatechin) also inhibited rhACE2.", "Quercetin inhibits rhACE2 activity.", "Polyphenols Inhibit rhACE2 Enzyme Activitya", "These results suggest an inhibitory effect of quercetin on the angiotensin-converting enzyme activity, similar to that of captopril."]}
{"id": 1002566, "claim": "Quercetin and its metabolites contain recombinant human angiotensin-converting enzyme 2 activity", "label": "REFUTED", "evidence": ["Quercetin metabolites (isorhamnetin, tamarixetin, 3,4-dihydroxyphenylacetic acid, and quercetin-3-glucuronide), rutinosides and glycosides of quercetin, and other flavonoids (luteolin, (±)-eriodictyol, and ()-epicatechin) also inhibited rhACE2.", "Quercetin inhibits rhACE2 activity.", "Polyphenols Inhibit rhACE2 Enzyme Activitya", "These results suggest an inhibitory effect of quercetin on the angiotensin-converting enzyme activity, similar to that of captopril."]}
{"id": 1002567, "claim": "Quercetin and its metabolites include recombinant human angiotensin-converting enzyme 2 activity", "label": "REFUTED", "evidence": ["Quercetin metabolites (isorhamnetin, tamarixetin, 3,4-dihydroxyphenylacetic acid, and quercetin-3-glucuronide), rutinosides and glycosides of quercetin, and other flavonoids (luteolin, (±)-eriodictyol, and ()-epicatechin) also inhibited rhACE2.", "Quercetin inhibits rhACE2 activity.", "Polyphenols Inhibit rhACE2 Enzyme Activitya", "These results suggest an inhibitory effect of quercetin on the angiotensin-converting enzyme activity, similar to that of captopril."]}
{"id": 1002568, "claim": "Pre-emptive low cost social distancing and enhanced hygiene implemented before local covid-19 transmission could decrease the number and severity of cases .", "label": "SUPPORTED", "evidence": ["Figure 1 available in the PDF version Enhanced hygiene and social distancing measures may reduce both numbers of cases and severity of cases through several mechanisms We suggest that a pre-emptive implementation of low cost interventions prior to detection, but in imminent expectation of community transmission should be considered because it may decrease both the total numbers of cases and severity of cases.", "Pre-emptive, low cost, hygiene enhancement and social distancing in the context of imminent community transmission of novel coronavirus COVID-19 should be considered.", "These low cost enhanced hygiene and physical distancing measures are applicable preemptively before confirmation of local community transmission or where transmission of SARSCoV2 appears to be under control.", "Hygiene measures mostly act on the second factor, as they reduce the risk of transmission if a contact occurs.", "Here we explore whether low cost pre-emptive enhanced hygiene and social distancing should be implemented prior to confirmation of community transmission in countries without, or with minimal, confirmed person-to-person transmission of COVID-19."]}
{"id": 1002569, "claim": "Pre-emptive low cost social distancing and enhanced hygiene implemented before local covid-19 transmission could increase the number and severity of cases.", "label": "REFUTED", "evidence": ["Figure 1 available in the PDF version Enhanced hygiene and social distancing measures may reduce both numbers of cases and severity of cases through several mechanisms We suggest that a pre-emptive implementation of low cost interventions prior to detection, but in imminent expectation of community transmission should be considered because it may decrease both the total numbers of cases and severity of cases.", "Pre-emptive, low cost, hygiene enhancement and social distancing in the context of imminent community transmission of novel coronavirus COVID-19 should be considered.", "These low cost enhanced hygiene and physical distancing measures are applicable preemptively before confirmation of local community transmission or where transmission of SARSCoV2 appears to be under control.", "Hygiene measures mostly act on the second factor, as they reduce the risk of transmission if a contact occurs.", "Here we explore whether low cost pre-emptive enhanced hygiene and social distancing should be implemented prior to confirmation of community transmission in countries without, or with minimal, confirmed person-to-person transmission of COVID-19."]}
{"id": 1002570, "claim": "Pre-emptive low cost social distancing and enhanced hygiene implemented before local covid-19 transmission could enhance the number and severity of cases.", "label": "REFUTED", "evidence": ["Figure 1 available in the PDF version Enhanced hygiene and social distancing measures may reduce both numbers of cases and severity of cases through several mechanisms We suggest that a pre-emptive implementation of low cost interventions prior to detection, but in imminent expectation of community transmission should be considered because it may decrease both the total numbers of cases and severity of cases.", "Pre-emptive, low cost, hygiene enhancement and social distancing in the context of imminent community transmission of novel coronavirus COVID-19 should be considered.", "These low cost enhanced hygiene and physical distancing measures are applicable preemptively before confirmation of local community transmission or where transmission of SARSCoV2 appears to be under control.", "Hygiene measures mostly act on the second factor, as they reduce the risk of transmission if a contact occurs.", "Here we explore whether low cost pre-emptive enhanced hygiene and social distancing should be implemented prior to confirmation of community transmission in countries without, or with minimal, confirmed person-to-person transmission of COVID-19."]}
{"id": 1002571, "claim": "Lockdown related travel behavior undermines the containment of sars-cov-2", "label": "SUPPORTED", "evidence": ["Appropriate messaging surrounding the announcement of lockdowns and measures to decrease unnecessary travel are important for preventing these unintended consequences of lockdowns.", "We find that travel surges following announcements of lockdowns can increase seeding of the epidemic in rural areas, undermining the goal of the lockdown of preventing disease spread."]}
{"id": 1002572, "claim": "Lockdown related travel behavior mores the containment of sars-cov-2", "label": "REFUTED", "evidence": ["Appropriate messaging surrounding the announcement of lockdowns and measures to decrease unnecessary travel are important for preventing these unintended consequences of lockdowns.", "We find that travel surges following announcements of lockdowns can increase seeding of the epidemic in rural areas, undermining the goal of the lockdown of preventing disease spread."]}
{"id": 1002573, "claim": "Coronavirus spread by people with no symptoms 'appears to be rare , ' who official says", "label": "SUPPORTED", "evidence": ["The spread of coronavirus by people not showing symptoms \"appears to be rare,\" a World Health Organization [WHO] official said Monday.", "CDC estimates that 35% of coronavirus patients don't have symptoms \"From the data we have, it still seems to be rare that an asymptomatic person actually transmits onward to a secondary individual,\" Van Kerkhove said on Monday."]}
{"id": 1002574, "claim": "Coronavirus spread by people with no symptoms 'appears to be considered,'who official says", "label": "REFUTED", "evidence": ["The spread of coronavirus by people not showing symptoms \"appears to be rare,\" a World Health Organization [WHO] official said Monday.", "CDC estimates that 35% of coronavirus patients don't have symptoms \"From the data we have, it still seems to be rare that an asymptomatic person actually transmits onward to a secondary individual,\" Van Kerkhove said on Monday."]}
{"id": 1002575, "claim": "Coronavirus spread by people with no symptoms 'appears to be reported,'who official says", "label": "REFUTED", "evidence": ["The spread of coronavirus by people not showing symptoms \"appears to be rare,\" a World Health Organization [WHO] official said Monday.", "CDC estimates that 35% of coronavirus patients don't have symptoms \"From the data we have, it still seems to be rare that an asymptomatic person actually transmits onward to a secondary individual,\" Van Kerkhove said on Monday."]}
{"id": 1002576, "claim": "Coronavirus spread by people with no symptoms 'appears to be infected,'who official says", "label": "REFUTED", "evidence": ["The spread of coronavirus by people not showing symptoms \"appears to be rare,\" a World Health Organization [WHO] official said Monday.", "CDC estimates that 35% of coronavirus patients don't have symptoms \"From the data we have, it still seems to be rare that an asymptomatic person actually transmits onward to a secondary individual,\" Van Kerkhove said on Monday."]}
{"id": 1002577, "claim": "Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle", "label": "SUPPORTED", "evidence": ["Antiviral strategies against human coronaviruses.", "Two targets of possible antiviral intervention were identified in the replication cycle of SARS-CoV."]}
{"id": 1002578, "claim": "Human lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle", "label": "REFUTED", "evidence": ["Antiviral strategies against human coronaviruses.", "Two targets of possible antiviral intervention were identified in the replication cycle of SARS-CoV."]}
{"id": 1002579, "claim": "Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral infection cycle", "label": "REFUTED", "evidence": ["Antiviral strategies against human coronaviruses.", "Two targets of possible antiviral intervention were identified in the replication cycle of SARS-CoV."]}
{"id": 1002580, "claim": "Woolworths to hold elderly and disabled-only shopping hour", "label": "SUPPORTED", "evidence": ["The move has been prompted by the unprecedented demand in supermarkets over the past week, which has seen many elderly and vulnerable people in the community missing out on vital items they may need when they shop, Woolworths announced on Monday.", "This temporary measure will give them, and those with a disability, the opportunity to shop before our stores officially open - helping them obtain the essential items they need most in a less crowded environment, Mr Peters said.", "Credit: AAP Share to FacebookShare to TwitterEmail Us Woolworths will open its doors exclusively to the elderly and people with disabilities for a dedicated shopping hour, after panic buying due to the coronavirus stripped shelves of essentials items."]}
{"id": 1002581, "claim": "Woolworths to hold new and disabled-only shopping hour", "label": "REFUTED", "evidence": ["The move has been prompted by the unprecedented demand in supermarkets over the past week, which has seen many elderly and vulnerable people in the community missing out on vital items they may need when they shop, Woolworths announced on Monday.", "This temporary measure will give them, and those with a disability, the opportunity to shop before our stores officially open - helping them obtain the essential items they need most in a less crowded environment, Mr Peters said.", "Credit: AAP Share to FacebookShare to TwitterEmail Us Woolworths will open its doors exclusively to the elderly and people with disabilities for a dedicated shopping hour, after panic buying due to the coronavirus stripped shelves of essentials items."]}
{"id": 1002582, "claim": "Woolworths to prevent elderly and disabled-only shopping hour", "label": "REFUTED", "evidence": ["The move has been prompted by the unprecedented demand in supermarkets over the past week, which has seen many elderly and vulnerable people in the community missing out on vital items they may need when they shop, Woolworths announced on Monday.", "This temporary measure will give them, and those with a disability, the opportunity to shop before our stores officially open - helping them obtain the essential items they need most in a less crowded environment, Mr Peters said.", "Credit: AAP Share to FacebookShare to TwitterEmail Us Woolworths will open its doors exclusively to the elderly and people with disabilities for a dedicated shopping hour, after panic buying due to the coronavirus stripped shelves of essentials items."]}
{"id": 1002583, "claim": "Woolworths to hold training and disabled-only shopping hour", "label": "REFUTED", "evidence": ["The move has been prompted by the unprecedented demand in supermarkets over the past week, which has seen many elderly and vulnerable people in the community missing out on vital items they may need when they shop, Woolworths announced on Monday.", "This temporary measure will give them, and those with a disability, the opportunity to shop before our stores officially open - helping them obtain the essential items they need most in a less crowded environment, Mr Peters said.", "Credit: AAP Share to FacebookShare to TwitterEmail Us Woolworths will open its doors exclusively to the elderly and people with disabilities for a dedicated shopping hour, after panic buying due to the coronavirus stripped shelves of essentials items."]}
{"id": 1002584, "claim": "Map suggests tb vaccine may help prevent covid-19", "label": "SUPPORTED", "evidence": ["Although tuberculosis is a bacterial disease, there are indications that BCG may help the immune system fight off viral infections as well."]}
{"id": 1002585, "claim": "Map suggests tb vaccine cannot help prevent covid-19", "label": "REFUTED", "evidence": ["Although tuberculosis is a bacterial disease, there are indications that BCG may help the immune system fight off viral infections as well."]}
{"id": 1002586, "claim": "Map suggests tb vaccine may help induce covid-19", "label": "REFUTED", "evidence": ["Although tuberculosis is a bacterial disease, there are indications that BCG may help the immune system fight off viral infections as well."]}
{"id": 1002587, "claim": "Map suggests tb vaccine may help cause covid-19", "label": "REFUTED", "evidence": ["Although tuberculosis is a bacterial disease, there are indications that BCG may help the immune system fight off viral infections as well."]}
{"id": 1002588, "claim": "India has first covid vaccine approved from dcgi , human trials to begin in july .", "label": "SUPPORTED", "evidence": ["Indias first COVID-19 vaccine COVAXIN gets DCGI approval for clinical trials", "The clinical trials of the experimental COVID-19 vaccine in humans are scheduled to begin in July 2020, Bharat Biotech said in a note.", "The company claims it is \"India's first vaccine candidate for COVID-19, developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV)\".", "According to the vaccine maker, human clinical trials of the experimental COVID-19 are scheduled to start across the country in July 2020.", "> COVAXIN, India's 1st indigenous COVID-19 vaccine, developed by Bharat > Biotech successfully enters human trials."]}
{"id": 1002589, "claim": "India has no covid vaccine approved from dcgi, human trials to begin in july.", "label": "REFUTED", "evidence": ["Indias first COVID-19 vaccine COVAXIN gets DCGI approval for clinical trials", "The clinical trials of the experimental COVID-19 vaccine in humans are scheduled to begin in July 2020, Bharat Biotech said in a note.", "The company claims it is \"India's first vaccine candidate for COVID-19, developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV)\".", "According to the vaccine maker, human clinical trials of the experimental COVID-19 are scheduled to start across the country in July 2020.", "> COVAXIN, India's 1st indigenous COVID-19 vaccine, developed by Bharat > Biotech successfully enters human trials."]}
{"id": 1002590, "claim": "China has first covid vaccine approved from dcgi, human trials to begin in july.", "label": "REFUTED", "evidence": ["Indias first COVID-19 vaccine COVAXIN gets DCGI approval for clinical trials", "The clinical trials of the experimental COVID-19 vaccine in humans are scheduled to begin in July 2020, Bharat Biotech said in a note.", "The company claims it is \"India's first vaccine candidate for COVID-19, developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV)\".", "According to the vaccine maker, human clinical trials of the experimental COVID-19 are scheduled to start across the country in July 2020.", "> COVAXIN, India's 1st indigenous COVID-19 vaccine, developed by Bharat > Biotech successfully enters human trials."]}
{"id": 1002591, "claim": "Who has first covid vaccine approved from dcgi, human trials to begin in july.", "label": "REFUTED", "evidence": ["Indias first COVID-19 vaccine COVAXIN gets DCGI approval for clinical trials", "The clinical trials of the experimental COVID-19 vaccine in humans are scheduled to begin in July 2020, Bharat Biotech said in a note.", "The company claims it is \"India's first vaccine candidate for COVID-19, developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV)\".", "According to the vaccine maker, human clinical trials of the experimental COVID-19 are scheduled to start across the country in July 2020.", "> COVAXIN, India's 1st indigenous COVID-19 vaccine, developed by Bharat > Biotech successfully enters human trials."]}
{"id": 1002592, "claim": "Hcq + zinc reduces mortality by 50 % in retrospective study at nyu", "label": "SUPPORTED", "evidence": ["But I am surprised you didnt mention the recent preprint from NYU about HCQ and zinc significantly decreasing mortality by 44%.", "Yohanan Weininger says: 20 May, 2020 at 4:46 am heh Mike R, Your post is empty without reference, link to \"the recent preprint from NYU about HCQ and zinc significantly decreasing mortality by 44%.", "You are leaving out a big part of the picture when you leave out the hydroxychloroquine and zinc interaction and leave out the well done retrospective study that suggested HCQ/zinc saved 44% almost twice the number of lives than compared to HCQ alone."]}
{"id": 1002593, "claim": "Hcq + zinc increases mortality by 50 % in retrospective study at nyu", "label": "REFUTED", "evidence": ["But I am surprised you didnt mention the recent preprint from NYU about HCQ and zinc significantly decreasing mortality by 44%.", "Yohanan Weininger says: 20 May, 2020 at 4:46 am heh Mike R, Your post is empty without reference, link to \"the recent preprint from NYU about HCQ and zinc significantly decreasing mortality by 44%.", "You are leaving out a big part of the picture when you leave out the hydroxychloroquine and zinc interaction and leave out the well done retrospective study that suggested HCQ/zinc saved 44% almost twice the number of lives than compared to HCQ alone."]}
{"id": 1002594, "claim": "Hcq + zinc increased mortality by 50 % in retrospective study at nyu", "label": "REFUTED", "evidence": ["But I am surprised you didnt mention the recent preprint from NYU about HCQ and zinc significantly decreasing mortality by 44%.", "Yohanan Weininger says: 20 May, 2020 at 4:46 am heh Mike R, Your post is empty without reference, link to \"the recent preprint from NYU about HCQ and zinc significantly decreasing mortality by 44%.", "You are leaving out a big part of the picture when you leave out the hydroxychloroquine and zinc interaction and leave out the well done retrospective study that suggested HCQ/zinc saved 44% almost twice the number of lives than compared to HCQ alone."]}
{"id": 1002595, "claim": "Closed environments facilitate secondary transmission of covid-19", "label": "SUPPORTED", "evidence": ["Closed environments facilitate secondary transmission of coronavirus disease 2019 (COVID-19).", "COVID-19 may transmit through aerosol.", "Conclusions It is plausible that closed environments contribute to secondary transmission of COVID-19 and promote superspreading events."]}
{"id": 1002596, "claim": "Closed environments prevent secondary transmission of covid-19", "label": "REFUTED", "evidence": ["Closed environments facilitate secondary transmission of coronavirus disease 2019 (COVID-19).", "COVID-19 may transmit through aerosol.", "Conclusions It is plausible that closed environments contribute to secondary transmission of COVID-19 and promote superspreading events."]}
{"id": 1002597, "claim": "Additional environments facilitate secondary transmission of covid-19", "label": "REFUTED", "evidence": ["Closed environments facilitate secondary transmission of coronavirus disease 2019 (COVID-19).", "COVID-19 may transmit through aerosol.", "Conclusions It is plausible that closed environments contribute to secondary transmission of COVID-19 and promote superspreading events."]}
{"id": 1002598, "claim": "China 's cansino bio advances covid-19 vaccine into phase 2 on preliminary safety data", "label": "SUPPORTED", "evidence": ["In fact, virtual enrollment of the phase 2 study where interested individuals can sign up via a QR code has already started, putting CanSino ahead of all the others on a long list of COVID-19 vaccine developers.", "(CanSino) In the global race to develop an effective vaccine to protect people against the novel coronavirus, Chinas CanSino Bio has leapt ahead.", "CanSino and its collaborators at the Academy of Military Medical Sciences Institute of Biotechnology plan to move their adenovirus type-5 vector-based recombinant COVID-19 vaccine, Ad5-nCoV, into phase 2 clinical trial in China soon, the company said in a disclosure (PDF) to the Hong Kong Stock Exchange on Thursday."]}
{"id": 1002599, "claim": "A's cansino bio advances covid-19 vaccine into phase 2 on preliminary safety data", "label": "REFUTED", "evidence": ["In fact, virtual enrollment of the phase 2 study where interested individuals can sign up via a QR code has already started, putting CanSino ahead of all the others on a long list of COVID-19 vaccine developers.", "(CanSino) In the global race to develop an effective vaccine to protect people against the novel coronavirus, Chinas CanSino Bio has leapt ahead.", "CanSino and its collaborators at the Academy of Military Medical Sciences Institute of Biotechnology plan to move their adenovirus type-5 vector-based recombinant COVID-19 vaccine, Ad5-nCoV, into phase 2 clinical trial in China soon, the company said in a disclosure (PDF) to the Hong Kong Stock Exchange on Thursday."]}
{"id": 1002600, "claim": "We's cansino bio advances covid-19 vaccine into phase 2 on preliminary safety data", "label": "REFUTED", "evidence": ["In fact, virtual enrollment of the phase 2 study where interested individuals can sign up via a QR code has already started, putting CanSino ahead of all the others on a long list of COVID-19 vaccine developers.", "(CanSino) In the global race to develop an effective vaccine to protect people against the novel coronavirus, Chinas CanSino Bio has leapt ahead.", "CanSino and its collaborators at the Academy of Military Medical Sciences Institute of Biotechnology plan to move their adenovirus type-5 vector-based recombinant COVID-19 vaccine, Ad5-nCoV, into phase 2 clinical trial in China soon, the company said in a disclosure (PDF) to the Hong Kong Stock Exchange on Thursday."]}
{"id": 1002601, "claim": "Sars-cov-2 infects and induces cytotoxic effects in human cardiomyocytes", "label": "SUPPORTED", "evidence": ["Conclusion: This study demonstrates that SARS-CoV-2 infects cardiomyocytes in vitro in an angiotensin-converting enzyme 2- and cathepsin-dependent manner."]}
{"id": 1002602, "claim": "Sars-cov-2 infects and induces cytotoxic effects in mice cardiomyocytes", "label": "REFUTED", "evidence": ["Conclusion: This study demonstrates that SARS-CoV-2 infects cardiomyocytes in vitro in an angiotensin-converting enzyme 2- and cathepsin-dependent manner."]}
{"id": 1002603, "claim": "County of santa clara identifies three additional early covid-19 deaths", "label": "SUPPORTED", "evidence": ["As the Medical Examiner-Coroner continues to carefully investigate deaths throughout the county, we anticipate additional deaths from COVID-19 will be identified.", "Today, the Medical Examiner-Coroner received confirmation from the CDC that tissue samples from both cases are positive for SARS-CoV-2 (the virus that causes COVID-19)."]}
{"id": 1002604, "claim": "County of santa clara identifies no additional early covid-19 deaths", "label": "REFUTED", "evidence": ["As the Medical Examiner-Coroner continues to carefully investigate deaths throughout the county, we anticipate additional deaths from COVID-19 will be identified.", "Today, the Medical Examiner-Coroner received confirmation from the CDC that tissue samples from both cases are positive for SARS-CoV-2 (the virus that causes COVID-19)."]}
{"id": 1002605, "claim": "County of santa clara identifies one additional early covid-19 deaths", "label": "REFUTED", "evidence": ["As the Medical Examiner-Coroner continues to carefully investigate deaths throughout the county, we anticipate additional deaths from COVID-19 will be identified.", "Today, the Medical Examiner-Coroner received confirmation from the CDC that tissue samples from both cases are positive for SARS-CoV-2 (the virus that causes COVID-19)."]}
{"id": 1002606, "claim": "County of santa clara identifies two additional early covid-19 deaths", "label": "REFUTED", "evidence": ["As the Medical Examiner-Coroner continues to carefully investigate deaths throughout the county, we anticipate additional deaths from COVID-19 will be identified.", "Today, the Medical Examiner-Coroner received confirmation from the CDC that tissue samples from both cases are positive for SARS-CoV-2 (the virus that causes COVID-19)."]}
{"id": 1002607, "claim": "The university of liverpool has developed an online database for checking drug-drug interactions with the experimental covid-19 specific medicinal products", "label": "SUPPORTED", "evidence": ["On the other hand, the Liverpool interactions group has provided prescribing resources where they categorized the interactions of experimental COVID-19 antiviral therapies as contraindicated medications, potential interactions requiring dose adjustment/close monitoring, potential interactions of weak intensity or no clinically significant interactions (University of Liverpool, 2020).", "The Liverpool Drug Interaction Group, based at the University of Liverpool in the United Kingdom, worked in collaboration with other research teams to gather data on a wide variety of drugs, and create a set of recommendations about potential drug interactions."]}
{"id": 1002608, "claim": "The university of liverpool has received an online database for checking drug-drug interactions with the experimental covid-19 specific medicinal products", "label": "REFUTED", "evidence": ["On the other hand, the Liverpool interactions group has provided prescribing resources where they categorized the interactions of experimental COVID-19 antiviral therapies as contraindicated medications, potential interactions requiring dose adjustment/close monitoring, potential interactions of weak intensity or no clinically significant interactions (University of Liverpool, 2020).", "The Liverpool Drug Interaction Group, based at the University of Liverpool in the United Kingdom, worked in collaboration with other research teams to gather data on a wide variety of drugs, and create a set of recommendations about potential drug interactions."]}
{"id": 1002609, "claim": "Active or latent tuberculosis increases susceptibility to covid-19 and disease severity", "label": "SUPPORTED", "evidence": ["Patients with active or latent TB were more susceptible to SARS-CoV-2, and COVID-19 symptom development and progression were more rapid and severe.", "Findings In this observational case-control study of 36 COVID-19 cases from Shenyang, China, we found tuberculosis history (both of active TB and latent TB) to be an important risk factor for SARS-CoV-2 infection.", "Meaning Tuberculosis status should be assessed carefully at patient admission and management and therapeutic strategies adjusted accordingly to prevent rapid development of severe COVID-19 complications."]}
{"id": 1002610, "claim": "Active or latent tuberculosis reduces susceptibility to covid-19 and disease severity", "label": "REFUTED", "evidence": ["Patients with active or latent TB were more susceptible to SARS-CoV-2, and COVID-19 symptom development and progression were more rapid and severe.", "Findings In this observational case-control study of 36 COVID-19 cases from Shenyang, China, we found tuberculosis history (both of active TB and latent TB) to be an important risk factor for SARS-CoV-2 infection.", "Meaning Tuberculosis status should be assessed carefully at patient admission and management and therapeutic strategies adjusted accordingly to prevent rapid development of severe COVID-19 complications."]}
{"id": 1002611, "claim": "Active or latent tuberculosis reduced susceptibility to covid-19 and disease severity", "label": "REFUTED", "evidence": ["Patients with active or latent TB were more susceptible to SARS-CoV-2, and COVID-19 symptom development and progression were more rapid and severe.", "Findings In this observational case-control study of 36 COVID-19 cases from Shenyang, China, we found tuberculosis history (both of active TB and latent TB) to be an important risk factor for SARS-CoV-2 infection.", "Meaning Tuberculosis status should be assessed carefully at patient admission and management and therapeutic strategies adjusted accordingly to prevent rapid development of severe COVID-19 complications."]}
{"id": 1002612, "claim": "Active or latent tuberculosis decreased susceptibility to covid-19 and disease severity", "label": "REFUTED", "evidence": ["Patients with active or latent TB were more susceptible to SARS-CoV-2, and COVID-19 symptom development and progression were more rapid and severe.", "Findings In this observational case-control study of 36 COVID-19 cases from Shenyang, China, we found tuberculosis history (both of active TB and latent TB) to be an important risk factor for SARS-CoV-2 infection.", "Meaning Tuberculosis status should be assessed carefully at patient admission and management and therapeutic strategies adjusted accordingly to prevent rapid development of severe COVID-19 complications."]}
{"id": 1002613, "claim": "Trump to declare national emergency on coronavirus to speed aid", "label": "SUPPORTED", "evidence": ["The national emergency declaration President Donald Trump delivered today increases states' authority to help low-income residents get testing and treatment for the new coronavirus.", "ET President Trump on Friday declared that the coronavirus pandemic is a national emergency, a designation that frees up as much as $50 billion in federal assistance to state and local governments overwhelmed by the spread of the virus, and makes it easier to surge medical resources to areas that need them most.", "It wasnt meant for this kind of an event. President Trump held a news conference to declare a national emergency in order to free up to $50 billion in federal funds to combat the spread of coronavirus.CreditCredit...Erin Schaff/The New York Times Mr. Trump on Friday afternoon officially declared a national emergency that he said would give states and territories access to up to $50 billion in federal funds to combat the spreading coronavirus epidemic."]}
{"id": 1002614, "claim": "Participants to declare national emergency on coronavirus to speed aid", "label": "REFUTED", "evidence": ["The national emergency declaration President Donald Trump delivered today increases states' authority to help low-income residents get testing and treatment for the new coronavirus.", "ET President Trump on Friday declared that the coronavirus pandemic is a national emergency, a designation that frees up as much as $50 billion in federal assistance to state and local governments overwhelmed by the spread of the virus, and makes it easier to surge medical resources to areas that need them most.", "It wasnt meant for this kind of an event. President Trump held a news conference to declare a national emergency in order to free up to $50 billion in federal funds to combat the spread of coronavirus.CreditCredit...Erin Schaff/The New York Times Mr. Trump on Friday afternoon officially declared a national emergency that he said would give states and territories access to up to $50 billion in federal funds to combat the spreading coronavirus epidemic."]}
{"id": 1002615, "claim": "Trump to declare national funding on coronavirus to speed aid", "label": "REFUTED", "evidence": ["The national emergency declaration President Donald Trump delivered today increases states' authority to help low-income residents get testing and treatment for the new coronavirus.", "ET President Trump on Friday declared that the coronavirus pandemic is a national emergency, a designation that frees up as much as $50 billion in federal assistance to state and local governments overwhelmed by the spread of the virus, and makes it easier to surge medical resources to areas that need them most.", "It wasnt meant for this kind of an event. President Trump held a news conference to declare a national emergency in order to free up to $50 billion in federal funds to combat the spread of coronavirus.CreditCredit...Erin Schaff/The New York Times Mr. Trump on Friday afternoon officially declared a national emergency that he said would give states and territories access to up to $50 billion in federal funds to combat the spreading coronavirus epidemic."]}
{"id": 1002616, "claim": "Trump to declare national research on coronavirus to speed aid", "label": "REFUTED", "evidence": ["The national emergency declaration President Donald Trump delivered today increases states' authority to help low-income residents get testing and treatment for the new coronavirus.", "ET President Trump on Friday declared that the coronavirus pandemic is a national emergency, a designation that frees up as much as $50 billion in federal assistance to state and local governments overwhelmed by the spread of the virus, and makes it easier to surge medical resources to areas that need them most.", "It wasnt meant for this kind of an event. President Trump held a news conference to declare a national emergency in order to free up to $50 billion in federal funds to combat the spread of coronavirus.CreditCredit...Erin Schaff/The New York Times Mr. Trump on Friday afternoon officially declared a national emergency that he said would give states and territories access to up to $50 billion in federal funds to combat the spreading coronavirus epidemic."]}
{"id": 1002617, "claim": "Early detection of superspreaders by mass group pool testing can mitigate covid-19 pandemic", "label": "SUPPORTED", "evidence": ["High viral loading allows efficient group matrix pool testing of population focused on detection of the superspreaders requiring remarkably small amount of tests."]}
{"id": 1002618, "claim": "Early detection of superspreaders by mass group pool testing cannot mitigate covid-19 pandemic", "label": "REFUTED", "evidence": ["High viral loading allows efficient group matrix pool testing of population focused on detection of the superspreaders requiring remarkably small amount of tests."]}
{"id": 1002619, "claim": "Further detection of superspreaders by mass group pool testing can mitigate covid-19 pandemic", "label": "REFUTED", "evidence": ["High viral loading allows efficient group matrix pool testing of population focused on detection of the superspreaders requiring remarkably small amount of tests."]}
{"id": 1002620, "claim": "Broadly-targeted autoreactivity is common in severe sars-cov-2 infection", "label": "SUPPORTED", "evidence": ["We recently identified activation of an autoimmune-prone B cell response pathway as correlate of severe COVID-19, raising the possibility of de novo autoreactive antibody production during the antiviral response.", "Here, we identify autoreactive antibodies as a common feature of severe COVID-19, identifying biomarkers of tolerance breaks that may indicate aggressive immunomodulation."]}
{"id": 1002621, "claim": "Broadly-independent autoreactivity is common in severe sars-cov-2 infection", "label": "REFUTED", "evidence": ["We recently identified activation of an autoimmune-prone B cell response pathway as correlate of severe COVID-19, raising the possibility of de novo autoreactive antibody production during the antiviral response.", "Here, we identify autoreactive antibodies as a common feature of severe COVID-19, identifying biomarkers of tolerance breaks that may indicate aggressive immunomodulation."]}
{"id": 1002622, "claim": "Herd immunity is not an answer to a pandemic", "label": "SUPPORTED", "evidence": ["Many researchers say pursuing herd immunity is a bad idea.", "And because variables can change, including R 0 and the number of people susceptible to a virus, herd immunity is not a steady state.", "Attempting to reach herd immunity via targeted infections is simply ludicrous, Andersen says.", "GRETA BAUER: If that were the situation, then there's no potential to develop a level of herd immunity sufficient to stop the infection."]}
{"id": 1002623, "claim": "Herd immunity is also an answer to a pandemic", "label": "REFUTED", "evidence": ["Many researchers say pursuing herd immunity is a bad idea.", "And because variables can change, including R 0 and the number of people susceptible to a virus, herd immunity is not a steady state.", "Attempting to reach herd immunity via targeted infections is simply ludicrous, Andersen says.", "GRETA BAUER: If that were the situation, then there's no potential to develop a level of herd immunity sufficient to stop the infection."]}
{"id": 1002624, "claim": "Herd immunity is still an answer to a pandemic", "label": "REFUTED", "evidence": ["Many researchers say pursuing herd immunity is a bad idea.", "And because variables can change, including R 0 and the number of people susceptible to a virus, herd immunity is not a steady state.", "Attempting to reach herd immunity via targeted infections is simply ludicrous, Andersen says.", "GRETA BAUER: If that were the situation, then there's no potential to develop a level of herd immunity sufficient to stop the infection."]}
{"id": 1002625, "claim": "Herd immunity is currently an answer to a pandemic", "label": "REFUTED", "evidence": ["Many researchers say pursuing herd immunity is a bad idea.", "And because variables can change, including R 0 and the number of people susceptible to a virus, herd immunity is not a steady state.", "Attempting to reach herd immunity via targeted infections is simply ludicrous, Andersen says.", "GRETA BAUER: If that were the situation, then there's no potential to develop a level of herd immunity sufficient to stop the infection."]}
{"id": 1002626, "claim": "Sinopharm 's inactivated coronavirus vaccine", "label": "SUPPORTED", "evidence": ["In SinoPharm's case, they inactivated the coronavirus with beta-propiolactone, which is a classic protein-alkylating compound.", "(wildpixel/GettyImages) Sinopharm has published clinical data on its adjuvanted SARS-CoV-2inactivated virus vaccine.", "On Monday, Nasdaq-listed Sinovac said its inactivated vaccine, called CoronaVac, induced neutralizing antibodies in over 90% of the 600 healthy volunteers in the phase 2 part of a phase 1/2 study."]}
{"id": 1002627, "claim": "Wepharm's inactivated coronavirus vaccine", "label": "REFUTED", "evidence": ["In SinoPharm's case, they inactivated the coronavirus with beta-propiolactone, which is a classic protein-alkylating compound.", "(wildpixel/GettyImages) Sinopharm has published clinical data on its adjuvanted SARS-CoV-2inactivated virus vaccine.", "On Monday, Nasdaq-listed Sinovac said its inactivated vaccine, called CoronaVac, induced neutralizing antibodies in over 90% of the 600 healthy volunteers in the phase 2 part of a phase 1/2 study."]}
{"id": 1002628, "claim": "Ipharm's inactivated coronavirus vaccine", "label": "REFUTED", "evidence": ["In SinoPharm's case, they inactivated the coronavirus with beta-propiolactone, which is a classic protein-alkylating compound.", "(wildpixel/GettyImages) Sinopharm has published clinical data on its adjuvanted SARS-CoV-2inactivated virus vaccine.", "On Monday, Nasdaq-listed Sinovac said its inactivated vaccine, called CoronaVac, induced neutralizing antibodies in over 90% of the 600 healthy volunteers in the phase 2 part of a phase 1/2 study."]}
{"id": 1002629, "claim": "Itpharm's inactivated coronavirus vaccine", "label": "REFUTED", "evidence": ["In SinoPharm's case, they inactivated the coronavirus with beta-propiolactone, which is a classic protein-alkylating compound.", "(wildpixel/GettyImages) Sinopharm has published clinical data on its adjuvanted SARS-CoV-2inactivated virus vaccine.", "On Monday, Nasdaq-listed Sinovac said its inactivated vaccine, called CoronaVac, induced neutralizing antibodies in over 90% of the 600 healthy volunteers in the phase 2 part of a phase 1/2 study."]}
{"id": 1002630, "claim": "Evidence is lacking to support vitamin d 's role in treatment and prevention.", "label": "SUPPORTED", "evidence": ["Experts have reached no firm consensus on whether vitamin D can help prevent MS given the lack of clinical trial evidence.", "In contrast to the observational studies, clinical trials have provided little support for the hypothesis that supplemental vitamin D reduces the risk of CVD or CVD mortality.", "Finally, NICE may be unlikely to recommend vitamin D supplementation on the basis of a trial that has no clear placebo arm.", "No studies have examined whether such screening for vitamin D deficiency results in improved health outcomes.", "However, clinical trials do not support a cause-and-effect relationship between vitamin D and weight loss."]}
{"id": 1002631, "claim": "Evidence is known to support vitamin d's role in treatment and prevention.", "label": "REFUTED", "evidence": ["Experts have reached no firm consensus on whether vitamin D can help prevent MS given the lack of clinical trial evidence.", "In contrast to the observational studies, clinical trials have provided little support for the hypothesis that supplemental vitamin D reduces the risk of CVD or CVD mortality.", "Finally, NICE may be unlikely to recommend vitamin D supplementation on the basis of a trial that has no clear placebo arm.", "No studies have examined whether such screening for vitamin D deficiency results in improved health outcomes.", "However, clinical trials do not support a cause-and-effect relationship between vitamin D and weight loss."]}
{"id": 1002632, "claim": "Evidence is used to support vitamin d's role in treatment and prevention.", "label": "REFUTED", "evidence": ["Experts have reached no firm consensus on whether vitamin D can help prevent MS given the lack of clinical trial evidence.", "In contrast to the observational studies, clinical trials have provided little support for the hypothesis that supplemental vitamin D reduces the risk of CVD or CVD mortality.", "Finally, NICE may be unlikely to recommend vitamin D supplementation on the basis of a trial that has no clear placebo arm.", "No studies have examined whether such screening for vitamin D deficiency results in improved health outcomes.", "However, clinical trials do not support a cause-and-effect relationship between vitamin D and weight loss."]}
{"id": 1002633, "claim": "Evidence is likely to support vitamin d's role in treatment and prevention.", "label": "REFUTED", "evidence": ["Experts have reached no firm consensus on whether vitamin D can help prevent MS given the lack of clinical trial evidence.", "In contrast to the observational studies, clinical trials have provided little support for the hypothesis that supplemental vitamin D reduces the risk of CVD or CVD mortality.", "Finally, NICE may be unlikely to recommend vitamin D supplementation on the basis of a trial that has no clear placebo arm.", "No studies have examined whether such screening for vitamin D deficiency results in improved health outcomes.", "However, clinical trials do not support a cause-and-effect relationship between vitamin D and weight loss."]}
{"id": 1002634, "claim": "A sars-cov-2 vaccine candidate would likely match all currently circulating strains", "label": "SUPPORTED", "evidence": ["The minimal diversity found among SARS-CoV-2 sequences can be explained by drift and bottleneck events as the virus spread away from its original epicenter in Wuhan, China.", "Our findings suggest that a single vaccine should be efficacious against current global strains."]}
{"id": 1002635, "claim": "A sars-cov-2 vaccine candidate would not match all currently circulating strains", "label": "REFUTED", "evidence": ["The minimal diversity found among SARS-CoV-2 sequences can be explained by drift and bottleneck events as the virus spread away from its original epicenter in Wuhan, China.", "Our findings suggest that a single vaccine should be efficacious against current global strains."]}
{"id": 1002636, "claim": "Personalized therapy approach for hospitalized patients with covid-19", "label": "SUPPORTED", "evidence": ["Personalized treatment decisions decreased early mortality (OR 0.144, CI 0.03-0.686; p=0.015)."]}
{"id": 1002637, "claim": "Personalized surveillance approach for hospitalized patients with covid-19", "label": "REFUTED", "evidence": ["Personalized treatment decisions decreased early mortality (OR 0.144, CI 0.03-0.686; p=0.015)."]}
{"id": 1002638, "claim": "Personalized screening approach for hospitalized patients with covid-19", "label": "REFUTED", "evidence": ["Personalized treatment decisions decreased early mortality (OR 0.144, CI 0.03-0.686; p=0.015)."]}
{"id": 1002639, "claim": "Personalized prediction approach for hospitalized patients with covid-19", "label": "REFUTED", "evidence": ["Personalized treatment decisions decreased early mortality (OR 0.144, CI 0.03-0.686; p=0.015)."]}
{"id": 1002640, "claim": "Human sars-cov-2 neutralizing antibody cor-101 demonstrates high efficacy in a covid-19 animal model and is ready to be used in clinical studies to treat covid-19 patients.", "label": "SUPPORTED", "evidence": ["The crystal structure of COR-101 in complex with SARS-CoV-2-RBD was solved at 2.0 A resolution showing that the antibody binds at the same region as the human coronavirus receptor ACE2 to SARS-CoV-2-RBD.", "The best antibody currently is in production to be clinically tested soon as immunotherapy to treat acute COVID-19.", "A large set of more than 750 human monoclonal antibodies recognizing SARS-CoV2 Spike (S) protein isolated by antibody phage display from human antibody libraries from healthy donors and convalescent COVID-19 patients underwent a fast track development process to identify lead molecule with optimal drug features for a passive vaccine.", "Here we report the isolation of two specific human monoclonal antibodies (termed CA1 and CB6) from a patient convalescing from COVID-19."]}
{"id": 1002641, "claim": "Human sars-cov-2 neutralizing antibody cor-3 demonstrates high efficacy in a covid-19 animal model and is ready to be used in clinical studies to treat covid-19 patients.", "label": "REFUTED", "evidence": ["The crystal structure of COR-101 in complex with SARS-CoV-2-RBD was solved at 2.0 A resolution showing that the antibody binds at the same region as the human coronavirus receptor ACE2 to SARS-CoV-2-RBD.", "The best antibody currently is in production to be clinically tested soon as immunotherapy to treat acute COVID-19.", "A large set of more than 750 human monoclonal antibodies recognizing SARS-CoV2 Spike (S) protein isolated by antibody phage display from human antibody libraries from healthy donors and convalescent COVID-19 patients underwent a fast track development process to identify lead molecule with optimal drug features for a passive vaccine.", "Here we report the isolation of two specific human monoclonal antibodies (termed CA1 and CB6) from a patient convalescing from COVID-19."]}
{"id": 1002642, "claim": "The disease-induced herd immunity level for covid-19 is substantially lower than the classical herd immunity level", "label": "SUPPORTED", "evidence": ["The classical > herd immunity level $hC$ is defined as $hC=1-1/R0$, where $R0$ is the > basic reproduction number, for covid-19 estimated to lie somewhere in the > range 2.2-3.5 depending on country and region.", "It is shown here that the > disease-induced herd immunity level $hD$, after an outbreak has taken place > in a country/region with a set of preventive measures put in place, is > actually substantially smaller than $hC$."]}
{"id": 1002643, "claim": "The disease-induced herd immunity level for covid-19 is substantially higher than the classical herd immunity level", "label": "REFUTED", "evidence": ["The classical > herd immunity level $hC$ is defined as $hC=1-1/R0$, where $R0$ is the > basic reproduction number, for covid-19 estimated to lie somewhere in the > range 2.2-3.5 depending on country and region.", "It is shown here that the > disease-induced herd immunity level $hD$, after an outbreak has taken place > in a country/region with a set of preventive measures put in place, is > actually substantially smaller than $hC$."]}
{"id": 1002644, "claim": "The disease-induced herd immunity level for covid-19 is substantially greater than the classical herd immunity level", "label": "REFUTED", "evidence": ["The classical > herd immunity level $hC$ is defined as $hC=1-1/R0$, where $R0$ is the > basic reproduction number, for covid-19 estimated to lie somewhere in the > range 2.2-3.5 depending on country and region.", "It is shown here that the > disease-induced herd immunity level $hD$, after an outbreak has taken place > in a country/region with a set of preventive measures put in place, is > actually substantially smaller than $hC$."]}
{"id": 1002645, "claim": "The disease-induced herd immunity level for covid-19 is substantially larger than the classical herd immunity level", "label": "REFUTED", "evidence": ["The classical > herd immunity level $hC$ is defined as $hC=1-1/R0$, where $R0$ is the > basic reproduction number, for covid-19 estimated to lie somewhere in the > range 2.2-3.5 depending on country and region.", "It is shown here that the > disease-induced herd immunity level $hD$, after an outbreak has taken place > in a country/region with a set of preventive measures put in place, is > actually substantially smaller than $hC$."]}
{"id": 1002646, "claim": "Covid-19 case mortality rates continue to decline in florida", "label": "SUPPORTED", "evidence": ["Case mortality rates declined consistently and significantly over the course of the four intervals: 57% among those aged 50-59 years; 62% among those aged 60-69 years; 52% among those aged 70-79 years; and 34% among those aged 80 or more years.", "During the fourth interval, an apparent rise in mortality among hospitalized patients in the same age group was mirrored by a significant decline in mortality among those not hospitalized."]}
{"id": 1002647, "claim": "Covid-19 case mortality rates continue to increase in florida", "label": "REFUTED", "evidence": ["Case mortality rates declined consistently and significantly over the course of the four intervals: 57% among those aged 50-59 years; 62% among those aged 60-69 years; 52% among those aged 70-79 years; and 34% among those aged 80 or more years.", "During the fourth interval, an apparent rise in mortality among hospitalized patients in the same age group was mirrored by a significant decline in mortality among those not hospitalized."]}
{"id": 1002648, "claim": "Covid-19 case mortality rates continue to occur in florida", "label": "REFUTED", "evidence": ["Case mortality rates declined consistently and significantly over the course of the four intervals: 57% among those aged 50-59 years; 62% among those aged 60-69 years; 52% among those aged 70-79 years; and 34% among those aged 80 or more years.", "During the fourth interval, an apparent rise in mortality among hospitalized patients in the same age group was mirrored by a significant decline in mortality among those not hospitalized."]}
{"id": 1002649, "claim": "Covid-19 case mortality rates continue to persist in florida", "label": "REFUTED", "evidence": ["Case mortality rates declined consistently and significantly over the course of the four intervals: 57% among those aged 50-59 years; 62% among those aged 60-69 years; 52% among those aged 70-79 years; and 34% among those aged 80 or more years.", "During the fourth interval, an apparent rise in mortality among hospitalized patients in the same age group was mirrored by a significant decline in mortality among those not hospitalized."]}
{"id": 1002650, "claim": "Poop tests stop covid-19 outbreak at university of arizona", "label": "SUPPORTED", "evidence": ["In Arizona, wastewater from a student dormitory contained viral RNA just days after studentswho had all tested negative for COVID-19moved into their rooms this month.", "28, 2020 , 2:40 PM By testing dorm wastewater for the coronavirus, the University of Arizona may have stomped out a potential outbreak before it could spread, The Washington Post reports.", "The university retested all 311 residents and dorm workers and found two students who were asymptomatic but positive for the virus; they were then quarantined, officials explained in a press conference."]}
{"id": 1002651, "claim": "Poop tests stop covid-19 outbreak at university of march", "label": "REFUTED", "evidence": ["In Arizona, wastewater from a student dormitory contained viral RNA just days after studentswho had all tested negative for COVID-19moved into their rooms this month.", "28, 2020 , 2:40 PM By testing dorm wastewater for the coronavirus, the University of Arizona may have stomped out a potential outbreak before it could spread, The Washington Post reports.", "The university retested all 311 residents and dorm workers and found two students who were asymptomatic but positive for the virus; they were then quarantined, officials explained in a press conference."]}
{"id": 1002652, "claim": "Poop tests stop covid-19 outbreak at university of hospital", "label": "REFUTED", "evidence": ["In Arizona, wastewater from a student dormitory contained viral RNA just days after studentswho had all tested negative for COVID-19moved into their rooms this month.", "28, 2020 , 2:40 PM By testing dorm wastewater for the coronavirus, the University of Arizona may have stomped out a potential outbreak before it could spread, The Washington Post reports.", "The university retested all 311 residents and dorm workers and found two students who were asymptomatic but positive for the virus; they were then quarantined, officials explained in a press conference."]}
{"id": 1002653, "claim": "A repurposed , blood gene signature is associated with poor outcomes in sars-cov-2", "label": "SUPPORTED", "evidence": ["We previously identified a 52-gene signature in peripheral blood, predictive of mortality in Idiopathic Pulmonary Fibrosis."]}
{"id": 1002654, "claim": "A repurposed, blood pressure signature is associated with poor outcomes in sars-cov-2", "label": "REFUTED", "evidence": ["We previously identified a 52-gene signature in peripheral blood, predictive of mortality in Idiopathic Pulmonary Fibrosis."]}
{"id": 1002655, "claim": "A repurposed, blood count signature is associated with poor outcomes in sars-cov-2", "label": "REFUTED", "evidence": ["We previously identified a 52-gene signature in peripheral blood, predictive of mortality in Idiopathic Pulmonary Fibrosis."]}
{"id": 1002656, "claim": "B cells and t cells mediate immunity to covid-19", "label": "SUPPORTED", "evidence": ["Robust immune responses with spike-specific neutralizing antibodies, memory B cells and circulating TFH cells have been found in patients who have recovered from COVID-19 infection8.", "Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19.", "Here, we discuss our current understanding of the relative contribution of B cells and T cells to immunity to SARS-CoV-2 and the implications for the development of effective treatments and vaccines for COVID-19.", "These T cells are probably cross-reactive with other HCoVs, but whether they can provide protection from COVID-19 disease remains to be determined."]}
{"id": 1002657, "claim": "B cells and t cells mediate exposure to covid-19", "label": "REFUTED", "evidence": ["Robust immune responses with spike-specific neutralizing antibodies, memory B cells and circulating TFH cells have been found in patients who have recovered from COVID-19 infection8.", "Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19.", "Here, we discuss our current understanding of the relative contribution of B cells and T cells to immunity to SARS-CoV-2 and the implications for the development of effective treatments and vaccines for COVID-19.", "These T cells are probably cross-reactive with other HCoVs, but whether they can provide protection from COVID-19 disease remains to be determined."]}
{"id": 1002658, "claim": "B cells and t cells mediate susceptibility to covid-19", "label": "REFUTED", "evidence": ["Robust immune responses with spike-specific neutralizing antibodies, memory B cells and circulating TFH cells have been found in patients who have recovered from COVID-19 infection8.", "Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19.", "Here, we discuss our current understanding of the relative contribution of B cells and T cells to immunity to SARS-CoV-2 and the implications for the development of effective treatments and vaccines for COVID-19.", "These T cells are probably cross-reactive with other HCoVs, but whether they can provide protection from COVID-19 disease remains to be determined."]}
{"id": 1002659, "claim": "B cells and t cells mediate fusion to covid-19", "label": "REFUTED", "evidence": ["Robust immune responses with spike-specific neutralizing antibodies, memory B cells and circulating TFH cells have been found in patients who have recovered from COVID-19 infection8.", "Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19.", "Here, we discuss our current understanding of the relative contribution of B cells and T cells to immunity to SARS-CoV-2 and the implications for the development of effective treatments and vaccines for COVID-19.", "These T cells are probably cross-reactive with other HCoVs, but whether they can provide protection from COVID-19 disease remains to be determined."]}
{"id": 1002660, "claim": "Large numbers of health care and frontline workers are refusing covid-19 vaccine.", "label": "SUPPORTED", "evidence": ["Why health care workers might refuse vaccination", "Fewer than half of the hospital workers at St. Elizabeth Community Hospital in Tehama County, Calif., were willing to be vaccinated, and around 20% to 40% of L.A. County's frontline workers have reportedly declined an opportunity to take the vaccine.", "While 27% of the public is \"vaccine hesitant\" -- saying they probably or definitely would not get a COVID-19 vaccine -- 29% of health care workers said the same, according to a recent Kaiser Family Foundation survey.", "Mike DeWine said he was \"troubled\" by the relatively low numbers of nursing home workers who have elected to take the vaccine, with DeWine stating that approximately 60% of nursing home staff declined the shot."]}
{"id": 1002661, "claim": "Low numbers of health care and frontline workers are refusing covid-19 vaccine.", "label": "REFUTED", "evidence": ["Why health care workers might refuse vaccination", "Fewer than half of the hospital workers at St. Elizabeth Community Hospital in Tehama County, Calif., were willing to be vaccinated, and around 20% to 40% of L.A. County's frontline workers have reportedly declined an opportunity to take the vaccine.", "While 27% of the public is \"vaccine hesitant\" -- saying they probably or definitely would not get a COVID-19 vaccine -- 29% of health care workers said the same, according to a recent Kaiser Family Foundation survey.", "Mike DeWine said he was \"troubled\" by the relatively low numbers of nursing home workers who have elected to take the vaccine, with DeWine stating that approximately 60% of nursing home staff declined the shot."]}
{"id": 1002662, "claim": "Large numbers of health care and frontline workers are receiving covid-19 vaccine.", "label": "REFUTED", "evidence": ["Why health care workers might refuse vaccination", "Fewer than half of the hospital workers at St. Elizabeth Community Hospital in Tehama County, Calif., were willing to be vaccinated, and around 20% to 40% of L.A. County's frontline workers have reportedly declined an opportunity to take the vaccine.", "While 27% of the public is \"vaccine hesitant\" -- saying they probably or definitely would not get a COVID-19 vaccine -- 29% of health care workers said the same, according to a recent Kaiser Family Foundation survey.", "Mike DeWine said he was \"troubled\" by the relatively low numbers of nursing home workers who have elected to take the vaccine, with DeWine stating that approximately 60% of nursing home staff declined the shot."]}
{"id": 1002663, "claim": "Lower numbers of health care and frontline workers are refusing covid-19 vaccine.", "label": "REFUTED", "evidence": ["Why health care workers might refuse vaccination", "Fewer than half of the hospital workers at St. Elizabeth Community Hospital in Tehama County, Calif., were willing to be vaccinated, and around 20% to 40% of L.A. County's frontline workers have reportedly declined an opportunity to take the vaccine.", "While 27% of the public is \"vaccine hesitant\" -- saying they probably or definitely would not get a COVID-19 vaccine -- 29% of health care workers said the same, according to a recent Kaiser Family Foundation survey.", "Mike DeWine said he was \"troubled\" by the relatively low numbers of nursing home workers who have elected to take the vaccine, with DeWine stating that approximately 60% of nursing home staff declined the shot."]}
{"id": 1002664, "claim": "Widely available lysosome targeting agents should be considered as a potential therapy for covid-19", "label": "SUPPORTED", "evidence": ["As some of these drugs, mostly antibiotics, were already empirically used in the treatment of COVID-19, we encourage our colleagues all over the world to publish patient data so potential efficacy of these agents can be evaluated in the clinical context and rapidly implemented in the therapeutic protocols if the beneficial effect on clinical outcome is observed.", "The main mechanism of action responsible for the favourable outcome of COVID-19 patients treated with CQ seems to be related to pH modulation- mediated effect on the endolysosomal trafficking, a characteristic of chemical compounds often called lysosomotropic agents because of the physico-chemical properties that enable them to passively diffuse through the endosomal membrane and undergo protonation-based trapping in the lumen of the acidic vesicles."]}
{"id": 1002665, "claim": "Widely available lysosome targeting agents cannot be considered as a potential therapy for covid-19", "label": "REFUTED", "evidence": ["As some of these drugs, mostly antibiotics, were already empirically used in the treatment of COVID-19, we encourage our colleagues all over the world to publish patient data so potential efficacy of these agents can be evaluated in the clinical context and rapidly implemented in the therapeutic protocols if the beneficial effect on clinical outcome is observed.", "The main mechanism of action responsible for the favourable outcome of COVID-19 patients treated with CQ seems to be related to pH modulation- mediated effect on the endolysosomal trafficking, a characteristic of chemical compounds often called lysosomotropic agents because of the physico-chemical properties that enable them to passively diffuse through the endosomal membrane and undergo protonation-based trapping in the lumen of the acidic vesicles."]}
{"id": 1002666, "claim": "Widely available lysosome targeting agents should be considered as a potential marker for covid-19", "label": "REFUTED", "evidence": ["As some of these drugs, mostly antibiotics, were already empirically used in the treatment of COVID-19, we encourage our colleagues all over the world to publish patient data so potential efficacy of these agents can be evaluated in the clinical context and rapidly implemented in the therapeutic protocols if the beneficial effect on clinical outcome is observed.", "The main mechanism of action responsible for the favourable outcome of COVID-19 patients treated with CQ seems to be related to pH modulation- mediated effect on the endolysosomal trafficking, a characteristic of chemical compounds often called lysosomotropic agents because of the physico-chemical properties that enable them to passively diffuse through the endosomal membrane and undergo protonation-based trapping in the lumen of the acidic vesicles."]}
{"id": 1002667, "claim": "Widely available lysosome targeting agents should be considered as a potential biomarker for covid-19", "label": "REFUTED", "evidence": ["As some of these drugs, mostly antibiotics, were already empirically used in the treatment of COVID-19, we encourage our colleagues all over the world to publish patient data so potential efficacy of these agents can be evaluated in the clinical context and rapidly implemented in the therapeutic protocols if the beneficial effect on clinical outcome is observed.", "The main mechanism of action responsible for the favourable outcome of COVID-19 patients treated with CQ seems to be related to pH modulation- mediated effect on the endolysosomal trafficking, a characteristic of chemical compounds often called lysosomotropic agents because of the physico-chemical properties that enable them to passively diffuse through the endosomal membrane and undergo protonation-based trapping in the lumen of the acidic vesicles."]}
{"id": 1002668, "claim": "Epidemiological analysis of an outbreak in hong kong revealed that blood group o was associated with a lower risk of sars-cov-2 infection .", "label": "SUPPORTED", "evidence": ["The findings revealed that the person having O blood type were less susceptible towards SARS-CoV infection in comparison with those having other blood types.", "The ABO gene stands out among the genes involved since O blood group individuals were shown to have very low odds of infection compared to non-O individuals in a hospital outbreak that occurred in March 2003 in Hong Kong (Cheng et al.", "Epidemiological analysis of a hospital outbreak in Hong Kong revealed that blood group O was associated with a low risk of infection.", "Yet, it is precisely what was observed in the case of a hospital outbreak of SARS in Hong Kong, where O blood group individuals appeared at a much lower risk of being infected by SARS-CoV than subjects of other blood types (Cheng et al."]}
{"id": 1002669, "claim": "Epidemiological analysis of an outbreak in hong kong revealed that blood group o was associated with a increased risk of sars-cov-2 infection.", "label": "REFUTED", "evidence": ["The findings revealed that the person having O blood type were less susceptible towards SARS-CoV infection in comparison with those having other blood types.", "The ABO gene stands out among the genes involved since O blood group individuals were shown to have very low odds of infection compared to non-O individuals in a hospital outbreak that occurred in March 2003 in Hong Kong (Cheng et al.", "Epidemiological analysis of a hospital outbreak in Hong Kong revealed that blood group O was associated with a low risk of infection.", "Yet, it is precisely what was observed in the case of a hospital outbreak of SARS in Hong Kong, where O blood group individuals appeared at a much lower risk of being infected by SARS-CoV than subjects of other blood types (Cheng et al."]}
{"id": 1002670, "claim": "Epidemiological analysis of an outbreak in hong kong revealed that blood group o was associated with a greater risk of sars-cov-2 infection.", "label": "REFUTED", "evidence": ["The findings revealed that the person having O blood type were less susceptible towards SARS-CoV infection in comparison with those having other blood types.", "The ABO gene stands out among the genes involved since O blood group individuals were shown to have very low odds of infection compared to non-O individuals in a hospital outbreak that occurred in March 2003 in Hong Kong (Cheng et al.", "Epidemiological analysis of a hospital outbreak in Hong Kong revealed that blood group O was associated with a low risk of infection.", "Yet, it is precisely what was observed in the case of a hospital outbreak of SARS in Hong Kong, where O blood group individuals appeared at a much lower risk of being infected by SARS-CoV than subjects of other blood types (Cheng et al."]}
{"id": 1002671, "claim": "Epidemiological analysis of an outbreak in hong kong revealed that blood group o was associated with a higher risk of sars-cov-2 infection.", "label": "REFUTED", "evidence": ["The findings revealed that the person having O blood type were less susceptible towards SARS-CoV infection in comparison with those having other blood types.", "The ABO gene stands out among the genes involved since O blood group individuals were shown to have very low odds of infection compared to non-O individuals in a hospital outbreak that occurred in March 2003 in Hong Kong (Cheng et al.", "Epidemiological analysis of a hospital outbreak in Hong Kong revealed that blood group O was associated with a low risk of infection.", "Yet, it is precisely what was observed in the case of a hospital outbreak of SARS in Hong Kong, where O blood group individuals appeared at a much lower risk of being infected by SARS-CoV than subjects of other blood types (Cheng et al."]}
{"id": 1002672, "claim": "Coronavirus hemagglutinin-esterase and spike proteins coevolve for functional balance and optimal virion avidity", "label": "SUPPORTED", "evidence": ["Structure, function and evolution of the hemagglutinin-esterase proteins of corona- and toroviruses.", "Human Coronavirus HKU1 Spike Protein Uses O-Acetylated Sialic Acid as an Attachment Receptor Determinant and Employs Hemagglutinin-Esterase Protein as a Receptor-Destroying Enzyme."]}
{"id": 1002673, "claim": "Coronavirus hemagglutinin-esterase and spike proteins coevolve for functional balance and blocking virion avidity", "label": "REFUTED", "evidence": ["Structure, function and evolution of the hemagglutinin-esterase proteins of corona- and toroviruses.", "Human Coronavirus HKU1 Spike Protein Uses O-Acetylated Sialic Acid as an Attachment Receptor Determinant and Employs Hemagglutinin-Esterase Protein as a Receptor-Destroying Enzyme."]}
{"id": 1002674, "claim": "Cytotoxic lymphocytes are dysregulated in multisystem inflammatory syndrome in children", "label": "SUPPORTED", "evidence": ["Together, these findings suggest dysregulated cytotoxic lymphocyte response to SARS-Cov-2 infection in MIS-C. Keywords: COVID-19, SARS-CoV-2, pediatrics, MIS-C ", "Multisystem inflammatory syndrome in children: getting to the heart of the matter."]}
{"id": 1002675, "claim": "Cytotoxic lymphocytes are dysregulated in multisystem neurological syndrome in children", "label": "REFUTED", "evidence": ["Together, these findings suggest dysregulated cytotoxic lymphocyte response to SARS-Cov-2 infection in MIS-C. Keywords: COVID-19, SARS-CoV-2, pediatrics, MIS-C ", "Multisystem inflammatory syndrome in children: getting to the heart of the matter."]}
{"id": 1002676, "claim": "Cytotoxic lymphocytes are dysregulated in multisystem heart syndrome in children", "label": "REFUTED", "evidence": ["Together, these findings suggest dysregulated cytotoxic lymphocyte response to SARS-Cov-2 infection in MIS-C. Keywords: COVID-19, SARS-CoV-2, pediatrics, MIS-C ", "Multisystem inflammatory syndrome in children: getting to the heart of the matter."]}
{"id": 1002677, "claim": "Cytotoxic lymphocytes are dysregulated in multisystem nervous syndrome in children", "label": "REFUTED", "evidence": ["Together, these findings suggest dysregulated cytotoxic lymphocyte response to SARS-Cov-2 infection in MIS-C. Keywords: COVID-19, SARS-CoV-2, pediatrics, MIS-C ", "Multisystem inflammatory syndrome in children: getting to the heart of the matter."]}
{"id": 1002678, "claim": "Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild covid-19", "label": "SUPPORTED", "evidence": ["Finally, we show that calprotectin plasma level and a routine flow cytometry assay detecting decreased frequencies of non-classical monocytes could discriminate patients who develop a severe form of COVID-19, suggesting a predictive value that deserves prospective evaluation."]}
{"id": 1002679, "claim": "Elevated calprotectin and abnormal myeloid cell subsets discriminate naturally from mild covid-19", "label": "REFUTED", "evidence": ["Finally, we show that calprotectin plasma level and a routine flow cytometry assay detecting decreased frequencies of non-classical monocytes could discriminate patients who develop a severe form of COVID-19, suggesting a predictive value that deserves prospective evaluation."]}
{"id": 1002680, "claim": "Phase 1 trial of a candidate recombinant virus-like particle vaccine for covid-19 disease produced in plants", "label": "SUPPORTED", "evidence": ["Added value of this study We report the results of the first clinical study of CoVLP, a virus-like particle (VLP) vaccine that is produced by transient transfection of Nicotiana benthamiana plants."]}
{"id": 1002681, "claim": "Phase 1 trial of a candidate recombinant virus-like particle vaccine for covid-19 disease produced in mice", "label": "REFUTED", "evidence": ["Added value of this study We report the results of the first clinical study of CoVLP, a virus-like particle (VLP) vaccine that is produced by transient transfection of Nicotiana benthamiana plants."]}
{"id": 1002682, "claim": "Covid-19 detected on multiple mink farms", "label": "SUPPORTED", "evidence": ["COVID-19 has now struck mink farms in the United States, too.", "Mink on each farm were most likely initially infected via transmission of the virus from farm workers with COVID-19.", "Mink can be infected by people with COVID-19, and evidence to date suggests mink-to-human transmission of SARS-CoV-2 is plausible.", "The Dutch government reported multiple cases of transmission from mink to farm staff, and several staffers on the Utah farms who came in contact with the mink have confirmed COVID-19."]}
{"id": 1002683, "claim": "Covid-19 died on multiple mink farms", "label": "REFUTED", "evidence": ["COVID-19 has now struck mink farms in the United States, too.", "Mink on each farm were most likely initially infected via transmission of the virus from farm workers with COVID-19.", "Mink can be infected by people with COVID-19, and evidence to date suggests mink-to-human transmission of SARS-CoV-2 is plausible.", "The Dutch government reported multiple cases of transmission from mink to farm staff, and several staffers on the Utah farms who came in contact with the mink have confirmed COVID-19."]}
{"id": 1002684, "claim": "Population-scale testing can suppress the spread of covid-19", "label": "SUPPORTED", "evidence": ["In addition to the rate of compliance and false negatives, the required rate of testing is dependent on the design of the testing regime, with concurrent testing outperforming random sampling of individuals.", "We show here that at a sufficient rate of testing and isolation, the R0 of SARS-CoV-2 would be reduced well below 1.0, and the epidemic would collapse.", "It would also be robust to failure, as even in the case where the testing rate would be insufficient to collapse the epidemic, it would still reduce the number of infected individuals in the population, improving both public health and economic conditions."]}
{"id": 1002685, "claim": "Population-scale testing can increase the spread of covid-19", "label": "REFUTED", "evidence": ["In addition to the rate of compliance and false negatives, the required rate of testing is dependent on the design of the testing regime, with concurrent testing outperforming random sampling of individuals.", "We show here that at a sufficient rate of testing and isolation, the R0 of SARS-CoV-2 would be reduced well below 1.0, and the epidemic would collapse.", "It would also be robust to failure, as even in the case where the testing rate would be insufficient to collapse the epidemic, it would still reduce the number of infected individuals in the population, improving both public health and economic conditions."]}
{"id": 1002686, "claim": "Population-scale testing can facilitate the spread of covid-19", "label": "REFUTED", "evidence": ["In addition to the rate of compliance and false negatives, the required rate of testing is dependent on the design of the testing regime, with concurrent testing outperforming random sampling of individuals.", "We show here that at a sufficient rate of testing and isolation, the R0 of SARS-CoV-2 would be reduced well below 1.0, and the epidemic would collapse.", "It would also be robust to failure, as even in the case where the testing rate would be insufficient to collapse the epidemic, it would still reduce the number of infected individuals in the population, improving both public health and economic conditions."]}
{"id": 1002687, "claim": "Population-scale testing can enhance the spread of covid-19", "label": "REFUTED", "evidence": ["In addition to the rate of compliance and false negatives, the required rate of testing is dependent on the design of the testing regime, with concurrent testing outperforming random sampling of individuals.", "We show here that at a sufficient rate of testing and isolation, the R0 of SARS-CoV-2 would be reduced well below 1.0, and the epidemic would collapse.", "It would also be robust to failure, as even in the case where the testing rate would be insufficient to collapse the epidemic, it would still reduce the number of infected individuals in the population, improving both public health and economic conditions."]}
{"id": 1002688, "claim": "Harnessing innate immunity to eliminate sars-cov-2 and ameliorate covid-19 disease", "label": "SUPPORTED", "evidence": ["The fact that many people infected with SARS-CoV-2 will clear the virus without even developing symptoms suggests that the immune system may hold the key to defeat this virus."]}
{"id": 1002689, "claim": "Harnessing innate immunity to complement sars-cov-2 and ameliorate covid-19 disease", "label": "REFUTED", "evidence": ["The fact that many people infected with SARS-CoV-2 will clear the virus without even developing symptoms suggests that the immune system may hold the key to defeat this virus."]}
{"id": 1002690, "claim": "Harnessing innate immunity to produce sars-cov-2 and ameliorate covid-19 disease", "label": "REFUTED", "evidence": ["The fact that many people infected with SARS-CoV-2 will clear the virus without even developing symptoms suggests that the immune system may hold the key to defeat this virus."]}
{"id": 1002691, "claim": "Harnessing innate immunity to induce sars-cov-2 and ameliorate covid-19 disease", "label": "REFUTED", "evidence": ["The fact that many people infected with SARS-CoV-2 will clear the virus without even developing symptoms suggests that the immune system may hold the key to defeat this virus."]}
{"id": 1002692, "claim": "Behavioral changes before lockdown , and decreased retail and recreation mobility during lockdown , contributed most to the successful control of the covid-19 epidemic in 35 western countries", "label": "SUPPORTED", "evidence": ["One third of the effect happened already on average 6 days before the lockdown, with lockdown itself causing another major drop in transmission.", "During lockdown, decreased mobility in retail and recreation was an independent predictor of lower R t during lockdown, while changes in other types of mobility were not.", "Our data suggest measures that will contribute to avoiding a second peak include a tight control on circumstances that facilitate massive spread such as large gatherings especially indoors, physical distancing, and mask use."]}
{"id": 1002693, "claim": "Behavioral changes before lockdown, and increased retail and recreation mobility during lockdown, contributed most to the successful control of the covid-19 epidemic in 35 western countries", "label": "REFUTED", "evidence": ["One third of the effect happened already on average 6 days before the lockdown, with lockdown itself causing another major drop in transmission.", "During lockdown, decreased mobility in retail and recreation was an independent predictor of lower R t during lockdown, while changes in other types of mobility were not.", "Our data suggest measures that will contribute to avoiding a second peak include a tight control on circumstances that facilitate massive spread such as large gatherings especially indoors, physical distancing, and mask use."]}
{"id": 1002694, "claim": "Behavioral changes before lockdown, and both retail and recreation mobility during lockdown, contributed most to the successful control of the covid-19 epidemic in 35 western countries", "label": "REFUTED", "evidence": ["One third of the effect happened already on average 6 days before the lockdown, with lockdown itself causing another major drop in transmission.", "During lockdown, decreased mobility in retail and recreation was an independent predictor of lower R t during lockdown, while changes in other types of mobility were not.", "Our data suggest measures that will contribute to avoiding a second peak include a tight control on circumstances that facilitate massive spread such as large gatherings especially indoors, physical distancing, and mask use."]}
{"id": 1002695, "claim": "Behavioral changes before lockdown, and daily retail and recreation mobility during lockdown, contributed most to the successful control of the covid-19 epidemic in 35 western countries", "label": "REFUTED", "evidence": ["One third of the effect happened already on average 6 days before the lockdown, with lockdown itself causing another major drop in transmission.", "During lockdown, decreased mobility in retail and recreation was an independent predictor of lower R t during lockdown, while changes in other types of mobility were not.", "Our data suggest measures that will contribute to avoiding a second peak include a tight control on circumstances that facilitate massive spread such as large gatherings especially indoors, physical distancing, and mask use."]}
{"id": 1002696, "claim": "Sars-cov-2 escapes cd8 t cell surveillance via mutations in mhc-i restricted epitopes.", "label": "SUPPORTED", "evidence": ["Here, we identified non-synonymous mutations in MHC-I restricted CD8+ T cell epitopes after deep sequencing of 747 SARS-CoV- 2 virus isolates.", "Our findings highlight the capacity of SARS- CoV-2 to subvert CD8+ T cell surveillance through escape mutations in MHCI- restricted viral epitopes.", "The findings of this current study show that effector T cells may give rise to SARS-CoV-2 mutations which escape immune surveillance."]}
{"id": 1002697, "claim": "Sars-cov-2 promotes cd8 t cell surveillance via mutations in mhc-i restricted epitopes.", "label": "REFUTED", "evidence": ["Here, we identified non-synonymous mutations in MHC-I restricted CD8+ T cell epitopes after deep sequencing of 747 SARS-CoV- 2 virus isolates.", "Our findings highlight the capacity of SARS- CoV-2 to subvert CD8+ T cell surveillance through escape mutations in MHCI- restricted viral epitopes.", "The findings of this current study show that effector T cells may give rise to SARS-CoV-2 mutations which escape immune surveillance."]}
{"id": 1002698, "claim": "Sars-cov-2 induced cd8 t cell surveillance via mutations in mhc-i restricted epitopes.", "label": "REFUTED", "evidence": ["Here, we identified non-synonymous mutations in MHC-I restricted CD8+ T cell epitopes after deep sequencing of 747 SARS-CoV- 2 virus isolates.", "Our findings highlight the capacity of SARS- CoV-2 to subvert CD8+ T cell surveillance through escape mutations in MHCI- restricted viral epitopes.", "The findings of this current study show that effector T cells may give rise to SARS-CoV-2 mutations which escape immune surveillance."]}
{"id": 1002699, "claim": "Sars-cov-2 induce cd8 t cell surveillance via mutations in mhc-i restricted epitopes.", "label": "REFUTED", "evidence": ["Here, we identified non-synonymous mutations in MHC-I restricted CD8+ T cell epitopes after deep sequencing of 747 SARS-CoV- 2 virus isolates.", "Our findings highlight the capacity of SARS- CoV-2 to subvert CD8+ T cell surveillance through escape mutations in MHCI- restricted viral epitopes.", "The findings of this current study show that effector T cells may give rise to SARS-CoV-2 mutations which escape immune surveillance."]}
{"id": 1002700, "claim": "Nearly half a million people may have had covid-19 in wuhan.", "label": "SUPPORTED", "evidence": ["That study estimated more than 232,000 people may have been infected in the first wave of Covid-19 in mainland China, four times the official figures.", "Advertisement Read more: In Wuhan, nearly half a million people may have had Covid-19, study shows.", "The figures suggest the previously unknown respiratory disease, labeled by international health officials as COVID-19, has considerable capacity to spread far beyond the 59,804 cases confirmed in China as of Thursday.", "China's CDC said the study had been conducted a month after China 'contained the first wave of the Covid-19 epidemic' and that it revealed a much higher prevalence rate found among Wuhan residents."]}
{"id": 1002701, "claim": "Nearly half a 100 people may have had covid-19 in wuhan.", "label": "REFUTED", "evidence": ["That study estimated more than 232,000 people may have been infected in the first wave of Covid-19 in mainland China, four times the official figures.", "Advertisement Read more: In Wuhan, nearly half a million people may have had Covid-19, study shows.", "The figures suggest the previously unknown respiratory disease, labeled by international health officials as COVID-19, has considerable capacity to spread far beyond the 59,804 cases confirmed in China as of Thursday.", "China's CDC said the study had been conducted a month after China 'contained the first wave of the Covid-19 epidemic' and that it revealed a much higher prevalence rate found among Wuhan residents."]}
{"id": 1002702, "claim": "Nearly half a hundred people may have had covid-19 in wuhan.", "label": "REFUTED", "evidence": ["That study estimated more than 232,000 people may have been infected in the first wave of Covid-19 in mainland China, four times the official figures.", "Advertisement Read more: In Wuhan, nearly half a million people may have had Covid-19, study shows.", "The figures suggest the previously unknown respiratory disease, labeled by international health officials as COVID-19, has considerable capacity to spread far beyond the 59,804 cases confirmed in China as of Thursday.", "China's CDC said the study had been conducted a month after China 'contained the first wave of the Covid-19 epidemic' and that it revealed a much higher prevalence rate found among Wuhan residents."]}
{"id": 1002703, "claim": "Nearly half a cent people may have had covid-19 in wuhan.", "label": "REFUTED", "evidence": ["That study estimated more than 232,000 people may have been infected in the first wave of Covid-19 in mainland China, four times the official figures.", "Advertisement Read more: In Wuhan, nearly half a million people may have had Covid-19, study shows.", "The figures suggest the previously unknown respiratory disease, labeled by international health officials as COVID-19, has considerable capacity to spread far beyond the 59,804 cases confirmed in China as of Thursday.", "China's CDC said the study had been conducted a month after China 'contained the first wave of the Covid-19 epidemic' and that it revealed a much higher prevalence rate found among Wuhan residents."]}
{"id": 1002704, "claim": "Coronavirus vaccine more than '90 % effective ' in preventing disease , study finds", "label": "SUPPORTED", "evidence": ["A more than 90% effective coronavirus vaccine would be roughly on par with one dose of a measles vaccination, which is about 93% effective, according to the Centers for Disease Control and Prevention.", "The company said that the analysis found that the vaccine was more than 90 percent effective in preventing the disease among trial volunteers who had no evidence of prior coronavirus infection.", "The news comes a week after Pfizer and BioNTech said their vaccine was more than 90% effective."]}
{"id": 1002705, "claim": "Coronavirus vaccine more under '90 % effective'in preventing disease, study finds", "label": "REFUTED", "evidence": ["A more than 90% effective coronavirus vaccine would be roughly on par with one dose of a measles vaccination, which is about 93% effective, according to the Centers for Disease Control and Prevention.", "The company said that the analysis found that the vaccine was more than 90 percent effective in preventing the disease among trial volunteers who had no evidence of prior coronavirus infection.", "The news comes a week after Pfizer and BioNTech said their vaccine was more than 90% effective."]}
{"id": 1002706, "claim": "Blood pressure medication improves covid-19 survival rates", "label": "SUPPORTED", "evidence": ["They found that the risk of severe Covid-19 illness and death was reduced for patients with high blood pressure who were taking Angiotensin-Converting Enzyme inhibitors (ACEi) or Angiotensin Receptor Blockers (ARB).", "\"Covid-19 patients with high blood pressure who were taking ACEi/ARB medications were 0.67 times less likely to have a critical or fatal outcome than those not taking these medications."]}
{"id": 1002707, "claim": "Blood pressure medication decreased covid-19 survival rates", "label": "REFUTED", "evidence": ["They found that the risk of severe Covid-19 illness and death was reduced for patients with high blood pressure who were taking Angiotensin-Converting Enzyme inhibitors (ACEi) or Angiotensin Receptor Blockers (ARB).", "\"Covid-19 patients with high blood pressure who were taking ACEi/ARB medications were 0.67 times less likely to have a critical or fatal outcome than those not taking these medications."]}
{"id": 1002708, "claim": "Blood pressure medication reduces covid-19 survival rates", "label": "REFUTED", "evidence": ["They found that the risk of severe Covid-19 illness and death was reduced for patients with high blood pressure who were taking Angiotensin-Converting Enzyme inhibitors (ACEi) or Angiotensin Receptor Blockers (ARB).", "\"Covid-19 patients with high blood pressure who were taking ACEi/ARB medications were 0.67 times less likely to have a critical or fatal outcome than those not taking these medications."]}
{"id": 1002709, "claim": "Blood pressure medication reduced covid-19 survival rates", "label": "REFUTED", "evidence": ["They found that the risk of severe Covid-19 illness and death was reduced for patients with high blood pressure who were taking Angiotensin-Converting Enzyme inhibitors (ACEi) or Angiotensin Receptor Blockers (ARB).", "\"Covid-19 patients with high blood pressure who were taking ACEi/ARB medications were 0.67 times less likely to have a critical or fatal outcome than those not taking these medications."]}
{"id": 1002710, "claim": "In 2017 , the cdc already knew there were evidences that healthy people wearing masks may prevent from getting infection", "label": "SUPPORTED", "evidence": ["Nevertheless, mechanistic studies found that surgical masks could prevent transmission of human coronavirus and influenza virus infections if worn by infected persons ( 2).", "However, as with hand hygiene, face masks might be able to reduce the transmission of other infections and therefore have value in an influenza pandemic when healthcare resources are stretched.", "In addition, persons caring for ill family members at home (e.g., a parent of a child exhibiting influenza symptoms) might use face masks to avoid infection when in close contact with a patient, just as health care personnel wear masks in health care settings."]}
{"id": 1002711, "claim": "In 1, the cdc already knew there were evidences that healthy people wearing masks may prevent from getting infection", "label": "REFUTED", "evidence": ["Nevertheless, mechanistic studies found that surgical masks could prevent transmission of human coronavirus and influenza virus infections if worn by infected persons ( 2).", "However, as with hand hygiene, face masks might be able to reduce the transmission of other infections and therefore have value in an influenza pandemic when healthcare resources are stretched.", "In addition, persons caring for ill family members at home (e.g., a parent of a child exhibiting influenza symptoms) might use face masks to avoid infection when in close contact with a patient, just as health care personnel wear masks in health care settings."]}
{"id": 1002712, "claim": "Using household data from bnei brak , israel , to estimate the relative susceptibility and infectivity of children", "label": "SUPPORTED", "evidence": ["To estimate relative transmission parameters, we employ a discrete stochastic model of the spread of infection within a household, allowing for susceptibility and infectivity parameters to differ among children and adults.", "To address this and adjust our analysis accordingly, we used the serological data to estimate under-detection rates in children and adults, and have then used these estimated rates to repeat our previous fitting of the household model to the data, while performing multiple imputations in the PCR testing data, imputing a fraction of the PCR-negative cases as infected.", "In this study we estimate susceptibility and infectivity of children compared to those of adults using households data.", "This study uses data on infections within households in order to estimate the susceptibility and infectivity of children compared to those of adults."]}
{"id": 1002713, "claim": "Using experimental data from bnei brak, israel, to estimate the relative susceptibility and infectivity of children", "label": "REFUTED", "evidence": ["To estimate relative transmission parameters, we employ a discrete stochastic model of the spread of infection within a household, allowing for susceptibility and infectivity parameters to differ among children and adults.", "To address this and adjust our analysis accordingly, we used the serological data to estimate under-detection rates in children and adults, and have then used these estimated rates to repeat our previous fitting of the household model to the data, while performing multiple imputations in the PCR testing data, imputing a fraction of the PCR-negative cases as infected.", "In this study we estimate susceptibility and infectivity of children compared to those of adults using households data.", "This study uses data on infections within households in order to estimate the susceptibility and infectivity of children compared to those of adults."]}
{"id": 1002714, "claim": "Using epidemiological data from bnei brak, israel, to estimate the relative susceptibility and infectivity of children", "label": "REFUTED", "evidence": ["To estimate relative transmission parameters, we employ a discrete stochastic model of the spread of infection within a household, allowing for susceptibility and infectivity parameters to differ among children and adults.", "To address this and adjust our analysis accordingly, we used the serological data to estimate under-detection rates in children and adults, and have then used these estimated rates to repeat our previous fitting of the household model to the data, while performing multiple imputations in the PCR testing data, imputing a fraction of the PCR-negative cases as infected.", "In this study we estimate susceptibility and infectivity of children compared to those of adults using households data.", "This study uses data on infections within households in order to estimate the susceptibility and infectivity of children compared to those of adults."]}
{"id": 1002715, "claim": "Using model data from bnei brak, israel, to estimate the relative susceptibility and infectivity of children", "label": "REFUTED", "evidence": ["To estimate relative transmission parameters, we employ a discrete stochastic model of the spread of infection within a household, allowing for susceptibility and infectivity parameters to differ among children and adults.", "To address this and adjust our analysis accordingly, we used the serological data to estimate under-detection rates in children and adults, and have then used these estimated rates to repeat our previous fitting of the household model to the data, while performing multiple imputations in the PCR testing data, imputing a fraction of the PCR-negative cases as infected.", "In this study we estimate susceptibility and infectivity of children compared to those of adults using households data.", "This study uses data on infections within households in order to estimate the susceptibility and infectivity of children compared to those of adults."]}
{"id": 1002716, "claim": "De novo design of potent and resilient hace2 decoys to neutralize sars-cov-2.", "label": "SUPPORTED", "evidence": ["We applied our design strategy to engineer, validate, and optimize de novo hACE2 decoys to neutralize SARS-CoV-2 infection (Fig.", "Our pipeline allowed the design, validation, and optimization of de novo hACE2 decoys to neutralize SARS-CoV-2.", "The high and specific binding affinity of the optimized de novo protein decoys translated into effective and specific in vitro neutralization of SARS-CoV-2 viral infection (Fig.", "Our pipeline allowed the design, validation, and optimization of de novo human angiotensin-converting enzyme 2 (hACE2) decoys to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."]}
{"id": 1002717, "claim": "De rational design of potent and resilient hace2 decoys to neutralize sars-cov-2.", "label": "REFUTED", "evidence": ["We applied our design strategy to engineer, validate, and optimize de novo hACE2 decoys to neutralize SARS-CoV-2 infection (Fig.", "Our pipeline allowed the design, validation, and optimization of de novo hACE2 decoys to neutralize SARS-CoV-2.", "The high and specific binding affinity of the optimized de novo protein decoys translated into effective and specific in vitro neutralization of SARS-CoV-2 viral infection (Fig.", "Our pipeline allowed the design, validation, and optimization of de novo human angiotensin-converting enzyme 2 (hACE2) decoys to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."]}
{"id": 1002718, "claim": "The zinc finger antiviral protein restricts sars-cov-2", "label": "SUPPORTED", "evidence": ["Strikingly, SARS-CoV-2 and its closest relatives from bats show the strongest CpG suppression among all known human and bat coronaviruses, respectively.", "Thus, our results identify ZAP as an effector of the IFN response against SARS-CoV-2, although this pandemic pathogen may be preadapted to the low CpG environment in humans.", "Type I, II and III IFNs all strongly inhibited SARS-CoV-2 and further induced ZAP expression.", "Here, we show that Zinc finger antiviral protein (ZAP) that specifically targets CpG dinucleotides in viral RNA sequences restricts SARS-CoV-2.", "Highlights SARS-CoV-2 and its closest bat relatives show strong CpG suppression IFN-β, -γ and -λ inhibit SARS-CoV-2 with high efficiency ZAP restricts SARS-CoV-2 and contributes to the antiviral effect of IFNs "]}
{"id": 1002719, "claim": "The zinc shock antiviral protein restricts sars-cov-2", "label": "REFUTED", "evidence": ["Strikingly, SARS-CoV-2 and its closest relatives from bats show the strongest CpG suppression among all known human and bat coronaviruses, respectively.", "Thus, our results identify ZAP as an effector of the IFN response against SARS-CoV-2, although this pandemic pathogen may be preadapted to the low CpG environment in humans.", "Type I, II and III IFNs all strongly inhibited SARS-CoV-2 and further induced ZAP expression.", "Here, we show that Zinc finger antiviral protein (ZAP) that specifically targets CpG dinucleotides in viral RNA sequences restricts SARS-CoV-2.", "Highlights SARS-CoV-2 and its closest bat relatives show strong CpG suppression IFN-β, -γ and -λ inhibit SARS-CoV-2 with high efficiency ZAP restricts SARS-CoV-2 and contributes to the antiviral effect of IFNs "]}
{"id": 1002720, "claim": "The zinc channel antiviral protein restricts sars-cov-2", "label": "REFUTED", "evidence": ["Strikingly, SARS-CoV-2 and its closest relatives from bats show the strongest CpG suppression among all known human and bat coronaviruses, respectively.", "Thus, our results identify ZAP as an effector of the IFN response against SARS-CoV-2, although this pandemic pathogen may be preadapted to the low CpG environment in humans.", "Type I, II and III IFNs all strongly inhibited SARS-CoV-2 and further induced ZAP expression.", "Here, we show that Zinc finger antiviral protein (ZAP) that specifically targets CpG dinucleotides in viral RNA sequences restricts SARS-CoV-2.", "Highlights SARS-CoV-2 and its closest bat relatives show strong CpG suppression IFN-β, -γ and -λ inhibit SARS-CoV-2 with high efficiency ZAP restricts SARS-CoV-2 and contributes to the antiviral effect of IFNs "]}
{"id": 1002721, "claim": "The zinc analog antiviral protein restricts sars-cov-2", "label": "REFUTED", "evidence": ["Strikingly, SARS-CoV-2 and its closest relatives from bats show the strongest CpG suppression among all known human and bat coronaviruses, respectively.", "Thus, our results identify ZAP as an effector of the IFN response against SARS-CoV-2, although this pandemic pathogen may be preadapted to the low CpG environment in humans.", "Type I, II and III IFNs all strongly inhibited SARS-CoV-2 and further induced ZAP expression.", "Here, we show that Zinc finger antiviral protein (ZAP) that specifically targets CpG dinucleotides in viral RNA sequences restricts SARS-CoV-2.", "Highlights SARS-CoV-2 and its closest bat relatives show strong CpG suppression IFN-β, -γ and -λ inhibit SARS-CoV-2 with high efficiency ZAP restricts SARS-CoV-2 and contributes to the antiviral effect of IFNs "]}
{"id": 1002722, "claim": "There is one , and only one strain of sars-cov-2", "label": "SUPPORTED", "evidence": ["Link David Cotton 14 May 2020, 2:38 am So far we have only identified one strain of sars cov 2.", "There is only one strain of SARS-CoV-2.", "If studies show that ALL genotypes have the SAME phenotypic expression - then we prove that \"there is only one strain of SARS-CoV-2\"."]}
{"id": 1002723, "claim": "There is one, and another one strain of sars-cov-2", "label": "REFUTED", "evidence": ["Link David Cotton 14 May 2020, 2:38 am So far we have only identified one strain of sars cov 2.", "There is only one strain of SARS-CoV-2.", "If studies show that ALL genotypes have the SAME phenotypic expression - then we prove that \"there is only one strain of SARS-CoV-2\"."]}
{"id": 1002724, "claim": "Treatment of covid-19 patients with convalescent plasma reveals a signal of significantly decreased mortality", "label": "SUPPORTED", "evidence": ["Effectiveness of convalescent plasma therapy in severe COVID-19 patients.", "Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality.", "In conclusion, this interim propensity scorematched analysis suggests that transfusion of high anti-RBD IgG titer COVID-19 convalescent plasma early in hospitalization reduces mortality in COVID-19 patients."]}
{"id": 1002725, "claim": "Treatment of covid-19 patients with convalescent plasma reveals a signal of significantly increased mortality", "label": "REFUTED", "evidence": ["Effectiveness of convalescent plasma therapy in severe COVID-19 patients.", "Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality.", "In conclusion, this interim propensity scorematched analysis suggests that transfusion of high anti-RBD IgG titer COVID-19 convalescent plasma early in hospitalization reduces mortality in COVID-19 patients."]}
{"id": 1002726, "claim": "Treatment of covid-19 patients with convalescent plasma reveals a signal of significantly elevated mortality", "label": "REFUTED", "evidence": ["Effectiveness of convalescent plasma therapy in severe COVID-19 patients.", "Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality.", "In conclusion, this interim propensity scorematched analysis suggests that transfusion of high anti-RBD IgG titer COVID-19 convalescent plasma early in hospitalization reduces mortality in COVID-19 patients."]}
{"id": 1002727, "claim": "Treatment of covid-19 patients with convalescent plasma reveals a signal of significantly increase mortality", "label": "REFUTED", "evidence": ["Effectiveness of convalescent plasma therapy in severe COVID-19 patients.", "Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality.", "In conclusion, this interim propensity scorematched analysis suggests that transfusion of high anti-RBD IgG titer COVID-19 convalescent plasma early in hospitalization reduces mortality in COVID-19 patients."]}
{"id": 1002728, "claim": "University of miami leads groundbreaking trial for covid-19 treatment.", "label": "SUPPORTED", "evidence": ["University of Miami Miller School of Medicine researchers led a unique and groundbreaking randomized controlled trial showing umbilical-cord derived mesenchymal stem cell infusions safely reduce risk of death and quicken time to recovery for the severest COVID-19 patients, according to results published in STEM CELLS Translational Medicine on January 5.", "The study's senior author, Camillo Ricordi, M.D., director of the Diabetes Research Institute (DRI) and Cell Transplant Center at the University of Miami Miller School of Medicine, said treating COVID-19 with mesenchymal stem cells makes sense.", "The studys senior author, Camillo Ricordi, M.D., director of the Diabetes Research Institute (DRI) and Cell Transplant Center at the University of Miami Miller School of Medicine, said treating COVID-19 with mesenchymal stem cells makes sense."]}
{"id": 1002729, "claim": "University of miami leads groundbreaking trial for covid-19 development.", "label": "REFUTED", "evidence": ["University of Miami Miller School of Medicine researchers led a unique and groundbreaking randomized controlled trial showing umbilical-cord derived mesenchymal stem cell infusions safely reduce risk of death and quicken time to recovery for the severest COVID-19 patients, according to results published in STEM CELLS Translational Medicine on January 5.", "The study's senior author, Camillo Ricordi, M.D., director of the Diabetes Research Institute (DRI) and Cell Transplant Center at the University of Miami Miller School of Medicine, said treating COVID-19 with mesenchymal stem cells makes sense.", "The studys senior author, Camillo Ricordi, M.D., director of the Diabetes Research Institute (DRI) and Cell Transplant Center at the University of Miami Miller School of Medicine, said treating COVID-19 with mesenchymal stem cells makes sense."]}
{"id": 1002730, "claim": "University of miami leads groundbreaking trial for covid-19 research.", "label": "REFUTED", "evidence": ["University of Miami Miller School of Medicine researchers led a unique and groundbreaking randomized controlled trial showing umbilical-cord derived mesenchymal stem cell infusions safely reduce risk of death and quicken time to recovery for the severest COVID-19 patients, according to results published in STEM CELLS Translational Medicine on January 5.", "The study's senior author, Camillo Ricordi, M.D., director of the Diabetes Research Institute (DRI) and Cell Transplant Center at the University of Miami Miller School of Medicine, said treating COVID-19 with mesenchymal stem cells makes sense.", "The studys senior author, Camillo Ricordi, M.D., director of the Diabetes Research Institute (DRI) and Cell Transplant Center at the University of Miami Miller School of Medicine, said treating COVID-19 with mesenchymal stem cells makes sense."]}
{"id": 1002731, "claim": "University of miami leads groundbreaking trial for covid-19 infection.", "label": "REFUTED", "evidence": ["University of Miami Miller School of Medicine researchers led a unique and groundbreaking randomized controlled trial showing umbilical-cord derived mesenchymal stem cell infusions safely reduce risk of death and quicken time to recovery for the severest COVID-19 patients, according to results published in STEM CELLS Translational Medicine on January 5.", "The study's senior author, Camillo Ricordi, M.D., director of the Diabetes Research Institute (DRI) and Cell Transplant Center at the University of Miami Miller School of Medicine, said treating COVID-19 with mesenchymal stem cells makes sense.", "The studys senior author, Camillo Ricordi, M.D., director of the Diabetes Research Institute (DRI) and Cell Transplant Center at the University of Miami Miller School of Medicine, said treating COVID-19 with mesenchymal stem cells makes sense."]}
{"id": 1002732, "claim": "Helsinki airport uses sniffer dogs to detect covid", "label": "SUPPORTED", "evidence": ["Dogs are also able to identify Covid-19 from a much smaller molecular sample than PCR tests, Helsinki airport said, needing only 10-100 molecules to detect the presence of the virus compared with the 18m needed by laboratory equipment.", "A dog is capable of detecting the presence of the coronavirus within 10 seconds and the entire process takes less than a minute to complete, according to Anna Hielm-Björkman of the University of Helsinki, who is overseeing the trial.", "Researchers in countries including Australia, France, Germany and Britain are reportedly working on similar projects but Finland is the first country in Europe to put dogs to work sniffing out the coronavirus."]}
{"id": 1002733, "claim": "Helsinki cats uses sniffer dogs to detect covid", "label": "REFUTED", "evidence": ["Dogs are also able to identify Covid-19 from a much smaller molecular sample than PCR tests, Helsinki airport said, needing only 10-100 molecules to detect the presence of the virus compared with the 18m needed by laboratory equipment.", "A dog is capable of detecting the presence of the coronavirus within 10 seconds and the entire process takes less than a minute to complete, according to Anna Hielm-Björkman of the University of Helsinki, who is overseeing the trial.", "Researchers in countries including Australia, France, Germany and Britain are reportedly working on similar projects but Finland is the first country in Europe to put dogs to work sniffing out the coronavirus."]}
{"id": 1002734, "claim": "Placentas from covid-19-positive pregnant women show injury", "label": "SUPPORTED", "evidence": ["I dont want to draw sweeping conclusions from a small study, but this preliminary glimpse into how COVID-19 might cause changes in the placenta carries some pretty significant implications for the health of a pregnancy.", "The placentas from 16 women who tested positive for COVID-19 while pregnant showed evidence of injury, according to pathological exams completed directly following birth, reports a new Northwestern Medicine study.", "The type of injury seen in the placentas shows abnormal blood flow between the mothers and their babies in utero, pointing to a new complication of COVID-19."]}
{"id": 1002735, "claim": "Placentas from covid-19-negative pregnant women show injury", "label": "REFUTED", "evidence": ["I dont want to draw sweeping conclusions from a small study, but this preliminary glimpse into how COVID-19 might cause changes in the placenta carries some pretty significant implications for the health of a pregnancy.", "The placentas from 16 women who tested positive for COVID-19 while pregnant showed evidence of injury, according to pathological exams completed directly following birth, reports a new Northwestern Medicine study.", "The type of injury seen in the placentas shows abnormal blood flow between the mothers and their babies in utero, pointing to a new complication of COVID-19."]}
{"id": 1002736, "claim": "Placentas from covid-19-free pregnant women show injury", "label": "REFUTED", "evidence": ["I dont want to draw sweeping conclusions from a small study, but this preliminary glimpse into how COVID-19 might cause changes in the placenta carries some pretty significant implications for the health of a pregnancy.", "The placentas from 16 women who tested positive for COVID-19 while pregnant showed evidence of injury, according to pathological exams completed directly following birth, reports a new Northwestern Medicine study.", "The type of injury seen in the placentas shows abnormal blood flow between the mothers and their babies in utero, pointing to a new complication of COVID-19."]}
{"id": 1002737, "claim": "Severe covid-19 infection is associated with increased antibody-mediated platelet apoptosis", "label": "SUPPORTED", "evidence": ["The strong correlations between apoptosis markers and increased D-Dimer levels as well as the incidence of thrombosis may indicate that antibody-mediated platelet apoptosis potentially contributes to sustained increased thromboembolic risk in ICU COVID-19 patients."]}
{"id": 1002738, "claim": "Acute covid-19 infection is associated with increased antibody-mediated platelet apoptosis", "label": "REFUTED", "evidence": ["The strong correlations between apoptosis markers and increased D-Dimer levels as well as the incidence of thrombosis may indicate that antibody-mediated platelet apoptosis potentially contributes to sustained increased thromboembolic risk in ICU COVID-19 patients."]}
{"id": 1002739, "claim": "Pfizer and biontech to submit emergency use authorization request today to the u.s. fda for covid-19 vaccine", "label": "SUPPORTED", "evidence": ["We look forward to the upcoming Vaccines and Related Biological Products Advisory Committee discussion and continue to work closely with the FDA and regulatory authorities worldwide to secure authorization of our vaccine candidate as quickly as possible. Filing for Emergency Use Authorization in the U.S. is a critical step in making our vaccine candidate available to the global population as quickly as possible, said Ugur Sahin, M.D., CEO and Co-founder of BioNTech.", "These forward-looking statements may include, but may not be limited to, statements concerning: BioNTechs efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our Phase 2/3 trial and/or in commercial use based on data observations to date; the expected timepoint for additional readouts on efficacy data of BNT162b2 in our Phase 2/3 trial; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; the timing for submission of manufacturing data to the FDA; our contemplated shipping and storage plan, including our estimated product shelflife at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021.", "From the start of the research program earlier this year, Pfizer and BioNTech have successfully supplied and distributed their investigational vaccine to more than 150 clinical trial sites across the U.S., as well as Europe, Latin America, and South Africa.", "This release contains forward-looking information about Pfizers efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine, the BNT162 mRNA vaccine program and modRNA candidate BNT162b2 (including qualitative assessments of available data, potential benefits, expectations for clinical trials, the submission of a request for Emergency Use Authorization and other regulatory submissions, the anticipated timing of regulatory submissions, regulatory approval or authorization and anticipated manufacturing, distribution and supply), that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements."]}
{"id": 1002740, "claim": "Pfizer and biontech to avoid emergency use authorization request today to the u.s. fda for covid-19 vaccine", "label": "REFUTED", "evidence": ["We look forward to the upcoming Vaccines and Related Biological Products Advisory Committee discussion and continue to work closely with the FDA and regulatory authorities worldwide to secure authorization of our vaccine candidate as quickly as possible. Filing for Emergency Use Authorization in the U.S. is a critical step in making our vaccine candidate available to the global population as quickly as possible, said Ugur Sahin, M.D., CEO and Co-founder of BioNTech.", "These forward-looking statements may include, but may not be limited to, statements concerning: BioNTechs efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our Phase 2/3 trial and/or in commercial use based on data observations to date; the expected timepoint for additional readouts on efficacy data of BNT162b2 in our Phase 2/3 trial; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; the timing for submission of manufacturing data to the FDA; our contemplated shipping and storage plan, including our estimated product shelflife at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021.", "From the start of the research program earlier this year, Pfizer and BioNTech have successfully supplied and distributed their investigational vaccine to more than 150 clinical trial sites across the U.S., as well as Europe, Latin America, and South Africa.", "This release contains forward-looking information about Pfizers efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine, the BNT162 mRNA vaccine program and modRNA candidate BNT162b2 (including qualitative assessments of available data, potential benefits, expectations for clinical trials, the submission of a request for Emergency Use Authorization and other regulatory submissions, the anticipated timing of regulatory submissions, regulatory approval or authorization and anticipated manufacturing, distribution and supply), that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements."]}
{"id": 1002741, "claim": "Ema recommends first covid-19 vaccine for authorisation in the eu.", "label": "SUPPORTED", "evidence": ["The Task Force is helping EU Member States and the European Commission to take quick and coordinated regulatory action on the development, authorisation and safety monitoring of treatments and vaccines intended for the treatment and prevention of COVID-19.", "First COVID-19 vaccine authorised for use in the European Union News & events", "EMAs scientific opinion paves the way for the first marketing authorisation of a COVID-19 vaccine in the EU by the European Commission, with all the safeguards, controls and obligations this entails.", "Links EMA recommendation: https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu Facts about COVID-19 vaccines on European Vaccination Information Portal: https://vaccination-info.eu/en/covid-19/covid-19-vaccines Announcement on market authorisation by the European Commission: Safe COVID-19 vaccines for Europeans"]}
{"id": 1002742, "claim": "Ema recommends no covid-19 vaccine for authorisation in the eu.", "label": "REFUTED", "evidence": ["The Task Force is helping EU Member States and the European Commission to take quick and coordinated regulatory action on the development, authorisation and safety monitoring of treatments and vaccines intended for the treatment and prevention of COVID-19.", "First COVID-19 vaccine authorised for use in the European Union News & events", "EMAs scientific opinion paves the way for the first marketing authorisation of a COVID-19 vaccine in the EU by the European Commission, with all the safeguards, controls and obligations this entails.", "Links EMA recommendation: https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu Facts about COVID-19 vaccines on European Vaccination Information Portal: https://vaccination-info.eu/en/covid-19/covid-19-vaccines Announcement on market authorisation by the European Commission: Safe COVID-19 vaccines for Europeans"]}
{"id": 1002743, "claim": "Ema recommends another covid-19 vaccine for authorisation in the eu.", "label": "REFUTED", "evidence": ["The Task Force is helping EU Member States and the European Commission to take quick and coordinated regulatory action on the development, authorisation and safety monitoring of treatments and vaccines intended for the treatment and prevention of COVID-19.", "First COVID-19 vaccine authorised for use in the European Union News & events", "EMAs scientific opinion paves the way for the first marketing authorisation of a COVID-19 vaccine in the EU by the European Commission, with all the safeguards, controls and obligations this entails.", "Links EMA recommendation: https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu Facts about COVID-19 vaccines on European Vaccination Information Portal: https://vaccination-info.eu/en/covid-19/covid-19-vaccines Announcement on market authorisation by the European Commission: Safe COVID-19 vaccines for Europeans"]}
{"id": 1002744, "claim": "Covid deaths at highest level since april as 100,000 americans are hospitalized", "label": "SUPPORTED", "evidence": ["An updated summary of todays key events: More than 100,000 Americans are now hospitalized with Covid-19, the highest number yet during the pandemic, and nearly double the number during earlier waves of the pandemic in April and July.", "This is the highest number yet recorded, and nearly twice as many people as were hospitalized at the peak of earlier coronavirus waves in April and July."]}
{"id": 1002745, "claim": "Covid deaths at highest level since 2001 as 100,000 americans are hospitalized", "label": "REFUTED", "evidence": ["An updated summary of todays key events: More than 100,000 Americans are now hospitalized with Covid-19, the highest number yet during the pandemic, and nearly double the number during earlier waves of the pandemic in April and July.", "This is the highest number yet recorded, and nearly twice as many people as were hospitalized at the peak of earlier coronavirus waves in April and July."]}
{"id": 1002746, "claim": "Covid deaths at highest level since 2009 as 100,000 americans are hospitalized", "label": "REFUTED", "evidence": ["An updated summary of todays key events: More than 100,000 Americans are now hospitalized with Covid-19, the highest number yet during the pandemic, and nearly double the number during earlier waves of the pandemic in April and July.", "This is the highest number yet recorded, and nearly twice as many people as were hospitalized at the peak of earlier coronavirus waves in April and July."]}
{"id": 1002747, "claim": "Covid children at highest level since april as 100,000 americans are hospitalized", "label": "REFUTED", "evidence": ["An updated summary of todays key events: More than 100,000 Americans are now hospitalized with Covid-19, the highest number yet during the pandemic, and nearly double the number during earlier waves of the pandemic in April and July.", "This is the highest number yet recorded, and nearly twice as many people as were hospitalized at the peak of earlier coronavirus waves in April and July."]}
{"id": 1002748, "claim": "Exploratory analysis of immunization records highlights decreased sars-cov-2 rates in individuals with recent non-covid-19 vaccinations", "label": "SUPPORTED", "evidence": ["Furthermore, age, race/ethnicity, and blood group stratified analyses reveal significantly lower SARS-CoV-2 rate among black individuals who have taken the PCV13 vaccine, with relative risk of 0.45 at the 5 year time horizon (n: 653, 95% CI: (0.32, 0.64), p-value: 6.9e-05).", "We find that polio, Hemophilus influenzae type-B (HIB), measles-mumps-rubella (MMR), varicella, pneumococcal conjugate (PCV13), geriatric flu, and hepatitis A / hepatitis B (HepA-HepB) vaccines administered in the past 1, 2, and 5 years are associated with decreased SARS-CoV-2 infection rates, even after adjusting for geographic SARS-CoV-2 incidence and testing rates, demographics, comorbidities, and number of other vaccinations.", "These findings suggest that additional pre-clinical and clinical studies are warranted to assess the protective effects of existing non-COVID-19 vaccines and explore underlying immunologic mechanisms."]}
{"id": 1002749, "claim": "Exploratory analysis of immunization records highlights increased sars-cov-2 rates in individuals with recent non-covid-19 vaccinations", "label": "REFUTED", "evidence": ["Furthermore, age, race/ethnicity, and blood group stratified analyses reveal significantly lower SARS-CoV-2 rate among black individuals who have taken the PCV13 vaccine, with relative risk of 0.45 at the 5 year time horizon (n: 653, 95% CI: (0.32, 0.64), p-value: 6.9e-05).", "We find that polio, Hemophilus influenzae type-B (HIB), measles-mumps-rubella (MMR), varicella, pneumococcal conjugate (PCV13), geriatric flu, and hepatitis A / hepatitis B (HepA-HepB) vaccines administered in the past 1, 2, and 5 years are associated with decreased SARS-CoV-2 infection rates, even after adjusting for geographic SARS-CoV-2 incidence and testing rates, demographics, comorbidities, and number of other vaccinations.", "These findings suggest that additional pre-clinical and clinical studies are warranted to assess the protective effects of existing non-COVID-19 vaccines and explore underlying immunologic mechanisms."]}
{"id": 1002750, "claim": "Exploratory analysis of immunization records highlights increasing sars-cov-2 rates in individuals with recent non-covid-19 vaccinations", "label": "REFUTED", "evidence": ["Furthermore, age, race/ethnicity, and blood group stratified analyses reveal significantly lower SARS-CoV-2 rate among black individuals who have taken the PCV13 vaccine, with relative risk of 0.45 at the 5 year time horizon (n: 653, 95% CI: (0.32, 0.64), p-value: 6.9e-05).", "We find that polio, Hemophilus influenzae type-B (HIB), measles-mumps-rubella (MMR), varicella, pneumococcal conjugate (PCV13), geriatric flu, and hepatitis A / hepatitis B (HepA-HepB) vaccines administered in the past 1, 2, and 5 years are associated with decreased SARS-CoV-2 infection rates, even after adjusting for geographic SARS-CoV-2 incidence and testing rates, demographics, comorbidities, and number of other vaccinations.", "These findings suggest that additional pre-clinical and clinical studies are warranted to assess the protective effects of existing non-COVID-19 vaccines and explore underlying immunologic mechanisms."]}
{"id": 1002751, "claim": "Exploratory analysis of immunization records highlights higher sars-cov-2 rates in individuals with recent non-covid-19 vaccinations", "label": "REFUTED", "evidence": ["Furthermore, age, race/ethnicity, and blood group stratified analyses reveal significantly lower SARS-CoV-2 rate among black individuals who have taken the PCV13 vaccine, with relative risk of 0.45 at the 5 year time horizon (n: 653, 95% CI: (0.32, 0.64), p-value: 6.9e-05).", "We find that polio, Hemophilus influenzae type-B (HIB), measles-mumps-rubella (MMR), varicella, pneumococcal conjugate (PCV13), geriatric flu, and hepatitis A / hepatitis B (HepA-HepB) vaccines administered in the past 1, 2, and 5 years are associated with decreased SARS-CoV-2 infection rates, even after adjusting for geographic SARS-CoV-2 incidence and testing rates, demographics, comorbidities, and number of other vaccinations.", "These findings suggest that additional pre-clinical and clinical studies are warranted to assess the protective effects of existing non-COVID-19 vaccines and explore underlying immunologic mechanisms."]}
{"id": 1002752, "claim": "Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ace2 , the receptor of 2019-ncov", "label": "SUPPORTED", "evidence": ["However, we observed significantly higher ACE2 gene expression in former smokers lung compared to non-smokers lung.", "In addition, we found that ACE2 gene is expressed in specific cell types related to smoking history and location.", "In bronchial epithelium, ACE2 is actively expressed in goblet cells of current smokers and club cells of non-smokers."]}
{"id": 1002753, "claim": "Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ace2, the receptor of hla-ncov", "label": "REFUTED", "evidence": ["However, we observed significantly higher ACE2 gene expression in former smokers lung compared to non-smokers lung.", "In addition, we found that ACE2 gene is expressed in specific cell types related to smoking history and location.", "In bronchial epithelium, ACE2 is actively expressed in goblet cells of current smokers and club cells of non-smokers."]}
{"id": 1002754, "claim": "Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ace2, the receptor of lps-ncov", "label": "REFUTED", "evidence": ["However, we observed significantly higher ACE2 gene expression in former smokers lung compared to non-smokers lung.", "In addition, we found that ACE2 gene is expressed in specific cell types related to smoking history and location.", "In bronchial epithelium, ACE2 is actively expressed in goblet cells of current smokers and club cells of non-smokers."]}
{"id": 1002755, "claim": "Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ace2, the receptor of mhc-ncov", "label": "REFUTED", "evidence": ["However, we observed significantly higher ACE2 gene expression in former smokers lung compared to non-smokers lung.", "In addition, we found that ACE2 gene is expressed in specific cell types related to smoking history and location.", "In bronchial epithelium, ACE2 is actively expressed in goblet cells of current smokers and club cells of non-smokers."]}
{"id": 1002756, "claim": "Confronting the notion that face masks reduce covid 'dose '", "label": "SUPPORTED", "evidence": ["\"Certainly, masks could probably block larger droplets, and that kind of gets into the area of the whole droplet-versus-aerosols debate,\" she said.", "\"They are putting people at risk by suggesting that that 'it'll be fine, you'll wear your face covering, and you'll get a low dose,'\" she said."]}
{"id": 1002757, "claim": "supported the notion that face masks reduce covid 'dose '", "label": "REFUTED", "evidence": ["\"Certainly, masks could probably block larger droplets, and that kind of gets into the area of the whole droplet-versus-aerosols debate,\" she said.", "\"They are putting people at risk by suggesting that that 'it'll be fine, you'll wear your face covering, and you'll get a low dose,'\" she said."]}
{"id": 1002758, "claim": "supports the notion that face masks reduce covid 'dose '", "label": "REFUTED", "evidence": ["\"Certainly, masks could probably block larger droplets, and that kind of gets into the area of the whole droplet-versus-aerosols debate,\" she said.", "\"They are putting people at risk by suggesting that that 'it'll be fine, you'll wear your face covering, and you'll get a low dose,'\" she said."]}
{"id": 1002759, "claim": "Confronting the notion that face masks reduce covid 'not '", "label": "REFUTED", "evidence": ["\"Certainly, masks could probably block larger droplets, and that kind of gets into the area of the whole droplet-versus-aerosols debate,\" she said.", "\"They are putting people at risk by suggesting that that 'it'll be fine, you'll wear your face covering, and you'll get a low dose,'\" she said."]}
{"id": 1002760, "claim": "Impaired cellular immunity to sars-cov-2 in severe covid-19 patients", "label": "SUPPORTED", "evidence": ["However, compared to healthy controls, the percentages and absolute numbers of both NK cells and CD8+ T cells were significantly reduced, accompanied with decreased IFNg expression in CD4+ T cells in peripheral blood from severe patients.", "Our work thus indicates that COVID-19 patients with severe symptoms are associated with defective cellular immunity, which not only provides insights on understanding the pathogenesis of COVID-19, but also has implications in developing an effective vaccine to SARS-CoV-2.", "Currently, though convalescent individuals have been shown with both cellular and humoral immune responses, there is very limited understanding on the immune responses, especially adaptive immune responses, in patients with severe COVID-19.", "Most notably, we failed in detecting SARS-CoV-2-specific IFNg production by peripheral blood lymphocytes from these patients."]}
{"id": 1002761, "claim": "promotes cellular immunity to sars-cov-2 in severe covid-19 patients", "label": "REFUTED", "evidence": ["However, compared to healthy controls, the percentages and absolute numbers of both NK cells and CD8+ T cells were significantly reduced, accompanied with decreased IFNg expression in CD4+ T cells in peripheral blood from severe patients.", "Our work thus indicates that COVID-19 patients with severe symptoms are associated with defective cellular immunity, which not only provides insights on understanding the pathogenesis of COVID-19, but also has implications in developing an effective vaccine to SARS-CoV-2.", "Currently, though convalescent individuals have been shown with both cellular and humoral immune responses, there is very limited understanding on the immune responses, especially adaptive immune responses, in patients with severe COVID-19.", "Most notably, we failed in detecting SARS-CoV-2-specific IFNg production by peripheral blood lymphocytes from these patients."]}
{"id": 1002762, "claim": "enhances cellular immunity to sars-cov-2 in severe covid-19 patients", "label": "REFUTED", "evidence": ["However, compared to healthy controls, the percentages and absolute numbers of both NK cells and CD8+ T cells were significantly reduced, accompanied with decreased IFNg expression in CD4+ T cells in peripheral blood from severe patients.", "Our work thus indicates that COVID-19 patients with severe symptoms are associated with defective cellular immunity, which not only provides insights on understanding the pathogenesis of COVID-19, but also has implications in developing an effective vaccine to SARS-CoV-2.", "Currently, though convalescent individuals have been shown with both cellular and humoral immune responses, there is very limited understanding on the immune responses, especially adaptive immune responses, in patients with severe COVID-19.", "Most notably, we failed in detecting SARS-CoV-2-specific IFNg production by peripheral blood lymphocytes from these patients."]}
{"id": 1002763, "claim": "Increased cellular immunity to sars-cov-2 in severe covid-19 patients", "label": "REFUTED", "evidence": ["However, compared to healthy controls, the percentages and absolute numbers of both NK cells and CD8+ T cells were significantly reduced, accompanied with decreased IFNg expression in CD4+ T cells in peripheral blood from severe patients.", "Our work thus indicates that COVID-19 patients with severe symptoms are associated with defective cellular immunity, which not only provides insights on understanding the pathogenesis of COVID-19, but also has implications in developing an effective vaccine to SARS-CoV-2.", "Currently, though convalescent individuals have been shown with both cellular and humoral immune responses, there is very limited understanding on the immune responses, especially adaptive immune responses, in patients with severe COVID-19.", "Most notably, we failed in detecting SARS-CoV-2-specific IFNg production by peripheral blood lymphocytes from these patients."]}
{"id": 1002764, "claim": "Platelets promote thromboinflammation in sars-cov-2 pneumonia", "label": "SUPPORTED", "evidence": ["Representative blood smear from patients with severe acute respiratory syndrome coronavirus 2 pneumonia showing platelet anisopoichilocytosis (AD), platelet satellitism (EH), and platelet engulfment by lymphocytes (F).", "Platelets and immune responses during thromboinflammation."]}
{"id": 1002765, "claim": "Platelets reduce thromboinflammation in sars-cov-2 pneumonia", "label": "REFUTED", "evidence": ["Representative blood smear from patients with severe acute respiratory syndrome coronavirus 2 pneumonia showing platelet anisopoichilocytosis (AD), platelet satellitism (EH), and platelet engulfment by lymphocytes (F).", "Platelets and immune responses during thromboinflammation."]}
{"id": 1002766, "claim": "Use of convalescent serum reduces severity of covid-19 in nonhuman primates", "label": "SUPPORTED", "evidence": ["However, and importantly, lower levels of SARS-CoV-2 in respiratory compartments, reduced gross and histopathological lesion severity in the lungs, and reductions in several parameters associated with coagulation and inflammatory processes were observed in monkeys that received convalescent sera versus untreated controls.", "Groups of SARS- CoV-2-infected animals were treated with pooled convalescent sera containing either high or low to moderate anti-SARS-CoV-2 neutralizing antibody titers."]}
{"id": 1002767, "claim": "Use of convalescent serum increased severity of covid-19 in nonhuman primates", "label": "REFUTED", "evidence": ["However, and importantly, lower levels of SARS-CoV-2 in respiratory compartments, reduced gross and histopathological lesion severity in the lungs, and reductions in several parameters associated with coagulation and inflammatory processes were observed in monkeys that received convalescent sera versus untreated controls.", "Groups of SARS- CoV-2-infected animals were treated with pooled convalescent sera containing either high or low to moderate anti-SARS-CoV-2 neutralizing antibody titers."]}
{"id": 1002768, "claim": "Loss of convalescent serum reduces severity of covid-19 in nonhuman primates", "label": "REFUTED", "evidence": ["However, and importantly, lower levels of SARS-CoV-2 in respiratory compartments, reduced gross and histopathological lesion severity in the lungs, and reductions in several parameters associated with coagulation and inflammatory processes were observed in monkeys that received convalescent sera versus untreated controls.", "Groups of SARS- CoV-2-infected animals were treated with pooled convalescent sera containing either high or low to moderate anti-SARS-CoV-2 neutralizing antibody titers."]}
{"id": 1002769, "claim": "Use of convalescent serum demonstrated severity of covid-19 in nonhuman primates", "label": "REFUTED", "evidence": ["However, and importantly, lower levels of SARS-CoV-2 in respiratory compartments, reduced gross and histopathological lesion severity in the lungs, and reductions in several parameters associated with coagulation and inflammatory processes were observed in monkeys that received convalescent sera versus untreated controls.", "Groups of SARS- CoV-2-infected animals were treated with pooled convalescent sera containing either high or low to moderate anti-SARS-CoV-2 neutralizing antibody titers."]}
{"id": 1002770, "claim": "Sequential infection with influenza a virus followed by severe acute respiratory syndrome coronavirus 2 leads to more severe disease and encephalitis in a mouse model of covid-19 .", "label": "SUPPORTED", "evidence": ["You are going to email the following Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19 Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website."]}
{"id": 1002771, "claim": "Sequential infection with influenza a virus followed by severe acute respiratory syndrome coronavirus 2 leads to more severe disease and encephalitis in a human model of covid-19.", "label": "REFUTED", "evidence": ["You are going to email the following Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19 Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website."]}
{"id": 1002772, "claim": "Sequential infection with influenza a virus followed by severe acute respiratory syndrome coronavirus 2 leads to more severe disease and encephalitis in a rat model of covid-19.", "label": "REFUTED", "evidence": ["You are going to email the following Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19 Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website."]}
{"id": 1002773, "claim": "Type iii interferons disrupt the lung epithelial barrier upon viral recognition", "label": "SUPPORTED", "evidence": ["3 IFN-λ signaling directly inhibits lung epithelia proliferation and impairs repair upon viral recognition.", "A. Wack , Type I and III interferons disrupt lung epithelial repair during recovery from viral infection.", "A. Ploss , Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo."]}
{"id": 1002774, "claim": "Type 1 interferons disrupt the lung epithelial barrier upon viral recognition", "label": "REFUTED", "evidence": ["3 IFN-λ signaling directly inhibits lung epithelia proliferation and impairs repair upon viral recognition.", "A. Wack , Type I and III interferons disrupt lung epithelial repair during recovery from viral infection.", "A. Ploss , Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo."]}
{"id": 1002775, "claim": "Type ifn interferons disrupt the lung epithelial barrier upon viral recognition", "label": "REFUTED", "evidence": ["3 IFN-λ signaling directly inhibits lung epithelia proliferation and impairs repair upon viral recognition.", "A. Wack , Type I and III interferons disrupt lung epithelial repair during recovery from viral infection.", "A. Ploss , Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo."]}
{"id": 1002776, "claim": "Type i interferons disrupt the lung epithelial barrier upon viral recognition", "label": "REFUTED", "evidence": ["3 IFN-λ signaling directly inhibits lung epithelia proliferation and impairs repair upon viral recognition.", "A. Wack , Type I and III interferons disrupt lung epithelial repair during recovery from viral infection.", "A. Ploss , Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo."]}
{"id": 1002777, "claim": "Covid-19 makes b cells forget , but t cells remember", "label": "SUPPORTED", "evidence": ["Most asymptomatic COVID-19 cases showed strong T cell responses even if only 60% of these individuals were seropositive for SARS-CoV-2.", "Two studies in this issue of Cell collectively suggest that, although SARS-CoV-2 infection may blunt long-lived antibody responses, immune memory might still be achieved through virus-specific memory T cells."]}
{"id": 1002778, "claim": "Covid-19 makes b cells do, but t cells remember", "label": "REFUTED", "evidence": ["Most asymptomatic COVID-19 cases showed strong T cell responses even if only 60% of these individuals were seropositive for SARS-CoV-2.", "Two studies in this issue of Cell collectively suggest that, although SARS-CoV-2 infection may blunt long-lived antibody responses, immune memory might still be achieved through virus-specific memory T cells."]}
{"id": 1002779, "claim": "Covid-19 makes b cells in, but t cells remember", "label": "REFUTED", "evidence": ["Most asymptomatic COVID-19 cases showed strong T cell responses even if only 60% of these individuals were seropositive for SARS-CoV-2.", "Two studies in this issue of Cell collectively suggest that, although SARS-CoV-2 infection may blunt long-lived antibody responses, immune memory might still be achieved through virus-specific memory T cells."]}
{"id": 1002780, "claim": "Covid-19 makes b cells only, but t cells remember", "label": "REFUTED", "evidence": ["Most asymptomatic COVID-19 cases showed strong T cell responses even if only 60% of these individuals were seropositive for SARS-CoV-2.", "Two studies in this issue of Cell collectively suggest that, although SARS-CoV-2 infection may blunt long-lived antibody responses, immune memory might still be achieved through virus-specific memory T cells."]}
{"id": 1002781, "claim": "A national mask mandate could save the u.s. economy $ 1 trillion , goldman sachs says", "label": "SUPPORTED", "evidence": ["Reducing the spread of the virus through mask-wearing, the analysts found, could be a substitute for strict lockdown measures that would otherwise shave 5%or $1 trillionoff the U.S. GDP."]}
{"id": 1002782, "claim": "A national mask mandate could decrease the u.s. economy $ 1 trillion, goldman sachs says", "label": "REFUTED", "evidence": ["Reducing the spread of the virus through mask-wearing, the analysts found, could be a substitute for strict lockdown measures that would otherwise shave 5%or $1 trillionoff the U.S. GDP."]}
{"id": 1002783, "claim": "A national mask mandate could reduce the u.s. economy $ 1 trillion, goldman sachs says", "label": "REFUTED", "evidence": ["Reducing the spread of the virus through mask-wearing, the analysts found, could be a substitute for strict lockdown measures that would otherwise shave 5%or $1 trillionoff the U.S. GDP."]}
{"id": 1002784, "claim": "Sars-cov-2 spike protein co-opts vegf-a/neuropilin-1 receptor signaling to induce analgesia", "label": "SUPPORTED", "evidence": ["Discussion Our data show that SARS-CoV-2 Spike protein subverts VEGF-A/NRP-1 pro- nociceptive signaling."]}
{"id": 1002785, "claim": "Sars-cov-2 spike protein co-opts vegf-a/neuropilin-1 receptor failed to induce analgesia", "label": "REFUTED", "evidence": ["Discussion Our data show that SARS-CoV-2 Spike protein subverts VEGF-A/NRP-1 pro- nociceptive signaling."]}
{"id": 1002786, "claim": "Harvard university professor and two chinese nationals charged in three separate china related cases", "label": "SUPPORTED", "evidence": ["These talent programs seek to lure Chinese overseas talent and foreign experts to bring their knowledge and experience to China and reward individuals for stealing proprietary information.", "In November 2018, NIH inquired of Harvard whether Lieber had failed to disclose his then-suspected relationship with WUT and Chinas Thousand Talents Plan.", "Lieber caused Harvard to falsely tell NIH that Lieber had no formal association with WUT after 2012, that WUT continued to falsely exaggerate his involvement with WUT in subsequent years, and that Lieber is not and has never been a participant in Chinas Thousand Talents Plan.", "During the interview, it is alleged that Ye falsely claimed that she had minimal contact with two NUDT professors who were high-ranking PLA officers."]}
{"id": 1002787, "claim": "Harvard university professor and four chinese nationals charged in three separate china related cases", "label": "REFUTED", "evidence": ["These talent programs seek to lure Chinese overseas talent and foreign experts to bring their knowledge and experience to China and reward individuals for stealing proprietary information.", "In November 2018, NIH inquired of Harvard whether Lieber had failed to disclose his then-suspected relationship with WUT and Chinas Thousand Talents Plan.", "Lieber caused Harvard to falsely tell NIH that Lieber had no formal association with WUT after 2012, that WUT continued to falsely exaggerate his involvement with WUT in subsequent years, and that Lieber is not and has never been a participant in Chinas Thousand Talents Plan.", "During the interview, it is alleged that Ye falsely claimed that she had minimal contact with two NUDT professors who were high-ranking PLA officers."]}
{"id": 1002788, "claim": "Harvard university professor and five chinese nationals charged in three separate china related cases", "label": "REFUTED", "evidence": ["These talent programs seek to lure Chinese overseas talent and foreign experts to bring their knowledge and experience to China and reward individuals for stealing proprietary information.", "In November 2018, NIH inquired of Harvard whether Lieber had failed to disclose his then-suspected relationship with WUT and Chinas Thousand Talents Plan.", "Lieber caused Harvard to falsely tell NIH that Lieber had no formal association with WUT after 2012, that WUT continued to falsely exaggerate his involvement with WUT in subsequent years, and that Lieber is not and has never been a participant in Chinas Thousand Talents Plan.", "During the interview, it is alleged that Ye falsely claimed that she had minimal contact with two NUDT professors who were high-ranking PLA officers."]}
{"id": 1002789, "claim": "Harvard university professor and three chinese nationals charged in three separate china related cases", "label": "REFUTED", "evidence": ["These talent programs seek to lure Chinese overseas talent and foreign experts to bring their knowledge and experience to China and reward individuals for stealing proprietary information.", "In November 2018, NIH inquired of Harvard whether Lieber had failed to disclose his then-suspected relationship with WUT and Chinas Thousand Talents Plan.", "Lieber caused Harvard to falsely tell NIH that Lieber had no formal association with WUT after 2012, that WUT continued to falsely exaggerate his involvement with WUT in subsequent years, and that Lieber is not and has never been a participant in Chinas Thousand Talents Plan.", "During the interview, it is alleged that Ye falsely claimed that she had minimal contact with two NUDT professors who were high-ranking PLA officers."]}
{"id": 1002790, "claim": "Relief therapeutics and neurorx meet 165 patient enrollment target in phase 2b/3 trial of rlf-100 for critical covid-19 with respiratory failure", "label": "SUPPORTED", "evidence": ["RLF-100 is being investigated in two placebo-controlled US Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19.", "While the companies have focused first on those patients who have no medical alternative and are at immediate risk of death, a phase 2b/3 trial with RLF-100 for inhaled use in patients with moderate and severe COVID-19 in order to prevent progression to respiratory failure is expected to start soon."]}
{"id": 1002791, "claim": "Sars-cov-2 desensitizes host cells to interferon through inhibition of the jak-stat pathway", "label": "SUPPORTED", "evidence": ["We performed systematic analyses of the JAK- STAT pathway in a broad range of cellular systems, including immortalized cell lines and primary-like cardiomyocytes, and found that several pathway components were targeted by SARS-CoV-2 leading to cellular desensitization to interferon.", "Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.", "This revealed universal inhibition of interferon signaling across cell types following SARS-CoV-2 infection."]}
{"id": 1002792, "claim": "Sars-cov-2 desensitizes tumor cells to interferon through inhibition of the jak-stat pathway", "label": "REFUTED", "evidence": ["We performed systematic analyses of the JAK- STAT pathway in a broad range of cellular systems, including immortalized cell lines and primary-like cardiomyocytes, and found that several pathway components were targeted by SARS-CoV-2 leading to cellular desensitization to interferon.", "Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.", "This revealed universal inhibition of interferon signaling across cell types following SARS-CoV-2 infection."]}
{"id": 1002793, "claim": "Sars-cov-2 desensitizes immune cells to interferon through inhibition of the jak-stat pathway", "label": "REFUTED", "evidence": ["We performed systematic analyses of the JAK- STAT pathway in a broad range of cellular systems, including immortalized cell lines and primary-like cardiomyocytes, and found that several pathway components were targeted by SARS-CoV-2 leading to cellular desensitization to interferon.", "Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.", "This revealed universal inhibition of interferon signaling across cell types following SARS-CoV-2 infection."]}
{"id": 1002794, "claim": "More than 137,000 people in uk receive first dose of covid vaccine in one week", "label": "SUPPORTED", "evidence": ["Published 16 December 2020 From: Department of Health and Social Care More than 137,000 people in the UK have received the first dose of the Pfizer/BioNTech COVID-19 vaccine in the first week of the largest vaccination programme in British history.", "Health and Social Care Secretary Matt Hancock said: > Thanks to the hard work of the NHS across the UK, over 137,000 people have > already received the first dose of the coronavirus vaccine."]}
{"id": 1002795, "claim": "More than 137,000 animals in uk receive first dose of covid vaccine in one week", "label": "REFUTED", "evidence": ["Published 16 December 2020 From: Department of Health and Social Care More than 137,000 people in the UK have received the first dose of the Pfizer/BioNTech COVID-19 vaccine in the first week of the largest vaccination programme in British history.", "Health and Social Care Secretary Matt Hancock said: > Thanks to the hard work of the NHS across the UK, over 137,000 people have > already received the first dose of the coronavirus vaccine."]}
{"id": 1002796, "claim": "More than 137,000 mice in uk receive first dose of covid vaccine in one week", "label": "REFUTED", "evidence": ["Published 16 December 2020 From: Department of Health and Social Care More than 137,000 people in the UK have received the first dose of the Pfizer/BioNTech COVID-19 vaccine in the first week of the largest vaccination programme in British history.", "Health and Social Care Secretary Matt Hancock said: > Thanks to the hard work of the NHS across the UK, over 137,000 people have > already received the first dose of the coronavirus vaccine."]}
{"id": 1002797, "claim": "More than 137,000 calves in uk receive first dose of covid vaccine in one week", "label": "REFUTED", "evidence": ["Published 16 December 2020 From: Department of Health and Social Care More than 137,000 people in the UK have received the first dose of the Pfizer/BioNTech COVID-19 vaccine in the first week of the largest vaccination programme in British history.", "Health and Social Care Secretary Matt Hancock said: > Thanks to the hard work of the NHS across the UK, over 137,000 people have > already received the first dose of the coronavirus vaccine."]}
{"id": 1002798, "claim": "Heat shock protein 70 is related to thermal inhibition of nuclear export of the influenza virus ribonucleoprotein complex .", "label": "SUPPORTED", "evidence": ["(2004) Heat shock protein 70 protects cells from cell cycle arrest and apoptosis induced by human immunodeficiency virus type 1 viral protein R. J Virol 78: 96979704.", "Hsp70 inhibits influenza virus polymerase activity in a dose- dependent manner.", "Heat shock protein 70 (Hsp70) mediates Zika virus entry, replication, and egress from host cells."]}
{"id": 1002799, "claim": "Heat shock protein 70 is resistant to thermal inhibition of nuclear export of the influenza virus ribonucleoprotein complex.", "label": "REFUTED", "evidence": ["(2004) Heat shock protein 70 protects cells from cell cycle arrest and apoptosis induced by human immunodeficiency virus type 1 viral protein R. J Virol 78: 96979704.", "Hsp70 inhibits influenza virus polymerase activity in a dose- dependent manner.", "Heat shock protein 70 (Hsp70) mediates Zika virus entry, replication, and egress from host cells."]}
{"id": 1002800, "claim": "Microsoft bing launches interactive covid-19 map to provide pandemic.", "label": "REFUTED", "evidence": ["(2004) Heat shock protein 70 protects cells from cell cycle arrest and apoptosis induced by human immunodeficiency virus type 1 viral protein R. J Virol 78: 96979704.", "Hsp70 inhibits influenza virus polymerase activity in a dose- dependent manner.", "Heat shock protein 70 (Hsp70) mediates Zika virus entry, replication, and egress from host cells."]}
{"id": 1002801, "claim": "Imbalanced host response to sars-cov-2 drives development of covid-19", "label": "SUPPORTED", "evidence": ["Cell and animal models of SARS-CoV-2 infection, in addition to transcriptional and serum profiling of COVID-19 patients, consistently revealed a unique and inappropriate inflammatory response.", "We propose that reduced innate antiviral defenses coupled with exuberant inflammatory cytokine production are the defining and driving features of COVID-19."]}
{"id": 1002802, "claim": "Imbalanced host response to sars-cov-2 prevents development of covid-19", "label": "REFUTED", "evidence": ["Cell and animal models of SARS-CoV-2 infection, in addition to transcriptional and serum profiling of COVID-19 patients, consistently revealed a unique and inappropriate inflammatory response.", "We propose that reduced innate antiviral defenses coupled with exuberant inflammatory cytokine production are the defining and driving features of COVID-19."]}
{"id": 1002803, "claim": "Imbalanced antiviral response to sars-cov-2 drives development of covid-19", "label": "REFUTED", "evidence": ["Cell and animal models of SARS-CoV-2 infection, in addition to transcriptional and serum profiling of COVID-19 patients, consistently revealed a unique and inappropriate inflammatory response.", "We propose that reduced innate antiviral defenses coupled with exuberant inflammatory cytokine production are the defining and driving features of COVID-19."]}
{"id": 1002804, "claim": "Brilacidin , a covid-19 drug candidate , exhibits potent in vitro antiviral activity against sars-cov-2", "label": "SUPPORTED", "evidence": ["Collectively, our data demonstrate that brilacidin exerts potent inhibition of SARS-CoV-2 and thus supports brilacidin as a promising COVID-19 drug candidate.", "We demonstrate that brilacidin, a synthetic small molecule with peptide-like properties, is capable of exerting potent in vitro antiviral activity against SARS-CoV-2, both as a standalone treatment and in combination with remdesivir, which is currently the only FDA-approved drug for the treatment of COVID-19.", "Brilacidin and remdesivir exhibit excellent synergistic activity against SARS-CoV-2."]}
{"id": 1002805, "claim": "Brilacidin, a covid-19 drug candidate, exhibits no in vitro antiviral activity against sars-cov-2", "label": "REFUTED", "evidence": ["Collectively, our data demonstrate that brilacidin exerts potent inhibition of SARS-CoV-2 and thus supports brilacidin as a promising COVID-19 drug candidate.", "We demonstrate that brilacidin, a synthetic small molecule with peptide-like properties, is capable of exerting potent in vitro antiviral activity against SARS-CoV-2, both as a standalone treatment and in combination with remdesivir, which is currently the only FDA-approved drug for the treatment of COVID-19.", "Brilacidin and remdesivir exhibit excellent synergistic activity against SARS-CoV-2."]}
{"id": 1002806, "claim": "Ct provides best diagnosis for covid-19", "label": "SUPPORTED", "evidence": ["The sensitivity of chest CT in suggesting COVID-19 was 97%, based on positive RT-PCR results.", "Compared to RT-PCR, chest CT imaging may be a more reliable, practical and rapid method to diagnose and assess COVID-19, especially in the epidemic area,\" the authors wrote.", "The researchers concluded that CT should be used as the primary screening tool for COVID-19.", "Recent research found that the sensitivity of CT for COVID-19 infection was 98% compared to RT-PCR sensitivity of 71%."]}
{"id": 1002807, "claim": "Ct provides best support for covid-19", "label": "REFUTED", "evidence": ["The sensitivity of chest CT in suggesting COVID-19 was 97%, based on positive RT-PCR results.", "Compared to RT-PCR, chest CT imaging may be a more reliable, practical and rapid method to diagnose and assess COVID-19, especially in the epidemic area,\" the authors wrote.", "The researchers concluded that CT should be used as the primary screening tool for COVID-19.", "Recent research found that the sensitivity of CT for COVID-19 infection was 98% compared to RT-PCR sensitivity of 71%."]}
{"id": 1002808, "claim": "Ct provides best agreement for covid-19", "label": "REFUTED", "evidence": ["The sensitivity of chest CT in suggesting COVID-19 was 97%, based on positive RT-PCR results.", "Compared to RT-PCR, chest CT imaging may be a more reliable, practical and rapid method to diagnose and assess COVID-19, especially in the epidemic area,\" the authors wrote.", "The researchers concluded that CT should be used as the primary screening tool for COVID-19.", "Recent research found that the sensitivity of CT for COVID-19 infection was 98% compared to RT-PCR sensitivity of 71%."]}
{"id": 1002809, "claim": "Ct provides best model for covid-19", "label": "REFUTED", "evidence": ["The sensitivity of chest CT in suggesting COVID-19 was 97%, based on positive RT-PCR results.", "Compared to RT-PCR, chest CT imaging may be a more reliable, practical and rapid method to diagnose and assess COVID-19, especially in the epidemic area,\" the authors wrote.", "The researchers concluded that CT should be used as the primary screening tool for COVID-19.", "Recent research found that the sensitivity of CT for COVID-19 infection was 98% compared to RT-PCR sensitivity of 71%."]}
{"id": 1002810, "claim": "Rlf-100 clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells", "label": "SUPPORTED", "evidence": ["NeuroRx and Relief Therapeutics have found that RLF-100 (aviptadil) led to rapid recovery from respiratory failure in critically ill patients with Covid-19.", "RLF-100 (aviptadil) shows rapid recovery from respiratory failure in critically ill Covid-19 patients.", "Article by Don Ward Hackett References: RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication FDA grants Expanded Access Protocol to RLF-100 (Aviptadil) for Respiratory Failure in COVID-19 Fact checked by Robert Carlson, MD Fact checked by Danielle Reiter, RN \\+ 1 Relevant Links: CDC Vaccination Schedules Vaccine Price List Vaccines for Children Report Vaccine Side Effects Sponsored Links: Discounts Appointments Clinical Trials Lab Tests "]}
{"id": 1002811, "claim": "Rlf-4 clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells", "label": "REFUTED", "evidence": ["NeuroRx and Relief Therapeutics have found that RLF-100 (aviptadil) led to rapid recovery from respiratory failure in critically ill patients with Covid-19.", "RLF-100 (aviptadil) shows rapid recovery from respiratory failure in critically ill Covid-19 patients.", "Article by Don Ward Hackett References: RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication FDA grants Expanded Access Protocol to RLF-100 (Aviptadil) for Respiratory Failure in COVID-19 Fact checked by Robert Carlson, MD Fact checked by Danielle Reiter, RN \\+ 1 Relevant Links: CDC Vaccination Schedules Vaccine Price List Vaccines for Children Report Vaccine Side Effects Sponsored Links: Discounts Appointments Clinical Trials Lab Tests "]}
{"id": 1002812, "claim": "Rlf-3 clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells", "label": "REFUTED", "evidence": ["NeuroRx and Relief Therapeutics have found that RLF-100 (aviptadil) led to rapid recovery from respiratory failure in critically ill patients with Covid-19.", "RLF-100 (aviptadil) shows rapid recovery from respiratory failure in critically ill Covid-19 patients.", "Article by Don Ward Hackett References: RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication FDA grants Expanded Access Protocol to RLF-100 (Aviptadil) for Respiratory Failure in COVID-19 Fact checked by Robert Carlson, MD Fact checked by Danielle Reiter, RN \\+ 1 Relevant Links: CDC Vaccination Schedules Vaccine Price List Vaccines for Children Report Vaccine Side Effects Sponsored Links: Discounts Appointments Clinical Trials Lab Tests "]}
{"id": 1002813, "claim": "Rlf-7 clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells", "label": "REFUTED", "evidence": ["NeuroRx and Relief Therapeutics have found that RLF-100 (aviptadil) led to rapid recovery from respiratory failure in critically ill patients with Covid-19.", "RLF-100 (aviptadil) shows rapid recovery from respiratory failure in critically ill Covid-19 patients.", "Article by Don Ward Hackett References: RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication FDA grants Expanded Access Protocol to RLF-100 (Aviptadil) for Respiratory Failure in COVID-19 Fact checked by Robert Carlson, MD Fact checked by Danielle Reiter, RN \\+ 1 Relevant Links: CDC Vaccination Schedules Vaccine Price List Vaccines for Children Report Vaccine Side Effects Sponsored Links: Discounts Appointments Clinical Trials Lab Tests "]}
{"id": 1002814, "claim": "Rfid microchips will not be injected with the covid-19 vaccine , altered video features bill and melinda gates.", "label": "SUPPORTED", "evidence": ["He also explains that the microchip is purely optional, however, and the U.S. government hasnt even decided if theyre going to use it. Steve Hofman, a spokesman of Apiject confirmed to Reuters via phone that this optional microchip will not be injected into the individual who receives the vaccine.", "COVID-19 vaccine syringes could contain RFID microchips on labels, but they wouldnt be injected into the individual that receives the vaccine."]}
{"id": 1002815, "claim": "Rfid microchips will only be injected with the covid-19 vaccine, altered video features bill and melinda gates.", "label": "REFUTED", "evidence": ["He also explains that the microchip is purely optional, however, and the U.S. government hasnt even decided if theyre going to use it. Steve Hofman, a spokesman of Apiject confirmed to Reuters via phone that this optional microchip will not be injected into the individual who receives the vaccine.", "COVID-19 vaccine syringes could contain RFID microchips on labels, but they wouldnt be injected into the individual that receives the vaccine."]}
{"id": 1002816, "claim": "Rfid microchips will also be injected with the covid-19 vaccine, altered video features bill and melinda gates.", "label": "REFUTED", "evidence": ["He also explains that the microchip is purely optional, however, and the U.S. government hasnt even decided if theyre going to use it. Steve Hofman, a spokesman of Apiject confirmed to Reuters via phone that this optional microchip will not be injected into the individual who receives the vaccine.", "COVID-19 vaccine syringes could contain RFID microchips on labels, but they wouldnt be injected into the individual that receives the vaccine."]}
{"id": 1002817, "claim": "Rfid microchips will then be injected with the covid-19 vaccine, altered video features bill and melinda gates.", "label": "REFUTED", "evidence": ["He also explains that the microchip is purely optional, however, and the U.S. government hasnt even decided if theyre going to use it. Steve Hofman, a spokesman of Apiject confirmed to Reuters via phone that this optional microchip will not be injected into the individual who receives the vaccine.", "COVID-19 vaccine syringes could contain RFID microchips on labels, but they wouldnt be injected into the individual that receives the vaccine."]}
{"id": 1002818, "claim": "New zealand eliminates covid-19", "label": "SUPPORTED", "evidence": ["At the time of publication, New Zealand had recorded fewer than 1500 confirmed cases of COVID-19, and 20 deaths.", "New Zealand recorded its first day of no new cases of coronavirus disease 2019 (COVID-19) early this week, more than a month after its strict lockdown began.", "Michael Baker, professor at the University of Otago's department of public health in Wellington, who has been advising the New Zealand Government on its response, said implementing a full lockdowninvolving the closure of schools and non-essential workplaces, a ban on social gatherings, and severe travel restrictionsenabled the country to consider elimination."]}
{"id": 1002819, "claim": "New zealandems covid-19", "label": "REFUTED", "evidence": ["At the time of publication, New Zealand had recorded fewer than 1500 confirmed cases of COVID-19, and 20 deaths.", "New Zealand recorded its first day of no new cases of coronavirus disease 2019 (COVID-19) early this week, more than a month after its strict lockdown began.", "Michael Baker, professor at the University of Otago's department of public health in Wellington, who has been advising the New Zealand Government on its response, said implementing a full lockdowninvolving the closure of schools and non-essential workplaces, a ban on social gatherings, and severe travel restrictionsenabled the country to consider elimination."]}
{"id": 1002820, "claim": "It zealand eliminates covid-19", "label": "REFUTED", "evidence": ["At the time of publication, New Zealand had recorded fewer than 1500 confirmed cases of COVID-19, and 20 deaths.", "New Zealand recorded its first day of no new cases of coronavirus disease 2019 (COVID-19) early this week, more than a month after its strict lockdown began.", "Michael Baker, professor at the University of Otago's department of public health in Wellington, who has been advising the New Zealand Government on its response, said implementing a full lockdowninvolving the closure of schools and non-essential workplaces, a ban on social gatherings, and severe travel restrictionsenabled the country to consider elimination."]}
{"id": 1002821, "claim": "Thus zealand eliminates covid-19", "label": "REFUTED", "evidence": ["At the time of publication, New Zealand had recorded fewer than 1500 confirmed cases of COVID-19, and 20 deaths.", "New Zealand recorded its first day of no new cases of coronavirus disease 2019 (COVID-19) early this week, more than a month after its strict lockdown began.", "Michael Baker, professor at the University of Otago's department of public health in Wellington, who has been advising the New Zealand Government on its response, said implementing a full lockdowninvolving the closure of schools and non-essential workplaces, a ban on social gatherings, and severe travel restrictionsenabled the country to consider elimination."]}
{"id": 1002822, "claim": "Erythrocytes reveal complement activation in patients with covid-19", "label": "SUPPORTED", "evidence": ["These findings suggest that novel erythrocyte- based diagnostics provide a method to identify patients with dysregulated complement activation.", "Here we report the presence of complement activation products on circulating erythrocytes from hospitalized COVID-19 patients using flow cytometry."]}
{"id": 1002823, "claim": "Erythrocytes suppress complement activation in patients with covid-19", "label": "REFUTED", "evidence": ["These findings suggest that novel erythrocyte- based diagnostics provide a method to identify patients with dysregulated complement activation.", "Here we report the presence of complement activation products on circulating erythrocytes from hospitalized COVID-19 patients using flow cytometry."]}
{"id": 1002824, "claim": "Erythrocytes inhibit complement activation in patients with covid-19", "label": "REFUTED", "evidence": ["These findings suggest that novel erythrocyte- based diagnostics provide a method to identify patients with dysregulated complement activation.", "Here we report the presence of complement activation products on circulating erythrocytes from hospitalized COVID-19 patients using flow cytometry."]}
{"id": 1002825, "claim": "The missing link in coronavirus jump from bats to humans could be pangolins , not snakes", "label": "SUPPORTED", "evidence": ["Now, a study refutes both ideas and suggests that scaly, anteater-like animals called pangolins are the missing link for SARS-CoV-2 transmission between bats and humans.", "A new study by University of Michigan researchers refutes both ideas and suggests that Malayan pangolins ( Manis javanica ) are the missing link for SARS- CoV-2 transmission between bats and humans.", "View all partners Email Twitter Facebook LinkedIn WhatsApp Messenger Pangolins, not snakes, may be the missing link for transmission of the new coronavirus from bats to humans."]}
{"id": 1002826, "claim": "The missing link in coronavirus jump from bats to humans could be pangolins, 2 snakes", "label": "REFUTED", "evidence": ["Now, a study refutes both ideas and suggests that scaly, anteater-like animals called pangolins are the missing link for SARS-CoV-2 transmission between bats and humans.", "A new study by University of Michigan researchers refutes both ideas and suggests that Malayan pangolins ( Manis javanica ) are the missing link for SARS- CoV-2 transmission between bats and humans.", "View all partners Email Twitter Facebook LinkedIn WhatsApp Messenger Pangolins, not snakes, may be the missing link for transmission of the new coronavirus from bats to humans."]}
{"id": 1002827, "claim": "The missing link in coronavirus jump from bats to humans could be pangolins, 20 snakes", "label": "REFUTED", "evidence": ["Now, a study refutes both ideas and suggests that scaly, anteater-like animals called pangolins are the missing link for SARS-CoV-2 transmission between bats and humans.", "A new study by University of Michigan researchers refutes both ideas and suggests that Malayan pangolins ( Manis javanica ) are the missing link for SARS- CoV-2 transmission between bats and humans.", "View all partners Email Twitter Facebook LinkedIn WhatsApp Messenger Pangolins, not snakes, may be the missing link for transmission of the new coronavirus from bats to humans."]}
{"id": 1002828, "claim": "The missing link in coronavirus jump from bats to humans could be pangolins, earlier snakes", "label": "REFUTED", "evidence": ["Now, a study refutes both ideas and suggests that scaly, anteater-like animals called pangolins are the missing link for SARS-CoV-2 transmission between bats and humans.", "A new study by University of Michigan researchers refutes both ideas and suggests that Malayan pangolins ( Manis javanica ) are the missing link for SARS- CoV-2 transmission between bats and humans.", "View all partners Email Twitter Facebook LinkedIn WhatsApp Messenger Pangolins, not snakes, may be the missing link for transmission of the new coronavirus from bats to humans."]}
{"id": 1002829, "claim": "Sleep after vaccination boosts immunological memory.", "label": "SUPPORTED", "evidence": ["Stronger responses could be elicited consistently from existing vaccines by simply using sleep to make them more effective.", "This research could pave the way for new vaccination strategies, in which patients are immunized at particular times of day, and when they can be sure of getting a good nights sleep.", "Sleep enhances the human antibody response to hepatitis A vaccination.", "The sleep-induced promotion of Th cell proliferation and the shift of the Th1/Th2 balance towards Th1 cytokines during early SWS-rich sleep likely represent further components of the immuno-enhancing influence of sleep after vaccination.", "Thus, sleep after vaccination can enhance the subsequent adaptive immune response like an adjuvant (see below)."]}
{"id": 1002830, "claim": "Time after vaccination boosts immunological memory.", "label": "REFUTED", "evidence": ["Stronger responses could be elicited consistently from existing vaccines by simply using sleep to make them more effective.", "This research could pave the way for new vaccination strategies, in which patients are immunized at particular times of day, and when they can be sure of getting a good nights sleep.", "Sleep enhances the human antibody response to hepatitis A vaccination.", "The sleep-induced promotion of Th cell proliferation and the shift of the Th1/Th2 balance towards Th1 cytokines during early SWS-rich sleep likely represent further components of the immuno-enhancing influence of sleep after vaccination.", "Thus, sleep after vaccination can enhance the subsequent adaptive immune response like an adjuvant (see below)."]}
{"id": 1002831, "claim": "Sterilizing immunity against sars-cov-2 in hamsters conferred by a novel recombinant subunit vaccine.", "label": "SUPPORTED", "evidence": ["Sterilizing immunity against SARS-CoV-2 in hamsters conferred by a novel recombinant subun", "Vaccine-induced neutralizing and cell-based receptor-blocking antibody titers correlated well with protective efficacy in hamsters, suggesting vaccine- elicited protection is immune-associated.", "This article has been published \"Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine.\"", "More importantly, the StriFK-FH002C immunization conferred sterilizing immunity to prevent SARS- CoV-2 infection and transmission, which also protected animals from virus- induced weight loss, COVID-19-like symptoms, and pneumonia in hamsters."]}
{"id": 1002832, "claim": "Sterilizing immunity against sars-cov-2 in hamsters conferred by a single recombinant subunit vaccine.", "label": "REFUTED", "evidence": ["Sterilizing immunity against SARS-CoV-2 in hamsters conferred by a novel recombinant subun", "Vaccine-induced neutralizing and cell-based receptor-blocking antibody titers correlated well with protective efficacy in hamsters, suggesting vaccine- elicited protection is immune-associated.", "This article has been published \"Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine.\"", "More importantly, the StriFK-FH002C immunization conferred sterilizing immunity to prevent SARS- CoV-2 infection and transmission, which also protected animals from virus- induced weight loss, COVID-19-like symptoms, and pneumonia in hamsters."]}
{"id": 1002833, "claim": "Johnson & johnson announces its first phase 3 covid-19 vaccine trial ensemble is fully enrolled.", "label": "SUPPORTED", "evidence": ["111 The large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) of the investigational Janssen COVID-19 single-dose vaccine candidate is now fully enrolled with approximately 45,000 participants.", "Phase 3 Trial (ensemble) of Investigational Janssen Covid-19 Single-dose Vaccine Candidate is Fully Enrolled With About 45,000 Participants.", "Learn More Our Company Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssens COVID-19 Vaccine Candidate Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssens COVID-19 Vaccine Candidate First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssens COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S NEW BRUNSWICK, N.J., September 23, 2020  Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi- country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies."]}
{"id": 1002834, "claim": "Johnson & johnson announces its final phase 3 covid-19 vaccine trial ensemble is fully enrolled.", "label": "REFUTED", "evidence": ["111 The large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) of the investigational Janssen COVID-19 single-dose vaccine candidate is now fully enrolled with approximately 45,000 participants.", "Phase 3 Trial (ensemble) of Investigational Janssen Covid-19 Single-dose Vaccine Candidate is Fully Enrolled With About 45,000 Participants.", "Learn More Our Company Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssens COVID-19 Vaccine Candidate Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssens COVID-19 Vaccine Candidate First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssens COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S NEW BRUNSWICK, N.J., September 23, 2020  Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi- country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies."]}
{"id": 1002835, "claim": "Johnson & johnson announces its last phase 3 covid-19 vaccine trial ensemble is fully enrolled.", "label": "REFUTED", "evidence": ["111 The large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) of the investigational Janssen COVID-19 single-dose vaccine candidate is now fully enrolled with approximately 45,000 participants.", "Phase 3 Trial (ensemble) of Investigational Janssen Covid-19 Single-dose Vaccine Candidate is Fully Enrolled With About 45,000 Participants.", "Learn More Our Company Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssens COVID-19 Vaccine Candidate Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssens COVID-19 Vaccine Candidate First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssens COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S NEW BRUNSWICK, N.J., September 23, 2020  Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi- country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies."]}
{"id": 1002836, "claim": "Johnson & johnson announces its second phase 3 covid-19 vaccine trial ensemble is fully enrolled.", "label": "REFUTED", "evidence": ["111 The large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) of the investigational Janssen COVID-19 single-dose vaccine candidate is now fully enrolled with approximately 45,000 participants.", "Phase 3 Trial (ensemble) of Investigational Janssen Covid-19 Single-dose Vaccine Candidate is Fully Enrolled With About 45,000 Participants.", "Learn More Our Company Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssens COVID-19 Vaccine Candidate Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssens COVID-19 Vaccine Candidate First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssens COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S NEW BRUNSWICK, N.J., September 23, 2020  Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi- country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies."]}
{"id": 1002837, "claim": "Covid-19 is transmitted through aerosols .", "label": "SUPPORTED", "evidence": ["Fomites and droplets have dominated our everyday understanding of COVID-19 transmission.", "The second possibility for how COVID-19 spreads is through droplets, small bits of saliva or respiratory fluid that infected individuals expel when they cough, sneeze, or talk."]}
{"id": 1002838, "claim": "Covid-19 is transmitted through torsols.", "label": "REFUTED", "evidence": ["Fomites and droplets have dominated our everyday understanding of COVID-19 transmission.", "The second possibility for how COVID-19 spreads is through droplets, small bits of saliva or respiratory fluid that infected individuals expel when they cough, sneeze, or talk."]}
{"id": 1002839, "claim": "Covid-19 is transmitted through mansols.", "label": "REFUTED", "evidence": ["Fomites and droplets have dominated our everyday understanding of COVID-19 transmission.", "The second possibility for how COVID-19 spreads is through droplets, small bits of saliva or respiratory fluid that infected individuals expel when they cough, sneeze, or talk."]}
{"id": 1002840, "claim": "Covid-19 is transmitted through arsols.", "label": "REFUTED", "evidence": ["Fomites and droplets have dominated our everyday understanding of COVID-19 transmission.", "The second possibility for how COVID-19 spreads is through droplets, small bits of saliva or respiratory fluid that infected individuals expel when they cough, sneeze, or talk."]}
{"id": 1002841, "claim": "Covid19 is a seasonal climate-driven disease across both hemispheres.", "label": "SUPPORTED", "evidence": ["Seasonality of Respiratory Viral Infections: Will COVID-19 Follow Suit?", "The problem of co-linearity in climate factors has challenged the search for environmental drivers of influenza in the past, and very similar issues now apply to COVID-19.", "Temperature, Humidity and Latitude Analysis to Predict Potential Spread and Seasonality for COVID-19."]}
{"id": 1002842, "claim": "Covid19 is a global climate-driven disease across both hemispheres.", "label": "REFUTED", "evidence": ["Seasonality of Respiratory Viral Infections: Will COVID-19 Follow Suit?", "The problem of co-linearity in climate factors has challenged the search for environmental drivers of influenza in the past, and very similar issues now apply to COVID-19.", "Temperature, Humidity and Latitude Analysis to Predict Potential Spread and Seasonality for COVID-19."]}
{"id": 1002843, "claim": "Covid19 is a major climate-driven disease across both hemispheres.", "label": "REFUTED", "evidence": ["Seasonality of Respiratory Viral Infections: Will COVID-19 Follow Suit?", "The problem of co-linearity in climate factors has challenged the search for environmental drivers of influenza in the past, and very similar issues now apply to COVID-19.", "Temperature, Humidity and Latitude Analysis to Predict Potential Spread and Seasonality for COVID-19."]}
{"id": 1002844, "claim": "Covid19 is a common climate-driven disease across both hemispheres.", "label": "REFUTED", "evidence": ["Seasonality of Respiratory Viral Infections: Will COVID-19 Follow Suit?", "The problem of co-linearity in climate factors has challenged the search for environmental drivers of influenza in the past, and very similar issues now apply to COVID-19.", "Temperature, Humidity and Latitude Analysis to Predict Potential Spread and Seasonality for COVID-19."]}
{"id": 1002845, "claim": "Ruxolitinib rapidly reduces acute respiratory distress syndrome in covid-19 disease .", "label": "SUPPORTED", "evidence": ["Ruxolitinib can be a therapeutic option for patients with respiratory insufficiency in COVID-19 related ARDS.", "Despite the limited number of patients collected, the results obtained are encouraging and indicate ruxolitinib as a potential therapeutic option for patients with severe COVID-19 related respiratory insufficiency.", "Based on these considerations, we hypothesized that immune- modulation with ruxolitinib might have been beneficial in reducing severity of ARDS in the context of COVID-19."]}
{"id": 1002846, "claim": "Ruxolitinib rapidly causes acute respiratory distress syndrome in covid-19 disease.", "label": "REFUTED", "evidence": ["Ruxolitinib can be a therapeutic option for patients with respiratory insufficiency in COVID-19 related ARDS.", "Despite the limited number of patients collected, the results obtained are encouraging and indicate ruxolitinib as a potential therapeutic option for patients with severe COVID-19 related respiratory insufficiency.", "Based on these considerations, we hypothesized that immune- modulation with ruxolitinib might have been beneficial in reducing severity of ARDS in the context of COVID-19."]}
{"id": 1002847, "claim": "Ruxolitinib rapidly cause acute respiratory distress syndrome in covid-19 disease.", "label": "REFUTED", "evidence": ["Ruxolitinib can be a therapeutic option for patients with respiratory insufficiency in COVID-19 related ARDS.", "Despite the limited number of patients collected, the results obtained are encouraging and indicate ruxolitinib as a potential therapeutic option for patients with severe COVID-19 related respiratory insufficiency.", "Based on these considerations, we hypothesized that immune- modulation with ruxolitinib might have been beneficial in reducing severity of ARDS in the context of COVID-19."]}
{"id": 1002848, "claim": "Ruxolitinib rapidly activates acute respiratory distress syndrome in covid-19 disease.", "label": "REFUTED", "evidence": ["Ruxolitinib can be a therapeutic option for patients with respiratory insufficiency in COVID-19 related ARDS.", "Despite the limited number of patients collected, the results obtained are encouraging and indicate ruxolitinib as a potential therapeutic option for patients with severe COVID-19 related respiratory insufficiency.", "Based on these considerations, we hypothesized that immune- modulation with ruxolitinib might have been beneficial in reducing severity of ARDS in the context of COVID-19."]}
{"id": 1002849, "claim": "First clinical use of lenzilumab to neutralize gm-csf in patients with severe and critical covid-19 pneumonia", "label": "SUPPORTED", "evidence": ["Methods Hospitalized patients with COVID-19 pneumonia and risk factors for poor outcomes were treated with lenzilumab 600 mg intravenously for three doses through an emergency single-use IND application.", "Conclusions In high-risk COVID-19 patients with severe and critical pneumonia, GM-CSF neutralization with lenzilumab was safe and associated with improved clinical outcomes, oxygen requirement, and cytokine storm.", "With this rationale, we used lenzilumab, an anti-human GM-CSF monoclonal antibody, to treat patients with severe and critical COVID-19 pneumonia.", "Lenzilumab was supplied by Humanigen, Inc. for the compassionate use treatment of COVID-19 subjects by investigators at the Mayo Clinics."]}
{"id": 1002850, "claim": "First clinical use of lenzilumab to neutralize gm-csf in patients without severe and critical covid-19 pneumonia", "label": "REFUTED", "evidence": ["Methods Hospitalized patients with COVID-19 pneumonia and risk factors for poor outcomes were treated with lenzilumab 600 mg intravenously for three doses through an emergency single-use IND application.", "Conclusions In high-risk COVID-19 patients with severe and critical pneumonia, GM-CSF neutralization with lenzilumab was safe and associated with improved clinical outcomes, oxygen requirement, and cytokine storm.", "With this rationale, we used lenzilumab, an anti-human GM-CSF monoclonal antibody, to treat patients with severe and critical COVID-19 pneumonia.", "Lenzilumab was supplied by Humanigen, Inc. for the compassionate use treatment of COVID-19 subjects by investigators at the Mayo Clinics."]}
{"id": 1002851, "claim": "Preprint finds increase in sars-related terms on chinese social media two weeks before first known covid19 case", "label": "SUPPORTED", "evidence": ["One such tool, the Global Public Health Intelligence Network (GPHIN), identified the SARS outbreak in China in 2003 more than two months earlier.", "View this figure The Baidu Index results for \"Feidian,\" \"SARS,\" \"pneumonia,\" and \"coronavirus\" rose rapidly on December 30, 2019, the day before the outbreak announcement.", "The WeChat Index hits for \"coronavirus\" rose the day before the outbreak was announced, with a peak on the day of the announcement, followed by another peak after the novel coronavirus was officially announced as the causative pathogen of the outbreak by China CDC (Figure 1)."]}
{"id": 1002852, "claim": "Preprint finds differences in sars-related terms on chinese social media two weeks before first known covid19 case", "label": "REFUTED", "evidence": ["One such tool, the Global Public Health Intelligence Network (GPHIN), identified the SARS outbreak in China in 2003 more than two months earlier.", "View this figure The Baidu Index results for \"Feidian,\" \"SARS,\" \"pneumonia,\" and \"coronavirus\" rose rapidly on December 30, 2019, the day before the outbreak announcement.", "The WeChat Index hits for \"coronavirus\" rose the day before the outbreak was announced, with a peak on the day of the announcement, followed by another peak after the novel coronavirus was officially announced as the causative pathogen of the outbreak by China CDC (Figure 1)."]}
{"id": 1002853, "claim": "Preprint finds increase in sars-related terms on chinese social media four weeks before first known covid19 case", "label": "REFUTED", "evidence": ["One such tool, the Global Public Health Intelligence Network (GPHIN), identified the SARS outbreak in China in 2003 more than two months earlier.", "View this figure The Baidu Index results for \"Feidian,\" \"SARS,\" \"pneumonia,\" and \"coronavirus\" rose rapidly on December 30, 2019, the day before the outbreak announcement.", "The WeChat Index hits for \"coronavirus\" rose the day before the outbreak was announced, with a peak on the day of the announcement, followed by another peak after the novel coronavirus was officially announced as the causative pathogen of the outbreak by China CDC (Figure 1)."]}
{"id": 1002854, "claim": "Preprint finds increase in sars-related terms on chinese social media 12 weeks before first known covid19 case", "label": "REFUTED", "evidence": ["One such tool, the Global Public Health Intelligence Network (GPHIN), identified the SARS outbreak in China in 2003 more than two months earlier.", "View this figure The Baidu Index results for \"Feidian,\" \"SARS,\" \"pneumonia,\" and \"coronavirus\" rose rapidly on December 30, 2019, the day before the outbreak announcement.", "The WeChat Index hits for \"coronavirus\" rose the day before the outbreak was announced, with a peak on the day of the announcement, followed by another peak after the novel coronavirus was officially announced as the causative pathogen of the outbreak by China CDC (Figure 1)."]}
{"id": 1002855, "claim": "Cepi establishes global network of laboratories to centralise assessment of covid-19 vaccine candidates", "label": "SUPPORTED", "evidence": ["Additionally, CEPI is developing a worldwide network of drug product manufacturers that may be available for COVAX supported COVID-19 vaccine manufacture.", "The network will use the same testing reagentsoriginating in the labs of Nexelis and PHEand follow common protocols to measure the immunogenicity of multiple COVID-19 vaccine candidates (both CEPI-funded and non-CEPI funded developers).", "Data obtained on the immunogenicity of CEPI-funded vaccine candidates will be used to inform and advance CEPIs COVID-19 vaccine portfolio by providing quick and accurate evaluation of its candidate vaccines."]}
{"id": 1002856, "claim": "Cepi establishes global network of data to centralise assessment of covid-19 vaccine candidates", "label": "REFUTED", "evidence": ["Additionally, CEPI is developing a worldwide network of drug product manufacturers that may be available for COVAX supported COVID-19 vaccine manufacture.", "The network will use the same testing reagentsoriginating in the labs of Nexelis and PHEand follow common protocols to measure the immunogenicity of multiple COVID-19 vaccine candidates (both CEPI-funded and non-CEPI funded developers).", "Data obtained on the immunogenicity of CEPI-funded vaccine candidates will be used to inform and advance CEPIs COVID-19 vaccine portfolio by providing quick and accurate evaluation of its candidate vaccines."]}
{"id": 1002857, "claim": "Professional and home-made face masks reduce exposure to respiratory infections among the general population", "label": "SUPPORTED", "evidence": ["Face- masks worn by the general population could be an accessible and affordable intervention, if effective when worn under routine circumstances.", "Conclusions/significance: Any type of general mask use is likely to decrease viral exposure and infection risk on a population level, in spite of imperfect fit and imperfect adherence, personal respirators providing most protection."]}
{"id": 1002858, "claim": "Professional and home-made face masks show exposure to respiratory infections among the general population", "label": "REFUTED", "evidence": ["Face- masks worn by the general population could be an accessible and affordable intervention, if effective when worn under routine circumstances.", "Conclusions/significance: Any type of general mask use is likely to decrease viral exposure and infection risk on a population level, in spite of imperfect fit and imperfect adherence, personal respirators providing most protection."]}
{"id": 1002859, "claim": "Professional and home-made face masks have exposure to respiratory infections among the general population", "label": "REFUTED", "evidence": ["Face- masks worn by the general population could be an accessible and affordable intervention, if effective when worn under routine circumstances.", "Conclusions/significance: Any type of general mask use is likely to decrease viral exposure and infection risk on a population level, in spite of imperfect fit and imperfect adherence, personal respirators providing most protection."]}
{"id": 1002860, "claim": "Gi symptoms may be common in patients with covid-19", "label": "SUPPORTED", "evidence": ["Digestive symptoms are common among patients with COVID-19.", "However, people with COVID-19 have reported many other symptoms, including digestive ones.", "Another noteworthy finding is that there may be prognostic implications associated with GI symptoms."]}
{"id": 1002861, "claim": "Gi symptoms cannot be common in patients with covid-19", "label": "REFUTED", "evidence": ["Digestive symptoms are common among patients with COVID-19.", "However, people with COVID-19 have reported many other symptoms, including digestive ones.", "Another noteworthy finding is that there may be prognostic implications associated with GI symptoms."]}
{"id": 1002862, "claim": "Cholesterol 25-hydroxylase suppresses sars-cov-2 replication by blocking membrane fusion", "label": "SUPPORTED", "evidence": ["25HC inhibits endosomal cholesterol export to block SARS-CoV-2 fusion.", "Collectively, our data support a model that 25HC suppresses SARS-CoV-2 S protein-mediated fusion, which inhibits virus replication, possibly by altering cholesterol levels."]}
{"id": 1002863, "claim": "Cholesterol 25-hydroxylase suppresses sars-cov-2 replication by promoting membrane fusion", "label": "REFUTED", "evidence": ["25HC inhibits endosomal cholesterol export to block SARS-CoV-2 fusion.", "Collectively, our data support a model that 25HC suppresses SARS-CoV-2 S protein-mediated fusion, which inhibits virus replication, possibly by altering cholesterol levels."]}
{"id": 1002864, "claim": "Cholesterol 25-hydroxylase suppresses sars-cov-2 replication by inducing membrane fusion", "label": "REFUTED", "evidence": ["25HC inhibits endosomal cholesterol export to block SARS-CoV-2 fusion.", "Collectively, our data support a model that 25HC suppresses SARS-CoV-2 S protein-mediated fusion, which inhibits virus replication, possibly by altering cholesterol levels."]}
{"id": 1002865, "claim": "Cholesterol 25-hydroxylase suppresses sars-cov-2 degradation by blocking membrane fusion", "label": "REFUTED", "evidence": ["25HC inhibits endosomal cholesterol export to block SARS-CoV-2 fusion.", "Collectively, our data support a model that 25HC suppresses SARS-CoV-2 S protein-mediated fusion, which inhibits virus replication, possibly by altering cholesterol levels."]}
{"id": 1002866, "claim": "High prevalence of sars-cov-2 antibodies in care homes affected by covid-19 ; a prospective cohort study in england", "label": "SUPPORTED", "evidence": ["More than two-thirds of residents and staff members had detectable antibodies against SARS-CoV-2 irrespective of their nasal swab RT-PCR positivity or symptoms status.", "Methods: Residents and staff had a convalescent blood sample for SARS-CoV-2 antibody levels and neutralising antibodies by SARS-COV-2 RT-PCR five weeks after the primary COVID-19 outbreak investigation.", "Conclusions: RT-PCR testing for SARS- CoV-2 significantly underestimates the true extent of an outbreak in institutional settings."]}
{"id": 1002867, "claim": "Low prevalence of sars-cov-2 antibodies in care homes affected by covid-19 ; a prospective cohort study in england", "label": "REFUTED", "evidence": ["More than two-thirds of residents and staff members had detectable antibodies against SARS-CoV-2 irrespective of their nasal swab RT-PCR positivity or symptoms status.", "Methods: Residents and staff had a convalescent blood sample for SARS-CoV-2 antibody levels and neutralising antibodies by SARS-COV-2 RT-PCR five weeks after the primary COVID-19 outbreak investigation.", "Conclusions: RT-PCR testing for SARS- CoV-2 significantly underestimates the true extent of an outbreak in institutional settings."]}
{"id": 1002868, "claim": "Engineering human ace2 to optimize binding to the spike protein of sars coronavirus 2", "label": "SUPPORTED", "evidence": ["The selection of ACE2 variants for high binding signal therefore reports not only on affinity, but also on presentation at the membrane of folded structure recognized by SARS-CoV-2 S. Whether these mutations selectively stabilize a virus-recognized local structure in ACE2 versus the global protein fold is unclear."]}
{"id": 1002869, "claim": "Engineering human tmprss2 to optimize binding to the spike protein of sars coronavirus 2", "label": "REFUTED", "evidence": ["The selection of ACE2 variants for high binding signal therefore reports not only on affinity, but also on presentation at the membrane of folded structure recognized by SARS-CoV-2 S. Whether these mutations selectively stabilize a virus-recognized local structure in ACE2 versus the global protein fold is unclear."]}
{"id": 1002870, "claim": "Engineering human dpp2 to optimize binding to the spike protein of sars coronavirus 2", "label": "REFUTED", "evidence": ["The selection of ACE2 variants for high binding signal therefore reports not only on affinity, but also on presentation at the membrane of folded structure recognized by SARS-CoV-2 S. Whether these mutations selectively stabilize a virus-recognized local structure in ACE2 versus the global protein fold is unclear."]}
{"id": 1002871, "claim": "Engineering human s2 to optimize binding to the spike protein of sars coronavirus 2", "label": "REFUTED", "evidence": ["The selection of ACE2 variants for high binding signal therefore reports not only on affinity, but also on presentation at the membrane of folded structure recognized by SARS-CoV-2 S. Whether these mutations selectively stabilize a virus-recognized local structure in ACE2 versus the global protein fold is unclear."]}
{"id": 1002872, "claim": "Significantly decreased mortality in a large cohort of coronavirus disease 2019 patients transfused early with convalescent plasma containing high-titer antisevere acute respiratory syndrome coronavirus 2 spike protein igg", "label": "SUPPORTED", "evidence": ["Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality."]}
{"id": 1002873, "claim": "Sars-cov-2 spike protein predicted to form complexes with host receptor protein orthologues from a broad range of mammals", "label": "SUPPORTED", "evidence": ["Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.", "Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates."]}
{"id": 1002874, "claim": "Sars-cov-2 spike protein predicted to form complexes with multiple receptor protein orthologues from a broad range of mammals", "label": "REFUTED", "evidence": ["Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.", "Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates."]}
{"id": 1002875, "claim": "Sars-cov-2 spike protein predicted to form complexes with different receptor protein orthologues from a broad range of mammals", "label": "REFUTED", "evidence": ["Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.", "Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates."]}
{"id": 1002876, "claim": "An engineered stable mini-protein to plug sars-cov2 spikes", "label": "SUPPORTED", "evidence": ["Therefore, molecular entities able to interfere with binding of the SARS-CoV-2 Spike protein to ACE2 have a great potential to inhibit viral entry.", "Starting from the available structural data on the interaction between SARS-CoV-2 Spike protein and the host ACE2 receptor, we here engineered a mini-protein with the aim of creating a soluble and stable Spike interactor.", "By plugging the Spike protein, our mini-protein constitutes a valid tool for the development of treatments against different types of coronavirus.", "This mini-protein, which was recombinantly produced in high yields, possesses a stable α helical conformation and is able to interact with the RBD of glycosylated Spike protein from SARS-CoV-2 with nanomolar affinity, as measured by microscale thermophoresis.", "Like other coronaviruses, this novel virus relies on the surface Spike glycoprotein to access the host cells, mainly through the interaction of its Receptor Binding Domain (RBD) with the human angiotensin- converting enzyme 2 (ACE2)."]}
{"id": 1002877, "claim": "An engineered stable mini-dna to plug sars-cov2 spikes", "label": "REFUTED", "evidence": ["Therefore, molecular entities able to interfere with binding of the SARS-CoV-2 Spike protein to ACE2 have a great potential to inhibit viral entry.", "Starting from the available structural data on the interaction between SARS-CoV-2 Spike protein and the host ACE2 receptor, we here engineered a mini-protein with the aim of creating a soluble and stable Spike interactor.", "By plugging the Spike protein, our mini-protein constitutes a valid tool for the development of treatments against different types of coronavirus.", "This mini-protein, which was recombinantly produced in high yields, possesses a stable α helical conformation and is able to interact with the RBD of glycosylated Spike protein from SARS-CoV-2 with nanomolar affinity, as measured by microscale thermophoresis.", "Like other coronaviruses, this novel virus relies on the surface Spike glycoprotein to access the host cells, mainly through the interaction of its Receptor Binding Domain (RBD) with the human angiotensin- converting enzyme 2 (ACE2)."]}
{"id": 1002878, "claim": "An engineered stable mini-cell to plug sars-cov2 spikes", "label": "REFUTED", "evidence": ["Therefore, molecular entities able to interfere with binding of the SARS-CoV-2 Spike protein to ACE2 have a great potential to inhibit viral entry.", "Starting from the available structural data on the interaction between SARS-CoV-2 Spike protein and the host ACE2 receptor, we here engineered a mini-protein with the aim of creating a soluble and stable Spike interactor.", "By plugging the Spike protein, our mini-protein constitutes a valid tool for the development of treatments against different types of coronavirus.", "This mini-protein, which was recombinantly produced in high yields, possesses a stable α helical conformation and is able to interact with the RBD of glycosylated Spike protein from SARS-CoV-2 with nanomolar affinity, as measured by microscale thermophoresis.", "Like other coronaviruses, this novel virus relies on the surface Spike glycoprotein to access the host cells, mainly through the interaction of its Receptor Binding Domain (RBD) with the human angiotensin- converting enzyme 2 (ACE2)."]}
{"id": 1002879, "claim": "An engineered stable mini-genome to plug sars-cov2 spikes", "label": "REFUTED", "evidence": ["Therefore, molecular entities able to interfere with binding of the SARS-CoV-2 Spike protein to ACE2 have a great potential to inhibit viral entry.", "Starting from the available structural data on the interaction between SARS-CoV-2 Spike protein and the host ACE2 receptor, we here engineered a mini-protein with the aim of creating a soluble and stable Spike interactor.", "By plugging the Spike protein, our mini-protein constitutes a valid tool for the development of treatments against different types of coronavirus.", "This mini-protein, which was recombinantly produced in high yields, possesses a stable α helical conformation and is able to interact with the RBD of glycosylated Spike protein from SARS-CoV-2 with nanomolar affinity, as measured by microscale thermophoresis.", "Like other coronaviruses, this novel virus relies on the surface Spike glycoprotein to access the host cells, mainly through the interaction of its Receptor Binding Domain (RBD) with the human angiotensin- converting enzyme 2 (ACE2)."]}
{"id": 1002880, "claim": "Therapeutically administered ribonucleoside analogue mk-4482/eidd-2801 blocks sars-cov-2 transmission in ferrets", "label": "SUPPORTED", "evidence": ["We previously reported the development of an orally efficacious ribonucleoside analogue inhibitor of influenza viruses, MK-4482/EIDD-2801 (refs.", "The samples from the source ferrets treated with MK-4482/EIDD-2801 and their contacts were PCR-negative for viral RNA.", "2: Therapeutic MK-4482/EIDD-2801 is orally efficacious against SARS- CoV-2 in ferrets."]}
{"id": 1002881, "claim": "Therapeutically administered ribonucleoside analogue mk-4482/eidd-2801 enhanced sars-cov-2 transmission in ferrets", "label": "REFUTED", "evidence": ["We previously reported the development of an orally efficacious ribonucleoside analogue inhibitor of influenza viruses, MK-4482/EIDD-2801 (refs.", "The samples from the source ferrets treated with MK-4482/EIDD-2801 and their contacts were PCR-negative for viral RNA.", "2: Therapeutic MK-4482/EIDD-2801 is orally efficacious against SARS- CoV-2 in ferrets."]}
{"id": 1002882, "claim": "Therapeutically administered ribonucleoside analogue mk-4482/eidd-2801 induced sars-cov-2 transmission in ferrets", "label": "REFUTED", "evidence": ["We previously reported the development of an orally efficacious ribonucleoside analogue inhibitor of influenza viruses, MK-4482/EIDD-2801 (refs.", "The samples from the source ferrets treated with MK-4482/EIDD-2801 and their contacts were PCR-negative for viral RNA.", "2: Therapeutic MK-4482/EIDD-2801 is orally efficacious against SARS- CoV-2 in ferrets."]}
{"id": 1002883, "claim": "Therapeutically administered ribonucleoside analogue mk-4482/eidd-2801 blocks sars-cov-2 production in ferrets", "label": "REFUTED", "evidence": ["We previously reported the development of an orally efficacious ribonucleoside analogue inhibitor of influenza viruses, MK-4482/EIDD-2801 (refs.", "The samples from the source ferrets treated with MK-4482/EIDD-2801 and their contacts were PCR-negative for viral RNA.", "2: Therapeutic MK-4482/EIDD-2801 is orally efficacious against SARS- CoV-2 in ferrets."]}
{"id": 1002884, "claim": "Local health officials announce new recommendations to reduce risk of spread of covid-19", "label": "SUPPORTED", "evidence": ["If there is a confirmed case of COVID-19, Public Health will work with the school and the district to determine the best measures including potential closure of the school.", "Taking these measures can help reduce the number of workers who come into contact with COVID-19 and help minimize absenteeism due to illness If you can feasibly avoid bringing large groups of people together, consider postponing events and gatherings.", "This is a critical moment in the growing outbreak of COVID-19 in King County and these measures can potentially impact the spread of the disease."]}
{"id": 1002885, "claim": "Local health officials announce new recommendations to increase risk of spread of covid-19", "label": "REFUTED", "evidence": ["If there is a confirmed case of COVID-19, Public Health will work with the school and the district to determine the best measures including potential closure of the school.", "Taking these measures can help reduce the number of workers who come into contact with COVID-19 and help minimize absenteeism due to illness If you can feasibly avoid bringing large groups of people together, consider postponing events and gatherings.", "This is a critical moment in the growing outbreak of COVID-19 in King County and these measures can potentially impact the spread of the disease."]}
{"id": 1002886, "claim": "Coronavirus 'map ' identifies key virus entry points into the body", "label": "SUPPORTED", "evidence": ["Thus, it was crucial to investigate how the virus could enter heart cells, by mapping the location of the SARS-CoV-2 receptor in the heart, and the proteases that enable the virus to gain entry to cells.", "This makes these cells the most likely initial infection route for the virus.\"", "The SARS-CoV-2 coronavirus requires two key proteins, called ACE2 and TMPRSS2, to enter human cells."]}
{"id": 1002887, "claim": "Coronavirus'map'identifies key virus entry points into the network", "label": "REFUTED", "evidence": ["Thus, it was crucial to investigate how the virus could enter heart cells, by mapping the location of the SARS-CoV-2 receptor in the heart, and the proteases that enable the virus to gain entry to cells.", "This makes these cells the most likely initial infection route for the virus.\"", "The SARS-CoV-2 coronavirus requires two key proteins, called ACE2 and TMPRSS2, to enter human cells."]}
{"id": 1002888, "claim": "Coronavirus'map'identifies key virus entry points into the file", "label": "REFUTED", "evidence": ["Thus, it was crucial to investigate how the virus could enter heart cells, by mapping the location of the SARS-CoV-2 receptor in the heart, and the proteases that enable the virus to gain entry to cells.", "This makes these cells the most likely initial infection route for the virus.\"", "The SARS-CoV-2 coronavirus requires two key proteins, called ACE2 and TMPRSS2, to enter human cells."]}
{"id": 1002889, "claim": "Coronavirus'map'identifies key virus entry points into the question", "label": "REFUTED", "evidence": ["Thus, it was crucial to investigate how the virus could enter heart cells, by mapping the location of the SARS-CoV-2 receptor in the heart, and the proteases that enable the virus to gain entry to cells.", "This makes these cells the most likely initial infection route for the virus.\"", "The SARS-CoV-2 coronavirus requires two key proteins, called ACE2 and TMPRSS2, to enter human cells."]}
{"id": 1002890, "claim": "Post-mortem examination of covid19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction", "label": "SUPPORTED", "evidence": ["A , Exudative diffuse alveolar damage (DAD) showing discrete hyaline Figure 2 Microscopic lung findings."]}
{"id": 1002891, "claim": "Post-mortem examination of covid19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs without vascular dysfunction", "label": "REFUTED", "evidence": ["A , Exudative diffuse alveolar damage (DAD) showing discrete hyaline Figure 2 Microscopic lung findings."]}
{"id": 1002892, "claim": "Adiposity is the crucial enhancer of covid-19", "label": "SUPPORTED", "evidence": ["Potential risks for severe COVID-19 in obesity before SARS-CoV-2 infection (a) and the mechanisms for adiposity- mediated exacerbation of COVID-19 (b).", "In conclusion, obese people have various factors including high likelihood of entry of SARS-CoV-2 into human vital tissues, elevated cytokines, endothelial dysfunction and procoagulant state, which may enhance the severity of COVID-19."]}
{"id": 1002893, "claim": "Adiposity is the crucial decr of covid-19", "label": "REFUTED", "evidence": ["Potential risks for severe COVID-19 in obesity before SARS-CoV-2 infection (a) and the mechanisms for adiposity- mediated exacerbation of COVID-19 (b).", "In conclusion, obese people have various factors including high likelihood of entry of SARS-CoV-2 into human vital tissues, elevated cytokines, endothelial dysfunction and procoagulant state, which may enhance the severity of COVID-19."]}
{"id": 1002894, "claim": "Adiposity is the natural enhancer of covid-19", "label": "REFUTED", "evidence": ["Potential risks for severe COVID-19 in obesity before SARS-CoV-2 infection (a) and the mechanisms for adiposity- mediated exacerbation of COVID-19 (b).", "In conclusion, obese people have various factors including high likelihood of entry of SARS-CoV-2 into human vital tissues, elevated cytokines, endothelial dysfunction and procoagulant state, which may enhance the severity of COVID-19."]}
{"id": 1002895, "claim": "Unposity is the crucial enhancer of covid-19", "label": "REFUTED", "evidence": ["Potential risks for severe COVID-19 in obesity before SARS-CoV-2 infection (a) and the mechanisms for adiposity- mediated exacerbation of COVID-19 (b).", "In conclusion, obese people have various factors including high likelihood of entry of SARS-CoV-2 into human vital tissues, elevated cytokines, endothelial dysfunction and procoagulant state, which may enhance the severity of COVID-19."]}
{"id": 1002896, "claim": "Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses", "label": "SUPPORTED", "evidence": ["Binding and neutralizing antibodies were higher in older adults.", "Increases in binding antibodies with RI were more frequent than increased neutralizing antibodies and virus shedding, and more frequent in younger compared to older adults."]}
{"id": 1002897, "claim": "Antibodies to coronaviruses are lower in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses", "label": "REFUTED", "evidence": ["Binding and neutralizing antibodies were higher in older adults.", "Increases in binding antibodies with RI were more frequent than increased neutralizing antibodies and virus shedding, and more frequent in younger compared to older adults."]}
{"id": 1002898, "claim": "Antibodies to coronaviruses are higher in infants compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses", "label": "REFUTED", "evidence": ["Binding and neutralizing antibodies were higher in older adults.", "Increases in binding antibodies with RI were more frequent than increased neutralizing antibodies and virus shedding, and more frequent in younger compared to older adults."]}
{"id": 1002899, "claim": "Antibodies to coronaviruses are higher in children compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses", "label": "REFUTED", "evidence": ["Binding and neutralizing antibodies were higher in older adults.", "Increases in binding antibodies with RI were more frequent than increased neutralizing antibodies and virus shedding, and more frequent in younger compared to older adults."]}
{"id": 1002900, "claim": "Expression of sars-cov-2 receptor ace2 and the protease tmprss2 suggests susceptibility of the human embryo in the first trimester", "label": "SUPPORTED", "evidence": ["Expression of ACE2 and TMPRSS2 in the pre-gastrulation human embryo.", "Here, we examine human pre-gastrulation embryos to determine the expression patterns of the genes ACE2 , encoding the SARS-CoV-2 receptor, and TMPRSS2 , encoding a protease that cleaves both the viral spike protein and the ACE2 receptor to facilitate infection.", "With these considerations in mind, we address here when in human development is the earliest stage at which SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), is first expressed and therefore when the human embryo could possibly become infected.", "2020The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study."]}
{"id": 1002901, "claim": "Expression of sars-cov-2 receptor ace2 and the protease tmprss2 inhibited susceptibility of the human embryo in the first trimester", "label": "REFUTED", "evidence": ["Expression of ACE2 and TMPRSS2 in the pre-gastrulation human embryo.", "Here, we examine human pre-gastrulation embryos to determine the expression patterns of the genes ACE2 , encoding the SARS-CoV-2 receptor, and TMPRSS2 , encoding a protease that cleaves both the viral spike protein and the ACE2 receptor to facilitate infection.", "With these considerations in mind, we address here when in human development is the earliest stage at which SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), is first expressed and therefore when the human embryo could possibly become infected.", "2020The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study."]}
{"id": 1002902, "claim": "Expression of sars-cov-2 receptor ace2 and the protease tmprss2 suggests susceptibility of the mouse embryo in the first trimester", "label": "REFUTED", "evidence": ["Expression of ACE2 and TMPRSS2 in the pre-gastrulation human embryo.", "Here, we examine human pre-gastrulation embryos to determine the expression patterns of the genes ACE2 , encoding the SARS-CoV-2 receptor, and TMPRSS2 , encoding a protease that cleaves both the viral spike protein and the ACE2 receptor to facilitate infection.", "With these considerations in mind, we address here when in human development is the earliest stage at which SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), is first expressed and therefore when the human embryo could possibly become infected.", "2020The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study."]}
{"id": 1002903, "claim": "Expression of sars-cov-2 receptor ace2 and the protease tmprss2 suggests susceptibility of the pig embryo in the first trimester", "label": "REFUTED", "evidence": ["Expression of ACE2 and TMPRSS2 in the pre-gastrulation human embryo.", "Here, we examine human pre-gastrulation embryos to determine the expression patterns of the genes ACE2 , encoding the SARS-CoV-2 receptor, and TMPRSS2 , encoding a protease that cleaves both the viral spike protein and the ACE2 receptor to facilitate infection.", "With these considerations in mind, we address here when in human development is the earliest stage at which SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), is first expressed and therefore when the human embryo could possibly become infected.", "2020The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study."]}
{"id": 1002904, "claim": "Rapid increase of a sars-cov-2 variant with multiple spike protein mutations observed in the united kingdom.", "label": "SUPPORTED", "evidence": ["The emergence of this variant raises concerns of a potential increase in transmissibility or propensity for SARS-CoV-2 re-infection of individuals.", "It is characterized by a spike protein mutation S: S477N, occurring in combination with N: M234I, A376T, ORF1a: M3087I, ORF1b: A176S, and most also with ORF1b: V767L K1141R, E1184D.", "Several new variants emerged in the fall of 2020, most notably: In the United Kingdom (UK), a new variant of SARS-CoV-2 (known as 20I/501Y.V1, VOC 202012/01, or B.1.1.7) emerged with an unusually large number of mutations.", "There is some evidence to indicate that one of the spike protein mutations, E484K, may affect neutralization by some polyclonal and monoclonal antibodies.1,2 P.1 lineage (a.k.a."]}
{"id": 1002905, "claim": "Rapid deletion of a sars-cov-2 variant with multiple spike protein mutations observed in the united kingdom.", "label": "REFUTED", "evidence": ["The emergence of this variant raises concerns of a potential increase in transmissibility or propensity for SARS-CoV-2 re-infection of individuals.", "It is characterized by a spike protein mutation S: S477N, occurring in combination with N: M234I, A376T, ORF1a: M3087I, ORF1b: A176S, and most also with ORF1b: V767L K1141R, E1184D.", "Several new variants emerged in the fall of 2020, most notably: In the United Kingdom (UK), a new variant of SARS-CoV-2 (known as 20I/501Y.V1, VOC 202012/01, or B.1.1.7) emerged with an unusually large number of mutations.", "There is some evidence to indicate that one of the spike protein mutations, E484K, may affect neutralization by some polyclonal and monoclonal antibodies.1,2 P.1 lineage (a.k.a."]}
{"id": 1002906, "claim": "Sars-cov-2 antibody responses do not predict covid-19 disease severity", "label": "SUPPORTED", "evidence": ["Cross reactivity was not detected in specimens with antinuclear antibodies and rheumatoid factor, or cases with previous diagnosis of viral infection including human coronavirus."]}
{"id": 1002907, "claim": "Sars-cov-2 antibody responses do help predict covid-19 disease severity", "label": "REFUTED", "evidence": ["Cross reactivity was not detected in specimens with antinuclear antibodies and rheumatoid factor, or cases with previous diagnosis of viral infection including human coronavirus."]}
{"id": 1002908, "claim": "Sars-cov-2 antibody responses do better predict covid-19 disease severity", "label": "REFUTED", "evidence": ["Cross reactivity was not detected in specimens with antinuclear antibodies and rheumatoid factor, or cases with previous diagnosis of viral infection including human coronavirus."]}
{"id": 1002909, "claim": "Sars-cov-2 antibody responses do directly predict covid-19 disease severity", "label": "REFUTED", "evidence": ["Cross reactivity was not detected in specimens with antinuclear antibodies and rheumatoid factor, or cases with previous diagnosis of viral infection including human coronavirus."]}
{"id": 1002910, "claim": "Pathology and pathogenesis of sars-cov-2 associated with fatal coronavirus disease , united states.", "label": "SUPPORTED", "evidence": ["An ongoing pandemic of coronavirus disease (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."]}
{"id": 1002911, "claim": "Pathology and pathogenesis of sars-cov-2 associated with fatal coronavirus disease, united worldwide.", "label": "REFUTED", "evidence": ["An ongoing pandemic of coronavirus disease (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."]}
{"id": 1002912, "claim": "Saliva sampling is an excellent option to increase the number of sars cov2 diagnostic tests in settings with supplies shortages", "label": "SUPPORTED", "evidence": ["In addition, it skips the need for swab sampling, decreases the risk of the healthcare personnel involved in this process, and accelerates the diagnostic procedure.", "Here, we show that saliva samples treated with a lysis buffer can serve as a suitable source for viral RNA detection, that is cheaper and can be as efficient as the classical protocol that involves column purification of the viral RNA.", "Detection of the viral genome through RT-qPCR is the golden standard for this test, however, the high demand of the materials and reagents needed to sample individuals, purify the viral RNA, and perform the RT-qPCR test has resulted in a worldwide shortage of several of these supplies."]}
{"id": 1002913, "claim": "Saliva sampling is an excellent option to reduce the number of sars cov2 diagnostic tests in settings with supplies shortages", "label": "REFUTED", "evidence": ["In addition, it skips the need for swab sampling, decreases the risk of the healthcare personnel involved in this process, and accelerates the diagnostic procedure.", "Here, we show that saliva samples treated with a lysis buffer can serve as a suitable source for viral RNA detection, that is cheaper and can be as efficient as the classical protocol that involves column purification of the viral RNA.", "Detection of the viral genome through RT-qPCR is the golden standard for this test, however, the high demand of the materials and reagents needed to sample individuals, purify the viral RNA, and perform the RT-qPCR test has resulted in a worldwide shortage of several of these supplies."]}
{"id": 1002914, "claim": "Saliva sampling is an excellent option to determine the number of sars cov2 diagnostic tests in settings with supplies shortages", "label": "REFUTED", "evidence": ["In addition, it skips the need for swab sampling, decreases the risk of the healthcare personnel involved in this process, and accelerates the diagnostic procedure.", "Here, we show that saliva samples treated with a lysis buffer can serve as a suitable source for viral RNA detection, that is cheaper and can be as efficient as the classical protocol that involves column purification of the viral RNA.", "Detection of the viral genome through RT-qPCR is the golden standard for this test, however, the high demand of the materials and reagents needed to sample individuals, purify the viral RNA, and perform the RT-qPCR test has resulted in a worldwide shortage of several of these supplies."]}
{"id": 1002915, "claim": "Measurement of sars-cov-2 rna in wastewater tracks community infection dynamics", "label": "SUPPORTED", "evidence": ["Our data show the utility of viral RNA monitoring in municipal wastewater for SARS-CoV-2 infection surveillance at a population-wide level.", "Identification of viral pathogen diversity in sewage sludge by metagenome analysis.", "In this study, we investigated how viral RNA concentrations in wastewater correlated with compiled testing and hospitalization data in a U.S. metropolitan area over ~10 weeks, corresponding to a first wave of SARS-CoV-2 infection."]}
{"id": 1002916, "claim": "Lack of sars-cov-2 rna in wastewater tracks community infection dynamics", "label": "REFUTED", "evidence": ["Our data show the utility of viral RNA monitoring in municipal wastewater for SARS-CoV-2 infection surveillance at a population-wide level.", "Identification of viral pathogen diversity in sewage sludge by metagenome analysis.", "In this study, we investigated how viral RNA concentrations in wastewater correlated with compiled testing and hospitalization data in a U.S. metropolitan area over ~10 weeks, corresponding to a first wave of SARS-CoV-2 infection."]}
{"id": 1002917, "claim": "Expression of sars-cov-2 rna in wastewater tracks community infection dynamics", "label": "REFUTED", "evidence": ["Our data show the utility of viral RNA monitoring in municipal wastewater for SARS-CoV-2 infection surveillance at a population-wide level.", "Identification of viral pathogen diversity in sewage sludge by metagenome analysis.", "In this study, we investigated how viral RNA concentrations in wastewater correlated with compiled testing and hospitalization data in a U.S. metropolitan area over ~10 weeks, corresponding to a first wave of SARS-CoV-2 infection."]}
{"id": 1002918, "claim": "Detection of sars-cov-2 nucleocapsid antigen from serum can aid in timing of covid-19 infection.", "label": "SUPPORTED", "evidence": ["Specific IgM antibodies to SARS- CoV-2 may be detectable in COVID-19 patients during the symptomatic phase of the disease.", "--- Qualitative detection of high affinity antibodies to SARS-CoV-2 nucleocapsid (N) protein, the virus that causes COVID-19, to aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.", "The combination of simultaneous SARS-CoV-2 antigen and antibody testing appeared to provide useful information for the timing of COVID-19.", "Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives, Clinical Microbiology and Infection , 2020].", "Our results suggest that SARS-CoV-2 N-antigenemia may be used as a diagnostic marker in acute COVID-19."]}
{"id": 1002919, "claim": "Detection of sars-cov-2 nucleocapsid antigen from serum cannot aid in timing of covid-19 infection.", "label": "REFUTED", "evidence": ["Specific IgM antibodies to SARS- CoV-2 may be detectable in COVID-19 patients during the symptomatic phase of the disease.", "--- Qualitative detection of high affinity antibodies to SARS-CoV-2 nucleocapsid (N) protein, the virus that causes COVID-19, to aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.", "The combination of simultaneous SARS-CoV-2 antigen and antibody testing appeared to provide useful information for the timing of COVID-19.", "Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives, Clinical Microbiology and Infection , 2020].", "Our results suggest that SARS-CoV-2 N-antigenemia may be used as a diagnostic marker in acute COVID-19."]}
{"id": 1002920, "claim": "Detection of sars-cov-2 nucleocapsid antigen from serum can aid in timing of covid-19 clearance.", "label": "REFUTED", "evidence": ["Specific IgM antibodies to SARS- CoV-2 may be detectable in COVID-19 patients during the symptomatic phase of the disease.", "--- Qualitative detection of high affinity antibodies to SARS-CoV-2 nucleocapsid (N) protein, the virus that causes COVID-19, to aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.", "The combination of simultaneous SARS-CoV-2 antigen and antibody testing appeared to provide useful information for the timing of COVID-19.", "Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives, Clinical Microbiology and Infection , 2020].", "Our results suggest that SARS-CoV-2 N-antigenemia may be used as a diagnostic marker in acute COVID-19."]}
{"id": 1002921, "claim": "Beta-thalassemia may protect against covid 19", "label": "SUPPORTED", "evidence": ["COVID-19: beta-thalassemia subjects immunised ?", "A study has showed a heme attack on the 1-beta chain of haemoglobin by COVID-19."]}
{"id": 1002922, "claim": "Beta-thalassemia cannot protect against covid 19", "label": "REFUTED", "evidence": ["COVID-19: beta-thalassemia subjects immunised ?", "A study has showed a heme attack on the 1-beta chain of haemoglobin by COVID-19."]}
{"id": 1002923, "claim": "Beta-thalassemia may protect with covid 19", "label": "REFUTED", "evidence": ["COVID-19: beta-thalassemia subjects immunised ?", "A study has showed a heme attack on the 1-beta chain of haemoglobin by COVID-19."]}
{"id": 1002924, "claim": "Covid-19 transmission messages should hinge on science", "label": "SUPPORTED", "evidence": ["It is possible to communicate uncertainty about the underlying science, apply the precautionary approach where uncertainty exists, and implement well-reasoned decisions about how best to limit the dissemination of COVID-19."]}
{"id": 1002925, "claim": "Covid-19 transmission messages should hinge on day", "label": "REFUTED", "evidence": ["It is possible to communicate uncertainty about the underlying science, apply the precautionary approach where uncertainty exists, and implement well-reasoned decisions about how best to limit the dissemination of COVID-19."]}
{"id": 1002926, "claim": "Dozens to be deliberately infected with coronavirus in uk human challenge trials", "label": "SUPPORTED", "evidence": ["A challenge trial accelerates this process as all volunteers get the vaccine, and all of them get infected with the virus."]}
{"id": 1002927, "claim": "Dozens to be experimentally infected with coronavirus in uk human challenge trials", "label": "REFUTED", "evidence": ["A challenge trial accelerates this process as all volunteers get the vaccine, and all of them get infected with the virus."]}
{"id": 1002928, "claim": "Your mask cuts own risk by 65 percent", "label": "SUPPORTED", "evidence": ["Masks create an effective barrier against droplets.", "We do know social distancing reduces the risk of transmitting the virus by 90 percent, and wearing masks decreases the risk by 65 percent."]}
{"id": 1002929, "claim": "Your mask increased own risk by 65 percent", "label": "REFUTED", "evidence": ["Masks create an effective barrier against droplets.", "We do know social distancing reduces the risk of transmitting the virus by 90 percent, and wearing masks decreases the risk by 65 percent."]}
{"id": 1002930, "claim": "Heterogeneity is essential for contact tracing", "label": "SUPPORTED", "evidence": ["In perspective, this highlights the necessity of incorporating social heterogeneity into models of mitigation strategies.", "This shows that mitigation of COVID-19 may be possible with contact tracing, and that epidemiological models must incorporate social network structure."]}
{"id": 1002931, "claim": "Heterogeneity is difficult for contact tracing", "label": "REFUTED", "evidence": ["In perspective, this highlights the necessity of incorporating social heterogeneity into models of mitigation strategies.", "This shows that mitigation of COVID-19 may be possible with contact tracing, and that epidemiological models must incorporate social network structure."]}
{"id": 1002932, "claim": "As us fumbles covid-19 testing , who warns social distancing is not enough", "label": "SUPPORTED", "evidence": ["adopts Bidens vaccine plan, threatens to punish slow states View more stories As the United States continues to struggle to ramp up basic testing for COVID-19, experts at the World Health Organization on Monday emphasized that countries should prioritize such testingand that social-distancing measures are not enough."]}
{"id": 1002933, "claim": "As us fumbles covid-19 testing, who warns social distancing is considered enough", "label": "REFUTED", "evidence": ["adopts Bidens vaccine plan, threatens to punish slow states View more stories As the United States continues to struggle to ramp up basic testing for COVID-19, experts at the World Health Organization on Monday emphasized that countries should prioritize such testingand that social-distancing measures are not enough."]}
{"id": 1002934, "claim": "As us fumbles covid-19 testing, who warns social distancing is necessary enough", "label": "REFUTED", "evidence": ["adopts Bidens vaccine plan, threatens to punish slow states View more stories As the United States continues to struggle to ramp up basic testing for COVID-19, experts at the World Health Organization on Monday emphasized that countries should prioritize such testingand that social-distancing measures are not enough."]}
{"id": 1002935, "claim": "As us fumbles covid-19 testing, who warns social distancing is required enough", "label": "REFUTED", "evidence": ["adopts Bidens vaccine plan, threatens to punish slow states View more stories As the United States continues to struggle to ramp up basic testing for COVID-19, experts at the World Health Organization on Monday emphasized that countries should prioritize such testingand that social-distancing measures are not enough."]}
{"id": 1002936, "claim": "Mass screening only found two positive cases out of 8,000 tests so far ; hungary", "label": "SUPPORTED", "evidence": ["Merkely, who is heading the project, said on Tuesday that the nationwide representative screeninghas produced just two positive results from 8,276 tests so far."]}
{"id": 1002937, "claim": "Mass screening only found 11 positive cases out of 8,000 tests so far ; hungary", "label": "REFUTED", "evidence": ["Merkely, who is heading the project, said on Tuesday that the nationwide representative screeninghas produced just two positive results from 8,276 tests so far."]}
{"id": 1002938, "claim": "Mass screening only found 10 positive cases out of 8,000 tests so far ; hungary", "label": "REFUTED", "evidence": ["Merkely, who is heading the project, said on Tuesday that the nationwide representative screeninghas produced just two positive results from 8,276 tests so far."]}
{"id": 1002939, "claim": "Mass screening only found 1 positive cases out of 8,000 tests so far ; hungary", "label": "REFUTED", "evidence": ["Merkely, who is heading the project, said on Tuesday that the nationwide representative screeninghas produced just two positive results from 8,276 tests so far."]}
{"id": 1002940, "claim": "The d614g mutation in the sars-cov2 spike protein increases infectivity in an ace2 receptor dependent manner", "label": "SUPPORTED", "evidence": ["Most prominent among these is the D614G amino acid substitution in the SARS-CoV2 Spike protein, which mediates viral entry.", "These results are consistent with the possibility that the Spike D614G mutant increases the infectivity of SARS- CoV2.", "Here, we synthesized and expressed the WT and D614G variant SARS-Cov2 Spike protein, and report that using a SARS-CoV2 Spike protein pseudotyped lentiviral vector we observe that the D614G variant Spike has >1/2 log10 increased infectivity in human cells expressing the human ACE2 protein as the viral receptor.", "The increased binding/fusion activity of the D614G Spike protein was corroborated in a cell fusion assay using Spike and ACE2 proteins expressed in different cells."]}
{"id": 1002941, "claim": "The d614g mutation in the sars-cov2 spike protein reduced infectivity in an ace2 receptor dependent manner", "label": "REFUTED", "evidence": ["Most prominent among these is the D614G amino acid substitution in the SARS-CoV2 Spike protein, which mediates viral entry.", "These results are consistent with the possibility that the Spike D614G mutant increases the infectivity of SARS- CoV2.", "Here, we synthesized and expressed the WT and D614G variant SARS-Cov2 Spike protein, and report that using a SARS-CoV2 Spike protein pseudotyped lentiviral vector we observe that the D614G variant Spike has >1/2 log10 increased infectivity in human cells expressing the human ACE2 protein as the viral receptor.", "The increased binding/fusion activity of the D614G Spike protein was corroborated in a cell fusion assay using Spike and ACE2 proteins expressed in different cells."]}
{"id": 1002942, "claim": "The d614g mutation in the sars-cov2 spike protein reduces infectivity in an ace2 receptor dependent manner", "label": "REFUTED", "evidence": ["Most prominent among these is the D614G amino acid substitution in the SARS-CoV2 Spike protein, which mediates viral entry.", "These results are consistent with the possibility that the Spike D614G mutant increases the infectivity of SARS- CoV2.", "Here, we synthesized and expressed the WT and D614G variant SARS-Cov2 Spike protein, and report that using a SARS-CoV2 Spike protein pseudotyped lentiviral vector we observe that the D614G variant Spike has >1/2 log10 increased infectivity in human cells expressing the human ACE2 protein as the viral receptor.", "The increased binding/fusion activity of the D614G Spike protein was corroborated in a cell fusion assay using Spike and ACE2 proteins expressed in different cells."]}
{"id": 1002943, "claim": "The d614g mutation in the sars-cov2 spike protein inhibited infectivity in an ace2 receptor dependent manner", "label": "REFUTED", "evidence": ["Most prominent among these is the D614G amino acid substitution in the SARS-CoV2 Spike protein, which mediates viral entry.", "These results are consistent with the possibility that the Spike D614G mutant increases the infectivity of SARS- CoV2.", "Here, we synthesized and expressed the WT and D614G variant SARS-Cov2 Spike protein, and report that using a SARS-CoV2 Spike protein pseudotyped lentiviral vector we observe that the D614G variant Spike has >1/2 log10 increased infectivity in human cells expressing the human ACE2 protein as the viral receptor.", "The increased binding/fusion activity of the D614G Spike protein was corroborated in a cell fusion assay using Spike and ACE2 proteins expressed in different cells."]}
{"id": 1002944, "claim": "96 % of covid-19 patients recover in beacon pharma 's favipira trial", "label": "SUPPORTED", "evidence": ["Daily Sun : https://www.daily-sun.com/printversion/details/492324/Favipiravir-recommended- for-Covid19-treatment 5.", "The Business Standard : https://tbsnews.net/coronavirus- chronicle/covid-19-bangladesh/96-covid-19-patients-recover-beacon-pharmas- favipira-trial By BPL"]}
{"id": 1002945, "claim": "96 % of covid-19 patients died in beacon pharma's favipira trial", "label": "REFUTED", "evidence": ["Daily Sun : https://www.daily-sun.com/printversion/details/492324/Favipiravir-recommended- for-Covid19-treatment 5.", "The Business Standard : https://tbsnews.net/coronavirus- chronicle/covid-19-bangladesh/96-covid-19-patients-recover-beacon-pharmas- favipira-trial By BPL"]}
{"id": 1002946, "claim": "The d614g mutation in sars-cov-2 spike increases transduction of multiple human cell types", "label": "SUPPORTED", "evidence": ["We show that in multiple cell lines, including human lung epithelial cells, that S-Virus carrying the D614G mutation is up to 8-fold more effective at transducing cells than wild-type S-Virus."]}
{"id": 1002947, "claim": "The d614g mutation in sars-cov-2 spike prevents transduction of multiple human cell types", "label": "REFUTED", "evidence": ["We show that in multiple cell lines, including human lung epithelial cells, that S-Virus carrying the D614G mutation is up to 8-fold more effective at transducing cells than wild-type S-Virus."]}
{"id": 1002948, "claim": "Cyclosporin a inhibits the replication of diverse coronaviruses", "label": "SUPPORTED", "evidence": ["CsA treatment inhibits coronavirus protein and RNA synthesis, and the production of infectious Fig.", "Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis.", "CsA inhibits the replication of GFP-expressing recombinant coronaviruses.", "CsA treatment inhibits coronavirus protein and RNA synthesis, and the production of infectious progeny."]}
{"id": 1002949, "claim": "Cyclosporin a hosts the replication of diverse coronaviruses", "label": "REFUTED", "evidence": ["CsA treatment inhibits coronavirus protein and RNA synthesis, and the production of infectious Fig.", "Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis.", "CsA inhibits the replication of GFP-expressing recombinant coronaviruses.", "CsA treatment inhibits coronavirus protein and RNA synthesis, and the production of infectious progeny."]}
{"id": 1002950, "claim": "Cyclosporin a focuss the replication of diverse coronaviruses", "label": "REFUTED", "evidence": ["CsA treatment inhibits coronavirus protein and RNA synthesis, and the production of infectious Fig.", "Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis.", "CsA inhibits the replication of GFP-expressing recombinant coronaviruses.", "CsA treatment inhibits coronavirus protein and RNA synthesis, and the production of infectious progeny."]}
{"id": 1002951, "claim": "Cyclosporin a inhibits the infection of diverse coronaviruses", "label": "REFUTED", "evidence": ["CsA treatment inhibits coronavirus protein and RNA synthesis, and the production of infectious Fig.", "Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis.", "CsA inhibits the replication of GFP-expressing recombinant coronaviruses.", "CsA treatment inhibits coronavirus protein and RNA synthesis, and the production of infectious progeny."]}
{"id": 1002952, "claim": "Urban air pollution may enhance covid-19 case-fatality and mortality rates in the united states", "label": "SUPPORTED", "evidence": ["Discussions and Conclusions Long-term exposure to NO2, which largely arises from urban combustion sources such as traffic, may enhance susceptibility to severe COVID-19 outcomes, independent of longterm PM2.5 and O3 exposure.", "While the risk factors of COVID-19 are still under investigation, environmental factors, such as urban air pollution, may play an important role in increasing population susceptibility to COVID-19 pathogenesis.", "Moreover, continuation of current efforts to lower traffic emissions and ambient air pollution levels may be an important component of reducing population-level risk of COVID-19 deaths.", "The results support targeted public health actions to protect residents from COVID-19 in heavily polluted regions with historically high NO2 levels."]}
{"id": 1002953, "claim": "Urban air pollution may decrease covid-19 case-fatality and mortality rates in the united states", "label": "REFUTED", "evidence": ["Discussions and Conclusions Long-term exposure to NO2, which largely arises from urban combustion sources such as traffic, may enhance susceptibility to severe COVID-19 outcomes, independent of longterm PM2.5 and O3 exposure.", "While the risk factors of COVID-19 are still under investigation, environmental factors, such as urban air pollution, may play an important role in increasing population susceptibility to COVID-19 pathogenesis.", "Moreover, continuation of current efforts to lower traffic emissions and ambient air pollution levels may be an important component of reducing population-level risk of COVID-19 deaths.", "The results support targeted public health actions to protect residents from COVID-19 in heavily polluted regions with historically high NO2 levels."]}
{"id": 1002954, "claim": "Urban air pollution may reduce covid-19 case-fatality and mortality rates in the united states", "label": "REFUTED", "evidence": ["Discussions and Conclusions Long-term exposure to NO2, which largely arises from urban combustion sources such as traffic, may enhance susceptibility to severe COVID-19 outcomes, independent of longterm PM2.5 and O3 exposure.", "While the risk factors of COVID-19 are still under investigation, environmental factors, such as urban air pollution, may play an important role in increasing population susceptibility to COVID-19 pathogenesis.", "Moreover, continuation of current efforts to lower traffic emissions and ambient air pollution levels may be an important component of reducing population-level risk of COVID-19 deaths.", "The results support targeted public health actions to protect residents from COVID-19 in heavily polluted regions with historically high NO2 levels."]}
{"id": 1002955, "claim": "Sars-cov-2 reactive t cells in uninfected individuals are likely expanded by beta-coronaviruses", "label": "SUPPORTED", "evidence": ["We find that no common human virus, other than beta-coronaviruses, can explain the pre- existing SARS-CoV-2 reactive T cells in uninfected individuals."]}
{"id": 1002956, "claim": "Sars-cov-2 reactive t cells in uninfected individuals are not expanded by beta-coronaviruses", "label": "REFUTED", "evidence": ["We find that no common human virus, other than beta-coronaviruses, can explain the pre- existing SARS-CoV-2 reactive T cells in uninfected individuals."]}
{"id": 1002957, "claim": "Sars-cov-2 reactive t cells in uninfected individuals are likely regulated by beta-coronaviruses", "label": "REFUTED", "evidence": ["We find that no common human virus, other than beta-coronaviruses, can explain the pre- existing SARS-CoV-2 reactive T cells in uninfected individuals."]}
{"id": 1002958, "claim": "Smoking prevalence is low in symptomatic patients admitted for covid-19 .", "label": "SUPPORTED", "evidence": ["The very low prevalence of smokers in our COVID-19 cohort seemingly replicates the findings that can be extracted from descriptive tables in Chinese reports and also in the recent US reports from New York City.", "21 patients (5%) were active smokers and 44 (10%) were ex-smokers, while 376 (85%) were non-smokers.", "The current study is useful since it suggests that smokers may carry some type of protective mechanism from symptomatic SARS-CoV-2 infection, although this should definitely be confirmed in specifically-designed, controlled studies.", "Active smokers were only 21, this number corresponding to less than 5% prevalence of active smokers, which is disproportionately low compared with the 24% prevalence of smokers in the general Italian population (p<0.001)."]}
{"id": 1002959, "claim": "Smoking prevalence is high in symptomatic patients admitted for covid-19.", "label": "REFUTED", "evidence": ["The very low prevalence of smokers in our COVID-19 cohort seemingly replicates the findings that can be extracted from descriptive tables in Chinese reports and also in the recent US reports from New York City.", "21 patients (5%) were active smokers and 44 (10%) were ex-smokers, while 376 (85%) were non-smokers.", "The current study is useful since it suggests that smokers may carry some type of protective mechanism from symptomatic SARS-CoV-2 infection, although this should definitely be confirmed in specifically-designed, controlled studies.", "Active smokers were only 21, this number corresponding to less than 5% prevalence of active smokers, which is disproportionately low compared with the 24% prevalence of smokers in the general Italian population (p<0.001)."]}
{"id": 1002960, "claim": "Smoking prevalence is highest in symptomatic patients admitted for covid-19.", "label": "REFUTED", "evidence": ["The very low prevalence of smokers in our COVID-19 cohort seemingly replicates the findings that can be extracted from descriptive tables in Chinese reports and also in the recent US reports from New York City.", "21 patients (5%) were active smokers and 44 (10%) were ex-smokers, while 376 (85%) were non-smokers.", "The current study is useful since it suggests that smokers may carry some type of protective mechanism from symptomatic SARS-CoV-2 infection, although this should definitely be confirmed in specifically-designed, controlled studies.", "Active smokers were only 21, this number corresponding to less than 5% prevalence of active smokers, which is disproportionately low compared with the 24% prevalence of smokers in the general Italian population (p<0.001)."]}
{"id": 1002961, "claim": "Smoking prevalence is common in symptomatic patients admitted for covid-19.", "label": "REFUTED", "evidence": ["The very low prevalence of smokers in our COVID-19 cohort seemingly replicates the findings that can be extracted from descriptive tables in Chinese reports and also in the recent US reports from New York City.", "21 patients (5%) were active smokers and 44 (10%) were ex-smokers, while 376 (85%) were non-smokers.", "The current study is useful since it suggests that smokers may carry some type of protective mechanism from symptomatic SARS-CoV-2 infection, although this should definitely be confirmed in specifically-designed, controlled studies.", "Active smokers were only 21, this number corresponding to less than 5% prevalence of active smokers, which is disproportionately low compared with the 24% prevalence of smokers in the general Italian population (p<0.001)."]}
{"id": 1002962, "claim": "Angiotensin-converting enzyme 2 , a sars-cov-2 receptor , is upregulated by interleukin-6 via stat3 signaling in rheumatoid synovium", "label": "SUPPORTED", "evidence": ["Our presenting data revealed that ACE2 expression was elevated in active rheumatoid synovium, and siRNA against STAT3 was able to downregulate ACE2 expression, which was in turn induced by IL-6 signaling."]}
{"id": 1002963, "claim": "Angiotensin-converting enzyme 2, a sars-cov-2 enzyme, is upregulated by interleukin-6 via stat3 signaling in rheumatoid synovium", "label": "REFUTED", "evidence": ["Our presenting data revealed that ACE2 expression was elevated in active rheumatoid synovium, and siRNA against STAT3 was able to downregulate ACE2 expression, which was in turn induced by IL-6 signaling."]}
{"id": 1002964, "claim": "Detection of sars-cov-2 in a cat owned by a covid-19affected patient in spain", "label": "SUPPORTED", "evidence": ["The present case report aims to describe evidence in Spain of SARS-CoV-2 infection in a 4-y-old domestic cat (European × Persian crossbreed).", "The cat seroconverted against SARS- CoV-2, further evidencing a productive infection in this animal.", "The present report describes a cat suffering from severe respiratory distress and thrombocytopenia living with a family with several members affected by COVID-19."]}
{"id": 1002965, "claim": "Scientists create antibody that defeats coronavirus in cell cultures", "label": "SUPPORTED", "evidence": ["From a report: The experimental antibody has neutralized the virus in cell cultures.", "It looks like scientists have created a monoclonal antibody that can defeat the new Coronavirus in the lab.", "In this case, the scientists used genetically modified mice to produce different antibodies to the spike proteins of coronaviruses.", "Scientists created a monoclonal antibody that can defeat the new coronavirus in the lab, an early but promising step in efforts to find treatments and curb the pandemic's spread.", "The experimental antibody has neutralized the virus in cell cultures."]}
{"id": 1002966, "claim": "Scientists create antibody that activate coronavirus in cell cultures", "label": "REFUTED", "evidence": ["From a report: The experimental antibody has neutralized the virus in cell cultures.", "It looks like scientists have created a monoclonal antibody that can defeat the new Coronavirus in the lab.", "In this case, the scientists used genetically modified mice to produce different antibodies to the spike proteins of coronaviruses.", "Scientists created a monoclonal antibody that can defeat the new coronavirus in the lab, an early but promising step in efforts to find treatments and curb the pandemic's spread.", "The experimental antibody has neutralized the virus in cell cultures."]}
{"id": 1002967, "claim": "Scientists create antibody that binds coronavirus in cell cultures", "label": "REFUTED", "evidence": ["From a report: The experimental antibody has neutralized the virus in cell cultures.", "It looks like scientists have created a monoclonal antibody that can defeat the new Coronavirus in the lab.", "In this case, the scientists used genetically modified mice to produce different antibodies to the spike proteins of coronaviruses.", "Scientists created a monoclonal antibody that can defeat the new coronavirus in the lab, an early but promising step in efforts to find treatments and curb the pandemic's spread.", "The experimental antibody has neutralized the virus in cell cultures."]}
{"id": 1002968, "claim": "Scientists create antibody that bind coronavirus in cell cultures", "label": "REFUTED", "evidence": ["From a report: The experimental antibody has neutralized the virus in cell cultures.", "It looks like scientists have created a monoclonal antibody that can defeat the new Coronavirus in the lab.", "In this case, the scientists used genetically modified mice to produce different antibodies to the spike proteins of coronaviruses.", "Scientists created a monoclonal antibody that can defeat the new coronavirus in the lab, an early but promising step in efforts to find treatments and curb the pandemic's spread.", "The experimental antibody has neutralized the virus in cell cultures."]}
{"id": 1002969, "claim": "Unfractionated heparin potently inhibits the binding of sars-cov-2 spike protein to a human cell line", "label": "SUPPORTED", "evidence": ["Unfractionated heparin inhibited spike protein binding with an IC50 value of <0.05U/ml whereas two low molecular weight heparins were much less effective.", "This suggests that heparin, particularly unfractionated forms, could be considered to reduce clinical manifestations of COVID-19 by inhibiting continuing viral infection.", "As the spike protein has previously been shown to bind heparin, a soluble glycosaminoglycan, we used a flow cytometry assay to determine the effect of heparin on spike protein binding to RT4 cells."]}
{"id": 1002970, "claim": "Unfractionated heparin potently leads the binding of sars-cov-2 spike protein to a human cell line", "label": "REFUTED", "evidence": ["Unfractionated heparin inhibited spike protein binding with an IC50 value of <0.05U/ml whereas two low molecular weight heparins were much less effective.", "This suggests that heparin, particularly unfractionated forms, could be considered to reduce clinical manifestations of COVID-19 by inhibiting continuing viral infection.", "As the spike protein has previously been shown to bind heparin, a soluble glycosaminoglycan, we used a flow cytometry assay to determine the effect of heparin on spike protein binding to RT4 cells."]}
{"id": 1002971, "claim": "Unfractionated heparin potently furthers the binding of sars-cov-2 spike protein to a human cell line", "label": "REFUTED", "evidence": ["Unfractionated heparin inhibited spike protein binding with an IC50 value of <0.05U/ml whereas two low molecular weight heparins were much less effective.", "This suggests that heparin, particularly unfractionated forms, could be considered to reduce clinical manifestations of COVID-19 by inhibiting continuing viral infection.", "As the spike protein has previously been shown to bind heparin, a soluble glycosaminoglycan, we used a flow cytometry assay to determine the effect of heparin on spike protein binding to RT4 cells."]}
{"id": 1002972, "claim": "Unfractionated heparin potently reacts the binding of sars-cov-2 spike protein to a human cell line", "label": "REFUTED", "evidence": ["Unfractionated heparin inhibited spike protein binding with an IC50 value of <0.05U/ml whereas two low molecular weight heparins were much less effective.", "This suggests that heparin, particularly unfractionated forms, could be considered to reduce clinical manifestations of COVID-19 by inhibiting continuing viral infection.", "As the spike protein has previously been shown to bind heparin, a soluble glycosaminoglycan, we used a flow cytometry assay to determine the effect of heparin on spike protein binding to RT4 cells."]}
{"id": 1002973, "claim": "Sars-cov-2 was already spreading in france in late december 2019", "label": "SUPPORTED", "evidence": ["Moreover, the absence of a link with China and the lack of recent travel suggest that the disease was already spreading among the French population at the end of December, 2019,\" they wrote.", "\"COVID-19 was already spreading in France in late December 2019, a month before the official first cases in the country,\" the team at Groupe Hospitalier Paris Seine in Saint-Denis wrote in a study published Sunday in the International Journal of Antimicrobial Agents."]}
{"id": 1002974, "claim": "Sars-cov-2 was not spreading in france in late december 2019", "label": "REFUTED", "evidence": ["Moreover, the absence of a link with China and the lack of recent travel suggest that the disease was already spreading among the French population at the end of December, 2019,\" they wrote.", "\"COVID-19 was already spreading in France in late December 2019, a month before the official first cases in the country,\" the team at Groupe Hospitalier Paris Seine in Saint-Denis wrote in a study published Sunday in the International Journal of Antimicrobial Agents."]}
{"id": 1002975, "claim": "Sars-cov-2 was already maintained in france in late december 2019", "label": "REFUTED", "evidence": ["Moreover, the absence of a link with China and the lack of recent travel suggest that the disease was already spreading among the French population at the end of December, 2019,\" they wrote.", "\"COVID-19 was already spreading in France in late December 2019, a month before the official first cases in the country,\" the team at Groupe Hospitalier Paris Seine in Saint-Denis wrote in a study published Sunday in the International Journal of Antimicrobial Agents."]}
{"id": 1002976, "claim": "Multi-level proteomics reveals host-perturbation strategies of sars-cov-2 and sars-cov", "label": "SUPPORTED", "evidence": ["The results highlight the functionality of individual proteins as well as vulnerability hotspots of SARS-CoV-2, which we targeted with clinically approved drugs.", "To understand how SARS-CoV-2 and related coronaviruses manipulate the host we here characterized interactome, proteome and signaling processes in a systems- wide manner.", "Projecting these data onto the global network of cellular interactions revealed relationships between the perturbations taking place upon SARS-CoV-2 infection at different layers and identified unique and common molecular mechanisms of SARS coronaviruses."]}
{"id": 1002977, "claim": "Multi-level proteomics reveals sub-perturbation strategies of sars-cov-2 and sars-cov", "label": "REFUTED", "evidence": ["The results highlight the functionality of individual proteins as well as vulnerability hotspots of SARS-CoV-2, which we targeted with clinically approved drugs.", "To understand how SARS-CoV-2 and related coronaviruses manipulate the host we here characterized interactome, proteome and signaling processes in a systems- wide manner.", "Projecting these data onto the global network of cellular interactions revealed relationships between the perturbations taking place upon SARS-CoV-2 infection at different layers and identified unique and common molecular mechanisms of SARS coronaviruses."]}
{"id": 1002978, "claim": "Multi-level proteomics reveals cross-perturbation strategies of sars-cov-2 and sars-cov", "label": "REFUTED", "evidence": ["The results highlight the functionality of individual proteins as well as vulnerability hotspots of SARS-CoV-2, which we targeted with clinically approved drugs.", "To understand how SARS-CoV-2 and related coronaviruses manipulate the host we here characterized interactome, proteome and signaling processes in a systems- wide manner.", "Projecting these data onto the global network of cellular interactions revealed relationships between the perturbations taking place upon SARS-CoV-2 infection at different layers and identified unique and common molecular mechanisms of SARS coronaviruses."]}
{"id": 1002979, "claim": "Multi-level proteomics reveals non-perturbation strategies of sars-cov-2 and sars-cov", "label": "REFUTED", "evidence": ["The results highlight the functionality of individual proteins as well as vulnerability hotspots of SARS-CoV-2, which we targeted with clinically approved drugs.", "To understand how SARS-CoV-2 and related coronaviruses manipulate the host we here characterized interactome, proteome and signaling processes in a systems- wide manner.", "Projecting these data onto the global network of cellular interactions revealed relationships between the perturbations taking place upon SARS-CoV-2 infection at different layers and identified unique and common molecular mechanisms of SARS coronaviruses."]}
{"id": 1002980, "claim": "Utah mink becomes first wild animal in us to test positive for coronavirus.", "label": "SUPPORTED", "evidence": ["A wild mink in Utah has become the first wild animal to test positive for COVID-19.", "Reuters reported that a U.S. Department of Agriculture (USDA) notice indicated that a free-ranging, wild mink that later tested positive for the coronavirus was captured near a mink farm in Utah where cases of the virus have been reported among the resident population.", "On Sunday, the International Society for the Infectious Diseases sent out an alert saying a wild mink in Utah had tested positive.", "A mink in Utah has tested positive for the contagion -- the first-ever known case in a wild animal, according to officials.", "Tom Koerner / USFWS A mink in Utah has become the first wild animal in the world to test positive for the new coronavirus, according to an alert sent out Sunday by the International Society for Infectious Diseases."]}
{"id": 1002981, "claim": "Utah mink becomes another wild animal in us to test positive for coronavirus.", "label": "REFUTED", "evidence": ["A wild mink in Utah has become the first wild animal to test positive for COVID-19.", "Reuters reported that a U.S. Department of Agriculture (USDA) notice indicated that a free-ranging, wild mink that later tested positive for the coronavirus was captured near a mink farm in Utah where cases of the virus have been reported among the resident population.", "On Sunday, the International Society for the Infectious Diseases sent out an alert saying a wild mink in Utah had tested positive.", "A mink in Utah has tested positive for the contagion -- the first-ever known case in a wild animal, according to officials.", "Tom Koerner / USFWS A mink in Utah has become the first wild animal in the world to test positive for the new coronavirus, according to an alert sent out Sunday by the International Society for Infectious Diseases."]}
{"id": 1002982, "claim": "Utah mink becomes no wild animal in us to test positive for coronavirus.", "label": "REFUTED", "evidence": ["A wild mink in Utah has become the first wild animal to test positive for COVID-19.", "Reuters reported that a U.S. Department of Agriculture (USDA) notice indicated that a free-ranging, wild mink that later tested positive for the coronavirus was captured near a mink farm in Utah where cases of the virus have been reported among the resident population.", "On Sunday, the International Society for the Infectious Diseases sent out an alert saying a wild mink in Utah had tested positive.", "A mink in Utah has tested positive for the contagion -- the first-ever known case in a wild animal, according to officials.", "Tom Koerner / USFWS A mink in Utah has become the first wild animal in the world to test positive for the new coronavirus, according to an alert sent out Sunday by the International Society for Infectious Diseases."]}
{"id": 1002983, "claim": "Utah mink becomes first domestic animal in us to test positive for coronavirus.", "label": "REFUTED", "evidence": ["A wild mink in Utah has become the first wild animal to test positive for COVID-19.", "Reuters reported that a U.S. Department of Agriculture (USDA) notice indicated that a free-ranging, wild mink that later tested positive for the coronavirus was captured near a mink farm in Utah where cases of the virus have been reported among the resident population.", "On Sunday, the International Society for the Infectious Diseases sent out an alert saying a wild mink in Utah had tested positive.", "A mink in Utah has tested positive for the contagion -- the first-ever known case in a wild animal, according to officials.", "Tom Koerner / USFWS A mink in Utah has become the first wild animal in the world to test positive for the new coronavirus, according to an alert sent out Sunday by the International Society for Infectious Diseases."]}
{"id": 1002984, "claim": "Sars-cov-2 detected in waste waters in barcelona on march 12 , 2019", "label": "SUPPORTED", "evidence": ["Researchers detected the presence of the virus that caused the disease in samples of waste water in Barcelona, collected in March 12, 2019."]}
{"id": 1002985, "claim": "Sars-cov-2 detected in waste waters in barcelona on jan 12, 2019", "label": "REFUTED", "evidence": ["Researchers detected the presence of the virus that caused the disease in samples of waste water in Barcelona, collected in March 12, 2019."]}
{"id": 1002986, "claim": "Sars-cov-2 detected in waste waters in barcelona on january 12, 2019", "label": "REFUTED", "evidence": ["Researchers detected the presence of the virus that caused the disease in samples of waste water in Barcelona, collected in March 12, 2019."]}
{"id": 1002987, "claim": "Sars-cov-2 detected in waste waters in barcelona on october 12, 2019", "label": "REFUTED", "evidence": ["Researchers detected the presence of the virus that caused the disease in samples of waste water in Barcelona, collected in March 12, 2019."]}
{"id": 1002988, "claim": "A mathematical model reveals the influence of population heterogeneity on herd immunity to sars-cov-2", "label": "SUPPORTED", "evidence": ["show that by introducing age and activity heterogeneities into population models for SARS-CoV-2, herd immunity can be achieved at a population-wide infection rate of 40%, considerably lower than previous estimates.", "Our simple model shows how the disease-induced herd immunity level may be substantially lower than the classical herd immunity level derived from mathematical models assuming homogeneous immunization."]}
{"id": 1002989, "claim": "A phylogenetic model reveals the influence of population heterogeneity on herd immunity to sars-cov-2", "label": "REFUTED", "evidence": ["show that by introducing age and activity heterogeneities into population models for SARS-CoV-2, herd immunity can be achieved at a population-wide infection rate of 40%, considerably lower than previous estimates.", "Our simple model shows how the disease-induced herd immunity level may be substantially lower than the classical herd immunity level derived from mathematical models assuming homogeneous immunization."]}
{"id": 1002990, "claim": "A linear model reveals the influence of population heterogeneity on herd immunity to sars-cov-2", "label": "REFUTED", "evidence": ["show that by introducing age and activity heterogeneities into population models for SARS-CoV-2, herd immunity can be achieved at a population-wide infection rate of 40%, considerably lower than previous estimates.", "Our simple model shows how the disease-induced herd immunity level may be substantially lower than the classical herd immunity level derived from mathematical models assuming homogeneous immunization."]}
{"id": 1002991, "claim": "A regression model reveals the influence of population heterogeneity on herd immunity to sars-cov-2", "label": "REFUTED", "evidence": ["show that by introducing age and activity heterogeneities into population models for SARS-CoV-2, herd immunity can be achieved at a population-wide infection rate of 40%, considerably lower than previous estimates.", "Our simple model shows how the disease-induced herd immunity level may be substantially lower than the classical herd immunity level derived from mathematical models assuming homogeneous immunization."]}
{"id": 1002992, "claim": "Clinical evidence does not support corticosteroid treatment for 2019-ncov lung injury", "label": "SUPPORTED", "evidence": ["No clinical data exist to indicate that net benefit is derived from corticosteroids in the treatment of respiratory infection due to RSV, influenza, SARS-CoV, or MERS-CoV.", "We conclude that corticosteroid treatment should not be used for the treatment of 2019-nCoV-induced lung injury or shock outside of a clinical trial.", "Corticosteroids have been investigated for respiratory syncytial virus (RSV) in clinical trials in children, with no conclusive evidence of benefit and are therefore not recommended."]}
{"id": 1002993, "claim": "Clinical evidence does indeed support corticosteroid treatment for 2019-ncov lung injury", "label": "REFUTED", "evidence": ["No clinical data exist to indicate that net benefit is derived from corticosteroids in the treatment of respiratory infection due to RSV, influenza, SARS-CoV, or MERS-CoV.", "We conclude that corticosteroid treatment should not be used for the treatment of 2019-nCoV-induced lung injury or shock outside of a clinical trial.", "Corticosteroids have been investigated for respiratory syncytial virus (RSV) in clinical trials in children, with no conclusive evidence of benefit and are therefore not recommended."]}
{"id": 1002994, "claim": "Clinical evidence does also support corticosteroid treatment for 2019-ncov lung injury", "label": "REFUTED", "evidence": ["No clinical data exist to indicate that net benefit is derived from corticosteroids in the treatment of respiratory infection due to RSV, influenza, SARS-CoV, or MERS-CoV.", "We conclude that corticosteroid treatment should not be used for the treatment of 2019-nCoV-induced lung injury or shock outside of a clinical trial.", "Corticosteroids have been investigated for respiratory syncytial virus (RSV) in clinical trials in children, with no conclusive evidence of benefit and are therefore not recommended."]}
{"id": 1002995, "claim": "Clinical evidence does still support corticosteroid treatment for 2019-ncov lung injury", "label": "REFUTED", "evidence": ["No clinical data exist to indicate that net benefit is derived from corticosteroids in the treatment of respiratory infection due to RSV, influenza, SARS-CoV, or MERS-CoV.", "We conclude that corticosteroid treatment should not be used for the treatment of 2019-nCoV-induced lung injury or shock outside of a clinical trial.", "Corticosteroids have been investigated for respiratory syncytial virus (RSV) in clinical trials in children, with no conclusive evidence of benefit and are therefore not recommended."]}
{"id": 1002996, "claim": "Rapid clinical recovery of critical covid-19 icu patient with respiratory failure treated with rlf-100 drug", "label": "SUPPORTED", "evidence": ["Four days earlier, Relief and NeuroRx said that RLF-100 showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19those on ventilators and ECMO (extracorporeal membrane oxygenation)who were treated under FDA Emergency Use IND authorization.", "August 2, 2020 \\- Critically ill COVID-19 patients recovered rapidly from respiratory failure after three days of treatment with RLF-100, a therapy granted fast-track designation in the United States, two drug companies said Sunday."]}
{"id": 1002997, "claim": "Rapid clinical recovery of critical covid-19 icu patient with respiratory failure treated with rlf-3 drug", "label": "REFUTED", "evidence": ["Four days earlier, Relief and NeuroRx said that RLF-100 showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19those on ventilators and ECMO (extracorporeal membrane oxygenation)who were treated under FDA Emergency Use IND authorization.", "August 2, 2020 \\- Critically ill COVID-19 patients recovered rapidly from respiratory failure after three days of treatment with RLF-100, a therapy granted fast-track designation in the United States, two drug companies said Sunday."]}
{"id": 1002998, "claim": "Rapid clinical recovery of critical covid-19 icu patient with respiratory failure treated with rlf-2 drug", "label": "REFUTED", "evidence": ["Four days earlier, Relief and NeuroRx said that RLF-100 showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19those on ventilators and ECMO (extracorporeal membrane oxygenation)who were treated under FDA Emergency Use IND authorization.", "August 2, 2020 \\- Critically ill COVID-19 patients recovered rapidly from respiratory failure after three days of treatment with RLF-100, a therapy granted fast-track designation in the United States, two drug companies said Sunday."]}
{"id": 1002999, "claim": "Using viral genomics to estimate undetected infections and extent of superspreading events for covid-19", "label": "SUPPORTED", "evidence": ["This genomics-informed modeling approach could estimate in near real-time critical surveillance metrics to inform ongoing COVID-19 response efforts.", "Using a Bayesian inference framework to fit a branching process model to viral phylogeny and time series case data, we estimated time-varying reproductive numbers and their variance, the total numbers of infected individuals, the probability of case detection over time, and the estimated time to detection of an outbreak for 12 locations in Europe, China, and the United States."]}
{"id": 1003000, "claim": "Using mathematical genomics to estimate undetected infections and extent of superspreading events for covid-19", "label": "REFUTED", "evidence": ["This genomics-informed modeling approach could estimate in near real-time critical surveillance metrics to inform ongoing COVID-19 response efforts.", "Using a Bayesian inference framework to fit a branching process model to viral phylogeny and time series case data, we estimated time-varying reproductive numbers and their variance, the total numbers of infected individuals, the probability of case detection over time, and the estimated time to detection of an outbreak for 12 locations in Europe, China, and the United States."]}
{"id": 1003001, "claim": "Mit team collaborates with 3m to develop rapid covid-19 test", "label": "SUPPORTED", "evidence": ["3M is collaborating with the Sikes Lab to jointly develop the test, including establishing novel processes for scaling it.", "We welcome this collaboration with 3M and what the partnership will make possible. The National Institutes of Health selected the rapid Covid-19 test for accelerated development and commercialization support, after rigorous review by an expert panel."]}
{"id": 1003002, "claim": "Mit team collaborates with 3m to prevent rapid covid-19 test", "label": "REFUTED", "evidence": ["3M is collaborating with the Sikes Lab to jointly develop the test, including establishing novel processes for scaling it.", "We welcome this collaboration with 3M and what the partnership will make possible. The National Institutes of Health selected the rapid Covid-19 test for accelerated development and commercialization support, after rigorous review by an expert panel."]}
{"id": 1003003, "claim": "Mit team collaborates with 3m to avoid rapid covid-19 test", "label": "REFUTED", "evidence": ["3M is collaborating with the Sikes Lab to jointly develop the test, including establishing novel processes for scaling it.", "We welcome this collaboration with 3M and what the partnership will make possible. The National Institutes of Health selected the rapid Covid-19 test for accelerated development and commercialization support, after rigorous review by an expert panel."]}
{"id": 1003004, "claim": "Kentucky governor cancels schools for at least 2 weeks", "label": "SUPPORTED", "evidence": ["Facebook Twitter WhatsApp SMS Email Print Save LOUISVILLE, Ky. (WDRB)  Public schools across Kentucky will close for at least two weeks starting Monday, heeding the recommendation from Gov.", "Andy Beshear's call to stem the spread of the coronavirus, schools across Kentucky  including Jefferson County Public Schools, the state's largest district  announced they would shut down their classrooms for weeks."]}
{"id": 1003005, "claim": "Kentucky governor cancels schools for at least 2 hours", "label": "REFUTED", "evidence": ["Facebook Twitter WhatsApp SMS Email Print Save LOUISVILLE, Ky. (WDRB)  Public schools across Kentucky will close for at least two weeks starting Monday, heeding the recommendation from Gov.", "Andy Beshear's call to stem the spread of the coronavirus, schools across Kentucky  including Jefferson County Public Schools, the state's largest district  announced they would shut down their classrooms for weeks."]}
{"id": 1003006, "claim": "Musc team releases plans for 3d printed masks", "label": "SUPPORTED", "evidence": ["Photos by Sarah Pack View 3D Printer Mask Details With the threat of a shortage of protective masks looming as the novel coronavirus pandemic grows, Medical University of South Carolina biomedical engineers and tinkerers had an inspired idea: unleash an army of makers from across the U.S. who could make such masks from 3D printers  a technology that, in recent years, has become widely available.", "The team is already printing masks at MUSC, even as they continue to perfect the design."]}
{"id": 1003007, "claim": "Musc team received plans for 3d printed masks", "label": "REFUTED", "evidence": ["Photos by Sarah Pack View 3D Printer Mask Details With the threat of a shortage of protective masks looming as the novel coronavirus pandemic grows, Medical University of South Carolina biomedical engineers and tinkerers had an inspired idea: unleash an army of makers from across the U.S. who could make such masks from 3D printers  a technology that, in recent years, has become widely available.", "The team is already printing masks at MUSC, even as they continue to perfect the design."]}
{"id": 1003008, "claim": "New 100 % accurate covid-19 antibody test approved for use in uk", "label": "SUPPORTED", "evidence": ["The testwhich has received its CE mark, meaning that it complies with EU safety rulesdetects the antibody IgG to identify whether a person has had covid-19."]}
{"id": 1003009, "claim": "New 95 % accurate covid-19 antibody test approved for use in uk", "label": "REFUTED", "evidence": ["The testwhich has received its CE mark, meaning that it complies with EU safety rulesdetects the antibody IgG to identify whether a person has had covid-19."]}
{"id": 1003010, "claim": "New 50 % accurate covid-19 antibody test approved for use in uk", "label": "REFUTED", "evidence": ["The testwhich has received its CE mark, meaning that it complies with EU safety rulesdetects the antibody IgG to identify whether a person has had covid-19."]}
{"id": 1003011, "claim": "New 10 % accurate covid-19 antibody test approved for use in uk", "label": "REFUTED", "evidence": ["The testwhich has received its CE mark, meaning that it complies with EU safety rulesdetects the antibody IgG to identify whether a person has had covid-19."]}
{"id": 1003012, "claim": "Transmissibility of covid-19 depends on the viral load around onset in adult and symptomatic patients", "label": "SUPPORTED", "evidence": ["In addition, viral load can be associated with infectiousness, especially in the acute phase of COVID-19."]}
{"id": 1003013, "claim": "Transmissibility of covid-19 depends on the viral load around onset in latent and symptomatic patients", "label": "REFUTED", "evidence": ["In addition, viral load can be associated with infectiousness, especially in the acute phase of COVID-19."]}
{"id": 1003014, "claim": "Transmissibility of covid-19 depends on the viral load around onset in mild and symptomatic patients", "label": "REFUTED", "evidence": ["In addition, viral load can be associated with infectiousness, especially in the acute phase of COVID-19."]}
{"id": 1003015, "claim": "Pre-covid-19 humoral immunity to common coronaviruses does not confer cross-protection against sars-cov-2", "label": "SUPPORTED", "evidence": ["Collectively, the results of our study indicate that pre-existing immunity to common coronaviruses does not confer cross-protection against SARS-CoV-2 in vivo.", "However, their presence did not translate into neutralizing activity against SARS-CoV-2 in vitro.", "Importantly, we detected serum IgG reactivity to common coronaviruses in the early sera of patients with severe COVID-19 before the appearance of anti- SARS-CoV-2 antibodies."]}
{"id": 1003016, "claim": "Pre-covid-19 humoral immunity to common coronaviruses does also confer cross-protection against sars-cov-2", "label": "REFUTED", "evidence": ["Collectively, the results of our study indicate that pre-existing immunity to common coronaviruses does not confer cross-protection against SARS-CoV-2 in vivo.", "However, their presence did not translate into neutralizing activity against SARS-CoV-2 in vitro.", "Importantly, we detected serum IgG reactivity to common coronaviruses in the early sera of patients with severe COVID-19 before the appearance of anti- SARS-CoV-2 antibodies."]}
{"id": 1003017, "claim": "Pre-covid-19 humoral immunity to common coronaviruses does only confer cross-protection against sars-cov-2", "label": "REFUTED", "evidence": ["Collectively, the results of our study indicate that pre-existing immunity to common coronaviruses does not confer cross-protection against SARS-CoV-2 in vivo.", "However, their presence did not translate into neutralizing activity against SARS-CoV-2 in vitro.", "Importantly, we detected serum IgG reactivity to common coronaviruses in the early sera of patients with severe COVID-19 before the appearance of anti- SARS-CoV-2 antibodies."]}
{"id": 1003018, "claim": "Pre-covid-19 humoral immunity to common coronaviruses does still confer cross-protection against sars-cov-2", "label": "REFUTED", "evidence": ["Collectively, the results of our study indicate that pre-existing immunity to common coronaviruses does not confer cross-protection against SARS-CoV-2 in vivo.", "However, their presence did not translate into neutralizing activity against SARS-CoV-2 in vitro.", "Importantly, we detected serum IgG reactivity to common coronaviruses in the early sera of patients with severe COVID-19 before the appearance of anti- SARS-CoV-2 antibodies."]}
{"id": 1003019, "claim": "Face masks considerably reduce covid-19 cases in germany", "label": "SUPPORTED", "evidence": ["There is a general perception in Germany that the mandatory use of face masks in public reduces COVID-19 incidences considerably."]}
{"id": 1003020, "claim": "Face masks considerably increase covid-19 cases in germany", "label": "REFUTED", "evidence": ["There is a general perception in Germany that the mandatory use of face masks in public reduces COVID-19 incidences considerably."]}
{"id": 1003021, "claim": "Face masks considerably increased covid-19 cases in germany", "label": "REFUTED", "evidence": ["There is a general perception in Germany that the mandatory use of face masks in public reduces COVID-19 incidences considerably."]}
{"id": 1003022, "claim": "Face masks considerably higher covid-19 cases in germany", "label": "REFUTED", "evidence": ["There is a general perception in Germany that the mandatory use of face masks in public reduces COVID-19 incidences considerably."]}
{"id": 1003023, "claim": "Covid-19 fatality is likely overestimated", "label": "SUPPORTED", "evidence": ["As accessibility and availability of testing for the novel coronavirus increases, the measured CFR will continue to drop, especially as subclinical and mild cases are identified.678 Alternatively, the CFR might not fall as much as in previous epidemics and pandemics, given the prolonged disease course of covid-19 or if mitigation measures or hospital resources prove inadequate.9101112 As with other pandemics, the final CFR for covid-19 will be determined after the pandemic and should not distract from the importance of aggressive, early mitigation to minimise spread of infection."]}
{"id": 1003024, "claim": "Covid-19 fatality is likely lowestimated", "label": "REFUTED", "evidence": ["As accessibility and availability of testing for the novel coronavirus increases, the measured CFR will continue to drop, especially as subclinical and mild cases are identified.678 Alternatively, the CFR might not fall as much as in previous epidemics and pandemics, given the prolonged disease course of covid-19 or if mitigation measures or hospital resources prove inadequate.9101112 As with other pandemics, the final CFR for covid-19 will be determined after the pandemic and should not distract from the importance of aggressive, early mitigation to minimise spread of infection."]}
{"id": 1003025, "claim": "Covid-19 fatality is rare overestimated", "label": "REFUTED", "evidence": ["As accessibility and availability of testing for the novel coronavirus increases, the measured CFR will continue to drop, especially as subclinical and mild cases are identified.678 Alternatively, the CFR might not fall as much as in previous epidemics and pandemics, given the prolonged disease course of covid-19 or if mitigation measures or hospital resources prove inadequate.9101112 As with other pandemics, the final CFR for covid-19 will be determined after the pandemic and should not distract from the importance of aggressive, early mitigation to minimise spread of infection."]}
{"id": 1003026, "claim": "Covid-19 economicity is likely overestimated", "label": "REFUTED", "evidence": ["As accessibility and availability of testing for the novel coronavirus increases, the measured CFR will continue to drop, especially as subclinical and mild cases are identified.678 Alternatively, the CFR might not fall as much as in previous epidemics and pandemics, given the prolonged disease course of covid-19 or if mitigation measures or hospital resources prove inadequate.9101112 As with other pandemics, the final CFR for covid-19 will be determined after the pandemic and should not distract from the importance of aggressive, early mitigation to minimise spread of infection."]}
{"id": 1003027, "claim": "Recurrent mutations in sars-cov-2 genomes isolated from mink point to rapid host-adaptation", "label": "SUPPORTED", "evidence": ["The repeat emergence of mutations across phylogenetically distinct lineages of the virus isolated from minks points to ongoing adaptation of SARS-CoV-2 to a new host.", "SARS-CoV-2 seems to transmit particularly well in mink farms with outbreaks reported in Spain, Sweden, the Netherlands, Italy, the USA and Denmark."]}
{"id": 1003028, "claim": "Recurrent mutations in sars-cov-2 genomes isolated from mink point to rapid virus-adaptation", "label": "REFUTED", "evidence": ["The repeat emergence of mutations across phylogenetically distinct lineages of the virus isolated from minks points to ongoing adaptation of SARS-CoV-2 to a new host.", "SARS-CoV-2 seems to transmit particularly well in mink farms with outbreaks reported in Spain, Sweden, the Netherlands, Italy, the USA and Denmark."]}
{"id": 1003029, "claim": "Recurrent mutations in sars-cov-2 genomes isolated from mink point to rapid replication-adaptation", "label": "REFUTED", "evidence": ["The repeat emergence of mutations across phylogenetically distinct lineages of the virus isolated from minks points to ongoing adaptation of SARS-CoV-2 to a new host.", "SARS-CoV-2 seems to transmit particularly well in mink farms with outbreaks reported in Spain, Sweden, the Netherlands, Italy, the USA and Denmark."]}
{"id": 1003030, "claim": "Recurrent mutations in sars-cov-2 genomes isolated from ck point to rapid host-adaptation", "label": "REFUTED", "evidence": ["The repeat emergence of mutations across phylogenetically distinct lineages of the virus isolated from minks points to ongoing adaptation of SARS-CoV-2 to a new host.", "SARS-CoV-2 seems to transmit particularly well in mink farms with outbreaks reported in Spain, Sweden, the Netherlands, Italy, the USA and Denmark."]}
{"id": 1003031, "claim": "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy", "label": "SUPPORTED", "evidence": ["Conclusions: Anticoagulant therapy mainly with low molecular weight heparin appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer.", "Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia."]}
{"id": 1003032, "claim": "Anticoagulant treatment is associated with increased mortality in severe coronavirus disease 2019 patients with coagulopathy", "label": "REFUTED", "evidence": ["Conclusions: Anticoagulant therapy mainly with low molecular weight heparin appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer.", "Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia."]}
{"id": 1003033, "claim": "Anticoagulant treatment is associated with elevated mortality in severe coronavirus disease 2019 patients with coagulopathy", "label": "REFUTED", "evidence": ["Conclusions: Anticoagulant therapy mainly with low molecular weight heparin appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer.", "Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia."]}
{"id": 1003034, "claim": "Brazilian health regulatory agency approves trial of oxford covid-19 vaccine", "label": "SUPPORTED", "evidence": ["We are delighted to be working with the talented team of investigators in Brazil on the COVID19 vaccine trial, as researchers and scientists around the world collaborate on clinical development work with unprecedented urgency to combat the global threat to human health that is coronavirus. Says Professor Andrew Pollard, Chief investigator of the Oxford Vaccine Trial at Oxford University.", "Brazil is a priority for the study because of the ascendant curve of the COVID-19.", "On 2 June, the Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials conducted by Oxford University and supported by AstraZeneca, considering 2,000 volunteers to be tested in the country."]}
{"id": 1003035, "claim": "National health regulatory agency approves trial of oxford covid-19 vaccine", "label": "REFUTED", "evidence": ["We are delighted to be working with the talented team of investigators in Brazil on the COVID19 vaccine trial, as researchers and scientists around the world collaborate on clinical development work with unprecedented urgency to combat the global threat to human health that is coronavirus. Says Professor Andrew Pollard, Chief investigator of the Oxford Vaccine Trial at Oxford University.", "Brazil is a priority for the study because of the ascendant curve of the COVID-19.", "On 2 June, the Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials conducted by Oxford University and supported by AstraZeneca, considering 2,000 volunteers to be tested in the country."]}
{"id": 1003036, "claim": "Low ambient humidity impairs barrier function and innate resistance against influenza infection", "label": "SUPPORTED", "evidence": ["(2019) Low ambient humidity impairs barrier function, innate resistance against influenza infection.", "Thus, our data suggest that controlling the relative humidity is important to prevent influenza infection and disease outcomes in the dry winter season."]}
{"id": 1003037, "claim": "Increased ambient humidity impairs barrier function and innate resistance against influenza infection", "label": "REFUTED", "evidence": ["(2019) Low ambient humidity impairs barrier function, innate resistance against influenza infection.", "Thus, our data suggest that controlling the relative humidity is important to prevent influenza infection and disease outcomes in the dry winter season."]}
{"id": 1003038, "claim": "High ambient humidity impairs barrier function and innate resistance against influenza infection", "label": "REFUTED", "evidence": ["(2019) Low ambient humidity impairs barrier function, innate resistance against influenza infection.", "Thus, our data suggest that controlling the relative humidity is important to prevent influenza infection and disease outcomes in the dry winter season."]}
{"id": 1003039, "claim": "Increasing ambient humidity impairs barrier function and innate resistance against influenza infection", "label": "REFUTED", "evidence": ["(2019) Low ambient humidity impairs barrier function, innate resistance against influenza infection.", "Thus, our data suggest that controlling the relative humidity is important to prevent influenza infection and disease outcomes in the dry winter season."]}
{"id": 1003040, "claim": "Polish doctor treats covid19 symptoms within 48h with amantadine .", "label": "SUPPORTED", "evidence": ["Amantadine as a drug to mitigate the effects of COVID-19 https://www.sciencedirect.com/science/article/pii/S030698772030654X 2.", "Amantadine Treatment for People with COVID-19 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290190/ 3.", "AVAILABLE SCHEME: > How to treat COVID-19 in 48 hours - scheme"]}
{"id": 1003041, "claim": "No doctor treats covid19 symptoms within 48h with amantadine.", "label": "REFUTED", "evidence": ["Amantadine as a drug to mitigate the effects of COVID-19 https://www.sciencedirect.com/science/article/pii/S030698772030654X 2.", "Amantadine Treatment for People with COVID-19 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290190/ 3.", "AVAILABLE SCHEME: > How to treat COVID-19 in 48 hours - scheme"]}
{"id": 1003042, "claim": "Polish colleagues treats covid19 symptoms within 48h with amantadine.", "label": "REFUTED", "evidence": ["Amantadine as a drug to mitigate the effects of COVID-19 https://www.sciencedirect.com/science/article/pii/S030698772030654X 2.", "Amantadine Treatment for People with COVID-19 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290190/ 3.", "AVAILABLE SCHEME: > How to treat COVID-19 in 48 hours - scheme"]}
{"id": 1003043, "claim": "Spatial profiling of lung sars-cov-2 and influenza virus infection dissects virus-specific host responses and gene signatures", "label": "SUPPORTED", "evidence": ["Here, we use spatial transcriptomics to generate an in- depth picture of the pulmonary transcriptional landscape of COVID-19 (10 patients), pandemic H1N1 (pH1N1) influenza (5) and uninfected control patients (4).", "Collectively, these data demonstrate that spatial transcriptomics is a powerful tool to identify novel gene signatures within tissues, offering new insights into the pathogenesis of SARS-COV-2 to aid in patient triage and treatment."]}
{"id": 1003044, "claim": "Quantitative profiling of lung sars-cov-2 and influenza virus infection dissects virus-specific host responses and gene signatures", "label": "REFUTED", "evidence": ["Here, we use spatial transcriptomics to generate an in- depth picture of the pulmonary transcriptional landscape of COVID-19 (10 patients), pandemic H1N1 (pH1N1) influenza (5) and uninfected control patients (4).", "Collectively, these data demonstrate that spatial transcriptomics is a powerful tool to identify novel gene signatures within tissues, offering new insights into the pathogenesis of SARS-COV-2 to aid in patient triage and treatment."]}
{"id": 1003045, "claim": "Molecular profiling of lung sars-cov-2 and influenza virus infection dissects virus-specific host responses and gene signatures", "label": "REFUTED", "evidence": ["Here, we use spatial transcriptomics to generate an in- depth picture of the pulmonary transcriptional landscape of COVID-19 (10 patients), pandemic H1N1 (pH1N1) influenza (5) and uninfected control patients (4).", "Collectively, these data demonstrate that spatial transcriptomics is a powerful tool to identify novel gene signatures within tissues, offering new insights into the pathogenesis of SARS-COV-2 to aid in patient triage and treatment."]}
{"id": 1003046, "claim": "Genetic profiling of lung sars-cov-2 and influenza virus infection dissects virus-specific host responses and gene signatures", "label": "REFUTED", "evidence": ["Here, we use spatial transcriptomics to generate an in- depth picture of the pulmonary transcriptional landscape of COVID-19 (10 patients), pandemic H1N1 (pH1N1) influenza (5) and uninfected control patients (4).", "Collectively, these data demonstrate that spatial transcriptomics is a powerful tool to identify novel gene signatures within tissues, offering new insights into the pathogenesis of SARS-COV-2 to aid in patient triage and treatment."]}
{"id": 1003047, "claim": "Confirmed cases not a relevant metric , says stanford university professor", "label": "SUPPORTED", "evidence": ["A burgeoning number of scientific leaders believe the current system of faculty incentives and rewards is misaligned with the needs of society and disconnected from the evidence about the causes of the reproducibility crisis and suboptimal quality of the scientific publication record.", "The numbers are almost meaningless, says Steve Goodman, a professor of epidemiology at Stanford University."]}
{"id": 1003048, "claim": "Confirmed cases had a relevant metric, says stanford university professor", "label": "REFUTED", "evidence": ["A burgeoning number of scientific leaders believe the current system of faculty incentives and rewards is misaligned with the needs of society and disconnected from the evidence about the causes of the reproducibility crisis and suboptimal quality of the scientific publication record.", "The numbers are almost meaningless, says Steve Goodman, a professor of epidemiology at Stanford University."]}
{"id": 1003049, "claim": "Confirmed cases have a relevant metric, says stanford university professor", "label": "REFUTED", "evidence": ["A burgeoning number of scientific leaders believe the current system of faculty incentives and rewards is misaligned with the needs of society and disconnected from the evidence about the causes of the reproducibility crisis and suboptimal quality of the scientific publication record.", "The numbers are almost meaningless, says Steve Goodman, a professor of epidemiology at Stanford University."]}
{"id": 1003050, "claim": "Confirmed cases is a relevant metric, says stanford university professor", "label": "REFUTED", "evidence": ["A burgeoning number of scientific leaders believe the current system of faculty incentives and rewards is misaligned with the needs of society and disconnected from the evidence about the causes of the reproducibility crisis and suboptimal quality of the scientific publication record.", "The numbers are almost meaningless, says Steve Goodman, a professor of epidemiology at Stanford University."]}
{"id": 1003051, "claim": "European commission authorises first safe and effective vaccine against covid-19.", "label": "SUPPORTED", "evidence": ["This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the European Medicines Agency (EMA) and is endorsed by the Member States."]}
{"id": 1003052, "claim": "European commission authorises another safe and effective vaccine against covid-19.", "label": "REFUTED", "evidence": ["This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the European Medicines Agency (EMA) and is endorsed by the Member States."]}
{"id": 1003053, "claim": "Comparative genomics suggests limited variability and similar evolutionary patterns between major clades of sars-cov-2", "label": "SUPPORTED", "evidence": ["While levels of genomic variability between SARS-CoV-2 isolates are limited, to our knowledge, it is not clear whether the observed patterns of variability in viral super-clades reflect ongoing adaptation of SARS-CoV-2, or merely genetic drift and founder effects.", "Although this study can not be conclusive, we believe that the evidence presented here is strongly consistent with the notion that the biased geographic distribution of SARS- CoV-2 isolates should not be associated with adaptive evolution of this novel pathogen.", "Here, we analyze more than 1100 complete, high quality SARS-CoV-2 genome sequences, and provide evidence for the absence of distinct evolutionary patterns/signatures in the genomes of the currently known major clades of SARS-CoV-2.", "We observe that while cross species adaptation of the virus is associated with hypervariability of specific protein coding regions (including the RDB domain of the spike protein), the more variable genomic regions between extant SARS- CoV-2 episomes correspond with the 3 and 5 UTRs, suggesting that at present viral protein coding genes should not be subjected to different adaptive evolutionary pressures in different viral strains."]}
{"id": 1003054, "claim": "Comparative genomics suggests wide variability and similar evolutionary patterns between major clades of sars-cov-2", "label": "REFUTED", "evidence": ["While levels of genomic variability between SARS-CoV-2 isolates are limited, to our knowledge, it is not clear whether the observed patterns of variability in viral super-clades reflect ongoing adaptation of SARS-CoV-2, or merely genetic drift and founder effects.", "Although this study can not be conclusive, we believe that the evidence presented here is strongly consistent with the notion that the biased geographic distribution of SARS- CoV-2 isolates should not be associated with adaptive evolution of this novel pathogen.", "Here, we analyze more than 1100 complete, high quality SARS-CoV-2 genome sequences, and provide evidence for the absence of distinct evolutionary patterns/signatures in the genomes of the currently known major clades of SARS-CoV-2.", "We observe that while cross species adaptation of the virus is associated with hypervariability of specific protein coding regions (including the RDB domain of the spike protein), the more variable genomic regions between extant SARS- CoV-2 episomes correspond with the 3 and 5 UTRs, suggesting that at present viral protein coding genes should not be subjected to different adaptive evolutionary pressures in different viral strains."]}
{"id": 1003055, "claim": "Comparative genomics suggests significant variability and similar evolutionary patterns between major clades of sars-cov-2", "label": "REFUTED", "evidence": ["While levels of genomic variability between SARS-CoV-2 isolates are limited, to our knowledge, it is not clear whether the observed patterns of variability in viral super-clades reflect ongoing adaptation of SARS-CoV-2, or merely genetic drift and founder effects.", "Although this study can not be conclusive, we believe that the evidence presented here is strongly consistent with the notion that the biased geographic distribution of SARS- CoV-2 isolates should not be associated with adaptive evolution of this novel pathogen.", "Here, we analyze more than 1100 complete, high quality SARS-CoV-2 genome sequences, and provide evidence for the absence of distinct evolutionary patterns/signatures in the genomes of the currently known major clades of SARS-CoV-2.", "We observe that while cross species adaptation of the virus is associated with hypervariability of specific protein coding regions (including the RDB domain of the spike protein), the more variable genomic regions between extant SARS- CoV-2 episomes correspond with the 3 and 5 UTRs, suggesting that at present viral protein coding genes should not be subjected to different adaptive evolutionary pressures in different viral strains."]}
{"id": 1003056, "claim": "Comparative genomics suggests large variability and similar evolutionary patterns between major clades of sars-cov-2", "label": "REFUTED", "evidence": ["While levels of genomic variability between SARS-CoV-2 isolates are limited, to our knowledge, it is not clear whether the observed patterns of variability in viral super-clades reflect ongoing adaptation of SARS-CoV-2, or merely genetic drift and founder effects.", "Although this study can not be conclusive, we believe that the evidence presented here is strongly consistent with the notion that the biased geographic distribution of SARS- CoV-2 isolates should not be associated with adaptive evolution of this novel pathogen.", "Here, we analyze more than 1100 complete, high quality SARS-CoV-2 genome sequences, and provide evidence for the absence of distinct evolutionary patterns/signatures in the genomes of the currently known major clades of SARS-CoV-2.", "We observe that while cross species adaptation of the virus is associated with hypervariability of specific protein coding regions (including the RDB domain of the spike protein), the more variable genomic regions between extant SARS- CoV-2 episomes correspond with the 3 and 5 UTRs, suggesting that at present viral protein coding genes should not be subjected to different adaptive evolutionary pressures in different viral strains."]}
{"id": 1003057, "claim": "Interferon-b trial shows positive results", "label": "SUPPORTED", "evidence": ["The study showed that hospitalised COVID-19 patients on nebulised interferon beta recovered quicker and that the drug was safe."]}
{"id": 1003058, "claim": "Interferon-b trial shows no results", "label": "REFUTED", "evidence": ["The study showed that hospitalised COVID-19 patients on nebulised interferon beta recovered quicker and that the drug was safe."]}
{"id": 1003059, "claim": "Saliva viral load is a dynamic unifying correlate of covid-19 severity and mortality.", "label": "SUPPORTED", "evidence": ["Saliva viral load correlates with key immunological markers of severity and mortality in Fig.", "Anti-spike (S) and anti-receptor binding domain (RBD) IgG levels were negatively correlated with saliva viral load showing a strong temporal association that could help distinguish severity and mortality in COVID-19.", "We found that saliva viral load was significantly higher in those with COVID-19 risk factors; that it correlated with increasing levels of disease severity and showed a superior ability over nasopharyngeal viral load as a predictor of mortality over time (AUC=0.90).", "Saliva viral load correlates with key immunological markers of severity and mortality in COVID-19.", "Initially, high saliva viral loads and higher loads for longer periods could indicate higher COVID-19 disease severity."]}
{"id": 1003060, "claim": "Influenza viral load is a dynamic unifying correlate of covid-19 severity and mortality.", "label": "REFUTED", "evidence": ["Saliva viral load correlates with key immunological markers of severity and mortality in Fig.", "Anti-spike (S) and anti-receptor binding domain (RBD) IgG levels were negatively correlated with saliva viral load showing a strong temporal association that could help distinguish severity and mortality in COVID-19.", "We found that saliva viral load was significantly higher in those with COVID-19 risk factors; that it correlated with increasing levels of disease severity and showed a superior ability over nasopharyngeal viral load as a predictor of mortality over time (AUC=0.90).", "Saliva viral load correlates with key immunological markers of severity and mortality in COVID-19.", "Initially, high saliva viral loads and higher loads for longer periods could indicate higher COVID-19 disease severity."]}
{"id": 1003061, "claim": "Saliva viral load is a dynamic unifying correlate of covid-19 severity and duration.", "label": "REFUTED", "evidence": ["Saliva viral load correlates with key immunological markers of severity and mortality in Fig.", "Anti-spike (S) and anti-receptor binding domain (RBD) IgG levels were negatively correlated with saliva viral load showing a strong temporal association that could help distinguish severity and mortality in COVID-19.", "We found that saliva viral load was significantly higher in those with COVID-19 risk factors; that it correlated with increasing levels of disease severity and showed a superior ability over nasopharyngeal viral load as a predictor of mortality over time (AUC=0.90).", "Saliva viral load correlates with key immunological markers of severity and mortality in COVID-19.", "Initially, high saliva viral loads and higher loads for longer periods could indicate higher COVID-19 disease severity."]}
{"id": 1003062, "claim": "Saliva viral load is a dynamic unifying correlate of covid-19 severity and prognosis.", "label": "REFUTED", "evidence": ["Saliva viral load correlates with key immunological markers of severity and mortality in Fig.", "Anti-spike (S) and anti-receptor binding domain (RBD) IgG levels were negatively correlated with saliva viral load showing a strong temporal association that could help distinguish severity and mortality in COVID-19.", "We found that saliva viral load was significantly higher in those with COVID-19 risk factors; that it correlated with increasing levels of disease severity and showed a superior ability over nasopharyngeal viral load as a predictor of mortality over time (AUC=0.90).", "Saliva viral load correlates with key immunological markers of severity and mortality in COVID-19.", "Initially, high saliva viral loads and higher loads for longer periods could indicate higher COVID-19 disease severity."]}
{"id": 1003063, "claim": "Adverse events were more common in those receiving the drug .", "label": "SUPPORTED", "evidence": ["Adverse events led to higher rates of early treatment discontinuation among patients who received nafcillin.", "Finally, we demonstrated that patients who received nafcillin were more likely to discontinue therapy due to adverse events than were patients who received oxacillin."]}
{"id": 1003064, "claim": "Adverse events were less common in those receiving the drug.", "label": "REFUTED", "evidence": ["Adverse events led to higher rates of early treatment discontinuation among patients who received nafcillin.", "Finally, we demonstrated that patients who received nafcillin were more likely to discontinue therapy due to adverse events than were patients who received oxacillin."]}
{"id": 1003065, "claim": "Adverse events were not common in those receiving the drug.", "label": "REFUTED", "evidence": ["Adverse events led to higher rates of early treatment discontinuation among patients who received nafcillin.", "Finally, we demonstrated that patients who received nafcillin were more likely to discontinue therapy due to adverse events than were patients who received oxacillin."]}
{"id": 1003066, "claim": "The sarscov2 spike protein alters barrier function in 2d static and 3d microfluidic in vitro models of the human bloodbrain barrier", "label": "SUPPORTED", "evidence": ["Thus, the results presented in this report explored whether deleterious outcomes from the SARS-COV-2 viral spike protein on primary human brain microvascular endothelial cells (hBMVECs) could be observed.", "Evidence provided suggests that the SARS-CoV-2 spike proteins trigger a pro-inflammatory response on brain endothelial cells that may contribute to an altered state of BBB function.", "Introduction of spike proteins to invitro models of the blood-brain barrier (BBB) showed significant changes to barrier properties."]}
{"id": 1003067, "claim": "Natural history , trajectory , and management of mechanically ventilated covid-19 patients in the united kingdom .", "label": "SUPPORTED", "evidence": ["Mechanically ventilated patients with COVID-19 have a different natural history and trajectory from descriptions of non-COVID ARDS patients, not predictable from admission physiology.", "Here, we present a data-driven analysis of granular, daily data from a representative proportion of patients undergoing invasive mechanical ventilation (IMV) within the United Kingdom (UK) to evaluate the complete natural history of COVID-19.", "Added value of this study This study provides a comprehensive analysis and visualisation of routine clinical measurements tracking the whole ICU time course of patients undergoing invasive mechanical ventilation for COVID-19."]}
{"id": 1003068, "claim": "Natural history, trajectory, and management of mechanically ventilated covid-19 patients in the united state.", "label": "REFUTED", "evidence": ["Mechanically ventilated patients with COVID-19 have a different natural history and trajectory from descriptions of non-COVID ARDS patients, not predictable from admission physiology.", "Here, we present a data-driven analysis of granular, daily data from a representative proportion of patients undergoing invasive mechanical ventilation (IMV) within the United Kingdom (UK) to evaluate the complete natural history of COVID-19.", "Added value of this study This study provides a comprehensive analysis and visualisation of routine clinical measurements tracking the whole ICU time course of patients undergoing invasive mechanical ventilation for COVID-19."]}
{"id": 1003069, "claim": "Immunological memory to sars-cov-2 assessed for up to 8 months after infection.", "label": "SUPPORTED", "evidence": ["Nevertheless, the current cross-sectional data describe well the dynamics of SARS-CoV-2 memory B cells, CD8+ T cell, and CD4+ T cell over 8 months PSO."]}
{"id": 1003070, "claim": "Immunological memory to sars-cov-2 assessed for up to 8 minutes after infection.", "label": "REFUTED", "evidence": ["Nevertheless, the current cross-sectional data describe well the dynamics of SARS-CoV-2 memory B cells, CD8+ T cell, and CD4+ T cell over 8 months PSO."]}
{"id": 1003071, "claim": "Immunological memory to sars-cov-2 assessed for up to 8 days after infection.", "label": "REFUTED", "evidence": ["Nevertheless, the current cross-sectional data describe well the dynamics of SARS-CoV-2 memory B cells, CD8+ T cell, and CD4+ T cell over 8 months PSO."]}
{"id": 1003072, "claim": "Immunological memory to sars-cov-2 assessed for up to 8 years after infection.", "label": "REFUTED", "evidence": ["Nevertheless, the current cross-sectional data describe well the dynamics of SARS-CoV-2 memory B cells, CD8+ T cell, and CD4+ T cell over 8 months PSO."]}
{"id": 1003073, "claim": "Two-component spike nanoparticle vaccine protects macaques from sars-cov-2 infection", "label": "SUPPORTED", "evidence": ["Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein."]}
{"id": 1003074, "claim": "Two-component spike nanoparticle vaccine infected macaques from sars-cov-2 infection", "label": "REFUTED", "evidence": ["Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein."]}
{"id": 1003075, "claim": "Type i interferon limits viral dissemination-driven clinical heterogeneity in a native murine betacoronavirus model of covid-19", "label": "SUPPORTED", "evidence": ["We find that extrapulmonary manifestations are due to viral metastasis and identify a critical role for type-I but not type-III interferons in preventing systemic viral dissemination.", "We find that whereas high viral inoculums uniformly led to hypoxemic respiratory failure and death, lethal dose 50% (LD50) inoculums led to a recapitulation of most hallmark clinical features of COVID-19, including lymphocytopenias, heart and liver damage, and autonomic dysfunction."]}
{"id": 1003076, "claim": "Type i interferon promotes viral dissemination-driven clinical heterogeneity in a native murine betacoronavirus model of covid-19", "label": "REFUTED", "evidence": ["We find that extrapulmonary manifestations are due to viral metastasis and identify a critical role for type-I but not type-III interferons in preventing systemic viral dissemination.", "We find that whereas high viral inoculums uniformly led to hypoxemic respiratory failure and death, lethal dose 50% (LD50) inoculums led to a recapitulation of most hallmark clinical features of COVID-19, including lymphocytopenias, heart and liver damage, and autonomic dysfunction."]}
{"id": 1003077, "claim": "Amazon deploys thermal cameras at warehouses to scan for fevers faster", "label": "SUPPORTED", "evidence": ["Amazon confirmed that some warehouses have implemented the systems to streamline checks."]}
{"id": 1003078, "claim": "Methods deploys thermal cameras at warehouses to scan for fevers faster", "label": "REFUTED", "evidence": ["Amazon confirmed that some warehouses have implemented the systems to streamline checks."]}
{"id": 1003079, "claim": "Crisprcas12-based detection of sars-cov-2", "label": "SUPPORTED", "evidence": ["1: A CRISPRCas12-based assay for detection of SARS-CoV-2."]}
{"id": 1003080, "claim": "Heartburn drug may have potential against covid-19", "label": "SUPPORTED", "evidence": ["Unpublished data from Wuhan, China, found better outcomes in COVID-19 patients who took famotidine while hospitalized."]}
{"id": 1003081, "claim": "Heartburn drug may have potential for covid-19", "label": "REFUTED", "evidence": ["Unpublished data from Wuhan, China, found better outcomes in COVID-19 patients who took famotidine while hospitalized."]}
{"id": 1003082, "claim": "Heartburn drug may have potential as covid-19", "label": "REFUTED", "evidence": ["Unpublished data from Wuhan, China, found better outcomes in COVID-19 patients who took famotidine while hospitalized."]}
{"id": 1003083, "claim": "Immune phenotyping based on neutrophil-to-lymphocyte ratio and igg predicts disease severity and outcome for patients with covid-19", "label": "SUPPORTED", "evidence": ["We developed an immune response phenotyping based on NLR and IgG that could act as a simple complementary tool to discriminate between severe and nonsevere COVID-19 patients and would be helpful in guiding clinical decision.", "Immune response phenotyping based on late IgG levels and neutrophil-to-lymphocyte ratio (NLR) was characterized to stratify patients with different disease severities and outcome.", "Methods Anti-SARS-CoV-2 IgG and IgM antibodies were determined by chemiluminescence analysis (CLIA) in COVID-19 patients from a single center in Wuhan.", "Interpretation COVID-19 severity is associated with increased IgG response, and an immune response phenotyping based on late IgG response and NLR could act as a simple complementary tool to discriminate between severe and nonsevere COVID-19 patients, and further predict their clinical outcome."]}
{"id": 1003084, "claim": "Immune phenotyping based on neutrophil-to-lymphocyte ratio and igg predicts disease severity and outcome for patients without covid-19", "label": "REFUTED", "evidence": ["We developed an immune response phenotyping based on NLR and IgG that could act as a simple complementary tool to discriminate between severe and nonsevere COVID-19 patients and would be helpful in guiding clinical decision.", "Immune response phenotyping based on late IgG levels and neutrophil-to-lymphocyte ratio (NLR) was characterized to stratify patients with different disease severities and outcome.", "Methods Anti-SARS-CoV-2 IgG and IgM antibodies were determined by chemiluminescence analysis (CLIA) in COVID-19 patients from a single center in Wuhan.", "Interpretation COVID-19 severity is associated with increased IgG response, and an immune response phenotyping based on late IgG response and NLR could act as a simple complementary tool to discriminate between severe and nonsevere COVID-19 patients, and further predict their clinical outcome."]}
{"id": 1003085, "claim": "Oxford university and phe confirm high-sensitivity of lateral flow tests following extensive clinical evaluation", "label": "SUPPORTED", "evidence": ["The evaluation published today concludes that the Innova, and other tests which meet PHE and Oxfords standards, should be used in asymptomatic, as they offer the advantage of reducing risk and increasing capacity in addition to Lighthouse and NHS labs.", "PHE Porton Downs labs have shown four lateral flow tests to have a sensitivity of more than 70% of all PCR positive cases but importantly catch all those with high viral loads, meaning they are effective in identifying the cases who are infectious and are most likely to transmit the disease."]}
{"id": 1003086, "claim": "Oxford university and phe confirm high-sensitivity of lateral flow tests without extensive clinical evaluation", "label": "REFUTED", "evidence": ["The evaluation published today concludes that the Innova, and other tests which meet PHE and Oxfords standards, should be used in asymptomatic, as they offer the advantage of reducing risk and increasing capacity in addition to Lighthouse and NHS labs.", "PHE Porton Downs labs have shown four lateral flow tests to have a sensitivity of more than 70% of all PCR positive cases but importantly catch all those with high viral loads, meaning they are effective in identifying the cases who are infectious and are most likely to transmit the disease."]}
{"id": 1003087, "claim": "An immune protein could prevent severe covid-19 -- if it is given at the right time", "label": "SUPPORTED", "evidence": ["These immune proteins suppress viral replication early in disease."]}
{"id": 1003088, "claim": "An immune protein cannot prevent severe covid-19 -- if it is given at the right time", "label": "REFUTED", "evidence": ["These immune proteins suppress viral replication early in disease."]}
{"id": 1003089, "claim": "An immune protein could induce severe covid-19 -- if it is given at the right time", "label": "REFUTED", "evidence": ["These immune proteins suppress viral replication early in disease."]}
{"id": 1003090, "claim": "An immune protein could cause severe covid-19 -- if it is given at the right time", "label": "REFUTED", "evidence": ["These immune proteins suppress viral replication early in disease."]}
{"id": 1003091, "claim": "The newly introduced sars-cov-2 variant a222v is rapidly spreading in lazio region , italy", "label": "SUPPORTED", "evidence": ["To establish the A222V variant involvement in the infection rise in Italy, all GISAID sequences from Italy and those from our Laboratory (Lazio) in the period June- October were analysed.", "A222V, first recognized in August, represents 11.2% of sequences in this period, reaching 100% of autochthonous sequences in October, supporting increased GV circulation in Italy."]}
{"id": 1003092, "claim": "The newly introduced sars-cov-2 variant a222v is not spreading in lazio region, italy", "label": "REFUTED", "evidence": ["To establish the A222V variant involvement in the infection rise in Italy, all GISAID sequences from Italy and those from our Laboratory (Lazio) in the period June- October were analysed.", "A222V, first recognized in August, represents 11.2% of sequences in this period, reaching 100% of autochthonous sequences in October, supporting increased GV circulation in Italy."]}
{"id": 1003093, "claim": "Fda is issuing this guidance to provide a policy to help expand the availability of general use face masks for the general public and particulate filtering facepiece respirators .", "label": "SUPPORTED", "evidence": ["The guidance states the FDA is looking to expand the availability of general use face masks for the general public and particulate filtering facepiece respirators for HCPs during this emergency.", "The recent guidance reflects how the FDA is adapting to the COVID-19 emergency.", "FDA is committed to providing timely guidance to support response efforts to this pandemic.", "Second, to facilitate the safe reuse and conservation of PPE for a medical purpose, FDA expressed interest in interacting with manufacturers on the decontamination of otherwise disposable face masks and filtering facepiece respirators to facilitate marketing authorization through an Emergency Use Authorization (EUA) for new decontamination devices."]}
{"id": 1003094, "claim": "Fda is not this guidance to provide a policy to help expand the availability of general use face masks for the general public and particulate filtering facepiece respirators.", "label": "REFUTED", "evidence": ["The guidance states the FDA is looking to expand the availability of general use face masks for the general public and particulate filtering facepiece respirators for HCPs during this emergency.", "The recent guidance reflects how the FDA is adapting to the COVID-19 emergency.", "FDA is committed to providing timely guidance to support response efforts to this pandemic.", "Second, to facilitate the safe reuse and conservation of PPE for a medical purpose, FDA expressed interest in interacting with manufacturers on the decontamination of otherwise disposable face masks and filtering facepiece respirators to facilitate marketing authorization through an Emergency Use Authorization (EUA) for new decontamination devices."]}
{"id": 1003095, "claim": "Who is issuing this guidance to provide a policy to help expand the availability of general use face masks for the general public and particulate filtering facepiece respirators.", "label": "REFUTED", "evidence": ["The guidance states the FDA is looking to expand the availability of general use face masks for the general public and particulate filtering facepiece respirators for HCPs during this emergency.", "The recent guidance reflects how the FDA is adapting to the COVID-19 emergency.", "FDA is committed to providing timely guidance to support response efforts to this pandemic.", "Second, to facilitate the safe reuse and conservation of PPE for a medical purpose, FDA expressed interest in interacting with manufacturers on the decontamination of otherwise disposable face masks and filtering facepiece respirators to facilitate marketing authorization through an Emergency Use Authorization (EUA) for new decontamination devices."]}
{"id": 1003096, "claim": "China is issuing this guidance to provide a policy to help expand the availability of general use face masks for the general public and particulate filtering facepiece respirators.", "label": "REFUTED", "evidence": ["The guidance states the FDA is looking to expand the availability of general use face masks for the general public and particulate filtering facepiece respirators for HCPs during this emergency.", "The recent guidance reflects how the FDA is adapting to the COVID-19 emergency.", "FDA is committed to providing timely guidance to support response efforts to this pandemic.", "Second, to facilitate the safe reuse and conservation of PPE for a medical purpose, FDA expressed interest in interacting with manufacturers on the decontamination of otherwise disposable face masks and filtering facepiece respirators to facilitate marketing authorization through an Emergency Use Authorization (EUA) for new decontamination devices."]}
{"id": 1003097, "claim": "Sars-cov-2 nsp1 binds the ribosomal mrna channel to inhibit translation", "label": "SUPPORTED", "evidence": ["First, Nsp1 acts as a strong inhibitor of translation, tightly binding ribosomes and reducing the pool of available ribosomes that can engage in translation.", "Following viral infection and translation of viral genomic mRNA (red), Nsp1 acts as a translation inhibitor, reducing the pool of ribosomes that can engage in translation.", "These findings suggest that the extra density can be assigned to Nsp1 that competes with mRNA for ribosome binding to inhibit translation.", "3: SARS-CoV-2 Nsp1 inhibits translation in HeLa cell lysates by binding to the 40S ribosomal subunit."]}
{"id": 1003098, "claim": "Sars-cov-2 nsp1 binds the ribosomal mrna channel to initiate translation", "label": "REFUTED", "evidence": ["First, Nsp1 acts as a strong inhibitor of translation, tightly binding ribosomes and reducing the pool of available ribosomes that can engage in translation.", "Following viral infection and translation of viral genomic mRNA (red), Nsp1 acts as a translation inhibitor, reducing the pool of ribosomes that can engage in translation.", "These findings suggest that the extra density can be assigned to Nsp1 that competes with mRNA for ribosome binding to inhibit translation.", "3: SARS-CoV-2 Nsp1 inhibits translation in HeLa cell lysates by binding to the 40S ribosomal subunit."]}
{"id": 1003099, "claim": "Sars-cov-2 nsp1 binds the ribosomal mrna channel to promote translation", "label": "REFUTED", "evidence": ["First, Nsp1 acts as a strong inhibitor of translation, tightly binding ribosomes and reducing the pool of available ribosomes that can engage in translation.", "Following viral infection and translation of viral genomic mRNA (red), Nsp1 acts as a translation inhibitor, reducing the pool of ribosomes that can engage in translation.", "These findings suggest that the extra density can be assigned to Nsp1 that competes with mRNA for ribosome binding to inhibit translation.", "3: SARS-CoV-2 Nsp1 inhibits translation in HeLa cell lysates by binding to the 40S ribosomal subunit."]}
{"id": 1003100, "claim": "Sars-cov-2 nsp1 binds the ribosomal mrna channel to activate translation", "label": "REFUTED", "evidence": ["First, Nsp1 acts as a strong inhibitor of translation, tightly binding ribosomes and reducing the pool of available ribosomes that can engage in translation.", "Following viral infection and translation of viral genomic mRNA (red), Nsp1 acts as a translation inhibitor, reducing the pool of ribosomes that can engage in translation.", "These findings suggest that the extra density can be assigned to Nsp1 that competes with mRNA for ribosome binding to inhibit translation.", "3: SARS-CoV-2 Nsp1 inhibits translation in HeLa cell lysates by binding to the 40S ribosomal subunit."]}
{"id": 1003101, "claim": "Self-reported symptoms of covid-19 including symptoms most predictive of sars-cov-2 infection , are heritable", "label": "SUPPORTED", "evidence": ["We are grateful to all the users of C-19 Covid Symptom Tracker app for their contribution to this study.", "TwinsUK volunteers (n=2633) completing the C-19 Covid symptom tracker app allowed classical twin studies of covid-19 symptoms including predicted covid-19, a symptom-based algorithm predicting true infection derived in app users tested for SARS-CoV-2."]}
{"id": 1003102, "claim": "Self-reported symptoms of covid-19 including symptoms not predictive of sars-cov-2 infection, are heritable", "label": "REFUTED", "evidence": ["We are grateful to all the users of C-19 Covid Symptom Tracker app for their contribution to this study.", "TwinsUK volunteers (n=2633) completing the C-19 Covid symptom tracker app allowed classical twin studies of covid-19 symptoms including predicted covid-19, a symptom-based algorithm predicting true infection derived in app users tested for SARS-CoV-2."]}
{"id": 1003103, "claim": "Self-reported symptoms of covid-19 including symptoms without predictive of sars-cov-2 infection, are heritable", "label": "REFUTED", "evidence": ["We are grateful to all the users of C-19 Covid Symptom Tracker app for their contribution to this study.", "TwinsUK volunteers (n=2633) completing the C-19 Covid symptom tracker app allowed classical twin studies of covid-19 symptoms including predicted covid-19, a symptom-based algorithm predicting true infection derived in app users tested for SARS-CoV-2."]}
{"id": 1003104, "claim": "'superspreader ' in south korea infects nearly 40 people with coronavirus", "label": "SUPPORTED", "evidence": ["More than half of those cases involve members of, or those somehow linked to, the religious sect, the Shincheonji Church of Jesus , where a so-called superspreader infected at least 37 people last week."]}
{"id": 1003105, "claim": "'superspreader'in south china infects nearly 40 people with coronavirus", "label": "REFUTED", "evidence": ["More than half of those cases involve members of, or those somehow linked to, the religious sect, the Shincheonji Church of Jesus , where a so-called superspreader infected at least 37 people last week."]}
{"id": 1003106, "claim": "Interleukin-7 to improve clinical outcomes in lymphopenic patients with covid-19 infection uk cohort", "label": "SUPPORTED", "evidence": ["Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial.", "Venet F, Foray AP, Villars-Mechin A, Malcus C, Poitevin-Later F, Lepape A, Monneret G. IL-7 restores lymphocyte functions in septic patients.", "Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whicheve [ Time Frame: 1 month ] A statistically significant increase of the absolute lymphocyte count (ALC) from randomization to day 30 or Hospital Discharge Secondary Outcome Measures : 1."]}
{"id": 1003107, "claim": "Interleukin-7 to reduce clinical outcomes in lymphopenic patients with covid-19 infection uk cohort", "label": "REFUTED", "evidence": ["Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial.", "Venet F, Foray AP, Villars-Mechin A, Malcus C, Poitevin-Later F, Lepape A, Monneret G. IL-7 restores lymphocyte functions in septic patients.", "Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whicheve [ Time Frame: 1 month ] A statistically significant increase of the absolute lymphocyte count (ALC) from randomization to day 30 or Hospital Discharge Secondary Outcome Measures : 1."]}
{"id": 1003108, "claim": "Interleukin-7 to improve clinical outcomes in lymphopenic patients without covid-19 infection uk cohort", "label": "REFUTED", "evidence": ["Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial.", "Venet F, Foray AP, Villars-Mechin A, Malcus C, Poitevin-Later F, Lepape A, Monneret G. IL-7 restores lymphocyte functions in septic patients.", "Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whicheve [ Time Frame: 1 month ] A statistically significant increase of the absolute lymphocyte count (ALC) from randomization to day 30 or Hospital Discharge Secondary Outcome Measures : 1."]}
{"id": 1003109, "claim": "Cd177 , a specific marker of neutrophil activation , is a hallmark of covid-19 severity and death.", "label": "SUPPORTED", "evidence": ["CD177, a neutrophil activation marker, characterized critically ill patients and marked disease progression and death.", "This signature included CD177, a specific neutrophil marker of activation, adhesion to the endothelium, and transmigration.", "The association of neutrophil activation signature with COVID-19 severity has also been described recently with CD177 gene being one of the most differentially expressed gene in advanced disease 53.", "CD177, a specific marker of neutrophil activation, is a hallmark of COVID-19 severity and "]}
{"id": 1003110, "claim": "Cd177, a specific marker of neutrophil activation, is a hallmark of covid-19 severity and development.", "label": "REFUTED", "evidence": ["CD177, a neutrophil activation marker, characterized critically ill patients and marked disease progression and death.", "This signature included CD177, a specific neutrophil marker of activation, adhesion to the endothelium, and transmigration.", "The association of neutrophil activation signature with COVID-19 severity has also been described recently with CD177 gene being one of the most differentially expressed gene in advanced disease 53.", "CD177, a specific marker of neutrophil activation, is a hallmark of COVID-19 severity and "]}
{"id": 1003111, "claim": "Cd177, a common marker of neutrophil activation, is a hallmark of covid-19 severity and death.", "label": "REFUTED", "evidence": ["CD177, a neutrophil activation marker, characterized critically ill patients and marked disease progression and death.", "This signature included CD177, a specific neutrophil marker of activation, adhesion to the endothelium, and transmigration.", "The association of neutrophil activation signature with COVID-19 severity has also been described recently with CD177 gene being one of the most differentially expressed gene in advanced disease 53.", "CD177, a specific marker of neutrophil activation, is a hallmark of COVID-19 severity and "]}
{"id": 1003112, "claim": "Cd177, a specific marker of neutrophil activation, is a hallmark of covid-19 severity and progression.", "label": "REFUTED", "evidence": ["CD177, a neutrophil activation marker, characterized critically ill patients and marked disease progression and death.", "This signature included CD177, a specific neutrophil marker of activation, adhesion to the endothelium, and transmigration.", "The association of neutrophil activation signature with COVID-19 severity has also been described recently with CD177 gene being one of the most differentially expressed gene in advanced disease 53.", "CD177, a specific marker of neutrophil activation, is a hallmark of COVID-19 severity and "]}
{"id": 1003113, "claim": "Genome-wide crispr screen reveals host genes that regulate sars-cov-2 infection", "label": "SUPPORTED", "evidence": ["Here we performed a genome-wide CRISPR screen with SARS-CoV-2 and identified known SARS-CoV-2 host factors including the receptor ACE2 and protease Cathepsin L. We additionally discovered novel pro-viral genes and pathways including the SWI/SNF chromatin remodeling complex and key components of the TGF-β signaling pathway."]}
{"id": 1003114, "claim": "Genome-wide crispr screen reveals two genes that regulate sars-cov-2 infection", "label": "REFUTED", "evidence": ["Here we performed a genome-wide CRISPR screen with SARS-CoV-2 and identified known SARS-CoV-2 host factors including the receptor ACE2 and protease Cathepsin L. We additionally discovered novel pro-viral genes and pathways including the SWI/SNF chromatin remodeling complex and key components of the TGF-β signaling pathway."]}
{"id": 1003115, "claim": "The neutrophil-to-lymphocyte ratio determines clinical efficacy of corticosteroid therapy in patients with covid-19.", "label": "SUPPORTED", "evidence": ["Therefore, our study has uncovered NLR as a clinical indicator to stratify COVID-19 patients in their response to corticosteroid therapy."]}
{"id": 1003116, "claim": "The neutrophil-to-lymphocyte ratio determines clinical efficacy of corticosteroid therapy in patients without covid-19.", "label": "REFUTED", "evidence": ["Therefore, our study has uncovered NLR as a clinical indicator to stratify COVID-19 patients in their response to corticosteroid therapy."]}
{"id": 1003117, "claim": "The neutrophil-to-lymphocyte ratio determines clinical efficacy of corticosteroid therapy in patients lacking covid-19.", "label": "REFUTED", "evidence": ["Therefore, our study has uncovered NLR as a clinical indicator to stratify COVID-19 patients in their response to corticosteroid therapy."]}
{"id": 1003118, "claim": "First covid-19 reinfection death recorded in netherlands", "label": "SUPPORTED", "evidence": ["Genetic studies determined that a 25-year-old man from Nevada contracted the coronavirus on two separate occasions.", "Like the elderly Dutch woman, he experienced a more severe second episode but was able to recover.", "The woman was not tested for Covid-19 in between her two hospital visits, but Dutch researchers wrote that \"the two strains differed\" and that they believed it \"is likely that the second episode was a reinfection rather than prolonged shedding.\""]}
{"id": 1003119, "claim": "3 covid-19 reinfection death recorded in netherlands", "label": "REFUTED", "evidence": ["Genetic studies determined that a 25-year-old man from Nevada contracted the coronavirus on two separate occasions.", "Like the elderly Dutch woman, he experienced a more severe second episode but was able to recover.", "The woman was not tested for Covid-19 in between her two hospital visits, but Dutch researchers wrote that \"the two strains differed\" and that they believed it \"is likely that the second episode was a reinfection rather than prolonged shedding.\""]}
{"id": 1003120, "claim": "22 covid-19 reinfection death recorded in netherlands", "label": "REFUTED", "evidence": ["Genetic studies determined that a 25-year-old man from Nevada contracted the coronavirus on two separate occasions.", "Like the elderly Dutch woman, he experienced a more severe second episode but was able to recover.", "The woman was not tested for Covid-19 in between her two hospital visits, but Dutch researchers wrote that \"the two strains differed\" and that they believed it \"is likely that the second episode was a reinfection rather than prolonged shedding.\""]}
{"id": 1003121, "claim": "B covid-19 reinfection death recorded in netherlands", "label": "REFUTED", "evidence": ["Genetic studies determined that a 25-year-old man from Nevada contracted the coronavirus on two separate occasions.", "Like the elderly Dutch woman, he experienced a more severe second episode but was able to recover.", "The woman was not tested for Covid-19 in between her two hospital visits, but Dutch researchers wrote that \"the two strains differed\" and that they believed it \"is likely that the second episode was a reinfection rather than prolonged shedding.\""]}
{"id": 1003122, "claim": "Pollen exposure weakens innate defense against respiratory viruses .", "label": "SUPPORTED", "evidence": ["Results: Pollen significantly diminished interferon-λ and pro-inflammatory chemokine responses of airway epithelia to rhinovirus and viral mimics and decreased nuclear translocation of interferon regulatory factors.", "In mice infected with RSV, co- exposure to pollen weakened expression of antiviral genes and increased pulmonary viral titers.", "Conclusion: The ability of pollen to suppress innate antiviral immunity, independent of allergy, suggests that high-risk population groups should avoid extensive outdoor activities when pollen and respiratory virus seasons coincide."]}
{"id": 1003123, "claim": "Pollen exposure musts innate defense against respiratory viruses.", "label": "REFUTED", "evidence": ["Results: Pollen significantly diminished interferon-λ and pro-inflammatory chemokine responses of airway epithelia to rhinovirus and viral mimics and decreased nuclear translocation of interferon regulatory factors.", "In mice infected with RSV, co- exposure to pollen weakened expression of antiviral genes and increased pulmonary viral titers.", "Conclusion: The ability of pollen to suppress innate antiviral immunity, independent of allergy, suggests that high-risk population groups should avoid extensive outdoor activities when pollen and respiratory virus seasons coincide."]}
{"id": 1003124, "claim": "Largest statistically significant study by 6,200 multi-country physicians on covid-19 uncovers treatment patterns and puts pandemic in context", "label": "SUPPORTED", "evidence": ["To create a centralized and dynamic knowledge base, Sermo, the largest global healthcare polling company and social platform for physicians, leveraged its capabilities to publish results of a COVID-19 study with more than 6,200 physicians in 30 countries."]}
{"id": 1003125, "claim": "No statistically significant study by 6,200 multi-country physicians on covid-19 uncovers treatment patterns and puts pandemic in context", "label": "REFUTED", "evidence": ["To create a centralized and dynamic knowledge base, Sermo, the largest global healthcare polling company and social platform for physicians, leveraged its capabilities to publish results of a COVID-19 study with more than 6,200 physicians in 30 countries."]}
{"id": 1003126, "claim": "Withanone and withaferin-a are predicted to interact with transmembrane protease serine 2 and block entry of sars-cov-2 into cells", "label": "SUPPORTED", "evidence": ["Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells All authors Vipul Kumar, Jaspreet Kaur Dhanjal, Priyanshu Bhargava, Ashish Kaul, Jia Wang, Huayue Zhang, Sunil C. Kaul, Renu Wadhwa & Durai Sundar https://doi.org/10.1080/07391102.2020.1775704 ", "Recently, SARS-CoV-2 was shown to use the ACE2 receptor for entry and the serine protease TMPRSS2 for S protein priming.", "Camostat mesylate (a serine protease inhibitor), well documented for the treatment of cancer, pancreatitis and liver fibrosis, has recently been shown to inhibit TMPRSS2 and entry of SARS-CoV-2 virus into the cells (Hoffmann et al., 2020)."]}
{"id": 1003127, "claim": "Withanone and withaferin-a are unable to interact with transmembrane protease serine 2 and block entry of sars-cov-2 into cells", "label": "REFUTED", "evidence": ["Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells All authors Vipul Kumar, Jaspreet Kaur Dhanjal, Priyanshu Bhargava, Ashish Kaul, Jia Wang, Huayue Zhang, Sunil C. Kaul, Renu Wadhwa & Durai Sundar https://doi.org/10.1080/07391102.2020.1775704 ", "Recently, SARS-CoV-2 was shown to use the ACE2 receptor for entry and the serine protease TMPRSS2 for S protein priming.", "Camostat mesylate (a serine protease inhibitor), well documented for the treatment of cancer, pancreatitis and liver fibrosis, has recently been shown to inhibit TMPRSS2 and entry of SARS-CoV-2 virus into the cells (Hoffmann et al., 2020)."]}
{"id": 1003128, "claim": "Common cold combats influenza", "label": "SUPPORTED", "evidence": ["The researchers found that even during months when both viruses were active, if the common cold virus was present, the flu virus was not.", "As the flu season approaches, a strained public health system may have a surprising ally  the common cold virus.", "Right: Influenza infection following exposure to common cold virus."]}
{"id": 1003129, "claim": "Common water combats influenza", "label": "REFUTED", "evidence": ["The researchers found that even during months when both viruses were active, if the common cold virus was present, the flu virus was not.", "As the flu season approaches, a strained public health system may have a surprising ally  the common cold virus.", "Right: Influenza infection following exposure to common cold virus."]}
{"id": 1003130, "claim": "Common air combats influenza", "label": "REFUTED", "evidence": ["The researchers found that even during months when both viruses were active, if the common cold virus was present, the flu virus was not.", "As the flu season approaches, a strained public health system may have a surprising ally  the common cold virus.", "Right: Influenza infection following exposure to common cold virus."]}
{"id": 1003131, "claim": "Two cold combats influenza", "label": "REFUTED", "evidence": ["The researchers found that even during months when both viruses were active, if the common cold virus was present, the flu virus was not.", "As the flu season approaches, a strained public health system may have a surprising ally  the common cold virus.", "Right: Influenza infection following exposure to common cold virus."]}
{"id": 1003132, "claim": "Fast-spreading u.k. virus variant raises alarms.", "label": "SUPPORTED", "evidence": ["We found that this lineage seems to be spreading much faster, says Tulio de Oliveira, a virologist at the University of KwaZulu-Natal whose work alerted U.K. scientists to the mutation.", "Variant Continues To Spread Around The World As Coronavirus Pandemic Enters 2021 More than 30 countries have reported cases of the highly transmissible U.K.", "And when scientists compared how fast this variant, named B.1.1.7, and others were spreading, they made a startling discovery: The virus seemed to have become more adept at transmitting between people."]}
{"id": 1003133, "claim": "Fast-spreading u.k. virus variant raises advantage.", "label": "REFUTED", "evidence": ["We found that this lineage seems to be spreading much faster, says Tulio de Oliveira, a virologist at the University of KwaZulu-Natal whose work alerted U.K. scientists to the mutation.", "Variant Continues To Spread Around The World As Coronavirus Pandemic Enters 2021 More than 30 countries have reported cases of the highly transmissible U.K.", "And when scientists compared how fast this variant, named B.1.1.7, and others were spreading, they made a startling discovery: The virus seemed to have become more adept at transmitting between people."]}
{"id": 1003134, "claim": "Study suggests coronavirus emerged much earlier than thought .", "label": "SUPPORTED", "evidence": ["Italian researchers told Reuters in March that they reported a higher than usual number of cases of severe pneumonia and flu in Lombardy in the last quarter of 2019 in a sign that the new coronavirus might have circulated earlier than previously thought.", "More evidence for the origin of the novel coronavirus has come from other viruses that scientists have found in animals.", "at the Hospital del Mar earlier this month.Credit...David Ramos/Getty Images By Carl Zimmer and Raphael Minder Published June 26, 2020Updated July 23, 2020 In a study not yet published in a journal, scientists have reported that the new coronavirus was present in wastewater in Barcelona, Spain in March 2019, a finding that, if confirmed, would show that the pathogen had emerged much earlier than previously thought."]}
{"id": 1003135, "claim": "Study suggests coronavirus emerged less earlier than thought.", "label": "REFUTED", "evidence": ["Italian researchers told Reuters in March that they reported a higher than usual number of cases of severe pneumonia and flu in Lombardy in the last quarter of 2019 in a sign that the new coronavirus might have circulated earlier than previously thought.", "More evidence for the origin of the novel coronavirus has come from other viruses that scientists have found in animals.", "at the Hospital del Mar earlier this month.Credit...David Ramos/Getty Images By Carl Zimmer and Raphael Minder Published June 26, 2020Updated July 23, 2020 In a study not yet published in a journal, scientists have reported that the new coronavirus was present in wastewater in Barcelona, Spain in March 2019, a finding that, if confirmed, would show that the pathogen had emerged much earlier than previously thought."]}
{"id": 1003136, "claim": "Study suggests coronavirus emerged later earlier than thought.", "label": "REFUTED", "evidence": ["Italian researchers told Reuters in March that they reported a higher than usual number of cases of severe pneumonia and flu in Lombardy in the last quarter of 2019 in a sign that the new coronavirus might have circulated earlier than previously thought.", "More evidence for the origin of the novel coronavirus has come from other viruses that scientists have found in animals.", "at the Hospital del Mar earlier this month.Credit...David Ramos/Getty Images By Carl Zimmer and Raphael Minder Published June 26, 2020Updated July 23, 2020 In a study not yet published in a journal, scientists have reported that the new coronavirus was present in wastewater in Barcelona, Spain in March 2019, a finding that, if confirmed, would show that the pathogen had emerged much earlier than previously thought."]}
{"id": 1003137, "claim": "Rlf-100 trial shows rapid recovery in covid-19 patients", "label": "SUPPORTED", "evidence": ["Share Via Read Full Story Doctors at a hospital here have used a new drug called RLF-100, also known as aviptadil, that has led to rapid recovery from respiratory failure in critically ill COVID-19 patients.", "RLF-100 (aviptadil) shows rapid recovery from respiratory failure in critically ill Covid-19 patients.", "NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) Relief today announced that RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19.", "NeuroRx and Relief Therapeutics have found that RLF-100 (aviptadil) led to rapid recovery from respiratory failure in critically ill patients with Covid-19.", "Patients with Critical COVID-19 were seen to have a rapid clearing of classic pneumonitis findings on x-ray, accompanied by an improvement in blood oxygen and a 50% or greater average decrease in laboratory markers associated with COVID-19 inflammation.2 clinicaltrials.gov NCT04311697."]}
{"id": 1003138, "claim": "Rlf-21 trial shows rapid recovery in covid-19 patients", "label": "REFUTED", "evidence": ["Share Via Read Full Story Doctors at a hospital here have used a new drug called RLF-100, also known as aviptadil, that has led to rapid recovery from respiratory failure in critically ill COVID-19 patients.", "RLF-100 (aviptadil) shows rapid recovery from respiratory failure in critically ill Covid-19 patients.", "NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) Relief today announced that RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19.", "NeuroRx and Relief Therapeutics have found that RLF-100 (aviptadil) led to rapid recovery from respiratory failure in critically ill patients with Covid-19.", "Patients with Critical COVID-19 were seen to have a rapid clearing of classic pneumonitis findings on x-ray, accompanied by an improvement in blood oxygen and a 50% or greater average decrease in laboratory markers associated with COVID-19 inflammation.2 clinicaltrials.gov NCT04311697."]}
{"id": 1003139, "claim": "Rlf-4 trial shows rapid recovery in covid-19 patients", "label": "REFUTED", "evidence": ["Share Via Read Full Story Doctors at a hospital here have used a new drug called RLF-100, also known as aviptadil, that has led to rapid recovery from respiratory failure in critically ill COVID-19 patients.", "RLF-100 (aviptadil) shows rapid recovery from respiratory failure in critically ill Covid-19 patients.", "NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) Relief today announced that RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19.", "NeuroRx and Relief Therapeutics have found that RLF-100 (aviptadil) led to rapid recovery from respiratory failure in critically ill patients with Covid-19.", "Patients with Critical COVID-19 were seen to have a rapid clearing of classic pneumonitis findings on x-ray, accompanied by an improvement in blood oxygen and a 50% or greater average decrease in laboratory markers associated with COVID-19 inflammation.2 clinicaltrials.gov NCT04311697."]}
{"id": 1003140, "claim": "Rlf-3 trial shows rapid recovery in covid-19 patients", "label": "REFUTED", "evidence": ["Share Via Read Full Story Doctors at a hospital here have used a new drug called RLF-100, also known as aviptadil, that has led to rapid recovery from respiratory failure in critically ill COVID-19 patients.", "RLF-100 (aviptadil) shows rapid recovery from respiratory failure in critically ill Covid-19 patients.", "NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) Relief today announced that RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19.", "NeuroRx and Relief Therapeutics have found that RLF-100 (aviptadil) led to rapid recovery from respiratory failure in critically ill patients with Covid-19.", "Patients with Critical COVID-19 were seen to have a rapid clearing of classic pneumonitis findings on x-ray, accompanied by an improvement in blood oxygen and a 50% or greater average decrease in laboratory markers associated with COVID-19 inflammation.2 clinicaltrials.gov NCT04311697."]}
{"id": 1003141, "claim": "First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 in the usa", "label": "SUPPORTED", "evidence": ["It was also the first known case of person-to-person transmission in the United States."]}
{"id": 1003142, "claim": "No known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 in the usa", "label": "REFUTED", "evidence": ["It was also the first known case of person-to-person transmission in the United States."]}
{"id": 1003143, "claim": "Another known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 in the usa", "label": "REFUTED", "evidence": ["It was also the first known case of person-to-person transmission in the United States."]}
{"id": 1003144, "claim": "Most known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 in the usa", "label": "REFUTED", "evidence": ["It was also the first known case of person-to-person transmission in the United States."]}
{"id": 1003145, "claim": "Surgical mask partition reduces the risk of noncontact transmission in a golden syrian hamster model for coronavirus disease 2019", "label": "SUPPORTED", "evidence": ["Surgical mask partition for challenged index or naive hamsters significantly reduced transmission to 25% (6/24, P = .018).", "Exposure to respiratory droplets can theoretically be reduced by surgical mask usage.", "Surgical mask partition for challenged index hamsters significantly reduced transmission to only 16.7% (2/12, P = .019) of exposed naive hamsters.", "Conclusions: SARS-CoV-2 could be transmitted by respiratory droplets or airborne droplet nuclei which could be reduced by surgical mask partition in the hamster model."]}
{"id": 1003146, "claim": "Surgical mask partition increases the risk of noncontact transmission in a golden syrian hamster model for coronavirus disease 2019", "label": "REFUTED", "evidence": ["Surgical mask partition for challenged index or naive hamsters significantly reduced transmission to 25% (6/24, P = .018).", "Exposure to respiratory droplets can theoretically be reduced by surgical mask usage.", "Surgical mask partition for challenged index hamsters significantly reduced transmission to only 16.7% (2/12, P = .019) of exposed naive hamsters.", "Conclusions: SARS-CoV-2 could be transmitted by respiratory droplets or airborne droplet nuclei which could be reduced by surgical mask partition in the hamster model."]}
{"id": 1003147, "claim": "Surgical mask partition increased the risk of noncontact transmission in a golden syrian hamster model for coronavirus disease 2019", "label": "REFUTED", "evidence": ["Surgical mask partition for challenged index or naive hamsters significantly reduced transmission to 25% (6/24, P = .018).", "Exposure to respiratory droplets can theoretically be reduced by surgical mask usage.", "Surgical mask partition for challenged index hamsters significantly reduced transmission to only 16.7% (2/12, P = .019) of exposed naive hamsters.", "Conclusions: SARS-CoV-2 could be transmitted by respiratory droplets or airborne droplet nuclei which could be reduced by surgical mask partition in the hamster model."]}
{"id": 1003148, "claim": "As coronavirus spreads , fewer americans see pandemic as a real threat", "label": "SUPPORTED", "evidence": ["Just about 56% of Americans consider the coronavirus a \"real threat,\" representing a drop  View on npr.org Mar 17, 2020 ShareLikeFlip "]}
{"id": 1003149, "claim": "As coronavirus spreads, and americans see pandemic as a real threat", "label": "REFUTED", "evidence": ["Just about 56% of Americans consider the coronavirus a \"real threat,\" representing a drop  View on npr.org Mar 17, 2020 ShareLikeFlip "]}
{"id": 1003150, "claim": "As coronavirus spreads,, americans see pandemic as a real threat", "label": "REFUTED", "evidence": ["Just about 56% of Americans consider the coronavirus a \"real threat,\" representing a drop  View on npr.org Mar 17, 2020 ShareLikeFlip "]}
{"id": 1003151, "claim": "As coronavirus spreads, as americans see pandemic as a real threat", "label": "REFUTED", "evidence": ["Just about 56% of Americans consider the coronavirus a \"real threat,\" representing a drop  View on npr.org Mar 17, 2020 ShareLikeFlip "]}
{"id": 1003152, "claim": "The sars-cov-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways", "label": "SUPPORTED", "evidence": ["We here reveal features of the coronavirus spike (S) protein, which optimize the virus towards different parts of the respiratory tract.", "Coronavirus spikes exhibit distinct temperature preference to precisely match the upper (~33°C) or lower (37°C) airways.", "SIGNIFICANCE STATEMENT The rapid spread of SARS-CoV-2, the cause of COVID-19, is related to abundant replication in the upper airways, which is not observed for other highly pathogenic human coronaviruses.", "Collectively, our findings indicate how the coronavirus spike protein is fine- tuned towards the temperature and protease conditions of the airways, to enhance virus transmission and pathology.", "Even stronger preference for the upper airway temperature of 33°C was evident for the S protein of HCoV-229E, a common cold coronavirus."]}
{"id": 1003153, "claim": "The sars-cov-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human cell", "label": "REFUTED", "evidence": ["We here reveal features of the coronavirus spike (S) protein, which optimize the virus towards different parts of the respiratory tract.", "Coronavirus spikes exhibit distinct temperature preference to precisely match the upper (~33°C) or lower (37°C) airways.", "SIGNIFICANCE STATEMENT The rapid spread of SARS-CoV-2, the cause of COVID-19, is related to abundant replication in the upper airways, which is not observed for other highly pathogenic human coronaviruses.", "Collectively, our findings indicate how the coronavirus spike protein is fine- tuned towards the temperature and protease conditions of the airways, to enhance virus transmission and pathology.", "Even stronger preference for the upper airway temperature of 33°C was evident for the S protein of HCoV-229E, a common cold coronavirus."]}
{"id": 1003154, "claim": "Transferrin receptor is another receptor for sars-cov-2 entry", "label": "SUPPORTED", "evidence": ["Collectively, this report indicates that TfR is another receptor for SARS-CoV-2 entry and a promising anti-COVID-19 target.", "TfR-virus co-localization is found both on the membranes and in the cytoplasma, suggesting SARS-CoV-2 transporting by TfR, the iron-transporting receptor shuttling between cell membranes and cytoplasma."]}
{"id": 1003155, "claim": "Transferrin receptor is not receptor for sars-cov-2 entry", "label": "REFUTED", "evidence": ["Collectively, this report indicates that TfR is another receptor for SARS-CoV-2 entry and a promising anti-COVID-19 target.", "TfR-virus co-localization is found both on the membranes and in the cytoplasma, suggesting SARS-CoV-2 transporting by TfR, the iron-transporting receptor shuttling between cell membranes and cytoplasma."]}
{"id": 1003156, "claim": "China raises alarm after 63 local infections found in hebei province on one day.", "label": "SUPPORTED", "evidence": ["More from South China Morning Post: Coronavirus: China says it can produce 1 billion doses of a Sinopharm vaccine this year Chinas first case of new coronavirus strain is no cause for alarm, says infectious disease expert Coronavirus: China must detect asymptomatic cases to prevent Lunar New Year spread China on alert for new coronavirus strain but flights from Britain continue This article Coronavirus: Chinese city in lockdown as Hebei province has biggest outbreak in months first appeared on South China Morning Post For the latest news from the South China Morning Post download our mobile app."]}
{"id": 1003157, "claim": "China raises alarm after 63 local infections found in hebei province on one month.", "label": "REFUTED", "evidence": ["More from South China Morning Post: Coronavirus: China says it can produce 1 billion doses of a Sinopharm vaccine this year Chinas first case of new coronavirus strain is no cause for alarm, says infectious disease expert Coronavirus: China must detect asymptomatic cases to prevent Lunar New Year spread China on alert for new coronavirus strain but flights from Britain continue This article Coronavirus: Chinese city in lockdown as Hebei province has biggest outbreak in months first appeared on South China Morning Post For the latest news from the South China Morning Post download our mobile app."]}
{"id": 1003158, "claim": "China raises alarm after 63 local infections found in hebei province on one year.", "label": "REFUTED", "evidence": ["More from South China Morning Post: Coronavirus: China says it can produce 1 billion doses of a Sinopharm vaccine this year Chinas first case of new coronavirus strain is no cause for alarm, says infectious disease expert Coronavirus: China must detect asymptomatic cases to prevent Lunar New Year spread China on alert for new coronavirus strain but flights from Britain continue This article Coronavirus: Chinese city in lockdown as Hebei province has biggest outbreak in months first appeared on South China Morning Post For the latest news from the South China Morning Post download our mobile app."]}
{"id": 1003159, "claim": "China raises alarm after 63 local infections found in hebei province on one week.", "label": "REFUTED", "evidence": ["More from South China Morning Post: Coronavirus: China says it can produce 1 billion doses of a Sinopharm vaccine this year Chinas first case of new coronavirus strain is no cause for alarm, says infectious disease expert Coronavirus: China must detect asymptomatic cases to prevent Lunar New Year spread China on alert for new coronavirus strain but flights from Britain continue This article Coronavirus: Chinese city in lockdown as Hebei province has biggest outbreak in months first appeared on South China Morning Post For the latest news from the South China Morning Post download our mobile app."]}
{"id": 1003160, "claim": "Blood thinners may improve survival among hospitalized covid-19 patients", "label": "SUPPORTED", "evidence": ["Patients were right-censored if they were hospitalized at the time of data-freeze... view more Credit: Mount Sinai Health System Treating hospitalized COVID-19 patients with anticoagulants--blood thinners that slow down clotting--may improve their chances of survival, researchers from the Mount Sinai COVID Informatics Center report.", "\"Using anticoagulants should be considered when patients get admitted to the ER and have tested positive for COVID-19 to possibly improve outcomes.", "The study found that hospitalized COVID-19 patients treated with anticoagulants had improved outcomes both in and out of the intensive care unit setting.", "Treatment with anticoagulants was associated with improved hospital survival among COVID-19 patients both in and out of the intensive care unit setting."]}
{"id": 1003161, "claim": "Blood thinners may reduce survival among hospitalized covid-19 patients", "label": "REFUTED", "evidence": ["Patients were right-censored if they were hospitalized at the time of data-freeze... view more Credit: Mount Sinai Health System Treating hospitalized COVID-19 patients with anticoagulants--blood thinners that slow down clotting--may improve their chances of survival, researchers from the Mount Sinai COVID Informatics Center report.", "\"Using anticoagulants should be considered when patients get admitted to the ER and have tested positive for COVID-19 to possibly improve outcomes.", "The study found that hospitalized COVID-19 patients treated with anticoagulants had improved outcomes both in and out of the intensive care unit setting.", "Treatment with anticoagulants was associated with improved hospital survival among COVID-19 patients both in and out of the intensive care unit setting."]}
{"id": 1003162, "claim": "Blood thinners may decrease survival among hospitalized covid-19 patients", "label": "REFUTED", "evidence": ["Patients were right-censored if they were hospitalized at the time of data-freeze... view more Credit: Mount Sinai Health System Treating hospitalized COVID-19 patients with anticoagulants--blood thinners that slow down clotting--may improve their chances of survival, researchers from the Mount Sinai COVID Informatics Center report.", "\"Using anticoagulants should be considered when patients get admitted to the ER and have tested positive for COVID-19 to possibly improve outcomes.", "The study found that hospitalized COVID-19 patients treated with anticoagulants had improved outcomes both in and out of the intensive care unit setting.", "Treatment with anticoagulants was associated with improved hospital survival among COVID-19 patients both in and out of the intensive care unit setting."]}
{"id": 1003163, "claim": "Blood thinners may limit survival among hospitalized covid-19 patients", "label": "REFUTED", "evidence": ["Patients were right-censored if they were hospitalized at the time of data-freeze... view more Credit: Mount Sinai Health System Treating hospitalized COVID-19 patients with anticoagulants--blood thinners that slow down clotting--may improve their chances of survival, researchers from the Mount Sinai COVID Informatics Center report.", "\"Using anticoagulants should be considered when patients get admitted to the ER and have tested positive for COVID-19 to possibly improve outcomes.", "The study found that hospitalized COVID-19 patients treated with anticoagulants had improved outcomes both in and out of the intensive care unit setting.", "Treatment with anticoagulants was associated with improved hospital survival among COVID-19 patients both in and out of the intensive care unit setting."]}
{"id": 1003164, "claim": "Oxford vaccine could be 59 % effective against asymptomatic infections , analysis shows", "label": "SUPPORTED", "evidence": ["The BMJ The Oxford and AstraZeneca covid-19 vaccine prevented some asymptomatic covid-19 infections in phase III trials, but the effect was mainly seen in the group who received a half dose first, followed by a full dose, the peer reviewed efficacy results have shown.1 The study, published in the Lancet , found that vaccine efficacy against asymptomatic transmission was 59% in the group that received a half dose followed by a standard dose (seven cases among 1120 participants versus 17 cases among 1127 participants in the control group), but just 4% in the group that received two standard doses (22 among 2168 participants versus 23 among 2223 for the control)."]}
{"id": 1003165, "claim": "Oxford vaccine cannot be 59 % effective against asymptomatic infections, analysis shows", "label": "REFUTED", "evidence": ["The BMJ The Oxford and AstraZeneca covid-19 vaccine prevented some asymptomatic covid-19 infections in phase III trials, but the effect was mainly seen in the group who received a half dose first, followed by a full dose, the peer reviewed efficacy results have shown.1 The study, published in the Lancet , found that vaccine efficacy against asymptomatic transmission was 59% in the group that received a half dose followed by a standard dose (seven cases among 1120 participants versus 17 cases among 1127 participants in the control group), but just 4% in the group that received two standard doses (22 among 2168 participants versus 23 among 2223 for the control)."]}
{"id": 1003166, "claim": "Sars-cov-2 infection induces robust , neutralizing antibody responses that are stable for at least three months", "label": "SUPPORTED", "evidence": ["We also show that titers are stable for at least a period approximating three months, and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2.", "One Sentence Summary Antibody responses induced by natural mild-to- moderate SARS-CoV-2 infection are robust, neutralizing and are stable for at least 3 months."]}
{"id": 1003167, "claim": "Sars-cov-2 infection induces robust, neutralizing antibody responses that are stable for at least three weeks", "label": "REFUTED", "evidence": ["We also show that titers are stable for at least a period approximating three months, and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2.", "One Sentence Summary Antibody responses induced by natural mild-to- moderate SARS-CoV-2 infection are robust, neutralizing and are stable for at least 3 months."]}
{"id": 1003168, "claim": "Early approval of a covid-19 vaccine could stymie the hunt for better ones", "label": "SUPPORTED", "evidence": ["The first vaccine to cross the finish line might be only marginally effective, yet it could become the enemy of the goodor even the greatcandidates in the wings by disrupting ongoing studies."]}
{"id": 1003169, "claim": "Early approval of a covid-19 vaccine could stymie the hunt for eradication ones", "label": "REFUTED", "evidence": ["The first vaccine to cross the finish line might be only marginally effective, yet it could become the enemy of the goodor even the greatcandidates in the wings by disrupting ongoing studies."]}
{"id": 1003170, "claim": "Plasma levels of soluble ace2 are associated with sex , metabolic syndrome , and its biomarkers in a large cohort , pointing to a possible mechanism for increased severity in covid-19", "label": "SUPPORTED", "evidence": ["The upregulation may be related to the tissue-specific patterns of increased SARS-CoV-2 infectivity in patients with cardiometabolic disease and/or liver damage and warrants further research on sACE2 as a potential biomarker for COVID-19 severity.", "Age and sex differences in soluble ACE2 may give insights for COVID-19.", "1 The associations of plasma sACE2 levels with sex, age, and metabolic syndrome (MetS)."]}
{"id": 1003171, "claim": "Plasma levels of soluble ace2 are inconsistent with sex, metabolic syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in covid-19", "label": "REFUTED", "evidence": ["The upregulation may be related to the tissue-specific patterns of increased SARS-CoV-2 infectivity in patients with cardiometabolic disease and/or liver damage and warrants further research on sACE2 as a potential biomarker for COVID-19 severity.", "Age and sex differences in soluble ACE2 may give insights for COVID-19.", "1 The associations of plasma sACE2 levels with sex, age, and metabolic syndrome (MetS)."]}
{"id": 1003172, "claim": "Repurposing of miglustat to inhibit the coronavirus severe acquired respiratory syndrome sars-cov-2.", "label": "SUPPORTED", "evidence": ["Repurposing of Miglustat to inhibit the coronavirus Severe Acquired Respiratory Syndrome S", "The mechanism resides in the inhibitory activity towards α-glucosidases that are involved in early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.", "The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.", "The mechanism resides in the inhibitory activity towards -glucosidases that are involved in early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.", "The activity of Miglustat is here demonstrated for SARS-CoV-2 at concentrations achievable in the plasma by current clinical regimens without cytotoxicity."]}
{"id": 1003173, "claim": "Repurposing of miglustat to investigate the coronavirus severe acquired respiratory syndrome sars-cov-2.", "label": "REFUTED", "evidence": ["Repurposing of Miglustat to inhibit the coronavirus Severe Acquired Respiratory Syndrome S", "The mechanism resides in the inhibitory activity towards α-glucosidases that are involved in early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.", "The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.", "The mechanism resides in the inhibitory activity towards -glucosidases that are involved in early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.", "The activity of Miglustat is here demonstrated for SARS-CoV-2 at concentrations achievable in the plasma by current clinical regimens without cytotoxicity."]}
{"id": 1003174, "claim": "Repurposing of miglustat to form the coronavirus severe acquired respiratory syndrome sars-cov-2.", "label": "REFUTED", "evidence": ["Repurposing of Miglustat to inhibit the coronavirus Severe Acquired Respiratory Syndrome S", "The mechanism resides in the inhibitory activity towards α-glucosidases that are involved in early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.", "The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.", "The mechanism resides in the inhibitory activity towards -glucosidases that are involved in early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.", "The activity of Miglustat is here demonstrated for SARS-CoV-2 at concentrations achievable in the plasma by current clinical regimens without cytotoxicity."]}
{"id": 1003175, "claim": "Repurposing of miglustat to study the coronavirus severe acquired respiratory syndrome sars-cov-2.", "label": "REFUTED", "evidence": ["Repurposing of Miglustat to inhibit the coronavirus Severe Acquired Respiratory Syndrome S", "The mechanism resides in the inhibitory activity towards α-glucosidases that are involved in early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.", "The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.", "The mechanism resides in the inhibitory activity towards -glucosidases that are involved in early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.", "The activity of Miglustat is here demonstrated for SARS-CoV-2 at concentrations achievable in the plasma by current clinical regimens without cytotoxicity."]}
{"id": 1003176, "claim": "Combined impacts of ventilation and mask effective filtration efficiency.", "label": "SUPPORTED", "evidence": ["Finally, the results demonstrate that the reductions provided by ventilation and masks are synergistic and multiplicative.", "The use of moderate to high effective filtration efficiency masks by all individuals present, on the other hand, was able to significantly reduce infection probability and could achieve reductions in infection probability by 5x, 10x, or even > 100x dependent on the mask used and use of a mask fitter.", "The results reinforce the use of properly donned masks to achieve reduced aerosol transmission of SARS-CoV-2 and other infectious diseases transmitted via respiratory aerosol indoors and provide new motivation to further improve the effective filtration efficiency of common face coverings through improved design, and/or the use of mask fitters.", "In this paper, we evaluate the efficacy of ventilation, mask effective filtration efficiency, and the combined effect of the two on the reduction of aerosol infection probability for COVID-19 in a classroom setting.", "However, effective filtration efficiencies approaching the mask material filtration efficiency were achievable using simple mask fitters."]}
{"id": 1003177, "claim": "Combined impacts of contamination and mask effective filtration efficiency.", "label": "REFUTED", "evidence": ["Finally, the results demonstrate that the reductions provided by ventilation and masks are synergistic and multiplicative.", "The use of moderate to high effective filtration efficiency masks by all individuals present, on the other hand, was able to significantly reduce infection probability and could achieve reductions in infection probability by 5x, 10x, or even > 100x dependent on the mask used and use of a mask fitter.", "The results reinforce the use of properly donned masks to achieve reduced aerosol transmission of SARS-CoV-2 and other infectious diseases transmitted via respiratory aerosol indoors and provide new motivation to further improve the effective filtration efficiency of common face coverings through improved design, and/or the use of mask fitters.", "In this paper, we evaluate the efficacy of ventilation, mask effective filtration efficiency, and the combined effect of the two on the reduction of aerosol infection probability for COVID-19 in a classroom setting.", "However, effective filtration efficiencies approaching the mask material filtration efficiency were achievable using simple mask fitters."]}
{"id": 1003178, "claim": "Combined impacts of water and mask effective filtration efficiency.", "label": "REFUTED", "evidence": ["Finally, the results demonstrate that the reductions provided by ventilation and masks are synergistic and multiplicative.", "The use of moderate to high effective filtration efficiency masks by all individuals present, on the other hand, was able to significantly reduce infection probability and could achieve reductions in infection probability by 5x, 10x, or even > 100x dependent on the mask used and use of a mask fitter.", "The results reinforce the use of properly donned masks to achieve reduced aerosol transmission of SARS-CoV-2 and other infectious diseases transmitted via respiratory aerosol indoors and provide new motivation to further improve the effective filtration efficiency of common face coverings through improved design, and/or the use of mask fitters.", "In this paper, we evaluate the efficacy of ventilation, mask effective filtration efficiency, and the combined effect of the two on the reduction of aerosol infection probability for COVID-19 in a classroom setting.", "However, effective filtration efficiencies approaching the mask material filtration efficiency were achievable using simple mask fitters."]}
{"id": 1003179, "claim": "Combined impacts of ph and mask effective filtration efficiency.", "label": "REFUTED", "evidence": ["Finally, the results demonstrate that the reductions provided by ventilation and masks are synergistic and multiplicative.", "The use of moderate to high effective filtration efficiency masks by all individuals present, on the other hand, was able to significantly reduce infection probability and could achieve reductions in infection probability by 5x, 10x, or even > 100x dependent on the mask used and use of a mask fitter.", "The results reinforce the use of properly donned masks to achieve reduced aerosol transmission of SARS-CoV-2 and other infectious diseases transmitted via respiratory aerosol indoors and provide new motivation to further improve the effective filtration efficiency of common face coverings through improved design, and/or the use of mask fitters.", "In this paper, we evaluate the efficacy of ventilation, mask effective filtration efficiency, and the combined effect of the two on the reduction of aerosol infection probability for COVID-19 in a classroom setting.", "However, effective filtration efficiencies approaching the mask material filtration efficiency were achievable using simple mask fitters."]}
{"id": 1003180, "claim": "Association of cardiac infection with sars-cov-2 in confirmed covid-19 autopsy cases", "label": "SUPPORTED", "evidence": ["Myocardial injury and COVID-19: Possible mechanisms.", "COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?"]}
{"id": 1003181, "claim": "Association of cardiac infection with sars-cov-2 in confirmed covid-19 treatment cases", "label": "REFUTED", "evidence": ["Myocardial injury and COVID-19: Possible mechanisms.", "COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?"]}
{"id": 1003182, "claim": "Lack of cardiac infection with sars-cov-2 in confirmed covid-19 autopsy cases", "label": "REFUTED", "evidence": ["Myocardial injury and COVID-19: Possible mechanisms.", "COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?"]}
{"id": 1003183, "claim": "Melatonin is significantly associated with survival of intubated covid-19 patients", "label": "SUPPORTED", "evidence": ["Additionally, melatonin exposure after intubation was statically associated with a positive outcome in COVID-19 patients (demographics and comorbidities adjusted HR: 0.127, 95% CI: 6.01E-02 - 0.269, p-value = 7.15E-08).", "Conclusions Melatonin exposure after intubation is significantly associated with a positive outcome in COVID-19 and non-COVID-19 patients.", "Melatonin exposure after intubation was statistically associated with a positive outcome in COVID-19 (demographics and comorbidities adjusted HR: 0.131, 95% CI: 7.76E-02 - 0.223, p-value = 8.19E-14) and non-COVID-19 (demographics and comorbidities adjusted HR: 0.278, 95% CI: 0.142 - 0.542, p-value = 1.72E-04) intubated patients.", "Additionally, melatonin exposure after intubation is significantly associated with a positive outcome in COVID-19 patients requiring mechanical ventilation."]}
{"id": 1003184, "claim": "Melatonin is not associated with survival of intubated covid-19 patients", "label": "REFUTED", "evidence": ["Additionally, melatonin exposure after intubation was statically associated with a positive outcome in COVID-19 patients (demographics and comorbidities adjusted HR: 0.127, 95% CI: 6.01E-02 - 0.269, p-value = 7.15E-08).", "Conclusions Melatonin exposure after intubation is significantly associated with a positive outcome in COVID-19 and non-COVID-19 patients.", "Melatonin exposure after intubation was statistically associated with a positive outcome in COVID-19 (demographics and comorbidities adjusted HR: 0.131, 95% CI: 7.76E-02 - 0.223, p-value = 8.19E-14) and non-COVID-19 (demographics and comorbidities adjusted HR: 0.278, 95% CI: 0.142 - 0.542, p-value = 1.72E-04) intubated patients.", "Additionally, melatonin exposure after intubation is significantly associated with a positive outcome in COVID-19 patients requiring mechanical ventilation."]}
{"id": 1003185, "claim": "Melatonin is significantly lower with survival of intubated covid-19 patients", "label": "REFUTED", "evidence": ["Additionally, melatonin exposure after intubation was statically associated with a positive outcome in COVID-19 patients (demographics and comorbidities adjusted HR: 0.127, 95% CI: 6.01E-02 - 0.269, p-value = 7.15E-08).", "Conclusions Melatonin exposure after intubation is significantly associated with a positive outcome in COVID-19 and non-COVID-19 patients.", "Melatonin exposure after intubation was statistically associated with a positive outcome in COVID-19 (demographics and comorbidities adjusted HR: 0.131, 95% CI: 7.76E-02 - 0.223, p-value = 8.19E-14) and non-COVID-19 (demographics and comorbidities adjusted HR: 0.278, 95% CI: 0.142 - 0.542, p-value = 1.72E-04) intubated patients.", "Additionally, melatonin exposure after intubation is significantly associated with a positive outcome in COVID-19 patients requiring mechanical ventilation."]}
{"id": 1003186, "claim": "Covid-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact", "label": "SUPPORTED", "evidence": ["The use of a symptom reducing vaccine will require twice as many people vaccinated than a susceptibility reducing vaccine with the same 90% VEDIS to prevent 50% of the infections and death over one year."]}
{"id": 1003187, "claim": "Covid-19 vaccines that reduce symptoms but do so block infection need higher coverage and faster rollout to achieve population impact", "label": "REFUTED", "evidence": ["The use of a symptom reducing vaccine will require twice as many people vaccinated than a susceptibility reducing vaccine with the same 90% VEDIS to prevent 50% of the infections and death over one year."]}
{"id": 1003188, "claim": "Covid-19 vaccines that reduce symptoms but do, block infection need higher coverage and faster rollout to achieve population impact", "label": "REFUTED", "evidence": ["The use of a symptom reducing vaccine will require twice as many people vaccinated than a susceptibility reducing vaccine with the same 90% VEDIS to prevent 50% of the infections and death over one year."]}
{"id": 1003189, "claim": "Covid-19 vaccines that reduce symptoms but do can block infection need higher coverage and faster rollout to achieve population impact", "label": "REFUTED", "evidence": ["The use of a symptom reducing vaccine will require twice as many people vaccinated than a susceptibility reducing vaccine with the same 90% VEDIS to prevent 50% of the infections and death over one year."]}
{"id": 1003190, "claim": "Attenuated influenza virions expressing the sars- cov-2 receptor-binding domain induce neutralizing antibodies in mice", "label": "SUPPORTED", "evidence": ["A single-dose intranasal inoculation of mice with ΔNA(RBD)-Flu elicits serum neutralizing antibody titers against SAR-CoV-2 comparable to those observed in humans following natural infection (~1:200).", "The resulting ΔNA(RBD)-Flu virus can be generated by reverse genetics and grown to high titers in cell culture."]}
{"id": 1003191, "claim": "Attenuated influenza virions expressing the sars- cov-2 receptor-binding domain induce neutralizing antibodies in humans", "label": "REFUTED", "evidence": ["A single-dose intranasal inoculation of mice with ΔNA(RBD)-Flu elicits serum neutralizing antibody titers against SAR-CoV-2 comparable to those observed in humans following natural infection (~1:200).", "The resulting ΔNA(RBD)-Flu virus can be generated by reverse genetics and grown to high titers in cell culture."]}
{"id": 1003192, "claim": "Attenuated influenza virions lacking the sars- cov-2 receptor-binding domain induce neutralizing antibodies in mice", "label": "REFUTED", "evidence": ["A single-dose intranasal inoculation of mice with ΔNA(RBD)-Flu elicits serum neutralizing antibody titers against SAR-CoV-2 comparable to those observed in humans following natural infection (~1:200).", "The resulting ΔNA(RBD)-Flu virus can be generated by reverse genetics and grown to high titers in cell culture."]}
{"id": 1003193, "claim": "Eli lilly begins testing covid-19 drug derived from blood of survivor", "label": "SUPPORTED", "evidence": ["A blood sample from an early U.S. survivor of COVID-19 is being used by Eli Lilly to develop an experimental drug, which is now undergoing human tests to examine the drug's ability to fight the coronavirus."]}
{"id": 1003194, "claim": "Eli lilly begins testing covid-19 drug derived from blood of donors", "label": "REFUTED", "evidence": ["A blood sample from an early U.S. survivor of COVID-19 is being used by Eli Lilly to develop an experimental drug, which is now undergoing human tests to examine the drug's ability to fight the coronavirus."]}
{"id": 1003195, "claim": "Eli lilly begins testing covid-19 drug derived from blood of healthy", "label": "REFUTED", "evidence": ["A blood sample from an early U.S. survivor of COVID-19 is being used by Eli Lilly to develop an experimental drug, which is now undergoing human tests to examine the drug's ability to fight the coronavirus."]}
{"id": 1003196, "claim": "Eli lilly begins testing covid-19 drug derived from blood of patients", "label": "REFUTED", "evidence": ["A blood sample from an early U.S. survivor of COVID-19 is being used by Eli Lilly to develop an experimental drug, which is now undergoing human tests to examine the drug's ability to fight the coronavirus."]}
{"id": 1003197, "claim": "Prophylactic intranasal administration of a tlr2 agonist reduces upper respiratory tract viral shedding in a sars-cov-2 challenge ferret model", "label": "SUPPORTED", "evidence": ["There was one ferret in Group 1 showing detectable, but below the quantifiable limit, viral RNA, and no other INNA-051 treated ferrets showing detectable viral RNA in lung tissue on day 3 and days 12-14 dpc This study provides evidence supporting a novel approach to prevent SARS-CoV-2 transmission, based on reduced viral shedding, following prophylactic i.n administration of INNA-051.", "We show that prophylactic intra-nasal administration of the TLR2/6 agonist INNA-051 in a SARS-CoV-2 ferret infection model effectively reduces levels of viral RNA in the nose and throat."]}
{"id": 1003198, "claim": "Prophylactic intranasal administration of a tlr2 agonist increases upper respiratory tract viral shedding in a sars-cov-2 challenge ferret model", "label": "REFUTED", "evidence": ["There was one ferret in Group 1 showing detectable, but below the quantifiable limit, viral RNA, and no other INNA-051 treated ferrets showing detectable viral RNA in lung tissue on day 3 and days 12-14 dpc This study provides evidence supporting a novel approach to prevent SARS-CoV-2 transmission, based on reduced viral shedding, following prophylactic i.n administration of INNA-051.", "We show that prophylactic intra-nasal administration of the TLR2/6 agonist INNA-051 in a SARS-CoV-2 ferret infection model effectively reduces levels of viral RNA in the nose and throat."]}
{"id": 1003199, "claim": "Prophylactic intranasal administration of a tlr2 agonist increased upper respiratory tract viral shedding in a sars-cov-2 challenge ferret model", "label": "REFUTED", "evidence": ["There was one ferret in Group 1 showing detectable, but below the quantifiable limit, viral RNA, and no other INNA-051 treated ferrets showing detectable viral RNA in lung tissue on day 3 and days 12-14 dpc This study provides evidence supporting a novel approach to prevent SARS-CoV-2 transmission, based on reduced viral shedding, following prophylactic i.n administration of INNA-051.", "We show that prophylactic intra-nasal administration of the TLR2/6 agonist INNA-051 in a SARS-CoV-2 ferret infection model effectively reduces levels of viral RNA in the nose and throat."]}
{"id": 1003200, "claim": "Prophylactic intranasal administration of a tlr2 agonist enhanced upper respiratory tract viral shedding in a sars-cov-2 challenge ferret model", "label": "REFUTED", "evidence": ["There was one ferret in Group 1 showing detectable, but below the quantifiable limit, viral RNA, and no other INNA-051 treated ferrets showing detectable viral RNA in lung tissue on day 3 and days 12-14 dpc This study provides evidence supporting a novel approach to prevent SARS-CoV-2 transmission, based on reduced viral shedding, following prophylactic i.n administration of INNA-051.", "We show that prophylactic intra-nasal administration of the TLR2/6 agonist INNA-051 in a SARS-CoV-2 ferret infection model effectively reduces levels of viral RNA in the nose and throat."]}
{"id": 1003201, "claim": "Theoretically , hla-a3.1 is the susceptible gene of sars coronavirus , and individuals without this susceptible gene are not easily affected or have resistance to the disease .", "label": "SUPPORTED", "evidence": ["These results support the hypothesis that the HLA-B4601 gene in Asian populations is correlated with the severity of SARS infection."]}
{"id": 1003202, "claim": "Theoretically, hla-a3.1 is the susceptible gene of sars coronavirus, and individuals without this susceptible gene are also easily affected or have resistance to the disease.", "label": "REFUTED", "evidence": ["These results support the hypothesis that the HLA-B4601 gene in Asian populations is correlated with the severity of SARS infection."]}
{"id": 1003203, "claim": "Sars-cov-2 differs from sars-cov in the requirements for receptor expression and proteolytic activation to trigger cell-cell fusion and is not inhibited by bromhexine", "label": "SUPPORTED", "evidence": ["Taken together, we observed robust SARS-CoV-2 spike protein-mediated cell-cell fusion that was not dependent on exogenous TMPRSS2 expression and that was not inhibited by Bromhexine.", "We observed that cell-cell fusion by SARS-CoV-S and SARS-CoV2-S was not inhibited by Bromhexine, and only SARS-CoV-S activity was slightly inhibited by Ambroxol in the presence of TMPRSS2.", "According to our results the Bromhexine-mediated enhancement was specific for SARS-CoV-2 spike protein and was not seen with VSV-G as fusion effector, nor did we observe significant effects with the SARS-CoV-2-S mutants and SARS-CoV-S (Figs."]}
{"id": 1003204, "claim": "Sars-cov-2 differs from sars-cov in the requirements for receptor expression and proteolytic activation to trigger cell-cell fusion and is primarily inhibited by bromhexine", "label": "REFUTED", "evidence": ["Taken together, we observed robust SARS-CoV-2 spike protein-mediated cell-cell fusion that was not dependent on exogenous TMPRSS2 expression and that was not inhibited by Bromhexine.", "We observed that cell-cell fusion by SARS-CoV-S and SARS-CoV2-S was not inhibited by Bromhexine, and only SARS-CoV-S activity was slightly inhibited by Ambroxol in the presence of TMPRSS2.", "According to our results the Bromhexine-mediated enhancement was specific for SARS-CoV-2 spike protein and was not seen with VSV-G as fusion effector, nor did we observe significant effects with the SARS-CoV-2-S mutants and SARS-CoV-S (Figs."]}
{"id": 1003205, "claim": "Sars-cov-2 differs from sars-cov in the requirements for receptor expression and proteolytic activation to trigger cell-cell fusion and is mainly inhibited by bromhexine", "label": "REFUTED", "evidence": ["Taken together, we observed robust SARS-CoV-2 spike protein-mediated cell-cell fusion that was not dependent on exogenous TMPRSS2 expression and that was not inhibited by Bromhexine.", "We observed that cell-cell fusion by SARS-CoV-S and SARS-CoV2-S was not inhibited by Bromhexine, and only SARS-CoV-S activity was slightly inhibited by Ambroxol in the presence of TMPRSS2.", "According to our results the Bromhexine-mediated enhancement was specific for SARS-CoV-2 spike protein and was not seen with VSV-G as fusion effector, nor did we observe significant effects with the SARS-CoV-2-S mutants and SARS-CoV-S (Figs."]}
{"id": 1003206, "claim": "Sars-cov-2 differs from sars-cov in the requirements for receptor expression and proteolytic activation to trigger cell-cell fusion and is specifically inhibited by bromhexine", "label": "REFUTED", "evidence": ["Taken together, we observed robust SARS-CoV-2 spike protein-mediated cell-cell fusion that was not dependent on exogenous TMPRSS2 expression and that was not inhibited by Bromhexine.", "We observed that cell-cell fusion by SARS-CoV-S and SARS-CoV2-S was not inhibited by Bromhexine, and only SARS-CoV-S activity was slightly inhibited by Ambroxol in the presence of TMPRSS2.", "According to our results the Bromhexine-mediated enhancement was specific for SARS-CoV-2 spike protein and was not seen with VSV-G as fusion effector, nor did we observe significant effects with the SARS-CoV-2-S mutants and SARS-CoV-S (Figs."]}
{"id": 1003207, "claim": "People are being encouraged to put up christmas lights to spread cheer while they 're social distancing.", "label": "SUPPORTED", "evidence": ["People around the country are putting up their Christmas lights and encouraging others to do the same."]}
{"id": 1003208, "claim": "People are not encouraged to put up christmas lights to spread cheer while they're social distancing.", "label": "REFUTED", "evidence": ["People around the country are putting up their Christmas lights and encouraging others to do the same."]}
{"id": 1003209, "claim": "People are being unable to put up christmas lights to spread cheer while they're social distancing.", "label": "REFUTED", "evidence": ["People around the country are putting up their Christmas lights and encouraging others to do the same."]}
{"id": 1003210, "claim": "First case of covid-19 reinfection confirmed", "label": "SUPPORTED", "evidence": ["But these researchers could not be more clear: \"We report the first case of reinfection of COVID-19,\" they wrote.", "The man was diagnosed with COVID-19 on March 26, hospitalized, then recovered."]}
{"id": 1003211, "claim": "No case of covid-19 reinfection confirmed", "label": "REFUTED", "evidence": ["But these researchers could not be more clear: \"We report the first case of reinfection of COVID-19,\" they wrote.", "The man was diagnosed with COVID-19 on March 26, hospitalized, then recovered."]}
{"id": 1003212, "claim": "Another case of covid-19 reinfection confirmed", "label": "REFUTED", "evidence": ["But these researchers could not be more clear: \"We report the first case of reinfection of COVID-19,\" they wrote.", "The man was diagnosed with COVID-19 on March 26, hospitalized, then recovered."]}
{"id": 1003213, "claim": "First case of covid-19 reinfection?", "label": "REFUTED", "evidence": ["But these researchers could not be more clear: \"We report the first case of reinfection of COVID-19,\" they wrote.", "The man was diagnosed with COVID-19 on March 26, hospitalized, then recovered."]}
{"id": 1003214, "claim": "Novartis bags mesoblast limited cell therapy , remestemcel-l for covid-19 ards .", "label": "SUPPORTED", "evidence": ["Jan 13, 2021 Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off Jan 12, 2021 Parkinson's Disease: How close are we to a cure?", "Per the agreement, Novartis will acquire the exclusive worldwide rights to develop, commercialize and manufacture remestemcel-L for ARDS and obtain access to an innovative cell-therapy platform with a range of potential applications in severe respiratory conditions and beyond.", "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: Discuss this template [e]: Edit this template []: You need to accept this checkbox.", "Novartis entered into an exclusive worldwide license and collaboration agreement with Mesoblast for the development, commercialization and manufacturing of remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19."]}
{"id": 1003215, "claim": "Novartis bags mesoblast limited cell death, remestemcel-l for covid-19 ards.", "label": "REFUTED", "evidence": ["Jan 13, 2021 Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off Jan 12, 2021 Parkinson's Disease: How close are we to a cure?", "Per the agreement, Novartis will acquire the exclusive worldwide rights to develop, commercialize and manufacture remestemcel-L for ARDS and obtain access to an innovative cell-therapy platform with a range of potential applications in severe respiratory conditions and beyond.", "]: dot [@]: at [MHRA]: Medicines and Healthcare products Regulatory Agency [JCVI]: Joint Committee for Vaccination and Immunisation [PMC]: Penske Media Corporation [ COVID-19]: coronavirus disease 2019 [COVID-19]: coronavirus disease 2019 [v]: View this template [t]: Discuss this template [e]: Edit this template []: You need to accept this checkbox.", "Novartis entered into an exclusive worldwide license and collaboration agreement with Mesoblast for the development, commercialization and manufacturing of remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS), including that associated with COVID-19."]}
{"id": 1003216, "claim": "Antibodies to sars-cov-2 are associated with protection against reinfection", "label": "SUPPORTED", "evidence": ["Overall, positive baseline anti-spike antibodies were associated with lower rates of PCR-positivity (with or without symptoms) (adjusted rate ratio 0.24 [95%CI 0.08-0.76, p=0.015]).", "Conclusions Prior SARS-CoV-2 infection that generated antibody responses offered protection from reinfection for most people in the six months following infection."]}
{"id": 1003217, "claim": "Antibodies to sars-cov-2 are associated without protection against reinfection", "label": "REFUTED", "evidence": ["Overall, positive baseline anti-spike antibodies were associated with lower rates of PCR-positivity (with or without symptoms) (adjusted rate ratio 0.24 [95%CI 0.08-0.76, p=0.015]).", "Conclusions Prior SARS-CoV-2 infection that generated antibody responses offered protection from reinfection for most people in the six months following infection."]}
{"id": 1003218, "claim": "Physical interventions to interrupt or reduce the spread of respiratory viruses", "label": "SUPPORTED", "evidence": ["Cochrane Review: Interventions for the interruption or reduction of the spread of respiratory viruses.", "We included physical interventions (screening at entry ports, isolation, quarantine, social distancing, barriers, personal protection, hand hygiene) to prevent respiratory virus transmission.", "The highest quality cluster-RCTs suggest respiratory virus spread can be prevented by hygienic measures, such as handwashing, especially around younger children.", "Interventions for the interruption or reduction of the spread of respiratory viruses."]}
{"id": 1003219, "claim": "Physical interventions to interrupt or promote the spread of respiratory viruses", "label": "REFUTED", "evidence": ["Cochrane Review: Interventions for the interruption or reduction of the spread of respiratory viruses.", "We included physical interventions (screening at entry ports, isolation, quarantine, social distancing, barriers, personal protection, hand hygiene) to prevent respiratory virus transmission.", "The highest quality cluster-RCTs suggest respiratory virus spread can be prevented by hygienic measures, such as handwashing, especially around younger children.", "Interventions for the interruption or reduction of the spread of respiratory viruses."]}
{"id": 1003220, "claim": "Favipiravir strikes the sars-cov-2 at its achilles heel , the rna polymerase", "label": "SUPPORTED", "evidence": ["Here we show that Favipiravir exerts an antiviral effect as a nucleotide analogue through a combination of chain termination, slowed RNA synthesis and lethal mutagenesis."]}
{"id": 1003221, "claim": "Favipiravir strikes the sars-cov-2 at its top heel, the rna polymerase", "label": "REFUTED", "evidence": ["Here we show that Favipiravir exerts an antiviral effect as a nucleotide analogue through a combination of chain termination, slowed RNA synthesis and lethal mutagenesis."]}
{"id": 1003222, "claim": "Favipiravir strikes the sars-cov-2 at its end heel, the rna polymerase", "label": "REFUTED", "evidence": ["Here we show that Favipiravir exerts an antiviral effect as a nucleotide analogue through a combination of chain termination, slowed RNA synthesis and lethal mutagenesis."]}
{"id": 1003223, "claim": "Covid-19 causes long-term lung and heart damage but it may improve with time", "label": "SUPPORTED", "evidence": ["Coronavirus patients recover faster if they undergo rehabilitation as soon as possible after coming off ventilators or leaving intensive care COVID-19 patients can suffer long-term lung and heart damage but, for many, this tends to improve over time, according to the first, prospective follow-up of patients infected with the coronavirus, presented at the European Respiratory Society International Congress.", "And nearly six in ten patients had heart problems after six weeks, although this may be only indirectly linked to COVID-19, a sign of the severity of the disease in general.", "COVID-19 patients can suffer long-term lung and heart damage but, for many, this tends to improve over time, according to Austrian scientists.", "Dr Sahanic's presentation is important because it is one of the first, comprehensive prospective follow-ups of these patients and shows the serious, long-term impact of COVID-19 on the lungs and heart.", "\"The bad news is that people show lung impairment from COVID-19 weeks after discharge; the good news is that the impairment tends to ameliorate over time, which suggests the lungs have a mechanism for repairing themselves,\" said Dr Sabina Sahanic, who is a clinical PhD student at the University Clinic in Innsbruck and part of the team that carried out the study, which includes Associate Professor Ivan Tancevski, Professor Judith Löffler-Ragg and Dr Thomas Sonnweber in Innsbruck."]}
{"id": 1003224, "claim": "Covid-19 reduces long-term lung and heart damage but it may improve with time", "label": "REFUTED", "evidence": ["Coronavirus patients recover faster if they undergo rehabilitation as soon as possible after coming off ventilators or leaving intensive care COVID-19 patients can suffer long-term lung and heart damage but, for many, this tends to improve over time, according to the first, prospective follow-up of patients infected with the coronavirus, presented at the European Respiratory Society International Congress.", "And nearly six in ten patients had heart problems after six weeks, although this may be only indirectly linked to COVID-19, a sign of the severity of the disease in general.", "COVID-19 patients can suffer long-term lung and heart damage but, for many, this tends to improve over time, according to Austrian scientists.", "Dr Sahanic's presentation is important because it is one of the first, comprehensive prospective follow-ups of these patients and shows the serious, long-term impact of COVID-19 on the lungs and heart.", "\"The bad news is that people show lung impairment from COVID-19 weeks after discharge; the good news is that the impairment tends to ameliorate over time, which suggests the lungs have a mechanism for repairing themselves,\" said Dr Sabina Sahanic, who is a clinical PhD student at the University Clinic in Innsbruck and part of the team that carried out the study, which includes Associate Professor Ivan Tancevski, Professor Judith Löffler-Ragg and Dr Thomas Sonnweber in Innsbruck."]}
{"id": 1003225, "claim": "Covid-19 inhibits long-term lung and heart damage but it may improve with time", "label": "REFUTED", "evidence": ["Coronavirus patients recover faster if they undergo rehabilitation as soon as possible after coming off ventilators or leaving intensive care COVID-19 patients can suffer long-term lung and heart damage but, for many, this tends to improve over time, according to the first, prospective follow-up of patients infected with the coronavirus, presented at the European Respiratory Society International Congress.", "And nearly six in ten patients had heart problems after six weeks, although this may be only indirectly linked to COVID-19, a sign of the severity of the disease in general.", "COVID-19 patients can suffer long-term lung and heart damage but, for many, this tends to improve over time, according to Austrian scientists.", "Dr Sahanic's presentation is important because it is one of the first, comprehensive prospective follow-ups of these patients and shows the serious, long-term impact of COVID-19 on the lungs and heart.", "\"The bad news is that people show lung impairment from COVID-19 weeks after discharge; the good news is that the impairment tends to ameliorate over time, which suggests the lungs have a mechanism for repairing themselves,\" said Dr Sabina Sahanic, who is a clinical PhD student at the University Clinic in Innsbruck and part of the team that carried out the study, which includes Associate Professor Ivan Tancevski, Professor Judith Löffler-Ragg and Dr Thomas Sonnweber in Innsbruck."]}
{"id": 1003226, "claim": "Pence tells governors coronavirus vaccine distribution could begin in two weeks", "label": "SUPPORTED", "evidence": ["\"We strongly believe the vaccine distribution process could begin as soon as the week of December 14,\" Pence said, according to audio of the call obtained by CBS News.", "We strongly believe the vaccine distribution process could begin as soon as the week of Dec. 14, Pence said on the call, according to CBS News.", "Siphiwe Sibeko, Associated Press Vice President Mike Pence recently told governors across the country that some doses of the COVID-19 vaccine could be distributed in two weeks, CBS News reports."]}
{"id": 1003227, "claim": "Pence tells governors coronavirus vaccine distribution could decrease in two weeks", "label": "REFUTED", "evidence": ["\"We strongly believe the vaccine distribution process could begin as soon as the week of December 14,\" Pence said, according to audio of the call obtained by CBS News.", "We strongly believe the vaccine distribution process could begin as soon as the week of Dec. 14, Pence said on the call, according to CBS News.", "Siphiwe Sibeko, Associated Press Vice President Mike Pence recently told governors across the country that some doses of the COVID-19 vaccine could be distributed in two weeks, CBS News reports."]}
{"id": 1003228, "claim": "Pence tells governors coronavirus vaccine distribution could persist in two weeks", "label": "REFUTED", "evidence": ["\"We strongly believe the vaccine distribution process could begin as soon as the week of December 14,\" Pence said, according to audio of the call obtained by CBS News.", "We strongly believe the vaccine distribution process could begin as soon as the week of Dec. 14, Pence said on the call, according to CBS News.", "Siphiwe Sibeko, Associated Press Vice President Mike Pence recently told governors across the country that some doses of the COVID-19 vaccine could be distributed in two weeks, CBS News reports."]}
{"id": 1003229, "claim": "Rare neurological disorder , guillain-barre syndrome , linked to covid-19", "label": "SUPPORTED", "evidence": ["Though there is clear clinical suspicion that COVID-19 can lead to Guillain- Barre Syndrome, many important questions remain.", "Science + Technology COVID-19 has been linked to neurological problems in those with severe disease."]}
{"id": 1003230, "claim": "Chronic neurological disorder, guillain-barre syndrome, linked to covid-19", "label": "REFUTED", "evidence": ["Though there is clear clinical suspicion that COVID-19 can lead to Guillain- Barre Syndrome, many important questions remain.", "Science + Technology COVID-19 has been linked to neurological problems in those with severe disease."]}
{"id": 1003231, "claim": "Rare neurological disorder, guillain-mouth syndrome, linked to covid-19", "label": "REFUTED", "evidence": ["Though there is clear clinical suspicion that COVID-19 can lead to Guillain- Barre Syndrome, many important questions remain.", "Science + Technology COVID-19 has been linked to neurological problems in those with severe disease."]}
{"id": 1003232, "claim": "Rare neurological disorder, guillain-endemic syndrome, linked to covid-19", "label": "REFUTED", "evidence": ["Though there is clear clinical suspicion that COVID-19 can lead to Guillain- Barre Syndrome, many important questions remain.", "Science + Technology COVID-19 has been linked to neurological problems in those with severe disease."]}
{"id": 1003233, "claim": "Viral epitope profiling of covid-19 patients reveals cross-reactivity and correlates of severity", "label": "SUPPORTED", "evidence": ["Our study reveals notable correlations between COVID-19 severity and both viral exposure history and overall strength of the antibody response to past infections.", "We mapped the landscape of linear epitopes in the SARS-CoV-2 proteome, characterized their specificity or cross- reactivity, and investigated serological and viral exposure history correlates of COVID-19 severity."]}
{"id": 1003234, "claim": "Viral epitope profiling of covid-19 patients reveals cross-reactivity and correlates of protection", "label": "REFUTED", "evidence": ["Our study reveals notable correlations between COVID-19 severity and both viral exposure history and overall strength of the antibody response to past infections.", "We mapped the landscape of linear epitopes in the SARS-CoV-2 proteome, characterized their specificity or cross- reactivity, and investigated serological and viral exposure history correlates of COVID-19 severity."]}
{"id": 1003235, "claim": "Treatment with an anti-ck2 synthetic peptide improves clinical response in covid-19 patients with pneumonia .", "label": "SUPPORTED", "evidence": ["Implications: Our preliminary findings suggest that this anti-CK2 clinical approach could be combined with standard-of-care in Covid-19 thus warranting larger studies."]}
{"id": 1003236, "claim": "Treatment with an anti-ck2 synthetic peptide inhibited clinical response in covid-19 patients with pneumonia.", "label": "REFUTED", "evidence": ["Implications: Our preliminary findings suggest that this anti-CK2 clinical approach could be combined with standard-of-care in Covid-19 thus warranting larger studies."]}
{"id": 1003237, "claim": "Treatment with an anti-ck2 synthetic peptide reduced clinical response in covid-19 patients with pneumonia.", "label": "REFUTED", "evidence": ["Implications: Our preliminary findings suggest that this anti-CK2 clinical approach could be combined with standard-of-care in Covid-19 thus warranting larger studies."]}
{"id": 1003238, "claim": "Ema endorses use of dexamethasone in covid-19 patients on oxygen or mechanical ventilation", "label": "SUPPORTED", "evidence": ["Dexamethasone was first considered a potential treatment for COVID-19 because of its ability to reduce inflammation, which plays an important role in the disease process in some patients who have been admitted to hospital with COVID-19.", "In patients receiving oxygen without mechanical ventilation, the figures were 23% with dexamethasone and 26% with usual care, with a relative reduction of about 20%.", "Dexamethasone can be taken by mouth or given as an injection or infusion (drip) into a vein.", "Based on the review of available data, EMA is endorsing the use of dexamethasone in adults and adolescents (from 12 years of age and weighing at least 40 kg) who require supplemental oxygen therapy.", "The CHMPs scientific opinion can be taken into account by EU member states and EMA when evaluating dexamethasone medicines for the treatment of COVID-19."]}
{"id": 1003239, "claim": "Ema endorses instead of dexamethasone in covid-19 patients on oxygen or mechanical ventilation", "label": "REFUTED", "evidence": ["Dexamethasone was first considered a potential treatment for COVID-19 because of its ability to reduce inflammation, which plays an important role in the disease process in some patients who have been admitted to hospital with COVID-19.", "In patients receiving oxygen without mechanical ventilation, the figures were 23% with dexamethasone and 26% with usual care, with a relative reduction of about 20%.", "Dexamethasone can be taken by mouth or given as an injection or infusion (drip) into a vein.", "Based on the review of available data, EMA is endorsing the use of dexamethasone in adults and adolescents (from 12 years of age and weighing at least 40 kg) who require supplemental oxygen therapy.", "The CHMPs scientific opinion can be taken into account by EU member states and EMA when evaluating dexamethasone medicines for the treatment of COVID-19."]}
{"id": 1003240, "claim": "Using symptom-based case predictions to identify host genetic factors that contribute to covid-19 susceptibility", "label": "SUPPORTED", "evidence": ["Using a previously reported COVID-19 prediction model, we show that it is possible to conduct a GWAS on predicted COVID-19 which benefits from a larger sample size in order to gain new insights into the genetic susceptibility of the disease.", "Recently, it was shown that it is possible to predict potential COVID-19 cases using cross- sectional self-reported disease-related symptoms.", "Furthermore, we find suggestive evidence that genetic variants for other viral infectious diseases do not overlap with COVID-19 susceptibility and that severity of COVID-19 may have a different genetic architecture compared to COVID-19 susceptibility."]}
{"id": 1003241, "claim": "Using symptom-based case predictions to identify novel genetic factors that contribute to covid-19 susceptibility", "label": "REFUTED", "evidence": ["Using a previously reported COVID-19 prediction model, we show that it is possible to conduct a GWAS on predicted COVID-19 which benefits from a larger sample size in order to gain new insights into the genetic susceptibility of the disease.", "Recently, it was shown that it is possible to predict potential COVID-19 cases using cross- sectional self-reported disease-related symptoms.", "Furthermore, we find suggestive evidence that genetic variants for other viral infectious diseases do not overlap with COVID-19 susceptibility and that severity of COVID-19 may have a different genetic architecture compared to COVID-19 susceptibility."]}
{"id": 1003242, "claim": "Oxford to trial new covid-19 test for individuals without symptoms", "label": "SUPPORTED", "evidence": ["Richard Hobbs, Nuffield Professor of Primary Care Health Sciences at the University of Oxford and lead on the study said: The results of this study will be important because some of the spread of COVID-19 happens before people get symptoms and self-isolate."]}
{"id": 1003243, "claim": "Oxford to trial new covid-19 therapy for individuals without symptoms", "label": "REFUTED", "evidence": ["Richard Hobbs, Nuffield Professor of Primary Care Health Sciences at the University of Oxford and lead on the study said: The results of this study will be important because some of the spread of COVID-19 happens before people get symptoms and self-isolate."]}
{"id": 1003244, "claim": "Oxford to trial new covid-19 vaccine for individuals without symptoms", "label": "REFUTED", "evidence": ["Richard Hobbs, Nuffield Professor of Primary Care Health Sciences at the University of Oxford and lead on the study said: The results of this study will be important because some of the spread of COVID-19 happens before people get symptoms and self-isolate."]}
{"id": 1003245, "claim": "Oxford to trial new covid-19 vaccines for individuals without symptoms", "label": "REFUTED", "evidence": ["Richard Hobbs, Nuffield Professor of Primary Care Health Sciences at the University of Oxford and lead on the study said: The results of this study will be important because some of the spread of COVID-19 happens before people get symptoms and self-isolate."]}
{"id": 1003246, "claim": "One-step test provides rapid and sensitive covid-19 detection", "label": "SUPPORTED", "evidence": ["In research, it has been shown to enable rapid, accurate, and highly sensitive detection of the Covid-19 virus SARS-CoV-2, with a simple protocol that requires minimal training and uses simple, readily available equipment, such as test tubes and water baths.", "As a result, the STOPCovid test allows for rapid, accurate, and highly sensitive detection of Covid-19 that can be conducted outside clinical laboratory settings."]}
{"id": 1003247, "claim": "Five-step test provides rapid and sensitive covid-19 detection", "label": "REFUTED", "evidence": ["In research, it has been shown to enable rapid, accurate, and highly sensitive detection of the Covid-19 virus SARS-CoV-2, with a simple protocol that requires minimal training and uses simple, readily available equipment, such as test tubes and water baths.", "As a result, the STOPCovid test allows for rapid, accurate, and highly sensitive detection of Covid-19 that can be conducted outside clinical laboratory settings."]}
{"id": 1003248, "claim": "Three-step test provides rapid and sensitive covid-19 detection", "label": "REFUTED", "evidence": ["In research, it has been shown to enable rapid, accurate, and highly sensitive detection of the Covid-19 virus SARS-CoV-2, with a simple protocol that requires minimal training and uses simple, readily available equipment, such as test tubes and water baths.", "As a result, the STOPCovid test allows for rapid, accurate, and highly sensitive detection of Covid-19 that can be conducted outside clinical laboratory settings."]}
{"id": 1003249, "claim": "Each-step test provides rapid and sensitive covid-19 detection", "label": "REFUTED", "evidence": ["In research, it has been shown to enable rapid, accurate, and highly sensitive detection of the Covid-19 virus SARS-CoV-2, with a simple protocol that requires minimal training and uses simple, readily available equipment, such as test tubes and water baths.", "As a result, the STOPCovid test allows for rapid, accurate, and highly sensitive detection of Covid-19 that can be conducted outside clinical laboratory settings."]}
{"id": 1003250, "claim": "Inferring change points in the spread of covid-19 reveals the effectiveness of interventions", "label": "SUPPORTED", "evidence": ["In general, our approach may help to infer the efficiency of measures taken in other countries and inform policy-makers about tightening, loosening, and selecting appropriate measures for containment of COVID-19.", "2 The timing and effectiveness of interventions strongly affect future COVID-19 cases.", "Download high-res image Open in new tab Download Powerpoint Bayesian inference of SIR model parameters from daily new cases of COVID-19 enables us to assess the impact of interventions."]}
{"id": 1003251, "claim": "Inferring change points in the absence of covid-19 reveals the effectiveness of interventions", "label": "REFUTED", "evidence": ["In general, our approach may help to infer the efficiency of measures taken in other countries and inform policy-makers about tightening, loosening, and selecting appropriate measures for containment of COVID-19.", "2 The timing and effectiveness of interventions strongly affect future COVID-19 cases.", "Download high-res image Open in new tab Download Powerpoint Bayesian inference of SIR model parameters from daily new cases of COVID-19 enables us to assess the impact of interventions."]}
{"id": 1003252, "claim": "The insert sequence in sars-cov-2 enhances spike protein cleavage by tmprss", "label": "SUPPORTED", "evidence": ["Thus, both the furin score and molecular docking revealed that the insertion sequence of SARS-CoV-2 facilitates the TMPRSS2 recognition and S protein cleavage.", "The two potential Spike protein cleavage sites of SARS-CoV and SARS- CoV-2 by TMPRSS2.", "We speculated that R682, R683 and R685 (red box) could be used as the most suitable substrates for TMPRSSs, which can increase the Spike protein cleavage efficiency of TMPRSSs, promote its activation and enhance SARS-CoV-2 infection."]}
{"id": 1003253, "claim": "The insert sequence in sars-cov-2 enhances spike protein production by tmprss", "label": "REFUTED", "evidence": ["Thus, both the furin score and molecular docking revealed that the insertion sequence of SARS-CoV-2 facilitates the TMPRSS2 recognition and S protein cleavage.", "The two potential Spike protein cleavage sites of SARS-CoV and SARS- CoV-2 by TMPRSS2.", "We speculated that R682, R683 and R685 (red box) could be used as the most suitable substrates for TMPRSSs, which can increase the Spike protein cleavage efficiency of TMPRSSs, promote its activation and enhance SARS-CoV-2 infection."]}
{"id": 1003254, "claim": "The n sequence in sars-cov-2 enhances spike protein cleavage by tmprss", "label": "REFUTED", "evidence": ["Thus, both the furin score and molecular docking revealed that the insertion sequence of SARS-CoV-2 facilitates the TMPRSS2 recognition and S protein cleavage.", "The two potential Spike protein cleavage sites of SARS-CoV and SARS- CoV-2 by TMPRSS2.", "We speculated that R682, R683 and R685 (red box) could be used as the most suitable substrates for TMPRSSs, which can increase the Spike protein cleavage efficiency of TMPRSSs, promote its activation and enhance SARS-CoV-2 infection."]}
{"id": 1003255, "claim": "The insert sequence in sars-cov-2 enhances spike protein formation by tmprss", "label": "REFUTED", "evidence": ["Thus, both the furin score and molecular docking revealed that the insertion sequence of SARS-CoV-2 facilitates the TMPRSS2 recognition and S protein cleavage.", "The two potential Spike protein cleavage sites of SARS-CoV and SARS- CoV-2 by TMPRSS2.", "We speculated that R682, R683 and R685 (red box) could be used as the most suitable substrates for TMPRSSs, which can increase the Spike protein cleavage efficiency of TMPRSSs, promote its activation and enhance SARS-CoV-2 infection."]}
{"id": 1003256, "claim": "Early hydroxychloroquine but not chloroquine use reduces icu admission in covid-19 patients", "label": "SUPPORTED", "evidence": ["Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.", "Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial."]}
{"id": 1003257, "claim": "Early hydroxychloroquine but also chloroquine use reduces icu admission in covid-19 patients", "label": "REFUTED", "evidence": ["Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.", "Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial."]}
{"id": 1003258, "claim": "Early hydroxychloroquine but only chloroquine use reduces icu admission in covid-19 patients", "label": "REFUTED", "evidence": ["Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.", "Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial."]}
{"id": 1003259, "claim": "Early hydroxychloroquine but with chloroquine use reduces icu admission in covid-19 patients", "label": "REFUTED", "evidence": ["Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.", "Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial."]}
{"id": 1003260, "claim": "Four volunteers who got pfizer 's vaccine developed bell 's palsy", "label": "SUPPORTED", "evidence": ["In Pfizers trial, all four participants who experienced Bells palsy received the vaccine.", "These are 3 of the 4 volunteers who developed Bells palsy after being vaccinated with the Pfizer (SIC) covid experimental vaccine.", "As the United Kingdom began administering people with the Pfizer-BioNTech vaccine, four people who got Pfizer's coronavirus vaccine in the firm's trial developed Bell's palsy, a form of temporary facial paralysis, according to US regulators' report on the shot.", "Ill go on to say there were deaths in the trial and none of them were linked to the vaccine. To be clear, four participants in the Pfizer vaccine trial and four participants in Modernas trial did experience Bells palsy."]}
{"id": 1003261, "claim": "Two volunteers who got pfizer's vaccine developed bell's palsy", "label": "REFUTED", "evidence": ["In Pfizers trial, all four participants who experienced Bells palsy received the vaccine.", "These are 3 of the 4 volunteers who developed Bells palsy after being vaccinated with the Pfizer (SIC) covid experimental vaccine.", "As the United Kingdom began administering people with the Pfizer-BioNTech vaccine, four people who got Pfizer's coronavirus vaccine in the firm's trial developed Bell's palsy, a form of temporary facial paralysis, according to US regulators' report on the shot.", "Ill go on to say there were deaths in the trial and none of them were linked to the vaccine. To be clear, four participants in the Pfizer vaccine trial and four participants in Modernas trial did experience Bells palsy."]}
{"id": 1003262, "claim": "Three volunteers who got pfizer's vaccine developed bell's palsy", "label": "REFUTED", "evidence": ["In Pfizers trial, all four participants who experienced Bells palsy received the vaccine.", "These are 3 of the 4 volunteers who developed Bells palsy after being vaccinated with the Pfizer (SIC) covid experimental vaccine.", "As the United Kingdom began administering people with the Pfizer-BioNTech vaccine, four people who got Pfizer's coronavirus vaccine in the firm's trial developed Bell's palsy, a form of temporary facial paralysis, according to US regulators' report on the shot.", "Ill go on to say there were deaths in the trial and none of them were linked to the vaccine. To be clear, four participants in the Pfizer vaccine trial and four participants in Modernas trial did experience Bells palsy."]}
